tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['Effect', 'of', 'Pelvic', 'Floor', 'Versus', 'Abdominal', 'Muscle', 'Exercises', 'on', 'Nocturia', 'and', 'Sleep', 'Quality', 'in', 'Women', 'With', 'Type', '2', 'Diabetes', '|', 'Nocturia', 'is', 'the', 'leading', 'cause', 'of', 'sleep', 'disruption', 'with', 'its', 'subsequent', 'negative', 'impact', 'on', 'general', 'health', 'and', 'QoL', 'for', 'a', 'large', 'proportion', 'of', 'the', 'adult', 'population', '.', 'Nocturia', 'is', 'prevalent', 'in', 'men', 'and', 'women', 'of', 'all', 'ages', 'but', 'may', 'be', 'particularly', 'bothersome', 'in', 'younger', 'adults', ',', 'in', 'whom', 'the', 'consequences', 'of', 'sleep', 'disturbance', 'may', 'be', 'more', 'detrimental', 'for', 'daytime', 'functioning', 'and', 'possibly', 'for', 'health', 'and', 'mortality', '.', 'The', 'underlying', 'causes', 'of', 'nocturia', 'obviously', 'influence', 'the', 'efficacy', 'of', 'different', 'treatment', 'options', '.', 'Because', 'a', 'major', 'cause', 'of', 'nocturia', 'is', 'overproduction', 'of', 'urine', 'at', 'night', ',', 'nocturia', 'may', 'not', 'respond', 'to', 'treatments', 'designed', 'to', 'reduce', 'urgency', 'and', 'increase', 'bladder', 'capacity', 'or', 'increase', 'urine', 'flow', ',', 'such', 'as', 'agents', 'for', 'the', 'management', 'of', 'bladder', 'outlet', 'obstruction', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05222477,NCT05222477,"Effect of Pelvic Floor Versus Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes | Nocturia is the leading cause of sleep disruption with its subsequent negative impact on general health and QoL for a large proportion of the adult population. Nocturia is prevalent in men and women of all ages but may be particularly bothersome in younger adults, in whom the consequences of sleep disturbance may be more detrimental for daytime functioning and possibly for health and mortality.The underlying causes of nocturia obviously influence the efficacy of different treatment options. Because a major cause of nocturia is overproduction of urine at night, nocturia may not respond to treatments designed to reduce urgency and increase bladder capacity or increase urine flow, such as agents for the management of bladder outlet obstruction.","[(10, 56, 'PHYSICAL', 'Pelvic Floor Versus Abdominal Muscle Exercises'), (60, 68, 'CONDITION', 'Nocturia'), (101, 116, 'CONDITION', 'Type 2 Diabetes'), (119, 127, 'CONDITION', 'Nocturia'), (152, 168, 'CONDITION', 'sleep disruption'), (279, 287, 'CONDITION', 'Nocturia'), (412, 429, 'CONDITION', 'sleep disturbance'), (541, 549, 'CONDITION', 'nocturia'), (640, 648, 'CONDITION', 'nocturia'), (686, 694, 'CONDITION', 'nocturia')]"
"['Carotid', 'Occlusion', 'Surgery', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'extracranial', '-', 'intracranial', 'bypass', 'surgery', 'when', 'added', 'to', 'best', 'medical', 'therapy', 'can', 'reduce', 'the', 'subsequent', 'risk', 'of', 'ipsilateral', 'stroke', 'in', 'high', '-', 'risk', 'patients', 'with', 'recently', 'symptomatic', 'carotid', 'occlusion', 'and', 'increased', 'cerebral', 'oxygen', 'extraction', 'fraction', 'measured', 'by', 'positron', 'emission', 'tomography', '(', 'PET', ')', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00029146,NCT00029146,Carotid Occlusion Surgery Study | The purpose of this study is to determine if extracranial-intracranial bypass surgery when added to best medical therapy can reduce the subsequent risk of ipsilateral stroke in high-risk patients with recently symptomatic carotid occlusion and increased cerebral oxygen extraction fraction measured by positron emission tomography (PET).,"[(0, 25, 'SURGICAL', 'Carotid Occlusion Surgery'), (79, 119, 'SURGICAL', 'extracranial-intracranial bypass surgery'), (189, 207, 'CONDITION', 'ipsilateral stroke'), (244, 273, 'CONDITION', 'symptomatic carotid occlusion')]"
"['A', 'Phase', '2', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Z160', 'in', 'Subjects', 'With', 'Postherpetic', 'Neuralgia', '|', 'This', 'study', 'will', 'compare', 'Z160', 'and', 'placebo', 'in', 'patients', 'with', 'Postherpetic', 'Neuralgia', 'for', 'safety', 'and', 'efficacy', 'for', 'a', 'period', 'of', '6', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01757873,NCT01757873,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia | This study will compare Z160 and placebo in patients with Postherpetic Neuralgia for safety and efficacy for a period of 6 weeks.","[(50, 57, 'CONTROL', 'Placebo'), (130, 134, 'DRUG', 'Z160'), (152, 174, 'CONDITION', 'Postherpetic Neuralgia'), (201, 205, 'DRUG', 'Z160'), (210, 217, 'CONTROL', 'placebo'), (235, 257, 'CONDITION', 'Postherpetic Neuralgia')]"
"['Skeletal', 'Muscle', 'as', 'a', 'Mediator', 'of', 'Exercise', 'Induced', 'Effects', 'on', 'Metabolism', '&', 'Cognitive', 'Function', ':', 'Role', 'for', 'Myokines', '&', 'miRNAs', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'specific', 'changes', 'in', 'muscle', 'secretory', 'profile', '(', 'myokines', ',', 'miRNA', ')', 'in', 'association', 'with', 'neurodegenerative', 'disease', 'progression', 'and', 'metabolic', 'dysfunction', '.', 'Next', 'the', 'investigators', 'would', 'like', 'to', 'determine', 'the', 'shift', 'in', 'the', 'muscle', 'secretory', 'activity', 'induced', 'by', 'regular', 'exercise', 'intervention', ',', 'which', 'the', 'investigators', 'think', 'could', 'be', 'translated', 'into', 'the', 'beneficial', 'changes', 'in', 'clinical', 'phenotypes', ',', 'determined', 'by', 'neuroimaging', ',', 'cognitive', 'function', 'tests', 'and', 'metabolic', 'phenotyping', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02253732,NCT02253732,"Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs | The purpose of this study is to determine specific changes in muscle secretory profile (myokines, miRNA) in association with neurodegenerative disease progression and metabolic dysfunction. Next the investigators would like to determine the shift in the muscle secretory activity induced by regular exercise intervention, which the investigators think could be translated into the beneficial changes in clinical phenotypes, determined by neuroimaging, cognitive function tests and metabolic phenotyping.","[(33, 41, 'PHYSICAL', 'Exercise'), (248, 273, 'CONDITION', 'neurodegenerative disease'), (290, 311, 'CONDITION', 'metabolic dysfunction'), (414, 443, 'PHYSICAL', 'regular exercise intervention')]"
"['Beta', 'Testing', 'of', 'a', 'New', 'Assessment', 'Protocol', 'for', 'Assessment', 'of', 'Complex', 'Therapies', 'in', 'Huntington', ""'s"", 'Disease', '(', 'HD', ')', '|', 'Huntington', ""'s"", 'disease', '(', 'HD', ')', 'is', 'an', 'inherited', 'neurodegenerative', 'disease', 'for', 'which', 'there', 'are', 'no', 'existing', 'disease', '-', 'modifying', 'treatments', '.', '\n\n', 'Repair', '-', 'HD', 'is', 'an', 'EU', 'FP7', 'consortium', 'that', 'aims', 'to', 'establish', 'all', 'the', 'preclinical', 'requirements', 'for', 'transplantation', 'of', 'stem', 'cell', '-', 'derived', 'neurons', 'in', 'HD', 'in', 'order', 'to', 'replace', 'those', 'lost', 'to', 'the', 'disease', 'process', '.', 'These', 'requirements', 'include', 'the', 'generation', 'of', 'new', 'clinical', 'assessments', 'for', 'detailed', 'monitoring', 'of', 'patients', 'with', 'HD', 'who', 'have', 'undergone', 'cell', 'replacement', 'therapy', '.', '\n\n', 'This', 'protocol', 'describes', 'the', 'beta', 'testing', 'of', 'a', 'new', 'clinical', 'assessment', 'battery', ':', 'Core', 'Assessment', 'Protocol', 'for', 'Intrastriatal', 'Transplantation', 'in', 'HD', 'version', '2', '(', 'CAPIT', '-', 'HD', 'beta', '/', 'CAPIT', '-', 'HD2', ')', '.', 'CAPIT', '-', 'HD', 'beta', 'represents', 'a', 'substantial', 'revision', 'of', 'a', 'previous', 'CAPIT', '-', 'HD', 'battery', 'published', 'over', '20', 'years', 'ago', ',', 'which', 'is', 'in', 'need', 'of', 'updating', 'in', 'order', 'to', 'accommodate', 'knowledge', 'from', 'clinical', 'transplant', 'studies', 'over', 'this', 'time', 'and', 'to', 'take', 'advantage', 'of', 'technological', 'advances', 'in', 'patient', 'assessment', '.', '\n\n', 'HD', 'is', 'a', 'complex', 'disorder', 'in', 'which', 'there', 'is', 'relentless', 'deterioration', 'of', 'motor', ',', 'cognitive', 'and', 'behavioural', 'functions', ',', 'usually', 'from', 'mid', '-', 'life', 'onwards', '.', 'The', 'original', 'CAPIT', 'battery', 'aimed', 'to', 'capture', 'elements', 'of', 'change', 'in', 'all', 'three', 'domains', ',', 'but', 'was', 'based', 'predominantly', 'on', 'subjective', 'semi', '-', 'quantitative', 'assessment', 'tools', 'that', 'have', 'poor', 'inter', '-', 'rater', 'reliability', '.', 'Moreover', ',', 'a', 'number', 'of', 'deficits', ',', 'such', 'as', 'impairments', 'in', 'social', 'cognition', ',', 'were', 'not', 'recognised', 'when', 'the', 'original', 'CAPIT', '-', 'HD', 'battery', 'was', 'constructed', ',', 'so', 'we', 'have', 'developed', 'novel', 'assessments', 'of', 'these', 'deficits', ',', 'some', 'of', 'which', 'are', 'included', 'in', 'CAPIT', '-', 'HD', 'beta', '.', 'The', 'beta', 'testing', 'will', 'take', 'place', 'in', 'established', 'HD', 'clinical', 'centres', 'in', 'Cardiff', ',', 'Manchester', ',', 'Paris', ',', 'and', 'Munster', 'by', 'teams', 'of', 'researchers', 'who', 'are', 'experienced', 'in', 'leading', 'clinic', 'research', 'in', 'HD', '.', 'Patients', 'with', 'early', 'to', 'moderate', 'HD', 'will', 'be', 'assessed', 'at', 'baseline', ',', 'and', 'at', 'one', 'and', 'twelve', 'months', 'later', ',', 'to', 'assess', 'the', 'reliability', 'and', 'sensitivity', 'of', 'the', 'CAPIT', '-', 'HD', 'beta', 'battery', '.', 'Arrangements', 'for', 'data', 'storage', 'and', 'analysis', 'are', 'in', 'place', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03119246,NCT03119246,"Beta Testing of a New Assessment Protocol for Assessment of Complex Therapies in Huntington's Disease (HD) | Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.

Repair-HD is an EU FP7 consortium that aims to establish all the preclinical requirements for transplantation of stem cell-derived neurons in HD in order to replace those lost to the disease process. These requirements include the generation of new clinical assessments for detailed monitoring of patients with HD who have undergone cell replacement therapy.

This protocol describes the beta testing of a new clinical assessment battery: Core Assessment Protocol for Intrastriatal Transplantation in HD version 2 (CAPIT-HD beta / CAPIT-HD2). CAPIT-HD beta represents a substantial revision of a previous CAPIT-HD battery published over 20 years ago, which is in need of updating in order to accommodate knowledge from clinical transplant studies over this time and to take advantage of technological advances in patient assessment.

HD is a complex disorder in which there is relentless deterioration of motor, cognitive and behavioural functions, usually from mid-life onwards. The original CAPIT battery aimed to capture elements of change in all three domains, but was based predominantly on subjective semi-quantitative assessment tools that have poor inter-rater reliability. Moreover, a number of deficits, such as impairments in social cognition, were not recognised when the original CAPIT-HD battery was constructed, so we have developed novel assessments of these deficits, some of which are included in CAPIT-HD beta. The beta testing will take place in established HD clinical centres in Cardiff, Manchester, Paris, and Munster by teams of researchers who are experienced in leading clinic research in HD. Patients with early to moderate HD will be assessed at baseline, and at one and twelve months later, to assess the reliability and sensitivity of the CAPIT-HD beta battery. Arrangements for data storage and analysis are in place.","[(81, 101, 'CONDITION', ""Huntington's Disease""), (103, 105, 'CONDITION', 'HD'), (109, 129, 'CONDITION', ""Huntington's disease""), (131, 133, 'CONDITION', 'HD'), (382, 384, 'CONDITION', 'HD'), (551, 553, 'CONDITION', 'HD'), (741, 743, 'CONDITION', 'HD'), (1074, 1076, 'CONDITION', 'HD'), (1718, 1720, 'CONDITION', 'HD'), (1855, 1857, 'CONDITION', 'HD'), (1873, 1893, 'CONDITION', 'early to moderate HD')]"
"['Quasi', '-', 'Experimental', 'Trial', 'of', 'the', 'Effect', 'of', 'Assertive', 'Community', 'Treatment', 'Among', 'Those', 'With', 'Severe', 'Mental', 'Disorder', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'assertive', 'community', 'treatment', 'in', 'Copenhagen', 'in', 'two', 'regions', 'compared', 'with', 'two', 'regions', 'where', 'this', 'treatment', 'was', 'not', 'implemented', '.', 'The', 'effect', 'on', 'user', 'satisfaction', ',', 'use', 'of', 'bed', 'days', ',', 'social', 'network', ',', 'global', 'assessment', 'of', 'functioning', ',', 'substance', 'misuse', 'will', 'be', 'evaluated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00225602,NCT00225602,"Quasi-Experimental Trial of the Effect of Assertive Community Treatment Among Those With Severe Mental Disorder | The aim of the study is to evaluate the effect of assertive community treatment in Copenhagen in two regions compared with two regions where this treatment was not implemented. The effect on user satisfaction, use of bed days, social network, global assessment of functioning, substance misuse will be evaluated.","[(42, 71, 'OTHER', 'Assertive Community Treatment'), (89, 111, 'CONDITION', 'Severe Mental Disorder'), (164, 193, 'OTHER', 'assertive community treatment')]"
"['Diet', 'and', 'Muscle', 'Function', 'In', 'Older', 'Adults', '|', 'This', 'research', 'study', 'was', 'conducted', 'to', 'investigate', 'the', 'effects', 'of', 'a', 'high', 'protein', 'diet', 'on', 'the', 'efficiency', 'of', 'energy', 'use', 'at', 'rest', 'and', 'at', 'low', '-', 'levels', 'of', 'physical', 'activity', '.', 'The', 'hypothesis', 'was', 'that', 'a', 'high', 'intake', 'of', 'dietary', 'protein', 'would', 'result', 'in', 'a', 'less', 'efficient', 'use', 'of', 'energy', 'in', 'skeletal', 'muscle', 'in', 'older', 'adults', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02069314,NCT02069314,Diet and Muscle Function In Older Adults | This research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. The hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.,"[(109, 126, 'OTHER', 'high protein diet'), (233, 263, 'OTHER', 'high intake of dietary protein')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', 'of', 'Deferiprone', 'in', 'Patients', 'With', 'Pantothenate', 'Kinase', '-', 'associated', 'Neurodegeneration', '(', 'PKAN', ')', '|', 'A', 'multi', '-', 'center', ',', 'placebo', 'controlled', ',', 'double', '-', 'blind', 'trial', 'comparing', 'the', 'efficacy', 'and', 'safety', 'of', '18', 'months', 'of', 'treatment', 'with', 'deferiprone', 'versus', 'placebo', 'in', 'patients', 'with', 'PKAN', '.', '\n\n', 'This', 'investigator', '-', 'initiated', 'trial', 'was', 'funded', 'by', 'the', 'European', 'Commission', ""'s"", 'Seventh', 'Framework', 'Programme', '(', 'FP7/2007', '-', '2013', ',', 'HEALTH', '-', 'F2', '-', '2011', ',', 'grant', 'agreement', 'No', '.', '277984', ')', 'to', 'the', 'TIRCON', 'consortium', '(', 'Treat', 'Iron', '-', 'Related', 'Childhood', '-', 'Onset', 'Neurodegeneration', ')', 'and', 'by', 'the', 'FDA', 'Office', 'of', 'Orphan', 'Products', 'Development', '(', 'OOPD', ')', '(', 'Dr.', 'Elliott', 'Vichinsky', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01741532,NCT01741532,"A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) | A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN.

This investigator-initiated trial was funded by the European Commission's Seventh Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON consortium (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA Office of Orphan Products Development (OOPD) (Dr. Elliott Vichinsky).","[(28, 35, 'CONTROL', 'Placebo'), (56, 67, 'DRUG', 'Deferiprone'), (85, 133, 'CONDITION', 'Pantothenate Kinase-associated Neurodegeneration'), (135, 139, 'CONDITION', 'PKAN'), (159, 166, 'CONTROL', 'placebo'), (263, 274, 'DRUG', 'deferiprone'), (282, 289, 'CONTROL', 'placebo'), (307, 311, 'CONDITION', 'PKAN')]"
"['Efficacy', 'and', 'Tolerability', 'of', 'Propiverine', 'Hydrochloride', 'Extended', 'Release', '(', 'ER', ')', 'Compared', 'to', 'Immediate', 'Release', '(', 'IR', ')', 'in', 'Patients', 'With', 'Neurogenic', 'Detrusor', 'Overactivity', '.', 'A', 'Randomized', ',', 'Double', 'Blind', ',', 'Parallel', 'Group', ',', 'Multicenter', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'compare', 'efficacy', 'and', 'safety', 'of', 'propiverine', 'hydrochloride', 'extended', 'and', 'immediate', 'release', 'formulations', 'in', 'patients', 'suffering', 'from', 'neurogenic', 'detrusor', 'overactivity', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01530620,NCT01530620,"Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial | The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.","[(29, 54, 'DRUG', 'Propiverine Hydrochloride'), (129, 161, 'CONDITION', 'Neurogenic Detrusor Overactivity'), (308, 333, 'DRUG', 'propiverine hydrochloride'), (405, 437, 'CONDITION', 'neurogenic detrusor overactivity')]"
"['Sleep', 'Quality', 'in', 'Pregnancy', 'and', 'Its', 'Impact', 'on', 'Pregnancy', 'Outcomes', '|', 'Hypothesis', ':', 'Sleep', 'Disorders', 'are', 'very', 'common', 'during', 'pregnancy', 'but', 'the', 'their', 'exact', 'role', 'in', 'causation', 'of', 'pregnancy', 'related', 'disorders', 'is', 'yet', 'to', 'be', 'determined', '.', 'OSA', 'can', 'complicate', 'pregnancy', 'given', 'the', 'risk', 'factors', 'of', 'weight', 'gain', ',', 'upper', 'displacement', 'of', 'the', 'diaphragm', ',', 'and', 'hormonal', '-', 'induced', 'hyperaemia', 'of', 'the', 'nasopharyngeal', 'passages', '.', 'SDB', 'confers', 'the', 'risk', 'of', 'hypertensive', 'disorders', 'of', 'pregnancy', 'and', 'is', 'associated', 'with', 'adverse', 'maternal', 'and', 'foetal', 'outcomes', '.', '\n\n', 'The', 'study', 'would', 'involve', 'pregnant', 'females', 'which', 'would', 'be', 'prospectively', 'followed', 'in', 'pregnancy', 'and', 'post', 'partum', 'to', 'know', 'the', 'prevalence', 'of', 'sleep', 'disorders', 'in', 'pregnancy', '.', 'Diagnosis', 'of', 'sleep', 'disorders', 'would', 'be', 'confirmed', 'by', 'overnight', 'polysomnography', 'and', 'ambulatory', 'blood', 'pressure', 'monitoring', '.', 'Pregnancy', 'outcomes', ',', 'both', 'maternal', 'and', 'fetal', 'would', 'be', 'recorded', 'and', 'its', 'relation', 'with', 'sleep', 'disorders', 'in', 'pregnancy', 'would', 'be', 'analysed', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT02016638,NCT02016638,"Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes | Hypothesis:Sleep Disorders are very common during pregnancy but the their exact role in causation of pregnancy related disorders is yet to be determined. OSA can complicate pregnancy given the risk factors of weight gain, upper displacement of the diaphragm, and hormonal-induced hyperaemia of the nasopharyngeal passages. SDB confers the risk of hypertensive disorders of pregnancy and is associated with adverse maternal and foetal outcomes.

The study would involve pregnant females which would be prospectively followed in pregnancy and post partum to know the prevalence of sleep disorders in pregnancy. Diagnosis of sleep disorders would be confirmed by overnight polysomnography and ambulatory blood pressure monitoring. Pregnancy outcomes, both maternal and fetal would be recorded and its relation with sleep disorders in pregnancy would be analysed.","[(17, 26, 'CONDITION', 'Pregnancy'), (45, 54, 'CONDITION', 'Pregnancy'), (116, 125, 'CONDITION', 'pregnancy'), (167, 176, 'CONDITION', 'pregnancy'), (220, 223, 'CONDITION', 'OSA'), (239, 248, 'CONDITION', 'pregnancy'), (389, 392, 'CONDITION', 'SDB'), (439, 448, 'CONDITION', 'pregnancy'), (535, 543, 'CONDITION', 'pregnant'), (593, 602, 'CONDITION', 'pregnancy'), (794, 803, 'CONDITION', 'Pregnancy'), (897, 906, 'CONDITION', 'pregnancy')]"
"['Prep', '-', 'to', '-', 'Play', ':', 'Comparing', 'the', 'Impact', 'of', 'Supported', 'and', 'Unsupported', 'Implementation', 'Strategies', 'on', 'the', 'Use', 'of', 'an', 'Injury', 'Prevention', 'Program', 'in', ""Women's"", '/', 'Girl', ""'s"", 'Community', 'Football', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'we', 'can', 'best', 'support', 'coaches', 'to', 'implement', 'an', 'injury', 'prevention', '(', 'IP', ')', 'program', '(', 'Prep', '-', 'to', '-', 'Play', ')', 'in', 'female', 'community', 'Australian', 'Football', '.', 'We', 'will', 'recruit', 'at', 'least', '140', 'female', 'community', 'football', 'teams', 'from', '15', 'different', 'football', 'leagues', 'in', 'Victoria', ',', 'Australia', '.', 'Teams', 'will', 'be', 'competing', 'in', 'U16', ',', 'U17', ',', 'U18', ',', 'U19', 'or', 'open', 'womens', 'competitions', '.', 'We', 'will', 'train', 'and', 'support', 'coaches', 'to', 'implement', 'the', 'IP', 'program', 'and', 'evaluate', 'the', 'effects', 'of', 'the', 'IP', 'program', 'on', 'injuries', 'across', 'two', 'football', 'seasons', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT04856241,NCT04856241,"Prep-to-Play: Comparing the Impact of Supported and Unsupported Implementation Strategies on the Use of an Injury Prevention Program in Women's/Girl's Community Football | The aim of this study is to determine how we can best support coaches to implement an injury prevention (IP) program (Prep-to-Play) in female community Australian Football. We will recruit at least 140 female community football teams from 15 different football leagues in Victoria, Australia. Teams will be competing in U16, U17, U18, U19 or open womens competitions. We will train and support coaches to implement the IP program and evaluate the effects of the IP program on injuries across two football seasons.","[(0, 12, 'BEHAVIOURAL', 'Prep-to-Play'), (38, 89, 'BEHAVIOURAL', 'Supported and Unsupported Implementation Strategies'), (107, 132, 'BEHAVIOURAL', 'Injury Prevention Program'), (258, 288, 'BEHAVIOURAL', 'injury prevention (IP) program'), (290, 302, 'BEHAVIOURAL', 'Prep-to-Play'), (591, 601, 'BEHAVIOURAL', 'IP program'), (634, 644, 'BEHAVIOURAL', 'IP program'), (648, 656, 'CONDITION', 'injuries')]"
"['Clinical', 'Study', 'Evaluating', 'the', 'Safety', 'of', 'Lactobacillus', 'Probiotic', 'in', 'Children', 'With', 'Drug', 'Resistant', 'Epilepsy', '|', 'Animal', 'and', 'human', 'studies', 'have', 'brought', 'up', 'evidence', 'supporting', 'Gut', 'microbial', 'disbalance', ',', 'namely', 'dysbiosis', ',', 'as', 'a', 'causative', 'factor', 'of', 'epilepsy', ',', 'especially', 'the', 'refractory', 'form', '.', 'thus', ',', 'probiotics', 'might', 'constitute', 'a', 'safe', ',', 'low', '-', 'cost', ',', 'and', 'effective', 'supplementary', 'therapy', 'in', 'patients', 'with', 'DRE', '.', '\n\n', 'The', 'Lactobacillus', 'population', 'is', 'probiotic', 'bacteria', 'that', 'have', 'a', 'beneficial', 'role', 'in', 'epilepsy', '.', 'Lactobacillus', 'can', 'influence', 'brain', 'function', 'through', 'the', 'modulation', 'of', 'GABA', ',', 'as', 'shown', 'in', 'rodent', 'models', '.', 'Moreover', ',', 'it', 'has', 'been', 'demonstrated', 'in', 'animal', 'models', 'of', 'epilepsy', 'and', 'in', 'human', 'epileptic', 'patients', 'that', 'probiotic', 'treatment', 'aimed', 'at', 'restoring', 'gut', 'microbiota', 'equilibrium', 'has', 'beneficial', 'effects', 'on', 'epileptic', 'symptoms', 'by', 'increasing', 'GABA', 'in', 'animals', 'and', 'the', 'levels', 'of', 'Bifidobacteria', 'and', 'Lactobacillus', 'in', 'humans', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05539287,NCT05539287,"Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy | Animal and human studies have brought up evidence supporting Gut microbial disbalance, namely dysbiosis, as a causative factor of epilepsy, especially the refractory form. thus, probiotics might constitute a safe, low-cost, and effective supplementary therapy in patients with DRE.

The Lactobacillus population is probiotic bacteria that have a beneficial role in epilepsy. Lactobacillus can influence brain function through the modulation of GABA, as shown in rodent models. Moreover, it has been demonstrated in animal models of epilepsy and in human epileptic patients that probiotic treatment aimed at restoring gut microbiota equilibrium has beneficial effects on epileptic symptoms by increasing GABA in animals and the levels of Bifidobacteria and Lactobacillus in humans.","[(40, 63, 'OTHER', 'Lactobacillus Probiotic'), (81, 104, 'CONDITION', 'Drug Resistant Epilepsy'), (201, 210, 'CONDITION', 'dysbiosis'), (237, 245, 'CONDITION', 'epilepsy'), (285, 295, 'OTHER', 'probiotics'), (384, 387, 'CONDITION', 'DRE'), (394, 418, 'OTHER', 'Lactobacillus population'), (422, 440, 'OTHER', 'probiotic bacteria'), (472, 480, 'CONDITION', 'epilepsy'), (482, 495, 'OTHER', 'Lactobacillus'), (639, 647, 'CONDITION', 'epilepsy'), (661, 670, 'CONDITION', 'epileptic'), (685, 704, 'OTHER', 'probiotic treatment'), (777, 786, 'CONDITION', 'epileptic')]"
"['Evaluation', 'of', 'the', 'Influence', 'of', 'Deep', 'Brain', 'Stimulation', 'on', 'the', 'Spinal', 'Deformities', 'Associated', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'intention', 'of', 'the', 'study', 'is', 'to', 'investigate', 'whether', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'will', 'improve', 'postural', 'deformities', 'of', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04524377,NCT04524377,Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease | The intention of the study is to investigate whether Deep Brain Stimulation (DBS) will improve postural deformities of patients with Parkinson's disease.,"[(31, 53, 'OTHER', 'Deep Brain Stimulation'), (61, 79, 'CONDITION', 'Spinal Deformities'), (96, 115, 'CONDITION', ""Parkinson's Disease""), (171, 193, 'OTHER', 'Deep Brain Stimulation'), (195, 198, 'OTHER', 'DBS'), (213, 233, 'CONDITION', 'postural deformities'), (251, 270, 'CONDITION', ""Parkinson's disease"")]"
"['Two', '-', 'phase', 'Randomized', 'Controlled', 'Trial', 'of', 'Low', 'and', 'Moderate', 'Dose', 'Methylphenidate', 'for', 'Non', '-', 'motor', 'and', 'Postural', 'Symptoms', 'in', 'Parkinson', ""'s"", 'Disease', '.', '|', 'This', 'project', 'aims', 'to', 'determine', 'if', 'methylphenidate', 'can', 'improve', 'deficits', 'in', 'attention', 'and', 'symptoms', 'of', 'orthostatic', 'hypotension', ',', 'two', 'common', 'non', '-', 'motor', 'symptoms', ',', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'Disease', '.', 'This', 'project', 'also', 'seeks', 'to', 'evaluate', 'the', 'effect', 'of', 'methylphenidate', 'on', 'postural', 'control', 'in', 'these', 'patients', ',', 'a', 'debilitating', 'motor', 'symptom', 'that', 'places', 'patients', 'at', 'an', 'increased', 'risk', 'of', 'falling', '.', 'This', 'study', 'will', 'build', 'on', 'existing', 'data', 'to', 'support', 'a', 'new', 'indication', 'for', 'the', 'use', 'of', 'methylphenidate', 'in', 'Parkinson', ""'s"", 'Disease', '.', 'Using', 'standard', 'and', 'objective', 'evaluations', ',', 'this', 'study', 'will', 'quantify', 'the', 'effect', 'of', 'methylphenidate', 'at', 'two', 'doses', 'on', 'attention', 'levels', ',', 'orthostatic', 'hypotension', ',', 'and', 'measures', 'of', 'postural', 'control', '.', 'Phase', 'I', 'of', 'the', 'study', 'will', 'compare', 'methylphenidate', '10', 'mg', 'three', 'times', 'daily', 'to', 'placebo', 'and', 'Phase', 'II', 'of', 'the', 'study', ',', 'for', 'those', 'tolerating', 'the', 'lower', 'dose', 'in', 'Phase', 'I', ',', 'will', 'compare', 'methylphenidate', '20', 'mg', 'three', 'times', 'daily', 'to', 'placebo', '.', 'By', 'incorporating', 'two', 'different', 'doses', ',', 'the', 'study', 'also', 'seeks', 'to', 'determine', 'if', 'any', 'improvements', 'are', 'dose', '-', 'related', '.', 'Secondary', 'endpoints', 'will', 'include', 'safety', 'assessments', '(', 'adverse', 'event', 'monitoring', 'and', 'vital', 'signs', ')', 'performed', 'every', '30', 'minutes', 'following', 'supervised', 'drug', 'administration', '.', 'Visual', 'analog', 'scales', 'will', 'be', 'presented', 'to', 'each', 'participant', 'before', 'treatment', 'and', 'following', 'the', 'final', 'dose', 'of', 'each', 'treatment', 'to', 'assess', 'changes', 'in', 'fatigue', '.', 'A', 'secondary', 'task', 'will', 'be', 'added', 'to', 'postural', 'tests', 'to', 'assess', 'the', 'influence', 'of', 'cognitive', 'processes', '.', 'It', 'is', 'hypothesized', 'that', 'methylphenidate', 'will', 'demonstrate', 'a', 'significant', 'beneficial', 'effect', 'on', 'all', 'outcomes', '.', 'It', 'is', 'projected', 'that', 'objective', 'improvements', 'will', 'be', 'observed', 'following', 'treatment', 'with', 'methylphenidate', 'at', 'both', 'doses', '(', '10', 'and', '20', 'mg', 'three', 'time', 'daily', ')', 'when', 'compared', 'to', 'placebo', '.', 'It', 'is', 'further', 'hypothesized', 'that', 'the', 'effects', 'will', 'be', 'dose', '-', 'related', 'and', 'therefore', 'more', 'profound', 'with', 'higher', 'doses', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01244269,NCT01244269,"Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. | This project aims to determine if methylphenidate can improve deficits in attention and symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on postural control in these patients, a debilitating motor symptom that places patients at an increased risk of falling. This study will build on existing data to support a new indication for the use of methylphenidate in Parkinson's Disease. Using standard and objective evaluations, this study will quantify the effect of methylphenidate at two doses on attention levels, orthostatic hypotension, and measures of postural control. Phase I of the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg three times daily to placebo. By incorporating two different doses, the study also seeks to determine if any improvements are dose-related. Secondary endpoints will include safety assessments (adverse event monitoring and vital signs) performed every 30 minutes following supervised drug administration. Visual analog scales will be presented to each participant before treatment and following the final dose of each treatment to assess changes in fatigue. A secondary task will be added to postural tests to assess the influence of cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant beneficial effect on all outcomes. It is projected that objective improvements will be observed following treatment with methylphenidate at both doses (10 and 20mg three time daily) when compared to placebo. It is further hypothesized that the effects will be dose-related and therefore more profound with higher doses.","[(63, 78, 'DRUG', 'Methylphenidate'), (97, 114, 'CONDITION', 'Postural Symptoms'), (118, 137, 'CONDITION', ""Parkinson's Disease""), (175, 190, 'DRUG', 'methylphenidate'), (203, 224, 'CONDITION', 'deficits in attention'), (241, 264, 'CONDITION', 'orthostatic hypotension'), (314, 333, 'CONDITION', ""Parkinson's Disease""), (385, 400, 'DRUG', 'methylphenidate'), (605, 620, 'DRUG', 'methylphenidate'), (624, 643, 'CONDITION', ""Parkinson's Disease""), (726, 741, 'DRUG', 'methylphenidate'), (776, 799, 'CONDITION', 'orthostatic hypotension'), (869, 884, 'DRUG', 'methylphenidate'), (911, 918, 'OTHER', 'placebo'), (1007, 1022, 'DRUG', 'methylphenidate'), (1049, 1056, 'OTHER', 'placebo'), (1606, 1621, 'DRUG', 'methylphenidate'), (1774, 1789, 'DRUG', 'methylphenidate'), (1852, 1859, 'OTHER', 'placebo')]"
"['Environmental', 'Design', 'for', 'Behavioral', 'Regulation', 'in', 'People', 'With', 'Dementia', '|', 'Individuals', 'with', 'dementia', 'present', 'with', 'changes', 'in', 'behaviors', 'throughout', 'the', 'continuum', 'of', 'cognitive', 'decline', '.', 'Environmental', 'features', 'may', 'be', 'influential', 'in', 'behavioral', 'regulation', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'feasibility', 'of', 'environmental', 'design', 'protocols', 'in', 'older', 'adults', 'with', 'dementia', 'and', 'their', 'caregivers', '.', 'Thirty', 'subjects', 'with', 'moderate', 'to', 'severe', 'Alzheimer', ""'s"", 'disease', 'as', 'primary', 'dementia', 'type', ',', 'and', 'their', 'caregivers', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'three', 'arms', ':', 'standard', 'care', ';', 'standard', 'environmental', 'design', 'protocol', ';', 'or', 'personalized', 'environmental', 'design', 'protocol', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O']",NCT04555616,NCT04555616,"Environmental Design for Behavioral Regulation in People With Dementia | Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.","[(0, 20, 'OTHER', 'Environmental Design'), (25, 46, 'BEHAVIOURAL', 'Behavioral Regulation'), (62, 70, 'CONDITION', 'Dementia'), (90, 98, 'CONDITION', 'dementia'), (161, 178, 'CONDITION', 'cognitive decline'), (225, 246, 'BEHAVIOURAL', 'behavioral regulation'), (306, 326, 'OTHER', 'environmental design'), (358, 366, 'CONDITION', 'dementia'), (410, 448, 'CONDITION', ""moderate to severe Alzheimer's disease""), (460, 468, 'CONDITION', 'dementia'), (545, 558, 'CONTROL', 'standard care'), (560, 589, 'OTHER', 'standard environmental design'), (603, 636, 'OTHER', 'personalized environmental design')]"
"['An', 'Open', '-', 'Label', ',', 'Dose', 'Escalation', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'Dose', '-', 'Range', 'Finding', 'of', 'Multiple', 'Doses', 'of', 'ISIS', '396443', 'Delivered', 'Intrathecally', 'to', 'Patients', 'With', 'Spinal', 'Muscular', 'Atrophy', '|', 'This', 'study', 'will', 'test', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'escalating', 'doses', 'of', 'nusinersen', '(', 'ISIS', '396443', ')', 'administered', 'into', 'the', 'spinal', 'fluid', 'either', 'two', 'or', 'three', 'times', 'over', 'the', 'duration', 'of', 'the', 'trial', ',', 'in', 'participants', 'with', 'spinal', 'muscular', 'atrophy', '(', 'SMA', ')', '.', '\n\n', 'Four', 'dose', 'levels', 'will', 'be', 'evaluated', 'sequentially', '.', 'Each', 'dose', 'level', 'will', 'be', 'studied', 'in', 'a', 'cohort', 'of', 'approximately', '8', 'participants', ',', 'where', 'all', 'participants', 'will', 'receive', 'active', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01703988,NCT01703988,"An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy | This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with spinal muscular atrophy (SMA).

Four dose levels will be evaluated sequentially. Each dose level will be studied in a cohort of approximately 8 participants, where all participants will receive active drug.","[(116, 127, 'DRUG', 'ISIS 396443'), (169, 192, 'CONDITION', 'Spinal Muscular Atrophy'), (286, 296, 'DRUG', 'nusinersen'), (298, 309, 'DRUG', 'ISIS 396443'), (425, 448, 'CONDITION', 'spinal muscular atrophy'), (450, 453, 'CONDITION', 'SMA')]"
"['Intensive', 'Training', 'of', 'Functional', 'Priorities', 'Reported', 'by', 'Adolescents', 'With', 'Cerebral', 'Palsy', '|', 'Adolescents', 'with', 'cerebral', 'palsy', '(', 'CP', ')', 'present', 'important', 'limitations', 'for', 'the', 'performance', 'of', 'daily', 'living', 'activities', '.', 'The', 'aims', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'feasibility', 'and', 'effects', 'of', 'an', 'intensive', 'goal', 'training', 'protocol', 'for', 'adolescents', 'with', 'CP', '.', 'He', 'hypothesize', 'that', 'adolescents', 'submitted', 'to', 'the', 'studied', 'protocol', 'will', 'present', 'improvements', 'in', 'performance', 'and', 'satisfaction', 'of', 'prioritized', 'functional', 'goals', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03530982,NCT03530982,Intensive Training of Functional Priorities Reported by Adolescents With Cerebral Palsy | Adolescents with cerebral palsy (CP) present important limitations for the performance of daily living activities. The aims of the study is to evaluate the feasibility and effects of an intensive goal training protocol for adolescents with CP. He hypothesize that adolescents submitted to the studied protocol will present improvements in performance and satisfaction of prioritized functional goals.,"[(0, 43, 'PHYSICAL', 'Intensive Training of Functional Priorities'), (73, 87, 'CONDITION', 'Cerebral Palsy'), (107, 121, 'CONDITION', 'cerebral palsy'), (123, 125, 'CONDITION', 'CP'), (276, 299, 'PHYSICAL', 'intensive goal training'), (330, 332, 'CONDITION', 'CP')]"
"['Effects', 'of', 'Upper', 'Extremity', 'Rehabilitation', 'Robot', 'and', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'on', 'Upper', 'Extremity', 'Function', 'Among', 'Subjects', 'With', 'Chronic', 'Stroke', '|', 'Comparison', 'of', 'real', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'and', 'sham', 'tDCS', 'combined', 'with', 'robot', 'training', 'for', 'upper', 'extremity', 'rehabilitation', 'in', 'subjects', 'with', 'chronic', 'stroke', '-', 'delayed', 'start', 'study', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04005131,NCT04005131,Effects of Upper Extremity Rehabilitation Robot and Transcranial Direct Current Stimulation on Upper Extremity Function Among Subjects With Chronic Stroke | Comparison of real transcranial direct current stimulation (tDCS) and sham tDCS combined with robot training for upper extremity rehabilitation in subjects with chronic stroke - delayed start study.,"[(27, 47, 'PHYSICAL', 'Rehabilitation Robot'), (52, 91, 'OTHER', 'Transcranial Direct Current Stimulation'), (140, 154, 'CONDITION', 'Chronic Stroke'), (176, 215, 'OTHER', 'transcranial direct current stimulation'), (217, 221, 'OTHER', 'tDCS'), (227, 236, 'CONTROL', 'sham tDCS'), (251, 265, 'PHYSICAL', 'robot training'), (318, 332, 'CONDITION', 'chronic stroke')]"
"['Assessing', 'the', 'Efficacy', 'of', 'Transcutaneous', 'Auricular', 'Vagus', 'Nerve', 'Stimulation', 'as', 'an', 'Anti', '-', 'inflammatory', 'Treatment', 'Following', 'Spinal', 'Cord', 'Injury', '|', 'The', 'goal', 'of', 'this', 'single', '-', 'blinded', 'randomized', ',', 'controlled', 'trial', 'is', 'to', 'assess', 'the', 'impact', 'of', '1', '-', 'hour', 'of', 'active', 'transcutaneous', 'auricular', 'vagus', 'nerve', 'stimulation', '(', 'taVNS', ')', 'vs', 'sham', 'taVNS', 'on', 'serum', 'biomarkers', 'of', 'the', 'inflammatory', 'reflex', 'and', 'inflammation', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '.', '\n\n', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'is', ':', 'whether', 'taVNS', 'is', 'a', 'safe', 'and', 'effective', 'anti', '-', 'inflammatory', 'intervention', 'for', 'individuals', 'with', 'SCI', '.', 'Participants', 'will', 'perform', 'a', 'single', '1', '-', 'hour', 'bout', 'of', 'the', 'respective', 'taVNS', 'treatment', 'with', 'blood', 'draws', 'prior', 'to', 'treatment', ',', 'immediately', 'following', 'treatment', ',', 'and', '24', 'hours', 'following', 'treatment', '.', 'Changes', 'in', 'biomarkers', 'between', 'the', 'active', 'and', 'sham', 'taVNS', 'conditions', 'will', 'be', 'compared', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O']",NCT05730049,NCT05730049,"Assessing the Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation as an Anti-inflammatory Treatment Following Spinal Cord Injury | The goal of this single-blinded randomized, controlled trial is to assess the impact of 1-hour of active transcutaneous auricular vagus nerve stimulation (taVNS) vs sham taVNS on serum biomarkers of the inflammatory reflex and inflammation in individuals with spinal cord injury.

The main question it aims to answer is: whether taVNS is a safe and effective anti-inflammatory intervention for individuals with SCI. Participants will perform a single 1-hour bout of the respective taVNS treatment with blood draws prior to treatment, immediately following treatment, and 24 hours following treatment. Changes in biomarkers between the active and sham taVNS conditions will be compared.","[(26, 74, 'OTHER', 'Transcutaneous Auricular Vagus Nerve Stimulation'), (119, 137, 'CONDITION', 'Spinal Cord Injury'), (238, 293, 'OTHER', 'active transcutaneous auricular vagus nerve stimulation'), (295, 300, 'OTHER', 'taVNS'), (305, 315, 'CONTROL', 'sham taVNS'), (367, 379, 'CONDITION', 'inflammation'), (400, 418, 'CONDITION', 'spinal cord injury'), (469, 474, 'OTHER', 'taVNS'), (551, 554, 'CONDITION', 'SCI'), (621, 626, 'OTHER', 'taVNS'), (786, 796, 'CONTROL', 'sham taVNS')]"
"['A', 'Brief', 'Intervention', 'Targeting', 'Anhedonia', 'in', 'Adolescents', ':', 'a', 'Feasibility', 'Randomised', 'Controlled', 'Trial', '|', 'Depression', 'is', 'a', 'common', 'mental', 'health', 'problem', 'that', 'often', 'begins', 'during', 'adolescence', '.', 'Onset', 'during', 'adolescence', 'can', 'be', 'disruptive', 'to', 'schoolwork', 'and', 'social', 'relationships', 'and', 'if', 'left', 'untreated', 'can', 'lead', 'to', 'recurrence', 'during', 'adulthood', ',', 'as', 'well', 'as', 'the', 'development', 'of', 'other', 'mental', 'health', 'problems', '.', 'Current', 'treatments', 'for', 'depression', '(', 'for', 'both', 'adults', 'and', 'young', 'people', ')', 'largely', 'focus', 'on', 'reducing', 'low', 'mood', 'and', 'do', 'not', 'effectively', 'tackle', 'the', 'other', 'hallmark', 'symptom', 'of', 'depression', ',', 'anhedonia', ',', 'which', 'is', 'characterised', 'as', 'a', 'loss', 'of', 'enjoyment/', 'pleasure', 'for', 'previously', 'enjoyed', 'activities', '.', 'Anhedonia', 'is', 'associated', 'with', 'increased', 'risk', 'of', 'suicidality', ',', 'so', 'should', 'be', 'an', 'important', 'treatment', 'target', '.', 'Whilst', 'some', 'adult', 'treatments', 'are', 'beginning', 'to', 'address', 'anhedonia', ',', 'little', 'research', 'has', 'focussed', 'on', 'young', 'people', '.', 'It', 'can', 'not', 'be', 'assumed', 'that', 'adult', 'treatments', 'will', 'work', 'identically', 'in', 'young', 'people', ',', 'particularly', 's', 'their', 'brains', 'are', 'still', 'maturing', 'compared', 'to', 'adults', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'complete', 'a', 'randomised', 'feasibility', 'trial', ',', 'to', 'see', 'if', 'it', 'is', 'possible', 'to', 'run', 'a', 'brief', 'talking', 'therapy', 'for', 'anhedonia', 'in', 'adolescent', 'depression', ',', 'by', 'targeting', 'one', 'promising', 'cognitive', 'factor', 'known', 'to', 'contribute', 'to', 'low', 'positive', 'affect', ':', 'positive', 'future', 'mental', 'imagery']","['O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05507385,NCT05507385,"A Brief Intervention Targeting Anhedonia in Adolescents: a Feasibility Randomised Controlled Trial | Depression is a common mental health problem that often begins during adolescence. Onset during adolescence can be disruptive to schoolwork and social relationships and if left untreated can lead to recurrence during adulthood, as well as the development of other mental health problems. Current treatments for depression (for both adults and young people) largely focus on reducing low mood and do not effectively tackle the other hallmark symptom of depression, anhedonia, which is characterised as a loss of enjoyment/ pleasure for previously enjoyed activities. Anhedonia is associated with increased risk of suicidality, so should be an important treatment target. Whilst some adult treatments are beginning to address anhedonia, little research has focussed on young people. It cannot be assumed that adult treatments will work identically in young people, particularly s their brains are still maturing compared to adults. The aim of this study is to complete a randomised feasibility trial, to see if it is possible to run a brief talking therapy for anhedonia in adolescent depression, by targeting one promising cognitive factor known to contribute to low positive affect: positive future mental imagery","[(31, 40, 'CONDITION', 'Anhedonia'), (101, 111, 'CONDITION', 'Depression'), (412, 422, 'CONDITION', 'depression'), (553, 563, 'CONDITION', 'depression'), (565, 574, 'CONDITION', 'anhedonia'), (667, 676, 'CONDITION', 'Anhedonia'), (825, 834, 'CONDITION', 'anhedonia'), (1134, 1155, 'BEHAVIOURAL', 'brief talking therapy'), (1160, 1169, 'CONDITION', 'anhedonia'), (1184, 1194, 'CONDITION', 'depression')]"
"['Randomized', 'Controlled', 'Trial', 'of', 'The', 'Safety', 'and', 'Efficacy', 'of', 'Aripiprazole', 'VS', 'Ziprasidone', 'in', 'Schizophrenic', 'Patients', 'With', 'Metabolic', 'Syndrome', 'and', 'Diabetes', 'Mellitus', '.', '|', 'Introduction', ':', '\n\n', 'Schizophrenia', 'is', 'a', 'serious', 'mental', 'illness', '.', 'For', 'majority', 'of', 'patients', 'it', 'is', 'a', 'lifetime', 'condition', ',', 'characterized', 'by', 'intermittent', 'episodes', 'of', 'hospitalization', 'due', 'to', 'relapse', 'or', 'acute', 'symptom', 'exacerbation', '.', 'The', 'nature', 'and', 'course', 'of', 'the', 'disorder', 'impose', 'significant', 'social', 'and', 'economic', 'burden', '.', 'Relapse', 'is', 'costly', ',', 'with', 'hospitalization', 'accounting', 'for', 'a', 'substantial', 'portion', 'of', 'healthcare', 'expenses', '.', 'Second', 'generation', 'antipsychotic', 'side', 'effect', 'such', 'as', 'metabolic', 'syndrome', 'and', 'diabetes', 'mellitus', 'will', 'contribute', 'additional', 'costs', 'to', 'the', 'treatment', '.', '\n\n', 'Many', 'studies', 'have', 'since', 'then', 'provided', 'convincing', 'evidence', 'for', 'a', 'high', 'risk', 'of', 'diabetes', 'and', 'other', 'glucose', 'abnormalities', ',', 'metabolic', 'syndrome', 'and', 'mortality', 'due', 'to', 'elevated', 'cardiovascular', 'risk', 'in', 'patients', 'with', 'schizophrenia', '.', '\n\n', 'However', 'many', 'studies', 'has', 'shown', 'the', 'effectiveness', 'and', 'safety', 'of', 'aripiprazole', 'and', 'ziprazidone', '.', 'In', 'one', 'of', 'the', 'study', ',', 'aripiprazole', 'showed', 'improvement', 'of', 'negative', 'schizophrenic', 'symptoms', 'by', '25', '%', 'and', '50', '%', 'of', 'functioning', 'level', 'from', 'baseline', '.', 'In', 'term', 'of', 'safety', ',', 'antipsychotics', 'considered', 'to', 'have', 'a', 'safer', 'metabolic', 'profile', 'were', 'amisulpride', ',', 'ziprasidone', 'and', 'aripiprazole', '.', '\n\n', 'Study', 'objectives', ':', '\n\n', 'To', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'ziprazidone', 'versus', 'aripiprazole', 'in', 'the', 'treatment', 'of', 'schizophrenia', 'patients', 'with', 'metabolic', 'syndrome', 'and', 'diabetes', 'mellitus', '.', '\n', 'To', 'investigate', 'the', 'reversibility', 'of', 'metabolic', 'syndrome', 'and', 'diabetes', 'parameters', 'following', 'the', 'treatment', 'with', 'ziprazidone', 'versus', 'aripiprazole', '.', '\n\n', 'Hypotheses', ':', '\n\n', '*', 'The', 'proportion', 'of', 'reversibility', 'of', 'metabolic', 'syndrome', 'and', 'diabetes', 'parameters', 'is', 'higher', 'following', 'the', 'treatment', 'of', 'ziprazidone', 'than', 'aripiprazole', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT01714011,NCT01714011,"Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. | Introduction:

Schizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation. The nature and course of the disorder impose significant social and economic burden. Relapse is costly, with hospitalization accounting for a substantial portion of healthcare expenses. Second generation antipsychotic side effect such as metabolic syndrome and diabetes mellitus will contribute additional costs to the treatment.

Many studies have since then provided convincing evidence for a high risk of diabetes and other glucose abnormalities, metabolic syndrome and mortality due to elevated cardiovascular risk in patients with schizophrenia.

However many studies has shown the effectiveness and safety of aripiprazole and ziprazidone.In one of the study, aripiprazole showed improvement of negative schizophrenic symptoms by 25% and 50% of functioning level from baseline. In term of safety, antipsychotics considered to have a safer metabolic profile were amisulpride, ziprasidone and aripiprazole.

Study objectives:

To investigate the safety and efficacy of ziprazidone versus aripiprazole in the treatment of schizophrenia patients with metabolic syndrome and diabetes mellitus.
To investigate the reversibility of metabolic syndrome and diabetes parameters following the treatment with ziprazidone versus aripiprazole.

Hypotheses:

* The proportion of reversibility of metabolic syndrome and diabetes parameters is higher following the treatment of ziprazidone than aripiprazole.","[(58, 70, 'DRUG', 'Aripiprazole'), (74, 85, 'DRUG', 'Ziprasidone'), (89, 102, 'CONDITION', 'Schizophrenic'), (117, 135, 'CONDITION', 'Metabolic Syndrome'), (140, 157, 'CONDITION', 'Diabetes Mellitus'), (176, 189, 'CONDITION', 'Schizophrenia'), (613, 631, 'CONDITION', 'metabolic syndrome'), (636, 653, 'CONDITION', 'diabetes mellitus'), (783, 791, 'CONDITION', 'diabetes'), (825, 843, 'CONDITION', 'metabolic syndrome'), (911, 924, 'CONDITION', 'schizophrenia'), (990, 1002, 'DRUG', 'aripiprazole'), (1007, 1018, 'DRUG', 'ziprazidone'), (1040, 1052, 'DRUG', 'aripiprazole'), (1084, 1097, 'CONDITION', 'schizophrenic'), (1177, 1191, 'DRUG', 'antipsychotics'), (1242, 1253, 'DRUG', 'amisulpride'), (1255, 1266, 'DRUG', 'ziprasidone'), (1271, 1283, 'DRUG', 'aripiprazole'), (1347, 1358, 'DRUG', 'ziprazidone'), (1366, 1378, 'DRUG', 'aripiprazole'), (1399, 1412, 'CONDITION', 'schizophrenia'), (1427, 1445, 'CONDITION', 'metabolic syndrome'), (1450, 1467, 'CONDITION', 'diabetes mellitus'), (1505, 1523, 'CONDITION', 'metabolic syndrome'), (1528, 1536, 'CONDITION', 'diabetes'), (1577, 1588, 'DRUG', 'ziprazidone'), (1596, 1608, 'DRUG', 'aripiprazole'), (1661, 1679, 'CONDITION', 'metabolic syndrome'), (1684, 1692, 'CONDITION', 'diabetes'), (1741, 1752, 'DRUG', 'ziprazidone'), (1758, 1770, 'DRUG', 'aripiprazole')]"
"['Effect', 'of', 'Technological', 'Processes', 'on', 'Nutritional', 'Quality', 'of', 'Meat', 'Proteins', '|', 'This', 'project', 'aims', 'to', 'assess', 'the', 'impact', 'of', 'technological', 'processes', 'of', 'meat', ',', 'as', 'cooking', 'conditions', ',', 'on', 'amino', 'acid', 'bioavailability', 'and', 'protein', 'metabolism', '.', 'The', 'hypothesis', 'is', 'that', ',', 'even', 'if', 'meat', 'is', 'considered', 'as', 'a', 'good', 'provider', 'of', 'fast', 'proteins', 'and', 'so', 'could', 'be', 'useful', 'to', 'prevent', 'sarcopenia', 'in', 'aged', 'people', ',', 'the', 'manner', 'it', 'is', 'cooked', 'can', 'change', 'its', 'digestion', 'rate', 'and', 'amino', 'acids', 'bioavailability', 'for', 'muscle', 'synthesis', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02157805,NCT02157805,"Effect of Technological Processes on Nutritional Quality of Meat Proteins | This project aims to assess the impact of technological processes of meat, as cooking conditions, on amino acid bioavailability and protein metabolism. The hypothesis is that, even if meat is considered as a good provider of fast proteins and so could be useful to prevent sarcopenia in aged people, the manner it is cooked can change its digestion rate and amino acids bioavailability for muscle synthesis.","[(10, 73, 'OTHER', 'Technological Processes on Nutritional Quality of Meat Proteins'), (118, 149, 'OTHER', 'technological processes of meat'), (349, 359, 'CONDITION', 'sarcopenia')]"
"['Dissemination', 'and', 'Implementation', 'of', 'Family', '-', 'Based', 'Treatment', 'in', 'Publicly', '-', 'Funded', 'Clinics', ':', 'Optimizing', 'Provider', 'Training', 'in', 'Eating', 'Disorders', '(', 'OPTED', ')', '|', 'This', 'is', 'a', 'randomized', 'controlled', 'trial', 'for', 'mental', 'health', 'clinicians', 'comparing', 'two', 'methods', 'of', 'training', 'in', 'family', '-', 'based', 'treatment', '(', 'FBT', ')', 'for', 'restrictive', 'eating', 'disorders', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05389657,NCT05389657,Dissemination and Implementation of Family-Based Treatment in Publicly-Funded Clinics: Optimizing Provider Training in Eating Disorders (OPTED) | This is a randomized controlled trial for mental health clinicians comparing two methods of training in family-based treatment (FBT) for restrictive eating disorders.,"[(36, 58, 'BEHAVIOURAL', 'Family-Based Treatment'), (119, 135, 'CONDITION', 'Eating Disorders'), (250, 272, 'BEHAVIOURAL', 'family-based treatment'), (274, 277, 'BEHAVIOURAL', 'FBT'), (283, 311, 'CONDITION', 'restrictive eating disorders')]"
"['Strengthening', 'Oropharyngeal', 'Muscles', 'as', 'a', 'Novel', 'Approach', 'to', 'Treat', 'Obstructive', 'Sleep', 'Apnea', 'After', 'Stroke', ':', 'A', 'Randomized', 'Feasibility', 'Study', '|', 'This', 'study', 'evaluates', 'the', 'feasibility', 'and', 'effectiveness', 'of', 'an', 'oropharyngeal', 'exercise', '(', 'O', '-', 'PE', ')', 'regimen', 'in', 'treating', 'post', '-', 'stroke', 'obstructive', 'sleep', 'apnea', ',', 'as', 'an', 'alternative', 'therapy', 'to', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', '.', 'Eligible', 'patients', 'will', 'be', 'randomized', '(', '1:1', ')', 'to', 'treatment', 'using', 'a', 'pre', '-', 'specified', 'schedule', 'of', 'O', '-', 'PEs', 'vs.', 'a', 'sham', 'control', 'arm', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O']",NCT04212260,NCT04212260,"Strengthening Oropharyngeal Muscles as a Novel Approach to Treat Obstructive Sleep Apnea After Stroke: A Randomized Feasibility Study | This study evaluates the feasibility and effectiveness of an oropharyngeal exercise (O-PE) regimen in treating post-stroke obstructive sleep apnea, as an alternative therapy to continuous positive airway pressure (CPAP). Eligible patients will be randomized (1:1) to treatment using a pre-specified schedule of O-PEs vs. a sham control arm.","[(0, 35, 'PHYSICAL', 'Strengthening Oropharyngeal Muscles'), (65, 88, 'CONDITION', 'Obstructive Sleep Apnea'), (95, 101, 'CONDITION', 'Stroke'), (197, 219, 'PHYSICAL', 'oropharyngeal exercise'), (221, 225, 'PHYSICAL', 'O-PE'), (247, 258, 'CONDITION', 'post-stroke'), (259, 282, 'CONDITION', 'obstructive sleep apnea'), (313, 348, 'OTHER', 'continuous positive airway pressure'), (350, 354, 'OTHER', 'CPAP'), (447, 452, 'PHYSICAL', 'O-PEs'), (459, 471, 'CONTROL', 'sham control')]"
"['A', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'of', 'Inositol', 'in', 'Trichotillomania', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'effectiveness', 'of', 'inositol', 'for', 'the', 'treatment', 'of', 'compulsive', 'hair', 'pulling', ',', 'also', 'known', 'as', 'trichotillomania', '.', 'Inositol', 'is', 'used', 'for', 'diabetic', 'nerve', 'pain', ',', 'panic', 'disorder', ',', 'high', 'cholesterol', ',', 'insomnia', ',', 'cancer', ',', 'depression', ',', 'schizophrenia', ',', 'Alzheimer', ""'s"", 'disease', ',', 'attention', 'deficit', '-', 'hyperactivity', 'disorder', '(', 'ADHD', ')', ',', 'autism', ',', 'promoting', 'hair', 'growth', ',', 'a', 'skin', 'disorder', 'called', 'psoriasis', ',', 'and', 'treating', 'side', 'effects', 'of', 'medical', 'treatment', 'with', 'some', 'medications', ',', 'including', 'lithium', '.', 'The', 'hypothesis', 'to', 'be', 'tested', 'is', 'that', 'Inositol', 'will', 'be', 'effective', 'and', 'well', 'tolerated', 'in', 'patients', 'with', 'trichotillomania', 'compared', 'to', 'placebo', '.', 'The', 'proposed', 'study', 'will', 'provide', 'needed', 'data', 'on', 'the', 'treatment', 'of', 'the', 'disabling', 'disorder', 'that', 'currently', 'lacks', 'a', 'clearly', 'effective', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01875445,NCT01875445,"A Double-Blind, Placebo-Controlled Study of Inositol in Trichotillomania | The purpose of this study is to evaluate the safety and effectiveness of inositol for the treatment of compulsive hair pulling, also known as trichotillomania. Inositol is used for diabetic nerve pain, panic disorder, high cholesterol, insomnia, cancer, depression, schizophrenia, Alzheimer's disease, attention deficit-hyperactivity disorder (ADHD), autism, promoting hair growth, a skin disorder called psoriasis, and treating side effects of medical treatment with some medications, including lithium. The hypothesis to be tested is that Inositol will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of the disabling disorder that currently lacks a clearly effective treatment.","[(16, 23, 'CONTROL', 'Placebo'), (44, 52, 'DRUG', 'Inositol'), (56, 72, 'CONDITION', 'Trichotillomania'), (148, 156, 'DRUG', 'inositol'), (178, 201, 'CONDITION', 'compulsive hair pulling'), (217, 233, 'CONDITION', 'trichotillomania'), (235, 243, 'DRUG', 'Inositol'), (616, 624, 'DRUG', 'Inositol'), (679, 695, 'CONDITION', 'trichotillomania'), (708, 715, 'CONTROL', 'placebo')]"
"['A', 'Multicentre', ',', 'Multinational', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', 'Study', 'Comparing', 'ACR16', 'Versus', 'Placebo', 'for', 'the', 'Symptomatic', 'Treatment', 'of', 'Huntington', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'ACR16', 'is', 'effective', 'and', 'safe', 'in', 'the', 'symptomatic', 'treatment', 'of', 'Huntington', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00665223,NCT00665223,"A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease | The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.","[(87, 92, 'DRUG', 'ACR16'), (100, 107, 'CONTROL', 'Placebo'), (141, 161, 'CONDITION', ""Huntington's Disease""), (209, 214, 'DRUG', 'ACR16'), (269, 289, 'CONDITION', ""Huntington's disease"")]"
"['The', 'Effect', 'of', 'a', 'Gluten', 'Free', 'Diet', 'on', 'the', 'Permeability', 'of', 'the', 'Blood', 'Brain', 'Barrier', 'in', 'Patients', 'With', 'Clinically', 'Isolated', 'Syndrome', 'Measured', 'by', 'Dynamic', 'Contrast', 'Enhanced', 'Magnetic', 'Resonance', 'Imaging', '|', 'Disruption', 'of', 'the', 'blood', 'brain', 'barrier', '(', 'BBB', ')', 'is', 'associated', 'with', 'inflammatory', 'conditions', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', '.', 'This', 'clinical', 'trial', 'aims', 'to', 'investigate', 'whether', 'following', 'a', 'gluten', '-', 'free', 'diet', '(', 'GFD', ')', 'for', 'six', 'months', 'can', 'contribute', 'to', 'normalizing', 'BBB', 'permeability', 'in', 'patients', 'with', 'newly', 'diagnosed', 'clinically', 'isolated', 'syndrome', '(', 'CIS', ')', 'and', 'multiple', 'sclerosis', '(', 'MS', ')', '.', 'Furthermore', ',', 'the', 'study', 'seeks', 'to', 'identify', 'possible', 'effects', 'of', 'a', 'GFD', 'on', 'markers', 'of', 'systemic', 'as', 'well', 'as', 'CNS', 'inflammation', '.', 'Lastly', ',', 'gut', 'permeability', 'is', 'measured', 'in', 'order', 'to', 'examine', 'whether', 'there', 'are', 'any', 'correlations', 'between', 'the', 'permeability', 'of', 'the', 'gut', 'and', 'the', 'BBB', 'as', 'well', 'as', 'the', 'inflammatory', 'state', 'in', 'the', 'intestine', 'and', 'CNS', '.', 'From', 'a', 'patient', ""'s"", 'view', ',', 'potential', 'positive', 'effects', 'of', 'a', 'GFD', 'will', 'be', 'manifested', 'through', 'an', 'alleviation', 'of', 'symptoms', ',', 'improved', 'quality', 'of', 'life', 'and', 'reduced', 'risk', 'of', 'CIS', 'progressing', 'to', 'MS', '.', 'Evaluating', 'a', 'possible', 'role', 'of', 'gluten', 'in', 'MS', 'pathogenesis', 'can', 'contribute', 'to', 'directing', 'future', 'research', 'and', 'optimizing', 'treatment', 'protocols', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03451955,NCT03451955,"The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging | Disruption of the blood brain barrier (BBB) is associated with inflammatory conditions of the central nervous system (CNS). This clinical trial aims to investigate whether following a gluten-free diet (GFD) for six months can contribute to normalizing BBB permeability in patients with newly diagnosed clinically isolated syndrome (CIS) and multiple sclerosis (MS). Furthermore, the study seeks to identify possible effects of a GFD on markers of systemic as well as CNS inflammation. Lastly, gut permeability is measured in order to examine whether there are any correlations between the permeability of the gut and the BBB as well as the inflammatory state in the intestine and CNS. From a patient's view, potential positive effects of a GFD will be manifested through an alleviation of symptoms, improved quality of life and reduced risk of CIS progressing to MS. Evaluating a possible role of gluten in MS pathogenesis can contribute to directing future research and optimizing treatment protocols.","[(16, 32, 'OTHER', 'Gluten Free Diet'), (97, 125, 'CONDITION', 'Clinically Isolated Syndrome'), (377, 393, 'OTHER', 'gluten-free diet'), (395, 398, 'OTHER', 'GFD'), (479, 523, 'CONDITION', 'newly diagnosed clinically isolated syndrome'), (525, 528, 'CONDITION', 'CIS'), (534, 552, 'CONDITION', 'multiple sclerosis'), (554, 556, 'CONDITION', 'MS'), (622, 625, 'OTHER', 'GFD'), (933, 936, 'OTHER', 'GFD'), (1037, 1040, 'CONDITION', 'CIS'), (1056, 1058, 'CONDITION', 'MS'), (1100, 1102, 'CONDITION', 'MS')]"
"['A', 'Randomized', 'Cross', '-', 'Over', 'Clinical', 'Trial', 'Comparing', 'Two', 'Non', '-', 'Surgical', 'Treatments', 'for', 'Severe', 'Blepharoptosis', '|', 'This', 'clinical', 'trial', 'will', 'evaluate', 'two', 'non', '-', 'surgical', 'devices', 'designed', 'to', 'improve', 'eye', 'lid', 'opening', 'for', 'patients', 'with', 'severe', 'Blepharoptosis', '(', 'incomplete', 'opening', 'of', 'the', 'eyelids', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04678115,NCT04678115,A Randomized Cross-Over Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis | This clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids).,"[(53, 76, 'OTHER', 'Non-Surgical Treatments'), (81, 102, 'CONDITION', 'Severe Blepharoptosis'), (143, 212, 'OTHER', 'non-surgical devices designed to improve eye lid opening for patients'), (218, 239, 'CONDITION', 'severe Blepharoptosis')]"
"['A', 'Comparison', 'of', 'the', 'Incidence', 'of', 'Symptomatic', 'Urinary', 'Tract', 'Infections', 'in', 'Children', 'With', 'Spina', 'Bifida', 'Using', 'Hydrophilic', 'or', 'Non', '-', 'hydrophilic', 'Polyvinyl', 'Chloride', 'Catheters', 'for', 'Clean', 'Intermittent', 'Catheterization', ':', 'a', 'Randomized', 'Cross', 'Over', 'Trial', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'was', 'to', 'determine', 'if', 'using', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'would', 'reduce', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', '(', 'UTI)in', 'children', 'with', 'spina', 'bifida', 'who', 'perform', 'clean', 'intermittent', 'catheterization', 'for', 'bladder', 'management', '.', 'The', 'hypothesis', 'was', 'that', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', 'would', 'be', 'significantly', 'reduced', '(', 'by', '25', '%', ')', 'in', 'users', 'of', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'when', 'compared', 'to', 'users', 'of', 'a', 'reused', 'polyvinyl', 'chloride', '(', 'PVC', ')', 'catheter', '.', 'Subjects', 'were', 'randomly', 'assigned', 'to', 'either', 'starting', 'the', 'study', 'with', 'PVC', 'catheter', 'for', '6', 'months', 'followed', 'by', 'the', 'hydrophilic', 'catheter', 'for', '6', 'months', 'or', 'visa', 'versa', '.', 'Each', 'subject', 'kept', 'a', 'weekly', 'diary', 'recording', 'urinary', 'tract', 'infections', 'symptoms', ',', 'hematuria', 'determined', 'by', 'urine', 'dipstick', ',', 'physician', 'visits', ',', 'days', 'of', 'missed', 'school', 'and', 'other', 'activities', '.', 'At', 'the', 'end', 'of', 'each', '6', 'months', 'subjects', 'completed', 'a', 'questionnaire', 'recording', 'their', 'comfort', 'and', 'satisfaction', 'in', 'using', 'the', 'PVC', 'or', 'hydrophilic', 'coated', 'catheter', '.', '70', 'subjects', 'were', 'randomized', 'and', '46', 'had', 'complete', 'data', '.', 'There', 'were', 'no', 'differences', 'in', 'febrile', 'UTI', ',', 'antibiotic', 'use', ',', 'healthcare', 'visits', 'or', 'school', 'days', 'missed', '.', 'The', 'incidence', 'of', 'self', 'reported', 'UTI', 'was', 'lower', 'in', 'the', 'PVC', 'group', 'than', 'the', 'hydrophilic', 'group', '.', '40', '%', 'of', 'subjects', 'indicated', 'that', 'the', 'hydrophilic', 'coated', 'catheter', 'was', 'slippery', 'and', 'difficult', 'to', 'handle', 'compared', 'to', '10', '%', 'for', 'the', 'PVC', 'catheter', '.', 'However', 'overall', 'satisfaction', 'was', 'no', 'different', 'between', 'products', '.', 'The', 'study', 'results', 'are', 'consistent', 'with', 'the', 'current', 'Cochrane', 'Review', 'that', 'there', 'is', 'a', 'lack', 'of', 'evidence', 'to', 'state', 'that', 'the', 'incidence', 'of', 'UTI', 'is', 'affected', 'by', 'multiuse', 'or', 'hydrophilic', 'catheter', 'use', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT01263392,NCT01263392,"A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial | The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. The hypothesis was that the incidence of symptomatic urinary tract infections would be significantly reduced (by 25%) in users of the SpeediCath hydrophilic catheter when compared to users of a reused polyvinyl chloride (PVC) catheter. Subjects were randomly assigned to either starting the study with PVC catheter for 6 months followed by the hydrophilic catheter for 6 months or visa versa. Each subject kept a weekly diary recording urinary tract infections symptoms, hematuria determined by urine dipstick, physician visits, days of missed school and other activities. At the end of each 6 months subjects completed a questionnaire recording their comfort and satisfaction in using the PVC or hydrophilic coated catheter. 70 subjects were randomized and 46 had complete data. There were no differences in febrile UTI, antibiotic use, healthcare visits or school days missed. The incidence of self reported UTI was lower in the PVC group than the hydrophilic group. 40% of subjects indicated that the hydrophilic coated catheter was slippery and difficult to handle compared to 10% for the PVC catheter. However overall satisfaction was no different between products. The study results are consistent with the current Cochrane Review that there is a lack of evidence to state that the incidence of UTI is affected by multiuse or hydrophilic catheter use.","[(33, 69, 'CONDITION', 'Symptomatic Urinary Tract Infections'), (87, 99, 'CONDITION', 'Spina Bifida'), (106, 165, 'OTHER', 'Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters'), (170, 204, 'CONDITION', 'Clean Intermittent Catheterization'), (298, 329, 'OTHER', 'SpeediCath hydrophilic catheter'), (360, 396, 'CONDITION', 'symptomatic urinary tract infections'), (419, 431, 'CONDITION', 'spina bifida'), (544, 580, 'CONDITION', 'symptomatic urinary tract infections'), (637, 668, 'OTHER', 'SpeediCath hydrophilic catheter'), (704, 737, 'CONTROL', 'polyvinyl chloride (PVC) catheter'), (805, 817, 'CONTROL', 'PVC catheter'), (847, 867, 'OTHER', 'hydrophilic catheter'), (1193, 1227, 'OTHER', 'PVC or hydrophilic coated catheter'), (1320, 1323, 'CONDITION', 'UTI'), (1413, 1416, 'CONDITION', 'UTI'), (1507, 1534, 'OTHER', 'hydrophilic coated catheter'), (1596, 1608, 'CONTROL', 'PVC catheter'), (1804, 1807, 'CONDITION', 'UTI'), (1823, 1859, 'OTHER', 'multiuse or hydrophilic catheter use')]"
"['Safety', 'and', 'Tolerability', 'of', 'Neurostimulation', 'in', 'Early', 'Stage', 'Parkinson', ""'s"", 'Disease', '|', 'Bilateral', 'subthalamic', 'nucleus', 'deep', 'brain', 'stimulation', '(', 'B', '-', 'STN', 'DBS', ')', 'is', 'one', 'of', 'the', 'most', 'effective', 'surgical', 'treatments', 'for', 'PD', 'patients', 'suffering', 'from', 'levodopa', '-', 'induced', 'motor', 'complications', '.', 'The', 'relatively', 'low', 'incidence', 'of', 'permanent', 'adverse', 'effects', 'and', 'the', 'potential', 'for', 'neuroprotection', 'and', 'alteration', 'of', 'the', 'natural', 'course', 'of', 'PD', 'suggest', 'a', 'highly', 'favorable', 'benefit', '-', 'to', '-', 'risk', 'ratio', 'of', 'this', 'procedure', '.', 'Since', 'neuroprotection', 'is', 'best', 'applied', 'early', 'in', 'the', 'disease', 'course', 'when', 'there', 'are', 'more', 'surviving', 'neurons', ',', 'we', 'believe', 'that', 'further', 'investigation', 'of', 'this', 'procedure', 'is', 'warranted', '.', 'The', 'proposed', 'pilot', 'study', 'will', 'provide', 'the', 'necessary', 'data', 'to', 'substantiate', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'procedure', 'as', 'well', 'as', 'provide', 'data', 'for', 'the', 'design', 'of', 'a', 'full', '-', 'scale', ',', 'multicenter', 'trial', 'to', 'investigate', 'the', 'hypothesis', 'that', 'B', '-', 'STN', 'DBS', 'is', 'a', 'safe', 'and', 'effective', 'treatment', 'to', 'slow', 'the', 'progression', 'of', 'PD', '.']","['O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00282152,NCT00282152,"Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease | Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications. The relatively low incidence of permanent adverse effects and the potential for neuroprotection and alteration of the natural course of PD suggest a highly favorable benefit-to-risk ratio of this procedure. Since neuroprotection is best applied early in the disease course when there are more surviving neurons, we believe that further investigation of this procedure is warranted. The proposed pilot study will provide the necessary data to substantiate the safety and tolerability of the procedure as well as provide data for the design of a full-scale, multicenter trial to investigate the hypothesis that B-STN DBS is a safe and effective treatment to slow the progression of PD.","[(27, 43, 'SURGICAL', 'Neurostimulation'), (47, 78, 'CONDITION', ""Early Stage Parkinson's Disease""), (81, 133, 'SURGICAL', 'Bilateral subthalamic nucleus deep brain stimulation'), (135, 144, 'SURGICAL', 'B-STN DBS'), (199, 201, 'CONDITION', 'PD'), (226, 262, 'CONDITION', 'levodopa-induced motor complications'), (400, 402, 'CONDITION', 'PD'), (873, 882, 'SURGICAL', 'B-STN DBS'), (944, 946, 'CONDITION', 'PD')]"
"['Randomized', ',', 'Controlled', ',', 'Open', '-', 'label', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Extracorporeal', 'Photopheresis', '(', 'ECP', ')', 'in', 'the', 'Treatment', 'of', 'Multiple', 'Sclerosis', '|', 'PHOMS', 'Study', 'is', 'a', 'randomized', ',', 'controlled', ',', 'open', '-', 'label', ',', 'prospective', ',', 'and', 'multicentric', 'clinical', 'trial', 'involving', 'outpatients', 'diagnosed', 'with', 'Secondary', 'Progressive', 'Multiple', 'Sclerosis', '(', 'SPMS', ')', 'or', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', '.', 'The', 'primary', 'objective', 'is', 'the', 'safety', 'profile', 'assessment', 'of', 'the', 'investigational', 'intervention', '(', 'Extracorporeal', 'Photopheresis', '-ECP', ')', 'and', 'its', 'preliminary', 'efficacy', 'evaluation', ',', 'while', 'the', 'secondary', 'objective', 'is', 'the', 'assessment', 'of', 'the', 'immune', 'response', 'profile', 'in', 'MS', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT05168384,NCT05168384,"Randomized, Controlled, Open-label Study Evaluating the Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis | PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS). The primary objective is the safety profile assessment of the investigational intervention (Extracorporeal Photopheresis -ECP) and its preliminary efficacy evaluation, while the secondary objective is the assessment of the immune response profile in MS patients.","[(79, 107, 'OTHER', 'Extracorporeal Photopheresis'), (109, 112, 'OTHER', 'ECP'), (134, 152, 'CONDITION', 'Multiple Sclerosis'), (290, 330, 'CONDITION', 'Secondary Progressive Multiple Sclerosis'), (332, 336, 'CONDITION', 'SPMS'), (341, 379, 'CONDITION', 'Relapsing-Remitting Multiple Sclerosis'), (381, 385, 'CONDITION', 'RRMS'), (480, 508, 'OTHER', 'Extracorporeal Photopheresis'), (509, 513, 'OTHER', '-ECP'), (638, 640, 'CONDITION', 'MS')]"
"['Prospective', ',', 'Randomized', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '2', 'Study', 'of', '4', '-', 'aminopyridine', ',', 'Atenolol', ',', 'or', 'Placebo', 'in', 'the', 'Treatment', 'of', 'Patients', 'With', 'Vestibular', 'Migraine', '|', 'This', 'phase', '2', 'randomized', 'study', 'will', 'be', 'used', 'to', 'test', 'the', 'efficacy', 'of', '4', '-', 'aminopyridine', '(', '4AP', ')', 'or', 'atenolol', 'to', 'reduce', 'severity', 'and', 'frequency', 'of', 'vestibular', 'and', 'headache', 'symptoms', 'of', 'vestibular', 'migriane', 'sufferers', '.', 'Blinded', 'study', 'drug', 'will', 'be', 'taken', 'by', 'mouth', 'twice', 'a', 'day', 'for', '14', 'weeks', 'on', 'study', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03578354,NCT03578354,"Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine | This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.","[(25, 32, 'CONTROL', 'Placebo'), (62, 77, 'DRUG', '4-aminopyridine'), (79, 87, 'DRUG', 'Atenolol'), (92, 99, 'CONTROL', 'Placebo'), (134, 153, 'CONDITION', 'Vestibular Migraine'), (223, 238, 'DRUG', '4-aminopyridine'), (240, 243, 'DRUG', '4AP'), (248, 256, 'DRUG', 'atenolol'), (329, 348, 'CONDITION', 'vestibular migriane')]"
"['Neuroprotective', 'Effect', 'of', 'High', 'Dose', 'Erythropoietin', 'in', 'Very', 'Preterm', 'Infants', '|', 'The', 'main', 'goal', 'of', 'this', 'trial', 'is', 'to', 'investigate', 'whether', 'early', 'administration', 'of', 'human', 'erythropoietin', '(', 'EPO', ')', 'in', 'very', 'preterm', 'infants', 'improves', 'neurodevelopmental', 'outcome', 'at', '24', 'months', 'corrected', 'age', '.', '\n\n', 'This', 'study', 'is', 'designed', 'as', 'randomized', ',', 'double', '-', 'masked', ',', 'placebo', 'controlled', 'multicenter', 'study', 'involving', 'at', 'least', '420', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00413946,NCT00413946,"Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants | The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.

This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.","[(36, 50, 'DRUG', 'Erythropoietin'), (59, 66, 'CONDITION', 'Preterm'), (161, 175, 'DRUG', 'erythropoietin'), (177, 180, 'DRUG', 'EPO'), (190, 197, 'CONDITION', 'preterm'), (324, 331, 'CONTROL', 'placebo')]"
"['Fluorescence', '-', 'guided', 'Resection', 'of', 'Malignant', 'Gliomas', 'With', '5', '-', 'Aminolevulinic', 'Acid', '(', '5', '-', 'ALA', ')', 'vs.', 'Conventional', 'Resection', '|', 'The', 'aim', 'of', 'the', 'study', '""', 'Fluorescence', '-', 'guided', 'resection', 'of', 'malignant', 'gliomas', 'with', '5', '-', 'Aminolevulinic', 'acid', '(', '5', '-', 'ALA', ')', 'vs.', 'conventional', 'resection', '""', 'is', 'to', 'determine', 'how', 'accurately', 'contrast', 'agent', '-', 'accumulating', 'tumour', 'can', 'be', 'removed', 'by', 'primary', 'surgery', 'and', 'to', 'assess', 'the', 'clinical', 'usefulness', 'of', 'this', 'method', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00241670,NCT00241670,"Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection | The aim of the study ""Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection"" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.","[(0, 29, 'SURGICAL', 'Fluorescence-guided Resection'), (33, 50, 'CONDITION', 'Malignant Gliomas'), (56, 77, 'DRUG', '5-Aminolevulinic Acid'), (79, 84, 'DRUG', '5-ALA'), (90, 112, 'CONTROL', 'Conventional Resection'), (137, 166, 'SURGICAL', 'Fluorescence-guided resection'), (170, 187, 'CONDITION', 'malignant gliomas'), (193, 214, 'DRUG', '5-Aminolevulinic acid'), (216, 221, 'DRUG', '5-ALA'), (227, 249, 'CONTROL', 'conventional resection'), (310, 316, 'CONDITION', 'tumour')]"
"['Intravenous', 'Saline', 'on', 'Exercise', 'Tolerance', 'in', 'Orthostatic', 'Intolerance', '|', 'The', 'investigators', 'will', 'test', 'whether', 'an', 'intravenous', 'infusion', 'of', 'saline', '(', 'salt', 'water', ')', 'will', 'improve', 'the', 'exercise', 'capacity', 'in', 'patients', 'with', 'postural', 'tachycardia', 'syndrome', '(', 'POTS', ')', '.']","['O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01000350,NCT01000350,Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance | The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).,"[(12, 18, 'DRUG', 'Saline'), (44, 67, 'CONDITION', 'Orthostatic Intolerance'), (133, 139, 'DRUG', 'saline'), (141, 151, 'DRUG', 'salt water'), (205, 234, 'CONDITION', 'postural tachycardia syndrome'), (236, 240, 'CONDITION', 'POTS')]"
"['Identification', 'of', 'Multi', '-', 'modal', 'Bio', '-', 'markers', 'for', 'Early', 'Diagnosis', 'and', 'Treatment', 'Prediction', 'in', 'Schizophrenia', 'Individuals', '|', 'This', 'study', 'aims', 'to', 'screen', 'and', 'validate', 'multi', '-', 'scale', 'bio', '-', 'markers', 'for', 'early', 'diagnosis', 'and', 'medication', 'monitoring', 'for', 'early', 'schizophrenia', ',', 'including', 'the', 'genetic', ',', 'neurobiochemistry', ',', 'neuroimaging', 'and', 'eletrophysiological', 'measures', '.', 'Based', 'on', 'the', 'validated', 'bio', '-', 'markers', ',', 'the', 'present', 'study', 'further', 'tries', 'to', 'build', 'several', 'prediction', 'models', 'for', 'early', 'differential', 'diagnosis', 'of', 'schizophrenia', 'from', 'healthy', 'controls', 'and', 'other', 'mental', 'diseases', '(', 'such', 'as', 'the', 'major', 'depression', 'and', 'anxiety', 'disorders', ')', ',', 'biological', 'sub', '-', 'typing', 'and', 'diagnosis', 'of', 'the', 'schizophrenia', 'sub', '-', 'types', ',', 'and', 'early', 'prediction', 'of', 'the', 'medication', 'effects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03790085,NCT03790085,"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals | This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.","[(90, 103, 'CONDITION', 'Schizophrenia'), (231, 250, 'CONDITION', 'early schizophrenia'), (480, 493, 'CONDITION', 'schizophrenia'), (639, 652, 'CONDITION', 'schizophrenia')]"
"['A', 'Comparison', 'Between', 'Two', 'Different', 'Oral', 'Appliance', 'Therapies', ':', 'Somnodent', 'vs', 'Herbst', 'Appliance', 'in', 'Patients', 'With', 'Mild', 'and', 'Moderate', 'OSA', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'is', 'a', 'common', 'chronic', 'sleep', 'disorder', 'that', 'often', 'requires', 'lifelong', 'care', '.', 'The', 'prevalence', 'in', 'the', 'Netherlands', 'is', 'estimated', 'around', '300.000', 'patients', '.', 'Due', 'to', 'longer', 'life', 'expectancy', 'and', 'increase', 'in', 'weight', 'in', 'the', 'general', 'population', ',', 'its', 'prevalence', 'is', 'expected', 'to', 'rise', '.', 'Patients', 'with', 'mild', 'and', 'moderate', 'OSA', 'are', 'treated', 'primarily', 'with', 'an', 'oral', 'appliance', 'at', 'present', 'time', '.', 'Different', 'oral', 'appliances', 'are', 'available', ',', 'but', 'most', 'used', 'is', 'the', 'mandibular', 'advancement', 'device', '(', 'MAD', ')', '.', 'This', 'study', 'focuses', 'on', 'two', 'different', 'types', 'of', 'MAD', ':', 'the', 'classic', 'Herbst', 'appliance', ',', 'which', 'is', 'attached', 'to', 'the', 'mandible', 'and', 'the', 'maxilla', 'and', 'has', 'an', 'iron', 'bar', 'to', 'regulate', 'the', 'open', 'space', ';', 'and', 'the', 'Somnodent', ',', 'which', 'consists', 'of', 'two', 'separate', 'splints', ',', 'fixed', 'on', 'the', 'mandible', 'and', 'the', 'maxilla', ',', 'but', 'has', 'no', 'iron', 'bar', 'attached', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02724865,NCT02724865,"A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA | Obstructive sleep apnea (OSA) is a common chronic sleep disorder that often requires lifelong care. The prevalence in the Netherlands is estimated around 300.000 patients. Due to longer life expectancy and increase in weight in the general population, its prevalence is expected to rise. Patients with mild and moderate OSA are treated primarily with an oral appliance at present time. Different oral appliances are available, but most used is the mandibular advancement device (MAD). This study focuses on two different types of MAD: the classic Herbst appliance, which is attached to the mandible and the maxilla and has an iron bar to regulate the open space; and the Somnodent, which consists of two separate splints, fixed on the mandible and the maxilla, but has no iron bar attached.","[(35, 59, 'OTHER', 'Oral Appliance Therapies'), (61, 70, 'OTHER', 'Somnodent'), (74, 90, 'OTHER', 'Herbst Appliance'), (108, 129, 'CONDITION', 'Mild and Moderate OSA'), (132, 155, 'CONDITION', 'Obstructive sleep apnea'), (157, 160, 'CONDITION', 'OSA'), (434, 455, 'CONDITION', 'mild and moderate OSA'), (486, 500, 'OTHER', 'oral appliance'), (528, 543, 'OTHER', 'oral appliances'), (580, 609, 'OTHER', 'mandibular advancement device'), (611, 614, 'OTHER', 'MAD'), (662, 665, 'OTHER', 'MAD'), (679, 695, 'OTHER', 'Herbst appliance'), (803, 812, 'OTHER', 'Somnodent')]"
"['A', 'Phase', '2', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Cross', '-', 'Over', 'Study', 'Of', 'The', 'Safety', 'And', 'Efficacy', 'Of', 'PF-03654746', 'In', 'Adults', 'With', 'Tourette', ""'s"", 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'an', 'investigational', 'compound', 'designated', 'PF-03654746', 'compared', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'adults', 'with', 'Tourette', ""'s"", 'Syndrome', '.', 'The', 'study', 'will', 'also', 'explore', 'the', 'pharmacokinetics', 'of', 'PF-03654746', 'in', 'adults', 'with', 'Tourette', ""'s"", 'Syndrome', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01475383,NCT01475383,"A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome | The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome. The study will also explore the pharmacokinetics of PF-03654746 in adults with Tourette's Syndrome.","[(49, 56, 'CONTROL', 'Placebo'), (116, 127, 'DRUG', 'PF-03654746'), (143, 162, 'CONDITION', ""Tourette's Syndrome""), (272, 283, 'DRUG', 'PF-03654746'), (296, 303, 'CONTROL', 'placebo'), (336, 355, 'CONDITION', ""Tourette's Syndrome""), (409, 420, 'DRUG', 'PF-03654746'), (436, 455, 'CONDITION', ""Tourette's Syndrome"")]"
"['Efficacy', 'of', 'Ultrasound', 'Versus', 'Short', 'Wave', 'Diathermy', 'in', 'the', 'Treatment', 'of', 'Lumbar', 'Disc', 'Herniation', ':', 'a', 'Randomised', 'Control', 'Study', '|', 'Chronic', 'low', 'back', 'pain', 'is', 'a', 'common', 'problem', 'which', 'results', 'in', 'reduced', 'functionality', ',', 'quality', 'of', 'life', 'and', 'general', 'well', 'being', '.', 'Conservative', 'treatment', 'includes', 'patient', 'education', ',', 'exercise', ',', 'maintaining', 'a', 'healthy', 'body', 'mass', 'index', 'and', 'appropriate', 'modifications', 'to', 'activities', 'of', 'daily', 'living', '.', 'Physical', 'modalities', 'are', 'used', 'to', 'support', 'the', 'mainstay', 'of', 'treatment', 'and', 'include', 'superficial', 'heat', ',', 'transcutaneous', 'electrical', 'nerve', 'stimulation', '(', 'TENS', ')', ',', 'ultrasound', ',', 'short', 'wave', 'diathermy', ',', 'traction', ',', 'and', 'complimentary', 'therapies', '.', '\n\n', 'In', 'the', 'clinical', 'practice', 'of', 'the', 'investigators', ',', 'diathermy', ',', 'in', 'the', 'form', 'of', 'ultrasound', 'and', 'short', 'wave', ',', 'is', 'used', 'to', 'heat', 'deeper', 'tissues', ',', 'increase', 'tissue', 'elasticity', 'and', 'metabolic', 'rate', 'and', 'reduce', 'pain', 'and', 'muscle', 'spasm', '.', 'The', 'medical', 'literature', 'to', 'date', 'states', 'that', 'further', 'studies', 'are', 'required', 'to', 'compare', 'the', 'efficacy', 'of', 'different', 'diathermy', 'modalities', 'in', 'the', 'treatment', 'of', 'lower', 'back', 'pain', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'ultrasound', 'to', 'that', 'of', 'short', 'wave', 'diathermy', 'and', 'a', 'treatment', 'program', 'which', 'does', 'not', 'include', 'diathermy', 'in', 'the', 'treatment', 'of', 'a', 'slipped', 'disc', '.']","['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT03835182,NCT03835182,"Efficacy of Ultrasound Versus Short Wave Diathermy in the Treatment of Lumbar Disc Herniation: a Randomised Control Study | Chronic low back pain is a common problem which results in reduced functionality, quality of life and general well being. Conservative treatment includes patient education, exercise, maintaining a healthy body mass index and appropriate modifications to activities of daily living. Physical modalities are used to support the mainstay of treatment and include superficial heat, transcutaneous electrical nerve stimulation (TENS), ultrasound, short wave diathermy , traction, and complimentary therapies.

In the clinical practice of the investigators, diathermy, in the form of ultrasound and short wave, is used to heat deeper tissues, increase tissue elasticity and metabolic rate and reduce pain and muscle spasm. The medical literature to date states that further studies are required to compare the efficacy of different diathermy modalities in the treatment of lower back pain.

The aim of this study was to compare the efficacy of ultrasound to that of short wave diathermy and a treatment program which does not include diathermy in the treatment of a slipped disc.","[(12, 22, 'OTHER', 'Ultrasound'), (30, 50, 'OTHER', 'Short Wave Diathermy'), (71, 93, 'CONDITION', 'Lumbar Disc Herniation'), (124, 145, 'CONDITION', 'Chronic low back pain'), (554, 564, 'OTHER', 'ultrasound'), (566, 586, 'OTHER', 'short wave diathermy'), (676, 685, 'OTHER', 'diathermy'), (702, 712, 'OTHER', 'ultrasound'), (717, 727, 'OTHER', 'short wave'), (950, 959, 'OTHER', 'diathermy'), (991, 1006, 'CONDITION', 'lower back pain'), (1062, 1072, 'OTHER', 'ultrasound'), (1084, 1104, 'OTHER', 'short wave diathermy'), (1111, 1161, 'CONTROL', 'treatment program which does not include diathermy'), (1184, 1196, 'CONDITION', 'slipped disc')]"
"['Pazopanib', 'Neoadjuvant', 'Trial', 'in', 'Non', '-', 'Rhabdomyosarcoma', 'Soft', 'Tissue', 'Sarcomas', '(', 'PAZNTIS', '):', 'A', 'Phase', 'II', '/', 'III', 'Randomized', 'Trial', 'of', 'Preoperative', 'Chemoradiation', 'or', 'Preoperative', 'Radiation', 'Plus', 'or', 'Minus', 'Pazopanib', '(', 'NSC', '#', '737754', ')', '|', 'This', 'randomized', 'phase', 'II', '/', 'III', 'trial', 'studies', 'how', 'well', 'pazopanib', ',', 'when', 'combined', 'with', 'chemotherapy', 'and', 'radiation', 'therapy', 'or', 'radiation', 'therapy', 'alone', ',', 'work', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'newly', 'diagnosed', 'non', '-', 'rhabdomyosarcoma', 'soft', 'tissue', 'sarcomas', 'that', 'can', 'eventually', 'be', 'removed', 'by', 'surgery', '.', 'Radiation', 'therapy', 'uses', 'high', 'energy', 'x', '-', 'rays', 'to', 'kill', 'tumor', 'cells', '.', 'Drugs', 'used', 'in', 'chemotherapy', ',', 'such', 'as', 'ifosfamide', 'and', 'doxorubicin', ',', 'work', 'in', 'different', 'ways', 'to', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', ',', 'either', 'by', 'killing', 'the', 'cells', ',', 'by', 'stopping', 'them', 'from', 'dividing', ',', 'or', 'by', 'stopping', 'them', 'from', 'spreading', '.', 'Pazopanib', 'may', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', 'by', 'blocking', 'some', 'of', 'the', 'enzymes', 'needed', 'for', 'cell', 'growth', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'these', 'therapies', 'can', 'be', 'safely', 'combined', 'and', 'if', 'they', 'work', 'better', 'when', 'given', 'together', 'in', 'treating', 'patients', 'with', 'non', '-', 'rhabdomyosarcoma', 'soft', 'tissue', 'sarcomas', '.']","['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT02180867,NCT02180867,"Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) | This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether these therapies can be safely combined and if they work better when given together in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.","[(0, 9, 'DRUG', 'Pazopanib'), (31, 72, 'CONDITION', 'Non-Rhabdomyosarcoma Soft Tissue Sarcomas'), (132, 146, 'OTHER', 'Chemoradiation'), (163, 172, 'RADIOTHERAPY', 'Radiation'), (187, 196, 'DRUG', 'Pazopanib'), (198, 209, 'DRUG', 'NSC# 737754'), (265, 274, 'DRUG', 'pazopanib'), (295, 307, 'OTHER', 'chemotherapy'), (312, 329, 'RADIOTHERAPY', 'radiation therapy'), (333, 356, 'CONTROL', 'radiation therapy alone'), (413, 454, 'CONDITION', 'non-rhabdomyosarcoma soft tissue sarcomas'), (498, 515, 'RADIOTHERAPY', 'Radiation therapy'), (548, 553, 'CONDITION', 'tumor'), (670, 675, 'CONDITION', 'tumor'), (780, 789, 'DRUG', 'Pazopanib'), (813, 818, 'CONDITION', 'tumor'), (1018, 1059, 'CONDITION', 'non-rhabdomyosarcoma soft tissue sarcomas')]"
"['Randomized', ',', 'Double', '-', 'blind', ',', 'Comparative', '-', 'effectiveness', 'Study', 'Comparing', 'Epidural', 'Steroid', 'Injections', 'to', 'Gabapentin', 'in', 'Patients', 'With', 'Lumbosacral', 'Radiculopathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'pharmacotherapy', 'or', 'epidural', 'steroid', 'injections', 'are', 'a', 'better', 'treatment', 'for', 'lumbosacral', 'radicular', 'pain', '.', '\n\n', '142', 'patients', 'referred', 'to', 'a', 'participating', 'pain', 'clinic', 'with', 'lumbosacral', 'radiculopathy', 'will', 'be', 'randomized', 'in', 'a', '1:1', 'ratio', 'to', 'receive', 'one', 'of', 'two', 'treatments', '.', 'Half', '(', 'n=71', ')', 'of', 'the', 'patients', 'will', 'be', 'allocated', 'to', 'receive', 'an', 'epidural', 'steroid', 'injection', '(', 'ESI', ';', 'group', 'I', ')', ',', 'with', 'an', 'equal', 'number', 'allocated', 'to', 'receive', 'gabapentin', '(', 'group', 'II', ')', '.', 'Patients', '&', 'evaluating', 'physicians', 'will', 'be', 'blinded', '.', 'Follow', '-', 'up', 'will', 'be', 'through', '3', '-', 'months', 'after', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01495923,NCT01495923,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy | The purpose of this study is to determine whether pharmacotherapy or epidural steroid injections are a better treatment for lumbosacral radicular pain.

142 patients referred to a participating pain clinic with lumbosacral radiculopathy will be randomized in a 1:1 ratio to receive one of two treatments. Half (n=71) of the patients will be allocated to receive an epidural steroid injection (ESI; group I), with an equal number allocated to receive gabapentin (group II). Patients & evaluating physicians will be blinded. Follow-up will be through 3-months after treatment.","[(77, 84, 'DRUG', 'Steroid'), (99, 109, 'DRUG', 'Gabapentin'), (127, 152, 'CONDITION', 'Lumbosacral Radiculopathy'), (233, 240, 'DRUG', 'steroid'), (279, 305, 'CONDITION', 'lumbosacral radicular pain'), (366, 391, 'CONDITION', 'lumbosacral radiculopathy'), (529, 536, 'DRUG', 'steroid'), (605, 615, 'DRUG', 'gabapentin')]"
"['Effect', 'and', 'Outcome', 'Predictors', 'on', 'Functional', 'Recovery', 'After', 'Comprehensive', 'Rehabilitation', 'for', 'Post', '-', 'acute', 'Care', '-Cerebrovascular', 'Diseases', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'and', 'outcome', 'predictors', 'on', 'functional', 'recovery', 'after', 'comprehensive', 'rehabilitation', 'for', 'post', '-', 'acute', 'care', '-cerebrovascular', 'diseases', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02311036,NCT02311036,Effect and Outcome Predictors on Functional Recovery After Comprehensive Rehabilitation for Post-acute Care -Cerebrovascular Diseases | The purpose of the study is to investigate the effects and outcome predictors on functional recovery after comprehensive rehabilitation for post-acute care -cerebrovascular diseases.,"[(59, 87, 'PHYSICAL', 'Comprehensive Rehabilitation'), (108, 133, 'CONDITION', '-Cerebrovascular Diseases'), (243, 271, 'PHYSICAL', 'comprehensive rehabilitation'), (292, 317, 'CONDITION', '-cerebrovascular diseases')]"
"['The', 'RETORNUS', 'Study', ':', 'Dual', 'Training', 'to', 'Restore', 'the', 'Function', 'of', 'Respiratory', 'Muscles', 'in', 'Stroke', 'Patients', '|', 'This', 'study', 'is', 'divided', 'for', 'development', 'in', 'two', 'complementary', 'work', 'packages', 'justified', 'by', 'the', 'need', 'to', 'incorporate', 'new', 'strategies', 'to', 'optimize', 'rehabilitation', 'outcomes', 'in', 'stroke', 'patients', '.', 'The', 'general', 'objectives', 'are', ':', '1', ')', 'to', 'determine', 'the', 'prevalence', 'of', 'respiratory', 'muscle', 'dysfunction', 'in', 'stroke', 'patients', ';', '2', ')', 'to', 'identify', 'the', 'existence', 'of', 'a', 'potential', 'amino', 'acid', 'marker', 'of', 'increased', 'risk', 'of', 'muscle', 'dysfunction', 'after', 'suffering', 'a', 'stroke', ';', '3', ')', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'incorporating', 'the', 'respiratory', 'muscle', 'training', 'as', 'an', 'innovative', 'adjuvant', 'therapy', 'in', 'stroke', 'rehabilitation', 'program', 'that', 'may', 'decrease', 'the', 'incidence', 'of', 'morbidity', 'and', 'mortality', 'in', 'the', 'medium', 'and', 'long', 'term', ';', 'and', '4', ')', 'to', 'quantify', 'the', 'potential', 'impact', 'of', 'respiratory', 'muscle', 'training', 'on', 'the', 'costs', 'of', 'care', 'for', 'stroke', 'patients', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02125760,NCT02125760,The RETORNUS Study: Dual Training to Restore the Function of Respiratory Muscles in Stroke Patients | This study is divided for development in two complementary work packages justified by the need to incorporate new strategies to optimize rehabilitation outcomes in stroke patients. The general objectives are: 1) to determine the prevalence of respiratory muscle dysfunction in stroke patients; 2) to identify the existence of a potential amino acid marker of increased risk of muscle dysfunction after suffering a stroke; 3) to evaluate the effectiveness of incorporating the respiratory muscle training as an innovative adjuvant therapy in stroke rehabilitation program that may decrease the incidence of morbidity and mortality in the medium and long term; and 4) to quantify the potential impact of respiratory muscle training on the costs of care for stroke patients.,"[(20, 33, 'PHYSICAL', 'Dual Training'), (84, 90, 'CONDITION', 'Stroke'), (266, 272, 'CONDITION', 'stroke'), (379, 385, 'CONDITION', 'stroke'), (516, 522, 'CONDITION', 'stroke'), (578, 605, 'PHYSICAL', 'respiratory muscle training'), (643, 649, 'CONDITION', 'stroke'), (804, 831, 'PHYSICAL', 'respiratory muscle training'), (857, 863, 'CONDITION', 'stroke')]"
"['A', 'Prospective', ',', 'Multi', '-', 'Center', ',', 'Double', '-', 'Blinded', ',', 'Placebo', '-', 'Controlled', 'Trial', 'to', 'Evaluate', 'the', 'Effectiveness', 'of', 'Patent', 'Foramen', 'Ovale', 'Closure', 'With', 'the', 'BioSTAR', 'Septal', 'Repair', 'Implant', 'to', 'Reduce', 'Refractory', 'Migraine', 'Headache', 'With', 'Aura', '.', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'safety', 'and', 'effectiveness', 'of', 'PFO', 'closure', 'with', 'the', 'BioSTAR', 'Septal', 'Repair', 'Implant', 'System', 'in', 'a', 'population', 'of', 'patients', 'that', 'have', 'refractory', 'migraine', '(', 'with', 'aura', ')', 'and', 'who', 'have', 'failed', 'medications', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00283738,NCT00283738,"A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura. | The objective of the study is to investigate the safety and effectiveness of PFO closure with the BioSTAR Septal Repair Implant System in a population of patients that have refractory migraine (with aura) and who have failed medications.","[(45, 52, 'CONTROL', 'Placebo'), (103, 131, 'SURGICAL', 'Patent Foramen Ovale Closure'), (141, 170, 'SURGICAL', 'BioSTAR Septal Repair Implant'), (181, 219, 'CONDITION', 'Refractory Migraine Headache With Aura'), (300, 311, 'SURGICAL', 'PFO closure'), (321, 350, 'SURGICAL', 'BioSTAR Septal Repair Implant'), (396, 415, 'CONDITION', 'refractory migraine'), (422, 426, 'CONDITION', 'aura')]"
"['A', 'Single', 'Arm', ',', 'Monocenter', 'Phase', 'II', 'Trial', 'of', 'RAD001', 'as', 'Monotherapy', 'in', 'the', 'Treatment', 'of', 'Neurofibromatosis', 'Type', '2', '-', 'Related', 'Vestibular', 'Schwannoma', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'if', 'RAD001', 'treatment', 'will', 'shrink', 'or', 'slow', 'the', 'growth', 'of', 'the', 'vestibular', 'schwannoma(s', ')', 'in', 'Neurofibromatosis', '2', '(', 'NF2', ')', 'patients', '.', 'Secondary', 'objectives', 'include', 'determining', 'if', 'RAD001', 'treatment', 'will', 'improve', 'hearing', 'ability', 'in', 'NF2', 'patients', '.', '\n\n', 'RAD001', 'is', 'an', 'oral', 'drug', 'that', 'is', 'approved', 'by', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'for', 'other', 'types', 'of', 'tumors', ',', 'it', 'is', 'not', 'approved', 'by', 'the', 'FDA', 'for', 'treatment', 'of', 'NF2', 'related', 'tumors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",NCT01345136,NCT01345136,"A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma | The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.

RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.","[(43, 49, 'DRUG', 'RAD001'), (85, 109, 'CONDITION', 'Neurofibromatosis Type 2'), (120, 141, 'CONDITION', 'Vestibular Schwannoma'), (188, 194, 'DRUG', 'RAD001'), (243, 267, 'CONDITION', 'vestibular schwannoma(s)'), (271, 290, 'CONDITION', 'Neurofibromatosis 2'), (292, 295, 'CONDITION', 'NF2'), (351, 357, 'DRUG', 'RAD001'), (400, 403, 'CONDITION', 'NF2'), (415, 421, 'DRUG', 'RAD001'), (512, 518, 'CONDITION', 'tumors'), (567, 570, 'CONDITION', 'NF2'), (579, 585, 'CONDITION', 'tumors')]"
"['A', 'Telehealth', 'Education', 'Program', 'for', 'Caregivers', 'of', 'Veterans', 'With', 'Dementia', '|', 'This', 'study', 'was', 'designed', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'Telehealth', 'Education', 'Program', '(', 'TEP', ')', 'on', 'outpatient', 'veterans', 'with', 'moderate', 'to', 'severe', 'dementia', 'and', 'their', 'spouse', 'caregivers', '.', 'The', 'TEP', 'is', 'a', 'program', 'of', 'education', ',', 'coping', 'skills', ',', 'problem', 'solving', 'and', 'support', 'presented', 'to', 'caregivers', 'of', 'veterans', 'with', 'dementia', 'by', 'teleconference', 'in', '10', 'weekly', ',', 'one', '-', 'hour', 'sessions', '.', 'The', 'TEP', 'was', 'based', 'on', 'a', 'stress', 'and', 'coping', 'model', 'aimed', 'to', 'enhance', 'the', 'knowledge', ',', 'skills', 'and', 'feelings', 'of', 'support', 'of', 'the', 'caregivers', 'who', 'participated', '.']","['O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00105638,NCT00105638,"A Telehealth Education Program for Caregivers of Veterans With Dementia | This study was designed to evaluate the impact of a Telehealth Education Program (TEP) on outpatient veterans with moderate to severe dementia and their spouse caregivers. The TEP is a program of education, coping skills, problem solving and support presented to caregivers of veterans with dementia by teleconference in 10 weekly, one-hour sessions. The TEP was based on a stress and coping model aimed to enhance the knowledge, skills and feelings of support of the caregivers who participated.","[(2, 30, 'BEHAVIOURAL', 'Telehealth Education Program'), (63, 71, 'CONDITION', 'Dementia'), (126, 154, 'BEHAVIOURAL', 'Telehealth Education Program'), (156, 159, 'BEHAVIOURAL', 'TEP'), (189, 216, 'CONDITION', 'moderate to severe dementia'), (250, 253, 'BEHAVIOURAL', 'TEP'), (365, 373, 'CONDITION', 'dementia'), (377, 391, 'BEHAVIOURAL', 'teleconference'), (429, 432, 'BEHAVIOURAL', 'TEP')]"
"['A', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Orexigenic', 'Therapy', 'With', 'Delta-9', '-', 'tetrahydrocannabinol', 'in', 'Advanced', 'Cancer', 'Patients', 'With', 'Chemosensory', 'Abnormalities', '-', 'a', 'Pilot', 'Study', '|', 'To', 'investigate', 'delta-9', '-', 'tetrahydrocannabinol', ""'s"", '(', 'THC', ')', 'ability', 'to', 'increase', 'food', 'intake', 'and', 'improve', 'food', 'enjoyment', 'for', 'advanced', 'cancer', 'patients', 'with', 'taste', 'and/or', 'smell', '(', 'chemosensory', ')', 'abnormalities', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00316563,NCT00316563,"A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study | To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.","[(28, 35, 'CONTROL', 'Placebo'), (90, 108, 'OTHER', 'Orexigenic Therapy'), (114, 142, 'DRUG', 'Delta-9-tetrahydrocannabinol'), (146, 161, 'CONDITION', 'Advanced Cancer'), (176, 202, 'CONDITION', 'Chemosensory Abnormalities'), (236, 264, 'DRUG', 'delta-9-tetrahydrocannabinol'), (268, 271, 'DRUG', 'THC'), (336, 351, 'CONDITION', 'advanced cancer'), (366, 413, 'CONDITION', 'taste and/or smell (chemosensory) abnormalities')]"
"['Investigation', 'of', 'the', 'NMDA', 'Receptor', 'System', 'in', 'Man', 'as', 'a', 'Potential', 'Surrogate', 'Marker', 'for', 'Deficit', 'Syndrome', 'in', 'Schizophrenia', ':', 'a', '[', '123]I', '-', 'CNS', '1261', 'Single', 'Photon', 'Emission', 'Tomography', '(', 'SPET', ')', 'Study', '|', 'This', 'study', 'was', 'designed', 'to', 'compare', 'the', '[', '123]I', '-', 'CNS', '1261', 'binding', 'to', 'NMDA', 'receptor', 'between', 'healthy', 'volunteers', 'and', 'different', 'subgroups', 'of', 'schizophrenic', 'patients', '.', 'Investigation', 'of', 'the', 'potential', 'influence', 'of', 'antipsychotic', 'and', 'concomitant', 'medication', 'on', '[', '123I', ']', 'CNS', '1261', 'binding', 'is', 'also', 'relevant', '.', 'Fifteen', 'healthy', 'subjects', '(', 'male', 'and', 'female', 'of', 'non', '-', 'child', 'bearing', 'potential', ')', 'will', 'be', 'recruited', 'and', '40', 'schizophrenic', 'patients', 'divided', 'in', '3', 'subgroups', 'as', 'indicated', 'before', ':', 'Subgroup', 'a', ')', 'treatment', '-', 'naive', ',', '(', 'n=10', ')', ';', 'Subgroup', 'b', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', '(', 'without', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15);Subgroup', 'c', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', 'fitting', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00364429,NCT00364429,"Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study | This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on [123I] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).","[(85, 101, 'CONDITION', 'Deficit Syndrome'), (105, 118, 'CONDITION', 'Schizophrenia'), (321, 334, 'CONDITION', 'schizophrenic'), (389, 402, 'DRUG', 'antipsychotic'), (573, 586, 'CONDITION', 'schizophrenic'), (714, 725, 'DRUG', 'risperidone'), (747, 763, 'CONDITION', 'deficit syndrome'), (826, 837, 'DRUG', 'risperidone'), (858, 874, 'CONDITION', 'deficit syndrome')]"
"['Cholinergic', 'Neurotransmission', '-', 'A', 'Common', 'Underlying', 'Mechanism', 'of', 'Cognitive', 'and', 'Gait', 'Impairment', 'in', 'Parkinson', 'Disease', '|', 'This', 'is', 'a', 'single', '-', 'site', 'non', '-', 'randomized', 'open', 'label', 'pilot', 'study', '.', 'The', 'investigators', 'will', 'use', 'accelerometer', '-', 'based', 'instrumented', 'gait', 'analysis', 'and', 'computerized', 'cognitive', 'testing', 'to', 'study', 'the', 'interaction', 'of', 'motor', 'and', 'cognitive', 'dysfunction', 'in', 'Parkinson', 'disease', 'dementia', '(', 'PDD', ')', ',', 'and', 'the', 'effect', 'of', 'rivastigmine', 'on', 'motor', 'and', 'cognitive', 'performance', '.', 'All', 'study', 'participants', 'will', 'be', 'tested', 'for', 'motor', 'and', 'cognitive', 'performance', 'at', 'baseline', '(', 'arm', '1', ')', '.', 'A', 'subgroup', 'of', 'study', 'participants', 'will', 'then', 'be', 'treated', 'with', 'rivastigmine', 'for', '12', 'weeks', '(', 'arm', '2', ')', ',', 'and', 'the', 'effect', 'of', 'this', 'treatment', 'on', 'gait', 'measures', 'and', 'cognitive', 'measures', 'will', 'be', 'analyzed', 'at', 'the', 'follow', '-', 'up', 'visit', '12', 'weeks', 'after', 'the', 'baseline', 'visit', '.', 'Specifically', ',', 'we', 'will', 'determine', 'which', 'components', 'of', 'motor', 'and', 'cognitive', 'impairment', 'are', 'associated', 'with', 'each', 'other', ',', 'and', 'which', 'components', 'of', 'the', 'two', 'domains', 'respond', 'to', 'rivastigmine', '-', 'mediated', 'stimulation', 'of', 'cholinergic', 'neurotransmission', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03840837,NCT03840837,"Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease | This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and the effect of rivastigmine on motor and cognitive performance. All study participants will be tested for motor and cognitive performance at baseline (arm 1). A subgroup of study participants will then be treated with rivastigmine for 12 weeks (arm 2), and the effect of this treatment on gait measures and cognitive measures will be analyzed at the follow-up visit 12 weeks after the baseline visit. Specifically, we will determine which components of motor and cognitive impairment are associated with each other, and which components of the two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.","[(65, 94, 'CONDITION', 'Cognitive and Gait Impairment'), (98, 115, 'CONDITION', 'Parkinson Disease'), (316, 347, 'CONDITION', 'motor and cognitive dysfunction'), (351, 377, 'CONDITION', 'Parkinson disease dementia'), (379, 382, 'CONDITION', 'PDD'), (403, 415, 'DRUG', 'rivastigmine'), (606, 618, 'DRUG', 'rivastigmine'), (841, 871, 'CONDITION', 'motor and cognitive impairment'), (955, 967, 'DRUG', 'rivastigmine')]"
"['A', 'Controlled', 'Trial', 'of', 'Sertraline', 'in', 'Young', 'Children', 'With', 'Fragile', 'X', 'Syndrome', '|', 'This', 'study', 'is', 'a', 'control', 'trial', 'of', 'sertraline', '(', 'Zoloft', ')', 'in', 'fragile', 'X', 'syndrome', 'children', 'aged', '2', 'years', 'to', '5', 'years', '8', 'months', 'old', '.', 'The', 'trial', 'is', 'six', 'months', 'long', ',', 'and', 'each', 'participant', 'will', 'receive', 'a', 'series', 'of', 'tests', 'at', 'both', 'the', 'beginning', 'and', 'end', 'of', 'the', 'study', '.', 'The', 'researchers', 'hope', 'to', 'show', 'improvements', 'in', 'language', 'and', 'a', 'decrease', 'in', 'autistic', 'symptoms', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01474746,NCT01474746,"A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome | This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and a decrease in autistic symptoms.","[(22, 32, 'DRUG', 'Sertraline'), (56, 74, 'CONDITION', 'Fragile X Syndrome'), (110, 120, 'DRUG', 'sertraline'), (122, 128, 'DRUG', 'Zoloft'), (133, 151, 'CONDITION', 'fragile X syndrome'), (397, 405, 'CONDITION', 'autistic')]"
"['Phase', 'I', ',', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Parallel', 'Study', 'to', 'Evaluate', 'the', 'Pharmacokinetics', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'One', 'Intramuscular', 'Injection', 'of', 'Risperidone', 'ISM', '®', 'at', 'Different', 'Dose', 'Strengths', 'in', 'Subjects', 'With', 'Schizophrenia', 'or', 'Schizoaffective', 'Disorder', '|', 'This', 'clinical', 'trial', 'is', 'designed', 'to', 'evaluate', 'different', 'dosages', 'of', 'risperidone', 'ISM', ',', 'a', 'new', 'long', '-', 'acting', 'injectable', 'form', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01788774,NCT01788774,"Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder | This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.","[(141, 152, 'DRUG', 'Risperidone'), (203, 216, 'CONDITION', 'Schizophrenia'), (220, 244, 'CONDITION', 'Schizoaffective Disorder'), (312, 323, 'DRUG', 'risperidone')]"
"['Treatment', 'of', 'Tinnitus', 'With', 'Noninvasive', 'Neuromodulation', 'and', 'Listening', 'Therapy', ':', 'A', 'Double', '-', 'blind', ',', 'Sham', '-', 'controlled', ',', 'Crossover', 'Study', '|', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'use', 'non', '-', 'invasive', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'combined', 'with', 'active', 'listening', 'therapy', 'to', 'treat', 'tinnitus', 'and', 'hyperacusis', 'and', 'related', 'conditions', '.']","['O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT04934371,NCT04934371,"Treatment of Tinnitus With Noninvasive Neuromodulation and Listening Therapy: A Double-blind, Sham-controlled, Crossover Study | The goal of this study is to use non-invasive transcranial direct current stimulation (tDCS) combined with active listening therapy to treat tinnitus and hyperacusis and related conditions.","[(13, 21, 'CONDITION', 'Tinnitus'), (27, 54, 'OTHER', 'Noninvasive Neuromodulation'), (59, 76, 'OTHER', 'Listening Therapy'), (94, 98, 'CONTROL', 'Sham'), (162, 214, 'OTHER', 'non-invasive transcranial direct current stimulation'), (216, 220, 'OTHER', 'tDCS'), (236, 260, 'OTHER', 'active listening therapy'), (270, 278, 'CONDITION', 'tinnitus'), (283, 294, 'CONDITION', 'hyperacusis')]"
"['Basic', 'Research', 'on', 'Carbon', 'Monoxide', ""'s"", 'Headache', 'Inducing', 'Characteristics', 'and', 'Effects', 'on', 'the', 'Cerebral', 'Arteries', 'and', 'Blood', 'Flow', 'in', 'a', 'Humane', 'Experimental', 'Headache', 'Model', '|', 'In', 'this', 'study', 'the', 'investigators', 'will', 'research', 'the', 'hypothesis', 'that', 'the', 'gas', 'carbon', 'monoxide', 'induces', 'headache', 'and', 'increases', 'the', 'blood', 'flow', 'velocity', 'in', 'the', 'middle', 'cerebral', 'artery', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02066558,NCT02066558,Basic Research on Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model | In this study the investigators will research the hypothesis that the gas carbon monoxide induces headache and increases the blood flow velocity in the middle cerebral artery.,"[(18, 44, 'CONDITION', ""Carbon Monoxide's Headache""), (147, 155, 'CONDITION', 'Headache'), (262, 270, 'CONDITION', 'headache')]"
"['Ovarian', 'Hormones', ',', 'Reward', 'Response', ',', 'and', 'Binge', 'Eating', 'in', 'Bulimia', 'Nervosa', ':', 'An', 'Experimental', 'Design', '|', 'This', 'pilot', 'study', 'experimentally', 'manipulates', 'ovarian', 'hormones', 'to', 'examine', 'the', 'direct', 'impact', 'of', 'estrogen', '(', 'E2', ')', 'and', 'progesterone', '(', 'P4', ')', 'on', 'binge', 'eating', 'symptom', 'burden', 'and', 'the', 'behavioral', 'reward', 'response', 'in', 'women', 'with', 'bulimia', 'nervosa', '(', 'n=15', ')', '.', 'This', 'is', 'completed', 'by', 'taking', 'medications', 'that', 'change', 'ovarian', 'hormone', 'levels', '.', 'This', 'line', 'of', 'research', 'could', 'lead', 'to', 'the', 'development', 'of', 'pharmacological', 'interventions', 'developed', 'to', 'target', 'specific', 'areas', 'of', 'the', 'brain', ',', 'brain', 'receptors', ',', 'or', 'pathways', 'identified', 'to', 'be', 'involved', 'in', 'the', 'mechanism', 'underlying', 'ovarian', 'hormone', 'change', 'and', 'binge', 'eating', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04225221,NCT04225221,"Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design | This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.","[(0, 16, 'OTHER', 'Ovarian Hormones'), (39, 51, 'CONDITION', 'Binge Eating'), (55, 70, 'CONDITION', 'Bulimia Nervosa'), (141, 157, 'OTHER', 'ovarian hormones'), (229, 241, 'CONDITION', 'binge eating'), (306, 321, 'CONDITION', 'bulimia nervosa'), (382, 397, 'OTHER', 'ovarian hormone'), (623, 638, 'OTHER', 'ovarian hormone'), (650, 662, 'CONDITION', 'binge eating')]"
"['Benefice', 'Assessment', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'Used', 'as', 'an', 'Additional', 'Procedure', 'to', 'Rehabilitation', 'Exercises', 'in', 'Patients', 'Suffering', 'From', 'Fibromyalgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'analgesic', 'effectiveness', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'used', 'as', 'an', 'additional', 'procedure', 'to', 'rehabilitation', 'exercises', 'in', 'patient', 'suffering', 'from', 'fibromyalgia', '.', '\n\n', 'A', 'double', 'blind', 'clinical', 'trial', 'with', 'two', 'randomized', 'parallel', 'groups', ':', '\n\n', 'Placebo', 'rTMS', 'and', 'rehabilitation', 'exercise', '\n', 'Active', 'rTMS', 'and', 'rehabilitation', 'exercise']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS']",NCT01308801,NCT01308801,"Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia | The purpose of this study is to determine the analgesic effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) used as an additional procedure to rehabilitation exercises in patient suffering from fibromyalgia.

A double blind clinical trial with two randomized parallel groups:

Placebo rTMS and rehabilitation exercise
Active rTMS and rehabilitation exercise","[(23, 67, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (103, 127, 'PHYSICAL', 'Rehabilitation Exercises'), (155, 167, 'CONDITION', 'Fibromyalgia'), (243, 287, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (289, 293, 'OTHER', 'rTMS'), (330, 354, 'PHYSICAL', 'rehabilitation exercises'), (381, 393, 'CONDITION', 'fibromyalgia'), (464, 476, 'CONTROL', 'Placebo rTMS'), (481, 504, 'PHYSICAL', 'rehabilitation exercise'), (505, 516, 'OTHER', 'Active rTMS'), (521, 544, 'PHYSICAL', 'rehabilitation exercise')]"
"['Studying', 'Human', 'Cognition', 'and', 'Neurological', 'Disorders', 'Using', 'ÂµECoG', 'Electrodes', '|', 'The', 'overall', 'purpose', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'human', 'cognition', 'and', 'human', 'epilepsy', 'by', 'working', 'with', 'patients', 'undergoing', 'clinical', 'treatment', 'for', 'pharmacologically', 'resistant', 'epilepsy', '.', 'The', 'investigators', 'will', 'investigate', 'human', 'cognition', 'by', 'conducting', 'controlled', 'experiments', 'that', 'focus', 'on', 'sensory', ',', 'motor', ',', 'and', 'cognitive', 'phenomena', 'such', 'as', 'sensory', 'processing', ',', 'memory', ',', 'and', 'language', '.', 'The', 'investigators', 'will', 'also', 'examine', 'the', 'neural', 'underpinnings', 'of', 'epilepsy', 'during', 'both', 'sleep', 'and', 'wakefulness', 'to', 'better', 'understand', 'both', 'the', 'foundations', 'of', 'epilepsy', 'and', 'how', 'epilepsy', 'affects', 'cognition', '.', 'The', 'investigators', 'hope', 'to', 'use', 'these', 'data', 'to', 'have', 'a', 'better', 'understanding', 'of', 'cognition', ',', 'epilepsy', ',', 'and', 'how', 'the', 'two', 'interact', '.', 'This', 'will', 'potentially', 'lead', 'to', 'better', 'markers', 'for', 'seizure', 'onsets', 'as', 'well', 'as', 'epilepsy', 'more', 'generally', '.', 'For', 'this', 'research', ',', 'the', 'investigators', 'will', 'use', 'μECoG', 'arrays', 'manufactured', 'by', 'commercial', 'partners', '.', 'These', 'arrays', 'have', 'passed', 'all', 'major', 'ISO', '10993', 'bio', '-', 'compatibility', 'tests', '.', 'Based', 'on', 'this', 'characterization', 'and', 'use', 'in', 'the', 'intraoperative', 'setting', '(', 'limited', 'duration', 'and', 'supervised', 'usage', ')', ',', 'these', 'devices', 'pose', 'a', 'minimal', 'risk', 'to', 'participants', '.', 'Data', 'will', 'be', 'analyzed', 'and', 'protected', 'using', 'the', 'Duke', 'SSRI', 'protected', 'research', 'data', 'network', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05132543,NCT05132543,"Studying Human Cognition and Neurological Disorders Using ÂµECoG Electrodes | The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use μECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.",[]
"['Focused', 'Ultrasound', 'Delivery', 'of', 'Exosomes', 'for', 'Treatment', 'of', 'Refractory', 'Depression', ',', 'Anxiety', ',', 'and', 'Neurodegenerative', 'Dementias', '|', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'exosome', 'deployment', 'with', 'concurrent', 'transcranial', 'ultrasound', 'in', 'patients', 'with', 'refractory', ',', 'treatment', 'resistant', 'depression', ',', 'anxiety', ',', 'and', 'neurodegenerative', 'dementia', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04202770,NCT04202770,"Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias | This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.","[(0, 39, 'OTHER', 'Focused Ultrasound Delivery of Exosomes'), (57, 78, 'CONDITION', 'Refractory Depression'), (80, 87, 'CONDITION', 'Anxiety'), (93, 120, 'CONDITION', 'Neurodegenerative Dementias'), (185, 192, 'OTHER', 'exosome'), (220, 243, 'OTHER', 'transcranial ultrasound'), (261, 303, 'CONDITION', 'refractory, treatment resistant depression'), (305, 312, 'CONDITION', 'anxiety'), (318, 344, 'CONDITION', 'neurodegenerative dementia')]"
"['Effect', 'of', 'Peripheral', 'Neuromodulation', 'on', 'Vaginal', 'Blood', 'Flow', '|', 'The', 'researchers', 'want', 'to', 'see', 'if', 'nerve', 'stimulation', 'interventions', 'cause', 'a', 'change', 'in', 'vaginal', 'blood', 'flow', '.', 'The', 'effect', 'of', 'this', 'intervention', 'will', 'be', 'compared', 'between', 'women', 'who', 'have', 'neurogenic', '(', 'spinal', 'cord', 'injury', ')', 'or', 'non', '-', 'neurogenic', 'dysfunction', 'and', 'healthy', 'women', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT04384172,NCT04384172,Effect of Peripheral Neuromodulation on Vaginal Blood Flow | The researchers want to see if nerve stimulation interventions cause a change in vaginal blood flow. The effect of this intervention will be compared between women who have neurogenic (spinal cord injury) or non-neurogenic dysfunction and healthy women.,"[(10, 36, 'OTHER', 'Peripheral Neuromodulation'), (92, 123, 'OTHER', 'nerve stimulation interventions'), (234, 295, 'CONDITION', 'neurogenic (spinal cord injury) or non-neurogenic dysfunction')]"
"['Glutamate', 'Concentrations', 'in', 'the', 'Brain', 'Over', 'the', 'Course', 'of', 'a', 'Migraine', '-', 'like', 'Attack', '|', 'To', 'investigate', 'the', 'glutaminergic', 'system', 'in', 'the', 'onset', 'of', 'migraine', '-', 'like', 'attacks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04220606,NCT04220606,Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack | To investigate the glutaminergic system in the onset of migraine-like attacks.,"[(59, 79, 'CONDITION', 'Migraine-like Attack'), (138, 159, 'CONDITION', 'migraine-like attacks')]"
"['Intranasal', 'Insulin', 'and', 'Post', '-', 'stroke', 'Cognition', ':', 'A', 'Pilot', 'Study', '|', 'Almost', 'two', '-', 'thirds', 'of', 'survivors', 'have', 'cognitive', 'impairment', '(', 'CI', ')', ',', 'manifested', 'as', 'memory', ',', 'language', ',', 'and', 'judgement', 'problems', '.', 'Post', '-', 'stroke', 'CI', 'at', '2', 'weeks', 'is', 'a', 'significant', 'predictor', 'of', 'long', '-', 'term', 'functional', 'outcome', ',', 'and', 'more', 'generally', ',', 'cognitive', 'impairments', 'have', 'a', 'major', 'impact', 'on', 'functional', 'outcome', 'and', 'ability', 'to', 'participate', 'in', 'rehabilitation', '.', 'CI', 'is', 'associated', 'with', 'increased', 'systemic', 'inflammation', '.', 'Intranasally', '-', 'administered', 'insulin', 'is', 'a', 'promising', 'new', 'therapy', 'for', 'enhancing', 'memory', 'in', 'patients', 'with', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', 'and', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', ',', 'shown', 'in', 'multiple', 'randomized', 'controlled', 'studies', '.', 'Likely', 'mechanisms', 'of', 'benefit', 'are', 'intranasal', 'insulin', ""'s"", 'ability', 'to', 'restore', 'normal', 'cerebral', 'insulin', 'signaling', '.', 'Based', 'on', 'the', 'overlap', 'in', 'cerebral', 'insulin', 'resistance', 'that', 'occurs', 'in', 'both', 'AD', 'and', 'post', '-', 'stroke', 'CI', ',', 'we', 'have', 'designed', 'an', 'innovative', 'proof', '-', 'of', '-', 'concept', ',', 'feasibility', 'trial', 'designed', 'to', 'provide', 'pilot', 'data', 'as', 'to', 'whether', 'post', '-', 'stroke', 'survivor', 'CI', 'and', 'caregiver', 'burden', 'is', 'improved', 'with', 'intranasal', 'insulin', 'early', 'after', 'stroke', '.', 'We', 'will', 'explore', 'the', 'impact', 'of', 'intranasal', 'insulin', 'on', 'inflammatory', 'biomarkers', ',', 'since', 'inflammation', 'is', 'a', 'major', 'underlying', 'cause', 'of', 'CI', ',', 'as', 'shown', 'by', 'others', 'and', 'in', 'our', 'preliminary', 'studies', 'of', 'VCAM-1', '.', 'Specific', 'Aims', 'are', ':', '1', '.', 'Determine', 'if', 'patients', 'with', 'ischemic', 'stroke', 'randomized', 'to', 'intranasal', 'insulin', '20', 'IU', 'BID', 'for', '3', 'weeks', 'have', 'improved', 'cognition', ',', 'compared', 'to', 'patients', 'who', 'receive', 'intranasal', 'saline', '.', 'Primary', 'outcome', 'is', 'a', 'composite', 'of', '(', 'a', ')', 'memory', 'and', 'executive', 'function', 'z', 'scores', '.', '2', '.', 'To', 'assess', 'the', 'impact', 'of', 'intranasal', 'insulin', 'vs', 'saline', 'on', 'change', 'in', 'inflammatory', 'biomarker', 'levels', '(', 'VCAM-1', ',', 'TNF', '-', 'alpha', ',', 'TNFR', '-', 'I', 'and', 'II', ')', 'before', 'and', 'after', 'the', 'treatment', 'period', '.', '3', '.', 'To', 'measure', 'differences', 'in', 'burden', 'among', 'caregivers', 'of', 'participants', 'in', 'the', 'intranasal', 'insulin', 'vs', 'intranasal', 'saline', 'groups', '.', 'We', 'will', 'prospectively', 'randomize', '40', 'subjects', 'to', 'intranasal', 'insulin', '(', '40', 'IU', ')', 'vs', 'saline', 'treatment', '.', 'Following', 'baseline', 'cognitive', 'testing', '2', 'weeks', 'post', 'stroke', ',', 'subjects', 'will', 'receive', 'the', 'assigned', 'treatment', 'for', '3', 'weeks', ',', 'followed', 'by', 'a', '3', '-', 'week', 'washout', 'period', ',', 'with', 'cognitive', 'testing', 'performed', 'after', 'the', 'treatment', 'and', 'washout', 'periods', 'and', 'again', 'at', '20', 'weeks', '.', 'The', 'proposed', 'study', 'will', 'provide', 'data', 'on', 'a', 'promising', 'method', 'for', 'treating', 'cognitive', 'function', 'in', 'stroke', 'patients', '.', 'If', 'effective', ',', 'our', 'pilot', 'data', 'will', 'set', 'the', 'stage', 'for', 'larger', 'phase', 'III', 'clinical', 'trials', '.']","['O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02810392,NCT02810392,"Intranasal Insulin and Post-stroke Cognition: A Pilot Study | Almost two-thirds of survivors have cognitive impairment (CI), manifested as memory, language, and judgement problems. Post-stroke CI at 2 weeks is a significant predictor of long-term functional outcome, and more generally, cognitive impairments have a major impact on functional outcome and ability to participate in rehabilitation. CI is associated with increased systemic inflammation. Intranasally-administered insulin is a promising new therapy for enhancing memory in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), shown in multiple randomized controlled studies. Likely mechanisms of benefit are intranasal insulin's ability to restore normal cerebral insulin signaling. Based on the overlap in cerebral insulin resistance that occurs in both AD and post-stroke CI, we have designed an innovative proof-of-concept, feasibility trial designed to provide pilot data as to whether post-stroke survivor CI and caregiver burden is improved with intranasal insulin early after stroke. We will explore the impact of intranasal insulin on inflammatory biomarkers, since inflammation is a major underlying cause of CI, as shown by others and in our preliminary studies of VCAM-1. Specific Aims are: 1. Determine if patients with ischemic stroke randomized to intranasal insulin 20 IU BID for 3 weeks have improved cognition, compared to patients who receive intranasal saline. Primary outcome is a composite of (a) memory and executive function z scores. 2. To assess the impact of intranasal insulin vs saline on change in inflammatory biomarker levels (VCAM-1, TNF-alpha, TNFR-I and II) before and after the treatment period. 3. To measure differences in burden among caregivers of participants in the intranasal insulin vs intranasal saline groups. We will prospectively randomize 40 subjects to intranasal insulin (40 IU) vs saline treatment. Following baseline cognitive testing 2 weeks post stroke, subjects will receive the assigned treatment for 3 weeks, followed by a 3-week washout period, with cognitive testing performed after the treatment and washout periods and again at 20 weeks. The proposed study will provide data on a promising method for treating cognitive function in stroke patients. If effective, our pilot data will set the stage for larger phase III clinical trials.","[(11, 18, 'DRUG', 'Insulin'), (23, 34, 'CONDITION', 'Post-stroke'), (98, 118, 'CONDITION', 'cognitive impairment'), (120, 122, 'CONDITION', 'CI'), (181, 192, 'CONDITION', 'Post-stroke'), (193, 195, 'CONDITION', 'CI'), (287, 308, 'CONDITION', 'cognitive impairments'), (397, 399, 'CONDITION', 'CI'), (478, 485, 'DRUG', 'insulin'), (551, 576, 'CONDITION', 'mild cognitive impairment'), (578, 581, 'CONDITION', 'MCI'), (587, 606, 'CONDITION', ""Alzheimer's disease""), (608, 610, 'CONDITION', 'AD'), (706, 713, 'DRUG', 'insulin'), (751, 758, 'DRUG', 'insulin'), (803, 810, 'DRUG', 'insulin'), (842, 844, 'CONDITION', 'AD'), (849, 860, 'CONDITION', 'post-stroke'), (861, 863, 'CONDITION', 'CI'), (977, 988, 'CONDITION', 'post-stroke'), (998, 1000, 'CONDITION', 'CI'), (1050, 1057, 'DRUG', 'insulin'), (1070, 1076, 'CONDITION', 'stroke'), (1119, 1126, 'DRUG', 'insulin'), (1205, 1207, 'CONDITION', 'CI'), (1319, 1334, 'CONDITION', 'ischemic stroke'), (1360, 1367, 'DRUG', 'insulin'), (1459, 1465, 'CONTROL', 'saline'), (1583, 1590, 'DRUG', 'insulin'), (1594, 1600, 'CONTROL', 'saline'), (1805, 1812, 'DRUG', 'insulin'), (1827, 1833, 'CONTROL', 'saline'), (1900, 1907, 'DRUG', 'insulin'), (1919, 1925, 'CONTROL', 'saline'), (1982, 1993, 'CONDITION', 'post stroke'), (2280, 2286, 'CONDITION', 'stroke')]"
"['A', 'Phase', 'II', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'STA-1', 'as', 'an', 'Add', '-', 'on', 'Treatment', 'to', 'Donepezil', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'STA-1', 'vs', 'placebo', 'as', 'an', 'add', '-', 'on', 'treatment', 'to', 'donepezil', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01255046,NCT01255046,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease | The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).","[(37, 44, 'CONTROL', 'Placebo'), (117, 122, 'DRUG', 'STA-1'), (149, 158, 'DRUG', 'Donepezil'), (176, 212, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (285, 290, 'DRUG', 'STA-1'), (294, 301, 'CONTROL', 'placebo'), (328, 337, 'DRUG', 'donepezil'), (355, 391, 'CONDITION', ""mild to moderate Alzheimer's Disease""), (393, 395, 'CONDITION', 'AD')]"
"['Acupuncture', 'for', 'the', 'Prevention', 'of', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Myringotomy', 'Tube', 'Placement', '|', 'Myringotomy', 'tube', 'placement', 'is', 'one', 'of', 'the', 'most', 'commonly', 'performed', 'operations', 'in', 'children', '.', 'Emergence', 'delirium', 'after', 'such', 'procedures', 'is', 'common', '.', 'During', 'emergence', 'delirium', 'children', 'can', 'become', 'both', 'a', 'danger', 'to', 'themselves', 'and', 'others', 'around', 'them', ',', 'including', 'family', 'members', 'and', 'hospital', 'staff', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'acupuncture', ',', 'when', 'used', 'in', 'combination', 'with', 'standard', 'anesthetic', 'management', ',', 'decreases', 'the', 'incidence', 'of', 'emergence', 'delirium', 'in', 'pediatric', 'patients', 'following', 'myringotomy', 'tube', 'placement', '.', 'Patients', 'with', 'and', 'without', 'premedication', 'of', 'midazolam', 'will', 'be', 'included', '.', 'A', 'secondary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'our', 'institution', ""'s"", 'actual', 'incidence', 'of', 'emergence', 'delirium', 'for', 'this', 'operation', 'using', 'a', 'validated', 'scale', ',', 'the', 'Pediatric', 'Anesthesia', 'Emergence', 'Delirium', '(', 'PAED', ')', 'scale', '.', 'We', 'will', 'also', 'compare', 'rates', 'of', 'emergence', 'delirium', 'in', 'patients', 'that', 'received', 'a', 'premedication', 'of', 'midazolam', 'versus', '(', 'V', ')', 'those', 'that', 'did', 'not', '(', 'NV', ')', '.', '\n\n', 'This', 'is', 'a', 'randomized', 'double', '-', 'blinded', 'trial', '.', 'We', 'will', 'enroll', '100', 'children', 'aged', '1', '-', '6', 'years', 'old', '.', 'Premedication', 'with', 'midazolam', 'will', 'be', 'decided', 'by', 'the', 'anesthesiologist', '.', 'If', 'needed', ',', 'the', 'patient', 'will', 'receive', 'a', 'standard', 'does', 'of', 'oral', 'midazolam', 'plus', 'acetaminophen', '(', 'V', ')', '.', 'If', 'the', 'patient', 'does', 'not', 'require', 'premedication', 'with', 'midazolam', ',', 'oral', 'acetaminophen', 'will', 'be', 'given', 'alone', '(', 'NV', ')', '.', '\n\n', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'acupuncture', 'with', 'standard', 'general', 'anesthesia', 'care', '(', 'A', ')', 'or', 'to', 'receive', 'standard', 'anesthetic', 'care', 'alone', '(', 'S', ')', '.', 'Patients', ',', 'their', 'family', 'members', 'and', 'recovery', 'registered', 'nurses', '(', 'RNs', ')', 'will', 'not', 'know', 'if', 'acupuncture', 'was', 'performed', '.', 'Intraoperative', 'anesthetic', 'techniques', 'will', 'be', 'standardized', 'and', 'include', 'inhaled', 'inductions', 'with', 'nitrous', 'oxide', 'and', 'sevoflurane', '.', 'Anesthesia', 'maintenance', 'will', 'be', 'inhaled', 'sevoflurane', 'and', 'the', 'usual', 'pain', 'medication', 'ketorolac', 'will', 'be', 'given', 'intramuscularly', 'prior', 'to', 'emergence', '.', 'Acupuncture', 'needles', 'will', 'be', 'placed', 'after', 'anesthesia', 'induction', 'and', 'removed', 'prior', 'to', 'leaving', 'the', 'operating', 'room', '.', 'A', 'total', 'of', '4', 'needles', 'will', 'be', 'placed', ',', 'one', 'in', 'each', 'wrist', 'at', 'the', 'Heart', '7', '(', 'HT7', ')', 'point', 'and', 'one', 'in', 'each', 'ear', 'at', 'the', 'Shen', 'Men', 'point', '.', 'The', 'needles', 'will', 'be', 'inserted', 'bilaterally', 'to', 'a', 'depth', 'of', '1.8', 'mm', '.', '\n\n', 'In', 'the', 'PACU', ',', 'a', 'blinded', 'study', 'observer', 'will', 'evaluate', 'the', 'patient', 'at', 'four', 'time', 'points', 'using', 'the', 'PAED', 'scale', ':', 'time', 'of', 'awakening', 'and', '5', ',', '10', '&', '15', 'minutes', 'after', 'awakening', '.', 'Follow', 'up', 'phone', 'calls', 'will', 'be', 'made', 'one', 'day', 'and', 'one', 'week', 'after', 'surgery', '.', 'Families', 'will', 'be', 'asked', 'about', 'behavior', 'after', 'discharge', ',', 'sleep', 'and', 'bed', '-', 'wetting', '.']","['B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02383004,NCT02383004,"Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement | Myringotomy tube placement is one of the most commonly performed operations in children. Emergence delirium after such procedures is common. During emergence delirium children can become both a danger to themselves and others around them, including family members and hospital staff.

The primary objective of this study is to determine if acupuncture, when used in combination with standard anesthetic management, decreases the incidence of emergence delirium in pediatric patients following myringotomy tube placement. Patients with and without premedication of midazolam will be included. A secondary objective of this study is to determine our institution's actual incidence of emergence delirium for this operation using a validated scale, the Pediatric Anesthesia Emergence Delirium (PAED) scale. We will also compare rates of emergence delirium in patients that received a premedication of midazolam versus (V) those that did not (NV).

This is a randomized double-blinded trial. We will enroll 100 children aged 1-6 years old. Premedication with midazolam will be decided by the anesthesiologist. If needed, the patient will receive a standard does of oral midazolam plus acetaminophen (V). If the patient does not require premedication with midazolam, oral acetaminophen will be given alone (NV).

Patients will then be randomized to receive either acupuncture with standard general anesthesia care (A) or to receive standard anesthetic care alone (S). Patients, their family members and recovery registered nurses (RNs) will not know if acupuncture was performed. Intraoperative anesthetic techniques will be standardized and include inhaled inductions with nitrous oxide and sevoflurane. Anesthesia maintenance will be inhaled sevoflurane and the usual pain medication ketorolac will be given intramuscularly prior to emergence. Acupuncture needles will be placed after anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the Heart 7 (HT7) point and one in each ear at the Shen Men point. The needles will be inserted bilaterally to a depth of 1.8 mm.

In the PACU, a blinded study observer will evaluate the patient at four time points using the PAED scale: time of awakening and 5, 10 & 15 minutes after awakening. Follow up phone calls will be made one day and one week after surgery. Families will be asked about behavior after discharge, sleep and bed-wetting.","[(0, 11, 'OTHER', 'Acupuncture'), (34, 52, 'CONDITION', 'Emergence Delirium'), (76, 102, 'CONDITION', 'Myringotomy Tube Placement'), (105, 131, 'CONDITION', 'Myringotomy tube placement'), (194, 212, 'CONDITION', 'Emergence delirium'), (253, 271, 'CONDITION', 'emergence delirium'), (445, 456, 'OTHER', 'acupuncture'), (488, 518, 'OTHER', 'standard anesthetic management'), (598, 624, 'CONDITION', 'myringotomy tube placement'), (669, 678, 'DRUG', 'midazolam'), (787, 805, 'CONDITION', 'emergence delirium'), (938, 956, 'CONDITION', 'emergence delirium'), (1002, 1011, 'DRUG', 'midazolam'), (1159, 1168, 'DRUG', 'midazolam'), (1270, 1279, 'DRUG', 'midazolam'), (1285, 1298, 'DRUG', 'acetaminophen'), (1355, 1364, 'DRUG', 'midazolam'), (1371, 1384, 'DRUG', 'acetaminophen'), (1463, 1474, 'OTHER', 'acupuncture'), (1480, 1512, 'OTHER', 'standard general anesthesia care'), (1531, 1561, 'CONTROL', 'standard anesthetic care alone'), (1652, 1663, 'OTHER', 'acupuncture'), (1773, 1786, 'DRUG', 'nitrous oxide'), (1791, 1802, 'DRUG', 'sevoflurane'), (1843, 1854, 'DRUG', 'sevoflurane'), (1885, 1894, 'DRUG', 'ketorolac'), (1945, 1956, 'OTHER', 'Acupuncture')]"
"['A', 'Clinical', 'Investigation', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Clenbuterol', 'on', 'Motor', 'Function', 'in', 'Individuals', 'With', 'Late', '-', 'onset', 'Pompe', 'Disease', 'and', 'Receiving', 'Enzyme', 'Replacement', 'Therapy', '|', 'Funding', 'Source-', 'FDA', 'OOPD', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'clenbuterol', 'on', 'motor', 'function', 'in', 'individuals', 'with', 'late', '-', 'onset', 'Pompe', 'disease', '(', 'LOPD', ')', 'who', 'are', 'treated', 'with', 'enzyme', 'replacement', 'therapy', '(', 'ERT', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT01942590,NCT01942590,"A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy | Funding Source- FDA OOPD

The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).","[(55, 66, 'DRUG', 'Clenbuterol'), (105, 170, 'CONDITION', 'Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy'), (270, 281, 'DRUG', 'clenbuterol'), (320, 399, 'CONDITION', 'late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy')]"
"['Ultrasound', '-', 'Guided', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'of', 'the', 'Median', 'Nerve', 'for', 'Carpal', 'Tunnel', 'Syndrome', '|', 'There', 'is', 'evidence', 'supporting', 'that', 'physical', 'therapy', 'interventions', 'can', 'be', 'effective', 'for', 'the', 'management', 'of', 'patients', 'with', 'CTS', '.', 'No', 'consensus', 'on', 'the', 'best', 'approach', 'exist', '.', 'It', 'seems', 'clear', 'that', 'the', 'median', 'nerve', 'is', 'affected', 'in', 'several', 'ways', '(', 'compression', ',', 'inflammation', ',', 'excursion', ')', 'in', 'carpal', 'tunnel', 'syndrome', '.', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'is', 'a', 'treatment', 'approach', 'consisting', 'of', 'the', 'application', 'of', 'an', 'electrical', 'current', 'throughout', 'needling', 'filaments', 'placed', 'close', 'to', 'the', 'nerve', ',', 'in', 'this', 'case', 'the', 'median', 'nerve', '.', 'The', 'purpose', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'compare', 'changes', 'in', 'function', ',', 'symptom', 'severity', 'and', 'the', 'intensity', 'of', 'pain', 'after', 'the', 'application', 'of', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'vs.', 'endoscopic', 'surgery', 'in', 'women', 'with', 'CTS', 'at', 'short-', 'and', 'long', '-', 'term', 'follow', '-', 'up', 'periods', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04246216,NCT04246216,"Ultrasound-Guided Percutaneous Electrical Nerve Stimulation of the Median Nerve for Carpal Tunnel Syndrome | There is evidence supporting that physical therapy interventions can be effective for the management of patients with CTS. No consensus on the best approach exist. It seems clear that the median nerve is affected in several ways (compression, inflammation, excursion) in carpal tunnel syndrome. Percutaneous Electrical Nerve Stimulation is a treatment approach consisting of the application of an electrical current throughout needling filaments placed close to the nerve, in this case the median nerve. The purpose of this clinical trial is to compare changes in function, symptom severity and the intensity of pain after the application of Percutaneous Electrical Nerve Stimulation vs. endoscopic surgery in women with CTS at short- and long-term follow-up periods.","[(0, 59, 'OTHER', 'Ultrasound-Guided Percutaneous Electrical Nerve Stimulation'), (84, 106, 'CONDITION', 'Carpal Tunnel Syndrome'), (227, 230, 'CONDITION', 'CTS'), (380, 402, 'CONDITION', 'carpal tunnel syndrome'), (404, 445, 'OTHER', 'Percutaneous Electrical Nerve Stimulation'), (721, 725, 'CONDITION', 'pain'), (751, 792, 'OTHER', 'Percutaneous Electrical Nerve Stimulation'), (797, 815, 'CONTROL', 'endoscopic surgery'), (830, 833, 'CONDITION', 'CTS')]"
"['Accuracy', 'of', 'Pulse', 'Oximetry', 'to', 'Detect', 'Sleep', 'Apnea', 'in', 'Frail', 'Hospitalized', 'Patients', '|', 'Sleep', 'apnea', 'syndrome', 'is', 'common', 'and', 'increases', 'with', 'age', '.', 'In', 'the', 'elderly', ',', 'symptoms', 'might', 'be', 'different', 'than', 'in', 'the', 'youngest', 'people', ',', 'and', 'its', 'consequences', 'might', 'be', 'severe', 'and', 'atypical', '(', 'falls', ',', 'functional', 'and', 'cognitive', 'decline', ')', '.', '\n\n', 'Today', ',', 'there', 'is', 'no', 'specific', 'tool', 'to', 'detect', 'sleep', 'apnea', 'in', 'the', 'elderly', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'accuracy', 'of', 'oximetry', 'for', 'detection', 'of', 'respiratory', 'disturbances', 'in', 'sleep', 'apnea', 'in', 'the', 'hospitalized', 'elderly', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT01294137,NCT01294137,"Accuracy of Pulse Oximetry to Detect Sleep Apnea in Frail Hospitalized Patients | Sleep apnea syndrome is common and increases with age. In the elderly, symptoms might be different than in the youngest people, and its consequences might be severe and atypical (falls, functional and cognitive decline).

Today, there is no specific tool to detect sleep apnea in the elderly. The goal of this study is to evaluate the accuracy of oximetry for detection of respiratory disturbances in sleep apnea in the hospitalized elderly.","[(37, 48, 'CONDITION', 'Sleep Apnea'), (82, 102, 'CONDITION', 'Sleep apnea syndrome'), (347, 358, 'CONDITION', 'sleep apnea'), (455, 479, 'CONDITION', 'respiratory disturbances'), (483, 494, 'CONDITION', 'sleep apnea')]"
"['Evaluation', 'of', 'the', 'Benefit', 'Provided', 'by', 'Sessions', 'of', 'Sophrology', 'on', 'the', 'Intraoperative', 'Management', 'of', 'Parkinsonian', 'Patients', 'in', 'the', 'Context', 'of', 'Deep', 'Brain', 'Stimulation', 'Surgery', '.', '|', 'Deep', 'brain', 'stimulation', 'surgery', ',', 'which', 'consists', 'of', 'intracerebral', 'implantation', 'of', 'electrodes', ',', 'is', 'considered', 'one', 'of', 'the', 'most', 'effective', 'techniques', 'for', 'controlling', 'the', 'motor', 'fluctuations', 'of', 'Parkinson', ""'s"", 'disease', '.', 'The', 'particularity', 'of', 'this', 'surgery', 'is', 'the', 'necessity', 'of', 'the', 'awakening', 'of', 'the', 'patient', 'for', 'the', 'correct', 'positioning', 'of', 'the', 'electrodes', ',', 'it', 'is', 'therefore', 'a', 'difficult', 'test', 'for', 'the', 'patient', '.', '\n\n', 'Medical', 'sophrology', 'is', 'an', 'ideal', 'strategy', 'to', 'optimize', 'the', 'comfort', 'of', 'the', 'patient', 'during', 'the', 'operation', 'thanks', 'to', 'its', 'anxiolytic', 'and', 'analgesic', 'virtues', 'while', 'guaranteeing', 'the', 'maintenance', 'of', 'a', 'good', 'patient', 'vigilance', 'favoring', 'the', 'cooperation', 'with', 'the', 'operating', 'room', 'team', '.', 'Indeed', ',', 'sophrology', 'is', 'a', 'body', '-', 'mediated', 'set', 'of', 'techniques', ',', 'at', 'the', 'crossroads', 'between', 'hypnosis', 'and', 'yoga', ',', 'which', 'makes', 'it', 'possible', 'to', 'find', 'a', 'balance', 'between', 'emotions', ',', 'thoughts', 'and', 'behaviors', '.', 'It', 'has', 'already', 'been', 'applied', 'in', 'other', 'fields', 'such', 'as', 'oncology', ',', 'pain', 'management', ',', 'preparation', 'for', 'childbirth', ',', 'and', 'for', '5', 'years', 'at', 'the', 'CHU', 'of', 'Rennes', 'for', 'preparation', 'for', 'the', 'intervention', 'of', 'deep', 'brain', 'stimulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03273816,NCT03273816,"Evaluation of the Benefit Provided by Sessions of Sophrology on the Intraoperative Management of Parkinsonian Patients in the Context of Deep Brain Stimulation Surgery. | Deep brain stimulation surgery, which consists of intracerebral implantation of electrodes, is considered one of the most effective techniques for controlling the motor fluctuations of Parkinson's disease. The particularity of this surgery is the necessity of the awakening of the patient for the correct positioning of the electrodes, it is therefore a difficult test for the patient.

Medical sophrology is an ideal strategy to optimize the comfort of the patient during the operation thanks to its anxiolytic and analgesic virtues while guaranteeing the maintenance of a good patient vigilance favoring the cooperation with the operating room team. Indeed, sophrology is a body-mediated set of techniques, at the crossroads between hypnosis and yoga, which makes it possible to find a balance between emotions, thoughts and behaviors. It has already been applied in other fields such as oncology, pain management, preparation for childbirth, and for 5 years at the CHU of Rennes for preparation for the intervention of deep brain stimulation.","[(50, 60, 'BEHAVIOURAL', 'Sophrology'), (97, 109, 'CONDITION', 'Parkinsonian'), (137, 159, 'OTHER', 'Deep Brain Stimulation'), (171, 193, 'OTHER', 'Deep brain stimulation'), (356, 375, 'CONDITION', ""Parkinson's disease""), (566, 576, 'BEHAVIOURAL', 'sophrology'), (831, 841, 'BEHAVIOURAL', 'sophrology'), (1193, 1215, 'OTHER', 'deep brain stimulation')]"
"['The', 'Debated', 'Role', 'of', 'Sleep', 'Studies', 'in', 'Patients', 'Under', 'Established', 'Home', 'Mechanical', 'Ventilation', '|', 'Patients', 'suffering', 'chronic', 'hypercapnic', 'respiratory', 'insufficiency', '(', 'e.g.', 'in', 'chronic', 'obstructive', 'pulmonary', 'disease', ',', 'obesity', 'hypoventilation', 'syndrome', ')', 'benefit', 'from', 'home', 'mechanical', 'ventilation', '.', 'These', 'patients', 'are', 'complex', ';', 'and', 'the', 'ventilator´s', 'parameters', 'should', 'be', 'set', '-', 'up', 'according', 'to', 'the', 'underlying', 'disease', 'and', 'particular', 'patient', ""'s"", 'characteristics', '.', 'The', 'non', '-', 'invasive', 'ventilation', 'therapy', 'is', 'mostly', 'titrated', 'while', 'the', 'patient', 'is', 'awake', ',', 'hence', 'Problems', ',', 'such', 'as', 'Patient', '-', 'Ventilator', 'asynchrony', ',', 'arising', 'while', 'sleeping', 'on', 'the', 'ventilator', 'therapy', 'would', 'remain', 'undetected', '.', '\n\n', 'Sleep', 'studies', ',', 'such', 'as', 'polysomnography', 'or', 'polygraphy', 'and', 'transcutaneous', 'carbon', 'dioxide', 'monitoring', 'could', 'be', 'valuable', 'tools', 'to', 'fine', '-', 'tune', 'the', 'ventilator', ""'s"", 'settings', '.', 'This', 'could', 'foster', 'the', 'ventilator´s', 'effectivity', 'and', 'patient', 'satisfaction', ',', 'thus', 'therapy', ""'s"", 'adherence', '.', 'Nevertheless', 'the', 'sleep', 'studies', 'are', 'expensive', ',', 'time', '-', 'consuming', 'and', 'not', 'widely', 'available', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'learn', 'the', 'findings', 'of', 'sleep', 'studies', 'when', 'they', 'are', 'performed', 'on', 'stable', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'as', 'part', 'of', 'their', 'routine', 'check', '-', 'ups', '.', 'In', 'this', 'context', ',', 'it', 'will', 'be', 'assessed', 'whether', 'the', 'sleep', 'studies', ""'"", 'findings', 'lead', 'to', 'a', 'change', '(', 'adjustment', ')', 'of', 'the', 'ventilator´s', 'therapy', '.', 'Moreover', ',', 'this', 'study', 'aims', 'to', 'investigate', 'whether', 'the', 'absence', 'of', 'sleep', 'studies', 'would', 'result', 'in', 'missing', 'important', 'events', 'that', 'require', 'an', 'adjustment', 'of', 'therapy', '.', 'The', 'results', 'of', 'this', 'study', 'could', 'provide', 'information', 'that', 'lead', 'to', 'a', 'more', 'standardized', 'protocol', 'of', 'follow', '-', 'up', 'checks', 'of', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'in', 'a', 'cost', '-', 'effective', 'manner', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03506906,NCT03506906,"The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation | Patients suffering chronic hypercapnic respiratory insufficiency (e.g. in chronic obstructive pulmonary disease, obesity hypoventilation syndrome) benefit from home mechanical ventilation. These patients are complex; and the ventilator´s parameters should be set-up according to the underlying disease and particular patient's characteristics. The non-invasive ventilation therapy is mostly titrated while the patient is awake, hence Problems, such as Patient-Ventilator asynchrony, arising while sleeping on the ventilator therapy would remain undetected.

Sleep studies, such as polysomnography or polygraphy and transcutaneous carbon dioxide monitoring could be valuable tools to fine-tune the ventilator's settings. This could foster the ventilator´s effectivity and patient satisfaction, thus therapy's adherence. Nevertheless the sleep studies are expensive, time-consuming and not widely available.

The aim of this study is to learn the findings of sleep studies when they are performed on stable patients on home mechanical ventilation as part of their routine check-ups. In this context, it will be assessed whether the sleep studies' findings lead to a change (adjustment) of the ventilator´s therapy. Moreover, this study aims to investigate whether the absence of sleep studies would result in missing important events that require an adjustment of therapy. The results of this study could provide information that lead to a more standardized protocol of follow-up checks of patients on home mechanical ventilation in a cost-effective manner.","[(64, 91, 'OTHER', 'Home Mechanical Ventilation'), (113, 158, 'CONDITION', 'chronic hypercapnic respiratory insufficiency'), (168, 205, 'CONDITION', 'chronic obstructive pulmonary disease'), (207, 239, 'CONDITION', 'obesity hypoventilation syndrome'), (254, 281, 'OTHER', 'home mechanical ventilation'), (442, 474, 'OTHER', 'non-invasive ventilation therapy'), (607, 625, 'OTHER', 'ventilator therapy'), (1111, 1138, 'OTHER', 'home mechanical ventilation'), (1285, 1305, 'OTHER', 'ventilator´s therapy'), (1599, 1621, 'OTHER', 'mechanical ventilation')]"
"['Effect', 'of', 'High', '-', 'quality', 'Pre', '-', 'operative', 'Videos', 'on', 'Patient', 'Anxiety', 'Levels', 'Prior', 'to', 'Ambulatory', 'Hand', 'Surgery', '|', 'Previous', 'research', 'has', 'shown', 'that', 'YouTube', 'is', 'a', 'poor', 'source', 'of', 'high', '-', 'quality', 'medical', 'information', '.', 'This', 'is', 'likely', 'because', 'there', 'is', 'no', 'regulation', 'of', 'the', 'content', 'on', 'YouTube', 'and', 'relatively', 'little', 'of', 'the', 'content', 'is', 'posted', 'by', 'qualified', 'medical', 'professionals', '.', 'It', 'is', 'known', 'that', 'up', 'to', '30', '%', 'of', 'patients', 'use', 'the', 'internet', 'to', 'research', 'the', 'procedure', 'they', 'will', 'be', 'having', 'and', 'given', 'the', 'increasing', 'popularity', 'of', 'YouTube', 'we', 'suspect', 'many', 'patients', 'are', 'using', 'YouTube', 'or', 'similar', 'sites', 'as', 'a', 'source', 'of', 'information', 'prior', 'to', 'elective', 'surgery', '.', 'There', 'are', 'likely', 'a', 'number', 'of', 'patient', 'factors', 'that', 'contribute', 'to', 'patients', 'seeking', 'out', 'videos', 'as', 'a', 'source', 'of', 'pre', '-', 'operative', 'medical', 'information', '.', 'Patient', 'age', ',', 'which', 'is', 'generally', 'inversely', 'correlated', 'to', 'computer', 'literacy', ',', 'may', 'have', 'a', 'role', '.', 'Patient', 'anxiety', 'and', 'pre', '-', 'operative', 'worrying', 'may', 'cause', 'a', 'patient', 'to', 'turn', 'to', 'the', 'internet', 'to', 'search', 'for', 'information', ',', 'and', 'the', 'poor', 'overall', 'quality', 'of', 'the', 'content', 'available', 'may', 'worsen', 'pre', '-', 'operative', 'anxiety', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'providing', 'patients', 'with', 'a', 'reliable', ',', 'high', '-', 'quality', 'video', 'about', 'their', 'condition', 'and', 'operation', 'prior', 'to', 'surgery', 'reduces', 'pre', '-', 'operative', 'anxiety', '.', 'Secondary', 'aims', 'are', 'to', 'determine', 'the', 'percentage', 'of', 'patients', 'that', 'independently', 'seek', 'out', 'videos', 'online', 'as', 'a', 'source', 'of', 'medical', 'information', 'prior', 'to', 'elective', 'hand', 'surgery', ',', 'identify', 'patient', 'attributes', 'that', 'are', 'associated', 'with', 'this', 'behavior', ',', 'and', 'understand', 'if', 'introducing', 'high', 'quality', 'pre', '-', 'surgical', 'videos', 'has', 'an', 'impact', 'on', 'post', '-', 'operative', 'patient', 'outcomes', 'and/or', 'patient', 'engagement', '.', 'The', 'investigators', 'hypothesize', 'that', 'providing', 'patients', 'with', 'high', '-', 'quality', 'pre', '-', 'operative', 'videos', 'will', 'reduce', 'pre', '-', 'operative', 'anxiety', '.', 'Its', 'is', 'also', 'expected', 'that', 'patients', 'who', 'seek', 'out', 'videos', 'on', 'their', 'own', 'for', 'pre', '-', 'operative', 'medical', 'information', 'will', 'be', 'younger', 'and', 'have', 'higher', 'anxiety', 'levels', 'and', 'pain', 'catastrophizing', 'scores', '.', 'Additionally', ',', 'the', 'investigators', 'hypothesize', 'that', 'patients', 'who', 'watch', 'high', '-', 'quality', 'pre', '-', 'operative', 'videos', 'may', 'have', 'better', 'short', 'term', 'post', '-', 'operative', 'outcomes', 'and', 'greater', 'engagement', 'in', 'their', 'care', 'than', 'their', 'counterparts', 'that', 'did', 'not', 'watch', 'videos', 'or', 'who', 'sought', 'out', 'videos', 'on', 'their', 'own', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT04424810,NCT04424810,"Effect of High-quality Pre-operative Videos on Patient Anxiety Levels Prior to Ambulatory Hand Surgery | Previous research has shown that YouTube is a poor source of high-quality medical information. This is likely because there is no regulation of the content on YouTube and relatively little of the content is posted by qualified medical professionals. It is known that up to 30% of patients use the internet to research the procedure they will be having and given the increasing popularity of YouTube we suspect many patients are using YouTube or similar sites as a source of information prior to elective surgery. There are likely a number of patient factors that contribute to patients seeking out videos as a source of pre-operative medical information. Patient age, which is generally inversely correlated to computer literacy, may have a role. Patient anxiety and pre-operative worrying may cause a patient to turn to the internet to search for information, and the poor overall quality of the content available may worsen pre-operative anxiety.

The primary objective of this study is to determine if providing patients with a reliable, high-quality video about their condition and operation prior to surgery reduces pre-operative anxiety. Secondary aims are to determine the percentage of patients that independently seek out videos online as a source of medical information prior to elective hand surgery, identify patient attributes that are associated with this behavior, and understand if introducing high quality pre-surgical videos has an impact on post-operative patient outcomes and/or patient engagement. The investigators hypothesize that providing patients with high-quality pre-operative videos will reduce pre-operative anxiety. Its is also expected that patients who seek out videos on their own for pre-operative medical information will be younger and have higher anxiety levels and pain catastrophizing scores. Additionally, the investigators hypothesize that patients who watch high-quality pre-operative videos may have better short term post-operative outcomes and greater engagement in their care than their counterparts that did not watch videos or who sought out videos on their own.","[(10, 43, 'OTHER', 'High-quality Pre-operative Videos'), (55, 62, 'CONDITION', 'Anxiety'), (90, 102, 'CONDITION', 'Hand Surgery'), (860, 867, 'CONDITION', 'anxiety'), (1045, 1052, 'CONDITION', 'anxiety'), (1136, 1164, 'OTHER', 'reliable, high-quality video'), (1240, 1247, 'CONDITION', 'anxiety'), (1515, 1547, 'OTHER', 'high quality pre-surgical videos'), (1683, 1716, 'OTHER', 'high-quality pre-operative videos'), (1743, 1750, 'CONDITION', 'anxiety'), (1890, 1897, 'CONDITION', 'anxiety'), (2006, 2039, 'OTHER', 'high-quality pre-operative videos'), (2161, 2177, 'CONTROL', 'not watch videos'), (2196, 2215, 'CONTROL', 'videos on their own')]"
"['IMPROVING', 'WALKING', 'AND', 'BALANCE', 'IN', 'VETERANS', 'WITH', 'TRAUMATIC', 'BRAIN', 'INJURY', ':', 'A', 'PILOT', 'STUDY', 'EXAMINING', 'FEASIBILITY', 'AND', 'DOSAGE', '|', 'This', 'is', 'a', 'case', 'series', 'study', 'evaluating', 'the', 'feasibility', 'and', 'dosage', 'of', 'Intensive', 'Mobility', 'Training', '(', 'IMT', ')', '.', 'Twelve', 'participants', 'with', 'chronic', ',', 'mild', '-', 'to', '-', 'moderate', ',', 'Traumatic', 'Brain', 'Injury', '(', 'TBI', ')', 'causing', 'significant', 'locomotor', 'impairment', ',', 'who', 'meet', 'these', 'specific', 'criteria', ',', 'will', 'be', 'recruited', '.', 'Location', 'and', 'nature', 'of', 'neural', 'insult', 'will', 'be', 'determined', 'by', 'multimodal', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', 'exam', '.', 'All', 'participants', 'will', 'receive', '3', 'hours', 'of', 'rehabilitation', 'per', 'day', 'for', '20', 'days', ',', 'focusing', 'on', 'gait', 'and', 'balance', '.', 'Locomotion', 'and', 'balance', 'will', 'be', 'comprehensively', 'tested', 'prior', 'to', 'IMT', ',', 'after', '10', 'days', 'of', 'IMT', ',', 'and', 'then', 'again', 'after', 'the', 'full', 'dose', 'of', 'IMT', '.', 'This', 'study', 'will', 'determine', 'the', 'feasibility', 'of', 'this', 'intervention', 'in', 'the', 'population', 'of', 'TBI', 'patients', ',', 'allow', 'an', 'estimate', 'of', 'effect', 'size', 'and', 'provide', 'initial', 'information', 'on', 'possible', 'neural', 'predictors', 'of', 'success', '.', 'Furthermore', 'the', 'investigators', 'will', 'be', 'able', 'to', 'determine', 'whether', 'the', 'dosage', 'of', '10', 'days', 'is', 'sufficient', 'or', 'whether', 'significant', 'improvements', 'are', 'made', 'with', '20', 'days', 'of', 'the', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01418976,NCT01418976,"IMPROVING WALKING AND BALANCE IN VETERANS WITH TRAUMATIC BRAIN INJURY: A PILOT STUDY EXAMINING FEASIBILITY AND DOSAGE | This is a case series study evaluating the feasibility and dosage of Intensive Mobility Training (IMT). Twelve participants with chronic, mild-to-moderate, Traumatic Brain Injury (TBI) causing significant locomotor impairment, who meet these specific criteria, will be recruited. Location and nature of neural insult will be determined by multimodal Magnetic Resonance Imaging (MRI) exam. All participants will receive 3 hours of rehabilitation per day for 20 days, focusing on gait and balance. Locomotion and balance will be comprehensively tested prior to IMT, after 10 days of IMT, and then again after the full dose of IMT. This study will determine the feasibility of this intervention in the population of TBI patients, allow an estimate of effect size and provide initial information on possible neural predictors of success. Furthermore the investigators will be able to determine whether the dosage of 10 days is sufficient or whether significant improvements are made with 20 days of the intervention.","[(47, 69, 'CONDITION', 'TRAUMATIC BRAIN INJURY'), (189, 216, 'PHYSICAL', 'Intensive Mobility Training'), (218, 221, 'PHYSICAL', 'IMT'), (249, 298, 'CONDITION', 'chronic, mild-to-moderate, Traumatic Brain Injury'), (300, 303, 'CONDITION', 'TBI'), (679, 682, 'PHYSICAL', 'IMT'), (701, 704, 'PHYSICAL', 'IMT'), (744, 747, 'PHYSICAL', 'IMT'), (833, 836, 'CONDITION', 'TBI')]"
"['Phase', '1', 'Study', 'of', 'B7', '-', 'H3', '-', 'Specific', 'CAR', 'T', 'Cell', 'Locoregional', 'Immunotherapy', 'for', 'Diffuse', 'Intrinsic', 'Pontine', 'Glioma', '/', 'Diffuse', 'Midline', 'Glioma', 'and', 'Recurrent', 'or', 'Refractory', 'Pediatric', 'Central', 'Nervous', 'System', 'Tumors', '|', 'This', 'is', 'a', 'Phase', '1', 'study', 'of', 'central', 'nervous', 'system', '(', 'CNS', ')', 'locoregional', 'adoptive', 'therapy', 'with', 'autologous', 'CD4', '+', 'and', 'CD8', '+', 'T', 'cells', 'lentivirally', 'transduced', 'to', 'express', 'a', 'B7H3', '-', 'specific', 'chimeric', 'antigen', 'receptor', '(', 'CAR', ')', 'and', 'EGFRt', '.', 'CAR', 'T', 'cells', 'are', 'delivered', 'via', 'an', 'indwelling', 'catheter', 'into', 'the', 'tumor', 'resection', 'cavity', 'or', 'ventricular', 'system', 'in', 'children', 'and', 'young', 'adults', 'with', 'diffuse', 'intrinsic', 'pontine', 'glioma', '(', 'DIPG', ')', ',', 'diffuse', 'midline', 'glioma', '(', 'DMG', ')', ',', 'and', 'recurrent', 'or', 'refractory', 'CNS', 'tumors', '.', '\n\n', 'A', 'child', 'or', 'young', 'adult', 'meeting', 'all', 'eligibility', 'criteria', ',', 'including', 'having', 'a', 'CNS', 'catheter', 'placed', 'into', 'the', 'tumor', 'resection', 'cavity', 'or', 'into', 'their', 'ventricular', 'system', ',', 'and', 'meeting', 'none', 'of', 'the', 'exclusion', 'criteria', ',', 'will', 'have', 'their', 'T', 'cells', 'collected', '.', 'The', 'T', 'cells', 'will', 'then', 'be', 'bioengineered', 'into', 'a', 'second', '-', 'generation', 'CAR', 'T', 'cell', 'that', 'targets', 'B7H3', '-', 'expressing', 'tumor', 'cells', '.', 'Patients', 'will', 'be', 'assigned', 'to', 'one', 'of', '3', 'treatment', 'arms', 'based', 'on', 'location', 'or', 'type', 'of', 'their', 'tumor', '.', 'Patients', 'with', 'supratentorial', 'tumors', 'will', 'be', 'assigned', 'to', 'Arm', 'A', ',', 'and', 'will', 'receive', 'their', 'treatment', 'into', 'the', 'tumor', 'cavity', '.', 'Patients', 'with', 'either', 'infratentorial', 'or', 'metastatic', '/', 'leptomeningeal', 'tumors', 'will', 'be', 'assigned', 'to', 'Arm', 'B', ',', 'and', 'will', 'have', 'their', 'treatment', 'delivered', 'into', 'the', 'ventricular', 'system', '.', 'The', 'first', '3', 'patients', 'enrolled', 'onto', 'the', 'study', 'must', 'be', 'at', 'least', '15', 'years', 'of', 'age', 'and', 'assigned', 'to', 'Arm', 'A', 'or', 'Arm', 'B.', 'Patients', 'with', 'DIPG', 'will', 'be', 'assigned', 'to', 'Arm', 'C', 'and', 'have', 'their', 'treatment', 'delivered', 'into', 'the', 'ventricular', 'system', '.', 'The', 'patient', ""'s"", 'newly', 'engineered', 'T', 'cells', 'will', 'be', 'administered', 'via', 'the', 'indwelling', 'catheter', 'for', 'two', 'courses', '.', 'In', 'the', 'first', 'course', 'patients', 'in', 'Arms', 'A', 'and', 'B', 'will', 'receive', 'a', 'weekly', 'dose', 'of', 'CAR', 'T', 'cells', 'for', 'three', 'weeks', ',', 'followed', 'by', 'a', 'week', 'off', ',', 'an', 'examination', 'period', ',', 'and', 'then', 'another', 'course', 'of', 'weekly', 'doses', 'for', 'three', 'weeks', '.', 'Patients', 'in', 'Arm', 'C', 'will', 'receive', 'a', 'dose', 'of', 'CAR', 'T', 'cells', 'every', 'other', 'week', 'for', '3', 'weeks', ',', 'followed', 'by', 'a', 'week', 'off', ',', 'an', 'examination', 'period', ',', 'and', 'then', 'dosing', 'every', 'other', 'week', 'for', '3', 'weeks', '.', 'Following', 'the', 'two', 'courses', ',', 'patients', 'in', 'all', 'Arms', 'will', 'undergo', 'a', 'series', 'of', 'studies', 'including', 'MRI', 'to', 'evaluate', 'the', 'effect', 'of', 'the', 'CAR', 'T', 'cells', 'and', 'may', 'have', 'the', 'opportunity', 'to', 'continue', 'receiving', 'additional', 'courses', 'of', 'CAR', 'T', 'cells', 'if', 'the', 'patient', 'has', 'not', 'had', 'adverse', 'effects', 'and', 'if', 'more', 'of', 'their', 'T', 'cells', 'are', 'available', '.', '\n\n', 'The', 'hypothesis', 'is', 'that', 'an', 'adequate', 'amount', 'of', 'B7H3', '-', 'specific', 'CAR', 'T', 'cells', 'can', 'be', 'manufactured', 'to', 'complete', 'two', 'courses', 'of', 'treatment', 'with', '3', 'or', '2', 'doses', 'given', 'on', 'a', 'weekly', 'schedule', 'followed', 'by', 'one', 'week', 'off', 'in', 'each', 'course', '.', 'The', 'other', 'hypothesis', 'is', 'that', 'B7H3', '-', 'specific', 'CAR', 'T', 'cells', 'can', 'safely', 'be', 'administered', 'through', 'an', 'indwelling', 'CNS', 'catheter', 'or', 'delivered', 'directly', 'into', 'the', 'brain', 'via', 'indwelling', 'catheter', 'to', 'allow', 'the', 'T', 'cells', 'to', 'directly', 'interact', 'with', 'the', 'tumor', 'cells', 'for', 'each', 'patient', 'enrolled', 'on', 'the', 'study', '.', 'Secondary', 'aims', 'of', 'the', 'study', 'will', 'include', 'evaluating', 'CAR', 'T', 'cell', 'distribution', 'with', 'the', 'cerebrospinal', 'fluid', '(', 'CSF', ')', ',', 'the', 'extent', 'to', 'which', 'CAR', 'T', 'cells', 'egress', 'or', 'traffic', 'into', 'the', 'peripheral', 'circulation', 'or', 'blood', 'stream', ',', 'and', ',', 'if', 'tissues', 'samples', 'from', 'multiple', 'timepoints', 'are', 'available', ',', 'also', 'evaluate', 'disease', 'response', 'to', 'B7', '-', 'H3', 'CAR', 'T', 'cell', 'locoregional', 'therapy', '.']","['O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O']",NCT04185038,NCT04185038,"Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and recurrent or refractory CNS tumors.

A child or young adult meeting all eligibility criteria, including having a CNS catheter placed into the tumor resection cavity or into their ventricular system, and meeting none of the exclusion criteria, will have their T cells collected. The T cells will then be bioengineered into a second-generation CAR T cell that targets B7H3-expressing tumor cells. Patients will be assigned to one of 3 treatment arms based on location or type of their tumor. Patients with supratentorial tumors will be assigned to Arm A, and will receive their treatment into the tumor cavity. Patients with either infratentorial or metastatic/leptomeningeal tumors will be assigned to Arm B, and will have their treatment delivered into the ventricular system. The first 3 patients enrolled onto the study must be at least 15 years of age and assigned to Arm A or Arm B. Patients with DIPG will be assigned to Arm C and have their treatment delivered into the ventricular system. The patient's newly engineered T cells will be administered via the indwelling catheter for two courses. In the first course patients in Arms A and B will receive a weekly dose of CAR T cells for three weeks, followed by a week off, an examination period, and then another course of weekly doses for three weeks. Patients in Arm C will receive a dose of CAR T cells every other week for 3 weeks, followed by a week off, an examination period, and then dosing every other week for 3 weeks. Following the two courses, patients in all Arms will undergo a series of studies including MRI to evaluate the effect of the CAR T cells and may have the opportunity to continue receiving additional courses of CAR T cells if the patient has not had adverse effects and if more of their T cells are available.

The hypothesis is that an adequate amount of B7H3-specific CAR T cells can be manufactured to complete two courses of treatment with 3 or 2 doses given on a weekly schedule followed by one week off in each course. The other hypothesis is that B7H3-specific CAR T cells can safely be administered through an indwelling CNS catheter or delivered directly into the brain via indwelling catheter to allow the T cells to directly interact with the tumor cells for each patient enrolled on the study. Secondary aims of the study will include evaluating CAR T cell distribution with the cerebrospinal fluid (CSF), the extent to which CAR T cells egress or traffic into the peripheral circulation or blood stream, and, if tissues samples from multiple timepoints are available, also evaluate disease response to B7-H3 CAR T cell locoregional therapy.","[(17, 42, 'SURGICAL', 'B7-H3-Specific CAR T Cell'), (74, 106, 'CONDITION', 'Diffuse Intrinsic Pontine Glioma'), (107, 129, 'CONDITION', 'Diffuse Midline Glioma'), (134, 197, 'CONDITION', 'Recurrent or Refractory Pediatric Central Nervous System Tumors'), (291, 416, 'SURGICAL', 'autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt'), (418, 429, 'SURGICAL', 'CAR T cells'), (480, 485, 'CONDITION', 'tumor'), (559, 591, 'CONDITION', 'diffuse intrinsic pontine glioma'), (593, 597, 'CONDITION', 'DIPG'), (600, 622, 'CONDITION', 'diffuse midline glioma'), (624, 627, 'CONDITION', 'DMG'), (634, 668, 'CONDITION', 'recurrent or refractory CNS tumors'), (776, 781, 'CONDITION', 'tumor'), (958, 986, 'SURGICAL', 'second-generation CAR T cell'), (1016, 1021, 'CONDITION', 'tumor'), (1117, 1122, 'CONDITION', 'tumor'), (1138, 1159, 'CONDITION', 'supratentorial tumors'), (1229, 1234, 'CONDITION', 'tumor'), (1264, 1314, 'CONDITION', 'infratentorial or metastatic/leptomeningeal tumors'), (1535, 1539, 'CONDITION', 'DIPG'), (1810, 1821, 'SURGICAL', 'CAR T cells'), (1984, 1995, 'SURGICAL', 'CAR T cells'), (2244, 2255, 'SURGICAL', 'CAR T cells'), (2329, 2340, 'SURGICAL', 'CAR T cells'), (2474, 2499, 'SURGICAL', 'B7H3-specific CAR T cells'), (2672, 2697, 'SURGICAL', 'B7H3-specific CAR T cells'), (2834, 2841, 'SURGICAL', 'T cells'), (2872, 2877, 'CONDITION', 'tumor'), (2976, 2986, 'SURGICAL', 'CAR T cell'), (3056, 3067, 'SURGICAL', 'CAR T cells'), (3233, 3249, 'SURGICAL', 'B7-H3 CAR T cell')]"
"['Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', ',', 'Active', '-', 'controlled', ',', 'Superiority', 'Study', 'to', 'Compare', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Ponesimod', 'to', 'Teriflunomide', 'in', 'Subjects', 'With', 'Relapsing', 'Multiple', 'Sclerosis', '|', 'International', 'clinical', 'trial', 'to', 'compare', 'ponesimod', 'and', 'teriflunomide', 'in', 'relapsing', 'multiple', 'sclerosis']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT02425644,NCT02425644,"Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis | International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis","[(130, 139, 'DRUG', 'Ponesimod'), (143, 156, 'DRUG', 'Teriflunomide'), (174, 202, 'CONDITION', 'Relapsing Multiple Sclerosis'), (245, 254, 'DRUG', 'ponesimod'), (259, 272, 'DRUG', 'teriflunomide'), (276, 304, 'CONDITION', 'relapsing multiple sclerosis')]"
"['Effectiveness', 'of', 'Dry', 'Needling', '(', 'DNHS', 'Technique', ')', 'in', 'Patients', 'With', 'Chronic', 'Stroke', '|', 'Study', 'hypothesis', ':', '\n\n', 'The', 'DNHS', 'technique', ',', 'performed', 'via', 'one', 'session', 'of', 'deep', 'dry', 'needling', 'of', 'myofascial', 'trigger', 'points', 'applied', 'to', 'the', 'biceps', 'brachii', ',', 'brachialis', ',', 'flexor', 'digitorum', 'superficialis', ',', 'flexor', 'digitorum', 'profundus', ',', 'triceps', 'brachii', ',', 'extensor', 'digitorum', 'and', 'adductor', 'pollicis', 'muscle', 'is', 'effective', 'for', 'decreasing', 'spasticity', 'and', 'muscle', 'stiffness', '(', 'both', 'of', 'which', 'are', 'components', 'of', 'hypertonia', ')', 'as', 'well', 'as', 'for', 'improving', 'the', 'upper', 'limb', 'function', 'of', 'the', 'previously', 'described', 'muscles', 'in', 'patients', 'with', 'chronic', 'cerebral', 'vascular', 'accident', '(', 'CVA', ')', ',', 'assessed', 'both', 'post', '-', 'intervention', 'and', 'after', '15', 'days', '.', '\n\n', 'General', 'aims', '\n\n', 'To', 'analyse', 'the', 'immediate', 'therapeutic', 'effect', 'of', 'the', 'DNHS', 'technique', 'and', 'the', 'effect', 'at', '15', 'days', 'follow', '-', 'up', ',', 'for', 'the', 'following', 'variables', ':', '\n\n', 'Spasticity', '\n', 'Muscle', 'stiffness', '\n', 'Upper', 'limb', 'function', '\n', 'Patient', 'perceived', 'quality', 'of', 'life', '\n\n', 'Materials', 'and', 'methods', 'Population', ':', 'patients', 'from', 'the', 'province', 'of', 'Zaragoza', '(', 'Spain', ')', 'diagnosed', 'with', 'a', 'haemorrhagic', 'or', 'ischemic', 'CVA', 'by', 'a', 'neurologist', '.', '\n\n', 'Recruitment', 'strategy', ':', 'recruitment', 'will', 'take', 'place', 'via', 'the', 'Stroke', 'Association', 'in', 'Aragon', '(', 'AIDA', ')', '[', 'Aragon', 'Stroke', 'Association', ']', 'in', 'the', 'province', 'of', 'Zaragoza', ',', 'Spain', ',', 'seeing', 'as', 'the', 'greater', 'proportion', 'of', 'patients', 'who', 'have', 'suffered', 'a', 'stroke', 'and', 'are', 'in', 'the', 'chronic', 'stage', 'of', 'the', 'illness', 'go', 'to', 'this', 'centre', 'to', 'receive', 'treatment', '.', 'Thus', ',', 'this', 'avoids', 'patients', 'having', 'to', 'travel', 'elsewhere', 'for', 'the', 'study', '.', 'Furthermore', ',', 'in', 'the', 'case', 'of', 'patients', 'who', 'wish', 'to', 'participate', 'in', 'the', 'study', 'after', 'having', 'received', 'information', 'via', 'third', 'persons', 'or', 'via', 'other', 'means', 'and', 'who', 'are', 'not', 'members', 'of', 'the', 'Association', 'or', 'do', 'not', 'attend', 'the', 'centre', 'on', 'a', 'regular', 'basis', ',', 'the', 'Association', 'AIDA', 'has', 'offered', 'to', 'allow', 'these', 'people', 'to', 'attend', 'for', 'free', ',', 'making', 'its', 'facilities', 'available', 'and', 'supporting', 'the', 'development', 'of', 'this', 'study', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03546517,NCT03546517,"Effectiveness of Dry Needling (DNHS Technique) in Patients With Chronic Stroke | Study hypothesis:

The DNHS technique, performed via one session of deep dry needling of myofascial trigger points applied to the biceps brachii, brachialis, flexor digitorum superficialis, flexor digitorum profundus, triceps brachii, extensor digitorum and adductor pollicis muscle is effective for decreasing spasticity and muscle stiffness (both of which are components of hypertonia) as well as for improving the upper limb function of the previously described muscles in patients with chronic cerebral vascular accident (CVA), assessed both post-intervention and after 15 days.

General aims

To analyse the immediate therapeutic effect of the DNHS technique and the effect at 15 days follow-up, for the following variables:

Spasticity
Muscle stiffness
Upper limb function
Patient perceived quality of life

Materials and methods Population: patients from the province of Zaragoza (Spain) diagnosed with a haemorrhagic or ischemic CVA by a neurologist.

Recruitment strategy: recruitment will take place via the Stroke Association in Aragon (AIDA) [Aragon Stroke Association] in the province of Zaragoza, Spain, seeing as the greater proportion of patients who have suffered a stroke and are in the chronic stage of the illness go to this centre to receive treatment. Thus, this avoids patients having to travel elsewhere for the study. Furthermore, in the case of patients who wish to participate in the study after having received information via third persons or via other means and who are not members of the Association or do not attend the centre on a regular basis, the Association AIDA has offered to allow these people to attend for free, making its facilities available and supporting the development of this study.","[(17, 29, 'OTHER', 'Dry Needling'), (31, 45, 'OTHER', 'DNHS Technique'), (64, 78, 'CONDITION', 'Chronic Stroke'), (104, 108, 'OTHER', 'DNHS'), (149, 195, 'OTHER', 'deep dry needling of myofascial trigger points'), (392, 402, 'CONDITION', 'spasticity'), (407, 423, 'CONDITION', 'muscle stiffness'), (457, 467, 'CONDITION', 'hypertonia'), (571, 605, 'CONDITION', 'chronic cerebral vascular accident'), (607, 610, 'CONDITION', 'CVA'), (730, 734, 'OTHER', 'DNHS'), (812, 822, 'CONDITION', 'Spasticity'), (823, 839, 'CONDITION', 'Muscle stiffness'), (1018, 1021, 'CONDITION', 'CVA'), (1264, 1270, 'CONDITION', 'stroke')]"
"['A', 'Phase', 'III', 'Study', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', '3APS', 'as', 'Add', '-', 'on', 'Therapy', 'in', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'Phase', '3', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', '3APS', 'as', 'an', 'add', '-', 'on', 'therapy', 'to', 'most', 'standard', 'medication', 'for', 'Alzheimer', ""'s"", 'disease', 'compared', 'to', 'placebo', '(', 'inactive', 'substance', 'pill', ')', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00217763,NCT00217763,A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease | The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.,"[(48, 52, 'DRUG', '3APS'), (74, 110, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (189, 193, 'DRUG', '3APS'), (247, 266, 'CONDITION', ""Alzheimer's disease""), (288, 311, 'CONTROL', 'inactive substance pill'), (330, 366, 'CONDITION', ""mild to moderate Alzheimer's disease"")]"
"['Remotely', 'Delivered', 'Environmental', 'Enrichment', 'Intervention', 'for', 'Traumatic', 'Brain', 'Injury', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'will', 'examine', 'the', 'behavioural', 'and', 'neurophysiological', 'efficacy', 'and', 'feasibility', 'of', 'an', 'online', 'spatial', 'navigation', 'intervention', 'for', 'improving', 'memory', 'and', 'brain', 'health', 'in', 'individuals', 'who', 'have', 'sustained', 'moderate', '-', 'severe', 'traumatic', 'brain', 'injury', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04331392,NCT04331392,Remotely Delivered Environmental Enrichment Intervention for Traumatic Brain Injury: A Randomized Controlled Trial | This study will examine the behavioural and neurophysiological efficacy and feasibility of an online spatial navigation intervention for improving memory and brain health in individuals who have sustained moderate-severe traumatic brain injury.,"[(19, 43, 'OTHER', 'Environmental Enrichment'), (61, 83, 'CONDITION', 'Traumatic Brain Injury'), (211, 236, 'OTHER', 'online spatial navigation'), (322, 360, 'CONDITION', 'moderate-severe traumatic brain injury')]"
"['An', 'Open', '-', 'Label', 'Study', 'of', 'Diazoxide', 'Choline', 'Controlled', '-', 'Release', 'Tablet', 'in', 'Patients', 'With', 'Prader', '-', 'Willi', 'Syndrome', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'monitor', 'the', 'long', '-', 'term', 'safety', 'of', 'DCCR', 'in', 'PWS', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O']",NCT04086810,NCT04086810,An Open-Label Study of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome | The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.,"[(23, 40, 'DRUG', 'Diazoxide Choline'), (84, 105, 'CONDITION', 'Prader-Willi Syndrome'), (182, 186, 'DRUG', 'DCCR'), (190, 193, 'CONDITION', 'PWS')]"
"['Comparison', 'of', 'Keppra', 'and', 'Clonidine', 'in', 'the', 'Treatment', 'of', 'Tics', 'in', 'Children', 'With', 'Tourette', 'Syndrome', '|', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'confirm', 'that', 'levetiracetam', 'has', 'a', 'better', 'tic', '-', 'suppressing', 'profile', 'than', 'that', 'of', 'the', 'widely', 'used', 'tic', '-', 'suppressing', 'medication', ',', 'clonidine', '.', 'More', 'specifically', ',', 'the', 'investigators', 'hypothesize', 'that', 'in', 'a', '15', 'week', 'placebo', 'run', '-', 'in', ',', 'double', '-', 'blind', ',', 'medication', 'cross', '-', 'over', 'trial', ';', 'levetiracetam', 'will', 'be', 'more', 'effective', 'and', 'have', 'fewer', 'side', '-', 'effects', 'than', 'clonidine', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00370838,NCT00370838,"Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome | The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effective and have fewer side-effects than clonidine.","[(14, 20, 'DRUG', 'Keppra'), (25, 34, 'DRUG', 'Clonidine'), (55, 59, 'CONDITION', 'Tics'), (77, 94, 'CONDITION', 'Tourette Syndrome'), (139, 152, 'DRUG', 'levetiracetam'), (166, 169, 'CONDITION', 'tic'), (219, 222, 'CONDITION', 'tic'), (247, 256, 'DRUG', 'clonidine'), (325, 332, 'CONTROL', 'placebo'), (384, 397, 'DRUG', 'levetiracetam'), (454, 463, 'DRUG', 'clonidine')]"
"['CPAP', 'Treatment', ':', 'Fixed', 'Versus', 'Auto', '-', 'adjusting', 'Mode', 'Impact', 'on', 'Clinical', 'Blood', 'Arterial', 'Pressure', '.', 'Randomised', ',', 'Controlled', 'and', 'Double', 'Blinded', 'Trial', 'in', 'SAOS', 'Patients', '|', 'Background', ':', 'Continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'is', 'the', 'first', 'line', 'therapy', 'for', 'obstructive', 'sleep', 'apnea', 'syndrome', '(', 'OSAS', ')', '.', 'Two', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'modalities', 'can', 'be', 'used', ':', 'Fixed', 'pressure', ',', 'in', 'which', 'the', 'effective', 'pressure', 'is', 'set', 'and', 'kept', 'constant', 'all', 'night', ',', 'and', 'auto', 'CPAP', 'devices', 'where', 'the', 'positive', 'pressure', 'changes', 'during', 'the', 'night', 'depend', 'on', 'patient', ""'s"", 'requirements', '.', '\n\n', 'Hypothesis', ':', 'Pressure', 'variations', 'associated', 'with', 'autoCPAP', 'functioning', 'can', 'lead', 'to', 'sleep', 'fragmentation', 'and', 'alterations', 'in', 'sleep', 'structure', '.', 'This', 'can', 'limit', 'blood', 'pressure', 'dipping', 'during', 'sleep', 'and', 'then', 'impact', 'clinical', 'blood', 'pressure', 'reduction', '.', '\n\n', 'Main', 'objective', ':', 'To', 'compare', 'in', 'a', 'randomized', 'controlled', 'trial', '4', 'months', 'clinical', 'blood', 'pressure', '(', 'BP', ')', 'evolution', 'depending', 'on', 'CPAP', 'mode', ':', 'fixed', 'pressure', 'versus', 'autoCPAP', '.', 'Secondary', 'outcomes', ':', 'Evolution', 'of', 'arterial', 'stiffness', ',', 'biological', 'parameters', ',', 'quality', 'of', 'life', 'and', 'symptoms', '.', '\n\n', 'Methods', ':', 'Patients', 'will', 'be', 'randomised', 'depending', 'on', 'CPAP', 'mode', '.', 'Baseline', 'and', '4', 'months', 'evaluation', 'will', 'include', ':', '24', '-', 'h', 'ambulatory', 'blood', 'pressure', 'monitoring', ',', 'clinical', 'BP', 'measurements', 'and', 'carotid', '-', 'to', '-', 'femoral', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', '.', 'Patients', 'will', 'also', 'complete', 'quality', 'of', 'life', 'and', 'symptoms', 'questionnaires', '.', '\n\n', '2', 'interim', 'analysis', 'will', 'be', 'carried', 'out', 'when', '150', 'and', '220', 'patients', 'respectively', 'will', 'have', 'completed', 'the', 'study', '.', 'The', 'Peto', ""'s"", 'method', 'will', 'be', 'used', 'to', 'correct', 'the', 'p', '-', 'values', '.']","['B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01090297,NCT01090297,"CPAP Treatment : Fixed Versus Auto-adjusting Mode Impact on Clinical Blood Arterial Pressure. Randomised, Controlled and Double Blinded Trial in SAOS Patients | Background: Continuous positive airway pressure (CPAP) is the first line therapy for obstructive sleep apnea syndrome (OSAS). Two positive airway pressure (PAP) modalities can be used: Fixed pressure, in which the effective pressure is set and kept constant all night, and auto CPAP devices where the positive pressure changes during the night depend on patient's requirements.

Hypothesis: Pressure variations associated with autoCPAP functioning can lead to sleep fragmentation and alterations in sleep structure. This can limit blood pressure dipping during sleep and then impact clinical blood pressure reduction.

Main objective: To compare in a randomized controlled trial 4 months clinical blood pressure (BP) evolution depending on CPAP mode: fixed pressure versus autoCPAP. Secondary outcomes: Evolution of arterial stiffness, biological parameters, quality of life and symptoms.

Methods: Patients will be randomised depending on CPAP mode. Baseline and 4 months evaluation will include: 24-h ambulatory blood pressure monitoring, clinical BP measurements and carotid-to-femoral pulse wave velocity (PWV). Patients will also complete quality of life and symptoms questionnaires.

2 interim analysis will be carried out when 150 and 220 patients respectively will have completed the study. The Peto's method will be used to correct the p-values.","[(0, 4, 'OTHER', 'CPAP'), (145, 149, 'CONDITION', 'SAOS'), (173, 208, 'OTHER', 'Continuous positive airway pressure'), (210, 214, 'OTHER', 'CPAP'), (246, 278, 'CONDITION', 'obstructive sleep apnea syndrome'), (280, 284, 'CONDITION', 'OSAS'), (346, 360, 'OTHER', 'Fixed pressure'), (434, 443, 'OTHER', 'auto CPAP'), (901, 905, 'OTHER', 'CPAP'), (912, 926, 'OTHER', 'fixed pressure'), (934, 942, 'OTHER', 'autoCPAP'), (1101, 1105, 'OTHER', 'CPAP')]"
"['The', 'Effects', 'of', 'Focal', 'Vibration', 'on', 'Central', 'and', 'Peripheral', 'Spasticity', 'in', 'Multiple', 'Sclerosis', 'Patients', '.', 'A', 'Randomized', ',', 'Multicenter', ',', 'Double', 'Blinded', 'vs', 'Placebo', 'Study', '|', 'This', 'trial', 'consists', 'of', 'application', 'of', 'little', 'devices', '(', 'named', 'Equistasi', '®', ')', 'generating', 'focal', 'vibrations', 'to', 'treat', 'spasticity', 'in', 'neurological', 'patients', ',', 'affected', 'by', 'multiple', 'sclerosis', '.', 'The', 'expected', 'effects', 'are', 'on', 'gait', 'and', 'postural', 'instability', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02848898,NCT02848898,"The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study | This trial consists of application of little devices (named Equistasi®) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis. The expected effects are on gait and postural instability.","[(15, 30, 'OTHER', 'Focal Vibration'), (34, 67, 'CONDITION', 'Central and Peripheral Spasticity'), (71, 89, 'CONDITION', 'Multiple Sclerosis'), (145, 152, 'CONTROL', 'Placebo'), (221, 230, 'OTHER', 'Equistasi'), (244, 260, 'OTHER', 'focal vibrations'), (270, 280, 'CONDITION', 'spasticity'), (319, 337, 'CONDITION', 'multiple sclerosis')]"
"['Systematic', 'Search', 'for', 'Primary', 'Immunodeficiency', 'in', 'Adults', 'With', 'Unexplained', 'Recurrent', 'and/or', 'Severe', 'Infections', 'With', 'Encapsulated', 'Bacteria', '|', 'Antibody', 'deficiencies', 'and', 'complement', 'deficiencies', 'are', 'the', 'most', 'frequent', 'Primary', 'immunodeficiencies', '(', 'PIDs', ')', 'in', 'adults', ',', 'and', 'are', 'associated', 'with', 'greatly', 'increased', 'susceptibility', 'to', 'recurrent', 'and/or', 'severe', 'bacterial', 'infections', '-', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', 'and', 'meningitis', '.', 'The', 'literature', 'data', 'suggest', 'that', 'PIDs', 'are', 'under', '-', 'diagnosed', 'in', 'adults', '.', 'The', 'current', 'European', 'and', 'US', 'guidelines', 'advocate', 'screening', 'adults', 'for', 'PIDs', 'if', 'they', 'present', 'recurrent', 'benign', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', ',', 'or', 'if', 'they', 'have', 'experienced', 'at', 'least', 'two', 'severe', 'bacterial', 'infections', 'and/or', 'have', 'a', 'recurrent', 'need', 'for', 'intravenous', 'antibiotics', '.', 'The', 'objective', 'of', 'the', 'demonstrate', 'the', 'interest', 'of', 'PIDs', 'screening', 'in', 'adult', 'patients', 'who', 'present', 'such', 'recurrent', 'infections', 'and/or', 'after', 'the', 'first', 'severe', 'bacterial', 'infection', ',', 'especially', 'when', 'the', 'patients', 'do', 'not', 'present', 'with', 'known', ',', 'etiologically', 'relevant', 'comorbidities', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02972281,NCT02972281,"Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria | Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections - especially upper and lower respiratory tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in adults. The current European and US guidelines advocate screening adults for PIDs if they present recurrent benign especially upper and lower respiratory tract infections, or if they have experienced at least two severe bacterial infections and/or have a recurrent need for intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in adult patients who present such recurrent infections and/or after the first severe bacterial infection, especially when the patients do not present with known, etiologically relevant comorbidities.","[(22, 46, 'CONDITION', 'Primary Immunodeficiency'), (62, 135, 'CONDITION', 'Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria'), (138, 159, 'CONDITION', 'Antibody deficiencies'), (164, 187, 'CONDITION', 'complement deficiencies'), (210, 236, 'CONDITION', 'Primary immunodeficiencies'), (238, 242, 'CONDITION', 'PIDs'), (315, 359, 'CONDITION', 'recurrent and/or severe bacterial infections'), (467, 471, 'CONDITION', 'PIDs'), (572, 576, 'CONDITION', 'PIDs'), (621, 665, 'CONDITION', 'upper and lower respiratory tract infections'), (715, 735, 'CONDITION', 'bacterial infections'), (843, 847, 'CONDITION', 'PIDs'), (893, 913, 'CONDITION', 'recurrent infections'), (937, 963, 'CONDITION', 'severe bacterial infection')]"
"['Testing', 'the', 'Effect', 'of', 'Speeded', 'Anomia', 'Therapy', 'in', 'Patients', 'With', 'Chronic', 'Post', '-', 'stroke', 'Aphasia', ':', 'a', 'Cross', '-', 'over', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'main', 'aim', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'a', 'novel', ',', 'speeded', 'anomia', 'therapy', '(', 'Conroy', 'et', 'al', '.', ',', '2018', ')', 'in', 'a', 'large', 'population', 'of', 'patients', 'with', 'chronic', 'post', '-', 'stroke', 'aphasia', '.', 'The', 'treatment', 'will', 'be', 'delivered', 'via', 'a', 'web', 'application', '(', 'QuickWord', ')', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05512884,NCT05512884,"Testing the Effect of Speeded Anomia Therapy in Patients With Chronic Post-stroke Aphasia: a Cross-over Randomized Controlled Trial | The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).","[(22, 44, 'OTHER', 'Speeded Anomia Therapy'), (62, 89, 'CONDITION', 'Chronic Post-stroke Aphasia'), (201, 223, 'OTHER', 'speeded anomia therapy'), (285, 312, 'CONDITION', 'chronic post-stroke aphasia')]"
"['Effects', 'of', 'Mechanical', 'Insufflation', '-', 'exsufflation', 'in', 'Stroke', 'Patients', 'With', 'Dysphagia', '-', 'Pilot', 'Study', '|', 'Stroke', 'patients', 'with', 'dysphagia', 'have', 'restrictive', 'lung', 'dysfunction', 'and', 'impaired', 'cough', 'response', '.', 'This', 'pilot', 'study', 'was', 'performed', 'to', 'determine', 'if', 'Mechanical', 'Insufflation', 'Exsufflation', '(', 'MIE', ')', 'therapy', 'can', 'help', 'recover', 'impaired', 'cough', 'function', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02080806,NCT02080806,Effects of Mechanical Insufflation-exsufflation in Stroke Patients With Dysphagia - Pilot Study | Stroke patients with dysphagia have restrictive lung dysfunction and impaired cough response. This pilot study was performed to determine if Mechanical Insufflation Exsufflation (MIE) therapy can help recover impaired cough function.,"[(11, 47, 'OTHER', 'Mechanical Insufflation-exsufflation'), (51, 57, 'CONDITION', 'Stroke'), (72, 81, 'CONDITION', 'Dysphagia'), (98, 104, 'CONDITION', 'Stroke'), (119, 128, 'CONDITION', 'dysphagia'), (146, 162, 'CONDITION', 'lung dysfunction'), (167, 190, 'CONDITION', 'impaired cough response'), (239, 275, 'OTHER', 'Mechanical Insufflation Exsufflation'), (277, 280, 'OTHER', 'MIE'), (307, 330, 'CONDITION', 'impaired cough function')]"
"['The', 'Role', 'of', 'Anxiety', 'Sensitivity', 'in', 'the', 'Maintenance', 'of', 'Chronic', 'Post', 'Concussion', 'Symptoms', '|', 'This', 'study', 'is', 'designed', 'to', 'investigate', 'factors', 'that', 'are', 'associated', 'with', 'prolonged', 'recovery', 'from', 'mild', 'head', 'injury', '.', 'The', 'investigators', 'are', 'particularly', 'interested', 'in', 'defining', 'the', 'impact', 'of', 'anxiety', 'related', 'variables', ',', 'such', 'as', 'health', 'anxiety', 'and', 'anxiety', 'sensitivity', 'in', 'the', 'maintenance', 'of', 'symptoms', '.', '\n\n', 'A', 'further', 'goal', 'of', 'the', 'study', 'is', 'the', 'evaluation', 'of', 'two', 'treatment', 'methods', 'that', 'have', 'been', 'proposed', 'to', 'be', 'effective', 'in', 'reducing', 'the', 'impact', 'of', 'post', 'concussion', 'symptoms', '.', 'The', 'investigators', 'hypothesize', 'that', 'a', 'treatment', 'which', 'is', 'directly', 'focused', 'on', 'changing', 'these', 'anxiety', 'related', 'variables', 'will', 'be', 'more', 'effective', 'than', 'one', 'that', 'does', 'not', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00871884,NCT00871884,"The Role of Anxiety Sensitivity in the Maintenance of Chronic Post Concussion Symptoms | This study is designed to investigate factors that are associated with prolonged recovery from mild head injury. The investigators are particularly interested in defining the impact of anxiety related variables, such as health anxiety and anxiety sensitivity in the maintenance of symptoms.

A further goal of the study is the evaluation of two treatment methods that have been proposed to be effective in reducing the impact of post concussion symptoms. The investigators hypothesize that a treatment which is directly focused on changing these anxiety related variables will be more effective than one that does not.","[(12, 19, 'CONDITION', 'Anxiety'), (54, 77, 'CONDITION', 'Chronic Post Concussion'), (184, 200, 'CONDITION', 'mild head injury'), (274, 281, 'CONDITION', 'anxiety'), (316, 323, 'CONDITION', 'anxiety'), (328, 335, 'CONDITION', 'anxiety'), (518, 533, 'CONDITION', 'post concussion'), (635, 642, 'CONDITION', 'anxiety')]"
"['Strategies', 'and', 'Techniques', 'for', 'the', 'Rehabilitation', 'of', 'Memory', 'Deficits', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'clinical', 'characteristics', 'of', 'MS', 'are', 'extremely', 'variable', 'from', 'one', 'patient', 'to', 'another', '.', 'In', 'about', '60', '%', 'of', 'cases', ',', 'motor', 'disabilities', 'are', 'associated', 'with', 'cognitive', 'deficits', '.', 'The', 'present', 'study', 'aims', 'to', 'compare', 'three', 'forms', 'of', 'cognitive', '/', 'motor', 'rehabilitation', 'in', 'three', 'groups', 'of', 'patients', 'with', 'MS', ':', 'rehabilitation', 'of', 'verbal', 'memory', 'with', 'the', 'Rehacom', 'program', ';', 'combined', 'rehabilitation', ',', 'associating', 'a', 'motor', 'rehabilitation', 'path', 'with', 'the', 'Rehacom', 'program', ';', 'only', 'motor', 'rehabilitation', 'course', '.', 'Aims', 'of', 'the', 'study', 'will', 'be', ':', 'to', 'verify', 'whether', 'the', 'combined', 'cognitive', '/', 'motor', 'rehabilitation', 'can', 'induce', 'a', 'significantly', 'greater', 'improvement', 'in', 'the', 'memory', 'performance', 'of', 'patients', 'with', 'MS', 'compared', 'to', 'rehabilitation', 'alone', ';', 'check', 'whether', 'any', 'improvement', 'is', 'objectively', 'verifiable', 'by', 'patients', 'and', 'the', 'impact', 'it', 'may', 'have', 'on', 'patients', ""'"", 'quality', 'of', 'life', ';', 'monitor', 'these', 'effects', 'after', '6', 'months', '.', '\n\n', 'For', 'these', 'purposes', ',', 'three', 'homogeneous', 'groups', 'of', '20', 'patients', 'each', 'will', 'be', 'enrolled', ',', 'diagnosed', 'with', 'MS', 'according', 'to', 'Mc', 'Donald', ""'s"", 'criteria', 'revisited', 'by', 'Polman', '(', '2011', ')', '.', 'The', 'study', 'will', 'be', 'divided', 'into', 'an', 'initial', 'clinical', ',', 'cognitive', ',', 'emotional', ',', 'quality', 'of', 'life', 'and', 'functional', 'self', '-', 'perception', '(', 'T0', ')', 'assessment', '.', 'Subsequently', ',', 'the', 'patients', 'assigned', 'to', 'the', 'three', 'conditions', 'will', 'be', 'provided', 'with', 'the', 'pre', '-', 'established', 'rehabilitation', 'treatments', 'for', 'a', 'total', 'duration', 'of', '12', 'weeks', ';', 'at', 'the', 'end', ',', 'each', 'patient', 'will', 'undergo', 'an', 'overall', 're', '-', 'evaluation', '(', 'T1', ')', '.', 'Finally', ',', 'a', 'further', 'overall', 'reassessment', 'will', 'be', 'carried', 'out', 'after', '6', 'months', ',', 'aimed', 'at', 'follow', '-', 'up', 'monitoring', '(', 'T2', ')', '.', '\n\n', 'Statistical', 'analyzes', 'will', 'be', 'of', 'two', 'types', ':', '\n\n', 'Within', 'Group', '(', 'aimed', 'at', 'assessing', 'any', 'improvement', 'in', 'the', 'cognitive', 'performance', 'of', 'each', 'group', 'of', 'patients', 'by', 'comparing', 'the', 'assessments', 'at', 'T0', 'with', 'those', 'at', 'T1', 'and', 'T2', ')', ';', 'Between', 'Group', '(', 'aimed', 'at', 'comparing', 'the', 'results', 'obtained', 'by', 'each', 'group', 'with', 'those', 'of', 'the', 'other', '2', 'groups', 'at', 'T0', ',', 'T1', ',', 'and', 'T2', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05462678,NCT05462678,"Strategies and Techniques for the Rehabilitation of Memory Deficits in Patients With Multiple Sclerosis | The clinical characteristics of MS are extremely variable from one patient to another. In about 60% of cases, motor disabilities are associated with cognitive deficits. The present study aims to compare three forms of cognitive / motor rehabilitation in three groups of patients with MS: rehabilitation of verbal memory with the Rehacom program; combined rehabilitation, associating a motor rehabilitation path with the Rehacom program; only motor rehabilitation course. Aims of the study will be: to verify whether the combined cognitive / motor rehabilitation can induce a significantly greater improvement in the memory performance of patients with MS compared to rehabilitation alone; check whether any improvement is objectively verifiable by patients and the impact it may have on patients' quality of life; monitor these effects after 6 months.

For these purposes, three homogeneous groups of 20 patients each will be enrolled, diagnosed with MS according to Mc Donald's criteria revisited by Polman (2011). The study will be divided into an initial clinical, cognitive, emotional, quality of life and functional self-perception (T0) assessment. Subsequently, the patients assigned to the three conditions will be provided with the pre-established rehabilitation treatments for a total duration of 12 weeks; at the end, each patient will undergo an overall re-evaluation (T1). Finally, a further overall reassessment will be carried out after 6 months, aimed at follow-up monitoring (T2).

Statistical analyzes will be of two types:

Within Group (aimed at assessing any improvement in the cognitive performance of each group of patients by comparing the assessments at T0 with those at T1 and T2); Between Group (aimed at comparing the results obtained by each group with those of the other 2 groups at T0, T1, and T2).","[(34, 67, 'OTHER', 'Rehabilitation of Memory Deficits'), (85, 103, 'CONDITION', 'Multiple Sclerosis'), (138, 140, 'CONDITION', 'MS'), (216, 234, 'CONDITION', 'motor disabilities'), (255, 273, 'CONDITION', 'cognitive deficits'), (394, 450, 'OTHER', 'rehabilitation of verbal memory with the Rehacom program'), (452, 475, 'OTHER', 'combined rehabilitation'), (491, 541, 'PHYSICAL', 'motor rehabilitation path with the Rehacom program'), (543, 575, 'CONTROL', 'only motor rehabilitation course'), (626, 667, 'OTHER', 'combined cognitive / motor rehabilitation'), (758, 760, 'CONDITION', 'MS'), (773, 793, 'CONTROL', 'rehabilitation alone'), (1057, 1059, 'CONDITION', 'MS')]"
"['Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '12', '-', 'Week', 'Parallel', 'Group', 'Study', 'to', 'Evaluate', 'Safety', 'and', 'Efficacy', 'of', 'Oral', 'Fampridine', '-', 'SR', 'in', 'Subjects', 'With', 'Moderate', 'to', 'Severe', 'Spasticity', 'Resulting', 'From', 'Chronic', ',', 'Incomplete', 'Spinal', 'Cord', 'Injury', '|', 'Normally', ',', 'nerve', 'fibers', 'carry', 'electrical', 'impulses', 'through', 'the', 'spinal', 'cord', ',', 'providing', 'communication', 'between', 'the', 'brain', 'and', 'the', 'arms', 'and', 'legs', '.', 'In', 'people', 'with', 'spinal', 'cord', 'injury', ',', 'some', 'fibers', 'may', 'be', 'destroyed', 'at', 'the', 'site', 'of', 'injury', ',', 'while', 'others', 'remain', 'connected', 'but', 'do', 'not', 'work', 'correctly', 'to', 'carry', 'electrical', 'impulses', '.', 'As', 'a', 'result', ',', 'subjects', 'with', 'an', 'incomplete', 'spinal', 'cord', 'injury', 'may', 'have', 'spasticity', 'which', 'is', 'muscle', 'spasms', 'or', 'muscle', 'stiffness', 'that', 'makes', 'movement', 'difficult', '.', 'Fampridine', '-', 'SR', 'is', 'an', 'experimental', 'drug', 'that', 'increases', 'the', 'ability', 'of', 'the', 'nerve', 'to', 'conduct', 'electrical', 'impulses', '.', 'This', 'study', 'will', 'examine', 'the', 'effects', 'of', 'Fampridine', '-', 'SR', 'on', 'moderate', 'to', 'severe', 'lower', '-', 'limb', 'spasticity', ',', 'as', 'well', 'as', 'the', 'effects', 'on', 'bodily', 'functions', 'such', 'as', 'bladder', 'control', ',', 'bowel', 'function', 'and', 'sexual', 'function', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'possible', 'risks', 'of', 'taking', 'Fampridine', '-', 'SR', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",NCT00041717,NCT00041717,"Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury | Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.","[(14, 21, 'CONTROL', 'Placebo'), (103, 113, 'DRUG', 'Fampridine'), (134, 163, 'CONDITION', 'Moderate to Severe Spasticity'), (179, 217, 'CONDITION', 'Chronic, Incomplete Spinal Cord Injury'), (374, 392, 'CONDITION', 'spinal cord injury'), (562, 591, 'CONDITION', 'incomplete spinal cord injury'), (601, 611, 'CONDITION', 'spasticity'), (621, 634, 'CONDITION', 'muscle spasms'), (638, 654, 'CONDITION', 'muscle stiffness'), (686, 696, 'DRUG', 'Fampridine'), (835, 845, 'DRUG', 'Fampridine'), (852, 892, 'CONDITION', 'moderate to severe lower-limb spasticity'), (1055, 1065, 'DRUG', 'Fampridine')]"
"['REMINISCENCES', ':', 'Reminiscence', 'Triggered', 'by', 'Virtual', 'Reality', 'for', 'Older', 'Adults', 'With', 'Mood', 'Disorders', '|', 'Presentation', '&', 'Pre', '-', 'screening', 'of', 'the', 'control', 'group', '/', 'reminiscence', 'group', 'Patient', '/', 'resident', 'pre', '-', 'screening', 'team', 'meeting', 'for', 'the', 'study', 'Explanation', 'and', 'proposal', 'of', 'the', 'study', 'to', 'patients', 'and', 'their', 'families', 'Signature', 'of', 'resident', '/', 'patient', 'and', 'family', 'consents', 'Audit', 'of', 'inclusion', 'and', 'non', '-', 'inclusion', 'criteria', 'Inclusion', 'Medical', 'advice', 'for', 'VR', 'Clinical', 'interview', 'with', 'the', 'family', 'or', 'legal', 'guardian', 'for', 'an', 'accurate', 'life', 'history', '+', 'an', 'anamnesis', 'interview', '(', 'psychologist', 'or', 'doctor', ')', 'with', 'the', 'patient', 'or', 'resident', '.', '\n\n', 'Creation', 'of', 'video', 'contents', 'Creation', 'of', 'personalized', 'video', 'contents', 'Clinical', 'scales', 'review', 'Evaluation', 'of', 'the', 'number', 'of', 'psychotropic', 'molecules', 'prescribed', '(', 'coordinating', 'doctor', ',', 'general', 'practitioner', ',', 'geriatrician', ')', '\n\n', 'Pre', '-', 'test', 'phase', 'with', 'the', 'patient', 'for', 'the', 'use', 'of', 'the', 'VR', 'headset', '\n', 'Randomisation', '\n', 'Session', 'procedure', 'As', 'previously', 'mentioned', ',', 'the', 'virtual', 'reality', 'sessions', 'will', 'take', 'place', 'in', 'a', 'quiet', 'setting', 'twice', 'a', 'week', 'in', 'the', 'living', 'or', 'hosting', 'residence', '.', 'The', 'sessions', 'will', 'be', 'hold', 'over', 'a', 'period', 'of', 'time', 'of', '6', 'weeks', '.', '\n\n', 'Each', 'subject', 'of', 'the', 'reminiscence', 'group', 'will', 'have', 'two', 'personalised', 'virtual', 'surroundings', '(', 'after', 'data', 'being', 'collected', 'from', 'team', 'and/or', 'families', ')', '.', '\n\n', 'The', 'virtual', 'environment', 'will', 'change', 'every', '3', 'weeks', 'in', 'order', 'to', 'avoid', 'the', 'phenomenon', 'of', 'habituation', '.', '\n\n', 'The', 'subjects', 'of', 'the', 'control', 'group', 'will', 'be', 'exposed', 'to', 'two', 'generic', 'virtual', 'settings', '(', 'beach', ',', 'mountain', 'etc', '.', ')', 'with', 'a', 'different', 'virtual', 'environment', 'every', '3', 'weeks', '.', '\n\n', 'During', 'the', 'session', ',', 'note', 'will', 'be', 'taken', 'on', 'the', 'subject', ""'s"", 'speech', '.', 'The', 'session', 'will', 'also', 'be', 'filmed', 'and/or', 'recorded', 'with', 'a', 'prior', 'signed', 'agreement', 'by', 'the', 'patient', 'or', 'his', 'representative', '.', '\n\n', '-', 'Last', 'session', '(', 'S6', ')', 'Review', 'of', 'clinical', 'scales', '(', 're', '-', 'testing', ')', 'Re', '-', 'evaluation', 'of', 'drug', 'prescriptions']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04442594,NCT04442594,"REMINISCENCES : Reminiscence Triggered by Virtual Reality for Older Adults With Mood Disorders | Presentation & Pre-screening of the control group / reminiscence group Patient/resident pre-screening team meeting for the study Explanation and proposal of the study to patients and their families Signature of resident/patient and family consents Audit of inclusion and non-inclusion criteria Inclusion Medical advice for VR Clinical interview with the family or legal guardian for an accurate life history + an anamnesis interview (psychologist or doctor) with the patient or resident.

Creation of video contents Creation of personalized video contents Clinical scales review Evaluation of the number of psychotropic molecules prescribed (coordinating doctor, general practitioner, geriatrician)

Pre-test phase with the patient for the use of the VR headset
Randomisation
Session procedure As previously mentioned, the virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.

Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).

The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.

The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) with a different virtual environment every 3 weeks.

During the session, note will be taken on the subject's speech. The session will also be filmed and/or recorded with a prior signed agreement by the patient or his representative.

- Last session (S6) Review of clinical scales (re-testing) Re-evaluation of drug prescriptions","[(42, 57, 'OTHER', 'Virtual Reality'), (80, 94, 'CONDITION', 'Mood Disorders'), (848, 858, 'OTHER', 'VR headset'), (920, 935, 'OTHER', 'virtual reality'), (1143, 1176, 'OTHER', 'personalised virtual surroundings'), (1238, 1257, 'OTHER', 'virtual environment'), (1391, 1415, 'CONTROL', 'generic virtual settings')]"
"['Double', '-', 'Blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Two', '-', 'Arm', ',', 'Multi', '-', 'Center', 'Phase', 'II', 'Trial', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'DP', '-', 'VPA', '(', 'up', 'to', '900', 'mg', ')', 'Once', 'Daily', 'for', '10', 'Weeks', 'in', 'Adult', 'Subjects', 'With', 'Migraine', '|', 'The', 'study', 'will', 'evaluate', 'if', 'DP', '-', 'VPA', ',', 'a', 'derivative', 'of', 'valproate', '(', 'a', 'drug', 'that', 'is', 'commonly', 'used', 'for', 'the', 'prevention', 'of', 'migraine', 'attacks', ')', ',', 'can', 'reduce', 'the', 'rate', 'of', 'migraine', 'attacks', '.', '\n\n', 'Migraine', 'patients', 'will', 'take', 'DP', '-', 'VPA', 'or', 'placebo', '(', 'an', 'inactive', 'look', '-', 'alike', 'drug', ')', 'every', 'morning', 'and', 'will', 'have', 'to', 'report', 'any', 'migraine', 'attacks', 'they', 'have', 'during', 'the', 'study', ""'s"", '18', '-', 'week', 'follow', 'up', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00640965,NCT00640965,"Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Two-Arm, Multi-Center Phase II Trial to Assess the Safety, Tolerability, and Efficacy of DP-VPA (up to 900 mg) Once Daily for 10 Weeks in Adult Subjects With Migraine | The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.

Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.","[(26, 33, 'CONTROL', 'Placebo'), (151, 157, 'DRUG', 'DP-VPA'), (220, 228, 'CONDITION', 'Migraine'), (258, 264, 'DRUG', 'DP-VPA'), (282, 291, 'DRUG', 'valproate'), (344, 360, 'CONDITION', 'migraine attacks'), (386, 402, 'CONDITION', 'migraine attacks'), (405, 413, 'CONDITION', 'Migraine'), (433, 439, 'DRUG', 'DP-VPA'), (443, 450, 'CONTROL', 'placebo'), (523, 539, 'CONDITION', 'migraine attacks')]"
"['A', 'Trial', 'of', 'Memantine', 'as', 'Symptomatic', 'Treatment', 'for', 'Early', 'Huntington', 'Disease', ';', 'a', 'Phase', 'IIb', 'Study', '|', 'Huntington', 'disease', 'is', 'characterized', 'by', 'difficulties', 'in', 'movement', 'and', 'thinking', '.', 'Psychological', 'disturbances', 'including', 'irritability', ',', 'aggression', ',', 'loss', 'of', 'interest', ',', 'depressed', 'mood', ',', 'obsessions', 'and', 'compulsions', ',', 'also', 'represent', 'common', 'symptoms', 'of', 'HD', '.', 'These', 'symptoms', 'are', 'distressing', 'both', 'for', 'HD', 'patients', 'and', 'their', 'caregivers', ',', 'contribute', 'to', 'the', 'loss', 'of', 'ability', 'to', 'carry', 'out', 'activities', 'of', 'daily', 'living', ',', 'and', 'present', 'a', 'major', 'treatment', 'challenge', 'for', 'physicians', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'memantine', 'on', 'movement', ',', 'thinking', 'and', 'emotional', 'difficulties', 'in', 'HD', 'patients', '.', 'Memantine', 'is', 'a', 'medication', 'originally', 'approved', 'for', 'the', 'treatment', 'of', 'aggression', 'and', 'agitation', 'in', 'patients', 'with', 'moderate', '-', 'to', '-', 'severe', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', ',', 'which', 'has', 'also', 'recently', 'been', 'shown', 'to', 'improve', 'the', 'behavioural', 'and', 'neuropathological', 'symptoms', 'in', 'a', 'mouse', 'model', 'of', 'Huntington', 'Disease', '(', 'HD', ')', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01458470,NCT01458470,"A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsions, also represent common symptoms of HD. These symptoms are distressing both for HD patients and their caregivers, contribute to the loss of ability to carry out activities of daily living, and present a major treatment challenge for physicians. The goal of this study is to determine the effect of memantine on movement, thinking and emotional difficulties in HD patients. Memantine is a medication originally approved for the treatment of aggression and agitation in patients with moderate-to-severe Alzheimer's disease (AD), which has also recently been shown to improve the behavioural and neuropathological symptoms in a mouse model of Huntington Disease (HD).","[(11, 20, 'DRUG', 'Memantine'), (50, 74, 'CONDITION', 'Early Huntington Disease'), (96, 114, 'CONDITION', 'Huntington disease'), (211, 223, 'CONDITION', 'irritability'), (225, 235, 'CONDITION', 'aggression'), (237, 253, 'CONDITION', 'loss of interest'), (255, 264, 'CONDITION', 'depressed'), (271, 281, 'CONDITION', 'obsessions'), (286, 297, 'CONDITION', 'compulsions'), (333, 335, 'CONDITION', 'HD'), (377, 379, 'CONDITION', 'HD'), (595, 604, 'DRUG', 'memantine'), (657, 659, 'CONDITION', 'HD'), (670, 679, 'DRUG', 'Memantine'), (737, 747, 'CONDITION', 'aggression'), (752, 761, 'CONDITION', 'agitation'), (937, 955, 'CONDITION', 'Huntington Disease'), (957, 959, 'CONDITION', 'HD')]"
"['Comparison', 'of', 'the', 'Efficacy', 'of', 'an', 'Internet', '-', 'based', 'Self', '-', 'help', 'Training', 'and', 'a', 'Well', '-', 'established', 'Outpatient', 'Group', 'Therapy', 'for', 'the', 'Treatment', 'of', 'Chronic', 'Tinnitus', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'an', 'internet', '-', 'based', 'guided', 'self', '-', 'help', 'training', 'for', 'chronic', 'tinnitus', 'with', 'a', 'well', '-', 'established', 'outpatient', 'group', 'therapy', 'and', 'a', 'discussion', 'forum', 'group', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT01205906,NCT01205906,Comparison of the Efficacy of an Internet-based Self-help Training and a Well-established Outpatient Group Therapy for the Treatment of Chronic Tinnitus: A Randomized Controlled Trial | The aim of this study is to compare the efficacy of an internet-based guided self-help training for chronic tinnitus with a well-established outpatient group therapy and a discussion forum group.,"[(33, 66, 'BEHAVIOURAL', 'Internet-based Self-help Training'), (73, 114, 'CONTROL', 'Well-established Outpatient Group Therapy'), (136, 152, 'CONDITION', 'Chronic Tinnitus'), (241, 281, 'BEHAVIOURAL', 'internet-based guided self-help training'), (286, 302, 'CONDITION', 'chronic tinnitus'), (310, 351, 'CONTROL', 'well-established outpatient group therapy'), (358, 380, 'CONTROL', 'discussion forum group')]"
"['The', 'Effectiveness', 'of', 'Supplementing', 'Supported', 'Employment', 'With', 'Behavioral', 'Skills', 'Training', '|', 'This', 'study', 'will', 'compare', 'employment', 'support', 'with', 'behavioral', 'skills', 'training', 'to', 'employment', 'support', 'alone', 'in', 'schizophrenia', 'patients', 'taking', 'either', 'risperidone', 'or', 'olanzapine', 'to', 'determine', 'which', 'is', 'more', 'effective', 'in', 'helping', 'the', 'patients', 'maintain', 'a', 'job', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00183625,NCT00183625,The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training | This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients maintain a job.,"[(35, 87, 'BEHAVIOURAL', 'Supported Employment With Behavioral Skills Training'), (114, 164, 'BEHAVIOURAL', 'employment support with behavioral skills training'), (168, 186, 'CONTROL', 'employment support'), (196, 209, 'CONDITION', 'schizophrenia'), (233, 244, 'DRUG', 'risperidone'), (248, 258, 'DRUG', 'olanzapine')]"
"['Non', '-', 'invasive', 'Neurostimulation', 'of', 'the', 'Vagus', 'Nerve', 'With', 'the', 'gammaCore', 'Device', 'for', 'the', 'Relief', 'of', 'Pain', 'and', 'Allodynia', 'Associated', 'With', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'gather', 'preliminary', 'information', 'on', 'the', 'safety', 'and', 'effectiveness', 'of', 'patient', 'self', '-', 'administration', 'of', 'a', 'noninvasive', 'neurostimulation', 'of', 'the', 'vagus', 'nerve', 'using', 'the', 'GammaCore', 'device', 'for', 'the', 'treatment', 'of', 'pain', 'and', 'allodynia', 'symptoms', 'associated', 'with', 'acute', 'migraine', 'in', 'adults', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",NCT03410628,NCT03410628,Non-invasive Neurostimulation of the Vagus Nerve With the gammaCore Device for the Relief of Pain and Allodynia Associated With Migraine | The purpose of this feasibility study is to gather preliminary information on the safety and effectiveness of patient self-administration of a noninvasive neurostimulation of the vagus nerve using the GammaCore device for the treatment of pain and allodynia symptoms associated with acute migraine in adults.,"[(0, 74, 'OTHER', 'Non-invasive Neurostimulation of the Vagus Nerve With the gammaCore Device'), (102, 111, 'CONDITION', 'Allodynia'), (128, 136, 'CONDITION', 'Migraine'), (282, 356, 'OTHER', 'noninvasive neurostimulation of the vagus nerve using the GammaCore device'), (387, 396, 'CONDITION', 'allodynia'), (422, 436, 'CONDITION', 'acute migraine')]"
"['Molecular', 'Profile', 'of', 'the', 'Evolution', 'of', 'Inclusion', 'Body', 'Myositis', '|', 'This', 'study', 'aims', 'at', 'assessing', 'the', 'gene', 'expression', 'in', 'the', 'muscles', 'of', 'patients', 'suffering', 'from', 'sporadic', 'Inclusion', 'Body', 'Myositis', '(', 'sIBM', ')', 'at', 'various', 'stages', 'of', 'the', 'disease', ',', 'by', 'comparison', 'with', 'muscles', 'of', 'control', 'subject', '.', 'The', 'investigators', 'use', 'the', 'RNA', '-', 'seq', 'technique', 'to', 'analyze', 'the', 'gene', 'expression', 'levels', 'and', 'potential', 'alternate', 'transcripts', ',', 'including', 'long', 'non', '-', 'coding', 'RNAs', '(', 'lncRNAs', ')', ',', 'in', 'muscle', 'tissue', 'samples', '.', 'The', 'gene', 'expression', 'profiles', 'will', 'point', 'to', 'the', 'genes', 'of', 'interest', 'that', 'can', 'then', 'become', 'the', 'object', 'of', 'future', 'studies', ',', 'in', 'which', 'epigenetic', 'changes', 'of', 'these', 'genes', 'will', 'be', 'explored', 'further', '.', 'The', 'value', 'of', 'those', 'possible', 'biomarkers', 'will', 'be', 'assessed', '.', 'The', 'investigators', 'will', 'also', 'evaluate', 'the', 'correlation', 'between', 'the', 'gene', 'expression', 'profile', ',', 'the', 'degree', 'of', 'functional', 'impairment', ',', 'the', 'histological', 'picture', 'and', 'the', 'presence', 'or', 'absence', 'of', 'autoantibodies', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03299335,NCT03299335,"Molecular Profile of the Evolution of Inclusion Body Myositis | This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject. The investigators use the RNA-seq technique to analyze the gene expression levels and potential alternate transcripts, including long non-coding RNAs (lncRNAs), in muscle tissue samples. The gene expression profiles will point to the genes of interest that can then become the object of future studies, in which epigenetic changes of these genes will be explored further. The value of those possible biomarkers will be assessed. The investigators will also evaluate the correlation between the gene expression profile, the degree of functional impairment, the histological picture and the presence or absence of autoantibodies.","[(38, 61, 'CONDITION', 'Inclusion Body Myositis'), (155, 187, 'CONDITION', 'sporadic Inclusion Body Myositis'), (189, 193, 'CONDITION', 'sIBM')]"
"['Effect', 'of', 'Extubation', 'Under', 'Deep', 'Anesthesia', 'on', 'Emergence', 'Agitation', 'of', 'Nasal', 'Surgery', '|', 'This', 'study', 'analyzed', 'the', 'relationship', 'between', 'extubation', 'timing', 'and', 'Emergence', 'agitation', 'in', '18', '-', '60', 'years', 'old', 'adults', 'undergoing', 'nasal', 'surgery', ',', 'such', 'as', 'nasal', 'septum', 'correction', ',', 'endoscopic', 'sinus', 'surgery', ',', 'and', 'nasal', 'bone', 'fracture', 'reduction', '.', 'The', 'number', 'of', 'agitation', ',', 'sedation', 'score', ',', 'pain', 'score', ',', 'operation', 'method', ',', 'analgesic', 'drugs', 'and', 'other', 'data', 'were', 'recorded', 'to', 'analyze', 'the', 'effect', 'of', 'deep', 'anesthesia', 'extubation', 'on', 'agitation', 'in', 'patients', 'with', 'nasal', 'surgery', '.', 'It', 'also', 'provides', 'a', 'clinical', 'basis', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'agitation', 'during', 'the', 'recovery', 'period', 'of', 'such', 'operations', 'in', 'adults', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04844333,NCT04844333,"Effect of Extubation Under Deep Anesthesia on Emergence Agitation of Nasal Surgery | This study analyzed the relationship between extubation timing and Emergence agitation in 18-60 years old adults undergoing nasal surgery, such as nasal septum correction, endoscopic sinus surgery, and nasal bone fracture reduction. The number of agitation, sedation score, pain score, operation method, analgesic drugs and other data were recorded to analyze the effect of deep anesthesia extubation on agitation in patients with nasal surgery. It also provides a clinical basis for the prevention and treatment of agitation during the recovery period of such operations in adults.","[(46, 65, 'CONDITION', 'Emergence Agitation'), (69, 82, 'CONDITION', 'Nasal Surgery'), (152, 171, 'CONDITION', 'Emergence agitation'), (209, 222, 'CONDITION', 'nasal surgery'), (232, 255, 'CONDITION', 'nasal septum correction'), (257, 281, 'CONDITION', 'endoscopic sinus surgery'), (287, 316, 'CONDITION', 'nasal bone fracture reduction'), (332, 341, 'CONDITION', 'agitation'), (516, 529, 'CONDITION', 'nasal surgery'), (601, 610, 'CONDITION', 'agitation')]"
"['Compression', 'Garments', 'in', 'the', 'Community', 'With', 'POTS', '|', 'Compression', 'Garments', 'are', 'a', 'commonly', 'prescribed', 'treatment', 'in', 'Postural', 'Orthostatic', 'Tachycardia', 'Syndrome', '(', 'POTS', ')', '.', 'The', 'effectiveness', 'of', 'a', 'proof', '-', 'of', '-', 'concept', 'compression', 'garment', 'has', 'been', 'demonstrated', 'in', 'an', 'acute', 'laboratory', 'setting', '.', 'It', 'is', 'not', 'known', 'if', 'commercially', 'available', 'compression', 'garments', 'that', 'participants', 'wear', 'in', 'their', 'every', 'day', 'lives', 'are', 'effective', 'at', 'improving', 'heart', 'rate', 'and', 'reducing', 'symptoms', 'in', 'POTS', '.', 'This', 'trial', 'will', 'evaluate', 'the', 'use', 'of', 'commercially', 'available', 'waist', '-', 'high', 'and', 'abdominal', 'compression', 'garments', 'in', 'adults', 'diagnosed', 'with', 'POTS', 'in', 'a', 'community', 'setting', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT04881318,NCT04881318,Compression Garments in the Community With POTS | Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS. This trial will evaluate the use of commercially available waist-high and abdominal compression garments in adults diagnosed with POTS in a community setting.,"[(0, 20, 'OTHER', 'Compression Garments'), (43, 47, 'CONDITION', 'POTS'), (50, 70, 'OTHER', 'Compression Garments'), (110, 151, 'CONDITION', 'Postural Orthostatic Tachycardia Syndrome'), (153, 157, 'CONDITION', 'POTS'), (200, 219, 'OTHER', 'compression garment'), (316, 336, 'OTHER', 'compression garments'), (448, 452, 'CONDITION', 'POTS'), (490, 558, 'OTHER', 'commercially available waist-high and abdominal compression garments'), (584, 588, 'CONDITION', 'POTS')]"
"['Comparison', 'of', 'the', 'Efficacy', 'and', 'Subjective', 'Comfort', 'of', 'a', 'Modified', 'AutoSet', 'Device', 'With', 'an', 'Existing', 'AutoSet', 'Device', '(', 'VPAP', 'Auto', ')', 'in', 'Treating', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'performance', 'of', 'the', 'modified', 'AutoSet', 'device', 'is', 'equivalent', 'or', 'better', 'than', 'the', 'existing', 'AutoSet', 'device', '(', 'VPAP', 'Auto', ')', 'in', 'the', 'efficacy', 'of', 'the', 'treatment', 'and', 'the', 'subjective', 'comfort', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00906958,NCT00906958,Comparison of the Efficacy and Subjective Comfort of a Modified AutoSet Device With an Existing AutoSet Device (VPAP Auto) in Treating Obstructive Sleep Apnea | The purpose of this study is to determine if the performance of the modified AutoSet device is equivalent or better than the existing AutoSet device (VPAP Auto) in the efficacy of the treatment and the subjective comfort.,"[(55, 78, 'OTHER', 'Modified AutoSet Device'), (96, 110, 'CONTROL', 'AutoSet Device'), (112, 121, 'CONTROL', 'VPAP Auto'), (135, 158, 'CONDITION', 'Obstructive Sleep Apnea'), (229, 252, 'OTHER', 'modified AutoSet device'), (295, 309, 'CONTROL', 'AutoSet device'), (311, 320, 'CONTROL', 'VPAP Auto')]"
"['The', 'Contribution', 'of', 'a', 'Speech', 'Perception', 'Intervention', 'to', 'the', 'Prevention', 'of', 'Phonological', 'Awareness', 'Deficits', 'in', 'Children', 'With', 'Speech', 'Sound', 'Disorders', '|', 'Recent', 'research', 'reveals', 'genetic', 'and', 'symptomatic', 'overlap', 'among', 'children', 'with', 'speech', 'sound', 'disorders', '(', 'i.e.', ',', 'those', 'who', '(', 'misarticulate', 'more', 'sounds', 'than', 'would', 'be', 'expected', 'for', 'their', 'age', ')', 'and', 'children', 'with', 'dyslexia', '(', 'i.e.', ',', 'those', 'who', 'struggle', 'to', 'learn', 'to', 'read', ')', '.', 'Children', 'who', 'have', 'speech', 'sound', 'disorders', 'as', 'preschoolers', 'are', 'at', 'risk', 'for', 'the', 'later', 'emergence', 'of', 'dyslexia', ',', 'a', 'risk', 'that', 'often', 'reveals', 'itself', 'in', 'the', 'form', 'of', 'poor', 'phonological', 'awareness', 'skills', 'during', 'the', 'preschool', 'period', '.', 'Traditional', 'speech', 'therapy', 'methods', 'focus', 'on', 'articulation', 'accuracy', 'and', 'do', 'not', 'focus', 'on', 'the', 'child', ""'s"", 'more', 'abstract', 'knowledge', 'of', 'the', 'sound', 'system', 'of', 'the', 'language', '.', 'The', 'ultimate', 'objective', 'of', 'this', 'research', 'program', 'is', 'to', 'prevent', 'reading', 'disability', 'in', 'children', 'who', 'present', 'with', 'speech', 'sounds', 'disorders', '.', 'The', 'relative', 'effectiveness', 'of', 'different', 'interventions', 'to', 'help', 'these', 'children', 'achieve', 'age', '-', 'appropriate', 'phonological', 'processing', 'skills', 'prior', 'to', 'school', 'entry', 'will', 'be', 'investigated', '.', 'It', 'is', 'expected', 'that', 'a', 'combination', 'of', 'treatment', 'approaches', 'that', 'focus', 'on', 'speech', 'perception', 'skills', 'and', 'vocabulary', 'knowledge', 'will', 'have', 'a', 'superior', 'impact', 'on', 'phonological', 'awareness', 'in', 'comparison', 'with', 'a', 'treatment', 'approach', 'that', 'focuses', 'solely', 'on', 'articulation', 'accuracy', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT00818428,NCT00818428,"The Contribution of a Speech Perception Intervention to the Prevention of Phonological Awareness Deficits in Children With Speech Sound Disorders | Recent research reveals genetic and symptomatic overlap among children with speech sound disorders (i.e., those who (misarticulate more sounds than would be expected for their age) and children with dyslexia (i.e., those who struggle to learn to read). Children who have speech sound disorders as preschoolers are at risk for the later emergence of dyslexia, a risk that often reveals itself in the form of poor phonological awareness skills during the preschool period. Traditional speech therapy methods focus on articulation accuracy and do not focus on the child's more abstract knowledge of the sound system of the language. The ultimate objective of this research program is to prevent reading disability in children who present with speech sounds disorders. The relative effectiveness of different interventions to help these children achieve age-appropriate phonological processing skills prior to school entry will be investigated. It is expected that a combination of treatment approaches that focus on speech perception skills and vocabulary knowledge will have a superior impact on phonological awareness in comparison with a treatment approach that focuses solely on articulation accuracy.","[(22, 52, 'OTHER', 'Speech Perception Intervention'), (123, 145, 'CONDITION', 'Speech Sound Disorders'), (224, 246, 'CONDITION', 'speech sound disorders'), (419, 441, 'CONDITION', 'speech sound disorders'), (888, 911, 'CONDITION', 'speech sounds disorders'), (1111, 1210, 'OTHER', 'combination of treatment approaches that focus on speech perception skills and vocabulary knowledge'), (1286, 1349, 'OTHER', 'treatment approach that focuses solely on articulation accuracy')]"
"['Treatment', 'of', 'Periodontitis', 'to', 'Prevent', 'Dementia', 'in', 'Older', 'Adults', 'With', 'Asymptomatic', 'Carotid', 'Artery', 'Stenosis', 'and', 'Mild', 'Cognitive', 'Impairment', '|', 'Periodontal', 'Disease', '(', 'PD', ')', 'is', 'present', 'in', '60+%', 'of', 'adults', '>', '65', 'years', 'and', 'is', 'associated', 'with', 'tobacco', 'smoking', ',', 'diabetes', ',', 'and', 'atherosclerosis', 'that', 'worsen', 'inflammation', ',', 'comorbidities', 'common', 'in', 'older', 'people', 'with', 'mild', 'to', 'moderate', 'cognitive', 'impairment', '(', 'MCI', ')', '.', 'Older', 'MCI', 'patients', 'are', 'prone', 'to', 'poor', 'oral', 'hygiene', 'and', 'dental', 'health', ',', 'which', 'if', 'untreated', 'worsens', 'inflammation', '-', 'mediated', 'brain', 'and', 'nervous', 'system', 'function', ',', 'and', 'accelerates', 'progression', 'to', 'dementia', '.', 'Asymptomatic', 'carotid', 'artery', 'stenosis', '(', 'ACAS', ')', 'is', 'often', 'a', 'silent', 'disease', 'detected', 'in', 'only', '~10', '%', 'of', 'older', 'adults', ',', 'and', 'may', 'have', 'a', 'strong', 'association', 'with', 'MCI', '.', 'This', 'study', 'examines', 'the', 'effects', 'of', 'intensive', 'therapy', 'for', 'periodontitis', 'on', 'cognition', 'in', 'high', '-', 'risk', 'older', 'people', 'with', 'ACAS', '.', 'Results', 'could', 'highlight', 'PD', 'as', 'a', 'readily', 'modifiable', 'risk', 'factor', 'for', 'dementia', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03755362,NCT03755362,"Treatment of Periodontitis to Prevent Dementia in Older Adults With Asymptomatic Carotid Artery Stenosis and Mild Cognitive Impairment | Periodontal Disease (PD) is present in 60+% of adults >65 years and is associated with tobacco smoking, diabetes, and atherosclerosis that worsen inflammation, comorbidities common in older people with mild to moderate cognitive impairment (MCI). Older MCI patients are prone to poor oral hygiene and dental health, which if untreated worsens inflammation-mediated brain and nervous system function, and accelerates progression to dementia. Asymptomatic carotid artery stenosis (ACAS) is often a silent disease detected in only ~10% of older adults, and may have a strong association with MCI. This study examines the effects of intensive therapy for periodontitis on cognition in high-risk older people with ACAS. Results could highlight PD as a readily modifiable risk factor for dementia.","[(0, 26, 'OTHER', 'Treatment of Periodontitis'), (38, 46, 'CONDITION', 'Dementia'), (68, 104, 'CONDITION', 'Asymptomatic Carotid Artery Stenosis'), (109, 134, 'CONDITION', 'Mild Cognitive Impairment'), (137, 156, 'CONDITION', 'Periodontal Disease'), (158, 160, 'CONDITION', 'PD'), (339, 376, 'CONDITION', 'mild to moderate cognitive impairment'), (378, 381, 'CONDITION', 'MCI'), (390, 393, 'CONDITION', 'MCI'), (568, 576, 'CONDITION', 'dementia'), (578, 614, 'CONDITION', 'Asymptomatic carotid artery stenosis'), (616, 620, 'CONDITION', 'ACAS'), (726, 729, 'CONDITION', 'MCI'), (766, 801, 'OTHER', 'intensive therapy for periodontitis'), (846, 850, 'CONDITION', 'ACAS'), (876, 878, 'CONDITION', 'PD'), (919, 927, 'CONDITION', 'dementia')]"
"['A', 'Phase', 'II', 'Study', 'of', 'Conformal', 'Radiotherapy', 'In', 'Patients', 'With', 'Low', '-', 'Grade', 'Gliomas', '|', 'RATIONALE', ':', 'Specialized', 'radiation', 'therapy', 'that', 'delivers', 'radiation', 'directly', 'to', 'the', 'tumor', 'may', 'kill', 'more', 'tumor', 'cells', 'and', 'cause', 'less', 'damage', 'to', 'normal', 'tissue', '.', '\n\n', 'PURPOSE', ':', 'This', 'phase', 'II', 'trial', 'is', 'studying', 'how', 'well', 'radiation', 'therapy', 'works', 'in', 'treating', 'young', 'patients', 'with', 'gliomas', '.']","['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00238264,NCT00238264,"A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas | RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.","[(20, 42, 'RADIOTHERAPY', 'Conformal Radiotherapy'), (60, 77, 'CONDITION', 'Low-Grade Gliomas'), (103, 120, 'RADIOTHERAPY', 'radiation therapy'), (161, 166, 'CONDITION', 'tumor'), (181, 186, 'CONDITION', 'tumor'), (284, 301, 'RADIOTHERAPY', 'radiation therapy'), (340, 347, 'CONDITION', 'gliomas')]"
"['To', 'assess', 'the', 'beneficial', 'and', 'adverse', 'effects', 'of', 'corticosteroid', 'treatment', 'for', 'optic', 'neuritis', '.', '\n\n', 'To', 'determine', 'the', 'natural', 'history', 'of', 'vision', 'in', 'patients', 'who', 'suffer', 'optic', 'neuritis', '.', '\n\n', 'To', 'identify', 'risk', 'factors', 'for', 'the', 'development', 'of', 'multiple', 'sclerosis', 'in', 'patients', 'with', 'optic', 'neuritis', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00000146,NCT00000146,"To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis.

To determine the natural history of vision in patients who suffer optic neuritis.

To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.","[(48, 62, 'DRUG', 'corticosteroid'), (77, 91, 'CONDITION', 'optic neuritis'), (160, 174, 'CONDITION', 'optic neuritis'), (225, 243, 'CONDITION', 'multiple sclerosis'), (261, 275, 'CONDITION', 'optic neuritis')]"
"['Medication', 'Intake', 'of', 'Solid', 'Dosage', 'Forms', ':', 'A', 'Risk', 'Factor', 'for', 'Patients', 'With', 'Stroke', '-', 'induced', 'Dysphagia', '?', '|', 'In', 'a', 'prospective', ',', 'quantitative', 'explorative', 'study', ',', 'the', 'risk', 'of', 'aspiration', 'and', 'penetration', 'when', 'swallowing', 'solid', 'pills', '(', 'placebo', ')', 'compared', 'to', 'a', 'crushed', 'placebo', 'pill', 'will', 'be', 'evaluated', 'during', 'a', 'routine', 'Fiberoptic', 'Endoscopic', 'Evaluation', 'of', 'Swallowing', '(', 'FEES', ')', '.', 'The', 'study', 'design', 'is', 'thus', 'a', 'quasi', '-', 'experimental', 'study', 'design', 'with', 'repeated', 'measurements', 'in', 'the', 'sense', 'of', 'a', 'pre', '-', 'posttest', '.', 'Each', 'patient', 'undergoes', 'a', 'baseline', 'examination', '(', 'routine', 'procedure', ')', 'followed', 'by', 'the', 'intervention', '(', 'administration', 'of', 'three', 'different', 'solid', 'pills', 'and', 'a', 'crushed', 'pill', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05173051,NCT05173051,"Medication Intake of Solid Dosage Forms: A Risk Factor for Patients With Stroke-induced Dysphagia? | In a prospective, quantitative explorative study, the risk of aspiration and penetration when swallowing solid pills (placebo) compared to a crushed placebo pill will be evaluated during a routine Fiberoptic Endoscopic Evaluation of Swallowing (FEES). The study design is thus a quasi-experimental study design with repeated measurements in the sense of a pre-posttest. Each patient undergoes a baseline examination (routine procedure) followed by the intervention (administration of three different solid pills and a crushed pill).","[(73, 79, 'CONDITION', 'Stroke'), (88, 97, 'CONDITION', 'Dysphagia')]"
"['Exercise', '-', 'based', 'Motivational', 'Interviewing', 'for', 'Fibromyalgia', '|', 'Fibromyalgia', '(', 'FMS', ')', ',', 'defined', 'as', 'the', 'presence', 'of', 'both', 'chronic', 'widespread', 'pain', 'and', 'the', 'finding', 'of', '11/18', 'tender', 'points', 'on', 'examination', ',', 'affects', '2', '%', 'of', 'the', 'general', 'population', '.', 'Drug', 'therapy', 'for', 'FMS', 'is', 'largely', 'symptomatic', 'as', 'there', 'is', 'not', 'yet', 'a', 'complete', 'understanding', 'of', 'the', 'pathogenesis', 'of', 'the', 'disease', '.', 'In', 'the', 'past', '17', 'years', ',', 'supervised', 'aerobic', 'exercise', 'has', 'emerged', 'as', 'an', 'important', 'treatment', 'modality', 'to', 'improve', 'pain', ',', 'aerobic', 'capacity', ',', 'function', ',', 'and', 'well', '-', 'being', '.', 'Individuals', 'who', 'are', 'able', 'to', 'adhere', 'to', 'exercise', 'almost', 'always', 'maintain', 'the', 'symptomatic', 'benefits', 'of', 'exercise', '.', 'Unfortunately', ',', 'the', 'rate', 'of', 'exercise', 'adherence', 'six', 'months', 'after', 'the', 'completion', 'of', 'a', 'well', '-', 'structured', 'supervised', 'exercise', 'program', 'is', 'disappointingly', 'low', '.', 'Furthermore', ',', 'although', 'the', 'efficacy', 'of', 'supervised', 'aerobic', 'exercise', 'in', 'the', 'research', 'setting', 'is', 'well', 'documented', ',', 'the', 'applicability', 'of', 'such', 'intervention', 'in', 'the', 'clinic', 'setting', 'is', 'doubtful', '.', 'Therefore', ',', 'we', 'propose', 'to', 'conduct', 'the', 'Research', 'to', 'Encourage', 'Exercise', 'for', 'Fibromyalgia', '(', 'REEF', ')', ',', 'a', 'randomized', 'attention', '-', 'controlled', 'trial', 'whose', 'primary', 'aim', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'telephone', '-', 'delivered', 'motivational', 'interviewing', '(', 'MI', ')', 'to', 'encourage', 'exercise', ',', 'in', 'improving', 'exercise', 'adherence', 'and', 'self', '-', 'report', 'physical', 'function', '(', 'co', '-', 'primary', 'outcome', 'measures', ')', 'for', 'FMS', 'patients', '.', 'REEF', 'will', 'enroll', '200', 'FMS', 'patients', ',', 'randomizing', 'them', 'to', 'either', 'the', 'MI', 'group', 'or', 'the', 'attention', '-', 'control', '(', 'AC', ')', 'group', '.', 'Participants', 'from', 'each', 'group', 'will', 'receive', 'a', 'total', 'of', '6', 'telephone', 'calls', 'within', 'a', '12', '-', 'week', 'period', '.', 'Prior', 'to', 'the', 'phone', 'calls', ',', 'participants', 'from', 'both', 'groups', 'will', 'receive', 'an', 'individualized', 'exercise', 'prescription', 'and', '2', 'supervised', 'exercise', 'training', 'sessions', 'to', 'get', 'them', 'started', 'on', 'an', 'exercise', 'program', '.', 'All', 'subjects', 'will', 'undergo', 'comprehensive', 'outcome', 'assessment', 'at', 'baseline', ',', 'week', '12', ',', 'week', '24', ',', 'and', 'week', '36', '.', 'The', 'secondary', 'aim', 'of', 'this', 'proposal', 'is', 'to', 'determine', 'the', 'mediators', 'between', 'MI', 'and', 'improvement', 'in', 'self', '-', 'report', 'physical', 'function', '.', 'The', 'proposed', 'research', 'is', 'significant', 'because', 'our', 'focus', 'is', 'the', 'promotion', 'of', 'adherence', 'to', 'an', 'exercise', 'program', ',', 'of', 'adequate', 'intensity', ',', 'in', 'order', 'to', 'maximize', 'functioning', 'and', 'well', '-', 'being', 'for', 'patients', 'with', 'FMS', '.', 'The', 'use', 'of', 'a', 'predominantly', 'home', '-', 'based', 'exercise', 'program', 'and', 'telephone', '-', 'delivered', 'MI', 'by', 'a', 'trained', 'licensed', 'practice', 'nurse', '(', 'LPN', ')', 'could', 'potentially', 'make', 'the', 'proposed', 'intervention', 'more', 'accessible', 'to', 'the', 'greater', 'majority', 'of', 'FMS', 'patients', '.', 'Furthermore', ',', 'if', 'proven', 'efficacious', ',', 'MI', 'could', 'readily', 'be', 'applied', 'to', 'other', 'chronically', 'painful', 'conditions', '(', 'e.g.', 'chronic', 'back', 'pain', ')', '.']","['B-PHYS', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00573612,NCT00573612,"Exercise-based Motivational Interviewing for Fibromyalgia | Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. Drug therapy for FMS is largely symptomatic as there is not yet a complete understanding of the pathogenesis of the disease. In the past 17 years, supervised aerobic exercise has emerged as an important treatment modality to improve pain, aerobic capacity, function, and well-being. Individuals who are able to adhere to exercise almost always maintain the symptomatic benefits of exercise. Unfortunately, the rate of exercise adherence six months after the completion of a well-structured supervised exercise program is disappointingly low. Furthermore, although the efficacy of supervised aerobic exercise in the research setting is well documented, the applicability of such intervention in the clinic setting is doubtful. Therefore, we propose to conduct the Research to Encourage Exercise for Fibromyalgia (REEF), a randomized attention-controlled trial whose primary aim is to evaluate the efficacy of telephone-delivered motivational interviewing (MI) to encourage exercise, in improving exercise adherence and self-report physical function (co-primary outcome measures) for FMS patients. REEF will enroll 200 FMS patients, randomizing them to either the MI group or the attention-control (AC) group. Participants from each group will receive a total of 6 telephone calls within a 12-week period. Prior to the phone calls, participants from both groups will receive an individualized exercise prescription and 2 supervised exercise training sessions to get them started on an exercise program. All subjects will undergo comprehensive outcome assessment at baseline, week 12, week 24, and week 36. The secondary aim of this proposal is to determine the mediators between MI and improvement in self-report physical function. The proposed research is significant because our focus is the promotion of adherence to an exercise program, of adequate intensity, in order to maximize functioning and well-being for patients with FMS. The use of a predominantly home-based exercise program and telephone-delivered MI by a trained licensed practice nurse (LPN) could potentially make the proposed intervention more accessible to the greater majority of FMS patients. Furthermore, if proven efficacious, MI could readily be applied to other chronically painful conditions (e.g. chronic back pain).","[(0, 8, 'PHYSICAL', 'Exercise'), (15, 40, 'BEHAVIOURAL', 'Motivational Interviewing'), (45, 57, 'CONDITION', 'Fibromyalgia'), (60, 72, 'CONDITION', 'Fibromyalgia'), (74, 77, 'CONDITION', 'FMS'), (131, 135, 'CONDITION', 'pain'), (246, 249, 'CONDITION', 'FMS'), (387, 403, 'PHYSICAL', 'aerobic exercise'), (462, 466, 'CONDITION', 'pain'), (550, 558, 'PHYSICAL', 'exercise'), (610, 618, 'PHYSICAL', 'exercise'), (647, 655, 'PHYSICAL', 'exercise'), (730, 738, 'PHYSICAL', 'exercise'), (820, 836, 'PHYSICAL', 'aerobic exercise'), (1157, 1182, 'BEHAVIOURAL', 'motivational interviewing'), (1184, 1186, 'BEHAVIOURAL', 'MI'), (1201, 1209, 'PHYSICAL', 'exercise'), (1224, 1232, 'PHYSICAL', 'exercise'), (1311, 1314, 'CONDITION', 'FMS'), (1346, 1349, 'CONDITION', 'FMS'), (1391, 1393, 'BEHAVIOURAL', 'MI'), (1407, 1424, 'CONTROL', 'attention-control'), (1426, 1428, 'CONTROL', 'AC'), (1605, 1628, 'PHYSICAL', 'individualized exercise'), (1648, 1667, 'PHYSICAL', 'supervised exercise'), (1712, 1720, 'PHYSICAL', 'exercise'), (1906, 1908, 'BEHAVIOURAL', 'MI'), (2050, 2058, 'PHYSICAL', 'exercise'), (2157, 2160, 'CONDITION', 'FMS'), (2200, 2208, 'PHYSICAL', 'exercise'), (2241, 2243, 'BEHAVIOURAL', 'MI'), (2379, 2382, 'CONDITION', 'FMS'), (2429, 2431, 'BEHAVIOURAL', 'MI')]"
"['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'the', 'effect', 'of', 'intraoperative', 'magnesium', 'on', 'remifentanil', '-', 'induced', 'postoperative', 'hyperalgesia', 'after', 'thyroidectomy']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND']",NCT01025245,NCT01025245,The purpose of this study is to study the effect of intraoperative magnesium on remifentanil-induced postoperative hyperalgesia after thyroidectomy,"[(67, 76, 'DRUG', 'magnesium'), (80, 92, 'DRUG', 'remifentanil'), (115, 127, 'CONDITION', 'hyperalgesia'), (134, 147, 'CONDITION', 'thyroidectomy')]"
"['Effect', 'of', 'Education', 'on', 'Prevalence', 'of', 'Kernicterus', 'in', 'Five', 'Regions', 'in', 'Nigeria', '|', 'This', 'study', 'examines', '(', 'a', ')', 'whether', 'introduction', 'of', 'public', ',', 'health', 'provider', ',', 'and', 'maternal', 'education', 'about', 'risks', 'of', 'jaundice', 'will', 'decrease', 'the', 'occurrence', 'of', 'ABE', 'compared', 'with', 'baseline', 'prevalence', '(', 'before', '-', 'after', 'design', ')', 'or', '(', 'b', ')', 'whether', 'antenatal', 'or', 'postpartum', 'instruction', 'to', 'mothers', 'will', 'decrease', 'the', 'incidence', 'of', 'ABE', 'compared', 'with', 'those', 'who', 'did', 'not', 'received', 'instruction', '(', 'concurrent', 'opportunistic', 'controls', 'in', 'phase', '2', ')', '.']","['O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02713464,NCT02713464,"Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria | This study examines (a) whether introduction of public, health provider, and maternal education about risks of jaundice will decrease the occurrence of ABE compared with baseline prevalence (before-after design) or (b) whether antenatal or postpartum instruction to mothers will decrease the incidence of ABE compared with those who did not received instruction (concurrent opportunistic controls in phase 2).","[(10, 19, 'BEHAVIOURAL', 'Education'), (37, 48, 'CONDITION', 'Kernicterus'), (126, 173, 'BEHAVIOURAL', 'public, health provider, and maternal education'), (189, 197, 'CONDITION', 'jaundice'), (230, 233, 'CONDITION', 'ABE'), (305, 340, 'BEHAVIOURAL', 'antenatal or postpartum instruction'), (383, 386, 'CONDITION', 'ABE'), (415, 439, 'CONTROL', 'not received instruction')]"
"['Clinical', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', '[', 'tDCS', ']', 'With', 'Standard', 'Aphasia', 'Therapy', '|', 'Study', 'Design', ':', 'This', 'is', 'a', 'within', '-', 'subjects', 'crossover', 'design', '.', 'Subjects', 'will', 'participate', 'in', 'the', 'procedures', 'twice', ',', 'once', 'under', 'each', 'condition', '(', 'active', 'vs.', 'sham', 'stimulation', ')', '.', 'The', 'order', 'of', 'conditions', 'will', 'be', 'counter', '-', 'balanced', 'across', 'subjects', '.', 'Stimulation', 'will', 'target', 'ventral', 'inferior', 'frontal', 'gyrus', '(', 'IFG', ')', 'and', 'will', 'be', 'paired', 'with', 'standard', 'speech', '-', 'language', 'therapy', '.', 'Outcome', 'measures', 'will', 'be', 'acquired', 'at', 'the', 'beginning', 'and', 'end', 'of', 'a', 'semester', 'of', 'standard', 'speech', '-', 'language', 'therapy', ',', 'and', 'at', 'follow', '-', 'up', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03272906,NCT03272906,"Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy | Study Design: This is a within-subjects crossover design. Subjects will participate in the procedures twice, once under each condition (active vs. sham stimulation). The order of conditions will be counter-balanced across subjects. Stimulation will target ventral inferior frontal gyrus (IFG) and will be paired with standard speech-language therapy. Outcome measures will be acquired at the beginning and end of a semester of standard speech-language therapy, and at follow-up.","[(24, 63, 'OTHER', 'Transcranial Direct Current Stimulation'), (65, 69, 'OTHER', 'tDCS'), (85, 92, 'CONDITION', 'Aphasia'), (250, 266, 'CONTROL', 'sham stimulation'), (429, 452, 'OTHER', 'speech-language therapy'), (539, 562, 'OTHER', 'speech-language therapy')]"
"['Bi', '-', 'Axial', 'Rotating', 'Magnetic', 'Field', 'Therapy', 'in', 'Refractory', 'Neuropathic', 'Foot', 'Pain', 'Secondary', 'to', 'Diabetic', 'Peripheral', 'Neuropathy', '.', 'Multi', '-', 'Center', ',', 'Randomized', 'Placebo', 'Controlled', 'Trial', '|', 'The', 'researchers', 'will', 'study', 'the', 'application', 'of', 'a', 'commercial', 'pulsed', 'magnetic', 'stimulating', 'device', 'to', 'the', 'feet', 'of', 'patients', 'with', 'moderate', '-', 'severe', 'foot', 'pain', 'secondary', 'to', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00123136,NCT00123136,"Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial | The researchers will study the application of a commercial pulsed magnetic stimulating device to the feet of patients with moderate-severe foot pain secondary to diabetic peripheral neuropathy (DPN).","[(0, 40, 'OTHER', 'Bi-Axial Rotating Magnetic Field Therapy'), (44, 76, 'CONDITION', 'Refractory Neuropathic Foot Pain'), (90, 120, 'CONDITION', 'Diabetic Peripheral Neuropathy'), (147, 154, 'CONTROL', 'Placebo'), (233, 260, 'OTHER', 'pulsed magnetic stimulating'), (297, 322, 'CONDITION', 'moderate-severe foot pain'), (336, 366, 'CONDITION', 'diabetic peripheral neuropathy'), (368, 371, 'CONDITION', 'DPN')]"
"['The', 'Potential', 'Therapeutic', 'Effect', 'of', 'Vitamin', 'D', 'Nasal', 'Drops', 'in', 'the', 'Treatment', 'of', 'Post', 'COVID-19', 'Parosmia', '|', 'The', 'current', 'study', 'will', 'be', 'a', 'pilot', 'study', 'for', 'a', 'randomized', 'controlled', 'trial', 'conducted', 'on', 'patients', 'recruited', 'from', 'the', 'outpatient', 'clinic', 'of', 'the', 'Otorhinolaryngology', 'Department', ',', 'Menoufia', 'Faculty', 'of', 'Medicine', 'To', 'evaluate', 'the', 'effect', 'of', 'vitamin', 'D', 'nasal', 'drops', 'in', 'the', 'treatment', 'of', 'post', 'COVID', '19', 'parosmia']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",NCT05269017,NCT05269017,"The Potential Therapeutic Effect of Vitamin D Nasal Drops in the Treatment of Post COVID-19 Parosmia | The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of vitamin D nasal drops in the treatment of post COVID 19 parosmia","[(36, 45, 'DRUG', 'Vitamin D'), (78, 100, 'CONDITION', 'Post COVID-19 Parosmia'), (330, 339, 'DRUG', 'vitamin D'), (372, 394, 'CONDITION', 'post COVID 19 parosmia')]"
"['Effects', 'of', 'Sound', 'Stimulation', ',', 'Somatosensory', 'Stimulation', ',', 'Vestibular', 'Stimulation', 'and', 'the', 'Combinations', 'on', 'Tinnitus', 'Loudness', 'and', 'Tinnitus', 'Related', 'Distress', 'in', 'Patients', '|', 'In', 'this', 'experiment', ',', 'patients', 'with', 'chronic', 'pure', 'tone', 'tinnitus', 'were', 'divided', 'into', 'three', 'groups', 'to', 'receive', 'auditory', 'stimulation', ',', 'somatosensory', 'stimulation', ',', 'vestibular', 'stimulation', 'and', 'combined', 'stimulation', ',', 'in', 'order', 'to', 'find', 'an', 'effective', 'way', 'to', 'treat', 'tinnitus']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",NCT04118907,NCT04118907,"Effects of Sound Stimulation, Somatosensory Stimulation, Vestibular Stimulation and the Combinations on Tinnitus Loudness and Tinnitus Related Distress in Patients | In this experiment, patients with chronic pure tone tinnitus were divided into three groups to receive auditory stimulation, somatosensory stimulation, vestibular stimulation and combined stimulation, in order to find an effective way to treat tinnitus","[(11, 28, 'OTHER', 'Sound Stimulation'), (30, 55, 'OTHER', 'Somatosensory Stimulation'), (57, 79, 'OTHER', 'Vestibular Stimulation'), (104, 112, 'CONDITION', 'Tinnitus'), (126, 134, 'CONDITION', 'Tinnitus'), (200, 226, 'CONDITION', 'chronic pure tone tinnitus'), (269, 289, 'OTHER', 'auditory stimulation'), (291, 316, 'OTHER', 'somatosensory stimulation'), (318, 340, 'OTHER', 'vestibular stimulation'), (345, 365, 'OTHER', 'combined stimulation'), (410, 418, 'CONDITION', 'tinnitus')]"
"['Outcomes', 'Mandate', 'National', 'Integration', 'With', 'Cannabis', 'as', 'Medicine', '|', 'This', 'will', 'be', 'a', 'multistate', ',', 'multicenter', 'clinical', 'study', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'medical', 'cannabis', 'for', 'a', 'wide', 'variety', 'of', 'chronic', 'medical', 'conditions', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03944447,NCT03944447,"Outcomes Mandate National Integration With Cannabis as Medicine | This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.","[(43, 51, 'OTHER', 'Cannabis'), (160, 176, 'OTHER', 'medical cannabis')]"
"['Intraoperative', 'Evaluation', 'of', 'Focused', 'Ultrasound', '-', 'induced', 'Blood', '-', 'brain', 'Barrier', 'Disruption', '|', 'This', 'study', 'seeks', 'to', 'determine', 'the', 'impact', 'of', 'focused', 'ultrasound', '(', 'FUS', ')', 'on', 'the', 'composition', 'of', 'the', 'tumor', 'extracellular', 'microenvironment', '.', 'Researchers', 'will', 'evaluate', 'regions', 'that', 'are', 'very', 'abnormal', ',', 'as', 'well', 'as', 'regions', 'that', 'have', 'less', 'evidence', 'of', 'disease', '.', 'A', 'sub', '-', 'portion', 'of', 'each', 'of', 'these', 'areas', 'will', 'be', 'targeted', 'by', 'focused', 'ultrasound', '.', 'Microdialysis', 'catheters', 'will', 'then', 'be', 'placd', 'into', 'each', 'region', 'that', 'has', 'and', 'has', 'not', 'been', 'exposed', 'to', 'FUS', '(', 'total', 'of', '4', 'catheters', ')', 'to', 'determine', 'how', 'FUS', 'impacts', 'the', 'the', 'brain', 'and', 'tumor', 'extracellular', 'metabolome', ',', 'including', 'concentration', 'of', 'routine', 'drugs', 'systemically', 'administered', 'prior', 'to', ',', 'and', 'during', 'surgery', '.', 'Researchers', 'hope', 'that', 'this', 'information', 'will', 'help', 'reveal', 'the', 'relative', 'contribution', 'of', 'blood', '-', 'derived', 'compounds', 'to', 'the', 'tumor', 'microenvironment', '.', 'If', 'successful', ',', 'microdialysis', 'could', 'be', 'leveraged', 'in', 'the', 'future', 'to', 'simultaneously', 'evaluate', 'pharmacokinetic', 'and', 'pharmacodynamic', 'impacts', 'of', 'future', 'candidate', 'therapies', ',', 'including', 'those', 'delivered', 'with', 'the', 'aid', 'of', 'FUS', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O']",NCT05733312,NCT05733312,"Intraoperative Evaluation of Focused Ultrasound-induced Blood-brain Barrier Disruption | This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.","[(29, 86, 'OTHER', 'Focused Ultrasound-induced Blood-brain Barrier Disruption'), (133, 151, 'OTHER', 'focused ultrasound'), (153, 156, 'OTHER', 'FUS'), (184, 189, 'CONDITION', 'tumor'), (392, 410, 'OTHER', 'focused ultrasound'), (509, 512, 'OTHER', 'FUS'), (553, 556, 'OTHER', 'FUS'), (583, 588, 'CONDITION', 'tumor'), (828, 833, 'CONDITION', 'tumor'), (1058, 1061, 'OTHER', 'FUS')]"
"['The', 'Effect', 'of', 'Intravenous', 'Infusions', 'of', 'Lidocaine', 'and', 'Magnesium', 'Versus', 'Lidocaine', 'and', 'Ketamine', 'Versus', 'Lidocaine', 'Alone', 'on', 'Recovery', 'Profile', 'and', 'Postoperative', 'Pain', 'After', 'Elective', 'Gynecological', 'Surgery', '|', 'The', 'aim', 'of', 'this', 'study', 'will', 'be', 'to', 'investigate', 'the', 'effect', 'of', 'a', 'combination', 'of', 'intravenous', 'infusions', 'of', 'lidocaine', 'and', 'magnesium', 'versus', 'a', 'combination', 'of', 'intravenous', 'infusions', 'of', 'lidocaine', 'and', 'ketamine', 'versus', 'an', 'intravenous', 'infusion', 'of', 'lidocaine', 'alone', 'on', 'recovery', 'profile', ',', 'quality', 'of', 'recovery', 'and', 'postoperative', 'pain', 'after', 'elective', 'gynecological', 'surgery']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT04622904,NCT04622904,"The Effect of Intravenous Infusions of Lidocaine and Magnesium Versus Lidocaine and Ketamine Versus Lidocaine Alone on Recovery Profile and Postoperative Pain After Elective Gynecological Surgery | The aim of this study will be to investigate the effect of a combination of intravenous infusions of lidocaine and magnesium versus a combination of intravenous infusions of lidocaine and ketamine versus an intravenous infusion of lidocaine alone on recovery profile, quality of recovery and postoperative pain after elective gynecological surgery","[(39, 48, 'DRUG', 'Lidocaine'), (53, 62, 'DRUG', 'Magnesium'), (70, 79, 'DRUG', 'Lidocaine'), (84, 92, 'DRUG', 'Ketamine'), (100, 109, 'DRUG', 'Lidocaine'), (140, 158, 'CONDITION', 'Postoperative Pain'), (165, 195, 'CONDITION', 'Elective Gynecological Surgery'), (299, 308, 'DRUG', 'lidocaine'), (313, 322, 'DRUG', 'magnesium'), (372, 381, 'DRUG', 'lidocaine'), (386, 394, 'DRUG', 'ketamine'), (429, 438, 'DRUG', 'lidocaine'), (490, 508, 'CONDITION', 'postoperative pain'), (515, 545, 'CONDITION', 'elective gynecological surgery')]"
"['A', 'Confirmatory', 'Investigation', 'of', 'the', 'Effectiveness', 'of', 'Sana', 'Treatment', 'in', 'Fibromyalgia', '|', 'This', 'is', 'study', 'designed', 'to', 'confirm', 'the', 'effectiveness', 'of', 'the', 'Sana', 'Device', 'in', 'patients', 'with', 'pain', 'due', 'to', 'fibromyalgia', 'on', 'quality', 'of', 'life', 'as', 'measured', 'by', 'the', 'Fibromyalgia', 'Impact', 'Questionnaire', 'Revised', '(', 'FIQR', ')', '.', 'It', 'is', 'a', 'two', 'arm', 'study', 'in', 'which', 'subjects', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'active', 'device', 'group', 'or', 'sham', '-', 'controlled', 'group', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O']",NCT05394610,NCT05394610,A Confirmatory Investigation of the Effectiveness of Sana Treatment in Fibromyalgia | This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.,"[(53, 67, 'OTHER', 'Sana Treatment'), (71, 83, 'CONDITION', 'Fibromyalgia'), (145, 156, 'OTHER', 'Sana Device'), (174, 178, 'CONDITION', 'pain'), (186, 198, 'CONDITION', 'fibromyalgia'), (363, 376, 'OTHER', 'active device'), (386, 390, 'CONTROL', 'sham')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Crossover', 'Comparison', 'of', 'Atomoxetine', 'and', 'Placebo', 'in', 'Child', 'Outpatients', 'With', 'Attention', '-', 'Deficit', '/', 'Hyperactivity', 'Disorder', ',', 'Reading', 'Disorder', ',', 'or', 'Comorbid', 'Attention', '-', 'Deficit', '/', 'Hyperactivity', 'Disorder', 'and', 'Reading', 'Disorder', '.', '|', 'To', 'test', 'the', 'hypothesis', 'that', 'a', '4', 'week', 'treatment', 'with', 'atomoxetine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'patients', 'with', 'combined', 'type', 'Attention', 'Deficit', '/', 'Hyperactivity', 'Disorder', '(', 'ADHD', ')', ',', 'patients', 'with', 'only', 'Reading', 'Disorder', ',', 'and', 'patients', 'with', 'combined', 'type', 'ADHD', 'and', 'Reading', 'Disorder', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT00191906,NCT00191906,"A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. | To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.","[(52, 63, 'DRUG', 'Atomoxetine'), (68, 75, 'CONTROL', 'Placebo'), (102, 119, 'CONDITION', 'Attention-Deficit'), (120, 142, 'CONDITION', 'Hyperactivity Disorder'), (144, 160, 'CONDITION', 'Reading Disorder'), (165, 191, 'CONDITION', 'Comorbid Attention-Deficit'), (192, 214, 'CONDITION', 'Hyperactivity Disorder'), (219, 235, 'CONDITION', 'Reading Disorder'), (291, 302, 'DRUG', 'atomoxetine'), (326, 333, 'CONTROL', 'placebo'), (351, 382, 'CONDITION', 'combined type Attention Deficit'), (383, 405, 'CONDITION', 'Hyperactivity Disorder'), (407, 411, 'CONDITION', 'ADHD'), (433, 449, 'CONDITION', 'Reading Disorder'), (483, 487, 'CONDITION', 'ADHD'), (492, 508, 'CONDITION', 'Reading Disorder')]"
"['Didgeridoo', 'Treatment', 'to', 'Improve', 'Pharyngeal', 'Compliance', 'in', 'Obstructive', 'Sleep', 'Apnea', '-', 'hypopnea', 'Syndrome', 'in', 'Children', ':', 'Proof', '-', 'of', '-', 'concept', 'Study', '|', 'The', 'therapeutic', 'management', 'of', 'Obstructive', 'Sleep', 'Apnoea', 'Syndrome', 'in', 'children', 'remains', 'a', 'debated', 'subject', ',', 'only', 'otorhinolaryngology', 'surgery', '(', 'adenoidectomy', ')', 'has', 'been', 'studied', 'on', 'a', 'large', 'scale', '.', 'Pathophysiologically', ',', 'increased', 'pharyngeal', 'collapsibility', 'is', 'a', 'major', 'endotype', 'of', 'the', 'disease', 'and', 'the', 'investigators', 'have', 'shown', 'that', 'this', 'surgery', 'can', 'improve', 'pharyngeal', 'compliance', '.', 'The', 'development', 'of', 'approaches', 'to', 'treat', 'pharyngeal', 'hypotonia', 'by', 'maxillofacial', 'rehabilitation', 'supports', 'the', 'treatment', 'of', 'this', 'endotype', '.', 'A', 'study', 'in', 'adults', 'showed', 'a', 'benefit', 'from', 'playing', 'the', 'didgeridoo', ',', 'a', 'wind', 'instrument', ',', 'for', '3', 'months', ',', 'without', 'pathophysiological', 'explanation', '.', 'The', 'investigators', 'hypothesise', 'that', 'playing', 'this', 'instrument', 'improves', 'pharyngeal', 'compliance', '(', 're', '-', 'education', 'effect', ')', 'in', 'a', 'similar', 'way', 'to', 'the', 'effect', 'observed', 'after', 'otorhinolaryngology', 'surgery', '.', '\n\n', 'This', 'proof', '-', 'of', '-', 'concept', 'study', 'aims', 'to', 'demonstrate', 'the', 'effect', 'of', 'didgeridoo', 'in', 'children', 'without', 'syndromic', 'pathology', 'with', 'a', 'formal', 'otorhinolaryngology', 'surgical', 'indication', 'resulting', 'from', 'tonsillar', 'hypertrophy', '(', 'Brodsky', 'grades', 'III', 'and', 'IV', ')', 'and', 'symptomatology', 'suggestive', 'of', 'Obstructive', 'Sleep', 'Apnoea', 'Syndrome', '(', 'Pediatric', 'Sleep', 'Questionnaire', 'score', '≥', '0.33', ')', '.', 'The', 'investigators', 'will', 'take', 'advantage', 'of', 'the', 'long', 'delay', 'in', 'performing', 'the', 'adenoidectomy', '(', '~6', 'months', ')', 'in', 'their', 'university', 'hospital', 'to', 'evaluate', ',', 'before', 'the', 'scheduled', 'surgery', ',', 'the', 'effect', 'of', 'the', 'didgeridoo', 'used', 'for', 'three', 'months', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O']",NCT05164211,NCT05164211,"Didgeridoo Treatment to Improve Pharyngeal Compliance in Obstructive Sleep Apnea-hypopnea Syndrome in Children: Proof-of-concept Study | The therapeutic management of Obstructive Sleep Apnoea Syndrome in children remains a debated subject, only otorhinolaryngology surgery (adenoidectomy) has been studied on a large scale. Pathophysiologically, increased pharyngeal collapsibility is a major endotype of the disease and the investigators have shown that this surgery can improve pharyngeal compliance. The development of approaches to treat pharyngeal hypotonia by maxillofacial rehabilitation supports the treatment of this endotype. A study in adults showed a benefit from playing the didgeridoo, a wind instrument, for 3 months, without pathophysiological explanation. The investigators hypothesise that playing this instrument improves pharyngeal compliance (re-education effect) in a similar way to the effect observed after otorhinolaryngology surgery.

This proof-of-concept study aims to demonstrate the effect of didgeridoo in children without syndromic pathology with a formal otorhinolaryngology surgical indication resulting from tonsillar hypertrophy (Brodsky grades III and IV) and symptomatology suggestive of Obstructive Sleep Apnoea Syndrome (Pediatric Sleep Questionnaire score ≥ 0.33). The investigators will take advantage of the long delay in performing the adenoidectomy (~6 months) in their university hospital to evaluate, before the scheduled surgery, the effect of the didgeridoo used for three months.","[(0, 20, 'OTHER', 'Didgeridoo Treatment'), (57, 98, 'CONDITION', 'Obstructive Sleep Apnea-hypopnea Syndrome'), (167, 200, 'CONDITION', 'Obstructive Sleep Apnoea Syndrome'), (688, 698, 'OTHER', 'didgeridoo'), (1023, 1033, 'OTHER', 'didgeridoo'), (1143, 1164, 'CONDITION', 'tonsillar hypertrophy'), (1226, 1259, 'CONDITION', 'Obstructive Sleep Apnoea Syndrome'), (1496, 1506, 'OTHER', 'didgeridoo')]"
"['Augmenting', 'Language', 'Therapy', 'for', 'Aphasia', ':', 'A', 'Randomized', 'Double', '-', 'Blind', 'Placebo', '-', 'Controlled', 'Trial', 'of', 'Levodopa', 'in', 'Combination', 'With', 'Speech', '-', 'Language', 'Therapy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'medication', 'levodopa', ',', 'in', 'combination', 'with', 'speech', '-', 'language', 'treatment', ',', 'on', 'the', 'language', 'outcome', 'of', 'study', 'subjects', 'with', 'nonfluent', 'aphasia', '(', 'i.e.', 'difficulty', 'with', 'the', 'comprehension', 'and', 'expression', 'of', 'spoken', 'and', 'written', 'language', ')', 'following', 'a', 'stroke', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01429077,NCT01429077,"Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy | The purpose of this study is to evaluate the effectiveness of the medication levodopa, in combination with speech-language treatment, on the language outcome of study subjects with nonfluent aphasia (i.e. difficulty with the comprehension and expression of spoken and written language) following a stroke.","[(11, 27, 'OTHER', 'Language Therapy'), (32, 39, 'CONDITION', 'Aphasia'), (67, 74, 'CONTROL', 'Placebo'), (95, 103, 'DRUG', 'Levodopa'), (124, 147, 'OTHER', 'Speech-Language Therapy'), (227, 235, 'DRUG', 'levodopa'), (257, 283, 'OTHER', 'speech-language treatment,'), (331, 348, 'CONDITION', 'nonfluent aphasia'), (448, 454, 'CONDITION', 'stroke')]"
"['Clinical', 'Trial', 'of', 'The', 'Boosting', 'Effect', 'of', 'Transcranial', 'Random', 'Noise', 'Stimulation', '(', 'tRNS', ')', 'in', 'Cognitive', 'Rehabilitation', 'of', 'Patients', 'With', 'Traumatic', 'Brain', 'Injury', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'tRNS', 'while', 'undergoing', 'computerized', 'cognitive', 'rehabilitation', 'therapy', 'to', 'conclude', 'if', 'this', 'combination', 'of', 'therapies', 'would', 'be', 'effective', 'for', 'the', 'cognitive', 'rehabilitation', 'of', 'patients', 'with', 'acquired', 'brain', 'damage', ',', 'such', 'as', 'traumatic', 'brain', 'injury', '.', 'We', 'want', 'to', 'study', 'the', 'therapeutic', 'potential', 'of', 'tRNS', 'to', 'enhance', 'the', 'therapeutic', 'outcome', 'of', 'cognitive', 'training', ',', 'studying', 'its', 'global', 'effect', 'over', 'the', 'rehabilitation', 'of', 'attention', ',', 'memory', 'and', 'executive', 'functions', ',', 'compared', 'to', 'sham', 'tRNS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT03696381,NCT03696381,"Clinical Trial of The Boosting Effect of Transcranial Random Noise Stimulation (tRNS) in Cognitive Rehabilitation of Patients With Traumatic Brain Injury | The main objective of this study is to evaluate the effects of tRNS while undergoing computerized cognitive rehabilitation therapy to conclude if this combination of therapies would be effective for the cognitive rehabilitation of patients with acquired brain damage, such as traumatic brain injury. We want to study the therapeutic potential of tRNS to enhance the therapeutic outcome of cognitive training, studying its global effect over the rehabilitation of attention, memory and executive functions, compared to sham tRNS.","[(41, 78, 'OTHER', 'Transcranial Random Noise Stimulation'), (80, 84, 'OTHER', 'tRNS'), (89, 113, 'OTHER', 'Cognitive Rehabilitation'), (131, 153, 'CONDITION', 'Traumatic Brain Injury'), (219, 223, 'OTHER', 'tRNS'), (241, 286, 'OTHER', 'computerized cognitive rehabilitation therapy'), (359, 383, 'OTHER', 'cognitive rehabilitation'), (401, 422, 'CONDITION', 'acquired brain damage'), (432, 454, 'CONDITION', 'traumatic brain injury'), (502, 506, 'OTHER', 'tRNS'), (545, 563, 'OTHER', 'cognitive training'), (674, 683, 'CONTROL', 'sham tRNS')]"
"['Effectiveness', 'of', 'Balance', 'Training', 'With', 'Kinesthetic', 'Ability', 'Trainer', '-', 'KAT2000', 'in', 'Patients', 'With', 'Peripheral', 'Neuropathic', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Study', '|', 'Objective', ':', 'To', 'determine', 'the', 'effectiveness', 'of', 'balance', 'training', 'with', 'Kinesthetic', 'Ability', 'Trainer', '2000', '(', 'KAT', '2000', ')', 'in', 'patients', 'with', 'peripheral', 'neuropathic', 'pain', 'related', 'balance', 'disorder', '.', '\n\n', 'Methods', ':', 'A', 'total', 'of', '60', 'patients', 'who', 'developed', 'peripheral', 'neuropathic', 'pain', '-', 'related', 'balance', 'impairment', 'in', 'the', 'chronic', 'phase', 'due', 'to', 'lumber', 'disc', 'herniation', ',', 'lumber', 'spondylosis', 'and', 'gonarthrosis', 'were', 'included', 'into', 'this', 'randomized', 'controlled', 'prospective', 'study', 'and', 'randomized', 'into', 'either', 'balance', 'exercises', 'groups', 'or', 'KAT', '2000', 'exercises', 'groups', '.', 'Balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'Group', '1', '(', 'n=30', ')', '.', 'In', 'addition', 'to', 'balance', 'exercises', ',', 'KAT', '2000', 'balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'group', '2', '(', 'n=30', ')', '.', 'All', 'patients', 'received', '45', '-', 'min', 'individualized', 'training', 'session', 'for', 'three', 'times', 'a', 'week', 'for', '4', 'weeks', '.', 'Patients', 'were', 'evaluated', 'according', 'to', 'pain', ',', 'static', 'and', 'dynamic', 'balance', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03359772,NCT03359772,"Effectiveness of Balance Training With Kinesthetic Ability Trainer-KAT2000 in Patients With Peripheral Neuropathic Pain: a Randomized Controlled Study | Objective: To determine the effectiveness of balance training with Kinesthetic Ability Trainer 2000 (KAT 2000) in patients with peripheral neuropathic pain related balance disorder.

Methods: A total of 60 patients who developed peripheral neuropathic pain-related balance impairment in the chronic phase due to lumber disc herniation, lumber spondylosis and gonarthrosis were included into this randomized controlled prospective study and randomized into either balance exercises groups or KAT 2000 exercises groups. Balance exercises were given all patients in Group 1 (n=30). In addition to balance exercises, KAT 2000 balance exercises were given all patients in group 2 (n=30). All patients received 45-min individualized training session for three times a week for 4 weeks. Patients were evaluated according to pain, static and dynamic balance and quality of life (QoL).","[(39, 74, 'PHYSICAL', 'Kinesthetic Ability Trainer-KAT2000'), (92, 119, 'CONDITION', 'Peripheral Neuropathic Pain'), (220, 252, 'PHYSICAL', 'Kinesthetic Ability Trainer 2000'), (254, 262, 'PHYSICAL', 'KAT 2000'), (281, 308, 'CONDITION', 'peripheral neuropathic pain'), (317, 333, 'CONDITION', 'balance disorder'), (382, 409, 'CONDITION', 'peripheral neuropathic pain'), (418, 425, 'CONDITION', 'balance'), (465, 487, 'CONDITION', 'lumber disc herniation'), (489, 507, 'CONDITION', 'lumber spondylosis'), (512, 524, 'CONDITION', 'gonarthrosis'), (616, 633, 'CONTROL', 'balance exercises'), (644, 662, 'PHYSICAL', 'KAT 2000 exercises'), (671, 688, 'CONTROL', 'Balance exercises'), (747, 764, 'CONTROL', 'balance exercises'), (766, 792, 'PHYSICAL', 'KAT 2000 balance exercises')]"
"['Phase', 'II', 'Randomized', 'Study', 'of', 'Stereotactic', 'Radiosurgery', 'Plus', 'Fractionated', 'Whole', '-', 'Brain', 'Radiotherapy', 'Vs', 'Fractionated', 'Whole', '-', 'Brain', 'Radiotherapy', 'Alone', 'for', 'Multiple', 'Primary', 'or', 'Metastatic', 'Brain', 'Tumors', '|', 'OBJECTIVES', ':', 'I.', 'Evaluate', 'whether', 'stereotactic', 'radiosurgery', 'provides', 'local', 'control', 'at', 'multiple', 'sites', 'in', 'patients', 'with', 'primary', 'or', 'metastatic', 'brain', 'tumors', ',', 'controlled', 'systemic', 'disease', ',', 'and', 'preserved', 'neurologic', 'function', '.', '\n\n', 'II', '.', 'Examine', 'survival', ',', 'clinical', 'outcome', ',', 'and', 'local', 'tumor', 'imaging', 'response', 'in', 'these', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00004659,NCT00004659,"Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors | OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function.

II. Examine survival, clinical outcome, and local tumor imaging response in these patients.","[(29, 54, 'RADIOTHERAPY', 'Stereotactic Radiosurgery'), (60, 97, 'RADIOTHERAPY', 'Fractionated Whole-Brain Radiotherapy'), (101, 144, 'CONTROL', 'Fractionated Whole-Brain Radiotherapy Alone'), (149, 192, 'CONDITION', 'Multiple Primary or Metastatic Brain Tumors'), (227, 252, 'RADIOTHERAPY', 'stereotactic radiosurgery'), (311, 345, 'CONDITION', 'primary or metastatic brain tumors'), (462, 467, 'CONDITION', 'tumor')]"
"['Phase', 'I', '/', 'II', 'Trial', 'of', 'Dasatinib', '(', 'Sprycel', ')', 'With', 'Radiation', 'Therapy', 'and', 'Concomitant', 'and', 'Adjuvant', 'Temozolomide', 'in', 'Patients', 'With', 'Newly', '-', 'Diagnosed', 'Glioblastoma', '|', 'Phase', 'I', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'define', 'the', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'radiotherapy', '(', 'RT', ')', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'glioblastoma', 'after', 'RT', '.', '\n\n', 'STUDY', 'DID', 'NOT', 'PROGRESS', 'TO', 'PHASE', 'II', 'PORTION', '.', '\n\n', 'Phase', 'II', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'determine', 'the', 'effectiveness', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'followed', 'by', 'adjuvant', 'temozolomide', 'with', 'concurrent', 'dasatinib', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', 'as', 'measured', 'by', 'overall', 'survival', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'determine', 'the', 'efficacy', 'of', 'this', 'treatment', 'as', 'measured', 'by', 'radiographic', 'response', '(', 'RR', ')', ',', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', 'and', 'time', 'to', 'progression', '(', 'TTP', ')', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'RT', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'GBM', 'after', 'RT', '.', '\n\n', 'Exploratory', 'Objectives', ':', '\n\n', '-To', 'correlate', 'tumor', 'genotype', ',', 'tumor', 'expression', 'of', 'dasatinib', 'target', 'proteins', '(', 'e.g.', 'Src', ',', 'EphA2', ',', 'c', '-', 'kit', 'and', 'PDGFR', ')', ',', 'and', 'PTEN', 'levels', 'with', 'response', 'to', 'therapy', 'with', 'dasatinib', 'and', 'temozolomide', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT00895960,NCT00895960,"Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma | Phase I:

Primary Objectives:

-To define the maximum tolerated dose (MTD) of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly-diagnosed glioblastoma (GBM).

Secondary Objectives:

To characterize the safety profile of dasatinib (Sprycel) in combination with radiotherapy (RT) and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with glioblastoma after RT.

STUDY DID NOT PROGRESS TO PHASE II PORTION.

Phase II:

Primary Objectives:

-To determine the effectiveness of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day followed by adjuvant temozolomide with concurrent dasatinib in patients with newly-diagnosed glioblastoma (GBM) as measured by overall survival.

Secondary Objectives:

To determine the efficacy of this treatment as measured by radiographic response (RR), progression-free survival (PFS) and time to progression (TTP).
To characterize the safety profile of dasatinib (Sprycel) in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with GBM after RT.

Exploratory Objectives:

-To correlate tumor genotype, tumor expression of dasatinib target proteins (e.g. Src, EphA2, c-kit and PDGFR), and PTEN levels with response to therapy with dasatinib and temozolomide.","[(20, 29, 'DRUG', 'Dasatinib'), (31, 38, 'DRUG', 'Sprycel'), (45, 62, 'RADIOTHERAPY', 'Radiation Therapy'), (92, 104, 'DRUG', 'Temozolomide'), (122, 150, 'CONDITION', 'Newly-Diagnosed Glioblastoma'), (231, 240, 'DRUG', 'dasatinib'), (242, 249, 'DRUG', 'Sprycel'), (256, 268, 'RADIOTHERAPY', 'radiotherapy'), (270, 272, 'RADIOTHERAPY', 'RT'), (301, 313, 'DRUG', 'temozolomide'), (315, 318, 'DRUG', 'TMZ'), (367, 395, 'CONDITION', 'newly-diagnosed glioblastoma'), (397, 400, 'CONDITION', 'GBM'), (465, 474, 'DRUG', 'dasatinib'), (476, 483, 'DRUG', 'Sprycel'), (505, 517, 'RADIOTHERAPY', 'radiotherapy'), (519, 521, 'RADIOTHERAPY', 'RT'), (539, 542, 'DRUG', 'TMZ'), (560, 579, 'CONDITION', 'newly-diagnosed GBM'), (619, 628, 'DRUG', 'dasatinib'), (630, 637, 'DRUG', 'Sprycel'), (668, 671, 'DRUG', 'TMZ'), (689, 701, 'CONDITION', 'glioblastoma'), (708, 710, 'RADIOTHERAPY', 'RT'), (825, 834, 'DRUG', 'dasatinib'), (836, 843, 'DRUG', 'Sprycel'), (850, 862, 'RADIOTHERAPY', 'radiotherapy'), (864, 866, 'RADIOTHERAPY', 'RT'), (895, 907, 'DRUG', 'temozolomide'), (909, 912, 'DRUG', 'TMZ'), (965, 977, 'DRUG', 'temozolomide'), (994, 1003, 'DRUG', 'dasatinib'), (1021, 1049, 'CONDITION', 'newly-diagnosed glioblastoma'), (1051, 1054, 'CONDITION', 'GBM'), (1301, 1310, 'DRUG', 'dasatinib'), (1312, 1319, 'DRUG', 'Sprycel'), (1341, 1343, 'RADIOTHERAPY', 'RT'), (1360, 1363, 'DRUG', 'TMZ'), (1381, 1400, 'CONDITION', 'newly-diagnosed GBM'), (1440, 1449, 'DRUG', 'dasatinib'), (1451, 1458, 'DRUG', 'Sprycel'), (1489, 1492, 'DRUG', 'TMZ'), (1510, 1513, 'CONDITION', 'GBM'), (1520, 1522, 'RADIOTHERAPY', 'RT'), (1564, 1569, 'CONDITION', 'tumor'), (1580, 1585, 'CONDITION', 'tumor'), (1600, 1609, 'DRUG', 'dasatinib'), (1708, 1717, 'DRUG', 'dasatinib'), (1722, 1734, 'DRUG', 'temozolomide')]"
"['Language', 'Assessment', 'and', 'Treatment', 'Following', 'Acquired', 'Brain', 'Injury', '|', 'People', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'often', 'experience', 'persistent', 'language', 'challenges', 'that', 'are', 'subtle', 'in', 'nature', 'and', 'not', 'readily', 'observable', 'to', 'others', '.', 'These', 'challenges', 'can', 'have', 'substantial', 'negative', 'effects', 'on', 'vocational', 'and', 'social', 'endeavors', 'despite', 'their', 'subtlety', '.', 'Even', 'though', 'these', 'challenges', 'are', 'prevalent', 'in', 'the', 'ABI', 'population', ',', 'limited', 'methods', 'exist', 'for', 'quantifying', 'and', 'remediating', 'them', '.', 'The', 'two', 'purposes', 'of', 'Phase', 'I', 'of', 'this', 'research', 'are', 'to', '(', 'a', ')', 'explore', 'methods', 'of', 'using', 'event', 'related', 'potential', '(', 'ERP', ')', 'recordings', 'to', 'quantify', 'language', 'processing', 'differences', 'between', 'people', 'with', 'and', 'without', 'ABI', 'and', '(', 'b', ')', 'correlate', 'behavioral', 'observations', 'from', 'language', 'tests', 'with', 'ERP', 'findings', '.', 'The', 'purpose', 'of', 'Phase', 'II', 'is', 'to', 'explore', 'the', 'use', 'of', 'game', '-', 'based', ',', 'group', 'activities', 'as', 'an', 'intervention', 'for', 'people', 'with', 'ABI', 'who', 'experience', 'word', '-', 'retrieval', 'challenges', '.', 'The', 'purpose', 'of', 'Phase', 'III', 'is', 'to', 'collect', 'post', '-', 'intervention', 'data', 'for', 'comparison', 'with', 'Phase', 'I', 'data', 'and', 'provide', 'evidence', 'about', 'the', 'effectiveness', 'of', 'the', 'intervention', 'program', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03320954,NCT03320954,"Language Assessment and Treatment Following Acquired Brain Injury | People with acquired brain injury (ABI) often experience persistent language challenges that are subtle in nature and not readily observable to others. These challenges can have substantial negative effects on vocational and social endeavors despite their subtlety. Even though these challenges are prevalent in the ABI population, limited methods exist for quantifying and remediating them. The two purposes of Phase I of this research are to (a) explore methods of using event related potential (ERP) recordings to quantify language processing differences between people with and without ABI and (b) correlate behavioral observations from language tests with ERP findings. The purpose of Phase II is to explore the use of game-based, group activities as an intervention for people with ABI who experience word-retrieval challenges. The purpose of Phase III is to collect post-intervention data for comparison with Phase I data and provide evidence about the effectiveness of the intervention program.","[(44, 65, 'CONDITION', 'Acquired Brain Injury'), (80, 101, 'CONDITION', 'acquired brain injury'), (103, 106, 'CONDITION', 'ABI'), (136, 155, 'CONDITION', 'language challenges'), (384, 387, 'CONDITION', 'ABI'), (658, 661, 'CONDITION', 'ABI'), (792, 820, 'BEHAVIOURAL', 'game-based, group activities'), (856, 859, 'CONDITION', 'ABI'), (875, 900, 'CONDITION', 'word-retrieval challenges')]"
"['A', 'Single', 'Dose', 'Study', 'to', 'Assess', 'the', 'Pharmacokinetics', 'of', 'SCH', '900800', 'Administered', 'as', 'Oral', 'Tablets', 'in', 'L', '-', 'DOPA', '-', 'treated', 'Subjects', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'assess', 'the', 'pharmacokinetics', 'of', 'SCH', '900800', 'in', 'participants', 'with', 'moderate', 'to', 'severe', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'being', 'treated', 'with', 'L', '-', 'DOPA', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O']",NCT01500707,NCT01500707,A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease | This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.,"[(54, 64, 'DRUG', 'SCH 900800'), (97, 103, 'DRUG', 'L-DOPA'), (126, 145, 'CONDITION', ""Parkinson's Disease""), (207, 217, 'DRUG', 'SCH 900800'), (239, 277, 'CONDITION', ""moderate to severe Parkinson's Disease""), (279, 281, 'CONDITION', 'PD'), (302, 308, 'DRUG', 'L-DOPA')]"
"['Long', 'Term', 'Treatment', 'With', 'Galantamine', 'In', 'Dementia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'efficacy', 'and', 'safety', 'of', 'galantamine', 'in', 'patients', 'with', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00216502,NCT00216502,Long Term Treatment With Galantamine In Dementia | The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.,"[(25, 36, 'DRUG', 'Galantamine'), (40, 48, 'CONDITION', 'Dementia'), (129, 140, 'DRUG', 'galantamine'), (158, 177, 'CONDITION', ""Alzheimer's disease"")]"
"['A', 'Phase', '3', 'Efficacy', 'and', 'Safety', 'Study', 'of', 'Ataluren', 'in', 'Patients', 'With', 'Nonsense', 'Mutation', 'Dystrophinopathy', '|', 'Dystrophinopathy', 'is', 'a', 'disease', 'continuum', 'that', 'includes', 'Duchenne', 'muscular', 'dystrophy', ',', 'which', 'develops', 'in', 'boys', '.', 'It', 'is', 'caused', 'by', 'a', 'mutation', 'in', 'the', 'gene', 'for', 'dystrophin', ',', 'a', 'protein', 'that', 'is', 'important', 'for', 'maintaining', 'normal', 'muscle', 'structure', 'and', 'function', '.', 'Loss', 'of', 'dystrophin', 'causes', 'muscle', 'fragility', 'that', 'leads', 'to', 'weakness', 'and', 'loss', 'of', 'walking', 'ability', '.', 'A', 'specific', 'type', 'of', 'mutation', ',', 'called', 'a', 'nonsense', '(', 'premature', 'stop', 'codon', ')', 'mutation', 'is', 'the', 'cause', 'of', 'dystrophinopathy', 'in', 'approximately', '10', '-', '15', 'percent', '(', '%', ')', 'of', 'boys', 'with', 'the', 'disease', '.', 'Ataluren', 'is', 'an', 'orally', 'delivered', ',', 'investigational', 'drug', 'that', 'has', 'the', 'potential', 'to', 'overcome', 'the', 'effects', 'of', 'the', 'nonsense', 'mutation', '.', 'The', 'main', 'goal', 'of', 'this', 'Phase', '3', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'ataluren', 'on', 'walking', 'ability', '.', 'The', 'effect', 'of', 'ataluren', 'on', 'physical', 'function', ',', 'quality', 'of', 'life', ',', 'and', 'activities', 'of', 'daily', 'living', 'will', 'be', 'evaluated', '.', 'This', 'study', 'will', 'also', 'provide', 'additional', 'information', 'on', 'the', 'long', '-', 'term', 'safety', 'of', 'ataluren', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT01826487,NCT01826487,"A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Dystrophinopathy | Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy in approximately 10-15 percent (%) of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. The main goal of this Phase 3 study is to evaluate the effect of ataluren on walking ability. The effect of ataluren on physical function, quality of life, and activities of daily living will be evaluated. This study will also provide additional information on the long-term safety of ataluren.","[(39, 47, 'DRUG', 'Ataluren'), (65, 99, 'CONDITION', 'Nonsense Mutation Dystrophinopathy'), (102, 118, 'CONDITION', 'Dystrophinopathy'), (156, 183, 'CONDITION', 'Duchenne muscular dystrophy'), (479, 519, 'CONDITION', 'nonsense (premature stop codon) mutation'), (536, 552, 'CONDITION', 'dystrophinopathy'), (614, 622, 'DRUG', 'Ataluren'), (722, 739, 'CONDITION', 'nonsense mutation'), (806, 814, 'DRUG', 'ataluren'), (849, 857, 'DRUG', 'ataluren'), (1026, 1034, 'DRUG', 'ataluren')]"
"['The', 'Norwegian', 'Study', 'of', 'Chronic', 'Fatigue', 'Syndrome', 'in', 'Adolescents', ':', 'Pathophysiology', 'and', 'Intervention', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'IS', 'to', '\n\n', 'explore', 'the', 'underlying', 'pathophysiology', 'of', 'chronic', 'fatigue', 'syndrome', '(', 'CFS', ')', 'in', 'adolescents', ',', 'particularly', 'focusing', 'on', 'genetics', ',', 'infections', '/', 'immunology', ',', 'endocrinology', ',', 'autonomic', 'control', 'and', 'cognitions', '\n', 'to', 'assess', 'the', 'effect', 'of', 'clonidine', '(', 'a', 'drug', 'that', 'attenuates', 'sympathetic', 'nervous', 'activity', ')', 'in', 'adolescent', 'CFS', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01040429,NCT01040429,"The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial | The purpose of this study IS to

explore the underlying pathophysiology of chronic fatigue syndrome (CFS) in adolescents, particularly focusing on genetics, infections/immunology, endocrinology, autonomic control and cognitions
to assess the effect of clonidine (a drug that attenuates sympathetic nervous activity) in adolescent CFS.","[(23, 47, 'CONDITION', 'Chronic Fatigue Syndrome'), (180, 204, 'CONDITION', 'chronic fatigue syndrome'), (206, 209, 'CONDITION', 'CFS'), (357, 366, 'DRUG', 'clonidine'), (435, 438, 'CONDITION', 'CFS')]"
"['Enhancing', 'Written', 'Communication', 'in', 'Persons', 'With', 'Aphasia', ':', 'A', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'a', 'computerized', 'speech', '-', 'language', 'treatment', 'delivered', 'by', 'a', 'virtual', 'therapist', '(', 'Oral', 'Reading', 'for', 'Language', 'in', 'Aphasia', '(', 'ORLA', ')', '+', 'Writing', ')', 'results', 'in', 'improved', 'written', 'communication', 'skills', 'of', 'study', 'participants', 'with', 'aphasia', '(', 'i.e.', ',', 'difficulty', 'with', 'the', 'comprehension', 'and', 'expression', 'of', 'spoken', 'and', 'written', 'language', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01790880,NCT01790880,"Enhancing Written Communication in Persons With Aphasia: A Clinical Trial | The purpose of this study is to evaluate whether a computerized speech-language treatment delivered by a virtual therapist (Oral Reading for Language in Aphasia (ORLA) + Writing) results in improved written communication skills of study participants with aphasia (i.e., difficulty with the comprehension and expression of spoken and written language).","[(48, 55, 'CONDITION', 'Aphasia'), (127, 165, 'OTHER', 'computerized speech-language treatment'), (181, 198, 'OTHER', 'virtual therapist'), (200, 236, 'OTHER', 'Oral Reading for Language in Aphasia'), (238, 242, 'OTHER', 'ORLA'), (246, 253, 'OTHER', 'Writing'), (331, 338, 'CONDITION', 'aphasia')]"
"['Aponeurotic', 'Stimulation', 'Effect', 'on', 'Parkinson', 'Bradykinesia', '|', 'Movement', 'slowness', '(', 'bradykinesia', ')', 'is', 'one', 'of', 'the', 'main', 'motor', 'symptoms', 'in', 'Parkinson', 'Disease', '(', 'PD', ')', '.', 'Several', 'studies', 'have', 'shown', 'that', 'patients', 'with', 'PD', 'exhibit', 'slowness', 'because', 'they', 'are', 'unable', 'to', 'modulate', ',', 'in', 'an', 'optimal', 'way', ',', 'the', 'velocity', 'of', 'voluntary', 'motor', 'acts', 'not', 'induced', 'by', 'external', 'stimulation', '.', 'Indeed', ',', 'these', 'patients', 'have', 'difficulties', 'to', 'integrate', 'multi', '-', 'sensorial', 'information', ',', 'mainly', 'proprioception', '.', '\n\n', 'The', 'investigators', 'investigated', 'changes', 'in', 'shoulder', 'velocity', 'during', 'pointing', 'movements', 'by', 'patients', 'with', 'PD', 'after', 'stimulation', 'of', 'soft', 'tissues', '(', 'aponeurosis', ')', 'of', 'upper', 'limb', 'muscles', '.', 'The', 'stimulation', 'consisted', 'of', 'manipulating', ',', 'with', 'a', 'hook', '(', 'the', 'diacutaneous', 'fibrolysis', 'method', ')', ',', 'the', 'aponeurotic', 'tissues', 'enrobing', 'the', 'heads', 'of', 'the', 'upper', 'limb', 'muscles', '.', 'This', 'technique', 'has', 'previously', 'been', 'shown', 'to', 'decrease', 'passive', 'tension', 'and', 'the', 'tendon', 'reflex', 'response', 'of', 'the', 'manipulated', 'muscle', 'group', '.', 'The', 'investigators', 'hypothesis', 'is', 'that', 'aponeurotic', 'manipulation', 'of', 'shoulder', 'muscles', 'therefore', 'creates', 'a', 'modification', 'in', 'the', 'proprioceptive', 'information', ',', 'which', 'in', 'return', 'temporarily', 'decreases', 'the', 'bradykinesia', 'of', 'shoulder', 'movements', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT01544738,NCT01544738,"Aponeurotic Stimulation Effect on Parkinson Bradykinesia | Movement slowness (bradykinesia) is one of the main motor symptoms in Parkinson Disease (PD). Several studies have shown that patients with PD exhibit slowness because they are unable to modulate, in an optimal way, the velocity of voluntary motor acts not induced by external stimulation. Indeed, these patients have difficulties to integrate multi-sensorial information, mainly proprioception.

The investigators investigated changes in shoulder velocity during pointing movements by patients with PD after stimulation of soft tissues (aponeurosis) of upper limb muscles. The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the upper limb muscles. This technique has previously been shown to decrease passive tension and the tendon reflex response of the manipulated muscle group. The investigators hypothesis is that aponeurotic manipulation of shoulder muscles therefore creates a modification in the proprioceptive information, which in return temporarily decreases the bradykinesia of shoulder movements.","[(0, 23, 'OTHER', 'Aponeurotic Stimulation'), (34, 43, 'CONDITION', 'Parkinson'), (44, 56, 'CONDITION', 'Bradykinesia'), (59, 76, 'CONDITION', 'Movement slowness'), (78, 90, 'CONDITION', 'bradykinesia'), (129, 146, 'CONDITION', 'Parkinson Disease'), (148, 150, 'CONDITION', 'PD'), (199, 201, 'CONDITION', 'PD'), (559, 561, 'CONDITION', 'PD'), (568, 631, 'OTHER', 'stimulation of soft tissues (aponeurosis) of upper limb muscles'), (693, 716, 'OTHER', 'diacutaneous fibrolysis'), (966, 1010, 'OTHER', 'aponeurotic manipulation of shoulder muscles'), (1121, 1133, 'CONDITION', 'bradykinesia')]"
"['Quality', 'Control', 'of', 'CE', '-', 'Certified', 'Phonak', 'Hearing', 'Aids', '-', '2018_07', '|', 'Phonak', 'Hearing', 'Systems', 'pass', 'through', 'different', 'development', 'and', 'study', 'stages', '.', 'At', 'an', 'early', 'stage', ',', 'feasibility', 'studies', 'are', 'conducted', 'to', 'investigate', 'new', 'algorithms', ',', 'features', 'and', 'functions', 'in', 'an', 'isolated', 'manner', '.', 'If', 'the', 'benefit', 'is', 'proven', ',', 'their', 'performance', 'is', 'then', 'investigated', 'regarding', 'interdependency', 'between', 'all', 'available', 'algorithms', ',', 'features', 'and', 'functions', 'running', 'in', 'parallel', 'in', 'a', 'hearing', 'aid', '(', 'pivotal', '/', 'pre', '-', 'validation', 'studies', ')', 'and', ',', 'as', 'a', 'result', ',', 'they', 'get', 'optimized', '.', 'Afterwards', ',', 'and', 'prior', 'to', 'product', 'launch', ',', 'the', 'Phonak', 'Hearing', 'Systems', 'undergo', 'a', 'final', 'quality', 'control', 'in', 'terms', 'of', 'clinical', 'trials', '.', 'This', 'is', 'a', 'pre', '-', 'validation', 'study', ',', 'investigating', 'optimized', 'algorithms', ',', 'features', ',', 'functions', 'and', 'wearing', 'comfort', '.', 'This', 'will', 'be', 'a', 'clinical', 'evaluation', 'which', 'will', 'be', 'conducted', 'mono', 'centric', 'at', 'Sonova', 'AG', 'Headquarters', 'based', 'in', 'Stäfa', '(', 'Switzerland', ')', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03555084,NCT03555084,"Quality Control of CE-Certified Phonak Hearing Aids - 2018_07 | Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).","[(19, 51, 'OTHER', 'CE-Certified Phonak Hearing Aids'), (64, 86, 'OTHER', 'Phonak Hearing Systems'), (443, 454, 'OTHER', 'hearing aid'), (571, 593, 'OTHER', 'Phonak Hearing Systems')]"
"['A', 'Pilot', 'Study', 'Assessing', 'the', 'Benefits', 'of', 'a', 'Dementia', 'Caregiver', 'Educational', 'Brochure', 'on', 'Decreased', 'Empathy', 'and', 'Emotion', 'Recognition', 'in', 'Patients', 'With', 'Neurodegenerative', 'Disease', '|', 'This', 'study', 'evaluates', 'an', 'educational', 'brochure', 'tailored', 'to', 'caregivers', 'of', 'people', 'with', 'Alzheimer', ""'s"", 'disease', ',', 'Parkinson', ""'s"", 'disease', 'dementia', ',', 'Lewy', 'body', 'disease', ',', 'frontotemporal', 'dementia', ',', 'and', 'vascular', 'disease', 'dementia', '.', 'The', 'goal', 'of', 'the', 'brochure', 'is', 'educating', 'caregivers', 'about', 'the', 'decreased', 'ability', 'to', 'detect', 'emotion', 'and', 'decreased', 'empathy', 'that', 'can', 'be', 'seen', 'in', 'dementia', ',', 'increasing', 'caregiver', 'competence', 'in', 'providing', 'care', ',', 'and', 'teaching', 'caregivers', 'ways', 'to', 'manage', 'over', 'time', 'that', 'lessens', 'burden', 'and', 'improves', 'quality', 'of', 'life', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04635540,NCT04635540,"A Pilot Study Assessing the Benefits of a Dementia Caregiver Educational Brochure on Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease | This study evaluates an educational brochure tailored to caregivers of people with Alzheimer's disease, Parkinson's disease dementia, Lewy body disease, frontotemporal dementia, and vascular disease dementia. The goal of the brochure is educating caregivers about the decreased ability to detect emotion and decreased empathy that can be seen in dementia, increasing caregiver competence in providing care, and teaching caregivers ways to manage over time that lessens burden and improves quality of life.","[(42, 81, 'BEHAVIOURAL', 'Dementia Caregiver Educational Brochure'), (144, 169, 'CONDITION', 'Neurodegenerative Disease'), (196, 239, 'BEHAVIOURAL', 'educational brochure tailored to caregivers'), (255, 274, 'CONDITION', ""Alzheimer's disease""), (276, 304, 'CONDITION', ""Parkinson's disease dementia""), (306, 323, 'CONDITION', 'Lewy body disease'), (325, 348, 'CONDITION', 'frontotemporal dementia'), (354, 379, 'CONDITION', 'vascular disease dementia'), (397, 405, 'BEHAVIOURAL', 'brochure'), (518, 526, 'CONDITION', 'dementia')]"
"['Subthalamic', 'Nucleus', 'Stimulation', 'Effect', 'on', 'Gait', 'Symmetry', 'and', 'Freezing', 'of', 'Gait', '|', 'Impact', 'of', 'unilateral', 'modulation', 'of', 'deep', 'brain', 'stimulation', 'of', 'the', 'subthalamic', 'nucleus', 'on', 'freezing', 'of', 'gait', 'in', 'Parkinson', ""'s"", 'disease']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT02704195,NCT02704195,Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait | Impact of unilateral modulation of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease,"[(0, 31, 'OTHER', 'Subthalamic Nucleus Stimulation'), (60, 76, 'CONDITION', 'Freezing of Gait'), (114, 163, 'OTHER', 'deep brain stimulation of the subthalamic nucleus'), (167, 183, 'CONDITION', 'freezing of gait'), (187, 206, 'CONDITION', ""Parkinson's disease"")]"
"['Efficacy', 'of', 'Inhaled', 'Cannabis', 'Versus', 'Placebo', 'for', 'the', 'Acute', 'Treatment', 'of', 'Migraine', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Crossover', 'Trial', '|', 'This', 'crossover', 'study', 'will', 'evaluate', '3', 'different', 'treatments', 'of', 'vaporized', 'cannabis', '(', 'THC', ',', 'THC', '/', 'CBD', 'mix', ',', 'and', 'CBD', ')', 'and', 'vaporized', 'placebo', 'cannabis', 'for', 'the', 'acute', 'treatment', 'of', 'migraine', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04360044,NCT04360044,"Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial | This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.","[(20, 28, 'OTHER', 'Cannabis'), (36, 43, 'CONTROL', 'Placebo'), (71, 79, 'CONDITION', 'Migraine'), (109, 116, 'CONTROL', 'Placebo'), (218, 226, 'OTHER', 'cannabis'), (228, 231, 'DRUG', 'THC'), (233, 236, 'DRUG', 'THC'), (237, 240, 'DRUG', 'CBD'), (250, 253, 'DRUG', 'CBD'), (259, 285, 'CONTROL', 'vaporized placebo cannabis'), (313, 321, 'CONDITION', 'migraine')]"
"['Correlation', 'of', 'Serum', 'Level', 'of', 'Perampanel', '(', 'PER', ')', 'Level', 'to', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'Levels', 'of', 'PER', '|', 'Perampanel', 'is', 'a', 'drug', 'used', 'to', 'treat', 'patients', 'with', 'epilepsy', '/', 'seizures', '.', 'This', 'study', 'is', 'designed', 'to', 'determine', 'how', 'much', 'perampanel', 'actually', 'crosses', 'the', 'blood', 'brain', 'barrier', 'into', 'the', 'cerebral', 'spinal', 'fluid', 'when', 'the', 'drug', 'is', 'taken', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04118829,NCT04118829,Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER | Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to determine how much perampanel actually crosses the blood brain barrier into the cerebral spinal fluid when the drug is taken.,"[(30, 40, 'DRUG', 'Perampanel'), (42, 45, 'DRUG', 'PER'), (92, 95, 'DRUG', 'PER'), (98, 108, 'DRUG', 'Perampanel'), (147, 155, 'CONDITION', 'epilepsy'), (156, 164, 'CONDITION', 'seizures'), (211, 221, 'DRUG', 'perampanel')]"
"['Pivotal', 'Study', 'of', 'the', 'Apnex', 'Medical', '™', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'to', 'Treat', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'benefits', 'and', 'risks', 'of', 'hypoglossal', 'nerve', 'stimulation', 'with', 'the', 'Apnex', 'Medical', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'as', 'a', 'potential', 'therapeutic', 'option', 'for', 'individuals', 'with', 'moderate', 'to', 'severe', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', 'that', 'have', 'failed', 'or', 'do', 'not', 'tolerate', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'therapy', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01446601,NCT01446601,Pivotal Study of the Apnex Medical™ Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea | The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate to severe Obstructive Sleep Apnea (OSA) that have failed or do not tolerate positive airway pressure (PAP) therapy.,"[(21, 65, 'OTHER', 'Apnex Medical™ Hypoglossal Nerve Stimulation'), (67, 71, 'OTHER', 'HGNS'), (89, 112, 'CONDITION', 'Obstructive Sleep Apnea'), (182, 211, 'OTHER', 'hypoglossal nerve stimulation'), (221, 264, 'OTHER', 'Apnex Medical Hypoglossal Nerve Stimulation'), (266, 270, 'OTHER', 'HGNS'), (334, 376, 'CONDITION', 'moderate to severe Obstructive Sleep Apnea'), (378, 381, 'CONDITION', 'OSA')]"
"['Efficacy', 'of', 'Proprioceptive', 'Neuromuscular', 'Facilitation', 'in', 'Pain', 'Relief', 'in', 'Women', 'With', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'the', 'contract', '-', 'relax', 'technique', 'of', 'proprioceptive', 'neuromuscular', 'facilitation', ',', 'and', 'the', 'static', 'stretching', 'exercise', 'are', 'effective', 'in', 'reducing', 'the', 'frequency', ',', 'intensity', 'and', 'duration', 'of', 'headache', 'and', 'in', 'improving', 'the', 'perception', 'of', 'quality', 'of', 'life', 'in', 'women', 'with', 'migraine', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02549885,NCT02549885,"Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief in Women With Migraine | The purpose of this study is to determine whether the contract-relax technique of proprioceptive neuromuscular facilitation, and the static stretching exercise are effective in reducing the frequency, intensity and duration of headache and in improving the perception of quality of life in women with migraine.","[(12, 53, 'PHYSICAL', 'Proprioceptive Neuromuscular Facilitation'), (57, 61, 'CONDITION', 'Pain'), (83, 91, 'CONDITION', 'Migraine'), (148, 217, 'PHYSICAL', 'contract-relax technique of proprioceptive neuromuscular facilitation'), (227, 253, 'PHYSICAL', 'static stretching exercise'), (321, 329, 'CONDITION', 'headache'), (395, 403, 'CONDITION', 'migraine')]"
"['Lactobacillus', 'Plantarum', 'PS128', 'May', 'Improve', 'Off', 'Duration', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'a', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'short', 'term', 'effects', '(', '12', 'Weeks', ')', 'of', 'Lactobacillus', 'plantarum', 'PS128', '(', 'PS128', ')', 'on', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'symptoms', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT04389762,NCT04389762,Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study | The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.,"[(0, 29, 'OTHER', 'Lactobacillus Plantarum PS128'), (58, 77, 'CONDITION', ""Parkinson's Disease""), (176, 205, 'OTHER', 'Lactobacillus plantarum PS128'), (207, 212, 'OTHER', 'PS128'), (217, 236, 'CONDITION', ""Parkinson's disease""), (238, 240, 'CONDITION', 'PD')]"
"['A', '48', '-', 'Week', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Evaluation', 'of', 'the', 'Comparative', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Exelon', '®', '10', 'and', '15', 'cm^2', 'Patch', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'Showing', 'Functional', 'and', 'Cognitive', 'Decline', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'support', 'the', 'optimal', 'use', 'of', 'rivastigmine', 'patch', 'in', 'long', '-', 'term', 'treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'in', 'patients', 'demonstrating', 'functional', 'and', 'cognitive', 'decline', 'at', 'the', 'target', 'maintenance', 'dose', 'of', 'rivastigmine', 'patch', '10', 'cm^2', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT00506415,NCT00506415,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline | The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm^2.","[(133, 139, 'DRUG', 'Exelon'), (179, 215, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (217, 219, 'CONDITION', 'AD'), (229, 261, 'CONDITION', 'Functional and Cognitive Decline'), (324, 336, 'DRUG', 'rivastigmine'), (369, 388, 'CONDITION', ""Alzheimer's Disease""), (415, 447, 'CONDITION', 'functional and cognitive decline'), (482, 494, 'DRUG', 'rivastigmine')]"
"['Effects', 'of', 'Repetitive', 'Subconcussive', 'Head', 'Impacts', 'on', 'Ocular', '-', 'motor', 'Function', 'and', 'Brain', '-', 'derived', 'Blood', 'Biomarker', '|', 'Repetitive', 'head', 'impacts', 'in', 'sports', 'and', 'military', 'may', 'cause', 'deleterious', 'effects', 'in', 'the', 'nervous', 'system', '.', 'Investigators', ""'"", 'previous', 'works', 'in', 'football', 'players', 'have', 'shown', 'promising', 'results', 'in', 'prediction', 'of', 'concussion', 'and', 'prevention', 'of', 'long', '-', 'term', 'defect', 'using', 'eye', '-', 'movement', 'paradigm', '(', 'ocular', '-', 'motor', 'system', ')', 'and', 'blood', 'biomarker', '.', 'However', ',', 'acute', 'head', 'impact', 'effects', 'on', 'aforementioned', 'parameters', 'remain', 'unknown', '.', 'Thus', ',', 'to', 'answer', 'a', 'critical', 'research', 'question', 'that', 'whether', 'or', 'not', 'ocular', '-', 'motor', 'system', 'and', 'brain', '-', 'derived', 'blood', 'biomarker', 'may', 'be', 'acutely', 'altered', 'following', '10', 'successions', 'of', 'controlled', 'soccer', 'heading', '.', 'To', 'answer', 'the', 'question', ',', 'investigators', 'hypothesized', 'that', 'acute', 'bout', 'of', 'soccer', 'heading', 'will', 'not', 'elicit', 'noticeable', 'change', 'in', 'subject', ""'s"", 'symptoms', 'but', 'to', 'induce', 'a', 'transient', 'defect', 'in', 'the', 'ocular', '-', 'motor', 'system', 'and', 'increase', 'plasma', 'expression', 'of', 'brain', '-', 'derived', 'biomarker', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03488381,NCT03488381,"Effects of Repetitive Subconcussive Head Impacts on Ocular-motor Function and Brain-derived Blood Biomarker | Repetitive head impacts in sports and military may cause deleterious effects in the nervous system. Investigators' previous works in football players have shown promising results in prediction of concussion and prevention of long-term defect using eye-movement paradigm (ocular-motor system) and blood biomarker. However, acute head impact effects on aforementioned parameters remain unknown. Thus, to answer a critical research question that whether or not ocular-motor system and brain-derived blood biomarker may be acutely altered following 10 successions of controlled soccer heading. To answer the question, investigators hypothesized that acute bout of soccer heading will not elicit noticeable change in subject's symptoms but to induce a transient defect in the ocular-motor system and increase plasma expression of brain-derived biomarker.","[(11, 48, 'CONDITION', 'Repetitive Subconcussive Head Impacts'), (110, 133, 'CONDITION', 'Repetitive head impacts'), (306, 316, 'CONDITION', 'concussion')]"
"['A', 'Patient', 'Centered', 'Approach', 'to', 'Successful', 'Community', 'Transition', 'After', 'Catastrophic', 'Injury', ':', 'Clinical', 'Trial', 'to', 'Evaluate', 'One', '-', 'to', '-', 'one', 'Peer', 'Mentoring', '|', 'The', 'research', 'will', 'examine', 'the', 'effects', 'of', 'enhanced', 'peer', 'mentor', 'interactions', 'on', 'facilitating', 'a', 'successful', 'transition', 'to', 'community', 'living', 'following', 'traumatic', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'Participants', 'in', 'the', 'research', 'will', 'be', 'assigned', 'to', 'either', '(', '1', ')', 'the', 'control', 'group', 'that', 'will', 'receive', 'traditional', 'peer', 'mentor', 'types', 'of', 'interactions', 'or', '(', '2', ')', 'to', 'the', 'intervention', 'group', 'that', 'will', 'receive', 'an', 'enhanced', 'peer', 'mentor', 'program', 'called', 'the', 'One', '-', 'on', '-', 'One', 'Initiative', '.', 'Assignment', 'to', 'one', 'of', 'these', 'two', 'groups', 'will', 'occur', 'randomly', 'on', 'admission', 'to', 'Shepherd', 'Center', ';', 'the', 'only', 'stratifying', 'criteria', 'is', 'injury', 'level', '-', 'C6', 'and', 'above', 'vs.', 'C7', 'and', 'below', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02274649,NCT02274649,A Patient Centered Approach to Successful Community Transition After Catastrophic Injury: Clinical Trial to Evaluate One-to-one Peer Mentoring | The research will examine the effects of enhanced peer mentor interactions on facilitating a successful transition to community living following traumatic spinal cord injury (SCI). Participants in the research will be assigned to either (1) the control group that will receive traditional peer mentor types of interactions or (2) to the intervention group that will receive an enhanced peer mentor program called the One-on-One Initiative. Assignment to one of these two groups will occur randomly on admission to Shepherd Center; the only stratifying criteria is injury level - C6 and above vs. C7 and below.,"[(69, 88, 'CONDITION', 'Catastrophic Injury'), (117, 142, 'BEHAVIOURAL', 'One-to-one Peer Mentoring'), (186, 219, 'BEHAVIOURAL', 'enhanced peer mentor interactions'), (290, 318, 'CONDITION', 'traumatic spinal cord injury'), (320, 323, 'CONDITION', 'SCI'), (422, 467, 'CONTROL', 'traditional peer mentor types of interactions'), (522, 550, 'BEHAVIOURAL', 'enhanced peer mentor program'), (562, 583, 'BEHAVIOURAL', 'One-on-One Initiative')]"
"['Reconstruction', 'of', 'the', 'Orbit', 'With', 'a', 'Bioresorbable', 'Polycaprolactone', 'Implant', '|', 'Patients', 'with', 'orbital', 'injuries', 'are', 'entered', 'into', 'the', 'trial', '.', 'Age', ':', '20', '-', '70', '.', 'After', 'obtaining', 'appropriate', 'consent', ',', 'they', 'are', 'entered', 'into', 'either', 'a', 'control', 'arm', 'where', 'reconstruction', 'of', 'the', 'orbit', 'is', 'done', 'with', 'a', 'titanium', 'mesh', '(', 'established', 'practice', ')', 'or', 'the', 'experimental', 'arm', 'where', 'reconstruction', 'is', 'by', 'a', 'bioresorbable', 'implant', 'made', 'of', 'polycaprolactone', '.', 'Patients', 'are', 'followuped', 'at', '1', 'week', ',', '1', 'month', ',', '3', 'months', ',', '6', 'months', '&', '12', 'months', '.', 'CT', 'scan', 'of', 'the', 'orbits', 'are', 'performed', 'preop', ',', '6', 'months', '&', '12', 'months', '.', 'End', 'point', 'is', 'the', '12', 'month', 'follow', '-', 'up', 'appointment', '.', 'Visual', 'acuity', ',', 'range', 'of', 'motion', ',', 'enophthalmos', '&', 'diplopia', 'are', 'assessed', 'in', 'follow', '-', 'up', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00233922,NCT00233922,"Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant | Patients with orbital injuries are entered into the trial. Age: 20 - 70. After obtaining appropriate consent, they are entered into either a control arm where reconstruction of the orbit is done with a titanium mesh (established practice) or the experimental arm where reconstruction is by a bioresorbable implant made of polycaprolactone. Patients are followuped at 1 week, 1 month, 3 months, 6 months & 12 months. CT scan of the orbits are performed preop, 6 months & 12 months. End point is the 12 month follow-up appointment. Visual acuity, range of motion, enophthalmos & diplopia are assessed in follow-up.","[(35, 73, 'OTHER', 'Bioresorbable Polycaprolactone Implant'), (90, 106, 'CONDITION', 'orbital injuries'), (278, 291, 'CONTROL', 'titanium mesh'), (368, 414, 'OTHER', 'bioresorbable implant made of polycaprolactone')]"
"['Non', '-', 'invasive', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'to', 'Improve', 'Cognitive', 'Efficiency', '|', 'Normal', 'aging', 'is', 'associated', 'with', 'a', 'progressive', 'decline', 'in', 'cognitive', 'functions', ',', 'especially', 'memory', '.', 'This', 'decline', 'in', 'cognitive', 'function', 'can', 'negatively', 'impact', 'the', 'quality', 'of', 'life', 'of', 'older', 'adults', '.', 'Although', 'there', 'are', 'currently', 'few', 'possibilities', 'to', 'prevent', 'and/or', 'slow', 'the', 'signs', 'of', 'cognitive', 'decline', ',', 'both', 'those', 'associated', 'with', 'age', 'and', 'neurodegenerative', 'pathologies', ',', 'one', 'of', 'the', 'non', '-', 'invasive', 'brain', 'stimulation', 'techniques', 'that', 'has', 'gained', 'attention', 'in', 'recent', 'years', 'is', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', '.', 'tDCS', 'is', 'a', 'technique', 'based', 'on', 'the', 'application', 'of', 'a', 'low', '-', 'intensity', '(', '<', '2', 'mA', ')', 'direct', 'electrical', 'current', 'between', 'two', 'large', '-', 'area', 'electrodes', 'placed', 'on', 'various', 'surface', 'areas', 'of', 'the', 'head', '.', 'Moreover', ',', 'according', 'to', 'safety', '-', 'related', 'meta', '-', 'analyses', 'it', 'is', 'a', 'very', 'safe', 'technique', ',', 'without', 'any', 'major', 'side', 'effects', ',', 'provided', 'that', 'internationally', 'established', 'safety', 'protocols', 'are', 'taken', 'into', 'account', 'in', 'its', 'application', '.', 'This', 'technique', 'has', 'recently', 'been', 'investigated', 'as', 'a', 'potential', 'treatment', 'for', 'both', 'healthy', 'elderly', 'people', 'and', 'people', 'with', 'mild', 'cognitive', 'impairment', 'and', 'Alzheimer', ""'s"", 'disease', 'in', 'several', 'cognitive', 'variables', ',', 'having', 'shown', 'encouraging', 'results', 'in', 'working', 'memory', 'learning', 'curves', ',', 'modulation', 'of', 'plasticity', 'and', 'recognition', 'tasks', '.', 'This', 'project', 'aims', 'to', 'implement', 'an', 'intervention', 'using', 'transcranial', 'direct', 'current', 'stimulation', 'in', 'healthy', 'older', 'adults', ',', 'MCI', 'and', 'AD', '.', 'The', 'main', 'objective', 'is', 'to', 'test', 'if', 'there', 'is', 'an', 'improvement', 'in', 'cognitive', 'efficiency', 'and', 'if', 'the', 'changes', 'are', 'maintained', 'over', 'time', '(', '1', 'month', ')', '.', 'For', 'this', 'purpose', ',', 'the', 'effect', 'of', 'the', 'technique', 'will', 'be', 'studied', 'on', 'participants', 'assigned', 'to', 'treatment', 'and', 'control', 'groups', ',', 'analyzing', 'the', 'possible', 'modifications', 'in', 'the', 'following', 'cognitive', 'variables', ':', 'cognitive', 'plasticity', 'and', 'learning', 'potential', ',', 'recognition', 'and', 'familiarity', 'and', 'false', 'alarms', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05216315,NCT05216315,"Non-invasive Transcranial Direct Current Stimulation to Improve Cognitive Efficiency | Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults. Although there are currently few possibilities to prevent and/or slow the signs of cognitive decline, both those associated with age and neurodegenerative pathologies, one of the non-invasive brain stimulation techniques that has gained attention in recent years is Transcranial Direct Current Stimulation (tDCS). tDCS is a technique based on the application of a low-intensity (< 2 mA) direct electrical current between two large-area electrodes placed on various surface areas of the head. Moreover, according to safety-related meta-analyses it is a very safe technique, without any major side effects, provided that internationally established safety protocols are taken into account in its application. This technique has recently been investigated as a potential treatment for both healthy elderly people and people with mild cognitive impairment and Alzheimer's disease in several cognitive variables, having shown encouraging results in working memory learning curves, modulation of plasticity and recognition tasks. This project aims to implement an intervention using transcranial direct current stimulation in healthy older adults, MCI and AD. The main objective is to test if there is an improvement in cognitive efficiency and if the changes are maintained over time (1 month). For this purpose, the effect of the technique will be studied on participants assigned to treatment and control groups, analyzing the possible modifications in the following cognitive variables: cognitive plasticity and learning potential, recognition and familiarity and false alarms.","[(0, 52, 'OTHER', 'Non-invasive Transcranial Direct Current Stimulation'), (133, 163, 'CONDITION', 'decline in cognitive functions'), (189, 218, 'CONDITION', 'decline in cognitive function'), (361, 378, 'CONDITION', 'cognitive decline'), (457, 498, 'OTHER', 'non-invasive brain stimulation techniques'), (544, 583, 'OTHER', 'Transcranial Direct Current Stimulation'), (585, 589, 'OTHER', 'tDCS'), (592, 596, 'OTHER', 'tDCS'), (1104, 1129, 'CONDITION', 'mild cognitive impairment'), (1134, 1153, 'CONDITION', ""Alzheimer's disease""), (1355, 1394, 'OTHER', 'transcranial direct current stimulation'), (1420, 1423, 'CONDITION', 'MCI'), (1428, 1430, 'CONDITION', 'AD')]"
"['Effects', 'of', 'High', '-', 'Frequency', 'Transcranial', 'Magnetic', 'Stimulation', 'on', 'Functional', 'Performance', 'of', 'Subjects', 'With', 'Incomplete', 'Spinal', 'Cord', 'Injury', ':', 'Study', 'Protocol', 'for', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'main', 'objective', 'is', 'to', 'conduct', 'a', 'study', 'protocol', 'to', 'investigate', 'the', 'effects', 'of', 'repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'on', 'sensory', 'and', 'motor', 'performance', 'of', 'individuals', 'with', 'incomplete', 'spinal', 'cord', 'injury', '(', 'iSCI', ')', '.', 'A', 'double', '-', 'blind', 'randomized', 'sham', '-', 'controlled', 'trial', 'of', 'patients', 'with', 'iSCI', 'will', 'be', 'conducted', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT02899637,NCT02899637,Effects of High-Frequency Transcranial Magnetic Stimulation on Functional Performance of Subjects With Incomplete Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial | The main objective is to conduct a study protocol to investigate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on sensory and motor performance of individuals with incomplete spinal cord injury (iSCI) . A double-blind randomized sham-controlled trial of patients with iSCI will be conducted.,"[(11, 59, 'OTHER', 'High-Frequency Transcranial Magnetic Stimulation'), (103, 132, 'CONDITION', 'Incomplete Spinal Cord Injury'), (265, 309, 'OTHER', 'repetitive Transcranial Magnetic Stimulation'), (311, 315, 'OTHER', 'rTMS'), (370, 399, 'CONDITION', 'incomplete spinal cord injury'), (401, 405, 'CONDITION', 'iSCI'), (435, 439, 'CONTROL', 'sham'), (474, 478, 'CONDITION', 'iSCI')]"
"['Effectiveness', 'of', 'Spinal', 'Manipulation', 'in', 'Addition', 'to', 'Standard', 'Pharmacological', 'Treatment', 'in', 'Fibromyalgia', ':', 'A', 'Blinded', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'spinal', 'manipulation', ',', 'which', 'is', 'a', 'potential', 'treatment', 'method', 'for', 'musculoskeletal', 'pain', ',', 'has', 'an', 'additional', 'contribution', 'in', 'patients', 'with', 'fibromyalgia', 'receiving', 'standard', 'pharmacological', 'treatment', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT04673058,NCT04673058,"Effectiveness of Spinal Manipulation in Addition to Standard Pharmacological Treatment in Fibromyalgia : A Blinded Randomized Clinical Trial | The aim of this study is to evaluate whether spinal manipulation, which is a potential treatment method for musculoskeletal pain, has an additional contribution in patients with fibromyalgia receiving standard pharmacological treatment.","[(17, 36, 'OTHER', 'Spinal Manipulation'), (90, 102, 'CONDITION', 'Fibromyalgia'), (188, 207, 'OTHER', 'spinal manipulation'), (251, 271, 'CONDITION', 'musculoskeletal pain'), (321, 333, 'CONDITION', 'fibromyalgia')]"
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', ',', 'Pilot', 'Analgesic', 'Efficacy', 'and', 'Safety', 'Study', 'of', 'T-62', 'in', 'Subjects', 'With', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'T-62', 'in', 'subjects', 'with', 'postherpetic', 'neuralgia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00809679,NCT00809679,"A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia | The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.","[(116, 120, 'DRUG', 'T-62'), (138, 160, 'CONDITION', 'Postherpetic Neuralgia'), (231, 235, 'DRUG', 'T-62'), (253, 275, 'CONDITION', 'postherpetic neuralgia')]"
"['Critical', 'Periods', 'After', 'Stroke', 'Study', '(', 'CPASS', ')', ';', 'Sensitive', 'Periods', 'and', 'Consumer', 'Preferences', ':', 'Optimizing', 'Upper', 'Extremity', 'Stroke', 'Rehabilitation', '|', 'To', 'perform', 'an', 'exploratory', 'single', 'center', 'randomized', 'study', 'that', 'will', 'form', 'the', 'basis', 'for', 'a', 'larger', 'scale', ',', 'more', 'definitive', 'randomized', 'clinical', 'trial', 'to', 'determine', 'the', 'optimal', 'time', 'after', 'stroke', 'for', 'intensive', 'motor', 'training', '.', 'The', 'investigators', 'will', 'perform', 'a', 'prospective', 'exploratory', 'study', 'of', 'upper', 'extremity', '(', 'UE', ')', 'motor', 'training', 'delivered', 'at', 'higher', 'than', 'usual', 'intensity', 'at', 'three', 'different', 'time', 'points', 'after', 'stroke', ':', '\n\n', 'early', '(', 'initiated', 'within', '30', 'days', ')', '\n', 'subacute', '/', 'outpatient', '(', 'initiated', 'within', '2', '-', '3', 'months', ')', '\n', 'chronic', '(', 'initiated', 'within', '6', '-', '9', 'months', ')', '\n\n', 'The', 'control', 'group', 'will', 'not', 'receive', 'the', 'therapy', 'intervention', 'during', 'the', '1', '-', 'year', 'study', '.', '\n\n', 'Outcome', 'measures', 'will', 'be', 'assessed', 'at', 'baseline', ',', 'pre', '-', 'treatment', ',', 'post', '-', 'treatment', ',', '6', 'months', 'and', 'one', 'year', 'after', 'stroke', 'onset', '.', '\n\n', 'Compared', 'to', 'individuals', 'randomized', 'during', 'the', 'outpatient', '(', '2', '-', '3', 'months', 'after', 'stroke', 'onset', ')', 'or', 'chronic', '(', '6', '-', '9', 'months', 'after', 'stroke', 'onset', ')', 'time', 'points', ',', 'participants', 'randomized', 'to', 'early', 'intensive', 'motor', 'training', 'will', 'show', 'greater', 'upper', 'extremity', 'motor', 'improvement', 'measured', 'at', 'one', 'year', 'post', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02235974,NCT02235974,"Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation | To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive motor training. The investigators will perform a prospective exploratory study of upper extremity (UE) motor training delivered at higher than usual intensity at three different time points after stroke:

early (initiated within 30 days)
subacute/outpatient (initiated within 2-3 months)
chronic (initiated within 6-9 months)

The control group will not receive the therapy intervention during the 1-year study.

Outcome measures will be assessed at baseline, pre-treatment, post-treatment, 6 months and one year after stroke onset.

Compared to individuals randomized during the outpatient (2-3 months after stroke onset) or chronic (6-9 months after stroke onset) time points, participants randomized to early intensive motor training will show greater upper extremity motor improvement measured at one year post stroke.","[(116, 122, 'CONDITION', 'Stroke'), (320, 326, 'CONDITION', 'stroke'), (331, 355, 'PHYSICAL', 'intensive motor training'), (423, 458, 'PHYSICAL', 'upper extremity (UE) motor training'), (537, 543, 'CONDITION', 'stroke'), (691, 714, 'CONTROL', 'not receive the therapy'), (860, 866, 'CONDITION', 'stroke'), (950, 956, 'CONDITION', 'stroke'), (1053, 1077, 'PHYSICAL', 'intensive motor training'), (1156, 1162, 'CONDITION', 'stroke')]"
"['ECASS', 'III', '-', 'European', 'Cooperative', 'Acute', 'Stroke', 'Study', 'III', ':', 'A', 'Placebo', 'Controlled', 'Trial', 'of', 'Alteplase', '(', 'Rt', '-', 'PA', ')', 'in', 'Acute', 'Ischemic', 'Hemispheric', 'Stroke', 'Where', 'Thrombolysis', 'is', 'Initiated', 'Between', '3', 'and', '4', 'Hours', '30', 'Minutes', 'After', 'Stroke', 'Onset', '|', 'To', 'collect', 'additional', 'confirmatory', 'data', 'on', 'alteplase(rt', '-', 'PA', ')', 'in', 'the', 'European', 'setting', 'and', 'to', 'demonstrate', 'that', 'the', 'treatment', 'of', 'patients', 'between', '3', 'and', '4.30', 'hours', 'of', 'onset', 'of', 'symptoms', 'of', 'acute', 'ischemic', 'stroke', 'with', 'rt', '-', 'PA', 'compared', 'to', 'placebo', '-', 'treated', 'patients', 'will', 'result', 'in', 'an', 'improved', 'clinical', 'outcome', 'without', 'increase', 'of', 'fatality', 'rate', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00153036,NCT00153036,ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset | To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.,"[(33, 45, 'CONDITION', 'Acute Stroke'), (59, 66, 'CONTROL', 'Placebo'), (87, 96, 'DRUG', 'Alteplase'), (98, 103, 'DRUG', 'Rt-PA'), (108, 141, 'CONDITION', 'Acute Ischemic Hemispheric Stroke'), (213, 219, 'CONDITION', 'Stroke'), (271, 287, 'DRUG', 'alteplase(rt-PA)'), (411, 432, 'CONDITION', 'acute ischemic stroke'), (438, 443, 'DRUG', 'rt-PA'), (456, 463, 'CONTROL', 'placebo')]"
"['Efficacy', 'of', 'Sibutramine', '-', 'induced', 'Weight', 'Loss', 'vs.', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'in', 'the', 'Treatment', 'of', 'Obese', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'observe', 'if', 'Sibutramine', 'is', 'effective', 'in', 'improving', 'the', 'symptoms', 'and', 'signs', 'of', 'sleep', 'apnea', 'in', 'obese', 'patients', '.', 'The', 'secondary', 'objectives', 'are', 'to', 'document', 'the', 'effects', 'of', 'Sibutramine', 'on', 'heart', 'rate', 'variability', 'and', '24', '-', 'h', 'arterial', 'pressure', 'values', '.', 'We', 'hypothesized', 'that', 'sibutramine', 'will', 'improve', 'sleep', 'disordered', 'breathing', ',', 'cardiac', 'autonomic', 'function', 'and', 'systemic', 'blood', 'pressure', 'in', 'obese', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00729963,NCT00729963,"Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea | The primary objective of this study is to observe if Sibutramine is effective in improving the symptoms and signs of sleep apnea in obese patients. The secondary objectives are to document the effects of Sibutramine on heart rate variability and 24-h arterial pressure values. We hypothesized that sibutramine will improve sleep disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnea (OSA).","[(12, 23, 'DRUG', 'Sibutramine'), (48, 83, 'OTHER', 'Continuous Positive Airway Pressure'), (85, 89, 'OTHER', 'CPAP'), (111, 116, 'CONDITION', 'Obese'), (131, 154, 'CONDITION', 'Obstructive Sleep Apnea'), (210, 221, 'DRUG', 'Sibutramine'), (274, 285, 'CONDITION', 'sleep apnea'), (289, 294, 'CONDITION', 'obese'), (361, 372, 'DRUG', 'Sibutramine'), (455, 466, 'DRUG', 'sibutramine'), (566, 571, 'CONDITION', 'obese'), (586, 609, 'CONDITION', 'obstructive sleep apnea'), (611, 614, 'CONDITION', 'OSA')]"
"['Phase', 'II', 'Clinical', 'Trial', ',', 'Use', 'of', 'KL16', '-', '012', 'in', 'Women', 'With', 'Fibromyalgia', 'Refractary', 'to', 'Conventional', 'Treatment', '.', '|', 'A', 'double', 'blind', 'randomized', 'placebo', 'controlled', 'trial', 'in', '44', 'women', 'with', 'fibromyalgia', 'and', 'persistent', 'symptoms', 'in', 'spite', 'of', 'use', 'of', 'conventional', 'pharmacotherapy', ',', 'will', 'be', 'performed', 'in', 'the', 'city', 'of', 'Valparaiso', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'either', 'placebo', 'or', 'active', 'principle', 'and', 'be', 'followed', 'for', '3', 'months', '.', 'Assesment', 'of', 'efficacy', 'and', 'safety', 'will', 'be', 'done', 'by', 'measurement', 'of', 'changes', 'in', 'their', 'Fibromyalgia', 'Impact', 'Questionnaire', '(', 'FIQ', ')', 'score', ',', 'Insomnia', 'Severity', 'Index', '(', 'ISI', ')', 'score', ',', 'pain', 'Visual', 'Analogue', 'Scale', '(', 'VAS', ')', 'score', ',', 'plasma', 'cytokine', 'levels', 'and', 'detection', 'of', 'adverse', 'effects', '.', '\n\n', 'The', 'active', 'principle', 'will', 'be', 'a', 'standardized', 'extract', 'of', 'cannabis', 'sativa', 'containing', '1', 'milligram', 'of', 'tetrahydrocannabinol', '(', 'THC', ')', 'and', '0.45', 'milligrams', 'cannabidiol', '(', 'CBD', ')', 'per', 'drop', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT04239469,NCT04239469,"Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment. | A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso. Patients will be randomized to either placebo or active principle and be followed for 3 months. Assesment of efficacy and safety will be done by measurement of changes in their Fibromyalgia Impact Questionnaire (FIQ) score, Insomnia Severity Index (ISI) score, pain Visual Analogue Scale (VAS) score, plasma cytokine levels and detection of adverse effects.

The active principle will be a standardized extract of cannabis sativa containing 1 milligram of tetrahydrocannabinol (THC) and 0.45 milligrams cannabidiol (CBD) per drop.","[(32, 40, 'DRUG', 'KL16-012'), (55, 104, 'CONDITION', 'Fibromyalgia Refractary to Conventional Treatment'), (176, 188, 'CONDITION', 'fibromyalgia'), (345, 352, 'CONTROL', 'placebo'), (484, 496, 'CONDITION', 'Fibromyalgia'), (710, 736, 'OTHER', 'extract of cannabis sativa'), (763, 783, 'DRUG', 'tetrahydrocannabinol'), (785, 788, 'DRUG', 'THC'), (810, 821, 'DRUG', 'cannabidiol'), (823, 826, 'DRUG', 'CBD')]"
"['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'gene', 'expression', 'and', 'activity', 'of', 'SIRT1', ',', 'and', 'forkhead', 'box', 'O3', 'pathway', 'by', 'means', 'of', 'investigating', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subjects', '.', 'Also', ',', 'we', 'investigate', 'the', 'effect', 'of', 'melatonin', 'on', 'interaction', 'between', 'SIRT1', 'activity', 'and', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subject', '.Additionally', ',', 'we', 'evaluate', 'effect', 'the', 'probable', 'effect', 'of', 'melatonin', 'treatment', 'on', 'gene', 'expression', 'and', 'activity', 'of', 'above', '-', 'mentioned', 'genes', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'of', 'healthy', 'subjects', '-', 'treated', 'with', 'H2O2', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02463318,NCT02463318,"The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.","[(176, 194, 'CONDITION', 'multiple sclerosis'), (252, 261, 'DRUG', 'melatonin'), (339, 357, 'CONDITION', 'multiple sclerosis'), (435, 444, 'DRUG', 'melatonin')]"
"['Deep', 'Brain', 'Stimulation', 'in', 'Laryngeal', 'Dystonia', 'and', 'Voice', 'Tremor', '|', 'The', 'goals', 'of', 'this', 'project', 'are', '1', ')', 'to', 'determine', 'the', 'incidence', 'of', 'neurological', 'voice', 'disorders', 'in', 'patients', 'with', 'dystonia', 'and', 'essential', 'tremor', 'undergoing', 'deep', 'brain', 'stimulation', '(', 'DBS', ')', ',', '2', ')', 'investigate', 'the', 'neuroimaging', 'and', 'intracranial', 'neurophysiology', 'correlates', 'of', 'voice', 'dysfunction', 'in', 'these', 'subjects', ',', 'and', 'subsequently', '3', ')', 'determine', 'the', 'effects', 'of', 'DBS', 'on', 'voice', 'function', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O']",NCT05150093,NCT05150093,"Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor | The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.","[(0, 22, 'OTHER', 'Deep Brain Stimulation'), (26, 44, 'CONDITION', 'Laryngeal Dystonia'), (49, 61, 'CONDITION', 'Voice Tremor'), (127, 155, 'CONDITION', 'neurological voice disorders'), (173, 181, 'CONDITION', 'dystonia'), (186, 202, 'CONDITION', 'essential tremor'), (214, 236, 'OTHER', 'deep brain stimulation'), (238, 241, 'OTHER', 'DBS'), (323, 340, 'CONDITION', 'voice dysfunction'), (405, 408, 'OTHER', 'DBS')]"
"['A', 'Randomized', ',', 'Open', 'Label', ',', 'Multiple', '-', 'dose', ',', '2', '-', 'way', 'Crossover', ',', 'Phase', 'I', 'Study', 'to', 'Compare', 'the', 'Safety', 'and', 'Pharmacokinetics', 'Profile', 'of', 'WID', '-', 'CLZ18', 'and', 'Clozaril', '100', 'mg', 'Tablet', '(', 'Clozapine', ')', 'After', 'Oral', 'Administration', 'in', 'Schizophrenia', 'Patients', '|', 'This', 'clinical', 'study', 'is', 'a', 'randomized', ',', 'open', 'label', ',', 'multiple', '-', 'dose', ',', '2', '-', 'way', 'crossover', ',', 'phase', 'I', '(', 'Bioequivalence', ')', 'study', 'to', 'compare', 'the', 'safety', 'and', 'pharmacokinetics', 'profile', 'of', 'WID', '-', 'CLZ18', 'and', 'Clozaril', '100', 'mg', 'tablet', '(', 'Clozapine', ')', 'after', 'oral', 'administration', 'in', 'schizophrenia', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04849026,NCT04849026,"A Randomized, Open Label, Multiple-dose, 2-way Crossover, Phase I Study to Compare the Safety and Pharmacokinetics Profile of WID-CLZ18 and Clozaril 100 mg Tablet (Clozapine) After Oral Administration in Schizophrenia Patients | This clinical study is a randomized, open label, multiple-dose, 2-way crossover, phase I (Bioequivalence) study to compare the safety and pharmacokinetics profile of WID-CLZ18 and Clozaril 100 mg tablet (Clozapine) after oral administration in schizophrenia patients.","[(126, 135, 'DRUG', 'WID-CLZ18'), (140, 148, 'DRUG', 'Clozaril'), (164, 173, 'DRUG', 'Clozapine'), (204, 217, 'CONDITION', 'Schizophrenia'), (395, 404, 'DRUG', 'WID-CLZ18'), (409, 417, 'DRUG', 'Clozaril'), (433, 442, 'DRUG', 'Clozapine'), (473, 486, 'CONDITION', 'schizophrenia')]"
"['Randomized', ',', 'Parallel', 'Safety', 'and', 'Efficacy', 'Study', 'of', 'Lipoic', 'Acid', 'in', 'Patients', 'With', 'Amyotrophic', 'Lateral', 'Sclerosis', '|', 'In', 'this', 'proposed', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'lipoic', 'acid', 'in', 'treatment', 'of', 'Amyotrophic', 'lateral', 'sclerosis', '(', 'ALS', ')', '.', 'The', 'study', 'will', 'recruit', '150', 'AD', 'patients', ',', 'and', 'then', 'these', 'patients', 'will', 'be', 'randomized', 'to', 'lipoic', 'acid', 'group', 'or', 'control', 'group', '(', '75', 'patients', 'per', 'arm', ')', 'for', '6', 'courses', 'for', 'about', '5', 'months', '.', 'Clinical', 'assessment', 'will', 'be', 'done', 'at', 'screen', '/', 'baseline', ',', '3th', 'course', 'and', '6th', 'course', '.', 'The', 'specific', 'aims', 'are', 'to', 'compare', 'lipoic', 'acid', 'versus', 'control', 'on', ':', 'motor', 'function', 'and', 'disease', 'progression', '.', 'During', 'the', 'study', 'period', ',', 'clinical', 'effect', 'index', 'will', 'be', 'recorded', ',', 'including', 'bulbar', 'function', ',', 'motor', 'function', ',', 'respiratory', 'function', ',', 'and', 'safety', 'index', 'including', 'blood', 'and', 'urine', 'routine', ',', 'liver', 'and', 'kidney', 'function', ',', 'coagulation', 'function', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04518540,NCT04518540,"Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis | In this proposed study, the investigators will evaluate the safety and efficacy of lipoic acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD patients, and then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 months. Clinical assessment will be done at screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid versus control on: motor function and disease progression. During the study period, clinical effect index will be recorded, including bulbar function, motor function, respiratory function, and safety index including blood and urine routine, liver and kidney function, coagulation function.","[(50, 61, 'DRUG', 'Lipoic Acid'), (79, 108, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (194, 205, 'DRUG', 'lipoic acid'), (222, 251, 'CONDITION', 'Amyotrophic lateral sclerosis'), (253, 256, 'CONDITION', 'ALS'), (345, 356, 'DRUG', 'lipoic acid'), (366, 373, 'CONTROL', 'control'), (549, 560, 'DRUG', 'lipoic acid'), (568, 575, 'CONTROL', 'control')]"
"['A', 'Double', '-', 'blind', ',', 'Double', '-', 'dummy', ',', 'Randomised', ',', 'Placebo', '-', 'controlled', ',', 'Four', '-', 'way', 'Crossover', 'Study', 'to', 'Investigate', 'the', 'Effect', 'of', 'Single', 'Oral', 'Doses', 'of', 'SB-649868', 'and', 'of', 'Zolpidem', 'in', 'a', 'Model', 'of', 'Noise', 'Induced', 'Situational', 'Insomnia', 'in', 'Healthy', 'Male', 'Volunteers', '.', '|', 'Subjects', 'will', 'be', 'screened', 'within', '28', 'days', '.', 'Each', 'treatment', 'session', 'will', 'consist', 'of', '2', 'PSG', 'nights', ',', 'study', 'drug', 'administration', 'and', 'noise', 'model', 'is', 'conducted', 'on', 'second', 'night', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00440323,NCT00440323,"A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers. | Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG nights, study drug administration and noise model is conducted on second night.","[(42, 49, 'CONTROL', 'Placebo'), (136, 145, 'DRUG', 'SB-649868'), (153, 161, 'DRUG', 'Zolpidem'), (176, 210, 'CONDITION', 'Noise Induced Situational Insomnia')]"
"['Comparison', 'of', 'Concussion', 'Education', 'Programs', 'and', 'Intent', 'to', 'Report', 'Concussion', 'in', 'High', 'School', 'Football', 'Athletes', '|', 'Importance', ':', 'Concussion', 'underreporting', 'leads', 'to', 'delays', 'in', 'diagnosis', 'and', 'treatment', ',', 'resulting', 'in', 'prolonged', 'recovery', '.', 'Athletes', ""'"", 'report', 'of', 'concussion', 'symptoms', 'is', 'therefore', 'an', 'important', 'component', 'of', 'risk', 'reduction', '.', 'Numerous', 'educational', 'interventions', 'to', 'improve', 'concussion', 'knowledge', 'and', 'reporting', 'exist', '.', '\n\n', 'Objective', ':', 'Evaluate', 'the', 'comparative', 'efficacy', 'of', 'three', 'concussion', 'education', 'programs', 'in', 'improving', 'concussion', '-', 'reporting', 'intention', '.', '\n\n', 'Design', ':', 'Randomized', 'clinical', 'trial', 'conducted', 'from', 'August', '2018', 'to', 'October', '2018', ',', 'with', 'assessment', 'before', ',', 'immediately', 'after', ',', 'and', 'one', '-', 'month', 'after', 'educational', 'intervention', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O']",NCT04492696,NCT04492696,"Comparison of Concussion Education Programs and Intent to Report Concussion in High School Football Athletes | Importance: Concussion underreporting leads to delays in diagnosis and treatment, resulting in prolonged recovery. Athletes' report of concussion symptoms is therefore an important component of risk reduction. Numerous educational interventions to improve concussion knowledge and reporting exist.

Objective: Evaluate the comparative efficacy of three concussion education programs in improving concussion-reporting intention.

Design: Randomized clinical trial conducted from August 2018 to October 2018, with assessment before, immediately after, and one-month after educational intervention.","[(14, 43, 'BEHAVIOURAL', 'Concussion Education Programs'), (65, 75, 'CONDITION', 'Concussion'), (123, 133, 'CONDITION', 'Concussion'), (246, 256, 'CONDITION', 'concussion'), (367, 377, 'CONDITION', 'concussion'), (464, 493, 'BEHAVIOURAL', 'concussion education programs'), (507, 517, 'CONDITION', 'concussion'), (681, 705, 'BEHAVIOURAL', 'educational intervention')]"
"['Effects', 'of', 'Different', 'Intensities', 'of', 'Passive', 'Static', 'Stretching', 'on', 'Flexibility', ',', 'Neuromuscular', 'and', 'Functional', 'Performance', 'in', 'Soccer', 'Athletes', ':', 'A', 'Blinded', ',', 'Randomized', 'Controlled', 'Trial', '.', '|', 'Intensity', 'is', 'a', '""', 'qualitative', '""', 'variable', 'of', 'a', 'muscle', 'stretching', 'protocol', ',', 'which', 'is', 'very', 'little', 'studied', 'due', 'to', 'its', 'inherent', 'characteristic', 'of', 'the', 'individual', 'being', 'stretched', '.', 'However', ',', 'it', 'was', 'pointed', 'out', 'as', 'an', 'important', 'factor', 'for', 'ADM', 'gain', '.', 'To', 'verify', 'the', 'effects', 'of', 'different', 'intensities', 'of', 'static', 'passive', 'stretching', 'on', 'flexibility', ',', 'neuromuscular', 'and', 'functional', 'performance', 'in', 'soccer', 'athletes', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03150563,NCT03150563,"Effects of Different Intensities of Passive Static Stretching on Flexibility, Neuromuscular and Functional Performance in Soccer Athletes: A Blinded, Randomized Controlled Trial. | Intensity is a ""qualitative"" variable of a muscle stretching protocol, which is very little studied due to its inherent characteristic of the individual being stretched. However, it was pointed out as an important factor for ADM gain. To verify the effects of different intensities of static passive stretching on flexibility, neuromuscular and functional performance in soccer athletes.","[(36, 61, 'OTHER', 'Passive Static Stretching'), (224, 251, 'OTHER', 'muscle stretching protocol,'), (466, 491, 'OTHER', 'static passive stretching')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Controlled', ',', 'Active', 'Comparator', ',', 'Phase', 'II', 'Study', 'to', 'Assess', 'the', 'Tolerance', 'and', 'Immunogenicity', 'of', 'Conjugate', 'Meningococcal', 'C', '(', 'MnCC', ')', 'Vaccine', 'in', 'Infants', 'When', 'Administered', 'in', 'Conjunction', 'With', 'Primary', 'DTP', '/', 'Hib', 'Vaccination', 'at', '2', ',', '3', ',', 'and', '4', 'Months', 'of', 'Age', '.', '|', 'Infant', 'phase', ':', 'To', 'determine', 'the', 'safety', 'of', 'and', 'production', 'of', 'antibodies', 'by', 'a', 'group', 'C', 'meningococcal', 'conjugate', 'vaccine', '(', 'MnCC', ')', ',', 'when', 'given', 'at', '2', ',', '3', ',', 'and', '4', 'months', 'of', 'age', 'with', 'routine', 'vaccines', '.', '\n\n', 'Booster', 'phase', ':', 'To', 'compare', 'the', 'safety', 'of', 'and', 'production', 'of', 'antibodies', 'by', 'MnCC', 'with', 'and', 'without', 'MMR', 'and', 'to', 'compare', 'the', 'antibody', 'response', 'to', 'that', 'produced', 'by', 'a', 'low', 'dose', 'of', 'plain', 'polysaccharide', 'vaccine', 'as', 'a', 'way', 'of', 'investigating', 'immune', 'memory']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00314041,NCT00314041,"A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age. | Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.

Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory","[(120, 160, 'DRUG', 'Conjugate Meningococcal C (MnCC) Vaccine'), (210, 237, 'DRUG', 'Primary DTP/Hib Vaccination'), (345, 384, 'DRUG', 'group C meningococcal conjugate vaccine'), (386, 390, 'DRUG', 'MnCC'), (529, 533, 'DRUG', 'MnCC'), (551, 554, 'DRUG', 'MMR'), (626, 654, 'DRUG', 'plain polysaccharide vaccine')]"
"['Strength', 'Training', 'in', 'Hospitalized', 'Patients', 'Using', 'the', 'Ghostly', 'App', ':', 'a', 'Feasibility', 'Study', '|', 'The', 'goal', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'evaluate', 'the', 'use', 'of', 'the', 'Ghostly', 'app', 'in', 'rehabilitation', 'of', 'stroke', 'patients', ',', 'elderly', 'and', 'patients', 'recovering', 'from', 'COVID-19', 'or', 'ICU', 'patients', '.', 'In', 'three', 'randomized', 'controlled', 'trials', ',', 'the', 'effect', 'of', 'a', 'strength', 'training', 'program', 'incorporated', 'in', 'the', 'Ghostly', 'app', 'will', 'be', 'assessed', 'for', '1', ')', 'stroke', 'patients', 'suffering', 'from', 'weakness', 'of', 'the', 'lower', 'limb', ',', '2', ')', 'frail', 'elderly', 'with', 'gait', 'difficulties', 'and', '3', ')', 'patients', 'recovering', 'from', 'COVID-19', 'or', 'ICU', 'patients', 'who', 'suffer', 'from', 'muscle', 'weakness', '.', 'Additionally', ',', 'the', 'effect', 'of', 'BFR', 'on', 'strength', 'gain', 'in', 'all', 'these', 'three', 'populations', 'will', 'be', 'tested', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05258500,NCT05258500,"Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study | The goal of this feasibility study is to evaluate the use of the Ghostly app in rehabilitation of stroke patients, elderly and patients recovering from COVID-19 or ICU patients. In three randomized controlled trials, the effect of a strength training program incorporated in the Ghostly app will be assessed for 1) stroke patients suffering from weakness of the lower limb, 2) frail elderly with gait difficulties and 3) patients recovering from COVID-19 or ICU patients who suffer from muscle weakness. Additionally, the effect of BFR on strength gain in all these three populations will be tested.","[(0, 17, 'PHYSICAL', 'Strength Training'), (53, 64, 'OTHER', 'Ghostly App'), (153, 164, 'OTHER', 'Ghostly app'), (186, 192, 'CONDITION', 'stroke'), (240, 248, 'CONDITION', 'COVID-19'), (321, 338, 'PHYSICAL', 'strength training'), (367, 378, 'OTHER', 'Ghostly app'), (403, 409, 'CONDITION', 'stroke'), (434, 460, 'CONDITION', 'weakness of the lower limb'), (484, 501, 'CONDITION', 'gait difficulties'), (534, 542, 'CONDITION', 'COVID-19'), (575, 590, 'CONDITION', 'muscle weakness')]"
"['Postural', 'Control', 'Intervention', 'With', 'the', 'Robotic', 'Trunk', '-', 'Support', '-', 'Trainer', '(', 'TruST', ')', 'in', 'Children', 'With', 'Cerebral', 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'efficacy', 'of', 'a', 'motor', 'learning', '-', 'based', 'postural', 'and', 'reaching', 'control', 'intervention', 'delivered', 'with', 'the', 'robotic', 'Trunk', '-', 'Support', '-', 'Trainer', '(', 'TruST', ')', 'compared', 'to', 'the', 'same', 'motor', 'learning', '-', 'based', 'intervention', 'delivered', 'with', 'Static', 'Trunk', 'Support', 'Equipment', 'in', 'children', 'with', 'cerebral', 'palsy', '(', 'CP', ')', 'classified', 'as', 'III', 'and', 'IV', 'with', 'the', 'Gross', 'Motor', 'Function', 'Classification', 'System', '(', 'GMFCS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04897347,NCT04897347,Postural Control Intervention With the Robotic Trunk-Support-Trainer (TruST) in Children With Cerebral Palsy: A Randomized Controlled Trial | The purpose of this study is to test the efficacy of a motor learning-based postural and reaching control intervention delivered with the robotic Trunk-Support-Trainer (TruST) compared to the same motor learning-based intervention delivered with Static Trunk Support Equipment in children with cerebral palsy (CP) classified as III and IV with the Gross Motor Function Classification System (GMFCS).,"[(39, 68, 'PHYSICAL', 'Robotic Trunk-Support-Trainer'), (70, 75, 'PHYSICAL', 'TruST'), (94, 108, 'CONDITION', 'Cerebral Palsy'), (197, 260, 'PHYSICAL', 'motor learning-based postural and reaching control intervention'), (288, 309, 'PHYSICAL', 'Trunk-Support-Trainer'), (311, 316, 'PHYSICAL', 'TruST'), (339, 372, 'PHYSICAL', 'motor learning-based intervention'), (388, 418, 'PHYSICAL', 'Static Trunk Support Equipment'), (436, 450, 'CONDITION', 'cerebral palsy'), (452, 454, 'CONDITION', 'CP')]"
"['The', 'Effect', 'of', 'Auditory', 'and', 'Tactile', 'Stimulus', 'on', 'Consciousness', ',', 'Oxygen', 'Saturation', ',', 'and', 'Mean', 'Arterial', 'Pressure', 'in', 'Traumatic', 'Coma', 'Patients', ':', 'A', 'Randomized', 'Controlled', 'Single', '-', 'Blind', 'Study', '|', 'This', 'study', 'focused', 'on', 'examining', 'the', 'effects', 'of', 'auditory', 'and', 'tactile', 'stimuli', 'to', 'reduce', 'sensory', 'deprivation', 'on', 'consciousness', ',', 'oxygen', 'saturation', 'and', 'mean', 'arterial', 'pressure', 'in', 'traumatic', 'coma', 'patients', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT05195606,NCT05195606,"The Effect of Auditory and Tactile Stimulus on Consciousness, Oxygen Saturation, and Mean Arterial Pressure in Traumatic Coma Patients: A Randomized Controlled Single-Blind Study | This study focused on examining the effects of auditory and tactile stimuli to reduce sensory deprivation on consciousness, oxygen saturation and mean arterial pressure in traumatic coma patients.","[(14, 43, 'OTHER', 'Auditory and Tactile Stimulus'), (111, 125, 'CONDITION', 'Traumatic Coma'), (228, 256, 'OTHER', 'auditory and tactile stimuli'), (353, 367, 'CONDITION', 'traumatic coma')]"
"['A', 'Multicenter', 'Extension', 'Study', 'to', 'Determine', 'the', 'Long', '-', 'Term', 'Safety', 'and', 'Efficacy', 'of', 'BG00012', 'in', 'Pediatric', 'Subjects', 'With', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'of', 'BG00012', 'in', 'subjects', 'who', 'completed', 'Study', '109MS202', '(', 'NCT02410200', ')', '.', 'Secondary', 'objectives', 'are', 'as', 'follows', ':', 'To', 'evaluate', 'the', 'long', '-', 'term', 'efficacy', 'of', 'BG00012', 'and', 'to', 'describe', 'the', 'long', '-', 'term', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'outcomes', 'in', 'subjects', 'who', 'completed', 'Study', '109MS202', '(', 'NCT02410200', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02555215,NCT02555215,A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis | The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).,"[(80, 87, 'DRUG', 'BG00012'), (115, 153, 'CONDITION', 'Relapsing-Remitting Multiple Sclerosis'), (230, 237, 'DRUG', 'BG00012'), (369, 376, 'DRUG', 'BG00012'), (407, 425, 'CONDITION', 'Multiple Sclerosis'), (427, 429, 'CONDITION', 'MS')]"
"['Imaginal', 'Exposure', 'I', 'Online', 'Study', '|', 'This', 'study', 'evaluates', 'if', 'imaginal', 'exposure', 'therapy', 'can', 'decrease', 'symptoms', 'of', 'eating', 'disorders', 'and', 'anxiety', ',', 'and', 'test', 'an', 'online', 'format', 'of', 'IE', 'to', 'maximize', 'its', 'ability', 'to', 'reach', 'as', 'many', 'individuals', 'with', 'eating', 'disorders', 'as', 'possible', '.', 'All', 'participants', 'will', 'complete', 'four', 'imaginal', 'exposure', 'sessions', 'and', 'will', 'complete', 'questionnaires', 'prior', 'to', 'receiving', 'this', 'treatment', ',', 'as', 'well', 'as', 'complete', 'follow', 'up', 'questionnaires', 'at', '1', '-', 'month', ',', '6', '-', 'month', ',', 'and', '12', '-', 'month', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03712748,NCT03712748,"Imaginal Exposure I Online Study | This study evaluates if imaginal exposure therapy can decrease symptoms of eating disorders and anxiety, and test an online format of IE to maximize its ability to reach as many individuals with eating disorders as possible. All participants will complete four imaginal exposure sessions and will complete questionnaires prior to receiving this treatment, as well as complete follow up questionnaires at 1-month, 6-month, and 12-month.","[(59, 84, 'OTHER', 'imaginal exposure therapy'), (110, 126, 'CONDITION', 'eating disorders'), (131, 138, 'CONDITION', 'anxiety'), (152, 171, 'OTHER', 'online format of IE'), (230, 246, 'CONDITION', 'eating disorders'), (296, 322, 'OTHER', 'imaginal exposure sessions')]"
"['Neural', 'Stem', 'Cells', 'Therapy', 'for', 'Cerebral', 'Palsy', ':', 'a', 'Prospective', ',', 'Randomized', ',', 'Parallel', '-', 'controlled', 'Trial', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'neural', 'stem', 'cells', '(', 'NSCs', ')', 'therapy', 'for', 'cerebral', 'palsy', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT03005249,NCT03005249,"Neural Stem Cells Therapy for Cerebral Palsy: a Prospective, Randomized, Parallel-controlled Trial | To evaluate the safety and efficacy of neural stem cells (NSCs) therapy for cerebral palsy.","[(0, 17, 'SURGICAL', 'Neural Stem Cells'), (30, 44, 'CONDITION', 'Cerebral Palsy'), (140, 157, 'SURGICAL', 'neural stem cells'), (159, 163, 'SURGICAL', 'NSCs'), (177, 191, 'CONDITION', 'cerebral palsy')]"
"['Effects', 'of', 'Empagliflozin', 'an', 'SGLT2', '-', 'Inhibitor', 'on', 'Healthy', 'Volunteers', 'With', 'Induced', 'Hypotonic', 'Hyponatremia', '-', 'the', 'DIVE', 'Study', '|', 'Empagliflozin', '(', 'Jardiance', ')', '®', 'is', 'a', 'sodium', 'glucose', 'co', '-', 'transporter', '2', '(', 'SGLT2)-Inhibitor', ',', 'which', 'is', 'a', 'new', 'treatment', 'option', 'developed', 'for', 'patients', 'with', 'diabetes', 'mellitus', 'type', '2', '.', 'The', 'SGLT2', 'is', 'expressed', 'in', 'the', 'proximal', 'tubule', 'and', 'reabsorbs', 'approximately', '90', 'percent', 'of', 'the', 'filtered', 'glucose', '.', 'The', 'inhibition', 'of', 'SGLT2', 'results', 'in', 'renal', 'excretion', 'of', 'glucose', 'with', 'subsequent', 'osmotic', 'diuresis', '.', 'This', 'mechanism', 'could', 'result', 'in', 'a', 'therapeutic', 'effect', 'in', 'patients', 'with', 'hypotonic', 'hyponatremia', 'as', 'in', 'the', 'syndrome', 'of', 'inappropriate', 'antidiuretic', 'hormone', '(', 'ADH', ')', 'secretion', '(', 'SIAD', ')', '.', 'Because', 'patients', 'with', 'SIAD', 'usually', 'have', 'several', 'comorbidities', 'and', 'different', 'medications', ',', 'studies', 'investigating', 'the', 'physiological', 'effects', 'are', 'difficult', 'to', 'interpret', '.', 'Therefore', 'a', 'model', 'to', 'study', 'the', 'possible', 'physiological', 'effect', 'of', 'SGLT2', '-', 'inhibitors', 'in', 'hypotonic', 'hyponatremia', 'as', 'in', 'SIAD', 'is', 'needed', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'empagliflozin', '(', 'Jardiance', ')', '®', 'has', 'an', 'effect', 'on', 'serum', 'sodium', 'levels', 'of', 'healthy', 'volunteers', 'with', 'induced', 'hypotonic', 'hyponatremia', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02729766,NCT02729766,"Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent osmotic diuresis. This mechanism could result in a therapeutic effect in patients with hypotonic hyponatremia as in the syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIAD). Because patients with SIAD usually have several comorbidities and different medications, studies investigating the physiological effects are difficult to interpret. Therefore a model to study the possible physiological effect of SGLT2-inhibitors in hypotonic hyponatremia as in SIAD is needed.

The aim of this study is to evaluate whether empagliflozin (Jardiance)® has an effect on serum sodium levels of healthy volunteers with induced hypotonic hyponatremia.","[(11, 24, 'DRUG', 'Empagliflozin'), (28, 43, 'DRUG', 'SGLT2-Inhibitor'), (79, 101, 'CONDITION', 'Hypotonic Hyponatremia'), (121, 134, 'DRUG', 'Empagliflozin'), (136, 145, 'DRUG', 'Jardiance'), (153, 202, 'DRUG', 'sodium glucose co-transporter 2 (SGLT2)-Inhibitor'), (565, 587, 'CONDITION', 'hypotonic hyponatremia'), (898, 914, 'DRUG', 'SGLT2-inhibitors'), (918, 940, 'CONDITION', 'hypotonic hyponatremia'), (1009, 1022, 'DRUG', 'empagliflozin'), (1024, 1033, 'DRUG', 'Jardiance'), (1108, 1130, 'CONDITION', 'hypotonic hyponatremia')]"
"['Early', 'Induced', 'Hypernatremia', 'for', 'the', 'Prevention', 'and', 'Management', 'of', 'Brain', 'Edema', 'in', 'Patients', 'With', 'Severe', 'Traumatic', 'Brain', 'Injury', 'in', 'a', 'University', 'Hospital', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'estimate', 'the', 'effect', 'of', 'an', 'early', 'induced', 'hypernatremia', 'protocol', '(', '150', '-', '155', 'milliequivalent', '/', 'L', ')', 'versus', 'normonatremia', 'plus', 'mannitol', '(', '135', '-', '145', 'milliequivalent', '/', 'L', ')', 'in', 'terms', 'of', 'neurologic', 'outcome', 'in', 'patients', 'with', 'severe', 'traumatic', 'brain', 'injury', 'managed', 'at', 'critical', 'care', 'unit', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02798601,NCT02798601,Early Induced Hypernatremia for the Prevention and Management of Brain Edema in Patients With Severe Traumatic Brain Injury in a University Hospital | The purpose of this study is to estimate the effect of an early induced hypernatremia protocol (150-155 milliequivalent/L) versus normonatremia plus mannitol (135 - 145 milliequivalent/L) in terms of neurologic outcome in patients with severe traumatic brain injury managed at critical care unit.,"[(0, 27, 'OTHER', 'Early Induced Hypernatremia'), (65, 76, 'CONDITION', 'Brain Edema'), (94, 123, 'CONDITION', 'Severe Traumatic Brain Injury'), (209, 236, 'OTHER', 'early induced hypernatremia'), (281, 294, 'OTHER', 'normonatremia'), (300, 308, 'DRUG', 'mannitol'), (387, 416, 'CONDITION', 'severe traumatic brain injury')]"
"['Robot', 'Based', 'Gait', 'Training', 'Therapy', 'for', 'Pediatric', 'Population', 'With', 'Cerebral', 'Palsy', 'Using', 'the', 'CPWalker', '|', 'This', 'trial', 'is', 'being', 'conducted', 'to', 'determine', 'if', 'the', 'CPWalker', 'can', 'be', 'used', 'as', 'a', 'gait', 'training', 'intervention', 'for', 'pediatric', 'patients', 'with', 'gait', 'impairments', 'due', 'to', 'cerebral', 'palsy']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT03937700,NCT03937700,Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker | This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy,"[(0, 25, 'PHYSICAL', 'Robot Based Gait Training'), (64, 78, 'CONDITION', 'Cerebral Palsy'), (89, 97, 'PHYSICAL', 'CPWalker'), (150, 158, 'PHYSICAL', 'CPWalker'), (176, 189, 'PHYSICAL', 'gait training'), (255, 269, 'CONDITION', 'cerebral palsy')]"
"['Effects', 'of', 'Electroacupuncture', 'and', 'Myofascial', 'Release', 'on', 'Pain', ',', 'Neck', 'Functions', 'and', 'Depression', 'Status', 'in', 'Patients', 'With', 'Tension', '-', 'Type', 'Headaches', '|', 'Tension', '-', 'type', 'headaches', '(', 'TTH', ')', 'last', 'from', 'thirty', 'minutes', 'to', 'seven', 'days', ',', 'were', 'ranked', 'second', 'among', 'the', 'primary', 'types', 'of', 'headaches', '.', 'The', 'diagnosis', 'of', 'TTH', 'is', 'made', 'according', 'to', 'the', 'diagnostic', 'criteria', 'of', 'the', 'Second', 'Beta', 'version', 'of', 'the', 'International', 'Classification', 'of', 'Headache', 'Disorders', '.', 'The', 'causes', 'of', 'TTH', 'include', 'the', 'activation', 'of', 'extremely', 'tense', 'peripheric', 'afferent', 'neurons', 'through', 'the', 'head', 'and', 'neck', 'muscles', ',', 'muscle', 'sensitivity', 'and', 'stress', '.', 'Additionally', ',', 'a', 'limited', 'range', 'of', 'motion', '(', 'ROM', ')', 'in', 'the', 'neck', 'may', 'also', 'lead', 'to', 'TTH', '.', '\n\n', 'The', 'treatment', 'of', 'TTH', 'involve', 'both', 'pharmacological', 'and', 'non', '-', 'pharmacological', 'methods', '.', 'It', 'is', 'known', 'that', 'the', 'pharmacological', 'treatment', 'of', 'TTH', 'has', 'a', 'limited', 'effect', '.', 'However', ',', 'previous', 'studies', 'have', 'shown', 'that', 'physical', 'therapy', 'programs', 'that', 'include', 'methods', 'such', 'as', 'acupuncture', ',', 'Transcutaneous', 'Electrical', 'Nerve', 'Stimulation', '(', 'TENS', ')', ',', 'exercise', ',', 'biofeedback', ',', 'manipulation', ',', 'cryotherapy', ',', 'massage', ',', 'strengthening', 'of', 'the', 'neck', 'muscles', ',', 'stretching', 'exercises', 'are', 'effective', 'in', 'alleviating', 'TTH', '.', '\n\n', 'It', 'has', 'been', 'observed', 'that', 'the', 'trigger', 'points', 'in', 'muscles', 'play', 'a', 'role', 'in', 'TTH', '.', 'Trigger', 'points', 'are', 'generally', 'defined', 'as', 'hyper', '-', 'irritable', 'points', 'inside', 'taut', 'bands', '.', 'It', 'has', 'been', 'demonstrated', 'that', 'myofascial', 'release', ',', 'which', 'is', 'applied', 'to', 'the', 'trigger', 'points', 'and', 'is', 'effective', 'in', 'relaxation', 'treatments', 'through', 'stimulation', 'of', 'the', 'neuromuscular', 'system', ',', 'relieves', 'headaches', 'via', 'muscle', 'relaxation', '.', 'Electroacupuncture', 'is', 'another', 'method', 'used', 'in', 'relieving', 'myofascial', 'pain', 'origin', 'that', 'involves', 'the', 'application', 'of', 'acupuncture', 'needles', 'to', 'particular', 'points', 'and', 'delivery', 'of', 'an', 'electrical', 'current', 'at', 'a', 'specific', 'frequency', '.', 'The', 'stimulation', 'of', 'muscle', 'and', 'skin', 'tissues', 'in', 'affected', 'areas', 'is', 'carried', 'out', 'by', 'means', 'of', 'needles', 'and', 'the', 'electrical', 'current', 'relieves', 'pain', 'and', 'muscle', 'spasms', '.', 'In', 'a', 'meta', '-', 'analysis', 'study', ',', 'it', 'was', 'found', 'that', 'electroacupuncture', 'had', 'a', 'higher', 'pain', '-', 'relieving', 'effect', '.', 'However', ',', 'a', 'review', 'of', 'related', 'studies', 'deemed', 'them', 'to', 'be', 'lacking', 'because', 'the', 'assessments', 'were', 'too', 'limited', 'to', 'make', 'it', 'possible', 'to', 'unequivocally', 'state', 'that', 'electroacupuncture', 'has', 'a', 'high', 'level', 'of', 'therapeutic', 'efficacy', '.', '\n\n', 'The', 'studies', 'performed', ',', 'however', ',', 'did', 'not', 'examine', 'the', 'efficacy', 'of', 'electroacupuncture', 'and', 'myofascial', 'release', 'on', 'TTH', '.', 'Given', 'that', 'situation', ',', 'the', 'purpose', 'of', 'our', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'electroacupuncture', 'and', 'myofascial', 'release', 'applied', 'to', 'points', 'of', 'tension', 'in', 'the', 'neck', 'muscles', 'and', 'trigger', 'points', 'of', 'people', 'suffering', 'from', 'TTH', 'in', 'terms', 'of', 'the', 'headache', 'intensity', 'and', 'frequency', ',', 'neck', 'functions', ',', 'sleep', 'quality', 'and', 'depression', 'status', '.']","['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04091100,NCT04091100,"Effects of Electroacupuncture and Myofascial Release on Pain, Neck Functions and Depression Status in Patients With Tension-Type Headaches | Tension-type headaches (TTH) last from thirty minutes to seven days, were ranked second among the primary types of headaches. The diagnosis of TTH is made according to the diagnostic criteria of the Second Beta version of the International Classification of Headache Disorders. The causes of TTH include the activation of extremely tense peripheric afferent neurons through the head and neck muscles, muscle sensitivity and stress. Additionally, a limited range of motion (ROM) in the neck may also lead to TTH.

The treatment of TTH involve both pharmacological and non-pharmacological methods. It is known that the pharmacological treatment of TTH has a limited effect. However, previous studies have shown that physical therapy programs that include methods such as acupuncture, Transcutaneous Electrical Nerve Stimulation (TENS), exercise, biofeedback, manipulation, cryotherapy, massage, strengthening of the neck muscles, stretching exercises are effective in alleviating TTH.

It has been observed that the trigger points in muscles play a role in TTH. Trigger points are generally defined as hyper-irritable points inside taut bands. It has been demonstrated that myofascial release, which is applied to the trigger points and is effective in relaxation treatments through stimulation of the neuromuscular system, relieves headaches via muscle relaxation. Electroacupuncture is another method used in relieving myofascial pain origin that involves the application of acupuncture needles to particular points and delivery of an electrical current at a specific frequency. The stimulation of muscle and skin tissues in affected areas is carried out by means of needles and the electrical current relieves pain and muscle spasms. In a meta-analysis study, it was found that electroacupuncture had a higher pain-relieving effect. However, a review of related studies deemed them to be lacking because the assessments were too limited to make it possible to unequivocally state that electroacupuncture has a high level of therapeutic efficacy.

The studies performed, however, did not examine the efficacy of electroacupuncture and myofascial release on TTH. Given that situation, the purpose of our study is to investigate the effects of electroacupuncture and myofascial release applied to points of tension in the neck muscles and trigger points of people suffering from TTH in terms of the headache intensity and frequency, neck functions, sleep quality and depression status.","[(11, 29, 'OTHER', 'Electroacupuncture'), (34, 52, 'OTHER', 'Myofascial Release'), (56, 60, 'CONDITION', 'Pain'), (81, 91, 'CONDITION', 'Depression'), (116, 138, 'CONDITION', 'Tension-Type Headaches'), (141, 163, 'CONDITION', 'Tension-type headaches'), (165, 168, 'CONDITION', 'TTH'), (256, 265, 'CONDITION', 'headaches'), (284, 287, 'CONDITION', 'TTH'), (433, 436, 'CONDITION', 'TTH'), (648, 651, 'CONDITION', 'TTH'), (671, 674, 'CONDITION', 'TTH'), (787, 790, 'CONDITION', 'TTH'), (910, 921, 'OTHER', 'acupuncture'), (1119, 1122, 'CONDITION', 'TTH'), (1196, 1199, 'CONDITION', 'TTH'), (1313, 1331, 'OTHER', 'myofascial release'), (1472, 1481, 'CONDITION', 'headaches'), (1486, 1503, 'OTHER', 'muscle relaxation'), (1505, 1523, 'OTHER', 'Electroacupuncture'), (1571, 1575, 'CONDITION', 'pain'), (1852, 1856, 'CONDITION', 'pain'), (1920, 1938, 'OTHER', 'electroacupuncture'), (1952, 1956, 'CONDITION', 'pain'), (2127, 2145, 'OTHER', 'electroacupuncture'), (2253, 2271, 'OTHER', 'electroacupuncture'), (2276, 2294, 'OTHER', 'myofascial release'), (2298, 2301, 'CONDITION', 'TTH'), (2383, 2401, 'OTHER', 'electroacupuncture'), (2406, 2424, 'OTHER', 'myofascial release'), (2518, 2521, 'CONDITION', 'TTH'), (2538, 2546, 'CONDITION', 'headache'), (2606, 2616, 'CONDITION', 'depression')]"
"['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'feasibility', 'and', 'efficacy', 'of', 'an', 'early', 'supervised', 'aerobic', 'exercise', 'program', 'for', 'patients', 'following', 'a', 'minor', 'ischemic', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00248222,NCT00248222,The purpose of this study is to examine the feasibility and efficacy of an early supervised aerobic exercise program for patients following a minor ischemic stroke.,"[(81, 116, 'PHYSICAL', 'supervised aerobic exercise program'), (142, 163, 'CONDITION', 'minor ischemic stroke')]"
"['Effect', 'of', 'Atypical', 'Antipsychotics', 'on', 'Gene', 'Expression', 'in', 'Soft', 'Tissues', 'of', 'Healthy', 'Subjects', '-', 'A', 'Placebo', 'Controlled', 'Randomised', 'Pilot', 'Study', '|', 'Schizophrenia', 'is', 'a', 'severe', 'chronic', 'and', 'disabling', 'mental', 'disorder', 'and', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'in', 'life', 'expectancy', '.', 'Atypical', 'antipsychotic', 'treatment', 'compliance', 'may', 'be', 'jeopardized', 'because', 'of', 'drug', 'induced', 'weight', 'gain', 'and', 'abnormalities', 'in', 'carbohydrate', 'and', 'lipid', 'metabolism', '.', '\n\n', 'Aim', ':', 'to', 'gain', 'data', 'on', 'drug', 'related', 'effects', 'on', 'gene', 'expression', 'and', 'regulation', 'with', 'special', 'regard', 'to', 'glucose', 'metabolism', '.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01185743,NCT01185743,"Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study | Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.

Aim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.","[(10, 33, 'DRUG', 'Atypical Antipsychotics'), (93, 100, 'CONTROL', 'Placebo'), (137, 150, 'CONDITION', 'Schizophrenia'), (268, 290, 'DRUG', 'Atypical antipsychotic')]"
"['Identification', 'of', 'Pre', '-', 'Malignant', 'Lesions', 'In', 'Pediatric', 'Patients', 'With', 'Neurofibromatosis', 'Type', '1', 'Using', 'Novel', 'Magnetic', 'Resonance', 'Imaging', 'Techniques', 'Paired', 'With', 'Artificial', 'Intelligence', '|', 'This', 'is', 'a', 'single', 'arm', 'pilot', 'trial', 'of', 'a', 'novel', 'whole', '-', 'body', 'Magnetic', 'Resonance', 'Imaging', 'paired', 'with', 'artificial', 'intelligence', 'intervention', ',', 'to', 'evaluate', 'feasibility', 'defined', 'as', 'scan', '-', 'rescan', 'reliability', ',', 'and', 'to', 'estimate', 'the', 'positive', 'predictive', 'value', 'of', 'changes', 'in', 'Magnetic', 'Resonance', 'Imaging', 'scans', 'from', 'baseline', 'to', '12', '-', 'month', 'visit', 'using', 'an', 'Artificial', 'Intelligence', 'algorithm', ',', 'among', '15', 'pediatric', 'patients', 'with', 'neurofibromatosis', 'type', '1', 'at', 'Cedars', '-', 'Sinai', 'Medical', 'Center', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04763109,NCT04763109,"Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence | This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm, among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.","[(18, 39, 'CONDITION', 'Pre-Malignant Lesions'), (67, 91, 'CONDITION', 'Neurofibromatosis Type 1'), (574, 598, 'CONDITION', 'neurofibromatosis type 1')]"
"['Cortical', 'Correlates', 'of', 'Gait', 'Automaticity', 'and', 'Daily', 'Life', 'Mobility', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'the', 'effects', 'of', 'a', 'novel', ',', 'personalized', ',', 'tactile', 'cueing', 'system', 'on', 'gait', 'automaticity', '.', 'The', 'researchers', 'hypothesized', 'that', 'step', '-', 'synchronized', 'tactile', 'cueing', 'will', 'reduce', 'prefrontal', 'cortex', 'activity', '(', 'improve', 'automaticity', ')', 'and', 'improve', 'gait', 'variability', '(', 'as', 'well', 'as', 'gait', 'speed', ')', '.', 'The', 'researchers', 'predict', 'that', 'improved', 'automaticity', 'with', 'improved', 'gait', 'variability', 'will', 'be', 'associated', 'with', 'increased', 'activation', 'of', 'other', 'than', 'prefrontal', 'cortical', 'areas', 'while', 'walking', '(', 'i.e.', ',', 'sensory', '-', 'motor', ')', '.', 'To', 'determine', 'the', 'effects', 'of', 'cueing', ',', '60', 'participants', 'with', 'PD', 'from', 'will', 'be', 'randomized', 'into', 'one', ',', 'of', 'two', ',', 'cueing', 'interventions', ':', '1', ')', 'personalized', ',', 'step', '-', 'synchronized', 'tactile', 'cueing', 'and', '2', ')', 'tactile', 'cueing', 'at', 'fixed', 'intervals', 'as', 'an', 'active', 'control', 'group', '.', 'In', 'addition', ',', 'the', 'researchers', 'will', 'explore', 'the', 'feasibility', 'and', 'potential', 'benefits', 'of', 'independent', 'use', 'of', 'tactile', 'cueing', 'during', 'a', 'week', 'in', 'daily', 'life', 'for', 'a', 'future', 'clinical', 'trial', '.', '\n\n', 'This', 'project', 'will', 'characterize', 'the', 'cortical', 'correlates', 'of', 'gait', 'automaticity', ',', 'the', 'changes', 'in', 'gait', 'automaticity', 'with', 'cueing', 'in', 'people', 'with', 'PD', ',', 'and', 'how', 'these', 'changes', 'translate', 'to', 'improvement', 'in', 'gait', 'and', 'turning', '.', 'The', 'long', '-', 'term', 'goal', 'is', 'to', 'unravel', 'the', 'mechanisms', 'of', 'impaired', 'gait', 'automaticity', 'in', 'PD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05818189,NCT05818189,"Cortical Correlates of Gait Automaticity and Daily Life Mobility in Parkinson's Disease | The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). The researchers predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. In addition, the researchers will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.

This project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with PD, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in PD.","[(68, 87, 'CONDITION', ""Parkinson's Disease""), (155, 190, 'OTHER', 'personalized, tactile cueing system'), (247, 279, 'OTHER', 'step-synchronized tactile cueing'), (657, 659, 'CONDITION', 'PD'), (727, 773, 'OTHER', 'personalized, step-synchronized tactile cueing'), (781, 814, 'CONTROL', 'tactile cueing at fixed intervals'), (946, 960, 'OTHER', 'tactile cueing'), (1134, 1140, 'OTHER', 'cueing'), (1156, 1158, 'CONDITION', 'PD'), (1309, 1311, 'CONDITION', 'PD')]"
"['Psychological', 'Assessment', 'and', 'Treatment', 'of', 'Chronic', 'Benign', 'Headache', '|', 'Subjects', 'with', 'chronic', 'migraine', 'or', 'tension', 'headaches', 'will', 'receive', '12', 'sessions', 'of', 'biofeedback', 'or', 'relaxation', 'training', 'after', 'fulfilling', 'screening', ',', 'intake', 'interviews', ',', '&', 'psychological', 'testing', 'requirements', '.', 'They', 'will', 'chart', 'headache', 'pain', ',', 'anger', 'level', ',', '&', 'medication', 'usage', 'throughout', 'baseline', ',', 'treatment', ',', 'and', '3', 'month', 'follow', '-', 'up', 'periods', '.', '\n\n', 'Migraine', 'sufferers', 'will', 'receive', 'a', 'combination', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'and', 'thermal', 'biofeedback', '(', 'learning', 'to', 'warm', 'hands', ')', '.', 'Subjects', 'are', 'randomly', 'assigned', 'to', 'receive', 'treatment', 'either', 'in', 'the', 'office', 'with', 'the', 'therapist', 'or', 'from', 'another', 'room', '(', 'where', 'communication', 'will', 'be', 'over', 'a', 'computer', ')', '.', 'The', 'research', 'is', 'designed', 'to', 'compare', 'the', 'effectiveness', 'of', 'treatment', 'based', 'on', 'location', '.', '\n\n', 'Tension', 'headache', 'sufferers', 'will', 'receive', 'training', 'in', 'how', 'to', 'reduce', 'their', 'muscle', 'tension', 'levels', '.', 'They', 'will', 'be', 'randomly', 'assigned', 'to', 'have', 'equipment', 'monitor', 'muscle', 'tension', 'levels', 'either', 'in', 'the', 'forehead', 'or', 'shoulder', 'regions', '.', 'The', 'research', 'is', 'designed', 'to', 'compare', 'the', 'effectiveness', 'of', 'feedback', 'to', 'the', 'forehead', 'versus', 'the', 'shoulder', 'muscles', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00018811,NCT00018811,"Psychological Assessment and Treatment of Chronic Benign Headache | Subjects with chronic migraine or tension headaches will receive 12 sessions of biofeedback or relaxation training after fulfilling screening, intake interviews, & psychological testing requirements. They will chart headache pain, anger level, & medication usage throughout baseline, treatment, and 3 month follow-up periods.

Migraine sufferers will receive a combination of progressive muscle relaxation training and thermal biofeedback (learning to warm hands). Subjects are randomly assigned to receive treatment either in the office with the therapist or from another room (where communication will be over a computer). The research is designed to compare the effectiveness of treatment based on location.

Tension headache sufferers will receive training in how to reduce their muscle tension levels. They will be randomly assigned to have equipment monitor muscle tension levels either in the forehead or shoulder regions. The research is designed to compare the effectiveness of feedback to the forehead versus the shoulder muscles.","[(42, 65, 'CONDITION', 'Chronic Benign Headache'), (82, 98, 'CONDITION', 'chronic migraine'), (102, 119, 'CONDITION', 'tension headaches'), (148, 159, 'OTHER', 'biofeedback'), (163, 182, 'OTHER', 'relaxation training'), (284, 297, 'CONDITION', 'headache pain'), (299, 304, 'CONDITION', 'anger'), (395, 403, 'CONDITION', 'Migraine'), (444, 482, 'OTHER', 'progressive muscle relaxation training'), (487, 506, 'OTHER', 'thermal biofeedback'), (780, 796, 'CONDITION', 'Tension headache'), (932, 946, 'CONDITION', 'muscle tension')]"
"['Phase', '2', 'Single-', 'Arm', 'Studies', 'of', 'Temozolomide', 'in', 'Combination', 'With', 'Topotecan', 'in', 'Refractory', 'and', 'Relapsed', 'Neuroblastoma', 'and', 'Other', 'Paediatric', 'Solid', 'Tumours', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'the', 'combination', 'of', 'Hycamtin', '(', 'Topotecan', ')', 'and', 'Temozolomide', 'is', 'effective', 'in', 'the', 'treatment', 'of', 'relapsed', 'and', 'refractory', 'neuroblastoma', 'and', 'other', 'paediatric', 'solid', 'tumors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00918320,NCT00918320,Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours | The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.,"[(31, 43, 'DRUG', 'Temozolomide'), (64, 73, 'DRUG', 'Topotecan'), (77, 114, 'CONDITION', 'Refractory and Relapsed Neuroblastoma'), (136, 149, 'CONDITION', 'Solid Tumours'), (220, 228, 'DRUG', 'Hycamtin'), (230, 239, 'DRUG', 'Topotecan'), (245, 257, 'DRUG', 'Temozolomide'), (291, 328, 'CONDITION', 'relapsed and refractory neuroblastoma'), (350, 362, 'CONDITION', 'solid tumors')]"
"['Comparison', 'of', 'Therapeutic', 'Effects', 'of', 'Greater', 'Occipital', 'Nerve', 'Block', ',', 'Topiramate', ',', 'and', 'Flunarizine', 'on', 'Episodic', 'Migraine', ':', 'A', 'Randomised', 'Parallel', 'Group', 'Study', '|', 'Background', ':', 'Preventive', 'drug', 'therapy', 'in', 'migraine', 'aims', 'to', 'reduce', 'the', 'attack', 'frequency', ',', 'severity', 'and', 'duration', 'of', 'headache', '.', 'Flunarizine', 'and', 'topiramate', 'are', 'widely', 'used', 'in', 'the', 'prevention', 'of', 'migraine', 'attacks', '.', 'Greater', 'occipital', 'nerve', 'block', '(', 'GONB', ')', 'is', 'an', 'alternative', 'treatment', 'option', 'for', 'the', 'prophylactic', 'treatment', 'of', 'migraine', '.', 'In', 'this', 'study', ',', 'investigators', 'compared', 'the', 'effectiveness', 'of', 'GONB', ',', 'topiramate', ',', 'and', 'flunarizine', 'in', 'terms', 'of', 'reduction', 'in', 'post', '-', 'treatment', 'VAS', 'scores', 'and', 'attack', 'frequencies', 'in', 'patients', 'with', 'episodic', 'migraine', 'in', 'a', 'four', '-', 'week', 'period', '.', '\n\n', 'Material', 'and', 'Methods', ':', 'At', 'least', 'one', 'hundred', 'and', 'twenty', 'migraine', 'patients', 'are', 'aimed', 'to', 'be', 'randomly', 'divided', 'into', 'three', 'treatment', 'groups', ',', 'namely', 'flunarizine', '(', 'n=40', ',', 'estimated', ')', ',', 'topiramate', '(', 'n=40', ',', 'estimated', ')', 'and', 'GONB', '(', 'n=40', ',', 'estimated', ')', '.', 'The', 'patients', 'will', 'be', 'followed', 'up', 'for', 'four', 'weeks', 'and', 'the', 'attack', 'frequencies', 'and', 'VAS', 'scores', 'will', 'be', 'recorded', 'weekly', '.', 'At', 'the', 'end', 'of', 'the', 'fourth', 'week', ',', 'the', 'response', 'rates', 'based', 'on', '50', '%', 'and', '75', '%', 'or', 'more', 'reduction', 'in', 'the', 'VAS', 'scores', 'and', 'attack', 'frequencies', 'will', 'be', 'calculated', '.', 'Group', '-', 'wise', 'comparisons', 'will', 'be', 'assessed', 'statistically', '.']","['O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03712917,NCT03712917,"Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine: A Randomised Parallel Group Study | Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks. Greater occipital nerve block (GONB) is an alternative treatment option for the prophylactic treatment of migraine. In this study, investigators compared the effectiveness of GONB, topiramate, and flunarizine in terms of reduction in post-treatment VAS scores and attack frequencies in patients with episodic migraine in a four-week period.

Material and Methods: At least one hundred and twenty migraine patients are aimed to be randomly divided into three treatment groups, namely flunarizine (n=40, estimated), topiramate (n=40, estimated) and GONB (n=40, estimated). The patients will be followed up for four weeks and the attack frequencies and VAS scores will be recorded weekly. At the end of the fourth week, the response rates based on 50% and 75% or more reduction in the VAS scores and attack frequencies will be calculated. Group-wise comparisons will be assessed statistically.","[(37, 66, 'SURGICAL', 'Greater Occipital Nerve Block'), (68, 78, 'DRUG', 'Topiramate'), (84, 95, 'DRUG', 'Flunarizine'), (99, 116, 'CONDITION', 'Episodic Migraine'), (193, 201, 'CONDITION', 'migraine'), (264, 272, 'CONDITION', 'headache'), (274, 285, 'DRUG', 'Flunarizine'), (290, 300, 'DRUG', 'topiramate'), (338, 354, 'CONDITION', 'migraine attacks'), (356, 385, 'SURGICAL', 'Greater occipital nerve block'), (387, 391, 'SURGICAL', 'GONB'), (462, 470, 'CONDITION', 'migraine'), (531, 535, 'SURGICAL', 'GONB'), (537, 547, 'DRUG', 'topiramate'), (553, 564, 'DRUG', 'flunarizine'), (656, 673, 'CONDITION', 'episodic migraine'), (752, 760, 'CONDITION', 'migraine'), (839, 850, 'DRUG', 'flunarizine'), (870, 880, 'DRUG', 'topiramate'), (903, 907, 'SURGICAL', 'GONB')]"
"['Study', 'of', 'Morphological', ',', 'Spectral', 'and', 'Metabolic', 'Manifestations', 'of', 'Neurological', 'Complications', 'in', 'Covid-19', 'Patients', '|', 'Viral', 'pandemics', ',', 'such', 'as', 'HIV', 'and', 'SARS', '-', 'Cov', '-', 'V1', ',', 'have', 'shown', 'that', 'they', 'can', 'lead', 'to', 'acute', 'and', '/', 'or', 'delayed', 'neurological', 'complications', '.', 'At', 'the', 'actual', 'context', 'of', 'the', 'pandemic', 'Coronavirus', 'disease', '2019', '(', 'COVID-19', ')', ',', 'neurological', 'manifestations', 'seem', 'to', 'be', 'confirmed', 'since', 'in', '85', '%', 'of', 'COVID-19', 'patients', ',', 'present', 'neurological', 'symptoms', ',', 'including', 'anosmia', ',', 'ageusia', ',', 'periorbital', 'pain', ',', 'dizziness', ',', 'fatigue', ',', 'even', 'moderate', 'headache', ',', 'moderate', 'memory', 'and/or', 'behavioral', 'disorders', '.', '\n\n', 'However', ',', 'these', 'neurological', 'manifestations', 'are', 'not', 'well', 'studied', 'and', 'their', 'radiological', 'features', 'are', 'not', 'well', 'described', '.', 'It', 'is', 'therefore', 'important', 'to', 'assess', 'these', 'potential', 'neurological', 'complications', 'in', 'COVID-19', 'patients', '.', 'To', 'the', 'investigator', 'knowledge', ',', 'there', 'is', 'no', 'previous', 'study', 'in', 'the', 'literature', 'describing', 'spectral', 'brain', 'changes', 'in', 'COVID', '+', 'patients', '.', 'Thus', ',', 'the', 'goal', 'of', 'this', 'work', 'is', 'to', 'describe', 'the', 'radiological', 'semiology', 'using', 'MRI', 'and', 'particularly', 'Magnetic', 'Resonance', 'Spectroscopic', '(', 'MRS', ')', 'biomarkers', 'in', 'the', 'evaluation', 'of', 'acute', 'and', '/', 'or', 'delayed', 'brain', 'damage', 'in', 'COVID', '+', 'patients', 'presenting', 'a', 'neurological', 'manifestations', 'that', 'are', 'initially', 'related', 'to', 'the', 'cranial', 'nerves', 'damage', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04546737,NCT04546737,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients | Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders.

However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.","[(95, 103, 'CONDITION', 'Covid-19'), (283, 307, 'CONDITION', 'Coronavirus disease 2019'), (309, 317, 'CONDITION', 'COVID-19'), (385, 393, 'CONDITION', 'COVID-19'), (773, 781, 'CONDITION', 'COVID-19'), (905, 910, 'CONDITION', 'COVID'), (1091, 1126, 'CONDITION', 'acute and / or delayed brain damage'), (1130, 1135, 'CONDITION', 'COVID'), (1222, 1243, 'CONDITION', 'cranial nerves damage')]"
"['Effect', 'of', 'Infraorbital', 'and', 'Infratrochlear', 'Nerve', 'Block', 'on', 'Emergence', 'Agitation', 'in', 'Patients', 'Undergoing', 'Septorhinoplasty', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'bilateral', 'infraorbital', 'and', 'infratrochlear', 'nerve', 'block', 'in', 'patients', 'undergoing', 'septorhinoplasty', 'are', 'effective', 'in', 'preventing', 'emergence', 'agitation', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02751268,NCT02751268,Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty: A Randomized Controlled Trial | The purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.,"[(10, 53, 'OTHER', 'Infraorbital and Infratrochlear Nerve Block'), (57, 76, 'CONDITION', 'Emergence Agitation'), (100, 116, 'CONDITION', 'Septorhinoplasty'), (200, 253, 'OTHER', 'bilateral infraorbital and infratrochlear nerve block'), (277, 293, 'CONDITION', 'septorhinoplasty'), (322, 341, 'CONDITION', 'emergence agitation')]"
"['Infra-', 'and', 'Supratentorial', 'Neuromonitoring', 'in', 'Patients', 'With', 'Posterior', 'Fossa', 'Lesions', ':', 'DUAL', '-', 'ICP', 'Trial', '|', 'Invasive', 'neuromonitoring', 'of', 'intracranial', 'pressure', '(', 'ICP', ')', 'is', 'an', 'important', 'element', 'of', 'neurosurgical', 'critical', 'care', 'that', 'is', 'used', 'primarily', 'as', 'an', 'indicator', 'of', 'adequate', 'cerebral', 'perfusion', 'in', 'patients', ',', 'when', 'clinical', 'observation', 'is', 'not', 'an', 'option', '.', 'Due', 'to', 'the', 'constraint', 'in', 'size', 'and', 'the', 'critical', 'structures', 'within', 'the', 'posterior', 'fossa', ',', 'detection', 'of', 'intracranial', 'pressure', 'particularly', 'in', 'the', 'postoperative', 'phase', 'has', 'been', 'deemed', 'desirable', 'in', 'patients', 'with', 'surgery', 'in', 'this', 'region', ',', 'particularly', 'in', 'those', 'subjected', 'to', 'prolonged', 'procedures', 'and', 'critical', 'care', '.', '\n\n', 'The', 'posterior', 'fossa', 'is', 'an', 'anatomically', 'constricted', 'compartment', 'with', 'narrow', 'spaces', 'and', 'intracranial', 'hypertension', 'quickly', 'leads', 'to', 'brainstem', 'damage', 'and', 'neurological', 'dysfunction', '.', 'ICP', 'in', 'the', 'supratentorial', 'space', 'not', 'necessarily', 'correlates', 'with', 'ICP', 'in', 'the', 'infratentorial', 'space', '.', 'Some', 'authors', 'claim', 'that', 'it', 'would', 'be', 'beneficial', 'to', 'measure', 'ICP', 'in', 'infratentorial', 'space', 'after', 'posterior', 'fossa', 'surgery', 'in', 'some', 'cases', '.', '\n\n', 'The', 'relationship', 'between', 'the', 'intracranial', 'pressure', 'profiles', 'in', 'the', 'supratentorial', 'and', 'infratentorial', 'compartments', 'remain', 'unclear', '.', 'After', 'a', 'neurosurgical', 'operation', 'in', 'the', 'posterior', 'fossa', 'there', 'are', 'most', 'likely', 'pressure', 'differences', 'between', 'supra-', 'and', 'infratentorial', 'spaces', '.', 'It', 'is', 'well', 'known', 'that', 'the', 'pressure', 'within', 'the', 'skull', 'is', 'unevenly', 'distributed', ',', 'with', 'appreciable', 'ICP', 'gradients', '.', '\n\n', 'Thus', ',', 'the', 'investigators', 'intend', 'to', 'apply', 'the', 'intracranial', 'multimodal', 'monitoring', 'in', 'both', 'infratentorial', 'and', 'supratentorial', 'compartments', 'simultaneously', '.', 'Such', 'coincident', 'measurements', 'most', 'likely', 'will', 'be', 'the', 'most', 'sensitive', 'way', 'to', 'assess', 'focal', 'swelling', ',', 'ischemia', 'and', 'tissue', 'perfusion', ',', 'or', 'other', 'relevant', 'complications', 'in', 'the', 'posterior', 'fossa', 'structures', '.', '\n\n', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'test', 'whether', 'direct', 'infratentorial', 'monitoring', 'is', 'a', 'more', 'efficacious', 'method', 'for', 'detecting', 'dynamic', 'changes', 'in', 'the', 'operative', 'compartment', 'and', 'whether', 'it', 'is', 'safe', ',', 'in', 'view', 'of', 'the', 'critical', 'structures', 'within', 'the', 'region', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05346471,NCT05346471,"Infra- and Supratentorial Neuromonitoring in Patients With Posterior Fossa Lesions: DUAL-ICP Trial | Invasive neuromonitoring of intracranial pressure (ICP) is an important element of neurosurgical critical care that is used primarily as an indicator of adequate cerebral perfusion in patients, when clinical observation is not an option. Due to the constraint in size and the critical structures within the posterior fossa, detection of intracranial pressure particularly in the postoperative phase has been deemed desirable in patients with surgery in this region, particularly in those subjected to prolonged procedures and critical care.

The posterior fossa is an anatomically constricted compartment with narrow spaces and intracranial hypertension quickly leads to brainstem damage and neurological dysfunction. ICP in the supratentorial space not necessarily correlates with ICP in the infratentorial space. Some authors claim that it would be beneficial to measure ICP in infratentorial space after posterior fossa surgery in some cases.

The relationship between the intracranial pressure profiles in the supratentorial and infratentorial compartments remain unclear. After a neurosurgical operation in the posterior fossa there are most likely pressure differences between supra- and infratentorial spaces. It is well known that the pressure within the skull is unevenly distributed, with appreciable ICP gradients.

Thus, the investigators intend to apply the intracranial multimodal monitoring in both infratentorial and supratentorial compartments simultaneously. Such coincident measurements most likely will be the most sensitive way to assess focal swelling, ischemia and tissue perfusion, or other relevant complications in the posterior fossa structures.

The goal of this study is to test whether direct infratentorial monitoring is a more efficacious method for detecting dynamic changes in the operative compartment and whether it is safe, in view of the critical structures within the region.","[(59, 82, 'CONDITION', 'Posterior Fossa Lesions'), (1676, 1684, 'CONDITION', 'ischemia')]"
"['Monitoring', 'and', 'Peer', 'Support', 'to', 'Improve', 'Treatment', 'Adherence', 'and', 'Outcomes', 'in', 'Patients', 'With', 'Overlap', 'Chronic', 'Obstructive', 'Pulmonary', 'Disease', 'and', 'Sleep', 'Apnea', 'Via', 'a', 'Large', 'PCORnet', 'Collaboration', '|', 'The', 'O2VERLAP', 'study', 'investigators', 'would', 'like', 'to', 'find', 'out', 'if', 'individuals', 'living', 'with', 'both', 'COPD', 'and', 'OSA', 'would', 'benefit', 'from', 'an', 'online', ',', 'educational', 'curriculum', ',', 'coupled', 'with', 'access', 'to', 'peer', 'support', '(', 'i.e.', 'telephone', 'and', 'online', 'chatting', 'with', 'peers', ')', 'and', 'remote', 'CPAP', 'adherence', 'monitoring', 'data', '.', 'The', 'curriculum', 'and', 'peer', 'coaching', 'is', 'meant', 'to', 'provide', 'participants', 'the', 'information', 'and', 'tools', 'they', 'need', 'to', 'be', 'more', 'compliant', 'in', 'using', 'their', 'CPAP', 'device', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O']",NCT03446768,NCT03446768,"Monitoring and Peer Support to Improve Treatment Adherence and Outcomes in Patients With Overlap Chronic Obstructive Pulmonary Disease and Sleep Apnea Via a Large PCORnet Collaboration | The O2VERLAP study investigators would like to find out if individuals living with both COPD and OSA would benefit from an online, educational curriculum, coupled with access to peer support (i.e. telephone and online chatting with peers) and remote CPAP adherence monitoring data. The curriculum and peer coaching is meant to provide participants the information and tools they need to be more compliant in using their CPAP device.","[(0, 27, 'BEHAVIOURAL', 'Monitoring and Peer Support'), (97, 134, 'CONDITION', 'Chronic Obstructive Pulmonary Disease'), (139, 150, 'CONDITION', 'Sleep Apnea'), (275, 279, 'CONDITION', 'COPD'), (284, 287, 'CONDITION', 'OSA'), (310, 340, 'BEHAVIOURAL', 'online, educational curriculum'), (365, 377, 'BEHAVIOURAL', 'peer support'), (437, 441, 'OTHER', 'CPAP'), (473, 483, 'BEHAVIOURAL', 'curriculum'), (488, 501, 'BEHAVIOURAL', 'peer coaching'), (607, 611, 'OTHER', 'CPAP')]"
"['Controlling', 'Femoral', 'Derotation', 'Osteotomy', 'In', 'Cerebral', 'Palsy', 'With', 'Electromagnetic', 'Tracking', '-', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'use', 'of', 'electromagnetic', 'tracking', 'in', 'transversal', 'plane', 'femoral', 'derotation', 'osteotomies', '.', 'The', 'goal', 'is', 'to', 'raise', 'the', 'precision', 'of', 'the', 'surgical', 'procedure', 'in', 'order', 'to', 'improve', 'the', 'outcome', 'in', 'short-', 'and', 'long', 'term', '.', 'All', 'patients', 'are', 'examined', 'with', 'an', 'instrumented', '3D', 'gait', 'analysis', 'pre-', 'and', 'one', 'year', 'postoperatively', '.', 'The', 'electromagnetic', 'tracking', 'system', 'is', 'evaluated', 'against', 'a', 'base', 'line', 'CT', 'or', 'MRI', 'scan', 'serving', 'as', 'reference', 'standard', 'pre-', 'and', 'postoperatively', '.']","['O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03518541,NCT03518541,Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking - A Randomized Controlled Trial | The study is designed to evaluate the use of electromagnetic tracking in transversal plane femoral derotation osteotomies. The goal is to raise the precision of the surgical procedure in order to improve the outcome in short- and long term. All patients are examined with an instrumented 3D gait analysis pre- and one year postoperatively. The electromagnetic tracking system is evaluated against a base line CT or MRI scan serving as reference standard pre- and postoperatively.,"[(12, 40, 'SURGICAL', 'Femoral Derotation Osteotomy'), (44, 58, 'CONDITION', 'Cerebral Palsy'), (64, 88, 'OTHER', 'Electromagnetic Tracking'), (168, 192, 'OTHER', 'electromagnetic tracking'), (214, 244, 'SURGICAL', 'femoral derotation osteotomies'), (467, 498, 'OTHER', 'electromagnetic tracking system')]"
"['The', 'Effectiveness', 'of', 'FMPO', 'in', 'Improving', 'the', 'Quality', 'of', 'Care', 'for', 'Persons', 'With', 'Severe', 'Mental', 'Illness', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'learn', 'how', 'to', 'help', 'veterans', 'play', 'a', 'stronger', 'role', 'in', 'shaping', 'their', 'mental', 'health', 'care', '.', 'Specifically', 'we', 'want', 'to', 'see', 'if', 'we', 'can', 'help', 'veterans', 'improve', 'their', 'mental', 'health', 'treatment', 'by', 'helping', 'them', 'decide', 'if', 'they', 'want', 'to', 'involve', 'family', 'in', 'their', 'mental', 'health', 'treatment', ',', 'and', 'if', 'so', ',', 'how', '.', 'The', 'study', 'will', 'compare', 'a', '""', 'family', 'member', 'provider', '""', 'program', 'to', 'an', '""', 'enhanced', 'treatment', 'as', 'usual', 'approach', '""', 'in', 'achieving', 'these', 'goals', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00466323,NCT00466323,"The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness | The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide if they want to involve family in their mental health treatment, and if so, how. The study will compare a ""family member provider"" program to an ""enhanced treatment as usual approach"" in achieving these goals.","[(21, 25, 'OTHER', 'FMPO'), (76, 97, 'CONDITION', 'Severe Mental Illness'), (437, 459, 'OTHER', 'family member provider'), (476, 512, 'CONTROL', 'enhanced treatment as usual approach')]"
"['Nitric', 'Oxide', 'Supplementation', 'as', 'a', 'Therapeutic', 'Intervention', 'in', 'Argininosuccinic', 'Aciduria', '|', 'This', 'is', 'a', 'study', 'involving', 'a', 'dietary', 'supplement', '.', 'Patients', 'with', 'argininosuccinic', 'aciduria', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'either', 'a', 'nitric', 'oxide', 'dietary', 'supplement', 'or', 'placebo', 'for', '2', 'weeks', ',', 'and', 'then', 'crossed', '-', 'over', 'to', 'receive', 'the', 'other', 'treatment', 'for', 'two', 'weeks', '.', '\n\n', 'The', 'investigators', 'expect', 'to', 'see', 'that', ':', '1', ')', 'Patients', 'with', 'ASA', 'will', 'have', 'a', 'decreased', 'ability', 'for', 'their', 'arteries', 'to', 'dilate', 'due', 'to', 'nitric', 'oxide', 'deficiency', ',', '2', ')', 'Treatment', 'of', 'ASA', 'with', 'the', 'nitric', 'oxide', 'supplement', 'will', 'improve', 'the', 'ability', 'of', 'their', 'arteries', 'to', 'dilate', ',', 'and', '3', ')', 'Through', 'the', 'testing', 'of', 'subjects', ""'"", 'fibroblasts', '(', 'cells', 'in', 'connective', 'tissue', 'that', 'produce', 'collagen', 'and', 'other', 'fibers', ')', ',', 'the', 'investigators', 'hope', 'to', 'predict', 'which', 'patients', 'may', 'respond', 'NO', 'supplementation', '.']","['B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",NCT02252770,NCT02252770,"Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinic Aciduria | This is a study involving a dietary supplement. Patients with argininosuccinic aciduria will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 2 weeks, and then crossed-over to receive the other treatment for two weeks.

The investigators expect to see that : 1) Patients with ASA will have a decreased ability for their arteries to dilate due to nitric oxide deficiency, 2) Treatment of ASA with the nitric oxide supplement will improve the ability of their arteries to dilate, and 3) Through the testing of subjects' fibroblasts (cells in connective tissue that produce collagen and other fibers), the investigators hope to predict which patients may respond NO supplementation.","[(0, 12, 'DRUG', 'Nitric Oxide'), (62, 87, 'CONDITION', 'Argininosuccinic Aciduria'), (152, 177, 'CONDITION', 'argininosuccinic aciduria'), (224, 236, 'DRUG', 'nitric oxide'), (259, 266, 'CONTROL', 'placebo'), (405, 408, 'CONDITION', 'ASA'), (475, 487, 'DRUG', 'nitric oxide'), (516, 519, 'CONDITION', 'ASA'), (529, 541, 'DRUG', 'nitric oxide'), (789, 791, 'DRUG', 'NO')]"
"['A', 'Phase', 'II', ',', 'Double', '-', 'Blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Dose', '-', 'Ranging', 'Study', 'Assessing', 'the', 'Efficacy', 'and', 'Safety', 'of', 'AC-3933', 'Tablets', 'Twice', 'Daily', 'in', 'Adults', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'efficacy', 'and', 'safety', 'of', 'different', 'doses', 'of', 'AC-3933', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'Disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00359944,NCT00359944,"A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease | The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.","[(38, 45, 'CONTROL', 'Placebo'), (130, 137, 'DRUG', 'AC-3933'), (173, 209, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (298, 305, 'DRUG', 'AC-3933'), (323, 359, 'CONDITION', ""mild to moderate Alzheimer's Disease"")]"
"['A', 'Pilot', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Initial', 'Effectiveness', 'of', 'the', 'Cala', 'ONE', 'Device', 'to', 'Repeatably', 'Aid', 'in', 'the', 'Symptomatic', 'Relief', 'of', 'Essential', 'Tremor', '|', 'Prospective', ',', 'multi', '-', 'center', ',', 'randomized', ',', 'controlled', 'study', 'designed', 'to', 'evaluate', 'safety', 'and', 'repeatable', 'effectiveness', '.', 'Subjects', 'will', 'be', 'randomized', '2:1:1', 'to', 'transcutaneous', 'afferent', 'patterned', 'stimulation', '(', 'TAPS', ')', ',', 'sham', ',', 'or', ""'"", 'no', 'intervention', ""'"", ',', 'respectively', '.', 'Subjects', 'randomized', 'to', 'the', 'TAPS', 'and', 'sham', 'arms', 'will', 'be', 'blinded', 'to', 'their', 'randomization', 'assignments', 'for', 'the', 'first', 'two', 'weeks', 'of', 'participation', '(', 'controlled', 'phase', ')', '.', 'After', 'the', 'first', 'two', 'weeks', ',', 'all', 'subjects', 'will', 'be', 'crossed', 'over', 'to', 'TAPS', '(', 'open', '-', 'label', 'phase', ')', 'for', '2', 'weeks', '.', 'During', 'study', 'participation', ',', 'all', 'subjects', 'are', 'to', 'remain', 'on', 'a', 'stable', 'dosage', 'of', 'medications', 'prescribed', 'for', 'the', 'treatment', 'of', 'essential', 'tremor', ',', 'if', 'applicable', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT03152136,NCT03152136,"A Pilot Study to Evaluate the Safety and Initial Effectiveness of the Cala ONE Device to Repeatably Aid in the Symptomatic Relief of Essential Tremor | Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no intervention', respectively. Subjects randomized to the TAPS and sham arms will be blinded to their randomization assignments for the first two weeks of participation (controlled phase). After the first two weeks, all subjects will be crossed over to TAPS (open-label phase) for 2 weeks. During study participation, all subjects are to remain on a stable dosage of medications prescribed for the treatment of essential tremor, if applicable.","[(70, 85, 'OTHER', 'Cala ONE Device'), (133, 149, 'CONDITION', 'Essential Tremor'), (303, 348, 'OTHER', 'transcutaneous afferent patterned stimulation'), (350, 354, 'OTHER', 'TAPS'), (357, 361, 'CONTROL', 'sham'), (367, 382, 'CONTROL', 'no intervention'), (426, 430, 'OTHER', 'TAPS'), (435, 439, 'CONTROL', 'sham'), (621, 625, 'OTHER', 'TAPS'), (779, 795, 'CONDITION', 'essential tremor')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '1/2', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'Pharmacodynamics', ',', 'and', 'Exploratory', 'Efficacy', 'of', 'AOC', '1020', 'Administered', 'Intravenously', 'to', 'Adult', 'Participants', 'With', 'Facioscapulohumeral', 'Muscular', 'Dystrophy', '(', 'FSHD', ')', '|', 'A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '1/2', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'Pharmacodynamics', ',', 'and', 'Exploratory', 'Efficacy', 'of', 'AOC', '1020', 'Administered', 'Intravenously', 'to', 'Adult', 'Participants', 'with', 'Facioscapulohumeral', 'Muscular', 'Dystrophy', '(', 'FSHD', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT05747924,NCT05747924,"A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)","[(28, 35, 'CONTROL', 'Placebo'), (166, 174, 'DRUG', 'AOC 1020'), (229, 267, 'CONDITION', 'Facioscapulohumeral Muscular Dystrophy'), (269, 273, 'CONDITION', 'FSHD'), (305, 312, 'CONTROL', 'Placebo'), (443, 451, 'DRUG', 'AOC 1020'), (506, 544, 'CONDITION', 'Facioscapulohumeral Muscular Dystrophy'), (546, 550, 'CONDITION', 'FSHD')]"
"['Preparation', 'for', 'End', '-', 'of', '-', 'Life', 'Decision', 'Making', 'in', 'Mild', 'Dementia', '|', 'The', 'proposed', 'study', 'will', 'adapt', 'and', 'pilot', 'test', 'an', 'efficacious', 'advance', 'care', 'planning', 'interventions', ',', 'Sharing', 'Patient', ""'s"", 'Illness', 'Representations', 'to', 'Increase', 'Trust', '(', 'SPIRIT', ')', ',', 'with', 'patients', 'with', 'mild', 'dementia', 'and', 'their', 'surrogates', 'to', 'promote', 'open', ',', 'honest', 'discussions', 'while', 'such', 'discussions', 'about', 'end', '-', 'of', '-', 'life', 'care', 'are', 'possible', '.', 'Patient', 'and', 'surrogate', 'decision', 'maker', 'dyads', 'will', 'participate', 'in', 'a', 'single', 'SPIRIT', 'session', 'and', 'will', 'then', 'have', 'a', 'follow', 'up', 'phone', 'call', '2', '-', '3', 'days', 'later', '.', 'One', 'year', 'after', 'the', 'SPIRIT', 'session', 'some', 'surrogates', 'will', 'be', 'contacted', 'to', 'provide', 'additional', 'feedback', 'about', 'the', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03311711,NCT03311711,"Preparation for End-of-Life Decision Making in Mild Dementia | The proposed study will adapt and pilot test an efficacious advance care planning interventions, Sharing Patient's Illness Representations to Increase Trust (SPIRIT), with patients with mild dementia and their surrogates to promote open, honest discussions while such discussions about end-of-life care are possible. Patient and surrogate decision maker dyads will participate in a single SPIRIT session and will then have a follow up phone call 2-3 days later. One year after the SPIRIT session some surrogates will be contacted to provide additional feedback about the intervention.","[(47, 60, 'CONDITION', 'Mild Dementia'), (160, 219, 'BEHAVIOURAL', ""Sharing Patient's Illness Representations to Increase Trust""), (221, 227, 'BEHAVIOURAL', 'SPIRIT'), (249, 262, 'CONDITION', 'mild dementia'), (452, 458, 'BEHAVIOURAL', 'SPIRIT'), (544, 550, 'BEHAVIOURAL', 'SPIRIT')]"
"['Placebo', '-', 'controlled', ',', 'Double', '-', 'blind', ',', 'Parallel', 'Group', ',', 'Fixed', 'Dose', 'Study', 'of', 'KW-6002', '(', 'Istradefylline', ')', 'in', 'the', 'Treatment', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'Phase', '2', 'Study', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'establish', 'the', 'efficacy', 'of', '20', 'mg', '/', 'day', 'and', '40', 'mg', '/', 'day', 'doses', 'of', 'istradefylline', 'for', 'reducing', 'the', 'mean', 'total', 'hours', 'of', 'awake', 'time', 'per', 'day', 'spent', 'in', 'the', 'OFF', 'state', 'in', 'patients', 'with', 'advanced', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'treated', 'with', 'levodopa', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT00455507,NCT00455507,"Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study) | The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.","[(70, 77, 'DRUG', 'KW-6002'), (79, 93, 'DRUG', 'Istradefylline'), (115, 134, 'CONDITION', ""Parkinson's Disease""), (244, 258, 'DRUG', 'istradefylline'), (355, 383, 'CONDITION', ""advanced Parkinson's disease""), (385, 387, 'CONDITION', 'PD'), (402, 410, 'CONDITION', 'levodopa')]"
"['North', 'Carolina', 'Genomic', 'Evaluation', 'by', 'Next', '-', 'generation', 'Exome', 'Sequencing', ',', '2', '|', 'The', '""', 'North', 'Carolina', 'Clinical', 'Genomic', 'Evaluation', 'by', 'Next', '-', 'gen', 'Exome', 'Sequencing', ',', '2', '(', 'NCGENES', '2', ')', '""', 'study', 'is', 'part', 'of', 'a', 'larger', 'consortium', 'project', 'investigating', 'the', 'clinical', 'utility', ',', 'or', 'net', 'benefit', 'of', 'an', 'intervention', 'on', 'patient', 'and', 'family', 'well', '-', 'being', 'as', 'well', 'as', 'diagnostic', 'efficacy', ',', 'management', 'planning', ',', 'and', 'medical', 'outcomes', '.', 'A', 'clinical', 'trial', 'will', 'be', 'implemented', 'to', 'compare', '(', '1', ')', 'first', '-', 'line', 'exome', 'sequencing', 'to', 'usual', 'care', 'and', '(', '2', ')', 'participant', 'pre', '-', 'visit', 'preparation', 'to', 'no', 'pre', '-', 'visit', 'preparation', '.', 'The', 'study', 'will', 'use', 'a', 'randomized', 'controlled', 'design', ',', 'with', '2x2', 'factorial', 'design', ',', 'coupled', 'with', 'patient', '-', 'reported', 'outcomes', 'and', 'comprehensive', 'clinical', 'data', 'collection', 'addressing', 'key', 'outcomes', ',', 'to', 'determine', 'the', 'net', 'impact', 'of', 'diagnostic', 'results', 'and', 'secondary', 'findings', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03548779,NCT03548779,"North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 | The ""North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)"" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.",[]
"['Addressing', 'Barriers', 'to', 'Adult', 'Hearing', 'Healthcare', '|', 'The', 'aim', 'of', 'this', 'project', 'is', 'to', 'develop', 'evidence', 'that', 'can', 'inform', 'hearing', 'health', 'care', 'best', 'practices', 'for', 'adults', 'between', 'the', 'ages', 'of', '65', '-', '75', ',', 'and', 'determine', 'what', 'level', 'of', 'involvement', 'by', 'the', 'primary', 'care', 'practitioner', '(', 'PCP', ')', 'is', 'required', 'to', 'inform', 'and', 'encourage', 'adults', 'age', '65', '-', '75', 'to', 'follow', 'through', 'with', 'routine', 'hearing', 'screening', '.', '\n\n', 'This', 'study', 'also', 'aims', 'to', 'evaluate', 'the', 'accuracy', 'of', 'assessment', 'of', 'medical', 'conditions', 'for', 'which', 'the', 'FDA', 'requires', 'physician', 'evaluation', 'and', 'management', 'prior', 'to', 'hearing', 'aid', 'fitting', ',', 'and', 'determine', 'which', 'medical', 'conditions', 'should', 'require', 'medical', 'evaluation', 'prior', 'to', 'hearing', 'aid', 'fitting', '.', '\n\n', 'The', 'results', 'of', 'this', 'study', 'should', 'provide', 'information', 'to', 'implement', 'changes', 'in', 'health', 'care', 'policy', 'to', 'facilitate', 'accessible', 'and', 'affordable', 'hearing', 'health', 'care', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02928107,NCT02928107,"Addressing Barriers to Adult Hearing Healthcare | The aim of this project is to develop evidence that can inform hearing health care best practices for adults between the ages of 65-75, and determine what level of involvement by the primary care practitioner (PCP) is required to inform and encourage adults age 65-75 to follow through with routine hearing screening.

This study also aims to evaluate the accuracy of assessment of medical conditions for which the FDA requires physician evaluation and management prior to hearing aid fitting, and determine which medical conditions should require medical evaluation prior to hearing aid fitting.

The results of this study should provide information to implement changes in health care policy to facilitate accessible and affordable hearing health care.",[]
"['Oxidative', 'Stress', 'in', 'Sleep', 'Apnea', 'and', 'Cardiac', 'Disease', '|', 'Sleep', '-', 'disordered', 'breathing', '(', 'SDB', ')', 'is', 'a', 'condition', 'in', 'which', 'a', 'person', 'experiences', 'frequent', 'breathing', 'pauses', 'during', 'sleep', ',', 'also', 'known', 'as', 'sleep', 'apnea', '.', 'There', 'is', 'evidence', 'that', 'the', 'recurrent', 'sleep', 'arousal', 'and', 'associated', 'shortage', 'of', 'oxygen', 'in', 'the', 'body', 'may', 'increase', 'risk', 'for', 'cardiovascular', 'disease', '(', 'CVD', ')', '.', 'It', 'is', 'believed', 'that', 'treatment', 'with', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'may', 'reduce', 'certain', 'risk', 'factors', 'for', 'heart', 'disease', ',', 'including', 'markers', 'of', 'inflammation', 'and', 'oxidative', 'stress', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effectiveness', 'of', 'CPAP', 'in', 'reducing', 'CVD', 'risk', 'factors', 'in', 'people', 'with', 'SDB', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00607893,NCT00607893,"Oxidative Stress in Sleep Apnea and Cardiac Disease | Sleep-disordered breathing (SDB) is a condition in which a person experiences frequent breathing pauses during sleep, also known as sleep apnea. There is evidence that the recurrent sleep arousal and associated shortage of oxygen in the body may increase risk for cardiovascular disease (CVD). It is believed that treatment with continuous positive airway pressure (CPAP) may reduce certain risk factors for heart disease, including markers of inflammation and oxidative stress. This study will evaluate the effectiveness of CPAP in reducing CVD risk factors in people with SDB.","[(20, 31, 'CONDITION', 'Sleep Apnea'), (36, 51, 'CONDITION', 'Cardiac Disease'), (54, 80, 'CONDITION', 'Sleep-disordered breathing'), (82, 85, 'CONDITION', 'SDB'), (186, 197, 'CONDITION', 'sleep apnea'), (318, 340, 'CONDITION', 'cardiovascular disease'), (342, 345, 'CONDITION', 'CVD'), (383, 418, 'OTHER', 'continuous positive airway pressure'), (420, 424, 'OTHER', 'CPAP'), (462, 475, 'CONDITION', 'heart disease'), (579, 583, 'OTHER', 'CPAP'), (596, 599, 'CONDITION', 'CVD'), (628, 631, 'CONDITION', 'SDB')]"
"['Effect', 'of', 'Excitatory', 'Theta', '-', 'Burst', 'Transcranial', 'Magnetic', 'Stimulation', 'on', 'Cognition', 'in', 'Patients', 'With', 'Both', 'Parkinson', ""'s"", 'Disease', 'and', 'Mild', 'Cognitive', 'Impairment', 'and', 'Analysis', 'of', 'Functional', 'and', 'Structural', 'Brain', 'Changes', 'After', 'Stimulation', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'affects', 'more', 'than', '100,000', 'Canadians', 'and', 'results', 'in', 'symptoms', 'affecting', 'both', 'motor', 'and', 'cognitive', '(', 'thinking', 'and', 'memory', ')', 'functions', '.', 'Parkinson', ""'s"", 'disease', 'with', 'Mild', 'Cognitive', 'Impairment', '(', 'MCI', ')', 'frequently', 'results', 'in', 'development', 'of', 'dementia', 'for', 'which', 'few', 'treatment', 'options', 'exist', '.', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'TMS', ')', 'is', 'used', 'to', 'alter', 'activity', 'in', 'the', 'outer', 'regions', 'of', 'the', 'brain', 'and', 'has', 'been', 'shown', 'in', 'previous', 'studies', 'to', 'increase', 'cognitive', 'performance', 'in', 'patients', 'with', 'different', 'disorders', '.', 'This', 'study', 'will', 'investigate', 'the', 'effectiveness', 'of', 'TMS', 'as', 'a', 'clinical', 'treatment', 'for', 'the', 'cognitive', 'deficits', 'associated', 'with', 'Parkinson', ""'s"", 'disease', '.', '64', 'male', 'and', 'female', 'participants', 'between', 'the', 'ages', 'of', '50', 'and', '90', 'will', 'attend', 'eight', 'study', 'visits', 'over', 'a', 'period', 'of', '63', 'to', '66', 'days', '.', 'This', 'study', 'is', 'a', 'double', '-', 'blind', 'randomized', 'clinical', 'trial', 'meaning', 'the', 'participant', 'will', 'be', 'assigned', 'by', 'chance', 'to', 'either', 'the', 'TMS', '-', 'treatment', 'group', 'or', 'the', 'Sham', '-', 'treatment', 'group', '.', 'Additionally', ',', 'a', 'combination', 'of', 'memory', 'and', 'thinking', 'tests', 'and', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', 'will', 'be', 'used', 'to', 'see', 'if', 'there', 'are', 'structural', 'and', 'functional', 'changes', 'within', 'the', 'brain', '.', 'Genotyping', 'and', 'blood', 'analysis', 'before', 'and', 'after', 'treatment', 'for', 'different', 'biomarkers', 'will', 'also', 'be', 'performed', 'and', 'these', 'data', 'will', 'be', 'compared', 'to', 'the', 'TMS', 'data', '.', 'Initially', ',', 'this', 'research', 'will', 'increase', 'knowledge', 'about', 'the', 'effects', 'of', 'TMS', 'on', 'various', 'brain', 'regions', '.', 'Ultimately', ',', 'we', 'will', 'be', 'able', 'to', 'determine', 'if', 'TMS', 'can', 'be', 'used', 'as', 'a', 'complementary', 'therapy', 'for', 'PD', 'to', 'improve', 'cognitive', 'performance', 'and', 'to', 'reduce', 'progression', 'into', 'dementia', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03243214,NCT03243214,"Effect of Excitatory Theta-Burst Transcranial Magnetic Stimulation on Cognition in Patients With Both Parkinson's Disease and Mild Cognitive Impairment and Analysis of Functional and Structural Brain Changes After Stimulation | Parkinson's disease (PD) affects more than 100,000 Canadians and results in symptoms affecting both motor and cognitive (thinking and memory) functions. Parkinson's disease with Mild Cognitive Impairment (MCI) frequently results in development of dementia for which few treatment options exist. Transcranial Magnetic Stimulation (TMS) is used to alter activity in the outer regions of the brain and has been shown in previous studies to increase cognitive performance in patients with different disorders. This study will investigate the effectiveness of TMS as a clinical treatment for the cognitive deficits associated with Parkinson's disease. 64 male and female participants between the ages of 50 and 90 will attend eight study visits over a period of 63 to 66 days. This study is a double-blind randomized clinical trial meaning the participant will be assigned by chance to either the TMS-treatment group or the Sham-treatment group. Additionally, a combination of memory and thinking tests and Magnetic Resonance Imaging (MRI) will be used to see if there are structural and functional changes within the brain. Genotyping and blood analysis before and after treatment for different biomarkers will also be performed and these data will be compared to the TMS data. Initially, this research will increase knowledge about the effects of TMS on various brain regions. Ultimately, we will be able to determine if TMS can be used as a complementary therapy for PD to improve cognitive performance and to reduce progression into dementia.","[(10, 66, 'OTHER', 'Excitatory Theta-Burst Transcranial Magnetic Stimulation'), (102, 121, 'CONDITION', ""Parkinson's Disease""), (126, 151, 'CONDITION', 'Mild Cognitive Impairment'), (228, 247, 'CONDITION', ""Parkinson's disease""), (249, 251, 'CONDITION', 'PD'), (381, 400, 'CONDITION', ""Parkinson's disease""), (406, 431, 'CONDITION', 'Mild Cognitive Impairment'), (433, 436, 'CONDITION', 'MCI'), (475, 483, 'CONDITION', 'dementia'), (523, 556, 'OTHER', 'Transcranial Magnetic Stimulation'), (558, 561, 'OTHER', 'TMS'), (783, 786, 'OTHER', 'TMS'), (854, 873, 'CONDITION', ""Parkinson's disease""), (1120, 1123, 'OTHER', 'TMS'), (1147, 1151, 'CONTROL', 'Sham'), (1492, 1495, 'OTHER', 'TMS'), (1572, 1575, 'OTHER', 'TMS'), (1646, 1649, 'OTHER', 'TMS'), (1693, 1695, 'CONDITION', 'PD'), (1760, 1768, 'CONDITION', 'dementia')]"
"['Phase', '2/3', 'Adaptive', 'Design', ',', 'Randomized', 'Double', '-', 'blind', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'DM199', 'for', 'the', 'Treatment', 'of', 'Acute', 'Ischemic', 'Stroke', '(', 'ReMEDy2', 'Trial', ')', '|', 'This', 'is', 'a', 'Phase', '2/3', 'study', 'evaluating', 'the', 'safety', 'and', 'efficacy', 'of', 'DM199', 'in', 'treating', 'participants', 'presenting', 'within', '24', 'hours', 'of', 'Acute', 'Ischemic', 'Stroke', '(', 'AIS', ')', 'onset', 'for', 'whom', 'fibrinolytics', 'and/or', 'a', 'catheter', '-', 'based', 'procedure', ',', 'mechanical', 'thrombectomy', '(', 'MT', ')', ',', 'are', 'not', 'medically', 'appropriate', 'or', 'available', 'due', 'to', 'constraints', 'of', 'clot', 'location', ',', 'comorbidity', 'risks', ',', 'and/or', 'time', 'from', 'estimated', 'onset', 'of', 'stroke', '.', 'The', 'double', '-', 'blinded', 'study', 'will', 'be', 'randomized', ',', 'placebo', 'controlled', 'at', 'approximately', '75', 'centers', 'in', 'the', 'U.S.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05065216,NCT05065216,"Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at approximately 75 centers in the U.S.","[(51, 58, 'CONTROL', 'Placebo'), (115, 120, 'DRUG', 'DM199'), (142, 163, 'CONDITION', 'Acute Ischemic Stroke'), (246, 251, 'DRUG', 'DM199'), (307, 328, 'CONDITION', 'Acute Ischemic Stroke'), (330, 333, 'CONDITION', 'AIS'), (564, 570, 'CONDITION', 'stroke'), (617, 624, 'CONTROL', 'placebo')]"
"['Additional', 'Effects', 'of', 'Motor', 'Imagery', 'Practice', 'With', 'Dual', 'Task', 'Training', 'in', 'Stroke', 'Patients', '|', 'The', 'importance', 'of', 'potent', 'rehabilitation', 'with', 'dual', 'task', 'balance', 'and', 'gait', 'training', 'is', 'improving', 'and', 'also', 'there', 'have', 'been', 'divergent', 'opinions', 'about', 'the', 'effectiveness', 'of', 'Motor', 'Imagery', 'on', 'balance', 'and', 'gait', 'function', '.', 'Dual', 'tasking', 'has', 'also', 'proved', 'beneficial', 'results', 'on', 'stroke', 'patients', '.', 'Mental', 'stimulation', 'with', 'task', 'performance', 'is', 'a', 'new', 'intervention', '..', 'So', 'the', 'purpose', 'of', 'my', 'study', 'is', 'to', 'investigate', 'the', 'combination', 'of', 'Motor', 'Imagery', 'Practice', 'and', 'dual', 'task', 'rehabilitative', 'training', 'on', 'balance', 'and', 'gait', 'targeting', 'the', 'population', 'of', 'post', 'stroke', 'patients']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04086004,NCT04086004,Additional Effects of Motor Imagery Practice With Dual Task Training in Stroke Patients | The importance of potent rehabilitation with dual task balance and gait training is improving and also there have been divergent opinions about the effectiveness of Motor Imagery on balance and gait function. Dual tasking has also proved beneficial results on stroke patients. Mental stimulation with task performance is a new intervention.. So the purpose of my study is to investigate the combination of Motor Imagery Practice and dual task rehabilitative training on balance and gait targeting the population of post stroke patients,"[(22, 44, 'OTHER', 'Motor Imagery Practice'), (50, 68, 'PHYSICAL', 'Dual Task Training'), (72, 78, 'CONDITION', 'Stroke'), (135, 170, 'PHYSICAL', 'dual task balance and gait training'), (255, 268, 'OTHER', 'Motor Imagery'), (299, 311, 'PHYSICAL', 'Dual tasking'), (350, 356, 'CONDITION', 'stroke'), (496, 518, 'OTHER', 'Motor Imagery Practice'), (523, 576, 'PHYSICAL', 'dual task rehabilitative training on balance and gait'), (605, 616, 'CONDITION', 'post stroke')]"
"['Phase', 'IIA', 'Open', '-', 'Label', ',', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'Trend', 'of', 'SCI', '-110', 'in', 'Patients', 'With', 'AD', 'and', 'Agitation', '|', 'As', 'of', 'today', ',', 'there', 'is', 'no', 'FDA', '-', 'approved', 'treatment', 'for', 'agitation', 'in', 'AD', '.', 'Hence', ',', 'it', 'is', 'still', 'considered', 'an', 'unmet', 'need', '.', '\n\n', 'Sporadic', 'observation', 'in', 'healthy', 'or', 'diagnosed', 'individuals', 'indicated', 'that', 'cannabis', 'products', ',', 'in', 'particular', ',', 'THC', 'have', 'calming', 'and', 'anti', '-', 'anxiety', 'effects', '.', 'These', 'observations', 'are', 'supported', 'by', 'basic', 'science', 'data', 'as', 'well', 'as', 'animal', 'experiments', '.', '\n\n', 'SCI', '-110', 'is', 'a', 'combination', 'of', '(', '1', ')', 'dronabinol', ',', 'the', 'active', 'ingredient', 'in', 'an', 'FDA', '-', 'approved', 'synthetic', 'analog', 'of', 'tetrahydrocannabinol', ',', 'the', 'psychoactive', 'molecule', 'in', 'the', 'cannabis', 'plant', ',', 'and', '(', '2', ')', 'palmitoylethanolamide', '.', '\n\n', 'In', 'the', 'present', 'study', ',', 'the', 'starting', 'daily', 'dose', 'for', 'all', 'subjects', 'is', '2.5', 'mg', 'dronabinol', 'and', '800', 'mg', 'PEA', 'and', 'will', 'be', 'gradually', 'increased', '(', 'every', '3', 'days', 'an', 'addition', 'of', '2.5', 'mg', 'dronabinol', 'per', 'day', ',', 'with', 'no', 'change', 'in', 'the', 'PEA', 'dose', ')', 'to', 'a', 'maximum', 'of', '12.5', 'mg', 'Dronebinol', 'and', '800', 'mg', 'PEA', 'per', 'day', '.', 'The', 'study', 'product', 'will', 'be', 'given', 'orally', ',', 'twice', 'daily', ',', 'to', 'add', '-', 'on', 'the', 'medical', 'treatment', '.', '\n\n', 'Study', 'Duration', 'per', 'patient', 'is', 'up', 'to', '64', 'days', ':', 'a.', 'screening', '(', '3', '-', '21', 'days', ')', ';', 'b.', 'treatment', 'phase', ':', '(', '1', ')', 'titration', '(', '15', '-', '23', 'days', ')', 'of', 'dronabinol', 'from', '2.5', 'to', '12.5', 'mg', 'or', 'up', 'to', 'the', 'maximal', 'subject', ""'s"", 'tolerated', 'dose', '(', '2', ')', 'Stabilization', 'phase', '(', '10', 'days', ')', 'until', 'end', 'of', 'treatment', 'on', 'the', 'highest', 'subject', ""'s"", 'daily', 'tolerated', 'dose', '.', 'c.', 'follow', '-', 'up', 'phase', '(', '7', 'days', ')', '-', 'until', 'the', 'end', '-', 'of', '-', 'study', '.', '\n\n', 'During', 'the', 'study', ',', 'the', 'tolerability', 'of', 'the', 'drug', ',', 'its', 'safety', '(', 'vital', 'signs', ',', 'physical', 'examinations', ',', 'blood', ',', 'and', 'urine', 'tests', 'and', 'side', 'effects', 'follow', '-', 'up', ')', 'as', 'well', 'as', 'changes', 'in', 'subject', ""'s"", 'condition', '(', 'using', 'CMAI', ',', 'MMSE', ',', 'SIB-8', 'questionnaires', ')', ',', 'appetite', 'and', 'sleep', 'quality', '(', 'SDI', ')', 'will', 'be', 'followed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05239390,NCT05239390,"Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation | As of today, there is no FDA-approved treatment for agitation in AD. Hence, it is still considered an unmet need.

Sporadic observation in healthy or diagnosed individuals indicated that cannabis products, in particular, THC have calming and anti-anxiety effects. These observations are supported by basic science data as well as animal experiments.

SCI -110 is a combination of (1) dronabinol, the active ingredient in an FDA-approved synthetic analog of tetrahydrocannabinol, the psychoactive molecule in the cannabis plant, and (2) palmitoylethanolamide.

In the present study, the starting daily dose for all subjects is 2.5 mg dronabinol and 800 mg PEA and will be gradually increased (every 3 days an addition of 2.5 mg dronabinol per day, with no change in the PEA dose) to a maximum of 12.5 mg Dronebinol and 800 mg PEA per day. The study product will be given orally, twice daily, to add-on the medical treatment.

Study Duration per patient is up to 64 days: a. screening (3-21 days); b. treatment phase: (1) titration (15-23 days) of dronabinol from 2.5 to 12.5 mg or up to the maximal subject's tolerated dose (2) Stabilization phase (10 days) until end of treatment on the highest subject's daily tolerated dose. c. follow-up phase (7 days) - until the end-of-study.

During the study, the tolerability of the drug, its safety (vital signs, physical examinations, blood, and urine tests and side effects follow-up) as well as changes in subject's condition (using CMAI, MMSE, SIB-8 questionnaires), appetite and sleep quality (SDI) will be followed.","[(82, 90, 'DRUG', 'SCI -110'), (108, 110, 'CONDITION', 'AD'), (115, 124, 'CONDITION', 'Agitation'), (179, 188, 'CONDITION', 'agitation'), (192, 194, 'CONDITION', 'AD'), (314, 322, 'OTHER', 'cannabis'), (348, 351, 'DRUG', 'THC'), (478, 486, 'DRUG', 'SCI -110'), (511, 521, 'DRUG', 'dronabinol'), (584, 604, 'DRUG', 'tetrahydrocannabinol'), (639, 647, 'OTHER', 'cannabis'), (663, 684, 'DRUG', 'palmitoylethanolamide'), (760, 770, 'DRUG', 'dronabinol'), (782, 785, 'DRUG', 'PEA'), (854, 864, 'DRUG', 'dronabinol'), (896, 899, 'DRUG', 'PEA'), (930, 940, 'DRUG', 'Dronebinol'), (952, 955, 'DRUG', 'PEA'), (1173, 1183, 'DRUG', 'dronabinol')]"
"['The', 'Early', 'Diagnosis', 'and', 'Prevention', 'of', 'Ischemic', 'Stroke', 'and', 'Cognition', 'Decline', 'Associated', 'With', 'Coronary', 'Artery', 'Disease', 'Combined', 'With', 'Cerebral', 'Artery', 'Stenosis', 'or', 'Arrhythmia', 'by', '24', '-', 'Hour', 'Simultaneous', 'Recorder', 'of', 'Electrocardiograph', 'and', 'Electroencephalography', '|', 'There', 'are', 'many', 'reports', 'about', 'the', 'association', 'of', 'coronary', 'artery', 'disease', '(', 'CAD', ')', 'and', 'cerebral', 'artery', 'stenosis', '(', 'CAS', ')', ',', 'which', 'had', 'been', 'proved', 'to', 'induce', 'stroke', 'and', 'cognition', 'decline', 'after', 'the', 'revascularization', 'including', 'coronary', 'bypass', 'surgery', '(', 'CABG', ')', 'or', 'percutaneous', 'coronary', 'intervention', '.', 'Perfusion', 'defect', 'on', 'nuclear', 'brain', 'scan', 'is', 'also', 'noted', 'to', 'correlate', 'with', 'these', 'neurological', 'complications', '.', 'On', 'the', 'other', 'hand', ',', 'the', 'perioperative', 'arrhythmia', 'and', 'following', 'cerebral', 'embolism', 'was', 'also', 'attributed', 'to', 'be', 'one', 'factor', 'inducing', 'such', 'neurological', 'hazards', '.', '\n\n', 'In', 'the', 'patients', 'with', 'coexistent', 'CAD', 'and', 'CAS', '(', '1st', 'group', ')', ',', 'and', 'also', 'the', 'patients', 'scheduled', 'for', 'CABG', 'or', 'percutaneous', 'coronary', 'intervention', '(', 'PCI', ')', '(', '2nd', 'group', ')', ',', 'we', ',', 'the', 'researchers', 'at', 'Far', 'Eastern', 'Memorial', 'Hospital', ',', 'attempted', 'to', 'integrate', 'all', 'the', 'parameters', 'mention', 'above', ',', 'including', 'angiography', 'of', 'coronary', 'and', 'cerebral', 'system', ',', 'quantitative', 'analysis', 'of', 'nuclear', 'brain', 'scan', ',', 'biochemical', 'profile', ',', 'and', 'signals', 'of', 'a', 'new', 'ambulatory', 'device', 'which', 'could', 'record', 'the', 'electrocardiograph', '(', 'ECG', ')', 'and', 'electroencephalograph', '(', 'EEG', ')', 'simultaneously', ',', 'in', 'order', 'to', 'define', 'the', 'correlation', 'between', 'them', '.', 'A', 'chorological', 'relation', 'between', 'EEG', 'signals', 'and', 'ECG', 'signals', 'is', 'our', 'first', 'target', 'to', 'be', 'worked', 'out', '.', 'Thereafter', ',', 'we', 'hope', 'to', 'establish', 'a', 'regression', 'model', 'of', 'all', 'involved', 'parameters', 'according', 'to', 'the', 'relation', '.', 'Such', 'a', 'model', ',', 'we', 'believe', ',', 'is', 'essential', 'not', 'only', 'to', 'explain', 'the', 'post', '-', 'CABG', 'neurological', 'complications', ',', 'but', 'to', 'prevent', 'them', '.', '\n\n', 'Furthermore', ',', 'for', 'the', 'undetermined', 'ischemic', 'stroke', 'patients', 'who', 'had', 'no', 'obvious', 'culprit', 'artery', 'or', 'embolism', 'source', ',', 'the', 'paroxysmal', 'arrhythmia', 'had', 'long', 'been', 'regarded', 'as', 'the', 'cause', '.', 'Whether', 'a', 'paroxysmal', 'atrial', 'fibrillation', ',', 'which', 'had', 'not', 'been', 'disclosed', 'by', 'routine', 'ECG', ',', 'could', 'induce', 'most', 'of', 'such', 'a', 'stroke', 'is', 'still', 'not', 'known', '.', 'With', 'this', 'new', 'ambulatory', 'device', 'which', 'could', 'record', 'the', 'electrocardiograph', '(', 'ECG', ')', 'and', 'electroencephalograph', '(', 'EEG', ')', 'simultaneously', ',', 'we', 'want', 'to', 'answer', 'the', 'question', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00247533,NCT00247533,"The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography | There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass surgery (CABG) or percutaneous coronary intervention. Perfusion defect on nuclear brain scan is also noted to correlate with these neurological complications. On the other hand, the perioperative arrhythmia and following cerebral embolism was also attributed to be one factor inducing such neurological hazards.

In the patients with coexistent CAD and CAS (1st group), and also the patients scheduled for CABG or percutaneous coronary intervention (PCI) (2nd group), we, the researchers at Far Eastern Memorial Hospital, attempted to integrate all the parameters mention above, including angiography of coronary and cerebral system, quantitative analysis of nuclear brain scan, biochemical profile, and signals of a new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, in order to define the correlation between them. A chorological relation between EEG signals and ECG signals is our first target to be worked out. Thereafter, we hope to establish a regression model of all involved parameters according to the relation. Such a model, we believe, is essential not only to explain the post-CABG neurological complications, but to prevent them.

Furthermore, for the undetermined ischemic stroke patients who had no obvious culprit artery or embolism source, the paroxysmal arrhythmia had long been regarded as the cause. Whether a paroxysmal atrial fibrillation, which had not been disclosed by routine ECG, could induce most of such a stroke is still not known. With this new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, we want to answer the question.","[(24, 75, 'OTHER', 'Prevention of Ischemic Stroke and Cognition Decline'), (92, 115, 'CONDITION', 'Coronary Artery Disease'), (130, 154, 'CONDITION', 'Cerebral Artery Stenosis'), (158, 168, 'CONDITION', 'Arrhythmia'), (172, 250, 'OTHER', '24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography'), (301, 324, 'CONDITION', 'coronary artery disease'), (326, 329, 'CONDITION', 'CAD'), (335, 359, 'CONDITION', 'cerebral artery stenosis'), (361, 364, 'CONDITION', 'CAS'), (399, 405, 'CONDITION', 'stroke'), (466, 489, 'CONDITION', 'coronary bypass surgery'), (491, 495, 'CONDITION', 'CABG'), (500, 534, 'CONDITION', 'percutaneous coronary intervention'), (664, 688, 'CONDITION', 'perioperative arrhythmia'), (703, 720, 'CONDITION', 'cerebral embolism'), (827, 830, 'CONDITION', 'CAD'), (835, 838, 'CONDITION', 'CAS'), (888, 892, 'CONDITION', 'CABG'), (896, 930, 'CONDITION', 'percutaneous coronary intervention'), (932, 935, 'CONDITION', 'PCI'), (1633, 1669, 'CONDITION', 'post-CABG neurological complications'), (1727, 1742, 'CONDITION', 'ischemic stroke'), (1810, 1831, 'CONDITION', 'paroxysmal arrhythmia'), (1879, 1909, 'CONDITION', 'paroxysmal atrial fibrillation'), (1984, 1990, 'CONDITION', 'stroke')]"
"['Prevalence', 'of', 'Epilepsy', 'and', 'Sleep', 'Wake', 'Disorders', 'in', 'Alzheimer', 'Disease', '|', 'Alzheimer', 'disease', 'is', 'the', 'most', 'common', 'of', 'the', 'neurodegenerative', 'diseases', '.', 'Epilepsy', 'and', 'sleep', 'wake', 'disorders', 'are', 'co', '-', 'morbid', 'conditions', 'of', 'Alzheimer', 'disease', '.', 'The', 'investigators', 'propose', 'a', 'prospective', 'study', 'using', 'long', '-', 'term', 'EEG', 'monitoring', 'in', 'combination', 'with', 'polysomnography', 'to', 'determine', 'prevalence', 'of', 'epilepsy', 'and', 'sleep', 'wake', 'disorders', 'in', 'Alzheimer', 'disease', ',', 'and', 'correlate', 'these', 'findings', 'with', 'clinical', 'data', ',', 'Alzheimer', 'disease', 'biomarkers', 'and', 'imaging', 'studies', '(', 'MRI', 'and', 'amyloid', '/', 'tau', '-', 'PET', ')', '.', 'In', 'selected', 'patients', ',', 'the', 'investigators', 'will', 'perform', 'EEG', 'studies', 'with', 'foramen', 'ovale', 'electrodes', '.', 'The', 'ultimate', 'goal', 'is', 'to', 'improve', 'the', 'outcome', 'of', 'patients', 'with', 'Alzheimer', 'disease', 'by', 'early', 'treatment', 'of', 'epilepsy', 'and', 'restoring', 'sleep', '-', 'wake', 'disturbances', '.']","['O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT03617497,NCT03617497,"Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease | Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a prospective study using long-term EEG monitoring in combination with polysomnography to determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.","[(14, 22, 'CONDITION', 'Epilepsy'), (27, 47, 'CONDITION', 'Sleep Wake Disorders'), (51, 68, 'CONDITION', 'Alzheimer Disease'), (71, 88, 'CONDITION', 'Alzheimer disease'), (143, 151, 'CONDITION', 'Epilepsy'), (156, 176, 'CONDITION', 'sleep wake disorders'), (205, 222, 'CONDITION', 'Alzheimer disease'), (364, 372, 'CONDITION', 'epilepsy'), (377, 397, 'CONDITION', 'sleep wake disorders'), (401, 418, 'CONDITION', 'Alzheimer disease'), (469, 486, 'CONDITION', 'Alzheimer disease'), (702, 719, 'CONDITION', 'Alzheimer disease'), (742, 750, 'CONDITION', 'epilepsy'), (765, 788, 'CONDITION', 'sleep-wake disturbances')]"
"['Comparing', 'the', 'Cognitive', 'Effects', 'of', 'Two', 'Exergame', 'Balance', 'Training', 'Systems', 'and', 'Traditional', 'Weight', 'Shifting', 'Training', 'in', 'Patients', 'With', 'Chronic', 'Stroke', '|', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', ':', 'compare', 'the', 'training', 'and', 'maintenance', 'effects', 'of', '3', 'balance', 'training', 'programs', '(', '2', 'kinds', 'of', 'exergame', 'systems', 'and', '1', 'conventional', 'weight', '-', 'shifting', 'training', 'program', ')', 'on', 'cognitive', 'function', 'of', 'subjects', 'with', 'chronic', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02553993,NCT02553993,Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke | The objective of this study was to: compare the training and maintenance effects of 3 balance training programs (2 kinds of exergame systems and 1 conventional weight-shifting training program) on cognitive function of subjects with chronic stroke.,"[(39, 64, 'PHYSICAL', 'Exergame Balance Training'), (77, 113, 'PHYSICAL', 'Traditional Weight Shifting Training'), (131, 145, 'CONDITION', 'Chronic Stroke'), (234, 259, 'PHYSICAL', 'balance training programs'), (272, 288, 'PHYSICAL', 'exergame systems'), (308, 332, 'PHYSICAL', 'weight-shifting training'), (381, 395, 'CONDITION', 'chronic stroke')]"
"['A', 'Phase', '1', 'Single', 'Ascending', 'Dose', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'Subcutaneous', 'CTI-1601', 'Versus', 'Placebo', 'in', 'Subjects', 'With', 'Friedreich', ""'s"", 'Ataxia', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'single', 'ascending', 'doses', 'of', 'CTI-1601', 'in', 'participants', 'with', 'Friedreich', ""'s"", 'ataxia']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT04176991,NCT04176991,"A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia","[(129, 137, 'DRUG', 'CTI-1601'), (145, 152, 'CONTROL', 'Placebo'), (170, 189, 'CONDITION', ""Friedreich's Ataxia""), (261, 269, 'DRUG', 'CTI-1601'), (291, 310, 'CONDITION', ""Friedreich's ataxia"")]"
"['A', 'Phase', 'IIa', ',', 'Randomized', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Active', 'Comparator-', 'and', 'Placebo', '-', 'Controlled', ',', 'Clinical', 'Trial', 'to', 'Study', 'the', 'Safety', 'and', 'Efficacy', 'of', 'MK8998', 'in', 'Acutely', 'Psychotic', 'Patients', 'With', 'Schizophrenia', '|', 'A', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'treatment', 'with', 'MK-8998', 'as', 'compared', 'to', 'placebo', 'and', 'olanzapine', 'for', 'acutely', 'psychotic', 'patients', 'with', 'schizophrenia', '.', 'The', 'primary', 'hypothesis', 'is', 'that', 'in', 'participants', 'undergoing', 'an', 'acute', 'psychotic', 'episode', 'of', 'schizophrenia', ',', 'MK-8998', '6', 'to', '8', 'mg', 'twice', 'daily', 'is', 'superior', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'symptoms', 'of', 'schizophrenia', 'as', 'measured', 'by', 'the', 'mean', 'change', 'from', 'baseline', 'in', 'the', 'Positive', 'and', 'Negative', 'Syndrome', 'Scale', '(', 'PANSS', ')', 'total', 'score', 'at', 'Week', '4', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00827918,NCT00827918,"A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia | A study to evaluate the safety and efficacy of treatment with MK-8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia. The primary hypothesis is that in participants undergoing an acute psychotic episode of schizophrenia, MK-8998 6 to 8 mg twice daily is superior to placebo in the treatment of symptoms of schizophrenia as measured by the mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 4.","[(75, 82, 'CONTROL', 'Placebo'), (146, 152, 'DRUG', 'MK8998'), (156, 173, 'CONDITION', 'Acutely Psychotic'), (188, 201, 'CONDITION', 'Schizophrenia'), (266, 273, 'DRUG', 'MK-8998'), (289, 296, 'CONTROL', 'placebo'), (301, 311, 'DRUG', 'olanzapine'), (316, 333, 'CONDITION', 'acutely psychotic'), (348, 361, 'CONDITION', 'schizophrenia'), (424, 439, 'CONDITION', 'acute psychotic'), (451, 464, 'CONDITION', 'schizophrenia'), (466, 473, 'DRUG', 'MK-8998'), (511, 518, 'CONTROL', 'placebo'), (551, 564, 'CONDITION', 'schizophrenia')]"
"['A', 'Novel', 'Diagnostic', 'Method', 'for', 'Exotropia', 'Using', 'Video', '-', 'oculography', '|', 'Thirty', '-', 'four', 'subjects', 'with', 'constant', 'exotropia', 'were', 'included', '.', 'Two', 'independent', 'ophthalmologists', 'measured', 'the', 'angle', 'of', 'ocular', 'deviation', 'using', 'alternate', 'prism', 'cover', 'test', '(', 'APCT', ')', '.', 'The', 'video', 'files', 'and', 'data', 'with', 'the', 'changes', 'in', 'ocular', 'deviation', 'during', 'the', 'alternate', 'cover', 'test', 'were', 'obtained', 'using', 'video', '-', 'oculography', '(', 'VOG', ')', '.', 'To', 'verify', 'the', 'accuracy', 'of', 'VOG', ',', 'Investigator', 'compared', 'the', 'value', 'obtained', 'using', 'VOG', 'and', 'the', 'angle', 'of', 'a', 'rotating', 'model', 'eye', ',', 'and', 'subsequently', 'made', 'a', 'new', 'linear', 'equation', 'using', 'these', 'data', '.', 'The', 'calculated', 'values', 'obtained', 'using', 'VOG', 'were', 'compared', 'with', 'those', 'obtained', 'using', 'APCT', 'to', 'determine', 'the', 'diagnostic', 'accuracy', 'of', 'VOG', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03119311,NCT03119311,"A Novel Diagnostic Method for Exotropia Using Video-oculography | Thirty-four subjects with constant exotropia were included. Two independent ophthalmologists measured the angle of ocular deviation using alternate prism cover test (APCT). The video files and data with the changes in ocular deviation during the alternate cover test were obtained using video-oculography (VOG). To verify the accuracy of VOG, Investigator compared the value obtained using VOG and the angle of a rotating model eye, and subsequently made a new linear equation using these data. The calculated values obtained using VOG were compared with those obtained using APCT to determine the diagnostic accuracy of VOG.","[(30, 39, 'CONDITION', 'Exotropia'), (92, 110, 'CONDITION', 'constant exotropia')]"
"['Understanding', 'the', 'Effect', 'of', 'Variances', 'on', 'Precision', 'in', 'Predictive', 'Coding', 'When', 'Walking', 'to', 'Music', 'and', 'Metronomes', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', 'With', 'Progressive', 'Subtypes', '.', '|', 'This', 'study', 'is', 'a', 'case', '-', 'control', 'study', ',', 'involving', 'persons', 'with', 'progressive', 'multiple', 'sclerosis', 'and', 'healthy', 'controls', '.', 'The', 'study', 'contains', '1', 'descriptive', 'and', '3', 'experimental', 'sessions', '.', 'In', 'the', 'descriptive', 'session', ',', 'participant', ""'s"", 'clinical', 'motor', 'and', 'cognitive', 'functions', 'are', 'collected', '.', 'In', 'the', 'first', 'experimental', 'session', ',', 'participant', ""'s"", 'beat', 'perception', 'and', 'synchronisation', 'abilities', 'is', 'examined', 'within', 'a', 'finger', 'tapping', 'paradigm', '.', 'In', 'the', 'following', 'experimental', 'sessions', 'participants', 'synchronsiation', 'abilities', 'is', 'examined', 'during', 'walking', 'paradigms', ',', 'to', 'music', 'and', 'metronomes', ',', 'with', 'period', 'and', 'phase', 'auditory', 'manipulations', '.', 'In', 'the', 'latter', 'twp', 'sessions', ',', 'apart', 'from', 'outcome', 'measures', 'of', 'synchronization', 'the', 'following', 'will', 'be', 'collected', 'as', 'well', ':', 'brain', 'activity', 'using', 'EEG', 'recordings', ',', 'spatio', '-', 'temporal', 'gait', 'parameters', ',', 'perceived', 'fatigue', ',', 'perceived', 'motivation', 'and', 'perceived', 'speed', 'of', 'walking', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04856384,NCT04856384,"Understanding the Effect of Variances on Precision in Predictive Coding When Walking to Music and Metronomes in Persons With Multiple Sclerosis With Progressive Subtypes. | This study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations. In the latter twp sessions, apart from outcome measures of synchronization the following will be collected as well: brain activity using EEG recordings, spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.","[(125, 169, 'CONDITION', 'Multiple Sclerosis With Progressive Subtypes'), (232, 262, 'CONDITION', 'progressive multiple sclerosis'), (967, 974, 'CONDITION', 'fatigue')]"
"['Low', '-', 'level', 'Mechanical', 'Vibration', ',', 'Bone', 'Density', ',', 'Bone', 'Resorption', 'and', 'Muscular', 'Strength', 'in', 'Ambulant', 'Children', 'Affected', 'by', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'Duchenne', 'muscular', 'dystrophy', '(', 'DMD', ')', 'is', 'a', 'X', '-', 'linked', 'recessive', 'disorder', 'due', 'to', 'a', 'mutation', 'of', 'the', 'dystrophin', 'gene', '(', 'Xp21', ')', '.', 'Dystrophin', 'is', 'a', 'sarcolemmal', 'protein', 'of', 'skeletal', 'and', 'cardiac', 'muscle', ',', 'and', 'its', 'absence', 'causes', 'progressive', 'muscle', 'degeneration', 'and', 'substitution', 'with', 'fat', 'and', 'connective', 'tissue', '.', 'The', 'progressive', 'muscle', 'degeneration', 'leads', 'to', 'loss', 'of', 'autonomous', 'walking', 'before', 'the', 'age', 'of', '15', 'years', 'and', 'death', 'for', 'cardiac', 'and/or', 'respiratory', 'failure', '.', 'There', 'are', 'no', 'specific', 'treatment', 'for', 'DMD', ',', 'and', 'the', 'standard', 'of', 'care', 'is', 'now', 'based', 'on', 'long', '-', 'term', 'corticosteroid', '(', 'CS', ')', 'use', '.', 'The', 'studies', 'on', 'bone', 'mass', 'in', 'DMD', 'are', 'very', 'few', ',', 'but', 'they', 'agree', 'in', 'reporting', 'the', 'presence', 'of', 'a', 'reduced', 'bone', 'mass', 'and', 'an', 'increased', 'rate', 'of', 'fractures', 'probably', 'due', 'to', 'long', '-', 'term', 'steroid', 'therapy', 'and', 'disuse', '-', 'osteopenia', '.', 'The', 'aim', 'of', 'this', 'study', ',', 'involving', '20', 'ambulant', 'DMD', 'boys', '(', 'age', '7', '-', '10', 'years', ')', 'has', 'been', 'the', 'evaluation', 'of', 'the', 'effects', 'of', 'low', '-', 'level', 'mechanical', 'vibrations', 'on', 'bone', 'in', 'a', 'group', 'of', 'ambulant', 'DMD', 'children', 'for', '1', 'year', ',', 'with', 'RDA', '-', 'adjusted', 'dietary', 'calcium', 'intake', 'and', '25OH', 'vitamin', 'D', 'supplementation', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O']",NCT05281120,NCT05281120,"Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy | Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.","[(0, 30, 'OTHER', 'Low-level Mechanical Vibration'), (117, 144, 'CONDITION', 'Duchenne Muscular Dystrophy'), (147, 174, 'CONDITION', 'Duchenne muscular dystrophy'), (176, 179, 'CONDITION', 'DMD'), (354, 385, 'CONDITION', 'progressive muscle degeneration'), (439, 470, 'CONDITION', 'progressive muscle degeneration'), (620, 623, 'CONDITION', 'DMD'), (729, 732, 'CONDITION', 'DMD'), (956, 959, 'CONDITION', 'DMD'), (1024, 1055, 'OTHER', 'low-level mechanical vibrations'), (1087, 1090, 'CONDITION', 'DMD'), (1138, 1145, 'DRUG', 'calcium'), (1157, 1171, 'DRUG', '25OH vitamin D')]"
"['A', 'Phase', 'III', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', '18', '-', 'mon', 'Ext', 'Study', 'Long', '-', 'term', 'Efficacy', '&', 'Safety', 'of', '50', '&', '100mg', '/', 'Day', 'Doses', 'of', 'Safinamide', ',', 'as', 'add', '-', 'on', 'Therapy', ',', 'in', 'Idiopathic', 'PD', 'Pts', 'With', 'Motor', 'Fluctuations', ',', 'Treated', 'With', 'Levodopa', ',', 'Who', 'May', 'be', 'Receiving', 'DA', ',', 'and/or', 'Anticholinergic', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'long', '-', 'term', 'efficacy', 'and', 'safety', 'of', 'two', 'doses', 'of', 'safinamide', '(', '50', 'and', '100', 'mg', '/', 'day', ',', 'p.o', ')', ',', 'compared', 'to', 'placebo', ',', 'as', 'add', '-', 'on', 'therapy', 'in', 'patients', 'with', 'idiopathic', 'Parkinson', ""'s"", 'disease', 'with', 'motor', 'fluctuations', ',', 'who', 'are', 'currently', 'receiving', 'a', 'stable', 'dose', 'of', 'levodopa', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT01286935,NCT01286935,"A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic | The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations, who are currently receiving a stable dose of levodopa.","[(27, 34, 'CONTROL', 'Placebo'), (119, 129, 'DRUG', 'Safinamide'), (153, 166, 'CONDITION', 'Idiopathic PD'), (176, 194, 'CONDITION', 'Motor Fluctuations'), (209, 217, 'DRUG', 'Levodopa'), (361, 371, 'DRUG', 'safinamide'), (410, 417, 'CONTROL', 'placebo'), (454, 484, 'CONDITION', ""idiopathic Parkinson's disease""), (490, 508, 'CONDITION', 'motor fluctuations'), (555, 563, 'DRUG', 'levodopa')]"
"['Late', 'Evening', 'and', 'Early', 'Morning', 'Protein', 'Supplement', 'to', 'Reduce', 'Readmissions', 'for', 'Hepatic', 'Encephalopathy', '|', 'Readmission', 'rates', 'for', 'patients', 'with', 'hepatic', 'encephalopathy', 'due', 'to', 'end', 'stage', 'liver', 'disease', 'are', 'high', '.', 'Hyperammonemia', 'contributes', 'significantly', 'to', 'encephalopathy', 'and', 'occurs', 'because', 'of', 'impaired', 'hepatic', 'ureagenesis', 'and', 'increased', 'skeletal', 'muscle', 'proteolysis', '.', 'We', 'propose', 'a', 'randomized', ',', '6', '-', 'month', 'nutritional', 'intervention', 'in', 'cirrhotic', 'patients', 'who', 'have', 'had', 'at', 'least', '1', 'admission', 'for', 'hepatic', 'encephalopathy', 'within', 'the', 'last', '6', 'months', '.', 'We', 'hypothesize', 'that', 'a', 'combination', 'of', 'late', 'evening', 'and', 'early', 'morning', 'protein', 'supplement', '(', 'Ensure', 'Enlive', ')', 'will', 'decrease', 'recurrent', 'hepatic', 'encephalopathy', 'and', 'consequent', 'readmission', 'rates', 'by', 'lowering', 'skeletal', 'muscle', 'proteolysis', 'and', 'improved', 'lean', 'body', 'mass', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04096014,NCT04096014,"Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy | Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1 admission for hepatic encephalopathy within the last 6 months. We hypothesize that a combination of late evening and early morning protein supplement (Ensure Enlive) will decrease recurrent hepatic encephalopathy and consequent readmission rates by lowering skeletal muscle proteolysis and improved lean body mass.","[(31, 49, 'OTHER', 'Protein Supplement'), (77, 99, 'CONDITION', 'Hepatic Encephalopathy'), (138, 160, 'CONDITION', 'hepatic encephalopathy'), (202, 216, 'CONDITION', 'Hyperammonemia'), (246, 260, 'CONDITION', 'encephalopathy'), (283, 311, 'CONDITION', 'impaired hepatic ureagenesis'), (326, 353, 'CONDITION', 'skeletal muscle proteolysis'), (388, 412, 'OTHER', 'nutritional intervention'), (473, 495, 'CONDITION', 'hepatic encephalopathy'), (590, 608, 'OTHER', 'protein supplement'), (610, 623, 'OTHER', 'Ensure Enlive'), (649, 671, 'CONDITION', 'hepatic encephalopathy'), (717, 744, 'CONDITION', 'skeletal muscle proteolysis')]"
"['Bupivacaine', 'Versus', 'Lidocaine', 'Local', 'Anesthesia', 'in', 'Elective', 'Outpatient', 'Hand', 'Surgery', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'use', 'of', 'local', 'anesthetics', 'has', 'become', 'an', 'important', 'aspect', 'of', 'pain', 'management', 'in', 'surgical', 'settings', 'and', 'is', 'currently', 'recommended', 'in', 'pain', 'management', 'guidelines', '.', '\n\n', 'Elective', 'outpatient', 'hand', 'surgeries', ',', 'such', 'as', 'carpal', 'tunnel', 'or', 'trigger', 'finger', 'release', ',', 'cause', 'minimum', 'tissue', 'disruption', 'and', 'are', 'short', 'in', 'duration', '.', 'As', 'a', 'result', ',', 'these', 'local', 'anesthetic', 'agents', 'are', 'a', 'major', 'component', 'in', 'post', '-', 'operative', 'pain', 'control', '.', 'The', 'most', 'commonly', 'used', 'local', 'anesthetic', 'agents', 'are', 'Lidocaine', 'and', 'Bupivacaine', '.', 'Lidocaine', 'acts', 'faster', '(', 'within', '2', '-', '5', 'minutes', 'of', 'injection', ')', 'and', 'for', 'this', 'reason', 'is', 'often', 'favored', 'in', 'outpatient', 'setting', 'for', 'pre', '-', 'incisional', 'injection', '.', 'However', 'its', 'effects', 'only', 'last', 'up', 'to', '2', 'hours', ',', 'without', 'epinephrine', ',', 'and', '3', 'hours', ',', 'with', 'epinephrine', '.', 'On', 'the', 'other', 'hand', ',', 'Bupivacaine', ',', 'has', 'a', 'slower', 'onset', 'of', 'action', '(', 'about', '5', '-', '10', 'minutes', 'after', 'injection', ')', 'but', 'its', 'effects', 'last', 'much', 'longer', ',', 'for', 'about', '4', '-', '8', 'hours', '.', 'The', 'delay', 'in', 'onset', 'of', 'action', 'makes', 'it', 'a', 'less', 'popular', 'option', 'as', 'a', 'primary', 'source', 'of', 'local', 'anesthesia', 'in', 'outpatient', 'hand', 'surgery', '.', '\n\n', 'Given', 'the', 'longer', 'duration', 'of', 'anesthesia', 'offered', 'by', 'Bupivacaine', ',', 'the', 'investigators', 'believe', 'that', 'by', 'giving', 'it', 'pre', '-', 'operatively', 'in', 'elective', 'outpatient', 'hand', 'surgeries', 'will', 'offer', 'more', 'effective', 'post', 'operative', 'pain', 'control', 'compared', 'to', 'using', 'Lidocaine', 'only', '.', 'There', 'is', 'limited', 'published', 'data', 'confirming', 'the', 'effectiveness', 'of', 'use', 'of', 'pre', '-', 'operative', 'Bupivicaine', 'in', 'improved', 'postoperative', 'pain', 'control', 'and', 'decreased', 'consumption', 'of', 'narcotics', '.', 'Therefore', ',', 'the', 'aim', 'in', 'this', 'study', 'is', 'to', 'compare', 'the', 'postoperative', 'pain', 'experienced', 'by', 'patients', 'undergoing', 'either', 'elective', 'carpal', 'tunnel', 'release', 'or', 'trigger', 'finger', 'release', 'as', 'well', 'as', 'their', 'use', 'of', 'pain', 'medications', 'when', 'the', 'incision', 'site', 'is', 'infiltrated', 'preemptively', 'with', 'Lidocaine', 'versus', 'Bupivacaine', '.', '\n\n', 'The', 'investigators', 'believe', 'that', 'adequate', 'post', 'surgical', 'pain', 'control', 'is', 'essential', 'for', 'patients', ""'"", 'full', 'functional', 'recovery', '.', 'Poorly', 'controlled', 'post', 'surgical', 'pain', 'increases', 'incidence', 'of', 'surgery', 'related', 'complications', 'and', 'thus', 'increased', 'health', 'care', 'costs', '.', 'It', 'can', 'also', 'reduce', 'patients', ""'"", 'mobility', ',', 'delay', 'their', 'return', 'to', 'full', 'function', ',', '.', 'If', 'poorly', 'controlled', ',', 'post', 'surgical', 'pain', 'may', 'progress', 'to', 'chronic', 'pain', 'and', 'rarely', 'complex', 'regional', 'pain', 'syndromes', 'may', 'ensue', '.']","['B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O']",NCT01751347,NCT01751347,"Bupivacaine Versus Lidocaine Local Anesthesia in Elective Outpatient Hand Surgery: A Randomized Controlled Trial | The use of local anesthetics has become an important aspect of pain management in surgical settings and is currently recommended in pain management guidelines.

Elective outpatient hand surgeries, such as carpal tunnel or trigger finger release, cause minimum tissue disruption and are short in duration. As a result, these local anesthetic agents are a major component in post-operative pain control. The most commonly used local anesthetic agents are Lidocaine and Bupivacaine. Lidocaine acts faster (within 2-5 minutes of injection) and for this reason is often favored in outpatient setting for pre-incisional injection. However its effects only last up to 2 hours, without epinephrine, and 3 hours, with epinephrine. On the other hand, Bupivacaine, has a slower onset of action (about 5-10 minutes after injection) but its effects last much longer, for about 4-8 hours. The delay in onset of action makes it a less popular option as a primary source of local anesthesia in outpatient hand surgery.

Given the longer duration of anesthesia offered by Bupivacaine, the investigators believe that by giving it pre-operatively in elective outpatient hand surgeries will offer more effective post operative pain control compared to using Lidocaine only. There is limited published data confirming the effectiveness of use of pre-operative Bupivicaine in improved postoperative pain control and decreased consumption of narcotics. Therefore, the aim in this study is to compare the postoperative pain experienced by patients undergoing either elective carpal tunnel release or trigger finger release as well as their use of pain medications when the incision site is infiltrated preemptively with Lidocaine versus Bupivacaine.

The investigators believe that adequate post surgical pain control is essential for patients' full functional recovery. Poorly controlled post surgical pain increases incidence of surgery related complications and thus increased health care costs. It can also reduce patients' mobility, delay their return to full function,. If poorly controlled, post surgical pain may progress to chronic pain and rarely complex regional pain syndromes may ensue.","[(0, 11, 'DRUG', 'Bupivacaine'), (19, 28, 'DRUG', 'Lidocaine'), (69, 81, 'CONDITION', 'Hand Surgery'), (178, 182, 'CONDITION', 'pain'), (247, 251, 'CONDITION', 'pain'), (296, 310, 'CONDITION', 'hand surgeries'), (337, 359, 'CONDITION', 'trigger finger release'), (488, 507, 'CONDITION', 'post-operative pain'), (568, 577, 'DRUG', 'Lidocaine'), (582, 593, 'DRUG', 'Bupivacaine'), (595, 604, 'DRUG', 'Lidocaine'), (793, 804, 'DRUG', 'epinephrine'), (824, 835, 'DRUG', 'epinephrine'), (856, 867, 'DRUG', 'Bupivacaine'), (1104, 1116, 'CONDITION', 'hand surgery'), (1170, 1181, 'DRUG', 'Bupivacaine'), (1307, 1326, 'CONDITION', 'post operative pain'), (1353, 1362, 'DRUG', 'Lidocaine'), (1454, 1465, 'DRUG', 'Bupivicaine'), (1478, 1496, 'CONDITION', 'postoperative pain'), (1596, 1614, 'CONDITION', 'postoperative pain'), (1691, 1713, 'CONDITION', 'trigger finger release'), (1738, 1742, 'CONDITION', 'pain'), (1811, 1820, 'DRUG', 'Lidocaine'), (1828, 1839, 'DRUG', 'Bupivacaine'), (1882, 1900, 'CONDITION', 'post surgical pain'), (1980, 1998, 'CONDITION', 'post surgical pain'), (2189, 2207, 'CONDITION', 'post surgical pain'), (2224, 2236, 'CONDITION', 'chronic pain'), (2256, 2279, 'CONDITION', 'regional pain syndromes')]"
"['Digital', 'Gaming', 'Used', 'to', 'Improve', 'the', 'Cognitive', 'Functioning', 'and', 'Well', '-', 'being', 'of', 'People', 'With', 'Traumatic', 'Brain', 'Injury', ':', 'a', 'Feasibility', 'Study', '|', 'The', 'purpose', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'determine', 'whether', 'digital', 'games', 'are', 'effective', 'and', 'acceptable', 'in', 'the', 'treatment', 'for', 'patients', 'with', 'traumatic', 'brain', 'injury', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02425527,NCT02425527,Digital Gaming Used to Improve the Cognitive Functioning and Well-being of People With Traumatic Brain Injury: a Feasibility Study | The purpose of this feasibility study is to determine whether digital games are effective and acceptable in the treatment for patients with traumatic brain injury.,"[(0, 14, 'OTHER', 'Digital Gaming'), (87, 109, 'CONDITION', 'Traumatic Brain Injury'), (195, 208, 'OTHER', 'digital games'), (273, 295, 'CONDITION', 'traumatic brain injury')]"
"['Impact', 'of', 'Novel', 'Rehabilitative', 'Approaches', 'for', 'Dysphagia', 'in', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', 'and', 'Related', 'Dementias', '|', 'The', 'overall', 'purpose', 'of', 'this', 'project', 'is', 'to', 'develop', 'effective', 'dysphagia', 'rehabilitative', 'interventions', 'for', 'patients', 'with', 'Alzheimer', ""'s"", 'Disease', 'and', 'related', 'dementias', 'at', 'risk', 'for', 'pneumonia', 'development', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03682081,NCT03682081,Impact of Novel Rehabilitative Approaches for Dysphagia in Patients With Alzheimer's Disease and Related Dementias | The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.,"[(16, 41, 'OTHER', 'Rehabilitative Approaches'), (46, 55, 'CONDITION', 'Dysphagia'), (73, 92, 'CONDITION', ""Alzheimer's Disease""), (105, 114, 'CONDITION', 'Dementias'), (177, 215, 'OTHER', 'dysphagia rehabilitative interventions'), (234, 253, 'CONDITION', ""Alzheimer's Disease""), (266, 275, 'CONDITION', 'dementias'), (288, 297, 'CONDITION', 'pneumonia')]"
"['Early', 'Behavioral', 'Intervention', 'to', 'Improve', 'Social', 'Communication', 'Function', 'in', 'Infants', 'With', 'Tuberous', 'Sclerosis', 'Complex', '|', 'The', 'investigators', 'are', 'running', 'an', 'intervention', 'study', 'for', 'young', 'children', 'with', 'Tuberous', 'Sclerosis', 'Complex', '(', 'TSC', ')', '.', 'The', 'study', 'will', 'include', 'free', 'play', '-', 'based', 'behavioral', 'intervention', 'that', 'may', 'improve', 'social', 'and', 'communication', 'skills', 'in', 'children', 'with', 'TSC', '.', 'Eligible', 'families', 'will', 'have', 'a', 'child', 'in', 'the', 'age', 'range', 'of', '12', '-', '36', 'months', ',', 'with', 'a', 'diagnosis', 'of', 'TSC', '.', 'A', 'parent', 'must', 'also', 'be', 'available', 'to', 'attend', 'the', 'weekly', 'intervention', 'sessions', 'at', 'UCLA', '.', '\n\n', 'The', 'intervention', 'will', 'focus', 'on', 'teaching', 'caregivers', 'skills', 'to', 'improve', 'the', 'social', 'and', 'communication', 'outcomes', 'of', 'their', 'children', '.', 'The', 'content', 'of', 'the', 'intervention', 'will', 'be', 'individually', 'tailored', 'to', 'the', 'child', ""'s"", 'developmental', 'level', '.', 'The', 'intervention', 'involves', 'pre', '-', 'assessments', ',', 'an', 'intervention', 'period', 'of', 'daily', '60', 'minute', 'sessions', 'for', '10', 'days', ',', 'followed', 'by', 'weekly', '60', 'minute', 'sessions', 'for', '10', 'weeks', ',', 'and', 'post', '-', 'assessments', '.', 'The', 'classroom', 'can', 'have', 'up', 'to', '3', 'parent', '-', 'child', 'dyad', 'and', 'the', 'curriculum', 'focuses', 'on', 'improving', 'social', '-', 'communication', 'and', 'play', 'skills', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02687633,NCT02687633,"Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex | The investigators are running an intervention study for young children with Tuberous Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that may improve social and communication skills in children with TSC. Eligible families will have a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be available to attend the weekly intervention sessions at UCLA.

The intervention will focus on teaching caregivers skills to improve the social and communication outcomes of their children. The content of the intervention will be individually tailored to the child's developmental level. The intervention involves pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3 parent-child dyad and the curriculum focuses on improving social-communication and play skills.","[(0, 29, 'BEHAVIOURAL', 'Early Behavioral Intervention'), (87, 113, 'CONDITION', 'Tuberous Sclerosis Complex'), (192, 218, 'CONDITION', 'Tuberous Sclerosis Complex'), (220, 223, 'CONDITION', 'TSC'), (249, 288, 'BEHAVIOURAL', 'free play-based behavioral intervention'), (355, 358, 'CONDITION', 'TSC'), (450, 453, 'CONDITION', 'TSC')]"
"['Exploring', 'the', 'Electro', '-', 'mechanical', 'Coupling', 'of', 'Fasciculations', 'in', 'Motor', 'Neuron', 'Disease', 'Using', 'Surface', 'Electromyography', 'and', 'Ultrasound', ':', 'a', 'Feasibility', 'Study', '|', 'Patients', 'with', 'motor', 'neurone', 'disease', 'typically', 'experience', 'relentless', 'motor', 'decline', 'and', 'die', 'within', 'three', 'years', 'of', 'symptom', 'onset', 'from', 'respiratory', 'muscle', 'weakness', '.', 'There', 'are', 'currently', 'no', 'effective', 'therapies', 'and', 'the', 'discovery', 'of', 'novel', 'therapies', 'is', 'hampered', 'by', 'the', 'lack', 'of', 'a', 'sensitive', 'disease', 'biomarker', '.', 'Consequently', ',', 'there', 'is', 'a', 'huge', 'drive', 'to', 'discover', 'novel', 'biomarkers', ',', 'which', 'can', 'reliably', 'track', 'disease', 'progression', 'over', 'time', '.', 'These', 'can', 'then', 'be', 'incorporated', 'into', 'clinical', 'drug', 'trials', 'to', 'expedite', 'effective', 'drug', 'discovery', '.', '\n\n', 'Muscle', 'fasciculations', 'represent', 'the', 'hyperexcitability', 'of', 'diseased', 'motor', 'neurons', 'and', 'are', 'almost', 'universally', 'present', 'from', 'the', 'early', 'stages', 'of', 'MND', '.', 'We', 'predict', 'that', 'the', 'site', ',', 'frequency', 'and', 'shape', 'of', 'fasciculations', 'might', 'provide', 'a', 'sensitive', 'measure', 'of', 'disease', 'progression', 'in', 'an', 'individual', '.', '\n\n', 'We', 'have', 'been', 'conducting', 'a', '12', '-', 'month', 'longitudinal', 'study', 'of', '25', 'patients', ',', 'performing', 'high', '-', 'density', 'surface', 'EMG', 'every', 'two', 'months', '.', 'We', 'have', 'validated', 'an', 'automated', 'technique', 'to', 'process', 'these', 'large', 'data', 'sets', '.', 'Ultrasound', 'is', 'widely', 'used', 'in', 'clinical', 'medicine', 'to', 'assess', 'anatomical', 'structure', 'in', 'a', 'safe', 'and', 'non', '-', 'invasive', 'way', '.', 'Dr', 'Emma', 'Hodson', '-', 'Tole', '(', 'Manchester', 'Metropolitan', 'University', ')', 'and', 'her', 'group', 'have', 'been', 'applying', 'this', 'to', 'the', 'analysis', 'of', 'fasciculations', 'in', 'healthy', 'individuals', 'and', 'patients', 'with', 'MND', '.', '\n\n', 'This', 'collaborative', 'project', 'will', 'explore', 'combining', 'these', 'two', 'techniques', 'simultaneously', 'in', 'patients', 'with', 'motor', 'neuron', 'disease', 'and', 'control', 'subjects', '.', 'The', 'goal', 'is', 'to', 'explore', 'the', 'nature', 'of', 'electro', '-', 'mechanical', 'coupling', 'related', 'to', 'fasciculations', 'and', 'to', 'determine', 'whether', 'any', 'of', 'these', 'properties', 'are', 'pathophysiological', '.', 'This', 'would', 'complement', 'other', 'studies', 'from', 'our', 'two', 'groups', ',', 'investigating', 'the', 'natural', 'history', 'and', 'potential', 'utility', 'of', 'fasciculations', 'as', 'a', 'biomarker', 'of', 'motor', 'neuron', 'health', 'in', 'MND', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05314348,NCT05314348,"Exploring the Electro-mechanical Coupling of Fasciculations in Motor Neuron Disease Using Surface Electromyography and Ultrasound: a Feasibility Study | Patients with motor neurone disease typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery.

Muscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. We predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual.

We have been conducting a 12-month longitudinal study of 25 patients, performing high-density surface EMG every two months. We have validated an automated technique to process these large data sets. Ultrasound is widely used in clinical medicine to assess anatomical structure in a safe and non-invasive way. Dr Emma Hodson-Tole (Manchester Metropolitan University) and her group have been applying this to the analysis of fasciculations in healthy individuals and patients with MND.

This collaborative project will explore combining these two techniques simultaneously in patients with motor neuron disease and control subjects. The goal is to explore the nature of electro-mechanical coupling related to fasciculations and to determine whether any of these properties are pathophysiological. This would complement other studies from our two groups, investigating the natural history and potential utility of fasciculations as a biomarker of motor neuron health in MND.","[(63, 83, 'CONDITION', 'Motor Neuron Disease'), (167, 188, 'CONDITION', 'motor neurone disease'), (809, 812, 'CONDITION', 'MND'), (1433, 1436, 'CONDITION', 'MND'), (1542, 1562, 'CONDITION', 'motor neuron disease'), (1921, 1924, 'CONDITION', 'MND')]"
"['Impact', 'of', 'Dexmedetomidine', 'Supplemented', 'Analgesia', 'on', 'Long', '-', 'term', 'Survival', 'in', 'Elderly', 'Patients', 'After', 'Cancer', 'Surgery', ':', 'a', 'Multicenter', 'Randomized', 'Controlled', 'Trial', '|', 'A', 'majority', 'of', 'the', 'elderly', 'patients', 'undergo', 'surgery', 'for', 'malignant', 'tumors', '.', 'For', 'these', 'patients', ',', 'postoperative', 'tumor', 'recurrence', 'and', 'metastasis', 'are', 'main', 'factors', 'that', 'worsen', 'long', '-', 'term', 'outcomes', '.', 'The', 'investigators', 'hypothesize', 'that', 'dexmedetomidine', 'supplemented', 'analgesia', 'in', 'elderly', 'patients', 'after', 'cancer', 'surgery', 'may', 'help', 'to', 'maintain', 'immune', 'function', 'and', 'improve', 'long', '-', 'term', 'outcomes', ',', 'possibly', 'by', 'relieving', 'stress', 'and', 'inflammatory', 'response', ',', 'improving', 'analgesic', 'efficacy', 'and', 'sleep', 'quality', ',', 'and', 'reducing', 'delirium', 'incidence', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03012971,NCT03012971,"Impact of Dexmedetomidine Supplemented Analgesia on Long-term Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial | A majority of the elderly patients undergo surgery for malignant tumors. For these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.","[(10, 25, 'DRUG', 'Dexmedetomidine'), (97, 111, 'CONDITION', 'Cancer Surgery'), (200, 228, 'CONDITION', 'surgery for malignant tumors'), (264, 280, 'CONDITION', 'tumor recurrence'), (285, 295, 'CONDITION', 'metastasis'), (380, 395, 'DRUG', 'dexmedetomidine'), (445, 459, 'CONDITION', 'cancer surgery'), (551, 557, 'CONDITION', 'stress'), (562, 583, 'CONDITION', 'inflammatory response'), (646, 654, 'CONDITION', 'delirium')]"
"['An', 'Open', '-', 'Label', ',', 'Multicenter', ',', 'Extension', 'Trial', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', 'and', 'Efficacy', 'of', 'Apitegromab', 'in', 'Patients', 'With', 'Type', '2', 'and', 'Type', '3', 'Spinal', 'Muscular', 'Atrophy', 'Who', 'Completed', 'Previous', 'Investigational', 'Trials', 'of', 'Apitegromab', '|', 'The', 'ONYX', 'study', 'is', 'an', 'Open', '-', 'Label', ',', 'Multicenter', ',', 'Extension', 'study', 'that', 'will', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'Apitegromab', 'in', 'Patients', 'with', 'Type', '2', 'and', 'Type', '3', 'SMA', 'who', 'have', 'completed', 'TOPAZ', 'or', 'SAPPHIRE', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05626855,NCT05626855,"An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab | The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.","[(93, 104, 'DRUG', 'Apitegromab'), (122, 163, 'CONDITION', 'Type 2 and Type 3 Spinal Muscular Atrophy'), (213, 224, 'DRUG', 'Apitegromab'), (345, 356, 'DRUG', 'Apitegromab'), (374, 395, 'CONDITION', 'Type 2 and Type 3 SMA')]"
"['A', 'Prospective', 'Study', 'on', 'Markers', 'of', 'Disease', 'Progression', 'and', 'Gait', 'Within', 'the', 'Parkinsonian', 'Population', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'evaluate', 'disease', 'progression', 'of', 'patients', 'with', 'Parkinsonian', 'syndrome', 'of', 'various', 'severity', 'through', 'regular', 'home', '-', 'based', 'gait', 'parameters', 'analysis', '.', '\n\n', 'We', 'identified', 'several', 'steps', 'in', 'this', 'project', ':', '\n\n', 'Acquisition', 'of', 'gait', 'data', 'in', '120', 'patients', 'with', 'Parkinsonism', 'at', 'different', 'stages', 'in', 'hospital', 'and', 'ecological', 'condition', '(', 'during', '10', 'days', 'at', 'home', ')', ',', 'in', 'a', 'repetitive', 'manner', ':', '\n\n', '30', 'Early', 'PD', 'patients', ',', 'before', '3', 'years', 'of', 'disease', 'duration', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'PD', 'patients', 'with', 'motor', 'fluctuations', '(', '5', 'to', '8', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'PD', 'patients', 'with', 'FoG', '(', '10', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\n', '30', 'patients', 'with', 'MSA', '(', 'less', 'than', '5', 'years', 'after', 'the', 'first', 'symptom', ')', '\n', 'Control', 'groups', 'will', 'be', 'composed', 'by', '30', 'healthy', 'volunteers', 'Correlation', 'analysis', 'with', 'clinical', 'measurements', 'and', 'biomarkers', ',', 'namely', 'blood', 'biomarkers', 'for', 'neurodegeneration', '(', '4HN', ',', 'NFLT', '…', ')', 'and', 'multimodal', 'MRI', 'repeated', 'assessments', '(', 'Iron', 'overload', ',', 'inflammation', 'and', 'degeneration', ')', 'and', 'genetic', 'panel', 'for', 'common', 'haplotypes', 'involved', 'in', 'Parkinsonism', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04653688,NCT04653688,"A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population | The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.

We identified several steps in this project:

Acquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:

30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)
30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)
30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)
30 patients with MSA (less than 5 years after the first symptom)
Control groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT …) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.","[(74, 86, 'CONDITION', 'Parkinsonian'), (175, 196, 'CONDITION', 'Parkinsonian syndrome'), (363, 375, 'CONDITION', 'Parkinsonism'), (487, 495, 'CONDITION', 'Early PD'), (565, 567, 'CONDITION', 'PD'), (660, 662, 'CONDITION', 'PD'), (1118, 1130, 'CONDITION', 'Parkinsonism')]"
"['Optimizing', 'Vibrational', 'Therapy', 'to', 'Improve', 'Gait', 'and', 'Balance', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'test', 'the', 'safety', ',', 'tolerability', ',', 'and', 'the', 'effect', 'of', 'vibration', '(', 'delivered', 'by', 'an', 'experimental', 'device', 'called', 'PDVibe2', ')', 'on', 'freezing', 'of', 'gait', '(', 'FOG', ')', 'in', 'persons', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'PDVibe2', 'was', 'developed', 'by', 'Resonate', 'Forward', ',', 'LLC', '(', 'RF', ')', '.', 'This', 'PDVibe2', 'was', 'designed', 'to', 'administer', 'vibration', 'therapy', 'to', 'the', 'wearer', 'to', 'improve', 'gait', 'and', 'balance', 'in', 'persons', 'with', 'PD', 'while', 'wearing', 'the', 'device', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT03883217,NCT03883217,"Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease | The purpose of this research study is to test the safety, tolerability, and the effect of vibration (delivered by an experimental device called PDVibe2) on freezing of gait (FOG) in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.","[(11, 30, 'OTHER', 'Vibrational Therapy'), (62, 81, 'CONDITION', ""Parkinson's Disease""), (174, 183, 'OTHER', 'vibration'), (228, 235, 'OTHER', 'PDVibe2'), (240, 256, 'CONDITION', 'freezing of gait'), (258, 261, 'CONDITION', 'FOG'), (279, 298, 'CONDITION', ""Parkinson's disease""), (300, 302, 'CONDITION', 'PD'), (309, 316, 'OTHER', 'PDVibe2'), (367, 374, 'OTHER', 'PDVibe2'), (402, 419, 'OTHER', 'vibration therapy'), (478, 480, 'CONDITION', 'PD')]"
"['A', 'Phase', 'IB', ',', 'Open', '-', 'Label', ',', 'Safety', 'Study', 'of', 'the', 'Combination', 'of', 'Sunitinib', 'and', 'Radiation', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Cancer', '|', 'This', 'study', 'is', 'using', 'the', 'combination', 'of', 'radiation', 'and', 'antiangiogenic', 'agents', '(', 'agents', 'that', 'destroy', 'existing', 'blood', 'vessels', ')', 'seems', 'to', 'be', 'an', 'approach', 'to', 'tumor', 'cure', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00437372,NCT00437372,"A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer | This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.","[(59, 68, 'DRUG', 'Sunitinib'), (73, 82, 'RADIOTHERAPY', 'Radiation'), (118, 124, 'CONDITION', 'Cancer'), (166, 175, 'RADIOTHERAPY', 'radiation'), (274, 279, 'CONDITION', 'tumor')]"
"['Tel', 'Aviv', 'Sourasky', 'Medical', 'Center', '|', 'Tourette', 'Syndrome', '(', 'TS', ')', 'is', 'a', 'disorder', 'characterized', 'by', 'motor', 'and', 'vocal', 'tics', '.', 'The', 'most', 'studied', 'and', 'promising', 'intervention', 'is', 'Habit', 'Reversal', 'Training', '(', 'HRT', ')', 'and', 'its', 'variations', ':', 'Behavioral', 'Comprehensive', 'Intervention', 'for', 'Tics', '(', 'CBIT', ')', '.', 'Group', 'intervention', 'for', 'children', 'with', 'TS', 'has', 'not', 'been', 'evaluated', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'CBIT', 'group', 'intervention', 'compared', 'with', 'Psycho', '-', 'Educational', '-', 'Supportive', 'group', 'in', 'terms', 'of', 'tic', 'severity', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02407951,NCT02407951,Tel Aviv Sourasky Medical Center | Tourette Syndrome (TS) is a disorder characterized by motor and vocal tics. The most studied and promising intervention is Habit Reversal Training (HRT) and its variations: Behavioral Comprehensive Intervention for Tics (CBIT). Group intervention for children with TS has not been evaluated. The aim of this study is to assess the efficacy of CBIT group intervention compared with Psycho-Educational-Supportive group in terms of tic severity.,"[(35, 52, 'CONDITION', 'Tourette Syndrome'), (54, 56, 'CONDITION', 'TS'), (89, 109, 'CONDITION', 'motor and vocal tics'), (158, 181, 'BEHAVIOURAL', 'Habit Reversal Training'), (183, 186, 'BEHAVIOURAL', 'HRT'), (208, 254, 'BEHAVIOURAL', 'Behavioral Comprehensive Intervention for Tics'), (256, 260, 'BEHAVIOURAL', 'CBIT'), (263, 281, 'BEHAVIOURAL', 'Group intervention'), (300, 302, 'CONDITION', 'TS'), (378, 401, 'BEHAVIOURAL', 'CBIT group intervention'), (416, 451, 'CONTROL', 'Psycho-Educational-Supportive group'), (464, 467, 'CONDITION', 'tic')]"
"['Effects', 'of', 'Repeated', 'Cannabis', 'Administration', 'on', 'Experimental', 'Pain', 'and', 'Abuse', 'Liability', 'in', 'Humans', '|', 'Chronic', 'pain', 'is', 'a', 'significant', 'public', 'health', 'concern', 'in', 'the', 'U.S.', ',', 'for', 'which', 'prescription', 'opioids', 'have', 'historically', 'been', 'the', 'standard', 'treatment', '.', 'This', 'has', 'resulted', 'in', 'striking', 'rates', 'of', 'opioid', 'use', 'disorders', 'and', 'fatal', 'overdoses', '.', 'Identifying', 'non', '-', 'opioid', 'medications', 'for', 'the', 'management', 'of', 'chronic', 'pain', 'with', 'minimal', 'abuse', 'liability', 'is', 'a', 'public', 'health', 'necessity', ',', 'and', 'cannabinoids', 'are', 'a', 'promising', 'drug', 'class', 'for', 'this', 'purpose', '.', 'More', 'than', '80', '%', 'of', 'medicinal', 'cannabis', 'users', 'report', 'pain', 'as', 'their', 'primary', 'medical', 'indication', '.', 'These', 'patients', 'tend', 'to', 'seek', 'products', 'that', 'are', 'low', 'in', 'delta-9', '-', 'tetrahydrocannabinol', '(', 'THC', ';', 'the', 'primary', 'psychoactive', ',', 'and', 'thus', 'intoxicating', ',', 'component', 'of', 'cannabis', ')', ',', 'and', 'high', 'in', 'cannabidiol', '(', 'CBD', ')', ',', 'a', 'cannabinoid', 'that', 'purportedly', 'has', 'therapeutic', 'benefit', 'for', 'pain', 'but', 'does', 'not', 'produce', 'intoxicating', 'effects', '[', '1', ']', '.', 'However', ',', 'there', 'are', 'few', 'well', '-', 'controlled', 'human', 'laboratory', 'studies', 'assessing', 'the', 'efficacy', 'of', 'high', '-', 'CBD', 'cannabis', 'for', 'pain', 'in', 'the', 'context', 'of', 'abuse', ',', 'and', 'even', 'less', 'is', 'known', 'regarding', 'the', 'effects', 'of', 'daily', 'repeated', 'use', 'of', 'cannabis', 'on', 'pain', 'and', 'its', 'relationship', 'to', 'abuse', 'liability', '.', '\n\n', 'The', 'proposed', 'randomized', ',', 'within', '-', 'subjects', ',', 'placebo', '-', 'controlled', '16', '-', 'day', 'crossover', 'inpatient', 'human', 'laboratory', 'pilot', 'study', '(', 'N', '=', '16', 'healthy', 'cannabis', 'users', ';', '8', 'men', ',', '8', 'women', ')', 'will', 'address', 'important', 'gaps', 'in', 'our', 'understanding', 'of', 'the', 'potential', 'therapeutic', 'utility', 'of', 'cannabis', 'for', 'pain', ':', '1', ')', 'If', 'repeated', 'cannabis', 'use', 'can', 'result', 'in', 'hyperalgesia', ';', '2', ')', 'If', 'tolerance', 'to', 'the', 'analgesic', 'and', 'abuse', '-', 'related', 'effects', 'of', 'cannabis', 'develops', 'and', 'is', 'reversible', '.', 'Two', 'distinct', 'modalities', 'of', 'experimental', 'pain', 'will', 'be', 'assessed', ':', 'The', 'Cold', 'Pressor', 'Test', '(', 'CPT', ')', 'and', 'Quantitative', 'Sensory', 'Testing', 'Thermal', 'Temporal', 'Summation', '(', 'QST', '-', 'TTS', ')', ',', 'and', 'participants', 'will', 'smoke', 'cannabis', '3x', '/', 'day', '.', 'Throughout', 'the', 'study', ',', 'experimental', 'pain', 'and', 'abuse', '-', 'related', 'effects', 'will', 'be', 'assessed', ',', 'as', 'will', 'sleep', 'and', 'subjective', 'mood', 'assessments', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04576507,NCT04576507,"Effects of Repeated Cannabis Administration on Experimental Pain and Abuse Liability in Humans | Chronic pain is a significant public health concern in the U.S., for which prescription opioids have historically been the standard treatment. This has resulted in striking rates of opioid use disorders and fatal overdoses. Identifying non-opioid medications for the management of chronic pain with minimal abuse liability is a public health necessity, and cannabinoids are a promising drug class for this purpose. More than 80% of medicinal cannabis users report pain as their primary medical indication. These patients tend to seek products that are low in delta-9-tetrahydrocannabinol (THC; the primary psychoactive, and thus intoxicating, component of cannabis), and high in cannabidiol (CBD), a cannabinoid that purportedly has therapeutic benefit for pain but does not produce intoxicating effects [1]. However, there are few well-controlled human laboratory studies assessing the efficacy of high-CBD cannabis for pain in the context of abuse, and even less is known regarding the effects of daily repeated use of cannabis on pain and its relationship to abuse liability.

The proposed randomized, within-subjects, placebo-controlled 16-day crossover inpatient human laboratory pilot study (N = 16 healthy cannabis users; 8 men, 8 women) will address important gaps in our understanding of the potential therapeutic utility of cannabis for pain: 1) If repeated cannabis use can result in hyperalgesia; 2) If tolerance to the analgesic and abuse-related effects of cannabis develops and is reversible. Two distinct modalities of experimental pain will be assessed: The Cold Pressor Test (CPT) and Quantitative Sensory Testing Thermal Temporal Summation (QST-TTS), and participants will smoke cannabis 3x/day. Throughout the study, experimental pain and abuse-related effects will be assessed, as will sleep and subjective mood assessments.","[(20, 28, 'OTHER', 'Cannabis'), (60, 64, 'CONDITION', 'Pain'), (97, 109, 'CONDITION', 'Chronic pain'), (378, 390, 'CONDITION', 'chronic pain'), (454, 466, 'DRUG', 'cannabinoids'), (529, 547, 'OTHER', 'medicinal cannabis'), (656, 684, 'DRUG', 'delta-9-tetrahydrocannabinol'), (686, 689, 'DRUG', 'THC'), (776, 787, 'DRUG', 'cannabidiol'), (789, 792, 'DRUG', 'CBD'), (797, 808, 'DRUG', 'cannabinoid'), (854, 858, 'CONDITION', 'pain'), (996, 1013, 'OTHER', 'high-CBD cannabis'), (1018, 1022, 'CONDITION', 'pain'), (1118, 1126, 'OTHER', 'cannabis'), (1130, 1134, 'CONDITION', 'pain'), (1219, 1226, 'CONTROL', 'placebo'), (1310, 1318, 'OTHER', 'cannabis'), (1431, 1439, 'OTHER', 'cannabis'), (1444, 1448, 'CONDITION', 'pain'), (1465, 1473, 'OTHER', 'cannabis'), (1568, 1576, 'OTHER', 'cannabis'), (1645, 1649, 'CONDITION', 'pain'), (1795, 1803, 'OTHER', 'cannabis'), (1847, 1851, 'CONDITION', 'pain')]"
"['MCLENA-1', ':', 'A', 'Phase', 'II', 'Clinical', 'Trial', 'for', 'the', 'Assessment', 'of', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'Lenalidomide', 'in', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'Due', 'to', 'Alzheimer', ""'s"", 'Disease', '|', 'Accumulating', 'evidence', 'indicates', 'that', 'inflammation', 'is', 'prominent', 'both', 'in', 'the', 'blood', 'and', 'central', 'nervous', 'system', '(', 'CNS', ')', 'of', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'patients', '.', 'These', 'data', 'suggest', 'that', 'systemic', 'inflammation', 'plays', 'a', 'crucial', 'role', 'in', 'the', 'cause', 'and', 'effects', 'of', 'AD', 'neuropathology', '.', 'Capitalizing', 'on', 'the', 'experience', 'from', 'a', 'previous', 'clinical', 'trial', 'with', 'thalidomide', ',', 'here', ',', 'the', 'investigators', 'hypothesize', 'that', 'modulating', 'both', 'systemic', 'and', 'CNS', 'inflammation', 'via', 'the', 'pleiotropic', 'immunomodulator', 'lenalidomide', 'is', 'a', 'putative', 'therapeutic', 'intervention', 'for', 'AD', 'if', 'administered', 'at', 'a', 'proper', 'time', 'window', 'during', 'the', 'course', 'of', 'the', 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04032626,NCT04032626,"MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.","[(96, 108, 'DRUG', 'Lenalidomide'), (126, 151, 'CONDITION', 'Mild Cognitive Impairment'), (159, 178, 'CONDITION', ""Alzheimer's Disease""), (298, 317, 'CONDITION', ""Alzheimer's disease""), (319, 321, 'CONDITION', 'AD'), (428, 430, 'CONDITION', 'AD'), (514, 525, 'DRUG', 'thalidomide'), (650, 662, 'DRUG', 'lenalidomide'), (706, 708, 'CONDITION', 'AD')]"
"['Collaborative', 'Care', 'for', 'Anxiety', 'and', 'Depression', 'in', 'Posttraumatic', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'evaluate', 'a', '6', 'month', 'change', 'in', 'quality', 'of', 'life', 'in', 'subjects', 'who', 'receive', 'collaborative', 'care', 'calls', 'compared', 'to', 'those', 'subjects', 'who', 'receive', 'usual', 'neurology', 'care', '.', 'This', 'is', 'a', '2', '-', 'site', 'trial', 'comparing', 'a', '24', 'week', 'neurology', '-', 'based', 'collaborative', 'care', 'program', 'to', 'usual', 'neurology', 'care', 'among', 'a', 'total', 'of', '60', 'adults', 'with', 'post', '-', 'traumatic', 'epilepsy', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05353452,NCT05353452,Collaborative Care for Anxiety and Depression in Posttraumatic Epilepsy | The purpose of this research is to evaluate a 6 month change in quality of life in subjects who receive collaborative care calls compared to those subjects who receive usual neurology care. This is a 2-site trial comparing a 24 week neurology-based collaborative care program to usual neurology care among a total of 60 adults with post-traumatic epilepsy.,"[(0, 18, 'OTHER', 'Collaborative Care'), (23, 30, 'CONDITION', 'Anxiety'), (35, 45, 'CONDITION', 'Depression'), (49, 71, 'CONDITION', 'Posttraumatic Epilepsy'), (178, 196, 'OTHER', 'collaborative care'), (242, 262, 'OTHER', 'usual neurology care'), (307, 341, 'OTHER', 'neurology-based collaborative care'), (353, 373, 'OTHER', 'usual neurology care'), (406, 429, 'CONDITION', 'post-traumatic epilepsy')]"
"['Intense', 'Physiotherapies', 'to', 'Improve', 'Function', 'in', 'Young', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'Cerebral', 'palsy', '(', 'CP', ')', 'is', 'a', 'non', '-', 'progressive', 'disorder', 'caused', 'by', 'an', 'insult', 'or', 'injury', 'to', 'the', 'brain', 'when', 'the', 'brain', 'is', 'most', 'rapidly', 'developing', 'and', 'which', 'results', 'in', 'some', 'motor', 'dysfunction', '.', 'Causes', 'for', 'the', 'injury', 'to', 'the', 'brain', 'are', 'numerous', 'and', 'can', 'occur', 'prior', 'to', 'birth', ',', 'during', 'the', 'birth', 'process', ',', 'or', 'within', 'the', 'first', 'few', 'months', 'following', 'birth', '.', 'The', 'motor', 'dysfunction', 'can', 'involve', 'any', 'or', 'all', 'four', 'extremities', 'but', 'most', 'often', 'affects', 'the', 'legs', ',', 'causing', 'abnormal', 'ambulation', '.', 'The', 'level', 'of', 'severity', 'depends', 'on', 'the', 'extent', 'of', 'the', 'injury', 'to', 'the', 'brain', 'and', 'can', 'be', 'mild', 'to', 'severe', '.', 'In', 'severe', 'instances', ',', 'the', 'child', 'is', 'dependent', 'on', 'others', 'for', 'all', 'his', '/', 'her', 'care', '.', '\n\n', 'There', 'is', 'no', 'known', 'cure', 'for', 'CP', ',', 'but', 'physical', 'and', 'occupational', 'therapies', 'are', 'administered', 'in', 'an', 'attempt', 'to', 'improve', 'function', '.', 'The', 'frequency', 'of', 'these', 'therapies', 'varies', 'from', 'once', 'a', 'week', '(', 'the', 'standard', 'of', 'care', 'in', 'the', 'Western', 'Hemisphere', ')', 'to', 'five', 'times', 'a', 'week', '(', 'the', 'standard', 'of', 'care', 'in', 'Asia', 'and', 'some', 'Eastern', 'European', 'countries', ')', '.', 'The', 'current', 'understanding', 'of', 'brain', 'plasticity', 'offers', 'a', 'theoretical', 'explanation', 'to', 'justify', 'the', 'more', 'intense', 'approach', '.', 'Active', 'repetitive', 'motor', 'skill', '-', 'directed', 'rehabilitation', 'utilizes', 'the', 'plasticity', 'of', 'the', 'brain', 'and', 'can', 'restore', 'some', 'function', '.', 'Intense', 'active', 'physiotherapy', 'can', 'stimulate', 'non', '-', 'injured', 'but', ""'"", 'dormant', ""'"", 'neurons', 'and', 'prevent', 'their', ""'"", 'natural', ""'"", 'degeneration', 'in', 'order', 'for', 'them', 'to', 'substitute', 'for', 'the', 'function', 'of', 'injured', 'neurons', '.', 'It', 'is', 'the', 'very', 'young', 'brain', 'that', 'is', 'most', 'likely', 'to', 'respond', 'to', 'this', 'therapy', '.', '\n\n', 'The', 'aim', 'of', 'this', 'proposal', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'administering', 'both', 'physical', 'and', 'occupational', 'therapy', 'five', 'times', 'each', 'week', 'for', '12', 'weeks', 'and', 'compare', 'it', 'with', 'the', 'standard', 'of', 'care', '(', 'SOC', ')', 'approach', 'of', 'one', 'time', 'each', 'week', 'in', 'children', 'between', 'the', 'ages', 'of', '12', 'months', 'and', '36', 'months', '.', 'This', 'is', 'the', 'first', 'randomized', 'crossover', 'trial', 'to', 'both', 'enroll', 'this', 'young', 'a', 'population', 'of', 'children', 'with', 'cerebral', 'palsy', 'as', 'well', 'as', 'to', 'evaluate', 'this', 'approach', 'from', 'both', 'the', 'therapists', 'and', 'the', 'parents', 'perspectives', '.', 'The', 'number', 'of', 'children', 'that', 'this', 'study', 'will', 'enroll', 'is', 'larger', 'than', 'in', 'most', 'CP', 'studies', '.', 'The', 'children', 'will', 'be', 'evaluated', 'clinically', 'with', 'two', 'validated', 'instruments', ',', 'one', 'of', 'which', 'was', 'designed', 'specifically', 'for', 'children', 'with', 'CP', 'and', 'is', 'administered', 'and', 'scored', 'by', 'certified', 'therapists', 'and', 'the', 'other', 'which', 'was', 'designed', 'for', 'children', 'with', 'developmental', 'disabilities', 'and', 'is', 'scored', 'by', 'the', 'child', ""'s"", 'care', 'provider', '.', 'A', 'sub', '-', 'set', 'of', 'children', 'will', 'have', 'a', 'special', 'type', 'of', 'MRI', 'to', 'evaluate', 'any', 'changes', 'in', 'the', 'neurological', 'structure', 'of', 'the', 'brain', '.', '\n\n', 'The', 'Department', 'of', 'Pediatrics', 'at', 'the', 'University', 'of', 'Arizona', 'recently', 'completed', 'a', 'collaborative', 'study', 'with', 'the', 'Neurologic', 'Department', 'at', 'the', 'Beijing', 'Children', ""'s"", 'Hospital', 'where', 'the', 'intense', 'approach', 'of', 'five', 'therapies', 'per', 'week', 'is', 'the', 'SOC', '.', 'The', 'positive', 'results', 'prompted', 'another', 'investigation', 'to', 'determine', 'if', 'such', 'an', 'approach', 'would', 'be', 'feasible', 'in', 'the', 'United', 'States', '.', 'A', 'compliance', 'rate', 'of', '81', '%', 'confirmed', 'feasibility', 'and', 'the', 'perception', 'that', 'parents', 'who', 'have', 'a', 'child', 'diagnosed', 'with', 'CP', 'will', 'do', 'whatever', 'they', 'can', 'to', 'improve', 'their', 'child', ""'s"", 'motor', 'function', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02167022,NCT02167022,"Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy | Cerebral palsy (CP) is a non-progressive disorder caused by an insult or injury to the brain when the brain is most rapidly developing and which results in some motor dysfunction. Causes for the injury to the brain are numerous and can occur prior to birth, during the birth process, or within the first few months following birth. The motor dysfunction can involve any or all four extremities but most often affects the legs, causing abnormal ambulation. The level of severity depends on the extent of the injury to the brain and can be mild to severe. In severe instances, the child is dependent on others for all his/her care.

There is no known cure for CP, but physical and occupational therapies are administered in an attempt to improve function. The frequency of these therapies varies from once a week (the standard of care in the Western Hemisphere) to five times a week (the standard of care in Asia and some Eastern European countries). The current understanding of brain plasticity offers a theoretical explanation to justify the more intense approach. Active repetitive motor skill-directed rehabilitation utilizes the plasticity of the brain and can restore some function. Intense active physiotherapy can stimulate non-injured but 'dormant' neurons and prevent their 'natural' degeneration in order for them to substitute for the function of injured neurons. It is the very young brain that is most likely to respond to this therapy.

The aim of this proposal is to evaluate the effect of administering both physical and occupational therapy five times each week for 12 weeks and compare it with the standard of care (SOC) approach of one time each week in children between the ages of 12 months and 36 months. This is the first randomized crossover trial to both enroll this young a population of children with cerebral palsy as well as to evaluate this approach from both the therapists and the parents perspectives. The number of children that this study will enroll is larger than in most CP studies. The children will be evaluated clinically with two validated instruments, one of which was designed specifically for children with CP and is administered and scored by certified therapists and the other which was designed for children with developmental disabilities and is scored by the child's care provider. A sub-set of children will have a special type of MRI to evaluate any changes in the neurological structure of the brain.

The Department of Pediatrics at the University of Arizona recently completed a collaborative study with the Neurologic Department at the Beijing Children's Hospital where the intense approach of five therapies per week is the SOC. The positive results prompted another investigation to determine if such an approach would be feasible in the United States. A compliance rate of 81% confirmed feasibility and the perception that parents who have a child diagnosed with CP will do whatever they can to improve their child's motor function.","[(0, 23, 'PHYSICAL', 'Intense Physiotherapies'), (67, 81, 'CONDITION', 'Cerebral Palsy'), (84, 98, 'CONDITION', 'Cerebral palsy'), (100, 102, 'CONDITION', 'CP'), (245, 262, 'CONDITION', 'motor dysfunction'), (420, 437, 'CONDITION', 'motor dysfunction'), (742, 744, 'CONDITION', 'CP'), (750, 785, 'PHYSICAL', 'physical and occupational therapies'), (1150, 1203, 'PHYSICAL', 'Active repetitive motor skill-directed rehabilitation'), (1272, 1300, 'PHYSICAL', 'Intense active physiotherapy'), (1608, 1641, 'PHYSICAL', 'physical and occupational therapy'), (1700, 1716, 'CONTROL', 'standard of care'), (1718, 1721, 'CONTROL', 'SOC'), (1912, 1926, 'CONDITION', 'cerebral palsy'), (2093, 2095, 'CONDITION', 'CP'), (2236, 2238, 'CONDITION', 'CP'), (2765, 2768, 'CONTROL', 'SOC'), (3006, 3008, 'CONDITION', 'CP')]"
"['A', '12', '-', 'month', 'Open', '-', 'label', 'Extension', 'Study', 'Evaluating', 'The', 'Safety', 'And', 'Tolerability', 'Of', 'Flexible', 'Doses', 'Of', 'Pregabalin', 'In', 'Pediatric', 'Patients', 'With', 'Partial', 'Onset', 'Seizures', '|', 'The', 'study', 'will', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'pregabalin', 'in', 'pediatric', 'patients', ',', 'age', '1', 'month', 'through', '16', 'years', ',', 'with', 'partial', 'onset', 'seizures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00448916,NCT00448916,"A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures | The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.","[(98, 108, 'DRUG', 'Pregabalin'), (136, 158, 'CONDITION', 'Partial Onset Seizures'), (226, 236, 'DRUG', 'pregabalin'), (295, 317, 'CONDITION', 'partial onset seizures')]"
"['Effect', 'of', 'Unimodal', '(', 'EEG', ')', 'and', 'Bimodal', '(', 'EEG', '-', 'fMRI', ')', 'Neurofeedback', 'on', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'Interventional', 'study', 'with', 'minimal', 'risks', 'and', 'constraints', ',', 'prospective', ',', 'monocentric', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03766113,NCT03766113,"Effect of Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback on Upper Limb Recovery After Stroke | Interventional study with minimal risks and constraints, prospective, monocentric.","[(10, 61, 'OTHER', 'Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback'), (85, 97, 'CONDITION', 'After Stroke')]"
"['Deciphering', 'the', 'Hormonal', 'and', 'Nociceptive', 'Mechanisms', 'Underlying', 'Bladder', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'some', 'women', 'with', 'dysmenorrhea', '(', 'painful', 'periods', ')', 'are', 'at', 'higher', 'future', 'risk', 'of', 'developing', 'chronic', 'pelvic', 'pain', '(', 'CPP', ')', 'and', 'if', 'oral', 'contraceptives', '(', 'OC', ')', 'can', 'be', 'used', 'to', 'reverse', 'this', 'chronic', 'pain', 'risk', '.', '\n\n', 'Investigators', 'will', 'examine', 'whether', 'dysmenorrhea', 'produces', 'CPP', 'via', 'repetitive', 'cross', 'organ', 'sensitization', '(', 'COS', ')', 'episodes', '.', 'The', 'use', 'of', 'cyclical', 'OCs', 'to', 'eliminate', 'dysmenorrhea', 'is', 'expected', 'to', 'reduce', 'COS', 'and', 'decrease', 'the', 'risk', 'of', 'developing', 'CPP', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02214550,NCT02214550,"Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain | The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk.

Investigators will examine whether dysmenorrhea produces CPP via repetitive cross organ sensitization (COS) episodes. The use of cyclical OCs to eliminate dysmenorrhea is expected to reduce COS and decrease the risk of developing CPP.","[(63, 75, 'CONDITION', 'Bladder Pain'), (139, 151, 'CONDITION', 'dysmenorrhea'), (210, 229, 'CONDITION', 'chronic pelvic pain'), (231, 234, 'CONDITION', 'CPP'), (243, 262, 'DRUG', 'oral contraceptives'), (264, 266, 'DRUG', 'OC'), (296, 308, 'CONDITION', 'chronic pain'), (351, 363, 'CONDITION', 'dysmenorrhea'), (373, 376, 'CONDITION', 'CPP'), (445, 457, 'DRUG', 'cyclical OCs'), (471, 483, 'CONDITION', 'dysmenorrhea'), (506, 509, 'CONDITION', 'COS'), (546, 549, 'CONDITION', 'CPP')]"
"['Open', '-', 'label', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Sodium', 'Oxybate', '(', 'Xyrem', '®', ')', 'in', 'the', 'Treatment', 'of', 'Two', 'Under', '-', 'recognized', 'Clinical', 'Conditions', ':', 'Post', '-', 'traumatic', 'Narcolepsy', 'and', 'Post', '-', 'traumatic', 'Hypersomnia', '|', 'The', 'study', 'evaluates', 'whether', 'the', 'use', 'of', 'Sodium', 'Oxybate', '(', 'Xyrem', '®', ')', 'in', 'TBI', 'patients', 'will', 'be', 'effective', 'in', 'reducing', 'symptoms', 'of', 'post', 'traumatic', 'narcolepsy', 'and', 'post', 'traumatic', 'hypersomnia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03626727,NCT03626727,Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia | The study evaluates whether the use of Sodium Oxybate (Xyrem®) in TBI patients will be effective in reducing symptoms of post traumatic narcolepsy and post traumatic hypersomnia.,"[(54, 68, 'DRUG', 'Sodium Oxybate'), (70, 75, 'DRUG', 'Xyrem'), (140, 165, 'CONDITION', 'Post-traumatic Narcolepsy'), (170, 196, 'CONDITION', 'Post-traumatic Hypersomnia'), (238, 252, 'DRUG', 'Sodium Oxybate'), (254, 259, 'DRUG', 'Xyrem'), (265, 268, 'CONDITION', 'TBI'), (325, 345, 'CONDITION', 'traumatic narcolepsy'), (350, 376, 'CONDITION', 'post traumatic hypersomnia')]"
"['Analysis', 'of', 'Cutaneous', 'Nerve', 'Biopsies', 'in', 'Gastrointestinal', 'Motility', 'Disorders', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'evaluate', 'cutaneous', 'nerve', 'biopsies', 'from', 'patients', 'with', 'refractory', 'gastrointestinal', 'motility', 'disorders', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'skin', 'biopsies', 'for', 'signs', 'of', 'small', 'fiber', 'neuropathy', 'in', 'GI', 'dysmotility', 'patients', ',', 'which', 'may', 'provide', 'a', 'better', 'understanding', 'of', 'the', 'underlying', 'pathology', 'of', 'their', 'condition', '.', 'Specifically', ',', 'identifying', 'any', 'small', 'fiber', 'neuropathy', 'that', 'may', 'exist', 'in', 'the', 'peripheral', 'nervous', 'system', 'may', 'help', 'us', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'presumed', 'enteric', 'neuropathy', 'that', 'may', 'be', 'involved', 'in', 'causing', 'GI', 'dysmotility', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04872452,NCT04872452,"Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders | This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders. The purpose of the study is to evaluate skin biopsies for signs of small fiber neuropathy in GI dysmotility patients, which may provide a better understanding of the underlying pathology of their condition. Specifically, identifying any small fiber neuropathy that may exist in the peripheral nervous system may help us to better understand the mechanism of presumed enteric neuropathy that may be involved in causing GI dysmotility.","[(40, 75, 'CONDITION', 'Gastrointestinal Motility Disorders'), (159, 205, 'CONDITION', 'refractory gastrointestinal motility disorders'), (274, 296, 'CONDITION', 'small fiber neuropathy'), (300, 314, 'CONDITION', 'GI dysmotility'), (444, 466, 'CONDITION', 'small fiber neuropathy'), (574, 592, 'CONDITION', 'enteric neuropathy'), (625, 639, 'CONDITION', 'GI dysmotility')]"
"['Pilot', 'Study', 'on', 'Feasibility', 'and', 'Safety', 'of', 'a', 'Gait', 'Auto', '-', 'rehabilitation', 'Program', 'by', 'Rhythmic', 'Auditory', 'Cueing', 'Delivered', 'by', 'BeatHealth', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'Physical', 'activity', 'has', 'demonstrated', 'its', 'beneficial', 'effect', 'on', 'functional', 'capabilities', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'PD', '.', 'However', ',', 'the', 'daily', 'physical', 'activity', 'remains', 'limited', 'in', 'these', 'patients', '.', 'Rhythmic', 'auditory', 'cueing', 'improves', 'spatio', '-', 'temporal', 'gait', 'parameters', 'in', 'patients', 'with', 'PD', '.', 'The', 'first', 'results', 'of', 'BeatHealth', 'studies', 'have', 'allowed', 'us', 'to', 'identify', 'the', 'best', 'musical', 'stimulation', 'to', 'improve', 'these', 'parameters', 'and', 'the', 'motivation', 'of', 'the', 'patients', '.', '\n\n', 'The', 'originality', 'of', 'this', 'study', 'is', 'to', 'propose', 'a', 'gait', 'auto', '-', 'rehabilitation', 'program', 'using', 'BeatHealth', 'device', 'with', 'optimal', 'auditory', 'cueing', 'during', 'four', 'weeks', 'in', 'ecological', 'conditions', 'in', 'PD', '.', '\n\n', 'Observance', '(', 'utilization', ""'s"", 'time', ')', ',', 'safety', '(', 'falls', ',', 'pain', ',', 'fatigability', ')', 'and', 'efficacy', '(', 'gait', 'parameters', ',', 'balance', ',', 'quality', 'of', 'life', ')', 'will', 'be', 'evaluated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02647242,NCT02647242,"Pilot Study on Feasibility and Safety of a Gait Auto-rehabilitation Program by Rhythmic Auditory Cueing Delivered by BeatHealth in Patients With Parkinson's Disease. | Physical activity has demonstrated its beneficial effect on functional capabilities and quality of life in patients with PD. However, the daily physical activity remains limited in these patients. Rhythmic auditory cueing improves spatio-temporal gait parameters in patients with PD. The first results of BeatHealth studies have allowed us to identify the best musical stimulation to improve these parameters and the motivation of the patients.

The originality of this study is to propose a gait auto-rehabilitation program using BeatHealth device with optimal auditory cueing during four weeks in ecological conditions in PD.

Observance (utilization's time), safety (falls, pain, fatigability) and efficacy (gait parameters, balance, quality of life) will be evaluated.","[(43, 75, 'PHYSICAL', 'Gait Auto-rehabilitation Program'), (79, 103, 'OTHER', 'Rhythmic Auditory Cueing'), (117, 127, 'OTHER', 'BeatHealth'), (145, 164, 'CONDITION', ""Parkinson's Disease""), (289, 291, 'CONDITION', 'PD'), (365, 389, 'OTHER', 'Rhythmic auditory cueing'), (448, 450, 'CONDITION', 'PD'), (473, 483, 'OTHER', 'BeatHealth'), (660, 692, 'PHYSICAL', 'gait auto-rehabilitation program'), (699, 709, 'OTHER', 'BeatHealth'), (792, 794, 'CONDITION', 'PD')]"
"['Roles', 'of', 'Almonds', 'in', 'Physical', 'Performance', '|', 'Investigators', 'specific', 'aims', 'are', 'to', 'compare', 'the', 'effects', 'of', 'consuming', 'daily', 'snacks', 'of', 'raw', ',', 'shelled', ',', 'unsalted', 'almonds', '(', '2.0', 'ounces', ')', 'versus', 'an', 'isocaloric', 'amount', 'of', 'another', 'commonly', 'consumed', 'snack', 'food', '(', 'pretzels', ')', 'on', 'energy', '(', 'vigor', ')', 'perception', 'and', 'physical', 'activity', ',', 'exercise', 'performance', '(', 'VO2max', 'and', 'measures', 'of', 'strength', ')', ',', 'strength', 'and', 'power', 'performance', 'as', 'well', 'as', 'muscle', 'soreness', 'recovery', 'after', 'strenuous', 'eccentrically', '-', 'biased', 'exercise', '.']","['O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04787718,NCT04787718,"Roles of Almonds in Physical Performance | Investigators specific aims are to compare the effects of consuming daily snacks of raw, shelled, unsalted almonds (2.0 ounces) versus an isocaloric amount of another commonly consumed snack food (pretzels) on energy (vigor) perception and physical activity, exercise performance (VO2max and measures of strength), strength and power performance as well as muscle soreness recovery after strenuous eccentrically-biased exercise.","[(9, 16, 'OTHER', 'Almonds'), (127, 157, 'OTHER', 'raw, shelled, unsalted almonds'), (240, 248, 'CONTROL', 'pretzels')]"
"['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Multiple', 'Dose', '-', 'ascending', ',', 'Placebo', '-', 'controlled', 'Study', 'in', 'Healthy', 'Volunteers', 'and', 'Parkinson', ""'s"", 'Disease', 'Patients', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'PK', 'of', 'Daily', 'Oral', 'Administration', 'of', 'Cogane', '™', 'Over', 'One', 'Month', '|', 'Phytopharm', 'plc', 'is', 'developing', 'Cogane', '™', 'which', 'is', 'a', 'new', 'medicine', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'find', 'out', 'if', 'Cogane', 'is', 'safe', 'and', 'well', 'tolerated', 'in', 'both', 'healthy', 'volunteers', 'and', 'Parkinson', ""'s"", 'disease', 'patients', 'and', 'to', 'determine', 'if', 'there', 'is', 'a', 'difference', 'in', 'the', 'way', 'that', 'the', 'body', 'deals', 'with', 'Cogane', '(', 'pharmacokinetics', ')', 'between', 'these', 'two', 'groups', '.', '\n\n', 'It', 'is', 'expected', 'that', 'the', 'study', 'will', 'prove', 'that', 'Cogane', '™', 'is', 'safe', 'and', 'well', 'tolerated', 'and', 'will', 'provide', 'us', 'with', 'a', 'pharmacokinetic', 'profile', 'for', 'both', 'subject', 'groups', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00875316,NCT00875316,"A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month | Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.

It is expected that the study will prove that Cogane™ is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.","[(53, 60, 'CONTROL', 'Placebo'), (104, 123, 'CONDITION', ""Parkinson's Disease""), (207, 213, 'DRUG', 'Cogane'), (261, 267, 'DRUG', 'Cogane'), (314, 333, 'CONDITION', ""Parkinson's disease""), (335, 337, 'CONDITION', 'PD'), (383, 389, 'DRUG', 'Cogane'), (448, 467, 'CONDITION', ""Parkinson's disease""), (555, 561, 'DRUG', 'Cogane'), (654, 660, 'DRUG', 'Cogane')]"
"['Brain', 'Network', 'Plasticity', 'in', 'Aphasic', 'Patients', 'Associated', 'With', 'Combined', 'Speech', 'Therapy', 'and', 'Transcranial', 'Direct', 'Current', 'Stimulation', '|', 'The', 'efficacy', 'of', 'conventional', 'speech', 'therapy', 'alone', 'for', 'aphasia', 'recovery', 'is', 'inconclusive', '.', 'The', 'prospective', 'study', 'will', 'monitor', 'the', 'effects', 'of', 'combined', 'language', 'therapy', 'and', 'tDCS', 'through', 'structural', 'and', 'functional', 'MRI', '.']","['O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05483556,NCT05483556,Brain Network Plasticity in Aphasic Patients Associated With Combined Speech Therapy and Transcranial Direct Current Stimulation | The efficacy of conventional speech therapy alone for aphasia recovery is inconclusive. The prospective study will monitor the effects of combined language therapy and tDCS through structural and functional MRI.,"[(28, 35, 'CONDITION', 'Aphasic'), (61, 84, 'OTHER', 'Combined Speech Therapy'), (89, 128, 'OTHER', 'Transcranial Direct Current Stimulation'), (147, 174, 'OTHER', 'conventional speech therapy'), (185, 192, 'CONDITION', 'aphasia'), (269, 294, 'OTHER', 'combined language therapy'), (299, 303, 'OTHER', 'tDCS')]"
"['Hybrid', '-', 'FES', 'Exercise', 'to', 'Prevent', 'Cardiovascular', 'Declines', 'in', 'Acute', 'SCI', '|', 'Each', 'year', ',', '11,000', 'people', 'suffer', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'in', 'the', 'U.S.', 'Within', 'the', 'first', 'year', ',', 'there', 'are', 'profound', 'declines', 'in', 'physiologic', 'function', ',', 'forming', 'the', 'underlying', 'substrate', 'for', 'future', 'cardiovascular', 'disease', '.', 'In', 'fact', ',', 'acquired', 'cardiovascular', 'disease', 'is', 'an', 'increasingly', 'recognized', 'consequence', 'of', 'SCI', 'and', 'is', 'the', 'leading', 'cause', 'of', 'death', 'in', 'SCI', '.', 'Though', 'incompletely', 'understood', ',', 'the', 'almost', '10', '-', 'fold', 'prevalence', 'of', 'cardiovascular', 'disease', 'results', 'in', 'part', 'from', 'profound', 'physiologic', ""'"", 'detraining', ""'"", 'resulting', 'from', 'motor', 'impairment', 'and', 'immobility', '.', 'Currently', ',', 'effective', 'interventions', 'preventing', 'acute', 'declines', 'that', 'lead', 'to', 'cardiovascular', 'compromise', 'and', 'increased', 'risk', 'in', 'SCI', 'are', 'lacking', '-', 'exercise', 'therapy', 'for', 'those', 'with', 'SCI', 'is', 'challenging', 'and', 'when', 'employed', ',', 'is', 'typically', 'limited', 'to', 'the', 'upper', 'body', '.', 'Recently', ',', 'the', 'investigators', 'refined', 'a', 'unique', 'form', 'of', 'exercise', 'for', 'those', 'with', 'SCI', 'that', 'specifically', 'mirrors', 'exercise', 'performed', 'by', 'those', 'without', 'SCI', '.', 'Functional', 'Electrical', 'Stimulation', '(', 'FES', ')', 'Row', 'Training', '(', 'RT', ')', 'couples', 'volitional', 'arm', 'and', 'electrically', 'controlled', 'leg', 'exercise', ',', 'resulting', 'in', 'a', 'hemodynamic', 'profile', 'that', 'produces', 'the', 'beneficial', 'cardiac', 'loading', 'conditions', 'of', 'large', 'muscle', 'mass', 'exercise', '.', 'As', 'such', ',', 'FES', '-', 'RT', 'may', 'be', 'a', 'safe', 'and', 'effective', 'way', 'to', 'attenuate', 'cardiovascular', 'declines', 'following', 'SCI', '.', 'The', 'investigators', 'aims', 'are', 'to', 'test', 'the', 'overall', 'hypotheses', 'that', 'FES', '-', 'RT', 'will', ':', '1', ')', 'mitigate', 'against', 'increased', 'visceral', 'adiposity', 'and', 'reduced', 'insulin', 'sensitivity', ',', '2', ')', 'prevent', 'worsening', 'lipid', 'profile', 'and', 'compromised', 'baroreflex', 'function', ',', 'and', '3', ')', 'counter', 'ventricular', 'wall', 'thickening', 'and', 'declining', 'ventricular', 'function', 'occurring', 'with', 'acute', 'SCI', ',', 'and', 'that', 'these', 'effects', 'will', 'be', 'greater', 'than', 'that', 'observed', 'with', 'an', 'arms', '-', 'only', 'exercise', 'group', '.', 'Changes', 'with', 'FES', '-', 'RT', 'will', 'be', 'compared', 'to', 'a', 'time', '(', 'wait', '-', 'list', ')', 'control', 'and', 'to', 'arms', '-', 'only', '-', 'RT', '.', 'Individuals', 'with', 'an', 'SCI', 'within', 'the', 'last', '3', '-', '6', 'months', 'will', 'be', 'randomized', 'to', 'FES', '-', 'RT', ',', 'to', 'a', 'time', 'control', ',', 'or', 'arms', '-', 'only', '-', 'RT', '.', 'Measures', 'will', 'be', 'made', 'at', 'baseline', 'and', '6', 'months', '.', 'The', 'investigators', 'work', 'will', 'provide', 'results', 'that', 'clearly', 'delineate', 'potential', 'health', 'benefits', 'of', 'FES', '-', 'RT', ',', 'and', 'if', 'FES', '-', 'RT', 'is', 'effective', 'in', 'a', 'majority', 'of', 'those', 'with', 'SCI', ',', 'its', 'application', ',', 'implementation', ',', 'and', 'integration', 'could', 'be', 'easily', 'replicated', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02139436,NCT02139436,"Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI | Each year, 11,000 people suffer a spinal cord injury (SCI) in the U.S. Within the first year, there are profound declines in physiologic function, forming the underlying substrate for future cardiovascular disease . In fact, acquired cardiovascular disease is an increasingly recognized consequence of SCI and is the leading cause of death in SCI. Though incompletely understood, the almost 10-fold prevalence of cardiovascular disease results in part from profound physiologic 'detraining' resulting from motor impairment and immobility. Currently, effective interventions preventing acute declines that lead to cardiovascular compromise and increased risk in SCI are lacking - exercise therapy for those with SCI is challenging and when employed, is typically limited to the upper body. Recently, the investigators refined a unique form of exercise for those with SCI that specifically mirrors exercise performed by those without SCI. Functional Electrical Stimulation (FES) Row Training (RT) couples volitional arm and electrically controlled leg exercise, resulting in a hemodynamic profile that produces the beneficial cardiac loading conditions of large muscle mass exercise. As such, FES-RT may be a safe and effective way to attenuate cardiovascular declines following SCI. The investigators aims are to test the overall hypotheses that FES-RT will: 1) mitigate against increased visceral adiposity and reduced insulin sensitivity, 2) prevent worsening lipid profile and compromised baroreflex function, and 3) counter ventricular wall thickening and declining ventricular function occurring with acute SCI, and that these effects will be greater than that observed with an arms-only exercise group. Changes with FES-RT will be compared to a time (wait-list) control and to arms-only-RT. Individuals with an SCI within the last 3-6 months will be randomized to FES-RT, to a time control, or arms-only-RT. Measures will be made at baseline and 6 months. The investigators work will provide results that clearly delineate potential health benefits of FES-RT, and if FES-RT is effective in a majority of those with SCI, its application, implementation, and integration could be easily replicated.","[(0, 19, 'PHYSICAL', 'Hybrid-FES Exercise'), (31, 54, 'CONDITION', 'Cardiovascular Declines'), (58, 67, 'CONDITION', 'Acute SCI'), (104, 122, 'CONDITION', 'spinal cord injury'), (124, 127, 'CONDITION', 'SCI'), (183, 215, 'CONDITION', 'declines in physiologic function'), (261, 283, 'CONDITION', 'cardiovascular disease'), (304, 326, 'CONDITION', 'cardiovascular disease'), (372, 375, 'CONDITION', 'SCI'), (413, 416, 'CONDITION', 'SCI'), (483, 505, 'CONDITION', 'cardiovascular disease'), (731, 734, 'CONDITION', 'SCI'), (781, 784, 'CONDITION', 'SCI'), (936, 939, 'CONDITION', 'SCI'), (1002, 1005, 'CONDITION', 'SCI'), (1007, 1064, 'PHYSICAL', 'Functional Electrical Stimulation (FES) Row Training (RT)'), (1261, 1267, 'PHYSICAL', 'FES-RT'), (1313, 1336, 'CONDITION', 'cardiovascular declines'), (1347, 1350, 'CONDITION', 'SCI'), (1415, 1421, 'PHYSICAL', 'FES-RT'), (1675, 1684, 'CONDITION', 'acute SCI'), (1752, 1770, 'CONTROL', 'arms-only exercise'), (1791, 1797, 'PHYSICAL', 'FES-RT'), (1820, 1844, 'CONTROL', 'time (wait-list) control'), (1852, 1864, 'CONTROL', 'arms-only-RT'), (1886, 1889, 'CONDITION', 'SCI'), (1939, 1945, 'PHYSICAL', 'FES-RT'), (1952, 1964, 'CONTROL', 'time control'), (1969, 1981, 'CONTROL', 'arms-only-RT'), (2127, 2133, 'PHYSICAL', 'FES-RT'), (2142, 2148, 'PHYSICAL', 'FES-RT'), (2190, 2193, 'CONDITION', 'SCI')]"
"['Effects', 'of', 'Enriched', 'Gardens', 'on', 'Cognition', 'and', 'Independence', 'of', 'Nursing', 'Home', 'Residents', 'With', 'Dementia', ':', 'a', 'Cluster', '-', 'controlled', 'Trial', '|', 'Comparing', 'the', 'effect', 'of', 'the', 'frequentation', 'of', 'an', 'enriched', 'garden', 'vs', 'sensory', 'conventional', 'garden', 'by', 'nursing', 'home', 'residents', 'with', 'Alzheimer', 'disease', '.', 'The', 'effects', 'will', 'be', 'evaluated', 'as', 'regards', 'to', 'cognitive', 'impairment', '(', 'MMSE', ')', ',', 'autonomy', '(', 'ADL', ')', 'and', 'prevention', 'of', 'falls', '(', 'Unipodal', 'stance', 'and', 'UpandGo', 'Test', ')']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04903171,NCT04903171,"Effects of Enriched Gardens on Cognition and Independence of Nursing Home Residents With Dementia: a Cluster-controlled Trial | Comparing the effect of the frequentation of an enriched garden vs sensory conventional garden by nursing home residents with Alzheimer disease. The effects will be evaluated as regards to cognitive impairment (MMSE), autonomy (ADL) and prevention of falls (Unipodal stance and UpandGo Test)","[(11, 27, 'OTHER', 'Enriched Gardens'), (89, 97, 'CONDITION', 'Dementia'), (176, 191, 'OTHER', 'enriched garden'), (195, 222, 'CONTROL', 'sensory conventional garden'), (254, 271, 'CONDITION', 'Alzheimer disease')]"
"['Paliperidone', 'Extended', 'Release', 'Tablets', 'for', 'the', 'Prevention', 'of', 'Relapse', 'in', 'Subjects', 'With', 'Schizophrenia', ':', 'A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'tolerability', 'and', 'safety', 'of', 'paliperidone', 'extended', 'release', '(', 'ER', ')', 'tablets', '(', 'between', '3', 'to', '12', 'milligram', '(', 'mg', ')', ',', 'once', 'a', 'day', ')', 'in', 'the', 'prevention', 'of', 'relapse', 'in', 'schizophrenia', 'participants', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01662310,NCT01662310,"Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study | The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.","[(0, 12, 'DRUG', 'Paliperidone'), (85, 98, 'CONDITION', 'Schizophrenia'), (128, 135, 'CONTROL', 'Placebo'), (253, 265, 'DRUG', 'paliperidone'), (373, 386, 'CONDITION', 'schizophrenia')]"
"['Protection', 'Against', 'Emboli', 'During', 'Carotid', 'Artery', 'Stenting', 'Using', 'a', '3', '-', 'in-1', 'Delivery', 'System', 'Comprised', 'of', 'a', 'Post', '-', 'dilation', 'Balloon', ',', 'Integrated', 'Embolic', 'Filter', 'and', 'a', 'Novel', 'Carotid', 'Stent', 'II', '|', 'A', 'prospective', ',', 'multicenter', 'single', '-', 'arm', ',', 'open', 'label', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'effectiveness', 'of', 'the', 'Neuroguard', 'IEP', 'System', 'for', 'the', 'treatment', 'of', 'carotid', 'artery', 'stenosis', 'in', 'subjects', 'at', 'elevated', 'risk', 'for', 'adverse', 'events', 'following', 'carotid', 'endarterectomy', '(', 'CEA', ')', '.', 'The', 'Neuroguard', 'IEP', 'System', 'is', 'a', '3', '-', 'in-1', 'carotid', 'stent', 'delivery', 'system', 'consisting', 'of', 'an', 'angioplasty', 'balloon', ',', 'an', 'integrated', 'embolic', 'protection', 'device', 'and', 'a', 'nitinol', 'self', '-', 'expanding', 'stent', 'loaded', 'over', 'the', 'balloon', 'and', 'constrained', 'by', 'an', 'outer', 'sheath', '.', 'Eligible', 'patients', 'between', '20', 'and', '80', 'years', 'of', 'age', 'have', 'been', 'diagnosed', 'with', 'either', 'de', '-', 'novo', 'atherosclerotic', 'or', 'post', 'CEA', 'restenotic', 'lesion(s', ')', 'in', 'the', 'internal', 'carotid', 'arteries', '(', 'ICA', ')', 'or', 'at', 'the', 'carotid', 'bifurcation', 'with', '≥50', '%', 'stenosis', 'if', 'symptomatic', 'or', '≥80', '%', 'stenosis', 'if', 'asymptomatic', '(', 'both', 'defined', 'by', 'angiography', 'using', 'NASCET', 'methodology', ')', '.', 'Symptomatic', 'patients', 'are', 'defined', 'as', 'having', 'stroke', 'or', 'TIA', 'ipsilateral', 'to', 'the', 'carotid', 'lesion', 'within', '180', 'days', 'of', 'the', 'procedure', 'within', 'the', 'hemisphere', 'supplied', 'by', 'the', 'target', 'vessel', '.', 'Enrolled', 'subjects', 'will', 'be', 'followed', 'at', '30', 'days', ',', '6', 'months', ',', '12', 'months', ',', '24', 'months', 'and', '36', 'months', '.']","['O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04201132,NCT04201132,"Protection Against Emboli During Carotid Artery Stenting Using a 3-in-1 Delivery System Comprised of a Post-dilation Balloon, Integrated Embolic Filter and a Novel Carotid Stent II | A prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis in subjects at elevated risk for adverse events following carotid endarterectomy (CEA). The Neuroguard IEP System is a 3-in-1 carotid stent delivery system consisting of an angioplasty balloon, an integrated embolic protection device and a nitinol self-expanding stent loaded over the balloon and constrained by an outer sheath. Eligible patients between 20 and 80 years of age have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid arteries (ICA) or at the carotid bifurcation with ≥50% stenosis if symptomatic or ≥80% stenosis if asymptomatic (both defined by angiography using NASCET methodology). Symptomatic patients are defined as having stroke or TIA ipsilateral to the carotid lesion within 180 days of the procedure within the hemisphere supplied by the target vessel. Enrolled subjects will be followed at 30 days, 6 months, 12 months, 24 months and 36 months.","[(19, 25, 'CONDITION', 'Emboli'), (33, 56, 'CONDITION', 'Carotid Artery Stenting'), (103, 124, 'SURGICAL', 'Post-dilation Balloon'), (126, 151, 'SURGICAL', 'Integrated Embolic Filter'), (158, 180, 'SURGICAL', 'Novel Carotid Stent II'), (287, 308, 'SURGICAL', 'Neuroguard IEP System'), (330, 353, 'CONDITION', 'carotid artery stenosis'), (412, 434, 'CONDITION', 'carotid endarterectomy'), (436, 439, 'CONDITION', 'CEA'), (446, 467, 'SURGICAL', 'Neuroguard IEP System'), (772, 820, 'CONDITION', 'atherosclerotic or post CEA restenotic lesion(s)'), (1056, 1062, 'CONDITION', 'stroke'), (1066, 1069, 'CONDITION', 'TIA'), (1089, 1103, 'CONDITION', 'carotid lesion')]"
"['Prospective', 'Data', 'Collect', 'Study', 'for', 'Development', 'of', 'Neurimelanin', 'Image', 'Analysis', 'System', '|', 'In', 'order', 'to', 'develop', 'an', 'image', 'analysis', 'system', 'that', 'automatically', 'detects', 'and', 'quantifies', 'neuromelanin', ',', 'this', 'study', 'aims', 'to', 'construct', 'a', 'database', 'of', 'a', 'wide', 'sample', 'by', 'collecting', 'brain', 'MRI', 'neuromelanin', 'images', 'prospectively', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05513794,NCT05513794,"Prospective Data Collect Study for Development of Neurimelanin Image Analysis System | In order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain MRI neuromelanin images prospectively.",[]
"['Exploit', 'the', 'Neural', 'Source', 'and', 'the', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', ""'s"", 'Disease', 'and', 'Multiple', 'System', 'Atrophy', '|', 'In', 'this', 'project', ',', 'the', 'investigators', 'will', 'deliver', 'a', '5', '-', 'day', 'session', 'of', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'to', 'the', 'leg', 'motor', 'cortex', 'of', 'the', 'FOG', 'patients', 'to', 'examine', 'whether', 'the', 'intervention', 'will', 'benefit', 'the', 'patients', 'in', 'a', 'double', 'blind', 'randomized', 'design', '.', 'Six', 'assessments', 'with', 'different', 'combinations', 'of', 'clinical', 'scaling', ',', 'gait', 'analysis', ',', 'electrophysiological', 'investigation', 'and', 'fMRI', 'examinations', 'before', 'and', 'after', 'tDCS', 'will', 'be', 'conducted', '.', 'The', 'treatment', 'and', 'placebo', 'groups', 'will', 'be', 'crossed', 'over', 'after', 'one', '-', 'month', 'washout', '.', 'The', 'investigators', 'will', 'investigate', 'whether', 'the', 'possible', 'tDCS', 'beneficial', 'effect', 'will', 'be', 'different', 'or', 'similar', 'in', 'patients', 'with', 'different', 'electric', 'sources', '.', 'In', 'addition', ',', 'how', 'long', 'the', 'possible', 'beneficial', 'effect', 'of', 'tDCS', 'can', 'be', 'consolidated', 'after', 'the', '5', '-', 'day', 'course', 'of', 'stimulation', 'is', 'also', 'crucial', '.', 'The', 'investigators', 'aim', 'to', 'peep', 'the', 'myth', 'of', 'FOG', 'in', 'PD', 'and', 'MSA', 'by', 'the', 'multi', '-', 'modality', 'approach', 'and', 'hope', 'the', 'study', 'will', 'benefit', 'the', 'long', 'suffering', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03721887,NCT03721887,"Exploit the Neural Source and the Feasibility of Transcranial Direct Current Stimulation for Freezing of Gait in Parkinson's Disease and Multiple System Atrophy | In this project, the investigators will deliver a 5-day session of transcranial direct current stimulation (tDCS) to the leg motor cortex of the FOG patients to examine whether the intervention will benefit the patients in a double blind randomized design. Six assessments with different combinations of clinical scaling, gait analysis, electrophysiological investigation and fMRI examinations before and after tDCS will be conducted. The treatment and placebo groups will be crossed over after one-month washout. The investigators will investigate whether the possible tDCS beneficial effect will be different or similar in patients with different electric sources. In addition, how long the possible beneficial effect of tDCS can be consolidated after the 5-day course of stimulation is also crucial. The investigators aim to peep the myth of FOG in PD and MSA by the multi-modality approach and hope the study will benefit the long suffering patients.","[(49, 88, 'OTHER', 'Transcranial Direct Current Stimulation'), (93, 109, 'CONDITION', 'Freezing of Gait'), (113, 132, 'CONDITION', ""Parkinson's Disease""), (137, 160, 'CONDITION', 'Multiple System Atrophy'), (230, 269, 'OTHER', 'transcranial direct current stimulation'), (271, 275, 'OTHER', 'tDCS'), (308, 311, 'CONDITION', 'FOG'), (574, 578, 'OTHER', 'tDCS'), (616, 623, 'CONTROL', 'placebo'), (733, 737, 'OTHER', 'tDCS'), (886, 890, 'OTHER', 'tDCS'), (1008, 1011, 'CONDITION', 'FOG'), (1015, 1017, 'CONDITION', 'PD'), (1022, 1025, 'CONDITION', 'MSA'), (1033, 1056, 'OTHER', 'multi-modality approach')]"
"['Effect', 'of', 'Oral', 'Motor', 'Exercises', 'and', 'Breathing', 'Exercises', 'for', 'Dysphagia', 'in', 'Parkinson', 'Disease', ':', 'Randomized', 'Clinical', 'Trial', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'a', 'chronic', ',', 'degenerative', 'disease', 'described', 'by', 'motors', 'and', 'non', '-', 'motors', 'symptoms', '.', 'Changes', 'in', 'swallowing', 'and', 'respiratory', 'dynamics', 'increase', 'risk', 'of', 'tracheal', 'aspiration', 'largely', 'responsible', 'for', 'increased', 'morbidity', 'and', 'mortality', 'in', 'this', 'population', '.', 'Thus', ',', 'interdisciplinary', 'rehabilitation', 'strategies', 'can', 'reduce', 'the', 'complications', 'of', 'dysphagia', ',', 'with', 'consequent', 'improvement', 'of', 'the', 'prognosis', 'of', 'individuals', 'with', 'PD', '.', 'Objective', ':', 'To', 'determine', 'the', 'impact', 'of', 'combined', 'oral', 'motor', 'exercises', 'and', 'breathing', 'exercises', 'on', 'swallowing', 'disorders', 'in', 'individuals', 'with', 'PD', '.', 'Method', ':', 'Clinical', 'trial', ',', 'randomized', 'and', 'blinded', 'for', 'the', 'examinator', '.', 'For', 'all', 'subjects', 'will', 'be', 'given', 'the', 'stage', 'of', 'PD', 'and', 'applied', 'quality', 'of', 'life', 'questionnaire', '.', 'The', 'swallowing', 'complaints', 'will', 'be', 'investigated', 'through', 'structured', 'questionnaire', 'and', 'functional', 'aspects', 'of', 'swallowing', 'with', 'videofluoroscopy', '.', 'The', 'Manovacuometry', 'Spirometry', 'will', 'determine', 'measures', 'of', 'respiratory', 'function', '.', 'The', 'assessment', 'of', 'vocal', 'and', 'speech', 'disorders', 'will', 'be', 'done', 'with', 'perceptive', ',', 'acoustic', ',', 'aerodynamic', 'and', 'electroglottographic', 'measures', 'as', 'well', 'as', 'analysis', 'of', 'intelligibility', '.', 'Three', 'groups', 'of', 'intervention', 'will', 'be', 'defined', ':', 'one', 'of', 'them', 'doing', 'oral', 'motor', 'exercises', 'for', 'swallowing', ',', 'one', 'doing', 'breathing', 'exercises', 'and', 'another', 'must', 'do', 'this', 'two', 'interventions', 'combined', '.', 'Effect', 'of', 'intervention', 'will', 'be', 'assessed', 'through', 'measures', 'of', 'swallowing', ',', 'breathing', ',', 'voice', 'and', 'speech', '.', 'The', 'groups', 'will', 'be', 'compared', ',', 'according', 'to', 'the', 'principle', 'of', '""', 'intention', 'to', 'treat', '""', 'by', 'appropriate', 'statistical', 'tests', ',', 'according', 'to', 'the', 'distribution', 'of', 'the', 'dependent', 'variables', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01420796,NCT01420796,"Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial | Parkinson's disease (PD) is a chronic, degenerative disease described by motors and non-motors symptoms. Changes in swallowing and respiratory dynamics increase risk of tracheal aspiration largely responsible for increased morbidity and mortality in this population. Thus, interdisciplinary rehabilitation strategies can reduce the complications of dysphagia, with consequent improvement of the prognosis of individuals with PD. Objective: To determine the impact of combined oral motor exercises and breathing exercises on swallowing disorders in individuals with PD. Method: Clinical trial, randomized and blinded for the examinator. For all subjects will be given the stage of PD and applied quality of life questionnaire. The swallowing complaints will be investigated through structured questionnaire and functional aspects of swallowing with videofluoroscopy. The Manovacuometry Spirometry will determine measures of respiratory function. The assessment of vocal and speech disorders will be done with perceptive, acoustic, aerodynamic and electroglottographic measures as well as analysis of intelligibility. Three groups of intervention will be defined: one of them doing oral motor exercises for swallowing, one doing breathing exercises and another must do this two interventions combined. Effect of intervention will be assessed through measures of swallowing, breathing, voice and speech. The groups will be compared, according to the principle of ""intention to treat"" by appropriate statistical tests, according to the distribution of the dependent variables.","[(10, 30, 'PHYSICAL', 'Oral Motor Exercises'), (35, 54, 'PHYSICAL', 'Breathing Exercises'), (59, 68, 'CONDITION', 'Dysphagia'), (72, 89, 'CONDITION', 'Parkinson Disease'), (119, 138, 'CONDITION', ""Parkinson's disease""), (140, 142, 'CONDITION', 'PD'), (392, 435, 'OTHER', 'interdisciplinary rehabilitation strategies'), (468, 477, 'CONDITION', 'dysphagia'), (544, 546, 'CONDITION', 'PD'), (595, 615, 'PHYSICAL', 'oral motor exercises'), (620, 639, 'PHYSICAL', 'breathing exercises'), (643, 663, 'CONDITION', 'swallowing disorders'), (684, 686, 'CONDITION', 'PD'), (799, 801, 'CONDITION', 'PD'), (849, 870, 'CONDITION', 'swallowing complaints'), (1082, 1108, 'CONDITION', 'vocal and speech disorders'), (1299, 1319, 'PHYSICAL', 'oral motor exercises'), (1346, 1365, 'PHYSICAL', 'breathing exercises')]"
"['A', 'Phase', '1', 'First', 'in', 'Human', 'Open', '-', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Pharmacokinetics', 'of', 'Single', 'Ascending', 'Doses', 'of', 'CVT-427', '(', 'Zolmitriptan', 'Inhalation', 'Powder', ')', 'In', 'Healthy', 'Adults', '|', 'This', 'study', 'is', 'the', 'first', 'study', 'in', 'humans', 'with', 'CVT-427', '(', 'zolmitriptan', 'inhalation', 'powder', ')', 'and', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'and', 'PK', 'of', 'single', 'ascending', 'doses', 'of', 'CVT-427', 'in', 'adult', 'healthy', 'volunteers', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT02609945,NCT02609945,"A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults | This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.","[(106, 113, 'DRUG', 'CVT-427'), (115, 127, 'DRUG', 'Zolmitriptan'), (212, 219, 'DRUG', 'CVT-427'), (221, 233, 'DRUG', 'zolmitriptan'), (343, 350, 'DRUG', 'CVT-427')]"
"['Clinical', 'Trial', 'for', 'the', 'Evaluation', 'of', 'the', 'Accuracy', 'of', 'Augmented', 'Reality', 'Based', 'Neuronavigation', 'System', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'test', 'augmented', 'reality', '(', 'AR', ')', 'based', 'neuronavigation', 'system', 'in', 'surgeries', 'for', 'patients', 'of', 'brain', 'neoplasm', 'or', 'cerebral', 'vascular', 'disease', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', '•', 'AR', 'based', 'neuronavigation', 'system', 'can', 'achieve', 'accuracy', 'that', 'is', 'not', 'inferior', 'to', 'conventional', 'intraoperative', 'navigation', 'system', '.', '\n\n', 'Participants', 'will', 'participate', 'the', 'study', 'after', 'informed', 'consent', '.', 'When', 'participants', 'undergo', 'surgery', 'for', 'their', 'brain', 'tumor', ',', 'we', 'will', 'set', 'up', '2', 'types', 'of', 'neuronavigation', ',', 'conventional', 'navigation', 'system', 'and', 'developed', 'AR', 'based', 'neuronavigation', 'system', '.', 'Surgeon', 'will', 'plan', 'and', 'conduct', 'surgery', 'based', 'on', 'only', 'conventional', 'navigation', 'system', ',', 'but', '3D', 'errors', 'at', 'several', 'selected', 'points', 'between', 'two', 'types', 'of', 'navigation', 'will', 'be', 'measured', 'and', 'analyzed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05776706,NCT05776706,"Clinical Trial for the Evaluation of the Accuracy of Augmented Reality Based Neuronavigation System | The goal of this clinical trial is to test augmented reality (AR) based neuronavigation system in surgeries for patients of brain neoplasm or cerebral vascular disease. The main questions it aims to answer are:

• AR based neuronavigation system can achieve accuracy that is not inferior to conventional intraoperative navigation system.

Participants will participate the study after informed consent. When participants undergo surgery for their brain tumor, we will set up 2 types of neuronavigation, conventional navigation system and developed AR based neuronavigation system. Surgeon will plan and conduct surgery based on only conventional navigation system, but 3D errors at several selected points between two types of navigation will be measured and analyzed.","[(53, 99, 'OTHER', 'Augmented Reality Based Neuronavigation System'), (145, 196, 'OTHER', 'augmented reality (AR) based neuronavigation system'), (226, 240, 'CONDITION', 'brain neoplasm'), (244, 269, 'CONDITION', 'cerebral vascular disease'), (316, 347, 'OTHER', 'AR based neuronavigation system'), (393, 438, 'CONTROL', 'conventional intraoperative navigation system'), (549, 560, 'CONDITION', 'brain tumor'), (605, 635, 'CONTROL', 'conventional navigation system'), (650, 681, 'OTHER', 'AR based neuronavigation system'), (735, 765, 'CONTROL', 'conventional navigation system')]"
"['Can', 'Dance', 'Therapy', 'Improve', 'Motor', 'Learning', 'in', 'Parkinson', ""'s"", 'Disease', '?', '|', 'In', 'order', 'to', 'find', 'the', 'most', 'effective', 'rehabilitative', 'therapies', 'for', 'Parkinsonian', 'patients', ',', 'the', 'present', 'study', 'is', 'aimed', 'to', 'evaluate', 'whether', ',', 'in', 'a', 'multidisciplinary', 'intensive', 'rehabilitation', 'treatment', ',', 'the', 'dance', 'therapy', ',', 'applied', 'to', 'the', 'motor', 'learning', ',', 'promote', 'additional', 'benefits', '.']","['O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03549793,NCT03549793,"Can Dance Therapy Improve Motor Learning in Parkinson's Disease? | In order to find the most effective rehabilitative therapies for Parkinsonian patients, the present study is aimed to evaluate whether, in a multidisciplinary intensive rehabilitation treatment, the dance therapy, applied to the motor learning, promote additional benefits.","[(4, 17, 'PHYSICAL', 'Dance Therapy'), (44, 63, 'CONDITION', ""Parkinson's Disease""), (132, 144, 'CONDITION', 'Parkinsonian'), (266, 279, 'PHYSICAL', 'dance therapy')]"
"['Theta', '-', 'Burst', '-', 'Stimulation', 'in', 'Der', 'frühen', 'Rehabilitation', 'Von', 'Schlaganfallpatienten', '|', 'The', 'present', 'prospective', ',', 'randomized', ',', 'controlled', ',', 'double', '-', 'blinded', 'trial', 'investigates', 'the', 'effects', 'of', 'intermittent', 'theta', '-', 'burst', 'stimulation', '(', 'iTBS', ')', 'during', 'the', 'early', 'rehabilitation', 'after', 'stroke', '.', 'Patients', 'with', 'hemipresis', 'will', 'receive', 'either', 'sham', 'or', 'real', 'iTBS', 'over', 'their', 'affected', 'hemispheres', 'before', 'occupational', 'therapy', 'for', '8', 'days', '.', 'Motor', 'recovery', 'is', 'assessed', 'one', 'day', 'after', 'the', 'intervention', 'phase', 'and', 'three', 'months', 'after', 'enrollment', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02910024,NCT02910024,"Theta-Burst-Stimulation in Der frühen Rehabilitation Von Schlaganfallpatienten | The present prospective, randomized, controlled, double-blinded trial investigates the effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after stroke. Patients with hemipresis will receive either sham or real iTBS over their affected hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after the intervention phase and three months after enrollment.","[(0, 23, 'OTHER', 'Theta-Burst-Stimulation'), (179, 215, 'OTHER', 'intermittent theta-burst stimulation'), (217, 221, 'OTHER', 'iTBS'), (261, 267, 'CONDITION', 'stroke'), (283, 293, 'CONDITION', 'hemipresis'), (314, 318, 'CONTROL', 'sham'), (327, 331, 'OTHER', 'iTBS'), (371, 391, 'OTHER', 'occupational therapy')]"
"['The', 'Effectiveness', 'of', 'Different', 'Pressure', 'of', 'Extracorporeal', 'Shock', 'Wave', 'Therapy', 'for', 'Management', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Peripheral', 'nerve', 'entrapment', 'neuropathies', 'are', 'the', 'most', 'common', 'mononeuropathies', 'in', 'clinical', 'practice', '.', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', ',', 'n.', 'It', 'occurs', 'as', 'a', 'result', 'of', 'compression', 'of', 'the', 'medianus', 'as', 'it', 'passes', 'through', 'the', 'carpal', 'tunnel', ',', 'a', 'narrow', 'osteofibrous', 'canal', '.', 'CTS', 'is', 'the', 'most', 'common', 'entrapment', 'neuropathy', 'of', 'the', 'upper', 'extremity', ',', 'affecting', 'approximately', '3', '%', 'of', 'the', 'general', 'adult', 'population', '.', '\n\n', 'This', 'study', ',', 'which', 'was', 'designed', 'as', 'a', 'randomized', 'controlled', 'study', ',', 'will', 'include', '36', 'patients', 'with', 'CTS', ',', 'aged', 'between', '18', '-', '65', ',', 'who', 'applied', 'to', 'Kırşehir', 'Ahi', 'Evran', 'University', 'Training', 'and', 'Research', 'Hospital', '.', 'In', 'our', 'study', ',', 'both', 'groups', 'will', 'be', 'given', '10', 'minutes', 'of', 'paraffin', ',', '20', 'minutes', 'of', 'TENS', ',', 'and', '10', 'repetitions', 'of', 'tendon', 'gliding', 'exercise', ',', '3', 'days', 'a', 'week', 'for', 'a', 'total', 'of', '3', 'weeks', '(', '9', 'sessions', ')', '.', 'EESDT', 'will', 'be', 'applied', 'once', 'a', 'week', 'in', 'both', 'groups', '(', 'one', 'group', 'at', '4', 'bar', 'and', 'the', 'other', 'at', '1.5', 'bar', 'pressure', ')', '.', 'Measurements', 'will', 'be', 'made', 'before', 'treatment', ',', 'after', 'treatment', ',', 'and', 'at', '12', 'weeks', 'post', '-', 'treatment', '.', '\n\n', 'In', 'the', 'literature', ',', 'different', 'pressure', 'parameters', 'were', 'used', 'in', 'studies', 'examining', 'the', 'efficacy', 'of', 'ESDT', 'in', 'the', 'treatment', 'of', 'CTS', '.', 'Although', 'ESDT', 'has', 'been', 'shown', 'to', 'have', 'a', 'curative', 'effect', 'on', 'CTS', ',', 'there', 'is', 'no', 'consensus', 'on', 'which', 'pressure', 'parameter', 'is', 'more', 'effective', '.', 'Therefore', ',', 'in', 'this', 'study', ',', 'the', 'effectiveness', 'of', 'ESDT', 'applied', 'at', 'different', 'pressure', 'parameters', 'in', 'the', 'treatment', 'of', 'CTS', 'will', 'be', 'examined', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT05681663,NCT05681663,"The Effectiveness of Different Pressure of Extracorporeal Shock Wave Therapy for Management of Carpal Tunnel Syndrome: a Randomized Controlled Trial | Peripheral nerve entrapment neuropathies are the most common mononeuropathies in clinical practice. Carpal Tunnel Syndrome (CTS), n. It occurs as a result of compression of the medianus as it passes through the carpal tunnel, a narrow osteofibrous canal. CTS is the most common entrapment neuropathy of the upper extremity, affecting approximately 3% of the general adult population.

This study, which was designed as a randomized controlled study, will include 36 patients with CTS, aged between 18-65, who applied to Kırşehir Ahi Evran University Training and Research Hospital. In our study, both groups will be given 10 minutes of paraffin, 20 minutes of TENS, and 10 repetitions of tendon gliding exercise, 3 days a week for a total of 3 weeks (9 sessions). EESDT will be applied once a week in both groups (one group at 4 bar and the other at 1.5 bar pressure). Measurements will be made before treatment, after treatment, and at 12 weeks post-treatment.

In the literature, different pressure parameters were used in studies examining the efficacy of ESDT in the treatment of CTS. Although ESDT has been shown to have a curative effect on CTS, there is no consensus on which pressure parameter is more effective. Therefore, in this study, the effectiveness of ESDT applied at different pressure parameters in the treatment of CTS will be examined.","[(43, 76, 'OTHER', 'Extracorporeal Shock Wave Therapy'), (95, 117, 'CONDITION', 'Carpal Tunnel Syndrome'), (251, 273, 'CONDITION', 'Carpal Tunnel Syndrome'), (275, 278, 'CONDITION', 'CTS'), (406, 409, 'CONDITION', 'CTS'), (631, 634, 'CONDITION', 'CTS'), (787, 795, 'OTHER', 'paraffin'), (811, 815, 'OTHER', 'TENS'), (839, 862, 'PHYSICAL', 'tendon gliding exercise'), (915, 920, 'OTHER', 'EESDT'), (1210, 1214, 'OTHER', 'ESDT'), (1235, 1238, 'CONDITION', 'CTS'), (1249, 1253, 'OTHER', 'ESDT'), (1298, 1301, 'CONDITION', 'CTS'), (1419, 1423, 'OTHER', 'ESDT'), (1485, 1488, 'CONDITION', 'CTS')]"
"['A', 'Prospective', ',', 'Randomized', ',', 'Single', 'Blind', ',', 'Parallel', '-', 'group', ',', 'Placebo', 'Controlled', 'Clinical', 'Study', 'to', 'Evaluate', 'the', 'Short', '-', 'term', 'Effectiveness', 'of', 'Combined', 'Occipital', 'and', 'Supraorbital', 'Transcutaneous', 'Nerve', 'Stimulation', '(', 'OS', '-', 'TNS', ')', 'in', 'Reducing', 'Migraine', 'Related', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'short', '-', 'term', 'effectiveness', 'of', 'combined', 'occipital', 'and', 'supraorbital', 'transcutaneous', 'nerve', 'stimulation', 'in', 'reducing', 'migraine', 'related', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",NCT02438553,NCT02438553,"A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain | The purpose of this study is to evaluate the short-term effectiveness of combined occipital and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.","[(57, 64, 'CONTROL', 'Placebo'), (135, 203, 'OTHER', 'Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation'), (205, 211, 'OTHER', 'OS-TNS'), (225, 233, 'CONDITION', 'Migraine'), (242, 246, 'CONDITION', 'Pain'), (322, 390, 'OTHER', 'combined occipital and supraorbital transcutaneous nerve stimulation'), (403, 411, 'CONDITION', 'migraine'), (420, 424, 'CONDITION', 'pain')]"
"['Motor', 'Imagery', 'and', 'Real', '-', 'time', 'Feedback', 'in', 'Stroke', 'Rehabilitation', '|', 'This', 'research', 'project', 'will', 'investigate', 'motor', 'imagery', 'training', 'in', 'stroke', 'rehabilitation', 'during', 'which', 'patients', 'receive', 'feedback', 'in', 'real', 'time', 'from', 'their', 'brain', 'activity', 'measured', 'with', 'ElectroEncephaloGraphy', '(', 'EEG', ')', '.', 'The', 'investigators', 'hypothesize', 'that', 'the', 'feedback', 'training', 'allows', 'to', 'internally', 'stimulate', 'brain', 'motor', 'networks', 'in', 'order', 'to', 'promote', 'functional', 'recovery', 'of', 'the', 'hand', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04847089,NCT04847089,Motor Imagery and Real-time Feedback in Stroke Rehabilitation | This research project will investigate motor imagery training in stroke rehabilitation during which patients receive feedback in real time from their brain activity measured with ElectroEncephaloGraphy (EEG). The investigators hypothesize that the feedback training allows to internally stimulate brain motor networks in order to promote functional recovery of the hand.,"[(0, 13, 'OTHER', 'Motor Imagery'), (18, 36, 'OTHER', 'Real-time Feedback'), (40, 46, 'CONDITION', 'Stroke'), (103, 125, 'OTHER', 'motor imagery training'), (129, 135, 'CONDITION', 'stroke'), (181, 202, 'OTHER', 'feedback in real time'), (312, 329, 'OTHER', 'feedback training')]"
"['Acute', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'of', 'Different', 'Frequencies', 'on', 'Balance', 'and', 'Functional', 'Mobility', 'of', 'Patients', 'With', 'Parkinson', ':', 'Crossover', '-', 'type', 'Controlled', 'Clinical', 'Trial', '|', 'Parkinson', ""'s"", 'disease', 'has', 'innumerous', 'motor', 'symptoms', 'that', 'impacting', 'on', 'the', 'functional', 'level', 'of', 'the', 'patient', ',', 'such', 'as', 'impairment', 'in', 'functional', 'mobility', 'and', 'balance', '.', 'Previous', 'studies', 'have', 'already', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'whole', 'body', 'vibration', ',', 'but', 'without', 'methodological', 'criteria', '.', 'The', 'use', 'of', 'whole', 'body', 'vibration', 'may', 'be', 'an', 'alternative', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'disease', '.', 'Therefore', ',', 'the', 'objective', 'of', 'the', 'study', 'is', 'to', 'verify', 'which', 'frequency', 'of', 'vibration', 'is', 'able', 'to', 'improve', 'the', 'balance', 'and', 'mobility', 'of', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04507490,NCT04507490,"Acute Effect of Whole Body Vibration of Different Frequencies on Balance and Functional Mobility of Patients With Parkinson: Crossover-type Controlled Clinical Trial | Parkinson's disease has innumerous motor symptoms that impacting on the functional level of the patient, such as impairment in functional mobility and balance . Previous studies have already aimed to evaluate the effectiveness of whole body vibration, but without methodological criteria. The use of whole body vibration may be an alternative for the treatment of Parkinson's disease. Therefore, the objective of the study is to verify which frequency of vibration is able to improve the balance and mobility of patients with Parkinson's disease.","[(16, 36, 'OTHER', 'Whole Body Vibration'), (114, 123, 'CONDITION', 'Parkinson'), (168, 187, 'CONDITION', ""Parkinson's disease""), (398, 418, 'OTHER', 'whole body vibration'), (468, 488, 'OTHER', 'whole body vibration'), (532, 551, 'CONDITION', ""Parkinson's disease""), (694, 713, 'CONDITION', ""Parkinson's disease"")]"
"['Optimization', 'of', '""', 'Powerful', 'Tools', 'for', 'Caregivers', '""', 'of', 'Dementia', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'if', 'a', 'psycho', '-', 'educational', 'intervention', 'for', 'caregivers', 'of', 'patients', 'with', 'dementia', 'will', 'decrease', 'caregiver', 'burden', ',', 'increase', 'caregiver', 'physical', 'activity', ',', 'and', 'decrease', 'the', 'reporting', 'of', 'behavioral', 'and', 'psychological', 'symptoms', 'of', 'the', 'person', 'with', 'dementia', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02697721,NCT02697721,"Optimization of ""Powerful Tools for Caregivers"" of Dementia Patients | The purpose of this study is to examine if a psycho-educational intervention for caregivers of patients with dementia will decrease caregiver burden, increase caregiver physical activity, and decrease the reporting of behavioral and psychological symptoms of the person with dementia.","[(17, 46, 'BEHAVIOURAL', 'Powerful Tools for Caregivers'), (51, 59, 'CONDITION', 'Dementia'), (116, 162, 'BEHAVIOURAL', 'psycho-educational intervention for caregivers'), (180, 188, 'CONDITION', 'dementia'), (346, 354, 'CONDITION', 'dementia')]"
"['A', 'Randomized', 'Placebo', '-', 'controlled', 'Trial', 'of', 'Glutamine', 'to', 'Reduce', 'the', 'Signs', 'and', 'Symptoms', 'of', 'Peripheral', 'Neuropathy', 'in', 'Breast', 'Cancer', 'Patients', 'With', 'a', 'Mild', 'Peripheral', 'Neuropathy', 'Receiving', 'Paclitaxel', 'Chemotherapy', '|', 'Patients', 'with', 'breast', 'cancer', 'receiving', 'paclitaxel', 'chemotherapy', 'who', 'have', 'mild', 'symptoms', 'of', 'peripheral', 'neuropathy', 'will', 'receive', 'glutamine', 'or', 'placebo', 'to', 'try', 'and', 'improve', 'symptoms', '.']","['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00195013,NCT00195013,A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy | Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.,"[(13, 20, 'CONTROL', 'Placebo'), (41, 50, 'DRUG', 'Glutamine'), (87, 108, 'CONDITION', 'Peripheral Neuropathy'), (112, 125, 'CONDITION', 'Breast Cancer'), (142, 168, 'CONDITION', 'Mild Peripheral Neuropathy'), (179, 189, 'DRUG', 'Paclitaxel'), (219, 232, 'CONDITION', 'breast cancer'), (243, 253, 'DRUG', 'paclitaxel'), (293, 314, 'CONDITION', 'peripheral neuropathy'), (328, 337, 'DRUG', 'glutamine'), (341, 348, 'CONTROL', 'placebo')]"
"['An', 'Open', '-', 'Label', 'Extension', 'Study', 'With', 'REQUIP', '(', 'Ropinirole', ')', 'CR', 'for', 'Subjects', 'From', 'Studies', '101468/165', ',', '101468/168', 'and', '101468/169', '|', 'To', 'evaluate', 'the', 'safety', 'profile', 'of', 'ropinirole', 'XL', 'during', 'long', '-', 'term', 'treatment', 'in', 'subjects', 'with', 'early', 'and', 'advanced', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT00632736,NCT00632736,"An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 | To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease","[(35, 41, 'DRUG', 'REQUIP'), (43, 53, 'DRUG', 'Ropinirole'), (158, 168, 'DRUG', 'ropinirole'), (216, 254, 'CONDITION', ""early and advanced Parkinson's disease"")]"
"['Different', 'Efficacy', 'Between', 'Rehabilitation', 'Therapy', 'and', 'Umbilical', 'Cord', 'Derived', 'Mesenchymal', 'Stem', 'Cells', 'Transplantation', 'in', 'Patients', 'With', 'Chronic', 'Spinal', 'Cord', 'Injury', 'in', 'China', '|', 'The', 'morbidity', 'of', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'is', 'increasing', 'year', 'by', 'year', 'significantly', 'in', 'China', '.', 'The', 'methods', 'to', 'treat', 'SCI', 'patients', 'in', 'sequela', 'stage', 'update', 'are', 'poor', '.', 'Though', 'traditional', 'rehabilitation', 'therapy', 'is', 'the', 'routine', 'method', 'to', 'treat', 'SCI', 'in', 'sequela', 'stage', ',', 'aiming', 'to', 'improve', 'the', 'neurological', 'disorders', 'of', 'these', 'patients', ',', 'such', 'as', 'sensory', 'disturbance', ',', 'dyskinesia', ',', 'autologous', 'adjustment', 'of', 'blood', 'pressure', ',', 'dysfunction', 'of', 'urination', ',', 'defecation', 'and', 'perspiration', ',', 'etc', '.', 'What', ""'s"", 'a', 'pity', ',', 'the', 'efficacy', 'of', 'the', 'rehabilitation', 'therapy', 'is', 'unsatisfactory', '.', 'Rehabilitation', 'Therapy', 'can', 'prevent', 'the', 'process', 'of', 'muscle', 'atrophy', 'and', 'joint', 'stiffness', '.', 'However', ',', 'it', 'can', 'not', 'repair', 'the', 'damaged', 'nerve', 'function', '.', 'Studies', 'show', 'that', 'mesenchymal', 'stem', 'cell', 'transplantation', 'can', 'remarkably', 'improve', 'the', 'neurological', 'function', 'of', 'SCI', 'in', 'animals', 'without', 'any', 'severe', 'side', 'effect', '.', '\n\n', 'In', 'this', 'study', ',', '300', 'patients', 'will', 'be', 'divided', 'into', 'three', 'groups', 'and', 'the', 'investigators', 'will', 'use', 'mesenchymal', 'stem', 'cells', 'derived', 'from', 'umbilical', 'cord', 'to', 'treat', '100', 'SCI', 'patients', '.', 'They', 'will', 'also', 'follow', 'up', '100', 'patients', 'who', 'only', 'receive', 'rehabilitation', 'and', 'another', '100', 'patients', 'who', 'accept', 'neither', 'stem', 'cell', 'therapy', 'nor', 'rehabilitation', '.', 'On', 'this', 'basis', ',', 'the', 'investigators', 'can', 'compare', 'the', 'efficacy', 'of', 'these', 'two', 'treatments', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01873547,NCT01873547,"Different Efficacy Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Chronic Spinal Cord Injury in China | The morbidity of spinal cord injury (SCI) is increasing year by year significantly in China. The methods to treat SCI patients in sequela stage update are poor. Though traditional rehabilitation therapy is the routine method to treat SCI in sequela stage, aiming to improve the neurological disorders of these patients, such as sensory disturbance, dyskinesia, autologous adjustment of blood pressure, dysfunction of urination, defecation and perspiration , etc. What's a pity, the efficacy of the rehabilitation therapy is unsatisfactory. Rehabilitation Therapy can prevent the process of muscle atrophy and joint stiffness. However, it can not repair the damaged nerve function. Studies show that mesenchymal stem cell transplantation can remarkably improve the neurological function of SCI in animals without any severe side effect.

In this study, 300 patients will be divided into three groups and the investigators will use mesenchymal stem cells derived from umbilical cord to treat 100 SCI patients. They will also follow up 100 patients who only receive rehabilitation and another 100 patients who accept neither stem cell therapy nor rehabilitation. On this basis, the investigators can compare the efficacy of these two treatments.","[(27, 49, 'PHYSICAL', 'Rehabilitation Therapy'), (54, 115, 'SURGICAL', 'Umbilical Cord Derived Mesenchymal Stem Cells Transplantation'), (133, 159, 'CONDITION', 'Chronic Spinal Cord Injury'), (188, 206, 'CONDITION', 'spinal cord injury'), (208, 211, 'CONDITION', 'SCI'), (285, 288, 'CONDITION', 'SCI'), (351, 373, 'PHYSICAL', 'rehabilitation therapy'), (405, 408, 'CONDITION', 'SCI'), (669, 691, 'PHYSICAL', 'rehabilitation therapy'), (711, 733, 'PHYSICAL', 'Rehabilitation Therapy'), (870, 907, 'SURGICAL', 'mesenchymal stem cell transplantation'), (960, 963, 'CONDITION', 'SCI'), (1101, 1151, 'SURGICAL', 'mesenchymal stem cells derived from umbilical cord'), (1165, 1168, 'CONDITION', 'SCI'), (1234, 1248, 'PHYSICAL', 'rehabilitation'), (1293, 1310, 'SURGICAL', 'stem cell therapy'), (1315, 1329, 'PHYSICAL', 'rehabilitation')]"
"['Use', 'of', 'BCAA', '-', 'rich', 'Protein', 'Supplements', 'for', 'Chronic', 'Stroke', 'Patients', 'to', 'Improve', 'the', 'Functional', 'Performance', '|', 'In', 'the', 'past', 'few', 'years', ',', 'Branched', 'Chain', 'Amino', 'Acid', '(', 'BCAA', ')', 'supplements', 'have', 'gradually', 'used', 'on', 'different', 'groups', '.', 'From', 'training', 'athletes', ',', 'maintaining', 'functions', 'of', 'healthy', 'elders', 'to', 'preventing', 'disabilities', 'of', 'people', 'that', 'ca', ""n't"", 'do', 'intense', 'exercises', '.', 'BCAAs', 'are', 'now', 'considered', 'to', 'be', 'able', 'to', 'prevent', 'muscle', 'atrophy', 'and', 'strength', 'loss', ',', 'also', 'possible', 'to', 'increase', 'strength', 'and', 'muscle', 'mass', 'if', 'combined', 'with', 'resistance', 'exercises', '.', 'Stroke', 'patients', 'have', 'difficulties', 'with', 'moving', ',', 'which', 'led', 'to', 'multiple', 'disabilities', ',', 'are', 'more', 'likely', 'to', 'have', 'sarcopenia', 'and', 'strength', 'loss', '.', 'Furthermore', ',', 'reducing', 'the', 'will', 'of', 'moving', 'or', 'walking', '.', 'Recently', ',', 'studies', 'showed', 'that', 'combined', 'BCAAs', 'with', 'resistance', 'exercises', 'can', 'effectively', 'increase', 'muscle', 'mass', ',', 'thus', 'commonly', 'used', 'on', 'training', 'athletes', '.', '\n\n', 'Although', 'aerobic', 'exercises', 'are', 'proven', 'to', 'be', 'more', 'likely', 'to', 'improve', 'walking', 'ability', 'of', 'chronic', 'stroke', 'patients', 'than', 'traditional', 'rehabilitation', ',', 'BCAAs', ""'"", 'effects', 'are', 'yet', 'to', 'be', 'proven', '.', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'explore', 'if', 'BCAAs', 'combined', 'with', 'moderate', 'intensity', 'exercises', 'can', 'prevent', 'muscle', 'atrophy', ',', 'loss', 'of', 'strength', 'and', 'cardiopulmonary', 'function', '.', '\n\n', 'This', 'is', 'a', 'randomized', 'control', 'trial', '.', 'Participants', 'are', 'randomly', 'assigned', 'to', 'either', 'experiment', 'or', 'control', 'groups', '.', 'Both', 'group', 'received', 'aerobic', 'exercise', '(', '30', 'min', 'in', 'a', 'session', ',', '3', 'days', 'a', 'week', ',', 'and', 'for', '8', 'weeks', ')', '.', 'Experiment', 'group', 'received', 'BCAA', 'supplement', 'immediately', 'after', 'the', 'exercise', 'while', 'the', 'control', 'group', 'receive', 'sham', 'product', '(', 'vitamins', ')', '.', 'The', 'outcome', 'measurements', '(', 'including', 'muscle', 'mass', ',', 'functional', 'measures', ',', 'and', 'quality', 'of', 'life', ')', 'are', 'performed', 'before', '(', '0', '-', 'wk', ')', 'and', 'after', '(', '8', '-', 'wk', ')', 'the', 'interventions', ',', 'also', 'after', 'interventions', 'in', '3', 'months', 'and', '6', 'months', 'for', 'follow', 'up', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03244527,NCT03244527,"Use of BCAA-rich Protein Supplements for Chronic Stroke Patients to Improve the Functional Performance | In the past few years, Branched Chain Amino Acid (BCAA) supplements have gradually used on different groups. From training athletes, maintaining functions of healthy elders to preventing disabilities of people that can't do intense exercises. BCAAs are now considered to be able to prevent muscle atrophy and strength loss, also possible to increase strength and muscle mass if combined with resistance exercises. Stroke patients have difficulties with moving, which led to multiple disabilities, are more likely to have sarcopenia and strength loss. Furthermore, reducing the will of moving or walking. Recently, studies showed that combined BCAAs with resistance exercises can effectively increase muscle mass, thus commonly used on training athletes.

Although aerobic exercises are proven to be more likely to improve walking ability of chronic stroke patients than traditional rehabilitation, BCAAs' effects are yet to be proven. Therefore, the aim of this study is to explore if BCAAs combined with moderate intensity exercises can prevent muscle atrophy, loss of strength and cardiopulmonary function.

This is a randomized control trial. Participants are randomly assigned to either experiment or control groups. Both group received aerobic exercise (30 min in a session, 3 days a week, and for 8 weeks). Experiment group received BCAA supplement immediately after the exercise while the control group receive sham product (vitamins). The outcome measurements (including muscle mass, functional measures, and quality of life) are performed before (0-wk) and after (8-wk) the interventions, also after interventions in 3 months and 6 months for follow up.","[(7, 11, 'DRUG', 'BCAA'), (41, 55, 'CONDITION', 'Chronic Stroke'), (128, 153, 'DRUG', 'Branched Chain Amino Acid'), (155, 159, 'DRUG', 'BCAA'), (348, 353, 'DRUG', 'BCAAs'), (519, 525, 'CONDITION', 'Stroke'), (748, 753, 'DRUG', 'BCAAs'), (946, 960, 'CONDITION', 'chronic stroke'), (1003, 1008, 'DRUG', 'BCAAs'), (1090, 1095, 'DRUG', 'BCAAs'), (1110, 1138, 'PHYSICAL', 'moderate intensity exercises'), (1346, 1362, 'PHYSICAL', 'aerobic exercise'), (1444, 1448, 'DRUG', 'BCAA')]"
"['Use', 'of', 'Remotely', 'Controlled', 'Mandibular', 'Positioner', '(', 'RCMP', ')', 'to', 'Predict', 'Treatment', 'Outcomes', 'of', 'Maxillomandibular', 'Advancement', 'Surgery', 'for', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', '.', '|', 'Maxillomandibular', 'advancement', '(', 'MMA', ')', 'surgery', ',', 'one', 'of', 'the', 'most', 'successful', 'surgical', 'procedures', 'for', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'is', 'predominantly', 'used', 'to', 'manage', 'patients', 'with', 'moderate', 'to', 'severe', 'OSA', '.', 'However', ',', 'limiting', 'factors', 'include', 'incomplete', 'response', 'in', 'some', 'cases', ',', 'unfavorable', 'facial', 'changes', 'as', 'a', 'result', 'of', 'large', 'advancements', ',', 'and', 'risk', 'of', 'malocclusion', 'or', 'malunion', '.', '\n\n', 'This', 'study', 'will', 'be', 'done', 'to', 'determine', 'predictors', 'of', 'success', 'with', 'MMA', 'surgery', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'OSA', '.', 'Studies', 'have', 'already', 'shown', 'the', 'value', 'of', 'a', 'remote', 'controlled', 'mandibular', 'positioner', '(', 'RCMP', ')', 'device', 'to', 'identify', 'the', 'correct', 'level', 'of', 'therapeutic', 'protrusion', 'needed', 'with', 'oral', 'appliance', 'therapy', '.', 'Moreover', ',', 'some', 'patients', 'experience', 'a', 'dose', 'dependent', 'improvement', 'in', 'sleep', 'parameters', 'based', 'on', 'the', 'degree', 'of', 'protrusion', 'during', 'the', 'titration', 'study', '.', 'Use', 'of', 'RCMP', 'as', 'a', 'means', 'to', 'identify', 'potential', 'candidates', 'for', 'MMA', ',', 'may', 'help', 'customize', 'treatment', 'options', 'for', 'patients', 'with', 'OSA', 'by', 'providing', 'predictive', 'value', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT03929549,NCT03929549,"Use of Remotely Controlled Mandibular Positioner (RCMP) to Predict Treatment Outcomes of Maxillomandibular Advancement Surgery for Obstructive Sleep Apnea (OSA). | Maxillomandibular advancement (MMA) surgery, one of the most successful surgical procedures for the treatment of obstructive sleep apnea (OSA), is predominantly used to manage patients with moderate to severe OSA. However, limiting factors include incomplete response in some cases, unfavorable facial changes as a result of large advancements, and risk of malocclusion or malunion.

This study will be done to determine predictors of success with MMA surgery in patients with moderate to severe OSA. Studies have already shown the value of a remote controlled mandibular positioner (RCMP) device to identify the correct level of therapeutic protrusion needed with oral appliance therapy. Moreover, some patients experience a dose dependent improvement in sleep parameters based on the degree of protrusion during the titration study. Use of RCMP as a means to identify potential candidates for MMA, may help customize treatment options for patients with OSA by providing predictive value.","[(7, 48, 'OTHER', 'Remotely Controlled Mandibular Positioner'), (50, 54, 'OTHER', 'RCMP'), (89, 126, 'CONDITION', 'Maxillomandibular Advancement Surgery'), (131, 154, 'CONDITION', 'Obstructive Sleep Apnea'), (156, 159, 'CONDITION', 'OSA'), (164, 207, 'CONDITION', 'Maxillomandibular advancement (MMA) surgery'), (277, 300, 'CONDITION', 'obstructive sleep apnea'), (302, 305, 'CONDITION', 'OSA'), (354, 376, 'CONDITION', 'moderate to severe OSA'), (612, 623, 'CONDITION', 'MMA surgery'), (641, 663, 'CONDITION', 'moderate to severe OSA'), (707, 746, 'OTHER', 'remote controlled mandibular positioner'), (748, 752, 'OTHER', 'RCMP'), (829, 843, 'OTHER', 'oral appliance'), (1006, 1010, 'OTHER', 'RCMP'), (1059, 1062, 'CONDITION', 'MMA'), (1119, 1122, 'CONDITION', 'OSA')]"
"['Sleep', '-', 'dependent', 'Memory', 'Processing', 'in', 'Schizophrenia', '|', 'The', 'investigators', 'will', 'test', 'the', 'hypothesis', 'that', 'the', 'sleep', 'medication', ',', 'eszopiclone', ',', 'can', 'normalize', 'brain', 'activity', 'during', 'sleep', 'and', 'improve', 'memory', 'in', 'patients', 'with', 'schizophrenia', '.', 'The', 'investigators', 'will', 'do', 'this', 'by', 'measuring', 'sleep', 'and', 'memory', 'performance', 'on', 'two', 'conditions', 'separated', 'by', 'one', 'week', ':', 'taking', '3', 'mg', 'of', 'eszopiclone', 'and', 'taking', 'placebo', '.', 'The', 'investigators', 'will', 'study', 'healthy', 'subjects', 'and', 'chronic', ',', 'medicated', 'outpatients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01641900,NCT01641900,"Sleep-dependent Memory Processing in Schizophrenia | The investigators will test the hypothesis that the sleep medication, eszopiclone, can normalize brain activity during sleep and improve memory in patients with schizophrenia. The investigators will do this by measuring sleep and memory performance on two conditions separated by one week: taking 3 mg of eszopiclone and taking placebo. The investigators will study healthy subjects and chronic, medicated outpatients with schizophrenia.","[(37, 50, 'CONDITION', 'Schizophrenia'), (123, 134, 'DRUG', 'eszopiclone'), (214, 227, 'CONDITION', 'schizophrenia'), (358, 369, 'DRUG', 'eszopiclone'), (381, 388, 'CONTROL', 'placebo'), (476, 489, 'CONDITION', 'schizophrenia')]"
"['Feasibility', 'Study', 'of', 'Tolerogenic', 'Fibroblasts', 'in', 'Patients', 'With', 'Refractory', 'Multiple', 'Sclerosis', '|', 'Fibroblasts', 'have', 'demonstrated', 'potent', 'immune', 'modulatory', 'and', 'therapeutic', 'activity', 'in', 'the', 'experimental', 'autoimmune', 'encephalomyelitis', '(', 'EAE', ')', 'model', 'of', 'multiple', 'sclerosis', ',', 'as', 'well', 'as', 'in', 'other', 'models', 'of', 'autoimmune', 'and', 'inflammatory', 'diseases', '.', '\n\n', 'This', 'study', 'will', 'assess', 'primary', 'safety', 'and', 'secondary', 'efficacy', 'endpoints', 'of', 'intravenous', 'administration', 'of', '100', 'million', 'tolerogenic', 'fibroblasts', 'to', '5', 'patients', 'with', 'relapsing', 'remitting', 'MS', 'resistant', 'to', 'interferon', '.', 'While', 'the', 'safety', 'of', 'fibroblasts', 'administered', 'clinically', 'is', 'established', ',', 'it', 'is', 'unknown', 'whether', 'these', 'cells', 'are', 'effective', 'in', 'the', 'treatment', 'of', 'multiple', 'sclerosis', '(', 'MS', ')', '.', '\n\n', 'Our', 'hypothesis', 'is', 'that', 'the', 'tolerogenic', 'fibroblasts', 'will', 'be', 'well', '-', 'tolerated', 'and', 'meet', 'our', 'primary', 'objective', '.', 'In', 'addition', ',', 'The', 'investigators', 'are', 'optimistic', 'that', 'they', 'will', 'see', 'signs', 'of', 'efficacy', 'based', 'on', 'the', 'following', ':', 'Neurological', 'assessment', 'of', 'the', 'MS', 'functional', 'composite', 'assessment', 'which', 'comprises', 'of', 'EDSS', ',', 'the', 'expanded', 'EDSS', '(', 'Rating', 'Neurologic', 'Impairment', 'in', 'Multiple', 'Sclerosis', ',', 'the', 'Scripps', 'neurological', 'rating', 'scale', '(', 'NRS', ')', ',', 'paced', 'auditory', 'serial', 'addition', 'test', '(', 'PASAT', ')', ',', 'the', 'nine', '-', 'hole', 'peg', 'test', ',', 'and', '25', '-', 'foot', 'walking', 'time', ',', 'short', '-', 'form', '36', '(', 'SF-36', ')', 'quality', 'of', 'life', 'questionnaire', 'and', 'gadolinium', '-', 'enhanced', 'MRI', 'scans', 'of', 'the', 'brain', 'and', 'cervical', 'spinal', 'cord', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05080270,NCT05080270,"Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory diseases.

This study will assess primary safety and secondary efficacy endpoints of intravenous administration of 100 million tolerogenic fibroblasts to 5 patients with relapsing remitting MS resistant to interferon. While the safety of fibroblasts administered clinically is established, it is unknown whether these cells are effective in the treatment of multiple sclerosis (MS).

Our hypothesis is that the tolerogenic fibroblasts will be well-tolerated and meet our primary objective. In addition, The investigators are optimistic that they will see signs of efficacy based on the following: Neurological assessment of the MS functional composite assessment which comprises of EDSS, the expanded EDSS (Rating Neurologic Impairment in Multiple Sclerosis, the Scripps neurological rating scale (NRS), paced auditory serial addition test (PASAT), the nine-hole peg test, and 25-foot walking time, short-form 36 (SF-36) quality of life questionnaire and gadolinium-enhanced MRI scans of the brain and cervical spinal cord.","[(21, 44, 'SURGICAL', 'Tolerogenic Fibroblasts'), (62, 91, 'CONDITION', 'Refractory Multiple Sclerosis'), (94, 105, 'SURGICAL', 'Fibroblasts'), (238, 256, 'CONDITION', 'multiple sclerosis'), (443, 466, 'SURGICAL', 'tolerogenic fibroblasts'), (486, 508, 'CONDITION', 'relapsing remitting MS'), (554, 565, 'SURGICAL', 'fibroblasts'), (674, 692, 'CONDITION', 'multiple sclerosis'), (694, 696, 'CONDITION', 'MS'), (727, 750, 'SURGICAL', 'tolerogenic fibroblasts'), (944, 946, 'CONDITION', 'MS'), (1055, 1073, 'CONDITION', 'Multiple Sclerosis')]"
"['Assessment', 'of', 'Risk', 'Factors', 'for', 'Hearing', 'Loss', 'as', 'a', 'Result', 'of', 'Exposure', 'to', 'Noise', 'During', 'Military', 'Training', 'in', 'the', 'IDF', '(', 'Israel', 'Defense', 'Forces', ')', ',', 'and', 'Examination', 'of', 'the', 'Effectiveness', 'of', 'Hearing', 'Protection', 'Video', 'vs', 'Formal', 'Training', '.', '|', 'As', 'part', 'of', 'the', 'proposed', 'work', ',', 'the', 'investigators', 'would', 'like', 'to', 'examine', 'whether', 'there', 'is', 'a', 'need', 'to', 'use', 'a', 'training', 'video', 'to', 'train', 'IDF', 'combat', 'soldiers', 'to', 'improve', 'the', 'use', 'of', 'ear', 'plugs', 'and', 'to', 'prevent', 'hearing', 'loss', 'from', 'exposure', 'to', 'noise', ',', 'and', 'to', 'characterize', 'the', 'hearing', 'impaired', 'epidemiology', 'of', 'recruits', 'and', 'the', 'basic', 'rate', 'of', 'hearing', 'loss', 'During', 'basic', 'training', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT03314116,NCT03314116,"Assessment of Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF (Israel Defense Forces), and Examination of the Effectiveness of Hearing Protection Video vs Formal Training. | As part of the proposed work, the investigators would like to examine whether there is a need to use a training video to train IDF combat soldiers to improve the use of ear plugs and to prevent hearing loss from exposure to noise, and to characterize the hearing impaired epidemiology of recruits and the basic rate of hearing loss During basic training.","[(31, 43, 'CONDITION', 'Hearing Loss'), (178, 202, 'OTHER', 'Hearing Protection Video'), (206, 221, 'OTHER', 'Formal Training'), (328, 342, 'OTHER', 'training video'), (394, 403, 'OTHER', 'ear plugs'), (419, 431, 'CONDITION', 'hearing loss'), (480, 496, 'CONDITION', 'hearing impaired'), (544, 556, 'CONDITION', 'hearing loss')]"
"['Achieving', 'Brain', 'Benefits', 'in', 'Covert', 'Stroke', 'Through', 'Aerobic', 'Exercise', '|', 'Silent', 'ischemic', ',', 'also', 'known', 'as', '""', 'covert', 'stroke', 'vascular', 'disease', '""', '(', 'CSVD', ')', ',', 'contributes', 'to', 'neurological', 'deficits', 'that', 'are', 'caused', 'by', 'damage', 'to', 'small', 'blood', 'vessels', 'in', 'the', 'brain', '.', 'CSVD', 'occurs', 'six', 'to', 'ten', 'times', 'more', 'often', 'that', 'an', 'acute', 'stroke', '.', 'It', 'is', 'misleading', 'to', 'think', ',', 'however', ',', 'that', 'CSVD', 'is', 'an', 'inevitable', 'part', 'of', '""', 'getting', 'old', '""', 'because', 'people', 'with', 'CSVD', 'are', 'at', 'high', 'risk', 'of', 'developing', 'an', 'acute', 'stroke', 'or', 'dementia', '.', 'In', 'fact', ',', 'people', 'with', 'more', 'CSVD', 'lesion', 'volume', 'are', 'more', 'likely', 'to', 'develop', 'day', 'to', 'day', 'problems', 'in', 'planning', ',', 'decision', '-', 'making', 'and', 'speed', 'of', 'thinking', '.', 'Unfortunately', ',', 'there', 'are', 'no', 'proven', 'therapies', 'designed', 'to', 'address', 'CSVD', '.', 'We', 'propose', 'to', 'test', 'whether', 'aerobic', 'exercise', 'is', 'an', 'intervention', 'that', 'can', 'combat', 'CSVD', 'because', 'the', 'disease', 'is', 'fundamentally', 'a', 'blood', 'flow', 'problem', 'that', 'may', 'be', 'improved', 'by', 'aerobic', 'exercise', '.', 'We', 'will', 'recruit', 'CSVD', 'adults', 'with', 'moderate', 'to', 'severe', 'lesion', 'burden', 'and', 'use', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'to', 'study', 'the', 'brain', 'in', 'terms', 'of', 'structure', ',', 'perfusion', 'and', 'function', '.', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'our', 'established', 'aerobic', 'exercise', 'program', 'or', 'a', 'control', 'stretching', 'program', '.', 'Both', 'groups', 'will', 'take', 'part', 'in', 'lab', 'exercise', 'sessions', ',', 'which', 'are', 'designed', 'to', 'monitor', 'progress', 'and', 'assess', 'adherence', 'to', 'the', 'program', '.', 'The', 'duration', 'and', 'intensity', 'of', 'their', 'exercise', 'will', 'increase', 'as', 'participants', 'progress', '.', 'We', 'will', 'use', 'activity', 'log', 'books', ',', 'phone', 'calls', 'and', 'extra', '""', 'booster', '""', 'exercise', 'sessions', ',', 'as', 'needed', ',', 'to', 'maximize', 'retention', 'and', 'adherence', '.', 'We', 'aim', 'to', 'show', 'that', 'aerobic', 'exercise', 'increases', 'cerebral', 'blood', 'flow', '(', 'CBF', ')', 'in', 'frontal', '-', 'subcortical', 'grey', 'matter', ',', 'supports', 'regional', 'tissue', 'growth', ',', 'and', 'improves', 'cognitive', 'function', 'in', 'CSVD', 'adults', 'with', 'substantial', 'risk', 'of', 'acute', 'stroke', 'and', 'dementia', '.', 'A', 'positive', 'outcome', 'of', 'this', 'research', 'will', 'provide', 'strong', 'support', 'for', 'additional', 'clinical', 'trials', 'aimed', 'at', 'sustaining', 'cognition', 'and', 'maintaining', 'independent', 'living', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02068391,NCT02068391,"Achieving Brain Benefits in Covert Stroke Through Aerobic Exercise | Silent ischemic, also known as ""covert stroke vascular disease"" (CSVD), contributes to neurological deficits that are caused by damage to small blood vessels in the brain. CSVD occurs six to ten times more often that an acute stroke. It is misleading to think, however, that CSVD is an inevitable part of ""getting old"" because people with CSVD are at high risk of developing an acute stroke or dementia. In fact, people with more CSVD lesion volume are more likely to develop day to day problems in planning, decision-making and speed of thinking. Unfortunately, there are no proven therapies designed to address CSVD. We propose to test whether aerobic exercise is an intervention that can combat CSVD because the disease is fundamentally a blood flow problem that may be improved by aerobic exercise. We will recruit CSVD adults with moderate to severe lesion burden and use magnetic resonance imaging (MRI) to study the brain in terms of structure, perfusion and function. Participants will be randomly assigned to either our established aerobic exercise program or a control stretching program. Both groups will take part in lab exercise sessions, which are designed to monitor progress and assess adherence to the program. The duration and intensity of their exercise will increase as participants progress. We will use activity log books, phone calls and extra ""booster"" exercise sessions, as needed, to maximize retention and adherence. We aim to show that aerobic exercise increases cerebral blood flow (CBF) in frontal-subcortical grey matter, supports regional tissue growth, and improves cognitive function in CSVD adults with substantial risk of acute stroke and dementia. A positive outcome of this research will provide strong support for additional clinical trials aimed at sustaining cognition and maintaining independent living.","[(28, 41, 'CONDITION', 'Covert Stroke'), (50, 66, 'PHYSICAL', 'Aerobic Exercise'), (101, 131, 'CONDITION', 'covert stroke vascular disease'), (134, 138, 'CONDITION', 'CSVD'), (241, 245, 'CONDITION', 'CSVD'), (289, 301, 'CONDITION', 'acute stroke'), (344, 348, 'CONDITION', 'CSVD'), (408, 412, 'CONDITION', 'CSVD'), (447, 459, 'CONDITION', 'acute stroke'), (499, 503, 'CONDITION', 'CSVD'), (682, 686, 'CONDITION', 'CSVD'), (715, 731, 'PHYSICAL', 'aerobic exercise'), (767, 771, 'CONDITION', 'CSVD'), (854, 870, 'PHYSICAL', 'aerobic exercise'), (888, 892, 'CONDITION', 'CSVD'), (1110, 1134, 'PHYSICAL', 'aerobic exercise program'), (1140, 1166, 'CONTROL', 'control stretching program'), (1333, 1341, 'PHYSICAL', 'exercise'), (1430, 1463, 'PHYSICAL', 'extra ""booster"" exercise sessions'), (1533, 1549, 'PHYSICAL', 'aerobic exercise'), (1690, 1694, 'CONDITION', 'CSVD'), (1727, 1739, 'CONDITION', 'acute stroke')]"
"['An', 'Open', '-', 'label', 'Naturalistic', 'Pragmatic', 'Study', 'to', 'Assess', 'the', 'Long', 'Term', 'Safety', 'of', 'BF2.649', '(', 'Pitolisant', ')', 'in', 'the', 'Treatment', 'of', 'Excessive', 'Daytime', 'Sleepiness', '(', 'EDS', ')', 'in', 'Narcolepsy', '(', '12', 'Months', 'Follow', '-', 'up', ',', 'Followed', 'by', 'a', 'Prolonged', 'Follow', 'up', ')', '|', 'This', 'is', 'a', 'multicentric', 'International', 'Phase', 'III', ',', 'Long', 'term', 'open', 'label', 'study(12', 'months)assessing', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'BF2.649', '(', 'Pitolisant)in', 'the', 'treatment', 'of', 'Excessive', 'Daytime', 'Sleepiness', '(', 'EDS', ')', 'in', 'narcoleptic', 'patients', 'with', 'or', 'without', 'cataplexy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01399606,NCT01399606,"An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) | This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.","[(77, 84, 'DRUG', 'BF2.649'), (86, 96, 'DRUG', 'Pitolisant'), (118, 146, 'CONDITION', 'Excessive Daytime Sleepiness'), (148, 151, 'CONDITION', 'EDS'), (156, 166, 'CONDITION', 'Narcolepsy'), (357, 364, 'DRUG', 'BF2.649'), (397, 425, 'CONDITION', 'Excessive Daytime Sleepiness'), (427, 430, 'CONDITION', 'EDS'), (435, 446, 'CONDITION', 'narcoleptic'), (472, 481, 'CONDITION', 'cataplexy')]"
"['A', 'Phase', 'I', 'Clinical', 'Trial', 'of', 'BAT4406F', 'Injection', 'on', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'in', 'Patients', 'With', 'Neuromyelitis', 'Optica', 'Spectrum', 'Disorders', '|', 'This', 'study', 'is', 'a', 'phase', 'I', 'clinical', 'study', 'of', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'BAT4406F', 'injection', 'in', 'patients', 'with', 'neuromyelitis', 'optica', 'spectrum', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04146285,NCT04146285,"A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders | This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.","[(28, 36, 'DRUG', 'BAT4406F'), (114, 153, 'CONDITION', 'Neuromyelitis Optica Spectrum Disorders'), (248, 256, 'DRUG', 'BAT4406F'), (284, 323, 'CONDITION', 'neuromyelitis optica spectrum disorders')]"
"['A', 'Phase', '2', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', 'Trial', 'inVEstigating', 'the', 'Effect', 'and', 'Safety', 'of', 'Several', 'Dosing', 'Regimens', 'of', 'LY3056480', 'in', 'Patients', 'With', 'STAble', 'Sensorineural', 'Hearing', 'Loss', '|', 'A', 'phase', '2', 'trial', 'with', 'LY3056480', 'in', 'patients', 'with', 'stable', 'SNHL']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT05061758,NCT05061758,"A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss | A phase 2 trial with LY3056480 in patients with stable SNHL","[(36, 43, 'CONTROL', 'Placebo'), (127, 136, 'DRUG', 'LY3056480'), (154, 187, 'CONDITION', 'STAble Sensorineural Hearing Loss'), (211, 220, 'DRUG', 'LY3056480'), (238, 249, 'CONDITION', 'stable SNHL')]"
"['Effectiveness', 'of', 'Multiple', 'Robotic', 'Gait', '-', 'Devices', 'for', 'Improving', 'Walking', 'Ability', 'in', 'Subacute', 'Stroke', 'Patients', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'know', 'the', 'effectiveness', 'of', 'different', 'robotic', 'devices', 'for', 'gait', 'rehabilitation', 'in', 'stroke', 'patients']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O']",NCT05811494,NCT05811494,Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients: A Randomized Controlled Trial | The purpose of this study is to know the effectiveness of different robotic devices for gait rehabilitation in stroke patients,"[(26, 46, 'OTHER', 'Robotic Gait-Devices'), (80, 95, 'CONDITION', 'Subacute Stroke'), (206, 221, 'OTHER', 'robotic devices'), (226, 245, 'OTHER', 'gait rehabilitation'), (249, 255, 'CONDITION', 'stroke')]"
"['Cognitive', 'Outcomes', 'After', 'Brain', 'Substructure', '-', 'informed', 'Radiation', 'Planning', 'in', 'Pediatric', 'Patients', '|', 'The', 'goal', 'of', 'this', 'trial', 'is', 'to', 'see', 'if', 'it', 'is', 'possible', 'to', 'better', 'plan', 'how', 'radiation', 'therapy', 'is', 'delivered', 'to', 'different', 'parts', 'of', 'the', 'brain', 'in', 'children', 'who', 'require', 'radiation', 'to', 'treat', 'their', 'tumor', ',', 'and', 'if', 'this', 'will', 'help', 'reduce', 'neurocognitive', '(', 'thinking', 'and', 'learning', ')', 'impairments', 'in', 'these', 'patients', '.', '\n\n', 'Patients', 'with', 'newly', 'diagnosed', 'brain', 'or', 'head', 'and', 'neck', 'tumors', 'who', 'are', 'having', 'radiation', 'therapy', 'will', 'have', 'neurocognitive', 'testing', 'and', 'MRI', 'imaging', '(', 'both', 'research', 'and', 'for', 'regular', 'care', ')', 'done', 'as', 'part', 'of', 'their', 'participation', 'in', 'the', 'study', '.', '\n\n', 'Survivors', 'of', 'childhood', 'brain', 'tumors', 'who', 'completed', 'radiation', 'therapy', 'at', 'least', 'two', 'years', 'before', 'joining', 'the', 'study', ',', 'and', 'have', 'not', 'had', 'a', 'recurrence', ',', 'will', 'have', 'neurocognitive', 'testing', 'and', 'research', 'MRIs', 'completed', '.', '\n\n', 'Healthy', 'children', 'will', 'also', 'be', 'enrolled', 'and', 'have', 'research', 'MRIs', 'done', '.', '\n\n', 'The', 'researchers', 'will', 'use', 'the', 'radiation', 'plan', 'to', 'determine', 'how', 'much', 'radiation', 'was', 'delivered', 'to', 'different', 'parts', 'of', 'the', 'brain', '.', 'The', 'investigators', 'will', 'use', 'the', 'MRIs', 'to', 'determine', 'how', 'the', 'normal', 'brain', 'is', 'changing', 'after', 'treatment', ';', 'and', 'how', 'this', 'compares', 'to', 'patients', 'who', 'had', 'standard', 'radiation', 'treatment', 'or', 'who', 'never', 'had', 'a', 'brain', 'tumor', '.', 'The', 'neurocognitive', 'testing', 'will', 'be', 'compared', 'among', 'different', 'groups', 'to', 'see', 'how', 'different', 'treatment', 'plans', 'affect', 'performance', 'on', 'neurocognitive', 'tests', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05658731,NCT05658731,"Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients | The goal of this trial is to see if it is possible to better plan how radiation therapy is delivered to different parts of the brain in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients.

Patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as part of their participation in the study.

Survivors of childhood brain tumors who completed radiation therapy at least two years before joining the study, and have not had a recurrence, will have neurocognitive testing and research MRIs completed.

Healthy children will also be enrolled and have research MRIs done.

The researchers will use the radiation plan to determine how much radiation was delivered to different parts of the brain. The investigators will use the MRIs to determine how the normal brain is changing after treatment; and how this compares to patients who had standard radiation treatment or who never had a brain tumor. The neurocognitive testing will be compared among different groups to see how different treatment plans affect performance on neurocognitive tests.","[(25, 71, 'OTHER', 'Brain Substructure-informed Radiation Planning'), (166, 183, 'RADIOTHERAPY', 'radiation therapy'), (253, 262, 'RADIOTHERAPY', 'radiation'), (278, 283, 'CONDITION', 'tumor'), (399, 444, 'CONDITION', 'newly diagnosed brain or head and neck tumors'), (460, 477, 'RADIOTHERAPY', 'radiation therapy'), (638, 650, 'CONDITION', 'brain tumors'), (665, 682, 'RADIOTHERAPY', 'radiation therapy'), (920, 934, 'OTHER', 'radiation plan'), (957, 966, 'RADIOTHERAPY', 'radiation'), (1155, 1183, 'CONTROL', 'standard radiation treatment'), (1203, 1214, 'CONDITION', 'brain tumor')]"
"['Rehabilitation', 'and', 'Cortical', 'Remodeling', 'After', 'Surgical', 'Intervention', 'for', 'Spinal', 'Cord', 'Injury', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effects', 'of', 'rehabilitation', 'on', 'dexterous', 'hand', 'movements', 'and', 'cortical', 'motor', 'map', 'changes', 'in', 'tetraplegic', 'patients', 'following', 'nerve', 'transfer', 'surgery', '.', 'The', 'working', 'hypothesis', 'is', 'that', 'robot', '-', 'assisted', ',', 'intensive', 'rehabilitation', 'will', 'support', 'the', 'return', 'of', 'hand', 'and', 'arm', 'function', 'and', 'strengthen', 'the', 'cortical', 'representations', 'of', 'targeted', 'muscles', '.', 'The', 'investigators', 'will', 'assess', 'this', 'through', 'TMS', 'mapping', 'and', 'clinical', 'measures', 'of', 'hand', 'and', 'arm', 'function', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04041063,NCT04041063,"Rehabilitation and Cortical Remodeling After Surgical Intervention for Spinal Cord Injury | The aim of this study is to determine the effects of rehabilitation on dexterous hand movements and cortical motor map changes in tetraplegic patients following nerve transfer surgery. The working hypothesis is that robot-assisted, intensive rehabilitation will support the return of hand and arm function and strengthen the cortical representations of targeted muscles. The investigators will assess this through TMS mapping and clinical measures of hand and arm function.","[(71, 89, 'CONDITION', 'Spinal Cord Injury'), (222, 233, 'CONDITION', 'tetraplegic'), (253, 275, 'CONDITION', 'nerve transfer surgery'), (308, 348, 'PHYSICAL', 'robot-assisted, intensive rehabilitation')]"
"['Burden', 'of', 'Obstructive', 'Sleep', 'Apnea', 'in', 'Stroke', '(', 'BOSAST', ')', '|', 'There', 'are', 'two', 'purposes', 'of', 'this', 'study', '.', 'The', 'first', 'purpose', 'is', 'to', 'define', 'the', 'frequency', 'of', 'obstructive', 'sleep', 'apnea', 'in', 'stroke', 'survivors', 'as', 'well', 'as', 'its', 'association', 'with', 'fatigue', 'and', 'quality', 'of', 'life', '.', 'The', 'second', 'purpose', 'is', 'to', 'determine', 'if', 'continuous', 'positive', 'airways', 'pressure', '(', 'CPAP', ')', 'treatment', 'can', 'have', 'a', 'beneficial', 'effect', 'on', 'these', 'patients', ""'"", 'fatigue', 'and', 'quality', 'of', 'life', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT00952211,NCT00952211,Burden of Obstructive Sleep Apnea in Stroke (BOSAST) | There are two purposes of this study. The first purpose is to define the frequency of obstructive sleep apnea in stroke survivors as well as its association with fatigue and quality of life. The second purpose is to determine if continuous positive airways pressure (CPAP) treatment can have a beneficial effect on these patients' fatigue and quality of life.,"[(10, 33, 'CONDITION', 'Obstructive Sleep Apnea'), (37, 43, 'CONDITION', 'Stroke'), (141, 164, 'CONDITION', 'obstructive sleep apnea'), (168, 174, 'CONDITION', 'stroke'), (217, 224, 'CONDITION', 'fatigue'), (284, 320, 'OTHER', 'continuous positive airways pressure'), (322, 326, 'OTHER', 'CPAP'), (386, 393, 'CONDITION', 'fatigue')]"
"['Phase', '2', 'Multi', 'Center', 'Prospective', 'Rand', '.', 'Double', 'Blind', 'Placebo', 'Cont', '.', 'Parallel', 'Design', 'Study', 'to', 'Evaluate', 'Safety', '&', 'Efficacy', 'of', 'Topical', 'Sirolimus', 'for', 'Cutaneous', 'Angiofibromas', 'in', 'Subjects', 'W/', 'Tuberous', 'Sclerosis', 'Complex', 'Followed', 'by', 'Opt', '.', 'Open', 'Label', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'sirolimus', '(', '0.2', '%', 'and', '0.4', '%', 'formulations', ')', 'and', 'its', 'vehicle', 'when', 'applied', 'topically', 'once', 'daily', 'for', '12', 'weeks', 'for', 'the', 'treatment', 'of', 'cutaneous', 'angiofibromas', 'in', 'pediatric', 'subjects', 'with', 'tuberous', 'sclerosis', 'complex', '(', 'TSC', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT03363763,NCT03363763,Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label | The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex (TSC).,"[(129, 138, 'DRUG', 'Sirolimus'), (143, 166, 'CONDITION', 'Cutaneous Angiofibromas'), (182, 208, 'CONDITION', 'Tuberous Sclerosis Complex'), (309, 318, 'DRUG', 'sirolimus'), (432, 455, 'CONDITION', 'cutaneous angiofibromas'), (483, 509, 'CONDITION', 'tuberous sclerosis complex'), (511, 514, 'CONDITION', 'TSC')]"
"['REN-1654', 'in', 'Post', '-', 'Herpetic', 'Neuralgia', ':', 'a', 'Multi', '-', 'Center', ',', 'Placebo', 'Controlled', ',', '3', '-', 'week', 'Dose', '-', 'Finding', 'Study', ',', 'With', 'a', '3', '-', 'Week', 'Active', '-', 'Treatment', 'Extension', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'gain', 'initial', 'safety', 'and', 'efficacy', 'data', 'on', 'the', 'experimental', 'agent', 'REN-1654', 'in', 'patients', 'with', 'painful', 'post', '-', 'herpetic', 'neuralgia', '(', 'PHN', ')', '.']","['B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00099528,NCT00099528,"REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension | The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).","[(0, 8, 'DRUG', 'REN-1654'), (12, 35, 'CONDITION', 'Post-Herpetic Neuralgia'), (53, 60, 'CONTROL', 'Placebo'), (239, 247, 'DRUG', 'REN-1654'), (273, 296, 'CONDITION', 'post-herpetic neuralgia'), (298, 301, 'CONDITION', 'PHN')]"
"['Computerized', 'Cognitive', 'Training', 'in', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'randomized', 'uncontrolled', 'single', '-', 'site', 'trial', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'two', 'novel', 'computerized', 'cognitive', 'enhancing', 'software', 'packages', 'for', 'improving', 'cognitive', 'and', 'behavioral', 'outcomes', 'in', 'patients', 'with', 'epilepsy', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02726191,NCT02726191,Computerized Cognitive Training in Epilepsy | The purpose of this randomized uncontrolled single-site trial is to evaluate the efficacy of two novel computerized cognitive enhancing software packages for improving cognitive and behavioral outcomes in patients with epilepsy.,"[(0, 31, 'OTHER', 'Computerized Cognitive Training'), (35, 43, 'CONDITION', 'Epilepsy'), (149, 199, 'OTHER', 'computerized cognitive enhancing software packages'), (265, 273, 'CONDITION', 'epilepsy')]"
"['A', 'Phase', 'II', 'Study', 'of', 'Conformal', 'Radiotherapy', 'In', 'Patients', 'With', 'Low', '-', 'Grade', 'Gliomas', '|', 'RATIONALE', ':', 'Specialized', 'radiation', 'therapy', 'that', 'delivers', 'radiation', 'directly', 'to', 'the', 'tumor', 'may', 'kill', 'more', 'tumor', 'cells', 'and', 'cause', 'less', 'damage', 'to', 'normal', 'tissue', '.', '\n\n', 'PURPOSE', ':', 'This', 'phase', 'II', 'trial', 'is', 'studying', 'how', 'well', 'radiation', 'therapy', 'works', 'in', 'treating', 'young', 'patients', 'with', 'gliomas', '.']","['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00238264,NCT00238264,"A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas | RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.","[(20, 42, 'RADIOTHERAPY', 'Conformal Radiotherapy'), (60, 77, 'CONDITION', 'Low-Grade Gliomas'), (103, 120, 'RADIOTHERAPY', 'radiation therapy'), (181, 186, 'CONDITION', 'tumor'), (284, 301, 'RADIOTHERAPY', 'radiation therapy'), (340, 347, 'CONDITION', 'gliomas')]"
"['Evaluation', 'and', 'Effects', 'of', 'a', 'Resistance', 'Training', 'Program', 'and', 'Its', 'Relationship', 'With', 'the', 'Labor', 'Inclusion', 'of', 'the', 'Disabled', 'Intellectual', '|', 'Resistance', 'exercise', '(', 'RE', ')', 'has', 'been', 'proposed', 'as', 'a', 'possible', 'strategy', 'for', 'prevention', 'and', 'rehabilitation', 'of', 'diseases', '.', 'The', 'increase', 'in', 'both', 'muscle', 'strength', 'and', 'the', 'ability', 'to', 'perform', 'tasks', 'of', 'day', '-', 'to', '-', 'day', 'work', 'environment', 'and', 'are', 'well', '-', 'characterized', 'benefits', 'of', 'this', 'type', 'of', 'training', '.', 'The', 'literature', 'has', 'been', 'investigating', 'the', 'effectiveness', 'of', 'the', 'RE', 'for', 'humans', ',', 'yet', 'few', 'studies', 'have', 'been', 'conducted', 'with', 'intellectual', 'disabilities', '(', 'ID', ')', '.', 'It', 'is', 'known', 'that', 'a', 'sedentary', 'lifestyle', 'contributes', 'to', 'the', 'development', 'of', 'cardiovascular', 'disease', ',', 'type', '2', 'diabetes', ',', 'hypertension', ',', 'arthritis', ',', 'and', 'stress', ',', 'depression', ',', 'difficulty', 'in', 'socializing', ',', 'stigma', 'and', 'discrimination', '.', 'In', 'particular', ',', 'the', 'ID', 'is', 'less', 'active', 'and', 'is', 'more', 'likely', 'to', 'develop', 'secondary', 'diseases', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01456910,NCT01456910,"Evaluation and Effects of a Resistance Training Program and Its Relationship With the Labor Inclusion of the Disabled Intellectual | Resistance exercise (RE) has been proposed as a possible strategy for prevention and rehabilitation of diseases. The increase in both muscle strength and the ability to perform tasks of day-to-day work environment and are well-characterized benefits of this type of training. The literature has been investigating the effectiveness of the RE for humans, yet few studies have been conducted with intellectual disabilities (ID). It is known that a sedentary lifestyle contributes to the development of cardiovascular disease, type 2 diabetes, hypertension, arthritis, and stress, depression, difficulty in socializing, stigma and discrimination. In particular, the ID is less active and is more likely to develop secondary diseases.","[(28, 55, 'PHYSICAL', 'Resistance Training Program'), (109, 130, 'CONDITION', 'Disabled Intellectual'), (133, 152, 'PHYSICAL', 'Resistance exercise'), (154, 156, 'PHYSICAL', 'RE'), (472, 474, 'PHYSICAL', 'RE'), (528, 553, 'CONDITION', 'intellectual disabilities'), (555, 557, 'CONDITION', 'ID'), (633, 655, 'CONDITION', 'cardiovascular disease'), (657, 672, 'CONDITION', 'type 2 diabetes'), (674, 686, 'CONDITION', 'hypertension'), (688, 697, 'CONDITION', 'arthritis'), (703, 709, 'CONDITION', 'stress'), (711, 721, 'CONDITION', 'depression'), (796, 798, 'CONDITION', 'ID')]"
"['A', '2', '-', 'year', ',', 'Prospective', ',', 'Blinded', '-', 'rater', ',', 'Open', '-', 'label', ',', 'Active', '-', 'controlled', ',', 'Multicenter', ',', 'Randomized', 'Study', 'of', 'Long', '-', 'term', 'Efficacy', 'and', 'Effectiveness', 'Comparing', 'Risperdal', '®', 'Consta', '®', 'and', 'Abilify', '®', '(', 'Aripiprazole', ')', 'in', 'Adults', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'two', 'antipsychotic', 'medications', ',', 'RisperdalÂ', '®', 'ConstaÂ', '®', 'versus', 'AbilifyÂ', '®', ',', 'over', 'a', '2', '-', 'year', 'treatment', 'period', 'in', 'the', 'long', '-', 'term', 'maintenance', 'of', 'patients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00299702,NCT00299702,"A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia | The purpose of this study is to compare the effectiveness of two antipsychotic medications, RisperdalÂ® ConstaÂ® versus AbilifyÂ®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.","[(149, 158, 'DRUG', 'Risperdal'), (160, 166, 'DRUG', 'Consta'), (172, 179, 'DRUG', 'Abilify'), (182, 194, 'DRUG', 'Aripiprazole'), (211, 224, 'CONDITION', 'Schizophrenia'), (319, 329, 'DRUG', 'RisperdalÂ'), (331, 338, 'DRUG', 'ConstaÂ'), (347, 355, 'DRUG', 'AbilifyÂ'), (435, 448, 'CONDITION', 'schizophrenia')]"
"['Effect', 'of', 'Magnesium', 'Sulfate', 'on', 'the', 'Incidence', 'of', 'Periventricular', 'Leukomalacia', 'in', 'the', 'Very', 'Preterm', 'Neonate', '|', 'Magnesium', 'is', 'neuroprotective', 'in', 'neonatal', 'animal', 'models', 'of', 'acquired', 'hypoxic', '-', 'ischemic', 'and/or', 'inflammatory', 'cerebral', 'lesions', '.', 'It', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'of', 'perinatal', 'death', 'and', 'cerebral', 'palsy', 'in', 'some', 'observational', 'studies', '.', '\n\n', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'if', 'prenatal', 'magnesium', 'sulfate', 'given', 'to', 'women', 'at', 'risk', 'of', 'preterm', 'birth', 'before', '33', 'week', ""'s"", 'gestation', 'is', 'neuroprotective', '.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00120588,NCT00120588,"Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate | Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies.

The objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.","[(10, 27, 'DRUG', 'Magnesium Sulfate'), (48, 76, 'CONDITION', 'Periventricular Leukomalacia'), (89, 96, 'CONDITION', 'Preterm'), (107, 116, 'DRUG', 'Magnesium'), (397, 414, 'DRUG', 'magnesium sulfate'), (441, 454, 'CONDITION', 'preterm birth')]"
"['Functional', 'Imaging', 'of', 'Social', 'Cognition', 'in', 'Premanifest', 'Huntington', ""'s"", 'Disease', '|', 'Huntington', ""'s"", 'disease', '(', 'HD', ')', 'is', 'a', 'genetic', 'progressive', 'fatal', 'neurodegenerative', 'disorder', '.', 'In', 'the', 'western', 'world', 'it', 'affects', '5', '-', '10', 'persons', 'per', '100000', '.', 'The', 'main', 'brain', 'changes', 'include', 'the', 'loss', 'of', 'brain', 'cells', 'in', 'subcortical', 'structures', '.', 'The', 'symptoms', 'of', 'HD', 'include', 'involuntary', 'movements', ',', 'cognitive', 'deterioration', 'and', 'behavioural', 'disturbances', '.', 'It', 'has', 'been', 'shown', 'that', 'changes', 'in', 'emotion', 'comprehension', 'occur', 'before', 'the', 'onset', 'of', 'the', 'motor', 'symptoms', '(', 'preHD', ')', '.', 'This', 'deficit', 'in', 'perception', 'of', 'emotions', 'has', 'been', 'primarily', 'investigated', 'by', 'means', 'of', 'facial', 'expressions', '.', 'However', ',', 'emotions', 'can', 'also', 'be', 'expressed', 'through', 'body', 'language', '.', 'Here', ',', 'the', 'investigators', 'propose', 'to', 'investigate', 'whether', 'the', 'emotion', 'comprehension', 'deficit', 'in', 'preHD', 'also', 'includes', 'body', 'language', 'comprehension', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02551705,NCT02551705,"Functional Imaging of Social Cognition in Premanifest Huntington's Disease | Huntington's disease (HD) is a genetic progressive fatal neurodegenerative disorder. In the western world it affects 5-10 persons per 100000. The main brain changes include the loss of brain cells in subcortical structures. The symptoms of HD include involuntary movements, cognitive deterioration and behavioural disturbances. It has been shown that changes in emotion comprehension occur before the onset of the motor symptoms (preHD). This deficit in perception of emotions has been primarily investigated by means of facial expressions. However, emotions can also be expressed through body language. Here, the investigators propose to investigate whether the emotion comprehension deficit in preHD also includes body language comprehension.","[(42, 74, 'CONDITION', ""Premanifest Huntington's Disease""), (77, 97, 'CONDITION', ""Huntington's disease""), (99, 101, 'CONDITION', 'HD'), (317, 319, 'CONDITION', 'HD'), (507, 512, 'CONDITION', 'preHD'), (740, 769, 'CONDITION', 'emotion comprehension deficit'), (773, 778, 'CONDITION', 'preHD')]"
"['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Vitamin', 'D', 'Supplementation', 'in', 'Multiple', 'Sclerosis', '|', 'Low', 'vitamin', 'D', 'levels', 'have', 'been', 'shown', 'to', 'increase', 'a', 'person', ""'s"", 'risk', 'of', 'developing', 'multiple', 'sclerosis', '(', 'MS', ')', ',', 'and', 'patients', 'with', 'MS', 'who', 'have', 'lower', 'vitamin', 'D', 'levels', 'are', 'at', 'increased', 'risk', 'of', 'having', 'attacks', '.', 'However', ',', 'it', 'is', 'not', 'known', 'if', 'giving', 'supplemental', 'vitamin', 'D', 'to', 'those', 'with', 'MS', 'reduces', 'the', 'risk', 'of', 'attacks', ',', 'and', 'some', 'research', 'suggests', 'that', 'vitamin', 'D', 'could', 'even', 'be', 'harmful', 'to', 'people', 'with', 'MS', '.', '\n\n', 'In', 'this', 'clinical', 'trial', ',', 'patients', 'with', 'relapsing', '-', 'remitting', 'MS', 'will', 'receive', 'high', '-', 'dose', 'or', 'low', '-', 'dose', 'oral', 'vitamin', 'D', 'in', 'addition', 'to', 'an', 'approved', 'therapy', 'for', 'MS', ',', 'glatiramer', 'acetate', '.', 'Patients', 'will', 'be', 'evaluated', 'for', 'two', 'years', ',', 'and', 'the', 'effect', 'of', 'high', '-', 'dose', 'vitamin', 'D', 'supplementation', 'on', 'the', 'rate', 'of', 'MS', 'attacks', 'and', 'on', 'the', 'number', 'of', 'new', 'lesions', 'and', 'change', 'in', 'brain', 'volume', 'on', 'MRI', 'will', 'be', 'determined', '.', 'Establishing', 'this', 'association', 'will', 'have', 'major', 'implications', 'for', 'the', 'treatment', 'of', 'individuals', 'with', 'MS', 'throughout', 'the', 'world', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT01490502,NCT01490502,"A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis | Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS.

In this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.","[(33, 42, 'DRUG', 'Vitamin D'), (62, 80, 'CONDITION', 'Multiple Sclerosis'), (87, 96, 'DRUG', 'vitamin D'), (162, 180, 'CONDITION', 'multiple sclerosis'), (182, 184, 'CONDITION', 'MS'), (205, 207, 'CONDITION', 'MS'), (223, 232, 'DRUG', 'vitamin D'), (329, 338, 'DRUG', 'vitamin D'), (353, 355, 'CONDITION', 'MS'), (417, 426, 'DRUG', 'vitamin D'), (464, 466, 'CONDITION', 'MS'), (507, 529, 'CONDITION', 'relapsing-remitting MS'), (570, 579, 'DRUG', 'vitamin D'), (619, 621, 'CONDITION', 'MS'), (623, 641, 'DRUG', 'glatiramer acetate'), (713, 722, 'DRUG', 'vitamin D'), (754, 756, 'CONDITION', 'MS'), (949, 951, 'CONDITION', 'MS')]"
"['Evaluation', 'of', 'Spa', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Fibromyalgia', ':', 'a', 'Randomized', ',', 'Controlled', ',', 'Open', 'Multicenter', 'Study', '|', 'Fibromyalgia', 'is', 'a', 'common', 'health', 'problem', 'that', 'causes', 'widespread', 'pain', 'and', 'tenderness', '(', 'sensitive', 'to', 'touch', ')', '.', 'The', 'pain', 'and', 'tenderness', 'tend', 'to', 'come', 'and', 'go', ',', 'and', 'move', 'about', 'the', 'body', '.', 'There', 'is', 'no', 'cure', 'for', 'fibromyalgia', '.', 'Complementary', 'and', 'alternative', 'therapy', 'such', 'as', 'acupuncture', ',', 'chiropractic', 'and', 'massage', 'therapy', ',', 'can', 'be', 'useful', 'to', 'manage', 'fibromyalgia', 'symptoms', '.', 'Many', 'of', 'these', 'treatments', 'have', 'not', 'been', 'well', 'tested', 'in', 'patients', 'with', 'fibromyalgia', '.', 'Fibromyalgia', 'affect', '3', 'to', '4', '%', 'of', 'the', 'general', 'population', 'and', '14', '%', 'of', 'patients', 'with', 'rheumatologic', 'disease', '.', 'Fibromyalgia', 'is', 'most', 'common', 'in', 'women', '90', '%', 'in', 'many', 'studies', '.', 'It', 'most', 'often', 'starts', 'in', 'middle', 'adulthood', '.', 'A', 'chronic', 'evolution', 'occured', 'for', 'Fibromyalgic', 'patients', 'with', 'a', 'major', 'alteration', 'of', 'quality', 'of', 'life', '.', '\n\n', 'Thermalgi', 'is', 'a', 'randomized', ',', 'multicentre', ',', 'open', 'label', 'trial', 'wich', 'aims', 'to', 'evaluate', 'the', 'effects', 'of', 'spa', 'therapy', 'in', 'rheumatologia', 'on', 'evolution', 'of', 'disability', 'in', 'daily', 'life', 'of', 'patients', 'with', 'fibromyalgia', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02265029,NCT02265029,"Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study | Fibromyalgia is a common health problem that causes widespread pain and tenderness (sensitive to touch). The pain and tenderness tend to come and go, and move about the body. There is no cure for fibromyalgia. Complementary and alternative therapy such as acupuncture, chiropractic and massage therapy, can be useful to manage fibromyalgia symptoms. Many of these treatments have not been well tested in patients with fibromyalgia. Fibromyalgia affect 3 to 4% of the general population and 14 % of patients with rheumatologic disease. Fibromyalgia is most common in women 90 % in many studies. It most often starts in middle adulthood. A chronic evolution occured for Fibromyalgic patients with a major alteration of quality of life.

Thermalgi is a randomized, multicentre, open label trial wich aims to evaluate the effects of spa therapy in rheumatologia on evolution of disability in daily life of patients with fibromyalgia.","[(14, 25, 'OTHER', 'Spa Therapy'), (46, 58, 'CONDITION', 'Fibromyalgia'), (112, 124, 'CONDITION', 'Fibromyalgia'), (175, 179, 'CONDITION', 'pain'), (184, 194, 'CONDITION', 'tenderness'), (221, 225, 'CONDITION', 'pain'), (230, 240, 'CONDITION', 'tenderness'), (308, 320, 'CONDITION', 'fibromyalgia'), (368, 379, 'OTHER', 'acupuncture'), (381, 393, 'OTHER', 'chiropractic'), (398, 413, 'OTHER', 'massage therapy'), (439, 451, 'CONDITION', 'fibromyalgia'), (530, 542, 'CONDITION', 'fibromyalgia'), (544, 556, 'CONDITION', 'Fibromyalgia'), (624, 645, 'CONDITION', 'rheumatologic disease'), (647, 659, 'CONDITION', 'Fibromyalgia'), (780, 792, 'CONDITION', 'Fibromyalgic'), (941, 952, 'OTHER', 'spa therapy'), (1028, 1040, 'CONDITION', 'fibromyalgia')]"
"['Transcutaneous', 'Stimulation', 'and', 'Mobility', 'Device', 'Use', 'for', 'Individuals', 'With', 'Neurologic', 'Conditions', '|', 'This', 'research', 'study', 'will', 'combine', 'non', '-', 'invasive', 'spinal', 'stimulation', 'with', 'mobility', 'devices', 'to', 'examine', 'the', 'acute', 'impact', 'of', 'the', 'individual', 'and', 'combined', 'effects', 'of', 'these', 'innovative', 'techniques', 'on', 'mobility', 'in', 'children', 'with', 'cerebral', 'palsy', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05520359,NCT05520359,Transcutaneous Stimulation and Mobility Device Use for Individuals With Neurologic Conditions | This research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.,"[(0, 26, 'OTHER', 'Transcutaneous Stimulation'), (31, 50, 'OTHER', 'Mobility Device Use'), (129, 160, 'OTHER', 'non-invasive spinal stimulation'), (166, 182, 'OTHER', 'mobility devices'), (310, 324, 'CONDITION', 'cerebral palsy')]"
"['Brain', 'Diseases', 'on', '7.0', 'T', 'Magnetic', 'Resonance', 'Imaging', '|', 'This', 'clinical', 'trial', 'studies', 'the', 'use', 'of', '7', '-', 'Tesla', '(', '7T)and', '3', 'T', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'in', 'detecting', 'brain', 'diseases', '.', '7', 'T', 'MRI', 'has', 'increased', 'detection', 'sensitivity', ',', 'including', 'more', 'accurate', 'lesion', 'delineation', ',', 'higher', 'inter', '-', 'rater', 'agreement', '.', 'Diagnostic', 'procedures', 'such', 'as', '7', 'T', 'MRI', 'may', 'help', 'ultimately', 'improved', 'diagnostic', 'and', 'therapies', 'confidence', 'to', 'inform', 'decision', 'making', 'than', 'standard', '3', 'T', 'MRI', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05287750,NCT05287750,"Brain Diseases on 7.0T Magnetic Resonance Imaging | This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.",[]
"['Interventional', 'Cross', '-', 'over', 'Study', 'to', 'Evaluate', 'the', 'Modulators', 'of', 'Efficacy', 'of', 'Alternating', 'Current', 'Brain', 'Stimulation', '(', 'tACS', ')', 'in', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', '|', 'Brain', 'oscillations', 'are', 'ubiquitous', 'in', 'the', 'human', 'brain', 'and', 'have', 'been', 'implicated', 'in', 'cognitive', 'and', 'behavioral', 'states', 'defined', 'in', 'precisely', 'tuned', 'neural', 'networks', '.', 'In', 'neurodegenerative', 'disorders', ',', 'neurodegeneration', 'is', 'accompanied', 'by', 'changes', 'in', 'oscillatory', 'activity', 'leading', 'to', 'the', 'emerging', 'concept', 'of', 'neurological', 'and', 'psychiatric', 'disorders', 'as', '""', 'oscillopathies', '""', '.', 'Alzheimer', ""'s"", 'disease', ',', 'which', 'accounts', 'for', 'the', 'vast', 'majority', 'of', 'age', '-', 'related', 'dementias', ',', 'is', 'characterised', 'by', 'a', 'prominent', 'disruption', 'of', 'oscillations', 'in', 'the', 'gamma', 'frequency', 'band', '.', 'The', 'restoration', 'of', 'gamma', 'oscillations', 'by', 'neural', 'entrainment', 'in', 'animal', 'models', 'of', 'Alzheimer', ""'s"", 'disease', 'have', 'shown', 'a', 'remarkable', 'decrease', 'in', 'the', 'pathological', 'burden', 'of', 'amyloid', 'and', 'tau', 'via', 'increased', 'microglial', 'activity', ',', 'resulting', 'in', 'a', 'significant', 'increase', 'of', 'cognitive', 'performances', '.', '\n\n', 'Transcranial', 'alternating', 'current', 'brain', 'stimulation', '(', 'tACS', ')', ',', 'is', 'a', 'neurophysiological', 'method', 'of', 'non', '-', 'invasive', 'modulation', 'of', 'the', 'excitability', 'of', 'the', 'central', 'nervous', 'system', 'that', 'is', 'having', 'an', 'increasingly', 'numerous', 'spectrum', 'of', 'potential', 'therapeutic', 'applications', '.', 'Recent', 'studies', 'have', 'demonstrated', 'the', 'effectiveness', 'of', 'this', 'method', 'in', 'modulating', 'the', 'natural', 'frequencies', 'of', 'cerebral', 'oscillation', ',', 'underlying', 'multiple', 'cognitive', 'processes', 'such', 'as', 'verbal', 'memory', ',', 'perception', 'and', 'working', 'memory', '.', 'On', 'the', 'basis', 'of', 'these', 'premises', ',', 'the', 'treatment', 'with', 'gamma', 'tACS', 'is', 'proposed', 'in', 'patients', 'affected', 'by', 'Alzheimer', ""'s"", 'disease', '.', '\n\n', 'In', 'this', 'randomized', ',', 'double', '-', 'blind', ',', 'sham', '-', 'controlled', ',', 'cross', '-', 'over', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'modulators', 'of', 'response', 'on', 'cognitive', 'measure', 'to', 'a', 'single', 'stimulation', 'with', 'gamma', 'tACS', 'on', 'the', 'posterior', 'parietal', 'cortex', 'in', 'patients', 'with', 'Mild', 'Cognitive', 'Impairment', 'due', 'to', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04842955,NCT04842955,"Interventional Cross-over Study to Evaluate the Modulators of Efficacy of Alternating Current Brain Stimulation (tACS) in Patients With Alzheimer's Disease | Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as ""oscillopathies"". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.

Transcranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory. On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.

In this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.","[(74, 111, 'OTHER', 'Alternating Current Brain Stimulation'), (113, 117, 'OTHER', 'tACS'), (136, 155, 'CONDITION', ""Alzheimer's Disease""), (510, 529, 'CONDITION', ""Alzheimer's disease""), (583, 592, 'CONDITION', 'dementias'), (762, 781, 'CONDITION', ""Alzheimer's disease""), (960, 1010, 'OTHER', 'Transcranial alternating current brain stimulation'), (1012, 1016, 'OTHER', 'tACS'), (1495, 1499, 'OTHER', 'tACS'), (1536, 1555, 'CONDITION', ""Alzheimer's disease""), (1592, 1596, 'CONTROL', 'sham'), (1736, 1779, 'OTHER', 'gamma tACS on the posterior parietal cortex'), (1797, 1822, 'CONDITION', 'Mild Cognitive Impairment'), (1830, 1849, 'CONDITION', ""Alzheimer's disease"")]"
"['Brain', 'Safe', ':', 'Consumer', 'Intervention', 'to', 'Reduce', 'Exposure', 'to', 'Drugs', 'Linked', 'to', 'Alzheimer', ""'s"", 'Disease', '|', 'This', 'study', 'is', 'an', 'RCT', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'Brain', 'Safe', 'on', 'reducing', 'anticholinergic', 'exposure', '.', 'Over', '42', 'months', ',', 'the', 'trial', 'will', 'enroll', '700', 'community', '-', 'dwelling', 'older', 'adults', 'who', 'were', 'prescribed', 'one', 'or', 'more', 'strong', 'anticholinergics', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'use', 'the', 'Brain', 'Safe', 'app', 'or', 'an', 'attention', 'control', 'medication', 'list', 'app', 'for', '12', 'months', ',', 'with', 'monthly', 'usage', 'reminders', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04121858,NCT04121858,"Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease | This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.","[(0, 10, 'OTHER', 'Brain Safe'), (72, 91, 'CONDITION', ""Alzheimer's Disease""), (148, 158, 'OTHER', 'Brain Safe'), (371, 385, 'OTHER', 'Brain Safe app'), (392, 429, 'OTHER', 'attention control medication list app')]"
"['Effect', 'of', 'Robot', 'Rehabilitation', 'Exercise', 'Training', 'on', 'Motor', 'Control', 'After', 'Stroke', '|', 'Stroke', 'is', 'a', 'leading', 'cause', 'of', 'neurological', 'disability', 'worldwide', ',', 'often', 'causing', 'significant', 'weakening', 'and', 'paresis', 'of', 'the', 'affected', 'arm', '.', 'National', 'spending', 'on', 'post', '-', 'stroke', 'rehabilitation', 'is', 'project', 'to', 'expand', '20', '%', 'to', '35', '%', 'through', '2010', '.', 'As', 'a', 'new', 'tool', 'for', 'therapists', ',', 'robotic', 'stroke', 'therapy', 'devices', 'have', 'the', 'potential', 'to', 'be', 'a', 'cost', '-', 'effective', 'device', 'aid', 'to', 'physical', 'therapy', 'and', 'enable', 'novel', 'modes', 'of', 'exercise', 'not', 'currently', 'available', '.', 'While', 'recent', 'studies', 'have', 'shown', 'chronic', 'patients', 'benefit', 'from', 'repetitive', 'practice', ',', 'it', 'is', 'not', 'clear', 'whether', 'they', 'improved', 'via', 'a', 'reduction', 'in', 'impairment', 'or', 'increased', 'functional', 'compensation', 'because', 'there', 'is', 'a', 'lack', 'of', 'standard', 'treatment', 'and', 'scales', 'to', 'assess', 'rehabilitation', 'efficacy', 'in', 'chronic', 'stroke', 'patients', '.', 'This', 'study', 'aims', 'to', 'reconcile', 'difference', 'performance', 'measurements', 'in', 'robotic', 'rehabilitation', 'to', 'assess', 'the', 'outcome', 'of', 'robotic', 'rehabilitation', 'training', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O']",NCT02331407,NCT02331407,"Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke | Stroke is a leading cause of neurological disability worldwide, often causing significant weakening and paresis of the affected arm. National spending on post-stroke rehabilitation is project to expand 20% to 35% through 2010. As a new tool for therapists, robotic stroke therapy devices have the potential to be a cost-effective device aid to physical therapy and enable novel modes of exercise not currently available. While recent studies have shown chronic patients benefit from repetitive practice, it is not clear whether they improved via a reduction in impairment or increased functional compensation because there is a lack of standard treatment and scales to assess rehabilitation efficacy in chronic stroke patients. This study aims to reconcile difference performance measurements in robotic rehabilitation to assess the outcome of robotic rehabilitation training.","[(10, 48, 'PHYSICAL', 'Robot Rehabilitation Exercise Training'), (72, 78, 'CONDITION', 'Stroke'), (81, 87, 'CONDITION', 'Stroke'), (235, 246, 'CONDITION', 'post-stroke'), (338, 360, 'PHYSICAL', 'robotic stroke therapy'), (784, 798, 'CONDITION', 'chronic stroke'), (877, 899, 'PHYSICAL', 'robotic rehabilitation'), (925, 956, 'PHYSICAL', 'robotic rehabilitation training')]"
"['Spine', 'Stereotactic', 'Body', 'Radiation', 'Therapy', 'for', 'Metastatic', 'Epidural', 'Spinal', 'Cord', ':', 'Prospective', 'Phase', 'II', 'Study', '|', 'Metastatic', 'epidural', 'spinal', 'cord', 'compression', '(', 'MESCC', ')', 'is', 'a', 'frequent', 'oncologic', 'emergency', 'that', 'requires', 'to', 'be', 'treated', 'promptly', '.', 'Although', 'direct', 'decompressive', 'surgery', 'is', 'the', 'most', 'effective', 'treatment', ',', 'surgery', 'is', 'only', 'used', 'in', 'selected', 'patients', 'because', 'most', 'patients', 'have', 'a', 'poor', 'overall', 'condition', 'and', 'short', 'life', 'expectancy', '.', 'Radiation', 'therapy', '(', 'RT', ')', ',', 'therefore', ',', 'is', 'the', 'most', 'commonly', 'used', 'for', 'patients', 'with', 'MESCC', ',', 'but', 'conventional', 'RT', 'alone', 'can', 'achieve', 'modest', 'neurologic', 'outcomes', '.', '\n\n', 'The', 'hypothesis', 'to', 'use', 'stereotactic', 'body', 'radiation', 'therapy', '(', 'SBRT', ')', 'for', 'MESCC', 'is', 'that', 'the', 'rapid', 'decompression', 'of', 'epidural', 'mass', ',', 'durable', 'local', 'control', 'and', 'subsequently', 'improved', 'neurologic', 'outcomes', 'compared', 'to', 'conventional', 'RT', 'are', 'expected', 'when', 'MESCC', 'is', 'treated', 'with', 'SBRT', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-RADIO', 'O']",NCT01826058,NCT01826058,"Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord: Prospective Phase II Study | Metastatic epidural spinal cord compression (MESCC) is a frequent oncologic emergency that requires to be treated promptly. Although direct decompressive surgery is the most effective treatment, surgery is only used in selected patients because most patients have a poor overall condition and short life expectancy. Radiation therapy (RT), therefore, is the most commonly used for patients with MESCC, but conventional RT alone can achieve modest neurologic outcomes.

The hypothesis to use stereotactic body radiation therapy (SBRT) for MESCC is that the rapid decompression of epidural mass, durable local control and subsequently improved neurologic outcomes compared to conventional RT are expected when MESCC is treated with SBRT.","[(0, 41, 'RADIOTHERAPY', 'Spine Stereotactic Body Radiation Therapy'), (46, 77, 'CONDITION', 'Metastatic Epidural Spinal Cord'), (108, 151, 'CONDITION', 'Metastatic epidural spinal cord compression'), (153, 158, 'CONDITION', 'MESCC'), (424, 441, 'RADIOTHERAPY', 'Radiation therapy'), (443, 445, 'RADIOTHERAPY', 'RT'), (503, 508, 'CONDITION', 'MESCC'), (514, 535, 'CONTROL', 'conventional RT alone'), (599, 634, 'RADIOTHERAPY', 'stereotactic body radiation therapy'), (636, 640, 'RADIOTHERAPY', 'SBRT'), (646, 651, 'CONDITION', 'MESCC'), (782, 797, 'CONTROL', 'conventional RT'), (816, 821, 'CONDITION', 'MESCC'), (838, 842, 'RADIOTHERAPY', 'SBRT')]"
"['Asymptomatic', 'Carotid', 'Surgery', 'Trial-2', '(', 'ACST-2', '):', 'an', 'International', 'Randomised', 'Trial', 'to', 'Compare', 'Carotid', 'Endarterectomy', 'With', 'Carotid', 'Artery', 'Stenting', 'to', 'Prevent', 'Stroke', '|', 'The', 'trial', 'randomise', 'patients', 'with', 'asymptomatic', 'carotid', 'artery', 'narrowing', 'in', 'whom', 'prompt', 'physical', 'intervention', 'is', 'thought', 'to', 'be', 'needed', ',', 'but', 'there', 'there', 'is', 'still', 'substantial', 'uncertainty', 'shared', 'by', 'patient', 'and', 'doctor', 'about', 'whether', 'surgery', 'or', 'stenting', 'is', 'the', 'more', 'appropriate', 'choice', '.', '\n\n', 'The', 'study', 'is', 'looking', 'at', 'immediate', 'risks', '(', 'within', 'one', 'month)and', 'at', 'long', 'term', 'benefits']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00883402,NCT00883402,"Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke | The trial randomise patients with asymptomatic carotid artery narrowing in whom prompt physical intervention is thought to be needed, but there there is still substantial uncertainty shared by patient and doctor about whether surgery or stenting is the more appropriate choice.

The study is looking at immediate risks (within one month)and at long term benefits","[(92, 114, 'SURGICAL', 'Carotid Endarterectomy'), (120, 143, 'SURGICAL', 'Carotid Artery Stenting'), (155, 161, 'CONDITION', 'Stroke'), (198, 235, 'CONDITION', 'asymptomatic carotid artery narrowing'), (390, 397, 'SURGICAL', 'surgery'), (401, 409, 'SURGICAL', 'stenting')]"
"['Masseter', 'Myofascial', 'Pain', 'Relief', 'Following', 'an', 'Intra', '-', 'muscular', 'Injection', 'With', 'Botulinum', 'Toxin', 'Type', 'A', ':', 'A', 'Randomized', 'Double', '-', 'blind', 'Controlled', 'Multicenter', 'Pilot', 'Study', '|', 'Investigating', 'the', 'effect', 'of', 'a', 'single', 'intramuscular', 'injection', 'with', 'botulinum', 'toxin', '(', 'BTX', ')', 'compared', 'to', 'NaCl', 'in', 'patients', 'with', 'jaw', 'muscle', 'myalgia', '.', '\n\n', 'This', 'investigation', 'is', 'designed', 'as', 'an', 'double', 'blind', 'multicenter', 'pilot', 'study', 'for', 'hypothesis', 'generation', 'on', '48', 'patients', 'with', 'chronic', 'jaw', 'muscle', 'myalgia', 'at', 'four', 'specialist', 'dental', 'clinics', '.', 'The', 'subjects', 'visit', 'the', 'clinic', 'on', '3', 'predefined', 'occasions', ',', 'one', 'telephone', 'call', 'and', 'one', 'scheduled', 'evaluation', 'by', 'mail', '.', '\n\n', 'The', 'objective', 'is', 'primarily', 'to', 'evaluate', 'the', 'change', 'in', 'number', 'of', 'days', 'with', 'pain', 'at', 'two', 'months', 'following', 'one', 'session', 'of', 'BTX', 'injections', 'of', 'the', 'masseter', 'and', 'temporalis', 'muscles', 'in', 'subjects', 'with', 'jaw', 'muscle', 'myalgia', 'pain', '.', '\n\n', 'The', 'outcome', 'of', 'this', 'study', 'will', 'serve', 'as', 'a', 'basis', 'for', 'a', 'later', 'randomized', 'controlled', 'trial']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04426123,NCT04426123,"Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A: A Randomized Double-blind Controlled Multicenter Pilot Study | Investigating the effect of a single intramuscular injection with botulinum toxin (BTX) compared to NaCl in patients with jaw muscle myalgia.

This investigation is designed as an double blind multicenter pilot study for hypothesis generation on 48 patients with chronic jaw muscle myalgia at four specialist dental clinics. The subjects visit the clinic on 3 predefined occasions, one telephone call and one scheduled evaluation by mail.

The objective is primarily to evaluate the change in number of days with pain at two months following one session of BTX injections of the masseter and temporalis muscles in subjects with jaw muscle myalgia pain.

The outcome of this study will serve as a basis for a later randomized controlled trial","[(75, 97, 'DRUG', 'Botulinum Toxin Type A'), (228, 243, 'DRUG', 'botulinum toxin'), (245, 248, 'DRUG', 'BTX'), (262, 266, 'DRUG', 'NaCl'), (284, 302, 'CONDITION', 'jaw muscle myalgia'), (425, 451, 'CONDITION', 'chronic jaw muscle myalgia'), (719, 722, 'DRUG', 'BTX'), (790, 808, 'CONDITION', 'jaw muscle myalgia')]"
"['Assessment', 'of', 'Service', 'and', 'Hearing', 'Dogs', '|', 'For', 'persons', 'with', 'impairments', 'and', 'certain', 'illnesses', 'the', 'use', 'of', 'service', 'dogs', 'may', 'have', 'positive', 'effect', '.', 'The', 'effects', 'of', 'using', 'these', 'dogs', 'to', 'assist', 'in', 'every', 'day', 'life', 'need', 'to', 'be', 'studied', 'further', '.', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'assess', 'how', 'health', 'care', 'consumption', 'was', 'effected', 'by', 'using', 'certified', 'service', 'dogs', 'and', 'to', 'study', 'the', 'cost', '-', 'effectiveness', 'of', 'having', 'a', 'certified', 'service', 'dog', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",NCT03270592,NCT03270592,Assessment of Service and Hearing Dogs | For persons with impairments and certain illnesses the use of service dogs may have positive effect. The effects of using these dogs to assist in every day life need to be studied further.The aim of the study was to assess how health care consumption was effected by using certified service dogs and to study the cost-effectiveness of having a certified service dog.,"[(14, 38, 'OTHER', 'Service and Hearing Dogs'), (58, 69, 'CONDITION', 'impairments'), (103, 115, 'OTHER', 'service dogs'), (324, 336, 'OTHER', 'service dogs'), (395, 406, 'OTHER', 'service dog')]"
"['ANRS', '12404', 'TIMPANI', ':', 'Tnf', 'Inhibitors', 'to', 'Reduce', 'Mortality', 'in', 'HIV-1', 'Infected', 'PAtients', 'With', 'Tuberculosis', 'meNIngitis', ':', 'a', 'Phase', 'II', ',', 'Multicenter', ',', 'Randomized', 'Clinical', 'Trial', '|', 'Randomized', 'phase', 'II', 'clinical', 'trial', 'which', 'aims', 'to', 'assess', 'the', 'impact', 'on', '3', '-', 'month', 'mortality', 'and', 'safety', 'of', 'adding', 'adalimumab', 'to', 'standard', 'treatment', '(', 'anti', '-', 'tuberculosis', 'drugs', 'and', 'corticosteroids', ')', 'in', 'HIV', 'patients', 'with', 'tuberculosis', 'meningitis', 'in', '3', 'countries', '(', 'Brazil', ',', 'Mozambique', ',', 'and', 'Zambia', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05590455,NCT05590455,"ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial | Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).","[(20, 34, 'DRUG', 'Tnf Inhibitors'), (58, 63, 'CONDITION', 'HIV-1'), (87, 110, 'CONDITION', 'Tuberculosis meNIngitis'), (274, 284, 'DRUG', 'adalimumab'), (356, 359, 'CONDITION', 'HIV'), (374, 397, 'CONDITION', 'tuberculosis meningitis')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Double', '-', 'Dummy', ',', 'Active', '-', 'Controlled', ',', 'Parallel', ',', 'Comparative', ',', 'Multicenter', ',', 'Phase', 'II', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'STA-1', 'Capsule', 'in', 'Patients', 'With', 'Vascular', 'Dementia', '(', 'Marrow', '-', 'Sea', 'Deficiency', ')', '|', 'The', 'objectives', 'of', 'this', 'phase', 'II', 'study', 'of', 'STA-1', 'capsule', 'was', 'to', 'make', 'preliminary', 'evaluation', 'on', 'clinical', 'efficacy', 'and', 'safety', 'of', 'STA-1', 'capsule', 'in', 'order', 'that', 'based', 'on', 'the', 'dosage', 'and', 'study', 'structure', 'planned', 'in', 'this', 'project', ',', 'the', 'dosage', 'and', 'study', 'structure', 'of', 'phase', 'III', 'study', 'can', 'be', 'confirmed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01475578,NCT01475578,"A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) | The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.","[(151, 164, 'OTHER', 'STA-1 Capsule'), (182, 199, 'CONDITION', 'Vascular Dementia'), (201, 222, 'CONDITION', 'Marrow-Sea Deficiency'), (267, 280, 'OTHER', 'STA-1 capsule'), (351, 364, 'OTHER', 'STA-1 capsule')]"
"['The', 'Identification', 'and', 'Prevention', 'of', 'Sarcopenia', 'in', 'Older', 'Patients', 'in', 'the', 'Acute', 'Hospital', 'Setting', '|', 'This', 'study', 'will', 'assess', 'whether', 'the', 'use', 'of', 'technology', 'using', 'the', 'Virtual', 'Gate', 'Device', '(', 'VGD', ')', 'will', 'prevent', 'or', 'minimize', 'the', 'development', 'of', 'hospital', 'acquired', 'Sarcopenia', 'resulting', 'from', 'Immobilization', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT04092790,NCT04092790,The Identification and Prevention of Sarcopenia in Older Patients in the Acute Hospital Setting | This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.,"[(37, 47, 'CONDITION', 'Sarcopenia'), (161, 180, 'OTHER', 'Virtual Gate Device'), (182, 185, 'OTHER', 'VGD'), (249, 259, 'CONDITION', 'Sarcopenia')]"
"['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Single', 'and', 'Repeated', 'Dose', 'Escalation', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'AUT00206', 'in', 'Healthy', 'Volunteers', '.', '|', 'The', 'study', 'medicine', 'is', 'a', 'potential', 'future', 'treatment', 'for', 'schizophrenia', ',', 'an', 'illness', 'that', 'affects', 'the', 'way', 'that', 'people', 'think', ',', 'feel', 'or', 'behave', '.', 'It', 'is', 'not', 'clear', 'what', 'causes', 'schizophrenia', ',', 'but', 'it', ""'s"", 'been', 'linked', 'to', 'chemical', 'imbalance', 'in', 'the', 'brain', '.', 'It', 'is', 'hoped', 'that', 'the', 'study', 'medicine', 'will', 'activate', 'specific', 'sites', 'in', 'the', 'brain', 'to', 'help', 'correct', 'that', 'imbalance', '.', 'Current', 'treatments', 'for', 'schizophrenia', 'do', ""n't"", 'work', 'very', 'well', 'and', 'can', 'cause', 'unpleasant', 'side', 'effects', '.', 'It', 'is', 'hoped', 'that', 'the', 'study', 'medicine', 'will', 'work', 'better', ',', 'and', 'have', 'fewer', 'side', 'effects', 'than', 'existing', 'medicines', '.', '\n\n', 'In', 'this', '2', 'part', 'study', '(', 'Parts', 'A', 'and', 'B', ')', ',', 'the', 'primary', 'aim', 'is', 'to', 'assess', 'how', 'safe', 'the', 'study', 'medicine', 'is', 'in', 'healthy', 'men', ',', 'aged', '18', '-', '45', 'years', ',', 'and', 'how', 'much', 'of', 'it', 'gets', 'into', 'the', 'blood', '.', 'Its', 'effects', 'on', 'the', 'brain', 'will', 'also', 'be', 'tested', '.', '\n\n', 'In', 'Part', 'A', ',', 'up', 'to', '24', 'participants', 'will', 'receive', 'up', 'to', '5', 'single', 'doses', 'of', 'the', 'study', 'medicine', '(', 'AUT00206', 'or', 'placebo', ')', 'by', 'mouth', ',', 'either', 'after', 'fasting', 'or', 'after', 'a', 'high', 'fat', 'breakfast', '.', 'The', 'study', 'medicine', 'has', 'never', 'been', 'given', 'to', 'humans', 'before', ',', 'so', 'the', 'initial', 'doses', 'will', 'be', 'small', 'and', 'the', 'dose', 'level', 'will', 'be', 'increased', 'as', 'the', 'study', 'progresses', '.', 'Participants', 'may', 'take', 'up', 'to', '14', 'weeks', 'to', 'finish', 'the', 'study', '.', 'They', ""'ll"", 'make', 'up', 'to', '22', 'outpatient', 'visits', ',', 'and', 'stay', 'on', 'the', 'ward', 'up', 'to', '5', 'times', ',', 'for', '3', 'nights', 'in', 'a', 'row', 'each', 'time', '.', '\n\n', 'In', 'Part', 'B', ',', '24', 'participants', 'will', 'receive', 'daily', 'doses', 'of', 'the', 'study', 'medicine', '(', 'AUT00206', 'or', 'placebo', ')', 'for', 'up', 'to', '28', 'days', '.', 'Participants', 'will', 'take', 'up', 'to', '10', 'weeks', 'to', 'finish', 'the', 'study', '.', 'They', ""'ll"", 'make', '6', 'outpatient', 'visits', ',', 'and', 'stay', 'on', 'the', 'ward', 'for', 'up', 'to', '30', 'nights', ',', 'depending', 'on', 'how', 'long', 'we', 'expect', 'it', 'to', 'take', 'until', 'blood', 'levels', 'of', 'the', 'study', 'medicine', 'level', 'off', '.', '\n\n', 'A', 'pharmaceutical', 'company', ',', 'Autifony', 'Therapeutics', 'Limited', ',', 'is', 'funding', 'the', 'study', '.', 'The', 'study', 'will', 'take', 'place', 'at', '1', 'centre', 'in', 'London', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02589262,NCT02589262,"A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers. | The study medicine is a potential future treatment for schizophrenia, an illness that affects the way that people think, feel or behave. It is not clear what causes schizophrenia, but it's been linked to chemical imbalance in the brain. It is hoped that the study medicine will activate specific sites in the brain to help correct that imbalance. Current treatments for schizophrenia don't work very well and can cause unpleasant side effects. It is hoped that the study medicine will work better, and have fewer side effects than existing medicines.

In this 2 part study (Parts A and B), the primary aim is to assess how safe the study medicine is in healthy men, aged 18-45 years, and how much of it gets into the blood. Its effects on the brain will also be tested.

In Part A, up to 24 participants will receive up to 5 single doses of the study medicine (AUT00206 or placebo) by mouth, either after fasting or after a high fat breakfast. The study medicine has never been given to humans before, so the initial doses will be small and the dose level will be increased as the study progresses. Participants may take up to 14 weeks to finish the study. They'll make up to 22 outpatient visits, and stay on the ward up to 5 times, for 3 nights in a row each time.

In Part B, 24 participants will receive daily doses of the study medicine (AUT00206 or placebo) for up to 28 days. Participants will take up to 10 weeks to finish the study. They'll make 6 outpatient visits, and stay on the ward for up to 30 nights, depending on how long we expect it to take until blood levels of the study medicine level off.

A pharmaceutical company, Autifony Therapeutics Limited, is funding the study. The study will take place at 1 centre in London.","[(28, 35, 'CONTROL', 'Placebo'), (167, 175, 'DRUG', 'AUT00206'), (1062, 1070, 'DRUG', 'AUT00206'), (1074, 1081, 'CONTROL', 'placebo'), (1544, 1552, 'DRUG', 'AUT00206'), (1556, 1563, 'CONTROL', 'placebo')]"
"['Pre', '-', 'emptive', 'Intravenous', 'Morphine', 'for', 'Acute', 'Post', '-', 'craniotomy', 'Pain', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '.', '|', 'We', 'propose', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'trial', 'to', 'evaluate', 'the', 'effect', 'of', 'intravenously', 'administered', 'morphine', 'at', 'surgery', 'conclusion', 'on', 'acute', 'postoperative', 'pain', 'in', 'patients', 'recovering', 'from', 'craniotomy', 'surgery', '.', 'Participating', 'adults', 'having', 'craniotomy', 'surgery', 'will', 'be', 'randomized', 'in', 'a', '1:1', 'ratio', 'to', 'intraoperative', 'intravenous', 'administration', 'of', '0.08', 'mg', '/', 'kg', 'morphine', 'at', 'dura', 'closure', ',', 'or', 'a', 'matching', 'placebo', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05117034,NCT05117034,"Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain: a Randomized, Double-blind, Placebo-controlled Trial. | We propose a double-blind randomized controlled trial to evaluate the effect of intravenously administered morphine at surgery conclusion on acute postoperative pain in patients recovering from craniotomy surgery. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.","[(24, 32, 'DRUG', 'Morphine'), (37, 63, 'CONDITION', 'Acute Post-craniotomy Pain'), (93, 100, 'CONTROL', 'Placebo'), (228, 236, 'DRUG', 'morphine'), (240, 247, 'CONDITION', 'surgery'), (262, 286, 'CONDITION', 'acute postoperative pain'), (315, 333, 'CONDITION', 'craniotomy surgery'), (363, 381, 'CONDITION', 'craniotomy surgery'), (475, 483, 'DRUG', 'morphine'), (515, 522, 'CONTROL', 'placebo')]"
"['Patient', '-', 'Oriented', 'TCM', 'Intervention', 'for', 'DSP', 'in', 'HIV', ':', 'A', 'Pilot', 'Study', '|', 'This', 'preliminary', 'study', 'will', 'investigate', 'the', 'use', 'of', 'Acupuncture', 'and', 'Moxibustion', '(', 'Acu', '/', 'Moxa', ')', 'for', 'distal', 'symmetric', 'peripheral', 'neuropathy', '(', 'DSP', ')', 'associated', 'with', 'HIV', 'applying', 'traditional', 'Chinese', 'medicine', '(', 'TCM', ')', 'evaluations', 'conducted', 'by', 'a', 'diagnostic', 'acupuncturist', '.', 'The', 'investigators', 'will', 'evaluate', 'the', 'role', 'of', 'Acu', '/', 'Moxa', 'in', 'reducing', 'the', 'symptoms', 'of', 'DSP', 'related', 'to', 'HIV', '/', 'AIDS', 'and', 'treatment', 'side', 'effects', '.', 'The', 'effects', 'of', 'symptom', 'reduction', 'on', 'quality', 'of', 'life', 'will', 'also', 'be', 'examined', '.', 'This', 'application', 'will', 'establish', 'a', 'proof', 'of', 'principle', 'for', 'the', 'role', 'of', 'Acu', '/', 'Moxa', 'in', 'the', 'treatment', 'of', 'DSP', 'and', 'provide', 'data', 'that', 'will', 'serve', 'as', 'a', 'foundation', 'for', 'establishing', 'a', 'future', 'larger', 'clinical', 'trial', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00826345,NCT00826345,Patient-Oriented TCM Intervention for DSP in HIV: A Pilot Study | This preliminary study will investigate the use of Acupuncture and Moxibustion (Acu/Moxa) for distal symmetric peripheral neuropathy (DSP) associated with HIV applying traditional Chinese medicine (TCM) evaluations conducted by a diagnostic acupuncturist. The investigators will evaluate the role of Acu/Moxa in reducing the symptoms of DSP related to HIV/AIDS and treatment side effects. The effects of symptom reduction on quality of life will also be examined. This application will establish a proof of principle for the role of Acu/Moxa in the treatment of DSP and provide data that will serve as a foundation for establishing a future larger clinical trial.,"[(17, 33, 'OTHER', 'TCM Intervention'), (38, 41, 'CONDITION', 'DSP'), (45, 48, 'CONDITION', 'HIV'), (117, 128, 'OTHER', 'Acupuncture'), (133, 144, 'OTHER', 'Moxibustion'), (146, 149, 'OTHER', 'Acu'), (150, 154, 'OTHER', 'Moxa'), (160, 198, 'CONDITION', 'distal symmetric peripheral neuropathy'), (200, 203, 'CONDITION', 'DSP'), (221, 224, 'CONDITION', 'HIV'), (234, 262, 'OTHER', 'traditional Chinese medicine'), (264, 267, 'OTHER', 'TCM'), (366, 369, 'OTHER', 'Acu'), (370, 374, 'OTHER', 'Moxa'), (403, 406, 'CONDITION', 'DSP'), (418, 421, 'CONDITION', 'HIV'), (422, 426, 'CONDITION', 'AIDS'), (599, 602, 'OTHER', 'Acu'), (603, 607, 'OTHER', 'Moxa'), (628, 631, 'CONDITION', 'DSP')]"
"['Evaluation', 'of', 'the', 'Upper', 'Airway', 'Collapse', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'by', 'Drug', 'Induced', 'Sleep', 'Endoscopy', 'According', 'to', 'the', 'Munich', 'Sleep', 'Video', 'Protocol', '|', 'This', 'is', 'a', 'prospective', ',', 'interventional', 'cohort', 'study', 'of', 'drug', '-', 'induced', 'sleep', 'endoscopy', '(', 'DISE', ')', '.', 'The', 'goal', 'is', 'to', 'evaluate', 'the', 'upper', 'airway', 'in', 'a', 'cohort', 'of', 'patients', 'with', 'obstructive', 'sleep', 'apnea', 'hypopnea', 'syndrome', '(', 'OSAHS', ')', 'diagnosed', 'in', 'a', 'prior', 'polysomnography', '.', '\n\n', 'This', 'study', 'correlates', 'the', 'sedation', 'level', 'measured', 'by', 'entropy', 'during', 'DISE', 'using', 'propofol', 'via', 'a', 'TCI', 'pump', 'with', 'the', 'local', 'obstruction', 'patterns', 'of', 'the', 'upper', 'airway', 'according', 'to', 'the', 'VOTE', 'classification', '.', '\n\n', 'As', 'OSAHS', 'is', 'a', 'widespread', 'disease', 'and', 'the', 'DISE', 'procedure', 'has', 'become', 'a', 'common', 'tool', 'for', 'diagnosis', 'and', 'evaluation', 'of', 'further', 'treatment', ',', 'a', 'growing', 'number', 'of', 'research', 'articles', 'deal', 'with', 'this', 'topic', '.', 'These', 'articles', 'are', 'available', 'through', 'pubmed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02588300,NCT02588300,"Evaluation of the Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy According to the Munich Sleep Video Protocol | This is a prospective, interventional cohort study of drug-induced sleep endoscopy (DISE). The goal is to evaluate the upper airway in a cohort of patients with obstructive sleep apnea hypopnea syndrome (OSAHS) diagnosed in a prior polysomnography.

This study correlates the sedation level measured by entropy during DISE using propofol via a TCI pump with the local obstruction patterns of the upper airway according to the VOTE classification.

As OSAHS is a widespread disease and the DISE procedure has become a common tool for diagnosis and evaluation of further treatment, a growing number of research articles deal with this topic. These articles are available through pubmed.","[(57, 89, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (330, 371, 'CONDITION', 'obstructive sleep apnea hypopnea syndrome'), (373, 378, 'CONDITION', 'OSAHS'), (620, 625, 'CONDITION', 'OSAHS')]"
"['Visual', 'Field', 'Restoration', 'in', 'Patients', 'With', 'Post', '-', 'stroke', 'Homonymous', 'Hemianopsia', '|', 'This', 'study', 'will', 'assess', 'the', 'effectiveness', 'of', 'a', 'stimulus', ',', 'in', 'the', 'blind', 'field', 'of', 'hemianopsic', 'patients', ',', 'to', 'restore', 'the', 'vision', 'of', 'patients', 'with', 'homonymous', 'hemianopsia', 'consecutive', 'to', 'stroke', '(', 'unilateral', 'occipital', 'lesion', ')', '.', 'Hemianopsia', 'occurs', 'in', '30', '%', 'of', 'strokes', 'regardless', 'of', 'the', 'cerebral', 'localization', 'and', 'in', '60', '%', 'of', 'stroke', 'interesting', 'the', 'territory', 'of', 'the', 'posterior', 'cerebral', 'artery', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02886663,NCT02886663,"Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia | This study will assess the effectiveness of a stimulus, in the blind field of hemianopsic patients, to restore the vision of patients with homonymous hemianopsia consecutive to stroke (unilateral occipital lesion). Hemianopsia occurs in 30% of strokes regardless of the cerebral localization and in 60% of stroke interesting the territory of the posterior cerebral artery.","[(0, 24, 'OTHER', 'Visual Field Restoration'), (42, 53, 'CONDITION', 'Post-stroke'), (54, 76, 'CONDITION', 'Homonymous Hemianopsia'), (125, 133, 'OTHER', 'stimulus'), (157, 168, 'CONDITION', 'hemianopsic'), (218, 240, 'CONDITION', 'homonymous hemianopsia'), (256, 262, 'CONDITION', 'stroke'), (294, 305, 'CONDITION', 'Hemianopsia'), (323, 330, 'CONDITION', 'strokes'), (385, 391, 'CONDITION', 'stroke')]"
"['Gypenosides', 'Treatment', 'for', 'Optic', 'Neuritis', ':', 'a', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'gypenosides', 'are', 'neuroprotective', 'in', 'patients', 'with', 'acute', 'optic', 'neuritis', '.']","['B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02976766,NCT02976766,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial | The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.","[(0, 11, 'DRUG', 'Gypenosides'), (26, 40, 'CONDITION', 'Optic Neuritis'), (70, 77, 'CONTROL', 'Placebo'), (147, 158, 'DRUG', 'gypenosides'), (196, 216, 'CONDITION', 'acute optic neuritis')]"
"['An', 'Open', '-', 'Label', 'Safety', 'And', 'Blood', 'Collection', 'Study', 'In', 'Mnb', 'Rlp2086', 'Vaccinated', 'Healthy', 'Adult', 'Volunteers', 'For', 'Immunological', 'Assay', 'Development', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'of', 'an', 'investigational', 'meningococcal', 'B', 'rLP2086', 'vaccine', 'in', 'adults', 'and', 'to', 'obtain', 'blood', 'samples', 'from', 'immunized', 'subjects', 'for', 'use', 'in', 'assay', 'development', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00780806,NCT00780806,An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development | The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.,"[(51, 62, 'DRUG', 'Mnb Rlp2086'), (211, 242, 'DRUG', 'meningococcal B rLP2086 vaccine')]"
"['Electrophysiological', 'Recordings', 'of', 'Deep', 'Brain', 'Stimulation', 'in', 'the', 'Basal', 'Ganglia', '|', 'The', 'pathology', 'of', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'and', 'the', 'mechanism', 'of', 'Deep', 'Brain', 'Stimulation', 'surgery', '(', 'DBS', ')', 'are', 'not', 'completely', 'understood', '.', 'The', 'recording', 'data', 'that', 'is', 'used', 'routinely', 'as', 'part', 'of', 'the', 'procedure', 'to', 'map', 'the', 'target', 'structures', ',', 'however', ',', 'may', 'be', 'analyzed', 'in', 'order', 'to', 'better', 'understand', 'the', 'neural', 'network', 'dynamics', 'in', 'PD', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'perform', 'simultaneous', 'neural', 'recordings', 'from', 'sub', '-', 'cortical', 'structures', '(', 'e.g.', 'subthalamic', 'nucleus', '[', 'STN', ']', 'or', 'globus', 'pallidus', 'internus', '[', 'GPi', ']', ')', 'and', 'the', 'cerebral', 'cortex', '.', 'These', 'simultaneous', 'recordings', 'may', 'provide', 'insight', 'in', 'the', 'pathology', 'of', 'PD', 'and', 'the', 'mechanism', 'of', 'DBS', '.', 'The', 'researchers', 'will', 'also', 'study', 'the', 'effects', 'of', 'anesthesia', 'level', 'on', 'neuron', 'synchronization', '.', 'Recordings', 'with', 'micro', '-', 'ECoG', 'grid', 'electrodes', 'in', 'the', 'cortex', 'show', 'improved', 'spatial', 'resolution', 'and', 'these', 'will', 'be', 'used', 'to', 'gain', 'better', 'understanding', 'of', 'cortical', 'network', 'dynamics', 'and', 'the', 'synchronization', 'with', 'subcortical', 'structures', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03088592,NCT03088592,"Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia | The pathology of Parkinson's disease (PD) and the mechanism of Deep Brain Stimulation surgery (DBS) are not completely understood. The recording data that is used routinely as part of the procedure to map the target structures, however, may be analyzed in order to better understand the neural network dynamics in PD. The purpose of the study is to perform simultaneous neural recordings from sub-cortical structures (e.g. subthalamic nucleus [STN] or globus pallidus internus [GPi]) and the cerebral cortex. These simultaneous recordings may provide insight in the pathology of PD and the mechanism of DBS. The researchers will also study the effects of anesthesia level on neuron synchronization . Recordings with micro-ECoG grid electrodes in the cortex show improved spatial resolution and these will be used to gain better understanding of cortical network dynamics and the synchronization with subcortical structures.","[(35, 78, 'OTHER', 'Deep Brain Stimulation in the Basal Ganglia'), (98, 117, 'CONDITION', ""Parkinson's disease""), (119, 121, 'CONDITION', 'PD'), (144, 174, 'OTHER', 'Deep Brain Stimulation surgery'), (176, 179, 'OTHER', 'DBS'), (395, 397, 'CONDITION', 'PD'), (660, 662, 'CONDITION', 'PD'), (684, 687, 'OTHER', 'DBS')]"
"['Music', 'Listening', 'for', 'Cardiorespiratory', 'Exercise', 'in', 'Inpatient', 'Stroke', 'Rehabilitation', '|', 'Stroke', 'survivors', 'struggle', 'to', 'meet', 'clinical', 'recommendations', 'for', 'physical', 'exercise', 'duration', 'and', 'intensity', '.', 'During', 'the', 'past', 'two', 'decades', ',', 'music', 'interventions', 'have', 'increasingly', 'shown', 'effectiveness', 'in', 'several', 'motor', 'tasks', 'in', 'stroke', 'rehabilitation', '.', 'Additionally', ',', 'music', 'has', 'been', 'found', 'effective', 'in', 'increasing', 'exercise', 'performance', 'in', 'athletes', 'and', 'other', 'clinical', 'populations', '.', 'Based', 'on', 'a', 'meta', '-', 'theoretical', 'review', 'paper', 'by', 'Clark', ',', 'Baker', '&', 'Taylor', '(', '2016', ')', ',', 'it', 'was', 'hypothesized', 'that', 'the', 'therapeutic', 'effects', 'of', 'music', 'in', 'physical', 'exercise', 'is', 'modulated', 'by', 'the', 'preference', 'and', 'task', '-', 'specificity', 'of', 'the', 'music', '.', 'We', 'will', 'test', 'this', 'hypothesis', 'using', 'a', 'three', '-', 'armed', 'randomized', 'cross', '-', 'over', 'design', 'comprised', 'of', 'the', 'following', 'auditory', 'conditions', ':', '1', ')', 'a', 'group', '-', 'tailored', 'playlist', '2', ')', 'radio', 'as', 'active', 'control', 'and', '3', ')', 'a', 'non', '-', 'music', 'control', 'condition', 'during', 'cycle', 'ergometry', 'cardiorespiratory', 'exercise', 'sessions', '.', 'Participants', 'are', 'inpatient', 'stroke', 'survivors', 'undergoing', 'rehabilitation', 'between', '2', '-', '12', 'weeks', 'post', 'infarct', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05398575,NCT05398575,"Music Listening for Cardiorespiratory Exercise in Inpatient Stroke Rehabilitation | Stroke survivors struggle to meet clinical recommendations for physical exercise duration and intensity. During the past two decades, music interventions have increasingly shown effectiveness in several motor tasks in stroke rehabilitation. Additionally, music has been found effective in increasing exercise performance in athletes and other clinical populations. Based on a meta-theoretical review paper by Clark, Baker & Taylor (2016), it was hypothesized that the therapeutic effects of music in physical exercise is modulated by the preference and task-specificity of the music. We will test this hypothesis using a three-armed randomized cross-over design comprised of the following auditory conditions: 1) a group-tailored playlist 2) radio as active control and 3) a non-music control condition during cycle ergometry cardiorespiratory exercise sessions. Participants are inpatient stroke survivors undergoing rehabilitation between 2-12 weeks post infarct.","[(0, 15, 'OTHER', 'Music Listening'), (20, 46, 'PHYSICAL', 'Cardiorespiratory Exercise'), (60, 66, 'CONDITION', 'Stroke'), (84, 90, 'CONDITION', 'Stroke'), (218, 237, 'OTHER', 'music interventions'), (302, 308, 'CONDITION', 'stroke'), (799, 822, 'OTHER', 'group-tailored playlist'), (826, 831, 'CONTROL', 'radio'), (859, 868, 'CONTROL', 'non-music'), (910, 936, 'PHYSICAL', 'cardiorespiratory exercise'), (974, 980, 'CONDITION', 'stroke'), (1036, 1048, 'CONDITION', 'post infarct')]"
"['Evaluating', 'the', 'Impact', 'of', 'Physical', 'Exercise', 'on', 'Mild', 'Alzheimer', ""'s"", 'Disease', 'in', 'a', 'Randomized', 'Clinical', 'Trial', ':', 'Quantification', 'With', '18F', '-FDG', 'and', '11C-', 'AcAc', 'PET', 'Imaging', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'a', '3', '-', 'month', 'walking', 'program', 'on', 'brain', 'energy', 'metabolism', 'in', 'patient', 'with', 'mild', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', '.', 'Two', 'groups', 'of', 'sedentary', 'patients', 'with', 'mild', 'AD', 'are', 'followed', 'and', 'compared', 'over', 'a', '3', '-', 'month', 'period', 'of', 'time', ':', 'Control', '(', 'non', '-', 'active', ')', 'and', 'walking', '(', 'from', '15', 'to', '45', 'minutes', 'of', 'exercise', 'on', 'a', 'treadmill', ',', '3', 'times', 'a', 'week', 'for', '12', 'weeks', ')', 'groups', '.', 'All', 'the', 'participants', 'are', 'evaluated', 'on', 'their', 'cognition', ',', 'brain', 'volumes', '(', 'MRI', ')', 'and', 'brain', 'fuel', 'consumption', '(', 'PET', 'scan', 'with', '18', '-', 'FDG', 'and', '11C', '-', 'AcAc', ')', 'at', 'the', 'beginning', 'and', 'at', 'the', 'end', 'of', 'the', 'study', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02708485,NCT02708485,"Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging | The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.","[(25, 42, 'PHYSICAL', 'Physical Exercise'), (46, 70, 'CONDITION', ""Mild Alzheimer's Disease""), (221, 236, 'PHYSICAL', 'walking program'), (280, 304, 'CONDITION', ""mild Alzheimer's disease""), (306, 308, 'CONDITION', 'AD'), (354, 356, 'CONDITION', 'AD'), (423, 433, 'CONTROL', 'non-active'), (439, 446, 'PHYSICAL', 'walking'), (473, 496, 'PHYSICAL', 'exercise on a treadmill')]"
"['Polyphenol', 'Rich', 'Supplementation', 'on', 'Markers', 'of', 'Recovery', 'From', 'Intense', 'Resistance', 'Exercise', '|', 'Strength', 'training', 'is', 'commonly', 'used', 'as', 'an', 'intervention', 'to', 'increase', 'muscle', 'mass', ',', 'thus', 'improving', 'a', 'person', ""'s"", 'ability', 'to', 'undertake', 'activities', 'of', 'daily', 'living', ',', 'or', 'enhance', 'athletic', 'performance', '.', 'The', 'strength', 'training', 'regimen', 'itself', ',', 'while', 'ultimately', 'having', 'beneficial', 'effects', ',', 'causes', 'muscle', 'fibers', 'to', 'be', 'damaged', ',', 'which', 'the', 'body', 'has', 'to', 'recover', 'from', '.', 'As', 'the', 'body', 'recovers', ',', 'it', 'rebuilds', 'the', 'muscle', 'tissue', 'and', 'after', 'multiple', 'consecutive', 'bouts', 'of', 'strength', 'training', ',', 'the', 'muscle', 'eventually', 'becomes', 'larger', 'and', 'stronger', '.', 'Thus', ',', 'it', 'is', 'the', 'recovery', 'from', 'strength', 'training', 'exercise', 'that', 'ultimately', 'determines', 'how', 'well', 'the', 'body', 'adapts', '.', 'Where', 'inadequate', 'recovery', 'could', 'eventually', 'lead', 'to', 'overtraining', 'and/or', 'injury', ',', 'optimizing', 'the', 'recovery', 'process', 'from', 'strength', 'training', 'could', 'maximize', 'strength', 'training', 'adaptations', '.', 'This', 'concept', 'of', 'optimizing', 'recovery', 'has', 'led', 'to', 'development', 'of', 'many', 'supplements', ',', 'including', 'antioxidants', ',', 'which', 'may', 'reduce', 'the', 'damage', 'associated', 'with', 'strength', 'training', 'activities', 'and', 'therefore', 'enhance', 'positive', 'adaptations', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'ability', 'of', 'a', 'polyphenol', 'rich', 'supplementation', 'to', 'aid', 'the', 'recovery', 'process', 'from', 'a', 'demanding', 'bout', 'of', 'resistance', 'exercise']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03540602,NCT03540602,"Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise | Strength training is commonly used as an intervention to increase muscle mass, thus improving a person's ability to undertake activities of daily living, or enhance athletic performance. The strength training regimen itself, while ultimately having beneficial effects, causes muscle fibers to be damaged, which the body has to recover from. As the body recovers, it rebuilds the muscle tissue and after multiple consecutive bouts of strength training, the muscle eventually becomes larger and stronger. Thus, it is the recovery from strength training exercise that ultimately determines how well the body adapts. Where inadequate recovery could eventually lead to overtraining and/or injury, optimizing the recovery process from strength training could maximize strength training adaptations. This concept of optimizing recovery has led to development of many supplements, including antioxidants, which may reduce the damage associated with strength training activities and therefore enhance positive adaptations. The purpose of this study is to assess the ability of a polyphenol rich supplementation to aid the recovery process from a demanding bout of resistance exercise","[(0, 10, 'DRUG', 'Polyphenol'), (1160, 1170, 'DRUG', 'polyphenol')]"
"['Ultrasound', '-', 'guided', 'Erector', 'Spinae', 'Plane', 'Block', 'Versus', 'Paravertebral', 'Block', 'for', 'Perioperative', 'Analgesia', ',', 'a', 'Randomized', 'Double', 'Blinded', 'Controlled', 'Trial', '|', 'There', 'are', 'very', 'few', 'randomized', 'controlled', 'trials', 'in', 'open', 'splenectomy', 'surgery', ',', 'which', 'compare', 'paravertebral', 'block', 'with', 'ESP', 'block', '.', 'The', 'purpose', 'of', 'this', 'randomized', 'controlled', 'trial', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'ultrasound', '-', 'guided', 'paravertebral', 'block', 'with', 'ESP', 'block', 'for', 'perioperative', 'analgesia', 'in', 'open', 'splenectomy', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05448469,NCT05448469,"Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block for Perioperative Analgesia, a Randomized Double Blinded Controlled Trial | There are very few randomized controlled trials in open splenectomy surgery, which compare paravertebral block with ESP block. The purpose of this randomized controlled trial is to compare the efficacy of ultrasound-guided paravertebral block with ESP block for perioperative analgesia in open splenectomy .","[(0, 44, 'OTHER', 'Ultrasound-guided Erector Spinae Plane Block'), (52, 71, 'OTHER', 'Paravertebral Block'), (199, 223, 'CONDITION', 'open splenectomy surgery'), (239, 258, 'OTHER', 'paravertebral block'), (264, 273, 'OTHER', 'ESP block'), (353, 390, 'OTHER', 'ultrasound-guided paravertebral block'), (396, 405, 'OTHER', 'ESP block'), (437, 453, 'CONDITION', 'open splenectomy')]"
"['Effects', 'of', 'Electrical', 'Stimulation', 'and', 'Vitamin', 'D', 'Supplementation', 'on', 'Bone', 'Health', 'Following', 'Spinal', 'Cord', 'Injury', '.', '|', 'Neurogenic', 'osteoporosis', 'is', 'a', 'common', 'complication', 'of', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'that', 'is', 'associated', 'with', 'low', 'impact', 'bone', 'fractures', '.', 'It', 'is', 'concerning', 'that', 'more', 'than', '46,000', 'Veterans', 'affected', 'with', 'SCI', 'and', 'are', 'at', 'risk', 'of', 'osteoporosis', 'and', 'possible', 'low', 'impact', 'fractures', '.', 'About', 'fifty', 'percent', 'of', 'all', 'individuals', 'with', 'SCI', 'will', 'develop', 'low', 'impact', 'fracture', 'in', 'their', 'life', 'time', '.', 'The', 'management', 'of', 'osteoporosis', '-', 'related', 'fractures', 'can', 'impose', 'substantial', 'economic', 'burden', 'on', 'the', 'health', 'care', 'system', ',', 'the', 'individual', 'and', 'the', 'families', '.', 'Previous', 'studies', 'did', 'not', 'succeed', 'in', 'reversing', 'the', 'process', 'of', 'bone', 'loss', 'after', 'SCI', '.', 'In', 'the', 'present', 'pilot', 'study', ',', 'we', 'will', 'evaluate', 'the', 'effect', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'Resistance', 'Training', 'in', 'combination', 'with', 'oral', 'Vitamin', 'D', 'supplementation', ',', 'on', 'bone', 'quality', 'in', 'Veterans', 'with', 'chronic', 'SCI', ',', 'using', 'a', 'randomized', 'experimental', 'design', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05008484,NCT05008484,"Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury. | Neurogenic osteoporosis is a common complication of spinal cord injury (SCI) that is associated with low impact bone fractures. It is concerning that more than 46,000 Veterans affected with SCI and are at risk of osteoporosis and possible low impact fractures. About fifty percent of all individuals with SCI will develop low impact fracture in their life time. The management of osteoporosis-related fractures can impose substantial economic burden on the health care system, the individual and the families. Previous studies did not succeed in reversing the process of bone loss after SCI. In the present pilot study, we will evaluate the effect of Neuromuscular Electrical Stimulation Resistance Training in combination with oral Vitamin D supplementation, on bone quality in Veterans with chronic SCI, using a randomized experimental design.","[(11, 33, 'OTHER', 'Electrical Stimulation'), (38, 47, 'DRUG', 'Vitamin D'), (89, 107, 'CONDITION', 'Spinal Cord Injury'), (111, 134, 'CONDITION', 'Neurogenic osteoporosis'), (163, 181, 'CONDITION', 'spinal cord injury'), (183, 186, 'CONDITION', 'SCI'), (212, 237, 'CONDITION', 'low impact bone fractures'), (301, 304, 'CONDITION', 'SCI'), (324, 336, 'CONDITION', 'osteoporosis'), (350, 370, 'CONDITION', 'low impact fractures'), (416, 419, 'CONDITION', 'SCI'), (433, 452, 'CONDITION', 'low impact fracture'), (491, 521, 'CONDITION', 'osteoporosis-related fractures'), (682, 691, 'CONDITION', 'bone loss'), (698, 701, 'CONDITION', 'SCI'), (762, 818, 'PHYSICAL', 'Neuromuscular Electrical Stimulation Resistance Training'), (844, 853, 'DRUG', 'Vitamin D'), (904, 915, 'CONDITION', 'chronic SCI')]"
"['Median', 'Nerve', 'Hydro', '-', 'dissection', 'Using', 'Single', 'Injection', 'of', 'Hyalase', 'as', 'a', 'Novel', 'Treatment', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'Double', 'Blind', 'Randomized', 'Clinical', 'Trial', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'a', 'common', 'peripheral', 'entrapment', 'neuropathy', ',', 'this', 'study', 'aims', 'to', 'investigate', 'if', ',', 'and', 'to', 'what', 'extent', 'hydro', '-', 'dissection', 'hyalase', 'and', 'saline', 'of', 'the', 'median', 'nerve', 'could', 'offer', 'symptoms', 'and', 'clinical', 'improvement']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03177915,NCT03177915,"Median Nerve Hydro-dissection Using Single Injection of Hyalase as a Novel Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial | Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline of the median nerve could offer symptoms and clinical improvement","[(0, 29, 'OTHER', 'Median Nerve Hydro-dissection'), (56, 63, 'DRUG', 'Hyalase'), (88, 110, 'CONDITION', 'Carpal Tunnel Syndrome'), (153, 175, 'CONDITION', 'Carpal tunnel syndrome'), (177, 180, 'CONDITION', 'CTS'), (282, 298, 'OTHER', 'hydro-dissection'), (299, 306, 'DRUG', 'hyalase'), (311, 317, 'DRUG', 'saline')]"
"['Clinical', 'Study', 'on', 'Efficacy', 'and', 'Safety', 'of', 'Warm', 'Acupuncture', 'in', 'Treatment', 'of', 'Cold', '-', 'sensitive', 'Fibromyalgia', 'Syndrome', '|', 'Non', '-', 'pharmaceutical', 'therapies', ',', 'such', 'as', 'acupuncture', ',', 'hydrotherapy', ',', 'and', 'meditative', 'exercises', '(', 'such', 'as', 'Qigong', '(', 'including', 'Tai', 'Chi', 'and', 'Ba', '-', 'Duan', '-', 'Jin', ')', ',', 'have', 'been', 'shown', 'to', 'reduce', 'pain', 'and', 'improve', 'physical', 'function', '.', 'The', 'management', 'recommendations', 'of', 'fibromyalgia', 'issued', 'by', 'the', 'European', 'Union', ',', 'Canada', ',', 'Germany', 'and', 'Israel', 'have', 'all', 'affirmed', 'the', '""', 'first', '-', 'line', '""', 'role', 'of', 'Non', '-', 'pharmaceutical', 'therapy', '.', 'Because', 'of', 'its', 'good', 'efficacy', 'and', 'safety', ',', 'acupuncture', 'therapy', 'has', 'been', 'recommended', 'in', 'the', 'management', 'guidelines', 'and', 'has', 'broad', 'application', 'prospects', '.', 'Warm', 'acupuncture', 'is', 'a', 'therapy', 'combining', 'acupuncture', 'and', 'moxibustion', ',', 'which', 'is', 'widely', 'used', 'in', 'the', 'treatment', 'of', 'various', 'painful', 'diseases', 'in', 'China', ',', 'especially', 'for', 'cold', '-', 'sensitive', 'patients', '.', 'This', 'study', 'aims', 'to', 'observe', 'the', 'safety', 'and', 'effectiveness', 'of', 'warm', 'acupuncture', 'in', 'the', 'treatment', 'of', 'cold', '-', 'sensitive', 'fibromyalgia', 'patients', ',', 'in', 'order', 'to', 'provide', 'a', 'more', 'alternative', 'non', '-', 'drug', 'therapy', 'for', 'this', 'particular', 'type', 'of', 'patients', 'with', 'fibromyalgia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05228990,NCT05228990,"Clinical Study on Efficacy and Safety of Warm Acupuncture in Treatment of Cold-sensitive Fibromyalgia Syndrome | Non-pharmaceutical therapies, such as acupuncture, hydrotherapy, and meditative exercises (such as Qigong (including Tai Chi and Ba-Duan-Jin), have been shown to reduce pain and improve physical function. The management recommendations of fibromyalgia issued by the European Union, Canada, Germany and Israel have all affirmed the ""first-line"" role of Non-pharmaceutical therapy. Because of its good efficacy and safety, acupuncture therapy has been recommended in the management guidelines and has broad application prospects. Warm acupuncture is a therapy combining acupuncture and moxibustion, which is widely used in the treatment of various painful diseases in China, especially for cold-sensitive patients . This study aims to observe the safety and effectiveness of warm acupuncture in the treatment of cold-sensitive fibromyalgia patients, in order to provide a more alternative non-drug therapy for this particular type of patients with fibromyalgia .","[(41, 57, 'OTHER', 'Warm Acupuncture'), (74, 110, 'CONDITION', 'Cold-sensitive Fibromyalgia Syndrome'), (151, 162, 'OTHER', 'acupuncture'), (282, 286, 'CONDITION', 'pain'), (352, 364, 'CONDITION', 'fibromyalgia'), (534, 545, 'OTHER', 'acupuncture'), (641, 657, 'OTHER', 'Warm acupuncture'), (681, 692, 'OTHER', 'acupuncture'), (697, 708, 'OTHER', 'moxibustion'), (886, 902, 'OTHER', 'warm acupuncture'), (923, 950, 'CONDITION', 'cold-sensitive fibromyalgia'), (1059, 1071, 'CONDITION', 'fibromyalgia')]"
"['Structured', 'Patient', 'Education', 'in', 'Combination', 'With', 'Physical', 'Exercise', 'as', 'Part', 'of', 'the', 'Integrated', 'Care', 'to', 'Chronically', 'Ill', 'Patients', 'With', 'Chronic', 'Obstructive', 'Pulmonary', 'Disease', ',', 'Heart', 'Failure', 'and', 'Stroke', '.', 'A', 'Randomized', 'Controlled', 'Intervention', 'Trial', '.', '|', 'This', 'study', 'addresses', 'self', 'management', 'and', 'maintenance', 'of', 'health', 'through', 'evaluation', 'of', 'a', 'program', 'of', 'patient', 'education', 'in', 'combination', 'with', 'physical', 'training', 'and', 'with', 'a', 'structured', 'follow', '-', 'up', '.', '\n\n', 'It', 'is', 'hypothesized', 'that', 'such', 'a', 'program', 'will', ':', '\n\n', 'improve', 'quality', 'of', 'life', ',', 'physical', 'functioning', ',', 'coping', 'in', 'everyday', '-', 'life', '\n', 'reduce', 'hospitalization', 'and', '(', 're-)admissions', 'for', 'patients', 'with', 'chronic', 'disease', ',', 'reduce', 'consumption', 'of', 'home', 'care', 'services', 'and', 'can', 'increase', 'consumption', 'of', 'general', 'practice', 'and', 'physiotherapy', 'services', 'in', 'primary', 'health', 'care', '.', '\n', 'improve', 'patient', 'satisfaction', 'and', 'health', 'care', 'providers', 'satisfaction']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00989456,NCT00989456,"Structured Patient Education in Combination With Physical Exercise as Part of the Integrated Care to Chronically Ill Patients With Chronic Obstructive Pulmonary Disease, Heart Failure and Stroke. A Randomized Controlled Intervention Trial. | This study addresses self management and maintenance of health through evaluation of a program of patient education in combination with physical training and with a structured follow-up.

It is hypothesized that such a program will:

improve quality of life, physical functioning, coping in everyday-life
reduce hospitalization and (re-)admissions for patients with chronic disease, reduce consumption of home care services and can increase consumption of general practice and physiotherapy services in primary health care.
improve patient satisfaction and health care providers satisfaction","[(0, 28, 'BEHAVIOURAL', 'Structured Patient Education'), (49, 66, 'PHYSICAL', 'Physical Exercise'), (131, 168, 'CONDITION', 'Chronic Obstructive Pulmonary Disease'), (170, 183, 'CONDITION', 'Heart Failure'), (188, 194, 'CONDITION', 'Stroke'), (329, 357, 'BEHAVIOURAL', 'program of patient education'), (378, 395, 'PHYSICAL', 'physical training')]"
"['An', 'Online', 'Self', '-', 'management', 'Program', 'for', 'Spinal', 'Cord', 'Injury', ':', 'Feasibility', 'Study', 'of', 'SCI&U', '|', 'Managing', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'is', 'a', 'life', '-', 'long', 'process', '.', 'Within', 'the', 'first', 'year', 'of', 'injury', ',', 'more', 'than', '50', '%', 'of', 'people', 'discharged', 'with', 'a', 'SCI', 'may', 'require', 're', '-', 'hospitalization', 'due', 'to', 'a', 'secondary', 'complication', ',', 'such', 'as', 'a', 'urinary', 'tract', 'infection', ',', 'pressure', 'ulcer', 'or', 'pneumonia', '.', 'Even', '20', 'years', 'post', '-', 'injury', ',', 're', '-', 'hospitalization', 'rates', 'remain', 'over', '30', '%', '.', 'While', 're', '-', 'hospitalization', 'rates', 'in', 'Canada', 'have', 'remained', 'high', 'for', 'more', 'than', '10', 'years', ',', 'the', 'length', 'of', 'stay', 'in', 'inpatient', 'rehabilitation', 'has', 'decreased', 'dramatically', ',', 'thereby', 'limiting', 'the', 'time', 'for', 'provision', 'of', 'health', 'information', 'and', 'skill', 'acquisition', 'in', 'the', 'inpatient', 'rehabilitation', 'setting', '.', 'There', 'is', 'growing', 'evidence', 'from', 'two', 'recent', 'pilot', 'trials', 'to', 'suggest', 'that', 'self', '-', 'management', 'programs', 'that', 'provide', 'appropriate', 'health', 'information', ',', 'skills', 'and', 'telephone', '-', 'based', 'support', 'for', 'community', '-', 'dwelling', 'patients', 'with', 'SCI', 'improves', 'health', 'behaviors', 'and', 'leads', 'to', 'reductions', 'in', 're', '-', 'hospitalization', '.', '\n\n', 'Goals', '/', 'Research', 'Aim', ':', 'To', 'conduct', 'a', 'pilot', 'RCT', '(', 'feasibility', 'study', ')', 'that', 'will', 'inform', 'the', 'design', 'of', 'a', 'definitive', 'RCT', 'to', 'determine', 'whether', 'an', 'online', 'self', '-', 'management', 'program', 'incorporating', 'trained', 'peer', 'health', 'coaches', '(', 'called', '""', 'SCI&U', '""', ')', 'compared', 'to', 'usual', 'care', 'will', 'result', 'in', 'improved', 'self', '-', 'management', 'skills', '(', 'short', '-', 'term', 'outcome', ')', 'and', 'lead', 'to', 'reduced', 'days', 'of', 'hospitalization', '(', 'long', '-', 'term', 'outcome', ')', 'due', 'to', 'secondary', 'complications', '.', 'This', 'pilot', 'study', 'is', 'a', 'two', '-', 'group', 'RCT', 'with', 'an', 'embedded', 'qualitative', 'component', '.', 'The', 'target', 'population', 'is', 'adults', 'with', 'SCI', 'who', 'have', 'been', 'discharged', 'from', 'inpatient', 'rehabilitation', 'and', 'living', 'in', 'the', 'community', '.', 'Sixty', 'subjects', 'will', 'be', 'recruited', 'from', 'across', 'Canada', 'with', 'a', 'focus', 'on', 'British', 'Columbia', 'and', 'Ontario', 'and', 'randomly', 'assigned', 'to', 'the', 'SCI&U', 'intervention', 'or', 'usual', 'care', '.', '\n\n', 'Evaluations', 'will', 'occur', 'at', 'baseline', ',', '2', ',', '6', ',', 'and', '12', 'months', '.']","['O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04474171,NCT04474171,"An Online Self-management Program for Spinal Cord Injury: Feasibility Study of SCI&U | Managing a spinal cord injury (SCI) is a life-long process. Within the first year of injury, more than 50% of people discharged with a SCI may require re-hospitalization due to a secondary complication, such as a urinary tract infection, pressure ulcer or pneumonia. Even 20 years post-injury, re-hospitalization rates remain over 30%. While re-hospitalization rates in Canada have remained high for more than 10 years, the length of stay in inpatient rehabilitation has decreased dramatically, thereby limiting the time for provision of health information and skill acquisition in the inpatient rehabilitation setting. There is growing evidence from two recent pilot trials to suggest that self-management programs that provide appropriate health information, skills and telephone-based support for community-dwelling patients with SCI improves health behaviors and leads to reductions in re-hospitalization.

Goals/Research Aim: To conduct a pilot RCT (feasibility study) that will inform the design of a definitive RCT to determine whether an online self-management program incorporating trained peer health coaches (called ""SCI&U"") compared to usual care will result in improved self-management skills (short-term outcome) and lead to reduced days of hospitalization (long-term outcome) due to secondary complications.This pilot study is a two-group RCT with an embedded qualitative component. The target population is adults with SCI who have been discharged from inpatient rehabilitation and living in the community. Sixty subjects will be recruited from across Canada with a focus on British Columbia and Ontario and randomly assigned to the SCI&U intervention or usual care.

Evaluations will occur at baseline, 2, 6, and 12 months.","[(3, 33, 'BEHAVIOURAL', 'Online Self-management Program'), (38, 56, 'CONDITION', 'Spinal Cord Injury'), (79, 84, 'BEHAVIOURAL', 'SCI&U'), (98, 116, 'CONDITION', 'spinal cord injury'), (118, 121, 'CONDITION', 'SCI'), (222, 225, 'CONDITION', 'SCI'), (920, 923, 'CONDITION', 'SCI'), (1133, 1163, 'BEHAVIOURAL', 'online self-management program'), (1178, 1205, 'BEHAVIOURAL', 'trained peer health coaches'), (1215, 1220, 'BEHAVIOURAL', 'SCI&U'), (1235, 1245, 'CONTROL', 'usual care'), (1522, 1525, 'CONDITION', 'SCI'), (1736, 1741, 'BEHAVIOURAL', 'SCI&U'), (1758, 1768, 'CONTROL', 'usual care')]"
"['MyHand', ':', 'An', 'Active', 'Hand', 'Orthosis', 'for', 'Stroke', 'Patients', '|', 'This', 'study', 'seeks', 'to', 'explore', 'the', 'efficacy', 'of', 'several', 'control', 'mechanisms', 'for', 'the', 'device', 'and', 'the', 'impact', 'of', 'a', 'device', 'training', 'program', 'on', 'its', 'utility', 'as', 'a', 'neuroprosthetic', 'and', 'training', 'tool', 'for', 'upper', 'limb', 'recovery', '.']","['B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03767894,NCT03767894,MyHand: An Active Hand Orthosis for Stroke Patients | This study seeks to explore the efficacy of several control mechanisms for the device and the impact of a device training program on its utility as a neuroprosthetic and training tool for upper limb recovery.,"[(0, 6, 'OTHER', 'MyHand'), (11, 31, 'OTHER', 'Active Hand Orthosis'), (36, 42, 'CONDITION', 'Stroke'), (160, 183, 'OTHER', 'device training program')]"
"['Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Individuals', 'With', 'Spinal', 'Cord', 'Injury', ':', 'A', 'Pilot', 'Study', '|', 'This', 'study', 'will', 'investigate', 'how', 'repetitive', 'transcranial', 'magnetic', 'stimulation', 'delivered', 'as', 'a', 'protocol', 'called', ""'"", 'continuous', 'theta', '-', 'burst', 'stimulation', '(', 'cTBS', ')', ""'"", 'alters', 'motor', 'output', 'and', 'force', 'control', 'to', 'a', 'muscle', 'in', 'the', 'forearm', 'and', 'touch', 'perception', 'in', 'individuals', 'with', 'chronic', ',', 'incomplete', 'spinal', 'cord', 'injury', '.', 'CTBS', 'is', 'a', 'non', '-', 'invasive', 'technique', 'that', 'involved', 'repetitive', 'delivery', 'of', 'transcranial', 'magnetic', 'stimulation', 'at', 'a', 'frequency', 'of', '30', 'Hz', 'over', 'the', 'arm', 'representation', 'in', 'the', 'primary', 'motor', 'or', 'sensory', 'cortex', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'cTBS', 'is', 'an', 'effective', 'intervention', 'to', 'increase', 'motor', 'output', 'to', 'a', 'muscle', 'and', 'increase', 'force', 'control', 'of', 'that', 'muscle', 'and', 'also', 'improve', 'the', 'sense', 'of', 'touch', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02351921,NCT02351921,"Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study | This study will investigate how repetitive transcranial magnetic stimulation delivered as a protocol called 'continuous theta-burst stimulation (cTBS)' alters motor output and force control to a muscle in the forearm and touch perception in individuals with chronic, incomplete spinal cord injury. CTBS is a non-invasive technique that involved repetitive delivery of transcranial magnetic stimulation at a frequency of 30 Hz over the arm representation in the primary motor or sensory cortex. The purpose of this study is to determine whether cTBS is an effective intervention to increase motor output to a muscle and increase force control of that muscle and also improve the sense of touch.","[(0, 44, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (65, 83, 'CONDITION', 'Spinal Cord Injury'), (133, 177, 'OTHER', 'repetitive transcranial magnetic stimulation'), (210, 244, 'OTHER', 'continuous theta-burst stimulation'), (246, 250, 'OTHER', 'cTBS'), (359, 397, 'CONDITION', 'chronic, incomplete spinal cord injury'), (399, 403, 'OTHER', 'CTBS'), (469, 502, 'OTHER', 'transcranial magnetic stimulation'), (645, 649, 'OTHER', 'cTBS')]"
"['Oestrogen', 'Withdrawal', 'in', 'Hypopituitary', 'Women', '|', 'By', 'exploring', 'hormonal', 'status', 'in', 'hypopituitary', 'women', 'during', 'oestrogen', 'treatment', 'and', 'without', 'estrogen', 'substitution', 'the', 'influence', 'on', 'sexhormones', 'and', 'organ', 'function', 'is', 'estimated', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00572390,NCT00572390,Oestrogen Withdrawal in Hypopituitary Women | By exploring hormonal status in hypopituitary women during oestrogen treatment and without estrogen substitution the influence on sexhormones and organ function is estimated.,"[(24, 37, 'CONDITION', 'Hypopituitary'), (78, 91, 'CONDITION', 'hypopituitary'), (105, 114, 'DRUG', 'oestrogen')]"
"['The', 'Motor', 'Control', 'Consequences', 'of', 'Excessive', 'Physical', 'Therapist', 'Support', 'in', 'Individuals', 'With', 'Stroke', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'systematically', 'determine', 'the', 'effect', 'of', 'unnecessary', 'physical', 'therapist', 'assistance', 'in', 'individuals', 'after', 'stroke', 'during', 'the', 'practice', 'of', 'an', 'upper', 'limb', 'task', 'on', 'an', 'individual', ""'s"", 'task', 'performance', 'and', 'their', 'underlying', 'motor', 'control', 'patterns', 'when', 'learning', '(', 'or', 're', '-', 'learning', ')', 'motor', 'skills', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04856527,NCT04856527,The Motor Control Consequences of Excessive Physical Therapist Support in Individuals With Stroke | The purpose of this study is to systematically determine the effect of unnecessary physical therapist assistance in individuals after stroke during the practice of an upper limb task on an individual's task performance and their underlying motor control patterns when learning (or re-learning) motor skills.,"[(91, 97, 'CONDITION', 'Stroke'), (234, 240, 'CONDITION', 'stroke')]"
"['Prevalence', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'in', 'Sarcoidosis', 'and', 'Impact', 'of', 'CPAP', 'Treatment', 'on', 'Associated', 'Fatigue', 'Status', '|', 'Sarcoidosis', 'is', 'a', 'multisystemic', 'granulomatous', 'disease', 'that', 'affects', 'individuals', 'worldwide', 'without', 'known', 'pathogenesis', ',', 'and', 'the', 'role', 'of', 'comorbidities', 'has', 'not', 'been', 'fully', 'assessed', 'in', 'the', 'scientific', 'literature', '.', 'An', 'increased', 'incidence', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'has', 'been', 'described', 'in', 'Sarcoidosis', 'although', 'this', 'association', 'has', 'not', 'been', 'explained', 'yet', 'and', 'no', 'data', 'is', 'available', 'about', 'the', 'effect', 'of', 'treatment', 'with', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'in', 'Sarcoidosis', '.', 'Also', ',', 'patients', 'affected', 'by', 'Sarcoidosis', 'usually', 'experience', 'a', 'state', 'of', 'physical', 'and', 'mental', 'weariness', 'called', 'fatigue', 'and', 'reported', 'in', 'approximately', '60', '-', '80', '%', 'sarcoid', 'patients', 'and', 'thought', 'to', 'be', 'a', 'consequence', 'of', 'inflammatory', 'mediators', 'but', 'the', 'high', 'prevalence', 'of', 'OSAS', 'could', 'be', 'a', 'remarkable', 'bias', 'in', 'clinical', 'evaluation', 'because', 'fatigue', 'is', 'also', 'strongly', 'associated', 'with', 'sleep', 'disorders', '.', '\n\n', 'Thus', ',', 'there', 'is', 'a', 'real', 'need', 'for', 'assessing', 'not', 'only', 'the', 'real', 'prevalence', 'of', 'OSAS', 'in', 'Sarcoidosis', 'but', 'also', 'the', 'effect', 'of', 'CPAP', 'treatment', 'on', 'fatigue', 'status', 'experienced', 'by', 'sarcoidotic', 'patients', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03926832,NCT03926832,"Prevalence of Obstructive Sleep Apnea Syndrome in Sarcoidosis and Impact of CPAP Treatment on Associated Fatigue Status | Sarcoidosis is a multisystemic granulomatous disease that affects individuals worldwide without known pathogenesis, and the role of comorbidities has not been fully assessed in the scientific literature. An increased incidence of Obstructive Sleep Apnea Syndrome (OSAS) has been described in Sarcoidosis although this association has not been explained yet and no data is available about the effect of treatment with Continuous Positive Airway Pressure (CPAP) in Sarcoidosis. Also, patients affected by Sarcoidosis usually experience a state of physical and mental weariness called fatigue and reported in approximately 60-80% sarcoid patients and thought to be a consequence of inflammatory mediators but the high prevalence of OSAS could be a remarkable bias in clinical evaluation because fatigue is also strongly associated with sleep disorders.

Thus, there is a real need for assessing not only the real prevalence of OSAS in Sarcoidosis but also the effect of CPAP treatment on fatigue status experienced by sarcoidotic patients.","[(14, 46, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (50, 61, 'CONDITION', 'Sarcoidosis'), (76, 80, 'OTHER', 'CPAP'), (105, 112, 'CONDITION', 'Fatigue'), (122, 133, 'CONDITION', 'Sarcoidosis'), (352, 384, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (386, 390, 'CONDITION', 'OSAS'), (414, 425, 'CONDITION', 'Sarcoidosis'), (539, 574, 'OTHER', 'Continuous Positive Airway Pressure'), (576, 580, 'OTHER', 'CPAP'), (585, 596, 'CONDITION', 'Sarcoidosis'), (625, 636, 'CONDITION', 'Sarcoidosis'), (704, 711, 'CONDITION', 'fatigue'), (749, 756, 'CONDITION', 'sarcoid'), (851, 855, 'CONDITION', 'OSAS'), (914, 921, 'CONDITION', 'fatigue'), (955, 970, 'CONDITION', 'sleep disorders'), (1046, 1050, 'CONDITION', 'OSAS'), (1054, 1065, 'CONDITION', 'Sarcoidosis'), (1089, 1093, 'OTHER', 'CPAP'), (1107, 1114, 'CONDITION', 'fatigue'), (1137, 1148, 'CONDITION', 'sarcoidotic')]"
"['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Double', '-', 'Blinded', ',', 'First', '-', 'in', '-', 'Human', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'of', 'Single', 'Ascending', 'Doses', '(', 'Part', 'A', ')', 'and', 'Multiple', 'Ascending', 'Doses', '(', 'Part', 'B', ')', 'of', 'NDX-1017', 'in', 'Healthy', 'Young', 'and', 'Elderly', 'Subjects', '|', 'This', 'Phase', '1', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blinded', ',', 'first', '-', 'in', '-', 'human', 'study', 'will', 'evaluate', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'single', 'and', 'multiple', 'ascending', 'doses', 'of', 'NDX-1017', 'in', 'healthy', 'young', 'and', 'elderly', 'subjects', ',', 'and', 'elderly', 'subjects', 'with', 'amnestic', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', ',', 'Alzheimer', ""'s"", 'disease', '(', 'mild', ',', 'mild', '-', 'to', '-', 'moderate', ',', 'or', 'moderate', ')', ',', 'or', 'mixed', 'dementia', 'with', 'Alzheimer', ""'s"", 'and', 'vascular', 'components', '(', 'mild', ',', 'mild', '-', 'to', '-', 'moderate', ',', 'or', 'moderate', ')', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03298672,NCT03298672,"A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects | This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).","[(14, 21, 'CONTROL', 'Placebo'), (202, 210, 'DRUG', 'NDX-1017'), (276, 283, 'CONTROL', 'placebo'), (432, 440, 'DRUG', 'NDX-1017'), (515, 540, 'CONDITION', 'mild cognitive impairment'), (542, 545, 'CONDITION', 'MCI'), (548, 567, 'CONDITION', ""Alzheimer's disease""), (610, 665, 'CONDITION', ""mixed dementia with Alzheimer's and vascular components"")]"
"['Stimulating', 'Self', 'Management', 'in', 'Patients', 'With', 'Fibromyalgia', 'Through', 'Web', '-', 'based', 'Situational', 'Feedback', '|', 'The', 'overall', 'objective', 'of', 'this', 'randomized', 'controlled', 'study', '(', 'RCT', ')', 'financed', 'by', 'the', 'Norwegian', 'Research', 'Council', '(', 'grant', 'no', '.', '182012', '/', 'V50', ')', 'is', 'to', 'establish', 'the', 'effectiveness', 'of', 'situational', 'feedback', 'to', 'the', 'self', '-', 'management', 'of', 'fibromyalgia', 'syndrome', '(', 'FMS', ')', 'using', 'innovative', 'means', 'of', 'patient', '-', 'provider', 'communication', 'in', 'a', 'randomized', 'controlled', 'study', '(', 'RCT', ')', '.', 'Thereby', 'this', 'project', 'will', 'contribute', 'to', 'the', 'knowledge', 'of', 'treatment', 'of', 'patients', 'with', 'FMS', '.', 'The', 'effectiveness', 'of', 'the', 'intervention', 'will', 'be', 'expressed', 'in', 'terms', 'of', 'a', ')', 'reduced', 'pain', ',', 'b', ')', 'psychometric', 'outcomes', ',', 'c', ')', 'quality', 'of', 'life', ',', 'd', ')', 'improved', 'engagement', 'in', 'daily', 'activities', 'and', 'e', ')', 'prevented', 'transition', 'to', 'chronic', 'disability', '.', 'We', 'furthermore', 'aim', 'to', '1', ')', 'determine', 'the', 'effectiveness', 'of', 'providing', 'regular', 'situational', 'feedback', 'in', 'enhancing', 'self', '-', 'management', 'and', ',', 'consequently', '2', ')', 'study', 'the', 'effectiveness', 'of', 'enhancing', 'self', '-', 'management', 'in', 'reducing', 'pain', 'and', 'physical', 'disability', '.', '\n\n', 'Self', '-', 'management', 'of', 'chronic', 'pain', 'is', 'increasingly', 'seen', 'as', 'an', 'important', 'tool', 'in', 'providing', 'adequate', 'care', 'to', 'patients', 'with', 'FMS', 'and', 'other', 'types', 'of', 'Chronic', 'Non', '-', 'malignant', 'Pain', '.', 'Enhancing', 'the', 'patient', ""'s"", 'self', '-', 'management', 'of', 'her', '/', 'his', 'condition', 'is', 'thought', 'to', 'be', 'effective', 'in', 'reducing', 'pain', 'and', 'disability', '.', 'However', ',', 'sufficient', 'empirical', 'evidence', 'to', 'support', 'this', 'is', 'yet', 'unavailable', '.', 'This', 'may', 'be', 'due', 'to', 'the', 'non', '-', 'situational', 'nature', 'of', 'many', 'interventions', 'studied', 'so', 'far', ':', 'Patients', 'are', 'taught', 'management', 'skills', 'in', 'a', 'clinical', 'setting', ',', 'and', 'may', 'not', 'be', 'able', 'to', 'successfully', 'use', 'these', 'skills', 'in', 'daily', 'care', '.', 'Therefore', ',', 'enhancing', 'self', '-', 'management', 'of', 'chronic', 'pain', ',', 'by', 'providing', 'immediate', 'feedback', 'that', 'is', 'directly', 'related', 'to', 'patient', ""'s"", 'daily', 'life', '(', '""', 'situational', '""', 'feedback', ')', 'complementary', 'to', 'care', '-', 'as', 'usual', ',', 'is', 'thought', 'to', 'be', 'more', 'effective', 'than', 'conventional', 'interventions', 'in', 'a', 'clinical', 'setting', '.', 'This', 'may', 'even', 'be', 'even', 'more', 'effective', 'when', 'the', 'patient', 'receives', 'quick', 'response', 'feedback', 'using', 'mobile', 'communication', 'technology', ',', 'i.e.', 'any', 'place', 'any', 'time', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01236209,NCT01236209,"Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback | The overall objective of this randomized controlled study (RCT) financed by the Norwegian Research Council (grant no. 182012/V50) is to establish the effectiveness of situational feedback to the self-management of fibromyalgia syndrome (FMS) using innovative means of patient-provider communication in a randomized controlled study (RCT). Thereby this project will contribute to the knowledge of treatment of patients with FMS. The effectiveness of the intervention will be expressed in terms of a) reduced pain, b) psychometric outcomes, c) quality of life, d) improved engagement in daily activities and e) prevented transition to chronic disability. We furthermore aim to 1) determine the effectiveness of providing regular situational feedback in enhancing self-management and, consequently 2) study the effectiveness of enhancing self-management in reducing pain and physical disability.

Self-management of chronic pain is increasingly seen as an important tool in providing adequate care to patients with FMS and other types of Chronic Non-malignant Pain. Enhancing the patient's self-management of her/his condition is thought to be effective in reducing pain and disability. However, sufficient empirical evidence to support this is yet unavailable. This may be due to the non-situational nature of many interventions studied so far: Patients are taught management skills in a clinical setting, and may not be able to successfully use these skills in daily care. Therefore, enhancing self-management of chronic pain, by providing immediate feedback that is directly related to patient's daily life (""situational"" feedback) complementary to care-as usual, is thought to be more effective than conventional interventions in a clinical setting. This may even be even more effective when the patient receives quick response feedback using mobile communication technology, i.e. any place any time.","[(45, 57, 'CONDITION', 'Fibromyalgia'), (66, 96, 'OTHER', 'Web-based Situational Feedback'), (266, 286, 'OTHER', 'situational feedback'), (313, 334, 'CONDITION', 'fibromyalgia syndrome'), (336, 339, 'CONDITION', 'FMS'), (367, 397, 'OTHER', 'patient-provider communication'), (522, 525, 'CONDITION', 'FMS'), (606, 610, 'CONDITION', 'pain'), (818, 846, 'OTHER', 'regular situational feedback'), (924, 949, 'OTHER', 'enhancing self-management'), (962, 966, 'CONDITION', 'pain'), (1012, 1024, 'CONDITION', 'chronic pain'), (1111, 1114, 'CONDITION', 'FMS'), (1134, 1160, 'CONDITION', 'Chronic Non-malignant Pain'), (1262, 1266, 'CONDITION', 'pain'), (1611, 1623, 'CONDITION', 'chronic pain'), (1707, 1729, 'OTHER', '""situational"" feedback'), (1800, 1848, 'CONTROL', 'conventional interventions in a clinical setting'), (1913, 1974, 'OTHER', 'quick response feedback using mobile communication technology')]"
"['Combined', 'Constraint', 'Therapy', 'and', 'Bimanual', 'Therapy', 'for', 'Children', 'With', 'Unilateral', 'Brain', 'Injury', '|', 'To', 'examine', 'efficacy', 'of', 'combined', 'unimanual', 'and', 'bimanual', 'intensive', 'therapy', 'in', 'children', 'with', 'unilateral', 'brain', 'injury', '.', 'A', 'key', 'question', 'in', 'hemiplegia', 'therapy', 'is', 'whether', 'the', 'affected', 'hand', 'should', 'be', 'trained', 'alone', 'or', 'in', 'tandem', 'with', 'the', 'other', 'hand', '.', 'In', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'CIMT', ')', ',', 'a', 'participant', ""'s"", 'less', '-', 'affected', 'upper', 'extremity', 'is', 'restricted', 'with', 'a', 'sling', ',', 'cast', ',', 'or', 'mitt', ',', 'while', 'the', 'participant', 'actively', 'uses', 'the', 'affected', 'arm', 'and', 'hand', 'in', 'skill', '-', 'based', 'therapeutic', 'activities', '.', 'Bimanual', 'therapy', ',', 'in', 'contrast', ',', 'engages', 'both', 'hands', 'in', 'therapeutic', 'movement', '.', 'Since', 'constraint', 'and', 'bimanual', 'therapy', 'target', 'different', 'aspects', 'of', 'hand', 'use', ',', 'they', 'could', 'have', 'synergistic', 'effects', 'on', 'hand', 'function', 'when', 'given', 'in', 'combination', '.']","['O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02840643,NCT02840643,"Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury | To examine efficacy of combined unimanual and bimanual intensive therapy in children with unilateral brain injury. A key question in hemiplegia therapy is whether the affected hand should be trained alone or in tandem with the other hand. In constraint-induced movement therapy (CIMT), a participant's less-affected upper extremity is restricted with a sling, cast, or mitt, while the participant actively uses the affected arm and hand in skill-based therapeutic activities. Bimanual therapy, in contrast, engages both hands in therapeutic movement. Since constraint and bimanual therapy target different aspects of hand use, they could have synergistic effects on hand function when given in combination.","[(9, 27, 'PHYSICAL', 'Constraint Therapy'), (32, 48, 'PHYSICAL', 'Bimanual Therapy'), (67, 90, 'CONDITION', 'Unilateral Brain Injury'), (116, 165, 'PHYSICAL', 'combined unimanual and bimanual intensive therapy'), (183, 206, 'CONDITION', 'unilateral brain injury'), (226, 236, 'CONDITION', 'hemiplegia'), (335, 370, 'PHYSICAL', 'constraint-induced movement therapy'), (372, 376, 'PHYSICAL', 'CIMT'), (569, 585, 'PHYSICAL', 'Bimanual therapy'), (650, 681, 'PHYSICAL', 'constraint and bimanual therapy')]"
"['Phase', 'I', 'Pre', '-', 'pilot', 'Open', '-', 'label', 'Clinical', 'Trial', 'of', 'Nabilone', 'for', 'Severe', 'Behavioural', 'Problems', '(', 'Aggression', ')', 'in', 'Adults', 'With', 'Intellectual', 'and', 'Developmental', 'Disabilities', '|', 'Innovative', 'treatments', 'are', 'urgently', 'needed', 'for', 'severe', 'behavioural', 'problems', '(', 'SBPs', ')', 'in', 'adults', 'with', 'intellectual', 'and', 'developmental', 'disabilities', '(', 'IDD', ')', '.', 'Although', 'a', 'synthetic', 'cannabinoid', ',', 'nabilone', 'may', 'be', 'a', 'plausible', 'and', 'safe', 'alternative', 'to', 'treat', 'SBP', ',', 'safety', 'and', 'efficacy', 'of', 'nabilone', 'in', 'people', 'with', 'IDD', 'has', 'never', 'been', 'evaluated', '.', 'The', 'investigators', 'propose', 'to', 'conduct', 'this', 'first', '-', 'ever', 'Phase', 'I', 'pre', '-', 'pilot', 'open', '-', 'label', 'clinical', 'trial', 'to', 'collect', 'data', 'on', 'the', 'tolerability', 'and', 'safety', 'profile', 'of', 'nabilone', 'in', 'adults', 'with', 'IDD', ',', 'and', 'explore', 'changes', 'in', 'SBP', 'pre-', 'and', 'post', '-', 'treatment', '.', 'The', 'results', 'will', 'inform', 'a', 'next', '-', 'stage', 'pilot', 'randomized', 'controlled', 'trial', ',', 'followed', 'by', 'a', 'fully', 'powered', 'trial', 'eventually', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05273320,NCT05273320,"Phase I Pre-pilot Open-label Clinical Trial of Nabilone for Severe Behavioural Problems (Aggression) in Adults With Intellectual and Developmental Disabilities | Innovative treatments are urgently needed for severe behavioural problems (SBPs) in adults with intellectual and developmental disabilities (IDD). Although a synthetic cannabinoid, nabilone may be a plausible and safe alternative to treat SBP, safety and efficacy of nabilone in people with IDD has never been evaluated. The investigators propose to conduct this first-ever Phase I pre-pilot open-label clinical trial to collect data on the tolerability and safety profile of nabilone in adults with IDD, and explore changes in SBP pre- and post-treatment. The results will inform a next-stage pilot randomized controlled trial, followed by a fully powered trial eventually.","[(47, 55, 'DRUG', 'Nabilone'), (60, 87, 'CONDITION', 'Severe Behavioural Problems'), (89, 99, 'CONDITION', 'Aggression'), (116, 159, 'CONDITION', 'Intellectual and Developmental Disabilities'), (208, 235, 'CONDITION', 'severe behavioural problems'), (237, 241, 'CONDITION', 'SBPs'), (258, 301, 'CONDITION', 'intellectual and developmental disabilities'), (303, 306, 'CONDITION', 'IDD'), (330, 341, 'DRUG', 'cannabinoid'), (343, 351, 'DRUG', 'nabilone'), (401, 404, 'CONDITION', 'SBP'), (429, 437, 'DRUG', 'nabilone'), (453, 456, 'CONDITION', 'IDD'), (638, 646, 'DRUG', 'nabilone'), (662, 665, 'CONDITION', 'IDD'), (690, 693, 'CONDITION', 'SBP')]"
"['Weight', 'Management', 'in', 'Spinal', 'Cord', 'Injury', '-', 'Intervention', 'and', 'Monitoring', 'Via', 'Tele', '-', 'Nutrition', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'provide', 'tele', '-', 'nutrition', 'counseling', 'after', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'During', 'the', 'three', 'months', 'of', 'participation', ',', 'subjects', 'will', 'be', 'given', 'an', 'iPad', 'and', 'the', 'iPad', 'will', 'be', 'used', 'to', 'record', 'meals', 'using', 'a', 'photo', 'journal', 'application', ',', 'YouAte', '.', 'In', 'addition', ',', 'subjects', 'will', 'receive', 'dietary', 'advice', 'two', 'times', 'a', 'month', 'with', 'a', 'registered', 'dietitian', '(', 'RD', ')', '.', 'The', 'dietitian', 'role', 'in', 'the', 'study', 'will', 'be', 'to', 'educate', 'healthy', 'weight', 'management', 'and', 'accommodate', 'any', 'cultural', 'and', 'behavioral', 'habits', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'show', 'that', 'the', 'proposed', 'tele', '-', 'nutrition', 'program', 'will', 'be', 'effective', 'with', 'weight', 'management', 'through', '3', '-', 'month', 'tele', '-', 'nutrition', 'counseling', 'via', 'iPad', 'FaceTime', '.', 'The', 'hypotheses', 'are', '1', ')', 'that', 'weight', 'and', 'waist', 'circumference', 'will', 'not', 'increase', 'after', '3', 'months', 'of', 'tele', '-', 'nutrition', 'program', ',', '2', ')', 'quality', 'of', 'life', 'will', 'improve', ',', 'and', '3', ')', 'quality', 'of', 'diet', 'will', 'improve', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03714217,NCT03714217,"Weight Management in Spinal Cord Injury - Intervention and Monitoring Via Tele-Nutrition | The purpose of the study is to provide tele-nutrition counseling after a spinal cord injury (SCI). During the three months of participation, subjects will be given an iPad and the iPad will be used to record meals using a photo journal application, YouAte. In addition, subjects will receive dietary advice two times a month with a registered dietitian (RD). The dietitian role in the study will be to educate healthy weight management and accommodate any cultural and behavioral habits. The objective of this study is to show that the proposed tele-nutrition program will be effective with weight management through 3-month tele-nutrition counseling via iPad FaceTime. The hypotheses are 1) that weight and waist circumference will not increase after 3 months of tele-nutrition program, 2) quality of life will improve, and 3) quality of diet will improve.","[(0, 17, 'BEHAVIOURAL', 'Weight Management'), (21, 39, 'CONDITION', 'Spinal Cord Injury'), (74, 88, 'BEHAVIOURAL', 'Tele-Nutrition'), (130, 155, 'BEHAVIOURAL', 'tele-nutrition counseling'), (164, 182, 'CONDITION', 'spinal cord injury'), (184, 187, 'CONDITION', 'SCI'), (340, 346, 'BEHAVIOURAL', 'YouAte'), (383, 397, 'BEHAVIOURAL', 'dietary advice'), (509, 526, 'BEHAVIOURAL', 'weight management'), (636, 658, 'BEHAVIOURAL', 'tele-nutrition program')]"
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fixed', '-', 'Dose', 'Once', '-', 'weekly', 'Oral', 'Aripiprazole', 'in', 'Children', 'and', 'Adolescents', 'With', 'Tourette', ""'s"", 'Disorder', '|', 'The', 'goal', 'of', 'the', 'current', 'trial', 'is', 'to', 'determine', 'efficacy', 'and', 'safety', 'of', 'once', '-', 'weekly', 'aripiprazole', 'in', 'reducing', 'Total', 'Tic', 'Severity', '(', 'TTS', ')', 'score', 'in', 'children', 'and', 'adolescents', 'with', 'Tourette', ""'s"", 'Disorder', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01418352,NCT01418352,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder | The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.","[(41, 48, 'CONTROL', 'Placebo'), (132, 144, 'DRUG', 'Aripiprazole'), (178, 197, 'CONDITION', ""Tourette's Disorder""), (281, 293, 'DRUG', 'aripiprazole'), (370, 389, 'CONDITION', ""Tourette's Disorder"")]"
"['Investigating', 'the', 'Effects', 'of', 'Combining', 'rTMS', 'With', 'Visual', 'Feedback', 'Training', 'to', 'Improve', 'Movements', 'in', 'the', 'Paretic', 'Lower', 'Limb', 'and', 'Gait', 'Performance', '|', 'After', 'stroke', ',', 'patients', 'often', 'experience', 'motor', 'deficits', 'that', 'interrupt', 'normal', 'lower', 'extremity', 'movement', 'and', 'gait', 'function', '.', 'Recent', 'developments', 'in', 'neuroimaging', 'have', 'focus', 'on', 'the', 'reasons', 'why', 'some', 'patients', 'recover', 'well', 'while', 'some', 'do', 'poorly', '.', 'However', ',', 'there', 'is', 'still', 'no', 'consensus', 'on', 'the', 'exact', 'mechanisms', 'involved', 'in', 'regaining', 'the', 'functions', 'after', 'rehabilitation', '.', 'Application', 'of', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'to', 'facilitate', 'neural', 'plasticity', 'during', 'stroke', 'treatment', 'has', 'recently', 'gained', 'considerable', 'attention', '.', 'The', 'possible', 'mechanism', 'through', 'which', 'rTMS', 'acts', 'is', 'based', 'on', 'the', 'interhemispheric', 'competition', '(', 'IHC', ')', 'model', ',', 'which', 'explains', 'that', 'patients', 'with', 'stroke', 'experience', 'alterations', 'in', 'cortical', 'excitability', 'and', 'exhibit', 'abnormally', 'high', 'interhemispheric', 'inhibition', 'from', 'the', 'unaffected', 'hemisphere', 'to', 'the', 'affected', 'hemisphere', '.', 'The', 'visual', 'feedback', 'training', 'can', 'improve', 'postural', 'control', 'and', 'enhance', 'motor', 'performance', '.', 'Several', 'rTMS', 'studies', 'have', 'evaluated', 'the', 'lower', 'extremity', 'dysfunction', 'following', 'stroke', ',', 'but', 'few', 'studies', 'have', 'explored', 'the', 'efficacy', 'of', 'applying', 'rTMS', 'on', 'the', 'lower', 'extremities', '.', 'We', 'expect', 'the', 'study', 'can', 'help', 'us', 'to', 'further', 'exploration', 'of', 'the', 'change', 'of', 'clinical', 'function', 'and', 'cortical', 'excitability', 'following', 'rTMS', 'and', 'visual', 'feedback', 'training', 'in', 'subjects', 'with', 'stroke', '.', 'In', 'addition', ',', 'the', 'results', 'of', 'this', 'project', 'will', 'be', 'provided', 'for', 'further', 'rehabilitation', 'programs', 'in', 'people', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03689491,NCT03689491,"Investigating the Effects of Combining rTMS With Visual Feedback Training to Improve Movements in the Paretic Lower Limb and Gait Performance | After stroke, patients often experience motor deficits that interrupt normal lower extremity movement and gait function. Recent developments in neuroimaging have focus on the reasons why some patients recover well while some do poorly. However, there is still no consensus on the exact mechanisms involved in regaining the functions after rehabilitation. Application of repetitive transcranial magnetic stimulation (rTMS) to facilitate neural plasticity during stroke treatment has recently gained considerable attention. The possible mechanism through which rTMS acts is based on the interhemispheric competition (IHC) model, which explains that patients with stroke experience alterations in cortical excitability and exhibit abnormally high interhemispheric inhibition from the unaffected hemisphere to the affected hemisphere. The visual feedback training can improve postural control and enhance motor performance. Several rTMS studies have evaluated the lower extremity dysfunction following stroke, but few studies have explored the efficacy of applying rTMS on the lower extremities. We expect the study can help us to further exploration of the change of clinical function and cortical excitability following rTMS and visual feedback training in subjects with stroke. In addition, the results of this project will be provided for further rehabilitation programs in people with stroke.","[(39, 43, 'OTHER', 'rTMS'), (49, 73, 'OTHER', 'Visual Feedback Training'), (150, 156, 'CONDITION', 'stroke'), (514, 558, 'OTHER', 'repetitive transcranial magnetic stimulation'), (560, 564, 'OTHER', 'rTMS'), (605, 611, 'CONDITION', 'stroke'), (703, 707, 'OTHER', 'rTMS'), (805, 811, 'CONDITION', 'stroke'), (979, 1003, 'OTHER', 'visual feedback training'), (1072, 1076, 'OTHER', 'rTMS'), (1142, 1148, 'CONDITION', 'stroke'), (1205, 1209, 'OTHER', 'rTMS'), (1362, 1366, 'OTHER', 'rTMS'), (1371, 1395, 'OTHER', 'visual feedback training'), (1413, 1419, 'CONDITION', 'stroke'), (1530, 1536, 'CONDITION', 'stroke')]"
"['An', 'Open', '-', 'Label', ',', 'Non', '-', 'Randomized', ',', 'Comparative', 'Study', 'Designed', 'to', 'Evaluate', 'the', 'Accuracy', 'and', 'Safety', 'of', 'HS-1000', 'Device', ',', 'a', 'Non', '-', 'Invasive', 'Brain', 'Monitor', '|', 'HS-1000', 'device', ',', 'a', 'proprietary', 'new', 'non', '-', 'invasive', 'brain', 'monitor', ',', 'is', 'expected', 'to', 'safely', 'and', 'accurately', 'monitor', 'physiological', 'signs', 'of', 'the', 'brain', 'with', 'minimal', 'discomfort', 'to', 'patients', ',', 'providing', 'information', 'about', 'normal', 'or', 'abnormal', 'brain', '-', 'related', 'conditions', 'and', 'providing', 'decision', '-', 'making', 'support', 'for', 'physicians', '.', 'Investigators', 'hypothesis', 'that', 'the', 'HS-1000', 'is', 'capable', 'of', 'detecting', 'and', 'monitoring', 'various', 'neuropathologies', ',', 'using', 'the', 'acoustic', 'raw', 'data', 'derived', 'from', 'the', 'noninvasive', 'procedure', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02775136,NCT02775136,"An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor | HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians. Investigators hypothesis that the HS-1000 is capable of detecting and monitoring various neuropathologies, using the acoustic raw data derived from the noninvasive procedure.",[]
"['A', 'Phase', 'II', ',', 'Open', '-', 'Label', ',', 'Single', 'Arm', 'Decentralized', 'Home', '-', 'Based', 'Approach', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Alectinib', 'in', 'Locally', '-', 'Advanced', 'or', 'Metastatic', 'ALK', '-', 'Positive', 'Solid', 'Tumors', '|', 'This', 'study', 'will', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'alectinib', 'in', 'participants', 'with', 'Anaplastic', 'Lymphoma', 'Kinase', '(', 'ALK)-positive', 'locally', 'advanced', 'or', 'metastatic', 'solid', 'tumors', 'other', 'than', 'lung', 'cancer', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04644315,NCT04644315,"A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.","[(114, 123, 'DRUG', 'Alectinib'), (127, 183, 'CONDITION', 'Locally-Advanced or Metastatic ALK-Positive Solid Tumors'), (238, 247, 'DRUG', 'alectinib'), (269, 354, 'CONDITION', 'Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors')]"
"['Immune', 'Modulation', 'Therapy', 'for', 'ERT', '-', 'naïve', 'or', 'ERT', '-', 'treated', 'Pompe', 'Disease', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'anti', '-', 'recombinant', 'human', 'acid', 'α', '-', 'glucosidase', '(', 'anti', '-', 'rhGAA', ')', 'antibody', 'titers', 'after', 'treatment', 'with', 'immune', 'modulation', 'therapy', 'in', 'patients', 'of', 'Pompe', 'disease', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02525172,NCT02525172,Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients | The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.,"[(0, 25, 'OTHER', 'Immune Modulation Therapy'), (30, 68, 'CONDITION', 'ERT-naïve or ERT-treated Pompe Disease'), (119, 160, 'DRUG', 'anti-recombinant human acid α-glucosidase'), (162, 172, 'DRUG', 'anti-rhGAA'), (252, 265, 'CONDITION', 'Pompe disease')]"
"['Effectiveness', 'and', 'Safety', 'of', 'Transcatheter', 'Patent', 'Foramen', 'Ovale', 'Closure', 'for', 'Migraine', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'effectiveness', 'and', 'safety', 'of', 'transcatheter', 'patent', 'foramen', 'ovale', 'closure', 'for', 'migraine', '.']","['O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'O']",NCT02127294,NCT02127294,Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine | The purpose of the study is to evaluate effectiveness and safety of transcatheter patent foramen ovale closure for migraine.,"[(28, 70, 'SURGICAL', 'Transcatheter Patent Foramen Ovale Closure'), (75, 83, 'CONDITION', 'Migraine'), (154, 196, 'SURGICAL', 'transcatheter patent foramen ovale closure'), (201, 209, 'CONDITION', 'migraine')]"
"['Ability', 'of', 'the', 'New', 'Vero', '-', 'cell', '-', 'derived', 'Inactivated', 'Japanese', 'Encephalitis', 'Vaccine', '(', 'IXIARO', ')', 'to', 'Elicit', 'a', 'Booster', 'Response', 'in', 'Travellers', 'Previously', 'Vaccinated', 'With', 'Traditional', 'Mouse', '-', 'brain', 'Derived', 'Vaccine', '(', 'JE', '-', 'MB', ')', '|', 'The', 'old', 'mouse', 'brain', 'derived', 'Japanese', 'encephalitis', 'vaccines', '(', 'MBJEV', ')', 'have', 'been', 'reported', 'to', 'cause', 'serious', 'adverse', 'effects', 'and', 'are', 'therefore', 'replaced', 'with', 'the', 'novel', 'Ixiaro', 'vaccine', '.', 'The', 'present', 'study', 'investigates', 'whether', 'vaccinees', 'primed', 'with', 'MBJEV', 'can', 'be', 'boosted', 'with', 'Ixiaro', '.', '\n\n', 'Travellers', 'receiving', 'Japanese', 'encephalitis', 'vaccines', 'are', 'enrolled', 'for', 'a', 'follow', '-', 'up', 'of', 'immune', 'responses', 'in', 'four', 'groups', ':', 'A', ')', 'primary', 'immunization', 'with', 'BMJEV', ',', 'B', ')', 'primary', 'and', 'secondary', 'immunizations', 'with', 'MBJEV', ',', 'C', ')', 'primary', 'immunizations', 'with', 'Ixiaro', 'and', 'S', ')', 'Primary', 'immunization', 'with', 'MBJEV', 'and', 'secondary', 'immunization', 'with', 'Ixiaro', '.', 'Immune', 'responses', 'are', 'followed', 'with', 'help', 'of', 'serum', 'samples', 'collected', 'before', 'and', 'after', 'vaccination', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01386827,NCT01386827,"Ability of the New Vero-cell-derived Inactivated Japanese Encephalitis Vaccine (IXIARO) to Elicit a Booster Response in Travellers Previously Vaccinated With Traditional Mouse-brain Derived Vaccine (JE-MB) | The old mouse brain derived Japanese encephalitis vaccines (MBJEV) have been reported to cause serious adverse effects and are therefore replaced with the novel Ixiaro vaccine. The present study investigates whether vaccinees primed with MBJEV can be boosted with Ixiaro.

Travellers receiving Japanese encephalitis vaccines are enrolled for a follow-up of immune responses in four groups: A) primary immunization with BMJEV, B) primary and secondary immunizations with MBJEV, C) primary immunizations with Ixiaro and S) Primary immunization with MBJEV and secondary immunization with Ixiaro. Immune responses are followed with help of serum samples collected before and after vaccination.","[(19, 78, 'DRUG', 'Vero-cell-derived Inactivated Japanese Encephalitis Vaccine'), (80, 86, 'DRUG', 'IXIARO'), (158, 197, 'DRUG', 'Traditional Mouse-brain Derived Vaccine'), (199, 204, 'DRUG', 'JE-MB'), (216, 266, 'DRUG', 'mouse brain derived Japanese encephalitis vaccines'), (268, 273, 'DRUG', 'MBJEV'), (369, 383, 'DRUG', 'Ixiaro vaccine'), (446, 451, 'DRUG', 'MBJEV'), (472, 478, 'DRUG', 'Ixiaro'), (627, 632, 'DRUG', 'BMJEV'), (678, 683, 'DRUG', 'MBJEV'), (715, 721, 'DRUG', 'Ixiaro'), (755, 760, 'DRUG', 'MBJEV'), (793, 799, 'DRUG', 'Ixiaro')]"
"['An', 'Open', '-', 'Label', ',', 'Safety', 'and', 'Tolerability', 'Study', 'of', 'Chronic', 'Intermittent', 'Use', 'of', 'Diazepam', 'Buccal', 'Film', '(', 'DBF', ')', 'in', 'Pediatric', ',', 'Adolescent', 'and', 'Adult', 'Subjects', 'With', 'Epilepsy', '|', 'This', 'Phase', '3', ',', 'multicenter', ',', 'open', '-', 'label', 'study', 'of', 'chronic', ',', 'intermittent', 'use', 'of', 'study', 'drug', '(', 'DBF', ')', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'buccal', 'formulation', 'of', 'diazepam', 'in', 'children', ',', 'adolescents', 'and', 'adults', 'with', 'intermittent', ',', 'stereotypic', 'episodes', 'of', 'frequent', 'seizure', 'activity', '(', 'eg', ',', 'seizure', 'clusters', ')', 'that', 'are', 'distinct', 'from', 'the', 'subject', ""'s"", 'usual', 'seizure', 'pattern', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03428360,NCT03428360,"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy | This Phase 3, multicenter, open-label study of chronic, intermittent use of study drug (DBF) is designed to evaluate the safety and tolerability of the buccal formulation of diazepam in children, adolescents and adults with intermittent, stereotypic episodes of frequent seizure activity (eg, seizure clusters) that are distinct from the subject's usual seizure pattern.","[(76, 84, 'DRUG', 'Diazepam'), (98, 101, 'DRUG', 'DBF'), (152, 160, 'CONDITION', 'Epilepsy'), (251, 254, 'DRUG', 'DBF'), (337, 345, 'DRUG', 'diazepam'), (387, 450, 'CONDITION', 'intermittent, stereotypic episodes of frequent seizure activity'), (456, 472, 'CONDITION', 'seizure clusters'), (517, 524, 'CONDITION', 'seizure')]"
"['Sarcopenia', 'and', 'Physical', 'fRailty', 'IN', 'Older', 'People', ':', 'Multi', '-', 'componenT', 'Treatment', 'Strategies', '(', 'SPRINTT', ')', '|', 'The', 'SPRINTT', 'study', 'will', 'evaluate', 'the', 'efficacy', 'of', 'a', 'multicomponent', 'intervention', 'programme', '(', 'physical', 'activity', ',', 'nutritional', 'counselling', '/', 'dietary', 'intervention', ',', 'and', 'information', 'and', 'communications', 'technology', 'intervention', ')', 'compared', 'with', 'a', 'healthy', 'aging', 'lifestyle', 'education', 'programme', 'on', 'mobility', 'disability', ',', 'in', 'non', '-', 'disabled', 'older', 'people', 'with', 'physical', 'frailty', 'and', 'sarcopenia', '.']","['B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT02582138,NCT02582138,"Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT) | The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility disability, in non-disabled older people with physical frailty and sarcopenia.","[(0, 10, 'CONDITION', 'Sarcopenia'), (15, 31, 'CONDITION', 'Physical fRailty'), (49, 85, 'OTHER', 'Multi-componenT Treatment Strategies'), (148, 185, 'OTHER', 'multicomponent intervention programme'), (187, 204, 'OTHER', 'physical activity'), (206, 250, 'OTHER', 'nutritional counselling/dietary intervention'), (256, 310, 'OTHER', 'information and communications technology intervention'), (328, 371, 'CONTROL', 'healthy aging lifestyle education programme'), (375, 394, 'CONDITION', 'mobility disability'), (430, 446, 'CONDITION', 'physical frailty'), (451, 461, 'CONDITION', 'sarcopenia')]"
"['Acupuncture', 'for', 'the', 'Sleep', 'Disorder', 'of', 'Chronic', 'Fatigue', 'Syndrome', '|', 'The', 'investigators', 'will', 'conduct', 'acupuncture', 'for', 'participants', 'with', 'chronic', 'fatigue', 'syndrome(CFS', ')', '.', 'Firstly', 'the', 'investigators', 'aim', 'to', 'figure', 'out', 'the', 'characteristic', 'of', 'sleep', 'structure', 'of', 'CFS', 'and', 'the', 'changes', 'caused', 'by', 'acupuncture', '.', 'Secondly', 'the', 'investigators', 'seek', 'to', 'investigate', 'the', 'characteristic', 'of', 'sleep', '-', 'wake', 'rhythm', ',', 'slow', 'wave', 'sleep(SWS)-rapid', 'eye', 'movement(REM)sleep', 'rhythm', ',', 'and', 'REM', 'sleep', 'rhythm', 'of', 'CFS', 'and', 'the', 'readjusting', 'of', 'acupuncture', 'for', 'it', '.', 'Thirdly', 'the', 'investigators', 'want', 'to', 'know', 'the', 'efficacy', 'of', 'acupuncture', 'for', 'relieving', 'the', 'fatigue', ',', 'reducing', 'accompanying', 'symptoms', 'and', 'for', 'improving', 'the', 'life', 'quality', 'of', 'CFS', '.']","['B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01534130,NCT01534130,"Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome | The investigators will conduct acupuncture for participants with chronic fatigue syndrome(CFS). Firstly the investigators aim to figure out the characteristic of sleep structure of CFS and the changes caused by acupuncture. Secondly the investigators seek to investigate the characteristic of sleep-wake rhythm, slow wave sleep(SWS)-rapid eye movement(REM)sleep rhythm, and REM sleep rhythm of CFS and the readjusting of acupuncture for it. Thirdly the investigators want to know the efficacy of acupuncture for relieving the fatigue, reducing accompanying symptoms and for improving the life quality of CFS.","[(0, 11, 'OTHER', 'Acupuncture'), (20, 34, 'CONDITION', 'Sleep Disorder'), (38, 62, 'CONDITION', 'Chronic Fatigue Syndrome'), (96, 107, 'OTHER', 'acupuncture'), (130, 145, 'CONDITION', 'chronic fatigue'), (246, 249, 'CONDITION', 'CFS'), (276, 287, 'OTHER', 'acupuncture'), (459, 462, 'CONDITION', 'CFS'), (486, 497, 'OTHER', 'acupuncture'), (561, 572, 'OTHER', 'acupuncture'), (591, 598, 'CONDITION', 'fatigue'), (669, 672, 'CONDITION', 'CFS')]"
"['An', 'Open', 'Label', 'Conversion', 'Study', 'of', 'Pramipexole', 'to', 'Ropinirole', 'Controlled', 'Release', '(', 'CR', ')', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'A', 'conversion', 'study', 'of', 'Mirapex', '(', 'pramipexole', ')', 'to', 'Requip', '(', 'ropinirole', ')', 'controlled', 'release', '(', 'CR', ')', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', 'to', 'determine', 'the', 'appropriate', 'conversion', 'ratio', 'and', 'side', 'effects', 'related', 'to', 'the', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00275275,NCT00275275,An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. | A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.,"[(34, 45, 'DRUG', 'Pramipexole'), (49, 59, 'DRUG', 'Ropinirole'), (101, 120, 'CONDITION', ""Parkinson's Disease""), (146, 153, 'DRUG', 'Mirapex'), (155, 166, 'DRUG', 'pramipexole'), (171, 177, 'DRUG', 'Requip'), (179, 189, 'DRUG', 'ropinirole'), (232, 251, 'CONDITION', ""Parkinson's disease"")]"
"['Feasibility', 'Study', 'of', 'Human', 'Umbilical', 'Cord', 'Tissue', '-', 'Derived', 'Mesenchymal', 'Stem', 'Cells', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'Allogeneic', 'human', 'umbilical', 'cord', 'tissue', '-', 'derived', 'stem', 'cells', 'injected', 'intravenously', '(', 'IV', ')', 'once', 'per', 'day', 'for', '7', 'days', 'is', 'a', 'safe', 'and', 'will', 'induce', 'a', 'therapeutic', 'effect', 'in', 'multiple', 'sclerosis', '(', 'MS', ')', 'patients', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT02034188,NCT02034188,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.,"[(21, 79, 'SURGICAL', 'Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells'), (97, 115, 'CONDITION', 'Multiple Sclerosis'), (118, 175, 'SURGICAL', 'Allogeneic human umbilical cord tissue-derived stem cells'), (278, 296, 'CONDITION', 'multiple sclerosis'), (298, 300, 'CONDITION', 'MS')]"
"['Optimizing', 'the', 'Use', 'of', 'Entonox', '®', 'During', 'Screening', 'Colonoscopy', ':', 'an', 'Open', 'Randomised', 'Controlled', 'Trial', '|', 'This', 'study', 'will', 'randomise', 'patients', 'undergoing', 'screening', 'colonoscopy', 'to', 'receive', 'Entonox', 'either', 'continuously', 'or', 'as', 'required', '.', '\n\n', 'Both', 'these', 'methods', 'are', 'used', 'in', 'the', 'published', 'studies', 'of', 'Entonox', 'and', 'in', 'clinical', 'practice', '.', '\n\n', 'Null', 'hypothesis', 'There', 'will', 'be', 'no', 'difference', 'in', 'pain', 'levels', 'between', 'these', 'two', 'methods', 'of', 'Entonox', 'administration']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT01865721,NCT01865721,"Optimizing the Use of Entonox® During Screening Colonoscopy: an Open Randomised Controlled Trial | This study will randomise patients undergoing screening colonoscopy to receive Entonox either continuously or as required.

Both these methods are used in the published studies of Entonox and in clinical practice.

Null hypothesis There will be no difference in pain levels between these two methods of Entonox administration","[(22, 29, 'DRUG', 'Entonox'), (38, 59, 'CONDITION', 'Screening Colonoscopy'), (145, 166, 'CONDITION', 'screening colonoscopy'), (178, 185, 'DRUG', 'Entonox'), (279, 286, 'DRUG', 'Entonox'), (361, 365, 'CONDITION', 'pain'), (402, 409, 'DRUG', 'Entonox')]"
"['SANTE', '-', 'Stimulation', 'of', 'the', 'Anterior', 'Nucleus', 'of', 'the', 'Thalamus', 'for', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'study', 'the', 'safety', 'and', 'effectiveness', 'of', 'bilateral', 'stimulation', 'of', 'the', 'anterior', 'nucleus', 'of', 'the', 'thalamus', 'as', 'adjunctive', 'therapy', 'for', 'reducing', 'the', 'frequency', 'of', 'seizures', 'in', 'adults', 'diagnosed', 'with', 'epilepsy', 'characterized', 'by', 'partial', '-', 'onset', 'seizures', ',', 'with', 'or', 'without', 'secondary', 'generalization', ',', 'that', 'are', 'refractory', 'to', 'antiepileptic', 'medications', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00101933,NCT00101933,"SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy | The purpose of this research is to study the safety and effectiveness of bilateral stimulation of the anterior nucleus of the thalamus as adjunctive therapy for reducing the frequency of seizures in adults diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to antiepileptic medications.","[(8, 59, 'OTHER', 'Stimulation of the Anterior Nucleus of the Thalamus'), (64, 72, 'CONDITION', 'Epilepsy'), (148, 209, 'OTHER', 'bilateral stimulation of the anterior nucleus of the thalamus'), (262, 270, 'CONDITION', 'seizures'), (296, 304, 'CONDITION', 'epilepsy'), (322, 344, 'CONDITION', 'partial-onset seizures'), (362, 386, 'CONDITION', 'secondary generalization'), (397, 436, 'CONDITION', 'refractory to antiepileptic medications')]"
"['Neurotropin', 'Treatment', 'of', 'Fibromyalgia', '|', 'This', 'study', 'will', 'examine', 'the', 'safety', 'and', 'effectiveness', 'of', 'the', 'experimental', 'drug', ',', 'neurotropin', ',', 'for', 'preventing', 'or', 'easing', 'pain', 'associated', 'with', 'fibromyalgia', '.', 'A', 'disorder', 'that', 'primarily', 'affects', 'women', ',', 'fibromyalgia', 'causes', 'widespread', 'aching', 'and', 'stiffness', 'in', 'muscles', '.', 'Neurotropin', 'has', 'been', 'used', 'in', 'Japan', 'for', 'many', 'years', 'to', 'treat', 'various', 'chronic', 'painful', 'conditions', ',', 'including', 'fibromyalgia', '.', '\n\n', 'Women', 'with', 'fibromyalgia', 'who', 'have', 'been', 'treated', 'unsuccessfully', 'with', 'standard', 'therapy', 'may', 'be', 'eligible', 'for', 'this', 'study', '.', 'Patients', 'must', 'have', 'a', 'history', 'of', 'widespread', 'pain', 'for', 'more', 'than', 'half', 'of', 'the', 'days', 'in', 'each', 'of', 'the', 'three', 'months', 'before', 'they', 'enter', 'the', 'study', '.', 'Candidates', 'are', 'screened', 'with', 'a', 'medical', 'history', ',', 'physical', 'examination', ',', 'blood', 'and', 'urine', 'tests', ',', 'questionnaires', 'and', 'an', 'electrocardiogram', '(', 'EKG', ')', '.', '\n\n', 'Participants', 'take', 'their', 'usual', 'medications', 'for', 'fibromyalgia', 'in', 'addition', 'to', 'either', 'neurotropin', 'or', 'a', 'placebo', '(', 'look', '-', 'alike', 'medicine', 'with', 'no', 'active', 'ingredient', ')', '.', 'At', '6', 'weeks', 'and', '12', 'weeks', 'into', 'the', 'study', ',', 'they', 'return', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', 'evaluation', 'of', 'their', 'sensitivity', 'to', 'pain', 'and', 'level', 'of', 'physical', 'capability', '.', 'After', '12', 'weeks', ',', 'study', 'subjects', '""', 'cross', '-', 'over', '""', 'their', 'medication', ';', 'that', 'is', ',', 'patients', 'who', 'took', 'neurotropin', 'for', 'the', 'first', '12', 'weeks', 'of', 'the', 'study', 'take', 'placebo', 'for', 'the', 'next', '12', 'weeks', ',', 'and', 'vice', '-', 'versa', '.', 'Again', ',', 'after', '6', 'and', '12', 'weeks', ',', 'patients', 'return', 'for', 'evaluation', '.', '\n\n', 'Participants', 'have', 'blood', 'and', 'urine', 'tests', 'six', 'times', 'during', 'the', 'study', 'and', 'complete', 'questionnaires', 'each', 'week', 'about', 'their', 'pain', ',', 'symptoms', ',', 'and', 'activities', '.']","['B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00366535,NCT00366535,"Neurotropin Treatment of Fibromyalgia | This study will examine the safety and effectiveness of the experimental drug, neurotropin, for preventing or easing pain associated with fibromyalgia. A disorder that primarily affects women, fibromyalgia causes widespread aching and stiffness in muscles. Neurotropin has been used in Japan for many years to treat various chronic painful conditions, including fibromyalgia.

Women with fibromyalgia who have been treated unsuccessfully with standard therapy may be eligible for this study. Patients must have a history of widespread pain for more than half of the days in each of the three months before they enter the study. Candidates are screened with a medical history, physical examination, blood and urine tests, questionnaires and an electrocardiogram (EKG).

Participants take their usual medications for fibromyalgia in addition to either neurotropin or a placebo (look-alike medicine with no active ingredient). At 6 weeks and 12 weeks into the study, they return to the NIH Clinical Center for evaluation of their sensitivity to pain and level of physical capability. After 12 weeks, study subjects ""cross-over"" their medication; that is, patients who took neurotropin for the first 12 weeks of the study take placebo for the next 12 weeks, and vice-versa. Again, after 6 and 12 weeks, patients return for evaluation.

Participants have blood and urine tests six times during the study and complete questionnaires each week about their pain, symptoms, and activities.","[(0, 11, 'DRUG', 'Neurotropin'), (25, 37, 'CONDITION', 'Fibromyalgia'), (119, 130, 'DRUG', 'neurotropin'), (157, 161, 'CONDITION', 'pain'), (178, 190, 'CONDITION', 'fibromyalgia'), (233, 245, 'CONDITION', 'fibromyalgia'), (297, 308, 'DRUG', 'Neurotropin'), (402, 414, 'CONDITION', 'fibromyalgia'), (428, 440, 'CONDITION', 'fibromyalgia'), (575, 579, 'CONDITION', 'pain'), (855, 867, 'CONDITION', 'fibromyalgia'), (890, 901, 'DRUG', 'neurotropin'), (907, 914, 'CONTROL', 'placebo'), (1082, 1086, 'CONDITION', 'pain'), (1210, 1221, 'DRUG', 'neurotropin'), (1263, 1270, 'CONTROL', 'placebo'), (1489, 1493, 'CONDITION', 'pain')]"
"['Screening', 'Brain', 'MRI', 'in', 'High', 'School', 'Football', ':', 'What', 'is', 'the', 'Risk', 'of', 'Traumatic', 'Brain', 'Injury', 'and', 'Does', 'the', 'Guardian', 'Cap', 'Reduce', 'the', 'Incidence', 'of', 'Injury', 'as', 'Determined', 'by', 'Fluid', '-', 'attenuated', 'Inversion', 'Recovery', '(', 'FLAIR', ')', 'and', 'Susceptibility', 'Weighted', 'Imaging', '(', 'SWI', ')', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', 'Sequences', '|', 'Screening', 'Brain', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'with', 'Fluid', '-', 'attenuated', 'Inversion', 'Recovery', '(', 'FLAIR', ')', 'and', 'Susceptibility', 'Weighted', 'Imaging', '(', 'SWI', ')', 'sequences', 'will', 'be', 'performed', 'pre', 'and', 'post', 'season', 'on', 'high', 'school', 'football', 'players', '.', 'One', 'set', 'of', 'players', 'will', 'wear', 'the', 'Guardian', 'Cap', 'on', 'their', 'five', 'star', 'rated', 'helmets', 'and', 'the', 'other', 'will', 'wear', 'five', 'star', 'rated', 'helmets', 'only', '.', 'The', 'investigators', 'will', 'compare', 'outcomes', 'of', 'ImPACT', 'scores', 'and', 'MRI', 'findings', 'between', 'the', 'two', 'groups', 'to', 'see', 'if', 'there', 'is', 'a', 'statistical', 'difference', 'in', 'reduction', 'of', 'injury', 'and', 'to', 'establish', 'what', 'the', 'baseline', 'level', 'of', 'MRI', 'findings', 'related', 'to', 'injury', 'from', 'high', 'school', 'football', 'is', 'as', 'well', 'as', 'what', 'the', 'baseline', 'level', 'of', 'injury', 'is', 'prior', 'to', 'the', 'start', 'of', 'the', 'season', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02757053,NCT02757053,Screening Brain MRI in High School Football: What is the Risk of Traumatic Brain Injury and Does the Guardian Cap Reduce the Incidence of Injury as Determined by Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) Magnetic Resonance Imaging (MRI) Sequences | Screening Brain magnetic resonance imaging (MRI) with Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) sequences will be performed pre and post season on high school football players. One set of players will wear the Guardian Cap on their five star rated helmets and the other will wear five star rated helmets only. The investigators will compare outcomes of ImPACT scores and MRI findings between the two groups to see if there is a statistical difference in reduction of injury and to establish what the baseline level of MRI findings related to injury from high school football is as well as what the baseline level of injury is prior to the start of the season.,"[(65, 87, 'CONDITION', 'Traumatic Brain Injury'), (101, 113, 'OTHER', 'Guardian Cap'), (547, 559, 'OTHER', 'Guardian Cap'), (617, 645, 'OTHER', 'five star rated helmets only')]"
"['A', 'Comparison', 'of', 'Tissue', 'Adhesive', 'Material', 'and', 'Suture', 'as', 'Wound', '-', 'closure', 'Techniques', '|', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'suture', '-', 'based', 'wound', 'closure', '(', 'n=50', ')', 'or', 'tissue', 'adhesive', '-', 'based', 'wound', 'closure', '(', 'n=50', ')', 'with', 'two', '-', 'component', 'skin', 'adhesive', 'Glubran', 'Tiss', '2', '®', '.', 'The', 'outcomes', 'will', 'be', 'assessed', 'during', 'the', 'follow', '-', 'up', 'period', 'at', 'intervals', 'of', '2', ',', '6', ',', 'and', '12', 'weeks', 'postoperatively', '.', 'A', 'scar', 'assessment', 'will', 'be', 'using', 'the', 'POSAS', '(', 'Patient', 'and', 'Observer', 'Scar', 'Assessment', 'Scale', ')', 'and', 'cosmetic', 'VAS', '(', 'Visual', 'Analog', 'Scale', ')', '.', 'The', 'VNRS', '(', 'Verbal', 'Number', 'Rating', 'Scale', ')', 'will', 'used', 'to', 'assess', 'pain', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05747989,NCT05747989,"A Comparison of Tissue Adhesive Material and Suture as Wound-closure Techniques | Participants will be randomly assigned to suture-based wound closure (n=50) or tissue adhesive-based wound closure (n=50) with two-component skin adhesive Glubran Tiss 2®. The outcomes will be assessed during the follow-up period at intervals of 2, 6, and 12 weeks postoperatively. A scar assessment will be using the POSAS (Patient and Observer Scar Assessment Scale) and cosmetic VAS (Visual Analog Scale). The VNRS (Verbal Number Rating Scale) will used to assess pain.","[(16, 40, 'SURGICAL', 'Tissue Adhesive Material'), (45, 51, 'SURGICAL', 'Suture'), (55, 60, 'CONDITION', 'Wound'), (124, 150, 'SURGICAL', 'suture-based wound closure'), (161, 196, 'SURGICAL', 'tissue adhesive-based wound closure'), (209, 251, 'SURGICAL', 'two-component skin adhesive Glubran Tiss 2'), (366, 370, 'CONDITION', 'scar')]"
"['Feasibility', 'of', 'Auditory', 'Nerve', 'Test', 'System', 'for', 'Optimization', 'of', 'Simultaneous', 'Translabyrinthine', 'Vestibular', 'Schwannoma', 'Resection', 'With', 'Cochlear', 'Implantation', '|', 'The', 'Auditory', 'Nerve', 'Test', 'System', '(', 'ANTS', ')', 'is', 'a', 'novel', 'device', 'that', 'stimulates', 'the', 'auditory', 'nerve', 'much', 'like', 'a', 'cochlear', 'implant', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'demonstrate', 'feasibility', 'of', 'the', 'ANTS', 'during', 'translabyrinthine', 'surgery', 'for', 'vestibular', 'schwannoma', 'resection', '.', 'If', 'the', 'auditory', 'nerve', 'is', 'kept', 'intact', ',', 'then', 'the', 'patients', 'will', 'also', 'receive', 'a', 'cochlear', 'implant', 'at', 'the', 'same', 'time', 'potentially', 'alleviating', 'the', 'morbidities', 'caused', 'by', 'a', 'vestibular', 'schwannoma', 'and', 'asymmetric', 'sensorineural', 'hearing', 'loss', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04241679,NCT04241679,"Feasibility of Auditory Nerve Test System for Optimization of Simultaneous Translabyrinthine Vestibular Schwannoma Resection With Cochlear Implantation | The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for vestibular schwannoma resection. If the auditory nerve is kept intact, then the patients will also receive a cochlear implant at the same time potentially alleviating the morbidities caused by a vestibular schwannoma and asymmetric sensorineural hearing loss.","[(15, 41, 'OTHER', 'Auditory Nerve Test System'), (75, 124, 'CONDITION', 'Translabyrinthine Vestibular Schwannoma Resection'), (130, 151, 'CONDITION', 'Cochlear Implantation'), (158, 184, 'OTHER', 'Auditory Nerve Test System'), (186, 190, 'OTHER', 'ANTS'), (338, 342, 'OTHER', 'ANTS'), (350, 411, 'CONDITION', 'translabyrinthine surgery for vestibular schwannoma resection'), (489, 505, 'CONDITION', 'cochlear implant'), (575, 596, 'CONDITION', 'vestibular schwannoma'), (601, 638, 'CONDITION', 'asymmetric sensorineural hearing loss')]"
"['Feasibility', 'and', 'Preliminary', 'Effects', 'of', 'Using', 'a', 'Music', '-', 'based', ',', 'Rhythm', '-', 'modulating', 'Wearable', 'Sensor', 'System', 'in', 'the', 'Community', 'in', 'Persons', 'With', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'music', ',', 'tailored', 'to', 'the', 'participant', ""'s"", 'cadence', ',', 'on', 'adherence', ',', 'quality', 'of', 'life', ',', 'gait', 'speed', ',', 'functional', 'mobility', ',', 'and', 'walking', 'activity', 'in', 'individuals', 'with', 'Parkinson', 'disease', 'when', 'used', 'in', 'the', 'home', 'and', 'community', 'environment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04891107,NCT04891107,"Feasibility and Preliminary Effects of Using a Music-based, Rhythm-modulating Wearable Sensor System in the Community in Persons With Parkinson Disease | The purpose of this clinical study is to evaluate the effects of music, tailored to the participant's cadence, on adherence, quality of life, gait speed, functional mobility, and walking activity in individuals with Parkinson disease when used in the home and community environment.","[(47, 100, 'OTHER', 'Music-based, Rhythm-modulating Wearable Sensor System'), (134, 151, 'CONDITION', 'Parkinson Disease'), (219, 263, 'OTHER', ""music, tailored to the participant's cadence""), (370, 387, 'CONDITION', 'Parkinson disease')]"
"['Improving', 'Obstructive', 'Sleep', 'Apnea', 'Management', 'Via', 'Wireless', 'Telemonitoring', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'is', 'a', 'major', 'chronic', 'condition', 'affecting', 'the', 'quality', 'of', 'life', 'of', 'up', 'to', 'one', '-', 'fifth', 'of', 'all', 'Veterans', '.', 'Because', 'of', 'disappointingly', 'low', 'adherence', 'to', 'the', 'gold', '-', 'standard', 'treatment', '(', 'continuous', 'positive', 'airway', 'pressure', 'therapy', '-', 'CPAP', ')', ',', 'the', 'Institute', 'of', 'Medicine', 'has', 'stated', 'that', 'new', 'adherence', 'strategies', 'are', 'needed', 'that', 'improve', 'the', 'quality', 'of', 'care', ',', 'reduce', 'social', 'and', 'economic', 'costs', ',', 'and', 'help', 'OSA', 'patients', 'live', 'happier', ',', 'healthier', ',', 'and', 'more', 'productive', 'lives', 'through', 'improved', 'clinical', 'management', '.', 'The', 'combination', 'of', 'a', 'self', '-', 'management', 'approach', 'along', 'with', 'emerging', 'wireless', 'technologies', 'has', 'strong', 'potential', 'to', 'increase', 'treatment', 'adherence', 'and', 'improve', 'outcomes', '.']","['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00682838,NCT00682838,"Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring | Obstructive sleep apnea (OSA) is a major chronic condition affecting the quality of life of up to one-fifth of all Veterans. Because of disappointingly low adherence to the gold-standard treatment (continuous positive airway pressure therapy - CPAP), the Institute of Medicine has stated that new adherence strategies are needed that improve the quality of care, reduce social and economic costs, and help OSA patients live happier, healthier, and more productive lives through improved clinical management. The combination of a self-management approach along with emerging wireless technologies has strong potential to increase treatment adherence and improve outcomes.","[(10, 33, 'CONDITION', 'Obstructive Sleep Apnea'), (49, 72, 'OTHER', 'Wireless Telemonitoring'), (75, 98, 'CONDITION', 'Obstructive sleep apnea'), (100, 103, 'CONDITION', 'OSA'), (481, 484, 'CONDITION', 'OSA'), (604, 628, 'BEHAVIOURAL', 'self-management approach'), (649, 670, 'OTHER', 'wireless technologies')]"
"['Effects', 'of', 'Different', 'Percentages', 'Body', 'Weight', 'Supported', 'Treadmill', 'Training', 'on', 'Gait', ',', 'Balance', ',', 'Quality', 'of', 'Life', 'and', 'Fatigue', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'A', 'Double', 'Blind', 'Randomized', 'Controlled', 'Trial', '|', 'Body', 'weight', 'supported', 'treadmill', 'training', '(', 'BWSTT', ')', 'is', 'an', 'important', 'rehabilitative', 'choice', 'for', 'neurologically', 'impaired', 'subjects', 'such', 'as', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'different', 'percentages', 'BWSTT', 'on', 'gait', ',', 'balance', ',', 'quality', 'of', 'life', 'and', 'fatigue', 'in', 'moderate', 'to', 'advanced', 'PD', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT03799887,NCT03799887,"Effects of Different Percentages Body Weight Supported Treadmill Training on Gait, Balance, Quality of Life and Fatigue in Parkinson's Disease: A Double Blind Randomized Controlled Trial | Body weight supported treadmill training (BWSTT) is an important rehabilitative choice for neurologically impaired subjects such as Parkinson's disease (PD). The aim of the study is to evaluate the effectiveness of different percentages BWSTT on gait, balance, quality of life and fatigue in moderate to advanced PD.","[(33, 73, 'PHYSICAL', 'Body Weight Supported Treadmill Training'), (112, 119, 'CONDITION', 'Fatigue'), (123, 142, 'CONDITION', ""Parkinson's Disease""), (189, 229, 'PHYSICAL', 'Body weight supported treadmill training'), (231, 236, 'PHYSICAL', 'BWSTT'), (321, 340, 'CONDITION', ""Parkinson's disease""), (342, 344, 'CONDITION', 'PD'), (426, 431, 'PHYSICAL', 'BWSTT'), (470, 477, 'CONDITION', 'fatigue'), (481, 504, 'CONDITION', 'moderate to advanced PD')]"
"['A', 'Prospective', ',', 'Randomized', 'Placebo', 'Controlled', 'Pilot', 'Study', 'to', 'Characterize', 'the', 'Intestinal', 'Microbiome', 'and', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Fecal', 'Microbiome', 'Changes', 'Following', 'Weekly', 'Administration', 'of', 'Lyophilized', 'PRIM', '-', 'DJ2727', 'Given', 'Orally', 'in', 'Subjects', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'characterize', 'the', 'intestinal', 'flora', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'and', 'to', 'determine', 'safety', 'and', 'trends', 'in', 'improvements', 'in', 'diversity', 'of', 'colonic', 'microbiome', 'following', 'fecal', 'microbiota', 'transplantation', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03026231,NCT03026231,"A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease | The purpose of this study is to characterize the intestinal flora in subjects with Parkinson's Disease (PD) and to determine safety and trends in improvements in diversity of colonic microbiome following fecal microbiota transplantation.","[(26, 33, 'CONTROL', 'Placebo'), (202, 213, 'DRUG', 'PRIM-DJ2727'), (244, 263, 'CONDITION', ""Parkinson's Disease""), (349, 368, 'CONDITION', ""Parkinson's Disease""), (370, 372, 'CONDITION', 'PD'), (470, 502, 'OTHER', 'fecal microbiota transplantation')]"
"['Multi', '-', 'Center', 'Project', ':', 'Supported', 'Speed', 'Treadmill', 'Training', 'Exercise', 'Program', '(', 'SSTTEP', ')', 'for', 'Marginally', 'Ambulatory', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'The', 'investigators', 'are', 'studying', 'the', 'effects', 'of', 'a', '12', '-', 'week', 'exercise', 'program', ',', 'consisting', 'of', 'either', ':', '\n\n', 'Walking', 'on', 'a', 'treadmill', 'with', 'partial', 'body', 'weight', '\n', 'Functional', 'exercise', 'program', '\n\n', 'The', 'investigators', 'would', 'like', 'to', 'know', 'the', 'effects', 'these', 'two', 'exercise', 'programs', 'have', 'on', 'the', 'quality', 'of', 'life', ',', 'muscle', 'strength', 'and', 'control', ',', 'coordination', ',', 'walking', ',', 'and', 'functional', 'movement', 'of', 'children', 'with', 'cerebral', 'palsy', 'who', 'are', 'marginal', 'ambulators', '.', 'This', 'is', 'a', 'randomized', 'control', 'trial', 'with', 'subjects', 'randomly', 'assigned', 'to', 'one', 'of', 'the', '2', 'groups', '.', 'Subjects', 'in', 'both', 'groups', 'will', 'be', 'seen', 'twice', 'a', 'day', 'for', 'two', 'weeks', 'at', 'our', 'hospital', 'for', 'intervention', 'and', 'parent', 'training', ',', 'and', 'then', 'participate', 'in', 'a', '10', 'week', 'home', '-', 'based', 'program', '.', 'During', 'each', 'subject', ""'s"", 'two', '-', 'week', 'clinic', '-', 'based', 'training', ',', 'a', 'parent', 'or', 'caregiver', 'is', 'trained', 'in', 'all', 'home', 'program', 'exercises', 'and/or', 'equipment', 'usage', '.', 'This', 'person', 'must', 'be', 'able', 'to', 'safely', 'perform', 'the', 'exercise', 'program', 'with', 'the', 'child', '.', 'Each', 'subject', 'will', 'also', 'need', 'to', 'participate', 'in', 'three', 'separate', '5', '-', 'hour', 'long', 'data', 'collection', 'sessions', 'scheduled', 'over', 'the', '4', 'month', 'study', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00467415,NCT00467415,"Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy | The investigators are studying the effects of a 12-week exercise program, consisting of either:

Walking on a treadmill with partial body weight
Functional exercise program

The investigators would like to know the effects these two exercise programs have on the quality of life, muscle strength and control, coordination, walking, and functional movement of children with cerebral palsy who are marginal ambulators. This is a randomized control trial with subjects randomly assigned to one of the 2 groups.Subjects in both groups will be seen twice a day for two weeks at our hospital for intervention and parent training, and then participate in a 10 week home-based program. During each subject's two-week clinic-based training, a parent or caregiver is trained in all home program exercises and/or equipment usage. This person must be able to safely perform the exercise program with the child. Each subject will also need to participate in three separate 5-hour long data collection sessions scheduled over the 4 month study period.","[(22, 73, 'PHYSICAL', 'Supported Speed Treadmill Training Exercise Program'), (75, 81, 'PHYSICAL', 'SSTTEP'), (123, 137, 'CONDITION', 'Cerebral Palsy'), (196, 212, 'PHYSICAL', 'exercise program'), (237, 284, 'PHYSICAL', 'Walking on a treadmill with partial body weight'), (285, 312, 'PHYSICAL', 'Functional exercise program'), (373, 390, 'PHYSICAL', 'exercise programs'), (513, 527, 'CONDITION', 'cerebral palsy'), (798, 816, 'PHYSICAL', 'home-based program'), (912, 934, 'PHYSICAL', 'home program exercises'), (1006, 1014, 'PHYSICAL', 'exercise')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'of', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'STX209', '(', 'Arbaclofen', ')', 'Administered', 'for', 'the', 'Treatment', 'of', 'Social', 'Function', 'in', 'Adolescents', 'and', 'Adults', 'With', 'Fragile', 'X', 'Syndrome', '|', 'To', 'explore', 'the', 'efficacy', ',', 'safety', 'and', 'tolerability', 'of', 'STX209', '(', 'arbaclofen', ')', 'administered', 'for', 'the', 'treatment', 'of', 'social', 'withdrawal', 'in', 'adolescents', 'and', 'adults', 'with', 'fragile', 'X', 'syndrome', '(', 'FXS', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT01282268,NCT01282268,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome | To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)","[(28, 35, 'CONTROL', 'Placebo'), (98, 104, 'DRUG', 'STX209'), (106, 116, 'DRUG', 'Arbaclofen'), (199, 217, 'CONDITION', 'Fragile X Syndrome'), (272, 278, 'DRUG', 'STX209'), (280, 290, 'DRUG', 'arbaclofen'), (326, 343, 'CONDITION', 'social withdrawal'), (375, 393, 'CONDITION', 'fragile X syndrome'), (395, 398, 'CONDITION', 'FXS')]"
"['AutoLITT', '™', 'FIM', 'Trial', '-', 'A', 'Prospective', 'First', '-', 'In', '-', 'Man', '(', 'FIM', ')', 'Safety', 'Trial', 'of', 'the', 'AutoLITT', 'Laser', 'Treatment', 'of', 'Recurrent', '/', 'Progressive', 'Brain', 'Tumors', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'performance', 'of', 'the', 'AutoLITT', 'system', 'for', 'the', 'treatment', 'of', 'recurrent', '/', 'progressive', 'glioblastoma', 'multiforme', 'tumors', '(', 'GBM', ')', '.']","['B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00747253,NCT00747253,AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors | The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).,"[(0, 8, 'OTHER', 'AutoLITT'), (75, 99, 'OTHER', 'AutoLITT Laser Treatment'), (103, 137, 'CONDITION', 'Recurrent/Progressive Brain Tumors'), (220, 235, 'OTHER', 'AutoLITT system'), (257, 309, 'CONDITION', 'recurrent/progressive glioblastoma multiforme tumors'), (311, 314, 'CONDITION', 'GBM')]"
"['RCT', 'Study', 'of', 'Liuwei', 'Dihuang', 'Pill', 'Preventing', 'and', 'Treating', 'Presbycusis', 'With', 'Shen', '(', 'Kidney)-Yin', 'Deficiency', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effects', 'and', 'safety', 'of', 'Liuwei', 'Dihuang', 'pill', 'and', 'placebo', 'in', 'presbycusis', 'with', 'Shen', '(', 'kidney)-yin', 'deficiency', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05125081,NCT05125081,RCT Study of Liuwei Dihuang Pill Preventing and Treating Presbycusis With Shen (Kidney)-Yin Deficiency | The objective of this study is to examine the effects and safety of Liuwei Dihuang pill and placebo in presbycusis with Shen (kidney)-yin deficiency.,"[(13, 32, 'OTHER', 'Liuwei Dihuang Pill'), (57, 68, 'CONDITION', 'Presbycusis'), (74, 102, 'CONDITION', 'Shen (Kidney)-Yin Deficiency'), (173, 192, 'OTHER', 'Liuwei Dihuang pill'), (197, 204, 'CONTROL', 'placebo'), (208, 219, 'CONDITION', 'presbycusis'), (225, 253, 'CONDITION', 'Shen (kidney)-yin deficiency')]"
"['Feasibility', 'and', 'Validity', 'of', 'Robotic', 'Assessments', 'With', 'the', 'ReHapticKnob', 'to', 'Characterize', 'Kinaesthesia', 'and', 'Haptic', 'Perception', 'of', 'the', 'Hand', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', ':', 'an', 'Exploratory', 'Study', '|', 'It', 'has', 'been', 'shown', 'that', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'have', 'impaired', 'kinaesthesia', 'and', 'haptic', 'perception', 'of', 'the', 'upper', 'limbs', '.', 'In', 'PD', 'patients', ',', 'these', 'impairments', 'might', 'be', 'involved', 'in', 'the', 'development', 'of', 'hypometria', 'or', 'bradykinesia', 'and', 'may', 'play', 'a', 'role', 'in', 'postural', 'deficits', ',', 'thereby', 'significantly', 'contributing', 'to', 'the', 'overall', 'disability', 'level', '.', '\n\n', 'Dedicated', 'conventional', 'or', 'robot', '-', 'assisted', 'training', 'might', 'improve', 'sensory', '-', 'motor', 'function', 'in', 'PD', 'patients', '.', 'In', 'order', 'to', 'provide', 'efficient', 'robot', '-', 'assisted', 'therapy', ',', 'robotic', 'devices', 'have', 'to', 'be', 'able', 'to', 'tailor', 'the', 'therapy', 'difficulty', 'to', 'the', 'individual', 'impairment', 'profile', 'of', 'each', 'patient', '.', 'For', 'difficulty', 'adaptation', 'in', 'robot', '-', 'assisted', 'therapy', ',', 'it', 'is', 'important', 'to', 'assess', 'the', 'impairment', 'profiles', 'with', 'the', 'same', 'robotic', 'platform', 'that', 'would', 'be', 'used', 'for', 'therapy', ',', 'therefore', 'minimizing', 'costs', 'or', 'potential', 'errors', 'coming', 'from', 'the', 'use', 'of', 'different', 'devices', '.', 'However', ',', 'up', 'to', 'now', ',', 'little', 'emphasis', 'has', 'been', 'placed', 'on', 'providing', 'sensory', '-', 'motor', 'robot', '-', 'assisted', 'therapy', 'for', 'the', 'upper', 'limbs', 'to', 'persons', 'with', 'PD', 'based', 'on', 'their', 'individual', 'level', 'of', 'impairment', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'therefore', 'to', 'evaluate', 'if', 'the', 'assessments', 'of', 'sensory', '-', 'motor', 'hand', 'function', 'implemented', 'on', 'a', 'robotic', 'device', 'for', 'hand', 'rehabilitation', ',', 'i.e.', 'the', 'ReHapticKnob', ',', 'are', 'suitable', 'to', 'measure', 'the', 'impairments', 'of', 'kinaesthesia', 'and', 'haptic', 'perception', 'observed', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'disease', '.', '\n\n', 'If', 'the', 'assessments', 'implemented', 'in', 'the', 'ReHapticKnob', 'are', 'sensitive', 'enough', 'to', 'detect', 'a', 'difference', 'between', 'the', 'sensory', '-', 'motor', 'function', 'of', 'PD', 'patients', 'and', 'healthy', 'subjects', ',', 'the', 'device', 'might', 'in', 'the', 'future', 'be', 'used', 'to', 'assess', 'improvements', 'before', 'and', 'after', 'sensory', '-', 'motor', 'therapy', '.', 'This', 'is', 'a', 'necessary', 'step', 'before', 'the', 'investigators', 'can', 'use', 'these', 'assessments', 'to', 'tailor', 'the', 'difficulty', 'level', 'of', 'the', 'therapy', 'performed', 'with', 'the', 'ReHapticKnob', 'and', 'to', 'investigate', 'the', 'benefits', 'and', 'impact', 'of', 'such', 'a', 'therapy', 'on', 'the', 'kinaesthetic', 'and', 'haptic', 'impairments', 'of', 'persons', 'with', 'PD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05245955,NCT05245955,"Feasibility and Validity of Robotic Assessments With the ReHapticKnob to Characterize Kinaesthesia and Haptic Perception of the Hand in Patients With Parkinson's Disease: an Exploratory Study | It has been shown that patients with Parkinson's disease (PD) have impaired kinaesthesia and haptic perception of the upper limbs. In PD patients, these impairments might be involved in the development of hypometria or bradykinesia and may play a role in postural deficits, thereby significantly contributing to the overall disability level.

Dedicated conventional or robot-assisted training might improve sensory-motor function in PD patients. In order to provide efficient robot-assisted therapy, robotic devices have to be able to tailor the therapy difficulty to the individual impairment profile of each patient. For difficulty adaptation in robot-assisted therapy, it is important to assess the impairment profiles with the same robotic platform that would be used for therapy, therefore minimizing costs or potential errors coming from the use of different devices. However, up to now, little emphasis has been placed on providing sensory-motor robot-assisted therapy for the upper limbs to persons with PD based on their individual level of impairment.

The aim of this study is therefore to evaluate if the assessments of sensory-motor hand function implemented on a robotic device for hand rehabilitation, i.e. the ReHapticKnob, are suitable to measure the impairments of kinaesthesia and haptic perception observed in subjects with Parkinson's disease.

If the assessments implemented in the ReHapticKnob are sensitive enough to detect a difference between the sensory-motor function of PD patients and healthy subjects, the device might in the future be used to assess improvements before and after sensory-motor therapy. This is a necessary step before the investigators can use these assessments to tailor the difficulty level of the therapy performed with the ReHapticKnob and to investigate the benefits and impact of such a therapy on the kinaesthetic and haptic impairments of persons with PD.","[(150, 169, 'CONDITION', ""Parkinson's Disease""), (231, 250, 'CONDITION', ""Parkinson's disease""), (252, 254, 'CONDITION', 'PD'), (328, 330, 'CONDITION', 'PD'), (399, 409, 'CONDITION', 'hypometria'), (413, 425, 'CONDITION', 'bradykinesia'), (627, 629, 'CONDITION', 'PD'), (1206, 1208, 'CONDITION', 'PD'), (1538, 1557, 'CONDITION', ""Parkinson's disease""), (1693, 1695, 'CONDITION', 'PD'), (2103, 2105, 'CONDITION', 'PD')]"
"['A', 'Phase', '2b', ',', '12', '-', 'week', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Multicenter', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'JZP385', 'in', 'the', 'Treatment', 'of', 'Adults', 'With', 'Moderate', 'to', 'Severe', 'Essential', 'Tremor', '|', 'This', 'is', 'a', '12', '-', 'week', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', ',', 'parallel', '-', 'group', ',', 'multicenter', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'JZP385', 'in', 'the', 'treatment', 'of', 'adult', 'participants', 'with', 'moderate', 'to', 'severe', 'ET', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05122650,NCT05122650,"A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor | This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.","[(35, 42, 'CONTROL', 'Placebo'), (131, 137, 'DRUG', 'JZP385'), (170, 205, 'CONDITION', 'Moderate to Severe Essential Tremor'), (241, 248, 'CONTROL', 'placebo'), (337, 343, 'DRUG', 'JZP385'), (388, 409, 'CONDITION', 'moderate to severe ET')]"
"['Lifestyle', 'Intervention', 'for', 'Early', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'comprehensive', 'lifestyle', 'changes', 'may', 'slow', ',', 'stop', ',', 'or', 'reverse', 'the', 'progression', 'of', 'early', '-', 'stage', 'Alzheimer', ""'s"", 'disease', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04606420,NCT04606420,"Lifestyle Intervention for Early Alzheimer's Disease | The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.","[(0, 22, 'BEHAVIOURAL', 'Lifestyle Intervention'), (27, 52, 'CONDITION', ""Early Alzheimer's Disease""), (116, 133, 'BEHAVIOURAL', 'lifestyle changes'), (180, 211, 'CONDITION', ""early-stage Alzheimer's disease"")]"
"['Smartphone', 'Medical', 'Applications', 'to', 'Reduce', 'Treatment', 'Dosage', 'Errors', 'in', 'Pediatric', 'Resuscitation', ';', 'a', 'Randomized', 'Simulation', 'Trial', '|', 'Medication', 'errors', 'are', 'common', 'in', 'children', '.', 'Characteristics', 'of', 'errors', 'during', 'critical', 'situations', 'in', 'the', 'Emergency', 'Department', 'are', 'ill', '-', 'defined', 'and', 'might', 'be', 'more', 'frequent', 'than', 'previously', 'thought', '.', 'However', ',', 'optimal', 'strategies', 'to', 'eliminate', 'the', 'risk', 'of', 'prescribing', 'errors', 'remain', 'unknown', '.', '\n\n', 'Many', 'smartphone', 'apps', 'have', 'been', 'suggested', 'over', 'the', 'last', 'years', 'with', 'some', 'of', 'them', 'designed', 'to', 'calculate', 'medication', 'dosage', 'for', 'children', '.', 'The', 'impact', 'of', 'these', 'apps', 'to', 'decrease', 'dosage', 'error', 'has', 'never', 'been', 'evaluated', 'in', 'resuscitation', 'setting', '.', '\n\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'whether', 'the', 'use', 'of', 'a', 'smartphone', 'application', 'designed', 'to', 'calculate', 'medication', 'doses', 'decreases', 'prescribing', 'errors', 'among', 'residents', 'during', 'pediatric', 'simulated', 'resuscitations', '.', '\n\n', 'This', 'will', 'be', 'a', 'crossover', '-', 'randomized', 'trial', 'using', 'high', 'fidelity', 'simulation', 'among', '40', 'residents', 'rotating', 'in', 'the', 'pediatric', 'emergency', 'department', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02958605,NCT02958605,"Smartphone Medical Applications to Reduce Treatment Dosage Errors in Pediatric Resuscitation; a Randomized Simulation Trial | Medication errors are common in children. Characteristics of errors during critical situations in the Emergency Department are ill-defined and might be more frequent than previously thought. However, optimal strategies to eliminate the risk of prescribing errors remain unknown.

Many smartphone apps have been suggested over the last years with some of them designed to calculate medication dosage for children. The impact of these apps to decrease dosage error has never been evaluated in resuscitation setting.

The aim of the study is to evaluate whether the use of a smartphone application designed to calculate medication doses decreases prescribing errors among residents during pediatric simulated resuscitations.

This will be a crossover-randomized trial using high fidelity simulation among 40 residents rotating in the pediatric emergency department.","[(0, 31, 'OTHER', 'Smartphone Medical Applications'), (42, 65, 'CONDITION', 'Treatment Dosage Errors'), (79, 92, 'CONDITION', 'Resuscitation'), (126, 143, 'CONDITION', 'Medication errors'), (370, 388, 'CONDITION', 'prescribing errors'), (576, 588, 'CONDITION', 'dosage error'), (698, 759, 'OTHER', 'smartphone application designed to calculate medication doses'), (770, 788, 'CONDITION', 'prescribing errors'), (832, 846, 'CONDITION', 'resuscitations')]"
"['Effectiveness', 'and', 'Clinical', 'Application', 'of', 'Multidisciplinary', 'Combined', 'Exercise', 'and', 'Nutrition', 'Intervention', 'for', 'Sarcopenic', 'Older', 'Adults', 'With', 'Metabolic', 'Syndrome', ':', 'Multicenter', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'aims', 'to', 'demonstrate', 'the', 'effect', 'of', 'combined', 'exercise', '-', 'nutrition', 'intervention', 'in', 'old', 'adults', 'with', 'sarcopenia', '.', 'This', 'study', 'will', 'be', 'conducted', 'with', 'prospectively', 'randomized', 'controlled', 'trial', 'comparing', 'outcome', 'of', 'combined', 'exercise', '-', 'nutrition', 'intervention', 'with', 'conventional', 'medical', 'care', '.', 'Handgrip', 'strength', ',', 'gait', 'speed', ',', 'knee', 'extensor', 'muscle', 'power', ',', 'physical', 'performance', ',', 'muscle', 'mass', 'using', 'DEXA', ',', 'quality', 'of', 'life', ',', 'activities', 'of', 'daily', 'living', ',', 'sarcopenia', 'screening', 'questionnaire', ',', 'nutritional', 'assessment', 'will', 'be', 'evaluated', 'on', 'baseline', ',', '12', '-', 'weeks', 'and', '24', '-', 'weeks', 'after', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04948736,NCT04948736,"Effectiveness and Clinical Application of Multidisciplinary Combined Exercise and Nutrition Intervention for Sarcopenic Older Adults With Metabolic Syndrome: Multicenter Randomized Controlled Trial | This study aims to demonstrate the effect of combined exercise-nutrition intervention in old adults with sarcopenia. This study will be conducted with prospectively randomized controlled trial comparing outcome of combined exercise-nutrition intervention with conventional medical care. Handgrip strength, gait speed, knee extensor muscle power, physical performance, muscle mass using DEXA, quality of life, activities of daily living, sarcopenia screening questionnaire, nutritional assessment will be evaluated on baseline, 12-weeks and 24-weeks after intervention.","[(42, 77, 'PHYSICAL', 'Multidisciplinary Combined Exercise'), (82, 104, 'OTHER', 'Nutrition Intervention'), (109, 119, 'CONDITION', 'Sarcopenic'), (138, 156, 'CONDITION', 'Metabolic Syndrome'), (245, 285, 'OTHER', 'combined exercise-nutrition intervention'), (305, 315, 'CONDITION', 'sarcopenia'), (414, 454, 'OTHER', 'combined exercise-nutrition intervention'), (460, 485, 'CONTROL', 'conventional medical care'), (637, 647, 'CONDITION', 'sarcopenia')]"
"['Preventing', 'Relapse', ':', 'Oral', 'Antipsychotics', 'Compared', 'To', 'Injectables', ':', 'Evaluating', 'Efficacy', '(', 'PROACTIVE', ')', '|', 'This', 'study', 'is', 'designed', 'to', 'find', 'out', 'whether', 'taking', 'antipsychotic', 'medication', 'once', 'every', 'two', 'weeks', 'by', 'injection', 'compared', 'to', 'taking', 'daily', 'oral', 'medication', 'will', 'help', 'people', 'with', 'schizophrenia', 'maintain', 'better', 'control', 'of', 'their', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00330863,NCT00330863,Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) | This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.,"[(142, 207, 'OTHER', 'taking antipsychotic medication once every two weeks by injection'), (220, 248, 'OTHER', 'taking daily oral medication'), (271, 284, 'CONDITION', 'schizophrenia')]"
"['A', 'Phase', '3', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'CLinical', 'Trial', 'to', 'Study', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Three', 'Doses', 'of', 'Lurasidone', 'HCl', 'in', 'Acutely', 'Psychotic', 'Patients', 'With', 'Schizophrenia', '|', 'Lurasidone', 'HCl', 'is', 'a', 'compound', 'being', 'developed', 'for', 'the', 'treatment', 'of', 'schizophrenia', '.', 'This', 'clinical', 'study', 'is', 'designed', 'to', 'test', 'the', 'hypothesis', 'that', 'lurasidone', 'is', 'more', 'efficacious', 'than', 'placebo', '.', 'The', 'study', 'will', 'also', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'lurasidone', 'as', 'compared', 'to', 'placebo', '.']","['O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT00549718,NCT00549718,"A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia | Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.","[(22, 29, 'CONTROL', 'Placebo'), (108, 122, 'DRUG', 'Lurasidone HCl'), (126, 143, 'CONDITION', 'Acutely Psychotic'), (158, 171, 'CONDITION', 'Schizophrenia'), (174, 188, 'DRUG', 'Lurasidone HCl'), (240, 253, 'CONDITION', 'schizophrenia'), (315, 325, 'DRUG', 'lurasidone'), (351, 358, 'CONTROL', 'placebo'), (420, 430, 'DRUG', 'lurasidone'), (446, 453, 'CONTROL', 'placebo')]"
"['Intranasal', 'AST-726', 'Treatment', 'for', 'Prophylaxis', 'of', 'Migraine', ':', 'A', 'Placebo', '-', 'Controlled', 'Clinical', 'Study', '|', 'The', 'purpose', 'of', 'this', 'migraine', 'prevention', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'AST-726', 'in', 'moderate', 'to', 'severe', 'migraine', 'patients', 'at', 'one', 'of', 'two', 'doses', 'compared', 'to', 'placebo', 'and', 'compared', 'to', 'a', 'baseline', 'period', 'as', 'measured', 'by', 'a', 'reduction', 'in', 'the', 'number', 'of', 'migraine', 'days', '.']","['O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00285402,NCT00285402,Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study | The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.,"[(11, 18, 'DRUG', 'AST-726'), (48, 56, 'CONDITION', 'Migraine'), (60, 67, 'CONTROL', 'Placebo'), (116, 124, 'CONDITION', 'migraine'), (184, 191, 'DRUG', 'AST-726'), (195, 222, 'CONDITION', 'moderate to severe migraine'), (264, 271, 'CONTROL', 'placebo'), (350, 358, 'CONDITION', 'migraine')]"
"['An', 'Open', 'Label', ',', 'Single', '-', 'dose', ',', 'Single', '-', 'period', 'Study', 'Designed', 'to', 'Assess', 'the', 'Mass', 'Balance', 'Recovery', ',', 'Metabolite', 'Profile', 'and', 'Metabolite', 'Identification', 'of', 'Carbon-14', 'BIA', '28', '-', '6156', 'in', 'Healthy', 'Male', 'Subjects', '|', 'The', 'study', 'is', 'designed', 'to', 'determine', 'the', 'absorption', ',', 'distribution', ',', 'metabolism', 'and', 'elimination', '(', 'ADME', ')', 'of', 'BIA', '28', '-', '6156', 'in', 'humans', ',', 'further', 'explore', 'the', 'PK', 'of', 'BIA', '28', '-', '6156', ',', 'evaluate', 'the', 'extent', 'of', 'distribution', 'of', 'total', 'radioactivity', 'into', 'blood', 'cells', ',', 'provide', 'additional', 'safety', 'and', 'tolerability', 'information', 'and', 'collect', 'samples', 'for', 'metabolite', 'profiling', 'and', 'structural', 'identification', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05220072,NCT05220072,"An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects | The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.","[(146, 167, 'DRUG', 'Carbon-14 BIA 28-6156'), (297, 308, 'DRUG', 'BIA 28-6156'), (346, 357, 'DRUG', 'BIA 28-6156')]"
"['The', 'Influence', 'of', 'a', 'tDCS', 'Combined', 'Long', '-', 'term', 'Motor', 'Training', 'Program', 'on', 'Structural', 'White', 'Matter', 'Changes', 'in', 'the', 'Brain', ',', 'Functionality', 'and', 'Psychological', 'Outcome', 'Measures', 'in', 'Multiple', 'Sclerosis', '.', '|', 'In', 'the', 'current', 'study', 'the', 'researchers', 'will', 'firstly', 'investigate', 'whether', 'a', 'bimanual', 'coordination', 'training', 'protocol', '(', '20', 'min', '/', 'day', ',', 'for', '8', 'consecutive', 'weeks', ')', 'correlates', 'with', 'changes', 'in', 'white', 'matter', 'architecture', 'and', 'improved', 'upper', '-', 'limb', 'functionality', 'in', 'patients', 'with', 'multiple', 'sclerosis', '.', 'Secondly', ',', 'the', 'researchers', 'predict', 'that', 'motor', 'learning', 'is', 'more', 'efficient', 'when', 'it', 'is', 'combined', 'with', 'anodal', 'transcranial', 'direct', 'current', '(', 'tDCS', ')', 'stimulation', 'on', 'the', 'left', 'primary', 'motor', 'cortex', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01279655,NCT01279655,"The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis. | In the current study the researchers will firstly investigate whether a bimanual coordination training protocol (20 min/day, for 8 consecutive weeks) correlates with changes in white matter architecture and improved upper-limb functionality in patients with multiple sclerosis. Secondly, the researchers predict that motor learning is more efficient when it is combined with anodal transcranial direct current (tDCS) stimulation on the left primary motor cortex.","[(19, 23, 'OTHER', 'tDCS'), (33, 57, 'PHYSICAL', 'Long-term Motor Training'), (167, 185, 'CONDITION', 'Multiple Sclerosis'), (261, 291, 'PHYSICAL', 'bimanual coordination training'), (447, 465, 'CONDITION', 'multiple sclerosis'), (564, 598, 'OTHER', 'anodal transcranial direct current'), (600, 604, 'OTHER', 'tDCS')]"
"['Interventional', 'Study', 'of', 'Growth', 'Hormone', 'Replacement', 'Therapy', 'in', 'Retired', 'Professional', 'Football', 'Players', 'With', 'Growth', 'Hormone', 'Deficiency', '|', 'This', 'is', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'parallel', '-', 'group', 'trial', 'with', 'an', 'open', '-', 'label', 'extension', 'to', 'evaluate', 'the', 'efficacy', 'of', 'growth', 'hormone', '(', 'GH', ')', 'on', 'cognitive', 'functions', 'of', 'retired', 'professional', 'football', 'players', 'with', 'growth', 'hormone', 'deficiency', '(', 'GHD', ')', '.']","['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04121780,NCT04121780,"Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency | This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).","[(24, 38, 'DRUG', 'Growth Hormone'), (105, 130, 'CONDITION', 'Growth Hormone Deficiency'), (169, 176, 'CONTROL', 'placebo'), (267, 281, 'DRUG', 'growth hormone'), (283, 285, 'DRUG', 'GH'), (356, 381, 'CONDITION', 'growth hormone deficiency'), (383, 386, 'CONDITION', 'GHD')]"
"['Safety', 'Monitoring', 'for', 'a', 'Novel', '3D', 'Printed', 'Mandibular', 'Advancement', 'Device', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'profile', 'of', 'the', 'novel', 'oral', 'appliance', '(', 'OA', ')', 'device', 'and', 'to', 'assess', 'patient', 'comfort', 'of', 'the', 'novel', 'OA', 'device', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",NCT05018234,NCT05018234,Safety Monitoring for a Novel 3D Printed Mandibular Advancement Device | The purpose of this study is to evaluate the safety profile of the novel oral appliance (OA )device and to assess patient comfort of the novel OA device.,"[(30, 70, 'OTHER', '3D Printed Mandibular Advancement Device'), (146, 160, 'OTHER', 'oral appliance'), (162, 164, 'OTHER', 'OA'), (216, 225, 'OTHER', 'OA device')]"
"['Nicotine', 'Receptor', 'Density', '&', 'Response', 'to', 'Nicotine', 'Patch', ':', 'Pt', '2', 'Extended', 'Treatment', '|', 'The', 'study', 'investigators', 'will', 'enroll', '45', 'treatment', 'seeking', ',', 'cigarette', 'smokers', 'with', 'a', 'Diagnostic', 'and', 'Statistical', 'Manual', '(', 'DSM', '-', 'IV', ')', 'diagnosis', 'of', 'schizophrenia', 'who', 'will', 'be', 'randomly', 'assigned', 'into', 'three', 'arms', 'of', 'treatment', 'for', 'smoking', 'cessation', 'treatment', ',', 'receiving', 'either', '1', '.', 'Control', ':', '""', 'standard', 'therapy', '""', '(', 'n=15', ')', ',', 'including', 'stepwise', 'monotherapy', 'of', 'nicotine', 'patch', 'or', 'bupropion', 'sustained', 'release', ',', '2', '.', 'Extended', 'treatment', 'with', 'combination', 'bupropion', ',', 'nicotine', 'patch', ',', 'and', 'nicotine', 'lozenge', 'for', '6', 'months', '(', 'n=15', ')', ',', 'or', '3', '.', 'Extended', 'treatment', 'with', 'combination', 'bupropion', ',', 'nicotine', 'patch', ',', 'and', 'nicotine', 'lozenge', 'for', '6', 'months', 'with', 'home', 'visits', '(', 'n=15', ')', 'and', 'phone', 'calls', 'to', 'the', 'home', 'or', 'living', 'facility', '.', 'During', 'all', 'treatments', ',', 'participants', 'will', 'receive', 'weekly', 'smoking', 'cessation', 'group', 'counseling', ',', 'as', 'is', 'standard', 'for', 'smoking', 'cessation', 'treatment', '.', 'At', 'the', 'time', 'of', 'enrollment', ',', 'participants', 'will', 'complete', 'a', 'one', '-', 'study', 'visit', 'lead', '-', 'in', 'to', 'complete', 'baseline', 'assessments', ',', 'psychological', 'and', 'medical', 'evaluation', ',', 'and', 'comprehensive', 'assessment', 'of', 'drug', 'use', 'to', 'determine', 'study', 'eligibility', '.', 'Once', 'determined', 'to', 'be', 'eligible', 'for', 'the', 'trial', ',', 'participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'the', 'treatment', 'arms', 'using', 'a', 'randomization', 'procedure', '.', 'The', '""', 'standard', 'therapy', '""', 'treatment', 'arm', ',', 'or', 'control', 'group', ',', 'will', 'receive', 'either', 'nicotine', 'patch', 'taper', 'starting', 'at', '21', 'milligrams', '(', 'mg', ')', 'daily', ',', 'nicotine', 'lozenge', 'as', 'needed', ',', 'and/or', 'bupropion', 'sustained', 'release', 'at', '150', 'mg', 'daily', 'for', '3', 'days', ',', 'then', '150', 'mg', 'twice', 'a', 'day', 'for', 'a', 'total', 'of', '12', 'weeks', '.', 'The', 'extended', 'therapy', 'arm', 'will', 'start', 'the', 'nicotine', 'patch', 'at', '21', 'mg', 'daily', 'with', 'as', 'needed', 'nicotine', 'lozenge', 'for', 'breakthrough', 'cravings', 'and', 'initiation', 'of', 'bupropion', 'sustained', 'release', 'at', '150', 'mg', 'daily', 'for', '3', 'days', 'a', 'week', 'prior', 'to', 'starting', 'nicotine', 'replacement', ',', 'then', '150', 'mg', 'twice', 'daily', 'for', '6', 'months', '(', 'as', 'tolerated', ')', '.', 'The', 'third', 'arm', 'will', 'be', 'identical', 'to', 'the', 'second', 'arm', 'except', 'for', 'the', 'added', 'home', 'visit', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT02676375,NCT02676375,"Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment | The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into three arms of treatment for smoking cessation treatment, receiving either 1. Control: ""standard therapy"" (n=15), including stepwise monotherapy of nicotine patch or bupropion sustained release, 2. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months (n=15), or 3. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months with home visits (n=15) and phone calls to the home or living facility. During all treatments, participants will receive weekly smoking cessation group counseling, as is standard for smoking cessation treatment. At the time of enrollment, participants will complete a one-study visit lead-in to complete baseline assessments, psychological and medical evaluation, and comprehensive assessment of drug use to determine study eligibility. Once determined to be eligible for the trial, participants will be randomly assigned to one of the treatment arms using a randomization procedure. The ""standard therapy"" treatment arm, or control group, will receive either nicotine patch taper starting at 21 milligrams (mg) daily, nicotine lozenge as needed, and/or bupropion sustained release at 150mg daily for 3 days, then 150 mg twice a day for a total of 12 weeks. The extended therapy arm will start the nicotine patch at 21mg daily with as needed nicotine lozenge for breakthrough cravings and initiation of bupropion sustained release at 150mg daily for 3 days a week prior to starting nicotine replacement, then 150 mg twice daily for 6 months (as tolerated). The third arm will be identical to the second arm except for the added home visit intervention.","[(40, 48, 'DRUG', 'Nicotine'), (140, 157, 'CONDITION', 'cigarette smokers'), (221, 234, 'CONDITION', 'schizophrenia'), (357, 373, 'CONTROL', 'standard therapy'), (417, 425, 'DRUG', 'nicotine'), (435, 444, 'DRUG', 'bupropion'), (503, 512, 'DRUG', 'bupropion'), (514, 522, 'DRUG', 'nicotine'), (534, 542, 'DRUG', 'nicotine'), (614, 623, 'DRUG', 'bupropion'), (625, 633, 'DRUG', 'nicotine'), (645, 653, 'DRUG', 'nicotine'), (680, 691, 'OTHER', 'home visits'), (703, 714, 'OTHER', 'phone calls'), (803, 837, 'BEHAVIOURAL', 'smoking cessation group counseling'), (1264, 1280, 'CONTROL', 'standard therapy'), (1335, 1343, 'DRUG', 'nicotine'), (1394, 1402, 'DRUG', 'nicotine'), (1429, 1438, 'DRUG', 'bupropion'), (1573, 1581, 'DRUG', 'nicotine'), (1617, 1625, 'DRUG', 'nicotine'), (1678, 1687, 'DRUG', 'bupropion'), (1757, 1765, 'DRUG', 'nicotine'), (1903, 1926, 'OTHER', 'home visit intervention')]"
"['Optimizing', 'a', 'Smartphone', 'Application', 'for', 'Individuals', 'With', 'Eating', 'Disorders', '|', 'This', 'study', 'will', 'augment', 'an', 'existing', 'mobile', 'application', 'for', 'individuals', 'with', 'eating', 'disorders', 'by', 'developing', 'adaptive', ',', 'tailored', 'content', 'targeting', 'remediation', 'of', 'cognitive', 'distortions', '.', 'The', 'adaptive', 'application', 'will', 'be', 'deployed', 'and', 'assessed', 'for', 'efficacy', 'relative', 'to', 'the', 'standard', 'product', 'in', 'a', 'randomized', 'controlled', 'trial', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02503098,NCT02503098,"Optimizing a Smartphone Application for Individuals With Eating Disorders | This study will augment an existing mobile application for individuals with eating disorders by developing adaptive, tailored content targeting remediation of cognitive distortions. The adaptive application will be deployed and assessed for efficacy relative to the standard product in a randomized controlled trial.","[(13, 35, 'OTHER', 'Smartphone Application'), (57, 73, 'CONDITION', 'Eating Disorders'), (112, 130, 'OTHER', 'mobile application'), (152, 168, 'CONDITION', 'eating disorders'), (183, 256, 'OTHER', 'adaptive, tailored content targeting remediation of cognitive distortions'), (262, 282, 'OTHER', 'adaptive application'), (342, 358, 'CONTROL', 'standard product')]"
"['The', 'Effect', 'Of', 'An', 'Anesthetic', 'Procedure', 'On', 'Post', 'Operative', 'Pain', 'Management', 'In', 'Carpal', 'Tunnel', 'Release', '|', 'Carpal', 'Tunnel', 'Syndrome', 'patients', 'undergoing', 'carpal', 'tunnel', 'release', 'surgery', 'performed', 'by', 'the', 'PI', 'will', 'receive', 'intra', '-', 'operative', 'injections', 'of', 'bupivacaine', '(', 'Marcaine', ')', '.', 'Two', 'groups', 'of', 'patients', 'will', 'be', 'randomly', 'selected', 'and', 'will', 'receive', 'either', '10cc', 'or', '20cc', 'of', 'injection', '.', 'Their', 'post', '-', 'operative', 'pain', 'scores', 'and', 'usage', 'of', 'post', '-', 'operative', 'pain', 'medication', 'will', 'be', 'recorded', 'and', 'analyzed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03729375,NCT03729375,The Effect Of An Anesthetic Procedure On Post Operative Pain Management In Carpal Tunnel Release | Carpal Tunnel Syndrome patients undergoing carpal tunnel release surgery performed by the PI will receive intra-operative injections of bupivacaine (Marcaine). Two groups of patients will be randomly selected and will receive either 10cc or 20cc of injection. Their post-operative pain scores and usage of post-operative pain medication will be recorded and analyzed.,"[(41, 60, 'CONDITION', 'Post Operative Pain'), (75, 96, 'CONDITION', 'Carpal Tunnel Release'), (99, 121, 'CONDITION', 'Carpal Tunnel Syndrome'), (142, 171, 'CONDITION', 'carpal tunnel release surgery'), (235, 246, 'DRUG', 'bupivacaine'), (248, 256, 'DRUG', 'Marcaine'), (365, 384, 'CONDITION', 'post-operative pain'), (405, 424, 'CONDITION', 'post-operative pain')]"
"['A', 'Phase', 'II', '/', 'III', ',', 'Multicentre', ',', '8', '-', 'week', 'run', '-', 'in', 'Phase', 'Followed', 'by', 'a', '12', '-', 'week', ',', 'Prospective', ',', 'Parallel', '-', 'group', ',', 'Double', '-', 'blind', ',', 'Randomized', 'Withdrawal', ',', 'Placebo', '-', 'controlled', 'Study', ',', 'With', 'a', '52', 'Week', 'Open', 'Label', 'Extension', ',', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Daily', '1.5', 'to', '3.5', 'mg', 'Basimglurant', 'in', 'Patients', 'With', 'Pain', 'Associated', 'With', 'Trigeminal', 'Neuralgia', 'With', 'Suboptimal', 'Response', 'to', 'Their', 'Current', 'Anti', '-', 'pain', 'Therapy', '.', '|', 'Trigeminal', 'neuralgia', '(', 'TN', ')', ',', 'also', 'called', '""', 'tic', 'douloureux', '""', ',', 'is', 'the', 'most', 'common', 'form', 'of', 'craniofacial', 'neuropathic', 'pain', 'and', 'is', 'considered', 'the', 'cause', 'of', 'one', 'of', 'the', 'most', 'painful', 'afflictions', 'known', 'in', 'medical', 'practice', '.', '\n\n', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', '1.5', 'mg', '-', '3.5', 'mg', 'basimglurant', 'in', 'adults', 'with', 'TN', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",NCT05217628,NCT05217628,"A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy. | Trigeminal neuralgia (TN), also called ""tic douloureux"", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.

This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.","[(138, 145, 'CONTROL', 'Placebo'), (260, 272, 'DRUG', 'Basimglurant'), (290, 294, 'CONDITION', 'Pain'), (311, 331, 'CONDITION', 'Trigeminal Neuralgia'), (395, 415, 'CONDITION', 'Trigeminal neuralgia'), (417, 419, 'CONDITION', 'TN'), (435, 449, 'CONDITION', 'tic douloureux'), (479, 508, 'CONDITION', 'craniofacial neuropathic pain'), (680, 692, 'DRUG', 'basimglurant'), (708, 710, 'CONDITION', 'TN')]"
"['A', 'Pilot', 'Trial', 'of', 'Lithium', 'in', 'Progressive', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'lithium', 'carbonate', 'is', 'safe', ',', 'well', '-', 'tolerated', ',', 'and', 'effective', 'at', 'treating', 'progressive', 'forms', 'of', 'multiple', 'sclerosis', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01259388,NCT01259388,"A Pilot Trial of Lithium in Progressive Multiple Sclerosis | The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.","[(17, 24, 'DRUG', 'Lithium'), (28, 58, 'CONDITION', 'Progressive Multiple Sclerosis'), (111, 128, 'DRUG', 'lithium carbonate'), (180, 219, 'CONDITION', 'progressive forms of multiple sclerosis')]"
"['Effects', 'of', 'Low', 'Laser', 'Therapy', 'on', 'Facial', 'Motor', 'Functions', 'Function', 'and', 'Synkinesis', 'in', 'Patients', 'With', 'Bell', ""'s"", 'Palsy', '|', 'To', 'determine', 'the', 'effects', 'of', 'low', '-', 'level', 'laser', 'therapy', 'on', 'facial', 'motor', 'functions', 'and', 'synkinesis', 'in', 'patients', 'with', 'bell', ""'s"", 'palsy']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT05707091,NCT05707091,Effects of Low Laser Therapy on Facial Motor Functions Function and Synkinesis in Patients With Bell's Palsy | To determine the effects of low-level laser therapy on facial motor functions and synkinesis in patients with bell's palsy,"[(11, 28, 'OTHER', 'Low Laser Therapy'), (96, 108, 'CONDITION', ""Bell's Palsy""), (139, 162, 'OTHER', 'low-level laser therapy'), (221, 233, 'CONDITION', ""bell's palsy"")]"
"['Screw', 'Retained', 'Arch', 'Bar', 'Versus', 'Conventional', 'Erich', ""'s"", 'Arch', 'Bar', 'in', 'Maxillomandibular', 'Fixation', '|', 'A', 'randomized', 'prospective', 'clinical', 'study', 'to', 'compare', 'screw', 'Retained', 'Arch', 'Bar', 'and', 'Conventional', 'Erich', ""'s"", 'Arch', 'Bar', 'in', 'Maxillomandibular', 'Fixation']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER']",NCT05401994,NCT05401994,Screw Retained Arch Bar Versus Conventional Erich's Arch Bar in Maxillomandibular Fixation | A randomized prospective clinical study to compare screw Retained Arch Bar and Conventional Erich's Arch Bar in Maxillomandibular Fixation,"[(0, 23, 'OTHER', 'Screw Retained Arch Bar'), (31, 60, 'OTHER', ""Conventional Erich's Arch Bar""), (64, 90, 'OTHER', 'Maxillomandibular Fixation'), (144, 167, 'OTHER', 'screw Retained Arch Bar'), (172, 201, 'OTHER', ""Conventional Erich's Arch Bar""), (205, 231, 'OTHER', 'Maxillomandibular Fixation')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Assess', 'the', 'Efficacy', 'and', 'Safety', 'of', 'XP13512', 'in', 'Patients', 'With', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'XP13512', 'taken', 'once', 'daily', 'compared', 'to', 'placebo', 'for', 'the', 'treatment', 'of', 'patients', 'suffering', 'from', 'Restless', 'Legs', 'Syndrome', '(', 'RLS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00298623,NCT00298623,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. | The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).","[(28, 35, 'CONTROL', 'Placebo'), (90, 97, 'DRUG', 'XP13512'), (115, 137, 'CONDITION', 'Restless Legs Syndrome'), (206, 213, 'DRUG', 'XP13512'), (243, 250, 'CONTROL', 'placebo'), (296, 318, 'CONDITION', 'Restless Legs Syndrome'), (320, 323, 'CONDITION', 'RLS')]"
"['Dual', 'Benefits', 'of', 'Vaginal', 'Estriol', ':', 'Improved', 'Urogenital', 'Health', 'and', 'Re', '-', 'myelination', 'in', 'Relapsing', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', '|', 'Study', 'to', 'evaluate', 'the', 'efficiency', 'of', 'vaginal', 'estriol', ',', 'as', 'a', 'treatment', 'for', 'urogenital', 'symptoms', 'in', 'female', 'patients', 'with', 'RRMS', '.', 'The', 'secondary', 'objective', 'is', 'to', 'evaluate', 'the', 'potential', 'role', 'of', 'vaginal', 'estriol', 'in', 're', '-', 'myelination', 'in', 'RRMS', 'patients', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03774407,NCT03774407,"Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) | Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.","[(25, 32, 'DRUG', 'Estriol'), (83, 121, 'CONDITION', 'Relapsing Remitting Multiple Sclerosis'), (123, 127, 'CONDITION', 'RRMS'), (175, 182, 'DRUG', 'estriol'), (247, 251, 'CONDITION', 'RRMS'), (322, 329, 'DRUG', 'estriol'), (351, 355, 'CONDITION', 'RRMS')]"
"['Phase', '2', 'Clinical', 'Trial', 'of', 'SGS-742', 'Therapy', 'in', 'Succinic', 'Semialdehyde', 'Dehydrogenase', 'Deficiency', '|', 'Objective', ':', '\n\n', 'To', 'perform', 'a', 'clinical', 'trial', 'assessing', 'the', 'safety', ',', 'tolerability', 'and', 'efficacy', 'of', 'the', 'GABA(B', ')', 'receptor', 'antagonist', 'SGS-742', 'in', 'patients', 'with', 'SSADH', 'deficiency', '.', '\n\n', 'Study', 'Population', ':', '\n\n', 'Twenty', '-', 'two', 'children', 'and', 'adults', 'with', 'SSADH', 'deficiency', '.', '\n\n', 'Design', ':', '\n\n', 'Double', '-', 'blind', ',', 'cross', '-', 'over', ',', 'phase', 'II', 'clinical', 'trial', '.', '\n\n', 'Outcome', 'Measures', ':', '\n\n', 'The', 'primary', 'outcome', 'measures', 'for', 'drug', 'efficacy', 'will', 'be', 'performance', 'on', 'neuropsychological', 'testing', 'and', 'responses', 'to', 'parent', 'questionnaire', '.', 'The', 'secondary', 'outcome', 'measure', 'will', 'be', 'TMS', 'parameters', 'of', 'cortical', 'excitation', 'and', 'inhibition', '.', 'The', 'outcome', 'measures', 'for', 'safety', 'will', 'include', 'clinical', 'examination', 'and', 'neuropsychological', 'tests', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02019667,NCT02019667,"Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency | Objective:

To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.

Study Population:

Twenty-two children and adults with SSADH deficiency.

Design:

Double-blind, cross-over, phase II clinical trial.

Outcome Measures:

The primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.","[(26, 33, 'DRUG', 'SGS-742'), (45, 91, 'CONDITION', 'Succinic Semialdehyde Dehydrogenase Deficiency'), (189, 216, 'DRUG', 'GABA(B) receptor antagonist'), (217, 224, 'DRUG', 'SGS-742'), (242, 258, 'CONDITION', 'SSADH deficiency'), (316, 332, 'CONDITION', 'SSADH deficiency')]"
"['Diffusion', 'Weighted', 'Magnetic', 'Resonance', 'Imaging', 'and', 'the', 'Optic', 'Nerve', 'Neuropathy', '.', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'create', 'a', 'new', ',', 'non', '-', 'invasive', 'and', 'safe', 'protocol', 'for', 'the', 'early', 'diagnosis', 'of', 'various', 'types', 'of', 'optic', 'neuropathies', 'with', 'the', 'use', 'of', 'diffusion', 'magnetic', 'resonance', 'imaging']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05353413,NCT05353413,"Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. | The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging","[(54, 76, 'CONDITION', 'Optic Nerve Neuropathy'), (198, 216, 'CONDITION', 'optic neuropathies')]"
"['Bright', 'Light', 'Therapy', 'for', 'Residual', 'Daytime', 'Symptoms', 'Associated', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'Sleep', 'apnea', 'is', 'one', 'of', 'the', 'most', 'common', 'chronic', 'condition', 'among', 'US', 'military', 'Veterans', ',', 'causing', 'sleepiness', ',', 'reduced', 'psychomotor', 'vigilance', 'and', 'depression', ',', 'which', 'undermine', 'daytime', 'functioning', 'and', 'quality', 'of', 'life', '.', 'Persistent', 'daytime', 'symptoms', 'of', 'sleepiness', 'in', 'individuals', 'with', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', 'who', 'are', 'using', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'are', 'associated', 'with', 'adverse', 'long', 'term', 'medical', 'and', 'functional', 'outcomes', '.', 'Residual', 'daytime', 'sleepiness', '(', 'RDS', ')', 'is', 'associated', 'with', 'reduced', 'occupational', 'and', 'family', 'functioning', 'and', 'overall', 'lower', 'quality', 'of', 'life', '.', 'Napping', 'is', 'a', 'common', 'behavior', 'among', 'individuals', 'with', 'OSA', 'and', 'RDS', 'and', 'has', 'been', 'linked', 'to', 'both', 'benefits', 'to', 'and', 'decline', 'in', 'health', 'and', 'functioning', '.', 'Longer', 'nap', 'times', 'may', 'maintain', ',', 'as', 'opposed', 'to', 'decrease', ',', 'sleepiness', 'by', 'promoting', 'sleep', 'inertia', 'and', 'can', 'contribute', 'to', 'maintaining', 'subclinical', 'circadian', 'alterations', 'that', 'result', 'in', 'higher', 'night', '-', 'tonight', 'variability', 'in', 'sleep', 'patterns', '.', 'Preliminary', 'studies', 'in', 'humans', 'and', 'animal', 'models', 'have', 'shown', 'persisting', 'alterations', 'of', 'circadian', 'rhythms', 'in', 'OSA', 'patients', ',', 'that', 'fail', 'to', 'normalize', 'with', 'CPAP', 'treatment', '.', 'CPAP', 'treatment', ',', 'while', 'effective', 'at', 'correcting', 'respiratory', 'events', 'and', 'night', 'time', 'blood', 'oxygen', 'saturation', 'levels', ',', 'does', 'not', 'necessarily', 're', '-', 'align', 'the', 'circadian', 'system', '.', 'Current', 'treatment', 'options', 'are', 'limited', 'to', 'stimulants', 'and', 'modafinil', ',', 'whose', 'long', '-', 'term', 'safety', 'profile', ',', 'effectiveness', 'and', 'impact', 'on', 'functional', 'recovery', 'is', 'largely', 'unknown', '.', 'Supplementary', 'exposure', 'to', 'bright', 'light', 'has', 'beneficial', 'effects', 'on', 'sleep', 'quality', 'and', 'daytime', 'vigilance', 'in', 'healthy', 'individuals', 'and', 'it', 'has', 'been', 'increasingly', 'applied', 'in', 'a', 'variety', 'of', 'sleep', 'and', 'neuropsychiatric', 'conditions', '.', 'However', ',', 'no', 'study', 'to', 'date', 'has', 'tested', 'the', 'application', 'of', 'BLT', 'to', 'treat', 'daytime', 'symptoms', 'associated', 'with', 'sleep', 'apnea', '.', 'The', 'investigators', ""'"", 'study', 'will', 'be', 'the', 'first', 'to', 'explore', 'the', 'role', 'of', 'Bright', 'Light', 'Therapy', '(', 'BLT', ')', ',', 'a', 'well', '-', 'established', 'non', '-', 'pharmacological', 'intervention', 'for', 'circadian', 'disturbances', ',', 'for', 'the', 'treatment', 'of', 'residual', 'daytime', 'symptoms', 'of', 'OSA', 'which', 'do', 'not', 'respond', 'to', 'CPAP', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04299009,NCT04299009,"Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea | Sleep apnea is one of the most common chronic condition among US military Veterans, causing sleepiness, reduced psychomotor vigilance and depression, which undermine daytime functioning and quality of life. Persistent daytime symptoms of sleepiness in individuals with Obstructive Sleep Apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Residual daytime sleepiness (RDS) is associated with reduced occupational and family functioning and overall lower quality of life. Napping is a common behavior among individuals with OSA and RDS and has been linked to both benefits to and decline in health and functioning. Longer nap times may maintain, as opposed to decrease, sleepiness by promoting sleep inertia and can contribute to maintaining subclinical circadian alterations that result in higher night-tonight variability in sleep patterns. Preliminary studies in humans and animal models have shown persisting alterations of circadian rhythms in OSA patients, that fail to normalize with CPAP treatment. CPAP treatment, while effective at correcting respiratory events and night time blood oxygen saturation levels, does not necessarily re-align the circadian system. Current treatment options are limited to stimulants and modafinil, whose long-term safety profile, effectiveness and impact on functional recovery is largely unknown. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. However, no study to date has tested the application of BLT to treat daytime symptoms associated with sleep apnea. The investigators' study will be the first to explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP.","[(0, 20, 'OTHER', 'Bright Light Therapy'), (67, 90, 'CONDITION', 'Obstructive Sleep Apnea'), (93, 104, 'CONDITION', 'Sleep apnea'), (185, 195, 'CONDITION', 'sleepiness'), (231, 241, 'CONDITION', 'depression'), (362, 385, 'CONDITION', 'Obstructive Sleep Apnea'), (387, 390, 'CONDITION', 'OSA'), (520, 547, 'CONDITION', 'Residual daytime sleepiness'), (549, 552, 'CONDITION', 'RDS'), (704, 707, 'CONDITION', 'OSA'), (712, 715, 'CONDITION', 'RDS'), (1129, 1132, 'CONDITION', 'OSA'), (1532, 1556, 'OTHER', 'exposure to bright light'), (1790, 1793, 'OTHER', 'BLT'), (1836, 1847, 'CONDITION', 'sleep apnea'), (1915, 1935, 'OTHER', 'Bright Light Therapy'), (1937, 1940, 'OTHER', 'BLT'), (2073, 2076, 'CONDITION', 'OSA')]"
"['A', 'Pilot', 'Study', 'of', 'Warm', 'and', 'Cold', 'Compress', 'to', 'Reduce', 'Injection', 'Site', 'Erythema', 'Due', 'to', 'Peginterferon', '-', 'beta-1a', 'in', 'Multiple', 'Sclerosis', '|', 'Peginterferon', '-', 'beta-1a', '(', 'PEG', ')', 'is', 'an', 'approved', 'treatment', 'for', 'relapsing', 'forms', 'of', 'MS', 'that', 'may', 'cause', 'injection', 'related', 'erythema', '.', 'This', 'is', 'a', 'randomized', 'controlled', 'cross', '-', 'over', 'trial', 'of', 'superficial', 'hot', 'and', 'cold', 'modalities', 'to', 'reduce', 'injection', 'site', 'erythema', 'caused', 'by', 'PEG', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT02490943,NCT02490943,A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis | Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.,"[(17, 39, 'OTHER', 'Warm and Cold Compress'), (50, 73, 'CONDITION', 'Injection Site Erythema'), (106, 124, 'CONDITION', 'Multiple Sclerosis'), (184, 205, 'CONDITION', 'relapsing forms of MS'), (221, 247, 'CONDITION', 'injection related erythema'), (301, 336, 'OTHER', 'superficial hot and cold modalities'), (347, 370, 'CONDITION', 'injection site erythema')]"
"['Effect', 'of', 'Eye', 'Mask', 'and', 'Earplugs', 'on', 'Prevention', 'of', 'Delirium', 'in', 'Intensive', 'Care', 'Patients', '|', 'This', 'research', 'is', 'planned', 'as', 'a', 'randomized', 'controlled', 'experimental', 'study', 'to', 'examine', 'the', 'effect', 'of', 'using', 'eye', 'mask', 'and', 'earplugs', 'in', 'preventing', 'delirium', 'with', 'evidence', '-', 'based', 'nonpharmacological', 'nursing', 'interventions', 'in', 'intensive', 'care', 'units', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT05000476,NCT05000476,Effect of Eye Mask and Earplugs on Prevention of Delirium in Intensive Care Patients | This research is planned as a randomized controlled experimental study to examine the effect of using eye mask and earplugs in preventing delirium with evidence-based nonpharmacological nursing interventions in intensive care units.,"[(10, 18, 'OTHER', 'Eye Mask'), (23, 31, 'OTHER', 'Earplugs'), (49, 57, 'CONDITION', 'Delirium'), (61, 75, 'CONDITION', 'Intensive Care'), (189, 197, 'OTHER', 'eye mask'), (202, 210, 'OTHER', 'earplugs'), (225, 233, 'CONDITION', 'delirium'), (298, 312, 'CONDITION', 'intensive care')]"
"['Stroke', 'Telemedicine', 'for', 'Arizona', 'Rural', 'Residents', 'Trial', '|', 'The', 'STARR', 'network', 'registry', 'consists', 'of', 'a', '4', 'spoke', '1', 'hub', 'system', '.', 'Which', 'will', 'consist', 'of', 'prospective', 'collection', ',', 'recording', ',', 'and', 'regular', 'analysis', 'of', 'telestroke', 'patient', 'consultation', 'and', 'care', 'data', 'for', 'the', 'purpose', 'of', 'quality', 'measure', 'assessment', 'and', 'improvement', 'and', 'benchmarking', 'against', 'other', 'national', 'and', 'international', 'telestroke', 'programs', '.']","['B-COND', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00829361,NCT00829361,"Stroke Telemedicine for Arizona Rural Residents Trial | The STARR network registry consists of a 4 spoke 1 hub system. Which will consist of prospective collection, recording, and regular analysis of telestroke patient consultation and care data for the purpose of quality measure assessment and improvement and benchmarking against other national and international telestroke programs.","[(0, 6, 'CONDITION', 'Stroke'), (7, 19, 'OTHER', 'Telemedicine'), (200, 231, 'OTHER', 'telestroke patient consultation'), (333, 385, 'CONTROL', 'other national and international telestroke programs')]"
"['A', 'Phase', '1', 'Dose', '-', 'escalation', 'and', 'Expansion', 'Study', 'of', 'BLZ-100', 'in', 'Pediatric', 'Subjects', 'With', 'Primary', 'Central', 'Nervous', 'System', 'Tumors', '|', 'Many', 'types', 'of', 'cancer', 'are', 'primarily', 'treated', 'with', 'surgery', 'and', 'patient', 'survival', 'is', 'directly', 'related', 'to', 'the', 'extent', 'to', 'which', 'the', 'tumor', 'is', 'able', 'to', 'be', 'removed', '.', 'It', 'is', 'often', 'difficult', 'for', 'surgeons', 'to', 'distinguish', 'tumor', 'tissue', 'from', 'normal', 'tissue', 'or', 'to', 'detect', 'tumor', 'cells', 'that', 'have', 'spread', 'from', 'the', 'original', 'tumor', 'site', ',', 'resulting', 'in', 'incomplete', 'removal', 'of', 'the', 'tumor', 'and', 'reduced', 'patient', 'survival', '.', 'In', 'some', 'sites', ',', 'such', 'as', 'the', 'brain', ',', 'it', 'is', 'critical', 'to', 'avoid', 'damage', 'to', 'normal', 'tissue', 'around', 'the', 'tumor', 'to', 'prevent', 'adverse', 'effects', 'of', 'surgery', 'on', 'function', '.', 'The', 'investigators', 'hypothesize', 'that', 'BLZ-100', 'will', 'improve', 'surgical', 'outcomes', 'by', 'allowing', 'surgeons', 'to', 'visualize', 'the', 'edges', 'of', 'the', 'tumor', 'and', 'small', 'groups', 'of', 'cancer', 'cells', 'that', 'have', 'spread', 'to', 'other', 'sites', 'in', 'real', '-', 'time', 'as', 'they', 'operate', '.', 'This', 'is', 'a', 'safety', 'study', 'to', 'assess', 'the', 'safety', 'of', 'BLZ-100', 'in', 'pediatric', 'patients', 'with', 'central', 'nervous', 'system', 'tumors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT02462629,NCT02462629,"A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors | Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.","[(49, 56, 'DRUG', 'BLZ-100'), (84, 121, 'CONDITION', 'Primary Central Nervous System Tumors'), (138, 144, 'CONDITION', 'cancer'), (248, 253, 'CONDITION', 'tumor'), (372, 377, 'CONDITION', 'tumor'), (419, 424, 'CONDITION', 'tumor'), (470, 475, 'CONDITION', 'tumor'), (599, 604, 'CONDITION', 'tumor'), (691, 698, 'DRUG', 'BLZ-100'), (781, 786, 'CONDITION', 'tumor'), (807, 813, 'CONDITION', 'cancer'), (929, 936, 'DRUG', 'BLZ-100'), (964, 993, 'CONDITION', 'central nervous system tumors')]"
"['A', '12', '-', 'week', ',', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Multicenter', ',', 'Fixed', 'Dose', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'a', '20', 'mg', '/', 'd', 'Oral', 'Dose', 'of', 'KW-6002', '(', 'Istradefylline', ')', 'as', 'Treatment', 'for', 'Parkinson', ""'s"", 'Disease', 'in', 'Patients', 'With', 'Motor', 'Response', 'Complications', 'on', 'Levodopa', '/', 'Carbidopa', 'Therapy', '.', '|', 'To', 'establish', 'the', 'efficacy', 'of', 'a', '20', 'mg', '/', 'day', 'dose', 'of', 'istradefylline', 'for', 'reducing', 'the', 'percentage', 'of', 'OFF', 'time', 'in', 'patients', 'with', 'advanced', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'treated', 'with', 'levodopa', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00199407,NCT00199407,"A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. | To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.","[(25, 32, 'CONTROL', 'Placebo'), (165, 172, 'DRUG', 'KW-6002'), (174, 188, 'DRUG', 'Istradefylline'), (207, 226, 'CONDITION', ""Parkinson's Disease""), (244, 272, 'CONDITION', 'Motor Response Complications'), (276, 284, 'DRUG', 'Levodopa'), (285, 294, 'DRUG', 'Carbidopa'), (355, 369, 'DRUG', 'istradefylline'), (427, 455, 'CONDITION', ""advanced Parkinson's disease""), (457, 459, 'CONDITION', 'PD'), (474, 482, 'DRUG', 'levodopa')]"
"['Effects', 'of', 'Terminal', 'Visual', 'Feedback', 'Therapy', 'After', 'Immersive', 'Virtual', 'Reality', 'in', 'Patients', 'With', 'Chronic', 'Shoulder', 'Pain', ':', 'Mixed', '-', 'Methods', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'effect', 'of', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality(VRi', ')', 'effects', 'on', 'pain', ',', 'kinesiophobia', ',', 'fear', 'of', 'pain', ',', 'disability', ',', 'self', '-', 'efficacy', ',', 'grip', 'strength', 'and', 'range', 'of', 'motion', 'in', 'motion', 'in', 'people', 'with', 'chronic', 'shoulder', 'pain', 'compare', 'with', 'just', 'VRi', '.', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'Can', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'decrease', 'movement', '-', 'evoked', 'pain', 'in', 'patients', 'with', 'chronic', 'shoulder', 'pain', 'compared', 'with', 'just', 'VRi', '?', '\n', 'Can', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'increase', 'shoulder', 'flexion', 'range', 'of', 'motion', 'in', 'patients', 'with', 'chronic', 'shoulder', 'pain', 'compared', 'with', 'just', 'VRi', '?', '\n\n', 'Participants', 'will', 'use', 'a', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'compared', 'with', 'just', 'specific', 'VRi', 'software']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05640661,NCT05640661,"Effects of Terminal Visual Feedback Therapy After Immersive Virtual Reality in Patients With Chronic Shoulder Pain : Mixed-Methods Randomized Clinical Trial | The goal of this clinical trial is effect of terminal visual feedback therapy following the use of immersive virtual reality(VRi) effects on pain,kinesiophobia, fear of pain, disability, self-efficacy, grip strength and range of motion in motion in people with chronic shoulder pain compare with just VRi. The main question[s] it aims to answer are:

Can terminal visual feedback therapy following the use of immersive virtual reality software decrease movement-evoked pain in patients with chronic shoulder pain compared with just VRi?
Can terminal visual feedback therapy following the use of immersive virtual reality software increase shoulder flexion range of motion in patients with chronic shoulder pain compared with just VRi?

Participants will use a visual feedback therapy following the use of immersive virtual reality software compared with just specific VRi software","[(11, 43, 'OTHER', 'Terminal Visual Feedback Therapy'), (50, 75, 'OTHER', 'Immersive Virtual Reality'), (93, 114, 'CONDITION', 'Chronic Shoulder Pain'), (204, 236, 'OTHER', 'terminal visual feedback therapy'), (300, 304, 'CONDITION', 'pain'), (320, 332, 'CONDITION', 'fear of pain'), (420, 441, 'CONDITION', 'chronic shoulder pain'), (460, 463, 'CONTROL', 'VRi'), (514, 546, 'OTHER', 'terminal visual feedback therapy'), (568, 593, 'OTHER', 'immersive virtual reality'), (650, 671, 'CONDITION', 'chronic shoulder pain'), (691, 694, 'CONTROL', 'VRi'), (700, 724, 'OTHER', 'terminal visual feedback'), (754, 779, 'OTHER', 'immersive virtual reality'), (848, 869, 'CONDITION', 'chronic shoulder pain'), (889, 892, 'CONTROL', 'VRi'), (919, 942, 'OTHER', 'visual feedback therapy'), (964, 989, 'OTHER', 'immersive virtual reality'), (1027, 1030, 'CONTROL', 'VRi')]"
"['Safety', 'of', 'Cultured', 'Allogeneic', 'Adult', 'Umbilical', 'Cord', 'Derived', 'Mesenchymal', 'Stem', 'Cell', 'Intravenous', 'Infusion', 'for', 'the', 'Treatment', 'of', 'Traumatic', 'Brain', 'Injury', '|', 'This', 'trial', 'will', 'study', 'the', 'safety', 'and', 'efficacy', 'of', 'intravenous', 'infusion', 'of', 'cultured', 'allogeneic', 'adult', 'umbilical', 'cord', 'derived', 'mesenchymal', 'stem', 'cells', 'for', 'the', 'treatment', 'of', 'traumatic', 'brain', 'injury']","['O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT05018832,NCT05018832,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury | This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of traumatic brain injury,"[(10, 80, 'SURGICAL', 'Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell'), (123, 145, 'CONDITION', 'Traumatic Brain Injury'), (221, 292, 'SURGICAL', 'cultured allogeneic adult umbilical cord derived mesenchymal stem cells'), (314, 336, 'CONDITION', 'traumatic brain injury')]"
"['Novel', 'Brain', 'Signal', 'Feedback', 'Paradigm', 'to', 'Enhance', 'Motor', 'Learning', 'After', 'Stroke', '|', 'Stroke', '(', '795,000', '/', 'year', 'in', 'the', 'US', 'and', '30', 'million', 'existing', 'stroke', 'survivors', 'in', 'the', 'world', ')', 'damages', 'brain', 'neural', 'structures', 'that', 'control', 'coordinated', 'upper', 'limb', 'movement', '.', 'To', 'most', 'effectively', 'target', 'the', 'brain', 'damage', ',', 'interventions', 'should', 'be', 'directed', 'so', 'as', 'to', 'restore', 'brain', 'control', 'serving', 'coordination', 'of', 'peripheral', 'neuromuscular', 'function', '.', 'Currently', ',', 'there', 'is', 'a', 'lack', 'of', 'a', 'transformative', 'intervention', 'strategy', ',', 'and', 'only', 'limited', 'efficacy', 'is', 'seen', 'in', 'response', 'to', 'neural', 'rehabilitation', 'that', 'is', 'only', 'peripherally', '-', 'directed', '(', 'limbs', 'e.g.', ')', 'or', 'only', 'directed', 'at', 'the', 'brain', '.', 'This', 'study', 'will', 'employ', 'a', 'novel', 'neural', 'feedback', 'approach', 'with', 'a', 'closed', '-', 'loop', ',', 'real', '-', 'time', 'paradigm', 'to', 'engage', 'and', 'retrain', 'existing', 'brain', 'function', 'after', 'stroke', '.', 'Real', '-', 'time', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'rtfMIR', ')', 'provides', 'neural', 'feedback', 'with', 'the', 'advantage', 'of', 'precisely', 'identifying', 'the', 'location', 'of', 'brain', 'activity', 'for', 'multiple', 'cognitive', 'and', 'emotional', 'tasks', '.', 'However', ',', 'the', 'rtfMRI', 'is', 'costly', 'and', 'precludes', 'motor', 'learning', 'that', 'requires', 'sitting', 'and', 'engaging', 'the', 'upper', 'limb', 'in', 'complex', 'motor', 'tasks', 'during', 'imaging', 'acquisition', '.', 'In', 'contrast', ',', 'real', '-', 'time', 'functional', 'near', '-', 'infrared', 'spectroscopy', '(', 'rtfNIRS', ')', ',', 'although', 'not', 'as', 'spatially', 'precise', 'as', 'rtfMRI', ',', 'offers', 'a', 'low', '-', 'cost', ',', 'portable', 'solution', 'to', 'provide', 'brain', 'neural', 'feedback', 'during', 'motor', 'learning', '.', 'This', 'proposal', 'will', 'utilize', 'both', 'technologies', 'in', 'a', 'hybrid', ',', 'sequential', 'motor', 'learning', 'protocol', '.', 'Moreover', ',', 'the', 'study', 'protocol', 'will', 'also', 'simultaneously', 'involve', 'both', 'central', 'effective', 'signals', '(', 'through', 'neural', 'feedback', ')', 'and', 'peripheral', 'affective', 'signals', 'by', 'employing', 'neutrally', '-', 'triggered', 'functional', 'electrical', 'stimulation', '(', 'FES)-assisted', 'coordination', 'practice', ',', 'which', 'produces', 'peripherally', '-', 'induced', 'affective', 'signals', 'from', 'muscle', 'and', 'joint', 'receptors', '.', 'This', 'novel', 'combination', 'intervention', 'protocol', 'will', 'engage', 'the', 'central', 'nervous', 'system', ',', 'motor', 'effective', 'pathway', 'training', 'along', 'with', 'induction', 'of', 'affective', 'signal', 'production', '(', 'FES', '-', 'assisted', 'practice', ')', ',', 'all', 'of', 'which', 'will', 'be', 'implemented', 'within', 'the', 'framework', 'of', 'evidence', '-', 'based', 'motor', 'learning', 'principles', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02856035,NCT02856035,"Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke | Stroke (795,000/year in the US and 30 million existing stroke survivors in the world) damages brain neural structures that control coordinated upper limb movement. To most effectively target the brain damage, interventions should be directed so as to restore brain control serving coordination of peripheral neuromuscular function. Currently, there is a lack of a transformative intervention strategy, and only limited efficacy is seen in response to neural rehabilitation that is only peripherally-directed (limbs e.g.) or only directed at the brain. This study will employ a novel neural feedback approach with a closed-loop, real-time paradigm to engage and retrain existing brain function after stroke. Real-time functional magnetic resonance imaging (rtfMIR) provides neural feedback with the advantage of precisely identifying the location of brain activity for multiple cognitive and emotional tasks. However, the rtfMRI is costly and precludes motor learning that requires sitting and engaging the upper limb in complex motor tasks during imaging acquisition. In contrast, real-time functional near-infrared spectroscopy (rtfNIRS), although not as spatially precise as rtfMRI, offers a low-cost, portable solution to provide brain neural feedback during motor learning. This proposal will utilize both technologies in a hybrid, sequential motor learning protocol. Moreover, the study protocol will also simultaneously involve both central effective signals (through neural feedback) and peripheral affective signals by employing neutrally-triggered functional electrical stimulation (FES)-assisted coordination practice, which produces peripherally-induced affective signals from muscle and joint receptors. This novel combination intervention protocol will engage the central nervous system, motor effective pathway training along with induction of affective signal production (FES-assisted practice), all of which will be implemented within the framework of evidence-based motor learning principles.","[(6, 36, 'OTHER', 'Brain Signal Feedback Paradigm'), (69, 75, 'CONDITION', 'Stroke'), (78, 84, 'CONDITION', 'Stroke'), (133, 139, 'CONDITION', 'stroke'), (661, 724, 'OTHER', 'neural feedback approach with a closed-loop, real-time paradigm'), (777, 783, 'CONDITION', 'stroke'), (851, 866, 'OTHER', 'neural feedback'), (1317, 1332, 'OTHER', 'neural feedback'), (1406, 1448, 'OTHER', 'hybrid, sequential motor learning protocol'), (1552, 1567, 'OTHER', 'neural feedback'), (1615, 1705, 'OTHER', 'neutrally-triggered functional electrical stimulation (FES)-assisted coordination practice'), (1879, 1911, 'OTHER', 'motor effective pathway training'), (1965, 1986, 'OTHER', 'FES-assisted practice')]"
"['A', 'Randomized', 'Evaluation', 'of', 'Short', 'Term', 'and', 'Long', 'Term', 'Outcome', 'After', 'Endovascular', 'Repair', 'by', 'Stenting', 'of', 'Carotid', 'Artery', 'Stenosis', 'in', 'Patients', 'With', 'Severe', '(', '70', '%', 'and', 'Higher', ')', 'Asymptomatic', 'Carotid', 'Stenosis', '|', 'Purpose', 'of', 'this', 'study', ':', '\n\n', 'Primary', ':', '\n\n', '•', 'Comparison', 'of', 'cardiovascular', 'mortality', 'and', 'morbidity', 'which', 'includes', 'cardiac', 'and', 'neurological', 'morbidity', '(', 'TIA', 'and', 'CVA', ')', 'in', 'the', 'two', 'invasive', 'treatments', 'of', 'asymptomatic', 'carotid', 'artery', 'stenosis', '\n\n', 'Secondary', ':', '\n\n', 'Comparison', 'of', 'non', 'cardiovascular', 'morbidity', 'caused', 'by', 'the', 'two', 'invasive', 'techniques', '\n\n', 'morbidity', 'at', 'the', 'site', 'of', 'incision', '(', 'infection', 'or', 'local', 'hematoma', ')', '\n', 'damage', 'to', 'cranial', 'nerves', '(', 'hypoglossus', ',', 'vagus', ')', '\n', 'brain', 'hyperperfusion', 'which', 'is', 'defined', 'as', 'severe', 'headache', 'which', 'is', 'not', 'responsive', 'to', 'analgesics', 'with', 'or', 'without', 'nausea', 'and', 'vomiting', '.', '\n', 'events', 'of', 'bradycardia', 'within', 'the', 'first', '24', 'hours', ',', 'clinically', 'evident', 'and/or', 'silent', '\n', 'microembolic', 'brain', 'events', 'immediately', 'after', 'the', 'procedure', 'and', 'their', 'relationship', 'with', 'morbidity', 'and/or', 'mortality', 'due', 'to', 'TIA', ""'s"", 'or', 'CVA', ""'s"", '\n', 'the', 'change', 'in', 'the', 'stenotic', 'carotid', 'artery', 'at', 'the', 'time', 'of', 'follow', 'up', 'with', 'duplex', 'of', 'neck', 'arteries', '\n', 'the', 'comparison', 'of', 'the', 'affect', 'of', 'the', 'two', 'procedures', 'on', 'patient', 'life', 'style']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00772278,NCT00772278,"A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis | Purpose of this study:

Primary:

• Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis

Secondary:

Comparison of non cardiovascular morbidity caused by the two invasive techniques

morbidity at the site of incision (infection or local hematoma)
damage to cranial nerves (hypoglossus, vagus)
brain hyperperfusion which is defined as severe headache which is not responsive to analgesics with or without nausea and vomiting.
events of bradycardia within the first 24 hours, clinically evident and/or silent
microembolic brain events immediately after the procedure and their relationship with morbidity and/or mortality due to TIA's or CVA's
the change in the stenotic carotid artery at the time of follow up with duplex of neck arteries
the comparison of the affect of the two procedures on patient life style","[(66, 97, 'SURGICAL', 'Endovascular Repair by Stenting'), (101, 124, 'CONDITION', 'Carotid Artery Stenosis'), (142, 195, 'CONDITION', 'Severe (70% and Higher) Asymptomatic Carotid Stenosis'), (385, 421, 'CONDITION', 'asymptomatic carotid artery stenosis')]"
"['Brain', 'Single', 'Photon', 'Emission', 'Computed', 'Tomography', 'and', 'Quantitative', 'Electroencephalography', 'In', 'Former', 'NFL', 'Players', ':', 'A', 'Single', '-', 'Site', 'Exploratory', 'Pilot', 'Study', '|', 'The', 'investigators', 'primary', 'objective', 'is', 'to', 'acquire', 'preliminary', 'data', 'on', 'one', '-', 'hundred', 'former', 'NFL', 'veterans', 'with', 'at', 'least', 'one', 'full', 'year', 'of', 'professional', 'service', 'using', 'brain', 'SPECT', 'imaging', 'in', 'order', 'to', 'assess', 'the', 'degree', 'to', 'which', 'NFL', 'football', 'puts', 'players', 'at', 'risk', 'for', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', '.', 'TBI', 'severity', 'shall', 'be', 'gauged', 'via', 'visual', 'inspection', 'by', 'a', 'clinician', 'trained', 'in', 'neuroanatomy', ',', 'and', 'also', 'by', 'a', 'statistical', 'comparison', 'of', 'subjects', ""'"", 'brains', 'to', 'an', 'in', '-', 'house', 'proprietary', 'database', 'comprised', 'of', 'the', 'brains', 'of', 'healthy', 'subjects', '.', '\n\n', 'The', 'investigators', 'secondary', 'objective', 'is', 'to', 'acquire', 'additional', 'data', 'on', 'these', 'players', 'such', 'that', 'investigators', 'may', 'establish', 'causative', 'factors', 'and', 'risks', 'associated', 'with', 'said', 'TBI', '.', '\n\n', 'The', 'investigators', 'tertiary', 'objective', 'is', 'to', 'acquire', 'data', 'on', 'subjects', 'using', 'various', 'mental', 'health', 'metrics', 'in', 'order', 'to', 'determine', 'the', 'effects', 'of', 'TBI', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01515839,NCT01515839,"Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study | The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL football puts players at risk for traumatic brain injury (TBI). TBI severity shall be gauged via visual inspection by a clinician trained in neuroanatomy, and also by a statistical comparison of subjects' brains to an in-house proprietary database comprised of the brains of healthy subjects.

The investigators secondary objective is to acquire additional data on these players such that investigators may establish causative factors and risks associated with said TBI.

The investigators tertiary objective is to acquire data on subjects using various mental health metrics in order to determine the effects of TBI.","[(409, 431, 'CONDITION', 'traumatic brain injury'), (433, 436, 'CONDITION', 'TBI'), (439, 442, 'CONDITION', 'TBI'), (841, 844, 'CONDITION', 'TBI'), (988, 991, 'CONDITION', 'TBI')]"
"['Etude', 'Pilote', 'évaluant', ""l'Effet"", 'du', 'Niveau', ""d'Immersion"", 'Sur', 'la', 'Fonction', 'Respiratoire', 'Des', 'Patients', 'tétraplégiques', 'bénéficiant', 'de', 'balnéothérapie', '|', 'Balneotherapy', 'is', 'a', 'physiotherapy', 'technique', 'which', 'allows', 'patients', 'to', 'work', 'out', 'in', 'a', 'weightless', 'environment', 'and', 'which', 'is', 'often', 'used', 'in', 'patients', 'with', 'spinal', 'cord', 'injury', '.', 'In', 'normal', 'subjects', ',', 'water', 'immersion', 'generates', 'a', 'reduction', 'in', 'lung', 'volumes', '.', 'The', 'effects', 'of', 'water', 'immersion', 'on', 'the', 'respiratory', 'function', 'of', 'spinal', 'cord', 'injury', 'patient', '(', 'who', 'are', 'liable', 'to', 'present', 'a', 'respiratory', 'failure', 'secondary', 'to', 'paralysis', ')', 'are', 'not', 'well', 'known', '.', 'They', 'could', 'be', 'deleterious', '(', 'by', 'majoring', 'respiratory', 'failure)or', 'beneficial', '(', 'by', 'mimicking', 'the', 'effect', 'of', 'a', 'corset', 'and', 'improving', 'respiratory', 'function', ')', '.', 'Therefore', ',', 'we', 'are', 'planning', 'to', 'study', 'the', 'effect', 'of', 'different', 'water', 'immersion', 'levels', 'on', 'the', 'respiratory', 'function', 'of', 'spinal', 'cord', 'injury', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O']",NCT01831414,NCT01831414,"Etude Pilote évaluant l'Effet du Niveau d'Immersion Sur la Fonction Respiratoire Des Patients tétraplégiques bénéficiant de balnéothérapie | Balneotherapy is a physiotherapy technique which allows patients to work out in a weightless environment and which is often used in patients with spinal cord injury. In normal subjects, water immersion generates a reduction in lung volumes. The effects of water immersion on the respiratory function of spinal cord injury patient (who are liable to present a respiratory failure secondary to paralysis) are not well known. They could be deleterious (by majoring respiratory failure)or beneficial (by mimicking the effect of a corset and improving respiratory function). Therefore, we are planning to study the effect of different water immersion levels on the respiratory function of spinal cord injury patients.","[(141, 154, 'PHYSICAL', 'Balneotherapy'), (287, 305, 'CONDITION', 'spinal cord injury'), (327, 342, 'PHYSICAL', 'water immersion'), (397, 412, 'PHYSICAL', 'water immersion'), (444, 462, 'CONDITION', 'spinal cord injury'), (500, 519, 'CONDITION', 'respiratory failure'), (771, 786, 'PHYSICAL', 'water immersion'), (825, 843, 'CONDITION', 'spinal cord injury')]"
"['Developing', 'A', 'Person', '-', 'centered', 'Internet', '-', 'based', 'Health', 'Action', 'Process', 'Approach', 'to', 'Promoting', 'Physical', 'Activity', 'in', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'implement', 'the', 'person', '-', 'centered', 'internet', '-', 'based', 'Health', 'Action', 'Process', 'Approach', 'to', 'promoting', 'physical', 'activity', 'in', 'people', 'with', 'Multiple', 'Sclerosis', '(', 'i.e.', ',', 'eHAPA', '-', 'MS', 'online', 'intervention', ')', 'and', 'assess', 'the', 'intervention', ""'s"", 'effectiveness', 'and', 'adherence', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05124522,NCT05124522,"Developing A Person-centered Internet-based Health Action Process Approach to Promoting Physical Activity in People With Multiple Sclerosis | The purpose of this study is to implement the person-centered internet-based Health Action Process Approach to promoting physical activity in people with Multiple Sclerosis (i.e., eHAPA-MS online intervention) and assess the intervention's effectiveness and adherence.","[(13, 65, 'OTHER', 'Person-centered Internet-based Health Action Process'), (88, 105, 'PHYSICAL', 'Physical Activity'), (121, 139, 'CONDITION', 'Multiple Sclerosis'), (188, 240, 'OTHER', 'person-centered internet-based Health Action Process'), (263, 280, 'PHYSICAL', 'physical activity'), (296, 314, 'CONDITION', 'Multiple Sclerosis'), (322, 350, 'OTHER', 'eHAPA-MS online intervention')]"
"['Application', 'of', 'a', 'Double', 'Blind', 'Clinical', 'Trial', 'Protocol', 'for', 'Evaluation', 'of', 'Healing', 'Action', 'of', 'P1G10', ',', 'From', 'V', 'Cundinamarcensis', 'to', 'Chronic', 'Neuropathic', 'Wounds', 'in', 'Diabetic', 'Foot', 'Ulcers', '.', '|', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'investigate', 'the', 'role', 'of', 'the', 'proteolytic', 'fraction', 'from', 'Vasconcellea', 'cundinamarcensis', ',', 'designated', 'as', 'P1G10', ',', 'on', 'healing', 'of', 'chronic', 'foot', 'ulcers', 'in', 'neuropathic', 'patients', 'diagnosed', 'with', 'diabetes', 'type', '2', '.', 'Fifty', 'patients', 'were', 'enrolled', 'in', 'a', 'prospective', ',', 'randomized', ',', 'double', '-', 'blind', 'trial', ',', 'to', 'verify', 'the', 'efﬁcacy', 'and', 'safety', 'of', 'a', 'topical', 'dressing', 'containing', '0.1', '%', 'P1G10', ',', 'versus', 'a', 'Hydrogel', '(', 'positive', 'control', ')', 'protocol', 'currently', 'applied', 'at', 'the', 'Health', 'Center', 'to', 'treat', 'this', 'condition', '.', 'Upon', 'completion', 'of', 'the', 'intervention', ',', 'the', 'outcome', 'evaluated', 'the', 'number', 'of', 'patients', 'attaining', 'full', 'epithelization', '(', '100', '%', ')', ',', 'or', 'at', 'least', '80', '%', 'healing', 'in', 'both', 'arms', '(', 'P1G10', 'versus', 'Hydrogel', ')', '.', 'Statistical', 'analysis', 'compared', 'the', 'endpoint', 'data', 'on', 'each', 'group', 'to', 'assess', 'the', 'signiﬁcance', 'of', 'differences', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03700580,NCT03700580,"Application of a Double Blind Clinical Trial Protocol for Evaluation of Healing Action of P1G10, From V Cundinamarcensis to Chronic Neuropathic Wounds in Diabetic Foot Ulcers. | The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on healing of chronic foot ulcers in neuropathic patients diagnosed with diabetes type 2. Fifty patients were enrolled in a prospective, randomized, double-blind trial, to verify the efﬁcacy and safety of a topical dressing containing 0.1% P1G10, versus a Hydrogel (positive control) protocol currently applied at the Health Center to treat this condition. Upon completion of the intervention, the outcome evaluated the number of patients attaining full epithelization (100%), or at least 80% healing in both arms (P1G10 versus Hydrogel). Statistical analysis compared the endpoint data on each group to assess the signiﬁcance of differences.","[(90, 95, 'DRUG', 'P1G10'), (124, 150, 'CONDITION', 'Chronic Neuropathic Wounds'), (154, 174, 'CONDITION', 'Diabetic Foot Ulcers'), (305, 310, 'DRUG', 'P1G10'), (326, 345, 'CONDITION', 'chronic foot ulcers'), (349, 360, 'CONDITION', 'neuropathic'), (385, 401, 'CONDITION', 'diabetes type 2.'), (552, 557, 'DRUG', 'P1G10'), (568, 576, 'CONTROL', 'Hydrogel'), (827, 832, 'DRUG', 'P1G10'), (840, 848, 'CONTROL', 'Hydrogel')]"
"['Evaluating', 'Evidence', '-', 'based', 'and', 'Sustainable', 'Application', 'of', 'Robotic', 'Exoskeletons', 'in', 'Rehabilitation', 'for', 'Those', 'With', 'Impaired', 'Mobility', '|', 'The', 'programme', 'is', 'designed', 'to', 'investigate', 'the', 'application', 'of', 'robotic', 'exoskeleton', 'in', 'different', 'levels', 'of', 'local', 'rehabilitation', 'facilities', '.', 'Feasibilities', ',', 'efficacy', ',', 'cost', '-', 'effectiveness', ',', 'patient', 'and', 'therapist', ""'s"", 'view', 'of', 'the', 'application', 'of', 'robotic', 'exoskeleton', 'will', 'be', 'evaluated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O']",NCT05659121,NCT05659121,"Evaluating Evidence-based and Sustainable Application of Robotic Exoskeletons in Rehabilitation for Those With Impaired Mobility | The programme is designed to investigate the application of robotic exoskeleton in different levels of local rehabilitation facilities. Feasibilities, efficacy, cost-effectiveness, patient and therapist's view of the application of robotic exoskeleton will be evaluated.","[(57, 77, 'PHYSICAL', 'Robotic Exoskeletons'), (111, 128, 'CONDITION', 'Impaired Mobility'), (191, 210, 'PHYSICAL', 'robotic exoskeleton'), (363, 382, 'PHYSICAL', 'robotic exoskeleton')]"
"['Detection', 'of', 'Silent', 'Atrial', 'Fibrillation', 'aFter', 'Ischemic', 'StrOke', '(', 'SAFFO', ')', 'Guided', 'by', 'Implantable', 'Loop', 'Recorder', '.', 'Multicentre', 'Italian', 'Trial', 'Based', 'on', 'Stroke', 'Unit', 'Network', 'With', 'Paired', 'Cardio', '-', 'Arrhythmology', 'Units', '(', 'Italian', 'Neurocardiology', 'Unit', 'Network', ')', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', ',', 'in', 'patients', 'with', 'first', '-', 'ever', 'atherothrombotic', 'or', 'lacunar', 'stroke', 'without', 'any', 'previous', 'history', 'of', 'atrial', 'fibrillation', '(', 'AF)/atrial', 'flutter', '(', 'AFL)/atrial', 'tachycardia', '(', 'AT', ')', ',', 'the', 'detection', 'of', 'AF', '/', 'AFL', '/', 'AT', '(', 'silent', 'or', 'symptomatic', ')', 'by', 'using', 'a', 'continuous', 'cardiac', 'rhythm', 'monitoring', 'with', 'implantable', 'loop', 'recorder', '(', 'ILR', ')', 'during', 'the', 'first', '12', 'months', 'of', 'observation', 'is', 'higher', 'than', 'the', 'detection', 'by', 'using', 'a', 'standard', 'cardiac', 'monitoring', '(', 'physical', 'exam', ',', '12', '-', 'lead', 'electrocardiogram', '[', 'ECG', ']', 'at', 'baseline', ',', '3', ',', '6', ',', 'and', '12', 'months', 'and', 'Holter', 'ECG', 'at', '3', 'months', ')', 'in', 'the', 'same', 'period', 'of', 'time', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02684825,NCT02684825,"Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) | The primary objective of this study is to evaluate whether, in patients with first-ever atherothrombotic or lacunar stroke without any previous history of atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT), the detection of AF/AFL/AT (silent or symptomatic) by using a continuous cardiac rhythm monitoring with implantable loop recorder (ILR) during the first 12 months of observation is higher than the detection by using a standard cardiac monitoring (physical exam, 12-lead electrocardiogram [ECG] at baseline, 3, 6, and 12 months and Holter ECG at 3 months) in the same period of time.","[(13, 39, 'CONDITION', 'Silent Atrial Fibrillation'), (46, 61, 'CONDITION', 'Ischemic StrOke'), (319, 364, 'CONDITION', 'first-ever atherothrombotic or lacunar stroke'), (397, 416, 'CONDITION', 'atrial fibrillation'), (463, 465, 'CONDITION', 'AT'), (485, 487, 'CONDITION', 'AF'), (488, 491, 'CONDITION', 'AFL'), (492, 494, 'CONDITION', 'AT')]"
"['Effects', 'of', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'Those', 'With', 'CI', 'and', 'HA', 'Users', '.', '|', 'The', 'goal', 'of', 'the', 'proposed', 'project', 'is', 'to', 'create', 'an', 'Audiobooks', 'for', 'Hearing', 'Loss', '(', 'HL', ')', 'App', '-', 'an', 'audiobook', 'App', 'that', 'has', 'a', 'wide', 'array', 'of', 'user', '-', 'selectable', 'features', 'designed', 'to', 'provide', 'auditory', 'training', '.', 'The', 'effects', 'of', 'the', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'those', 'With', 'CI', 'and', 'HA', 'Users', 'was', 'measured', 'with', 'a', '6', '-', 'week', 'trial', 'of', 'using', 'the', 'app', 'and', 'measuring', 'changes', 'in', 'listener', 'abilities', 'and', 'adherence', 'to', 'the', 'program', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04231396,NCT04231396,Effects of Audiobooks for Hearing Loss App as Auditory Training for Those With CI and HA Users. | The goal of the proposed project is to create an Audiobooks for Hearing Loss (HL) App - an audiobook App that has a wide array of user-selectable features designed to provide auditory training. The effects of the Audiobooks for Hearing Loss App as Auditory Training for those With CI and HA Users was measured with a 6-week trial of using the app and measuring changes in listener abilities and adherence to the program.,"[(11, 42, 'OTHER', 'Audiobooks for Hearing Loss App'), (46, 63, 'OTHER', 'Auditory Training'), (79, 94, 'CONDITION', 'CI and HA Users'), (147, 183, 'OTHER', 'Audiobooks for Hearing Loss (HL) App'), (273, 290, 'OTHER', 'auditory training'), (311, 342, 'OTHER', 'Audiobooks for Hearing Loss App'), (379, 394, 'CONDITION', 'CI and HA Users')]"
"['Phase', 'IB', 'Follow', '-', 'up', ',', 'Controlled', ',', 'Parallel', 'Group', ',', 'Single', '-', 'center', 'Study', 'to', 'Assess', 'a', 'Second', 'Boost', 'Immunization', 'With', 'AFFITOPE', '®', 'PD01A', 'With', 'Regard', 'to', 'Safety', '/', 'Tolerability', ',', 'Immunological', 'and', 'Clinical', 'Activity', 'in', 'Patients', 'Who', 'Have', 'Participated', 'in', 'the', 'AFF008', 'Program', '|', 'This', 'is', 'a', 'follow', '-', 'up', 'study', 'to', 'assess', 'safety', 'and', 'clinical', 'activity', 'of', 'continued', 'AFFITOPE', '®', 'PD01A', 'vaccinations', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.', 'Patients', ',', 'who', 'have', 'already', 'participated', 'in', 'the', 'AFF008', 'program', 'will', 'be', 'involved', 'and', 'will', 'receive', 'a', 'second', 'boost', 'immunization', 'with', 'AFFITOPE', '®', 'PD01A.', 'One', 'study', 'site', 'in', 'Vienna', '(', 'Austria', ')', 'will', 'be', 'involved', '.', '\n\n', 'In', 'addition', ',', 'up', 'to', '6', 'patients', 'will', 'be', 'offered', 'participation', 'within', 'an', 'untreated', 'control', 'Group', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O']",NCT02618941,NCT02618941,"Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program | This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® PD01A vaccinations in patients with Parkinson's disease. Patients, who have already participated in the AFF008 program will be involved and will receive a second boost immunization with AFFITOPE® PD01A. One study site in Vienna (Austria) will be involved.

In addition, up to 6 patients will be offered participation within an untreated control Group.","[(111, 126, 'DRUG', 'AFFITOPE® PD01A'), (335, 350, 'DRUG', 'AFFITOPE® PD01A'), (381, 400, 'CONDITION', ""Parkinson's disease""), (531, 547, 'DRUG', 'AFFITOPE® PD01A.'), (672, 689, 'CONTROL', 'untreated control')]"
"['Digital', 'Interventions', 'in', 'Neuro', '-', 'Rehabilitation', '(', 'DINR', '):', 'A', 'Digital', 'Neuro', 'Intervention', '(', 'DNI', ')', 'for', 'Word', 'Retrieval', '(', 'Anomia', ')', '|', 'iTALKBetter', 'will', 'provide', 'an', 'app', '-', 'based', 'therapy', 'for', 'people', 'with', 'word', 'retrieval', 'difficulties', 'who', 'have', 'had', 'a', 'stroke', '.', '\n\n', 'This', 'study', 'aims', 'to', 'test', 'the', 'therapy', 'application', 'for', 'people', 'with', 'naming', 'difficulties', 'through', 'a', 'small', 'scale', 'randomized', 'controlled', 'trial', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04566081,NCT04566081,"Digital Interventions in Neuro-Rehabilitation (DINR): A Digital Neuro Intervention (DNI) for Word Retrieval (Anomia) | iTALKBetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke.

This study aims to test the therapy application for people with naming difficulties through a small scale randomized controlled trial.","[(0, 45, 'OTHER', 'Digital Interventions in Neuro-Rehabilitation'), (47, 51, 'OTHER', 'DINR'), (56, 82, 'OTHER', 'Digital Neuro Intervention'), (84, 87, 'OTHER', 'DNI'), (109, 115, 'CONDITION', 'Anomia'), (119, 130, 'OTHER', 'iTALKBetter'), (147, 164, 'OTHER', 'app-based therapy'), (181, 208, 'CONDITION', 'word retrieval difficulties'), (224, 230, 'CONDITION', 'stroke'), (297, 316, 'CONDITION', 'naming difficulties')]"
"['Pilot', 'Study', 'to', 'Investigate', 'the', 'Efficacy', 'of', 'L', '-', 'arginine', 'Therapy', 'on', 'Endothelium', '-', 'dependent', 'Vasodilation', '&', 'Mitochondrial', 'Metabolism', 'in', 'MELAS', 'Syndrome', '.', '|', 'MELAS', 'patients', 'suffer', 'from', 'exercise', 'intolerance', ',', 'weakness', ',', 'poor', 'vision', 'or', 'blindness', ',', 'poor', 'growth', ',', 'developmental', 'delay', ',', 'and', 'deafness', '.', 'They', 'also', 'have', 'unique', ""'"", 'stroke', '-', 'like', ""'"", 'episodes', '(', 'SLEs', ')', 'which', 'are', 'not', 'due', 'to', 'blockages', 'of', 'large', 'or', 'medium', 'arteries', '.', 'These', ""'"", 'strokes', ""'"", 'are', 'thought', 'to', 'be', 'due', 'to', 'energy', 'failure', 'of', 'very', 'small', 'brain', 'blood', 'vessels', 'combined', 'with', 'energy', 'failure', 'in', 'the', 'mitochondria', '(', 'cell', 'battery', ')', 'of', 'the', 'brain', 'cells', ',', 'especially', 'in', 'the', 'back', 'region', 'of', 'the', 'brain', 'in', 'the', 'vision', 'centre', '.', 'This', 'leads', 'to', 'visual', 'loss', 'and', 'paralysis', '.', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'these', 'SLEs', 'at', 'the', 'level', 'of', 'the', 'brain', 'cells', 'and', 'small', 'blood', 'vessels', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01603446,NCT01603446,"Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome. | MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.","[(43, 53, 'DRUG', 'L-arginine'), (130, 144, 'CONDITION', 'MELAS Syndrome'), (148, 153, 'CONDITION', 'MELAS'), (303, 325, 'CONDITION', ""'stroke-like' episodes""), (327, 331, 'CONDITION', 'SLEs'), (400, 407, 'CONDITION', 'strokes'), (751, 755, 'CONDITION', 'SLEs')]"
"['Fit', 'Families', 'Program', ':', 'A', 'Multisite', 'Study', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'twofold', '.', 'First', ',', 'the', 'investigator', 'wants', 'to', 'identify', 'the', 'effect', 'of', 'a', '12', '-', 'week', 'online', 'fundamental', 'motor', 'skills', '(', 'FMS', ')', '(', 'e.g.', ',', 'throwing', ',', 'catching', ',', 'running', ')', 'intervention', 'on', 'active', 'participation', 'in', 'physical', 'recreation', 'activities', 'as', 'well', 'as', 'a', 'variety', 'of', 'other', 'factors(parental', 'stress', ',', 'parental', 'self', '-', 'efficacy', ',', 'and', 'children', ""'s"", 'adaptive', 'skills', ')', '.', 'Second', ',', 'the', 'investigator', 'also', 'wants', 'to', 'identify', 'patterns', ',', 'benefits', ',', 'constraints', ',', 'and', 'strategies', 'to', 'active', 'participation', 'in', 'physical', 'recreation', 'activities', 'among', 'families', 'of', 'children', 'with', 'developmental', 'disabilities', 'such', 'as', 'autism', ',', 'down', 'syndrome', ',', 'etc', '(', 'post', '-', 'program', ')', 'via', 'focus', 'groups', 'interviews', '(', 'via', 'zoom', ')', 'with', 'parents', '.', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'two', 'protocols', ':', '1', ')', 'Intervention', 'group', 'and', '2', ')', 'wait', '-', 'listed', 'home', '-', 'based', 'group', '.', 'Participants', 'in', 'both', 'groups', 'will', 'receive', 'an', 'activity', 'booklet', '(', 'in', 'the', 'form', 'of', 'an', 'App', ')', 'and', 'physical', 'education', '-', 'related', 'activity', 'items', '(', 'e.g.', ',', 'ball', ',', 'hoop', ')', '.', 'The', 'investigator', 'hypothesizes', 'that', 'both', 'the', 'intervention', 'group', 'will', 'improve', 'in', 'all', 'measures', 'from', 'pre', 'to', 'post', 'compared', 'to', 'the', 'wait', '-', 'list', 'control', 'group', '.', 'The', 'study', 'team', 'wants', 'to', 'determine', 'if', 'the', 'differences', 'in', 'the', 'intervention', 'group', 'differ', 'significantly', 'or', 'are', 'equitable', 'in', 'terms', 'of', 'gains', 'in', 'all', 'areas', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05451459,NCT05451459,"Fit Families Program: A Multisite Study | The purpose of the study is twofold. First, the investigator wants to identify the effect of a 12-week online fundamental motor skills (FMS) (e.g., throwing, catching, running) intervention on active participation in physical recreation activities as well as a variety of other factors(parental stress, parental self-efficacy, and children's adaptive skills). Second, the investigator also wants to identify patterns, benefits, constraints, and strategies to active participation in physical recreation activities among families of children with developmental disabilities such as autism, down syndrome, etc (post-program) via focus groups interviews (via zoom) with parents. Participants will be randomly assigned to one of two protocols: 1) Intervention group and 2) wait-listed home-based group. Participants in both groups will receive an activity booklet (in the form of an App) and physical education-related activity items (e.g., ball, hoop). The investigator hypothesizes that both the intervention group will improve in all measures from pre to post compared to the wait-list control group. The study team wants to determine if the differences in the intervention group differ significantly or are equitable in terms of gains in all areas.","[(145, 176, 'PHYSICAL', 'online fundamental motor skills'), (178, 181, 'PHYSICAL', 'FMS'), (623, 629, 'CONDITION', 'autism'), (631, 644, 'CONDITION', 'down syndrome'), (811, 833, 'CONTROL', 'wait-listed home-based'), (930, 971, 'PHYSICAL', 'physical education-related activity items'), (1117, 1126, 'CONTROL', 'wait-list')]"
"['Dual', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'dTDCS)-Enhanced', 'Therapy', 'After', 'Hemorrhagic', 'Strokes', 'and', 'VEGF', '|', 'This', 'study', 'will', 'evaluate', 'the', 'feasibility', 'of', 'dual', 'tDCS', 'to', 'improve', 'arm', 'motor', 'function', 'in', 'chronic', 'stroke', 'patients', '.', 'In', 'addition', 'it', 'will', 'collect', 'pilot', 'data', 'on', 'the', 'blood', 'biomarkers', 'associated', 'with', 'treatment', 'effect', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03857243,NCT03857243,Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy After Hemorrhagic Strokes and VEGF | This study will evaluate the feasibility of dual tDCS to improve arm motor function in chronic stroke patients. In addition it will collect pilot data on the blood biomarkers associated with treatment effect.,"[(0, 69, 'OTHER', 'Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy'), (76, 95, 'CONDITION', 'Hemorrhagic Strokes'), (100, 104, 'DRUG', 'VEGF'), (151, 160, 'OTHER', 'dual tDCS'), (194, 208, 'CONDITION', 'chronic stroke')]"
"['Transdermal', 'Vagal', 'Stimulation', 'for', 'the', 'Treatment', 'of', 'Postural', 'Tachycardia', 'Syndrome', '|', 'Some', 'patients', 'experience', 'high', 'heart', 'rates', 'and', 'symptoms', 'of', 'light', '-', 'headedness', ',', 'fatigue', ',', 'headache', 'during', 'standing', 'despite', 'well', 'maintained', 'blood', 'pressure', '.', '\n\n', 'These', 'patient', 'are', 'disabled', 'and', 'ca', ""n't"", 'be', 'in', 'upright', 'position', 'for', 'a', 'longer', 'time', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'whether', 'electrical', 'stimulation', 'of', 'a', 'nerve', 'through', 'a', 'skin', 'of', 'the', 'ear', 'may', 'improve', 'heart', 'rate', 'response', 'and', 'reduce', 'disabling', 'symptoms', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02281097,NCT02281097,"Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome | Some patients experience high heart rates and symptoms of light-headedness, fatigue, headache during standing despite well maintained blood pressure.

These patient are disabled and can't be in upright position for a longer time. The purpose of this study is to test whether electrical stimulation of a nerve through a skin of the ear may improve heart rate response and reduce disabling symptoms.","[(0, 29, 'OTHER', 'Transdermal Vagal Stimulation'), (51, 80, 'CONDITION', 'Postural Tachycardia Syndrome'), (141, 157, 'CONDITION', 'light-headedness'), (159, 166, 'CONDITION', 'fatigue'), (168, 176, 'CONDITION', 'headache'), (358, 417, 'OTHER', 'electrical stimulation of a nerve through a skin of the ear')]"
"['Hypoglossal', 'Acupuncture', 'for', 'Dysgeusia', 'in', 'Gynecologic', 'Cancer', 'Patients', 'Undergoing', 'Chemotherapy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'randomized', 'controlled', 'trial', 'aims', 'to', 'investigate', 'hypoglossal', 'acupuncture', 'in', 'comparison', 'to', 'sham', 'acupuncture', 'and', 'standard', 'medical', 'treatment', '(', 'dietary', 'recommendations', ')', 'in', 'the', 'treatment', 'of', 'dysgeusia', 'in', 'cancer', 'patients', 'undergoing', 'chemotherapy', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O']",NCT02304913,NCT02304913,Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial | This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.,"[(0, 23, 'OTHER', 'Hypoglossal Acupuncture'), (28, 37, 'CONDITION', 'Dysgeusia'), (41, 59, 'CONDITION', 'Gynecologic Cancer'), (80, 92, 'CONDITION', 'Chemotherapy'), (179, 202, 'OTHER', 'hypoglossal acupuncture'), (220, 236, 'CONTROL', 'sham acupuncture'), (269, 292, 'CONTROL', 'dietary recommendations'), (314, 323, 'CONDITION', 'dysgeusia'), (327, 333, 'CONDITION', 'cancer'), (354, 366, 'CONDITION', 'chemotherapy')]"
"['Evaluating', 'the', 'Efficacy', 'of', 'PKU', 'Synergy', 'in', 'Patients', 'Expressing', 'Phenylketonuria', 'or', 'Hyperphenylalaninemia', '|', 'This', 'study', 'centres', 'around', 'a', 'new', 'one', '-', 'a', '-', 'day', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'for', 'phenylketonuria', 'patients', '.', 'Fifty', 'eligible', 'adults', '(', '≥', '16', 'years', ')', 'with', 'proven', 'phenylketonuria', 'or', 'hyperphenylalaninemia', 'will', 'be', 'recruited', 'and', 'randomly', 'allocated', 'to', 'one', 'of', 'two', 'intervention', 'arms', '(', 'n', '=', '25', 'per', 'arm', ')', '.', 'Following', 'a', '3', '-', 'day', 'baseline', 'period', ',', 'and', 'in', 'addition', 'to', 'routine', 'nutritional', 'management', ',', 'patients', 'will', 'receive', 'either', 'one', 'sachet', 'of', 'the', 'new', 'protein', 'substitute', 'daily', '(', 'intervention', ')', 'or', 'continue', 'their', 'usual', 'dietary', 'and/or', 'protein', 'substitute', 'regimen', '(', 'maximum', 'of', '1', 'protein', 'substitute', 'per', 'day', '(', 'equal', 'to', '20', 'g', 'protein', 'equivalent', ')', 'control', ')', 'for', '28', 'days', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03167697,NCT03167697,"Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia | This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. Fifty eligible adults (≥ 16 years) with proven phenylketonuria or hyperphenylalaninemia will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.","[(27, 38, 'OTHER', 'PKU Synergy'), (62, 77, 'CONDITION', 'Phenylketonuria'), (81, 102, 'CONDITION', 'Hyperphenylalaninemia'), (147, 184, 'OTHER', 'phenylalanine-free protein substitute'), (189, 204, 'CONDITION', 'phenylketonuria'), (262, 277, 'CONDITION', 'phenylketonuria'), (281, 302, 'CONDITION', 'hyperphenylalaninemia'), (448, 478, 'OTHER', 'routine nutritional management'), (531, 549, 'OTHER', 'protein substitute'), (589, 636, 'CONTROL', 'usual dietary and/or protein substitute regimen')]"
"['A', 'Multisite', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Trial', 'Evaluating', 'Pitolisant', '(', 'BF2.649', ')', 'For', 'Alcohol', 'Use', 'Disorder', 'Treatment', '|', 'The', 'study', 'primary', 'end', 'point', 'is', 'the', 'decrease', 'in', 'the', 'number', 'of', 'monthly', 'heavy', 'drinking', 'days', '(', 'HDD', ')', '(', '≥', '60', 'g', '/', 'day', 'in', 'men', 'and', '≥', '40', 'g', '/', 'd', 'in', 'women', ')', 'from', 'baseline', 'to', 'the', 'end', 'of', 'the', 'double', 'blind', 'Randomized', 'Treatment', '(', 'RT', ')', '.', '\n\n', 'The', 'Secondary', 'end', 'points', 'will', 'be', 'designed', 'to', 'assess', 'safety', 'and', 'tolerability', 'and', 'to', 'further', 'investigate', 'the', 'effect', 'of', 'pitolisant', 'on', 'other', 'alcohol', 'use', 'criteria', '(', 'e.g.', 'total', 'alcohol', 'consumption', ',', 'number', 'of', 'abstinence', 'days', ')', ',', 'craving', 'as', 'well', 'as', 'the', 'improvement', 'in', 'mental', 'health', '(', 'depression', ',', 'sleep', ')', 'and', 'quality', 'of', 'life', '.', '\n\n', 'Total', 'alcohol', 'consumption', '(', 'TAC', ')', 'from', 'baseline', 'to', 'end', 'of', 'treatment', '.', 'TAC', 'was', 'defined', 'as', 'mean', 'daily', 'alcohol', 'consumption', 'in', 'g', '/', 'day', 'over', 'a', 'month', '(', '28', 'days', ')', '.', '\n', 'Percent', 'of', 'patients', 'without', 'HDDs', 'during', 'the', '24', 'weeks', 'RT', 'phase', 'of', 'the', 'study', '.', '(', 'Continuous', 'Controlled', 'Drinking', '=', 'CCD', ')', '\n', 'Percent', 'of', 'Abstinent', 'Days', 'during', 'RT', 'phase', '(', 'PAD', ')', '\n', 'Continuous', 'Abstinence', 'Duration', 'from', 'baseline', 'during', '24', 'weeks', 'RT', 'phase', '(', 'CAD', ')', '\n', '4', '-', 'week', 'point', 'prevalence', 'abstinence', 'at', 'end', 'of', 'treatment', '\n', 'Improvement', 'in', 'alcohol', 'biomarkers', '(', 'e.g.', 'ALAT', ',', 'ASAT', ',', '%', 'CDT', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Craving', '(', 'Obsessive', 'Compulsive', 'Drinking', 'Scale', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Beck', 'Depression', 'Inventory', '(', 'BDI', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'RT', 'phase', '.', '\n', 'Treatment', 'retention', 'during', '24', 'week', 'RT', '\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'RT', 'phase', '\n', 'Percent', 'patients', 'without', 'HDDs', 'during', 'the', 'OL', 'follow', 'up', 'period', '\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'OL', 'phase', '\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'OL', 'phase', '\n', 'Treatment', 'retention', 'OL', 'phase', 'Safety', 'will', 'be', 'assessed', 'by', 'evaluation', 'of', 'treatment', 'emergent', 'adverse', 'events', '(', 'TEAE', ')', ',', 'physical', 'examinations', ',', 'clinical', 'laboratory', 'tests', '(', 'blood', 'chemistry', ',', 'hematology', ',', 'and', 'urinalysis', ')', ',', 'subsequent', 'end', 'of', 'treatment', 'potential', 'withdrawal', ',', 'evaluation', 'scales', 'and', 'physical', 'examination', ',', 'measurement', 'of', 'heart', 'rate', ',', 'blood', 'pressure', ',', 'and', 'body', 'weight', 'at', 'each', 'study', 'visit', ')', 'V0', '-', 'FU5', ')', '.', 'If', 'at', 'ECG', 'Fridericia', ""'s"", 'corrected', 'QT', 'interval', '≥', '500', 'ms', 'or', 'if', 'difference', 'to', 'baseline', 'is', '≥', '60', 'ms', 'it', 'will', 'be', 'required', 'to', 'check', 'ECG', 'by', 'second', 'measurement', 'after', 'lying', 'down', '10', 'minutes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02800083,NCT02800083,"A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment | The study primary end point is the decrease in the number of monthly heavy drinking days (HDD) (≥ 60 g/day in men and ≥ 40 g/d in women) from baseline to the end of the double blind Randomized Treatment (RT).

The Secondary end points will be designed to assess safety and tolerability and to further investigate the effect of pitolisant on other alcohol use criteria (e.g. total alcohol consumption, number of abstinence days), craving as well as the improvement in mental health (depression, sleep) and quality of life.

Total alcohol consumption (TAC) from baseline to end of treatment. TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
Percent of patients without HDDs during the 24 weeks RT phase of the study. (Continuous Controlled Drinking=CCD)
Percent of Abstinent Days during RT phase (PAD)
Continuous Abstinence Duration from baseline during 24 weeks RT phase (CAD)
4-week point prevalence abstinence at end of treatment
Improvement in alcohol biomarkers (e.g. ALAT, ASAT, % CDT) during 24 week RT phase
Craving (Obsessive Compulsive Drinking Scale) during 24 week RT phase
Beck Depression Inventory (BDI) during 24 week RT phase
Quality of sleep (Pittsburgh Sleep Quality Index) during RT phase.
Treatment retention during 24 week RT
Quality of life (SF-12) during RT phase
Percent patients without HDDs during the OL follow up period
Quality of life (SF-12) during OL phase
Quality of sleep (Pittsburgh Sleep Quality Index) during OL phase
Treatment retention OL phase Safety will be assessed by evaluation of treatment emergent adverse events (TEAE), physical examinations, clinical laboratory tests (blood chemistry, hematology, and urinalysis), subsequent end of treatment potential withdrawal, evaluation scales and physical examination, measurement of heart rate, blood pressure, and body weight at each study visit )V0-FU5). If at ECG Fridericia's corrected QT interval ≥ 500 ms or if difference to baseline is ≥ 60 ms it will be required to check ECG by second measurement after lying down 10 minutes.","[(38, 45, 'CONTROL', 'Placebo'), (74, 84, 'DRUG', 'Pitolisant'), (86, 93, 'DRUG', 'BF2.649'), (99, 119, 'CONDITION', 'Alcohol Use Disorder'), (459, 469, 'DRUG', 'pitolisant')]"
"['A', 'Multi', '-', 'center', ',', 'Open', '-', 'label', ',', 'Uncontrolled', ',', 'Single', '-', 'arm', ',', 'Extension', 'Study', 'to', 'Determine', 'the', 'Long', '-', 'term', 'Safety', 'and', 'Tolerability', 'of', 'Oral', 'Lucerastat', 'in', 'Adult', 'Subjects', 'With', 'Fabry', 'Disease', '|', 'A', 'study', 'to', 'determine', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'oral', 'lucerastat', 'in', 'adult', 'subjects', 'with', 'Fabry', 'disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT03737214,NCT03737214,"A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease","[(129, 139, 'DRUG', 'Lucerastat'), (163, 176, 'CONDITION', 'Fabry Disease'), (246, 256, 'DRUG', 'lucerastat'), (280, 293, 'CONDITION', 'Fabry disease')]"
"['A', 'Clinical', 'Study', 'of', 'the', 'Oticon', 'Medical', 'Ponto', '4.5', 'mm', 'Wide', 'Implant', '|', 'To', 'assess', 'implant', 'stability', ',', 'implant', 'loss', ',', 'adverse', 'skin', 'reactions', ',', 'and', 'Quality', 'of', 'Life', 'Benefit', 'following', 'implantation', 'of', 'the', 'Ponto', '4.5', 'mm', 'Wide', 'Diameter', 'implant', '.', 'Secondary', ':', 'to', 'determine', 'the', 'feasibility', 'of', 'fitting', 'the', 'sound', 'processor', '3', 'weeks', 'after', 'surgical', 'implantation', ',', 'and', 'to', 'investigate', 'if', 'the', 'type', 'of', 'skin', 'reactions', 'following', 'implantation', 'could', 'be', 'related', 'to', 'the', 'demographic', 'data', 'of', 'subjects', 'and', 'the', 'type', 'of', 'surgical', 'technique', 'used']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01671176,NCT01671176,"A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant | To assess implant stability, implant loss, adverse skin reactions, and Quality of Life Benefit following implantation of the Ponto 4.5mm Wide Diameter implant. Secondary: to determine the feasibility of fitting the sound processor 3 weeks after surgical implantation, and to investigate if the type of skin reactions following implantation could be related to the demographic data of subjects and the type of surgical technique used","[(24, 63, 'OTHER', 'Oticon Medical Ponto 4.5mm Wide Implant'), (191, 224, 'OTHER', 'Ponto 4.5mm Wide Diameter implant')]"
"['Genetic', 'Study', 'of', 'Age', 'Related', 'Hearing', 'Loss', '|', 'Age', '-', 'related', 'hearing', 'loss', ',', 'or', 'presbyacusis', ',', 'is', 'one', 'of', 'the', 'most', 'common', 'chronically', 'handicapped', 'conditions', 'for', 'the', 'elderly', '.', 'Many', 'factors', 'including', 'genetics', ',', 'diet', ',', 'diseases', ',', 'drugs', ',', 'socioeconomic', 'factors', 'and', 'environmental', 'variables', 'were', 'considered', 'to', 'be', 'related', 'to', 'the', 'development', 'of', 'presbyacusis', '.', 'Evidences', 'have', 'shown', 'that', 'genetic', 'factors', 'play', 'an', 'important', 'role', 'on', 'presbyacusis', '.', 'However', ',', 'which', 'genes', 'or', 'their', 'genotypes', 'are', 'associated', 'with', 'presbycusis', 'remain', 'unknown', '.', '\n\n', 'The', 'aim', 'of', 'this', 'project', 'was', 'to', 'evaluate', 'the', 'association', 'between', 'the', 'genotype', 'of', 'candidate', 'genes', 'and', 'presbyacusis', 'by', 'cross', '-', 'section', 'and', 'case', '-', 'control', 'study', '.', 'In', 'the', 'first', 'stage', ',', 'the', 'investigators', 'plan', 'to', 'select', '700', 'healthy', 'subjects', 'older', 'than', '50', 'with', 'symmetric', ',', 'sensorineural', 'hearing', 'loss', '.', 'The', 'subjects', 'will', 'receive', 'basic', 'otologic', 'examination', ',', 'pure', 'tone', 'audiometry', ',', 'questionnaire', ',', 'and', 'genotype', 'analysis', '.', 'Because', 'gender', 'and', 'age', 'would', 'affect', 'hearing', 'loss', 'significantly', ',', 'The', 'investigators', 'will', 'convert', 'the', 'hearing', 'level', 'of', 'all', 'subjects', 'into', 'a', 'gender', 'and', 'age', 'independent', 'Z', '-', 'score', 'according', 'to', 'ISO', '7029', 'standard', '.', 'And', ',', 'The', 'investigators', 'define', 'subjects', 'within', 'higher', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'presbyacusis', 'group', ',', 'and', 'subjects', 'within', 'lower', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'control', 'group', '.', 'Finally', ',', 'The', 'investigators', 'perform', 'Chi', 'square', 'analysis', 'to', 'test', 'the', 'association', 'between', 'genotype', 'of', 'candidate', 'genes', 'or', 'their', 'combinations', 'in', 'both', 'groups', ',', 'and', 'calculate', 'the', 'odds', 'ratio', 'for', 'presbyacusis', 'between', 'different', 'genotype', 'of', 'candidate', 'genes', '.', 'Further', 'more', ',', 'we', 'will', 'evaluate', 'the', 'effect', 'of', 'genotype', 'of', 'candidate', 'genes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'the', 'severity', 'of', 'presbyacusis', 'by', 'multivariate', 'logistic', 'regression', '.', '\n\n', 'In', 'the', 'second', 'stage', ',', 'The', 'investigators', 'wish', 'to', 'know', 'the', 'pattern', 'of', 'genotype', 'and', 'hearing', 'level', 'in', 'the', 'high', 'risk', 'families', ',', 'according', 'to', 'results', 'from', 'the', 'first', 'stage', ',', 'by', 'description', 'and', 'case', '-', 'control', 'study', '.', 'The', 'investigators', 'will', 'perform', 't', '-', 'test', 'to', 'evaluate', 'the', 'difference', 'of', 'Z', '-', 'score', 'in', 'both', 'groups', '.', 'Besides', ',', 'The', 'investigators', 'try', 'to', 'evaluate', 'the', 'effects', 'of', 'genotypes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'hearing', 'level', 'in', 'high', 'risk', 'families', 'by', 'multivariate', 'logistic', 'regression', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01732289,NCT01732289,"Genetic Study of Age Related Hearing Loss | Age-related hearing loss, or presbyacusis, is one of the most common chronically handicapped conditions for the elderly. Many factors including genetics, diet, diseases, drugs, socioeconomic factors and environmental variables were considered to be related to the development of presbyacusis. Evidences have shown that genetic factors play an important role on presbyacusis. However, which genes or their genotypes are associated with presbycusis remain unknown.

The aim of this project was to evaluate the association between the genotype of candidate genes and presbyacusis by cross-section and case-control study. In the first stage, the investigators plan to select 700 healthy subjects older than 50 with symmetric, sensorineural hearing loss. The subjects will receive basic otologic examination, pure tone audiometry, questionnaire, and genotype analysis. Because gender and age would affect hearing loss significantly, The investigators will convert the hearing level of all subjects into a gender and age independent Z-score according to ISO 7029 standard. And, The investigators define subjects within higher 30 % of Z-score as the presbyacusis group, and subjects within lower 30% of Z-score as the control group. Finally, The investigators perform Chi square analysis to test the association between genotype of candidate genes or their combinations in both groups, and calculate the odds ratio for presbyacusis between different genotype of candidate genes. Further more, we will evaluate the effect of genotype of candidate genes, environment factors, and gene-environmental interaction on the severity of presbyacusis by multivariate logistic regression.

In the second stage, The investigators wish to know the pattern of genotype and hearing level in the high risk families, according to results from the first stage, by description and case-control study. The investigators will perform t-test to evaluate the difference of Z-score in both groups. Besides, The investigators try to evaluate the effects of genotypes, environment factors, and gene-environmental interaction on hearing level in high risk families by multivariate logistic regression.","[(29, 41, 'CONDITION', 'Hearing Loss'), (56, 68, 'CONDITION', 'hearing loss'), (755, 792, 'CONDITION', 'symmetric, sensorineural hearing loss'), (944, 956, 'CONDITION', 'hearing loss')]"
"['Analysis', 'of', 'Cortical', 'Activity', 'in', 'Individuals', 'With', 'Cybersickness', 'Under', 'the', 'Influence', 'of', 'Multi', '-', 'sensory', 'Conditions', 'in', 'Virtual', 'Reality', ':', 'a', 'Randomized', 'Crossover', 'Study', '|', 'Cybersickness', '(', 'CS', ')', 'is', 'characterized', 'as', 'a', 'type', 'of', 'visually', 'induced', 'motion', 'sickness', ',', 'similar', 'to', 'traditional', 'motion', 'sickness', ',', 'with', 'specific', 'clinical', 'presentations', 'such', 'as', 'dizziness', ',', 'eyestrain', ',', 'oculomotor', 'disorders', ',', 'blurred', 'vision', 'and', 'spatial', 'disorientation', '.', 'It', 'can', 'be', 'triggered', 'when', 'experiencing', 'virtual', 'reality', '(', 'VR', ')', ',', 'and', 'it', 'affects', 'approximately', '20', '%', 'to', '80', '%', 'of', 'individuals', 'who', 'use', 'these', 'resources', '.', 'Furthermore', ',', 'the', 'underlying', 'mechanisms', 'of', 'CS', 'are', 'not', 'fully', 'understood', 'and', 'the', 'use', 'of', 'virtual', 'environments', 'that', 'have', 'become', 'increasingly', 'recurrent', 'in', 'several', 'sectors', 'deserves', 'attention', ',', 'as', 'VR', 'is', 'becoming', 'commonplace', 'in', 'methods', 'and', 'techniques', 'of', 'assessment', ',', 'diagnosis', 'and', 'treatment', '.', 'Objective', ':', 'to', 'analyze', 'cortical', 'electrophysiological', 'activity', 'using', 'electroencephalography', '(', 'EEGq', ')', 'in', 'individuals', 'with', 'SC', ',', 'under', 'the', 'influence', 'of', 'different', 'audiovisual', 'conditions', '.', 'Methodology', ':', 'The', 'study', 'is', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'clinical', 'trial', ',', 'the', 'sample', 'for', 'survey', 'satisfaction', 'N=', '42', 'participants', ',', 'the', 'public', 'were', 'university', 'students', 'from', 'the', 'Universidade', 'Federal', 'do', 'Delta', 'Parnaíba', '(', 'UFDPar', ')', 'of', 'both', 'sexes', ',', 'aged', 'between', '18', 'to', '28', 'years', ',', 'those', 'who', 'agreed', ',', 'underwent', 'screening', ',', 'those', 'who', 'met', 'the', 'criteria', 'and', 'fit', ',', 'were', 'randomized', 'and', 'allocated', 'to', 'one', 'each', 'of', '02', 'conditions', ',', '(', 'C1', '-', 'video', 'only', ')', 'and', '(', 'C2', '-', 'associated', 'with', 'binaural', 'audio', ')', ',', 'three', 'times', 'in', 'each', 'condition', ',', 'with', 'a', 'duration', 'of', '10', 'minutes', 'of', 'immersion', ',', 'with', 'evaluation', '(', 'pre', ')', 'before', '(', 'post', ')', 'with', 'QEEG', 'and', 'Sickness', 'Questionnaire', '(', 'SSQ', ')', ',', 'exposure', 'to', 'virtual', 'content', 'was', 'on', 'regular', 'alternate', 'days', ',', 'with', 'a', '24', '-', 'hour', 'interval', 'between', 'each', 'virtual', 'exposure', ',', 'at', 'the', 'end', 'of', 'each', 'condition', ',', 'there', 'will', 'be', 'a', '14', '-', 'day', 'washout', 'and', 'crossover', 'between', 'the', 'conditions', ',', 'and', 'after', 'the', 'last', 'intervention', ',', 'there', 'will', 'be', 'a', '7', '-', 'day', 'follow', '-', 'up', 'and', 'reassessment', 'with', 'qEEG', 'and', 'SSQ', '.', 'The', 'study', 'will', 'be', 'carried', 'out', 'under', 'all', 'cleaning', 'and', 'prevention', 'care', 'in', 'the', 'fight', 'against', 'the', 'Covid-19', 'pandemic', ',', 'data', 'collection', 'will', 'be', 'at', 'the', 'Brain', 'Mapping', 'and', 'Functionality', 'Laboratory', '(', 'LAMCEF', ')', 'of', 'the', 'Federal', 'University', 'of', 'Delta', 'do', 'Parnaíba', ',', 'Piauí', ',', 'Brazil', '.', 'Results', ':', 'The', 'condition', 'with', 'binaural', 'stimulation', 'is', 'expected', 'to', 'promote', 'neuromodulation', 'and', 'reduction', 'of', 'CS', 'symptoms', ',', 'compared', 'to', 'the', 'control', 'condition', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05534880,NCT05534880,"Analysis of Cortical Activity in Individuals With Cybersickness Under the Influence of Multi-sensory Conditions in Virtual Reality: a Randomized Crossover Study | Cybersickness (CS) is characterized as a type of visually induced motion sickness, similar to traditional motion sickness, with specific clinical presentations such as dizziness, eyestrain, oculomotor disorders, blurred vision and spatial disorientation. It can be triggered when experiencing virtual reality (VR), and it affects approximately 20% to 80% of individuals who use these resources. Furthermore, the underlying mechanisms of CS are not fully understood and the use of virtual environments that have become increasingly recurrent in several sectors deserves attention, as VR is becoming commonplace in methods and techniques of assessment, diagnosis and treatment. Objective: to analyze cortical electrophysiological activity using electroencephalography (EEGq) in individuals with SC, under the influence of different audiovisual conditions. Methodology: The study is a double-blind randomized controlled clinical trial, the sample for survey satisfaction N= 42 participants, the public were university students from the Universidade Federal do Delta Parnaíba (UFDPar) of both sexes, aged between 18 to 28 years, those who agreed, underwent screening, those who met the criteria and fit, were randomized and allocated to one each of 02 conditions, (C1 - video only) and (C2 - associated with binaural audio), three times in each condition, with a duration of 10 minutes of immersion, with evaluation (pre) before (post) with QEEG and Sickness Questionnaire (SSQ), exposure to virtual content was on regular alternate days, with a 24-hour interval between each virtual exposure, at the end of each condition, there will be a 14-day washout and crossover between the conditions, and after the last intervention, there will be a 7-day follow-up and reassessment with qEEG and SSQ. The study will be carried out under all cleaning and prevention care in the fight against the Covid-19 pandemic, data collection will be at the Brain Mapping and Functionality Laboratory (LAMCEF) of the Federal University of Delta do Parnaíba, Piauí, Brazil. Results: The condition with binaural stimulation is expected to promote neuromodulation and reduction of CS symptoms, compared to the control condition.","[(50, 63, 'CONDITION', 'Cybersickness'), (87, 130, 'OTHER', 'Multi-sensory Conditions in Virtual Reality'), (163, 176, 'CONDITION', 'Cybersickness'), (178, 180, 'CONDITION', 'CS'), (212, 244, 'CONDITION', 'visually induced motion sickness'), (269, 284, 'CONDITION', 'motion sickness'), (331, 340, 'CONDITION', 'dizziness'), (342, 351, 'CONDITION', 'eyestrain'), (353, 373, 'CONDITION', 'oculomotor disorders'), (375, 389, 'CONDITION', 'blurred vision'), (394, 416, 'CONDITION', 'spatial disorientation'), (456, 471, 'OTHER', 'virtual reality'), (473, 475, 'OTHER', 'VR'), (600, 602, 'CONDITION', 'CS'), (643, 663, 'OTHER', 'virtual environments'), (746, 748, 'OTHER', 'VR'), (956, 958, 'CONDITION', 'SC'), (1429, 1439, 'CONTROL', 'video only'), (1467, 1481, 'OTHER', 'binaural audio'), (2240, 2260, 'OTHER', 'binaural stimulation'), (2317, 2319, 'CONDITION', 'CS')]"
"['Modular', 'Scheduled', 'Telephone', 'Intervention', 'for', 'Caregivers', 'of', 'Persons', 'With', 'Traumatic', 'Brain', 'Injury', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'seeks', 'to', 'determine', 'if', 'problem', '-', 'based', 'telephone', 'counseling', 'improves', 'quality', 'of', 'life', 'and', 'emotional', 'well', '-', 'being', 'for', 'caregivers', 'of', 'persons', 'with', 'moderate', 'to', 'severe', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00692575,NCT00692575,Modular Scheduled Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury: A Randomized Controlled Trial | This study seeks to determine if problem-based telephone counseling improves quality of life and emotional well-being for caregivers of persons with moderate to severe traumatic brain injury (TBI).,"[(0, 40, 'BEHAVIOURAL', 'Modular Scheduled Telephone Intervention'), (161, 195, 'BEHAVIOURAL', 'problem-based telephone counseling')]"
"['Effectiveness', 'of', 'a', 'Telehealth', 'Group', 'for', 'Improving', 'Peer', 'Relationships', 'for', 'Adolescents', 'With', 'Neurofibromatosis', 'Type', '1', '|', 'This', 'is', 'an', 'open', 'trial', 'of', 'the', 'UCLA', 'PEERS', 'protocol', 'delivered', 'via', 'Telehealth', 'with', 'teens', 'with', 'neurofibromatosis', 'type', '1', 'whose', 'parents', 'report', 'that', 'they', 'have', 'difficulty', 'making', 'and', 'keeping', 'friends', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04856514,NCT04856514,Effectiveness of a Telehealth Group for Improving Peer Relationships for Adolescents With Neurofibromatosis Type 1 | This is an open trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.,"[(19, 35, 'BEHAVIOURAL', 'Telehealth Group'), (90, 114, 'CONDITION', 'Neurofibromatosis Type 1'), (180, 190, 'BEHAVIOURAL', 'Telehealth'), (207, 231, 'CONDITION', 'neurofibromatosis type 1')]"
"['Assessment', 'of', 'the', 'Effect', 'of', 'Treatment', 'Pathways', ',', 'Adherence', ',', 'and', 'Treatment', 'Efficacy', 'in', 'Parkinson', ""'s"", 'Disease', 'Subjects', 'Randomized', 'to', 'SPECT', 'Imaging', 'of', 'the', 'Dopamine', 'Transporter', '(', 'Ioflupane', 'I123', 'Injection', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'impact', 'of', 'imaging', 'the', 'brain', 'as', 'a', 'diagnostic', 'tool', 'in', 'the', 'management', 'of', 'early', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01788696,NCT01788696,"Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection) | The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic tool in the management of early Parkinson's disease (PD).","[(85, 104, 'CONDITION', ""Parkinson's Disease""), (314, 339, 'CONDITION', ""early Parkinson's disease""), (341, 343, 'CONDITION', 'PD')]"
"['Multiparametric', 'Biomarkers', 'to', 'Predict', 'the', 'Response', 'to', 'Different', 'Protocols', 'of', 'Motor', '-', 'cognitive', 'Rehabilitation', 'in', 'Parkinson', ""'s"", 'Disease', 'Subjects', 'With', 'Postural', 'Instability', 'and', 'Gait', 'Disorders', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'effects', 'of', '2', 'different', 'dosages', 'and', 'modalities', 'of', 'motor', '-', 'cognitive', 'rehabilitation', 'in', 'Parkinson', ""'s"", 'disease', 'with', 'postural', 'instability', 'and', 'gait', 'disorders', '(', 'PD', '-', 'PIGD', ')', 'on', 'clinical', 'features', ',', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'at', 'short', '-', 'term', '(', '2', 'months', ')', 'and', 'long', '-', 'term', '(', '7', 'months', ')', 'follow', '-', 'up', '.', 'Fifty', 'subjects', 'with', 'PD', '-', 'PIGD', 'will', 'be', 'randomized', 'in', '2', 'training', 'groups', ':', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'the', 'DUAL', '-', 'TASK', 'groups', '.', 'The', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'group', 'will', 'perform', 'a', 'dual', '-', 'task', 'gait', '/', 'balance', 'training', 'consisting', 'of', 'action', 'observation', 'training', '(', 'AOT', ')', 'and', 'motor', 'imagery', '(', 'MI', ')', 'combined', 'with', 'practicing', 'the', 'observed', '-', 'imagined', 'exercises', ';', 'DUAL', '-', 'TASK', 'group', 'will', 'perform', 'the', 'same', 'exercises', 'combined', 'with', 'watching', 'landscape', 'videos', '.', 'The', 'training', 'will', 'last', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'per', 'session', '.', '\n\n', 'Before', 'and', 'after', 'training', '(', 'W6', ')', ',', 'all', 'the', 'patients', 'will', 'undergo', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'Neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', 'and', 'serum', 'biomarkers', 'will', 'be', 'also', 'repeated', 'at', 'the', '14', '-', 'week', 'follow', '-', 'up', '(', 'W14', ')', 'to', 'assess', 'maintenance', 'of', 'results', '.', '\n\n', 'Patients', 'of', 'both', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'DUAL', '-', 'TASK', 'groups', 'will', 'be', 'further', 'randomized', 'to', 'repeat', 'the', 'training', '(', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'each', 'session', ')', 'starting', 'at', 'W14', '(', 'DUAL', '-', 'TASK+AOT', '-', 'MI_DOUBLE', 'and', 'DUAL', '-', 'TASK_DOUBLE', 'groups', ')', '.', 'After', 'six', 'weeks', '(', 'W20', ')', 'all', 'the', 'subjects', 'repeating', 'the', 'training', 'will', 'be', 'evaluated', '(', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', ')', '.', 'At', '28', '-', 'week', 'follow', '-', 'up', '(', 'W28', ')', ',', 'the', 'whole', 'sample', 'of', 'patients', 'will', 'be', 'assessed', 'with', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'MRI', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'All', 'MRI', 'scans', 'will', 'be', 'acquired', 'at', 'least', '12', 'hours', 'after', 'last', 'dopaminergic', 'therapy', 'administration', 'to', 'mitigate', 'the', 'pharmacological', 'effects', 'on', 'neural', 'activity', '.', 'Twenty', 'age-', 'and', 'sex', '-', 'matched', 'healthy', 'controls', 'will', 'be', 'recruited', 'to', 'perform', 'gait', '/', 'balance', 'and', 'cognitive', '/', 'behavioral', 'assessments', ',', 'blood', 'sample', 'and', 'brain', 'MRI', 'acquisition', 'at', 'baseline', '.', 'The', 'secondary', 'aims', 'of', 'the', 'study', 'are', 'to', 'define', 'the', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'of', 'PD', '-', 'PIGD', 'patients', 'presenting', 'different', 'clinical', 'features', '(', 'e.g.', 'presence', 'of', 'mild', 'cognitive', 'impairment', ',', 'freezing', 'of', 'gait', ',', 'falls', 'and', 'mood', 'disturbances', ')', 'and', 'to', 'evaluate', 'the', 'role', 'of', 'blood', '-', 'based', 'and', 'neuroimaging', 'biomarkers', ',', 'together', 'with', 'clinical', 'characteristics', ',', 'in', 'predicting', 'the', 'response', 'to', 'different', 'dosages', 'of', 'rehabilitation', 'in', 'PD', '-', 'PIGD', 'throughout', 'the', 'development', 'of', 'a', 'machine', '-', 'learning', 'algorithm', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05799690,NCT05799690,"Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders | The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session.

Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results.

Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.","[(77, 107, 'OTHER', 'Motor-cognitive Rehabilitation'), (111, 130, 'CONDITION', ""Parkinson's Disease""), (145, 165, 'CONDITION', 'Postural Instability'), (170, 184, 'CONDITION', 'Gait Disorders'), (275, 305, 'OTHER', 'motor-cognitive rehabilitation'), (309, 328, 'CONDITION', ""Parkinson's disease""), (334, 354, 'CONDITION', 'postural instability'), (359, 373, 'CONDITION', 'gait disorders'), (375, 382, 'CONDITION', 'PD-PIGD'), (527, 534, 'CONDITION', 'PD-PIGD'), (576, 592, 'OTHER', 'DUAL-TASK+AOT-MI'), (601, 610, 'OTHER', 'DUAL-TASK'), (623, 639, 'OTHER', 'DUAL-TASK+AOT-MI'), (661, 692, 'PHYSICAL', 'dual-task gait/balance training'), (707, 734, 'OTHER', 'action observation training'), (736, 739, 'OTHER', 'AOT'), (745, 758, 'OTHER', 'motor imagery'), (760, 762, 'OTHER', 'MI'), (822, 831, 'OTHER', 'DUAL-TASK'), (884, 909, 'OTHER', 'watching landscape videos'), (1344, 1360, 'OTHER', 'DUAL-TASK+AOT-MI'), (1365, 1374, 'OTHER', 'DUAL-TASK'), (2285, 2292, 'CONDITION', 'PD-PIGD'), (2359, 2384, 'CONDITION', 'mild cognitive impairment'), (2386, 2402, 'CONDITION', 'freezing of gait'), (2404, 2409, 'CONDITION', 'falls'), (2414, 2431, 'CONDITION', 'mood disturbances'), (2611, 2618, 'CONDITION', 'PD-PIGD')]"
"['FEATHERS', '2.0', ':', 'Functional', 'Engagement', 'in', 'Assistive', 'Therapy', 'Through', 'Exercise', 'Robotics', 'v2.0', '|', 'This', 'project', 'is', 'a', 'continuing', 'study', 'from', 'the', 'FEATHERS', 'project', '(', 'NCT02290353', ')', 'which', 'focuses', 'on', 'developing', 'novel', 'home', 'therapy', 'program', 'for', 'persons', 'with', 'hemiparesis', '.', 'This', 'study', 'will', 'focus', 'on', 'examining', 'motor', 'behaviour', 'and', 'adaptation', 'in', 'neurodevelopmental', 'hemiparesis', '(', 'cerebral', 'palsy', ',', 'acquired', 'brain', 'injury', '(', 'ABI', ')', ')', '.', 'New', 'algorithms', 'for', 'motion', 'control', 'involved', 'in', 'encouraging', 'active', 'movement', 'are', 'developed', 'and', 'will', 'be', 'tested', ',', 'but', 'the', 'study', 'has', 'the', 'same', 'therapeutic', 'goal', 'and', 'focus', 'as', 'the', 'original', 'FEATHERS', 'project', 'of', 'creating', 'an', 'engaging', 'at', '-', 'home', 'bimanual', 'upper', 'limb', 'training', 'program', '.', 'By', 'incorporating', 'existing', 'gaming', 'technology', ',', 'we', 'hope', 'to', 'discover', 'novel', 'ways', 'to', 'adapt', 'commercial', 'motion', 'tracking', 'controllers', 'and', 'visual', 'feedback', 'into', 'engaging', 'rehabilitative', 'learning', 'tools', '.', 'This', 'study', 'will', 'focus', 'on', 'a', 'basic', 'science', 'aspect', 'of', 'human', 'bimanual', 'movements', 'that', 'can', 'be', 'incorporated', 'into', 'future', 'applications', 'of', 'the', 'full', 'FEATHERS', 'project', 'devices', '.', 'We', 'believe', 'that', 'together', 'these', 'approaches', 'will', 'yield', 'interventions', 'that', 'significantly', 'improve', 'functional', 'ability', 'and', 'lead', 'to', 'improved', 'quality', 'of', 'life', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03766711,NCT03766711,"FEATHERS 2.0: Functional Engagement in Assistive Therapy Through Exercise Robotics v2.0 | This project is a continuing study from the FEATHERS project (NCT02290353) which focuses on developing novel home therapy program for persons with hemiparesis. This study will focus on examining motor behaviour and adaptation in neurodevelopmental hemiparesis (cerebral palsy, acquired brain injury (ABI)). New algorithms for motion control involved in encouraging active movement are developed and will be tested, but the study has the same therapeutic goal and focus as the original FEATHERS project of creating an engaging at-home bimanual upper limb training program. By incorporating existing gaming technology, we hope to discover novel ways to adapt commercial motion tracking controllers and visual feedback into engaging rehabilitative learning tools. This study will focus on a basic science aspect of human bimanual movements that can be incorporated into future applications of the full FEATHERS project devices. We believe that together these approaches will yield interventions that significantly improve functional ability and lead to improved quality of life.","[(39, 56, 'OTHER', 'Assistive Therapy'), (65, 82, 'PHYSICAL', 'Exercise Robotics'), (237, 248, 'CONDITION', 'hemiparesis'), (319, 349, 'CONDITION', 'neurodevelopmental hemiparesis'), (351, 365, 'CONDITION', 'cerebral palsy'), (367, 388, 'CONDITION', 'acquired brain injury'), (390, 393, 'CONDITION', 'ABI'), (624, 660, 'PHYSICAL', 'bimanual upper limb training program'), (688, 705, 'OTHER', 'gaming technology'), (758, 785, 'OTHER', 'motion tracking controllers'), (790, 805, 'OTHER', 'visual feedback'), (820, 849, 'PHYSICAL', 'rehabilitative learning tools')]"
"['LEAD', 'IT', '!', 'An', 'App', 'to', 'Enable', 'Persons', 'With', 'Early', 'Stage', 'Dementia', 'to', 'Lead', 'Group', 'Activities', 'for', 'Their', 'Peers', '|', 'The', 'proposed', 'Phase', '2', 'project', 'will', 'involve', 'the', 'further', 'development', 'and', 'evaluation', 'of', 'LEAD', 'IT', '!', ',', 'which', 'is', 'a', 'tablet', '-', 'based', 'app', 'designed', 'to', 'enable', 'persons', 'with', 'dementia', 'to', 'lead', 'activities', 'for', 'their', 'peers', '(', 'i.e.', ',', 'other', 'persons', 'with', 'dementia', ')', '.', 'The', 'study', 'will', 'examine', 'the', 'clinical', 'outcomes', 'of', 'long', '-', 'term', 'use', 'of', 'the', 'app', 'by', 'both', 'Resident', 'Leaders', '(', 'RLs', ')', 'and', 'Resident', 'Players', '(', 'RPs', ')', '.', '\n\n', 'The', 'Specific', 'Aims', 'of', 'the', 'proposed', 'Phase', '2', 'project', 'are', 'to', ':', '\n\n', 'Develop', 'improved', 'Beta', '1', 'and', 'Beta', '2', 'Versions', 'of', 'LEAD', 'IT', '!', 'with', 'sufficient', 'content', 'to', 'facilitate', 'six', 'activities', 'twice', 'per', 'week', 'for', '4.5', 'months', '.', '\n', 'Examine', 'the', 'extent', 'to', 'which', 'RLs', 'are', 'able', 'to', 'serve', 'as', 'leaders', 'while', 'using', 'LEAD', 'IT', '!', '\n', 'Examine', 'the', 'effects', 'of', 'resident', '-', 'led', 'LEAD', 'IT', '!', 'programming', 'on', 'RPs', '.', '\n', 'Examine', 'PWD', 'and', 'staff', 'satisfaction', 'with', 'LEAD', 'IT', '!']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER']",NCT05516342,NCT05516342,"LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers | The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with dementia). The study will examine the clinical outcomes of long-term use of the app by both Resident Leaders (RLs) and Resident Players (RPs).

The Specific Aims of the proposed Phase 2 project are to:

Develop improved Beta 1 and Beta 2 Versions of LEAD IT! with sufficient content to facilitate six activities twice per week for 4.5 months.
Examine the extent to which RLs are able to serve as leaders while using LEAD IT!
Examine the effects of resident-led LEAD IT! programming on RPs.
Examine PWD and staff satisfaction with LEAD IT!","[(0, 8, 'OTHER', 'LEAD IT!'), (12, 15, 'OTHER', 'App'), (39, 59, 'CONDITION', 'Early Stage Dementia'), (187, 195, 'OTHER', 'LEAD IT!'), (208, 224, 'OTHER', 'tablet-based app'), (257, 265, 'CONDITION', 'dementia'), (327, 335, 'CONDITION', 'dementia'), (407, 410, 'OTHER', 'app'), (577, 585, 'OTHER', 'LEAD IT!'), (743, 751, 'OTHER', 'LEAD IT!'), (788, 796, 'OTHER', 'LEAD IT!'), (857, 865, 'OTHER', 'LEAD IT!')]"
"['Influence', 'of', 'Combined', 'Vitamin', 'D', 'Supplementation', 'and', 'Resistance', 'Exercise', 'Training', 'on', 'Musculoskeletal', 'Health', 'in', 'Frail', 'Older', 'Men', 'and', 'Women', '(', 'EXVITD', ')', '|', 'This', 'study', 'aims', 'to', 'determine', 'whether', 'vitamin', 'D3', 'supplementation', 'is', 'any', 'more', 'effective', 'in', 'improving', 'musculoskeletal', 'function', 'when', 'combined', 'with', 'exercise', 'training', 'compared', 'with', 'exercise', 'training', 'alone', '.']","['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT02467153,NCT02467153,Influence of Combined Vitamin D Supplementation and Resistance Exercise Training on Musculoskeletal Health in Frail Older Men and Women (EXVITD) | This study aims to determine whether vitamin D3 supplementation is any more effective in improving musculoskeletal function when combined with exercise training compared with exercise training alone.,"[(22, 31, 'DRUG', 'Vitamin D'), (52, 80, 'PHYSICAL', 'Resistance Exercise Training'), (110, 115, 'CONDITION', 'Frail'), (184, 194, 'DRUG', 'vitamin D3'), (290, 307, 'PHYSICAL', 'exercise training'), (322, 345, 'CONTROL', 'exercise training alone')]"
"['An', 'Open', '-', 'Label', ',', 'Parallel', '-', 'Group', ',', 'Repeat', '-', 'Dose', 'Study', 'to', 'Investigate', 'the', 'Effects', 'of', 'End', 'Stage', 'Renal', 'Disease', 'and', 'Haemodialysis', 'on', 'the', 'Pharmacokinetics', 'of', 'Ropinirole', '(', 'Study', 'RRL103628', ')', '|', 'This', 'study', 'will', 'investigate', 'the', 'effects', 'of', 'severe', 'renal', 'impairment', 'and', 'hemodialysis', 'on', 'the', 'characteristics', 'of', 'the', 'drug', ',', 'ropinirole', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00422994,NCT00422994,"An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) | This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.","[(79, 102, 'CONDITION', 'End Stage Renal Disease'), (107, 120, 'CONDITION', 'Haemodialysis'), (148, 158, 'DRUG', 'Ropinirole'), (222, 245, 'CONDITION', 'severe renal impairment'), (250, 262, 'CONDITION', 'hemodialysis'), (299, 309, 'DRUG', 'ropinirole')]"
"['The', 'Impact', 'of', 'Respiratory', 'Muscle', 'Training', 'on', 'the', 'Therapy', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'respiratory', 'muscle', 'training', 'by', 'means', 'of', 'normocapnic', 'hyperpnea', 'leads', 'to', 'clinical', 'and', 'polysomnographical', 'improvements', 'in', 'patients', 'with', 'mild', 'to', 'intermediate', 'sleep', 'apnea', 'syndrome', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00936286,NCT00936286,The Impact of Respiratory Muscle Training on the Therapy of Obstructive Sleep Apnea Syndrome (OSAS) Patients | The purpose of this study is to determine whether respiratory muscle training by means of normocapnic hyperpnea leads to clinical and polysomnographical improvements in patients with mild to intermediate sleep apnea syndrome.,"[(14, 41, 'PHYSICAL', 'Respiratory Muscle Training'), (60, 92, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (94, 98, 'CONDITION', 'OSAS'), (161, 188, 'PHYSICAL', 'respiratory muscle training'), (201, 222, 'PHYSICAL', 'normocapnic hyperpnea'), (294, 335, 'CONDITION', 'mild to intermediate sleep apnea syndrome')]"
"['Effect', 'of', 'Zydena', '(', 'Udenafil', ')', 'on', 'Cerebral', 'Blood', 'Flow', 'and', 'Peripheral', 'Blood', 'Viscosity', 'in', 'Normal', 'and', 'Subcortical', 'Vascular', 'Cognitive', 'Impairment', 'Subjects', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'Zydena', '(', 'Udenafil', ')', 'has', 'effect', 'on', 'cerebral', 'blood', 'flow', 'and', 'peripheral', 'blood', 'viscosity', 'in', 'normal', 'and', 'subcortical', 'vascular', 'cognitive', 'impairment', 'subjects', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O']",NCT01466543,NCT01466543,Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects | The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.,"[(10, 16, 'DRUG', 'Zydena'), (18, 26, 'DRUG', 'Udenafil'), (85, 137, 'CONDITION', 'Normal and Subcortical Vascular Cognitive Impairment'), (199, 205, 'DRUG', 'Zydena'), (207, 215, 'DRUG', 'Udenafil'), (285, 337, 'CONDITION', 'normal and subcortical vascular cognitive impairment')]"
"['Flexible', 'Representation', 'of', 'Speech', 'in', 'the', 'Supratemporal', 'Plane', '|', 'The', 'overarching', 'goal', 'of', 'this', 'exploratory', 'research', 'is', 'to', 'understand', 'the', 'dynamic', 'and', 'flexible', 'nature', 'of', 'speech', 'processing', 'in', 'the', 'human', 'supratemporal', 'plane', '.', 'The', 'temporal', 'lobe', 'has', 'long', 'been', 'established', 'as', 'a', 'region', 'of', 'interest', 'in', 'the', 'speech', 'perception', 'and', 'processing', 'literature', 'because', 'it', 'contains', 'the', 'auditory', 'cortex', '.', 'More', 'recently', ',', 'research', 'has', 'localized', 'the', 'supratemporal', 'plane', 'as', 'an', 'area', 'that', 'exhibits', 'response', 'specificity', 'to', 'acoustic', 'properties', 'of', 'complex', 'auditory', 'signals', 'like', 'speech', '.', 'The', 'supratemporal', 'plane', ',', 'comprised', 'of', 'Heschl', ""'s"", 'gyrus', ',', 'the', 'planum', 'polare', ',', 'and', 'the', 'planum', 'temporale', ',', 'is', 'capable', 'of', 'the', 'rapid', 'spectrotemporal', 'analysis', 'required', 'to', 'map', 'acoustic', 'information', 'to', 'linguistic', 'representation', '.', 'Neural', 'activity', 'in', 'this', 'area', ',', 'however', ',', 'is', 'rarely', 'studied', 'directly', 'because', 'it', 'is', 'difficult', 'to', 'access', 'with', 'non', '-', 'invasive', 'measures', 'like', 'scalp', 'electroencephalography', '(', 'EEG', ')', '.', 'Capitalizing', 'on', 'the', 'unique', 'opportunity', 'to', 'access', 'these', 'areas', 'via', 'routine', 'clinical', 'stereoelectroencephalography', '(', 'sEEG', ')', 'in', 'a', 'patient', 'population', ',', 'this', 'study', 'seeks', 'to', 'understand', 'how', 'cortical', 'responses', 'reflect', 'the', 'diagnosticity', 'of', 'two', 'acoustic', '-', 'phonetic', 'dimensions', 'of', 'interest', 'and', 'how', 'responses', 'rapidly', 'and', 'flexibly', 'adapt', 'to', 'changes', 'in', 'listening', 'demands', '.', 'Examining', 'how', 'neural', 'response', 'to', 'voice', 'onset', 'time', '(', 'VOT', ')', 'and', 'fundamental', 'frequency', '(', 'F0', ')', 'modulates', 'as', 'a', 'function', 'of', 'perceptual', 'weight', 'carried', 'in', 'signaling', 'phoneme', 'categories', ',', 'and', 'identifying', 'how', 'changes', 'in', 'listening', 'context', 'shift', 'perceptual', 'weight', ',', 'will', 'provide', 'invaluable', 'data', 'that', 'indicates', 'how', 'speech', 'processing', 'flexibly', 'adapts', 'to', 'short', '-', 'term', 'acoustic', 'patterns', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05209386,NCT05209386,"Flexible Representation of Speech in the Supratemporal Plane | The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.",[]
"['An', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Two', '-', 'Period', 'Crossover', 'Study', 'to', 'Demonstrate', 'the', 'Bioequivalence', 'of', 'a', 'Tablet', 'Formulation', 'of', 'Rosiglitazone', 'XR', '(', 'BRL-049653', ')', '8', 'mg', 'Manufactured', 'at', 'Two', 'Different', 'Sites', 'in', 'Healthy', 'Volunteers', 'in', 'Fasting', 'Conditions', '|', 'The', 'present', 'pharmacokinetic', 'study', 'is', 'designed', 'to', 'compare', 'bioavailability', 'and', 'assess', 'bioequivalence', 'of', 'two', 'Rosiglitazone', 'XR', 'formulations', 'produced', 'at', 'two', 'different', 'sites', '.', 'Both', 'formulations', 'will', 'be', 'tested', 'in', 'fasting', 'healthy', 'volunteers']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00468897,NCT00468897,"An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions | The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers","[(115, 128, 'DRUG', 'Rosiglitazone'), (133, 143, 'DRUG', 'BRL-049653'), (337, 350, 'DRUG', 'Rosiglitazone')]"
"['Feasibility', 'Randomised', 'Controlled', 'Trial', '(', 'RCT', ')', 'of', 'Advanced', 'Cognitive', 'Stimulation', 'Therapy', '(', 'ACST', ')', 'for', 'People', 'With', 'Moderate', 'to', 'Severe', 'Dementia', '|', 'This', 'study', 'is', 'a', 'feasibility', 'randomised', 'controlled', 'trial', '(', 'RCT', ')', 'for', 'an', 'evidence', '-', 'based', 'intervention', 'for', 'people', 'with', 'moderate', 'to', 'severe', 'dementia', '.', 'The', 'psychosocial', 'intervention', 'is', 'adapted', 'from', 'Cognitive', 'Stimulation', 'Therapy', '(', 'CST', ')', 'and', 'developed', 'within', 'the', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'framework', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04550975,NCT04550975,Feasibility Randomised Controlled Trial (RCT) of Advanced Cognitive Stimulation Therapy (ACST) for People With Moderate to Severe Dementia | This study is a feasibility randomised controlled trial (RCT) for an evidence-based intervention for people with moderate to severe dementia. The psychosocial intervention is adapted from Cognitive Stimulation Therapy (CST) and developed within the Medical Research Council (MRC) framework.,"[(49, 87, 'BEHAVIOURAL', 'Advanced Cognitive Stimulation Therapy'), (89, 93, 'BEHAVIOURAL', 'ACST'), (111, 138, 'CONDITION', 'Moderate to Severe Dementia'), (254, 281, 'CONDITION', 'moderate to severe dementia'), (329, 358, 'BEHAVIOURAL', 'Cognitive Stimulation Therapy'), (360, 363, 'BEHAVIOURAL', 'CST')]"
"['Study', 'of', 'Dexmedetomidine', 'as', 'an', 'Effective', 'Sedative', 'to', 'Treat', 'Acute', 'ICU', 'Delirium', '|', 'The', 'purpose', 'of', 'the', 'research', 'is', 'to', 'see', 'if', 'dexmedetomidine', '(', 'a', 'drug', 'that', 'has', 'a', 'calming', 'effect', '-', 'a', 'sedative', ')', 'is', 'effective', 'for', 'the', 'treatment', 'of', 'acute', 'delirium']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT00351299,NCT00351299,Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium | The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium,"[(9, 24, 'DRUG', 'Dexmedetomidine'), (59, 77, 'CONDITION', 'Acute ICU Delirium'), (121, 136, 'DRUG', 'dexmedetomidine'), (219, 233, 'CONDITION', 'acute delirium')]"
"['Early', 'and', 'Late', 'Postoperative', 'Analgesia', 'and', 'Recovery', 'Effects', 'of', 'Programmed', 'Intermittent', 'Bolus', 'Infusion', 'of', 'Thoracic', 'Paravertebral', 'Block', 'for', 'Hepatectomy', ':', 'A', 'Prospective', ',', 'Randomized', ',', 'Double', '-', 'blinded', ',', 'Controlled', 'Study', '|', 'Hepatectomy', 'induces', 'moderate', 'to', 'severe', 'postoperative', 'pain', '.', 'Patient', '-', 'controlled', 'intravenous', 'analgesia', 'has', 'been', 'used', 'in', 'many', 'medical', 'centers', 'for', 'post', '-', 'hepatectomy', 'analgesia', ',', 'but', 'the', 'effects', 'are', 'limited', 'and', 'often', 'cause', 'undesirable', 'adverse', 'effects', '.', '\n\n', 'Regional', 'Block', 'has', 'been', 'used', 'for', 'postoperative', 'analgesia', 'in', 'many', 'surgeries', '.', 'Some', 'studies', 'suggest', 'that', 'regional', 'analgesia', 'has', 'an', 'opioid', '-', 'sparing', 'effect', 'and', 'can', 'reduce', 'the', 'incidence', 'of', 'chronic', 'pain', '.', 'Also', ',', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'is', 'better', 'than', 'continuous', 'infusion', ',', 'with', 'less', 'analgesic', 'consumption', 'and', 'fewer', 'adverse', 'effects', '.', '\n\n', 'Studies', 'on', 'the', 'early', 'and', 'late', 'postoperative', 'analgesia', 'and', 'recovery', 'effects', 'of', 'paravertebral', 'block', 'for', 'open', 'hepatectomy', 'are', 'scarce', '.', 'Therefore', ',', 'the', 'investigators', 'aim', 'to', 'conduct', 'a', 'prospective', ',', 'randomized', ',', 'subject', 'and', 'assessor', '-', 'blinded', ',', 'parallel', '-', 'group', ',', 'placebo', '-', 'controlled', 'study', 'to', 'test', 'the', 'hypothesis', 'that', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'of', 'right', 'thoracic', 'paravertebral', 'block', 'reduces', 'postoperative', 'intravenous', 'analgesic', 'use', 'and', 'pain', 'scores', 'and', 'improved', 'patients', ""'"", 'satisfaction', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04304274,NCT04304274,"Early and Late Postoperative Analgesia and Recovery Effects of Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block for Hepatectomy: A Prospective, Randomized, Double-blinded, Controlled Study | Hepatectomy induces moderate to severe postoperative pain. Patient-controlled intravenous analgesia has been used in many medical centers for post-hepatectomy analgesia, but the effects are limited and often cause undesirable adverse effects.

Regional Block has been used for postoperative analgesia in many surgeries. Some studies suggest that regional analgesia has an opioid-sparing effect and can reduce the incidence of chronic pain. Also, the programmed intermittent bolus infusion is better than continuous infusion, with less analgesic consumption and fewer adverse effects.

Studies on the early and late postoperative analgesia and recovery effects of paravertebral block for open hepatectomy are scarce. Therefore, the investigators aim to conduct a prospective, randomized, subject and assessor-blinded, parallel-group, placebo-controlled study to test the hypothesis that the programmed intermittent bolus infusion of right thoracic paravertebral block reduces postoperative intravenous analgesic use and pain scores and improved patients' satisfaction.","[(63, 133, 'OTHER', 'Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block'), (138, 149, 'CONDITION', 'Hepatectomy'), (213, 224, 'CONDITION', 'Hepatectomy'), (266, 270, 'CONDITION', 'pain'), (457, 471, 'OTHER', 'Regional Block'), (639, 651, 'CONDITION', 'chronic pain'), (663, 701, 'OTHER', 'programmed intermittent bolus infusion'), (876, 895, 'OTHER', 'paravertebral block'), (905, 916, 'CONDITION', 'hepatectomy'), (1046, 1053, 'CONTROL', 'placebo'), (1103, 1179, 'OTHER', 'programmed intermittent bolus infusion of right thoracic paravertebral block'), (1232, 1236, 'CONDITION', 'pain')]"
"['Eccentric', 'Motor', 'Training', 'With', 'Neuromodulation', 'and', 'Biomarkers', 'for', 'Rehabilitation', 'Readiness', 'in', 'Subacute', 'SCI', '|', 'The', 'investigators', 'are', 'studying', 'a', 'new', 'rehabilitation', 'treatment', 'for', 'individuals', 'trying', 'to', 'recover', 'walking', 'after', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'investigators', 'will', 'test', 'conditions', 'in', 'the', 'blood', 'and', 'spinal', 'fluid', 'to', 'determine', 'the', 'best', 'time', 'to', 'start', 'this', 'new', 'training', 'program', '.', 'This', 'will', 'include', 'checking', 'for', 'certain', 'features', 'called', 'biomarkers', 'by', 'testing', 'participants', ""'"", 'spinal', 'fluid', 'and', 'blood', 'and', 'compare', 'these', 'features', 'to', 'individuals', 'without', 'SCI', '.', 'These', 'features', 'will', 'help', 'investigators', 'determine', 'when', 'to', 'start', 'the', 'new', 'training', 'program', ',', 'either', 'right', 'away', 'or', 'waiting', 'for', '3', 'months', '.', 'The', 'new', 'training', 'program', 'uses', 'walking', 'downhill', 'on', 'a', 'slight', 'slope', 'on', 'a', 'treadmill', 'while', 'muscles', 'that', 'are', 'not', 'working', 'normally', 'are', 'stimulated', 'to', 'contract', 'using', 'low', 'levels', 'of', 'electricity', '.', 'Adding', 'this', 'stimulation', 'will', 'allow', 'people', 'to', 'practice', 'walking', 'and', 'other', 'skills', 'even', 'though', 'full', 'muscle', 'control', 'has', 'not', 'recovered', '.', 'This', 'new', 'program', 'will', 'be', 'in', 'addition', 'to', 'any', 'other', 'rehabilitation', 'therapy', 'and', 'will', 'not', 'replace', 'standard', 'rehabilitation', '.', 'The', 'hope', 'is', 'to', 'see', 'if', 'downhill', 'training', 'with', 'muscle', 'stimulation', ',', 'when', 'delivered', 'at', 'the', 'most', 'ideal', 'time', ',', 'will', 'improve', 'trunk', 'and', 'leg', 'movement', ',', 'walking', ',', 'and', 'overall', 'function', '.', 'This', 'recovery', 'of', 'movement', 'and', 'function', 'will', 'be', 'compared', 'to', 'people', 'with', 'SCI', 'receiving', 'standard', 'rehabilitation', 'alone', '.', 'Certain', 'regions', 'of', 'the', 'brain', 'and', 'spinal', 'cord', 'will', 'also', 'be', 'studied', 'using', 'MRI', 'scans', 'to', 'determine', 'if', 'these', 'are', 'affected', 'by', 'the', 'training', 'and', 'compare', 'to', 'individuals', 'without', 'SCI', '.', 'The', 'total', 'length', 'of', 'the', 'study', 'for', 'SCI', 'participants', 'will', 'be', 'up', 'to', '16', 'weeks', 'if', 'in', 'the', 'standard', 'of', 'care', 'group', 'and', 'up', 'to', '33', 'weeks', 'if', 'in', 'the', 'trained', 'group', '.', 'Healthy', 'control', 'participants', 'will', 'be', 'involved', 'for', '1', '-', '2', 'visits', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05337982,NCT05337982,"Eccentric Motor Training With Neuromodulation and Biomarkers for Rehabilitation Readiness in Subacute SCI | The investigators are studying a new rehabilitation treatment for individuals trying to recover walking after spinal cord injury (SCI). The investigators will test conditions in the blood and spinal fluid to determine the best time to start this new training program. This will include checking for certain features called biomarkers by testing participants' spinal fluid and blood and compare these features to individuals without SCI. These features will help investigators determine when to start the new training program, either right away or waiting for 3 months. The new training program uses walking downhill on a slight slope on a treadmill while muscles that are not working normally are stimulated to contract using low levels of electricity. Adding this stimulation will allow people to practice walking and other skills even though full muscle control has not recovered. This new program will be in addition to any other rehabilitation therapy and will not replace standard rehabilitation. The hope is to see if downhill training with muscle stimulation, when delivered at the most ideal time, will improve trunk and leg movement, walking, and overall function. This recovery of movement and function will be compared to people with SCI receiving standard rehabilitation alone. Certain regions of the brain and spinal cord will also be studied using MRI scans to determine if these are affected by the training and compare to individuals without SCI. The total length of the study for SCI participants will be up to 16 weeks if in the standard of care group and up to 33 weeks if in the trained group. Healthy control participants will be involved for 1-2 visits.","[(0, 24, 'PHYSICAL', 'Eccentric Motor Training'), (30, 45, 'OTHER', 'Neuromodulation'), (93, 105, 'CONDITION', 'Subacute SCI'), (145, 169, 'PHYSICAL', 'rehabilitation treatment'), (218, 236, 'CONDITION', 'spinal cord injury'), (238, 241, 'CONDITION', 'SCI'), (358, 374, 'PHYSICAL', 'training program'), (540, 543, 'CONDITION', 'SCI'), (616, 632, 'PHYSICAL', 'training program'), (685, 701, 'PHYSICAL', 'training program'), (707, 723, 'PHYSICAL', 'walking downhill'), (1041, 1063, 'PHYSICAL', 'rehabilitation therapy'), (1085, 1108, 'CONTROL', 'standard rehabilitation'), (1132, 1173, 'PHYSICAL', 'downhill training with muscle stimulation'), (1353, 1356, 'CONDITION', 'SCI'), (1367, 1390, 'CONTROL', 'standard rehabilitation'), (1566, 1569, 'CONDITION', 'SCI'), (1605, 1608, 'CONDITION', 'SCI')]"
"['Effect', 'of', 'Silkworms', '(', 'Bombyx', 'Mori', 'L.', ')', 'Pupae', 'Extracts', 'on', 'Musculoskeletal', 'Biomarkers', 'in', 'Adults', 'With', 'With', 'Relatively', 'Low', 'Muscle', 'Mass', ':', 'a', 'Randomized', ',', 'Double', '-', 'blinded', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'investigators', 'conduct', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'to', 'investigate', 'the', 'effects', 'of', 'silkworms', '(', 'Bombyx', 'mori', 'L.', ')', 'pupae', 'extracts', 'on', 'muscle', 'strength', ',', 'muscle', 'mass', ',', 'and', 'muscle', 'function', 'in', 'adults', 'with', 'relative', 'sarcopenia', 'for', '12', 'weeks', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT04994054,NCT04994054,"Effect of Silkworms (Bombyx Mori L.) Pupae Extracts on Musculoskeletal Biomarkers in Adults With With Relatively Low Muscle Mass: a Randomized, Double-blinded, Placebo-controlled Trial | The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of silkworms (Bombyx mori L.) pupae extracts on muscle strength, muscle mass, and muscle function in adults with relative sarcopenia for 12 weeks.","[(10, 51, 'OTHER', 'Silkworms (Bombyx Mori L.) Pupae Extracts'), (113, 128, 'CONDITION', 'Low Muscle Mass'), (160, 167, 'CONTROL', 'Placebo'), (241, 248, 'CONTROL', 'placebo'), (296, 337, 'OTHER', 'silkworms (Bombyx mori L.) pupae extracts'), (406, 425, 'CONDITION', 'relative sarcopenia')]"
"['Acute', 'Effect', 'of', 'Topical', 'Menthol', 'on', 'Pain', 'Symptoms', 'in', 'Slaughterhouse', 'Workers', 'With', 'Symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'Randomized', 'Controlled', 'Trial', '|', 'Topical', 'menthol', 'gels', 'are', 'classified', ""'"", 'topical', 'analgesics', ""'"", 'and', 'are', 'used', 'to', 'relieve', 'pain', 'of', 'the', 'musculoskeletal', 'system', '.', 'However', ',', 'double', '-', 'blind', 'randomized', 'controlled', 'trials', 'are', 'lacking', '.', 'Here', 'the', 'investigators', 'examine', '-', 'in', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'cross', '-', 'over', 'trial', '-', 'the', 'acute', 'effect', 'of', 'topical', 'menthol', '(', 'Biofreeze', ')', 'and', 'placebo', '(', 'gel', 'with', 'a', 'menthol', 'scent', ')', 'on', 'pain', 'symptoms', 'in', 'slaughterhouse', 'workers', 'with', 'symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01716767,NCT01716767,"Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial | Topical menthol gels are classified 'topical analgesics' and are used to relieve pain of the musculoskeletal system. However, double-blind randomized controlled trials are lacking. Here the investigators examine - in a double-blind randomized controlled cross-over trial - the acute effect of topical menthol (Biofreeze) and placebo (gel with a menthol scent) on pain symptoms in slaughterhouse workers with symptoms of Carpal Tunnel Syndrome.","[(24, 31, 'DRUG', 'Menthol'), (35, 39, 'CONDITION', 'Pain'), (92, 114, 'CONDITION', 'Carpal Tunnel Syndrome'), (154, 161, 'DRUG', 'menthol'), (227, 231, 'CONDITION', 'pain'), (447, 454, 'DRUG', 'menthol'), (456, 465, 'DRUG', 'Biofreeze'), (480, 504, 'CONTROL', 'gel with a menthol scent'), (509, 513, 'CONDITION', 'pain'), (566, 588, 'CONDITION', 'Carpal Tunnel Syndrome')]"
"['Remediation', 'of', 'Emotional', 'Deficits', 'in', 'Multiple', 'Sclerosis', 'and', 'Traumatic', 'Brain', 'Injury', ':', 'A', 'Piolt', 'Study', '|', 'This', 'study', 'will', 'examine', 'the', 'efficacy', 'of', 'a', 'clinical', 'intervention', 'for', 'improving', 'emotional', 'processing', 'in', 'individuals', 'with', 'MS', 'and', 'TBI.(1)The', 'main', 'outcome', 'measure', 'will', 'be', 'changes', 'in', 'emotional', 'processing', 'measures', 'from', 'pre', 'to', 'post', 'treatment', '.', '\n\n', '(', '2)This', 'study', 'will', 'also', 'assess', 'the', 'impact', 'of', 'the', 'emotional', 'processing', 'intervention', 'on', 'changes', 'in', 'pre', 'and', 'post', 'treatment', 'depression', 'and', 'anxiety', ',', 'as', 'well', 'as', 'fatigue.(3', ')', 'This', 'study', 'will', 'additionally', 'measure', 'the', 'impact', 'of', 'the', 'emotional', 'processing', 'intervention', 'on', 'cognitive', 'functioning', ',', 'specifically', 'processing', 'speed', ',', 'attention', 'and', 'executive', 'abilities', '.', 'This', 'will', 'be', 'accomplished', 'through', 'the', 'completion', 'of', 'a', 'neuropsychological', 'battery', 'prior', 'to', 'and', 'following', 'the', 'completion', 'of', 'treatment.(4)Finally', ',', 'the', 'investigators', 'will', 'measure', 'the', 'impact', 'of', 'the', 'intervention', 'on', 'quality', 'of', 'life', 'and', 'social', 'functioning', ',', 'utilizing', 'a', 'pre', 'and', 'post', 'treatment', 'assessment', 'consisting', 'of', 'measures', 'of', 'self', '-', 'efficacy', ',', 'quality', 'of', 'life', ',', 'functional', 'abilities', ',', 'and', 'awareness', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04408274,NCT04408274,"Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury: A Piolt Study | This study will examine the efficacy of a clinical intervention for improving emotional processing in individuals with MS and TBI.(1)The main outcome measure will be changes in emotional processing measures from pre to post treatment.

(2)This study will also assess the impact of the emotional processing intervention on changes in pre and post treatment depression and anxiety, as well as fatigue.(3) This study will additionally measure the impact of the emotional processing intervention on cognitive functioning, specifically processing speed, attention and executive abilities. This will be accomplished through the completion of a neuropsychological battery prior to and following the completion of treatment.(4)Finally, the investigators will measure the impact of the intervention on quality of life and social functioning, utilizing a pre and post treatment assessment consisting of measures of self-efficacy, quality of life, functional abilities, and awareness.","[(15, 33, 'CONDITION', 'Emotional Deficits'), (37, 55, 'CONDITION', 'Multiple Sclerosis'), (60, 82, 'CONDITION', 'Traumatic Brain Injury'), (151, 198, 'OTHER', 'intervention for improving emotional processing'), (219, 221, 'CONDITION', 'MS'), (385, 418, 'OTHER', 'emotional processing intervention'), (456, 466, 'CONDITION', 'depression'), (471, 478, 'CONDITION', 'anxiety'), (558, 591, 'OTHER', 'emotional processing intervention')]"
"['Risperidone', 'Long', '-', 'Acting', 'for', 'Alcohol', 'and', 'Schizophrenia', 'Treatment', '(', 'R', '-', 'LAST', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'oral', 'risperidone', '(', 'Risperdal', ')', 'to', 'risperidone', 'long', '-', 'acting', '(', 'Consta', ')', 'in', 'reducing', 'alcohol', 'use', 'in', 'persons', 'diagnosed', 'with', 'schizophrenia', 'or', 'schizoaffective', 'disorder', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT00130923,NCT00130923,Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) | The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.,"[(0, 11, 'DRUG', 'Risperidone'), (40, 53, 'CONDITION', 'Schizophrenia'), (136, 147, 'DRUG', 'risperidone'), (149, 158, 'DRUG', 'Risperdal'), (163, 174, 'DRUG', 'risperidone'), (188, 194, 'DRUG', 'Consta'), (208, 219, 'CONDITION', 'alcohol use'), (246, 259, 'CONDITION', 'schizophrenia'), (263, 287, 'CONDITION', 'schizoaffective disorder')]"
"['Effect', 'of', 'EPA', 'and', 'HMB', 'on', 'Diaphragm', 'and', 'Limb', 'Muscle', 'Strength', 'in', 'Mechanically', 'Ventilated', 'Patients', '|', 'The', 'investigators', 'will', 'determine', 'if', 'administration', 'of', 'HMB', '(', 'hydroxymethylbutyrate', ')', 'or', 'EPA', '(', 'eicosapentaenoic', 'acid', ')', 'will', 'increase', 'diaphragm', 'and', 'limb', 'muscle', 'strength', 'for', 'patients', 'on', 'breathing', 'machines', 'in', 'an', 'intensive', 'care', 'unit', '.', 'The', 'investigators', 'will', 'first', 'measure', 'the', 'strength', 'of', 'the', 'diaphragm', 'and', 'a', 'limb', 'muscle', '(', 'the', 'quadriceps)using', 'magnetic', 'stimulators', 'to', 'activate', 'these', 'muscles', '.', 'Muscle', 'size', 'will', 'be', 'measured', 'by', 'using', 'an', 'ultrasound', 'to', 'measure', 'diaphragm', 'thickness', 'and', 'quadriceps', 'thickness', '.', 'The', 'investigators', 'will', 'also', 'perform', 'a', 'vastus', 'lateralis', 'muscle', 'biopsy', '.', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'placebo', '(', 'saline', '30', 'ml', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ',', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'or', 'the', 'combination', 'of', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', 'and', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', '.', 'Drugs', 'will', 'be', 'given', 'for', '10', 'days', ';', 'at', 'the', 'end', 'of', 'this', 'time', '(', 'on', 'day', '11', ')', ',', 'strength', 'measurements', ',', 'ultrasound', 'muscle', 'size', 'measurements', ',', 'and', 'the', 'vastus', 'lateralis', 'biopsy', 'will', 'be', 'repeated', '.', 'On', 'day', '21', 'an', 'additional', 'followup', 'set', 'of', 'diaphragm', 'and', 'quadriceps', 'strength', 'and', 'size', 'measurements', 'will', 'be', 'made', '(', 'the', 'biopsy', 'will', 'not', 'be', 'repeated', 'for', 'this', 'last', 'set', 'of', 'measurements', ')', '.', 'Patients', 'will', 'be', 'followed', 'clinically', 'and', 'patient', 'outcomes', '(', 'mortality', ',', 'duration', 'of', 'mechanical', 'ventilation', 'after', 'study', 'entry', ')', 'will', 'be', 'recorded', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01270516,NCT01270516,"Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients | The investigators will determine if administration of HMB (hydroxymethylbutyrate) or EPA (eicosapentaenoic acid) will increase diaphragm and limb muscle strength for patients on breathing machines in an intensive care unit. The investigators will first measure the strength of the diaphragm and a limb muscle (the quadriceps)using magnetic stimulators to activate these muscles. Muscle size will be measured by using an ultrasound to measure diaphragm thickness and quadriceps thickness. The investigators will also perform a vastus lateralis muscle biopsy. Patients will then be randomized to receive either placebo (saline 30 ml every 12 hours via the GI tract, EPA (1000 mg given every 12 hours via the GI tract), HMB (1500 mg given every 12 hours via the GI tract), or the combination of EPA (1000 mg given every 12 hours via the GI tract) and HMB (1500 mg given every 12 hours via the GI tract). Drugs will be given for 10 days; at the end of this time (on day 11), strength measurements, ultrasound muscle size measurements, and the vastus lateralis biopsy will be repeated. On day 21 an additional followup set of diaphragm and quadriceps strength and size measurements will be made (the biopsy will not be repeated for this last set of measurements). Patients will be followed clinically and patient outcomes (mortality, duration of mechanical ventilation after study entry) will be recorded.","[(10, 13, 'DRUG', 'EPA'), (18, 21, 'DRUG', 'HMB'), (63, 86, 'CONDITION', 'Mechanically Ventilated'), (152, 155, 'DRUG', 'HMB'), (157, 178, 'DRUG', 'hydroxymethylbutyrate'), (183, 186, 'DRUG', 'EPA'), (188, 209, 'DRUG', 'eicosapentaenoic acid'), (276, 294, 'CONDITION', 'breathing machines'), (716, 722, 'DRUG', 'saline'), (762, 765, 'DRUG', 'EPA'), (815, 818, 'DRUG', 'HMB'), (890, 893, 'DRUG', 'EPA'), (946, 949, 'DRUG', 'HMB')]"
"['Pilot', 'Study', 'of', 'EEG', 'and', 'Cerebral', 'Blood', 'Flow', 'Biofeedback', 'Training', 'in', 'Remediating', 'Cognitive', 'and', 'Behavioral', 'Deficits', 'in', 'Adults', 'With', 'a', 'Dementing', 'Illness', '.', '|', 'This', 'study', 'measures', 'whether', 'the', 'symptoms', 'of', 'frontotemporal', 'dementia', '(', 'FTD', ')', 'can', 'be', 'successfully', 'treated', 'by', '(', 'a', ')', 'biofeedback', 'training', 'to', 'increase', 'brain', 'blood', 'flow', ',', '(', 'b', ')', 'biofeedback', 'to', 'increase', 'the', 'frequency', 'of', 'the', 'brain', ""'s"", 'dominant', 'brainwave', 'rhythm', ',', 'and', '(', 'c', ')', 'rhythmic', 'stimulation', 'to', 'increase', 'the', 'brain', ""'s"", 'dominant', 'brainwave', 'frequency', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01168466,NCT01168466,"Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness. | This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.","[(23, 63, 'OTHER', 'Cerebral Blood Flow Biofeedback Training'), (79, 112, 'CONDITION', 'Cognitive and Behavioral Deficits'), (130, 139, 'CONDITION', 'Dementing'), (195, 218, 'CONDITION', 'frontotemporal dementia'), (220, 223, 'CONDITION', 'FTD'), (260, 280, 'OTHER', 'biofeedback training'), (315, 326, 'OTHER', 'biofeedback'), (403, 423, 'OTHER', 'rhythmic stimulation')]"
"['Analysis', 'of', 'the', 'Electrical', 'Muscle', 'Activity', 'and', 'Resistance', 'to', 'Movement', 'After', 'Pplication', 'Neuromuscular', 'Electrical', 'Stimulation', '(', 'EENM', ')', 'in', 'Patients', 'With', 'Hemiparesis', 'Spastic', '.', '|', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'when', 'applied', 'in', 'the', 'agonist', 'and', 'antagonist', 'muscles', 'of', 'spastic', 'hemiparetic', 'patients', '.', '\n\n', 'The', 'specific', 'objectives', 'are', ':', '\n\n', 'Evaluate', 'the', 'resistance', 'movement', ',', 'strength', 'and', 'muscle', 'electrical', 'activity', 'before', 'and', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'spastic', 'muscle', '(', 'gastrocnemius', ')', '.', '\n', 'Evaluate', 'the', 'resistance', 'movement', ',', 'strength', 'and', 'muscle', 'electrical', 'activity', 'before', 'and', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'the', 'spastic', 'antagonist', 'muscle', '(', 'tibialis', 'anterior', ')', '.', '\n', 'Compare', 'the', 'risk', 'of', 'falls', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'both', 'muscles', 'studied', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O']",NCT01945151,NCT01945151,"Analysis of the Electrical Muscle Activity and Resistance to Movement After Pplication Neuromuscular Electrical Stimulation (EENM) in Patients With Hemiparesis Spastic. | To evaluate and compare the effects of Neuromuscular Electrical Stimulation when applied in the agonist and antagonist muscles of spastic hemiparetic patients.

The specific objectives are:

Evaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in spastic muscle (gastrocnemius).
Evaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in the spastic antagonist muscle (tibialis anterior).
Compare the risk of falls after application of Neuromuscular Electrical Stimulation in both muscles studied.","[(87, 123, 'OTHER', 'Neuromuscular Electrical Stimulation'), (125, 129, 'OTHER', 'EENM'), (148, 167, 'CONDITION', 'Hemiparesis Spastic'), (210, 246, 'OTHER', 'Neuromuscular Electrical Stimulation'), (301, 320, 'CONDITION', 'spastic hemiparetic'), (468, 504, 'OTHER', 'Neuromuscular Electrical Stimulation'), (508, 522, 'CONDITION', 'spastic muscle'), (646, 682, 'OTHER', 'Neuromuscular Electrical Stimulation'), (690, 715, 'CONDITION', 'spastic antagonist muscle'), (784, 820, 'OTHER', 'Neuromuscular Electrical Stimulation')]"
"['Constipation', 'is', 'a', 'common', 'disorder', 'and', 'current', 'treatments', 'are', 'unsatisfactory', '.', 'Biofeedback', 'may', 'help', 'patients', 'with', 'constipation', 'and', 'dyssynergic', 'defecation', ',', 'but', 'its', 'efficacy', 'is', 'unproven', 'and', 'whether', 'this', 'is', 'due', 'to', 'behavioral', 'modification', 'or', 'excessive', 'attention', 'is', 'unknown', '.', 'Methods', ':', 'In', 'a', 'prospective', 'randomized', 'trial', ',', 'the', 'investigators', 'investigated', 'the', 'efficacy', 'of', 'Biofeedback', '(', 'manometric-', 'assisted', 'anal', 'relaxation', ',', 'muscle', 'coordination', 'and', 'simulated', 'defecation', 'training', ')', ',', 'with', 'either', 'sham', 'feedback', 'therapy', '(', 'Sham', ')', 'or', 'standard', 'therapy', '(', 'diet', ',', 'exercise', ',', 'laxatives', ';', 'Standard', ')', 'in', '77', 'subjects', '(', '69', 'women', ')', 'with', 'dyssynergic', 'defecation', '.', 'Primary', 'outcome', 'measures', 'included', 'presence', 'of', 'dyssynergia', ',', 'balloon', 'expulsion', 'time', ',', 'number', 'of', 'complete', 'spontaneous', 'bowel', 'movements', '(', 'CSBM', ')', ',', 'and', 'global', 'bowel', 'satisfaction', '.', 'Data', 'analyzed', 'per', 'protocol', '.']","['B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00257842,NCT00257842,"Constipation is a common disorder and current treatments are unsatisfactory. Biofeedback may help patients with constipation and dyssynergic defecation, but its efficacy is unproven and whether this is due to behavioral modification or excessive attention is unknown. Methods: In a prospective randomized trial, the investigators investigated the efficacy of Biofeedback (manometric- assisted anal relaxation, muscle coordination and simulated defecation training), with either sham feedback therapy (Sham) or standard therapy (diet, exercise, laxatives; Standard) in 77 subjects (69 women) with dyssynergic defecation. Primary outcome measures included presence of dyssynergia, balloon expulsion time, number of complete spontaneous bowel movements (CSBM), and global bowel satisfaction. Data analyzed per protocol.","[(0, 12, 'CONDITION', 'Constipation'), (77, 88, 'PHYSICAL', 'Biofeedback'), (112, 124, 'CONDITION', 'constipation'), (129, 151, 'CONDITION', 'dyssynergic defecation'), (359, 370, 'PHYSICAL', 'Biofeedback'), (372, 463, 'PHYSICAL', 'manometric- assisted anal relaxation, muscle coordination and simulated defecation training'), (478, 499, 'CONTROL', 'sham feedback therapy'), (528, 532, 'CONTROL', 'diet'), (534, 542, 'CONTROL', 'exercise'), (544, 553, 'CONTROL', 'laxatives'), (596, 618, 'CONDITION', 'dyssynergic defecation'), (666, 677, 'CONDITION', 'dyssynergia')]"
"['Randomized', 'Controlled', 'Trial', 'of', 'Valganciclovir', 'for', 'Cytomegalovirus', 'Infected', 'Hearing', 'Impaired', 'Infants', ':', 'ValEAR', 'Trial', '|', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'clinical', 'benefit', 'and', 'safety', 'of', 'antiviral', 'therapy', 'for', 'asymptomatic', 'congenital', 'cytomegalovirus', '(', 'cCMV', ')', 'infected', 'hearing', '-', 'impaired', 'infants', '.', 'We', 'will', 'conduct', 'a', 'multi', '-', 'center', 'double', '-', 'blind', 'randomized', 'placebo', '-', 'controlled', 'trial', 'to', 'determine', 'whether', 'hearing', '-', 'impaired', 'infants', 'with', 'asymptomatic', 'cCMV', 'have', 'better', 'hearing', 'and', 'language', 'outcomes', 'if', 'they', 'receive', 'valganciclovir', 'antiviral', 'treatment', '.', 'We', 'will', 'also', 'determine', 'the', 'safety', 'of', 'antiviral', 'valganciclovir', 'therapy', 'for', 'asymptomatic', 'cCMV', '-', 'infected', 'hearing', 'impaired', 'infants', '.', 'This', 'study', 'will', 'be', 'unique', 'in', 'that', 'the', 'cohort', 'enrolled', 'will', 'only', 'include', 'hearing', '-', 'impaired', 'infants', 'with', 'asymptomatic', 'cCMV', '.', '\n\n', 'Primary', 'Objective', ':', 'To', 'determine', 'if', 'treatment', 'of', 'cCMV', '-', 'infected', 'hearing', 'impaired', 'infants', 'with', 'isolated', 'hearing', 'loss', 'with', 'the', 'antiviral', 'drug', 'valganciclovir', 'reduces', 'the', 'mean', 'slope', 'of', 'total', 'hearing', 'thresholds', 'over', 'the', '20', 'months', 'after', 'randomization', 'compared', 'to', 'untreated', 'cCMV', '-', 'infected', 'infants', 'with', 'isolated', 'hearing', 'loss', '.', '\n\n', 'Main', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'determine', 'if', 'valganciclovir', 'treatment', 'improves', 'the', 'following', 'outcomes', 'when', 'compared', 'to', 'the', 'control', 'group', ':', '\n\n', 'The', 'slope', 'of', 'best', 'ear', 'hearing', 'thresholds', 'over', 'the', '20', 'months', 'after', 'randomization', '.', '\n', 'The', 'MacArthur', '-', 'Bates', 'Communicative', 'Development', 'Inventory', '(', 'CDI', ')', 'percentile', 'score', 'for', 'words', 'produced', 'at', '20', 'months', 'of', 'age', '.', '\n', 'To', 'evaluate', 'safety', 'measures', 'based', 'on', 'all', 'grade', '3', 'or', 'greater', 'new', 'adverse', 'events', 'designated', 'by', 'the', 'NIAID', 'Division', 'of', 'AIDS', '(', 'DAIDS', ')', 'toxicity', 'tables', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03107871,NCT03107871,"Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial | The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants. We will conduct a multi-center double-blind randomized placebo-controlled trial to determine whether hearing-impaired infants with asymptomatic cCMV have better hearing and language outcomes if they receive valganciclovir antiviral treatment. We will also determine the safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired infants. This study will be unique in that the cohort enrolled will only include hearing-impaired infants with asymptomatic cCMV.

Primary Objective: To determine if treatment of cCMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir reduces the mean slope of total hearing thresholds over the 20 months after randomization compared to untreated cCMV-infected infants with isolated hearing loss.

Main Secondary Objectives:

To determine if valganciclovir treatment improves the following outcomes when compared to the control group:

The slope of best ear hearing thresholds over the 20 months after randomization.
The MacArthur-Bates Communicative Development Inventory (CDI) percentile score for words produced at 20 months of age.
To evaluate safety measures based on all grade 3 or greater new adverse events designated by the NIAID Division of AIDS (DAIDS) toxicity tables.","[(31, 45, 'DRUG', 'Valganciclovir'), (50, 65, 'CONDITION', 'Cytomegalovirus'), (75, 91, 'CONDITION', 'Hearing Impaired'), (220, 259, 'CONDITION', 'asymptomatic congenital cytomegalovirus'), (261, 265, 'CONDITION', 'cCMV'), (276, 292, 'CONDITION', 'hearing-impaired'), (357, 364, 'CONTROL', 'placebo'), (403, 419, 'CONDITION', 'hearing-impaired'), (433, 450, 'CONDITION', 'asymptomatic cCMV'), (509, 523, 'DRUG', 'valganciclovir'), (592, 606, 'DRUG', 'valganciclovir'), (619, 636, 'CONDITION', 'asymptomatic cCMV'), (646, 662, 'CONDITION', 'hearing impaired'), (744, 760, 'CONDITION', 'hearing-impaired'), (774, 791, 'CONDITION', 'asymptomatic cCMV'), (842, 855, 'CONDITION', 'cCMV-infected'), (856, 872, 'CONDITION', 'hearing impaired'), (932, 946, 'DRUG', 'valganciclovir'), (1059, 1072, 'CONDITION', 'cCMV-infected'), (1154, 1168, 'DRUG', 'valganciclovir')]"
"['A', 'Multi', '-', 'center', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', 'Design', ',', 'Prospective', ',', 'Phase', 'II', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Donepezil', 'and', 'Combined', 'With', 'GV1001', 'in', 'Alzheimer', 'Patients', '|', 'This', 'clinical', 'study', 'is', 'designed', 'as', 'a', 'multi', '-', 'center', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'parallel', 'design', ',', 'prospective', ',', 'phase', 'II', 'clinical', 'trial', '.', '\n\n', 'An', 'eligible', 'subject', 'who', 'meets', 'inclusion', 'and', 'exclusion', 'criteria', 'is', 'randomly', 'assigned', 'to', 'three', 'groups', ':', 'study', 'group', '1', '(', 'GV1001', '0.56', 'mg', ')', ',', 'study', 'group', '2', '(', 'GV1001', '1.12', 'mg', ')', 'or', 'placebo', 'group', '.', 'A', 'randomized', 'subject', 'is', 'administered', 'either', 'GV1001', 'or', 'placebo', 'in', 'a', 'total', 'of', '14', 'times', 'and', 'will', 'be', 'evaluated', 'for', 'the', 'efficacy', 'and', 'safety', 'at', 'week', 'of', '24', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03184467,NCT03184467,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients | This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.

An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.","[(42, 49, 'CONTROL', 'Placebo'), (155, 164, 'DRUG', 'Donepezil'), (183, 189, 'DRUG', 'GV1001'), (193, 202, 'CONDITION', 'Alzheimer'), (291, 298, 'CONTROL', 'placebo'), (483, 489, 'DRUG', 'GV1001'), (515, 521, 'DRUG', 'GV1001'), (534, 541, 'CONTROL', 'placebo'), (593, 599, 'DRUG', 'GV1001'), (603, 610, 'CONTROL', 'placebo')]"
"['MIND', ':', 'An', 'RCT', 'of', 'Care', 'Coordination', 'for', 'Community', '-', 'living', 'Person', 'With', 'Dementia', '|', 'This', 'is', 'a', '24', '-', 'month', ',', 'prospective', ',', 'single-', 'blind', ',', 'randomized', 'controlled', 'trial', 'evaluating', 'the', 'MIND', 'at', 'Home', '-', 'streamlined', 'dementia', 'care', 'coordination', 'intervention', '(', 'called', 'MIND', '-', 'S', ')', 'in', 'a', 'cohort', 'of', '300', 'community', '-', 'living', 'persons', 'with', 'dementia', 'and', 'their', 'family', 'caregivers', 'in', 'the', 'Greater', 'Baltimore', 'area', '.', 'Participants', 'receiving', 'MIND', '-', 'S', 'will', 'get', '18', 'months', 'of', 'care', 'coordination', 'by', 'an', 'interdisciplinary', 'team', 'comprised', 'of', 'trained', 'memory', 'care', 'coordinators', '(', 'non', '-', 'clinical', ')', ',', 'a', 'psychiatric', 'nurse', ',', 'and', 'geriatric', 'psychiatrist', '.', 'The', 'intervention', 'involves', '4', 'key', 'components', ':', 'identification', 'of', 'needs', 'and', 'individualized', 'care', 'planning', '(', 'persons', 'with', 'dementia', '(', 'PWD', ')', 'and', 'care', 'giver', '(', 'CG', ')', 'needs', ')', ';', 'dementia', 'education', 'and', 'skill', 'building', ';', 'coordination', ',', 'referral', 'and', 'linkage', 'of', 'services', ';', 'and', 'care', 'monitoring', '.', 'Participants', 'in', 'the', 'comparison', 'group', 'will', 'receive', 'an', 'initial', 'in', '-', 'home', 'needs', 'assessment', 'and', 'will', 'be', 'given', 'the', 'written', 'results', 'along', 'with', 'any', 'recommendations', 'for', 'care', 'that', 'are', 'indicated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02396082,NCT02396082,"MIND: An RCT of Care Coordination for Community-living Person With Dementia | This is a 24-month, prospective, single- blind, randomized controlled trial evaluating the MIND at Home-streamlined dementia care coordination intervention (called MIND-S) in a cohort of 300 community-living persons with dementia and their family caregivers in the Greater Baltimore area. Participants receiving MIND-S will get 18 months of care coordination by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (persons with dementia (PWD) and care giver (CG) needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.Participants in the comparison group will receive an initial in-home needs assessment and will be given the written results along with any recommendations for care that are indicated.","[(67, 75, 'CONDITION', 'Dementia'), (169, 233, 'BEHAVIOURAL', 'MIND at Home-streamlined dementia care coordination intervention'), (242, 248, 'BEHAVIOURAL', 'MIND-S'), (299, 307, 'CONDITION', 'dementia'), (390, 396, 'BEHAVIOURAL', 'MIND-S'), (419, 436, 'BEHAVIOURAL', 'care coordination'), (621, 677, 'OTHER', 'identification of needs and individualized care planning'), (692, 700, 'CONDITION', 'dementia'), (735, 772, 'OTHER', 'dementia education and skill building'), (774, 820, 'OTHER', 'coordination, referral and linkage of services'), (895, 927, 'CONTROL', 'initial in-home needs assessment')]"
"['Telemedicine', 'to', 'Enhance', 'Adherence', 'to', 'Continuous', 'Positive', 'Airway', 'Pressure', 'Therapy', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', ';', 'a', 'Randomized', 'Placebo', '-', 'controlled', 'Prospective', 'Study', '|', 'We', 'hypothesize', 'that', 'the', 'use', 'of', 'telemedicine', 'combined', 'with', 'support', 'interventions', 'by', 'short', 'messages', ',', 'telephone', 'calls', 'and', 'ambulatory', 'visits', 'to', 'control', 'CPAP', 'treatment', 'during', 'the', 'first', 'month', 'improves', 'adherence', 'and', 'reduces', 'unresolved', 'side', 'effects', 'of', 'therapy', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'an', 'OSAS', 'treatment', 'program', 'is', 'to', 'successfully', 'implement', 'indicated', 'CPAP', 'in', 'the', 'highest', 'possible', 'proportion', 'of', 'patients', 'in', 'order', 'to', 'lower', 'the', 'proportion', 'of', 'untreated', 'OSAS', 'in', 'the', 'population', '.', 'On', 'an', 'individual', 'basis', ',', 'it', 'has', 'been', 'shown', 'that', 'a', 'longer', 'duration', 'of', 'CPAP', 'use', 'is', 'associated', 'with', 'better', 'outcomes', 'in', 'terms', 'of', 'daytime', 'functioning', 'and', 'in', 'the', 'control', 'of', 'metabolic', 'and', 'blood', 'pressure', 'effects', 'of', 'CPAP', '.', 'For', 'our', 'study', ',', 'we', 'have', 'therefore', 'decided', 'to', 'use', '2', 'co', '-', 'primary', 'endpoints', ',', 'taking', 'into', 'account', 'both', 'aspects', 'of', 'adherence', 'mentioned', '.', 'Cardiovascular', 'complications', 'are', 'a', 'major', 'concern', 'in', 'OSAS', 'patients', '.', 'Effective', 'CPAP', 'treatment', 'has', 'been', 'shown', 'to', 'reduce', 'surrogate', 'measures', 'of', 'cardiovascular', 'risk', '.', 'We', 'hypothesize', 'that', 'intensified', 'efforts', 'for', 'CPAP', 'adherence', 'with', 'telemedicine', 'has', 'a', 'positive', 'impact', 'on', 'a', 'number', 'of', 'surrogate', 'measures', 'of', 'the', 'cardiovascular', 'risk', 'at', '1', 'and', '6', 'months', 'of', 'treatment', '.']","['B-BEH', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01715194,NCT01715194,"Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study | We hypothesize that the use of telemedicine combined with support interventions by short messages, telephone calls and ambulatory visits to control CPAP treatment during the first month improves adherence and reduces unresolved side effects of therapy.

The primary objective of an OSAS treatment program is to successfully implement indicated CPAP in the highest possible proportion of patients in order to lower the proportion of untreated OSAS in the population. On an individual basis, it has been shown that a longer duration of CPAP use is associated with better outcomes in terms of daytime functioning and in the control of metabolic and blood pressure effects of CPAP. For our study, we have therefore decided to use 2 co-primary endpoints, taking into account both aspects of adherence mentioned. Cardiovascular complications are a major concern in OSAS patients. Effective CPAP treatment has been shown to reduce surrogate measures of cardiovascular risk. We hypothesize that intensified efforts for CPAP adherence with telemedicine has a positive impact on a number of surrogate measures of the cardiovascular risk at 1 and 6 months of treatment.","[(0, 12, 'BEHAVIOURAL', 'Telemedicine'), (37, 72, 'OTHER', 'Continuous Positive Airway Pressure'), (98, 130, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (145, 152, 'CONTROL', 'Placebo'), (215, 227, 'BEHAVIOURAL', 'telemedicine'), (242, 320, 'BEHAVIOURAL', 'support interventions by short messages, telephone calls and ambulatory visits'), (332, 336, 'OTHER', 'CPAP'), (466, 470, 'CONDITION', 'OSAS'), (528, 532, 'OTHER', 'CPAP'), (626, 630, 'CONDITION', 'OSAS'), (718, 722, 'OTHER', 'CPAP'), (856, 860, 'OTHER', 'CPAP'), (1043, 1047, 'CONDITION', 'OSAS'), (1068, 1072, 'OTHER', 'CPAP'), (1195, 1199, 'OTHER', 'CPAP'), (1215, 1227, 'BEHAVIOURAL', 'telemedicine')]"
"['Effectiveness', 'of', 'Modified', 'Constraint', '-', 'induced', 'Movement', 'Therapy', 'and', 'Self', '-', 'regulation', 'Learning', 'for', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'This', 'study', 'examines', 'the', 'effect', 'of', 'combining', 'modified', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'mCIMT', ')', 'and', 'self', '-', 'regulation', '(', 'SR', ')', 'in', 'promoting', 'upper', 'limb', 'function', 'of', 'children', 'with', 'hemiplegic', 'cerebral', 'palsy', '(', 'CP', ')', 'studying', 'in', 'a', 'school', '-', 'based', 'setting', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02957708,NCT02957708,Effectiveness of Modified Constraint-induced Movement Therapy and Self-regulation Learning for Children With Hemiplegic Cerebral Palsy | This study examines the effect of combining modified constraint-induced movement therapy (mCIMT) and self-regulation (SR) in promoting upper limb function of children with hemiplegic cerebral palsy (CP) studying in a school-based setting.,"[(17, 61, 'PHYSICAL', 'Modified Constraint-induced Movement Therapy'), (66, 90, 'BEHAVIOURAL', 'Self-regulation Learning'), (109, 134, 'CONDITION', 'Hemiplegic Cerebral Palsy'), (181, 225, 'PHYSICAL', 'modified constraint-induced movement therapy'), (227, 232, 'PHYSICAL', 'mCIMT'), (238, 253, 'BEHAVIOURAL', 'self-regulation'), (255, 257, 'BEHAVIOURAL', 'SR'), (309, 334, 'CONDITION', 'hemiplegic cerebral palsy'), (336, 338, 'CONDITION', 'CP')]"
"['Leaving', 'the', 'Wheelchair', 'Behind', '-', 'Treating', 'CRPS', '-', 'II', 'With', 'Exposure', 'Therapy', 'Combined', 'With', 'Cortical', 'Interventions', ':', 'a', 'Series', 'of', 'Case', 'Reports', '|', 'Consecutive', 'patients', 'with', 'long', '-', 'standing', 'complex', 'regional', 'pain', 'syndrome', 'II', 'in', 'a', 'lower', 'limb', 'are', 'treated', 'with', 'graded', 'exposure', 'therapy', 'in', 'vivo', 'in', 'combination', 'with', 'methods', 'targeting', 'cortical', 'reorganisation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03174249,NCT03174249,Leaving the Wheelchair Behind - Treating CRPS-II With Exposure Therapy Combined With Cortical Interventions: a Series of Case Reports | Consecutive patients with long-standing complex regional pain syndrome II in a lower limb are treated with graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.,"[(41, 48, 'CONDITION', 'CRPS-II'), (54, 70, 'OTHER', 'Exposure Therapy'), (85, 107, 'OTHER', 'Cortical Interventions'), (176, 209, 'CONDITION', 'complex regional pain syndrome II'), (243, 266, 'OTHER', 'graded exposure therapy'), (295, 336, 'OTHER', 'methods targeting cortical reorganisation')]"
"['Treatment', 'of', 'Restless', 'Legs', 'Symptoms', 'With', 'Pramipexole', 'to', 'Improve', 'the', 'Outcomes', 'of', 'Protracted', 'Opioid', 'Withdrawal', 'in', 'OUD', ':', 'A', 'Pilot', 'Double', '-', 'blind', ',', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'investigators', 'propose', 'to', 'test', 'the', 'use', 'of', 'pramipexole', 'in', 'patients', 'being', 'treated', 'for', 'Opioid', 'Use', 'Disorder', 'to', 'test', 'its', 'ability', 'to', 'reduce', 'symptoms', 'of', 'both', 'Restless', 'Legs', 'Syndrome', 'and', 'protracted', 'opioid', 'withdrawal', 'and', 'thereby', 'promote', 'initiation', ',', 'engagement', ',', 'and', 'retention', 'in', 'treatment', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04759703,NCT04759703,"Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical Trial | The investigators propose to test the use of pramipexole in patients being treated for Opioid Use Disorder to test its ability to reduce symptoms of both Restless Legs Syndrome and protracted opioid withdrawal and thereby promote initiation, engagement, and retention in treatment.","[(13, 26, 'CONDITION', 'Restless Legs'), (41, 52, 'DRUG', 'Pramipexole'), (80, 108, 'CONDITION', 'Protracted Opioid Withdrawal'), (112, 115, 'CONDITION', 'OUD'), (212, 223, 'DRUG', 'pramipexole'), (254, 273, 'CONDITION', 'Opioid Use Disorder'), (321, 343, 'CONDITION', 'Restless Legs Syndrome'), (348, 376, 'CONDITION', 'protracted opioid withdrawal')]"
"['Phase', 'II', 'Study', 'of', 'Nonsense', 'Readthrough', 'Compound', 'NPC-14', '(', 'Arbekacin', 'Sulfate', ')', 'to', 'Explore', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'in', 'Duchenne', 'Muscular', 'Dystrophy', 'Patients', '(', 'NORTH', 'POLE', 'DMD', 'Study', ')', '|', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', 'is', 'inherited', 'neuromuscular', 'disorders', 'due', 'to', 'mutation', 'in', 'the', 'gene', 'that', 'encodes', 'critical', 'muscle', 'protein', 'called', 'dystrophin', '.', 'Currently', ',', 'there', 'is', 'no', 'effective', 'treatment', 'option', 'for', 'the', 'disease', '.', 'A', 'pharmacological', 'approach', 'by', 'promoting', 'mRNA', 'translation', 'regardless', 'of', 'the', 'presence', 'of', 'premature', 'stop', 'codons', 'by', 'nonsense', 'mutation', ',', 'called', 'the', 'readthrough', 'strategy', ',', 'has', 'been', 'developing', 'recently', 'for', 'DMD', 'with', 'nonsense', 'mutation', '.', 'NPC-14', 'is', 'a', 'candidate', 'compound', 'for', 'the', 'readthrough', 'strategy', ',', 'since', 'effective', 'readthrough', 'activities', 'were', 'demonstrated', 'in', 'nonclinical', 'studies', '.', 'This', 'study', 'is', 'a', 'phase', 'II', 'study', 'designed', 'to', 'assess', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'NPC-14', 'in', 'ambulant', 'DMD', 'patients', 'with', 'nonsense', 'mutation', 'that', 'were', 'confirmed', 'by', 'whole', 'genome', 'analysis', '.', 'These', 'goals', 'will', 'be', 'accomplished', 'by', 'monitoring', 'adverse', 'events', 'by', 'physical', 'examination', ',', 'cardiac', ',', 'pulmonary', ',', 'auditory', ',', 'balance', ',', 'and', 'laboratory', 'tests', 'as', 'safety', 'endpoints', ',', 'and', 'dystrophin', 'expression', 'in', 'muscle', 'biopsy', 'as', 'primary', 'efficacy', 'endpoint', ',', 'muscle', 'function', '(', 'NSAA', ',', 'timed', 'test', ',', 'muscle', 'strength', '(', 'QMT', ',', 'MMT', ')', ',', 'dairy', 'activities', 'by', 'lifecorder', ')', ',', 'and', 'biomarkers', 'as', 'secondary', 'efficacy', 'endpoints', '.', 'The', 'study', 'is', 'a', 'randomized', ',', 'double', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'in', '21', 'DMD', 'patients', '.', 'After', 'screening', ',', 'eligible', 'patients', 'are', 'allocated', 'dynamically', 'to', 'weekly', 'NPC-14', 'or', 'a', 'placebo', '(', 'saline', ')', 'in', 'a', '2:1', 'ratio', 'and', 'will', 'receive', 'study', 'drugs', 'for', '36', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01918384,NCT01918384,"Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study) | Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.","[(48, 54, 'DRUG', 'NPC-14'), (56, 73, 'DRUG', 'Arbekacin Sulfate'), (124, 151, 'CONDITION', 'Duchenne Muscular Dystrophy'), (186, 213, 'CONDITION', 'Duchenne Muscular Dystrophy'), (215, 218, 'CONDITION', 'DMD'), (605, 608, 'CONDITION', 'DMD'), (633, 639, 'DRUG', 'NPC-14'), (863, 869, 'DRUG', 'NPC-14'), (882, 885, 'CONDITION', 'DMD'), (1391, 1398, 'CONTROL', 'placebo'), (1422, 1425, 'CONDITION', 'DMD'), (1507, 1513, 'DRUG', 'NPC-14'), (1519, 1526, 'CONTROL', 'placebo'), (1528, 1534, 'CONTROL', 'saline')]"
"['Impact', 'of', 'Brain', 'Connectome', 'and', 'Personality', 'on', 'Cognitive', 'Rehabilitation', 'in', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'aims', 'to', 'apply', 'baseline', 'MRI', 'and', 'neuropsychological', 'measures', 'to', 'predict', 'patient', 'responses', 'to', 'behavioral', 'cognitive', 'rehabilitation', '.', 'Training', 'will', 'take', 'place', 'over', '12', 'weeks', ',', '1', 'hour', 'per', 'day', ',', '5', 'days', 'per', 'week', '.', '\n\n', 'The', 'investigator', 'hypothesizes', 'the', 'following', ':', '\n\n', '[', '1a', ']', 'The', 'investigator', 'expects', 'that', 'individuals', 'with', 'low', 'baseline', 'Conscientiousness', 'will', 'experience', 'a', 'lower', 'magnitude', 'of', 'overall', 'cognitive', 'improvement', 'following', 'rehabilitation', '\n\n', 'b', ']', 'The', 'investigator', 'expects', 'the', 'impact', 'of', 'Conscientiousness', 'on', 'fidelity', 'of', 'rehabilitation', 'will', 'in', 'part', 'be', 'moderated', 'by', 'individual', 'differences', 'in', 'program', 'adherence', 'and', 'executive', 'function', '\n', 'a', ']', 'The', 'investigator', 'expects', 'that', 'individual', 'differences', 'in', 'structural', 'and', 'functional', 'connectome', 'disturbances', 'will', 'in', 'part', 'explain', 'differences', 'in', 'participant', 'responses', 'to', 'cognitive', 'rehabilitation', '.', '\n\n', 'This', 'study', 'will', 'also', 'serve', 'to', 'supplement', 'the', 'sample', 'of', 'participants', 'for', 'the', 'current', 'IRB', 'approved', 'study', '(', '(', 'IRB', ':', '603069', ',', 'Title', ':', 'A', 'case', '-', 'control', ',', '5', '-', 'year', 'follow', '-', 'up', 'study', 'of', 'cardiovascular', ',', 'environmental', 'and', 'genetic', 'risk', 'factors', 'for', 'disease', 'progression', 'in', 'patients', 'with', 'multiple', 'sclerosis', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT03306875,NCT03306875,"Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis | This study aims to apply baseline MRI and neuropsychological measures to predict patient responses to behavioral cognitive rehabilitation. Training will take place over 12 weeks, 1 hour per day, 5 days per week.

The investigator hypothesizes the following:

[1a] The investigator expects that individuals with low baseline Conscientiousness will experience a lower magnitude of overall cognitive improvement following rehabilitation

b] The investigator expects the impact of Conscientiousness on fidelity of rehabilitation will in part be moderated by individual differences in program adherence and executive function
a] The investigator expects that individual differences in structural and functional connectome disturbances will in part explain differences in participant responses to cognitive rehabilitation.

This study will also serve to supplement the sample of participants for the current IRB approved study ((IRB: 603069, Title: A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with multiple sclerosis.","[(46, 70, 'BEHAVIOURAL', 'Cognitive Rehabilitation'), (74, 92, 'CONDITION', 'Multiple Sclerosis'), (197, 232, 'BEHAVIOURAL', 'behavioral cognitive rehabilitation'), (886, 910, 'BEHAVIOURAL', 'cognitive rehabilitation'), (1176, 1194, 'CONDITION', 'multiple sclerosis')]"
"['The', 'Effect', 'of', 'Intraoperative', 'Variations', 'in', 'Positive', '-', 'End', 'Expiratory', 'Pressure', 'on', 'Subdural', 'Pressure', ',', 'Optic', 'Nerve', 'Sheath', 'Diameter', ',', 'Lung', 'Compliance', 'and', 'Brain', 'Perfusion', 'Pressure', 'in', 'Supratentorial', 'Tumor', 'Surgery', '|', 'We', 'aim', 'to', 'determine', 'the', 'level', 'of', 'intraoperative', 'PEEP', 'that', 'optimizes', 'lung', 'compliance', 'without', 'causing', 'a', 'rise', 'in', 'subdural', 'pressure', 'and', 'if', 'we', 'can', 'utilize', 'optic', 'nerve', 'sheath', 'diameter', 'measurement', 'as', 'an', 'indicator', 'for', 'ICP', 'while', 'optimizing', 'lung', 'compliance', 'during', 'supratentorial', 'tumor', 'surgeries', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04316208,NCT04316208,"The Effect of Intraoperative Variations in Positive-End Expiratory Pressure on Subdural Pressure, Optic Nerve Sheath Diameter, Lung Compliance and Brain Perfusion Pressure in Supratentorial Tumor Surgery | We aim to determine the level of intraoperative PEEP that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize optic nerve sheath diameter measurement as an indicator for ICP while optimizing lung compliance during supratentorial tumor surgeries.","[(14, 75, 'OTHER', 'Intraoperative Variations in Positive-End Expiratory Pressure'), (175, 203, 'CONDITION', 'Supratentorial Tumor Surgery'), (239, 258, 'OTHER', 'intraoperative PEEP'), (460, 490, 'CONDITION', 'supratentorial tumor surgeries')]"
"['Smell', 'in', 'Covid-19', 'and', 'Efficacy', 'of', 'Nasal', 'Theophylline', '|', 'Evidence', 'of', 'COVID-19', 'related', 'anosmia', 'and', 'dysgeusia', 'continues', 'to', 'accumulate', 'daily', '.', '\n\n', 'Currently', ',', 'up', 'to', '80', '%', 'of', 'patients', 'report', 'subjective', 'olfactory', 'dysfunction', '(', 'OD', ')', ',', 'and', 'prevalence', 'using', 'objective', 'olfactory', 'testing', 'could', 'be', 'even', 'higher', '.', '\n\n', 'We', 'propose', 'a', 'phase', 'II', 'single', '-', 'site', ',', 'double', '-', 'blinded', ',', 'placebo', '-', 'controlled', 'randomized', 'clinical', 'trial', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'intranasal', 'theophylline', ',', 'a', 'known', 'phosphodiesterase', 'inhibitor', 'in', 'the', 'treatment', 'of', 'asthma', ',', 'as', 'a', 'possible', 'treatment', 'for', 'COVID-19', 'related', 'OD', '.', 'Theophylline', 'has', 'shown', 'benefit', 'in', 'similar', 'clinical', 'trials', 'for', 'post', '-', 'viral', 'OD', '.']","['O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04789499,NCT04789499,"Smell in Covid-19 and Efficacy of Nasal Theophylline | Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily.

Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher.

We propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.","[(9, 17, 'CONDITION', 'Covid-19'), (40, 52, 'DRUG', 'Theophylline'), (67, 75, 'CONDITION', 'COVID-19'), (84, 91, 'CONDITION', 'anosmia'), (96, 105, 'CONDITION', 'dysgeusia'), (189, 210, 'CONDITION', 'olfactory dysfunction'), (212, 214, 'CONDITION', 'OD'), (340, 347, 'CONTROL', 'placebo'), (436, 448, 'DRUG', 'theophylline'), (542, 550, 'CONDITION', 'COVID-19'), (559, 561, 'CONDITION', 'OD'), (563, 575, 'DRUG', 'Theophylline'), (625, 638, 'CONDITION', 'post-viral OD')]"
"['Functional', 'Navigation', 'in', 'Surgery', 'of', 'Cerebral', 'Tumors', 'and', 'Vascular', 'Malformations', ':', 'a', 'Prospective', ',', 'Single', 'Arm', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'assess', 'accuracy', ',', 'advantages', 'of', 'functional', 'neuronavigation', 'and', 'calculate', 'safe', 'distance', 'from', 'motor', 'areas', 'to', 'brain', 'tumors', 'and', 'vascular', 'malformations', 'in', 'image', '-', 'guided', 'surgery', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O']",NCT05484219,NCT05484219,"Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations: a Prospective, Single Arm Clinical Trial | The purpose of the study is to assess accuracy, advantages of functional neuronavigation and calculate safe distance from motor areas to brain tumors and vascular malformations in image-guided surgery.","[(0, 32, 'SURGICAL', 'Functional Navigation in Surgery'), (36, 51, 'CONDITION', 'Cerebral Tumors'), (56, 78, 'CONDITION', 'Vascular Malformations'), (185, 211, 'SURGICAL', 'functional neuronavigation'), (260, 272, 'CONDITION', 'brain tumors'), (277, 299, 'CONDITION', 'vascular malformations'), (303, 323, 'SURGICAL', 'image-guided surgery')]"
"['A', 'Phase', '3', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', 'Study', 'of', 'Ustekinumab', 'in', 'Participants', 'With', 'Active', 'Polymyositis', 'and', 'Dermatomyositis', 'Who', 'Have', 'Not', 'Adequately', 'Responded', 'to', 'One', 'or', 'More', 'Standard', '-', 'of', '-', 'care', 'Treatments', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'ustekinumab', 'in', 'participants', 'with', 'active', 'polymyositis', '(', 'PM)/dermatomyositis', '(', 'DM', ')', 'despite', 'receiving', '1', 'or', 'more', 'standard', '-', 'of', '-', 'care', 'treatments', '(', 'for', 'example', ',', 'glucocorticoids', 'and/or', 'immunomodulators', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03981744,NCT03981744,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).","[(50, 57, 'CONTROL', 'Placebo'), (94, 105, 'DRUG', 'Ustekinumab'), (127, 146, 'CONDITION', 'Active Polymyositis'), (151, 166, 'CONDITION', 'Dermatomyositis'), (303, 314, 'DRUG', 'ustekinumab'), (336, 381, 'CONDITION', 'active polymyositis (PM)/dermatomyositis (DM)')]"
"['Immune', 'Lot', 'Consistency', ',', 'Immunogenicity', ',', 'and', 'Safety', 'of', 'an', 'Investigational', 'Quadrivalent', 'Meningococcal', 'Conjugate', 'Vaccine', 'in', 'Adolescents', 'and', 'Adults', 'Aged', '10', 'to', '55', 'Years', '|', 'The', 'purpose', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'immune', 'lot', 'consistency', 'of', 'Meningococcal', 'Polysaccharide', '(', 'Serogroups', 'A', ',', 'C', ',', 'Y', 'and', 'W', ')', 'Tetanus', 'Toxoid', '(', 'MenACYW', ')', 'Conjugate', 'vaccine', 'and', 'the', 'immune', 'non', '-', 'inferiority', 'compared', 'to', 'the', 'licensed', 'vaccine', 'Menactra', '®', ',', 'and', 'describe', 'the', 'safety', 'and', 'additional', 'immunogenicity', 'of', 'these', 'study', 'vaccines', 'in', 'adolescents', 'and', 'adults', '10', 'to', '55', 'years', 'of', 'age', 'in', 'the', 'United', 'States', '(', 'US', ')', '.', '\n\n', 'Primary', 'Objectives', ':', '\n\n', 'To', 'demonstrate', 'the', 'immune', 'lot', 'consistency', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'with', 'respect', 'to', 'serum', 'bactericidal', 'assay', 'using', 'human', 'complement', '(', 'hSBA', ')', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', '.', '\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '®', '.', '\n\n', 'Secondary', 'Objective', ':', '\n\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '®', 'in', 'the', 'adult', 'population', '(', '18', 'to', '55', 'years', 'old', ')', '.', '\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '®', 'in', 'the', 'adolescent', 'population', '(', '10', 'to', '17', 'years', 'old', ')', '.', '\n', 'To', 'compare', 'the', 'hSBA', 'vaccine', 'seroresponses', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'for', 'each', 'of', '3', 'lots', 'of', 'MenACYW', 'Conjugate', 'vaccine', '30', 'days', '(', '+14', 'days', ')', 'after', 'vaccination', '.', '\n', 'To', 'compare', 'the', 'hSBA', 'antibody', 'GMTs', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'Menactra', '®', '.', '\n\n', 'Observational', 'Objectives', ':', '\n\n', 'To', 'describe', 'the', 'safety', 'profile', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'and', 'that', 'of', 'the', 'licensed', 'Menactra', '®', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",NCT02842853,NCT02842853,"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra®, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).

Primary Objectives:

To demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).
To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra®.

Secondary Objective:

To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adult population (18 to 55 years old).
To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adolescent population (10 to 17 years old).
To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.
To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra®.

Observational Objectives:

To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra®.","[(73, 117, 'DRUG', 'Quadrivalent Meningococcal Conjugate Vaccine'), (233, 331, 'DRUG', 'Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine'), (396, 404, 'DRUG', 'Menactra'), (742, 767, 'DRUG', 'MenACYW Conjugate vaccine'), (1022, 1047, 'DRUG', 'MenACYW Conjugate vaccine'), (1145, 1153, 'DRUG', 'Menactra'), (1332, 1357, 'DRUG', 'MenACYW Conjugate vaccine'), (1455, 1463, 'DRUG', 'Menactra'), (1664, 1689, 'DRUG', 'MenACYW Conjugate vaccine'), (1787, 1795, 'DRUG', 'Menactra'), (1955, 1980, 'DRUG', 'MenACYW Conjugate vaccine'), (2128, 2153, 'DRUG', 'MenACYW Conjugate vaccine'), (2204, 2212, 'DRUG', 'Menactra'), (2277, 2302, 'DRUG', 'MenACYW Conjugate vaccine'), (2328, 2336, 'DRUG', 'Menactra')]"
"['Evaluation', 'of', 'a', 'Dementia', 'Care', 'Training', 'With', 'Virtual', 'Reality', 'and', 'Support', 'Program', 'for', 'Home', 'Care', 'Staff', '|', 'This', 'study', 'aims', 'to', 'evaluate', 'a', 'dementia', 'care', 'training', 'with', 'virtual', 'reality', 'and', 'peer', 'support', 'program', 'on', 'dementia', 'care', 'knowledge', ',', 'attitude', ',', 'care', 'competence', ',', 'work', 'stress', ',', 'and', 'empathy', 'of', 'home', 'care', 'staff', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04788992,NCT04788992,"Evaluation of a Dementia Care Training With Virtual Reality and Support Program for Home Care Staff | This study aims to evaluate a dementia care training with virtual reality and peer support program on dementia care knowledge, attitude, care competence, work stress, and empathy of home care staff.","[(16, 59, 'OTHER', 'Dementia Care Training With Virtual Reality'), (64, 99, 'BEHAVIOURAL', 'Support Program for Home Care Staff'), (132, 175, 'OTHER', 'dementia care training with virtual reality'), (180, 200, 'BEHAVIOURAL', 'peer support program'), (204, 212, 'CONDITION', 'dementia')]"
"['Feasibility', 'Study', 'of', 'GlaxoSmithKline', 'Biologicals', ""'"", 'GSK2202083A', 'Vaccine', 'in', 'Healthy', 'Infants', 'at', '2', ',', '4', 'and', '12', 'Months', 'of', 'Age', '|', 'This', 'study', 'will', 'evaluate', 'the', 'safety', 'and', 'immunogenicity', 'of', 'GSK', 'Biologicals', ""'"", 'GSK2202083', 'vaccine', 'co', '-', 'administered', 'with', 'Prevenar', '13', '®', 'at', '2', ',', '4', 'and', '12', 'months', 'of', 'age', 'and', 'with', 'Rotarix', '™', 'at', '2', 'and', '4', 'months', 'of', 'age', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01090453,NCT01090453,"Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age | This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.","[(50, 69, 'DRUG', 'GSK2202083A Vaccine'), (195, 213, 'DRUG', 'GSK2202083 vaccine'), (235, 243, 'DRUG', 'Prevenar'), (286, 293, 'DRUG', 'Rotarix')]"
"['A', 'Prospective', ',', 'Randomized', ',', 'Controlled', 'Multicenter', 'Trial', 'of', 'Probiotics', 'and', 'Prebiotics', 'to', 'Improve', 'the', 'Efficacy', 'of', 'Antipsychotics', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'In', 'this', 'study', ',', 'investigators', 'will', 'evaluate', 'the', 'efficacy', 'and', 'related', 'mechanism', 'of', 'probiotics', 'and', 'prebiotics', 'as', 'an', 'add', '-', 'on', 'treatment', 'in', 'improving', 'the', 'antipsychotic', 'induced', 'psychotic', 'syndrome', ',', 'the', 'cognitive', 'impairment', ',', 'gastrointestinal', 'function', ',', 'and', 'metabolic', 'disorders', 'in', 'schizophrenia', 'patients', ',', 'through', 'genotype', 'identification', ',', 'psychopathology', ',', 'neuropsychology', ',', 'biochemical', 'evaluation', 'and', 'other', 'methods', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04291469,NCT04291469,"A Prospective, Randomized, Controlled Multicenter Trial of Probiotics and Prebiotics to Improve the Efficacy of Antipsychotics in Patients With Schizophrenia | In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.","[(59, 69, 'OTHER', 'Probiotics'), (74, 84, 'OTHER', 'Prebiotics'), (144, 157, 'CONDITION', 'Schizophrenia'), (241, 251, 'OTHER', 'probiotics'), (256, 266, 'OTHER', 'prebiotics'), (307, 347, 'CONDITION', 'antipsychotic induced psychotic syndrome'), (429, 442, 'CONDITION', 'schizophrenia')]"
"['A', 'Phase', '2', 'Study', 'of', 'Blinatumomab', '(', 'NSC', '#', '765986', ')', 'in', 'Combination', 'With', 'Nivolumab', '(', 'NSC', '#', '748726', ')', ',', 'a', 'Checkpoint', 'Inhibitor', 'of', 'PD-1', ',', 'in', 'B', '-', 'ALL', 'Patients', 'Aged', '>', '/=', '1', 'to', '<', '31', 'Years', 'Old', 'With', 'First', 'Relapse', '|', 'This', 'phase', 'II', 'trial', 'studies', 'the', 'effect', 'of', 'nivolumab', 'in', 'combination', 'with', 'blinatumomab', 'compared', 'to', 'blinatumomab', 'alone', 'in', 'treating', 'patients', 'with', 'B', '-', 'cell', 'acute', 'lymphoblastic', 'leukemia', '(', 'B', '-', 'ALL', ')', 'that', 'has', 'come', 'back', '(', 'relapsed', ')', '.', 'Down', 'syndrome', 'patients', 'with', 'relapsed', 'B', '-', 'ALL', 'are', 'included', 'in', 'this', 'study', '.', 'Blinatumomab', 'is', 'an', 'antibody', ',', 'which', 'is', 'a', 'protein', 'that', 'identifies', 'and', 'targets', 'specific', 'molecules', 'in', 'the', 'body', '.', 'Blinatumomab', 'searches', 'for', 'and', 'attaches', 'itself', 'to', 'the', 'cancer', 'cell', '.', 'Once', 'attached', ',', 'an', 'immune', 'response', 'occurs', 'which', 'may', 'kill', 'the', 'cancer', 'cell', '.', 'Nivolumab', 'is', 'a', 'medicine', 'that', 'may', 'boost', 'a', 'patient', ""'s"", 'immune', 'system', '.', 'Giving', 'nivolumab', 'in', 'combination', 'with', 'blinatumomab', 'may', 'cause', 'the', 'cancer', 'to', 'stop', 'growing', 'for', 'a', 'period', 'of', 'time', ',', 'and', 'for', 'some', 'patients', ',', 'it', 'may', 'lessen', 'the', 'symptoms', ',', 'such', 'as', 'pain', ',', 'that', 'are', 'caused', 'by', 'the', 'cancer', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04546399,NCT04546399,"A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse | This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.","[(19, 31, 'DRUG', 'Blinatumomab'), (66, 75, 'DRUG', 'Nivolumab'), (94, 122, 'DRUG', 'Checkpoint Inhibitor of PD-1'), (127, 132, 'CONDITION', 'B-ALL'), (176, 189, 'CONDITION', 'First Relapse'), (234, 243, 'DRUG', 'nivolumab'), (264, 276, 'DRUG', 'blinatumomab'), (289, 301, 'DRUG', 'blinatumomab'), (334, 369, 'CONDITION', 'B-cell acute lymphoblastic leukemia'), (371, 376, 'CONDITION', 'B-ALL'), (398, 406, 'CONDITION', 'relapsed'), (409, 422, 'CONDITION', 'Down syndrome'), (437, 451, 'CONDITION', 'relapsed B-ALL'), (480, 492, 'DRUG', 'Blinatumomab'), (588, 600, 'DRUG', 'Blinatumomab'), (641, 647, 'CONDITION', 'cancer'), (714, 720, 'CONDITION', 'cancer'), (727, 736, 'DRUG', 'Nivolumab'), (800, 809, 'DRUG', 'nivolumab'), (830, 842, 'DRUG', 'blinatumomab'), (857, 863, 'CONDITION', 'cancer'), (961, 965, 'CONDITION', 'pain'), (990, 996, 'CONDITION', 'cancer')]"
"['A', 'Phase', '2', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'Target', 'Engagement', 'of', 'ACI-24', 'in', 'Adults', 'With', 'Down', 'Syndrome', '|', 'This', 'study', 'is', 'a', 'prospective', 'multicenter', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', ',', 'randomized', 'study', 'to', 'assess', 'the', 'effect', 'of', 'one', 'dose', 'ACI-24', 'versus', 'placebo', 'over', 'a', '74', '-', 'week', 'treatment', 'period', 'and', '26', '-', 'week', 'safety', 'follow', '-', 'up', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04373616,NCT04373616,"A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome | This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.","[(36, 43, 'CONTROL', 'Placebo'), (121, 127, 'DRUG', 'ACI-24'), (143, 156, 'CONDITION', 'Down Syndrome'), (200, 207, 'CONTROL', 'placebo'), (284, 290, 'DRUG', 'ACI-24'), (298, 305, 'CONTROL', 'placebo')]"
"['Investigation', 'of', 'the', 'Effects', 'of', 'Exercise', 'Program', 'Applied', 'on', 'Postoperative', 'Period', 'in', 'Patients', 'With', 'Chiari', 'Type', '1', 'Malformation', '|', 'This', 'study', 'will', 'be', 'conducted', 'in', 'Hacettepe', 'University', 'Faculty', 'of', 'Medicine', 'Neurosurgery', 'Department', 'and', 'Hacettepe', 'University', 'Faculty', 'of', 'Physical', 'Therapy', 'and', 'Rehabilitation', '.', '\n\n', 'The', 'study', 'was', 'designed', 'as', 'a', 'randomized', 'controlled', 'trial', '.', 'At', 'the', 'beginning', 'of', 'the', 'study', ',', 'demographic', 'data', 'and', 'characteristics', 'of', 'the', 'cases', 'will', 'be', 'recorded', '.', 'Patients', 'will', 'be', 'evaluated', 'in', 'three', 'different', 'periods', 'throughout', 'the', 'study', '.', 'The', 'first', 'assessments', 'will', 'be', 'performed', 'on', 'the', 'first', 'day', 'after', 'the', 'patient', ""'s"", 'condition', 'is', 'appropriate', 'after', 'the', 'surgical', 'procedure', 'for', 'Type', '1', 'CM', '.', 'Following', 'this', 'evaluation', ',', 'all', 'patients', 'will', 'be', 'divided', 'into', 'two', 'groups', 'using', '.', 'a', 'simple', 'randomization', 'method', '.', 'The', 'first', 'group', 'will', 'be', 'exercised', 'for', '6', 'weeks', 'while', 'the', 'second', 'group', 'will', 'not', 'be', 'intervened', 'during', 'this', 'period', 'and', 'will', 'be', 'followed', 'as', 'a', 'control', 'group', '.', 'Immediately', 'after', 'the', 'exercise', 'program', 'administered', 'to', 'the', 'first', 'group', 'after', '6', 'weeks', ',', 'both', 'groups', 'will', 'undergo', 'second', 'assessments', '.', 'After', 'these', 'assessment', 'measures', ',', 'the', 'same', 'exercise', 'program', 'in', 'the', 'first', 'group', 'will', 'be', 'applied', 'to', 'the', 'second', 'group', 'only', 'this', 'time', 'for', '6', 'weeks', '.', 'In', 'the', 'meantime', ',', 'the', 'first', 'group', 'will', 'stop', 'their', 'exercise', 'programs', '.', 'After', 'the', '6', '-', 'week', 'exercise', 'program', 'of', 'the', 'second', 'group', 'has', 'ended', ',', 'both', 'groups', 'will', 'be', 'given', 'the', 'third', 'assessment', ',', 'the', 'final', 'assessment', '.', '\n\n', 'At', 'the', 'beginning', 'of', 'the', 'study', ',', 'demographic', 'data', ',', 'characteristics', 'and', 'disease', 'information', 'will', 'be', 'recorded', '.', '\n\n', 'The', 'evaluations', 'to', 'be', 'made', 'are', 'summarized', 'below', ':', '\n\n', 'Visual', 'Analogue', 'Scale', ',', 'pain', 'threshold', 'and', 'pain', 'tolerance', 'tests', ',', 'Neck', 'Disability', 'Index', ',', 'for', 'the', 'determination', 'of', 'pain', 'level', 'in', 'the', 'neck', 'region', 'and', 'throughout', 'the', 'body', '\n', 'Cervical', 'range', 'of', 'motion', '(', 'Performance', 'Attainment', 'Associates', ',', 'St.', 'Paul', ',', 'MN', ',', '55117', ',', 'United', 'States', ')', '(', 'CROM', '3', ')', 'device', 'for', 'the', 'evaluation', 'of', 'the', 'cervical', 'region', '.', '\n', 'Berg', 'Balance', 'Scale', 'for', 'evaluation', 'of', 'performance', '-', 'based', 'balance', ',', '\n', 'Timed', 'Rise', 'Walk', 'Test', ',', 'Sharpened', 'Romberg', 'test', 'and', '""', '8', '""', 'shaped', 'walk', 'test', '(', 'F8WT', ')', 'for', 'evaluation', 'of', 'fall', 'risk', ',', 'static', 'and', 'dynamic', 'balance', ',', '\n', 'The', 'International', 'Ataxia', 'Assessment', 'Scale', '(', 'ICARS', ')', 'for', 'coordination', ',', '\n', 'Grip', 'Ability', 'Test', '(', 'GAT', ')', 'for', 'the', 'assessment', 'of', 'fine', 'motor', 'skill', 'in', 'the', 'upper', 'extremity', ',', '\n', 'Posture', 'evaluation', ',', '\n', 'Eating', 'Assessment', 'Tool', '(', 'EAT-10', ')', 'for', 'evaluation', 'of', 'swallowing', 'function', '\n', 'For', 'daily', 'living', 'activities', ',', 'Barthel', 'Daily', 'Living', 'Activities', 'Index', ',', '\n', 'For', 'the', 'quality', 'of', 'life', ',', 'the', 'Short', 'Form', '36', 'questionnaire', 'will', 'be', 'used', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04073667,NCT04073667,"Investigation of the Effects of Exercise Program Applied on Postoperative Period in Patients With Chiari Type 1 Malformation | This study will be conducted in Hacettepe University Faculty of Medicine Neurosurgery Department and Hacettepe University Faculty of Physical Therapy and Rehabilitation.

The study was designed as a randomized controlled trial. At the beginning of the study, demographic data and characteristics of the cases will be recorded. Patients will be evaluated in three different periods throughout the study. The first assessments will be performed on the first day after the patient's condition is appropriate after the surgical procedure for Type 1 CM. Following this evaluation, all patients will be divided into two groups using. a simple randomization method. The first group will be exercised for 6 weeks while the second group will not be intervened during this period and will be followed as a control group. Immediately after the exercise program administered to the first group after 6 weeks, both groups will undergo second assessments. After these assessment measures, the same exercise program in the first group will be applied to the second group only this time for 6 weeks. In the meantime, the first group will stop their exercise programs. After the 6-week exercise program of the second group has ended, both groups will be given the third assessment, the final assessment.

At the beginning of the study, demographic data, characteristics and disease information will be recorded.

The evaluations to be made are summarized below:

Visual Analogue Scale, pain threshold and pain tolerance tests, Neck Disability Index, for the determination of pain level in the neck region and throughout the body
Cervical range of motion (Performance Attainment Associates, St. Paul, MN, 55117, United States) (CROM 3) device for the evaluation of the cervical region.
Berg Balance Scale for evaluation of performance-based balance,
Timed Rise Walk Test, Sharpened Romberg test and ""8"" shaped walk test (F8WT) for evaluation of fall risk, static and dynamic balance,
The International Ataxia Assessment Scale (ICARS) for coordination,
Grip Ability Test (GAT) for the assessment of fine motor skill in the upper extremity,
Posture evaluation,
Eating Assessment Tool (EAT-10) for evaluation of swallowing function
For daily living activities, Barthel Daily Living Activities Index,
For the quality of life, the Short Form 36 questionnaire will be used.","[(32, 40, 'PHYSICAL', 'Exercise'), (98, 124, 'CONDITION', 'Chiari Type 1 Malformation'), (665, 674, 'CONDITION', 'Type 1 CM'), (860, 877, 'CONTROL', 'not be intervened'), (960, 968, 'PHYSICAL', 'exercise'), (1111, 1119, 'PHYSICAL', 'exercise'), (1260, 1268, 'PHYSICAL', 'exercise'), (1296, 1304, 'PHYSICAL', 'exercise')]"
"['Examining', 'the', 'Effects', 'of', 'an', '8', '-', 'Week', 'Open', 'Label', 'Nature', '-', 'Based', 'Park', 'Visit', 'Program', 'on', 'the', 'Quality', 'of', 'Life', ',', 'Behaviors', 'and', 'Cognitive', 'Symptoms', 'of', 'Individuals', 'With', 'Dementia', 'and', 'Their', 'Caregivers', '|', 'The', 'overall', 'goals', 'of', 'our', 'project', 'is', 'to', 'understand', 'the', 'effects', 'of', 'participating', 'in', 'park', 'visits', 'and', 'nature', '-', 'based', 'activities', 'for', 'people', 'living', 'with', 'dementia', 'and', 'their', 'caregivers', '.', 'Nature', '-', 'based', 'activities', 'such', 'as', 'park', 'visits', 'can', 'have', 'beneficial', 'effects', 'on', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'physical', 'health', '.', 'However', ',', 'there', 'may', 'be', 'barriers', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'that', 'may', 'prevent', 'them', 'from', 'engaging', 'in', 'park', 'visits', '.', 'The', 'Nature', 'Connections', 'park', 'visit', 'program', 'will', 'provide', 'education', 'sessions', 'for', '10', 'persons', 'living', 'with', 'dementia', 'and', '10', 'caregivers', 'highlighting', 'the', 'beneficial', 'effects', 'of', 'park', 'visits', 'and', 'address', 'common', 'barriers', 'to', 'participating', 'in', 'park', 'visits', '.', 'Following', 'the', 'education', 'session', 'participants', 'will', 'be', 'provided', 'with', 'weekly', 'telephone', '/', 'internet', 'support', 'meetings', 'for', 'participants', 'to', 'share', 'their', 'experiences', 'with', 'park', 'visits', 'and', 'to', 'address', 'any', 'challenges', 'individuals', 'encountered', 'when', 'trying', 'to', 'complete', 'their', 'visits', '.', 'The', 'impact', 'of', 'park', 'visits', 'on', 'quality', 'of', 'life', ',', 'behaviours', ',', 'and', 'measures', 'of', 'stress', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'will', 'be', 'assessed', 'over', '8', 'weeks', '.', 'Following', 'completion', 'of', 'the', 'program', 'participants', 'will', 'provide', 'an', 'evaluation', 'of', 'the', 'program', 'to', 'understand', 'their', 'experience', 'and', 'satisfaction', 'with', 'the', 'program', '.', 'This', 'project', 'will', 'provide', 'new', 'information', 'about', 'the', 'effects', 'of', 'park', 'visits', 'as', 'a', 'practical', 'strategy', 'to', 'improve', 'the', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'measures', 'of', 'stress', 'for', 'both', 'people', 'with', 'dementia', 'and', 'caregivers', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT05527587,NCT05527587,"Examining the Effects of an 8-Week Open Label Nature-Based Park Visit Program on the Quality of Life, Behaviors and Cognitive Symptoms of Individuals With Dementia and Their Caregivers | The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers. Nature-based activities such as park visits can have beneficial effects on quality of life, psychological symptoms and physical health. However, there may be barriers for people with dementia and their caregivers that may prevent them from engaging in park visits. The Nature Connections park visit program will provide education sessions for 10 persons living with dementia and 10 caregivers highlighting the beneficial effects of park visits and address common barriers to participating in park visits. Following the education session participants will be provided with weekly telephone/internet support meetings for participants to share their experiences with park visits and to address any challenges individuals encountered when trying to complete their visits. The impact of park visits on quality of life, behaviours, and measures of stress for people with dementia and their caregivers will be assessed over 8 weeks. Following completion of the program participants will provide an evaluation of the program to understand their experience and satisfaction with the program. This project will provide new information about the effects of park visits as a practical strategy to improve the quality of life, psychological symptoms and measures of stress for both people with dementia and caregivers.","[(46, 77, 'OTHER', 'Nature-Based Park Visit Program'), (155, 163, 'CONDITION', 'Dementia'), (269, 280, 'OTHER', 'park visits'), (285, 308, 'OTHER', 'nature-based activities'), (332, 340, 'CONDITION', 'dementia'), (363, 386, 'OTHER', 'Nature-based activities'), (395, 406, 'OTHER', 'park visits'), (546, 554, 'CONDITION', 'dementia'), (615, 626, 'OTHER', 'park visits'), (632, 669, 'OTHER', 'Nature Connections park visit program'), (729, 737, 'CONDITION', 'dementia'), (795, 806, 'OTHER', 'park visits'), (855, 866, 'OTHER', 'park visits'), (935, 977, 'OTHER', 'weekly telephone/internet support meetings'), (1027, 1038, 'OTHER', 'park visits'), (1145, 1156, 'OTHER', 'park visits'), (1228, 1236, 'CONDITION', 'dementia'), (1509, 1520, 'OTHER', 'park visits'), (1644, 1652, 'CONDITION', 'dementia')]"
"['Long', '-', 'term', ',', 'Prospective', 'Study', 'Evaluating', 'Clinical', 'and', 'Molecular', 'Biomarkers', 'of', 'Epileptogenesis', 'in', 'a', 'Genetic', 'Model', 'of', 'Epilepsy', '-', 'Tuberous', 'Sclerosis', 'Complex', '|', 'The', 'primary', 'objective', 'of', 'clinical', 'part', 'of', 'EPISTOP', 'project', 'is', 'to', 'identify', 'the', 'clinical', 'and', 'molecular', 'biomarkers', 'of', 'epileptogenesis', 'in', 'a', 'prospective', 'clinical', 'study', 'of', 'patients', 'with', 'TSC', '.', '\n\n', 'Secondary', 'objective', 'of', 'the', 'clinical', 'part', 'of', 'EPISTOP', 'is', 'to', 'compare', 'the', 'effects', 'of', 'standard', 'antiepileptic', 'treatment', 'in', 'patients', 'diagnosed', 'as', 'having', 'epilepsy', 'after', 'clinical', 'seizures', 'vs', 'after', 'electroencephalographic', 'epileptiform', 'discharges', ',', 'in', 'a', 'randomized', 'trial', 'in', 'TSC', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02098759,NCT02098759,"Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex | The primary objective of clinical part of EPISTOP project is to identify the clinical and molecular biomarkers of epileptogenesis in a prospective clinical study of patients with TSC.

Secondary objective of the clinical part of EPISTOP is to compare the effects of standard antiepileptic treatment in patients diagnosed as having epilepsy after clinical seizures vs after electroencephalographic epileptiform discharges, in a randomized trial in TSC patients.","[(115, 123, 'CONDITION', 'Epilepsy'), (126, 152, 'CONDITION', 'Tuberous Sclerosis Complex'), (334, 337, 'CONDITION', 'TSC'), (421, 453, 'OTHER', 'standard antiepileptic treatment'), (486, 494, 'CONDITION', 'epilepsy'), (602, 605, 'CONDITION', 'TSC')]"
"['A', 'Phase', '1', ',', 'Open', '-', 'Label', 'Study', 'to', 'Evaluate', 'the', 'Absorption', ',', 'Metabolism', ',', 'and', 'Excretion', 'of', '[', '14C]-BIIB074', 'in', 'Healthy', 'Male', 'Subjects', '|', 'The', 'primary', 'objectives', 'of', 'the', 'study', 'are', ':', 'To', 'determine', 'the', 'mass', 'balance', 'and', 'routes', 'of', 'elimination', 'of', 'BIIB074', 'and', 'its', 'known', 'metabolites', 'following', 'administration', 'of', 'a', 'single', 'oral', 'dose', 'of', 'BIIB074', 'in', 'healthy', 'male', 'participants', 'and', 'To', 'describe', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'BIIB074', 'and', 'its', 'known', 'metabolites', 'and', 'the', 'disposition', 'profiles', 'of', 'total', 'radioactivity', 'in', 'whole', 'blood', 'and', 'plasma', 'following', 'a', 'single', 'oral', 'dose', '.', 'The', 'secondary', 'objectives', 'of', 'this', 'study', 'are', ':', 'To', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'BIIB074', 'in', 'healthy', 'participants', 'and', 'To', 'identify', 'and', 'characterize', 'any', 'additional', 'metabolites', 'of', 'BIIB074', 'in', 'plasma', ',', 'urine', ',', 'and', 'feces', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02751905,NCT02751905,"A Phase 1, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-BIIB074 in Healthy Male Subjects | The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To describe the pharmacokinetics (PK) of BIIB074 and its known metabolites and the disposition profiles of total radioactivity in whole blood and plasma following a single oral dose. The secondary objectives of this study are: To assess the safety and tolerability of BIIB074 in healthy participants and To identify and characterize any additional metabolites of BIIB074 in plasma, urine, and feces.","[(85, 98, 'DRUG', '[14C]-BIIB074'), (226, 233, 'DRUG', 'BIIB074'), (310, 317, 'DRUG', 'BIIB074'), (392, 399, 'DRUG', 'BIIB074'), (619, 626, 'DRUG', 'BIIB074'), (714, 721, 'DRUG', 'BIIB074')]"
"['Antiplatelet', 'vs', 'R', '-', 'tPA', 'for', 'Acute', 'Mild', 'Ischemic', 'Stroke', ':', 'a', 'Prospective', ',', 'Random', ',', 'Blinded', 'Assessment', 'of', 'Outcome', 'and', 'Open', 'Label', 'Multi', '-', 'center', 'Study', '|', 'Acute', 'ischemic', 'stroke', '(', 'AIS', ')', 'is', 'one', 'of', 'common', 'diseases', 'with', 'significant', 'morbidity', ',', 'mortality', 'and', 'disability', '.', 'A', 'wide', 'array', 'of', 'studies', 'confirms', 'that', 'intravenous', 'thrombolytic', 'therapy', 'with', 'alteplase', 'can', 'effectively', 'improve', 'the', 'functional', 'prognosis', 'in', 'acute', 'ischemic', 'stroke', '.', 'Thus', 'all', 'guidelines', 'recommended', 'the', 'intravenous', 'thrombolytic', 'therapy', 'with', 'alteplase', 'for', 'acute', 'ischemic', 'stroke', 'within', '4.5', 'hours', 'from', 'stroke', 'onset', '.', '\n\n', 'Minor', 'stroke', 'is', 'usually', 'defined', 'as', 'NIHSS', 'score', '≤', '3', 'or', '5，although', 'it', 'accounts', 'for', '1/2', '-', '2/3', 'of', 'AIS', ',', 'the', 'evidence', 'of', 'thrombolysis', 'is', 'insufficient', '.', 'A', 'study', 'from', 'Canada', 'shows', 'that', '28.5', '%', 'of', 'patients', 'with', 'minor', 'stroke', 'who', 'have', 'not', 'receive', 'rt', '-', 'pa', 'thrombolytic', 'therapy', 'are', 'unable', 'to', 'walk', 'independently', 'when', 'discharged', '.', 'Based', 'on', 'such', 'a', 'consideration', ',', 'the', 'PRISMS', 'study', 'further', 'compares', 'the', 'efficacy', 'and', 'safety', 'of', 'thrombolytic', 'therapy', 'with', 'antithrombotic', 'therapy', 'in', 'patients', 'with', 'minor', 'stroke', '.', 'Unfortunately', ',', 'the', 'study', 'has', 'been', 'early', 'terminated', 'due', 'to', 'the', 'sponsorship', 'reason', 'in', '2018', ',', 'with', 'only', '313', 'cases', 'enrolled', '.', 'The', 'preliminary', 'results', 'shows', 'that', 'there', 'is', 'no', 'significant', 'difference', 'of', 'the', '90', '-', 'day', 'neurological', 'function', 'between', 'the', 'two', 'groups', ',', 'while', 'the', 'safety', 'of', 'the', 'treatment', 'group', 'with', 'alteplase', 'has', 'a', 'higher', 'rate', 'of', 'symptomatic', 'intracranial', 'hemorrhage', '.', 'The', 'patient', 'receiving', 'thrombolysis', 'can', 'not', 'be', 'given', 'antithrombolytic', 'therapy', 'within', '24', 'hours', 'even', 'if', 'the', 'patient', ""'s"", 'condition', 'has', 'worsened', ',', 'is', 'clinically', 'more', 'puzzling', '.', '\n\n', 'The', 'CHANCE', 'study', 'in', '2013', 'shows', 'that', 'the', 'efficacy', 'of', 'aspirin', 'with', 'clopidogrel', 'is', 'superior', 'to', 'aspirin', 'alone', 'with', 'minor', 'stroke', '(', 'NIHSS', '<', '3', ')', 'or', 'TIA(ABCD2', '<', '4', ')', '.', 'The', 'POINT', 'study', 'in', '2018', 'further', 'confirmed', 'the', 'efficacy', 'and', 'safety', 'of', 'intensive', 'antithrombotic', 'therapy', 'within', '12', 'hours', 'of', 'onset', 'with', 'minor', 'stroke', '.', '\n\n', 'Based', 'on', 'the', 'above', 'discussion', ',', 'this', 'study', 'aims', 'to', 'explore', 'the', 'efficacy', 'and', 'safety', 'of', 'aspirin', 'with', 'clopidogrel', 'vs', 'alteplase', 'in', 'the', 'treatment', 'of', 'acute', 'minor', 'stroke', '.']","['B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03661411,NCT03661411,"Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke: a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study | Acute ischemic stroke (AIS) is one of common diseases with significant morbidity, mortality and disability. A wide array of studies confirms that intravenous thrombolytic therapy with alteplase can effectively improve the functional prognosis in acute ischemic stroke. Thus all guidelines recommended the intravenous thrombolytic therapy with alteplase for acute ischemic stroke within 4.5 hours from stroke onset.

Minor stroke is usually defined as NIHSS score ≤ 3 or 5，although it accounts for 1/2-2/3 of AIS, the evidence of thrombolysis is insufficient. A study from Canada shows that 28.5% of patients with minor stroke who have not receive rt-pa thrombolytic therapy are unable to walk independently when discharged. Based on such a consideration,the PRISMS study further compares the efficacy and safety of thrombolytic therapy with antithrombotic therapy in patients with minor stroke. Unfortunately, the study has been early terminated due to the sponsorship reason in 2018, with only 313 cases enrolled. The preliminary results shows that there is no significant difference of the 90-day neurological function between the two groups, while the safety of the treatment group with alteplase has a higher rate of symptomatic intracranial hemorrhage. The patient receiving thrombolysis can not be given antithrombolytic therapy within 24 hours even if the patient's condition has worsened, is clinically more puzzling.

The CHANCE study in 2013 shows that the efficacy of aspirin with clopidogrel is superior to aspirin alone with minor stroke (NIHSS < 3) or TIA(ABCD2 < 4). The POINT study in 2018 further confirmed the efficacy and safety of intensive antithrombotic therapy within 12 hours of onset with minor stroke.

Based on the above discussion, this study aims to explore the efficacy and safety of aspirin with clopidogrel vs alteplase in the treatment of acute minor stroke.","[(0, 12, 'DRUG', 'Antiplatelet'), (16, 21, 'DRUG', 'R-tPA'), (26, 52, 'CONDITION', 'Acute Mild Ischemic Stroke'), (143, 164, 'CONDITION', 'Acute ischemic stroke'), (166, 169, 'CONDITION', 'AIS'), (327, 336, 'DRUG', 'alteplase'), (389, 410, 'CONDITION', 'acute ischemic stroke'), (486, 495, 'DRUG', 'alteplase'), (500, 521, 'CONDITION', 'acute ischemic stroke'), (544, 550, 'CONDITION', 'stroke'), (559, 571, 'CONDITION', 'Minor stroke'), (651, 654, 'CONDITION', 'AIS'), (756, 768, 'CONDITION', 'minor stroke'), (790, 795, 'DRUG', 'rt-pa'), (1024, 1036, 'CONDITION', 'minor stroke'), (1333, 1342, 'DRUG', 'alteplase'), (1622, 1629, 'DRUG', 'aspirin'), (1635, 1646, 'DRUG', 'clopidogrel'), (1662, 1669, 'DRUG', 'aspirin'), (1681, 1693, 'CONDITION', 'minor stroke'), (1857, 1869, 'CONDITION', 'minor stroke'), (1957, 1964, 'DRUG', 'aspirin'), (1970, 1981, 'DRUG', 'clopidogrel'), (1985, 1994, 'DRUG', 'alteplase'), (2015, 2033, 'CONDITION', 'acute minor stroke')]"
"['Comparison', 'of', 'the', 'Effects', 'of', 'Subcostal', 'Anterior', 'Quadratus', 'Lumborum', 'Block', 'and', 'Thoracic', 'Paravertebral', 'Block', 'on', 'Postoperative', 'Acute', 'Pain', 'in', 'Laparoscopic', 'Nephrectomy', 'Surgery', '|', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'evaluate', 'the', 'effects', 'of', 'subcostal', 'anterior', 'quadratus', 'lumborum', 'block', '(', 'S', '-', 'QLB3', ')', 'and', 'thoracic', 'paravertebral', 'block', '(', 'TPVB', ')', 'on', 'postoperative', 'acute', 'pain', 'scores', 'and', 'opioid', 'consumption', 'in', 'the', 'first', '24', 'hours', 'after', 'laparoscopic', 'nephrectomy', 'surgery', '.']","['O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05191966,NCT05191966,"Comparison of the Effects of Subcostal Anterior Quadratus Lumborum Block and Thoracic Paravertebral Block on Postoperative Acute Pain in Laparoscopic Nephrectomy Surgery | In this study, it was aimed to evaluate the effects of subcostal anterior quadratus lumborum block (S-QLB3) and thoracic paravertebral block (TPVB) on postoperative acute pain scores and opioid consumption in the first 24 hours after laparoscopic nephrectomy surgery.","[(29, 72, 'SURGICAL', 'Subcostal Anterior Quadratus Lumborum Block'), (77, 105, 'SURGICAL', 'Thoracic Paravertebral Block'), (109, 133, 'CONDITION', 'Postoperative Acute Pain'), (137, 169, 'CONDITION', 'Laparoscopic Nephrectomy Surgery'), (227, 270, 'SURGICAL', 'subcostal anterior quadratus lumborum block'), (272, 279, 'SURGICAL', 'S-QLB3)'), (284, 312, 'SURGICAL', 'thoracic paravertebral block'), (314, 318, 'SURGICAL', 'TPVB'), (406, 438, 'CONDITION', 'laparoscopic nephrectomy surgery')]"
"['The', 'investigators', 'aimed', 'in', 'this', 'study', 'to', 'investigate', 'the', 'effects', 'of', '4', 'weeks', 'robot', '-', 'assisted', 'locomotor', 'training', 'on', 'motor', 'recovery', 'of', 'lower', 'extremities', 'and', 'walking', 'ability', 'compared', 'with', 'the', 'conventional', 'gait', 'training', 'in', 'subacute', 'post', '-', 'stroke', 'non', '-', 'ambulatory', 'hemiplegic', 'patients', '.', '\n\n', '72', 'first', '-', 'ever', 'stroke', 'patients', 'who', 'could', 'not', 'walk', 'independently', '(', 'FAC', '<', '2', ')', ',', 'and', 'suffered', 'within', '6', 'months', 'were', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '.', 'The', 'subjects', 'with', 'congestive', 'heart', 'failure', ',', 'malignancies', ',', 'cardiopulmonary', 'dysfunctions', ',', 'and', 'who', 'could', 'not', 'walk', 'independently', 'before', 'stroke', 'attack', 'were', 'excluded', '.', '\n\n', 'Two', 'groups', 'received', '30', 'minutes', 'conventional', 'gait', 'training', 'including', 'Neurodevelopmental', 'Treatment', '(', 'NDT', ')', 'basically', '.', 'The', 'robotic', 'assisted', 'locomotor', 'training', 'group', 'received', 'additional', 'robotic', '-', 'assisted', 'gait', 'therapy', 'for', '30minutes', 'with', 'Lokomat', '®', '(', 'Hocoma', ',', 'Zurich', ',', 'Switzerland', ')', 'daily', 'for', '4', 'weeks', ',', 'and', 'the', 'conventional', 'gait', 'training', 'group', 'received', 'additional', 'daily', 'conventional', 'gait', 'training', 'with', 'NDT', 'for', 'the', 'same', 'periods', '.', 'The', 'independent', 'walking', 'ability(FAC', '≥', '3', ')', ',', 'Functional', 'Ambulation', 'Category', '(', 'FAC', ')', ',', 'Motricity', 'index', '(', 'MI', ')', ',', 'Fugl', '-', 'Meyer', 'assessment', '(', 'FMA', ')', ',', 'Modified', 'Barthel', 'Index', '(', 'MBI', ')', ',', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'for', 'each', 'lower', 'extremity', 'muscles', 'were', 'assessed', 'before', ',', 'during', '(', '2weeks', ')', 'and', 'after', 'training', '.', 'And', 'the', 'independent', 'walking', 'ability', 'were', 'followed', 'until', '3', 'months', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01726998,NCT01726998,"The investigators aimed in this study to investigate the effects of 4 weeks robot-assisted locomotor training on motor recovery of lower extremities and walking ability compared with the conventional gait training in subacute post-stroke non-ambulatory hemiplegic patients.

72 first-ever stroke patients who could not walk independently (FAC < 2), and suffered within 6 months were enrolled and randomly assigned into 2 groups. The subjects with congestive heart failure, malignancies, cardiopulmonary dysfunctions, and who could not walk independently before stroke attack were excluded.

Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment (NDT) basically. The robotic assisted locomotor training group received additional robotic-assisted gait therapy for 30minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods. The independent walking ability(FAC ≥ 3), Functional Ambulation Category (FAC), Motricity index (MI), Fugl-Meyer assessment (FMA), Modified Barthel Index (MBI), Medical Research Council (MRC) for each lower extremity muscles were assessed before, during (2weeks) and after training. And the independent walking ability were followed until 3 months.","[(76, 109, 'PHYSICAL', 'robot-assisted locomotor training'), (187, 213, 'CONTROL', 'conventional gait training'), (217, 263, 'CONDITION', 'subacute post-stroke non-ambulatory hemiplegic'), (278, 295, 'CONDITION', 'first-ever stroke'), (561, 567, 'CONDITION', 'stroke'), (622, 648, 'CONTROL', 'conventional gait training'), (659, 687, 'CONTROL', 'Neurodevelopmental Treatment'), (689, 692, 'CONTROL', 'NDT'), (709, 744, 'PHYSICAL', 'robotic assisted locomotor training'), (771, 800, 'PHYSICAL', 'robotic-assisted gait therapy'), (820, 827, 'PHYSICAL', 'Lokomat'), (945, 971, 'CONTROL', 'conventional gait training'), (977, 980, 'PHYSICAL', 'NDT')]"
"['Rapid', 'Response', 'to', 'Day', 'Hospital', 'Treatment', 'in', 'Bulimia', 'Nervosa', 'and', 'Purging', 'Disorder', ':', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'an', 'Intervention', 'to', 'Facilitate', 'Early', 'Symptom', 'Change', '|', 'Treatments', 'for', 'bulimia', 'nervosa', '(', 'BN', ')', 'have', 'relatively', 'high', 'rates', 'of', 'nonremission', 'and', 'relapse', ',', 'meaning', 'that', 'improving', 'treatments', 'is', 'a', 'high', 'priority', 'in', 'this', 'area', '.', 'Rapid', 'response', 'to', 'treatment', '-cessation', 'of', 'binge', 'eating', 'and', 'vomiting', 'symptoms', 'within', 'the', 'first', 'weeks', 'of', 'treatment', '-', 'is', 'a', 'robust', 'predictor', 'of', 'improved', 'post', '-', 'treatment', 'outcomes', 'and', 'lower', 'relapse', 'rates', ',', 'but', 'no', 'study', 'has', 'tried', 'to', 'facilitate', 'rapid', 'response', 'as', 'a', 'means', 'of', 'improving', 'treatment', 'outcomes', '.', 'The', 'present', 'study', 'responds', 'to', 'this', 'gap', 'in', 'the', 'literature', 'by', 'testing', 'a', '4', '-', 'session', 'CBT', '-', 'based', 'individual', 'intervention', 'for', 'rapid', 'response', '(', 'i.e.', ',', '""', 'CBT', '-', 'RR', '""', ')', ',', 'designed', 'to', 'augment', 'standard', 'day', 'hospital', '(', 'DH', ')', 'treatment', 'for', 'BN', 'and', 'Purging', 'Disorder', '(', 'PD', ')', 'by', 'focusing', 'on', 'strategies', 'and', 'skills', 'for', 'rapid', 'symptom', 'interruption', '.', 'CBT', '-', 'RR', 'will', 'be', 'compared', 'to', 'a', 'matched', '-', 'intensity', 'augmentative', 'motivational', 'interviewing', '(', 'MI', ')', 'intervention', '.', 'Participants', 'will', 'be', 'recruited', 'from', 'a', 'hospital', '-', 'based', 'day', 'program', 'for', 'eating', 'disorders', ',', 'and', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'the', 'two', 'conditions', 'in', 'addition', 'to', 'the', 'DH', 'as', 'usual', '.', 'participants', 'will', 'be', 'assessed', 'at', 'pre', '-', 'intervention', ',', 'post', '-', 'intervention', ',', 'week', '4', 'of', 'DH', ',', 'post', '-', 'DH', ',', 'and', '6', 'months', 'follow', '-', 'up', '.', 'It', 'is', 'hypothesized', 'that', 'compared', 'to', 'those', 'who', 'receive', 'MI', ',', 'patients', 'who', 'receive', 'CBT', '-', 'RR', 'will', 'be', 'more', 'likely', 'to', 'exhibit', 'a', 'rapid', 'response', 'to', 'day', 'hospital', 'treatment', '(', 'i.e.', ',', '<', '/=', '3', 'binge', 'eating', 'and/or', 'vomiting', 'episodes', 'in', 'the', 'first', '4', 'weeks', ')', '.', 'It', 'is', 'further', 'hypothesized', 'that', 'patients', 'who', 'receive', 'CBT', '-', 'RR', 'will', 'exhibit', 'fewer', 'binge', 'eating', 'and/or', 'vomiting', 'episodes', 'at', 'post', '-', 'DH', 'and', 'at', '6', '-', 'month', 'follow', '-', 'up', '.', 'Potential', 'mediators', 'and', 'moderators', 'of', 'these', 'hypothesized', 'treatment', 'effects', 'will', 'be', 'examined', 'on', 'an', 'exploratory', 'basis', ',', 'including', 'self', '-', 'efficacy', ',', 'motivation', ',', 'and', 'hope', '(', 'potential', 'mediators', ')', ',', 'and', 'emotion', 'regulation', ',', 'depression', ',', 'cognitive', 'psychopathology', 'of', 'eating', 'disorders', ',', 'and', 'working', 'alliance', 'with', 'the', 'therapist', '(', 'potential', 'moderators', ')', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02444065,NCT02444065,"Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder: A Randomized Controlled Trial of an Intervention to Facilitate Early Symptom Change | Treatments for bulimia nervosa (BN) have relatively high rates of nonremission and relapse, meaning that improving treatments is a high priority in this area. Rapid response to treatment -cessation of binge eating and vomiting symptoms within the first weeks of treatment - is a robust predictor of improved post-treatment outcomes and lower relapse rates, but no study has tried to facilitate rapid response as a means of improving treatment outcomes. The present study responds to this gap in the literature by testing a 4-session CBT-based individual intervention for rapid response (i.e., ""CBT-RR""), designed to augment standard day hospital (DH) treatment for BN and Purging Disorder (PD) by focusing on strategies and skills for rapid symptom interruption. CBT-RR will be compared to a matched-intensity augmentative motivational interviewing (MI) intervention. Participants will be recruited from a hospital-based day program for eating disorders, and will be randomly assigned to one of the two conditions in addition to the DH as usual. participants will be assessed at pre-intervention, post-intervention, week 4 of DH, post-DH, and 6 months follow-up. It is hypothesized that compared to those who receive MI, patients who receive CBT-RR will be more likely to exhibit a rapid response to day hospital treatment (i.e., </= 3 binge eating and/or vomiting episodes in the first 4 weeks). It is further hypothesized that patients who receive CBT-RR will exhibit fewer binge eating and/or vomiting episodes at post-DH and at 6-month follow-up. Potential mediators and moderators of these hypothesized treatment effects will be examined on an exploratory basis, including self-efficacy, motivation, and hope (potential mediators), and emotion regulation, depression, cognitive psychopathology of eating disorders, and working alliance with the therapist (potential moderators).","[(0, 40, 'BEHAVIOURAL', 'Rapid Response to Day Hospital Treatment'), (44, 59, 'CONDITION', 'Bulimia Nervosa'), (64, 80, 'CONDITION', 'Purging Disorder'), (183, 198, 'CONDITION', 'bulimia nervosa'), (200, 202, 'CONDITION', 'BN'), (327, 365, 'BEHAVIOURAL', 'Rapid response to treatment -cessation'), (562, 576, 'BEHAVIOURAL', 'rapid response'), (701, 753, 'BEHAVIOURAL', 'CBT-based individual intervention for rapid response'), (762, 768, 'BEHAVIOURAL', 'CBT-RR'), (833, 835, 'CONDITION', 'BN'), (840, 856, 'CONDITION', 'Purging Disorder'), (858, 860, 'CONDITION', 'PD'), (931, 937, 'BEHAVIOURAL', 'CBT-RR'), (960, 1016, 'CONTROL', 'matched-intensity augmentative motivational interviewing'), (1018, 1020, 'CONTROL', 'MI'), (1105, 1121, 'CONDITION', 'eating disorders'), (1385, 1387, 'CONTROL', 'MI'), (1410, 1416, 'BEHAVIOURAL', 'CBT-RR'), (1618, 1624, 'BEHAVIOURAL', 'CBT-RR'), (1970, 1986, 'CONDITION', 'eating disorders')]"
"['Effects', 'of', 'Dexmedetomidine', 'on', 'Delirium', 'Duration', 'of', 'Non', '-', 'intubated', 'ICU', 'Patients', '(', '4D', 'Trial', ')', '|', 'The', 'primary', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'whether', 'dexmedetomidine', 'is', 'effective', 'in', 'treating', 'agitated', 'delirium', 'of', 'non', '-', 'intubated', 'ICI', 'patients']","['O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03317067,NCT03317067,Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial) | The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients,"[(11, 26, 'DRUG', 'Dexmedetomidine'), (30, 38, 'CONDITION', 'Delirium'), (147, 162, 'DRUG', 'dexmedetomidine'), (197, 205, 'CONDITION', 'delirium')]"
"['Comparison', 'Between', 'a', 'Gluten', '-', 'free', 'Diet', 'and', 'a', 'Hypocaloric', 'Diet', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Fibromyalgia', 'and', 'Celiac', '-', 'type', 'Symptoms', '|', 'Fibromyalgia', 'patients', 'frequently', 'suffer', 'from', 'symptoms', 'similar', 'to', 'those', 'of', 'adult', 'celiac', 'disease', ',', 'raising', 'the', 'possibility', 'that', 'some', 'fibromyalgia', 'patients', 'experience', 'oligosymptomatic', 'celiac', 'disease', 'or', 'non', '-', 'celiac', 'gluten', 'intolerance', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effect', 'of', 'a', 'gluten', '-', 'free', 'diet', 'with', 'a', 'hypocaloric', 'diet', 'in', 'patients', 'with', 'fibromyalgia', 'and', 'celiac', '-', 'type', 'symptoms', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01881360,NCT01881360,"Comparison Between a Gluten-free Diet and a Hypocaloric Diet for the Treatment of Patients With Fibromyalgia and Celiac-type Symptoms | Fibromyalgia patients frequently suffer from symptoms similar to those of adult celiac disease, raising the possibility that some fibromyalgia patients experience oligosymptomatic celiac disease or non-celiac gluten intolerance. The objective of this study is to compare the effect of a gluten-free diet with a hypocaloric diet in patients with fibromyalgia and celiac-type symptoms.","[(21, 37, 'OTHER', 'Gluten-free Diet'), (44, 60, 'OTHER', 'Hypocaloric Diet'), (96, 108, 'CONDITION', 'Fibromyalgia'), (113, 133, 'CONDITION', 'Celiac-type Symptoms'), (136, 148, 'CONDITION', 'Fibromyalgia'), (216, 230, 'CONDITION', 'celiac disease'), (266, 278, 'CONDITION', 'fibromyalgia'), (316, 330, 'CONDITION', 'celiac disease'), (345, 363, 'CONDITION', 'gluten intolerance'), (423, 439, 'OTHER', 'gluten-free diet'), (447, 463, 'OTHER', 'hypocaloric diet'), (481, 493, 'CONDITION', 'fibromyalgia'), (498, 518, 'CONDITION', 'celiac-type symptoms')]"
"['The', 'Effects', 'of', 'a', 'Biomechanical', 'Based', 'Tai', 'Chi', 'Intervention', 'Program', 'on', 'Postural', 'Stability', 'and', 'Gait', 'in', 'People', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'associated', 'with', 'changes', 'in', 'gait', 'and', 'posture', 'that', 'can', 'lead', 'to', 'a', 'higher', 'frequency', 'of', 'falls', 'and', 'injuries', 'in', 'this', 'population', '.', 'Research', 'has', 'shown', 'a', 'positive', 'effect', 'of', 'tai', 'chi', '(', 'TC', ')', 'training', 'on', 'the', 'movement', 'capacity', 'for', 'those', 'with', 'PD', ',', 'however', 'the', 'understanding', 'of', 'the', 'impact', 'of', 'TC', 'training', 'on', 'gait', 'and', 'postural', 'stability', 'in', 'PD', 'is', 'lacking', '.', 'This', 'study', 'aims', 'to', 'examine', 'the', 'impact', 'of', 'a', 'biomechanical', '-', 'based', 'TC', 'intervention', 'on', 'dynamic', 'postural', 'stability', 'and', 'how', 'it', 'relates', 'to', 'walking', 'performance', '.', 'It', 'is', 'hypothesized', 'that', 'the', 'effects', 'of', 'the', 'TC', 'intervention', 'will', 'help', 'to', 'improve', 'measures', 'relating', 'to', 'postural', 'stability', ',', 'gait', ',', 'and', 'cognition', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04644367,NCT04644367,"The Effects of a Biomechanical Based Tai Chi Intervention Program on Postural Stability and Gait in People With Parkinson's Disease | Parkinson's disease (PD) is associated with changes in gait and posture that can lead to a higher frequency of falls and injuries in this population. Research has shown a positive effect of tai chi (TC) training on the movement capacity for those with PD, however the understanding of the impact of TC training on gait and postural stability in PD is lacking. This study aims to examine the impact of a biomechanical-based TC intervention on dynamic postural stability and how it relates to walking performance. It is hypothesized that the effects of the TC intervention will help to improve measures relating to postural stability, gait, and cognition.","[(17, 65, 'PHYSICAL', 'Biomechanical Based Tai Chi Intervention Program'), (112, 131, 'CONDITION', ""Parkinson's Disease""), (134, 153, 'CONDITION', ""Parkinson's disease""), (155, 157, 'CONDITION', 'PD'), (324, 331, 'PHYSICAL', 'tai chi'), (333, 335, 'PHYSICAL', 'TC'), (386, 388, 'CONDITION', 'PD'), (433, 444, 'PHYSICAL', 'TC training'), (479, 481, 'CONDITION', 'PD'), (537, 572, 'OTHER', 'biomechanical-based TC intervention'), (689, 704, 'OTHER', 'TC intervention')]"
"['COveRs', 'to', 'impRove', 'EsthetiC', 'ouTcome', 'After', 'Surgery', 'for', 'Chronic', 'Subdural', 'hemAtoma', 'by', 'buRr', 'Hole', 'Trepanation', '(', 'CORRECT', '-', 'SCAR', ')', '-', 'a', 'Single', '-', 'blinded', ',', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'clinical', '-', 'functional', 'result', 'after', 'frontal', 'and', 'parietal', 'burr', '-', 'hole', 'trepanation', 'for', 'the', 'treatment', 'of', 'chronic', 'subdural', 'hematoma', '(', 'cSDH', ')', 'is', 'effective', 'with', 'regards', 'to', 'control', 'of', 'the', 'hematoma', 'and', 'regression', 'of', 'symptoms', '(', 'headache', ',', 'decreased', 'vigilance', 'and', 'neurological', 'deficits', ')', '.', 'However', ',', 'in', 'patients', 'the', 'treatment', 'may', 'leave', 'visible', 'depressions', 'of', 'the', 'scalp', ',', 'just', 'above', 'the', 'trepanation', 'sites', ',', 'that', 'typically', 'develop', 'gradually', 'after', 'weeks', '-', 'months', 'after', 'the', 'procedure', '.', 'A', 'considerable', 'proportion', 'of', 'patients', 'find', 'this', 'aesthetically', ',', 'functionally', 'and', 'psychologically', 'disturbing', ';', 'the', 'skin', 'depressions', 'may', 'even', 'cause', 'pain', 'or', 'interfere', 'with', 'activities', 'of', 'daily', 'living', ',', 'such', 'as', 'combing', ',', 'etc', '.', '\n\n', 'An', 'effective', 'method', 'would', 'exist', 'to', 'avoid', 'this', 'undesired', 'treatment', 'effect', ':', 'Before', 'the', 'skin', 'is', 'closed', ',', 'a', 'permeable', 'titanium', 'burr', '-', 'hole', 'plate', 'could', 'be', 'attached', 'above', 'the', 'trepanation', 'site', 'in', 'order', 'to', 'prevent', 'the', 'skin', 'from', 'sinking', 'into', 'the', 'bony', 'defect', '.', 'However', ',', 'this', 'is', 'rarely', 'done', 'today', ',', 'likely', 'because', 'there', 'is', 'no', 'evidence', 'that', 'this', 'treatment', 'modification', 'is', 'effective', 'and', 'safe', '.', 'Moreover', ',', 'as', 'material', 'is', 'implanted', ',', 'this', 'causes', 'additional', 'costs', '.', '\n\n', 'The', 'primary', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'the', 'application', 'of', 'burr', '-', 'hole', 'plates', 'on', 'both', 'the', 'frontal', 'and', 'parietal', 'burr', '-', 'hole', 'in', 'the', 'context', 'of', 'burr', '-', 'hole', 'trepanation', 'for', 'the', 'treatment', 'of', 'cSDH', 'can', 'improve', 'patient', 'satisfaction', 'with', 'the', 'aesthetic', 'result', 'of', 'the', 'surgery', '.', '\n\n', 'In', 'addition', ',', 'the', 'study', 'is', 'intended', 'to', 'demonstrate', 'that', 'this', 'additional', 'measure', 'will', 'not', 'result', 'in', 'poorer', 'hematoma', 'control', ',', 'poorer', 'clinical', '/', 'neurological', 'outcomes', ',', 'or', 'additional', 'complications', 'for', 'the', 'patient', '.', '\n\n', 'In', 'a', 'prospective', ',', 'single', '-', 'blind', 'and', 'controlled', 'approach', ',', 'we', 'randomize', '80', 'patients', 'with', 'uni-', 'or', 'bilateral', 'cSDH', 'into', 'an', 'intervention', 'group', '(', 'with', 'burr', '-', 'hole', 'plates', ')', 'or', 'into', 'a', 'control', 'group', '(', 'without', 'burr', '-', 'hole', 'plates', ')', '.', '\n\n', 'The', 'primary', 'end', 'result', 'of', 'the', 'study', 'is', 'the', 'patient', ""'s"", 'reported', 'satisfaction', 'with', 'the', 'aesthetic', 'outcome', 'of', 'the', 'surgical', 'scar', '.', 'Secondary', 'results', 'are', 'pain', ',', 'functionality', ',', 'neurological', 'status', ',', 'health', '-', 'related', 'quality', 'of', 'life', ',', 'residual', 'hematoma', 'volume', ',', 'and', 'complications', '(', 'according', 'to', 'Clavien', '-', 'Dindo', 'scale', ';', 'especially', 're', '-', 'operation', 'rate', 'for', 'recurring', 'cSDH', 'and', 'infections', ')', '.', '\n\n', 'The', 'study', 'corresponds', 'to', 'a', 'modern', 'approach', ',', 'since', 'today', ""'s"", 'patients', 'not', 'only', 'expect', 'favorable', 'treatment', 'results', 'for', 'their', 'disease', ',', 'but', 'the', 'therapy', 'should', 'also', 'avoid', 'permanent', 'undesired', 'side', '-', 'effects', ',', 'if', 'possible', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03755349,NCT03755349,"COveRs to impRove EsthetiC ouTcome After Surgery for Chronic Subdural hemAtoma by buRr Hole Trepanation (CORRECT-SCAR) - a Single-blinded, Randomized Controlled Trial | The clinical-functional result after frontal and parietal burr-hole trepanation for the treatment of chronic subdural hematoma (cSDH) is effective with regards to control of the hematoma and regression of symptoms (headache, decreased vigilance and neurological deficits). However, in patients the treatment may leave visible depressions of the scalp, just above the trepanation sites, that typically develop gradually after weeks - months after the procedure. A considerable proportion of patients find this aesthetically, functionally and psychologically disturbing; the skin depressions may even cause pain or interfere with activities of daily living, such as combing, etc.

An effective method would exist to avoid this undesired treatment effect: Before the skin is closed, a permeable titanium burr-hole plate could be attached above the trepanation site in order to prevent the skin from sinking into the bony defect. However, this is rarely done today, likely because there is no evidence that this treatment modification is effective and safe. Moreover, as material is implanted, this causes additional costs.

The primary aim of this study is to evaluate whether the application of burr-hole plates on both the frontal and parietal burr-hole in the context of burr-hole trepanation for the treatment of cSDH can improve patient satisfaction with the aesthetic result of the surgery.

In addition, the study is intended to demonstrate that this additional measure will not result in poorer hematoma control, poorer clinical/neurological outcomes, or additional complications for the patient.

In a prospective, single-blind and controlled approach, we randomize 80 patients with uni- or bilateral cSDH into an intervention group (with burr-hole plates) or into a control group (without burr-hole plates).

The primary end result of the study is the patient's reported satisfaction with the aesthetic outcome of the surgical scar. Secondary results are pain, functionality, neurological status, health-related quality of life, residual hematoma volume, and complications (according to Clavien-Dindo scale; especially re-operation rate for recurring cSDH and infections).

The study corresponds to a modern approach, since today's patients not only expect favorable treatment results for their disease, but the therapy should also avoid permanent undesired side-effects, if possible.","[(53, 78, 'CONDITION', 'Chronic Subdural hemAtoma'), (82, 103, 'CONDITION', 'buRr Hole Trepanation'), (206, 248, 'CONDITION', 'frontal and parietal burr-hole trepanation'), (270, 295, 'CONDITION', 'chronic subdural hematoma'), (297, 301, 'CONDITION', 'cSDH'), (347, 355, 'CONDITION', 'hematoma'), (536, 547, 'CONDITION', 'trepanation'), (951, 985, 'OTHER', 'permeable titanium burr-hole plate'), (1362, 1421, 'OTHER', 'burr-hole plates on both the frontal and parietal burr-hole'), (1440, 1461, 'CONDITION', 'burr-hole trepanation'), (1483, 1487, 'CONDITION', 'cSDH'), (1858, 1880, 'CONDITION', 'uni- or bilateral cSDH'), (1914, 1930, 'OTHER', 'burr-hole plates'), (1957, 1981, 'CONTROL', 'without burr-hole plates'), (2214, 2222, 'CONDITION', 'hematoma'), (2327, 2331, 'CONDITION', 'cSDH')]"
"['Comparative', 'Low', 'and', 'High', 'Dose', 'of', 'Dexmedethomidine', 'Can', 'Stabilize', 'Hemodynamics', 'and', 'Blood', 'Loss', 'in', 'Pituitary', 'Tumor', 'Removal', 'by', 'Transphenoid', 'Approach', '|', 'Transnasal', 'transsphenoidal', '(', 'TNTS', ')', 'resection', 'of', 'pituitary', 'tumors', 'involves', 'wide', 'fluctuation', 'in', 'hemodynamic', 'parameter', 'and', 'causes', 'hypertension', 'and', 'tachycardia', 'due', 'to', 'intense', 'noxious', 'stimuli', 'during', 'various', 'stages', 'of', 'surgery', '.', 'None', 'of', 'routinely', 'used', 'anesthetic', 'agents', 'effectively', 'blunts', 'the', 'undesirable', 'hemodynamic', 'responses', ',', 'and', 'therefore', 'usually', 'there', 'is', 'a', 'need', 'to', 'use', 'increased', 'doses', 'of', 'anesthetic', 'agents', '.', 'Dexmedetomidine', '(', 'DEX', ')', 'an', 'α-2', 'adrenergic', 'receptor', 'agonist', ',', 'because', 'its', 'sympatholytic', 'and', 'antinociceptive', 'properties', 'may', 'ensure', 'optimal', 'intraoperative', 'hemodynamic', 'stability', 'during', 'critical', 'moments', 'of', 'surgical', 'manipulation', '.', 'In', 'addition', ',', 'DEX', 'reduced', 'the', 'anesthetic', 'requirement', 'with', 'rapid', 'recovery', 'at', 'the', 'end', 'of', 'surgery', '.', 'The', 'main', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'the', 'effect', 'of', 'DEX', 'on', 'perioperative', 'hemodynamics', ',', 'anesthetic', 'requirements']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03132259,NCT03132259,"Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach | Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. None of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. Dexmedetomidine (DEX) an α-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. In addition, DEX reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic requirements","[(33, 49, 'DRUG', 'Dexmedethomidine'), (95, 143, 'CONDITION', 'Pituitary Tumor Removal by Transphenoid Approach'), (146, 209, 'CONDITION', 'Transnasal transsphenoidal (TNTS) resection of pituitary tumors'), (272, 284, 'CONDITION', 'hypertension'), (289, 300, 'CONDITION', 'tachycardia'), (548, 563, 'DRUG', 'Dexmedetomidine'), (565, 568, 'DRUG', 'DEX'), (573, 604, 'DRUG', 'α-2 adrenergic receptor agonist'), (782, 785, 'DRUG', 'DEX'), (920, 923, 'DRUG', 'DEX')]"
"['Efficacy', 'and', 'Safety', 'of', 'the', 'Rivastigmine', 'Transdermal', 'Patch', 'in', 'Patients', 'With', 'Probable', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'goal', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'the', 'rivastigmine', 'transdermal', 'patch', 'in', 'patients', 'with', 'probable', 'Alzheimer', ""'s"", 'Disease', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00099242,NCT00099242,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease | The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.,"[(27, 39, 'DRUG', 'Rivastigmine'), (84, 103, 'CONDITION', ""Alzheimer's Disease""), (184, 196, 'DRUG', 'rivastigmine'), (241, 260, 'CONDITION', ""Alzheimer's Disease"")]"
"['A', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Effect', 'of', 'Risperidone', 'Extended', '-', 'Release', 'Injectable', 'Suspension', '(', 'TV-46000', ')', 'for', 'Subcutaneous', 'Use', 'as', 'Maintenance', 'Treatment', 'in', 'Adult', 'and', 'Adolescent', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'TV-46000', '.', 'The', 'primary', 'safety', 'and', 'tolerability', 'endpoint', 'is', 'the', 'frequency', 'of', 'all', 'adverse', 'events', ',', 'including', 'serious', 'adverse', 'events', '.', 'For', 'new', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '80', 'weeks', '(', 'including', 'a', 'screening', 'period', 'of', 'up', 'to', '4', 'weeks', ',', 'a', '12', '-', 'week', 'oral', 'conversion', '/', 'stabilization', 'stage', '[', 'Stage', '1', ']', ',', 'a', '56', '-', 'week', 'double', '-', 'blind', 'maintenance', 'stage', '[', 'Stage', '2', ']', ',', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'For', 'roll', '-', 'over', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '64', 'weeks', '(', 'including', 'up', 'to', '56', 'weeks', 'in', 'the', 'maintenance', 'stage', '[', 'Stage', '2', ']', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'Participants', 'who', 'started', 'Stage', '2', 'who', 'relapse', 'or', 'meet', '1', 'or', 'more', 'of', 'the', 'withdrawal', 'criteria', 'should', 'be', 'invited', 'to', 'perform', 'the', 'Early', 'Termination', 'visit', 'as', 'soon', 'as', 'possible', 'within', '4', 'weeks', 'of', 'the', 'last', 'injection', '.', 'Participants', 'who', 'withdraw', 'from', 'the', 'study', 'before', 'completing', 'the', '56', '-', 'week', 'maintenance', 'stage', 'will', 'have', 'follow', '-', 'up', 'procedures', 'and', 'assessments', 'performed', 'at', 'their', 'follow', '-', 'up', 'visits', '.', 'During', 'the', 'follow', '-', 'up', 'period', ',', 'participants', 'will', 'be', 'treated', 'according', 'to', 'the', 'investigator', ""'s"", 'judgment', '.', '\n\n', 'All', 'participants', 'will', 'be', 'treated', 'with', 'active', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03893825,NCT03893825,"A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events. For new participants, the total duration of participant participation in the study is planned to be up to 80 weeks (including a screening period of up to 4 weeks, a 12-week oral conversion/stabilization stage [Stage 1], a 56-week double-blind maintenance stage [Stage 2], and a follow-up period [8 weeks]). For roll-over participants, the total duration of participant participation in the study is planned to be up to 64 weeks (including up to 56 weeks in the maintenance stage [Stage 2] and a follow-up period [8 weeks]). Participants who started Stage 2 who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Early Termination visit as soon as possible within 4 weeks of the last injection. Participants who withdraw from the study before completing the 56-week maintenance stage will have follow-up procedures and assessments performed at their follow-up visits. During the follow-up period, participants will be treated according to the investigator's judgment.

All participants will be treated with active drug.","[(60, 71, 'DRUG', 'Risperidone'), (112, 120, 'DRUG', 'TV-46000'), (206, 219, 'CONDITION', 'Schizophrenia'), (313, 321, 'DRUG', 'TV-46000')]"
"['Cognitive', 'Reserve', 'and', 'Linguistic', 'Resilience', 'in', 'Bilingual', 'Hispanics', 'With', 'Primary', 'Progressive', 'Aphasia', '|', 'Difficulties', 'with', 'speech', 'and', 'language', 'are', 'the', 'first', 'and', 'most', 'notable', 'symptoms', 'of', 'primary', 'progressive', 'aphasia', '(', 'PPA', ')', '.', 'While', 'there', 'is', 'evidence', 'that', 'demonstrates', 'positive', 'effects', 'of', 'speech', '-', 'language', 'treatment', 'for', 'individuals', 'with', 'PPA', 'who', 'only', 'speak', 'one', 'language', '(', 'monolinguals', ')', ',', 'there', 'is', 'a', 'significant', 'need', 'for', 'investigating', 'the', 'effects', 'of', 'treatment', 'that', 'is', 'optimized', 'for', 'bilingual', 'speakers', 'with', 'PPA', '.', 'This', 'stage', '2', 'efficacy', 'clinical', 'trial', 'seeks', 'to', 'establish', 'the', 'effects', 'of', 'culturally', 'and', 'linguistically', 'tailored', 'speech', '-', 'language', 'interventions', 'administered', 'to', 'bilingual', 'individuals', 'with', 'PPA', '.', '\n\n', 'The', 'overall', 'aim', 'of', 'the', 'intervention', 'component', 'of', 'this', 'study', 'is', 'to', 'establish', 'the', 'relationships', 'between', 'the', 'bilingual', 'experience', '(', 'e.g.', ',', 'how', 'often', 'each', 'language', 'is', 'used', ',', 'how', '""', 'strong', '""', 'each', 'language', 'is', ')', 'and', 'treatment', 'response', 'of', 'bilinguals', 'with', 'PPA', '.', 'Specifically', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'benefits', 'of', 'tailored', 'speech', '-', 'language', 'intervention', 'administered', 'in', 'both', 'languages', 'to', 'bilingual', 'individuals', 'with', 'PPA', '(', '60', 'individuals', 'will', 'be', 'recruited', ')', '.', 'The', 'investigators', 'will', 'conduct', 'an', 'assessment', 'before', 'treatment', ',', 'after', 'treatment', 'and', 'at', 'two', 'follow', '-', 'ups', '(', '6', 'and', '12', '-', 'months', 'post', '-', 'treatment', ')', 'in', 'both', 'languages', '.', 'When', 'possible', ',', 'a', 'structural', 'scan', 'of', 'the', 'brain', '(', 'magnetic', 'resonance', 'image', ')', 'will', 'be', 'collected', 'before', 'treatment', 'in', 'order', 'to', 'identify', 'if', 'brain', 'regions', 'implicated', 'in', 'bilingualism', 'are', 'associated', 'with', 'response', 'to', 'treatment', '.', 'In', 'addition', 'to', 'the', 'intervention', 'described', 'herein', ',', '30', 'bilingual', 'individuals', 'with', 'PPA', 'will', 'be', 'recruited', 'to', 'complete', 'behavioral', 'cognitive', '-', 'linguistic', 'testing', 'and', 'will', 'not', 'receive', 'intervention', '.', 'Results', 'will', 'provide', 'important', 'knowledge', 'about', 'the', 'neural', 'mechanisms', 'of', 'language', 're', '-', 'learning', 'and', 'will', 'address', 'how', 'specific', 'characteristics', 'of', 'bilingualism', 'influence', 'cognitive', 'reserve', 'and', 'linguistic', 'resilience', 'in', 'PPA', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05741853,NCT05741853,"Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia | Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.

The overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how ""strong"" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.","[(72, 99, 'CONDITION', 'Primary Progressive Aphasia'), (183, 210, 'CONDITION', 'primary progressive aphasia'), (212, 215, 'CONDITION', 'PPA'), (327, 330, 'CONDITION', 'PPA'), (492, 495, 'CONDITION', 'PPA'), (568, 636, 'OTHER', 'culturally and linguistically tailored speech-language interventions'), (680, 683, 'CONDITION', 'PPA'), (926, 929, 'CONDITION', 'PPA'), (993, 1030, 'OTHER', 'tailored speech-language intervention'), (1092, 1095, 'CONDITION', 'PPA'), (1581, 1584, 'CONDITION', 'PPA'), (1664, 1688, 'CONTROL', 'not receive intervention'), (1902, 1905, 'CONDITION', 'PPA')]"
"['Double', '-', 'blind', ',', 'Double', '-', 'simulation', ',', 'Risperidone', '-', 'controlled', ',', 'Multicentre', 'Clinical', 'Trial', 'of', 'Iloperidone', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'This', 'research', 'is', 'a', 'Randomized', ',', 'double', '-', 'blind', ',', 'risperidone', '-', 'controlled', ',', 'multicenter', 'clinical', 'study', '.', 'Chinese', 'subjects', 'with', 'Ischemic', 'Schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02453893,NCT02453893,"Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia | This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.","[(31, 42, 'DRUG', 'Risperidone'), (84, 95, 'DRUG', 'Iloperidone'), (113, 126, 'CONDITION', 'Schizophrenia'), (174, 185, 'DRUG', 'risperidone'), (248, 270, 'CONDITION', 'Ischemic Schizophrenia')]"
"['Restoring', 'High', 'Dimensional', 'Hand', 'Function', 'to', 'Persons', 'With', 'Chronic', 'High', 'Tetraplegia', '|', 'This', 'study', 'is', 'for', 'people', 'who', 'have', 'a', 'paralyzed', 'arm', 'and', 'hand', 'from', 'a', 'spinal', 'cord', 'injury', ',', 'who', 'have', 'also', 'received', 'a', 'recording', 'electrode', 'array', 'in', 'the', 'brain', 'as', 'part', 'of', 'the', 'BrainGate', 'study', '.', 'The', 'study', 'will', 'look', 'at', 'the', 'ability', 'of', 'these', 'participants', 'to', 'control', 'different', 'grasping', 'patterns', 'of', 'the', 'hand', ',', 'both', 'in', 'virtual', 'reality', 'and', 'in', 'his', '/', 'her', 'actual', 'hand', '.', 'Movement', 'of', 'the', 'participant', ""'s"", 'hand', 'is', 'controlled', 'by', 'a', 'functional', 'electrical', 'stimulation', '(', 'FES', ')', 'system', ',', 'which', 'involves', 'small', 'electrodes', 'implanted', 'in', 'the', 'arm', ',', 'shoulder', 'and', 'hand', 'that', 'use', 'small', 'electrical', 'currents', 'to', 'activate', 'the', 'appropriate', 'muscles', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03482310,NCT03482310,"Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia | This study is for people who have a paralyzed arm and hand from a spinal cord injury, who have also received a recording electrode array in the brain as part of the BrainGate study. The study will look at the ability of these participants to control different grasping patterns of the hand, both in virtual reality and in his/her actual hand. Movement of the participant's hand is controlled by a functional electrical stimulation (FES) system, which involves small electrodes implanted in the arm, shoulder and hand that use small electrical currents to activate the appropriate muscles.","[(57, 81, 'CONDITION', 'Chronic High Tetraplegia'), (120, 129, 'CONDITION', 'paralyzed'), (150, 168, 'CONDITION', 'spinal cord injury'), (481, 514, 'OTHER', 'functional electrical stimulation'), (516, 519, 'OTHER', 'FES')]"
"['Compliance', ',', 'Tolerance', 'and', 'Acceptability', 'of', 'a', 'Tablet', 'Protein', 'Substitute', 'for', 'the', 'Dietary', 'Management', 'of', 'Phenylketonuria', '|', 'Thirty', 'eligible', 'PKU', 'patients', '(', '≥', '8', 'years', ')', ',', 'identified', 'as', 'tablet', 'protein', 'substitute', 'users', ',', 'will', 'be', 'recruited', '.', 'Patients', 'will', 'firstly', 'observe', 'a', '7', '-', 'day', 'baseline', 'period', ',', 'in', 'which', 'participants', 'will', 'continue', 'with', 'their', 'existing', 'diet', ',', 'protein', 'substitute', 'and', 'multi', 'vitamin', 'prescription', '.', 'Patients', 'will', 'then', 'receive', 'the', 'phaenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'daily', 'for', '28', 'days', 'in', 'addition', 'to', 'appropriate', 'nutritional', 'management', '.', 'The', 'aim', 'of', 'this', 'prospective', ',', 'single', 'arm', 'trial', 'is', 'to', 'evaluate', 'the', 'acceptability', '(', 'compliance', ',', 'tolerance', 'and', 'palatability', ')', 'of', 'the', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'in', 'patients', 'with', 'proven', 'PKU', '.', 'The', 'primary', 'outcome', 'measure', 'is', 'compliance', ',', 'with', 'secondary', 'outcome', 'measures', 'of', 'gastrointestinal', 'tolerance', ',', 'acceptability', ',', 'blood', 'amino', 'acids', ',', 'dietary', 'intake', ',', 'anthropometry', 'and', 'safety', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03333720,NCT03333720,"Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria | Thirty eligible PKU patients (≥ 8 years), identified as tablet protein substitute users, will be recruited. Patients will firstly observe a 7-day baseline period, in which participants will continue with their existing diet, protein substitute and multi vitamin prescription. Patients will then receive the phaenylalanine-free protein substitute tablets daily for 28 days in addition to appropriate nutritional management. The aim of this prospective, single arm trial is to evaluate the acceptability (compliance, tolerance and palatability) of the phenylalanine-free protein substitute tablets in patients with proven PKU. The primary outcome measure is compliance, with secondary outcome measures of gastrointestinal tolerance, acceptability, blood amino acids, dietary intake, anthropometry and safety.","[(52, 70, 'OTHER', 'Protein Substitute'), (101, 116, 'CONDITION', 'Phenylketonuria'), (135, 138, 'CONDITION', 'PKU'), (182, 200, 'OTHER', 'protein substitute'), (426, 464, 'OTHER', 'phaenylalanine-free protein substitute'), (669, 706, 'OTHER', 'phenylalanine-free protein substitute'), (739, 742, 'CONDITION', 'PKU')]"
"['Impact', 'of', 'Various', 'Sedation', 'Regimens', 'on', 'the', 'Incidence', 'of', 'Post', '-', 'sedation', 'Delirium', 'in', 'Patients', 'Receiving', 'Mechanical', 'Ventilation', '|', 'Sedation', 'drugs', 'that', 'are', 'commonly', 'used', 'in', 'ICU', 'in', 'treatment', 'of', 'ARDS', ',', 'includes', 'propofol', ',', 'midazolam', 'and', 'dexmedetomidine', '.', 'Among', 'these', ',', 'both', 'dexmedetomidine', 'and', 'propofol', 'have', 'been', 'reported', 'to', 'be', 'used', 'together', 'with', 'midazolam', 'in', 'ICU', 'and', 'the', 'combination', 'of', 'propofol', 'and', 'midazolam', 'is', 'most', 'commonly', 'used', ',', 'but', 'things', 'follow', 'include', 'a', 'high', 'incidence', 'rate', 'of', 'delirium', ',', 'But', 'the', 'combination', 'of', 'midazolam', 'and', 'dexmedetomidine', 'may', 'have', 'complementary', 'advantages', 'and', 'could', 'have', 'be', 'a', 'better', 'choice', 'for', 'sedation', '.', 'In', 'this', 'study', ',', 'we', 'attempted', 'to', 'observe', 'the', 'effects', 'of', 'two', 'different', 'drug', 'regimens', 'on', 'delirium', 'incidence', 'rates', 'in', 'severe', 'ARDS', 'patients', ""'"", ':', 'midazolam', 'and', 'propofol', 'vs', 'propofol', 'and', 'dexmedetomidine', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT02117726,NCT02117726,"Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation | Sedation drugs that are commonly used in ICU in treatment of ARDS, includes propofol, midazolam and dexmedetomidine . Among these, both dexmedetomidine and propofol have been reported to be used together with midazolam in ICU and the combination of propofol and midazolam is most commonly used, but things follow include a high incidence rate of delirium, But the combination of midazolam and dexmedetomidine may have complementary advantages and could have be a better choice for sedation. In this study, we attempted to observe the effects of two different drug regimens on delirium incidence rates in severe ARDS patients' : midazolam and propofol vs propofol and dexmedetomidine .","[(18, 35, 'OTHER', 'Sedation Regimens'), (56, 78, 'CONDITION', 'Post-sedation Delirium'), (101, 123, 'CONDITION', 'Mechanical Ventilation'), (187, 191, 'CONDITION', 'ARDS'), (202, 210, 'DRUG', 'propofol'), (212, 221, 'DRUG', 'midazolam'), (226, 241, 'DRUG', 'dexmedetomidine'), (262, 277, 'DRUG', 'dexmedetomidine'), (282, 290, 'DRUG', 'propofol'), (335, 344, 'DRUG', 'midazolam'), (375, 383, 'DRUG', 'propofol'), (388, 397, 'DRUG', 'midazolam'), (472, 480, 'CONDITION', 'delirium'), (505, 514, 'DRUG', 'midazolam'), (519, 534, 'DRUG', 'dexmedetomidine'), (675, 698, 'OTHER', 'different drug regimens'), (702, 710, 'CONDITION', 'delirium'), (737, 741, 'CONDITION', 'ARDS'), (754, 763, 'DRUG', 'midazolam'), (768, 776, 'DRUG', 'propofol'), (780, 788, 'DRUG', 'propofol'), (793, 808, 'DRUG', 'dexmedetomidine')]"
"['New', 'Methods', 'of', 'Dynamic', 'Pupillometrics', 'in', 'Subjects', 'With', 'Visual', 'and', 'Color', 'Vision', 'Pathologies', 'for', 'the', 'Detection', ',', 'Functional', 'Diagnosis', 'and', 'Follow', '-', 'up', 'of', 'These', 'Pathologies', '|', 'The', 'development', 'of', 'new', 'oculometry', 'techniques', 'allows', 'fine', 'and', 'dynamic', 'measurements', 'of', 'pupillary', 'diameter', 'and', 'use', 'in', 'routine', 'clinical', 'practice', '.', '\n\n', 'The', 'preliminary', 'results', 'obtained', 'with', 'innovative', 'devices', 'on', 'healthy', 'sjuets', 'make', 'it', 'possible', 'to', 'envisage', 'a', 'clinical', 'study', 'on', 'a', 'population', 'of', 'patients', 'suffering', 'from', 'retinal', 'pathologies', '.', '\n\n', 'This', 'is', 'a', '""', 'proof', 'of', 'concept', '""', 'study', ',', 'which', ',', 'if', 'the', 'expected', 'results', 'are', 'confirmed', ',', 'will', 'make', 'it', 'possible', 'to', 'consider', 'a', 'study', 'on', 'a', 'larger', 'population', ',', 'as', 'well', 'as', 'the', 'industrial', 'development', 'of', 'a', 'commercial', 'device', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04909398,NCT04909398,"New Methods of Dynamic Pupillometrics in Subjects With Visual and Color Vision Pathologies for the Detection, Functional Diagnosis and Follow-up of These Pathologies | The development of new oculometry techniques allows fine and dynamic measurements of pupillary diameter and use in routine clinical practice.

The preliminary results obtained with innovative devices on healthy sjuets make it possible to envisage a clinical study on a population of patients suffering from retinal pathologies.

This is a ""proof of concept"" study, which, if the expected results are confirmed, will make it possible to consider a study on a larger population, as well as the industrial development of a commercial device.","[(55, 90, 'CONDITION', 'Visual and Color Vision Pathologies'), (475, 494, 'CONDITION', 'retinal pathologies')]"
"['Bimodal', 'and', 'Coaxial', 'High', 'Resolution', 'Ophtalmic', 'Imaging', '|', 'The', 'knowledge', 'of', 'the', 'pathogenesis', 'of', 'retinal', 'affections', ',', 'a', 'major', 'cause', 'of', 'blindness', ',', 'has', 'greatly', 'benefited', 'from', 'recent', 'advances', 'in', 'retinal', 'imaging', '.', 'However', ',', 'optical', 'aberrations', 'of', 'the', 'ocular', 'media', 'limit', 'the', 'resolution', 'that', 'can', 'be', 'achieved', 'by', 'current', 'techniques', '.', '\n\n', 'The', 'use', 'of', 'an', 'adaptive', 'optics', 'system', 'improves', 'the', 'resolution', 'of', 'ophthalmoscopes', 'by', 'several', 'orders', 'of', 'magnitude', ',', 'allowing', 'the', 'visualization', 'of', 'many', 'retinal', 'microstructures', ':', 'photoreceptors', ',', 'vessels', ',', 'bundles', 'of', 'nerve', 'fibers', '.', '\n\n', 'Recently', ',', 'the', 'development', 'of', 'the', 'coupling', 'of', 'the', 'two', 'main', 'imaging', 'techniques', ',', 'the', 'Adaptive', 'Optics', 'Ophthalmoscope', 'with', 'Optical', 'Coherence', 'Tomography', ',', 'enables', 'unparalleled', 'three', '-', 'dimensional', 'in', 'vivo', 'cell', '-', 'scale', 'imaging', ',', 'while', 'remaining', 'comfortable', 'for', 'the', 'patients', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'project', 'is', 'to', 'evaluate', 'the', 'performance', 'of', 'this', 'system', 'for', 'imaging', 'micrometric', 'retinal', 'structures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04620876,NCT04620876,"Bimodal and Coaxial High Resolution Ophtalmic Imaging | The knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging. However, optical aberrations of the ocular media limit the resolution that can be achieved by current techniques.

The use of an adaptive optics system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many retinal microstructures: photoreceptors, vessels, bundles of nerve fibers.

Recently, the development of the coupling of the two main imaging techniques, the Adaptive Optics Ophthalmoscope with Optical Coherence Tomography, enables unparalleled three-dimensional in vivo cell-scale imaging, while remaining comfortable for the patients.

The purpose of this project is to evaluate the performance of this system for imaging micrometric retinal structures.","[(130, 139, 'CONDITION', 'blindness')]"
"['A', 'Randomised', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Desmoteplase', 'in', 'Subjects', 'With', 'Acute', 'Ischemic', 'Stroke', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'desmoteplase', 'is', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'acute', 'ischaemic', 'stroke', 'when', 'given', 'within', '3', 'to', '9', 'hours', 'from', 'onset', 'of', 'stroke', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00856661,NCT00856661,"A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke | The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.","[(43, 50, 'CONTROL', 'Placebo'), (117, 129, 'DRUG', 'Desmoteplase'), (147, 168, 'CONDITION', 'Acute Ischemic Stroke'), (220, 232, 'DRUG', 'desmoteplase'), (289, 311, 'CONDITION', 'acute ischaemic stroke'), (357, 363, 'CONDITION', 'stroke')]"
"['Music', 'Intervention', 'and', 'Transcranial', 'Electrical', 'Stimulation', 'for', 'Treating', 'Neurological', 'Diseases', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'a', 'musical', 'interventionand', 'non', '-', 'invasive', 'brain', 'stimulation', 'in', 'neurological', 'patients', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'to', 'evaluate', 'the', 'residual', 'neuroplastic', 'processes', 'in', 'DOC', 'state', 'related', 'to', 'music', 'exposure', '\n', 'to', 'determine', 'the', 'putative', 'modulation', 'of', 'the', 'aforementioned', 'processes', 'and', 'the', 'clinical', 'outcome', 'of', 'DOC', 'patients', 'by', 'non', '-', 'pharmacological', 'strategies', ',', 'i.e.', ',', 'electric', '(', 'tDCS', ')', 'and', 'music', 'stimulation', '\n', 'to', 'evaluate', 'the', 'impact', 'of', 'this', 'intervention', 'on', 'caregiver', ""'s"", 'burden', 'and', 'psychological', 'distress', '.', '\n\n', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'three', 'different', 'music', '-', 'listening', 'intervention', 'groups', '.', 'Primary', 'outcomes', 'will', 'be', 'clinical', ',', 'that', 'is', 'based', 'on', 'the', 'neurologist', ""'s"", 'observations', 'of', 'clinical', 'improvement', ',', 'and', 'neurophysiological', ',', 'collected', 'pre', '-', 'intervention', ',', 'post', '-', 'intervention', 'and', 'post', '-', 'placebo', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05706831,NCT05706831,"Music Intervention and Transcranial Electrical Stimulation for Treating Neurological Diseases | The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:

to evaluate the residual neuroplastic processes in DOC state related to music exposure
to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
to evaluate the impact of this intervention on caregiver's burden and psychological distress.

Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.","[(0, 18, 'OTHER', 'Music Intervention'), (23, 58, 'OTHER', 'Transcranial Electrical Stimulation'), (72, 93, 'CONDITION', 'Neurological Diseases'), (185, 215, 'OTHER', 'non-invasive brain stimulation'), (357, 371, 'OTHER', 'music exposure'), (523, 560, 'OTHER', 'electric (tDCS) and music stimulation'), (721, 736, 'OTHER', 'music-listening'), (945, 952, 'CONTROL', 'placebo')]"
"['D', '-', 'cycloserine', 'Augmented', 'Treatment', ':', 'Enhancing', 'Extinction', 'Learning', 'in', 'Youth', 'With', 'Tic', 'Disorders', '|', 'This', 'pilot', 'study', 'aims', 'evaluate', 'the', 'feasibility', 'and', 'initial', 'efficacy', 'of', 'behavior', 'therapy', 'augmented', 'by', 'd', '-', 'cycloserine', '(', 'DCS', ')', 'compared', 'to', 'behavior', 'therapy', 'augmented', 'by', 'placebo', '.', 'After', 'an', 'initial', 'assessment', 'to', 'determine', 'eligibility', ',', 'youth', 'with', 'TD', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'four', 'sessions', 'of', 'behavior', 'therapy', 'augmented', 'by', 'either', 'DCS', 'or', 'placebo', '.', 'D', '-', 'cycloserine', 'is', 'an', 'FDA', '-', 'approved', 'antibiotic', 'medication', 'that', 'has', 'been', 'shown', 'to', 'enhance', 'extinction', 'learning', 'in', 'several', 'studies', '.', 'The', 'investigators', ""'"", 'proof', '-', 'of', '-', 'concept', 'work', 'has', 'found', 'that', 'a', 'single', 'session', 'of', 'DCS', '-', 'augmented', 'behavior', 'therapy', 'reduced', 'the', 'severity', 'of', 'tics', 'targeted', 'in', 'treatment', 'on', 'the', 'Hopkins', 'Motor', '/', 'Vocal', 'Tic', 'Scale', '(', 'HM', '/', 'VTS', ')', 'compared', 'to', 'placebo', '-', 'augmented', 'behavior', 'therapy', '.', 'This', 'highlights', 'the', 'exciting', 'potential', 'of', 'combining', 'DCS', 'with', 'behavior', 'therapy', 'to', 'improve', 'reductions', 'in', 'tic', 'severity', '.', 'However', ',', 'prior', 'to', 'a', 'large', '-', 'scale', 'clinical', 'trial', ',', 'it', 'is', 'essential', 'to', 'determine', 'the', 'feasibility', 'and', 'efficacy', 'of', 'augmenting', 'behavior', 'therapy', 'with', 'DCS', 'over', 'multiple', 'treatment', 'sessions', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT04357951,NCT04357951,"D-cycloserine Augmented Treatment: Enhancing Extinction Learning in Youth With Tic Disorders | This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment to determine eligibility, youth with TD will be randomly assigned to receive four sessions of behavior therapy augmented by either DCS or placebo. D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. The investigators' proof-of-concept work has found that a single session of DCS-augmented behavior therapy reduced the severity of tics targeted in treatment on the Hopkins Motor/Vocal Tic Scale (HM/VTS) compared to placebo-augmented behavior therapy. This highlights the exciting potential of combining DCS with behavior therapy to improve reductions in tic severity. However, prior to a large-scale clinical trial, it is essential to determine the feasibility and efficacy of augmenting behavior therapy with DCS over multiple treatment sessions.","[(0, 13, 'DRUG', 'D-cycloserine'), (79, 92, 'CONDITION', 'Tic Disorders'), (166, 182, 'BEHAVIOURAL', 'behavior therapy'), (196, 209, 'DRUG', 'd-cycloserine'), (211, 214, 'DRUG', 'DCS'), (228, 265, 'CONTROL', 'behavior therapy augmented by placebo'), (332, 334, 'CONDITION', 'TD'), (389, 405, 'BEHAVIOURAL', 'behavior therapy'), (426, 429, 'DRUG', 'DCS'), (433, 440, 'CONTROL', 'placebo'), (442, 455, 'DRUG', 'D-cycloserine'), (644, 647, 'DRUG', 'DCS'), (658, 674, 'BEHAVIOURAL', 'behavior therapy'), (699, 703, 'CONDITION', 'tics'), (784, 818, 'CONTROL', 'placebo-augmented behavior therapy'), (872, 875, 'DRUG', 'DCS'), (881, 897, 'BEHAVIOURAL', 'behavior therapy'), (923, 926, 'CONDITION', 'tic'), (1057, 1073, 'BEHAVIOURAL', 'behavior therapy'), (1079, 1082, 'DRUG', 'DCS')]"
"['Does', 'Early', 'Supination', 'and', 'External', 'Rotation', 'Repositioning', 'in', 'Children', 'With', 'Birth', 'Related', 'Brachial', 'Plexus', 'Injury', 'Have', 'Benefit', '?', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'the', 'Sup', '-', 'ER', 'Protocol', '.', '|', 'This', 'study', 'evaluates', 'the', 'ability', 'of', 'a', 'supination', 'and', 'external', 'rotation', 'protocol', 'to', 'improve', 'the', 'arm', 'function', 'and', 'anatomy', 'of', 'children', 'with', 'birth', 'related', 'brachial', 'plexus', 'injuries', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01933438,NCT01933438,Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol. | This study evaluates the ability of a supination and external rotation protocol to improve the arm function and anatomy of children with birth related brachial plexus injuries.,"[(5, 21, 'OTHER', 'Early Supination'), (26, 57, 'OTHER', 'External Rotation Repositioning'), (75, 111, 'CONDITION', 'Birth Related Brachial Plexus Injury'), (220, 230, 'OTHER', 'supination'), (235, 252, 'OTHER', 'external rotation'), (319, 357, 'CONDITION', 'birth related brachial plexus injuries')]"
"['Pressure', 'Ulcer', 'Prevention', 'for', 'SCI', 'Using', 'a', 'Tele', 'Home', 'Program', '|', 'NRI', 'research', 'focuses', 'on', 'nursing', 'interventions', 'that', 'are', 'patient', '-', 'centered', ',', 'culturally', 'congruent', ',', 'cost', '-', 'effective', 'and', 'outcome', '-', 'driven', '.', 'High', 'priority', 'populations', 'of', 'interest', 'are', 'veterans', 'with', 'Spinal', 'Cord', 'Injuries', '(', 'SCI', ')', '.', 'The', 'development', 'of', 'innovative', 'tele', 'home', 'techniques', 'for', 'preventing', 'pressure', 'ulcers', 'in', 'veterans', 'with', 'SCI', 'is', 'of', 'high', 'importance', 'in', 'the', 'VA', '.', 'Our', 'findings', 'may', 'provide', 'clinicians', 'with', 'improved', 'methods', 'for', 'skin', 'and', 'wound', 'assessment', 'and', 'more', 'effective', 'and', 'efficient', 'PUP', 'strategies', 'for', 'Hispanic', 'and', 'non', 'Hispanic', 'veterans', '.', 'The', 'new', 'model', 'for', 'primary', 'care', ',', 'the', 'patient', '-', 'centered', 'Medical', 'Home', 'provides', 'an', 'exciting', 'change', 'in', 'the', 'VA', 'that', 'can', 'benefit', 'from', 'the', 'proposed', 'project', '.']","['B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01166828,NCT01166828,"Pressure Ulcer Prevention for SCI Using a Tele Home Program | NRI research focuses on nursing interventions that are patient-centered, culturally congruent, cost-effective and outcome-driven. High priority populations of interest are veterans with Spinal Cord Injuries (SCI). The development of innovative tele home techniques for preventing pressure ulcers in veterans with SCI is of high importance in the VA. Our findings may provide clinicians with improved methods for skin and wound assessment and more effective and efficient PUP strategies for Hispanic and non Hispanic veterans. The new model for primary care, the patient-centered Medical Home provides an exciting change in the VA that can benefit from the proposed project.","[(0, 14, 'CONDITION', 'Pressure Ulcer'), (30, 33, 'CONDITION', 'SCI'), (42, 59, 'OTHER', 'Tele Home Program'), (248, 268, 'CONDITION', 'Spinal Cord Injuries'), (270, 273, 'CONDITION', 'SCI'), (306, 326, 'OTHER', 'tele home techniques'), (342, 357, 'CONDITION', 'pressure ulcers'), (375, 378, 'CONDITION', 'SCI'), (624, 653, 'OTHER', 'patient-centered Medical Home')]"
"['Prospective', 'Comparative', 'Multicenter', 'Study', 'on', 'the', 'Medico', '-', 'economical', 'Impact', 'of', 'the', 'Brindley', 'Technique', 'in', 'the', 'Management', 'of', 'Neurogenic', 'Bladder', 'in', 'Patients', 'With', 'Injured', 'Spinal', 'Cord', '|', 'Bladder', 'dysfunction', 'is', 'a', 'major', 'problem', 'in', 'patients', 'with', 'complete', 'spinal', 'cord', 'lesions', '.', 'For', 'patients', 'presenting', 'incontinence', 'or', 'risk', 'for', 'kidney', ',', 'two', 'major', 'conventional', 'alternatives', 'are', 'possible', ':', 'conservative', 'therapies', '(', 'muscarinic', 'receptor', 'antagonists', ',', 'vanilloids', 'drugs', 'and', 'botulinum', 'toxin', 'in', 'association', 'with', 'catheterization', ')', 'and', 'surgical', 'techniques', 'intervening', 'in', 'the', 'nervous', 'and', 'urinary', 'system', '.', '\n\n', 'Among', 'these', 'last', 'alternatives', ',', 'the', 'Brindley', 'technique', '(', 'anterior', 'sacral', 'root', 'stimulation', 'with', 'posterior', 'rhizotomy', ')', 'is', 'the', 'only', 'technique', 'allowing', 'for', 'the', 'restauration', 'of', 'bladder', 'function', ',', 'continence', ',', 'and', 'micturition', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'Brindley', 'technique', 'with', 'the', 'first', 'conventional', 'approach', 'in', 'France', 'from', 'a', 'medical', 'and', 'economical', 'point', 'of', 'view', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00221767,NCT00221767,"Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord | Bladder dysfunction is a major problem in patients with complete spinal cord lesions. For patients presenting incontinence or risk for kidney, two major conventional alternatives are possible : conservative therapies (muscarinic receptor antagonists, vanilloids drugs and botulinum toxin in association with catheterization) and surgical techniques intervening in the nervous and urinary system.

Among these last alternatives, the Brindley technique (anterior sacral root stimulation with posterior rhizotomy) is the only technique allowing for the restauration of bladder function, continence, and micturition. The purpose of the study is to compare the Brindley technique with the first conventional approach in France from a medical and economical point of view.","[(81, 99, 'SURGICAL', 'Brindley Technique'), (121, 139, 'CONDITION', 'Neurogenic Bladder'), (157, 176, 'CONDITION', 'Injured Spinal Cord'), (179, 198, 'CONDITION', 'Bladder dysfunction'), (235, 263, 'CONDITION', 'complete spinal cord lesions'), (611, 629, 'SURGICAL', 'Brindley technique'), (631, 688, 'SURGICAL', 'anterior sacral root stimulation with posterior rhizotomy'), (835, 853, 'SURGICAL', 'Brindley technique')]"
"['Improved', 'Orthostatic', 'Tolerance', '=', 'Better', 'Cognitive', 'Function', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'Does', 'a', 'Successful', 'Treatment', 'of', 'Orthostatic', 'Hypotension', 'Measurably', 'Enhance', 'Attention', 'and', 'Memory', 'Functions', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Study', 'on', 'orthostatic', 'Hypotension', 'in', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT03900000,NCT03900000,Improved Orthostatic Tolerance = Better Cognitive Function in Parkinson's Disease: Does a Successful Treatment of Orthostatic Hypotension Measurably Enhance Attention and Memory Functions in Parkinson's Disease | Study on orthostatic Hypotension in Parkinson's disease,"[(62, 81, 'CONDITION', ""Parkinson's Disease""), (101, 137, 'OTHER', 'Treatment of Orthostatic Hypotension'), (191, 210, 'CONDITION', ""Parkinson's Disease""), (249, 268, 'CONDITION', ""Parkinson's disease"")]"
"['A', 'Phase', 'III', ',', 'Randomized', ',', 'Multicenter', ',', 'Parallel', '-', 'group', ',', 'Open', '-', 'Label', 'Study', 'Evaluating', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Long', '-', 'Acting', 'Intramuscular', 'Cabotegravir', 'and', 'Rilpivirine', 'for', 'Maintenance', 'of', 'Virologic', 'Suppression', 'Following', 'Switch', 'From', 'an', 'Integrase', 'Inhibitor', 'Single', 'Tablet', 'Regimen', 'in', 'HIV-1', 'Infected', 'Antiretroviral', 'Therapy', 'Naive', 'Adult', 'Participants', '|', 'The', 'First', 'Long', '-', 'Acting', 'Injectable', 'Regimen', '(', 'FLAIR', ')', 'study', 'is', 'being', 'conducted', 'to', 'establish', 'if', 'human', 'immunodeficiency', 'virus', 'type-1', '(', 'HIV-1', ')', 'infected', 'adult', 'participants', 'whose', 'virus', 'is', 'virologically', 'suppressed', 'on', 'an', 'integrase', 'inhibitor', 'single', 'tablet', 'regimen', '(', 'INI', 'STR', ')', 'will', 'remain', 'suppressed', 'after', 'switching', 'to', 'a', 'two', '-', 'drug', 'intramuscular', '(', 'IM', ')', 'long', '-', 'acting', '(', 'LA', ')', 'regimen', 'of', 'cabotegravir', '(', 'CAB', ')', 'and', 'rilpivirine', '(', 'RPV', ')', '.', 'In', 'this', 'study', ',', 'the', 'INI', 'STR', 'will', 'be', 'limited', 'to', 'abacavir', '/', 'dolutegravir', '/', 'lamivudine', '(', 'ABC', '/', 'DTG/3TC', ')', '.', 'FLAIR', 'is', 'a', 'Phase', '3', ',', 'multi', '-', 'phase', ',', 'randomized', ',', 'open', 'label', ',', 'active', '-', 'controlled', ',', 'multicenter', ',', 'parallel', '-', 'group', ',', 'non', '-', 'inferiority', 'study', 'in', 'HIV-1', ',', 'anti', '-', 'retroviral', 'therapy', '(', 'ART)-naïve', 'adult', 'participants', '.', 'This', 'study', 'is', 'designed', 'to', 'demonstrate', 'the', 'non', '-', 'inferior', 'antiviral', 'activity', 'of', 'switching', 'to', 'a', 'two', 'drug', 'CAB', 'LA', '400', 'mg', '+', 'RPV', 'LA', '600', 'mg', 'regimen', 'every', '4', 'weeks', '(', 'Q4W', ':', 'monthly', ')', 'compared', 'to', 'remaining', 'on', 'ABC', '/', 'DTG/3TC', 'over', '48', 'weeks', '(', '4', 'weeks', 'oral', 'CAB', '+', 'RPV', ',', '44', 'weeks', 'LA', 'therapy', ')', '.', 'Participants', 'who', 'are', 'HLA', '-', 'B*5701', 'positive', 'at', 'Screening', 'may', 'enroll', 'into', 'the', 'study', 'and', 'receive', 'DTG', 'plus', 'a', 'non', '-', 'abacavir', 'containing', 'dual', 'nucleoside', 'reverse', 'transcriptase', 'inhibitor', '(', 'NRTI', ')', 'regimen', '.', 'Eligible', 'participants', 'will', 'enroll', 'into', 'the', 'Induction', 'Phase', 'of', 'the', 'study', 'and', 'receive', 'ABC', '/', 'DTG/3TC', 'for', '20', 'weeks', '(', 'Week', '[', '-20', ']', 'to', 'Day', '1', ')', '.', 'Participants', 'who', 'have', 'an', 'HIV', '1', 'ribose', 'nucleic', 'acid', '(', 'RNA', ')', '<', '50', 'copies', 'per', 'milliliter', '(', 'c', '/', 'mL', ')', 'at', 'Week', '(', '-4', ')', 'will', 'be', 'randomized', '(', '1:1', ')', 'into', 'the', 'Maintenance', 'Phase', 'at', 'Day', '1', 'to', 'either', 'continue', 'ABC', '/', 'DTG/3TC', 'or', 'to', 'discontinue', 'ABC', '/', 'DTG/3TC', 'and', 'begin', 'oral', 'therapy', 'with', 'CAB', '30', 'mg', '+', 'RPV', '25', 'mg', 'once', 'daily', 'for', 'approximately', '4', 'Weeks', ',', 'followed', 'by', 'monthly', 'CAB', 'LA', '+', 'RPV', 'LA', 'injections', 'from', 'visit', 'Week', '4b', 'until', 'study', 'completion', 'or', 'withdrawal', '.', 'Participants', 'who', 'successfully', 'complete', 'Week', '100', '(', 'without', 'meeting', 'study', 'defined', 'withdrawal', 'criteria', 'and', 'who', 'remain', 'virologically', 'suppressed', 'through', 'Week', '96', ':', 'HIV-1', 'RNA', '<', '50', 'c', '/', 'mL', ')', 'will', 'be', 'given', 'the', 'option', 'to', 'switch', 'to', 'the', 'LA', 'arm', 'in', 'the', 'Extension', 'Phase', '(', 'using', 'an', 'optional', 'oral', 'lead', '-', 'in', 'with', 'CAB', '+', 'RPV', ')', 'or', 'be', 'withdrawn', 'from', 'the', 'study', '.', 'Participants', 'will', 'continue', 'to', 'receive', 'injections', 'every', '4', 'weeks', 'during', 'the', 'Extension', 'Phase', 'until', 'CAB', 'LA', 'and', 'RPV', 'LA', 'are', 'either', 'locally', 'approved', 'and', 'commercially', 'available', ',', 'the', 'participant', 'no', 'longer', 'derives', 'clinical', 'benefit', ',', 'the', 'participant', 'meets', 'a', 'protocol', '-', 'defined', 'reason', 'for', 'discontinuation', ',', 'or', 'until', 'development', 'of', 'either', 'CAB', 'LA', 'or', 'RPV', 'LA', 'is', 'terminated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT02938520,NCT02938520,"A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants | The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.","[(150, 162, 'DRUG', 'Cabotegravir'), (167, 178, 'DRUG', 'Rilpivirine'), (245, 264, 'DRUG', 'Integrase Inhibitor'), (290, 295, 'CONDITION', 'HIV-1'), (305, 333, 'CONDITION', 'Antiretroviral Therapy Naive'), (445, 480, 'CONDITION', 'human immunodeficiency virus type-1'), (482, 487, 'CONDITION', 'HIV-1'), (563, 582, 'DRUG', 'integrase inhibitor'), (715, 727, 'DRUG', 'cabotegravir'), (729, 732, 'DRUG', 'CAB'), (738, 749, 'DRUG', 'rilpivirine'), (751, 754, 'DRUG', 'RPV'), (803, 811, 'DRUG', 'abacavir'), (812, 824, 'DRUG', 'dolutegravir'), (825, 835, 'DRUG', 'lamivudine'), (837, 840, 'DRUG', 'ABC'), (841, 848, 'DRUG', 'DTG/3TC'), (981, 986, 'CONDITION', 'HIV-1'), (1145, 1148, 'DRUG', 'CAB'), (1161, 1164, 'DRUG', 'RPV'), (1237, 1240, 'DRUG', 'ABC'), (1241, 1248, 'DRUG', 'DTG/3TC'), (1277, 1280, 'DRUG', 'CAB'), (1283, 1286, 'DRUG', 'RPV'), (1331, 1350, 'CONDITION', 'HLA-B*5701 positive'), (1402, 1405, 'DRUG', 'DTG'), (1437, 1484, 'DRUG', 'dual nucleoside reverse transcriptase inhibitor'), (1486, 1490, 'DRUG', 'NRTI'), (1585, 1588, 'DRUG', 'ABC'), (1589, 1596, 'DRUG', 'DTG/3TC'), (1658, 1663, 'CONDITION', 'HIV 1'), (1816, 1819, 'DRUG', 'ABC'), (1820, 1827, 'DRUG', 'DTG/3TC'), (1846, 1849, 'DRUG', 'ABC'), (1850, 1857, 'DRUG', 'DTG/3TC'), (1886, 1889, 'DRUG', 'CAB'), (1898, 1901, 'DRUG', 'RPV'), (1966, 1969, 'DRUG', 'CAB'), (1975, 1978, 'DRUG', 'RPV'), (2206, 2211, 'CONDITION', 'HIV-1'), (2335, 2338, 'DRUG', 'CAB'), (2341, 2344, 'DRUG', 'RPV'), (2474, 2477, 'DRUG', 'CAB'), (2485, 2488, 'DRUG', 'RPV'), (2700, 2703, 'DRUG', 'CAB'), (2710, 2713, 'DRUG', 'RPV')]"
"['A', 'Treatment', 'Protocol', 'for', 'Management', 'of', 'Fatigue', 'in', 'Parkinson', ""'s"", 'Disease', 'Using', 'Cognitive', 'Behavioral', 'Therapy', '|', 'Fatigue', 'affects', 'more', 'than', 'half', 'of', 'people', 'living', 'with', 'Parkinson', ""'s"", 'disease', '.', 'Despite', 'its', 'prevalence', ',', 'treatment', 'options', 'remain', 'limited', '.', 'To', 'improve', 'patient', 'outcome', ',', 'a', 'group', 'treatment', 'protocol', 'was', 'developed', 'for', 'PD', 'fatigue', 'management', 'primarily', 'using', 'cognitive', 'behavioral', 'therapy', '.', 'The', 'program', 'focuses', 'on', 'assisting', 'individuals', 'with', 'PD', 'who', 'experience', 'fatigue', 'to', 'establish', 'proper', 'sleep', 'hygiene', 'habits', 'and', 'a', 'physical', 'exercise', 'routine', 'to', 'meet', 'the', 'end', 'goal', 'of', 'reducing', 'fatigue', '.', 'The', 'aim', 'of', 'the', 'group', 'is', 'to', 'change', 'negative', 'thoughts', 'and', 'behavior', 'regarding', 'changing', 'sleep', 'hygiene', 'habits', 'and', 'exercise', 'behavior', 'into', 'positive', 'ones', '.', 'This', 'is', 'a', 'feasibility', 'project', 'that', 'aims', 'to', 'explore', 'the', 'feasibility', 'of', 'this', 'protocol', 'as', 'well', 'as', 'to', 'produce', 'a', 'treatment', 'protocol', 'that', 'is', 'able', 'to', 'be', 'replicated', 'by', 'other', 'occupational', 'therapists', 'and', 'health', 'professionals', 'who', 'serve', 'the', 'PD', 'population', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03747848,NCT03747848,"A Treatment Protocol for Management of Fatigue in Parkinson's Disease Using Cognitive Behavioral Therapy | Fatigue affects more than half of people living with Parkinson's disease. Despite its prevalence, treatment options remain limited. To improve patient outcome, a group treatment protocol was developed for PD fatigue management primarily using cognitive behavioral therapy. The program focuses on assisting individuals with PD who experience fatigue to establish proper sleep hygiene habits and a physical exercise routine to meet the end goal of reducing fatigue. The aim of the group is to change negative thoughts and behavior regarding changing sleep hygiene habits and exercise behavior into positive ones. This is a feasibility project that aims to explore the feasibility of this protocol as well as to produce a treatment protocol that is able to be replicated by other occupational therapists and health professionals who serve the PD population.","[(39, 46, 'CONDITION', 'Fatigue'), (50, 69, 'CONDITION', ""Parkinson's Disease""), (76, 104, 'BEHAVIOURAL', 'Cognitive Behavioral Therapy'), (107, 114, 'CONDITION', 'Fatigue'), (160, 179, 'CONDITION', ""Parkinson's disease""), (312, 314, 'CONDITION', 'PD'), (315, 322, 'CONDITION', 'fatigue'), (350, 378, 'BEHAVIOURAL', 'cognitive behavioral therapy'), (430, 432, 'CONDITION', 'PD'), (448, 455, 'CONDITION', 'fatigue'), (469, 489, 'OTHER', 'proper sleep hygiene'), (503, 520, 'PHYSICAL', 'physical exercise'), (562, 569, 'CONDITION', 'fatigue'), (947, 949, 'CONDITION', 'PD')]"
"['Improving', 'Blood', 'Pressure', 'Control', 'in', 'Stroke', 'Patients', 'by', 'Increasing', 'Access', 'to', 'a', 'Home', 'Blood', 'Pressure', 'Monitor', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'learn', 'whether', 'providing', 'teaching', 'with', 'a', 'low', '-', 'cost', 'device', 'can', 'help', 'to', 'improve', 'blood', 'pressure', ',', 'health', 'outcomes', ',', 'patient', 'self', '-', 'efficacy', 'without', 'exacerbating', 'inequity', 'between', 'advantaged', 'and', 'disadvantaged', 'patients', '.', '\n\n', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'Does', 'providing', 'a', 'free', 'home', 'blood', 'pressure', 'cuff', 'improve', 'control', 'of', 'hypertension', '?', '\n', 'Does', 'providing', 'a', 'free', 'home', 'blood', 'pressure', 'cuff', 'have', 'a', 'greater', 'impact', 'on', 'control', 'of', 'hypertension', 'in', 'disadvantaged', 'populations', '?', '\n', 'Does', 'improved', 'control', 'of', 'home', 'blood', 'pressure', 'decrease', 'adverse', 'patient', 'outcomes', '?', '\n\n', 'Participants', 'will', 'be', 'asked', 'to', '\n\n', 'Take', 'their', 'blood', 'pressure', 'at', 'home', 'and', 'records', 'the', 'results', '\n', 'Participate', 'in', 'follow', '-', 'up', 'phone', 'calls', 'from', 'investigators', 'at', 'at', '3', 'and', '6', 'months', '\n\n', 'Researchers', 'will', 'compare', 'patients', 'provided', 'with', 'home', 'blood', 'pressure', 'monitors', 'to', 'those', 'who', 'are', 'provided', 'with', 'routine', 'education']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05730465,NCT05730465,"Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor | The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.

The main question[s] it aims to answer are:

Does providing a free home blood pressure cuff improve control of hypertension?
Does providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?
Does improved control of home blood pressure decrease adverse patient outcomes?

Participants will be asked to

Take their blood pressure at home and records the results
Participate in follow-up phone calls from investigators at at 3 and 6 months

Researchers will compare patients provided with home blood pressure monitors to those who are provided with routine education","[(36, 42, 'CONDITION', 'Stroke'), (78, 105, 'OTHER', 'Home Blood Pressure Monitor'), (422, 446, 'OTHER', 'home blood pressure cuff'), (466, 478, 'CONDITION', 'hypertension'), (502, 526, 'OTHER', 'home blood pressure cuff'), (563, 575, 'CONDITION', 'hypertension')]"
"['Effects', 'of', 'Transcranial', 'Electric', 'Stimulation', 'on', 'Associative', 'Memory', 'Formation', 'in', 'Healthy', 'Elderly', 'Participants', 'as', 'Well', 'as', 'in', 'Individuals', 'With', 'Memory', 'Impairment', '|', 'Previous', 'studies', 'showed', 'that', 'transcranial', 'electric', 'stimulation', '(', 'tES', ')', 'applied', 'over', 'the', 'prefrontal', 'cortex', 'improves', 'cognitive', 'performance', 'in', 'healthy', 'elderly', 'adults', 'as', 'well', 'as', 'in', 'patients', 'suffering', 'from', 'mild', 'cognitive', 'impairment', 'or', 'early', 'Alzheimer', ""'s"", 'disease', '.', 'Therefore', ',', 'tES', 'methods', 'might', 'be', 'a', 'useful', 'intervention', 'tool', 'for', 'patients', 'suffering', 'from', 'memory', 'impairment', 'in', 'early', 'terms', 'of', 'the', 'disease', '.', '\n\n', 'The', 'present', 'study', 'aims', 'at', 'establishing', 'a', 'connection', 'between', 'the', 'stimulation', '-', 'induced', 'changes', 'on', 'associative', 'memory', 'performance', 'and', 'its', 'underlying', 'neurophysiological', 'parameters', '.', 'tES', 'effects', 'and', 'their', 'underlying', 'mechanisms', 'will', 'be', 'compared', 'between', 'healthy', 'elderly', 'controls', 'and', 'clinical', 'study', 'populations', 'receiving', 'either', 'real', 'or', 'sham', 'tES', 'over', 'the', 'left', 'ventrolateral', 'prefrontal', 'cortex', 'during', 'an', 'associative', 'memory', 'task', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03351452,NCT03351452,"Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment | Previous studies showed that transcranial electric stimulation (tES) applied over the prefrontal cortex improves cognitive performance in healthy elderly adults as well as in patients suffering from mild cognitive impairment or early Alzheimer's disease. Therefore, tES methods might be a useful intervention tool for patients suffering from memory impairment in early terms of the disease.

The present study aims at establishing a connection between the stimulation-induced changes on associative memory performance and its underlying neurophysiological parameters. tES effects and their underlying mechanisms will be compared between healthy elderly controls and clinical study populations receiving either real or sham tES over the left ventrolateral prefrontal cortex during an associative memory task.","[(11, 44, 'OTHER', 'Transcranial Electric Stimulation'), (140, 157, 'CONDITION', 'Memory Impairment'), (189, 222, 'OTHER', 'transcranial electric stimulation'), (224, 227, 'OTHER', 'tES'), (359, 384, 'CONDITION', 'mild cognitive impairment'), (388, 413, 'CONDITION', ""early Alzheimer's disease""), (426, 429, 'OTHER', 'tES'), (502, 519, 'CONDITION', 'memory impairment'), (728, 731, 'OTHER', 'tES'), (878, 886, 'CONTROL', 'sham tES')]"
"['An', 'Evaluation', 'of', 'the', 'Clinical', 'Efficacy', 'of', 'Massage', 'Therapy', 'in', 'a', 'Multisensory', 'Environment', 'for', 'Residents', 'With', 'Severe', 'and', 'Profound', 'Intellectual', 'Disabilities', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'multisensory', 'environment', '(', 'MSE', ')', 'and/or', 'massage', 'therapy', '(', 'MT', ')', 'in', 'residents', 'with', 'severe', 'and', 'profound', 'intellectual', 'disabilities', '(', 'ID', ')', 'who', 'received', 'massage', 'therapy', 'in', 'MSE', ',', 'activities', 'in', 'MSE', 'alone', ',', 'massage', 'therapy', 'in', 'usual', 'care', 'environment', ',', 'or', 'usual', 'care', 'with', 'attention', '.', '\n\n', 'Since', 'there', 'has', 'not', 'yet', 'been', 'any', 'conclusive', 'evidence', 'to', 'show', 'the', 'clinical', 'efficacy', 'of', 'MT', 'and', 'MSE', 'on', 'relaxation', 'and', 'reducing', 'challenging', 'behaviours', ',', 'the', 'following', 'null', 'hypotheses', 'are', 'suggested', ':', '\n\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'reducing', 'heart', 'and', 'respiration', 'rates', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'usual', 'care', 'only', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.', '\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'adaptive', 'behaviours', 'and', 'levels', 'of', 'alertness', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'control', 'group', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.', '\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'frequency', 'and', 'severity', 'of', 'challenging', 'behaviours', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'control', 'group', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02120820,NCT02120820,"An Evaluation of the Clinical Efficacy of Massage Therapy in a Multisensory Environment for Residents With Severe and Profound Intellectual Disabilities | The aim of this study is to evaluate the effectiveness of multisensory environment (MSE) and/or massage therapy (MT) in residents with severe and profound intellectual disabilities (ID) who received massage therapy in MSE, activities in MSE alone, massage therapy in usual care environment, or usual care with attention.

Since there has not yet been any conclusive evidence to show the clinical efficacy of MT and MSE on relaxation and reducing challenging behaviours, the following null hypotheses are suggested:

There will not be any differences on reducing heart and respiration rates between MT-MSE, MT, MSE, and usual care only over the 10-week intervention period and a 2-week follow-up.
There will not be any differences on adaptive behaviours and levels of alertness between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.
There will not be any differences on frequency and severity of challenging behaviours between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.","[(42, 57, 'OTHER', 'Massage Therapy'), (63, 87, 'OTHER', 'Multisensory Environment'), (107, 152, 'CONDITION', 'Severe and Profound Intellectual Disabilities'), (213, 237, 'OTHER', 'multisensory environment'), (239, 242, 'OTHER', 'MSE'), (251, 266, 'OTHER', 'massage therapy'), (268, 270, 'OTHER', 'MT'), (290, 335, 'CONDITION', 'severe and profound intellectual disabilities'), (337, 339, 'CONDITION', 'ID'), (354, 369, 'OTHER', 'massage therapy'), (373, 376, 'OTHER', 'MSE'), (378, 401, 'OTHER', 'activities in MSE alone'), (403, 444, 'OTHER', 'massage therapy in usual care environment'), (449, 474, 'CONTROL', 'usual care with attention'), (563, 565, 'OTHER', 'MT'), (570, 573, 'OTHER', 'MSE'), (753, 759, 'OTHER', 'MT-MSE'), (761, 763, 'OTHER', 'MT'), (765, 768, 'OTHER', 'MSE'), (774, 789, 'CONTROL', 'usual care only'), (940, 946, 'OTHER', 'MT-MSE'), (948, 950, 'OTHER', 'MT'), (952, 955, 'OTHER', 'MSE'), (961, 968, 'CONTROL', 'control'), (1130, 1136, 'OTHER', 'MT-MSE'), (1138, 1140, 'OTHER', 'MT'), (1142, 1145, 'OTHER', 'MSE'), (1151, 1158, 'CONTROL', 'control')]"
"['Drug', 'Eluting', 'Stenting', 'and', 'Aggressive', 'Medical', 'Treatment', 'for', 'Preventing', 'Recurrent', 'Stroke', 'in', 'Intracranial', 'Atherosclerotic', 'Disease', 'Trial', ':', 'a', 'Prospective', ',', 'Randomized', ',', 'Open', '-', 'labelled', ',', 'Blinded', 'End', '-', 'point', 'Trial', '(', 'DREAM', '-', 'PRIDE', ')', '|', 'The', 'aim', 'of', 'DREAM', '-', 'PRIDE', 'is', 'to', 'evaluate', 'whether', 'implantation', 'of', 'drug', '-', 'eluting', 'stent', '(', 'DES', ')', 'combined', 'with', 'aggressive', 'medical', 'treatment', 'is', 'more', 'efficacious', 'in', 'prevention', 'of', '1', '-', 'year', 'stroke', 'recurrence', 'than', 'standard', 'medical', 'treatment', 'alone', 'for', 'symptomatic', 'intracranial', 'atherosclerotic', 'disease', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04948749,NCT04948749,"Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE) | The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.","[(0, 21, 'OTHER', 'Drug Eluting Stenting'), (26, 54, 'OTHER', 'Aggressive Medical Treatment'), (70, 86, 'CONDITION', 'Recurrent Stroke'), (90, 126, 'CONDITION', 'Intracranial Atherosclerotic Disease'), (278, 296, 'OTHER', 'drug-eluting stent'), (298, 301, 'OTHER', 'DES'), (317, 345, 'OTHER', 'aggressive medical treatment'), (390, 407, 'CONDITION', 'stroke recurrence'), (422, 445, 'CONTROL', 'medical treatment alone'), (450, 498, 'CONDITION', 'symptomatic intracranial atherosclerotic disease')]"
"['A', '52', '-', 'week', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'an', 'Intramuscular', 'Depot', 'Formulation', 'of', 'Aripiprazole', 'as', 'Maintenance', 'Treatment', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'the', 'trial', 'was', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', ',', 'and', 'tolerability', 'of', 'an', 'intramuscular', 'depot', 'formulation', 'of', 'aripiprazole', 'as', 'maintenance', 'treatment', 'in', 'patients', 'with', 'schizophrenia', '.', '\n\n', 'The', 'trial', 'was', 'designed', 'into', '4', 'treatment', 'phases', '.', 'Phase', '1', 'was', 'designed', 'to', 'allow', 'for', 'a', 'patient', 'to', 'be', 'converted', 'from', 'their', 'current', 'antipsychotic', 'treatment', 'to', 'oral', 'non', '-', 'generic', 'aripiprazole', 'monotherapy', '(', 'oral', 'conversion', 'phase', 'from', '4', 'to', '6', 'weeks', ')', '.', 'During', 'Phase', '2', ',', 'the', 'patient', 'was', 'stabilized', 'on', 'oral', 'non', '-', 'generic', 'aripiprazole', 'monotherapy', '(', 'oral', 'stabilization', 'phase', 'from', 'a', 'minimum', 'of', '4', 'weeks', 'to', 'a', 'maximum', 'of', '12', 'weeks', ')', '.', 'Once', 'the', 'patient', 'was', 'stabilized', 'in', 'Phase', '2', ',', 'they', 'entered', 'Phase', '3', ',', 'the', 'single', '-', 'blind', 'intramuscular', '(', 'IM', ')', 'depot', 'aripiprazole', 'stabilization', 'phase', '.', 'The', 'goal', 'of', 'the', 'phase', 'was', 'to', 'stabilize', 'the', 'patient', 'on', 'the', 'IM', 'depot', 'aripiprazole', 'formulation', 'for', 'a', 'minimum', 'of', '12', 'weeks', 'to', 'a', 'maximum', 'of', '36', 'weeks', '.', 'When', 'the', 'patient', 'was', 'stabilized', ',', 'they', 'were', 'eligible', 'to', 'be', 'randomized', 'into', 'the', 'double', '-', 'blind', 'IM', 'depot', 'maintenance', 'phase', '(', 'Phase', '4', ')', '.', 'During', 'Phase', '4', ',', 'the', 'patient', 'was', 'assessed', 'for', 'exacerbation', 'of', 'psychotic', 'symptoms', 'and/or', 'impending', 'relapse', 'for', 'up', 'to', '52', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00705783,NCT00705783,"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia | The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.

The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.","[(50, 57, 'CONTROL', 'Placebo'), (167, 179, 'DRUG', 'Aripiprazole'), (222, 235, 'CONDITION', 'Schizophrenia'), (359, 371, 'DRUG', 'aripiprazole'), (414, 427, 'CONDITION', 'schizophrenia'), (601, 613, 'DRUG', 'aripiprazole'), (732, 744, 'DRUG', 'aripiprazole'), (944, 956, 'DRUG', 'aripiprazole'), (1045, 1057, 'DRUG', 'aripiprazole'), (1312, 1321, 'CONDITION', 'psychotic')]"
"['Cost', 'Effective', 'Strategy', 'to', 'Evaluate', 'Veterans', 'With', 'Sleep', 'Apnea', '|', 'This', 'research', 'study', 'is', 'comparing', 'home', 'and', 'in', '-', 'laboratory', 'testing', 'of', 'veterans', 'with', 'suspected', 'obstructive', 'sleep', 'apnea', ',', 'a', 'common', 'breathing', 'disorder', 'during', 'sleep', '.', 'It', 'is', 'hoped', 'that', 'home', 'testing', 'will', 'be', 'equally', 'effective', 'in', 'improving', 'quality', 'of', 'life', 'but', 'have', 'lower', 'cost', 'than', 'in', '-', 'lab', 'testing', '.', 'These', 'findings', 'will', 'allow', 'veterans', 'to', 'have', 'greater', 'access', 'to', 'diagnosis', 'and', 'treatment', 'of', 'their', 'sleep', 'apnea', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00880165,NCT00880165,"Cost Effective Strategy to Evaluate Veterans With Sleep Apnea | This research study is comparing home and in-laboratory testing of veterans with suspected obstructive sleep apnea, a common breathing disorder during sleep. It is hoped that home testing will be equally effective in improving quality of life but have lower cost than in-lab testing. These findings will allow veterans to have greater access to diagnosis and treatment of their sleep apnea.","[(50, 61, 'CONDITION', 'Sleep Apnea'), (97, 127, 'OTHER', 'home and in-laboratory testing'), (155, 178, 'CONDITION', 'obstructive sleep apnea'), (239, 251, 'OTHER', 'home testing'), (332, 346, 'OTHER', 'in-lab testing'), (442, 453, 'CONDITION', 'sleep apnea')]"
"['A', 'Positron', 'Emission', 'Tomography', 'Study', 'to', 'Assess', 'the', 'Level', 'and', 'Duration', 'of', 'Occupancy', 'of', 'Serotonin-1A', 'Receptors', 'Produced', 'by', 'Single', 'Oral', 'Doses', 'of', 'SRA-444', 'in', 'Healthy', 'Elderly', 'Subjects', 'and', 'in', 'Subjects', 'With', 'Alzheimer', 'Disease', '|', 'The', 'study', 'will', 'include', 'a', 'preliminary', 'pharmacokinetics', '(', 'PK', ')', '/', 'safety', '/', 'tolerability', 'evaluation', 'in', 'healthy', 'elderly', 'subjects', 'followed', 'by', 'the', 'Receptor', 'Occupancy', '(', 'RO', ')', 'evaluations', 'in', 'healthy', 'elderly', 'subjects', 'and', 'in', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT00499200,NCT00499200,A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease | The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.,"[(142, 149, 'DRUG', 'SRA-444'), (199, 216, 'CONDITION', 'Alzheimer Disease'), (428, 447, 'CONDITION', ""Alzheimer's Disease""), (449, 451, 'CONDITION', 'AD')]"
"['NMDA', '-', 'Receptor', 'Blockade', 'With', 'Eliprodil', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Patients', 'with', 'Parkinson', ""'s"", 'disease', 'are', 'missing', 'the', 'chemical', 'neurotransmitter', 'dopamine', '.', 'This', 'occurs', 'as', 'a', 'result', 'of', 'destructive', 'changes', 'in', 'an', 'area', 'of', 'the', 'brain', 'responsible', 'for', 'making', 'dopamine', ',', 'the', 'basal', 'ganglia', '.', 'Patients', 'with', 'the', 'disease', 'experience', ',', 'rigid', 'muscles', ',', 'stooped', 'posture', ',', 'and', 'a', 'shuffling', '-', 'type', 'walk', '(', 'gait', ')', '.', '\n\n', 'In', 'this', 'study', 'researchers', 'plan', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'drug', 'eliprodil', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'Disease', '.', 'Eliprodil', 'works', 'by', 'blocking', 'special', 'receptors', '(', 'NMDA', ')', 'that', 'are', 'associated', 'with', 'the', 'symptoms', 'of', 'Parkinson', ""'s"", 'Disease', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00001929,NCT00001929,"NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease | Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait).

In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.","[(0, 22, 'DRUG', 'NMDA-Receptor Blockade'), (28, 37, 'DRUG', 'Eliprodil'), (41, 60, 'CONDITION', ""Parkinson's Disease""), (77, 96, 'CONDITION', ""Parkinson's disease""), (450, 459, 'DRUG', 'eliprodil'), (481, 500, 'CONDITION', ""Parkinson's Disease""), (502, 511, 'DRUG', 'Eliprodil'), (596, 615, 'CONDITION', ""Parkinson's Disease"")]"
"['Effect', 'of', 'Square-', 'Stepping', 'Exercises', 'on', 'Mobility', ',', 'Balance', 'and', 'Knee', 'Joint', 'Position', 'Sense', 'in', 'Individuals', 'With', 'Multiple', 'Sclerosis', '|', 'Square', 'stepping', 'exercises', 'can', 'promote', 'correct', 'foot', 'placement', ',', 'fast', 'and', 'coordinated', 'step', 'patterns', ',', 'and', 'sensory', '-', 'motor', 'interaction', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effect', 'of', 'square', 'stepping', 'exercises', 'on', 'mobility', ',', 'balance', 'and', 'knee', 'joint', 'position', 'sense', 'in', 'individuals', 'with', 'multiple', 'sclerosis', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05682963,NCT05682963,"Effect of Square- Stepping Exercises on Mobility, Balance and Knee Joint Position Sense in Individuals With Multiple Sclerosis | Square stepping exercises can promote correct foot placement, fast and coordinated step patterns, and sensory-motor interaction. The aim of this study is to examine the effect of square stepping exercises on mobility, balance and knee joint position sense in individuals with multiple sclerosis.","[(10, 36, 'PHYSICAL', 'Square- Stepping Exercises'), (108, 126, 'CONDITION', 'Multiple Sclerosis'), (129, 154, 'PHYSICAL', 'Square stepping exercises'), (308, 333, 'PHYSICAL', 'square stepping exercises'), (405, 423, 'CONDITION', 'multiple sclerosis')]"
"['Phase', 'I', 'Study', 'of', 'Vaccination', 'With', 'Dendritic', 'Cells', 'Loaded', 'With', 'Brain', 'Tumor', 'Stem', 'Cells', 'for', 'Recurrent', 'or', 'Progressive', 'Malignant', 'Gliomas', '|', 'This', 'is', 'a', 'single', 'center', 'Phase', 'I', 'study', 'to', 'determine', 'the', 'safety', 'and', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'autologous', 'dendritic', 'cells', '(', 'DCs', ')', 'loaded', 'with', 'allogeneic', 'brain', 'tumor', 'stem', 'cells', 'administered', 'as', 'a', 'vaccination', 'in', 'children', 'and', 'adults', 'with', 'recurrent', 'brain', 'tumors', '.', 'Once', 'the', 'MTD', 'has', 'been', 'determined', ',', 'we', 'will', 'conduct', 'a', 'phase', 'II', 'study', 'to', 'determine', 'efficacy', '.', '\n\n', 'Clinical', 'trials', 'that', 'utilize', 'DCs', 'for', 'immunotherapy', 'have', 'demonstrated', 'significant', 'survival', 'benefit', 'for', 'patients', 'who', 'exhibit', 'robust', 'immune', 'responses', 'against', 'tumor', 'cells', '.', 'Unfortunately', ',', 'at', 'the', 'present', 'time', 'the', 'majority', 'of', 'tumor', 'patients', 'are', 'unable', 'to', 'mount', 'an', 'adequate', 'immune', 'response', 'and', 'thus', 'succumb', 'to', 'their', 'tumors', '.', 'We', 'postulate', 'that', 'the', 'inability', 'to', 'generate', 'an', 'appropriate', 'immune', 'response', 'in', 'these', 'patients', 'is', 'due', 'to', 'a', 'lack', 'of', 'sufficient', 'numbers', 'of', 'appropriate', 'T', 'cells', 'due', 'to', 'an', 'inadequate', 'source', 'of', 'tumor', 'antigens', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT01171469,NCT01171469,"Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas | This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults with recurrent brain tumors. Once the MTD has been determined, we will conduct a phase II study to determine efficacy.

Clinical trials that utilize DCs for immunotherapy have demonstrated significant survival benefit for patients who exhibit robust immune responses against tumor cells. Unfortunately, at the present time the majority of tumor patients are unable to mount an adequate immune response and thus succumb to their tumors. We postulate that the inability to generate an appropriate immune response in these patients is due to a lack of sufficient numbers of appropriate T cells due to an inadequate source of tumor antigens.","[(34, 84, 'SURGICAL', 'Dendritic Cells Loaded With Brain Tumor Stem Cells'), (89, 131, 'CONDITION', 'Recurrent or Progressive Malignant Gliomas'), (232, 310, 'SURGICAL', 'autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells'), (369, 391, 'CONDITION', 'recurrent brain tumors'), (513, 534, 'SURGICAL', 'DCs for immunotherapy'), (639, 644, 'CONDITION', 'tumor'), (703, 708, 'CONDITION', 'tumor'), (792, 798, 'CONDITION', 'tumors'), (986, 991, 'CONDITION', 'tumor')]"
"['A', 'Single', '-', 'center', ',', 'Open', 'Trials', 'to', 'Evaluate', 'the', 'Safety', 'of', 'Freeze', '-', 'dried', 'Group', 'ACYW135', 'Meningococcal', 'Conjugate', 'Vaccine', '|', 'Safety', 'Evaluation', 'of', 'freeze', '-', 'dried', 'Group', 'ACYW135', 'Meningococcal', 'conjugate', 'vaccine', 'in', 'healthy', 'people', 'above', '2', '-', 'months', '-', 'old']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02481232,NCT02481232,"A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine | Safety Evaluation of freeze-dried Group ACYW135 Meningococcal conjugate vaccine in healthy people above 2-months-old","[(68, 105, 'DRUG', 'Group ACYW135 Meningococcal Conjugate'), (150, 187, 'DRUG', 'Group ACYW135 Meningococcal conjugate')]"
"['Pharmacovigilance', 'in', 'Gerontopsychiatric', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'multicenter', '-', 'study', 'is', 'to', 'investigate', 'safety', 'of', 'psychopharmacological', 'treatment', 'and', 'rates', 'of', 'adverse', 'drug', 'reactions', 'in', 'gerontopsychiatric', 'inpatients', '.', 'Elderly', 'people', 'are', 'at', 'higher', 'risk', 'for', 'developing', 'side', 'effects', 'under', 'pharmacological', 'treatment', 'due', 'to', 'an', 'altered', 'metabolic', 'situation', ',', 'higher', 'comorbidity', 'rates', 'and', 'often', 'polypharmacy', '.', 'Furthermore', 'gerontopsychiatric', 'patients', 'can', 'often', 'not', 'articulate', 'their', 'symptoms', 'clearly', ',', 'for', 'example', 'due', 'to', 'pronounced', 'cognitive', 'impairment', '.', '\n\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'gain', 'valid', 'data', 'of', 'possible', 'adverse', 'drug', 'reaction', 'rates', ',', 'their', 'potential', 'risk', 'factors', 'and', 'outcome', ',', 'as', 'well', 'as', 'medical', 'prescription', 'practises', '.', '\n\n', 'To', 'assess', 'these', 'outcomes', 'an', 'intensive', 'pharmacovigilance', '-', 'monitoring', 'will', 'be', 'conducted', 'at', 'the', 'five', 'participating', 'study', 'sites', '.', '\n\n', 'At', 'Baseline', 'demographic', 'data', ',', 'previous', 'and', 'present', 'disorders', ',', 'use', 'of', 'drugs', ',', 'previous', 'and', 'present', 'medication', ',', 'quality', 'of', 'life', ',', 'cognitive', 'function', ',', 'physical', 'examination', 'results', ',', 'laboratory', 'results', 'and', 'ECG', 'will', 'be', 'assessed', '.', '\n\n', 'Afterwards', 'patients', 'are', 'visited', 'weekly', 'and', 'screened', 'for', 'possible', 'adverse', 'drug', 'reactions', '.', 'All', 'adverse', 'drug', 'reactions', 'will', 'be', 'coded', 'in', 'the', 'MedDRA', '-', 'system', '.', '\n\n', 'In', 'case', 'of', 'a', 'possible', 'serious', 'adverse', 'drug', 'reaction', 'serum', 'levels', 'of', 'all', 'psychotropic', 'substances', 'applicated', 'will', 'be', 'assessed', '.', 'Drug', 'combinations', 'will', 'be', 'analysed', 'using', 'an', 'established', 'advanced', 'bioinformatic', 'tool', '(', 'mediQ', ')', '.', 'Diagnosis', ',', 'medication', 'intake', 'and', 'possible', 'adverse', 'drug', 'reactions', 'are', 'documented', 'continually', '.', '\n\n', '2', 'weeks', 'after', 'discharge', 'from', 'the', 'ward', ',', 'patients', 'will', 'be', 'contacted', 'by', 'phone', 'to', 'assess', 'catamnestic', 'data', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02374567,NCT02374567,"Pharmacovigilance in Gerontopsychiatric Patients | The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment.

The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises.

To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites.

At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed.

Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system.

In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually.

2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.",[]
"['Risperidone', 'Depot', '(', 'Microspheres', ')', 'vs.', 'Placebo', 'in', 'the', 'Treatment', 'of', 'Subjects', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'and', 'safety', 'of', 'a', 'long', '-', 'acting', 'injectable', 'formulation', 'of', 'risperidone', '(', 'an', 'antipsychotic', 'medication', ')', 'versus', 'placebo', 'for', 'the', 'treatment', 'of', 'the', 'symptoms', 'of', 'schizophrenia', 'over', 'a', '12', '-', 'week', 'period', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00253136,NCT00253136,Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia | The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a 12-week period.,"[(0, 11, 'DRUG', 'Risperidone'), (37, 44, 'CONTROL', 'Placebo'), (79, 92, 'CONDITION', 'Schizophrenia'), (206, 217, 'DRUG', 'risperidone'), (222, 246, 'DRUG', 'antipsychotic medication'), (255, 262, 'CONTROL', 'placebo'), (300, 313, 'CONDITION', 'schizophrenia')]"
"['Below', 'the', 'Belt', ':', 'Non', '-', 'invasive', 'Neuromodulation', 'to', 'Treat', 'Bladder', ',', 'Bowel', ',', 'and', 'Sexual', 'Dysfunction', 'Following', 'Spinal', 'Cord', 'Injury', '|', 'Recent', 'findings', 'have', 'demonstrated', 'that', 'electrical', 'stimulation', 'to', 'the', 'spinal', 'cord', '(', 'i.e.', 'implanted', 'electrodes', ')', 'can', 'significantly', 'recover', 'bladder', ',', 'bowel', ',', 'and', 'sexual', 'function', 'after', 'injury', '.', 'While', 'promising', ',', 'a', 'major', 'drawback', 'is', 'that', 'individuals', 'must', 'undergo', 'a', 'highly', 'invasive', 'and', 'expensive', 'surgical', 'procedure', 'to', 'implant', 'the', 'stimulator', 'on', 'top', 'of', 'the', 'spinal', 'cord', '.', 'Moreover', ',', 'the', 'inability', 'to', 're', '-', 'position', 'the', 'implanted', 'stimulator', 'considerably', 'limits', 'the', 'flexibility', 'of', 'this', 'procedure', '.', '\n\n', 'In', 'this', 'project', ',', 'the', 'investigators', 'propose', 'a', 'comprehensive', 'clinical', 'study', 'examining', 'the', 'effects', 'of', 'TCSCS', 'in', 'promoting', 'recovery', 'of', 'these', 'crucial', 'functions', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'This', 'non', '-', 'invasive', 'therapeutic', 'modality', 'uses', 'electrodes', 'applied', 'over', 'the', 'skin', 'to', 'deliver', 'electrical', 'stimulation', '.', 'It', 'is', 'based', 'on', 'the', 'same', 'principles', 'of', 'ground', '-', 'breaking', 'work', 'from', 'the', 'investigator', ""'s"", 'group', 'and', 'others', ',', 'showing', 'that', 'stimulation', 'of', 'the', 'spinal', 'cord', 'can', 'promote', 'motor', 'and', 'autonomic', '(', 'cardiovascular', ',', 'bladder', ',', 'bowel', ')', 'recovery', 'in', 'individuals', 'with', 'chronic', 'SCI', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04604951,NCT04604951,"Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury | Recent findings have demonstrated that electrical stimulation to the spinal cord (i.e. implanted electrodes) can significantly recover bladder, bowel, and sexual function after injury. While promising, a major drawback is that individuals must undergo a highly invasive and expensive surgical procedure to implant the stimulator on top of the spinal cord. Moreover, the inability to re-position the implanted stimulator considerably limits the flexibility of this procedure.

In this project, the investigators propose a comprehensive clinical study examining the effects of TCSCS in promoting recovery of these crucial functions in individuals with spinal cord injury (SCI). This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.","[(16, 44, 'OTHER', 'Non-invasive Neuromodulation'), (54, 92, 'CONDITION', 'Bladder, Bowel, and Sexual Dysfunction'), (103, 121, 'CONDITION', 'Spinal Cord Injury'), (163, 204, 'OTHER', 'electrical stimulation to the spinal cord'), (699, 704, 'OTHER', 'TCSCS'), (774, 792, 'CONDITION', 'spinal cord injury'), (794, 797, 'CONDITION', 'SCI'), (844, 910, 'OTHER', 'electrodes applied over the skin to deliver electrical stimulation'), (1026, 1056, 'OTHER', 'stimulation of the spinal cord'), (1151, 1162, 'CONDITION', 'chronic SCI')]"
"['Neuromuscular', 'and', 'Biomechanical', 'Control', 'of', 'Lower', 'Limb', 'Loading', 'in', 'Individuals', 'With', 'Chronic', 'Stroke', '|', 'Stroke', 'is', 'the', 'leading', 'cause', 'of', 'long', '-', 'term', 'disability', 'in', 'the', 'U.S.', 'Individuals', 'with', 'hemiparesis', 'due', 'to', 'stroke', 'often', 'have', 'difficulty', 'bearing', 'weight', 'on', 'their', 'legs', 'and', 'transferring', 'weight', 'from', 'one', 'leg', 'to', 'the', 'other', '.', 'The', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', 'is', 'important', 'during', 'functional', 'movements', 'such', 'as', 'rising', 'from', 'a', 'chair', ',', 'standing', 'and', 'walking', '.', 'Diminished', 'weight', 'transfer', 'contributes', 'to', 'asymmetries', 'during', 'walking', 'which', 'commonly', 'leads', 'to', 'greater', 'energy', 'expenditure', '.', 'Moreover', ',', 'deficits', 'in', 'bearing', 'weight', 'on', 'the', 'paretic', 'leg', 'contribute', 'to', 'lateral', 'instability', 'and', 'are', 'associated', 'with', 'decreased', 'walking', 'speed', 'and', 'increased', 'risk', 'of', 'falling', 'in', 'individuals', 'post', '-', 'stroke', '.', 'These', 'functional', 'limitations', 'affect', 'community', 'participation', 'and', 'life', 'quality', '.', 'Thus', ',', 'restoring', 'the', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', ',', 'i.e.', ',', 'limb', 'loading', ',', 'is', 'a', 'critical', 'goal', 'for', 'rehabilitation', 'post', '-', 'stroke', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'identify', 'the', 'impairments', 'in', 'neuromechanical', 'mechanisms', 'of', 'limb', 'loading', 'and', 'determine', 'whether', 'limb', 'loading', 'responses', 'can', 'be', 'retrained', 'by', 'induced', 'forced', 'limb', 'loading', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",NCT03694028,NCT03694028,"Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke | Stroke is the leading cause of long-term disability in the U.S. Individuals with hemiparesis due to stroke often have difficulty bearing weight on their legs and transferring weight from one leg to the other. The ability to bear weight on the legs is important during functional movements such as rising from a chair, standing and walking. Diminished weight transfer contributes to asymmetries during walking which commonly leads to greater energy expenditure. Moreover, deficits in bearing weight on the paretic leg contribute to lateral instability and are associated with decreased walking speed and increased risk of falling in individuals post-stroke. These functional limitations affect community participation and life quality. Thus, restoring the ability to bear weight on the legs, i.e., limb loading, is a critical goal for rehabilitation post-stroke. The purpose of this research is to identify the impairments in neuromechanical mechanisms of limb loading and determine whether limb loading responses can be retrained by induced forced limb loading.","[(82, 96, 'CONDITION', 'Chronic Stroke'), (99, 105, 'CONDITION', 'Stroke'), (180, 191, 'CONDITION', 'hemiparesis'), (199, 205, 'CONDITION', 'stroke'), (743, 754, 'CONDITION', 'post-stroke'), (948, 959, 'CONDITION', 'post-stroke'), (1132, 1159, 'PHYSICAL', 'induced forced limb loading')]"
"['A', 'Comparison', 'of', 'the', 'Therapeutic', 'Effect', 'Between', 'Head', '-', 'point', 'Acupuncture', 'and', 'Conventional', 'Body', 'Acupuncture', 'on', 'Insomnia', ':', 'A', 'Randomized', 'Controlled', 'Case', 'Study', '|', 'The', 'investigators', 'will', 'conduct', 'a', 'single', '-', 'center', ',', 'and', 'randomized', 'controlled', 'cases', 'study', '.', 'A', 'total', 'of', '120', 'participants', 'with', 'insomnia', 'will', 'be', 'enrolled', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'therapeutic', 'effect', 'between', 'head', '-', 'acupoints', 'acupuncture', 'and', 'body', '-', 'acupoints', 'acupuncture', 'on', 'Insomnia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'O']",NCT04405427,NCT04405427,"A Comparison of the Therapeutic Effect Between Head-point Acupuncture and Conventional Body Acupuncture on Insomnia: A Randomized Controlled Case Study | The investigators will conduct a single-center, and randomized controlled cases study. A total of 120 participants with insomnia will be enrolled. The aim of the study is to compare the therapeutic effect between head-acupoints acupuncture and body-acupoints acupuncture on Insomnia.","[(47, 69, 'PHYSICAL', 'Head-point Acupuncture'), (74, 103, 'CONTROL', 'Conventional Body Acupuncture'), (107, 115, 'CONDITION', 'Insomnia'), (274, 282, 'CONDITION', 'insomnia'), (367, 393, 'PHYSICAL', 'head-acupoints acupuncture'), (398, 424, 'CONTROL', 'body-acupoints acupuncture'), (428, 436, 'CONDITION', 'Insomnia')]"
"['Progressive', 'Modular', 'Rebalancing', '(', 'RMP', ')', 'System', 'Rehabilitation', 'Combined', 'With', 'Sensory', 'Cues', 'for', 'Rehabilitation', 'of', 'Patients', 'With', 'PD', ':', 'a', 'Randomized', ',', 'Controlled', 'Trial', 'With', 'Crossover', '.', '|', 'In', 'the', 'present', 'study', ',', 'the', 'investigators', 'propose', 'a', 'rehabilitative', 'program', 'for', 'Parkinson', ""'"", 'disease', 'based', 'on', 'the', 'combination', 'of', 'a', 'neurocognitive', 'method', ',', 'i.e.', 'visual', 'sensory', 'cues', ',', 'with', 'a', 'neurophysiological', 'method', ',', 'i.e.', 'RMP', ',', 'in', 'a', 'randomized', 'controlled', 'trial', 'with', 'cross', '-', 'over', '.', 'The', 'rationale', 'herein', 'was', 'that', 'the', 'RMP', 'may', 'globally', 'improve', 'patients', 'in', 'terms', 'of', 'trunk', 'control', ',', 'motor', 'performance', ',', 'muscle', 'tone', ',', 'endurance', 'and', 'so', 'on', ',', 'predisposing', 'them', 'to', 'improvement', 'of', 'the', 'gait', 'rhythm', 'and', 'automaticity', 'induced', 'by', 'use', 'of', 'the', 'visual', 'external', 'cues', '.', '\n\n', 'The', 'primary', 'aim', 'of', 'this', 'pilot', ',', 'randomized', ',', 'controlled', ',', 'trial', 'with', 'crossover', 'was', 'to', 'establish', 'whether', 'a', '8', '-', 'week', 'exercise', 'program', 'focused', 'at', 'improving', 'gait', 'in', 'people', 'with', 'PD', 'was', 'more', 'effective', 'than', 'a', 'same', '-', 'duration', 'program', 'of', 'standard', 'physiotherapy', '.', 'The', 'secondary', 'aim', 'was', 'to', 'evaluate', 'the', 'effect', 'on', 'the', 'disease', ""'s"", 'severity', '.', 'At', 'this', 'aims', 'investigators', 'used', 'a', 'quantitative', '3D', 'motion', 'analysis', 'system', 'to', 'evaluate', 'gait', 'parameters', 'and', 'UPDRS', '-', 'II', 'and', 'UPDR', '-', 'III', 'and', 'H', '-', 'Y', 'staging', 'to', 'evaluate', 'the', 'severity', 'of', 'the', 'disease', '.', '\n\n', 'The', 'investigators', 'hypothesised', 'that', 'the', 'both', 'exercise', 'programs', 'will', 'improve', 'standard', 'physiotherapy', ',', 'however', 'the', 'proposed', 'program', 'will', 'yield', 'better', 'improvements', 'for', 'the', 'people', 'with', 'PD', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03346265,NCT03346265,"Progressive Modular Rebalancing (RMP) System Rehabilitation Combined With Sensory Cues for Rehabilitation of Patients With PD: a Randomized, Controlled Trial With Crossover. | In the present study, the investigators propose a rehabilitative program for Parkinson' disease based on the combination of a neurocognitive method, i.e. visual sensory cues, with a neurophysiological method, i.e. RMP, in a randomized controlled trial with cross-over. The rationale herein was that the RMP may globally improve patients in terms of trunk control, motor performance, muscle tone, endurance and so on, predisposing them to improvement of the gait rhythm and automaticity induced by use of the visual external cues.

The primary aim of this pilot, randomized, controlled, trial with crossover was to establish whether a 8-week exercise program focused at improving gait in people with PD was more effective than a same-duration program of standard physiotherapy. The secondary aim was to evaluate the effect on the disease's severity. At this aims investigators used a quantitative 3D motion analysis system to evaluate gait parameters and UPDRS-II and UPDR-III and H-Y staging to evaluate the severity of the disease.

The investigators hypothesised that the both exercise programs will improve standard physiotherapy, however the proposed program will yield better improvements for the people with PD.","[(0, 59, 'PHYSICAL', 'Progressive Modular Rebalancing (RMP) System Rehabilitation'), (74, 105, 'OTHER', 'Sensory Cues for Rehabilitation'), (123, 125, 'CONDITION', 'PD'), (226, 248, 'OTHER', 'rehabilitative program'), (253, 271, 'CONDITION', ""Parkinson' disease""), (302, 323, 'OTHER', 'neurocognitive method'), (330, 349, 'OTHER', 'visual sensory cues'), (358, 383, 'PHYSICAL', 'neurophysiological method'), (390, 393, 'PHYSICAL', 'RMP'), (479, 482, 'PHYSICAL', 'RMP'), (817, 859, 'PHYSICAL', 'exercise program focused at improving gait'), (875, 877, 'CONDITION', 'PD'), (929, 951, 'CONTROL', 'standard physiotherapy'), (1255, 1272, 'PHYSICAL', 'exercise programs'), (1286, 1308, 'CONTROL', 'standard physiotherapy'), (1390, 1392, 'CONDITION', 'PD')]"
"['Effect', 'of', 'Nebivolol', 'on', 'Blood', 'Pressure', 'in', 'a', 'Model', 'of', 'Hypertension', 'Sensitive', 'to', 'Potentiation', 'of', 'Nitric', 'Oxide', 'Bioactivity', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'the', 'antihypertensive', 'drug', ',', 'nebivolol', '(', 'Bystolic', ')', ',', 'compared', 'to', 'metoprolol', '(', 'Lopressor', ')', 'and', 'sildenafil', '(', 'Viagra', ')', 'on', 'blood', 'pressure', 'in', 'patients', 'with', 'autonomic', 'failure', 'and', 'supine', 'hypertension', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT01044693,NCT01044693,"Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in patients with autonomic failure and supine hypertension.","[(10, 19, 'DRUG', 'Nebivolol'), (52, 64, 'CONDITION', 'Hypertension'), (203, 212, 'DRUG', 'nebivolol'), (214, 222, 'DRUG', 'Bystolic'), (237, 247, 'DRUG', 'metoprolol'), (249, 258, 'DRUG', 'Lopressor'), (264, 274, 'DRUG', 'sildenafil'), (276, 282, 'DRUG', 'Viagra'), (319, 336, 'CONDITION', 'autonomic failure'), (341, 360, 'CONDITION', 'supine hypertension')]"
"['A', 'Phase', 'II', 'Randomized', 'Trial', 'of', 'Lenalidomide', '(', 'NSC', '#', '703813', ')', 'in', 'Pediatric', 'Patients', 'With', 'Recurrent', ',', 'Refractory', 'or', 'Progressive', 'Juvenile', 'Pilocytic', 'Astrocytomas', 'and', 'Optic', 'Pathway', 'Gliomas', '|', 'This', 'randomized', 'phase', 'II', 'trial', 'studies', 'how', 'well', 'low', '-', 'dose', 'lenalidomide', 'works', 'compared', 'with', 'high', '-', 'dose', 'lenalidomide', 'in', 'treating', 'younger', 'patients', 'with', 'juvenile', 'pilocytic', 'astrocytomas', 'or', 'optic', 'nerve', 'pathway', 'gliomas', 'that', 'have', 'come', 'back', '(', 'recurrent', ')', ',', 'have', 'not', 'responded', 'to', 'treatment', '(', 'refractory', ')', ',', 'or', 'are', 'growing', ',', 'spreading', ',', 'or', 'getting', 'worse', '(', 'progressive', ')', '.', 'Lenalidomide', 'is', 'classified', 'as', 'an', 'immunomodulatory', 'drug', 'as', 'it', 'boosts', 'the', 'immune', 'system', '.', 'It', 'has', 'other', 'potential', 'anti', '-', 'tumor', 'effects', ',', 'for', 'example', ',', 'it', 'may', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', 'by', 'blocking', 'blood', 'flow', 'to', 'the', 'tumor', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'low', '-', 'dose', 'lenalidomide', 'is', 'more', 'or', 'less', 'effective', 'than', 'high', '-', 'dose', 'lenalidomide', 'in', 'treating', 'patients', 'with', 'juvenile', 'pilocytic', 'astrocytomas', 'or', 'optic', 'nerve', 'pathway', 'gliomas', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01553149,NCT01553149,"A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas | This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide is classified as an immunomodulatory drug as it boosts the immune system. It has other potential anti-tumor effects, for example, it may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas.","[(31, 43, 'DRUG', 'Lenalidomide'), (86, 154, 'CONDITION', 'Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas'), (159, 180, 'CONDITION', 'Optic Pathway Gliomas'), (240, 252, 'DRUG', 'lenalidomide'), (283, 295, 'DRUG', 'lenalidomide'), (330, 361, 'CONDITION', 'juvenile pilocytic astrocytomas'), (365, 392, 'CONDITION', 'optic nerve pathway gliomas'), (531, 543, 'DRUG', 'Lenalidomide'), (700, 705, 'CONDITION', 'tumor'), (742, 747, 'CONDITION', 'tumor'), (786, 798, 'DRUG', 'lenalidomide'), (840, 852, 'DRUG', 'lenalidomide'), (879, 910, 'CONDITION', 'juvenile pilocytic astrocytomas'), (914, 941, 'CONDITION', 'optic nerve pathway gliomas')]"
"['Role', 'of', 'Saffron', 'and', 'Chamomile', 'and', 'Their', 'Active', 'Compounds', 'in', 'the', 'Management', 'of', 'Parkinson', 'Disease', 'in', 'the', 'Context', 'of', 'Psychometric', 'and', 'Biochemical', 'Measures', '|', 'In', 'multitudinous', 'preclinical', 'studies', ',', 'Saffron', 'and', 'Chamomile', 'are', 'found', 'effective', 'in', 'treating', 'PD', '.', 'They', 'can', 'mitigate', 'the', 'neurodegenerative', 'progression', 'of', 'the', 'disease', 'by', 'curtailing', 'dopaminergic', 'and', 'neuronal', 'loss', 'and', 'by', 'inhibiting', 'alpha', '-', 'synuclein', 'aggregation', '.', 'They', 'also', 'possess', 'antioxidant', 'and', 'anti', '-', 'inflammatory', 'activities', '.', 'The', 'synergism', 'of', 'both', 'drugs', 'can', 'manage', 'Parkinson', ""'s"", 'disease', 'and', 'related', 'neurological', 'disorders', 'although', ',', 'clinical', 'trials', 'are', 'needed', 'for', 'further', 'elaboration', '.', 'Therefore', ',', 'the', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'Saffron', 'and', 'Chamomile', 'and', 'their', 'active', 'compounds', 'in', 'treating', 'Parkinson', ""'s"", 'disease', '.', 'This', 'combination', 'may', 'change', 'psychometric', 'measures', '(', 'MDS', '-', 'Unified', 'Parkinson', ""'s"", 'Disease', 'Rating', 'Scale', ')', ',', 'biomarkers', '(', 'including', 'Alpha', '-', 'synuclein', ')', ',', 'and', 'oxidative', 'stress', '-', 'related', 'to', 'Parkinson', ""'s"", 'disease', '.', 'This', 'combination', 'along', 'with', 'conventional', 'therapy', 'might', 'be', 'beneficial', 'in', 'managing', 'patients', 'with', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT05696665,NCT05696665,"Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures | In multitudinous preclinical studies, Saffron and Chamomile are found effective in treating PD. They can mitigate the neurodegenerative progression of the disease by curtailing dopaminergic and neuronal loss and by inhibiting alpha-synuclein aggregation. They also possess antioxidant and anti-inflammatory activities. The synergism of both drugs can manage Parkinson's disease and related neurological disorders although, clinical trials are needed for further elaboration. Therefore, the purpose of the study is to evaluate the effects of Saffron and Chamomile and their active compounds in treating Parkinson's disease. This combination may change psychometric measures (MDS-Unified Parkinson's Disease Rating Scale), biomarkers (including Alpha-synuclein), and oxidative stress-related to Parkinson's disease. This combination along with conventional therapy might be beneficial in managing patients with Parkinson's disease","[(8, 15, 'OTHER', 'Saffron'), (20, 29, 'OTHER', 'Chamomile'), (78, 95, 'CONDITION', 'Parkinson Disease'), (192, 199, 'OTHER', 'Saffron'), (204, 213, 'OTHER', 'Chamomile'), (246, 248, 'CONDITION', 'PD'), (512, 531, 'CONDITION', ""Parkinson's disease""), (695, 702, 'OTHER', 'Saffron'), (707, 716, 'OTHER', 'Chamomile'), (756, 775, 'CONDITION', ""Parkinson's disease""), (919, 935, 'CONDITION', 'oxidative stress'), (947, 966, 'CONDITION', ""Parkinson's disease""), (1063, 1082, 'CONDITION', ""Parkinson's disease"")]"
"['Innovative', 'Treatment', 'of', 'Chemotherapy', '-', 'Induced', 'Painful', 'Peripheral', 'Neuropathy', 'in', 'Adolescents', 'and', 'Young', 'Adults', 'With', 'Cancer', ':', 'A', 'Two', 'Arm', 'Pilot', 'Study', '|', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'Scrambler', 'therapy', '(', 'ST', ')', 'for', 'chemotherapy', '-', 'induced', 'painful', 'peripheral', 'neuropathy', '(', 'CIPN', ')', ',', 'and', 'the', 'impact', 'of', 'ST', 'on', 'physical', 'functioning', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'adolescents', 'and', 'young', 'adults', '(', 'AYA', ')', 'cancer', 'patients', '.', '\n\n', 'In', 'this', 'proposed', 'study', ',', 'we', 'will', 'conduct', 'a', 'two', '-', 'arm', 'prospective', ',', 'randomized', 'wait', '-', 'list', 'controlled', 'clinical', 'trial', 'to', 'investigate', 'the', 'effectiveness', 'of', 'ST', 'on', 'pain', 'and', 'CIPN', 'in', 'AYAs', 'with', 'cancer', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT05357469,NCT05357469,"Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study | To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients.

In this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.","[(24, 74, 'CONDITION', 'Chemotherapy-Induced Painful Peripheral Neuropathy'), (112, 118, 'CONDITION', 'Cancer'), (183, 200, 'OTHER', 'Scrambler therapy'), (202, 204, 'OTHER', 'ST'), (210, 260, 'CONDITION', 'chemotherapy-induced painful peripheral neuropathy'), (262, 266, 'CONDITION', 'CIPN'), (287, 289, 'OTHER', 'ST'), (378, 384, 'CONDITION', 'cancer'), (542, 544, 'OTHER', 'ST'), (548, 552, 'CONDITION', 'pain'), (557, 561, 'CONDITION', 'CIPN'), (575, 581, 'CONDITION', 'cancer')]"
"['Effect', 'of', 'Augmentation', 'of', 'Cerebral', 'Blood', 'Flow', 'on', 'Neuropsychometric', 'Performance', 'After', 'Carotid', 'Endarterectomy', 'in', 'Type', 'II', 'Diabetic', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'we', 'can', 'reduce', 'the', 'incidence', 'of', 'cognitive', 'dysfunction', '-', 'difficulty', 'in', 'performing', 'certain', 'pencil', '-', 'paper', ',', 'memory', ',', 'finger', 'dexterity', 'and', 'thinking', 'type', 'of', 'tasks', 'called', 'neuropsychometric', 'tests', '-', 'in', 'patients', 'with', 'adult', 'onset', 'diabetes', 'mellitus', '(', 'DM', ')', 'undergoing', 'surgery', 'on', 'the', 'carotid', 'artery', '(', 'CEA', ')', '.', '\n\n', 'We', 'hypothesize', 'that', 'cognitive', 'dysfunction', 'can', 'be', 'decreased', 'in', 'patients', 'with', 'type', 'II', 'DM', 'by', 'augmenting', 'cerebral', 'blood', 'flow', 'with', 'a', 'shunt', 'during', 'carotid', 'endarterectomy', 'compared', 'to', 'patients', 'with', 'Type', 'II', 'DM', 'who', 'are', 'treated', 'with', '""', 'conventional', '""', 'management', 'in', 'which', 'a', 'shunt', 'is', 'placed', 'only', 'if', 'the', 'electroencephalogram', '(', 'EEG', ')', 'indicates', 'cerebral', 'ischemia', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00597545,NCT00597545,"Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients | The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction - difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests - in patients with adult onset diabetes mellitus (DM) undergoing surgery on the carotid artery (CEA).

We hypothesize that cognitive dysfunction can be decreased in patients with type II DM by augmenting cerebral blood flow with a shunt during carotid endarterectomy compared to patients with Type II DM who are treated with ""conventional"" management in which a shunt is placed only if the electroencephalogram (EEG) indicates cerebral ischemia.","[(10, 45, 'OTHER', 'Augmentation of Cerebral Blood Flow'), (85, 107, 'CONDITION', 'Carotid Endarterectomy'), (111, 127, 'CONDITION', 'Type II Diabetic'), (215, 236, 'CONDITION', 'cognitive dysfunction'), (400, 417, 'CONDITION', 'diabetes mellitus'), (419, 421, 'CONDITION', 'DM'), (434, 463, 'CONDITION', 'surgery on the carotid artery'), (465, 468, 'CONDITION', 'CEA'), (492, 513, 'CONDITION', 'cognitive dysfunction'), (548, 558, 'CONDITION', 'type II DM'), (600, 605, 'OTHER', 'shunt'), (613, 635, 'CONDITION', 'carotid endarterectomy'), (662, 672, 'CONDITION', 'Type II DM'), (694, 719, 'CONTROL', '""conventional"" management'), (731, 736, 'OTHER', 'shunt'), (796, 813, 'CONDITION', 'cerebral ischemia')]"
"['The', 'Multicenter', 'Phase', 'II', 'Clinical', 'Trial', 'for', 'Evaluation', 'of', 'Safety', 'and', 'Efficacy', 'Using', 'Low', 'Dose', 'Irradiation', 'With', 'Alzheimer', ""'s"", 'Disease', '|', 'This', 'is', 'a', 'phase', 'II', ',', 'multicenter', ',', 'prospective', ',', 'randomized', 'controlled', 'trial', 'to', 'treat', 'patients', 'with', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'using', 'low', '-', 'dose', 'irradiation', '(', 'LDIR', ')', '.', 'This', 'study', 'aims', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'LDIR', 'to', 'whole', 'brain', 'in', 'patients', 'with', 'AD', 'and', 'to', 'determine', 'the', 'potentially', 'applicable', 'radiation', 'dose', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O']",NCT05635968,NCT05635968,"The Multicenter Phase II Clinical Trial for Evaluation of Safety and Efficacy Using Low Dose Irradiation With Alzheimer's Disease | This is a phase II, multicenter, prospective, randomized controlled trial to treat patients with Alzheimer's disease (AD) using low-dose irradiation (LDIR). This study aims to evaluate the safety and efficacy of LDIR to whole brain in patients with AD and to determine the potentially applicable radiation dose.","[(84, 104, 'RADIOTHERAPY', 'Low Dose Irradiation'), (110, 129, 'CONDITION', ""Alzheimer's Disease""), (229, 248, 'CONDITION', ""Alzheimer's disease""), (250, 252, 'CONDITION', 'AD'), (260, 280, 'RADIOTHERAPY', 'low-dose irradiation'), (282, 286, 'RADIOTHERAPY', 'LDIR'), (344, 348, 'RADIOTHERAPY', 'LDIR'), (381, 383, 'CONDITION', 'AD'), (428, 437, 'RADIOTHERAPY', 'radiation')]"
"['Demonstration', 'of', 'mGluR5', 'Overexpression', 'in', 'Amish', 'and', 'Mennonite', 'CNTNAP2', 'Mutation', 'Carriers', '|', 'The', 'primary', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'evaluate', 'the', 'utility', 'of', 'mGluR5', 'binding', 'as', 'measured', 'by', 'PET', 'as', 'a', 'biomarker', 'of', 'the', 'CNTNAP2', 'mutation', 'and', 'related', '/mTOR', 'kinase', 'pathway', 'dysregulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02572206,NCT02572206,Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers | The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.,"[(62, 78, 'CONDITION', 'CNTNAP2 Mutation'), (214, 230, 'CONDITION', 'CNTNAP2 mutation')]"
"['A', 'Randomised', 'Control', 'Trial', 'to', 'Determine', 'the', 'Effectiveness', 'of', 'Sensory', 'Stimulation', 'Program', 'in', 'Reducing', 'the', 'Length', 'of', 'Time', 'Spent', 'by', 'Severely', 'Brain', 'Injured', 'Patients', 'in', 'a', 'Vegetative', 'State', 'in', 'the', 'Acute', 'Hospital', 'Environment', '|', 'A', 'randomised', 'control', 'trial', 'of', 'patients', 'who', 'have', 'a', 'severe', 'brain', 'injury', 'to', 'determine', 'if', 'patients', 'who', 'receive', 'a', 'standardised', 'sensory', 'stimulation', 'program', 'emerge', 'earlier', 'from', 'a', 'vegetative', 'state', '.', 'The', 'experimental', 'group', 'would', 'receive', ',', 'in', 'addition', 'to', 'their', 'normal', 'occuaptional', 'therapy', ',', 'sensory', 'stimulation', 'which', 'would', 'involve', 'the', 'daily', 'application', 'of', 'stimulation', 'to', 'all', 'five', 'senses', 'using', 'the', 'Sensory', 'Modalities', 'Assessment', 'and', 'Rehabilitation', 'Technique', '(', 'SMART', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O']",NCT00163878,NCT00163878,"A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment | A randomised control trial of patients who have a severe brain injury to determine if patients who receive a standardised sensory stimulation program emerge earlier from a vegetative state. The experimental group would receive, in addition to their normal occuaptional therapy, sensory stimulation which would involve the daily application of stimulation to all five senses using the Sensory Modalities Assessment and Rehabilitation Technique (SMART).","[(61, 88, 'OTHER', 'Sensory Stimulation Program'), (129, 151, 'CONDITION', 'Severely Brain Injured'), (166, 182, 'CONDITION', 'Vegetative State'), (269, 288, 'CONDITION', 'severe brain injury'), (328, 360, 'OTHER', 'standardised sensory stimulation'), (391, 407, 'CONDITION', 'vegetative state'), (475, 495, 'OTHER', 'occuaptional therapy'), (497, 516, 'OTHER', 'sensory stimulation'), (603, 661, 'OTHER', 'Sensory Modalities Assessment and Rehabilitation Technique'), (663, 668, 'OTHER', 'SMART')]"
"['A', 'Long', '-', 'Term', 'Study', 'of', 'XP13512', 'Versus', 'Placebo', 'Treatment', 'Assessing', 'Maintenance', 'of', 'Efficacy', 'and', 'Safety', 'in', 'Patients', 'With', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'assess', 'the', 'maintenance', 'of', 'efficacy', 'of', 'gabapentin', 'enacarbil', '(', 'GEn', ',', 'XP13512', ')', 'taken', 'once', 'daily', 'in', 'the', 'long', '-', 'term', 'treatment', 'of', 'patients', 'suffering', 'from', 'Restless', 'Legs', 'Syndrome', '(', 'RLS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT00311363,NCT00311363,"A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome. | The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).","[(21, 28, 'DRUG', 'XP13512'), (36, 43, 'CONTROL', 'Placebo'), (116, 138, 'CONDITION', 'Restless Legs Syndrome'), (222, 242, 'DRUG', 'gabapentin enacarbil'), (244, 247, 'DRUG', 'GEn'), (249, 256, 'DRUG', 'XP13512'), (329, 351, 'CONDITION', 'Restless Legs Syndrome'), (353, 356, 'CONDITION', 'RLS')]"
"['Management', 'of', 'Consecutive', 'Exotropia', 'and', 'Its', 'Effect', 'on', 'Ocular', 'Motility', '|', 'Patients', 'with', 'consecutive', 'exotropia', 'will', 'be', 'managed', 'by', 'medial', 'rectus', 'muscle', 'advancement', '+', '/-', 'resection', 'or', 'medial', 'rectus', 'muscle', 'advancement', '+', '/-', 'lateral', 'rectus', 'recession']","['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER']",NCT04961021,NCT04961021,Management of Consecutive Exotropia and Its Effect on Ocular Motility | Patients with consecutive exotropia will be managed by medial rectus muscle advancement +/- resection or medial rectus muscle advancement +/- lateral rectus recession,"[(14, 35, 'CONDITION', 'Consecutive Exotropia'), (86, 107, 'CONDITION', 'consecutive exotropia'), (127, 159, 'OTHER', 'medial rectus muscle advancement'), (164, 209, 'OTHER', 'resection or medial rectus muscle advancement'), (214, 238, 'OTHER', 'lateral rectus recession')]"
"['Outcome', 'Evaluation', 'of', 'Solutions', 'for', 'Wellness', 'and', 'Team', 'Solutions', 'Program', 'in', 'Patients', 'With', 'Severe', 'Mental', 'Illness', '|', 'Obesity', 'is', 'increasing', 'at', 'an', 'alarming', 'rate', 'in', 'patients', 'with', 'schizophrenia', ',', 'possibly', 'in', 'association', 'with', 'the', 'increased', 'use', 'of', 'atypical', 'antipsychotics', '.', 'In', 'order', 'to', 'address', 'the', 'weight', 'and', 'metabolic', 'syndrome', 'issues', ',', 'Manhattan', 'Psychiatric', 'Center', '(', 'MPC', ')', 'has', 'implemented', 'the', 'Solutions', 'for', 'Wellness', 'and', 'Team', 'Solutions', 'Program', '.', 'This', 'program', 'is', 'designed', 'to', 'create', 'a', 'supportive', ',', 'educational', 'and', 'monitoring', 'environment', 'to', 'stabilize', 'both', 'the', 'psychiatric', 'and', 'medical', 'conditions', 'and', 'to', 'prepare', 'patients', 'for', 'independent', 'management', 'of', 'their', 'psychiatric', 'and', 'physical', 'health', 'condition', 'in', 'the', 'community', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00661869,NCT00661869,"Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness | Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.","[(36, 71, 'OTHER', 'Wellness and Team Solutions Program'), (89, 110, 'CONDITION', 'Severe Mental Illness'), (113, 120, 'CONDITION', 'Obesity'), (172, 185, 'CONDITION', 'schizophrenia'), (297, 315, 'CONDITION', 'metabolic syndrome'), (393, 428, 'OTHER', 'Wellness and Team Solutions Program')]"
"['Clinical', 'Outcomes', 'of', 'Human', 'Amniotic', 'Membrane', 'and', 'Allogeneic', 'Mesenchymal', 'Stem', 'Cells', 'Composite', 'Augmentation', 'for', 'Nerve', 'Transfer', 'Procedure', 'in', 'Brachial', 'Plexus', 'Injury', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'investigate', 'the', 'utility', 'of', 'composite', 'wrapping', 'comprising', 'human', 'amniotic', 'membrane', 'and', 'allogeneic', 'adipose', '-', 'derived', 'mesenchymal', 'stem', 'cells', '(', 'HAM', '-', 'AdMSC', ')', 'for', 'augmentation', 'of', 'nerve', 'transfer', 'procedure', 'in', 'upper', 'TBPI', 'patients']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04654286,NCT04654286,Clinical Outcomes of Human Amniotic Membrane and Allogeneic Mesenchymal Stem Cells Composite Augmentation for Nerve Transfer Procedure in Brachial Plexus Injury Patients | The purpose of this clinical trial is to investigate the utility of composite wrapping comprising human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC) for augmentation of nerve transfer procedure in upper TBPI patients,"[(21, 105, 'SURGICAL', 'Human Amniotic Membrane and Allogeneic Mesenchymal Stem Cells Composite Augmentation'), (110, 124, 'SURGICAL', 'Nerve Transfer'), (138, 160, 'CONDITION', 'Brachial Plexus Injury'), (270, 347, 'SURGICAL', 'human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells'), (349, 358, 'SURGICAL', 'HAM-AdMSC'), (380, 394, 'SURGICAL', 'nerve transfer'), (408, 418, 'CONDITION', 'upper TBPI')]"
"['Pathophysiology', 'of', 'Non', 'Motor', 'Signs', 'and', 'Compensatory', 'Mechanisms', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'Role', 'of', 'the', 'Serotoninergic', 'and', 'Dopaminergic', 'Lesions', 'Studied', 'by', 'PET', '|', 'Parkinson', ""'s"", 'disease', 'is', 'characterized', 'by', 'a', 'large', 'number', 'of', 'non', 'motor', ',', 'especially', 'neuropsychiatric', ',', 'signs', '.', 'Their', 'pathophysiology', 'is', 'complex', 'but', 'the', 'role', 'of', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'dysfunction', 'is', 'suggested', 'by', 'several', 'studies', '.', 'In', 'addition', ',', 'the', 'serotoninergic', 'system', 'is', 'involved', 'in', 'the', 'pathophysiology', 'of', 'dyskinesias', '.', 'Very', 'few', 'studies', 'have', 'analyzed', 'the', 'abnormalities', 'of', 'these', 'two', 'neurotransmission', 'systems', 'at', 'disease', 'onset', ',', 'in', 'de', 'novo', 'PD', 'patients', '.', 'Furthermore', ',', 'the', 'parallel', 'evolution', 'of', 'the', 'degeneration', 'of', 'the', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'with', 'disease', 'progression', 'remains', 'unknown', '.', 'Thus', 'the', 'present', 'study', 'aims', 'at', 'determining', ',', 'by', 'using', 'PET', 'and', '11C', '-', 'PE2I', 'and', '11C', '-', 'DASB', 'the', 'respective', 'role', 'of', 'the', 'serotoninergic', 'and', 'dopaminergic', 'systems', 'dysfunction', 'in', 'motor', 'and', 'non', 'motor', 'manifestations', 'in', 'PD', ',', 'at', 'different', 'evolution', 'stages', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02038608,NCT02038608,"Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET | Parkinson's disease is characterized by a large number of non motor, especially neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and serotoninergic systems dysfunction is suggested by several studies. In addition, the serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies have analyzed the abnormalities of these two neurotransmission systems at disease onset, in de novo PD patients. Furthermore, the parallel evolution of the degeneration of the dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role of the serotoninergic and dopaminergic systems dysfunction in motor and non motor manifestations in PD, at different evolution stages.","[(66, 85, 'CONDITION', ""Parkinson's Disease""), (156, 175, 'CONDITION', ""Parkinson's disease""), (602, 604, 'CONDITION', 'PD'), (963, 965, 'CONDITION', 'PD')]"
"['A', 'Randomized', 'Placebo', 'Controlled', ',', 'Double', '-', 'blind', 'Phase', 'II', 'Study', 'to', 'Explore', 'the', 'Safety', ',', 'Efficacy', 'and', 'Pharmacokinetics', 'of', 'Sonlicromanol', 'in', 'Children', 'With', 'Genetically', 'Confirmed', 'Mitochondrial', 'Disease', '|', 'This', 'a', 'randomized', 'placebo', 'controlled', ',', 'double', '-', 'blind', 'phase', 'II', 'study', 'to', 'explore', 'the', 'pharmacokinetics', ',', 'safety', 'and', 'efficacy', 'of', 'sonlicromanol', 'in', 'children', '(', 'from', 'birth', 'to', '17', 'years', ')', 'with', 'genetically', 'confirmed', 'mitochondrial', 'disease', 'of', 'which', 'the', 'gene', 'defect', 'is', 'known', 'to', 'decrease', 'one', 'or', 'more', 'oxidative', 'phosphorylation', 'system', 'enzymes', 'and', 'who', 'suffer', 'from', 'motor', 'symptoms', '(', '""', 'KHENERGYC', '""', ')', '.']","['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04846036,NCT04846036,"A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease | This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms (""KHENERGYC"").","[(13, 20, 'CONTROL', 'Placebo'), (117, 130, 'DRUG', 'Sonlicromanol'), (170, 191, 'CONDITION', 'Mitochondrial Disease'), (212, 219, 'CONTROL', 'placebo'), (316, 329, 'DRUG', 'sonlicromanol'), (394, 415, 'CONDITION', 'mitochondrial disease'), (535, 549, 'CONDITION', 'motor symptoms')]"
"['The', 'Effect', 'of', 'Amantadine', 'on', 'Movement', 'Disorder', 'in', 'Ataxia', '-', 'Telangiectasia', '|', 'Ataxia', '-', 'Telangiectasia', 'A', '-', 'T', 'is', 'a', 'neurodegenerative', 'disorder', 'of', 'the', 'cerebellum', ',', 'manifesting', 'with', 'ataxia', ',', 'as', 'well', 'as', 'extrapyramidal', 'features', '.', 'Treatment', 'of', 'A', '-', 'T', 'is', 'discouraging', ',', 'since', 'no', 'treatment', 'seems', 'to', 'change', 'the', 'course', 'of', 'disease', ',', 'but', 'improvement', 'can', 'be', 'achieved', 'by', 'symptomatic', 'treatment', 'of', 'the', 'bothersome', 'movement', 'disorder', '.', 'While', 'various', 'dopaminergic', 'agents', 'are', 'occasionally', 'used', ',', 'reports', 'of', 'benefit', 'are', 'rather', 'sparse', 'and', 'anecdotal', '.', 'Amantadine', ',', 'a', 'well', 'known', 'drug', 'used', 'in', 'influenza', 'as', 'well', 'as', 'movement', 'disorder', 'of', 'Parkinson', ',', 'has', 'been', 'proved', 'to', 'improve', 'various', 'other', 'types', 'of', 'movement', 'disorder', 'as', 'ataxia', ',', 'chorea', ',', 'dystonia', ',', 'akinesia', 'and', 'attention', 'span', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'weather', 'amantadine', 'sulphate', 'improves', 'ataxia', 'and', 'the', 'movement', 'disorder', '(', 'bradykinesia', ',', 'parkinsonism', ',', 'dystonia', ',', 'chorea', ')', ',', 'as', 'well', 'as', 'the', 'general', 'well', 'being', 'in', 'patients', 'with', 'A', '-', 'T.']","['O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT00950196,NCT00950196,"The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia | Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to change the course of disease, but improvement can be achieved by symptomatic treatment of the bothersome movement disorder . While various dopaminergic agents are occasionally used, reports of benefit are rather sparse and anecdotal. Amantadine, a well known drug used in influenza as well as movement disorder of Parkinson, has been proved to improve various other types of movement disorder as ataxia, chorea, dystonia, akinesia and attention span. The purpose of this study is to investigate weather amantadine sulphate improves ataxia and the movement disorder (bradykinesia, parkinsonism, dystonia, chorea), as well as the general well being in patients with A-T.","[(14, 24, 'DRUG', 'Amantadine'), (28, 45, 'CONDITION', 'Movement Disorder'), (49, 70, 'CONDITION', 'Ataxia-Telangiectasia'), (73, 94, 'CONDITION', 'Ataxia-Telangiectasia'), (95, 98, 'CONDITION', 'A-T'), (167, 173, 'CONDITION', 'ataxia'), (224, 227, 'CONDITION', 'A-T'), (507, 517, 'DRUG', 'Amantadine'), (587, 596, 'CONDITION', 'Parkinson'), (669, 675, 'CONDITION', 'ataxia'), (677, 683, 'CONDITION', 'chorea'), (685, 693, 'CONDITION', 'dystonia'), (695, 703, 'CONDITION', 'akinesia'), (776, 795, 'DRUG', 'amantadine sulphate'), (805, 811, 'CONDITION', 'ataxia'), (820, 837, 'CONDITION', 'movement disorder'), (839, 851, 'CONDITION', 'bradykinesia'), (853, 865, 'CONDITION', 'parkinsonism'), (867, 875, 'CONDITION', 'dystonia'), (877, 883, 'CONDITION', 'chorea'), (937, 941, 'CONDITION', 'A-T.')]"
"['Development', 'of', 'Imaging', ',', 'Clinical', 'and', 'Biochemical', 'Bio', '-', 'Markers', 'for', 'Parkinson', ""'s"", 'Disease', '|', 'We', 'propose', 'to', 'build', 'on', 'preliminary', 'data', 'evaluating', 'non', '-', 'dopaminergic', '/', 'non', '-', 'motor', 'clinical', 'biomarkers', 'to', 'more', 'fully', 'assess', 'these', 'markers', 'at', 'the', 'threshold', 'of', 'Parkinson', 'disease', '(', 'PD', ')', '.', '\n\n', 'Development', 'of', 'reliable', 'biomarkers', 'for', 'both', 'dopaminergic', 'and', 'non', '-', 'dopaminergic', 'manifestations', 'of', 'Parkinson', 'disease', '(', 'PD', ')', 'and', 'related', 'disorders', 'may', 'dramatically', 'accelerate', 'research', 'on', 'PD', 'etiology', ',', 'pathophysiology', ',', 'and', 'therapeutics', '.', 'Biomarkers', 'are', 'broadly', 'defined', 'as', 'characteristics', 'that', 'are', 'objectively', 'measured', 'and', 'evaluated', 'as', 'indicators', 'of', 'normal', 'biological', 'processes', ',', 'pathogenic', 'processes', ',', 'or', 'pharmacologic', 'responses', 'to', 'a', 'therapeutic', 'intervention', '.', 'Specific', 'biomarkers', 'may', 'be', 'useful', 'at', 'the', 'onset', 'of', 'neurodegeneration', ',', 'the', 'onset', 'of', 'disease', ',', 'and/or', 'to', 'mark', 'disease', 'progression', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00315250,NCT00315250,"Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease | We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD).

Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression.","[(65, 84, 'CONDITION', ""Parkinson's Disease""), (240, 257, 'CONDITION', 'Parkinson disease'), (259, 261, 'CONDITION', 'PD'), (361, 378, 'CONDITION', 'Parkinson disease'), (380, 382, 'CONDITION', 'PD'), (446, 448, 'CONDITION', 'PD')]"
"['Exercise', 'Training', 'as', 'an', 'Intervention', 'to', 'Improve', 'Muscle', 'Function', 'and', 'Recovery', 'Following', 'Bed', 'Rest', 'in', 'Older', 'Adults', 'With', 'Type', '2', 'Diabetes', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'gather', 'data', 'on', 'how', 'exercise', 'can', 'help', 'recovery', 'of', 'muscle', 'mass', ',', 'strength', ',', 'and', 'physical', 'function', 'after', 'bedrest', 'in', 'older', 'adults', 'with', 'pre', '-', 'diabetes', 'and', 'type', '2', 'diabetes', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04057677,NCT04057677,"Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes | The purpose of this research is to gather data on how exercise can help recovery of muscle mass, strength, and physical function after bedrest in older adults with pre-diabetes and type 2 diabetes.","[(0, 17, 'PHYSICAL', 'Exercise Training'), (117, 132, 'CONDITION', 'Type 2 Diabetes'), (189, 197, 'PHYSICAL', 'exercise'), (299, 311, 'CONDITION', 'pre-diabetes'), (316, 331, 'CONDITION', 'type 2 diabetes')]"
"['Effect', 'of', 'Sensory', 'Integration', 'Therapy', 'on', 'Balance', 'and', 'Functional', 'Mobility', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', '|', 'Purpose', ':', 'to', 'investigate', 'the', 'effect', 'of', 'sensory', 'integration', 'therapy', 'on', 'balance', 'and', 'functional', 'mobility', 'in', 'children', 'with', 'spastic', 'diplegic', 'cerebral', 'palsy', '.', 'Methods', ':', 'children', 'with', 'spastic', 'cerebral', 'palsy', ',', 'the', 'children', 'were', 'assigned', 'to', 'a', 'control', 'group', 'and', 'a', 'study', 'group', '.', 'Balance', 'was', 'assessed', 'using', 'the', 'Biodex', 'balance', 'system', 'and', 'functional', 'mobility', 'was', 'assessed', 'using', 'the', 'Timed', 'Up', 'and', 'Go', 'test', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05614713,NCT05614713,"Effect of Sensory Integration Therapy on Balance and Functional Mobility in Children With Spastic Cerebral Palsy | Purpose: to investigate the effect of sensory integration therapy on balance and functional mobility in children with spastic diplegic cerebral palsy. Methods: children with spastic cerebral palsy, the children were assigned to a control group and a study group. Balance was assessed using the Biodex balance system and functional mobility was assessed using the Timed Up and Go test.","[(10, 72, 'PHYSICAL', 'Sensory Integration Therapy on Balance and Functional Mobility'), (90, 112, 'CONDITION', 'Spastic Cerebral Palsy'), (153, 215, 'PHYSICAL', 'sensory integration therapy on balance and functional mobility'), (233, 264, 'CONDITION', 'spastic diplegic cerebral palsy'), (289, 311, 'CONDITION', 'spastic cerebral palsy')]"
"['The', 'Effects', 'of', 'Standardized', 'Physical', 'Therapy', 'and', 'Functional', 'Strength', 'Training', 'on', 'Upper', 'Limb', 'Function', 'and', 'Neuromuscular', 'Weakness', 'After', 'Stroke', ':', 'a', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'hypothesis', 'that', 'adding', 'functional', 'strength', 'training', 'to', 'UK', 'conventional', 'therapy', 'improves', 'muscle', 'function', 'and', 'walking', 'than', 'either', 'UK', 'conventional', 'therapy', 'alone', 'or', 'increased', 'intensity', 'of', 'UK', 'conventional', 'therapy', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00360789,NCT00360789,The Effects of Standardized Physical Therapy and Functional Strength Training on Upper Limb Function and Neuromuscular Weakness After Stroke: a Pilot Study | The purpose of this study is to test the hypothesis that adding functional strength training to UK conventional therapy improves muscle function and walking than either UK conventional therapy alone or increased intensity of UK conventional therapy.,"[(15, 44, 'PHYSICAL', 'Standardized Physical Therapy'), (49, 77, 'PHYSICAL', 'Functional Strength Training'), (134, 140, 'CONDITION', 'Stroke'), (222, 250, 'PHYSICAL', 'functional strength training'), (257, 277, 'PHYSICAL', 'conventional therapy'), (330, 356, 'CONTROL', 'conventional therapy alone'), (360, 406, 'CONTROL', 'increased intensity of UK conventional therapy')]"
"['Comparison', 'of', 'Therapeutic', 'Strategies', 'With', 'Cholinesterase', 'Inhibitors', ':', 'Stop', 'or', 'Still', '(', 'SOS', ')', 'Trial', '|', 'Cholinesterase', 'inhibitors', '(', 'CI', ')', 'remain', 'the', 'only', 'drugs', 'with', 'a', 'recognized', 'efficacy', 'in', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'in', 'spite', 'of', 'enormous', 'research', 'efforts', '.', 'However', ',', 'these', 'drugs', 'presented', 'as', '""', 'symptomatic', 'treatment', '""', 'of', 'AD', 'are', 'considered', 'as', 'having', 'only', 'a', 'weak', 'effect', 'on', 'the', 'course', 'of', 'AD', '.', 'The', 'reimbursement', 'of', 'these', 'drugs', 'is', 'regularly', 'challenged', 'due', 'to', 'the', 'lack', 'of', 'evidence', 'for', 'the', 'impact', 'of', 'these', 'drugs', 'on', 'milestones', 'stages', 'of', 'AD', 'evolution', '(', 'survival', 'without', 'severe', 'dementia', ',', 'restriction', 'in', 'Basic', 'Activities', 'of', 'Daily', 'Living', '-', 'BADL', ')', 'and', 'on', 'major', 'consequences', 'in', 'public', 'health', '(', 'hospitalization', 'and', 'institutionalization', ')', '.', 'The', 'great', 'majority', 'of', 'previous', 'randomized', 'controlled', 'trials', 'conducted', 'with', 'CI', 'have', 'had', 'a', 'too', 'short', 'duration', 'and', 'the', 'end', 'points', 'were', 'limited', 'to', 'cognition', '(', 'ADAS', 'Cog', 'scale', ')', ',', 'IADL', '(', 'Instrumental', 'Activities', 'of', 'Daily', 'Living', ')', 'function', 'and', 'Global', 'Impression', 'of', 'Change', '.', 'New', 'evidences', 'from', 'the', 'DOMINO', 'trial', '(', '1', ')', 'conducted', 'in', 'UK', ',', 'independently', 'of', 'the', 'pharmaceutical', 'industry', ',', 'showed', 'that', 'the', 'true', 'effect', 'of', 'CI', 'might', 'be', 'more', 'to', 'avoid', 'or', 'to', 'delay', 'the', 'cognitive', 'or', 'functional', 'decline', 'in', 'AD', 'than', 'to', 'improve', 'patients', ';', 'the', 'institutionalisation', '(', '2', ')', 'was', 'also', 'delayed', '.', 'However', ',', 'this', 'trial', 'was', 'conducted', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'AD', ',', 'and', 'the', 'interest', 'of', 'the', 'drugs', 'at', 'the', 'mild', 'to', 'moderate', 'stage', 'remains', 'questionable', '.', '\n\n', 'The', 'investigators', 'have', 'shown', 'that', 'a', 'good', 'surrogate', 'marker', 'of', 'survival', 'without', 'severe', 'dementia', 'would', 'be', 'an', 'increase', 'of', 'ADAS', 'Cog', 'scale', 'of', 'more', 'than', 'six', 'points', '(', '3', ')', '.', 'A', 'post', 'hoc', 'reanalysis', 'of', 'the', 'pivotal', 'RCT', 'with', 'two', 'CI', 'showed', 'that', 'in', 'mild', 'to', 'moderate', 'patients', ',', 'CI', 'was', 'associated', 'with', 'a', '15', '%', 'decrease', 'of', 'patients', 'with', 'a', 'deterioration', 'of', 'ADAS', '-', 'Cog', 'of', 'more', 'than', 'six', 'points', 'in', 'six', 'months', '.', 'Thus', 'at', 'the', 'beginning', 'of', 'dementia', 'the', 'real', 'effect', 'of', 'CI', 'might', 'be', 'more', 'of', 'delaying', 'the', 'cognitive', 'and', 'functional', 'decline', ',', 'than', 'to', 'improve', 'the', 'patients', '.', 'The', 'main', 'objective', 'of', 'the', 'SOS', 'trial', 'is', 'to', 'demonstrate', 'that', 'the', 'benefit', 'of', 'CI', 'at', 'the', 'early', 'phase', 'of', 'dementia', 'is', 'the', 'same', 'as', 'at', 'the', 'later', 'phase', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03454646,NCT03454646,"Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial | Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as ""symptomatic treatment"" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.

The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.","[(42, 67, 'DRUG', 'Cholinesterase Inhibitors'), (97, 122, 'DRUG', 'Cholinesterase inhibitors'), (124, 126, 'DRUG', 'CI'), (180, 216, 'CONDITION', ""mild to moderate Alzheimer's disease""), (218, 220, 'CONDITION', 'AD'), (322, 324, 'CONDITION', 'AD'), (386, 388, 'CONDITION', 'AD'), (529, 531, 'CONDITION', 'AD'), (560, 575, 'CONDITION', 'severe dementia'), (795, 797, 'DRUG', 'CI'), (1114, 1116, 'DRUG', 'CI'), (1191, 1193, 'CONDITION', 'AD'), (1318, 1339, 'CONDITION', 'moderate to severe AD'), (1502, 1517, 'CONDITION', 'severe dementia'), (1636, 1638, 'DRUG', 'CI'), (1681, 1683, 'DRUG', 'CI'), (1828, 1836, 'CONDITION', 'dementia'), (1856, 1858, 'DRUG', 'CI'), (1889, 1921, 'CONDITION', 'cognitive and functional decline'), (2027, 2029, 'DRUG', 'CI'), (2037, 2060, 'CONDITION', 'early phase of dementia')]"
"['Pain', 'Exposure', 'Physical', 'Therapy', 'Or', 'Conservative', 'Therapy', 'for', 'Patients', 'With', 'Complex', 'Regional', 'Pain', 'Syndrome', 'Type', 'I', '|', 'The', 'current', 'Dutch', 'CBO', 'guideline', 'treatment', 'of', 'Complex', 'Regional', 'Pain', 'Syndrome', 'Type', 'I', '(', 'CRPS-1', ')', 'is', 'very', 'disappointing', 'with', 'chronification', ',', 'disability', 'and', 'subsequent', 'high', 'medical', 'costs', 'and', 'personal', 'suffering', '.', 'A', 'possible', 'better', 'treatment', 'is', 'intensive', 'function', '-', 'oriented', 'physical', 'therapy', 'or', 'Pain', 'Exposure', 'in', 'Physical', 'Therapy', '(', 'PEPT', ')', '.', 'However', ',', 'there', 'are', 'no', 'adequate', 'studies', 'performed', 'that', 'demonstrate', 'the', 'efficacy', 'of', 'PEPT', 'and', 'therefore', 'PEPT', 'is', 'lacking', 'in', 'the', 'Dutch', 'CBO', 'CRPS-1', 'guidelines', '.', 'Despite', 'a', 'lacking', 'scientific', 'argumentation', ',', 'the', 'PEPT', 'approach', 'or', 'Macedonian', 'therapy', ',', 'is', 'now', 'being', 'adopted', 'on', 'a', 'large', 'scale', 'among', 'physical', 'therapists', 'in', 'The', 'Netherlands', '.', 'There', 'are', 'two', 'level', 'C', 'retrospective', 'cohort', 'studies', 'demonstrating', 'a', 'promising', 'and', 'clinical', 'relevant', 'beneficial', 'effect', 'on', 'pain', 'and', 'function', 'after', 'PEPT', '.', 'In', 'response', 'to', 'the', 'growing', 'demand', 'for', 'scientific', 'argumentation', 'among', 'doctors', 'and', 'physical', 'therapists', 'with', 'respect', 'to', 'the', 'efficacy', 'of', 'PEPT', ',', 'we', 'conducted', 'a', 'pilot', 'study', 'at', 'the', 'UMC', 'St', 'Radboud', 'Nijmegen', '.', 'The', 'results', 'of', 'this', 'pilot', 'study', 'were', 'very', 'promising', 'and', 'therefore', ',', 'we', 'decided', 'to', 'design', 'a', 'large', 'RCT', 'to', 'investigate', 'the', 'treatment', 'effects', 'and', 'costs', 'in', 'CRPS', 'patients', 'treated', 'with', 'PEPT', 'compared', 'to', 'CRPS', 'patients', 'treated', 'with', 'usual', 'therapy', 'according', 'to', 'the', 'Dutch', 'CBO', 'guidelines', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00817128,NCT00817128,"Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I | The current Dutch CBO guideline treatment of Complex Regional Pain Syndrome Type I (CRPS-1) is very disappointing with chronification, disability and subsequent high medical costs and personal suffering. A possible better treatment is intensive function-oriented physical therapy or Pain Exposure in Physical Therapy (PEPT). However, there are no adequate studies performed that demonstrate the efficacy of PEPT and therefore PEPT is lacking in the Dutch CBO CRPS-1 guidelines. Despite a lacking scientific argumentation, the PEPT approach or Macedonian therapy, is now being adopted on a large scale among physical therapists in The Netherlands. There are two level C retrospective cohort studies demonstrating a promising and clinical relevant beneficial effect on pain and function after PEPT. In response to the growing demand for scientific argumentation among doctors and physical therapists with respect to the efficacy of PEPT, we conducted a pilot study at the UMC St Radboud Nijmegen. The results of this pilot study were very promising and therefore, we decided to design a large RCT to investigate the treatment effects and costs in CRPS patients treated with PEPT compared to CRPS patients treated with usual therapy according to the Dutch CBO guidelines.","[(0, 30, 'PHYSICAL', 'Pain Exposure Physical Therapy'), (34, 54, 'CONTROL', 'Conservative Therapy'), (73, 110, 'CONDITION', 'Complex Regional Pain Syndrome Type I'), (158, 195, 'CONDITION', 'Complex Regional Pain Syndrome Type I'), (197, 203, 'CONDITION', 'CRPS-1'), (348, 392, 'PHYSICAL', 'intensive function-oriented physical therapy'), (396, 429, 'PHYSICAL', 'Pain Exposure in Physical Therapy'), (431, 435, 'PHYSICAL', 'PEPT'), (520, 524, 'PHYSICAL', 'PEPT'), (539, 543, 'PHYSICAL', 'PEPT'), (572, 578, 'CONDITION', 'CRPS-1'), (639, 643, 'PHYSICAL', 'PEPT'), (656, 674, 'PHYSICAL', 'Macedonian therapy'), (880, 884, 'CONDITION', 'pain'), (904, 908, 'PHYSICAL', 'PEPT'), (1043, 1047, 'PHYSICAL', 'PEPT'), (1258, 1262, 'CONDITION', 'CRPS'), (1285, 1289, 'PHYSICAL', 'PEPT'), (1302, 1306, 'CONDITION', 'CRPS'), (1329, 1342, 'CONTROL', 'usual therapy')]"
"['A', 'Multimodal', 'Individualized', 'Intervention', 'to', 'Prevent', 'Functional', 'Decline', 'After', 'Stroke', '.', 'A', 'Randomized', 'Controlled', 'Trial', 'on', 'Long', '-', 'term', 'Follow', '-', 'up', 'After', 'Stroke', '(', 'The', 'LAST', '-', 'long', 'Trial', ')', '|', 'Despite', 'the', 'improved', 'treatment', 'of', 'acute', 'stroke', 'over', 'the', 'past', 'decades', ',', 'those', 'suffering', 'from', 'stroke', 'still', 'are', 'at', 'an', 'increased', 'risk', 'of', 'functional', 'and', 'cognitive', 'decline', 'in', 'the', 'long', 'term', '.', 'The', 'most', 'common', 'consequences', 'of', 'stroke', 'are', 'functional', 'impairments', ',', 'cognitive', 'impairments', ',', 'depression', 'and', 'fatigue', '.', 'These', 'are', 'also', 'regarded', 'as', 'barriers', 'to', 'achieve', 'optimal', 'adherence', 'to', 'the', 'guidelines', 'regarding', 'secondary', 'prevention', '.', 'The', 'primary', 'aim', 'of', 'this', 'project', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'a', 'multimodal', 'individualized', 'intervention', 'to', 'prevent', 'functional', 'decline', 'in', 'the', 'long', 'term', 'after', 'stroke', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03859063,NCT03859063,"A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial) | Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.","[(2, 40, 'OTHER', 'Multimodal Individualized Intervention'), (52, 70, 'CONDITION', 'Functional Decline'), (77, 83, 'CONDITION', 'Stroke'), (144, 150, 'CONDITION', 'Stroke'), (209, 221, 'CONDITION', 'acute stroke'), (266, 272, 'CONDITION', 'stroke'), (307, 339, 'CONDITION', 'functional and cognitive decline'), (390, 396, 'CONDITION', 'stroke'), (401, 423, 'CONDITION', 'functional impairments'), (425, 446, 'CONDITION', 'cognitive impairments'), (448, 458, 'CONDITION', 'depression'), (463, 470, 'CONDITION', 'fatigue'), (657, 695, 'OTHER', 'multimodal individualized intervention'), (749, 755, 'CONDITION', 'stroke')]"
"['Open', 'Spina', 'Bifida', 'Fetoscopic', 'Repair', 'Project', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'assess', 'a', 'new', 'fetal', 'surgery', 'approach', 'to', 'repair', 'open', 'spina', 'bifida', '.', 'The', 'fetal', 'group', 'hypothesis', 'is', 'to', 'perform', 'a', 'minimally', 'invasive', 'procedure', 'using', 'a', 'fetoscopic', 'technique', 'in', 'order', 'to', 'access', 'to', 'amniotic', 'cavity', 'and', 'make', 'the', 'endoscopic', 'repair', '.', 'This', 'approach', 'will', 'allow', 'investigators', 'to', 'make', 'the', 'closure', 'of', 'the', 'defect', 'and', 'avoid', 'the', 'use', 'of', 'an', 'hysterotomy', ',', 'reducing', 'the', 'risk', 'of', 'maternal', 'complications', 'as', 'uterine', 'dehiscence', '(', 'rupture', ')', ',', 'hemorrhage', 'and', 'preterm', 'premature', 'rupture', 'of', 'membranes', '(', 'PPROM', ')', ',', 'the', 'patient', 'also', 'will', 'be', 'able', 'to', 'have', 'a', 'vaginal', 'delivery', '.']","['B-COND', 'I-COND', 'I-COND', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03562286,NCT03562286,"Open Spina Bifida Fetoscopic Repair Project | The aim of the study is to assess a new fetal surgery approach to repair open spina bifida. The fetal group hypothesis is to perform a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair. This approach will allow investigators to make the closure of the defect and avoid the use of an hysterotomy, reducing the risk of maternal complications as uterine dehiscence (rupture), hemorrhage and preterm premature rupture of membranes (PPROM), the patient also will be able to have a vaginal delivery.","[(0, 17, 'CONDITION', 'Open Spina Bifida'), (18, 35, 'SURGICAL', 'Fetoscopic Repair'), (86, 99, 'SURGICAL', 'fetal surgery'), (119, 136, 'CONDITION', 'open spina bifida'), (218, 238, 'SURGICAL', 'fetoscopic technique'), (290, 307, 'SURGICAL', 'endoscopic repair')]"
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Efficacy', 'and', 'Safety', 'Study', 'With', 'an', 'Open', '-', 'Label', 'Treatment', 'Period', 'of', 'Fremanezumab', 'Administered', 'Subcutaneously', 'Monthly', 'or', 'Quarterly', 'for', 'the', 'Preventive', 'Treatment', 'of', 'Migraine', 'in', 'Adult', 'Chinese', 'Patients', '|', 'Primary', 'Objective', ':', '\n\n', 'To', 'demonstrate', 'the', 'efficacy', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'subcutaneous', '(', 'sc', ')', 'injections', 'to', 'adult', 'Chinese', 'participants', 'with', 'migraine', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'further', 'demonstrate', 'the', 'efficacy', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'sc', 'injections', '.', '\n', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'sc', 'injections', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05458011,NCT05458011,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients | Primary Objective:

To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.

Secondary Objectives:

To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.
To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.","[(41, 48, 'CONTROL', 'Placebo'), (125, 137, 'DRUG', 'Fremanezumab'), (219, 227, 'CONDITION', 'Migraine'), (307, 319, 'DRUG', 'fremanezumab'), (422, 430, 'CONDITION', 'migraine'), (495, 507, 'DRUG', 'fremanezumab'), (604, 616, 'DRUG', 'fremanezumab')]"
"['Multicenter', ',', 'Open', '-', 'label', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', '(', 'by', 'Blinded', 'Reading', ')', 'of', 'Contrast', '-', 'Enhanced', 'Magnetic', 'Resonance', 'Angiography', '(', 'MRA', ')', 'After', 'a', 'Single', 'Intravenous', 'Injection', 'of', '0.1', 'mmol', '/', 'kg', 'Gadobutrol', 'in', 'Subjects', 'With', 'Known', 'or', 'Suspected', 'Vascular', 'Disease', 'of', 'the', 'Supra', '-', 'aortic', 'Vessels', '|', 'Subjects', 'referred', 'for', 'a', 'routine', 'CTA', '(', 'computed', 'tomography', 'angiography', ')', 'or', 'MRA', '(', 'magnetic', 'resonance', 'angiography', ')', 'will', 'be', 'invited', 'to', 'participate', 'in', 'the', 'study', 'and', 'subjects', 'will', 'be', 'involved', 'in', 'the', 'study', 'for', 'between', '2', 'and', '12', 'days', '.', 'Two', 'to', 'three', 'visits', 'to', 'the', 'study', 'doctor', 'will', 'be', 'required', '.', '\n\n', 'This', 'study', 'will', 'compare', 'the', 'diagnostic', 'results', 'of', 'Gadobutrol', 'enhanced', 'MRA', 'images', 'with', 'MRA', 'images', 'taken', 'without', 'contrast', 'agent', 'using', 'images', 'from', 'a', 'CTA', 'as', 'the', 'standard', 'of', 'reference', ',', 'which', 'may', 'have', 'been', 'performed', 'up', 'to', '60', 'days', 'prior', 'to', 'enrolment', '.', 'If', 'a', 'CTA', 'has', 'not', 'been', 'performed', 'in', 'this', 'prior', 'time', 'period', ',', 'a', 'CTA', 'is', 'required', 'for', 'the', 'study', '.', '\n\n', 'MRA', 'and', 'CTA', 'images', 'will', 'be', 'collected', 'for', 'an', 'independent', 'review', '(', 'blinded', 'read', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01344447,NCT01344447,"Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels | Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.

This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.

MRA and CTA images will be collected for an independent review (blinded read).","[(244, 288, 'CONDITION', 'Vascular Disease of the Supra-aortic Vessels')]"
"['Effects', 'of', 'Comprehensive', 'Augmented', 'and', 'Virtual', 'Reality', 'for', 'Upper', 'Limb', 'Rehabilitation', 'in', 'First', '-', 'Ever', 'Stroke', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'assess', 'the', 'efficacy', 'of', 'augmented', 'and', 'virtual', 'reality', '-', 'based', 'rehabilitation', 'programs', 'on', 'improving', 'upper', 'extremity', 'function', 'in', 'subacute', 'stroke', 'patients', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT05193539,NCT05193539,Effects of Comprehensive Augmented and Virtual Reality for Upper Limb Rehabilitation in First-Ever Stroke Patients | The purpose of this study was to assess the efficacy of augmented and virtual reality-based rehabilitation programs on improving upper extremity function in subacute stroke patients.,"[(11, 54, 'OTHER', 'Comprehensive Augmented and Virtual Reality'), (88, 105, 'CONDITION', 'First-Ever Stroke'), (173, 232, 'OTHER', 'augmented and virtual reality-based rehabilitation programs'), (274, 289, 'CONDITION', 'subacute stroke')]"
"['BC109', '-', 'Investigation', 'of', 'an', 'Updated', 'Bone', '-', 'anchored', 'Sound', 'Processor', '|', 'The', 'study', 'is', 'a', 'prospective', ',', 'single', '-', 'center', ',', 'comparative', ',', 'cross', '-', 'over', 'study', 'with', 'within', '-', 'subject', 'control', 'design', '.', 'In', 'the', 'investigation', 'an', 'updated', 'sound', 'processor', 'will', 'be', 'tested', 'at', 'compared', 'to', 'the', 'CE', 'marked', 'Ponto', '3', 'SuperPower', 'sound', 'processor', '(', 'available', 'on', 'the', 'market', 'since', 'December', '2016', ')', 'in', 'order', 'to', 'establish', 'marketing', 'claim(s', ')', 'on', 'the', 'updated', 'sound', 'processor', '.', '\n\n', 'The', 'performance', 'of', 'the', 'two', 'sound', 'processors', 'will', 'be', 'evaluated', 'via', 'speech', 'and', 'hearing', 'tests', ',', 'and', 'patient', 'reported', 'outcomes', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05086809,NCT05086809,"BC109 - Investigation of an Updated Bone-anchored Sound Processor | The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor.

The performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.","[(28, 65, 'OTHER', 'Updated Bone-anchored Sound Processor'), (201, 224, 'OTHER', 'updated sound processor'), (259, 303, 'CONTROL', 'CE marked Ponto 3 SuperPower sound processor'), (398, 421, 'OTHER', 'updated sound processor')]"
"['Studio', 'Monocentrico', 'in', 'Doppio', 'Cieco', 'Randomizzato', ""Dell'Effetto"", 'di', 'Una', 'Miscela', 'di', 'Flavonoidi', 'ed', 'Acidi', 'Grassi', 'Naturali', 'in', 'Pazienti', 'Affetti', 'da', 'Distrofia', 'Muscolare', '|', 'The', 'study', 'aimed', 'to', 'assess', 'the', 'safety', 'and', ',', 'partially', ',', 'the', 'efficacy', 'of', 'dietary', 'supplementation', 'of', 'a', 'flavonoids-', ',', 'DHA-', 'and', 'EPA', '-', 'based', 'natural', 'supplement', 'in', 'non', '-', 'ambulant', 'DMD', 'boys', 'and', 'in', 'a', 'cohort', 'of', 'LGMD', 'and', 'FSHD', 'patients', 'to', 'compare', 'its', 'effect', 'in', 'MDs', 'of', 'different', 'aetiology', 'and', 'to', 'eventually', 'highlight', 'any', 'differences', 'in', 'inflammatory', 'involved', 'pathways', '.', 'To', 'assess', 'safety', ',', 'patient', ""'s"", 'laboratory', 'parameters', 'were', 'monitored', 'and', 'adverse', 'events', 'recorded', ',', 'while', 'efficacy', 'was', 'evaluated', 'through', 'performance', 'scale', 'questionnaire', 'and', 'strength', 'measurement', '(', '6', 'minute', 'walking', 'test', 'and', 'Biodex', 'System', '4', 'Dynamometer', 'parameter', 'evaluation', ')', '.', 'This', 'study', 'was', 'conceived', 'as', 'proof', 'of', 'principle', 'for', 'the', 'safe', 'use', 'of', 'flavonoids', '/', 'omega3s', '-', 'based', 'compound', 'as', 'an', 'adjuvant', 'in', 'the', 'management', 'of', 'neuromuscular', 'disorders', ';', 'besides', ',', 'its', 'efficacy', 'in', 'alleviating', 'symptoms', 'linked', 'to', 'secondary', 'effects', 'of', 'genetic', 'mutation', 'as', 'inflammation', ',', 'muscular', 'pain', 'and', 'weakness', 'was', 'assessed', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT03317171,NCT03317171,"Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare | The study aimed to assess the safety and, partially, the efficacy of dietary supplementation of a flavonoids-, DHA- and EPA-based natural supplement in non-ambulant DMD boys and in a cohort of LGMD and FSHD patients to compare its effect in MDs of different aetiology and to eventually highlight any differences in inflammatory involved pathways. To assess safety, patient's laboratory parameters were monitored and adverse events recorded, while efficacy was evaluated through performance scale questionnaire and strength measurement (6 minute walking test and Biodex System 4 Dynamometer parameter evaluation). This study was conceived as proof of principle for the safe use of flavonoids/omega3s-based compound as an adjuvant in the management of neuromuscular disorders; besides, its efficacy in alleviating symptoms linked to secondary effects of genetic mutation as inflammation, muscular pain and weakness was assessed.","[(259, 270, 'DRUG', 'flavonoids-'), (272, 276, 'DRUG', 'DHA-'), (281, 284, 'DRUG', 'EPA'), (326, 329, 'CONDITION', 'DMD'), (354, 358, 'CONDITION', 'LGMD'), (363, 367, 'CONDITION', 'FSHD'), (402, 405, 'CONDITION', 'MDs'), (841, 851, 'DRUG', 'flavonoids'), (852, 859, 'DRUG', 'omega3s'), (1033, 1045, 'CONDITION', 'inflammation'), (1047, 1060, 'CONDITION', 'muscular pain')]"
"['Action', 'of', 'the', 'Amantadine', 'on', 'Post', 'Stroke', 'Aphasic', 'Patients', ""'"", 'Language', 'and', 'Communication', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'test', 'the', 'action', 'of', 'the', 'amantadine', ',', 'as', 'DOPA', '-', 'agonist', ',', 'in', 'a', 'double', 'blind', 'cross', '-', 'over', 'trial', ',', 'amantadine', '/', 'placebo', ',', 'on', 'the', 'verbal', 'fluency', 'of', 'chronic', 'post', 'stroke', 'aphasic', 'patients', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O']",NCT00821691,NCT00821691,"Action of the Amantadine on Post Stroke Aphasic Patients' Language and Communication | The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic patients.","[(14, 24, 'DRUG', 'Amantadine'), (28, 39, 'CONDITION', 'Post Stroke'), (40, 47, 'CONDITION', 'Aphasic'), (143, 153, 'DRUG', 'amantadine'), (208, 218, 'DRUG', 'amantadine'), (221, 228, 'CONTROL', 'placebo'), (255, 274, 'CONDITION', 'chronic post stroke'), (275, 282, 'CONDITION', 'aphasic')]"
"['Applying', 'Transcutaneous', 'Auricular', 'Vagus', 'Nerve', 'Stimulation', 'to', 'Treat', 'Fibromyalgia', '|', 'In', 'this', 'research', 'study', 'we', 'want', 'to', 'learn', 'more', 'about', 'if', 'transcutaneous', 'electrical', 'nerve', 'stimulation', '(', 'TENS', ')', ',', 'a', 'safe', 'electrical', 'stimulation', 'tool', ',', 'can', 'relieve', 'Fibromyalgia', 'pain', '.', 'A', 'total', 'of', '60', 'subjects', 'with', 'Fibromyalgia', 'will', 'be', 'enrolled', 'in', 'this', 'study', 'at', 'Massachusetts', 'General', 'Hospital', ',', 'Charlestown', 'Navy', 'Yard', 'campus', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04777500,NCT04777500,"Applying Transcutaneous Auricular Vagus Nerve Stimulation to Treat Fibromyalgia | In this research study we want to learn more about if transcutaneous electrical nerve stimulation (TENS), a safe electrical stimulation tool, can relieve Fibromyalgia pain. A total of 60 subjects with Fibromyalgia will be enrolled in this study at Massachusetts General Hospital, Charlestown Navy Yard campus.","[(9, 57, 'OTHER', 'Transcutaneous Auricular Vagus Nerve Stimulation'), (67, 79, 'CONDITION', 'Fibromyalgia'), (136, 179, 'OTHER', 'transcutaneous electrical nerve stimulation'), (181, 185, 'OTHER', 'TENS'), (236, 248, 'CONDITION', 'Fibromyalgia'), (249, 253, 'CONDITION', 'pain'), (283, 295, 'CONDITION', 'Fibromyalgia')]"
"['Determination', 'of', 'the', 'Optimal', 'Mandibular', 'Position', 'During', 'Oral', 'Appliance', 'Therapy', 'With', 'a', 'Mandibular', 'Advancement', 'Device', 'in', 'Patients', 'Diagnosed', 'With', 'Obstructive', 'Sleep', 'Apnea', '.', '|', 'In', 'this', 'prospective', 'randomized', 'cross', '-', 'over', 'trial', ',', '3', 'different', 'titration', 'procedures', 'will', 'be', 'compared', ':', '\n\n', 'titration', 'of', 'the', 'mandibular', 'advancement', 'device', '(', 'MAD', ')', 'in', 'the', 'home', 'setting', 'based', 'on', 'both', 'the', 'physical', 'limits', 'of', 'the', 'patient', ""'s"", 'mandibular', 'protrusion', 'and', 'the', 'resolution', 'of', 'subjective', 'complaints', ',', 'as', 'currently', 'often', 'used', 'in', 'routine', 'clinical', 'practice', ';', '\n', 'an', 'overnight', 'titration', 'PSG', 'using', 'the', 'remotely', 'controlled', 'mandibular', 'positioner', '(', 'RCMP', ')', 'with', 'stepwise', 'mandibular', 'protrusion', 'until', 'respiratory', 'events', 'are', 'reduced', 'and', '\n', 'incremental', 'protrusion', 'of', 'the', 'mandible', 'during', 'DISE', 'using', 'the', 'RCMP', 'until', 'upper', 'airway', 'collapse', 'at', 'all', 'collapsible', 'levels', 'is', 'eliminated', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'prospectively', 'compare', 'the', 'target', 'protrusion', ',', 'as', 'well', 'as', 'the', 'treatment', 'outcome', 'in', 'terms', 'of', 'treatment', 'efficacy', ',', 'of', 'the', '3', 'different', 'titration', 'protocols', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03716648,NCT03716648,"Determination of the Optimal Mandibular Position During Oral Appliance Therapy With a Mandibular Advancement Device in Patients Diagnosed With Obstructive Sleep Apnea. | In this prospective randomized cross-over trial, 3 different titration procedures will be compared:

titration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used in routine clinical practice;
an overnight titration PSG using the remotely controlled mandibular positioner (RCMP) with stepwise mandibular protrusion until respiratory events are reduced and
incremental protrusion of the mandible during DISE using the RCMP until upper airway collapse at all collapsible levels is eliminated.

The aim of this study is to prospectively compare the target protrusion, as well as the treatment outcome in terms of treatment efficacy, of the 3 different titration protocols.","[(56, 78, 'OTHER', 'Oral Appliance Therapy'), (86, 115, 'OTHER', 'Mandibular Advancement Device'), (143, 166, 'CONDITION', 'Obstructive Sleep Apnea'), (288, 317, 'OTHER', 'mandibular advancement device'), (319, 322, 'OTHER', 'MAD')]"
"['Fragility', 'Assessment', 'in', 'Adults', 'With', 'ADHD', 'and', 'Mental', 'Retardation', ',', 'Advancing', 'Age', '|', 'Frailty', 'is', 'a', 'age', 'dependent', 'physiological', 'state', 'of', 'vulnerability', '.', 'Frailty', 'is', 'screened', 'by', 'the', 'phenotypic', 'model', '(', '5', 'clinical', 'criteria', ')', 'or', 'the', 'cumulative', 'model', '(', 'various', 'clinical', 'and', 'biological', 'criteria', ')', '.', 'Currently', ',', 'aging', 'with', 'autism', 'spectrum', 'disorder', 'and', 'mental', 'retardation', '(', 'ADS', '-', 'MR', ')', 'is', 'poor', 'described', '.', 'Nevertheless', 'many', 'data', 'indicate', 'that', 'people', 'with', 'ADS', '-', 'MR', 'may', 'present', 'an', 'early', 'aging', '.', '\n\n', 'Principal', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'frailty', 'in', 'people', 'with', 'ADS', '-', 'MR', 'aged', 'over', '20', 'years', 'depend', 'on', 'age', '.', 'Secondary', 'aims', 'are', 'to', 'evaluate', 'frailty', 'prevalence', ',', 'to', 'describe', 'with', 'details', 'health', 'according', 'to', 'age', ',', 'and', 'to', 'verify', 'the', 'frailty', 'index', 'validity', 'for', 'predicting', 'falls', ',', 'hospitalisation', 'and', 'death', ',', 'in', 'this', 'population', 'of', 'ADS', '-', 'MR', 'patients', 'aged', 'over', '20', 'years', '.', '\n\n', 'This', 'monocentric', 'and', 'prospective', 'study', 'will', 'include', '60', 'ADS', '-', 'MR', 'patients', 'aged', 'over', '20', 'years', 'and', 'living', 'in', 'Languedoc', '-', 'Roussillon', ""'s"", 'medico', '-', 'social', 'care', 'homes', '.', 'Patients', 'are', 'evaluated', 'at', 'the', 'time', 'of', 'inclusion', '.', 'Frailty', 'index', 'is', 'calculated', 'from', '104', 'clinical', 'and', 'biological', 'criteria', '.', 'Furthermore', 'the', 'investigator', 'staff', 'collect', 'data', 'about', 'ADS', 'severity', '(', 'CARS', ')', ',', 'adaptative', 'and', 'intellectual', 'functionning', '(', 'Vineland', ')', ',', 'and', 'psychiatric', 'and', 'somatic', 'comorbidities', '(', 'Reiss', 'scale', ',', 'DSQIID', 'and', 'CIRS', ')', '.', 'Falls', ',', 'hospitalisations', 'or', 'death', 'occurrence', 'is', 'then', 'collected', 'every', 'year', 'during', '5', 'years', '.', '\n\n', 'The', 'connection', 'between', 'frailty', 'index', 'and', 'age', 'will', 'be', 'studied', 'using', 'linear', 'regression', '.', 'The', 'frailty', 'index', 'validity', 'will', 'be', 'analysed', 'using', 'ROC', 'curves', '.', 'Modelisation', 'of', 'the', 'falls', ',', 'hospitalisations', 'or', 'death', 'risk', 'in', 'the', '5', 'years', 'after', 'the', 'initial', 'evaluation', 'will', 'help', 'in', 'identification', 'of', 'the', 'more', 'frailty', 'predictive', 'criteria', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT02791321,NCT02791321,"Fragility Assessment in Adults With ADHD and Mental Retardation, Advancing Age | Frailty is a age dependent physiological state of vulnerability. Frailty is screened by the phenotypic model (5 clinical criteria) or the cumulative model (various clinical and biological criteria). Currently, aging with autism spectrum disorder and mental retardation (ADS-MR) is poor described. Nevertheless many data indicate that people with ADS-MR may present an early aging.

Principal aim of this study is to determine if frailty in people with ADS-MR aged over 20 years depend on age. Secondary aims are to evaluate frailty prevalence, to describe with details health according to age, and to verify the frailty index validity for predicting falls, hospitalisation and death, in this population of ADS-MR patients aged over 20 years.

This monocentric and prospective study will include 60 ADS-MR patients aged over 20 years and living in Languedoc-Roussillon's medico-social care homes. Patients are evaluated at the time of inclusion. Frailty index is calculated from 104 clinical and biological criteria. Furthermore the investigator staff collect data about ADS severity (CARS), adaptative and intellectual functionning (Vineland), and psychiatric and somatic comorbidities (Reiss scale, DSQIID and CIRS). Falls, hospitalisations or death occurrence is then collected every year during 5 years.

The connection between frailty index and age will be studied using linear regression. The frailty index validity will be analysed using ROC curves. Modelisation of the falls, hospitalisations or death risk in the 5 years after the initial evaluation will help in identification of the more frailty predictive criteria.","[(36, 40, 'CONDITION', 'ADHD'), (45, 63, 'CONDITION', 'Mental Retardation'), (81, 88, 'CONDITION', 'Frailty'), (146, 153, 'CONDITION', 'Frailty'), (302, 326, 'CONDITION', 'autism spectrum disorder'), (331, 349, 'CONDITION', 'mental retardation'), (351, 357, 'CONDITION', 'ADS-MR'), (427, 433, 'CONDITION', 'ADS-MR'), (510, 517, 'CONDITION', 'frailty'), (533, 539, 'CONDITION', 'ADS-MR'), (605, 612, 'CONDITION', 'frailty'), (787, 793, 'CONDITION', 'ADS-MR'), (879, 885, 'CONDITION', 'ADS-MR'), (1151, 1154, 'CONDITION', 'ADS'), (1679, 1686, 'CONDITION', 'frailty')]"
"['Multimodal', 'Treatment', 'of', 'Phonological', 'Alexia', ':', 'Behavioral', '&', 'fMRI', 'Outcomes', '|', 'This', 'study', 'offers', '90', '-', '120', 'hours', 'of', '1:1', 'training', 'to', 'improve', 'reading', 'skills', 'in', 'adults', 'who', 'have', 'poor', 'reading', 'skills', 'following', 'a', 'stroke', '.', 'Specifically', ',', 'this', 'study', 'is', 'designed', 'to', 'improve', 'skill', 'in', 'sounding', 'out', 'words', 'for', 'reading', 'and', 'spelling', '.', 'The', 'overall', 'time', 'commitment', 'for', 'participation', 'in', 'this', 'study', 'is', 'approximately', '11', '-', '30', 'weeks', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00827268,NCT00827268,"Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes | This study offers 90-120 hours of 1:1 training to improve reading skills in adults who have poor reading skills following a stroke. Specifically, this study is designed to improve skill in sounding out words for reading and spelling. The overall time commitment for participation in this study is approximately 11-30 weeks.","[(24, 43, 'CONDITION', 'Phonological Alexia'), (108, 146, 'OTHER', '1:1 training to improve reading skills'), (198, 204, 'CONDITION', 'stroke')]"
"['A', 'Randomized', 'Phase', 'III', 'Study', 'of', 'Sodium', 'Thiosulfate', 'for', 'the', 'Prevention', 'of', 'Cisplatin', '-', 'Induced', 'Ototoxicity', 'in', 'Children', '|', 'RATIONALE', ':', 'Sodium', 'thiosulfate', 'may', 'reduce', 'or', 'prevent', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'cancer', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'sodium', 'thiosulfate', 'is', 'more', 'effective', 'than', 'no', 'additional', 'treatment', 'in', 'preventing', 'hearing', 'loss', '.', '\n\n', 'PURPOSE', ':', 'This', 'randomized', 'phase', 'III', 'trial', 'is', 'studying', 'sodium', 'thiosulfate', 'to', 'see', 'how', 'well', 'it', 'works', 'in', 'preventing', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'newly', 'diagnosed', 'germ', 'cell', 'tumor', ',', 'hepatoblastoma', ',', 'medulloblastoma', ',', 'neuroblastoma', ',', 'osteosarcoma', ',', 'or', 'other', 'malignancy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT00716976,NCT00716976,"A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children | RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss.

PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.","[(32, 50, 'DRUG', 'Sodium Thiosulfate'), (73, 102, 'CONDITION', 'Cisplatin-Induced Ototoxicity'), (128, 146, 'DRUG', 'Sodium thiosulfate'), (169, 181, 'CONDITION', 'hearing loss'), (210, 219, 'CONDITION', 'cisplatin'), (224, 230, 'CONDITION', 'cancer'), (260, 278, 'DRUG', 'sodium thiosulfate'), (340, 352, 'CONDITION', 'hearing loss'), (408, 426, 'DRUG', 'sodium thiosulfate'), (466, 478, 'CONDITION', 'hearing loss'), (507, 516, 'CONDITION', 'cisplatin'), (537, 552, 'CONDITION', 'germ cell tumor'), (554, 568, 'CONDITION', 'hepatoblastoma'), (570, 585, 'CONDITION', 'medulloblastoma'), (587, 600, 'CONDITION', 'neuroblastoma'), (602, 614, 'CONDITION', 'osteosarcoma'), (625, 635, 'CONDITION', 'malignancy')]"
"['Multi', '-', 'Center', ',', 'Open', '-', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fabrazyme', 'in', 'Patients', 'With', 'Fabry', 'Disease', 'That', 'Previously', 'Participated', 'in', 'the', 'AGAL-008', '-', '00', 'Study', '|', 'People', 'with', 'Fabry', 'Disease', 'have', 'an', 'alteration', 'in', 'their', 'genetic', 'material', '(', 'DNA', ')', 'which', 'causes', 'a', 'deficiency', 'of', 'the', 'alpha', '-', 'galactosidase', 'A', 'enzyme', '.', 'Fabrazyme', '(', 'agalsidase', 'beta', ')', 'is', 'a', 'drug', 'that', 'helps', 'to', 'break', 'down', 'and', 'removes', 'certain', 'types', 'of', 'fatty', 'substances', 'called', '""', 'glycolipids', '""', '.', 'These', 'glycolipids', 'are', 'normally', 'present', 'within', 'the', 'body', 'in', 'most', 'cells', '.', 'In', 'Fabry', 'disease', ',', 'glycolipids', 'build', 'up', 'in', 'various', 'tissues', 'such', 'as', 'the', 'liver', ',', 'kidney', ',', 'skin', ',', 'and', 'blood', 'vessels', 'because', 'a', '-', 'galactosidase', 'A', 'is', 'not', 'present', ',', 'or', 'is', 'present', 'in', 'small', 'quantities', '.', 'The', 'build', 'up', 'of', 'glycolipid', '(', 'globatriaosylceramide', 'or', 'GL-3', ')', 'levels', 'in', 'these', 'tissues', 'in', 'particular', 'is', 'thought', 'to', 'cause', 'the', 'clinical', 'symptoms', 'that', 'are', 'common', 'to', 'Fabry', 'disease', '.', 'This', 'study', 'analyzed', 'the', 'safety', 'and', 'efficacy', 'of', 'Fabrazyme', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'Fabry', 'disease', 'that', 'previously', 'participated', 'in', 'the', 'AGAL-008', '-', '00', '(', 'NCT0074984', ')', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00081497,NCT00081497,"Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study | People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to break down and removes certain types of fatty substances called ""glycolipids"". These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globatriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study analyzed the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease that previously participated in the AGAL-008-00 (NCT0074984) study.","[(61, 70, 'DRUG', 'Fabrazyme'), (88, 101, 'CONDITION', 'Fabry Disease'), (170, 183, 'CONDITION', 'Fabry Disease'), (298, 307, 'DRUG', 'Fabrazyme'), (309, 324, 'DRUG', 'agalsidase beta'), (502, 515, 'CONDITION', 'Fabry disease'), (843, 856, 'CONDITION', 'Fabry disease'), (905, 914, 'DRUG', 'Fabrazyme'), (949, 962, 'CONDITION', 'Fabry disease')]"
"['Effectiveness', 'of', 'Unilateral', 'Versus', 'Bilateral', 'Intensive', 'Training', 'in', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'This', '3', '-', 'year', 'research', 'project', 'aims', 'to', 'investigate', 'and', 'compare', 'the', 'immediate', 'and', 'long', '-', 'term', 'treatment', 'effectiveness', 'as', 'well', 'as', 'motor', 'improving', 'curve', 'and', 'potential', 'predictors', 'of', 'the', 'unimanual', 'intensive', 'training', 'and', 'bimanual', 'intensive', 'training', 'protocols', 'with', 'an', 'equivalent', 'intervention', 'period', 'in', 'children', 'with', 'hemiplegic', 'CP', 'and', 'children', 'with', 'CP', 'with', 'apparently', 'one', 'side', 'affected', '.', 'In', 'addition', ',', 'based', 'on', 'the', 'ICF', '-', 'CY', 'model', ',', 'comprehensive', 'outcome', 'measures', 'including', 'motor', 'functions', 'as', 'well', 'as', 'psychological', 'functions', 'will', 'be', 'included', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02808156,NCT02808156,"Effectiveness of Unilateral Versus Bilateral Intensive Training in Children With Cerebral Palsy | This 3-year research project aims to investigate and compare the immediate and long-term treatment effectiveness as well as motor improving curve and potential predictors of the unimanual intensive training and bimanual intensive training protocols with an equivalent intervention period in children with hemiplegic CP and children with CP with apparently one side affected. In addition, based on the ICF-CY model, comprehensive outcome measures including motor functions as well as psychological functions will be included.","[(17, 63, 'PHYSICAL', 'Unilateral Versus Bilateral Intensive Training'), (81, 95, 'CONDITION', 'Cerebral Palsy'), (276, 304, 'PHYSICAL', 'unimanual intensive training'), (309, 336, 'PHYSICAL', 'bimanual intensive training'), (403, 416, 'CONDITION', 'hemiplegic CP'), (435, 437, 'CONDITION', 'CP')]"
"['A', 'Comparison', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Topiramate', 'Versus', 'Placebo', 'for', 'the', 'Prophylaxis', 'of', 'Chronic', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'effectiveness', 'of', 'topiramate', 'as', 'compared', 'to', 'placebo', 'for', 'the', 'prevention', 'of', 'headaches', 'in', 'patients', 'with', 'chronic', 'migraine', '.', 'Topiramate', 'has', 'been', 'approved', 'to', 'prevent', 'migraine', 'headaches', 'as', 'well', 'as', 'in', 'the', 'treatment', 'of', 'epilepsy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00210912,NCT00210912,A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine | The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine. Topiramate has been approved to prevent migraine headaches as well as in the treatment of epilepsy.,"[(43, 53, 'DRUG', 'Topiramate'), (61, 68, 'CONTROL', 'Placebo'), (92, 108, 'CONDITION', 'Chronic Migraine'), (182, 192, 'DRUG', 'topiramate'), (208, 215, 'CONTROL', 'placebo'), (238, 247, 'CONDITION', 'headaches'), (265, 281, 'CONDITION', 'chronic migraine'), (283, 293, 'DRUG', 'Topiramate'), (323, 341, 'CONDITION', 'migraine headaches')]"
"['Reduction', 'of', 'Aspiration', 'Through', 'Cohesive', 'Thin', 'Liquids', '(', 'CTL', ')', 'in', 'Patients', 'With', 'Mild', 'Oropharyngeal', 'Dysphagia', 'Due', 'to', 'Ischemic', '/', 'Hemorrhagic', 'Cerebral', 'Cause', '(', 'Stroke', ')', '|', 'The', 'aim', 'of', 'the', 'trial', 'is', 'to', 'identify', 'any', 'systematic', 'effect', 'of', 'cohesiveness', 'on', 'the', 'efficacy', 'of', 'swallowing', 'in', 'patients', 'having', 'dysphagia', 'problems', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02522351,NCT02522351,Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke) | The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.,"[(32, 53, 'OTHER', 'Cohesive Thin Liquids'), (55, 58, 'OTHER', 'CTL'), (77, 105, 'CONDITION', 'Mild Oropharyngeal Dysphagia'), (113, 148, 'CONDITION', 'Ischemic/Hemorrhagic Cerebral Cause'), (150, 156, 'CONDITION', 'Stroke'), (283, 292, 'CONDITION', 'dysphagia')]"
"['Gamma', 'Knife', 'Thalamotomy', 'for', 'Treatment', 'of', 'Essential', 'Tremor', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'effects', '(', 'good', 'and', 'bad', ')', 'of', 'gamma', 'knife', 'radiosurgery', 'for', 'essential', 'tremor', '.', 'The', 'gamma', 'knife', 'places', 'a', 'small', 'lesion', 'in', 'the', 'brain', 'to', 'suppress', 'tremors', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02255929,NCT02255929,Gamma Knife Thalamotomy for Treatment of Essential Tremor | The purpose of this study is to examine effects (good and bad) of gamma knife radiosurgery for essential tremor. The gamma knife places a small lesion in the brain to suppress tremors.,"[(0, 23, 'RADIOTHERAPY', 'Gamma Knife Thalamotomy'), (41, 57, 'CONDITION', 'Essential Tremor'), (126, 150, 'RADIOTHERAPY', 'gamma knife radiosurgery'), (155, 171, 'CONDITION', 'essential tremor'), (177, 188, 'RADIOTHERAPY', 'gamma knife'), (236, 243, 'CONDITION', 'tremors')]"
"['Using', 'Advanced', 'Driver', 'Assistance', 'Systems', '(', 'ADAS', ')', 'as', 'an', 'Intervention', 'Strategy', 'for', 'Drivers', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'impacts', 'an', 'individual', ""'s"", 'fitness', 'to', 'drive', 'in', 'a', 'number', 'of', 'ways', 'that', 'increase', 'the', 'crash', 'risk', 'in', 'this', 'population', '.', 'Current', 'vehicle', 'automation', 'technologies', 'are', 'available', ',', 'that', 'although', 'designed', 'for', 'the', 'general', 'public', ',', 'may', 'help', 'drivers', 'with', 'PD', 'stay', 'on', 'the', 'roads', 'longer', 'and', 'safer', 'than', 'currently', 'possible', '.', 'Using', 'a', 'driving', 'simulator', '(', 'a', 'safe', 'and', 'cost', '-', 'effective', 'alternative', 'with', 'no', 'impact', 'on', 'licensing', 'for', 'participants', ')', ',', 'this', 'study', 'will', 'investigate', 'the', 'feasibility', 'and', 'preliminary', 'efficacy', 'of', 'utilizing', 'in', '-', 'vehicle', 'technology', '(', 'i.e.', ',', 'a', 'simulated', 'lane', 'change', 'assistance', 'system', ')', 'to', 'address', 'critical', 'driving', 'errors', 'in', 'individuals', 'with', 'mild', 'to', 'moderate', 'Parkinson', ""'s"", 'disease', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT03195608,NCT03195608,"Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease | Parkinson's disease (PD) impacts an individual's fitness to drive in a number of ways that increase the crash risk in this population. Current vehicle automation technologies are available, that although designed for the general public, may help drivers with PD stay on the roads longer and safer than currently possible. Using a driving simulator (a safe and cost-effective alternative with no impact on licensing for participants), this study will investigate the feasibility and preliminary efficacy of utilizing in-vehicle technology (i.e., a simulated lane change assistance system) to address critical driving errors in individuals with mild to moderate Parkinson's disease.","[(6, 40, 'OTHER', 'Advanced Driver Assistance Systems'), (42, 46, 'OTHER', 'ADAS'), (93, 112, 'CONDITION', ""Parkinson's Disease""), (115, 134, 'CONDITION', ""Parkinson's disease""), (136, 138, 'CONDITION', 'PD'), (374, 376, 'CONDITION', 'PD'), (631, 652, 'OTHER', 'in-vehicle technology'), (662, 701, 'OTHER', 'simulated lane change assistance system'), (758, 794, 'CONDITION', ""mild to moderate Parkinson's disease"")]"
"['High', '-', 'Dose', 'Immunosuppressive', 'Therapy', 'Using', 'Carmustine', ',', 'Etoposide', ',', 'Cytarabine', ',', 'and', 'Melphalan', '(', 'BEAM', ')', '+', 'Thymoglobulin', 'Followed', 'by', 'Syngeneic', 'or', 'Autologous', 'Hematopoietic', 'Cell', 'Transplantation', 'for', 'Patients', 'With', 'Autoimmune', 'Neurologic', 'Diseases', '|', 'This', 'phase', 'II', 'trial', 'studies', 'the', 'side', 'effects', 'and', 'how', 'well', 'carmustine', ',', 'etoposide', ',', 'cytarabine', 'and', 'melphalan', 'together', 'with', 'antithymocyte', 'globulin', 'before', 'a', 'stem', 'cell', 'transplant', 'works', 'in', 'treating', 'patients', 'with', 'autoimmune', 'neurologic', 'disease', 'that', 'did', 'not', 'respond', 'to', 'previous', 'therapy', '.', 'In', 'autoimmune', 'neurological', 'diseases', ',', 'the', 'patient', ""'s"", 'own', 'immune', 'system', ""'"", 'attacks', ""'"", 'the', 'nervous', 'system', 'which', 'might', 'include', 'the', 'brain', '/', 'spinal', 'cord', 'and/or', 'the', 'peripheral', 'nerves', '.', 'Giving', 'high', '-', 'dose', 'chemotherapy', ',', 'including', 'carmustine', ',', 'etoposide', ',', 'cytarabine', ',', 'melphalan', ',', 'and', 'antithymocyte', 'globulin', ',', 'before', 'a', 'stem', 'cell', 'transplant', 'weakens', 'the', 'immune', 'system', 'and', 'may', 'help', 'stop', 'the', 'immune', 'system', 'from', ""'"", 'attacking', ""'"", 'a', 'patient', ""'s"", 'nervous', 'system', '.', 'When', 'the', 'patient', ""'s"", 'own', '(', 'autologous', ')', 'stem', 'cells', 'are', 'infused', 'into', 'the', 'patient', 'they', 'help', 'the', 'bone', 'marrow', 'make', 'red', 'blood', 'cells', ',', 'white', 'blood', 'cells', ',', 'and', 'platelets', 'so', 'the', 'blood', 'counts', 'can', 'improve', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00716066,NCT00716066,"High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases | This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.","[(42, 52, 'DRUG', 'Carmustine'), (54, 63, 'DRUG', 'Etoposide'), (65, 75, 'DRUG', 'Cytarabine'), (81, 90, 'DRUG', 'Melphalan'), (92, 96, 'DRUG', 'BEAM'), (100, 113, 'DRUG', 'Thymoglobulin'), (126, 184, 'SURGICAL', 'Syngeneic or Autologous Hematopoietic Cell Transplantation'), (203, 233, 'CONDITION', 'Autoimmune Neurologic Diseases'), (294, 304, 'DRUG', 'carmustine'), (306, 315, 'DRUG', 'etoposide'), (317, 327, 'DRUG', 'cytarabine'), (332, 341, 'DRUG', 'melphalan'), (356, 378, 'DRUG', 'antithymocyte globulin'), (388, 408, 'SURGICAL', 'stem cell transplant'), (441, 470, 'CONDITION', 'autoimmune neurologic disease'), (516, 548, 'CONDITION', 'autoimmune neurological diseases'), (700, 712, 'DRUG', 'chemotherapy'), (724, 734, 'DRUG', 'carmustine'), (736, 745, 'DRUG', 'etoposide'), (747, 757, 'DRUG', 'cytarabine'), (759, 768, 'DRUG', 'melphalan'), (774, 796, 'DRUG', 'antithymocyte globulin'), (807, 827, 'SURGICAL', 'stem cell transplant'), (958, 981, 'SURGICAL', '(autologous) stem cells')]"
"['Applications', 'of', 'Nanotechnology', 'and', 'Chemical', 'Sensors', 'for', 'the', 'Detection', 'and', 'Identification', 'of', 'Multiple', 'Sclerosis', ',', 'In', 'Comparison', 'to', 'Other', 'Autoimmune', 'and', 'Neurological', 'Diseases', 'by', 'Exhalation', 'Samples', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'complex', 'multi', '-', 'factorial', 'disease', ',', 'with', 'underlying', 'both', 'genetic', 'and', 'environmental', 'factors', '.', 'Different', 'populations', 'have', 'different', 'susceptibility', 'to', 'MS', '.', 'The', 'disease', 'is', 'characterized', 'by', '2', 'main', 'phenotypes', ':', 'relapsing', '-', 'remitting', 'or', 'progressive', 'course', '.', 'Clinical', 'disability', 'is', 'due', 'to', 'distraction', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', 'myelin', '.', '\n\n', 'Repair', 'processes', 'are', 'mainly', 'noted', 'after', 'the', 'acute', 'relapse', '-', 'and', 'recovery', 'of', 'function', 'can', 'be', 'spontaneous', '.', 'However', ',', 'in', 'severe', 'relapses', 'sometimes', 'there', 'is', 'need', 'for', 'STEROID', 'TREATMENT', '.', '\n\n', 'For', 'the', 'long', 'term', 'prophylaxis', '-', 'following', 'the', 'increased', 'understanding', 'of', 'the', 'disease', ',', 'in', 'the', 'last', '10', '-', '15', 'years', ',', 'there', 'are', 'new', 'immunotherapies', 'available', '(', 'COPAXON', '/', 'TEVA', ';', 'Interferon', '-beta', ')', '.', 'However', 'these', 'can', 'attenuate', 'the', 'disease', '(', 'reduce', 'the', 'number', 'of', 'relapses', 'per', 'year', ')', 'but', 'can', 'not', 'cure', 'it', '.', 'Also', ',', 'they', 'are', 'beneficial', 'in', 'only', '~40', '%', 'of', 'the', 'Relapsing', '-Remitting', 'patients', '.', '\n\n', 'Currently', 'there', 'are', 'no', 'biomarkers', 'available', 'for', 'MS', '(', 'other', 'than', 'oligoclonal', 'Immunoglobulin', 'G', '(', 'IgG', ')', 'in', 'the', 'cervical', 'spine', 'fluid', '(', 'CSF', ')', '-', 'which', 'helps', 'confirm', 'diagnosis', 'but', 'require', 'an', 'invasive', 'procedure', 'and', 'are', 'not', 'correlated', 'with', 'disease', 'activity', 'nor', 'response', 'to', 'therapy', ')', 'and', 'monitoring', 'of', 'MS', 'and', 'its', 'treatment', 'is', 'by', 'magnetic', 'resonance', 'Imaging', '(', 'MRI', ')', '-', 'which', 'is', 'an', 'expensive', 'procedure', '.', '\n\n', 'Dr', 'Hossam', 'Haick', 'from', 'the', 'Technion', 'developed', 'an', 'electronic', 'nose', 'based', 'on', 'nanomaterials', 'for', 'diagnosis', 'of', 'diseases', '(', 'e.g.', ',', 'cancer', ',', 'kidney', 'failure', ',', 'etc', '.', ')', 'via', 'breath', 'samples', '.', 'The', 'research', 'hypothesis', 'is', 'that', 'Biomarkers', 'of', 'CNS', 'inflammation', 'and/or', 'neurodegeneration', 'and/or', 'CNS', 'repair', 'in', 'persons', 'with', 'MS', 'can', 'be', 'detected', 'by', 'the', '""', 'electronic', 'nose', '""', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01465087,NCT01465087,"Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples | Multiple Sclerosis (MS) is a complex multi-factorial disease, with underlying both genetic and environmental factors. Different populations have different susceptibility to MS. The disease is characterized by 2 main phenotypes: relapsing-remitting or progressive course. Clinical disability is due to distraction of the central nervous system (CNS) myelin.

Repair processes are mainly noted after the acute relapse - and recovery of function can be spontaneous. However, in severe relapses sometimes there is need for STEROID TREATMENT.

For the long term prophylaxis - following the increased understanding of the disease, in the last 10-15 years, there are new immunotherapies available (COPAXON / TEVA; Interferon -beta). However these can attenuate the disease (reduce the number of relapses per year) but cannot cure it. Also, they are beneficial in only ~40 % of the Relapsing -Remitting patients.

Currently there are no biomarkers available for MS (other than oligoclonal Immunoglobulin G (IgG) in the cervical spine fluid (CSF) - which helps confirm diagnosis but require an invasive procedure and are not correlated with disease activity nor response to therapy) and monitoring of MS and its treatment is by magnetic resonance Imaging (MRI) - which is an expensive procedure.

Dr Hossam Haick from the Technion developed an electronic nose based on nanomaterials for diagnosis of diseases (e.g., cancer, kidney failure, etc.) via breath samples.The research hypothesis is that Biomarkers of CNS inflammation and/or neurodegeneration and/or CNS repair in persons with MS can be detected by the ""electronic nose"".","[(92, 110, 'CONDITION', 'Multiple Sclerosis'), (196, 214, 'CONDITION', 'Multiple Sclerosis'), (216, 218, 'CONDITION', 'MS'), (369, 371, 'CONDITION', 'MS'), (1150, 1152, 'CONDITION', 'MS'), (1388, 1390, 'CONDITION', 'MS'), (1774, 1776, 'CONDITION', 'MS')]"
"['Antipsychotic', 'Effects', 'of', 'Oxytocin', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'intranasal', 'oxytocin', 'versus', 'intranasal', 'placebo', 'to', 'improve', 'symptoms', 'in', 'schizophrenia', 'patients', 'who', 'have', 'residual', 'symptoms', 'despite', 'being', 'on', 'adequate', 'treatment', 'with', 'antipsychotic', 'medication', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01621737,NCT01621737,Antipsychotic Effects of Oxytocin | The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.,"[(25, 33, 'DRUG', 'Oxytocin'), (104, 112, 'DRUG', 'oxytocin'), (131, 138, 'CONTROL', 'placebo'), (162, 175, 'CONDITION', 'schizophrenia')]"
"['RNS', '®', 'System', 'Responsive', 'Stimulation', 'for', 'Adolescents', 'With', 'Epilepsy', 'Study', '|', 'To', 'demonstrate', 'that', 'the', 'RNS', 'System', 'is', 'safe', 'and', 'effective', 'as', 'an', 'adjunctive', 'therapy', 'in', 'individuals', 'age', '12', 'through', '17', 'years', 'with', 'medically', 'refractory', 'partial', 'onset', 'epilepsy', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04839601,NCT04839601,RNS® System Responsive Stimulation for Adolescents With Epilepsy Study | To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.,"[(0, 34, 'OTHER', 'RNS® System Responsive Stimulation'), (56, 64, 'CONDITION', 'Epilepsy'), (97, 107, 'OTHER', 'RNS System'), (209, 242, 'CONDITION', 'refractory partial onset epilepsy')]"
"['Randomized', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Efficacy', ',', 'Safety', ',', 'and', 'Pharmacokinetic', 'Study', 'of', 'ACTIMMUNE', '®', '(', 'Interferon', 'γ-1b', ')', 'in', 'Children', 'and', 'Young', 'Adults', 'With', 'Friedreich', ""'s"", 'Ataxia', '|', 'The', 'purpose', 'of', 'this', 'phase', '3', 'randomized', ',', 'multi', '-', 'center', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'ACTIMMUNE', '®', '(', 'interferon', '-', 'γ', '1b', ')', 'in', 'the', 'treatment', 'of', 'Friedreich', ""'s"", 'Ataxia', '(', 'FA', ')', 'and', 'to', 'evaluate', 'the', 'pharmacokinetic', '(', 'PK', ')', 'characteristics', 'of', 'ACTIMMUNE', '®', 'in', 'FA', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O']",NCT02415127,NCT02415127,"Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | The purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study is to evaluate the efficacy and safety of ACTIMMUNE® (interferon-γ 1b) in the treatment of Friedreich's Ataxia (FA) and to evaluate the pharmacokinetic (PK) characteristics of ACTIMMUNE® in FA patients.","[(39, 46, 'CONTROL', 'Placebo'), (106, 115, 'DRUG', 'ACTIMMUNE'), (118, 133, 'DRUG', 'Interferon γ-1b'), (169, 188, 'CONDITION', ""Friedreich's Ataxia""), (259, 266, 'CONTROL', 'placebo'), (326, 335, 'DRUG', 'ACTIMMUNE'), (338, 353, 'DRUG', 'interferon-γ 1b'), (375, 394, 'CONDITION', ""Friedreich's Ataxia""), (396, 398, 'CONDITION', 'FA'), (460, 469, 'DRUG', 'ACTIMMUNE'), (474, 476, 'CONDITION', 'FA')]"
"['A', 'Multicenter', ',', 'Interventional', ',', 'Open', '-', 'label', 'Study', 'to', 'Monitor', 'the', 'Evolution', 'of', 'Motor', 'Function', 'in', 'SMA', 'Type', 'II', 'Adults', 'Patients', 'Treated', 'With', 'SPINRAZA', '®', '|', 'SPINRAZA', '®', '(', 'Nusinersen', ')', 'is', 'the', 'first', 'intrathecal', 'administered', 'drug', 'which', 'was', 'approved', 'by', 'the', 'FDA', 'to', 'treat', 'SMA', 'children', 'and', 'adults', '(', '2016', ')', '.', 'The', 'aim', 'is', 'to', 'monitor', 'the', 'evolution', 'of', 'the', 'Motor', 'Function', 'Measure-32', 'for', 'SMA', 'type', 'II', 'adult', 'patients', 'treated', 'with', 'SPINRAZA', '®', '(', 'Nusinersen', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O']",NCT04159987,NCT04159987,"A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA® | SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).","[(94, 105, 'CONDITION', 'SMA Type II'), (135, 143, 'DRUG', 'SPINRAZA'), (147, 155, 'DRUG', 'SPINRAZA'), (158, 168, 'DRUG', 'Nusinersen'), (252, 255, 'CONDITION', 'SMA'), (357, 368, 'CONDITION', 'SMA type II'), (397, 405, 'DRUG', 'SPINRAZA'), (408, 418, 'DRUG', 'Nusinersen')]"
"['Effect', 'of', 'Simultaneous', 'Dual', 'Stimulation', 'on', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'dual', '-', 'mode', 'non', '-', 'invasive', 'brain', 'stimulation', '(', 'NIBS', ')', 'with', 'high', '-', 'frequency', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'over', 'the', 'primary', 'motor', 'cortex', 'of', 'the', 'lower', 'leg', 'and', 'anodal', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'over', 'the', 'left', 'dorsolateral', 'prefrontal', 'cortex', 'compared', 'with', 'rTMS', 'alone', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'with', 'freezing', 'of', 'gait', '(', 'FOG', ')', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT02850159,NCT02850159,Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease | The purpose of this study is to investigate the effect of dual-mode non-invasive brain stimulation (NIBS) with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex compared with rTMS alone in patients with Parkinson's disease (PD) with freezing of gait (FOG).,"[(10, 39, 'OTHER', 'Simultaneous Dual Stimulation'), (63, 82, 'CONDITION', ""Parkinson's Disease""), (143, 183, 'OTHER', 'dual-mode non-invasive brain stimulation'), (185, 189, 'OTHER', 'NIBS'), (196, 255, 'OTHER', 'high-frequency repetitive transcranial magnetic stimulation'), (257, 261, 'OTHER', 'rTMS'), (321, 360, 'OTHER', 'transcranial direct current stimulation'), (362, 366, 'OTHER', 'tDCS'), (427, 437, 'CONTROL', 'rTMS alone'), (455, 474, 'CONDITION', ""Parkinson's disease""), (476, 478, 'CONDITION', 'PD'), (485, 501, 'CONDITION', 'freezing of gait'), (503, 506, 'CONDITION', 'FOG')]"
"['Large', 'Scale', 'Implementation', 'of', 'Community', 'Based', 'Mental', 'Health', 'Care', 'for', 'People', 'With', 'Severe', 'and', 'Enduring', 'Mental', 'Ill', 'Health', 'in', 'Europe', '|', 'A', 'single', '-', 'blinded', 'hybrid', 'effectiveness', '-', 'implementation', 'trial', '(', 'Type', 'II', ')', ',', 'that', 'both', 'evaluates', 'the', 'intervention', 'outcomes', '(', 'clinical', 'and', 'service', 'use', 'outcomes', ')', 'through', 'patient', '-', 'randomization', 'in', 'the', 'implementation', 'sites', ',', 'as', 'well', 'as', 'evaluates', 'the', 'implementation', 'strategy', 'chosen', 'for', 'the', 'intervention', 'and', 'its', 'impact', 'on', 'implementation', 'outcomes', '(', 'e.g.', 'adoption', ',', 'fidelity', ',', 'acceptability', 'and', 'maintenance', '(', 'continued', 'implementation', ')', 'of', 'the', 'intervention', ')', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03922425,NCT03922425,"Large Scale Implementation of Community Based Mental Health Care for People With Severe and Enduring Mental Ill Health in Europe | A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).","[(30, 64, 'OTHER', 'Community Based Mental Health Care'), (81, 118, 'CONDITION', 'Severe and Enduring Mental Ill Health')]"
"['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Multicenter', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Multiple', 'Dose', 'Regimens', 'of', 'CHF', '5074', '(', '200', ',', '400', ',', '600', 'mg', '/', 'Day', 'for', 'up', 'to', '12', 'Weeks', ')', 'and', 'to', 'Explore', 'the', 'Effects', 'on', 'Potential', 'Markers', 'of', 'Clinical', 'Efficacy', 'in', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'ascending', 'oral', 'doses', 'of', 'CHF', '5074', 'after', 'prolonged', 'administration', 'to', 'patients', 'with', 'mild', 'cognitive', 'impairment', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01421056,NCT01421056,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment | The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.","[(14, 21, 'CONTROL', 'Placebo'), (121, 129, 'DRUG', 'CHF 5074'), (258, 283, 'CONDITION', 'Mild Cognitive Impairment'), (382, 390, 'DRUG', 'CHF 5074'), (439, 464, 'CONDITION', 'mild cognitive impairment')]"
"['CoMBat', 'Insomnia', ':', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'Cognitive', '-', 'Behavioral', 'vs.', 'Mindfulness', '-', 'Based', 'Treatment', 'for', 'TBI', '-', 'Related', 'Insomnia', 'and', 'Post', '-', 'Traumatic', 'Stress', 'Symptoms', '|', 'This', 'study', 'is', 'a', 'prospective', 'two', '-', 'arm', ',', 'single', 'blind', 'randomized', 'controlled', 'trial', 'design', 'to', 'compare', 'the', 'clinical', 'effectiveness', 'of', 'telemedicine', '-', 'delivered', ',', '6', '-', 'session', ',', 'standardized', 'cognitive', 'behavioral', 'therapy', 'for', 'insomnia', '(', 'CBT', '-', 'I', ')', 'and', 'mindfulness', '-', 'based', 'treatment', 'for', 'insomnia', '(', 'MBTI', ')', 'in', 'treating', 'insomnia', 'symptoms', 'and', 'ameliorating', 'depressive', 'symptoms', 'in', 'persons', 'with', 'mild', 'to', 'moderate', 'TBI', 'and', 'comorbid', 'Post', '-', 'Traumatic', 'Stress', 'Symptoms', '(', 'PTSS', ')', 'and', 'insomnia', 'symptoms', 'in', 'a', '360', 'patients', '.', 'Participants', 'will', 'undergo', 'assessment', '(', 'psychosocial', 'questionnaires', ',', 'neurocognitive', 'testing', ',', 'sleep', 'monitoring', ')', 'at', 'baseline', ',', 'at', 'the', 'end', 'of', 'treatment', ',', 'and', 'at', '6-', 'and', '12', '-', 'weeks', 'post', '-', 'treatment', '.', 'The', 'primary', 'outcome', 'is', 'sleep', 'as', 'measured', 'by', 'the', 'Insomnia', 'Severity', 'Index', '(', 'ISI', ')', '.']","['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05663034,NCT05663034,"CoMBat Insomnia: A Randomized Controlled Trial of Cognitive-Behavioral vs. Mindfulness-Based Treatment for TBI-Related Insomnia and Post-Traumatic Stress Symptoms | This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).","[(7, 15, 'CONDITION', 'Insomnia'), (50, 102, 'BEHAVIOURAL', 'Cognitive-Behavioral vs. Mindfulness-Based Treatment'), (107, 127, 'CONDITION', 'TBI-Related Insomnia'), (132, 153, 'CONDITION', 'Post-Traumatic Stress'), (339, 367, 'BEHAVIOURAL', 'cognitive behavioral therapy'), (372, 380, 'CONDITION', 'insomnia'), (382, 385, 'BEHAVIOURAL', 'CBT'), (393, 420, 'BEHAVIOURAL', 'mindfulness-based treatment'), (425, 433, 'CONDITION', 'insomnia'), (435, 439, 'BEHAVIOURAL', 'MBTI'), (453, 461, 'CONDITION', 'insomnia'), (488, 498, 'CONDITION', 'depressive'), (524, 544, 'CONDITION', 'mild to moderate TBI'), (558, 588, 'CONDITION', 'Post-Traumatic Stress Symptoms'), (590, 594, 'CONDITION', 'PTSS'), (600, 608, 'CONDITION', 'insomnia')]"
"['Sleep', '-', 'Disordered', 'Breathing', 'and', 'CPAP', 'After', 'Adenotonsillectomy', 'in', 'Children', '|', 'Obstructive', 'sleep', '-', 'disordered', 'breathing', '(', 'SDB', ')', 'affects', '2', '-', '3', '%', 'of', 'children', 'and', 'may', 'lead', 'to', 'problems', 'with', 'nighttime', 'sleep', 'and', 'daytime', 'behavior', ',', 'learning', ',', 'sleepiness', ',', 'and', 'mood', '.', 'Adenotonsillectomy', '(', 'AT', ')', 'is', 'the', 'second', 'most', 'common', 'surgical', 'procedure', 'in', 'children', '.', 'It', 'is', 'now', 'performed', 'more', 'often', 'for', 'suspected', 'SDB', 'than', 'for', 'any', 'other', 'indication', '.', 'However', ',', 'recent', 'studies', 'indicate', 'that', 'many', 'if', 'not', 'most', 'children', 'still', 'have', 'SDB', 'after', 'AT', ',', 'and', 'many', 'still', 'have', 'learning', 'or', 'behavioral', 'problems', 'associated', 'with', 'SDB', '.', 'The', 'goals', 'of', 'this', 'study', 'are', ':', '(', '1', ')', 'to', 'assess', 'the', 'extent', 'that', 'behavior', ',', 'cognition', ',', 'and', 'sleepiness', 'in', 'children', 'can', 'improve', 'with', 'Continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'treatment', 'after', 'AT', ',', 'and', '(', '2', ')', 'to', 'identify', 'which', 'patients', 'stand', 'to', 'gain', 'most', 'from', 'post', '-', 'operative', 'assessment', 'and', 'treatment', '.']","['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01554527,NCT01554527,"Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children | Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood. Adenotonsillectomy (AT) is the second most common surgical procedure in children. It is now performed more often for suspected SDB than for any other indication. However, recent studies indicate that many if not most children still have SDB after AT, and many still have learning or behavioral problems associated with SDB. The goals of this study are: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with Continuous positive airway pressure (CPAP) treatment after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment.","[(0, 26, 'CONDITION', 'Sleep-Disordered Breathing'), (42, 60, 'SURGICAL', 'Adenotonsillectomy'), (75, 113, 'CONDITION', 'Obstructive sleep-disordered breathing'), (115, 118, 'CONDITION', 'SDB'), (245, 263, 'SURGICAL', 'Adenotonsillectomy'), (265, 267, 'SURGICAL', 'AT'), (372, 375, 'CONDITION', 'SDB'), (482, 485, 'CONDITION', 'SDB'), (492, 494, 'SURGICAL', 'AT'), (564, 567, 'CONDITION', 'SDB'), (693, 728, 'OTHER', 'Continuous positive airway pressure'), (730, 734, 'OTHER', 'CPAP'), (752, 754, 'SURGICAL', 'AT')]"
"['Evaluation', 'of', 'a', 'Program', 'to', 'Increase', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'This', 'study', 'will', 'examine', 'the', 'feasibility', 'and', 'effect', 'of', 'a', 'program', 'that', 'combines', 'exercise', 'and', 'feedback', 'from', 'a', 'wearable', 'device', 'on', 'upper', 'limb', 'movement', 'practice', 'and', 'function', 'in', 'individuals', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04232163,NCT04232163,Evaluation of a Program to Increase Upper Limb Recovery After Stroke | This study will examine the feasibility and effect of a program that combines exercise and feedback from a wearable device on upper limb movement practice and function in individuals with stroke.,"[(62, 68, 'CONDITION', 'Stroke'), (149, 157, 'PHYSICAL', 'exercise'), (162, 193, 'OTHER', 'feedback from a wearable device'), (259, 265, 'CONDITION', 'stroke')]"
"['The', 'Effects', 'of', '6', '-', 'month', 'Supplementation', 'With', 'Creatine', 'and', 'Guanidinoacetic', 'Acid', 'on', 'Biomarkers', 'of', 'Sarcopenia', 'in', 'Elderly', '|', 'Sarcopenia', '-', 'driven', 'brain', 'and', 'muscle', 'creatine', 'deficit', 'could', 'be', 'seen', 'as', 'a', 'distinctive', 'pathological', 'facet', 'of', 'this', 'condition', ',', 'and', 'this', 'might', 'be', 'approached', 'with', 'targeted', 'therapies', 'in', 'aim', 'to', 'restore', 'creatine', 'homeostasis', 'in', 'target', 'tissues', '.', 'Among', 'potential', 'therapeutic', 'candidates', ',', 'guanidinoacetate', '(', 'GAA', ')', 'appears', 'recently', 'as', 'a', 'direct', 'precursor', 'of', 'creatine', 'that', 'may', 'favorably', 'upregulate', 'muscle', 'and', 'brain', 'creatine', 'concentration', '.', 'Interestingly', ',', 'GAA', '-', 'creatine', 'mixture', 'was', 'found', 'to', 'be', 'superior', 'than', 'creatine', 'itself', 'to', 'effectively', 'improves', 'bioenergetics', 'in', 'the', 'human', 'brain', 'and', 'muscle', 'in', 'healthy', 'humans', ',', 'perhaps', 'due', 'to', 'the', 'unique', 'transportability', 'features', 'of', 'this', 'combination', '.', 'Here', ',', 'we', 'plan', 'to', 'evaluate', 'does', 'creatine', '-', 'GAA', 'supplementation', 'affects', 'various', 'biomarkers', 'of', 'sarcopenia', 'in', 'elderly', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT04652921,NCT04652921,"The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly | Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.","[(44, 52, 'DRUG', 'Creatine'), (57, 77, 'DRUG', 'Guanidinoacetic Acid'), (95, 105, 'CONDITION', 'Sarcopenia'), (119, 129, 'CONDITION', 'Sarcopenia'), (154, 170, 'CONDITION', 'creatine deficit'), (311, 319, 'DRUG', 'creatine'), (391, 407, 'DRUG', 'guanidinoacetate'), (409, 412, 'DRUG', 'GAA'), (456, 464, 'DRUG', 'creatine'), (512, 520, 'DRUG', 'creatine'), (551, 554, 'DRUG', 'GAA'), (555, 563, 'DRUG', 'creatine'), (809, 817, 'DRUG', 'creatine'), (818, 821, 'DRUG', 'GAA'), (868, 878, 'CONDITION', 'sarcopenia')]"
"['Correlation', 'Between', 'the', ""'"", 'Nine', 'Holes', 'Peg', 'Test', ""'"", 'Performance', 'and', 'the', 'Triple', 'Stimulation', 'Technique', 'Within', 'a', 'Group', 'a', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'main', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'Triple', 'Stimulation', 'Technique', '(', 'TST', ')', 'can', 'be', 'correlated', 'to', 'performance', 'in', 'the', 'manual', 'dexterity', ""'"", 'nine', 'holes', 'peg', ""'"", 'test', ',', 'within', 'a', 'control', 'group', 'and', 'a', 'group', 'of', 'patients', 'with', 'multiple', 'sclerosis', '.', '\n\n', 'TST', '(', 'Triple', 'stimulation', 'technique', ')', 'combines', 'two', 'techniques', 'used', 'in', 'neurologic', 'diagnosis', ':', 'magnetic', 'stimulation', 'and', 'electroneuromyography', '.', 'It', 'is', 'based', 'on', 'the', 'principle', 'of', 'two', 'collisions', 'between', 'the', 'descending', 'central', 'stimulation', '(', 'magnetic', 'stimulation', ')', 'and', 'the', 'ascending', 'peripheric', 'stimulation', '.', 'TST', 'allows', 'to', 'better', 'quantify', 'central', 'nervous', 'system', 'diseases', '.', 'The', 'abnormal', 'amplitude', 'registered', 'by', 'TST', 'is', 'proportional', 'to', 'the', 'intensity', 'of', 'conduction', 'disorders', '.', 'The', 'evaluation', 'of', 'these', 'disorders', 'is', 'more', 'precise', 'than', 'with', 'the', 'magnetic', 'stimulation', 'technique', 'alone', '.', '\n\n', 'The', 'Nine', 'Hole', 'Pegs', 'technique', 'is', 'a', 'simple', 'manual', 'dexterity', 'test', ',', 'commonly', 'used', 'in', 'ergotherapy', '.', 'The', 'participant', 'tries', 'to', 'place', '9', 'pegs', 'in', 'a', '9', 'holes', 'perforated', 'plate', ',', 'and', 'then', 'tries', 'to', 'remove', 'them', 'as', 'quickly', 'as', 'possible', '.', 'The', 'hand', 'must', 'stay', 'in', 'a', 'depression', 'within', 'the', 'plate', ',', 'thereby', 'insuring', 'a', 'constant', 'distance', 'between', 'the', 'hand', 'and', 'the', 'pegs', '.', '\n\n', 'The', 'nine', 'hole', 'peg', 'will', 'be', 'realized', 'first', ',', 'and', 'the', 'triple', 'stimulation', 'examination', 'performed', 'after', '.', 'The', 'acquired', 'data', 'will', 'be', 'analyzed', 'in', 'order', 'to', 'find', 'a', 'correlation', 'between', 'the', 'impairment', 'level', 'given', 'by', 'these', 'two', 'tests', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02805634,NCT02805634,"Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis | The main goal of this study is to determine if the Triple Stimulation Technique (TST) can be correlated to performance in the manual dexterity 'nine holes peg' test, within a control group and a group of patients with multiple sclerosis.

TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.

The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.

The nine hole peg will be realized first, and the triple stimulation examination performed after. The acquired data will be analyzed in order to find a correlation between the impairment level given by these two tests.","[(126, 144, 'CONDITION', 'Multiple Sclerosis'), (365, 383, 'CONDITION', 'multiple sclerosis')]"
"['Multimodal', 'Assessment', 'of', 'the', 'Inflammatory', 'Atheromatous', 'Plaque', ':', 'Comparison', 'Between', '68Ga', '-', 'NODAGA', '-', 'RGD', 'PET', '/', 'CT', ',', '18F', '-', 'FDG', 'PET', '/', 'CT', ',', 'MRI', 'AND', 'US', '|', 'The', 'present', 'study', 'aims', 'at', 'assessing', 'the', 'ability', 'of', '68Ga', '-', 'NODAGA', '-', 'RGD', 'PET', '/', 'CT', 'for', 'the', 'detection', 'of', 'inflammatory', 'atheromatous', 'plaques', 'in', 'the', 'carotid', 'arteries', ',', 'compared', 'to', '18F', '-', 'FDG', 'PET', '/', 'CT', ',', 'MRI', 'and', 'US', 'and', 'to', 'determine', 'the', 'contribution', 'of', 'each', 'imaging', 'technique', '.', 'Current', 'gold', 'standard', 'for', 'inflammation', 'is', 'histopathology', '.', '\n\n', 'Hypothesis', ':', '68Ga', '-', 'NODAGA', '-', 'RGD', 'might', 'give', 'a', 'better', 'initial', 'evaluation', 'of', 'patients', 'with', 'atheromatous', 'plaques', 'in', 'the', 'carotid', 'artery', 'eligible', 'for', 'endarterectomy', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01608516,NCT01608516,"Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US | The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology.

Hypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.","[(29, 61, 'CONDITION', 'Inflammatory Atheromatous Plaque'), (231, 264, 'CONDITION', 'inflammatory atheromatous plaques'), (534, 554, 'CONDITION', 'atheromatous plaques')]"
"['Age', 'and', 'Body', 'Position', 'on', 'Handgrip', 'Strength', 'and', 'Movement', 'Coordination', 'of', 'Upper', 'Limb', '|', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'analyze', 'the', 'importance', 'of', 'the', 'position', 'of', 'the', 'body', 'and', 'the', 'examined', 'upper', 'limb', 'on', 'the', 'parameters', 'of', 'movement', 'coordination', 'and', 'hand', 'grip', 'strength', 'in', 'various', 'age', 'groups', 'of', 'people', 'after', 'a', 'stroke', 'and', 'healthy', 'individuals', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT05008302,NCT05008302,Age and Body Position on Handgrip Strength and Movement Coordination of Upper Limb | The aim of the study was to analyze the importance of the position of the body and the examined upper limb on the parameters of movement coordination and hand grip strength in various age groups of people after a stroke and healthy individuals.,"[(298, 304, 'CONDITION', 'stroke')]"
"['Influence', 'of', 'Apelin', 'Levels', 'on', 'Postoperative', 'Cognitive', 'Disorders', 'After', 'Orthopedic', 'Surgery', 'in', 'Elderlies', '|', 'No', 'successful', 'strategy', 'is', 'proposed', 'to', 'patients', 'submitted', 'to', 'important', 'surgery', 'to', 'reduce', 'the', 'incidence', 'of', 'postoperative', 'cognitive', 'disorders', '(', 'POCD', ')', 'onset', '.', 'This', 'project', 'propose', 'to', 'measure', 'plasma', 'levels', 'of', 'apelin', 'in', 'wide', 'population', 'submitted', 'to', 'orthopedic', 'surgery', '.', 'Apelin', 'could', 'be', 'involved', 'in', 'anti', '-', 'inflammatory', 'processes', '.', 'Apelin', 'levels', 'before', 'and', 'after', 'surgery', 'correlated', 'to', 'postoperative', 'cognitive', 'disorders', 'symptom', 'measured', 'by', 'PET', '-', 'Scan', 'could', 'be', 'an', 'important', 'predictive', 'or', 'diagnostic', 'marker', 'to', 'adapt', 'therapeutic', 'strategy', 'to', 'fight', 'against', 'postoperative', 'cognitive', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02574234,NCT02574234,Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies | No successful strategy is proposed to patients submitted to important surgery to reduce the incidence of postoperative cognitive disorders (POCD) onset. This project propose to measure plasma levels of apelin in wide population submitted to orthopedic surgery. Apelin could be involved in anti-inflammatory processes. Apelin levels before and after surgery correlated to postoperative cognitive disorders symptom measured by PET-Scan could be an important predictive or diagnostic marker to adapt therapeutic strategy to fight against postoperative cognitive disorders.,"[(30, 63, 'CONDITION', 'Postoperative Cognitive Disorders'), (70, 88, 'CONDITION', 'Orthopedic Surgery'), (209, 242, 'CONDITION', 'postoperative cognitive disorders'), (244, 248, 'CONDITION', 'POCD'), (345, 363, 'CONDITION', 'orthopedic surgery'), (475, 508, 'CONDITION', 'postoperative cognitive disorders'), (639, 672, 'CONDITION', 'postoperative cognitive disorders')]"
"['U', '-', 'Health', 'Service', 'Using', 'Mobile', 'Device', 'for', 'Improvement', 'of', 'Post', '-', 'Stroke', 'Upper', 'Limb', 'Function', 'and', 'Aphasia', '|', 'Provides', 'mobile', 'programs', 'for', 'occupational', 'and', 'speech', 'therapy', 'to', 'patients', 'with', 'stroke', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O']",NCT01815905,NCT01815905,U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia | Provides mobile programs for occupational and speech therapy to patients with stroke.,"[(0, 36, 'OTHER', 'U-Health Service Using Mobile Device'), (56, 67, 'CONDITION', 'Post-Stroke'), (92, 99, 'CONDITION', 'Aphasia'), (111, 126, 'OTHER', 'mobile programs'), (131, 162, 'OTHER', 'occupational and speech therapy'), (180, 186, 'CONDITION', 'stroke')]"
"['IGF-1', 'Therapy', 'and', 'Muscle', 'Function', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'IGF-1', 'therapy', 'improves', 'or', 'preserves', 'muscle', 'function', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT01207908,NCT01207908,IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy | The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).,"[(0, 5, 'DRUG', 'IGF-1'), (37, 64, 'CONDITION', 'Duchenne Muscular Dystrophy'), (117, 122, 'DRUG', 'IGF-1'), (172, 199, 'CONDITION', 'Duchenne Muscular Dystrophy'), (201, 204, 'CONDITION', 'DMD')]"
"['Pilot', 'Phase', '1', 'Clinical', 'Trial', 'of', 'PET', 'Scanning', 'in', 'Tau', 'Protein', 'Deposition', 'and', 'Connectome', 'Analysis', 'in', 'Traumatic', 'Encephalopathy', 'Syndrome', '(', 'TES', ')', 'Cohort', 'With', 'a', 'Probable', 'Chronic', 'Traumatic', 'Encephalopathy', '(', 'CTE', ')', 'Pattern', 'of', 'Neurodegenerative', 'Disease', '|', 'This', 'pilot', 'study', 'aims', 'to', 'assess', 'if', 'participants', 'that', 'meet', 'the', 'criteria', 'for', 'a', 'TES', 'diagnosis', 'have', 'a', 'specific', 'tau', 'deposition', 'profile', 'on', 'PET', 'scanning', 'using', 'the', 'PET', 'tau', 'binding', 'ligand', '-', '[', '18F', ']', 'PI-2620', '.', 'It', 'is', 'hoped', 'this', 'study', 'will', 'highlight', 'potential', 'diagnostic', 'tests', 'of', 'TES', 'diagnosis', ',', 'the', 'in', '-', 'life', 'correlate', 'of', 'CTE', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05490576,NCT05490576,"Pilot Phase 1 Clinical Trial of PET Scanning in Tau Protein Deposition and Connectome Analysis in Traumatic Encephalopathy Syndrome (TES) Cohort With a Probable Chronic Traumatic Encephalopathy (CTE) Pattern of Neurodegenerative Disease | This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - [18F] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.","[(98, 131, 'CONDITION', 'Traumatic Encephalopathy Syndrome'), (133, 136, 'CONDITION', 'TES'), (161, 193, 'CONDITION', 'Chronic Traumatic Encephalopathy'), (195, 198, 'CONDITION', 'CTE'), (316, 319, 'CONDITION', 'TES'), (503, 506, 'CONDITION', 'TES'), (543, 546, 'CONDITION', 'CTE')]"
"['Comparative', 'Effectiveness', 'of', 'Two', 'Self', '-', 'guided', 'Web', '-', 'based', 'Interventions', 'for', 'Youth', 'and', 'Young', 'Adults', 'With', 'Migraine', '|', 'This', 'randomized', 'controlled', 'trial', 'will', 'compare', 'the', 'effectiveness', 'of', 'two', 'online', 'self', '-', 'guided', 'programs', 'for', 'youth', 'and', 'young', 'adults', 'with', 'migraine', 'against', 'usual', 'care', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT03504150,NCT03504150,Comparative Effectiveness of Two Self-guided Web-based Interventions for Youth and Young Adults With Migraine | This randomized controlled trial will compare the effectiveness of two online self-guided programs for youth and young adults with migraine against usual care.,"[(33, 68, 'OTHER', 'Self-guided Web-based Interventions'), (101, 109, 'CONDITION', 'Migraine'), (183, 210, 'OTHER', 'online self-guided programs'), (243, 251, 'CONDITION', 'migraine'), (260, 270, 'CONTROL', 'usual care')]"
"['An', 'Evaluation', 'of', 'Clinical', 'Pharmacist', '-', 'led', 'Intervention', 'on', 'Clinical', 'Outcomes', 'in', 'Patients', 'With', 'Ischemic', 'Stroke', '|', 'Clinical', 'pharmacy', 'specialists', 'are', 'in', 'an', 'ideal', 'position', 'to', 'assist', 'medical', 'teams', 'in', 'the', 'management', 'of', 'patients', 'with', 'ischemic', 'stroke', '.', 'Given', 'their', 'extensive', 'and', 'specialized', 'knowledge', 'regarding', 'medication', 'efficacy', ',', 'safety', ',', 'and', 'cost', '-', 'effective', 'use', 'as', 'well', 'as', 'their', 'ability', 'to', 'critically', 'review', ',', 'interpret', 'and', 'apply', 'the', 'results', 'from', 'clinical', 'studies', 'to', 'patient', 'care', ',', 'clinical', 'pharmacy', 'specialists', 'have', 'the', 'potential', 'to', 'have', 'a', 'significant', 'impact', 'on', 'stroke', 'care', 'delivery', '.', 'There', 'are', 'numerous', 'opportunities', 'for', 'clinical', 'pharmacy', 'specialists', 'to', 'become', 'more', 'extensively', 'involved', 'in', 'the', 'delivery', 'of', 'care', 'to', 'these', 'high', '-', 'risk', 'patients', '.', 'However', ',', 'to', '-', 'date', 'there', 'are', 'few', 'studies', 'demonstrating', 'the', 'impact', 'of', 'clinical', 'pharmacy', 'specialists', 'on', 'outcomes', 'of', 'patients', 'with', 'stroke', 'Stroke', 'is', 'the', 'third', 'leading', 'cause', 'of', 'death', 'in', 'the', 'United', 'States', '(', 'U.S.', ')', 'and', 'the', 'most', 'common', 'life', '-', 'threatening', 'neurologic', 'disorder.1', 'Stroke', 'is', 'a', 'leading', 'cause', 'of', 'long', '-', 'term', 'disability', 'and', 'results', 'in', 'significant', 'individual', 'and', 'societal', 'financial', 'burdens', '.', 'In', '2006', ',', 'stroke', 'accounted', 'for', '1', 'of', 'every', '18', 'deaths', 'and', 'ischemic', 'stroke', 'accounted', 'for', '87', '%', 'of', 'all', 'strokes.1', 'In', 'the', 'U.S.', ',', 'out', 'of', 'the', 'approximately', '795,000', 'people', 'who', 'develop', 'a', 'stroke', 'each', 'year', ',', 'approximately', '185,000', '(', '23', '%', ')', 'are', 'recurrent', 'events.1', 'After', 'the', 'first', 'year', ',', 'the', 'average', 'annual', 'risk', 'for', 'recurrent', 'stroke', 'is', '4%.2', 'Patients', 'who', 'survive', 'at', 'least', '30', 'days', 'after', 'a', 'first', '-', 'ever', 'stroke', ',', 'have', 'an', 'average', 'annual', 'risk', 'of', 'death', 'of', '9.1', '%', ',', 'much', 'of', 'the', 'risk', 'due', 'to', 'nonstroke', 'cardiovascular', 'disease', '.', '\n\n', 'Despite', 'the', 'evidence', 'supporting', 'the', 'use', 'of', 'various', 'therapeutic', 'interventions', 'within', 'the', 'ischemic', 'stroke', 'population', ',', 'a', 'significant', 'proportion', 'of', 'patients', 'continue', 'to', 'have', 'uncontrolled', 'risk', 'factors', 'and', 'remain', 'undertreated.26', '-', '30', 'A', 'recent', 'prospective', 'study', 'of', 'more', 'than', '4933', 'high', '-', 'risk', 'patients', 'reported', 'that', ',', 'as', 'compared', 'to', 'patients', 'with', 'coronary', 'artery', 'disease', ',', 'patients', 'with', 'cerebrovascular', 'disease', 'are', 'undertreated', 'and', 'thus', 'less', 'likely', 'to', 'achieve', 'blood', 'pressure', '(', '45.3', '%', 'vs.', '57.3', '%', ';', 'p<0.001', ')', 'and', 'lipid', '(', '19.4', '%', 'vs.', '30.5', '%', ';', 'p<0.001', ')', 'targets.28', 'Although', 'the', 'reasons', 'for', 'the', 'so', '-', 'called', '""', 'treatment', 'gap', '""', 'have', 'not', 'been', 'explored', 'specifically', 'within', 'this', 'population', ',', 'data', 'from', 'studies', 'within', 'the', 'coronary', 'artery', 'disease', 'population', 'suggest', 'that', 'provider', ',', 'patient', 'and', 'health', 'care', 'system', 'factors', 'likely', 'all', 'contribute', '.', '\n\n', 'This', 'will', 'be', 'the', 'first', ',', 'prospective', ',', 'randomized', 'study', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'clinical', 'pharmacist', 'disease', 'management', 'program', 'on', 'both', 'surrogate', 'and', 'clinical', 'outcomes', 'for', 'patients', 'with', 'non', '-', 'cardioembolic', 'ischemic', 'stroke', '.', '\n\n', 'This', 'will', 'be', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'a', 'clinical', 'pharmacist', '-', 'led', 'disease', 'management', 'intervention', 'by', 'the', 'Clinical', 'Pharmacy', 'Cardiac', 'Risk', 'Service', '(', 'CPCRS', ')', 'to', 'usual', 'care', '(', 'UC', ')', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O']",NCT01876667,NCT01876667,"An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke | Clinical pharmacy specialists are in an ideal position to assist medical teams in the management of patients with ischemic stroke. Given their extensive and specialized knowledge regarding medication efficacy, safety, and cost-effective use as well as their ability to critically review, interpret and apply the results from clinical studies to patient care, clinical pharmacy specialists have the potential to have a significant impact on stroke care delivery. There are numerous opportunities for clinical pharmacy specialists to become more extensively involved in the delivery of care to these high-risk patients. However, to-date there are few studies demonstrating the impact of clinical pharmacy specialists on outcomes of patients with stroke Stroke is the third leading cause of death in the United States (U.S.) and the most common life-threatening neurologic disorder.1 Stroke is a leading cause of long-term disability and results in significant individual and societal financial burdens. In 2006, stroke accounted for 1 of every 18 deaths and ischemic stroke accounted for 87% of all strokes.1 In the U.S., out of the approximately 795,000 people who develop a stroke each year, approximately 185,000 (23%) are recurrent events.1 After the first year, the average annual risk for recurrent stroke is 4%.2 Patients who survive at least 30 days after a first-ever stroke, have an average annual risk of death of 9.1%, much of the risk due to nonstroke cardiovascular disease.

Despite the evidence supporting the use of various therapeutic interventions within the ischemic stroke population, a significant proportion of patients continue to have uncontrolled risk factors and remain undertreated.26-30 A recent prospective study of more than 4933 high-risk patients reported that, as compared to patients with coronary artery disease, patients with cerebrovascular disease are undertreated and thus less likely to achieve blood pressure (45.3% vs. 57.3%; p<0.001) and lipid (19.4% vs. 30.5%; p<0.001) targets.28 Although the reasons for the so-called ""treatment gap"" have not been explored specifically within this population, data from studies within the coronary artery disease population suggest that provider, patient and health care system factors likely all contribute.

This will be the first, prospective, randomized study to evaluate the impact of a clinical pharmacist disease management program on both surrogate and clinical outcomes for patients with non-cardioembolic ischemic stroke.

This will be a randomized, controlled study comparing a clinical pharmacist-led disease management intervention by the Clinical Pharmacy Cardiac Risk Service (CPCRS) to usual care (UC).","[(17, 53, 'OTHER', 'Clinical Pharmacist-led Intervention'), (92, 107, 'CONDITION', 'Ischemic Stroke'), (110, 139, 'OTHER', 'Clinical pharmacy specialists'), (224, 239, 'CONDITION', 'ischemic stroke'), (469, 498, 'OTHER', 'clinical pharmacy specialists'), (550, 556, 'CONDITION', 'stroke'), (609, 638, 'OTHER', 'clinical pharmacy specialists'), (795, 824, 'OTHER', 'clinical pharmacy specialists'), (854, 860, 'CONDITION', 'stroke'), (861, 867, 'CONDITION', 'Stroke'), (991, 997, 'CONDITION', 'Stroke'), (1120, 1126, 'CONDITION', 'stroke'), (1166, 1181, 'CONDITION', 'ischemic stroke'), (1284, 1290, 'CONDITION', 'stroke'), (1413, 1419, 'CONDITION', 'stroke'), (1485, 1491, 'CONDITION', 'stroke'), (1686, 1701, 'CONDITION', 'ischemic stroke'), (1971, 1994, 'CONDITION', 'cerebrovascular disease'), (2481, 2527, 'OTHER', 'clinical pharmacist disease management program'), (2586, 2619, 'CONDITION', 'non-cardioembolic ischemic stroke'), (2678, 2733, 'OTHER', 'clinical pharmacist-led disease management intervention'), (2741, 2779, 'OTHER', 'Clinical Pharmacy Cardiac Risk Service'), (2781, 2786, 'OTHER', 'CPCRS'), (2791, 2801, 'CONTROL', 'usual care'), (2803, 2805, 'CONTROL', 'UC')]"
"['Resistance', 'Exercise', 'Effect', 'on', 'Physical', 'Performance', 'and', 'Functional', 'Status', 'in', 'Sarcopenic', 'Older', 'Women', '|', 'Aging', 'is', 'characterized', 'by', 'a', 'progressive', 'loss', 'of', 'multiple', 'physical', 'and', 'cognitive', 'abilities', '.', 'From', 'these', 'changes', ',', 'the', 'most', 'important', 'one', 'is', 'the', 'loss', 'of', 'muscle', 'mass', ',', 'which', 'has', 'been', 'called', '""', 'sarcopenia', '""', '.', 'Resistance', 'exercise', 'is', 'a', 'therapeutic', 'approach', 'for', 'sarcopenia', ',', 'nevertheless', 'there', 'is', 'no', 'universal', 'consensus', '.', 'Therefore', ',', 'this', 'research', 'is', 'interested', 'in', 'determining', 'the', 'effect', 'of', 'a', 'resistance', 'exercise', 'program', 'on', 'physical', 'performance', 'and/or', 'functional', 'status', 'in', 'sarcopenic', 'older', 'women', '.', 'The', 'main', 'study', 'hypothesis', 'is', 'that', 'a', 'program', 'of', 'resistance', 'exercise', 'will', 'improve', 'physical', 'performance', 'and', 'functional', 'status', 'in', 'sarcopenic', 'older', 'women', 'compared', 'against', 'general', 'recommendations', '.', '\n\n', 'This', 'is', 'a', 'single', '-', 'blind', ',', 'controlled', 'clinical', 'trial', ',', 'including', 'women', '>', '70', 'years', ',', 'living', 'in', 'the', 'community', 'with', 'sarcopenia', '.', 'Those', 'who', 'agree', 'to', 'participate', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'the', 'following', 'groups', ':', '\n\n', 'Resistance', 'Exercise', 'Group', '\n', 'General', 'Recommendations', 'Group', '(', 'control', ')', 'The', 'study', 'will', 'last', '24', 'weeks', ',', 'with', '4', 'measurements', 'performed', 'at', 'baseline', ',', 'week', '6', ',', '12', 'and', '24', '.', 'Multilevel', 'models', '(', 'random', 'effects', ')', 'will', 'be', 'constructed', 'for', 'the', 'comparison', 'between', 'the', 'two', 'groups', '.', 'Tests', 'will', 'be', 'conducted', 'with', 'a', 'P=0.05', 'and', 'confidence', 'intervals', 'at', '95', '%', '.', 'This', 'protocol', 'has', 'been', 'approved', 'by', 'the', 'local', 'ethics', 'committee', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01829009,NCT01829009,"Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women | Aging is characterized by a progressive loss of multiple physical and cognitive abilities. From these changes, the most important one is the loss of muscle mass, which has been called ""sarcopenia"". Resistance exercise is a therapeutic approach for sarcopenia, nevertheless there is no universal consensus. Therefore, this research is interested in determining the effect of a resistance exercise program on physical performance and/or functional status in sarcopenic older women. The main study hypothesis is that a program of resistance exercise will improve physical performance and functional status in sarcopenic older women compared against general recommendations.

This is a single-blind, controlled clinical trial, including women> 70 years, living in the community with sarcopenia. Those who agree to participate, will be randomly assigned to one of the following groups:

Resistance Exercise Group
General Recommendations Group (control) The study will last 24 weeks, with 4 measurements performed at baseline, week 6, 12 and 24. Multilevel models (random effects) will be constructed for the comparison between the two groups. Tests will be conducted with a P=0.05 and confidence intervals at 95%. This protocol has been approved by the local ethics committee.","[(0, 19, 'PHYSICAL', 'Resistance Exercise'), (76, 86, 'CONDITION', 'Sarcopenic'), (286, 296, 'CONDITION', 'sarcopenia'), (299, 318, 'PHYSICAL', 'Resistance exercise'), (349, 359, 'CONDITION', 'sarcopenia'), (477, 504, 'PHYSICAL', 'resistance exercise program'), (557, 567, 'CONDITION', 'sarcopenic'), (617, 647, 'PHYSICAL', 'program of resistance exercise'), (707, 717, 'CONDITION', 'sarcopenic'), (747, 770, 'CONTROL', 'general recommendations'), (880, 890, 'CONDITION', 'sarcopenia'), (983, 1002, 'PHYSICAL', 'Resistance Exercise'), (1009, 1032, 'CONTROL', 'General Recommendations')]"
"['Effect', 'of', 'Aquatic', 'Exercise', 'on', 'Paraspinal', 'and', 'Gluteal', 'Morphology', 'and', 'Function', 'in', 'Patients', 'With', 'Chronic', 'Low', 'Back', 'Pain', '|', 'The', 'goal', 'of', 'this', 'pilot', 'randomized', 'controlled', 'trial', 'is', 'to', 'compare', 'the', 'effects', 'of', 'aquatic', 'therapy', 'versus', 'standard', 'care', 'on', 'paraspinal', 'and', 'gluteal', 'morphology', 'and', 'function', 'in', 'individuals', 'with', 'chronic', 'low', 'back', 'pain', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'What', 'are', 'the', 'effects', 'of', 'aquatic', 'therapy', 'versus', 'standard', 'care', 'on', 'a', ')', 'paraspinal', 'and', 'gluteal', 'muscle', 'size', ',', 'composition', '(', 'e.g.', ',', 'fatty', 'infiltration', ')', 'and', 'b', ')', 'lumbar', 'and', 'gluteal', 'muscle', 'strength', 'in', 'individuals', 'with', 'chronic', 'LBP', '?', '\n', 'Is', 'aquatic', 'therapy', 'more', 'effective', 'than', 'standard', 'care', 'to', 'improve', 'pain', ',', 'function', 'and', 'psychological', 'factors', '(', 'e.g.', ',', 'kinesiophobia', ',', 'catastrophizing', ',', 'anxiety', ',', 'and', 'depression', ')', '?', '\n', 'Is', 'using', 'a', 'digital', 'application', '""', 'play', 'the', 'pain', '""', 'feasible', 'to', 'monitor', 'pain', 'levels', 'and', 'the', 'activities', 'that', 'participants', 'used', 'to', 'cope', 'with', 'pain', '?', '\n\n', 'Participants', 'will', 'be', 'assigned', 'to', 'either', 'the', 'aquatic', 'therapy', 'group', 'or', 'standard', 'care', 'group', 'where', 'they', 'will', 'undergo', 'a', '10', '-', 'week', 'intervention', 'including', 'two', '60', '-', 'minute', 'session', 'per', 'week', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05823857,NCT05823857,"Effect of Aquatic Exercise on Paraspinal and Gluteal Morphology and Function in Patients With Chronic Low Back Pain | The goal of this pilot randomized controlled trial is to compare the effects of aquatic therapy versus standard care on paraspinal and gluteal morphology and function in individuals with chronic low back pain.The main questions it aims to answer are:

What are the effects of aquatic therapy versus standard care on a) paraspinal and gluteal muscle size, composition (e.g., fatty infiltration) and b) lumbar and gluteal muscle strength in individuals with chronic LBP?
Is aquatic therapy more effective than standard care to improve pain, function and psychological factors (e.g., kinesiophobia, catastrophizing, anxiety, and depression)?
Is using a digital application ""play the pain"" feasible to monitor pain levels and the activities that participants used to cope with pain?

Participants will be assigned to either the aquatic therapy group or standard care group where they will undergo a 10-week intervention including two 60-minute session per week.","[(10, 26, 'PHYSICAL', 'Aquatic Exercise'), (94, 115, 'CONDITION', 'Chronic Low Back Pain'), (198, 213, 'PHYSICAL', 'aquatic therapy'), (221, 234, 'CONTROL', 'standard care'), (305, 326, 'CONDITION', 'chronic low back pain'), (394, 409, 'PHYSICAL', 'aquatic therapy'), (574, 585, 'CONDITION', 'chronic LBP'), (590, 605, 'PHYSICAL', 'aquatic therapy'), (626, 639, 'CONTROL', 'standard care'), (651, 655, 'CONDITION', 'pain'), (699, 712, 'CONDITION', 'kinesiophobia'), (714, 729, 'CONDITION', 'catastrophizing'), (731, 738, 'CONDITION', 'anxiety'), (744, 754, 'CONDITION', 'depression'), (768, 803, 'OTHER', 'digital application ""play the pain""'), (824, 828, 'CONDITION', 'pain'), (891, 895, 'CONDITION', 'pain'), (942, 957, 'PHYSICAL', 'aquatic therapy'), (967, 980, 'CONTROL', 'standard care')]"
"['Virtual', 'Reality', 'Augmented', 'Gait', 'Adaptation', 'in', 'Stroke', 'Survivors', '|', 'The', 'major', 'problem', 'in', 'stroke', 'survivors', 'that', 'is', 'being', 'addressed', 'in', 'this', 'research', 'project', 'is', 'walking', 'asymmetry', ',', 'i.e.', ',', 'difference', 'between', 'the', 'legs', 'during', 'walking', '(', 'e.g.', 'steps', 'on', 'the', 'more', 'affected', 'side', 'are', 'longer', 'than', 'the', 'other', ')', '.', 'A', 'potential', 'solution', 'to', 'this', 'problem', 'is', 'using', 'new', 'technology', 'like', 'virtual', 'reality', 'during', 'walking', 'training', 'to', 'make', 'stroke', 'survivors', 'have', 'a', 'better', 'sense', 'of', 'their', 'asymmetry', '.', 'A', 'second', 'problem', 'that', 'we', 'aim', 'to', 'address', 'in', 'this', 'study', 'is', 'whether', 'asymmetry', 'is', 'accurately', 'felt', 'by', 'the', 'stroke', 'survivors', 'and', 'how', 'we', 'can', 'address', 'it', '.', 'Our', 'ongoing', 'work', 'on', 'the', 'effects', 'of', 'virtual', 'reality', 'on', 'learning', 'new', 'walking', 'tasks', 'in', 'stroke', 'survivors', 'indicates', 'that', 'virtual', 'reality', 'maybe', 'particularly', 'important', 'for', 'those', 'with', 'walking', 'asymmetry', '.', 'In', 'this', 'study', ',', 'we', 'plan', 'to', 'recruit', 'stroke', 'survivors', 'who', 'have', 'such', 'asymmetries', 'during', 'walking', 'and', 'have', 'them', 'learn', 'a', 'new', 'walking', 'task', 'in', 'virtual', 'reality', '.', 'We', 'will', 'also', 'test', 'the', 'stroke', 'survivors', 'to', 'determine', 'if', 'there', 'is', 'a', 'relationship', 'between', 'how', 'well', 'they', 'learn', 'the', 'new', 'task', 'with', 'their', 'ability', 'to', 'feel', 'asymmetry', 'accurately', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03787693,NCT03787693,"Virtual Reality Augmented Gait Adaptation in Stroke Survivors | The major problem in stroke survivors that is being addressed in this research project is walking asymmetry, i.e., difference between the legs during walking (e.g. steps on the more affected side are longer than the other). A potential solution to this problem is using new technology like virtual reality during walking training to make stroke survivors have a better sense of their asymmetry. A second problem that we aim to address in this study is whether asymmetry is accurately felt by the stroke survivors and how we can address it. Our ongoing work on the effects of virtual reality on learning new walking tasks in stroke survivors indicates that virtual reality maybe particularly important for those with walking asymmetry. In this study, we plan to recruit stroke survivors who have such asymmetries during walking and have them learn a new walking task in virtual reality. We will also test the stroke survivors to determine if there is a relationship between how well they learn the new task with their ability to feel asymmetry accurately.","[(0, 41, 'OTHER', 'Virtual Reality Augmented Gait Adaptation'), (45, 51, 'CONDITION', 'Stroke'), (85, 91, 'CONDITION', 'stroke'), (154, 171, 'CONDITION', 'walking asymmetry'), (354, 369, 'OTHER', 'virtual reality'), (377, 393, 'PHYSICAL', 'walking training'), (402, 408, 'CONDITION', 'stroke'), (560, 566, 'CONDITION', 'stroke'), (639, 654, 'OTHER', 'virtual reality'), (688, 694, 'CONDITION', 'stroke'), (720, 735, 'OTHER', 'virtual reality'), (833, 839, 'CONDITION', 'stroke'), (864, 890, 'CONDITION', 'asymmetries during walking'), (933, 948, 'OTHER', 'virtual reality'), (972, 978, 'CONDITION', 'stroke')]"
"['An', 'Open', '-', 'label', ',', 'Randomized', 'Trial', 'of', 'Intramuscular', '(', 'IM', ')', 'Olanzapine', 'Versus', 'Intramuscular', 'Combination', 'of', 'Haloperidol', 'and', 'Lorazepam', 'in', 'the', 'Treatment', 'of', 'Acute', 'Agitation', 'in', 'Schizophrenia', '|', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'intramuscular', '10', 'mg', 'olanzapine', 'versus', 'intramuscular', '5', 'mg', 'haloperidol', 'plus', 'lorazepam', '2', 'mg', 'in', 'the', 'treatment', 'of', 'acute', 'agitated', 'schizophrenic', 'patients', 'of', 'Taiwanese', 'populations', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT00797277,NCT00797277,"An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia | The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese populations.","[(54, 64, 'DRUG', 'Olanzapine'), (101, 112, 'DRUG', 'Haloperidol'), (117, 126, 'DRUG', 'Lorazepam'), (147, 162, 'CONDITION', 'Acute Agitation'), (166, 179, 'CONDITION', 'Schizophrenia'), (266, 276, 'DRUG', 'olanzapine'), (303, 314, 'DRUG', 'haloperidol'), (320, 329, 'DRUG', 'lorazepam'), (355, 369, 'CONDITION', 'acute agitated'), (370, 383, 'CONDITION', 'schizophrenic')]"
"['Examining', 'the', 'Effects', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'and', 'Task', '-', 'specific', 'Practice', 'on', 'Cortical', 'Modulation', 'Among', 'Individuals', 'With', 'Unilateral', 'Spatial', 'Neglect', 'Post', 'Stroke', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'effects', 'of', 'three', 'different', 'rehabilitation', 'training', 'sessions', 'that', 'combine', 'non', '-', 'invasive', 'brain', 'stimulation', '(', 'transcranial', 'direct', 'current', 'stimulation', ',', 'tDCS', ')', 'with', 'arm', 'rehabilitation', 'training', '(', 'repetitive', 'task', '-', 'specific', 'practice', ',', 'RTP', ')', 'for', 'individuals', 'with', 'unilateral', 'spatial', 'neglect', 'following', 'stroke', '.', 'This', 'study', 'is', 'designed', 'to', 'determine', 'the', 'effects', 'of', 'tDCS', '+', 'RTP', 'on', 'the', 'excitability', 'in', 'the', 'brain', ',', 'attention', 'to', 'the', 'affected', 'side', ',', 'and', 'arm', 'movement', 'ability', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02892097,NCT02892097,"Examining the Effects of Transcranial Direct Current Stimulation and Task-specific Practice on Cortical Modulation Among Individuals With Unilateral Spatial Neglect Post Stroke | The purpose of this study is to test the effects of three different rehabilitation training sessions that combine non-invasive brain stimulation (transcranial direct current stimulation, tDCS) with arm rehabilitation training (repetitive task-specific practice, RTP) for individuals with unilateral spatial neglect following stroke. This study is designed to determine the effects of tDCS + RTP on the excitability in the brain, attention to the affected side, and arm movement ability.","[(25, 64, 'OTHER', 'Transcranial Direct Current Stimulation'), (69, 91, 'PHYSICAL', 'Task-specific Practice'), (138, 164, 'CONDITION', 'Unilateral Spatial Neglect'), (170, 176, 'CONDITION', 'Stroke'), (293, 323, 'OTHER', 'non-invasive brain stimulation'), (325, 364, 'OTHER', 'transcranial direct current stimulation'), (366, 370, 'OTHER', 'tDCS'), (377, 404, 'PHYSICAL', 'arm rehabilitation training'), (406, 439, 'PHYSICAL', 'repetitive task-specific practice'), (441, 444, 'PHYSICAL', 'RTP'), (467, 493, 'CONDITION', 'unilateral spatial neglect'), (504, 510, 'CONDITION', 'stroke'), (563, 567, 'OTHER', 'tDCS'), (570, 573, 'PHYSICAL', 'RTP')]"
"['Development', 'and', 'Validation', 'of', 'a', 'Diagnosis', 'Questionnaire', 'of', 'Primary', 'Parkinsonian', 'Pain', ':', 'the', '3', 'PDQ', 'Primary', 'Parkinsonian', 'Pain', 'Diagnostic', 'Questionnaire', '|', 'Development', 'and', 'validation', 'of', 'a', 'diagnosis', 'questionnaire', 'of', 'parkinsonian', 'primary', 'pain', ':', 'the', '""', 'Primary', 'Parkinsonian', 'Pain', 'Diagnostic', 'Questionnaire', '""', '(', '3PDQ', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03940872,NCT03940872,"Development and Validation of a Diagnosis Questionnaire of Primary Parkinsonian Pain: the 3 PDQ Primary Parkinsonian Pain Diagnostic Questionnaire | Development and validation of a diagnosis questionnaire of parkinsonian primary pain: the ""Primary Parkinsonian Pain Diagnostic Questionnaire"" (3PDQ)","[(59, 84, 'CONDITION', 'Primary Parkinsonian Pain'), (96, 121, 'CONDITION', 'Primary Parkinsonian Pain'), (208, 233, 'CONDITION', 'parkinsonian primary pain'), (240, 265, 'CONDITION', 'Primary Parkinsonian Pain')]"
"['Surgical', 'Resection', 'of', 'Latent', 'Brain', 'Tumors', 'Prior', 'to', 'Recurrence', '|', 'This', 'clinical', 'trial', 'evaluates', 'the', 'side', 'effects', 'and', 'possible', 'benefits', 'of', 'operating', 'on', 'brain', 'tumors', 'prior', 'to', 'the', 'tumor', 'coming', 'back', '(', 'recurrence', ')', '.', 'Understanding', 'when', 'surgery', 'is', 'most', 'useful', 'to', 'patients', 'with', 'brain', 'tumors', 'is', 'important', '.', 'Some', 'patients', 'may', 'undergo', 'chemotherapy', 'or', 'radiation', 'but', 'still', 'have', 'visible', 'tumor', 'remaining', 'after', 'treatment', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'compare', 'outcomes', 'of', 'those', 'who', 'have', 'surgery', 'after', 'chemotherapy', 'or', 'radiation', ',', 'but', 'prior', 'to', 'tumor', 'recurrence', ',', 'to', 'those', 'who', 'have', 'surgery', 'at', 'a', 'different', 'time', ',', 'or', 'no', 'surgery', 'at', 'all', '.']","['B-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT04810871,NCT04810871,"Surgical Resection of Latent Brain Tumors Prior to Recurrence | This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.","[(0, 18, 'SURGICAL', 'Surgical Resection'), (22, 61, 'CONDITION', 'Latent Brain Tumors Prior to Recurrence'), (149, 161, 'CONDITION', 'brain tumors'), (175, 180, 'CONDITION', 'tumor'), (266, 278, 'CONDITION', 'brain tumors'), (368, 373, 'CONDITION', 'tumor'), (471, 510, 'SURGICAL', 'surgery after chemotherapy or radiation'), (516, 541, 'CONDITION', 'prior to tumor recurrence'), (561, 588, 'SURGICAL', 'surgery at a different time'), (593, 610, 'CONTROL', 'no surgery at all')]"
"['Phase', '1/2a', 'Randomized', 'Controlled', 'Study', 'for', 'Treatment', 'of', 'Early-', 'to', 'Moderate', 'Stage', 'Multiple', 'System', 'Atrophy', 'Patients', 'With', 'the', 'Investigational', 'Allogeneic', 'Cell', 'Therapy', 'Product', ',', 'hOMSC300', '|', 'Purpose', 'of', 'this', 'phase', '1/2a', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'efficacy', 'of', 'intrathecal', 'administration', 'of', 'allogeneic', 'human', 'oral', 'mucosa', 'stem', 'cells', '(', 'hOMSCs', ')', 'in', 'patients', 'suffering', 'from', 'early', 'to', 'moderate', 'stage', 'Multiple', 'System', 'Atrophy', '(', 'MSA', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05698017,NCT05698017,"Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300 | Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA) .","[(56, 104, 'CONDITION', 'Early- to Moderate Stage Multiple System Atrophy'), (139, 170, 'SURGICAL', 'Allogeneic Cell Therapy Product'), (172, 180, 'SURGICAL', 'hOMSC300'), (286, 325, 'SURGICAL', 'allogeneic human oral mucosa stem cells'), (327, 333, 'SURGICAL', 'hOMSCs'), (362, 409, 'CONDITION', 'early to moderate stage Multiple System Atrophy'), (411, 414, 'CONDITION', 'MSA')]"
"['Optimal', 'Encephalitis', '/', 'Meningitis', 'Roadmap', 'Via', 'Precise', 'Diagnosis', 'and', 'Treatment', '|', 'Encephalitis', 'and', 'meningitis', 'are', 'serious', 'central', 'nervous', 'system', 'diseases', '.', 'There', 'is', 'currently', 'a', 'lack', 'of', 'comprehensive', 'and', 'accurate', 'diagnosis', 'and', 'treatment', 'pathways', '.', 'Therefore', ',', 'we', 'conducted', 'this', 'multicenter', ',', 'prospective', ',', 'and', 'randomized', 'controlled', 'study', '.', 'It', 'was', 'designed', 'to', 'evaluate', 'the', 'diagnostic', 'performance', 'and', 'its', 'impact', 'on', 'the', 'outcomes', 'of', 'the', 'patients', 'enrolled', '.', 'As', 'such', ',', 'we', 'came', 'to', 'the', 'results', 'of', 'the', 'optimal', 'process', 'of', 'diagnosis', 'and', 'treatment', 'strategy', 'of', 'encephalitis', '/', 'meningeal', 'syndromes', 'with', 'improved', 'effective', 'treatments', '.']","['O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT04946682,NCT04946682,"Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment | Encephalitis and meningitis are serious central nervous system diseases. There is currently a lack of comprehensive and accurate diagnosis and treatment pathways. Therefore, we conducted this multicenter, prospective, and randomized controlled study. It was designed to evaluate the diagnostic performance and its impact on the outcomes of the patients enrolled. As such, we came to the results of the optimal process of diagnosis and treatment strategy of encephalitis/meningeal syndromes with improved effective treatments.","[(8, 20, 'CONDITION', 'Encephalitis'), (21, 31, 'CONDITION', 'Meningitis'), (78, 90, 'CONDITION', 'Encephalitis'), (95, 105, 'CONDITION', 'meningitis'), (535, 547, 'CONDITION', 'encephalitis'), (548, 567, 'CONDITION', 'meningeal syndromes')]"
"['A', 'Phase', '2', ',', 'Randomized', ',', 'Double', 'Blind', ',', 'Placebo', 'Controlled', ',', 'Dose', 'Range', 'Finding', 'Study', 'to', 'Access', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Intramuscular', 'Injection', 'of', 'Human', 'Placenta-', 'Derived', 'Cells', '(', 'PDA-002', ')', 'in', 'Subjects', 'With', 'Diabetic', 'Peripheral', 'Neuropathy', '.', '|', 'This', 'is', 'a', 'Phase', '2', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'dose', 'range', 'finding', 'study', 'in', 'subjects', 'who', 'have', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', '.', 'The', 'study', 'will', 'enroll', 'approximately', '24', 'subjects', '.', 'Subjects', 'will', 'be', 'randomized', 'to', 'receive', 'one', 'of', '3', 'treatments', ':', 'PDA-002', '(', '3', 'x', '10', '^', '6', 'cells', ')', ',', 'PDA-002', '(', '30', 'x', '10', '^', '6', 'cells', ')', ',', 'or', 'placebo', '(', 'vehicle', 'control', ')', 'in', 'a', '1:1:1', 'randomization', 'approach', '.', 'Investigational', 'product', 'or', 'placebo', 'will', 'be', 'administered', 'monthly', '(', '3', 'administrations', 'total', 'on', 'Study', 'Days', '1', ',', '29', ',', 'and', '57', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02552277,NCT02552277,"A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy. | This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects. Subjects will be randomized to receive one of 3 treatments: PDA-002 (3 x 10^6 cells), PDA-002 (30 x 10^6 cells), or placebo (vehicle control) in a 1:1:1 randomization approach. Investigational product or placebo will be administered monthly (3 administrations total on Study Days 1, 29, and 57).","[(37, 44, 'CONTROL', 'Placebo'), (146, 175, 'SURGICAL', 'Human Placenta- Derived Cells'), (177, 184, 'SURGICAL', 'PDA-002'), (203, 233, 'CONDITION', 'Diabetic Peripheral Neuropathy'), (282, 289, 'CONTROL', 'placebo'), (348, 378, 'CONDITION', 'diabetic peripheral neuropathy'), (380, 383, 'CONDITION', 'DPN'), (495, 502, 'SURGICAL', 'PDA-002'), (521, 528, 'SURGICAL', 'PDA-002'), (560, 575, 'CONTROL', 'vehicle control'), (639, 646, 'CONTROL', 'placebo')]"
"['A', 'Prospective', ',', 'Multicenter', ',', 'Randomized', 'Controlled', 'Trial', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'the', 'STARFlex', '®', 'Septal', 'Closure', 'System', 'Versus', 'Best', 'Medical', 'Therapy', 'in', 'Patients', 'With', 'a', 'Stroke', 'and/or', 'Transient', 'Ischemic', 'Attack', 'Due', 'to', 'Presumed', 'Paradoxical', 'Embolism', 'Through', 'a', 'Patent', 'Foramen', 'Ovale', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'the', 'STARFlex', '®', 'septal', 'closure', 'system', 'will', 'safely', 'and', 'effectively', 'prevent', 'a', 'recurrent', 'embolic', 'stroke', '/', 'transient', 'ischemic', 'attack', '(', 'TIA', ')', 'and', 'mortality', 'in', 'patients', 'with', 'a', 'PFO', 'and', 'to', 'demonstrate', 'superiority', 'of', 'the', 'STARFlex', '®', 'device', 'compared', 'to', 'best', 'medical', 'therapy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00201461,NCT00201461,"A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale | The primary objective of the study is to determine whether the STARFlex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the STARFlex® device compared to best medical therapy.","[(99, 130, 'OTHER', 'STARFlex® Septal Closure System'), (138, 158, 'CONTROL', 'Best Medical Therapy'), (178, 184, 'CONDITION', 'Stroke'), (192, 217, 'CONDITION', 'Transient Ischemic Attack'), (234, 254, 'CONDITION', 'Paradoxical Embolism'), (265, 285, 'CONDITION', 'Patent Foramen Ovale'), (351, 382, 'OTHER', 'STARFlex® septal closure system'), (421, 445, 'CONDITION', 'recurrent embolic stroke'), (446, 471, 'CONDITION', 'transient ischemic attack'), (473, 476, 'CONDITION', 'TIA'), (511, 514, 'CONDITION', 'PFO'), (553, 569, 'OTHER', 'STARFlex® device'), (582, 602, 'CONTROL', 'best medical therapy')]"
"['Ambroxol', 'as', 'a', 'Novel', 'Disease', 'Modifying', 'Treatment', 'for', 'Lewy', 'Body', 'Dementia', '|', 'This', 'is', 'a', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', 'investigating', 'whether', 'the', 'medication', 'Ambroxol', 'is', 'safe', ',', 'effectiveness', 'and', 'well', 'tolerated', 'for', 'the', 'treatment', 'of', 'Lewy', 'Body', 'Dementia', '(', 'LBD', ')', '.', 'Currently', 'the', 'main', 'treatments', 'for', 'patients', 'with', 'LBD', 'target', 'symptom', 'management', '.', 'However', ',', 'none', 'of', 'the', 'medications', 'treat', 'the', 'underlying', 'cause', 'of', 'the', 'disease', ',', 'which', 'includes', 'the', 'accumulation', 'of', 'protein', 'in', 'the', 'brain', '.', 'Therefore', ',', 'even', 'if', 'patients', 'respond', 'well', 'to', 'symptomatic', 'treatment', ',', 'they', 'continue', 'to', 'deteriorate', '.', 'Therefore', ',', 'the', 'purpose', 'of', 'the', 'current', 'study', 'is', 'to', 'make', 'sure', 'Ambroxol', 'is', 'safe', 'to', 'take', 'long', 'term', 'and', 'to', 'test', 'the', 'effects', 'of', 'Ambroxol', 'in', 'treating', 'the', 'cognitive', 'impairments', 'associated', 'with', 'LBD', 'by', 'modifying', 'the', 'underlying', 'causes', 'of', 'the', 'disease', '.', '\n\n', 'There', 'will', 'be', 'a', 'total', 'of', '15', 'people', 'participating', 'this', 'this', 'study', ',', 'which', 'will', 'last', '52', 'weeks', '.', 'Over', 'the', 'study', 'period', 'patients', 'will', 'undergo', 'clinical', ',', 'neuropsychological', 'and', 'neuroimaging', 'assessment', 'to', 'assess', 'changes', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04405596,NCT04405596,"Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia | This is a randomized, placebo-controlled, double-blind study investigating whether the medication Ambroxol is safe,effectiveness and well tolerated for the treatment of Lewy Body Dementia (LBD). Currently the main treatments for patients with LBD target symptom management. However, none of the medications treat the underlying cause of the disease, which includes the accumulation of protein in the brain. Therefore, even if patients respond well to symptomatic treatment, they continue to deteriorate. Therefore, the purpose of the current study is to make sure Ambroxol is safe to take long term and to test the effects of Ambroxol in treating the cognitive impairments associated with LBD by modifying the underlying causes of the disease.

There will be a total of 15 people participating this this study, which will last 52 weeks. Over the study period patients will undergo clinical, neuropsychological and neuroimaging assessment to assess changes.","[(0, 8, 'DRUG', 'Ambroxol'), (52, 70, 'CONDITION', 'Lewy Body Dementia'), (95, 102, 'CONTROL', 'placebo'), (171, 179, 'DRUG', 'Ambroxol'), (242, 260, 'CONDITION', 'Lewy Body Dementia'), (262, 265, 'CONDITION', 'LBD'), (316, 319, 'CONDITION', 'LBD'), (637, 645, 'DRUG', 'Ambroxol'), (699, 707, 'DRUG', 'Ambroxol'), (724, 745, 'CONDITION', 'cognitive impairments'), (762, 765, 'CONDITION', 'LBD')]"
"['Measurement', 'and', 'Modification', 'of', 'Threat', 'Interpretation', 'Bias', 'in', 'Neurodegenerative', 'Movement', 'Disorders', '(', 'Aims', '2', '&', '3', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'conduct', 'a', 'pilot', 'open', 'trial', 'of', 'a', 'web', '-', 'based', 'cognitive', 'bias', 'modification', 'intervention', 'to', 'reduce', 'anxiety', 'symptoms', 'in', 'persons', 'with', 'Huntington', ""'s"", 'disease', 'and', 'persons', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05126862,NCT05126862,Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) | The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.,"[(16, 58, 'BEHAVIOURAL', 'Modification of Threat Interpretation Bias'), (62, 98, 'CONDITION', 'Neurodegenerative Movement Disorders'), (175, 225, 'BEHAVIOURAL', 'web-based cognitive bias modification intervention'), (236, 243, 'CONDITION', 'anxiety'), (269, 289, 'CONDITION', ""Huntington's disease""), (307, 326, 'CONDITION', ""Parkinson's disease"")]"
"['Efficacy', 'and', 'Tolerability', 'of', 'Magnetic', 'Seizure', 'Therapy', '(', 'MST', ')', 'as', 'an', 'Alternative', 'to', 'Electroconvulsive', 'Therapy', '(', 'ECT', ')', 'for', 'Treatment', 'Resistant', 'Depression', ',', 'Schizophrenia', ',', 'and', 'Obsessive', 'Compulsive', 'Disorder', '|', 'Electroconvulsive', 'therapy', '(', 'ECT', ')', 'has', 'unparalleled', 'efficacy', 'in', 'treating', 'severe', 'depression', ',', 'and', 'is', 'also', 'useful', 'in', 'treatment', '-', 'refractory', 'cases', 'of', 'schizophrenia', 'and', 'obsessive', 'compulsive', 'disorder', '(', 'OCD', ')', '.', 'However', ',', 'its', 'use', 'is', 'limited', 'by', 'significant', 'adverse', 'effects', 'on', 'memory', 'and', 'cognition', '.', 'In', 'addition', ',', 'ECT', 'can', 'not', 'be', 'precisely', 'targeted', ',', 'since', 'it', 'relies', 'on', 'unpredictable', 'pathways', 'of', 'electrical', 'conduction', 'through', 'the', 'brain', '.', 'Magnetic', 'seizure', 'therapy', '(', 'MST', ')', 'is', 'currently', 'under', 'investigation', 'as', 'a', 'targetable', ',', 'cognition', '-', 'sparing', 'alternative', 'to', 'ECT', '.', 'MST', 'uses', 'magnetic', 'fields', 'rather', 'than', 'electrical', 'stimuli', 'for', 'seizure', 'induction', ',', 'dramatically', 'reducing', 'the', 'passage', 'of', 'induced', 'current', 'through', 'undesired', 'brain', 'regions', '.', '10', 'years', 'of', 'experimental', 'studies', 'have', 'established', 'the', 'safety', 'of', 'MST', 'in', 'animal', 'and', 'human', 'subjects', '.', 'This', 'pilot', 'study', 'will', 'investigate', 'whether', 'MST', 'has', 'similar', 'efficacy', 'to', 'ECT', ',', 'with', 'fewer', 'cognitive', 'side', 'effects', ',', 'in', 'patients', 'with', 'severe', 'depression', ',', 'schizophrenia', ',', 'and', 'OCD', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01596608,NCT01596608,"Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder | Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD). However, its use is limited by significant adverse effects on memory and cognition. In addition, ECT cannot be precisely targeted, since it relies on unpredictable pathways of electrical conduction through the brain. Magnetic seizure therapy (MST) is currently under investigation as a targetable, cognition-sparing alternative to ECT. MST uses magnetic fields rather than electrical stimuli for seizure induction, dramatically reducing the passage of induced current through undesired brain regions. 10 years of experimental studies have established the safety of MST in animal and human subjects. This pilot study will investigate whether MST has similar efficacy to ECT, with fewer cognitive side effects, in patients with severe depression, schizophrenia, and OCD.","[(29, 53, 'OTHER', 'Magnetic Seizure Therapy'), (55, 58, 'OTHER', 'MST'), (81, 106, 'CONTROL', 'Electroconvulsive Therapy'), (108, 111, 'CONTROL', 'ECT'), (117, 197, 'CONDITION', 'Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder'), (200, 225, 'CONTROL', 'Electroconvulsive therapy'), (227, 230, 'CONTROL', 'ECT'), (270, 288, 'CONDITION', 'severe depression,'), (311, 388, 'CONDITION', 'treatment-refractory cases of schizophrenia and obsessive compulsive disorder'), (390, 393, 'CONDITION', 'OCD'), (493, 496, 'CONTROL', 'ECT'), (613, 637, 'OTHER', 'Magnetic seizure therapy'), (639, 642, 'OTHER', 'MST'), (727, 730, 'CONTROL', 'ECT'), (732, 735, 'OTHER', 'MST'), (961, 964, 'OTHER', 'MST'), (1037, 1040, 'OTHER', 'MST'), (1065, 1068, 'CONTROL', 'ECT'), (1122, 1163, 'CONDITION', 'severe depression, schizophrenia, and OCD')]"
"['RISE', '(', 'Rehabilitation', 'Intervention', 'for', 'People', 'With', 'Schizophrenia', 'in', 'Ethiopia', '):', 'a', 'Cluster', '-', 'randomised', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'community', '-', 'based', 'rehabilitation', 'plus', 'facility', '-', 'based', 'care', 'is', 'superior', 'to', 'facility', '-', 'based', 'care', 'alone', 'in', 'reducing', 'disability', 'related', 'to', 'schizophrenia', 'in', 'rural', 'Ethiopia', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT02160249,NCT02160249,RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia): a Cluster-randomised Trial | The purpose of this study is to determine whether community-based rehabilitation plus facility-based care is superior to facility-based care alone in reducing disability related to schizophrenia in rural Ethiopia.,"[(6, 33, 'OTHER', 'Rehabilitation Intervention'), (50, 63, 'CONDITION', 'Schizophrenia'), (157, 187, 'OTHER', 'community-based rehabilitation'), (193, 212, 'OTHER', 'facility-based care'), (228, 253, 'CONTROL', 'facility-based care alone'), (288, 301, 'CONDITION', 'schizophrenia')]"
"['TachoSil', '®', 'Versus', 'Current', 'Practice', 'in', 'Dura', 'Sealing', 'Techniques', 'for', 'the', 'Prevention', 'of', 'Post', '-', 'operative', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'Leaks', 'in', 'Patients', 'Undergoing', 'Skull', 'Base', 'Surgery', ':', 'An', 'Open', 'Label', ',', 'Randomised', ',', 'Controlled', ',', 'Multi', '-', 'centre', ',', 'Parallel', 'Group', 'Efficacy', 'and', 'Safety', 'Trial', '.', '|', 'The', 'primary', 'objective', 'is', 'to', 'demonstrate', 'superiority', 'of', 'TachoSil', '®', 'compared', 'to', 'current', 'practice', 'as', 'an', 'adjunct', 'in', 'sealing', 'the', 'dura', 'mater', '.', 'The', 'efficacy', 'of', 'the', 'dura', 'mater', 'sealing', 'must', 'be', 'evaluated', 'post', '-', 'operatively', '.', 'The', 'secondary', 'objective', 'is', 'to', 'evaluate', 'the', 'safety', 'of', 'TachoSil', '®', 'as', 'an', 'adjunct', 'in', 'sealing', 'the', 'dura', 'mater', '.', '\n\n', 'The', 'trial', 'population', 'will', 'consist', 'of', '726', 'randomised', '(', '1:1', ')', 'patients', 'elected', 'for', 'skull', 'base', 'surgery', '.', 'The', 'trial', 'duration', 'consists', 'of', 'screening', ',', 'surgery', ',', 'efficacy', 'follow', '-', 'up', 'after', '7±1', 'weeks', 'and', 'safety', 'follow', '-', 'up', '28±2', 'weeks', 'after', 'surgery', '.']","['B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01355627,NCT01355627,"TachoSil® Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial. | The primary objective is to demonstrate superiority of TachoSil® compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated post-operatively. The secondary objective is to evaluate the safety of TachoSil® as an adjunct in sealing the dura mater.

The trial population will consist of 726 randomised (1:1) patients elected for skull base surgery. The trial duration consists of screening, surgery, efficacy follow-up after 7±1 weeks and safety follow-up 28±2 weeks after surgery.","[(0, 8, 'OTHER', 'TachoSil'), (17, 33, 'CONTROL', 'Current Practice'), (83, 129, 'CONDITION', 'Post-operative Cerebrospinal Fluid (CSF) Leaks'), (153, 171, 'CONDITION', 'Skull Base Surgery'), (325, 333, 'OTHER', 'TachoSil'), (533, 541, 'OTHER', 'TachoSil'), (664, 682, 'CONDITION', 'skull base surgery')]"
"['E', '-', 'Rehabilitation', ':', 'Aerobic', 'Resistance', 'Training', 'for', 'Stroke', 'Survivors', '|', 'This', 'pilot', 'study', 'intends', 'to', 'evaluate', 'an', 'online', 'exercise', 'video', 'rehabilitation', 'program', 'for', 'stroke', 'survivors', 'with', 'moderate', 'disability', 'compared', 'to', 'usual', 'care', '.', 'The', 'intervention', 'videos', 'combine', 'aerobic', 'and', 'resistance', 'training', 'using', 'a', 'latex', 'resistance', 'band', ',', 'Thera', 'band', '®', 'elastic', 'band', ',', 'specifically', 'designed', 'for', 'rehabilitation', '.', 'This', 'study', 'will', 'aim', 'to', 'show', 'that', 'for', 'patients', 'suffering', 'acute', 'ischemic', 'stroke', 'resulting', 'in', 'disability', ',', 'at', '-', 'home', 'physical', 'therapy', 'with', 'aerobic', 'exercise', 'videos', 'will', 'improve', 'depression', 'level', 'and', 'aerobic', 'capacity', 'more', 'than', 'usual', 'care', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02938000,NCT02938000,"E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors | This pilot study intends to evaluate an online exercise video rehabilitation program for stroke survivors with moderate disability compared to usual care. The intervention videos combine aerobic and resistance training using a latex resistance band, Thera band® elastic band, specifically designed for rehabilitation. This study will aim to show that for patients suffering acute ischemic stroke resulting in disability, at-home physical therapy with aerobic exercise videos will improve depression level and aerobic capacity more than usual care.","[(18, 45, 'PHYSICAL', 'Aerobic Resistance Training'), (50, 56, 'CONDITION', 'Stroke'), (109, 153, 'PHYSICAL', 'online exercise video rehabilitation program'), (158, 164, 'CONDITION', 'stroke'), (212, 222, 'CONTROL', 'usual care'), (256, 317, 'PHYSICAL', 'aerobic and resistance training using a latex resistance band'), (319, 343, 'PHYSICAL', 'Thera band® elastic band'), (443, 464, 'CONDITION', 'acute ischemic stroke'), (520, 543, 'PHYSICAL', 'aerobic exercise videos')]"
"['Treatment', 'of', 'Tinnitus', 'With', 'Migraine', 'Medications', ':', 'A', 'Randomized', 'Clinical', 'Trial', '|', 'Tinnitus', 'represents', 'one', 'of', 'the', 'most', 'common', 'and', 'distressing', 'otologic', 'problems', ',', 'and', 'it', 'causes', 'various', 'somatic', 'and', 'psychological', 'disorders', 'that', 'interfere', 'with', 'the', 'quality', 'of', 'life', '.', 'It', 'is', 'well', '-', 'understood', 'that', 'many', 'factors', ',', 'such', 'as', 'poor', 'education', ',', 'lower', 'income', ',', 'or', 'occupational', ',', 'and', 'recreational', 'activity', 'associated', 'with', 'high', 'noise', 'exposure', ',', 'influences', 'the', 'prevalence', 'and', 'risk', 'of', 'tinnitus', '.', 'Although', 'the', 'economic', 'and', 'emotional', 'impact', 'of', 'tinnitus', 'is', 'large', ',', 'there', 'is', 'currently', 'no', 'FDA', '-', 'approved', 'medication', 'to', 'treat', 'this', 'condition', '.', 'However', ',', 'there', 'are', 'pharmacological', 'options', 'to', 'address', 'the', 'stress', ',', 'anxiety', ',', 'and', 'depression', 'that', 'are', 'caused', 'by', 'tinnitus', '.', 'In', 'this', 'project', ',', 'we', 'intend', 'to', 'use', 'medications', 'for', 'patients', 'with', 'tinnitus', 'in', 'order', 'to', 'decrease', 'the', 'impact', 'of', 'tinnitus', 'on', 'their', 'daily', 'life', 'and', 'activities', '.']","['O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04404439,NCT04404439,"Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial | Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. It is well-understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influences the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, we intend to use medications for patients with tinnitus in order to decrease the impact of tinnitus on their daily life and activities.","[(13, 21, 'CONDITION', 'Tinnitus'), (27, 47, 'OTHER', 'Migraine Medications'), (79, 87, 'CONDITION', 'Tinnitus'), (453, 461, 'CONDITION', 'tinnitus'), (509, 517, 'CONDITION', 'tinnitus'), (657, 663, 'CONDITION', 'stress'), (665, 672, 'CONDITION', 'anxiety'), (678, 688, 'CONDITION', 'depression'), (708, 716, 'CONDITION', 'tinnitus'), (782, 790, 'CONDITION', 'tinnitus'), (826, 834, 'CONDITION', 'tinnitus')]"
"['PNOC023', ':', 'Open', 'Label', 'Phase', '1', 'and', 'Target', 'Validation', 'Study', 'of', 'ONC206', 'in', 'Children', 'and', 'Young', 'Adults', 'With', 'Newly', 'Diagnosed', 'or', 'Recurrent', 'Diffuse', 'Midline', 'Glioma', '(', 'DMG', ')', ',', 'and', 'Other', 'Recurrent', 'Primary', 'Malignant', 'Central', 'Nervous', 'System', '(', 'CNS', ')', 'Tumors', '|', 'This', 'phase', 'I', 'trial', 'studies', 'the', 'effects', 'and', 'best', 'dose', 'of', 'ONC206', 'alone', 'or', 'in', 'combination', 'with', 'radiation', 'therapy', 'in', 'treating', 'patients', 'with', 'diffuse', 'midline', 'gliomas', 'that', 'is', 'newly', 'diagnosed', 'or', 'has', 'come', 'back', '(', 'recurrent', ')', 'or', 'other', 'recurrent', 'primary', 'malignant', 'CNS', 'tumors', '.', 'ONC206', 'is', 'a', 'recently', 'discovered', 'compound', 'that', 'may', 'stop', 'cancer', 'cells', 'from', 'growing', '.', 'This', 'drug', 'has', 'been', 'shown', 'in', 'laboratory', 'experiments', 'to', 'kill', 'brain', 'tumor', 'cells', 'by', 'causing', 'a', 'so', 'called', '""', 'stress', 'response', '""', 'in', 'tumor', 'cells', '.', 'This', 'stress', 'response', 'causes', 'cancer', 'cells', 'to', 'die', ',', 'but', 'without', 'affecting', 'normal', 'cells', '.', 'ONC206', 'alone', 'or', 'in', 'combination', 'with', 'radiation', 'therapy', 'may', 'be', 'effective', 'in', 'treating', 'newly', 'diagnosed', 'or', 'recurrent', 'diffuse', 'midline', 'gliomas', 'and', 'other', 'recurrent', 'primary', 'malignant', 'CNS', 'tumors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04732065,NCT04732065,"PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors | This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called ""stress response"" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells. ONC206 alone or in combination with radiation therapy may be effective in treating newly diagnosed or recurrent diffuse midline gliomas and other recurrent primary malignant CNS tumors.","[(59, 65, 'DRUG', 'ONC206'), (100, 151, 'CONDITION', 'Newly Diagnosed or Recurrent Diffuse Midline Glioma'), (153, 156, 'CONDITION', 'DMG'), (169, 232, 'CONDITION', 'Recurrent Primary Malignant Central Nervous System (CNS) Tumors'), (291, 297, 'DRUG', 'ONC206'), (327, 344, 'RADIOTHERAPY', 'radiation therapy'), (371, 394, 'CONDITION', 'diffuse midline gliomas'), (457, 495, 'CONDITION', 'recurrent primary malignant CNS tumors'), (497, 503, 'DRUG', 'ONC206'), (552, 558, 'CONDITION', 'cancer'), (638, 649, 'CONDITION', 'brain tumor'), (700, 705, 'CONDITION', 'tumor'), (741, 747, 'CONDITION', 'cancer'), (798, 804, 'DRUG', 'ONC206'), (834, 851, 'RADIOTHERAPY', 'radiation therapy'), (881, 933, 'CONDITION', 'newly diagnosed or recurrent diffuse midline gliomas'), (944, 982, 'CONDITION', 'recurrent primary malignant CNS tumors')]"
"['Spectral', 'Domain', 'Optical', 'Coherence', 'Tomography', 'Imaging', 'of', 'the', 'Eyes', 'of', 'Neonates', '|', 'Brief', 'Summary', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'better', 'characterize', 'the', 'retina', 'and', 'optic', 'nerve', 'in', 'newborns', 'using', 'spectral', 'domain', 'optical', 'coherence', 'tomography', '(', 's', '-', 'oct', ')', '.', 'This', 'new', 'technology', 'provides', 'a', 'very', 'detailed', 'cross', '-', 'section', 'picture', 'of', 'the', 'cellular', 'layers', 'in', 'the', 'retina', 'and', 'a', '3', '-', 'dimensional', 'picture', 'of', 'the', 'optic', 'nerve', 'head', 'and', 'the', 'fovea', '(', 'the', 'center', 'of', 'the', 'retina', 'that', 'provides', 'the', 'most', 'accurate', 'vision', ')', '.', 'These', 'images', 'have', 'been', 'used', 'by', 'doctors', 'for', 'more', 'than', '5', 'years', 'to', 'help', 'diagnose', 'and', 'treat', 'adults', 'with', 'eye', 'diseases', ',', 'such', 'as', 'macular', 'degeneration', ',', 'diabetic', 'retinopathy', ',', 'retinal', 'detachments', ',', 'and', 'melanoma', '.', 'But', ',', 'it', 'has', 'never', 'been', 'studied', 'in', 'newborns', '.', 'In', 'newborns', ',', 'it', 'would', 'potentially', 'help', 'in', 'the', 'diagnoses', 'of', 'glaucoma', ',', 'optic', 'nerve', 'hypoplasia', ',', 'foveal', 'hypoplasia', ',', 'and', 'colobomata', 'among', 'many', 'other', 'disorders', '.', 'Prior', 'to', 'diagnosing', 'disorders', ',', 'it', 'is', 'necessary', 'to', 'establish', 'normal', 'values', '.', 'It', 'is', 'the', 'purpose', 'of', 'this', 'investigation', 'to', 'study', 'the', 'retina', 'and', 'optic', 'nerves', 'in', 'neonates', 'to', 'establish', 'normal', 'values', '.', '\n\n', 'After', 'a', 'parent', 'of', 'a', 'normal', 'newborn', 'provides', 'a', 'written', 'consent', ',', 'the', 'baby', 'will', 'be', 'taken', 'to', 'the', 'Eye', 'Clinic', 'where', 'the', 'instrument', 'is', 'located', '.', 'The', 'baby', 'will', 'be', 'swaddled', 'in', 'one', 'or', 'more', 'blankets', 'as', 'needed', '.', 'The', 'infants', 'will', 'be', 'held', 'in', 'front', 'of', 'the', 'instrument', 'by', 'a', 'nurse', '.', 'The', 'technician', 'will', 'move', 'the', 'lens', 'of', 'the', 'instrument', 'to', 'about', '2', 'to', '4', 'inches', 'from', 'the', 'baby', ""'s"", 'eye', '.', 'The', 'mild', 'light', 'from', 'the', 'instrument', 'will', 'then', 'enter', 'the', 'eye', 'for', 'a', 'few', 'seconds', 'to', 'obtain', 'the', 'desired', 'image', '.', 'The', 'image', 'can', 'be', 'captured', 'through', 'an', 'immobile', 'eye', 'within', '5', 'seconds', '.', 'If', 'the', 'baby', 'is', 'fussy', ',', 'he', 'or', 'she', 'may', 'be', 'given', 'a', 'few', 'drops', 'of', 'a', 'sugar', '(', 'sucrose', ')', 'solution', 'on', 'a', 'pacifier', 'for', 'calming', '.', 'Although', 'the', 'images', 'can', 'usually', 'be', 'secured', 'through', 'a', 'normal', 'pupil', ',', 'if', 'the', 'pupil', 'is', 'found', 'to', 'be', 'too', 'small', ',', 'two', 'drops', 'of', 'Cyclomydril', 'will', 'be', 'placed', 'on', 'the', 'eye', 'for', 'dilation', '.', 'This', 'is', 'the', 'eye', 'drop', 'used', 'everyday', 'in', 'the', 'Eye', 'Clinic', 'and', 'nursery', 'to', 'dilate', 'the', 'pupils', 'of', 'babies', '.', 'The', 'dilation', 'will', 'last', 'for', 'about', '6', 'to', '10', 'hours', '.', 'After', 'the', 'test', ',', 'the', 'baby', 'will', 'return', 'to', 'the', 'nursery', 'or', 'be', 'discharged', 'home', 'as', 'intended', 'by', 'the', 'Neonatology', 'Division', '.', '\n\n', 'There', 'is', 'minimal', 'risk', 'associated', 'with', 'this', 'investigation', '.', 'The', 'instrument', 'is', 'non', '-', 'invasive', 'and', 'does', 'not', 'touch', 'the', 'eye', '.', 'The', 'babies', 'will', 'be', 'swaddled', 'and', 'held', 'by', 'a', 'nurse', 'to', 'prevent', 'any', 'contact', 'with', 'the', 'machine', '.', 'The', 'eye', 'drop', 'to', 'be', 'used', 'if', 'needed', 'for', 'dilation', 'has', 'been', 'used', 'on', 'babies', 'at', 'Harbor', 'for', 'about', '30', 'years', '.', 'It', 'has', 'been', 'found', 'to', 'very', 'safe', '.', 'The', 'fact', 'that', 'we', 'will', 'study', 'only', 'term', '(', 'not', 'premature', 'babies', ')', 'and', 'will', 'apply', 'only', 'two', 'drops', 'if', 'needed', 'should', 'minimize', 'any', 'risk', 'from', 'the', 'eye', 'drop', '.', '\n\n', 'An', 'ethical', 'issue', 'to', 'consider', 'is', 'that', 'while', 'the', 'study', 'will', 'provide', 'important', 'information', 'that', 'will', 'undoubtedly', 'help', 'babies', 'in', 'the', 'future', ',', 'it', 'will', 'probably', 'not', 'benefit', 'the', 'baby', 'being', 'studied', '.', 'However', ',', 'if', 'the', 'baby', 'has', 'an', 'undetected', 'retinal', 'or', 'optic', 'nerve', 'problem', ',', 'the', 'study', 'may', 'reveal', 'it', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01404247,NCT01404247,"Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates | Brief Summary

The purpose of this study is to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). This new technology provides a very detailed cross-section picture of the cellular layers in the retina and a 3-dimensional picture of the optic nerve head and the fovea (the center of the retina that provides the most accurate vision). These images have been used by doctors for more than 5 years to help diagnose and treat adults with eye diseases, such as macular degeneration, diabetic retinopathy, retinal detachments, and melanoma. But, it has never been studied in newborns. In newborns, it would potentially help in the diagnoses of glaucoma, optic nerve hypoplasia, foveal hypoplasia, and colobomata among many other disorders. Prior to diagnosing disorders, it is necessary to establish normal values. It is the purpose of this investigation to study the retina and optic nerves in neonates to establish normal values.

After a parent of a normal newborn provides a written consent, the baby will be taken to the Eye Clinic where the instrument is located. The baby will be swaddled in one or more blankets as needed. The infants will be held in front of the instrument by a nurse. The technician will move the lens of the instrument to about 2 to 4 inches from the baby's eye. The mild light from the instrument will then enter the eye for a few seconds to obtain the desired image. The image can be captured through an immobile eye within 5 seconds. If the baby is fussy, he or she may be given a few drops of a sugar (sucrose) solution on a pacifier for calming. Although the images can usually be secured through a normal pupil, if the pupil is found to be too small, two drops of Cyclomydril will be placed on the eye for dilation. This is the eye drop used everyday in the Eye Clinic and nursery to dilate the pupils of babies. The dilation will last for about 6 to 10 hours. After the test, the baby will return to the nursery or be discharged home as intended by the Neonatology Division.

There is minimal risk associated with this investigation. The instrument is non-invasive and does not touch the eye. The babies will be swaddled and held by a nurse to prevent any contact with the machine. The eye drop to be used if needed for dilation has been used on babies at Harbor for about 30 years. It has been found to very safe. The fact that we will study only term (not premature babies) and will apply only two drops if needed should minimize any risk from the eye drop.

An ethical issue to consider is that while the study will provide important information that will undoubtedly help babies in the future, it will probably not benefit the baby being studied. However, if the baby has an undetected retinal or optic nerve problem, the study may reveal it.",[]
"['A', 'Phase', '3', ',', 'Randomized', ',', 'Multi', '-', 'Center', ',', 'Multi', '-', 'National', ',', 'Double', '-', 'Blind', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', 'and', 'Pharmacokinetics', 'of', 'Once', 'Daily', 'Versus', 'Twice', 'Daily', 'Dosing', 'of', 'Genz-112638', 'in', 'Patients', 'With', 'Gaucher', 'Disease', 'Type', '1', 'Who', 'Have', 'Demonstrated', 'Clinical', 'Stability', 'on', 'a', 'Twice', 'Daily', 'Dose', 'of', 'Genz-112638', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'once', 'daily', '(', 'QD', ')', 'versus', 'twice', 'daily', '(', 'BID', ')', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', 'in', 'participants', 'with', 'Gaucher', 'disease', 'type', '1', 'who', 'had', 'demonstrated', 'clinical', 'stability', 'on', 'BID', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', '.', 'The', 'secondary', 'objective', 'was', 'to', 'evaluate', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'Genz-99067', 'when', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', 'was', 'administered', 'QD', 'and', 'BID', 'in', 'participants', 'with', 'Gaucher', 'disease', 'type', '1', 'who', 'had', 'demonstrated', 'clinical', 'stability', 'on', 'BID', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O']",NCT01074944,NCT01074944,"A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638 | The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).","[(169, 180, 'DRUG', 'Genz-112638'), (198, 220, 'CONDITION', 'Gaucher Disease Type 1'), (287, 298, 'DRUG', 'Genz-112638'), (431, 450, 'DRUG', 'eliglustat tartrate'), (452, 463, 'DRUG', 'Genz-112638'), (486, 508, 'CONDITION', 'Gaucher disease type 1'), (566, 585, 'DRUG', 'eliglustat tartrate'), (587, 598, 'DRUG', 'Genz-112638'), (670, 680, 'DRUG', 'Genz-99067'), (686, 705, 'DRUG', 'eliglustat tartrate'), (707, 718, 'DRUG', 'Genz-112638'), (769, 791, 'CONDITION', 'Gaucher disease type 1'), (849, 868, 'DRUG', 'eliglustat tartrate'), (870, 881, 'DRUG', 'Genz-112638')]"
"['Complications', 'of', 'Exchange', 'Transfusion', 'in', 'Neonates', '|', 'Exchange', 'transfusion', 'is', 'effective', 'and', 'considered', 'to', 'be', 'safe', 'procedure', ';', 'however', ',', 'it', 'is', 'not', 'without', 'risks', '.', 'Complications', 'have', 'been', 'reported', 'and', 'mortality', 'rates', 'vary', 'from', '0.5', 'to', '3.3', '%', '.', 'therefore', ',', 'the', 'current', 'recommendation', 'for', 'performing', 'exchange', 'transfusion', 'are', 'based', 'on', 'balance', 'between', 'the', 'risks', 'of', 'encephalopathy', 'and', 'complications', 'related', 'to', 'the', 'procedure', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03195049,NCT03195049,"Complications of Exchange Transfusion in Neonates | Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .","[(17, 37, 'OTHER', 'Exchange Transfusion'), (52, 72, 'OTHER', 'Exchange transfusion'), (287, 307, 'OTHER', 'exchange transfusion'), (350, 364, 'CONDITION', 'encephalopathy')]"
"['Action', 'Observation', 'and', 'Motor', 'Imagery', 'Induced', 'Hypoalgesia', 'in', 'Asymptomatic', 'Subjects', '|', 'This', 'study', 'evaluates', 'the', 'influence', 'of', 'motor', 'imagery', 'and', 'the', 'observation', 'of', 'actions', 'on', 'pain', 'perception', '.', 'Participants', 'in', 'this', 'study', 'are', 'asymptomatic', 'subjects', 'who', 'will', 'perform', 'an', 'IM', 'and', 'AO', 'protocol', 'of', 'an', 'aerobic', 'exercise', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03959449,NCT03959449,Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects | This study evaluates the influence of motor imagery and the observation of actions on pain perception. Participants in this study are asymptomatic subjects who will perform an IM and AO protocol of an aerobic exercise.,"[(0, 18, 'OTHER', 'Action Observation'), (23, 36, 'OTHER', 'Motor Imagery'), (122, 135, 'OTHER', 'motor imagery'), (144, 166, 'OTHER', 'observation of actions'), (170, 174, 'CONDITION', 'pain'), (260, 262, 'OTHER', 'IM'), (267, 269, 'OTHER', 'AO')]"
"['Effectiveness', 'of', 'Qigong', 'vs.', 'Physiotherapy', 'to', 'Improve', 'Quality', 'of', 'Life', 'of', 'Women', 'With', 'Fibromyalgia', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'analyze', 'the', 'effectiveness', 'of', 'a', 'Physiotherapy', 'treatment', 'versus', 'a', 'Qigong', 'exercise', 'programme', 'improving', 'quality', 'of', 'life', 'of', 'subjects', 'with', 'Fibromyalgia', '.']","['O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04328142,NCT04328142,Effectiveness of Qigong vs. Physiotherapy to Improve Quality of Life of Women With Fibromyalgia: A Randomized Controlled Trial | This study analyze the effectiveness of a Physiotherapy treatment versus a Qigong exercise programme improving quality of life of subjects with Fibromyalgia.,"[(17, 23, 'PHYSICAL', 'Qigong'), (28, 41, 'PHYSICAL', 'Physiotherapy'), (83, 95, 'CONDITION', 'Fibromyalgia'), (171, 184, 'PHYSICAL', 'Physiotherapy'), (204, 210, 'PHYSICAL', 'Qigong'), (273, 285, 'CONDITION', 'Fibromyalgia')]"
"['XanaMIA', '-', 'DR', 'A', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Dose', 'Ranging', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Pharmacodynamics', 'and', 'Safety', 'of', 'Xanamem', '®', 'in', 'Healthy', 'Elderly', 'Volunteers', '|', 'Xanamem', '®', 'is', 'being', 'developed', 'as', 'a', 'potential', 'drug', 'for', 'Mild', 'Cognitive', 'Impairment', 'in', 'Alzheimer', ""'s"", 'disease', '.', 'This', 'study', 'drug', 'has', 'been', 'designed', 'to', 'change', 'the', 'cortisol', 'levels', 'in', 'the', 'brain', '.', 'Cortisol', 'is', 'a', 'naturally', 'occurring', 'hormone', 'in', 'the', 'body', '.', 'It', 'is', 'believed', 'that', 'reducing', 'the', 'level', 'of', 'cortisol', 'will', 'be', 'a', 'benefit', 'in', 'the', 'treatment', 'of', 'Mild', 'Cognitive', 'Impairment', 'in', 'Alzheimer', ""'s"", 'disease', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'in', 'older', 'volunteers', 'is', 'to', 'investigate', 'the', 'smallest', 'dose', 'of', 'Xanamem', '®', '(', '5', 'mg', 'or', '10', 'mg', ')', 'which', 'works', 'and', 'to', 'investigate', 'which', 'dose', 'in', 'this', 'study', 'will', 'be', 'used', 'in', 'the', 'upcoming', 'clinical', 'trials', 'in', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04983368,NCT04983368,"XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem® in Healthy Elderly Volunteers | Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's disease.

The purpose of this study in older volunteers is to investigate the smallest dose of Xanamem® (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.","[(27, 34, 'CONTROL', 'Placebo'), (121, 128, 'DRUG', 'Xanamem'), (162, 169, 'DRUG', 'Xanamem'), (622, 629, 'DRUG', 'Xanamem')]"
"['Trans', '-', 'spinal', 'Electrical', 'Stimulation', 'to', 'Restore', 'Upper', 'Extremity', 'Functions', 'in', 'Individuals', 'With', 'Traumatic', 'Brain', 'Injury', '(', 'TBI', ')', 'or', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', '.', '|', 'The', 'objective', 'of', 'this', 'research', 'study', 'is', 'to', 'find', 'the', 'efficacy', 'of', 'trans', '-', 'spinal', 'electrical', 'stimulation', ',', 'a', 'non', '-', 'invasive', 'neurostimulation', 'method', 'to', 'modulate', 'the', 'functions', 'of', 'spinal', 'cord', 'neurocircuits', ',', 'on', 'improving', 'upper', '-', 'extremity', 'functions', 'such', 'as', 'reaching', 'and', 'grasping', 'in', 'individuals', 'suffering', 'with', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', 'or', 'cervical', 'spinal', 'cord', 'injury', '(', 'SCI', ')', ';', 'and', 'to', 'find', 'the', 'physiological', 'changes', 'in', 'the', 'neuromuscular', 'systems', 'after', 'this', 'new', 'intervention', 'with', 'high', '-', 'resolution', 'electrophysiology', 'and', 'biomedical', 'imaging', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04183998,NCT04183998,"Trans-spinal Electrical Stimulation to Restore Upper Extremity Functions in Individuals With Traumatic Brain Injury (TBI) or Spinal Cord Injury (SCI). | The objective of this research study is to find the efficacy of trans-spinal electrical stimulation, a non-invasive neurostimulation method to modulate the functions of spinal cord neurocircuits, on improving upper-extremity functions such as reaching and grasping in individuals suffering with traumatic brain injury (TBI) or cervical spinal cord injury (SCI); and to find the physiological changes in the neuromuscular systems after this new intervention with high-resolution electrophysiology and biomedical imaging.","[(0, 35, 'OTHER', 'Trans-spinal Electrical Stimulation'), (93, 115, 'CONDITION', 'Traumatic Brain Injury'), (117, 120, 'CONDITION', 'TBI'), (125, 143, 'CONDITION', 'Spinal Cord Injury'), (145, 148, 'CONDITION', 'SCI'), (217, 252, 'OTHER', 'trans-spinal electrical stimulation'), (448, 470, 'CONDITION', 'traumatic brain injury'), (472, 475, 'CONDITION', 'TBI'), (480, 507, 'CONDITION', 'cervical spinal cord injury'), (509, 512, 'CONDITION', 'SCI')]"
"['Mild', 'Cognitive', 'Impairment', 'and', 'Obstructive', 'Sleep', 'Apnea', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'has', 'been', 'linked', 'to', 'increased', 'risk', 'for', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', ',', 'but', 'little', 'prospective', 'evidence', 'exists', 'on', 'the', 'effects', 'of', 'OSA', 'treatment', 'in', 'preclinical', 'AD', '.', 'The', 'objective', 'was', 'to', 'determine', 'if', 'CPAP', 'treatment', 'adherence', ',', 'controlling', 'for', 'baseline', 'differences', ',', 'predicts', 'cognitive', 'and', 'everyday', 'function', 'after', '1', 'year', 'in', 'older', 'adults', 'with', 'MCI', 'and', 'to', 'determine', 'effect', 'sizes', 'for', 'a', 'larger', 'trial', '.', 'The', 'aim', 'of', 'the', 'Mild', 'Cognitive', 'Impairment', 'and', 'Obstructive', 'Sleep', 'Apnea', '(', 'Memories', '1', ')', 'trial', 'was', 'to', 'determine', 'whether', 'CPAP', 'treatment', 'adherence', ',', 'controlling', 'for', 'any', 'baseline', 'differences', 'in', 'OSA', 'severity', ',', 'ApoE4', ',', 'and', 'other', 'previously', 'identified', 'demographic', 'and', 'patient', 'factors', ',', 'might', 'predict', 'cognitive', 'and', 'everyday', 'function', 'after', '1', 'year', 'in', 'older', 'adults', 'with', 'amnestic', 'MCI', '.']","['B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01482351,NCT01482351,"Mild Cognitive Impairment and Obstructive Sleep Apnea | Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD. The objective was to determine if CPAP treatment adherence, controlling for baseline differences, predicts cognitive and everyday function after 1 year in older adults with MCI and to determine effect sizes for a larger trial. The aim of the Mild Cognitive Impairment and Obstructive Sleep Apnea (Memories 1) trial was to determine whether CPAP treatment adherence, controlling for any baseline differences in OSA severity, ApoE4, and other previously identified demographic and patient factors, might predict cognitive and everyday function after 1 year in older adults with amnestic MCI.","[(0, 25, 'CONDITION', 'Mild Cognitive Impairment'), (30, 53, 'CONDITION', 'Obstructive Sleep Apnea'), (56, 79, 'CONDITION', 'Obstructive sleep apnea'), (81, 84, 'CONDITION', 'OSA'), (124, 143, 'CONDITION', ""Alzheimer's disease""), (145, 147, 'CONDITION', 'AD'), (207, 210, 'CONDITION', 'OSA'), (224, 238, 'CONDITION', 'preclinical AD'), (274, 278, 'OTHER', 'CPAP'), (413, 416, 'CONDITION', 'MCI'), (482, 507, 'CONDITION', 'Mild Cognitive Impairment'), (512, 535, 'CONDITION', 'Obstructive Sleep Apnea'), (580, 584, 'OTHER', 'CPAP'), (650, 653, 'CONDITION', 'OSA'), (825, 828, 'CONDITION', 'MCI')]"
"['A', 'Phase', 'I', ',', 'Open', '-', 'Label', 'Study', 'of', 'CERE-120', '(', 'Adeno', '-', 'Associated', 'Virus', 'Serotype', '2', '[', 'AAV2]-Neurturin[NTN', ']', 'to', 'Assess', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Intrastriatal', 'Delivery', 'to', 'Subjects', 'With', 'Idiopathic', 'Parkinson', ""'s"", 'Disease', '|', 'This', 'is', 'a', 'Phase', 'I', 'dose', 'escalating', 'open', '-', 'label', 'study', 'designed', 'to', 'assess', 'the', 'safety', ',', 'tolerability', 'and', 'biologic', 'activity', 'of', 'an', 'in', 'vivo', 'AAV2', 'mediated', 'delivery', 'of', 'the', 'gene', 'encoding', 'NTN', '(', 'CERE-120', ')', '.', '\n\n', 'Twelve', '(', 'up', 'to', '18', ')', 'subjects', 'will', 'receive', 'one', 'of', 'two', 'open', '-', 'label', 'doses', 'of', 'CERE-120', 'via', 'bilateral', 'stereotactic', 'injections', 'targeting', 'the', 'putaminal', 'region', 'of', 'the', 'brain', '.', 'Subjects', 'will', 'be', 'enrolled', 'in', 'one', 'of', 'two', 'cohorts', ',', 'a', 'low', '-', 'dose', 'cohort', 'of', 'six', 'subjects', 'followed', 'by', 'a', 'high', 'dose', 'cohort', 'of', 'six', 'subjects', '.', '\n\n', 'The', 'design', 'of', 'this', 'study', 'is', 'such', 'that', 'the', 'primary', 'objective', ',', 'the', 'evaluation', 'of', 'safety', 'and', 'tolerability', ',', 'will', 'be', 'assessed', 'by', 'frequent', 'observations', 'for', 'adverse', 'events', ',', 'clinical', 'laboratory', 'test', 'results', ',', 'imaging', '(', 'MRI', ')', ',', 'neuropsychometric', 'testing', ',', 'and', 'evaluations', 'of', 'disease', 'status', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00252850,NCT00252850,"A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease | This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).

Twelve (up to 18) subjects will receive one of two open-label doses of CERE-120 via bilateral stereotactic injections targeting the putaminal region of the brain. Subjects will be enrolled in one of two cohorts, a low-dose cohort of six subjects followed by a high dose cohort of six subjects.

The design of this study is such that the primary objective, the evaluation of safety and tolerability, will be assessed by frequent observations for adverse events, clinical laboratory test results, imaging (MRI), neuropsychometric testing, and evaluations of disease status.","[(31, 39, 'OTHER', 'CERE-120'), (41, 96, 'OTHER', 'Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]'), (178, 208, 'CONDITION', ""Idiopathic Parkinson's Disease""), (334, 389, 'OTHER', 'in vivo AAV2 mediated delivery of the gene encoding NTN'), (391, 399, 'OTHER', 'CERE-120'), (474, 482, 'OTHER', 'CERE-120')]"
"['Evaluation', 'of', 'The', 'Perceive', ',', 'Recall', ',', 'Plan', 'and', 'Perform', 'Intervention', 'for', 'Persons', 'With', 'Cognitive', 'Impairments', 'After', 'Brain', 'Injuries', 'in', 'Community', 'Rehabilitation', ':', 'Single', 'Case', 'Experimental', 'Study', '|', 'Background', ':', 'There', 'is', 'a', 'need', 'for', 'standardized', 'interventions', 'in', 'community', 'rehabilitation', 'that', 'can', 'improve', 'everyday', 'task', 'performance', 'for', 'older', 'adults', 'with', 'cognitive', 'challenges', 'after', 'acquired', 'brain', 'injury', '.', 'Older', 'adults', 'are', 'often', 'excluded', 'from', 'research', 'due', 'to', 'strict', 'inclusion', 'criteria', '.', 'It', 'is', 'critical', 'for', 'a', 'sustainable', 'health', 'service', 'system', 'that', 'these', 'patients', 'are', 'empowered', 'and', 'reach', 'their', 'maximum', 'level', 'of', 'independence', '.', 'The', 'Perceive', ',', 'Recall', ',', 'Plan', 'and', 'Perform', 'System', '(', 'PRPP', ')', 'of', 'Intervention', 'can', 'be', 'applied', 'by', 'Occupational', 'Therapists', '(', 'OT', ')', 'for', 'clients', 'with', 'cognitive', 'challenges', 'to', 'enhance', 'mastery', 'of', 'needed', 'or', 'desired', 'everyday', 'tasks', '.', 'There', 'is', 'no', 'current', 'evidence', 'for', 'the', 'effectiveness', 'of', 'this', 'intervention', 'for', 'this', 'population', '.', '\n\n', 'Purpose', ':', 'A', 'clinical', 'trial', 'to', 'investigate', 'the', 'effectiveness', 'of', 'the', 'PRPP', 'intervention', 'for', 'older', 'persons', 'with', 'cognitive', 'impairments', 'after', 'brain', 'injury', 'in', 'the', 'context', 'of', 'community', '-', 'based', 'rehabilitation', '.', '\n\n', 'Method', ':', 'In', 'PRPP', 'intervention', 'the', 'OT', 'uses', 'systematically', 'instructions', 'in', 'task', 'training', 'to', 'support', 'a', 'client', 'to', 'use', 'cognitive', 'strategies', 'efficiently', '.', 'The', 'everyday', 'tasks', 'used', 'for', 'training', 'should', 'be', 'valued', 'by', 'the', 'participant', 'and', 'useful', 'in', 'their', 'rehabilitation', '.', 'The', 'tasks', 'could', 'include', 'different', 'parts', 'of', 'morning', 'routines', ',', 'simple', 'or', 'complex', 'meal', 'planning', 'or', 'preparation', ',', 'use', 'of', 'cell', 'phone', ',', 'leisure', 'activities', ',', 'or', 'other', 'household', 'and', 'community', 'activities', '.', 'At', 'best', 'the', 'skills', 'are', 'generalized', 'throughout', 'all', 'everyday', 'activities', ',', 'and', 'the', 'OTs', ""'"", 'role', 'as', 'a', 'cognitive', 'mediator', 'fades', 'as', 'participants', 'internalize', 'the', 'strategies', '.', 'The', 'participants', 'receive', 'PRPP', 'intervention', '3', 'times', 'a', 'week', 'for', '3', 'weeks', ',', 'every', 'session', 'last', 'for', '45', '-', '60', 'minutes', '.', '\n\n', 'The', 'participants', ""'"", 'task', 'mastery', 'and', 'cognitive', 'strategy', 'use', 'will', 'be', 'measured', 'at', 'least', '5', 'times', 'in', 'each', 'phase', ':', 'baseline', ',', 'intervention', ',', 'after', 'the', 'intervention', ',', 'and', '4', 'weeks', 'after', 'the', 'discharge', 'from', 'rehabilitation', '.', 'The', 'measurement', 'scores', 'at', 'baseline', 'act', 'controls', 'and', 'are', 'therefore', 'compared', 'with', 'the', 'other', 'phases', 'for', 'the', 'same', 'participant', '.', 'The', 'same', 'procedure', 'will', 'be', 'repeated', 'for', 'the', 'other', 'participants', ',', 'but', 'then', 'with', 'a', 'staggered', 'intervention', 'phase', '.', 'A', 'staggered', 'intervention', 'phase', 'acts', 'as', 'a', 'control', 'between', 'participants', 'and', 'allows', 'to', 'see', 'if', 'changes', 'occur', 'only', 'when', 'the', 'intervention', 'is', 'introduced', '.', '\n\n', 'Implications', 'for', 'practice', ':', 'The', 'investigators', 'assume', 'that', 'this', 'systematic', 'intervention', 'will', 'improve', 'everyday', 'task', 'performance', ',', 'and', 'will', 'in', 'turn', 'contribute', 'to', 'empowerment', 'and', 'independence', 'of', 'older', 'adults', 'with', 'cognitive', 'challenges', 'after', 'brain', 'injuries', '.']","['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT05148247,NCT05148247,"Evaluation of The Perceive, Recall, Plan and Perform Intervention for Persons With Cognitive Impairments After Brain Injuries in Community Rehabilitation: Single Case Experimental Study | Background: There is a need for standardized interventions in community rehabilitation that can improve everyday task performance for older adults with cognitive challenges after acquired brain injury. Older adults are often excluded from research due to strict inclusion criteria. It is critical for a sustainable health service system that these patients are empowered and reach their maximum level of independence. The Perceive, Recall, Plan and Perform System (PRPP) of Intervention can be applied by Occupational Therapists (OT) for clients with cognitive challenges to enhance mastery of needed or desired everyday tasks. There is no current evidence for the effectiveness of this intervention for this population.

Purpose: A clinical trial to investigate the effectiveness of the PRPP intervention for older persons with cognitive impairments after brain injury in the context of community-based rehabilitation.

Method: In PRPP intervention the OT uses systematically instructions in task training to support a client to use cognitive strategies efficiently. The everyday tasks used for training should be valued by the participant and useful in their rehabilitation. The tasks could include different parts of morning routines, simple or complex meal planning or preparation, use of cell phone, leisure activities, or other household and community activities. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as participants internalize the strategies. The participants receive PRPP intervention 3 times a week for 3 weeks, every session last for 45-60 minutes.

The participants' task mastery and cognitive strategy use will be measured at least 5 times in each phase: baseline, intervention, after the intervention, and 4 weeks after the discharge from rehabilitation. The measurement scores at baseline act controls and are therefore compared with the other phases for the same participant. The same procedure will be repeated for the other participants, but then with a staggered intervention phase. A staggered intervention phase acts as a control between participants and allows to see if changes occur only when the intervention is introduced.

Implications for practice: The investigators assume that this systematic intervention will improve everyday task performance, and will in turn contribute to empowerment and independence of older adults with cognitive challenges after brain injuries.","[(18, 65, 'BEHAVIOURAL', 'Perceive, Recall, Plan and Perform Intervention'), (83, 104, 'CONDITION', 'Cognitive Impairments'), (111, 125, 'CONDITION', 'Brain Injuries'), (129, 153, 'BEHAVIOURAL', 'Community Rehabilitation'), (250, 274, 'BEHAVIOURAL', 'community rehabilitation'), (340, 360, 'CONDITION', 'cognitive challenges'), (376, 388, 'CONDITION', 'brain injury'), (610, 651, 'BEHAVIOURAL', 'Perceive, Recall, Plan and Perform System'), (653, 657, 'BEHAVIOURAL', 'PRPP'), (739, 759, 'CONDITION', 'cognitive challenges'), (976, 980, 'BEHAVIOURAL', 'PRPP'), (1017, 1038, 'CONDITION', 'cognitive impairments'), (1045, 1057, 'CONDITION', 'brain injury'), (1076, 1106, 'BEHAVIOURAL', 'community-based rehabilitation'), (1120, 1124, 'BEHAVIOURAL', 'PRPP'), (1746, 1750, 'BEHAVIOURAL', 'PRPP'), (2242, 2264, 'CONTROL', 'staggered intervention'), (2274, 2296, 'CONTROL', 'staggered intervention'), (2627, 2647, 'CONDITION', 'cognitive challenges'), (2654, 2668, 'CONDITION', 'brain injuries')]"
"['Assessing', 'the', 'Effect', 'of', '1072', 'nm', 'Infrared', '(', 'IR', ')', 'Phototherapy', 'on', 'the', 'Behavioral', 'and', 'Cognitive', 'Symptoms', 'Associated', 'With', 'Early', 'and', 'Mid', '-', 'stage', 'Dementia', ':', 'a', 'Randomized', 'Placebo', '-', 'controlled', 'Clinical', 'Trial', '.', '|', 'This', 'study', 'will', 'employ', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'approach', 'to', 'assess', 'the', 'effect', 'of', '1072', 'nm', 'infrared', '(', 'IR', ')', 'phototherapy', 'on', 'the', 'behavioral', 'and', 'cognitive', 'symptoms', 'associated', 'with', 'early', 'and', 'mid', '-', 'stage', 'dementia', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01059877,NCT01059877,"Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial. | This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.","[(24, 57, 'OTHER', '1072nm Infrared (IR) Phototherapy'), (115, 144, 'CONDITION', 'Early and Mid-stage Dementia:'), (234, 241, 'CONTROL', 'placebo'), (286, 319, 'OTHER', '1072nm infrared (IR) phototherapy'), (377, 405, 'CONDITION', 'early and mid-stage dementia')]"
"['Robotic', 'Walking', 'for', 'Children', 'Who', 'Can', 'not', 'Walk', '|', 'A', 'common', 'problem', 'among', 'children', 'with', 'nervous', 'system', 'disorders', 'is', 'difficulty', 'walking', 'on', 'their', 'own', '.', 'This', 'has', 'impacts', 'beyond', 'mobility', 'including', 'short', 'and', 'long', '-', 'term', 'health', 'conditions', 'associated', 'with', 'physical', 'inactivity', 'and', 'different', 'developmental', 'experiences', 'as', 'a', 'result', 'of', 'the', 'mobility', 'impairments', '.', 'A', 'robotic', 'trainer', 'can', 'both', 'provide', 'rehabilitation', 'and', 'be', 'an', 'assistive', 'device', 'to', 'help', 'compensate', 'for', 'difficulties', '.', 'Figuring', 'out', 'how', 'to', 'prescribe', 'it', 'is', 'critical', 'to', 'improve', 'daily', 'life', 'for', 'children', 'with', 'significant', 'disabilities', '.', 'Preliminary', 'use', 'of', 'robotic', 'trainers', 'have', 'shown', 'many', 'benefits', ',', 'such', 'as', 'better', 'head', 'control', 'and', 'improved', 'independence', 'in', 'transfers', ',', 'which', 'greatly', 'increases', 'ability', 'to', 'live', 'independently', '.', 'Additionally', ',', 'vital', 'functions', 'that', 'are', 'frequently', 'impaired', 'in', 'those', 'with', 'less', 'physical', 'activity', ',', 'such', 'as', 'sleep', 'and', 'bowel', 'habits', ',', 'seem', 'to', 'improve', '.', 'Finally', ',', 'these', 'children', 'enjoy', 'using', 'them', '.', '\n\n', 'This', 'project', 'aims', 'to', 'determine', 'who', 'is', 'most', 'likely', 'to', 'benefit', 'from', 'training', 'with', 'a', 'robotic', 'trainer', 'and', 'investigate', 'key', 'details', 'about', 'the', 'dose', 'of', 'training', 'that', 'is', 'needed', '.', 'Families', 'that', 'are', 'already', 'using', 'or', 'hope', 'to', 'use', 'robotic', 'training', 'need', 'this', 'data', 'to', 'help', 'improve', 'their', 'access', 'to', 'the', 'intervention', '.', 'Clinicians', 'need', 'this', 'systematic', 'approach', 'to', 'building', 'evidence', 'to', 'ensure', 'a', 'future', 'multi', '-', 'centre', 'randomized', 'control', 'trial', 'is', 'well', 'designed', '.', 'This', 'study', 'is', 'needed', 'to', 'help', 'improve', 'the', 'lives', 'of', 'those', 'who', 'live', 'with', 'significant', 'disabilities', '.', 'The', 'objective', 'is', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'delivering', 'robotic', 'gait', 'training', 'at', 'home', '.', 'Integral', 'in', 'this', 'study', 'is', 'capturing', 'the', 'user', 'perspectives', '.', 'This', 'will', 'both', 'provide', 'preliminary', 'evidence', '-', 'based', 'advice', 'to', 'potential', 'users', ',', 'their', 'families', ',', 'and', 'clinicians', 'as', 'well', 'as', 'provide', 'key', 'metrics', 'to', 'design', 'a', 'definitive', 'multi', '-', 'centre', 'randomized', 'control', 'trial', '.', '\n\n', 'The', 'investigators', 'will', 'provide', 'robotic', 'gait', 'trainers', ',', 'specifically', 'Trexo', 'robotic', 'gait', 'trainers', ',', 'to', 'participants', 'and', 'their', 'families', 'to', 'use', 'in', 'their', 'home', 'communities', 'for', '12', 'weeks', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'intensive', 'robotic', 'gait', 'training', 'in', 'people', 'who', 'can', 'not', 'walk', 'independently', '.', 'Assessments', 'will', 'be', 'completed', 'throughout', 'the', 'duration', 'of', 'study', ',', 'including', 'before', ',', 'during', ',', 'and', 'after', 'the', 'training', 'intervention', ',', 'with', 'the', 'goal', 'of', 'evaluating', 'a', 'wide', 'range', 'of', 'feasibility', 'considerations', 'and', 'impacts', 'from', 'robotic', 'training', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O']",NCT05473676,NCT05473676,"Robotic Walking for Children Who Cannot Walk | A common problem among children with nervous system disorders is difficulty walking on their own. This has impacts beyond mobility including short and long-term health conditions associated with physical inactivity and different developmental experiences as a result of the mobility impairments. A robotic trainer can both provide rehabilitation and be an assistive device to help compensate for difficulties. Figuring out how to prescribe it is critical to improve daily life for children with significant disabilities. Preliminary use of robotic trainers have shown many benefits, such as better head control and improved independence in transfers, which greatly increases ability to live independently. Additionally, vital functions that are frequently impaired in those with less physical activity, such as sleep and bowel habits, seem to improve. Finally, these children enjoy using them.

This project aims to determine who is most likely to benefit from training with a robotic trainer and investigate key details about the dose of training that is needed. Families that are already using or hope to use robotic training need this data to help improve their access to the intervention. Clinicians need this systematic approach to building evidence to ensure a future multi-centre randomized control trial is well designed. This study is needed to help improve the lives of those who live with significant disabilities. The objective is to evaluate the feasibility and impacts of delivering robotic gait training at home. Integral in this study is capturing the user perspectives. This will both provide preliminary evidence-based advice to potential users, their families, and clinicians as well as provide key metrics to design a definitive multi-centre randomized control trial.

The investigators will provide robotic gait trainers, specifically Trexo robotic gait trainers, to participants and their families to use in their home communities for 12 weeks to evaluate the feasibility and impacts of intensive robotic gait training in people who cannot walk independently. Assessments will be completed throughout the duration of study, including before, during, and after the training intervention, with the goal of evaluating a wide range of feasibility considerations and impacts from robotic training.","[(0, 15, 'PHYSICAL', 'Robotic Walking'), (321, 341, 'CONDITION', 'mobility impairments'), (345, 360, 'PHYSICAL', 'robotic trainer'), (587, 603, 'PHYSICAL', 'robotic trainers'), (1024, 1039, 'PHYSICAL', 'robotic trainer'), (1158, 1174, 'PHYSICAL', 'robotic training'), (1544, 1565, 'PHYSICAL', 'robotic gait training'), (1867, 1888, 'PHYSICAL', 'robotic gait trainers'), (1903, 1930, 'PHYSICAL', 'Trexo robotic gait trainers'), (2066, 2087, 'PHYSICAL', 'robotic gait training'), (2344, 2360, 'PHYSICAL', 'robotic training')]"
"['The', 'purpose', 'is', 'to', 'compare', 'the', 'effects', 'of', 'tDCS', 'and', 'constraint', 'induced', 'movement', 'therapy', '(', 'CIMT', ')', 'in', 'the', 'premotor', 'cortex', 'vs.', 'primary', 'motor', 'cortex', 'in', 'severely', 'subacute', 'stroke', 'survivors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O']",NCT02628561,NCT02628561,The purpose is to compare the effects of tDCS and constraint induced movement therapy (CIMT) in the premotor cortex vs. primary motor cortex in severely subacute stroke survivors.,"[(41, 45, 'OTHER', 'tDCS'), (50, 85, 'PHYSICAL', 'constraint induced movement therapy'), (87, 91, 'PHYSICAL', 'CIMT'), (144, 168, 'CONDITION', 'severely subacute stroke')]"
"['Effect', 'of', 'Neural', 'Mobilization', 'Techniques', 'on', 'Pain', ',', 'and', 'Hip', 'and', 'Knee', 'Range', 'of', 'Motion', 'on', 'Lumbosacral', 'Radiculopathy', 'Patients', 'With', 'Peripheral', 'Sensitization', '|', 'The', 'primary', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'effects', 'of', 'slider', 'and', 'tensioner', 'techniques', 'on', 'pain', ',', 'hip', 'and', 'knee', 'ROM', 'in', 'lumbosacral', 'radiculopathy', 'patients', 'with', 'peripheral', 'sensitization', '.', 'A', 'secondary', 'purpose', 'was', 'to', 'evaluate', 'the', 'correlation', 'between', 'these', 'outcomes', 'measurements', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03621878,NCT03621878,"Effect of Neural Mobilization Techniques on Pain, and Hip and Knee Range of Motion on Lumbosacral Radiculopathy Patients With Peripheral Sensitization | The primary purpose of this study was to investigate the effects of slider and tensioner techniques on pain, hip and knee ROM in lumbosacral radiculopathy patients with peripheral sensitization. A secondary purpose was to evaluate the correlation between these outcomes measurements.","[(10, 40, 'PHYSICAL', 'Neural Mobilization Techniques'), (44, 48, 'CONDITION', 'Pain'), (86, 111, 'CONDITION', 'Lumbosacral Radiculopathy'), (126, 150, 'CONDITION', 'Peripheral Sensitization'), (221, 252, 'PHYSICAL', 'slider and tensioner techniques'), (256, 260, 'CONDITION', 'pain'), (282, 307, 'CONDITION', 'lumbosacral radiculopathy'), (322, 346, 'CONDITION', 'peripheral sensitization')]"
"['Hypersensitivity', 'to', 'Phosphodiesterase', '5', 'Inhibition', 'in', 'Post', '-', 'Traumatic', 'Headache', ':', 'A', 'Randomized', 'Clinical', 'Trial', '|', 'To', 'investigate', 'whether', 'sildenafil', '(', 'phosphodiesterase', '5', 'inhibitor', ')', 'induces', 'migraine', '-', 'like', 'headache', 'in', 'people', 'with', 'persistent', 'post', '-', 'traumatic', 'headache', '(', 'PTH', ')', 'attributed', 'to', 'mild', 'traumatic', 'brain', 'injury', '(', 'mTBI', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05669885,NCT05669885,Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache: A Randomized Clinical Trial | To investigate whether sildenafil (phosphodiesterase 5 inhibitor) induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).,"[(54, 77, 'CONDITION', 'Post-Traumatic Headache'), (183, 191, 'CONDITION', 'migraine'), (197, 205, 'CONDITION', 'headache'), (221, 255, 'CONDITION', 'persistent post-traumatic headache'), (257, 260, 'CONDITION', 'PTH'), (276, 303, 'CONDITION', 'mild traumatic brain injury'), (305, 309, 'CONDITION', 'mTBI')]"
"['Abobotulinumtoxina', 'Efficacy', 'in', 'Post', '-', 'Traumatic', 'Headache', '|', 'This', 'study', 'will', 'evaluate', 'the', 'efficacy', 'of', 'abobotulinumtoxina', 'on', 'Veterans', 'with', 'post', '-', 'traumatic', 'headache']","['B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",NCT03928496,NCT03928496,Abobotulinumtoxina Efficacy in Post-Traumatic Headache | This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache,"[(0, 18, 'DRUG', 'Abobotulinumtoxina'), (31, 54, 'CONDITION', 'Post-Traumatic Headache'), (98, 116, 'DRUG', 'abobotulinumtoxina'), (134, 157, 'CONDITION', 'post-traumatic headache')]"
"['Predictors', 'of', 'Response', 'to', 'an', 'Intensive', 'Bimanual', 'Intervention', 'in', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'Motor', 'disorders', 'related', 'to', 'cerebral', 'palsy', 'are', 'often', 'accompanied', 'by', 'sensory', ',', 'cognitive', ',', 'perceptive', ',', 'communication', 'and', 'behavioural', 'impairments', '.', 'It', 'has', 'already', 'been', 'shown', 'that', 'intensive', 'bimanual', 'intervention', 'can', 'improve', 'arm', 'movement', ',', 'but', 'its', 'impact', 'on', 'the', 'spontaneous', 'use', 'of', 'the', 'most', 'affected', 'arm', 'in', 'everyday', 'life', 'remains', 'to', 'be', 'established', '.', 'This', 'project', 'aims', 'to', 'understand', 'the', 'impacts', 'of', 'an', 'intensive', 'bimanual', 'therapy', 'on', 'uni-', 'and', 'bi', '-', 'manual', 'motor', 'functions', 'as', 'well', 'as', 'the', 'spontaneous', 'use', 'of', 'the', 'most', 'affected', 'arm', '.', 'Predictive', 'value', 'of', 'neuroimaging', 'variables', 'will', 'also', 'be', 'assessed', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05423171,NCT05423171,"Predictors of Response to an Intensive Bimanual Intervention in Children With Cerebral Palsy | Motor disorders related to cerebral palsy are often accompanied by sensory, cognitive, perceptive, communication and behavioural impairments. It has already been shown that intensive bimanual intervention can improve arm movement, but its impact on the spontaneous use of the most affected arm in everyday life remains to be established. This project aims to understand the impacts of an intensive bimanual therapy on uni- and bi-manual motor functions as well as the spontaneous use of the most affected arm. Predictive value of neuroimaging variables will also be assessed.","[(29, 60, 'PHYSICAL', 'Intensive Bimanual Intervention'), (78, 92, 'CONDITION', 'Cerebral Palsy'), (122, 136, 'CONDITION', 'cerebral palsy'), (268, 299, 'PHYSICAL', 'intensive bimanual intervention'), (483, 509, 'PHYSICAL', 'intensive bimanual therapy')]"
"['Effects', 'and', 'Underlying', 'Mechanisms', 'of', 'Photobiomodulation', '(', 'PBM', ')', 'on', 'Health', 'and', 'Well', '-', 'Being', '|', 'The', 'goal', 'of', 'this', 'clinical', 'study', 'is', 'to', 'assess', 'the', 'effects', 'of', 'different', 'photobiomodulation', '(', 'PBM', ')', 'conditions', 'in', 'men', 'and', 'women', 'between', '25', 'and', '65', 'years', 'old', 'with', 'daytime', 'sleepiness', '/', 'drowsiness', 'and', '/or', 'mild', 'mood', 'complaints', 'but', 'be', 'otherwise', 'healthy', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'Does', 'PBM', 'significantly', 'affect', 'health', 'and', 'well', '-', 'being', '?', '\n', 'Are', 'PBM', 'effects', 'wavelength', 'dependent', '?', '\n', 'Are', 'PBM', 'effects', 'pulse', 'dependent', '?', '\n', 'Are', 'the', 'eyes', 'needed', 'to', 'assert', 'an', 'PBM', 'effect', 'or', 'is', 'exposure', 'only', 'to', 'the', 'skin', 'sufficient', '?', '\n', 'What', 'are', 'the', 'cellular', ',', 'metabolic', 'pathways', 'underlying', 'the', 'systemic', 'effects', 'of', 'PBM', '.', '\n\n', 'Participants', 'will', 'have', 'to', ':', '\n\n', 'Exposed', 'themselves', '5', 'times', 'per', 'week', 'during', '2', 'weeks', 'to', 'the', 'PBM', 'stimuli', 'between', '9:30', 'and', '12:30', '.', '\n', 'A', 'week', 'before', 'the', 'baseline', 'measurement', ',', 'participants', 'will', 'have', 'to', 'start', 'wearing', 'a', 'Fitbit', 'Versa', '3', ',', 'and', 'will', 'have', 'to', 'continuously', 'wear', 'until', 'the', 'end', 'of', 'the', 'study', '.', '\n', 'In', 'the', 'afternoon', 'of', 'the', 'baseline', 'day', 'as', 'well', 'as', 'in', 'the', 'afternoons', 'after', '5', 'and', '10', 'PBM', 'sessions', '(', 'week', '1', 'and', 'week', '2', ',', 'respectively', ')', ',', 'participants', 'will', 'have', 'to', 'go', 'to', 'the', 'lab', 'for', 'blood', 'withdraw', '.', '\n', 'In', 'the', 'evening', 'of', 'the', 'baseline', 'day', 'as', 'well', 'as', 'in', 'the', 'evenings', 'after', '5', 'and', '10', 'PBM', 'sessions', '(', 'week', '1', 'and', 'week', '2', ',', 'respectively', ')', ',', 'participants', 'will', 'have', 'to', 'collect', 'saliva', 'samples', 'as', 'well', 'as', 'to', 'complete', 'questionnaires', '.', '\n\n', 'It', 'will', 'be', 'a', 'double', '-', 'blind', 'placebo', '-', 'controlled', 'field', 'study', 'with', 'a', 'between', 'subject', 'comparison', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05619133,NCT05619133,"Effects and Underlying Mechanisms of Photobiomodulation (PBM) on Health and Well-Being | The goal of this clinical study is to assess the effects of different photobiomodulation (PBM) conditions in men and women between 25 and 65 years old with daytime sleepiness/drowsiness and /or mild mood complaints but be otherwise healthy. The main question it aims to answer are:

Does PBM significantly affect health and well-being?
Are PBM effects wavelength dependent?
Are PBM effects pulse dependent?
Are the eyes needed to assert an PBM effect or is exposure only to the skin sufficient?
What are the cellular, metabolic pathways underlying the systemic effects of PBM.

Participants will have to:

Exposed themselves 5 times per week during 2 weeks to the PBM stimuli between 9:30 and 12:30.
A week before the baseline measurement, participants will have to start wearing a Fitbit Versa 3, and will have to continuously wear until the end of the study.
In the afternoon of the baseline day as well as in the afternoons after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to go to the lab for blood withdraw.
In the evening of the baseline day as well as in the evenings after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to collect saliva samples as well as to complete questionnaires.

It will be a double-blind placebo-controlled field study with a between subject comparison.","[(37, 55, 'OTHER', 'Photobiomodulation'), (57, 60, 'OTHER', 'PBM'), (159, 177, 'OTHER', 'photobiomodulation'), (179, 182, 'OTHER', 'PBM'), (245, 263, 'CONDITION', 'daytime sleepiness'), (264, 274, 'CONDITION', 'drowsiness'), (283, 303, 'CONDITION', 'mild mood complaints'), (377, 380, 'OTHER', 'PBM'), (429, 432, 'OTHER', 'PBM'), (467, 470, 'OTHER', 'PBM'), (529, 532, 'OTHER', 'PBM'), (661, 664, 'OTHER', 'PBM'), (753, 756, 'OTHER', 'PBM'), (871, 885, 'OTHER', 'Fitbit Versa 3'), (1031, 1034, 'OTHER', 'PBM'), (1216, 1219, 'OTHER', 'PBM'), (1379, 1386, 'CONTROL', 'placebo')]"
"['Comparison', 'of', 'Aquatic', 'and', 'Land', '-', 'based', 'Group', 'Exercise', 'for', 'Individuals', 'With', 'Parkinson', 'Disease', '|', 'This', 'study', 'will', 'investigate', 'the', 'impact', 'of', 'land', 'based', 'or', 'aquatic', 'based', 'group', 'exercise', 'on', 'the', 'balance', ',', 'walking', ',', 'balance', 'confidence', ',', 'and', 'quality', 'of', 'life', 'of', 'people', 'with', 'idiopathic', 'Parkinson', 'disease', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'participate', 'in', 'a', 'land', 'based', 'or', 'aquatic', 'based', 'group', 'exercise', 'program', '2', 'times', 'per', 'week', 'for', '12', 'weeks', '.', 'Prior', 'to', 'and', 'after', 'participation', ',', 'balance', ',', 'walking', ',', 'quality', 'of', 'life', ',', 'and', 'balance', 'confidence', 'will', 'be', 'measured', 'by', 'a', 'blinded', 'examiner', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04291027,NCT04291027,"Comparison of Aquatic and Land-based Group Exercise for Individuals With Parkinson Disease | This study will investigate the impact of land based or aquatic based group exercise on the balance, walking, balance confidence, and quality of life of people with idiopathic Parkinson disease. Participants will be randomized to participate in a land based or aquatic based group exercise program 2 times per week for 12 weeks. Prior to and after participation, balance, walking, quality of life, and balance confidence will be measured by a blinded examiner.","[(14, 51, 'PHYSICAL', 'Aquatic and Land-based Group Exercise'), (73, 90, 'CONDITION', 'Parkinson Disease'), (135, 177, 'PHYSICAL', 'land based or aquatic based group exercise'), (258, 286, 'CONDITION', 'idiopathic Parkinson disease'), (340, 390, 'PHYSICAL', 'land based or aquatic based group exercise program')]"
"['A', 'Phase', '2', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', ',', 'Tolerability', ',', 'Efficacy', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'Patients', '|', 'AOC', '1001', '-', 'CS2', '(', 'MARINA', '-', 'OLE', ')', 'is', 'a', 'Phase', '2', 'extension', 'of', 'the', 'AOC', '1001', '-', 'CS1', '(', 'MARINA', ')', 'study', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'efficacy', ',', 'pharmacokinetics', 'and', 'pharmacodynamics', 'of', 'multiple', '-', 'doses', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'patients']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05479981,NCT05479981,"A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients | AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients","[(126, 134, 'DRUG', 'AOC 1001'), (171, 196, 'CONDITION', 'Myotonic Dystrophy Type 1'), (198, 201, 'CONDITION', 'DM1'), (405, 413, 'DRUG', 'AOC 1001'), (450, 475, 'CONDITION', 'Myotonic Dystrophy Type 1'), (477, 480, 'CONDITION', 'DM1')]"
"['Impact', 'of', 'a', 'Novel', 'Sleep', 'Apnea', 'Management', 'Group', 'Intervention', 'on', 'Positive', 'Airway', 'Pressure', 'Adherence', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'randomized', 'controlled', 'trial', 'will', 'evaluate', 'people', 'who', 'have', 'moderate', '-', 'to', '-', 'severe', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'and', 'have', 'been', 'newly', 'prescribed', 'a', 'Positive', 'Airway', 'Pressure', '(', 'PAP', ')', 'machine', '.', 'Patients', 'with', 'suboptimal', 'adherence', ',', 'defined', 'by', 'the', 'Center', 'of', 'Medicare', 'and', 'Medicaid', 'criteria', '(', '<', '70', '%', 'usage', 'and', '<', '4', 'hours', 'of', 'average', 'daily', 'PAP', 'usage', ')', 'will', 'be', 'identified', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'examine', 'the', 'impact', 'of', 'the', 'sleep', 'apnea', 'management', '(', 'SAM', ')', 'grouped', 'based', '-', 'intervention', 'on', 'positive', 'airway', 'pressure', 'adherence', 'and', 'patient', 'report', 'outcomes', 'questionnaires', '(', 'quality', 'of', 'life', ',', 'daytime', 'sleepiness', 'and', 'depressive', 'symptoms', ')', 'and', 'PAP', 'barrier', 'questionnaire', 'compared', 'to', 'a', 'patient', 'group', 'managed', 'by', 'regular', 'non', '-', 'sleep', 'prescribing', 'provider', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT03835702,NCT03835702,"Impact of a Novel Sleep Apnea Management Group Intervention on Positive Airway Pressure Adherence: A Randomized Controlled Trial | This randomized controlled trial will evaluate people who have moderate-to-severe obstructive sleep apnea (OSA), and have been newly prescribed a Positive Airway Pressure (PAP) machine. Patients with suboptimal adherence, defined by the Center of Medicare and Medicaid criteria (<70 % usage and <4 hours of average daily PAP usage) will be identified. The purpose of this research is to examine the impact of the sleep apnea management (SAM) grouped based-intervention on positive airway pressure adherence and patient report outcomes questionnaires (quality of life, daytime sleepiness and depressive symptoms) and PAP barrier questionnaire compared to a patient group managed by regular non-sleep prescribing provider.","[(18, 46, 'BEHAVIOURAL', 'Sleep Apnea Management Group'), (63, 87, 'OTHER', 'Positive Airway Pressure'), (194, 236, 'CONDITION', 'moderate-to-severe obstructive sleep apnea'), (238, 241, 'CONDITION', 'OSA'), (277, 301, 'OTHER', 'Positive Airway Pressure'), (303, 306, 'OTHER', 'PAP'), (452, 455, 'OTHER', 'PAP'), (544, 599, 'BEHAVIOURAL', 'sleep apnea management (SAM) grouped based-intervention'), (603, 627, 'OTHER', 'positive airway pressure'), (747, 750, 'OTHER', 'PAP'), (812, 850, 'CONTROL', 'regular non-sleep prescribing provider')]"
"['A', 'Pilot', 'Study', 'of', '68Ga', '-', 'Dotatate', 'PET', 'CT', 'for', 'Radiation', 'Treatment', 'Response', 'Assessment', 'in', 'Meningiomas', '|', 'This', 'phase', 'I', 'trial', 'studies', 'how', 'well', 'gallium', 'Ga', '68', '-', 'DOTATATE', 'positron', 'emission', 'tomography', '(', 'PET)/computed', 'tomography', '(', 'CT', ')', 'works', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.', 'Giving', 'Gallium', 'Ga', '68', '-', 'DOTATATE', 'before', 'PET', '/', 'CT', 'scan', 'may', 'work', 'better', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03953131,NCT03953131,A Pilot Study of 68Ga-Dotatate PET CT for Radiation Treatment Response Assessment in Meningiomas | This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiomas.,"[(85, 96, 'CONDITION', 'Meningiomas'), (268, 279, 'CONDITION', 'meningiomas'), (390, 401, 'CONDITION', 'meningiomas')]"
"['Pilot', 'Study', 'of', 'Continuing', 'Aspirin', 'Versus', 'Switching', 'to', 'Clopidogrel', 'After', 'Stroke', 'or', 'Transient', 'Ischemic', 'Attack', '|', 'Pilot', 'study', 'of', 'continuing', 'aspirin', 'versus', 'switching', 'to', 'clopidogrel', 'after', 'stroke', 'or', 'transient', 'ischemic', 'attack', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00363753,NCT00363753,Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack | Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.,"[(26, 33, 'DRUG', 'Aspirin'), (54, 65, 'DRUG', 'Clopidogrel'), (72, 78, 'CONDITION', 'Stroke'), (82, 107, 'CONDITION', 'Transient Ischemic Attack'), (136, 143, 'DRUG', 'aspirin'), (164, 175, 'DRUG', 'clopidogrel'), (182, 188, 'CONDITION', 'stroke'), (192, 217, 'CONDITION', 'transient ischemic attack')]"
"['Consequences', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'on', 'the', 'Outcome', 'and', 'the', 'Survival', 'After', 'Ischemic', 'Subtentorial', 'Stroke', '.', 'Impact', 'of', 'the', 'Treatment', 'With', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', '|', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'is', 'associated', 'with', 'stroke', 'as', 'a', 'risk', 'factor', 'but', 'little', 'is', 'known', 'about', 'the', 'consequences', 'of', 'OSAS', 'on', 'the', 'outcome', 'and', 'the', 'survival', 'after', 'stroke', '.', 'The', 'aim', 'of', 'the', 'investigators', 'study', 'is', 'first', 'to', 'evaluate', 'the', 'outcome', 'and', 'the', 'survival', 'of', 'patients', 'with', 'stroke', 'depending', 'of', 'OSAS', '(', 'presence', 'and', 'severity', 'of', 'OSAS', ')', 'and', 'second', 'to', 'compare', 'the', 'outcome', 'and', 'survival', 'of', 'patients', 'with', 'severe', 'OSAS', 'depending', 'on', 'the', 'treatment', 'of', 'the', 'syndrome', 'with', 'nocturnal', 'continuous', 'positive', 'airway', 'pressure', '.', 'The', 'investigators', 'hypothesis', 'is', 'that', 'OSAS', 'is', 'associated', 'with', 'worst', 'survival', 'and', 'outcome', 'and', 'needs', 'to', 'be', 'treated', 'at', 'the', 'subacute', 'phase', 'of', 'stroke', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01561677,NCT01561677,Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP) | Obstructive Sleep Apnea Syndrome (OSAS) is associated with stroke as a risk factor but little is known about the consequences of OSAS on the outcome and the survival after stroke. The aim of the investigators study is first to evaluate the outcome and the survival of patients with stroke depending of OSAS (presence and severity of OSAS) and second to compare the outcome and survival of patients with severe OSAS depending on the treatment of the syndrome with nocturnal continuous positive airway pressure. The investigators hypothesis is that OSAS is associated with worst survival and outcome and needs to be treated at the subacute phase of stroke.,"[(16, 48, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (50, 54, 'CONDITION', 'OSAS'), (94, 122, 'CONDITION', 'Ischemic Subtentorial Stroke'), (153, 188, 'OTHER', 'Continuous Positive Airway Pressure'), (190, 194, 'OTHER', 'CPAP'), (198, 230, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (232, 236, 'CONDITION', 'OSAS'), (257, 263, 'CONDITION', 'stroke'), (327, 331, 'CONDITION', 'OSAS'), (370, 376, 'CONDITION', 'stroke'), (480, 486, 'CONDITION', 'stroke'), (500, 504, 'CONDITION', 'OSAS'), (531, 535, 'CONDITION', 'OSAS'), (608, 612, 'CONDITION', 'OSAS'), (671, 706, 'OTHER', 'continuous positive airway pressure'), (745, 749, 'CONDITION', 'OSAS'), (827, 851, 'CONDITION', 'subacute phase of stroke')]"
"['Facing', 'Eating', 'Disorder', 'Fears', 'for', 'Anorexia', 'Nervosa', ':', 'A', 'Virtual', 'Relapse', 'Prevention', 'Program', 'Targeted', 'at', 'Approach', 'and', 'Avoidance', 'Behaviors', '|', 'FED', '-', 'F', 'is', 'a', 'modular', 'treatment', 'that', 'enhances', 'exposure', 'therapy', 'with', 'psychoeducation', 'and', 'cognitive', 'skills', 'teaching', 'how', 'to', 'face', 'fears', 'of', '(', 'a', ')', 'food', ',', '(', 'b', ')', 'weight', 'gain', ',', '(', 'c', ')', 'interoception', '/', 'body', ',', 'and', '(', 'd', ')', 'social', 'situations', '.', 'The', 'study', 'goals', 'are', 'to', '(', '1', ')', 'refine', 'and', 'test', 'the', 'acceptability', 'and', 'feasibility', 'of', 'FED', '-', 'F', 'treatment', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'test', 'if', 'this', 'treatment', 'outperforms', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'delivered', 'post', '-', 'acute', 'treatment', 'as', 'adjunctive', 'to', 'stepdown', 'specialty', 'care', '(', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'to', 'examine', 'if', 'treatment', 'targets', 'the', 'hypothesized', 'mechanism', 'of', 'action', ':', 'approach', 'behaviors', '(', 'Phase', 'II', ')', '.', 'These', 'goals', 'will', 'lead', 'to', 'a', 'highly', 'deployable', 'and', 'accessible', 'virtual', 'treatment', 'targeted', 'at', 'core', 'AN', 'mechanisms', 'that', 'predict', 'relapse', '.', 'Specific', 'aims', 'are', 'to', '(', '1', ')', 'refine', 'FED', '-', 'F', 'into', 'a', 'fully', 'virtual', 'format', 'with', 'input', 'from', 'patients', 'and', 'stakeholders', 'and', 'collect', 'preliminary', 'data', '(', 'N=10', ')', 'on', 'its', 'feasibility', 'and', 'acceptability', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'conduct', 'a', 'small', 'pilot', 'RCT', '(', 'randomized', 'controlled', 'trial', ')', 'of', 'FED', '-', 'F', '(', 'n=30', ')', 'as', 'compared', 'to', 'TAU', '(', 'n=30', ';', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'examine', 'if', 'FED', '-', 'F', 'targets', 'approach', '/', 'avoidance', 'behaviors', 'and', 'test', 'if', 'this', 'mechanism', 'is', 'associated', 'with', 'clinical', 'outcomes', '(', 'Phase', 'II', ')', '.']","['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05596799,NCT05596799,"Facing Eating Disorder Fears for Anorexia Nervosa: A Virtual Relapse Prevention Program Targeted at Approach and Avoidance Behaviors | FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment targets the hypothesized mechanism of action: approach behaviors (Phase II). These goals will lead to a highly deployable and accessible virtual treatment targeted at core AN mechanisms that predict relapse. Specific aims are to (1) refine FED-F into a fully virtual format with input from patients and stakeholders and collect preliminary data (N=10) on its feasibility and acceptability (Phase I), (2) conduct a small pilot RCT (randomized controlled trial) of FED-F (n=30) as compared to TAU (n=30; Phase II), and (3) examine if FED-F targets approach/avoidance behaviors and test if this mechanism is associated with clinical outcomes (Phase II).","[(7, 28, 'CONDITION', 'Eating Disorder Fears'), (33, 49, 'CONDITION', 'Anorexia Nervosa'), (53, 87, 'BEHAVIOURAL', 'Virtual Relapse Prevention Program'), (135, 140, 'BEHAVIOURAL', 'FED-F'), (258, 263, 'CONDITION', 'fears'), (425, 440, 'BEHAVIOURAL', 'FED-F treatment'), (491, 509, 'CONTROL', 'treatment as usual'), (511, 514, 'CONTROL', 'TAU'), (804, 806, 'CONDITION', 'AN'), (872, 877, 'BEHAVIOURAL', 'FED-F'), (1095, 1100, 'BEHAVIOURAL', 'FED-F'), (1123, 1126, 'CONTROL', 'TAU'), (1164, 1169, 'BEHAVIOURAL', 'FED-F')]"
"['Clinical', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Roflumilast', 'in', 'Type', '2', 'Diabetic', 'Patients', 'With', 'Diabetic', 'Neuropathy', '|', 'Evaluation', 'of', 'the', 'side', 'effects', 'and', 'efficacy', 'of', 'roflumilast', 'on', 'glycemic', 'parameters', ',', 'insulin', 'resistance', ',', 'oxidative', 'and', 'inflammatory', 'markers', 'in', 'Type', '2', 'diabetic', 'patients', 'with', 'diabetic', 'neuropathy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05369793,NCT05369793,"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy | Evaluation of the side effects and efficacy of roflumilast on glycemic parameters, insulin resistance, oxidative and inflammatory markers in Type 2 diabetic patients with diabetic neuropathy.","[(53, 64, 'DRUG', 'Roflumilast'), (68, 83, 'CONDITION', 'Type 2 Diabetic'), (98, 117, 'CONDITION', 'Diabetic Neuropathy'), (167, 178, 'DRUG', 'roflumilast'), (261, 276, 'CONDITION', 'Type 2 diabetic'), (291, 310, 'CONDITION', 'diabetic neuropathy')]"
"['Meditation', '-', 'Relaxation', '(', 'MR', 'Therapy', ')', 'for', 'Sleep', 'Paralysis', ':', 'A', 'Pilot', 'Study', 'in', 'Patients', 'With', 'Narcolepsy', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', ',', 'with', 'a', 'small', '-', 'scale', 'pilot', 'study', ',', 'the', 'efficacy', 'of', 'Meditation', 'Relaxation', 'therapy', 'for', 'Sleep', 'Paralyses', 'in', 'patients', 'with', 'narcolepsy', '.', 'The', 'study', 'involves', 'two', 'arms', ',', 'with', 'intervention', 'with', 'Meditation', 'Relaxation', 'therapy', 'or', 'sham', 'over', 'a', 'period', 'of', 'three', 'months', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04483310,NCT04483310,"Meditation-Relaxation (MR Therapy) for Sleep Paralysis: A Pilot Study in Patients With Narcolepsy | The aim of the study is to evaluate, with a small-scale pilot study, the efficacy of Meditation Relaxation therapy for Sleep Paralyses in patients with narcolepsy. The study involves two arms, with intervention with Meditation Relaxation therapy or sham over a period of three months.","[(0, 21, 'BEHAVIOURAL', 'Meditation-Relaxation'), (23, 33, 'BEHAVIOURAL', 'MR Therapy'), (39, 54, 'CONDITION', 'Sleep Paralysis'), (87, 97, 'CONDITION', 'Narcolepsy'), (185, 214, 'BEHAVIOURAL', 'Meditation Relaxation therapy'), (219, 234, 'CONDITION', 'Sleep Paralyses'), (252, 262, 'CONDITION', 'narcolepsy'), (316, 345, 'BEHAVIOURAL', 'Meditation Relaxation therapy'), (349, 353, 'CONTROL', 'sham')]"
"['An', 'Exploratory', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Immune', 'Tolerance', 'Induction', '(', 'ITI', ')', 'in', 'Patients', 'With', 'Pompe', 'Disease', 'Who', 'Have', 'Previously', 'Received', 'Myozyme', '|', 'An', 'exploratory', ',', 'open', '-', 'labeled', 'study', 'of', 'participants', 'with', 'Pompe', 'disease', ',', 'who', 'had', 'previously', 'received', 'Myozyme', '®', '(', 'alglucosidase', 'alfa', ')', 'treatment', ',', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', 'and', 'clinical', 'benefit', 'of', '2', 'Immune', 'Tolerance', 'Induction', '(', 'ITI', ')', 'regimens', 'in', 'combination', 'with', 'Myozyme', '®', '.', 'Eligible', 'participants', 'who', 'were', 'then', 'receiving', 'Myozyme', '®', 'therapy', 'were', 'enrolled', 'into', 'the', 'study', ',', 'and', 'were', 'followed', 'for', 'a', 'minimum', 'of', '18', 'months', 'on', '-', 'study', '(', 'a', '6', '-', 'month', 'ITI', 'treatment', 'module', 'and', 'a', '12', '-', 'month', 'follow', '-', 'up', 'module', 'on', 'Myozyme', '®', 'alone', ')', '.', 'Eligible', 'participants', 'were', 'followed', 'for', 'a', 'minimum', 'of', '18', 'months', 'on', 'treatment', 'or', ',', 'if', 'a', 'participant', 'was', '<', '6', 'months', 'of', 'age', 'at', 'the', 'time', 'of', 'enrollment', ',', 'until', 'the', 'participant', 'was', '2', 'years', 'of', 'age', '.', 'Both', 'cross', '-', 'reacting', 'immunologic', 'material', '(', 'CRIM)-negative', 'and', 'CRIM', '-', 'positive', 'participants', 'were', 'eligible', 'for', 'Regimen', 'A', 'depending', 'if', 'they', 'met', 'the', 'required', 'criteria', '.', 'Regimen', 'B', ',', 'however', ',', 'was', 'limited', 'to', 'CRIM', '-', 'negative', 'participants', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00701701,NCT00701701,"An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme | An exploratory, open-labeled study of participants with Pompe disease, who had previously received Myozyme® (alglucosidase alfa) treatment, to evaluate the efficacy, safety and clinical benefit of 2 Immune Tolerance Induction (ITI) regimens in combination with Myozyme®. Eligible participants who were then receiving Myozyme® therapy were enrolled into the study, and were followed for a minimum of 18 months on-study (a 6-month ITI treatment module and a 12-month follow-up module on Myozyme® alone). Eligible participants were followed for a minimum of 18 months on treatment or, if a participant was <6 months of age at the time of enrollment, until the participant was 2 years of age. Both cross-reacting immunologic material (CRIM)-negative and CRIM-positive participants were eligible for Regimen A depending if they met the required criteria. Regimen B, however, was limited to CRIM-negative participants.","[(51, 77, 'OTHER', 'Immune Tolerance Induction'), (79, 82, 'OTHER', 'ITI'), (101, 114, 'CONDITION', 'Pompe Disease'), (144, 151, 'DRUG', 'Myozyme'), (210, 223, 'CONDITION', 'Pompe disease'), (253, 260, 'DRUG', 'Myozyme'), (263, 281, 'DRUG', 'alglucosidase alfa'), (353, 379, 'OTHER', 'Immune Tolerance Induction'), (381, 384, 'OTHER', 'ITI'), (415, 422, 'DRUG', 'Myozyme'), (471, 478, 'DRUG', 'Myozyme'), (583, 586, 'OTHER', 'ITI'), (639, 646, 'DRUG', 'Myozyme')]"
"['Metformin', 'Experience', 'on', 'Minimal', 'Hepatic', 'Encephalopathy', 'in', 'Patients', 'With', 'Liver', 'Cirrhosis', '|', 'Primary', 'aim', ':', '\n\n', '-To', 'assess', 'the', 'effect', 'of', 'metformin', 'use', 'on', 'the', 'treatment', 'of', 'minimal', 'hepatic', 'encephalopathy', 'in', 'patients', 'with', 'liver', 'cirrhosis', '.', '\n\n', 'Secondary', 'aim', ':', '\n\n', '-To', 'evaluate', 'if', 'metformin', 'is', 'a', 'safety', 'drug', 'in', 'patients', 'showing', 'liver', 'cirrhosis', '.']","['B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02470546,NCT02470546,"Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis | Primary aim:

-To assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Secondary aim:

-To evaluate if metformin is a safety drug in patients showing liver cirrhosis.","[(0, 9, 'DRUG', 'Metformin'), (24, 54, 'CONDITION', 'Minimal Hepatic Encephalopathy'), (72, 87, 'CONDITION', 'Liver Cirrhosis'), (129, 138, 'DRUG', 'metformin'), (163, 193, 'CONDITION', 'minimal hepatic encephalopathy'), (211, 226, 'CONDITION', 'liver cirrhosis'), (261, 270, 'DRUG', 'metformin'), (308, 323, 'CONDITION', 'liver cirrhosis')]"
"['Exploring', 'the', 'Effects', 'of', 'Spinal', 'Cord', 'Stimulation', 'in', 'Parkinson', ""'s"", 'Disease', '.', '|', 'Parkinson', 'Disease', '(', 'PD', ')', 'patients', 'experience', 'a', 'variety', 'of', 'motor', 'issues', 'such', 'as', 'walking', 'difficulties', ',', 'loss', 'of', 'balance', ',', 'and', 'freezing', 'while', 'walking', ',', 'which', 'impacts', 'their', 'quality', 'of', 'life', '.', 'Some', 'symptoms', ',', 'like', 'freezing', 'of', 'gait', '(', 'FOG', ')', ',', 'do', 'not', 'respond', 'to', 'medications', 'typically', 'used', 'to', 'treat', 'PD', '.', 'Current', 'surgical', 'procedures', 'used', 'to', 'alleviate', 'PD', 'symptoms', 'also', 'do', 'not', 'always', 'improve', 'FOG', '.', 'Since', 'many', 'traditional', 'therapies', 'have', 'failed', 'for', 'the', 'treatment', 'of', 'FOG', ',', 'researchers', 'have', 'proposed', 'the', 'use', 'of', 'newer', 'treatments', '.', 'Recent', 'research', 'in', 'animal', 'models', 'and', 'clinical', 'human', 'data', 'using', 'SCS', 'has', 'produced', 'promising', 'results', ',', 'specifically', 'showing', 'improvement', 'in', 'FOG', 'with', 'the', 'use', 'of', 'SCS', 'in', 'patients', 'with', 'PD', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'spinal', 'cord', 'stimulation', '(', 'SCS', ')', 'for', 'the', 'management', 'of', 'freezing', 'of', 'gait', '(', 'FOG', ')', 'that', 'does', 'not', 'respond', 'to', 'conventional', 'treatments', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'investigators', 'hypothesize', 'that', 'SCS', 'significantly', 'decreases', 'FOG', 'episodes', 'in', 'patients', 'with', 'PD', '.', '\n\n', 'Assess', 'the', 'safety', ',', 'tolerability', 'and', 'preliminary', 'evidence', 'of', 'effectiveness', 'of', 'upper', 'thoracic', 'spinal', 'cord', 'stimulation', 'for', 'freezing', 'of', 'gait', 'in', 'Parkinson', ""'s"", '(', 'PD', ')', 'patients', '.', '\n', 'Explore', 'the', 'effects', 'of', 'two', 'SCS', 'programming', 'paradigms', 'on', 'motor', ',', 'nonmotor', 'and', 'quality', 'of', 'life', 'measures', 'in', 'PD', 'patients', 'with', 'freezing', 'of', 'gait', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03526991,NCT03526991,"Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. | Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using SCS has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD.

The purpose of this study is to evaluate the effectiveness of spinal cord stimulation (SCS) for the management of freezing of gait (FOG) that does not respond to conventional treatments in subjects with Parkinson's disease (PD). The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD.

Assess the safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients.
Explore the effects of two SCS programming paradigms on motor, nonmotor and quality of life measures in PD patients with freezing of gait.","[(25, 48, 'OTHER', 'Spinal Cord Stimulation'), (52, 71, 'CONDITION', ""Parkinson's Disease""), (75, 92, 'CONDITION', 'Parkinson Disease'), (94, 96, 'CONDITION', 'PD'), (195, 217, 'CONDITION', 'freezing while walking'), (276, 292, 'CONDITION', 'freezing of gait'), (294, 297, 'CONDITION', 'FOG'), (354, 356, 'CONDITION', 'PD'), (404, 406, 'CONDITION', 'PD'), (443, 446, 'CONDITION', 'FOG'), (514, 517, 'CONDITION', 'FOG'), (637, 640, 'OTHER', 'SCS'), (709, 712, 'CONDITION', 'FOG'), (729, 732, 'OTHER', 'SCS'), (750, 752, 'CONDITION', 'PD'), (817, 840, 'OTHER', 'spinal cord stimulation'), (842, 845, 'OTHER', 'SCS'), (869, 885, 'CONDITION', 'freezing of gait'), (887, 890, 'CONDITION', 'FOG'), (958, 977, 'CONDITION', ""Parkinson's disease""), (979, 981, 'CONDITION', 'PD'), (1019, 1022, 'OTHER', 'SCS'), (1047, 1050, 'CONDITION', 'FOG'), (1077, 1079, 'CONDITION', 'PD'), (1159, 1197, 'OTHER', 'upper thoracic spinal cord stimulation'), (1202, 1218, 'CONDITION', 'freezing of gait'), (1222, 1233, 'CONDITION', ""Parkinson's""), (1235, 1237, 'CONDITION', 'PD'), (1276, 1279, 'OTHER', 'SCS'), (1353, 1355, 'CONDITION', 'PD'), (1370, 1386, 'CONDITION', 'freezing of gait')]"
"['An', 'Ascending', 'Multiple', 'Dose', 'Study', 'of', 'the', 'Safety', ',', 'Pharmacokinetics', '(', 'PK', ')', ',', 'and', 'Pharmacodynamics', '(', 'PD', ')', 'of', 'SAM-531', 'Administered', 'Orally', 'to', 'Healthy', 'Young', 'and', 'Elderly', 'Subjects', '|', 'To', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'ascending', 'multiple', 'oral', 'doses', 'of', 'SAM-531', ',', 'an', 'investigational', 'drug', ',', 'in', 'healthy', 'young', 'adult', 'and', 'elderly', 'subjects', '.', 'To', 'assess', 'the', 'pharmacokinetics', '(', 'PK', ')', 'and', 'pharmacodynamics', '(', 'PD', ')', 'profiles', 'of', 'multiple', 'oral', 'doses', 'of', 'SAM-531', 'in', 'healthy', 'young', 'adult', 'and', 'elderly', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00480818,NCT00480818,"An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects | To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.","[(100, 107, 'DRUG', 'SAM-531'), (242, 249, 'DRUG', 'SAM-531'), (417, 424, 'DRUG', 'SAM-531')]"
"['Octreotide', 'Efficacy', 'and', 'Safety', 'in', 'First', '-', 'line', 'Acromegalic', 'Patients', '|', 'Primary', 'Acromegaly', 'is', 'a', 'clinical', 'and', 'metabolic', 'disease', 'caused', 'by', 'growth', 'hormone', '(', 'GH', ')', 'hypersecretion', 'from', 'a', 'pituitary', 'adenoma', 'and', 'is', 'an', 'insidious', ',', 'chronic', 'disease', 'that', 'is', 'associated', 'with', 'bony', 'and', 'soft', 'tissue', 'overgrowth', '.', 'Goals', 'of', 'therapy', 'are', 'to', 'eradicate', 'the', 'tumor', ',', 'suppress', 'GH', 'secretion', ',', 'normalize', 'IGF', '-', 'I', 'levels', ',', 'and', 'preserve', 'normal', 'pituitary', 'function', '.', '\n\n', 'This', 'study', 'will', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'octreotide', 'as', 'primary', 'therapy', 'for', 'the', 'treatment', 'of', 'acromegaly', 'and', 'as', 'therapy', 'for', 'patients', 'with', 'acromegaly', 'and', 'a', 'pituitary', 'macroadenoma', 'or', 'microadenoma', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00171886,NCT00171886,"Octreotide Efficacy and Safety in First-line Acromegalic Patients | Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth. Goals of therapy are to eradicate the tumor, suppress GH secretion, normalize IGF-I levels, and preserve normal pituitary function.

This study will evaluate the safety and efficacy of octreotide as primary therapy for the treatment of acromegaly and as therapy for patients with acromegaly and a pituitary macroadenoma or microadenoma.","[(0, 10, 'DRUG', 'Octreotide'), (45, 56, 'CONDITION', 'Acromegalic'), (68, 86, 'CONDITION', 'Primary Acromegaly'), (175, 192, 'CONDITION', 'pituitary adenoma'), (472, 482, 'DRUG', 'octreotide'), (523, 533, 'CONDITION', 'acromegaly'), (567, 577, 'CONDITION', 'acromegaly'), (584, 606, 'CONDITION', 'pituitary macroadenoma'), (610, 622, 'CONDITION', 'microadenoma')]"
"['Defining', 'Targets', 'for', 'Tic', 'Detection', 'and', 'Suppression', 'in', 'Tourette', 'Syndrome', 'Deep', 'Brain', 'Stimulation', '|', 'The', 'investigators', 'will', 'implant', 'and', 'monitor', '8', 'research', 'subjects', 'with', 'a', 'subcortical', 'closed', '-', 'loop', 'system', 'for', 'detection', 'and', 'suppression', 'of', 'tics', '.', 'The', 'project', 'will', 'use', 'the', 'FDA', '-', 'approved', '""', 'Medtronic', 'Percept', 'PC', '""', 'device', ',', 'which', 'is', 'an', 'implantable', 'neurostimulator', 'capable', 'of', 'recording', 'neural', 'signals', '.', 'The', 'study', 'will', 'target', 'the', 'CM', 'nucleus', 'of', 'the', 'thalamus', 'and', 'the', 'aGPi', 'in', 'each', 'brain', 'hemisphere', 'from', 'each', 'subject', 'and', 'we', 'will', 'connect', 'the', 'two', 'leads', 'placed', 'in', 'each', 'brain', 'hemisphere', 'to', 'two', 'Percept', 'devices', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05371041,NCT05371041,"Defining Targets for Tic Detection and Suppression in Tourette Syndrome Deep Brain Stimulation | The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics. The project will use the FDA-approved ""Medtronic Percept PC"" device, which is an implantable neurostimulator capable of recording neural signals. The study will target the CM nucleus of the thalamus and the aGPi in each brain hemisphere from each subject and we will connect the two leads placed in each brain hemisphere to two Percept devices.","[(21, 24, 'CONDITION', 'Tic'), (54, 71, 'CONDITION', 'Tourette Syndrome'), (72, 94, 'OTHER', 'Deep Brain Stimulation'), (167, 197, 'OTHER', 'subcortical closed-loop system'), (231, 235, 'CONDITION', 'tics'), (276, 296, 'OTHER', 'Medtronic Percept PC'), (318, 345, 'OTHER', 'implantable neurostimulator')]"
"['An', 'Evaluation', 'of', 'the', 'Effectiveness', 'of', 'Adherence', 'Therapy', 'for', 'Schizophrenia', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'When', 'compared', 'with', 'those', 'in', 'the', 'control', '(', 'usual', 'care', ')', 'group', ',', 'participants', 'in', 'the', 'AT', 'group', 'are', 'expected', 'to', 'demonstrate', 'significant', 'improvements', 'immediately', 'and', 'at', 'three', ',', 'six', 'and', '12', 'months', 'after', 'completion', 'of', 'the', 'intervention', 'in', ':', 'level', 'of', 'medication', 'adherence', ',', 'readmission', 'rate', ',', 'mental', 'status', ',', 'insight', 'into', 'treatment', ',', 'and', 'level', 'of', 'functioning', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01780116,NCT01780116,"An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial | When compared with those in the control (usual care) group, participants in the AT group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in: level of medication adherence, readmission rate, mental status, insight into treatment, and level of functioning.","[(38, 55, 'BEHAVIOURAL', 'Adherence Therapy'), (60, 73, 'CONDITION', 'Schizophrenia'), (148, 158, 'CONTROL', 'usual care'), (187, 189, 'BEHAVIOURAL', 'AT')]"
"['Proprioception', 'Testing', 'in', 'Persons', 'With', 'Sensorimotor', 'Impairment', '|', 'In', 'this', 'study', ',', 'an', 'FDA', '-', 'cleared', 'device', 'and', 'type', 'of', 'treatment', 'called', '""', 'AMES', ',', '""', 'which', 'stands', 'for', 'Assisted', 'Movement', 'with', 'Enhanced', 'Sensation', ',', 'will', 'be', 'used', 'to', 'determine', 'whether', 'sensation', 'in', 'the', 'upper', 'limb', 'of', 'individuals', 'with', 'incomplete', 'spinal', 'cord', 'injuries', ',', 'acquired', 'brain', 'injury', ',', 'or', 'stroke', 'improves', 'along', 'with', 'movement', 'through', 'treatment', '.', 'We', 'hypothesize', 'that', 'measureable', 'improvement', 'in', 'the', 'sensation', 'of', 'the', 'upper', 'limb', 'will', 'precede', 'improvement', 'in', 'functional', 'movement', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01974635,NCT01974635,"Proprioception Testing in Persons With Sensorimotor Impairment | In this study, an FDA-cleared device and type of treatment called ""AMES,"" which stands for Assisted Movement with Enhanced Sensation, will be used to determine whether sensation in the upper limb of individuals with incomplete spinal cord injuries, acquired brain injury, or stroke improves along with movement through treatment. We hypothesize that measureable improvement in the sensation of the upper limb will precede improvement in functional movement.","[(39, 62, 'CONDITION', 'Sensorimotor Impairment'), (132, 136, 'PHYSICAL', 'AMES'), (156, 197, 'PHYSICAL', 'Assisted Movement with Enhanced Sensation'), (281, 312, 'CONDITION', 'incomplete spinal cord injuries'), (314, 335, 'CONDITION', 'acquired brain injury'), (340, 346, 'CONDITION', 'stroke')]"
"['Handwriting', 'Interventions', 'for', 'People', 'With', 'Parkinson', ""'s"", '|', 'Background', ':', 'Problems', 'with', 'handwriting', 'are', 'frustrating', 'and', 'debilitating', 'and', 'affect', 'the', 'majority', 'of', 'people', 'with', 'Parkinson', ""'s"", '.', 'Manifest', 'as', 'micrographia', 'it', 'is', 'a', 'distinctive', 'feature', 'of', 'the', 'condition', 'characterised', 'by', 'small', 'handwriting', 'and/or', 'a', 'progressive', 'reduction', 'in', 'size', 'through', 'a', 'sentence[2', ']', 'coupled', 'with', 'a', 'reduction', 'in', 'writing', 'speed', 'and', 'legibility', '.', '\n\n', 'In', 'Parkinson', ""'s"", 'impaired', 'automaticity', 'is', 'thought', 'to', 'contribute', 'to', 'handwriting', 'deficits', 'and', 'attention', 'has', 'been', 'shown', 'to', 'improve', 'both', ""'"", 'consistent', ""'"", '(', 'small', 'handwriting', ')', 'and', ""'"", 'progressive', ""'"", '(', 'progressive', 'reduction', 'in', 'letter', 'size', 'through', 'a', 'sentence', ')', 'aspects', 'of', 'the', 'symptom', '.', 'Moreover', ',', 'recent', 'interventional', 'studies', 'indicate', 'handwriting', 'may', 'be', 'improved', 'through', 'practice', '.', 'This', 'study', 'is', 'investigating', 'a', 'novel', 'handwriting', 'practice', 'stimulus', 'to', 'improve', 'symptoms', 'of', 'micrograpthia', '\n\n', 'Question', ':', 'Is', 'a', 'diverging', 'line', 'cued', 'handwriting', 'intervention', 'potentially', 'more', 'effective', 'at', 'improving', 'symptoms', 'of', 'mircograpthia', 'than', 'a', 'parallel', 'line', 'cued', 'handwriting', 'intervention', 'in', 'people', 'with', 'Parkinson', ""'s"", '?', '\n\n', 'Specifically', ',', 'an', 'assessor', 'blind', 'randomised', 'controlled', 'exploratory', 'trial', 'will', ':', '\n\n', 'Estatimate', 'the', 'effect', 'of', 'the', 'intervention', 'on', 'measures', 'of', ':', 'Handwriting', 'amplitude', '(', 'consistent', 'and', 'progressive', 'reduction', ')', ',', 'hand', 'writing', 'performance', 'and', 'percieved', 'handwriting', 'difficulties', '.', '\n', 'Explore', 'the', 'appropriateness', 'of', 'these', 'outcome', 'measures', '\n', 'Explore', 'the', 'approriateness', 'of', 'eligibilty', 'criteria', '\n', 'Explore', 'intervention', 'fidelity', '\n', 'Explore', 'participants', 'views', 'of', 'the', 'intervention', '\n\n', 'Design', ':', 'A', 'phase', 'II', 'exploratory', 'randomised', 'controlled', 'trial', 'of', 'a', 'handwriting', 'intervention', 'with', 'an', 'active', 'comparator', 'control', 'group', 'and', 'blinded', 'assessments', '\n\n', 'Setting', ':', 'The', 'intervention', 'will', 'be', 'carried', 'out', 'at', 'home', '\n\n', 'Sample', 'size', ':', 'This', 'study', 'is', 'not', 'designed', 'to', 'determine', 'efficacy', '.', 'The', 'aim', 'to', 'recruit', 'a', 'total', 'of', '50', 'people', '(', '25', 'people', 'per', 'group', ')', 'in', 'order', 'to', 'estimate', 'the', 'effects', 'on', 'outcome', 'measures', 'and', 'achieve', 'the', 'aims', 'of', 'this', 'exploratory', 'trial', '.', '\n\n', 'Assessment', ':', 'Participants', 'will', 'be', 'asked', 'to', 'follow', 'their', 'usual', 'Parkinson', ""'s"", 'medication', 'regime', 'and', 'if', 'they', 'have', 'ON', 'and', 'OFF', 'periods', ',', 'assessments', 'will', 'be', 'carried', 'out', 'during', 'ON', 'state', '.', '\n\n', 'Duration', 'and', 'follow', '-', 'up', ':', 'the', 'assessment', 'is', 'schedule', '0Weeks', '(', 'baseline', ')', ',', '6weeks', '(', 'end', 'intervention', ')', 'and', '12weeks', '(', 'follow', 'up', ')', '.', 'Assessments', 'will', 'be', 'carried', 'out', 'by', 'a', 'researcher', 'blind', 'to', 'trial', 'arm', 'allocation', 'using', 'all', 'outcome', 'measures', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03369587,NCT03369587,"Handwriting Interventions for People With Parkinson's | Background: Problems with handwriting are frustrating and debilitating and affect the majority of people with Parkinson's. Manifest as micrographia it is a distinctive feature of the condition characterised by small handwriting and/or a progressive reduction in size through a sentence[2] coupled with a reduction in writing speed and legibility.

In Parkinson's impaired automaticity is thought to contribute to handwriting deficits and attention has been shown to improve both 'consistent' (small handwriting) and 'progressive' (progressive reduction in letter size through a sentence) aspects of the symptom. Moreover, recent interventional studies indicate handwriting may be improved through practice. This study is investigating a novel handwriting practice stimulus to improve symptoms of micrograpthia

Question: Is a diverging line cued handwriting intervention potentially more effective at improving symptoms of mircograpthia than a parallel line cued handwriting intervention in people with Parkinson's?

Specifically, an assessor blind randomised controlled exploratory trial will:

Estatimate the effect of the intervention on measures of: Handwriting amplitude (consistent and progressive reduction), hand writing performance and percieved handwriting difficulties.
Explore the appropriateness of these outcome measures
Explore the approriateness of eligibilty criteria
Explore intervention fidelity
Explore participants views of the intervention

Design: A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments

Setting: The intervention will be carried out at home

Sample size: This study is not designed to determine efficacy. The aim to recruit a total of 50 people (25 people per group) in order to estimate the effects on outcome measures and achieve the aims of this exploratory trial.

Assessment: Participants will be asked to follow their usual Parkinson's medication regime and if they have ON and OFF periods, assessments will be carried out during ON state.

Duration and follow-up: the assessment is schedule 0Weeks (baseline), 6weeks (end intervention) and 12weeks (follow up). Assessments will be carried out by a researcher blind to trial arm allocation using all outcome measures.","[(0, 25, 'OTHER', 'Handwriting Interventions'), (42, 53, 'CONDITION', ""Parkinson's""), (166, 177, 'CONDITION', ""Parkinson's""), (191, 203, 'CONDITION', 'micrographia'), (407, 418, 'CONDITION', ""Parkinson's""), (799, 828, 'OTHER', 'handwriting practice stimulus'), (852, 865, 'CONDITION', 'micrograpthia'), (882, 926, 'OTHER', 'diverging line cued handwriting intervention'), (1000, 1043, 'CONTROL', 'parallel line cued handwriting intervention'), (1059, 1070, 'CONDITION', ""Parkinson's""), (1583, 1607, 'OTHER', 'handwriting intervention'), (2016, 2027, 'CONDITION', ""Parkinson's"")]"
"['Post', '-', 'operative', 'Pain', 'in', 'Children', 'With', 'Cerebral', 'Palsy', 'Following', 'Major', 'Hip', 'Surgery', ':', 'a', 'Double', 'Blind', 'Randomised', 'Placebo', 'Controlled', 'Trial', 'of', 'Pre', '-', 'operative', 'Botulinum', 'Toxin', 'Type', 'A', '|', 'Cerebral', 'palsy', 'is', 'common', '.', 'It', 'affects', 'approximately', '3', 'per', '1000', 'children', '.', 'Hip', 'displacement', 'due', 'to', 'muscle', 'tightness', '(', 'spasticity', ')', 'occurs', 'in', 'up', 'to', 'half', 'of', 'the', 'more', 'severely', 'affected', 'children', ',', 'and', 'many', 'of', 'these', 'children', 'require', 'major', '(', 'bony', ')', 'hip', 'surgery', '.', 'After', 'bony', 'hip', 'surgery', 'the', 'management', 'of', 'pain', 'is', 'very', 'difficult', ',', 'as', 'spasticity', 'tends', 'to', 'increase', 'and', 'causes', 'painful', 'spasms', 'which', 'are', 'difficult', 'to', 'control', '.', 'Botulinum', 'Toxin', 'injections', 'are', 'known', 'to', 'reduce', 'spasticity', 'and', 'therefore', 'should', 'also', 'reduce', 'pain', '.', 'These', 'injections', 'take', 'at', 'least', 'a', 'week', 'to', 'work', ',', 'but', 'the', 'effects', 'can', 'last', 'for', 'months', '.', 'Botulinum', 'Toxin', 'is', 'already', 'an', 'established', 'treatment', 'for', 'chronic', 'hip', 'pain', 'prior', 'to', 'surgery', '.', 'The', 'investigators', 'aim', 'to', 'find', 'out', 'whether', 'Botulinum', 'Toxin', 'injections', 'can', 'reduce', 'post', '-', 'operative', 'pain', '.', 'The', 'identification', 'of', 'the', 'level', 'of', 'pain', 'can', 'be', 'challenging', 'because', 'most', 'of', 'these', 'children', 'are', 'unable', 'to', 'communicate', 'verbally', '.', 'The', 'investigators', 'are', 'therefore', 'using', 'a', 'validated', 'pain', 'scoring', 'tool', 'that', 'was', 'designed', 'especially', 'for', 'such', 'children', '.', 'This', 'study', 'will', 'be', 'the', 'first', 'to', 'describe', 'fully', 'the', 'pain', 'experience', 'of', 'children', 'with', 'cerebral', 'palsy', 'undergoing', 'this', 'type', 'of', 'major', 'surgery', '.', 'The', 'investigators', 'will', 'compare', 'Botulinum', 'Toxin', 'injections', 'with', 'placebo', '(', 'non', '-', 'active', ')', 'injections', '.', 'There', 'is', 'a', 'high', 'emotional', 'and', 'financial', 'burden', 'on', 'the', 'families', 'of', 'these', 'children', '.', 'Families', 'describe', 'high', 'levels', 'of', 'emotional', 'distress', 'around', 'the', 'time', 'of', 'surgery', ',', 'particularly', 'when', 'their', 'child', 'is', 'in', 'pain', '.', 'Difficulty', 'with', 'pain', 'control', 'post', 'operatively', 'may', 'delay', 'discharge', 'from', 'hospital', 'and', 'parental', 'return', 'to', 'work', '.', 'It', 'causes', 'disrupted', 'sleep', 'for', 'the', 'child', 'and', 'family', 'and', 'may', 'delay', 'the', 'child', ""'s"", 'return', 'to', 'school', '.', 'The', 'results', 'of', 'this', 'study', 'will', 'be', 'shared', 'with', 'professionals', 'and', 'families', 'at', 'international', 'conferences', 'and', 'in', 'scientific', 'and', 'popular', '(', 'patient', '-', 'based', ')', 'publications', '.', 'This', 'study', 'can', 'not', 'be', 'undertaken', 'in', 'adults', 'with', 'cerebral', 'palsy', 'as', 'they', 'only', 'rarely', 'undergo', 'this', 'sort', 'of', 'surgery', '.']","['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01437644,NCT01437644,"Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A | Cerebral palsy is common. It affects approximately 3 per 1000 children. Hip displacement due to muscle tightness (spasticity) occurs in up to half of the more severely affected children, and many of these children require major (bony) hip surgery. After bony hip surgery the management of pain is very difficult, as spasticity tends to increase and causes painful spasms which are difficult to control. Botulinum Toxin injections are known to reduce spasticity and therefore should also reduce pain. These injections take at least a week to work, but the effects can last for months. Botulinum Toxin is already an established treatment for chronic hip pain prior to surgery. The investigators aim to find out whether Botulinum Toxin injections can reduce post-operative pain. The identification of the level of pain can be challenging because most of these children are unable to communicate verbally. The investigators are therefore using a validated pain scoring tool that was designed especially for such children. This study will be the first to describe fully the pain experience of children with cerebral palsy undergoing this type of major surgery. The investigators will compare Botulinum Toxin injections with placebo (non-active) injections. There is a high emotional and financial burden on the families of these children. Families describe high levels of emotional distress around the time of surgery, particularly when their child is in pain. Difficulty with pain control post operatively may delay discharge from hospital and parental return to work. It causes disrupted sleep for the child and family and may delay the child's return to school. The results of this study will be shared with professionals and families at international conferences and in scientific and popular (patient-based) publications. This study cannot be undertaken in adults with cerebral palsy as they only rarely undergo this sort of surgery.","[(0, 19, 'CONDITION', 'Post-operative Pain'), (37, 51, 'CONDITION', 'Cerebral Palsy'), (62, 79, 'CONDITION', 'Major Hip Surgery'), (107, 114, 'CONTROL', 'Placebo'), (149, 171, 'DRUG', 'Botulinum Toxin Type A'), (174, 188, 'CONDITION', 'Cerebral palsy'), (288, 298, 'CONDITION', 'spasticity'), (396, 420, 'CONDITION', 'major (bony) hip surgery'), (428, 444, 'CONDITION', 'bony hip surgery'), (463, 467, 'CONDITION', 'pain'), (490, 500, 'CONDITION', 'spasticity'), (577, 592, 'DRUG', 'Botulinum Toxin'), (624, 634, 'CONDITION', 'spasticity'), (668, 672, 'CONDITION', 'pain'), (758, 773, 'DRUG', 'Botulinum Toxin'), (814, 830, 'CONDITION', 'chronic hip pain'), (891, 906, 'DRUG', 'Botulinum Toxin'), (929, 948, 'CONDITION', 'post-operative pain'), (985, 989, 'CONDITION', 'pain'), (1126, 1130, 'CONDITION', 'pain'), (1243, 1247, 'CONDITION', 'pain'), (1276, 1290, 'CONDITION', 'cerebral palsy'), (1361, 1376, 'DRUG', 'Botulinum Toxin'), (1393, 1424, 'CONTROL', 'placebo (non-active) injections'), (1624, 1628, 'CONDITION', 'pain'), (1646, 1650, 'CONDITION', 'pain'), (2043, 2057, 'CONDITION', 'cerebral palsy')]"
"['The', 'Evaluation', 'of', 'the', 'Toffee', 'Nasal', 'Pillows', 'Mask', 'for', 'the', 'Treatment', 'of', 'Obstructive', 'Sleep', 'Apnea', '|', 'This', 'investigation', 'is', 'a', 'prospective', ',', 'non', '-', 'randomized', ',', 'non', '-', 'blinded', 'study', '.', 'This', 'investigation', 'is', 'designed', 'to', 'evaluate', 'the', 'performance', ',', 'comfort', 'and', 'ease', 'of', 'use', 'of', 'the', 'F&P', 'Toffee', 'nasal', 'pillows', 'mask', 'amongst', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'patients', '.', 'Up', 'to', '45', 'OSA', 'patients', 'will', 'be', 'recruited', 'from', 'the', 'Ohio', 'Sleep', 'Medical', 'Institute', '(', 'OSMI', ')']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03242148,NCT03242148,"The Evaluation of the Toffee Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea | This investigation is a prospective, non-randomized, non-blinded study. This investigation is designed to evaluate the performance, comfort and ease of use of the F&P Toffee nasal pillows mask amongst obstructive sleep apnea (OSA) patients. Up to 45 OSA patients will be recruited from the Ohio Sleep Medical Institute (OSMI)","[(22, 47, 'OTHER', 'Toffee Nasal Pillows Mask'), (69, 92, 'CONDITION', 'Obstructive Sleep Apnea'), (258, 287, 'OTHER', 'F&P Toffee nasal pillows mask'), (296, 319, 'CONDITION', 'obstructive sleep apnea'), (321, 324, 'CONDITION', 'OSA'), (345, 348, 'CONDITION', 'OSA')]"
"['Pre-', 'vs.', 'Postoperative', 'Scalp', 'Block', 'for', 'Pain', 'Control', 'After', 'Supratentorial', 'Craniotomy', '|', 'Study', 'was', 'designed', 'to', 'evaluate', 'optimal', 'timing', 'for', 'selective', 'scalp', 'block', 'in', 'patients', 'undergoing', 'general', 'anesthesia', 'for', 'supratentorial', 'craniotomy', '.', 'Pain', 'score', 'assessed', 'by', 'visual', 'analog', 'scale', '(', 'VAS', ')', 'preoperatively', '(', 'baseline', ')', 'and', 'after', 'extubation', 'at', '2', ',', '6', ',', '12', 'and', '24', 'hours', ';', 'time', 'first', 'request', 'of', 'a', 'patient', 'for', 'rescue', 'analgesia', ';', 'intraoperative', 'anesthetics', 'and', 'opioids', 'consumption', ';', 'awakening', 'time', ';', 'perioperative', 'complications', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04344132,NCT04344132,"Pre- vs. Postoperative Scalp Block for Pain Control After Supratentorial Craniotomy | Study was designed to evaluate optimal timing for selective scalp block in patients undergoing general anesthesia for supratentorial craniotomy.Pain score assessed by visual analog scale (VAS) preoperatively (baseline) and after extubation at 2, 6, 12 and 24 hours; time first request of a patient for rescue analgesia; intraoperative anesthetics and opioids consumption; awakening time; perioperative complications.","[(0, 34, 'OTHER', 'Pre- vs. Postoperative Scalp Block'), (39, 43, 'CONDITION', 'Pain'), (58, 83, 'CONDITION', 'Supratentorial Craniotomy'), (136, 157, 'OTHER', 'selective scalp block'), (204, 229, 'CONDITION', 'supratentorial craniotomy'), (230, 234, 'CONDITION', 'Pain')]"
"['Evaluation', 'of', 'the', 'Safety', 'and', 'Effectiveness', 'of', 'Bilateral', 'Exablate', 'Ablation', 'of', 'the', 'Pallidothalamic', 'Tract', '(', 'PTT', ')', 'for', 'the', 'Treatment', 'of', 'the', 'Motor', 'Complications', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', '|', 'Evaluate', 'the', 'Safety', 'and', 'Effectiveness', 'of', 'Staged', 'Bilateral', 'Exablate', 'Ablation', 'of', 'the', 'Pallidothalamic', 'Tract', '(', 'PTT', ')', 'for', 'the', 'Treatment', 'of', 'the', 'Motor', 'Complications', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04728295,NCT04728295,Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD) | Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).,"[(46, 102, 'OTHER', 'Bilateral Exablate Ablation of the Pallidothalamic Tract'), (104, 107, 'OTHER', 'PTT'), (134, 153, 'CONDITION', 'Motor Complications'), (157, 176, 'CONDITION', ""Parkinson's Disease""), (178, 180, 'CONDITION', 'PD'), (232, 288, 'OTHER', 'Bilateral Exablate Ablation of the Pallidothalamic Tract'), (290, 293, 'OTHER', 'PTT'), (320, 339, 'CONDITION', 'Motor Complications'), (343, 362, 'CONDITION', ""Parkinson's Disease""), (364, 366, 'CONDITION', 'PD')]"
"['Effects', 'of', 'Exercise', 'Training', 'on', 'Learning', 'and', 'Memory', 'Outcomes', 'in', 'Multiple', 'Sclerosis', '|', 'The', 'two', 'primary', 'study', 'objectives', 'involve', 'examining', 'the', 'effects', 'of', 'treadmill', 'walking', 'exercise', 'training', 'versus', 'stretching', '-', 'and', '-', 'toning', 'activities', 'on', 'the', 'primary', 'and', 'secondary', 'outcomes', '.', '\n\n', 'Specific', 'Aim', '1', ':', 'The', 'first', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'learning', 'and', 'memory', 'outcomes', 'in', 'fully', '-', 'ambulatory', 'persons', 'with', 'MS', 'who', 'have', 'impairment', 'in', 'learning', 'new', 'information', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'undergo', 'treadmill', 'walking', 'exercise', 'training', 'will', 'demonstrate', 'improvements', 'in', 'learning', 'and', 'memory', 'relative', 'to', 'those', 'who', 'undergo', 'stretching', '-', 'and', '-', 'toning', 'activities', '.', '\n\n', 'Specific', 'Aim', '2', ':', 'The', 'second', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'hippocampal', 'volume', ',', 'hippocampal', 'resting', '-', 'state', 'functional', 'connectivity', ',', 'and', 'cardiorespiratory', 'fitness', 'in', 'those', 'persons', 'with', 'MS', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'are', 'randomly', 'assigned', 'to', 'the', 'treadmill', 'walking', 'exercise', 'condition', 'will', 'demonstrate', 'increases', 'in', 'hippocampal', 'volume', 'and', 'resting', '-', 'state', 'functional', 'connectivity', '(', 'i.e.', ',', 'adaptive', 'increases', ')', 'and', 'improved', 'cardiorespiratory', 'fitness', 'relative', 'to', 'those', 'in', 'the', 'stretching', '-', 'and', '-', 'toning', 'condition', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",NCT03319771,NCT03319771,"Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis | The two primary study objectives involve examining the effects of treadmill walking exercise training versus stretching-and-toning activities on the primary and secondary outcomes.

Specific Aim 1: The first specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on learning and memory outcomes in fully-ambulatory persons with MS who have impairment in learning new information. We hypothesize that those who undergo treadmill walking exercise training will demonstrate improvements in learning and memory relative to those who undergo stretching-and-toning activities.

Specific Aim 2: The second specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on hippocampal volume, hippocampal resting-state functional connectivity, and cardiorespiratory fitness in those persons with MS. We hypothesize that those who are randomly assigned to the treadmill walking exercise condition will demonstrate increases in hippocampal volume and resting-state functional connectivity (i.e., adaptive increases) and improved cardiorespiratory fitness relative to those in the stretching-and-toning condition.","[(11, 28, 'PHYSICAL', 'Exercise Training'), (64, 82, 'CONDITION', 'Multiple Sclerosis'), (151, 177, 'PHYSICAL', 'treadmill walking exercise'), (194, 226, 'CONTROL', 'stretching-and-toning activities'), (347, 373, 'PHYSICAL', 'treadmill walking exercise'), (400, 414, 'CONTROL', 'active control'), (490, 492, 'CONDITION', 'MS'), (580, 606, 'PHYSICAL', 'treadmill walking exercise'), (699, 731, 'CONTROL', 'stretching-and-toning activities'), (815, 841, 'PHYSICAL', 'treadmill walking exercise'), (868, 882, 'CONTROL', 'active control'), (1019, 1021, 'CONDITION', 'MS'), (1082, 1108, 'PHYSICAL', 'treadmill walking exercise'), (1301, 1322, 'CONTROL', 'stretching-and-toning')]"
"['Voice', 'Biomarkers', 'to', 'Predict', 'Excessive', 'Daytime', 'Sleepiness', '|', 'This', 'study', 'aims', 'at', 'measuring', 'the', 'impact', 'of', 'a', 'night', 'of', 'sleep', 'deprivation', 'over', 'the', 'vocal', 'characteristics', 'of', 'healthy', 'subjects', '.', 'To', 'do', 'so', ',', 'the', 'subjects', 'takes', 'a', 'Multiple', 'Sleep', 'Latency', 'Test', '(', 'MSLT', ')', 'the', 'day', 'after', 'a', 'night', 'of', 'total', 'sleep', 'deprivation', '(', 'or', 'a', 'supervised', 'normal', 'night', 'for', 'the', 'control', 'subjects', ')', '.', 'Before', 'each', 'iteration', 'of', 'the', 'MSLT', ',', 'the', 'subjects', 'are', 'recorded', 'during', 'the', 'reading', 'of', 'a', 'text', 'and', 'fill', 'three', 'medical', 'questionnaires', ':', 'Karolinska', 'Sleepiness', 'Scale', '(', 'KSS', ')', ',', 'Visual', 'Analogue', 'Scale', 'for', 'Fatigue', '(', 'VAS', '-', 'F', ')', 'and', 'Visual', 'Analogue', 'Scale', 'for', 'Anxiety', '(', 'VAS', '-', 'A', ')', ',', 'allowing', 'to', 'link', 'variations', 'of', 'vocal', 'markers', 'to', 'the', 'variations', 'of', 'these', 'measures', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04942574,NCT04942574,"Voice Biomarkers to Predict Excessive Daytime Sleepiness | This study aims at measuring the impact of a night of sleep deprivation over the vocal characteristics of healthy subjects.To do so, the subjects takes a Multiple Sleep Latency Test (MSLT) the day after a night of total sleep deprivation (or a supervised normal night for the control subjects). Before each iteration of the MSLT, the subjects are recorded during the reading of a text and fill three medical questionnaires : Karolinska Sleepiness Scale (KSS), Visual Analogue Scale for Fatigue (VAS-F) and Visual Analogue Scale for Anxiety (VAS-A), allowing to link variations of vocal markers to the variations of these measures.","[(28, 56, 'CONDITION', 'Excessive Daytime Sleepiness')]"
"['Concurrent', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'Local', 'Field', 'Potential', 'Analysis', 'and', 'Stimulation', 'in', 'a', 'Closed', '-', 'Loop', 'Neuromodulation', 'Device', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'allow', 'the', 'investigation', 'of', 'local', 'field', 'potential', '(', 'LFP', ')', 'signals', 'in', 'patients', 'treated', 'with', 'DBS', 'of', 'the', 'STN', '.', 'This', 'study', 'will', 'identify', 'common', 'LFP', 'biomarkers', 'observed', 'as', 'a', 'function', 'of', 'disease', 'symptoms', ',', 'medication', 'effect', ',', 'fluctuations', 'in', 'disease', ',', 'and', 'changes', 'resulting', 'from', 'adjustments', 'from', 'current', 'standard', 'practices', 'of', 'DBS', 'programming', '.', 'The', 'data', 'collected', 'and', 'LFP', 'markers', 'identified', 'will', 'serve', 'as', 'guidelines', 'for', 'future', 'stimulation', 'predicted', 'programming', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02731365,NCT02731365,"Concurrent Deep Brain Stimulation (DBS) Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device | The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming. The data collected and LFP markers identified will serve as guidelines for future stimulation predicted programming.","[(11, 33, 'OTHER', 'Deep Brain Stimulation'), (35, 38, 'OTHER', 'DBS'), (92, 126, 'OTHER', 'Closed-Loop Neuromodulation Device'), (258, 261, 'OTHER', 'DBS'), (461, 498, 'CONTROL', 'standard practices of DBS programming')]"
"['Physiological', 'Study', 'of', 'the', 'Critical', 'Closing', 'Airway', 'Pressure', 'in', 'a', 'Population', 'of', 'Didgeridoo', 'Players', '|', 'Obstructive', 'sleep', 'apnea', 'is', 'characterised', 'by', 'an', 'abnormal', 'upper', 'airway', 'collapsibility', '.', 'Upper', 'airway', 'collapsibility', 'can', 'be', 'evaluated', 'through', 'critical', 'closure', 'airway', 'pressure', '(', 'Pcrit', ')', '.', 'Didgeridoo', 'is', 'a', 'traditional', 'australian', 'musical', 'instrument', 'involving', 'circular', 'respiration', ',', 'a', 'breathing', 'technique', 'involving', 'mouth', 'muscles', '.', 'We', 'hypothesize', 'that', 'didgeridoo', 'players', 'have', 'a', 'lower', 'risk', 'of', 'airway', 'collapsibility', 'due', 'to', 'circular', 'breathing', 'technique']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT05606653,NCT05606653,"Physiological Study of the Critical Closing Airway Pressure in a Population of Didgeridoo Players | Obstructive sleep apnea is characterised by an abnormal upper airway collapsibility. Upper airway collapsibility can be evaluated through critical closure airway pressure (Pcrit). Didgeridoo is a traditional australian musical instrument involving circular respiration, a breathing technique involving mouth muscles. We hypothesize that didgeridoo players have a lower risk of airway collapsibility due to circular breathing technique","[(79, 89, 'OTHER', 'Didgeridoo'), (100, 123, 'CONDITION', 'Obstructive sleep apnea'), (162, 183, 'CONDITION', 'airway collapsibility'), (280, 290, 'OTHER', 'Didgeridoo'), (437, 447, 'OTHER', 'didgeridoo'), (477, 498, 'CONDITION', 'airway collapsibility')]"
"['Optimizing', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Motor', 'Recovery', 'From', 'Severe', 'Post', '-', 'stroke', 'Hemiparesis', '|', 'Individuals', 'who', 'experienced', 'a', 'stroke', 'over', 'one', 'year', 'ago', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', '1', 'of', '4', 'different', 'conditions', 'of', 'brain', 'stimulation', '.', 'All', 'individuals', 'will', 'receive', 'therapy', 'of', 'the', 'hand', 'and', 'arm', 'following', 'the', 'stimulation', '.', 'This', 'study', 'will', 'try', 'to', 'determine', 'which', 'brain', 'stimulation', 'condition', 'leads', 'to', 'the', 'greatest', 'improvement', 'in', 'hand', 'and', 'arm', 'function', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04574973,NCT04574973,Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis | Individuals who experienced a stroke over one year ago will be randomly assigned to receive 1 of 4 different conditions of brain stimulation. All individuals will receive therapy of the hand and arm following the stimulation. This study will try to determine which brain stimulation condition leads to the greatest improvement in hand and arm function.,"[(11, 50, 'OTHER', 'Transcranial Direct Current Stimulation'), (75, 105, 'CONDITION', 'Severe Post-stroke Hemiparesis'), (138, 144, 'CONDITION', 'stroke'), (231, 248, 'OTHER', 'brain stimulation'), (373, 390, 'OTHER', 'brain stimulation')]"
"['Demonstration', 'of', 'mGluR5', 'Overexpression', 'in', 'Amish', 'and', 'Mennonite', 'CNTNAP2', 'Mutation', 'Carriers', '|', 'The', 'primary', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'evaluate', 'the', 'utility', 'of', 'mGluR5', 'binding', 'as', 'measured', 'by', 'PET', 'as', 'a', 'biomarker', 'of', 'the', 'CNTNAP2', 'mutation', 'and', 'related', '/mTOR', 'kinase', 'pathway', 'dysregulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02572206,NCT02572206,Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers | The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.,"[(62, 78, 'CONDITION', 'CNTNAP2 Mutation'), (214, 230, 'CONDITION', 'CNTNAP2 mutation')]"
"['Effect', 'of', 'Duloxetine', '30/60', 'mg', 'Once', 'Daily', 'Versus', 'Placebo', 'in', 'Adolescents', 'With', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'duloxetine', 'is', 'safe', 'and', 'effective', 'in', 'the', 'treatment', 'of', 'adolescents', 'with', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '(', 'JPFS', ')', '.', '\n\n', 'This', 'trial', 'consists', 'of', 'two', 'distinct', 'study', 'periods', '.', 'A', 'blinded', 'treatment', 'period', 'of', '13', 'weeks', 'and', 'an', 'open', 'label', 'extension', 'period', 'of', '26', 'weeks', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01237587,NCT01237587,"Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome | The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).

This trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.","[(10, 20, 'DRUG', 'Duloxetine'), (48, 55, 'CONTROL', 'Placebo'), (76, 114, 'CONDITION', 'Juvenile Primary Fibromyalgia Syndrome'), (167, 177, 'DRUG', 'duloxetine'), (237, 275, 'CONDITION', 'Juvenile Primary Fibromyalgia Syndrome'), (277, 281, 'CONDITION', 'JPFS')]"
"['The', 'Effect', 'of', 'Low', '-', 'İntensity', 'Combined', 'Exercises', 'on', 'Fatigue', ',', 'Balance', 'and', 'Quality', 'of', 'Life', 'in', 'Patients', 'With', 'Early', 'Stage', 'ALS', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'low', '-', 'intensity', 'combined', 'exercises', 'on', 'balance', ',', 'fatigue', 'and', 'quality', 'of', 'life', 'applied', 'to', 'patients', 'with', 'ALS', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05716074,NCT05716074,"The Effect of Low-İntensity Combined Exercises on Fatigue, Balance and Quality of Life in Patients With Early Stage ALS | The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS.","[(14, 46, 'PHYSICAL', 'Low-İntensity Combined Exercises'), (50, 57, 'CONDITION', 'Fatigue'), (104, 119, 'CONDITION', 'Early Stage ALS'), (177, 209, 'PHYSICAL', 'low-intensity combined exercises'), (222, 229, 'CONDITION', 'fatigue'), (275, 278, 'CONDITION', 'ALS')]"
"['Double', '-', 'blind', 'Randomized', 'Trial', 'of', 'Rituximab', 'Versus', 'Placebo', 'in', 'Polyneuropathy', 'Associated', 'With', 'Anti', '-', 'MAG', 'IgM', 'Monoclonal', 'Gammopathy', '|', 'Polyneuropathy', 'associated', 'with', 'anti', '-', 'MAG', 'monoclonal', 'IgM', 'gammopathy', 'is', 'responsive', 'of', 'mainly', 'a', 'sensory', 'deficit', 'in', 'predominantly', 'males', ',', 'aged', '40', '-', '70', 'years', '.', 'Significantly', 'high', 'serum', 'anti', '-', 'MAG', 'antibodies', 'are', 'linked', 'with', 'demyelinating', 'features', 'of', 'the', 'peripheral', 'nerves', '.', 'Rituximab', ',', 'an', 'anti', '-', 'CD', '20', 'monoclonal', 'antibody', 'is', 'a', 'new', 'drug', 'which', 'reduces', 'B', '-', 'lymphocytes', '.', 'This', 'study', 'will', 'test', 'the', 'safety', 'and', 'efficacy', 'of', 'rituximab', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'anti', '-', 'MAG', 'polyneuropathy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00259974,NCT00259974,"Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy | Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.","[(33, 42, 'DRUG', 'Rituximab'), (50, 57, 'CONTROL', 'Placebo'), (61, 75, 'CONDITION', 'Polyneuropathy'), (92, 126, 'CONDITION', 'Anti-MAG IgM Monoclonal Gammopathy'), (129, 143, 'CONDITION', 'Polyneuropathy'), (160, 194, 'CONDITION', 'anti-MAG monoclonal IgM gammopathy'), (388, 397, 'DRUG', 'Rituximab'), (402, 432, 'DRUG', 'anti-CD 20 monoclonal antibody'), (524, 533, 'DRUG', 'rituximab'), (568, 591, 'CONDITION', 'anti-MAG polyneuropathy')]"
"['Anakinra', 'in', 'Patients', 'With', 'Refractory', 'Idiopathic', 'Inflammatory', 'Myopathies', '|', 'To', 'investigate', 'the', 'effect', 'of', 'the', 'interleukin-1', '(', 'IL-1', ')', 'blocking', 'agent', ',', 'anakinra', ',', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'inflammatory', 'myopathies', '.', '\n\n', 'Patients', 'and', 'methods', ':', 'Fifteen', 'patients', 'with', 'refractory', 'polymyositis', '(', 'PM', ')', ',', 'dermatomyositis', '(', 'DM', ')', ',', 'or', 'inclusion', 'body', 'myositis', '(', 'IBM', ')', 'were', 'treated', 'with', '100', 'mg', 'anakinra', 'subcutaneously', 'per', 'day', 'during', '12', 'months', '.', 'Outcome', 'measures', 'included', 'myositis', 'disease', 'activity', 'score', 'with', 'improvement', 'defined', 'according', 'to', 'The', 'International', 'Myositis', 'Assessment', 'and', 'Clinical', 'Studies', 'Group', '(', 'IMACS', ')', 'and', 'for', 'muscle', 'performance', 'the', 'functional', 'index', 'of', 'myositis', '(', 'FI', ')', '.', 'In', 'addition', 'repeat', 'muscle', 'biopsies', 'were', 'performed']","['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01165008,NCT01165008,"Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies | To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.

Patients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed","[(0, 8, 'DRUG', 'Anakinra'), (26, 71, 'CONDITION', 'Refractory Idiopathic Inflammatory Myopathies'), (107, 142, 'DRUG', 'interleukin-1 (IL-1) blocking agent'), (144, 152, 'DRUG', 'anakinra'), (171, 214, 'CONDITION', 'treatment-resistant inflammatory myopathies'), (261, 284, 'CONDITION', 'refractory polymyositis'), (286, 288, 'CONDITION', 'PM'), (291, 306, 'CONDITION', 'dermatomyositis'), (308, 310, 'CONDITION', 'DM'), (316, 339, 'CONDITION', 'inclusion body myositis'), (341, 344, 'CONDITION', 'IBM'), (371, 379, 'DRUG', 'anakinra'), (447, 455, 'CONDITION', 'myositis'), (641, 649, 'CONDITION', 'myositis')]"
"['Evaluation', 'of', 'the', 'Animal', 'Intervention', 'Used', 'as', 'Therapy', '.', 'Impact', 'of', 'Animal', '-', 'assisted', 'Therapy', 'on', 'the', 'Well', '-', 'being', 'in', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'animal', '-', 'assisted', 'therapy', '(', 'AAT', ')', 'is', 'now', 'considered', 'a', 'non', '-', 'drug', 'care', 'and', 'is', 'often', 'used', 'in', 'geriatrics', '.', 'Many', 'studies', 'have', 'shown', 'a', 'link', 'between', 'the', 'presence', 'of', 'the', 'animal', 'and', 'the', 'psycho', '-', 'behavioral', 'symptoms', 'decrease', 'in', 'dementia', '(', 'PBSD', ')', 'such', 'as', 'depression', ',', 'anxiety', 'or', 'irritability', 'that', 'affects', 'their', 'quality', 'of', 'life', 'and', 'improved', 'cognitive', 'abilities', '.', 'However', ',', 'many', 'methodological', 'flaws', 'in', 'these', 'researches', 'exist', '.', '\n\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'AAT', 'on', 'the', 'well', '-', 'being', 'of', 'patients', 'with', 'Alzheimer', 'disease', '(', 'AD', ')', 'at', 'the', 'stage', 'of', 'Major', 'Neuro', 'Cognitive', 'Disorder', '(', 'NCD', ')', 'at', 'short', 'and', 'medium', 'term', '(', 'before', 'care', ',', 'during', 'care', '(', 'at', 'the', 'beginning', 'and', 'end', 'of', 'each', 'session', ')', ',', '1', 'week', 'after', ',', '2', 'weeks', 'and', '1', 'month', 'after', 'the', 'last', 'session', ')', 'compared', 'to', 'a', 'group', 'receiving', 'the', 'same', 'stimulation', 'without', 'the', 'dog', ""'s"", 'response', '.', '\n\n', 'Patients', 'will', 'be', 'seen', 'in', 'groups', 'of', '4', 'to', '6', 'people', 'at', '8', 'workshops', '.', '2', 'groups', 'will', 'be', 'formed', ':', 'AAT', 'group', 'versus', 'control', 'group', '.', 'The', 'only', 'difference', 'between', 'these', 'two', 'groups', 'is', 'the', 'intervention', 'of', 'the', 'dog', 'at', 'each', 'workshop', 'in', 'the', 'AAT', 'group', '.', '\n\n', 'Each', 'workshop', 'will', 'consist', 'of', 'three', 'identical', 'times', '.', 'It', 'will', 'begin', 'with', 'a', '15', 'minute', 'introductory', 'activity', ',', 'the', 'first', 'goal', 'will', 'be', 'to', 'establish', 'a', 'relationship', 'with', 'patients', '(', 'patients', '-', 'patients', 'and', 'patients', '-', 'caregivers', ')', 'and', 'a', '40', 'minute', 'cognitive', 'stimulation', ',', 'identical', 'in', 'the', '2', 'groups', ',', 'will', 'be', 'proposed', 'and', 'finally', '5', 'minutes', 'will', 'be', 'devoted', 'to', 'the', 'closing', 'of', 'the', 'session', 'This', 'study', 'should', 'highlight', 'a', 'positive', 'effect', 'of', 'animal', 'assisted', 'therapy', 'on', 'the', 'well', '-', 'being', ',', 'PBSD', ',', 'depression', ',', 'anxiety', 'and', 'cognitive', 'abilities', 'and', 'a', 'long', '-', 'term', 'retention', 'of', 'these', 'positive', 'effects', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02829801,NCT02829801,"Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease | The animal-assisted therapy (AAT) is now considered a non-drug care and is often used in geriatrics. Many studies have shown a link between the presence of the animal and the psycho-behavioral symptoms decrease in dementia (PBSD) such as depression, anxiety or irritability that affects their quality of life and improved cognitive abilities. However, many methodological flaws in these researches exist.

The aim of the study is to evaluate the effectiveness of AAT on the well-being of patients with Alzheimer disease (AD) at the stage of Major Neuro Cognitive Disorder (NCD) at short and medium term (before care, during care (at the beginning and end of each session), 1 week after, 2 weeks and 1 month after the last session) compared to a group receiving the same stimulation without the dog's response.

Patients will be seen in groups of 4 to 6 people at 8 workshops. 2 groups will be formed: AAT group versus control group. The only difference between these two groups is the intervention of the dog at each workshop in the AAT group.

Each workshop will consist of three identical times. It will begin with a 15 minute introductory activity, the first goal will be to establish a relationship with patients (patients-patients and patients-caregivers) and a 40 minute cognitive stimulation, identical in the 2 groups, will be proposed and finally 5 minutes will be devoted to the closing of the session This study should highlight a positive effect of animal assisted therapy on the well-being, PBSD, depression, anxiety and cognitive abilities and a long-term retention of these positive effects.","[(18, 37, 'OTHER', 'Animal Intervention'), (65, 88, 'OTHER', 'Animal-assisted Therapy'), (124, 143, 'CONDITION', ""Alzheimer's Disease""), (150, 173, 'OTHER', 'animal-assisted therapy'), (175, 178, 'OTHER', 'AAT'), (290, 312, 'OTHER', 'presence of the animal'), (360, 368, 'CONDITION', 'dementia'), (384, 394, 'CONDITION', 'depression'), (396, 403, 'CONDITION', 'anxiety'), (609, 612, 'OTHER', 'AAT'), (648, 665, 'CONDITION', 'Alzheimer disease'), (667, 669, 'CONDITION', 'AD'), (687, 717, 'CONDITION', 'Major Neuro Cognitive Disorder'), (719, 722, 'CONDITION', 'NCD'), (911, 954, 'CONTROL', ""same stimulation without the dog's response""), (1011, 1020, 'OTHER', 'workshops'), (1047, 1050, 'OTHER', 'AAT'), (1131, 1154, 'OTHER', 'intervention of the dog'), (1179, 1182, 'OTHER', 'AAT'), (1423, 1444, 'OTHER', 'cognitive stimulation'), (1607, 1630, 'OTHER', 'animal assisted therapy'), (1656, 1666, 'CONDITION', 'depression'), (1668, 1675, 'CONDITION', 'anxiety')]"
"['Safety', 'and', 'Therapeutic', 'Measures', 'of', 'Cathodal', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'Tdcs', ')', 'in', 'Patients', 'With', 'Refractory', 'Focal', 'Epilepsy', '|', 'This', 'is', 'a', 'single', 'site', ',', 'non', '-', 'randomized', ',', 'prospective', ',', 'open', '-', 'label', ',', 'interventional', 'pilot', '/', 'feasibility', 'study', '.', 'Patients', 'recruited', 'will', 'have', 'medically', '-', 'refractory', 'focal', 'neocortical', 'epilepsy', ',', 'defined', 'on', 'the', 'basis', 'of', 'presence', 'of', 'focal', 'spikes', 'and', '(', 'if', 'available', ')', 'focal', 'seizure', 'onsets', 'originating', 'from', 'the', 'lateral', 'cortical', 'surface', 'of', 'any', 'lobe', '.', 'All', 'patients', 'and', 'referring', 'physicians', 'will', 'be', 'requested', 'to', 'maintain', 'their', 'current', 'antiepileptic', 'drugs', 'throughout', 'the', 'study', 'with', 'changes', 'after', 'enrollment', 'permitted', 'only', 'to', 'maintain', 'pre', '-', 'enrollment', 'drug', 'levels', ',', 'or', 'if', 'clinically', 'necessary', '.', 'The', 'primary', 'outcome', 'measure', 'will', 'be', 'the', 'change', 'in', 'seizure', 'frequency', '(', 'seizures', '/', 'week', ')', 'as', 'compared', 'to', 'baseline', '.', '\n\n', 'Patients', 'with', 'medically', '-', 'refractory', 'neocortical', 'epilepsy', 'will', 'receive', 'cathodal', 'tDCS', 'administered', 'to', 'the', 'seizure', 'focus', 'for', '10', 'sessions', 'over', 'a', '2', '-', 'week', 'period', 'with', 'the', 'allowance', 'of', 'make', '-', 'up', 'sessions', 'in', 'week', 'three', '.', 'Subjects', 'will', 'be', 'evaluated', 'at', 'baseline', ',', 'during', 'the', 'stimulation', 'sessions', ',', 'and', '8', 'weeks', 'after', 'the', 'completion', 'of', 'the', 'tDCS', 'visits']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O']",NCT02866240,NCT02866240,"Safety and Therapeutic Measures of Cathodal Transcranial Direct Current Stimulation (Tdcs) in Patients With Refractory Focal Epilepsy | This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral cortical surface of any lobe. All patients and referring physicians will be requested to maintain their current antiepileptic drugs throughout the study with changes after enrollment permitted only to maintain pre-enrollment drug levels, or if clinically necessary. The primary outcome measure will be the change in seizure frequency (seizures/week) as compared to baseline.

Patients with medically-refractory neocortical epilepsy will receive cathodal tDCS administered to the seizure focus for 10 sessions over a 2-week period with the allowance of make-up sessions in week three. Subjects will be evaluated at baseline, during the stimulation sessions, and 8 weeks after the completion of the tDCS visits","[(35, 83, 'OTHER', 'Cathodal Transcranial Direct Current Stimulation'), (85, 89, 'OTHER', 'Tdcs'), (108, 133, 'CONDITION', 'Refractory Focal Epilepsy'), (269, 316, 'CONDITION', 'medically-refractory focal neocortical epilepsy'), (386, 399, 'CONDITION', 'focal seizure'), (752, 759, 'CONDITION', 'seizure'), (771, 779, 'CONDITION', 'seizures'), (826, 867, 'CONDITION', 'medically-refractory neocortical epilepsy'), (881, 894, 'OTHER', 'cathodal tDCS'), (915, 922, 'CONDITION', 'seizure'), (1133, 1137, 'OTHER', 'tDCS')]"
"['Effects', 'of', 'Different', 'Montages', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'on', 'the', 'Risk', 'of', 'Falls', 'and', 'Lower', 'Limb', 'Function', 'for', 'Acute', 'Stroke', 'Patients', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'has', 'shown', 'promising', 'results', 'in', 'the', 'modulation', 'of', 'cortical', 'excitability', 'and', 'the', 'promotion', 'of', 'neuronal', 'plasticity', 'after', 'stroke', '.', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effectiveness', 'of', 'three', 'different', 'montages', 'of', 'tDCS', '(', 'anodal', ',', 'cathodal', 'and', 'bilateral', ')', 'in', 'reducing', 'the', 'risk', 'of', 'falls', 'and', 'recovery', 'of', 'lower', 'limb', 'function', 'in', 'acute', 'stroke', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT02422173,NCT02422173,"Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial | Transcranial direct current stimulation (tDCS) has shown promising results in the modulation of cortical excitability and the promotion of neuronal plasticity after stroke. The purpose of this study was to compare the effectiveness of three different montages of tDCS (anodal, cathodal and bilateral) in reducing the risk of falls and recovery of lower limb function in acute stroke patients.","[(33, 72, 'OTHER', 'Transcranial Direct Current Stimulation'), (80, 93, 'CONDITION', 'Risk of Falls'), (122, 134, 'CONDITION', 'Acute Stroke'), (177, 216, 'OTHER', 'Transcranial direct current stimulation'), (218, 222, 'OTHER', 'tDCS'), (342, 348, 'CONDITION', 'stroke'), (440, 444, 'OTHER', 'tDCS'), (494, 507, 'CONDITION', 'risk of falls'), (547, 559, 'CONDITION', 'acute stroke')]"
"['Randomized', 'Controlled', 'Trial', 'Evaluating', 'the', 'Efficacy', 'of', 'Polyethylene', 'Glycol', '3350', '-', 'electrolyte', 'Solution', '(', 'GoLYTELY', '®', ')', 'in', 'Patients', 'With', 'Hepatic', 'Encephalopathy', '.', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'find', 'out', 'if', 'the', 'laxative', 'polyethylene', 'glycol', '(', 'also', 'known', 'as', 'GoLYTELY', '®', 'or', 'Miralax', '®', ')', 'can', 'treat', 'your', 'hepatic', 'encephalopathy', '(', 'confusion', 'due', 'to', 'your', 'liver', 'disease', 'and/or', 'cirrhosis', ')', 'better', 'and/or', 'more', 'safely', 'than', 'lactulose', '(', 'another', 'laxative', ')', '.', 'In', 'this', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'if', 'polyethylene', 'glycol', '(', 'GoLYTELY', '®', ')', 'is', 'more', 'effective', 'than', 'lactulose', 'on', 'neurocognition', '(', 'memory', 'and', 'thinking', 'skills', ')', 'and', 'determine', 'if', 'it', 'decreases', 'the', 'hospital', 'stay', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01283152,NCT01283152,"Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy. | This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators will evaluate if polyethylene glycol (GoLYTELY®) is more effective than lactulose on neurocognition (memory and thinking skills) and determine if it decreases the hospital stay.","[(55, 100, 'DRUG', 'Polyethylene Glycol 3350-electrolyte Solution'), (102, 110, 'DRUG', 'GoLYTELY'), (130, 152, 'CONDITION', 'Hepatic Encephalopathy'), (209, 228, 'DRUG', 'polyethylene glycol'), (244, 252, 'DRUG', 'GoLYTELY'), (257, 264, 'DRUG', 'Miralax'), (282, 304, 'CONDITION', 'hepatic encephalopathy'), (391, 400, 'DRUG', 'lactulose'), (471, 490, 'DRUG', 'polyethylene glycol'), (492, 500, 'DRUG', 'GoLYTELY'), (526, 535, 'DRUG', 'lactulose')]"
"['Cognitive', '-', 'based', 'Rehabilitation', 'Platform', 'of', 'Hand', 'Grasp', 'After', 'Spinal', 'Cord', 'Injury', 'Using', 'Virtual', 'Reality', 'and', 'Instrumented', 'Wearables', '|', 'Rehabilitation', 'of', 'functional', 'movements', 'after', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'requires', 'commitment', 'and', 'engagement', 'to', 'the', 'processes', 'of', 'physical', 'therapy', '.', 'Outcomes', 'may', 'be', 'improved', 'by', 'techniques', 'that', 'strengthen', 'cognitive', 'connections', 'between', 'users', 'and', 'physical', 'therapy', 'exercises', '.', '\n\n', 'The', 'investigators', 'will', 'investigate', 'combinations', 'of', 'virtual', 'reality', 'and', 'innovative', 'wearable', 'technology', 'to', 'accelerate', 'rehabilitation', 'of', 'hand', 'grasp', 'and', 'reach', '.', 'These', 'devices', 'use', 'multi', '-', 'sensory', 'feedback', 'to', 'enhance', 'the', 'sense', 'of', 'agency', ',', 'or', 'feelings', 'of', 'control', ',', 'and', 'better', 'train', 'movements', 'during', 'physical', 'rehabilitation', 'exercises', '.', 'The', 'investigators', 'will', 'measure', 'the', 'effect', 'of', 'these', 'devices', 'on', 'improving', 'the', 'speed', ',', 'efficiency', ',', 'and', 'accuracy', 'of', 'performed', 'movements', 'in', 'Veterans', 'with', 'SCI', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04577573,NCT04577573,"Cognitive-based Rehabilitation Platform of Hand Grasp After Spinal Cord Injury Using Virtual Reality and Instrumented Wearables | Rehabilitation of functional movements after spinal cord injury (SCI) requires commitment and engagement to the processes of physical therapy. Outcomes may be improved by techniques that strengthen cognitive connections between users and physical therapy exercises.

The investigators will investigate combinations of virtual reality and innovative wearable technology to accelerate rehabilitation of hand grasp and reach. These devices use multi-sensory feedback to enhance the sense of agency, or feelings of control, and better train movements during physical rehabilitation exercises. The investigators will measure the effect of these devices on improving the speed, efficiency, and accuracy of performed movements in Veterans with SCI.","[(0, 39, 'OTHER', 'Cognitive-based Rehabilitation Platform'), (60, 78, 'CONDITION', 'Spinal Cord Injury'), (85, 100, 'OTHER', 'Virtual Reality'), (105, 127, 'OTHER', 'Instrumented Wearables'), (175, 193, 'CONDITION', 'spinal cord injury'), (195, 198, 'CONDITION', 'SCI'), (255, 271, 'PHYSICAL', 'physical therapy'), (368, 394, 'PHYSICAL', 'physical therapy exercises'), (448, 463, 'OTHER', 'virtual reality'), (468, 498, 'OTHER', 'innovative wearable technology'), (571, 593, 'OTHER', 'multi-sensory feedback'), (684, 717, 'PHYSICAL', 'physical rehabilitation exercises'), (867, 870, 'CONDITION', 'SCI')]"
"['An', 'Open', '-', 'Label', ',', 'Non', '-', 'Randomized', 'Study', 'Designed', 'to', 'Evaluate', 'the', 'Correlation', 'of', 'HS-1000', 'Device', 'Capabilities', 'in', 'the', 'Diagnosis', 'and', 'Assessment', 'of', 'Patients', 'After', 'Concussion', 'With', 'Clinical', 'Evaluation', '|', 'The', 'HeadSense', '(', 'HS', ')', 'HS-1000', 'device', ',', 'a', 'new', 'non', '-', 'invasive', 'brain', 'monitor', 'is', 'expected', 'to', 'safely', 'and', 'accurately', 'monitor', 'concussed', 'patients', 'with', 'minimal', 'discomfort', ',', 'potentially', 'providing', 'a', 'new', 'modality', 'for', 'concussion', 'measurement', '.', 'The', 'device', 'is', 'based', 'on', 'advanced', 'signal', 'analysis', 'algorithms', 'that', 'analyze', 'a', 'very', 'low', 'frequency', 'acoustic', 'signal', '(', 'within', 'the', 'audible', 'range', ')', 'generated', 'by', 'the', 'device', '.', 'The', 'acoustic', 'signal', 'is', 'transmitted', 'using', 'a', 'small', 'transmitter', ',', 'placed', 'in', 'the', 'participant', ""'s"", 'ear', ',', 'and', 'picked', 'by', 'an', 'acoustic', 'sensor', 'placed', 'in', 'the', 'other', 'ear', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02699346,NCT02699346,"An Open-Label, Non-Randomized Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion With Clinical Evaluation | The HeadSense (HS) HS-1000 device, a new non-invasive brain monitor is expected to safely and accurately monitor concussed patients with minimal discomfort, potentially providing a new modality for concussion measurement. The device is based on advanced signal analysis algorithms that analyze a very low frequency acoustic signal (within the audible range) generated by the device. The acoustic signal is transmitted using a small transmitter, placed in the participant's ear, and picked by an acoustic sensor placed in the other ear.","[(154, 164, 'CONDITION', 'Concussion'), (305, 314, 'CONDITION', 'concussed'), (390, 400, 'CONDITION', 'concussion')]"
"['Stepped', 'Care', 'in', 'the', 'Treatment', 'of', 'Trichotillomania', '|', 'Trichotillomania', '(', 'TTM', ')', ',', 'repetitive', 'pulling', 'out', 'of', 'one', ""'s"", 'own', 'hair', 'to', 'the', 'extent', 'that', 'noticeable', 'hair', 'loss', 'occurs', ',', 'is', 'a', 'distressing', 'condition', 'interfering', 'substantially', 'with', 'functioning', 'and', 'quality', 'of', 'life', '.', 'The', 'longterm', 'objective', 'of', 'this', 'research', 'is', 'to', 'determine', 'whether', 'psychological', 'treatment', 'of', 'TTM', 'could', 'be', 'disseminated', 'more', 'effectively', 'by', 'using', 'a', 'stepped', 'care', 'model', 'in', 'which', 'less', 'intensive', 'interventions', 'are', 'tried', 'first', ',', 'with', 'more', 'intensive', 'interventions', 'used', 'only', 'if', 'initial', 'treatment', 'proves', 'insufficient', '.', 'This', 'project', 'is', 'a', 'pilot', 'study', 'of', 'the', 'first', 'two', 'steps', 'in', 'a', 'stepped', 'care', 'model', 'of', 'treatment', '.', 'After', 'baseline', 'assessment', ',', '50', 'participants', 'with', 'TTM', 'will', 'be', 'randomly', 'assigned', 'to', '(', 'a', ')', 'Immediate', 'condition', ',', 'in', 'which', 'they', 'are', 'offered', '10', '-', 'week', 'self', '-', 'help', 'treatment', 'via', 'an', 'interactive', 'website', '(', 'Step', '1', ')', 'or', '(', 'b', ')', 'Wait', 'List', '/', 'Delayed', 'Start', 'condition', ',', 'a', '10', '-', 'week', 'wait', 'list', 'prior', 'to', 'being', 'offered', 'Step', '1', '.', 'In', 'each', 'condition', ',', 'at', 'the', 'end', 'of', 'Step', '1', ',', 'participants', 'will', 'be', 'offered', '8', 'weeks', 'of', 'in', '-', 'person', 'habit', 'reversal', 'training', 'provided', 'by', 'psychology', 'graduate', 'students', '(', 'Step', '2', ')', '.', 'TTM', 'symptoms', 'will', 'be', 'measured', 'from', 'baseline', 'through', 'a', 'follow', '-', 'up', '3', 'months', 'after', 'the', 'end', 'of', 'Step', '2', ',', 'as', 'will', 'depression', ',', 'anxiety', ',', 'quality', 'of', 'life', ',', 'functional', 'impairment', ',', 'treatment', 'utilization', ',', 'and', 'treatment', 'satisfaction', '.', '\n\n', 'The', 'specific', 'aims', 'of', 'the', 'study', 'are', ':', '\n\n', 'To', 'gather', 'preliminary', 'data', 'on', 'the', 'efficacy', 'of', 'web', '-', 'based', 'self', '-', 'help', ',', 'compared', 'to', 'wait', 'list', 'control', ';', '\n', 'To', 'characterize', 'the', 'acceptability', 'of', 'stepped', 'care', 'to', 'patients', 'with', 'TTM', 'by', 'assessing', 'the', 'proportion', 'of', 'enrolled', 'participants', 'who', 'proceed', 'from', 'step', '1', 'to', 'step', '2', 'treatment', ';', '\n', 'To', 'evaluate', 'the', 'convergent', 'validity', 'of', 'four', 'decision', 'rules', 'for', 'concluding', 'that', 'a', 'patient', 'with', 'TTM', 'has', 'benefited', 'sufficiently', 'from', 'a', 'treatment', 'step', ':', '(', 'a', ')', 'No', 'longer', 'meeting', 'TTM', 'diagnostic', 'criteria', ';', '(', 'b', ')', 'Showing', 'a', '25', '%', 'or', 'greater', 'reduction', 'in', 'total', 'scores', 'on', 'self', '-', 'report', 'and', 'clinician', '-', 'rated', 'TTM', 'symptoms', ';', '(', 'c', ')', 'achieving', 'complete', 'abstinence', 'from', 'hair', '-', 'pulling', ';', 'and', '(', 'd', ')', 'clinically', 'significant', 'response', 'on', 'both', 'self', '-', 'report', 'and', 'clinician', '-', 'rated', 'TTM', 'symptom', 'measures', '\n', 'To', 'evaluate', 'the', 'concurrent', 'and', 'predictive', 'validity', 'of', 'criteria', 'for', 'sufficient', 'benefit', 'from', 'a', 'treatment', 'step', 'by', 'relating', 'them', 'to', 'treatment', 'satisfaction', ',', 'treatment', 'utilization', ',', 'and', 'scores', 'on', 'a', 'measure', 'of', 'functional', 'impairment', 'from', 'TTM', '.']","['B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01118637,NCT01118637,"Stepped Care in the Treatment of Trichotillomania | Trichotillomania (TTM), repetitive pulling out of one's own hair to the extent that noticeable hair loss occurs, is a distressing condition interfering substantially with functioning and quality of life. The longterm objective of this research is to determine whether psychological treatment of TTM could be disseminated more effectively by using a stepped care model in which less intensive interventions are tried first, with more intensive interventions used only if initial treatment proves insufficient. This project is a pilot study of the first two steps in a stepped care model of treatment. After baseline assessment, 50 participants with TTM will be randomly assigned to (a) Immediate condition, in which they are offered 10-week self-help treatment via an interactive website (Step 1) or (b) Wait List/Delayed Start condition, a 10-week wait list prior to being offered Step 1. In each condition, at the end of Step 1, participants will be offered 8 weeks of in-person habit reversal training provided by psychology graduate students (Step 2). TTM symptoms will be measured from baseline through a follow-up 3 months after the end of Step 2, as will depression, anxiety, quality of life, functional impairment , treatment utilization, and treatment satisfaction.

The specific aims of the study are:

To gather preliminary data on the efficacy of web-based self-help, compared to wait list control;
To characterize the acceptability of stepped care to patients with TTM by assessing the proportion of enrolled participants who proceed from step 1 to step 2 treatment;
To evaluate the convergent validity of four decision rules for concluding that a patient with TTM has benefited sufficiently from a treatment step: (a) No longer meeting TTM diagnostic criteria; (b) Showing a 25% or greater reduction in total scores on self-report and clinician-rated TTM symptoms; (c) achieving complete abstinence from hair-pulling; and (d) clinically significant response on both self-report and clinician-rated TTM symptom measures
To evaluate the concurrent and predictive validity of criteria for sufficient benefit from a treatment step by relating them to treatment satisfaction, treatment utilization, and scores on a measure of functional impairment from TTM.","[(0, 12, 'BEHAVIOURAL', 'Stepped Care'), (33, 49, 'CONDITION', 'Trichotillomania'), (52, 68, 'CONDITION', 'Trichotillomania'), (70, 73, 'CONDITION', 'TTM'), (320, 343, 'BEHAVIOURAL', 'psychological treatment'), (347, 350, 'CONDITION', 'TTM'), (401, 419, 'BEHAVIOURAL', 'stepped care model'), (619, 637, 'BEHAVIOURAL', 'stepped care model'), (700, 703, 'CONDITION', 'TTM'), (819, 838, 'BEHAVIOURAL', 'interactive website'), (855, 878, 'CONTROL', 'Wait List/Delayed Start'), (1022, 1055, 'BEHAVIOURAL', 'in-person habit reversal training'), (1107, 1110, 'CONDITION', 'TTM'), (1213, 1223, 'CONDITION', 'depression'), (1225, 1232, 'CONDITION', 'anxiety'), (1410, 1429, 'BEHAVIOURAL', 'web-based self-help'), (1443, 1452, 'CONTROL', 'wait list'), (1499, 1511, 'BEHAVIOURAL', 'stepped care'), (1529, 1532, 'CONDITION', 'TTM'), (1725, 1728, 'CONDITION', 'TTM'), (1801, 1804, 'CONDITION', 'TTM'), (1916, 1919, 'CONDITION', 'TTM'), (2063, 2066, 'CONDITION', 'TTM'), (2313, 2316, 'CONDITION', 'TTM')]"
"['A', 'Phase', '1', '-', '3', ',', 'Double', '-', 'Blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'Intrathecally', 'Administered', 'ION373', 'in', 'Patients', 'With', 'Alexander', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'ION373', 'in', 'improving', 'or', 'stabilizing', 'gross', 'motor', 'function', 'across', 'the', 'full', 'range', 'of', 'affected', 'domains', 'in', 'patients', 'with', 'AxD.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",NCT04849741,NCT04849741,"A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease | The purpose of this study is to evaluate the safety and efficacy of ION373 in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.","[(39, 46, 'CONTROL', 'Placebo'), (166, 172, 'DRUG', 'ION373'), (190, 207, 'CONDITION', 'Alexander Disease'), (278, 284, 'DRUG', 'ION373'), (393, 397, 'CONDITION', 'AxD.')]"
"['A', 'Multicenter', ',', 'Open', '-', 'label', 'Extension', ',', 'Multiple', 'Dose', ',', 'Parallel', 'Group', 'Study', 'To', 'Investigate', 'The', 'Long', '-', 'term', 'Safety', 'And', 'Tolerability', 'Of', 'Aab-003', '(', 'Pf-05236812', ')', 'Administered', 'Intravenously', 'In', 'Subjects', 'With', 'Mild', 'To', 'Moderate', 'Alzheimer', ""'s"", 'Disease', 'Previously', 'Treated', 'With', 'Aab-003', 'Or', 'Placebo', 'In', 'Protocol', 'B2601001', '|', 'This', 'is', 'a', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'multiple', 'doses', 'of', 'AAB-003', '(', 'PF-05236812', ')', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', ""'s"", 'Disease', '.', 'Patients', 'who', 'complete', 'study', 'B2601001', 'may', 'participate', 'in', 'this', 'trial', 'and', 'receive', 'AAB-003', '(', 'PF-05236812', ')', '.', 'Each', 'patient', ""'s"", 'participation', 'will', 'last', 'approximately', '52', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01369225,NCT01369225,"A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001 | This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.","[(129, 136, 'DRUG', 'Aab-003'), (138, 149, 'DRUG', 'Pf-05236812'), (195, 231, 'CONDITION', ""Mild To Moderate Alzheimer's Disease""), (256, 263, 'DRUG', 'Aab-003'), (267, 274, 'CONTROL', 'Placebo'), (375, 382, 'DRUG', 'AAB-003'), (384, 395, 'DRUG', 'PF-05236812'), (414, 450, 'CONDITION', ""mild to moderate Alzheimer's Disease""), (531, 538, 'DRUG', 'AAB-003'), (540, 551, 'DRUG', 'PF-05236812')]"
"['Evaluation', 'of', 'the', 'Effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'and', 'Mirror', 'Therapy', 'in', 'Hemiplegia', 'Rehabilitation', ';', 'Prospective', ',', 'Randomized', ',', 'Controlled', ',', 'Single', '-', 'Blinded', 'Study', '|', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'evaluate', 'whether', 'or', 'not', 'NMES', 'in', 'front', 'of', 'the', 'mirror', 'brings', 'an', 'additional', 'benefit', 'to', 'mirror', 'therapy', 'alone', 'or', 'NMES', 'alone', 'on', 'upper', 'extremity', 'motor', 'and', 'functional', 'development', ',', 'spasticity', ',', 'anxiety', ',', 'depression', ',', 'cognitive', 'function', 'and', 'activities', 'of', 'daily', 'living', ',', 'and', 'neuropathic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04913506,NCT04913506,"Evaluation of the Effects of Neuromuscular Electrical Stimulation and Mirror Therapy in Hemiplegia Rehabilitation; Prospective, Randomized, Controlled, Single-Blinded Study | In this study, it was aimed to evaluate whether or not NMES in front of the mirror brings an additional benefit to mirror therapy alone or NMES alone on upper extremity motor and functional development, spasticity, anxiety, depression, cognitive function and activities of daily living, and neuropathic pain.","[(29, 65, 'OTHER', 'Neuromuscular Electrical Stimulation'), (70, 84, 'OTHER', 'Mirror Therapy'), (88, 98, 'CONDITION', 'Hemiplegia'), (230, 257, 'OTHER', 'NMES in front of the mirror'), (290, 310, 'CONTROL', 'mirror therapy alone'), (314, 324, 'CONTROL', 'NMES alone'), (378, 388, 'CONDITION', 'spasticity'), (390, 397, 'CONDITION', 'anxiety'), (399, 409, 'CONDITION', 'depression'), (466, 482, 'CONDITION', 'neuropathic pain')]"
"['Efficacy', 'of', 'Hypnotherapy', 'Compared', 'to', 'a', 'Wait', '-', 'list', 'Control', 'Group', 'in', 'the', 'Treatment', 'of', 'Agoraphobia', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'Hypnotherapy', 'for', 'the', 'treatment', 'of', 'Agoraphobia', 'compared', 'to', 'a', 'wait', '-', 'list', 'control', 'group', '.']","['O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",NCT03684577,NCT03684577,Efficacy of Hypnotherapy Compared to a Wait-list Control Group in the Treatment of Agoraphobia | The purpose of the study is to compare the efficacy of Hypnotherapy for the treatment of Agoraphobia compared to a wait-list control group.,"[(12, 24, 'BEHAVIOURAL', 'Hypnotherapy'), (39, 56, 'CONTROL', 'Wait-list Control'), (83, 94, 'CONDITION', 'Agoraphobia'), (152, 164, 'BEHAVIOURAL', 'Hypnotherapy'), (186, 197, 'CONDITION', 'Agoraphobia'), (212, 229, 'CONTROL', 'wait-list control')]"
"['The', 'Effect', 'of', 'Vaporized', 'Cannabis', 'on', 'Neuropathic', 'Pain', 'in', 'Spinal', 'Cord', 'Injury', '|', 'This', 'study', 'will', 'demonstrate', 'that', 'vaporized', 'marijuana', 'results', 'in', 'antinociception', 'when', 'compared', 'to', 'placebo', 'in', 'subjects', 'with', 'spinal', 'cord', 'injury', '.', 'To', 'further', 'evaluate', 'potential', 'benefits', 'and', 'side', 'effects', ',', 'the', 'effect', 'of', 'different', 'strengths', 'of', 'cannabis', 'on', 'mood', ',', 'cognition', ',', 'and', 'psychomotor', 'performance', 'will', 'also', 'be', 'measured', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01555983,NCT01555983,"The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury | This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.","[(24, 32, 'OTHER', 'Cannabis'), (36, 52, 'CONDITION', 'Neuropathic Pain'), (56, 74, 'CONDITION', 'Spinal Cord Injury'), (120, 129, 'OTHER', 'marijuana'), (174, 181, 'CONTROL', 'placebo'), (199, 217, 'CONDITION', 'spinal cord injury'), (313, 321, 'OTHER', 'cannabis')]"
"['Randomised', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', ',', 'Placebo', '-', 'controlled', ',', 'Fixed', '-', 'dose', 'Study', 'of', 'Rasagiline', 'in', 'Early', 'Parkinson', ""'s"", 'Disease', 'Patients', 'Not', 'Treated', 'With', 'Levodopa', 'in', 'China', '|', 'Rasagiline', 'has', 'been', 'developed', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', ',', 'as', 'monotherapy', 'in', 'early', 'PD', 'patients', 'not', 'treated', 'with', 'levodopa', ',', 'and', 'as', 'adjunct', 'therapy', 'to', 'levodopa', 'in', 'levodopa', '-', 'treated', 'PD', 'patients', 'with', 'motor', 'fluctuations', '.', '\n\n', 'The', 'rationale', 'for', 'conducting', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'tolerability', ',', 'and', 'safety', 'of', 'rasagiline', 'compared', 'to', 'placebo', 'in', 'Chinese', 'PD', 'patients', 'not', 'treated', 'with', 'levodopa', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT01556165,NCT01556165,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China | Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor fluctuations.

The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.","[(42, 49, 'CONTROL', 'Placebo'), (82, 92, 'DRUG', 'Rasagiline'), (96, 121, 'CONDITION', ""Early Parkinson's Disease""), (148, 156, 'DRUG', 'Levodopa'), (168, 178, 'DRUG', 'Rasagiline'), (219, 238, 'CONDITION', ""Parkinson's Disease""), (240, 242, 'CONDITION', 'PD'), (263, 271, 'CONDITION', 'early PD'), (334, 342, 'DRUG', 'levodopa'), (346, 354, 'DRUG', 'levodopa'), (363, 365, 'CONDITION', 'PD'), (498, 508, 'DRUG', 'rasagiline'), (521, 528, 'CONTROL', 'placebo'), (540, 542, 'CONDITION', 'PD'), (569, 577, 'DRUG', 'levodopa')]"
"['Developing', 'Effective', 'Response', 'Inhibition', 'Training', 'for', 'Symptom', 'Relief', 'in', 'Obsessive', '-', 'Compulsive', 'and', 'Related', 'Disorders', 'and', 'Trichotillomania', '|', 'Obsessive', '-', 'compulsive', 'disorder', '(', 'OCD', ')', 'and', 'its', 'related', 'disorders', '(', 'e.g.', ',', 'trichotillomania', ')', 'are', 'characterized', 'by', 'the', 'marked', 'difficulty', 'in', 'inhibiting', 'unwanted', 'or', 'inappropriate', 'responses', '.', 'There', 'is', 'compelling', 'evidence', 'that', 'poor', 'response', 'inhibition', 'is', 'a', 'core', 'cognitive', 'feature', 'of', 'OCD', 'and', 'its', 'related', 'disorders', ',', 'but', 'no', 'effective', 'intervention', 'exists', 'that', 'directly', 'attempts', 'to', 'address', 'this', 'problematic', 'cognitive', 'deficiency', '.', 'This', 'study', 'will', 'examine', 'the', 'feasibility', 'and', 'clinical', 'utility', 'of', 'a', 'computerized', 'cognitive', 'training', 'program', 'designed', 'to', 'improve', 'response', 'inhibition', 'among', 'individuals', 'diagnosed', 'with', 'OCD', 'or', 'trichotillomania', '.', 'This', 'training', 'program', 'offers', 'systematic', 'practice', 'of', 'response', 'inhibition', 'in', 'the', 'form', 'of', 'a', '40', '-', 'level', 'computer', 'game', '.', 'Individuals', 'with', 'these', 'conditions', 'will', 'be', 'randomized', 'to', 'either', '8', 'sessions', 'of', '(', 'a', ')', 'computerized', 'response', 'inhibition', 'training', '(', 'RIT', ')', 'or', '(', 'b', ')', 'placebo', 'computer', 'training', '(', 'PLT', ')', '.', 'We', 'hypothesize', 'that', 'RIT', 'will', 'outperform', 'PLT', 'in', 'improving', 'response', 'inhibition', 'capabilities', 'and', 'reducing', 'relevant', 'clinical', 'symptoms', '.', 'In', 'sum', ',', 'this', 'project', 'is', 'expected', 'to', 'generate', 'important', 'knowledge', 'to', 'guide', 'the', 'development', 'of', 'effective', 'computer', '-', 'based', 'treatment', 'approaches', 'that', 'may', 'help', 'reduce', 'critical', 'problems', 'of', 'existing', 'treatments', 'such', 'as', 'suboptimal', 'patient', 'retention', 'and', 'treatment', 'under', '-', 'utilization', ',', 'thereby', 'improving', 'overall', 'treatment', 'response', 'rates', 'among', 'individuals', 'suffering', 'from', 'OCD', 'and', 'related', 'conditions', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT02059980,NCT02059980,"Developing Effective Response Inhibition Training for Symptom Relief in Obsessive-Compulsive and Related Disorders and Trichotillomania | Obsessive-compulsive disorder (OCD) and its related disorders (e.g., trichotillomania) are characterized by the marked difficulty in inhibiting unwanted or inappropriate responses. There is compelling evidence that poor response inhibition is a core cognitive feature of OCD and its related disorders, but no effective intervention exists that directly attempts to address this problematic cognitive deficiency. This study will examine the feasibility and clinical utility of a computerized cognitive training program designed to improve response inhibition among individuals diagnosed with OCD or trichotillomania.This training program offers systematic practice of response inhibition in the form of a 40-level computer game. Individuals with these conditions will be randomized to either 8 sessions of (a) computerized response inhibition training (RIT) or (b) placebo computer training (PLT). We hypothesize that RIT will outperform PLT in improving response inhibition capabilities and reducing relevant clinical symptoms. In sum, this project is expected to generate important knowledge to guide the development of effective computer-based treatment approaches that may help reduce critical problems of existing treatments such as suboptimal patient retention and treatment under-utilization, thereby improving overall treatment response rates among individuals suffering from OCD and related conditions.","[(21, 49, 'BEHAVIOURAL', 'Response Inhibition Training'), (72, 114, 'CONDITION', 'Obsessive-Compulsive and Related Disorders'), (119, 135, 'CONDITION', 'Trichotillomania'), (138, 167, 'CONDITION', 'Obsessive-compulsive disorder'), (169, 172, 'CONDITION', 'OCD'), (207, 223, 'CONDITION', 'trichotillomania'), (409, 412, 'CONDITION', 'OCD'), (528, 548, 'CONDITION', 'cognitive deficiency'), (616, 655, 'BEHAVIOURAL', 'computerized cognitive training program'), (729, 732, 'CONDITION', 'OCD'), (736, 752, 'CONDITION', 'trichotillomania'), (782, 824, 'BEHAVIOURAL', 'systematic practice of response inhibition'), (842, 864, 'BEHAVIOURAL', '40-level computer game'), (947, 988, 'BEHAVIOURAL', 'computerized response inhibition training'), (990, 993, 'BEHAVIOURAL', 'RIT'), (1002, 1027, 'CONTROL', 'placebo computer training'), (1029, 1032, 'CONTROL', 'PLT'), (1055, 1058, 'BEHAVIOURAL', 'RIT'), (1075, 1078, 'CONTROL', 'PLT'), (1521, 1524, 'CONDITION', 'OCD')]"
"['Caregiver', 'Burden', 'and', 'Depression', ':', 'Caring', 'for', 'Those', 'Who', 'Care', 'for', 'Others', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effectiveness', 'of', 'support', 'group', 'intervention', 'for', 'primary', 'caregivers', 'of', 'a', 'person', 'with', 'dementia', 'or', 'similar', 'cognitive', 'impairment', '.']","['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02690896,NCT02690896,Caregiver Burden and Depression: Caring for Those Who Care for Others | The purpose of this study is to examine the effectiveness of support group intervention for primary caregivers of a person with dementia or similar cognitive impairment.,"[(21, 31, 'CONDITION', 'Depression'), (133, 159, 'BEHAVIOURAL', 'support group intervention')]"
"['A', 'Prospective', ',', 'International', ',', 'Multi', '-', 'centric', ',', 'Open', '-', 'label', 'Study', 'to', 'Assess', 'the', 'Efficacy', 'of', 'an', 'Extended', 'Injection', 'Interval', 'Schedule', 'of', 'Lanreotide', 'Autogel', '120', 'mg', 'in', 'Acromegalic', 'Subjects', 'Who', 'Are', 'Biochemically', 'Controlled', 'on', 'the', 'Long', 'Term', 'Treatment', 'With', 'Octreotide', 'LAR', '10', 'or', '20', 'mg', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'an', 'extended', 'injection', 'interval', 'schedule', 'of', 'lanreotide', 'Autogel', '120', 'mg', 'in', 'acromegalic', 'subjects', 'who', 'are', 'biochemically', 'controlled', 'on', 'long', 'term', 'treatment', 'with', 'octreotide', 'LAR', '10', 'or', '20', 'mg']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT00701363,NCT00701363,"A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg | The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg","[(131, 141, 'DRUG', 'Lanreotide'), (160, 171, 'CONDITION', 'Acromegalic'), (246, 256, 'DRUG', 'Octreotide'), (372, 382, 'DRUG', 'lanreotide'), (401, 412, 'CONDITION', 'acromegalic'), (483, 493, 'DRUG', 'octreotide')]"
"['French', 'Language', 'Validation', 'of', 'the', 'Phone', 'Version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', '(', 'MoCA', ')', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'validate', 'a', 'french', 'version', 'of', 'the', '5', 'minutes', 'version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', 'as', 'compared', 'to', 'the', 'french', 'full', 'version', 'of', 'this', 'test', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03232697,NCT03232697,French Language Validation of the Phone Version of the Montreal Cognitive Assessment (MoCA) | The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.,[]
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', 'Phase', '3', 'Study', 'of', 'Masitinib', 'as', 'add', '-', 'on', 'Therapy', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '|', 'Masitinib', 'is', 'an', 'orally', 'administered', 'tyrosine', 'kinase', 'inhibitor', 'that', 'targets', 'activated', 'cells', 'of', 'the', 'neuroimmune', 'system', '(', 'mast', 'cells', 'and', 'microglia', ')', '.', 'Study', 'AB21004', 'will', 'evaluate', 'masitinib', 'as', 'an', 'adjunct', 'to', 'cholinesterase', 'inhibitor', 'and/or', 'memantine', 'in', 'patients', 'with', 'mild', '-', 'to', '-', 'moderate', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05564169,NCT05564169,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease | Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.","[(41, 48, 'CONTROL', 'Placebo'), (93, 102, 'DRUG', 'Masitinib'), (138, 174, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (177, 186, 'DRUG', 'Masitinib'), (213, 238, 'DRUG', 'tyrosine kinase inhibitor'), (350, 359, 'DRUG', 'masitinib'), (377, 401, 'DRUG', 'cholinesterase inhibitor'), (409, 418, 'DRUG', 'memantine'), (436, 472, 'CONDITION', ""mild-to-moderate Alzheimer's disease"")]"
"['A', 'Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', 'Controlled', 'Trial', 'of', 'FMT', 'Combined', 'With', 'Antipsychotic', 'Drugs', 'to', 'Improve', 'the', 'Efficacy', 'of', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'explore', 'whether', 'repeated', 'oral', 'fecal', 'capsules', 'could', 'improve', 'outcomes', 'in', 'patients', 'with', 'schizophrenia', 'receiving', 'conventional', 'antipsychotic', 'drugs', '.', 'This', 'study', 'was', 'divided', 'into', 'screening', 'period', '(', '1', 'week', ')', 'and', 'treatment', 'period', '(', '8', 'weeks', ')', '.', 'Subjects', 'who', 'met', 'the', 'inclusion', 'criteria', 'during', 'the', 'screening', 'period', 'entered', 'the', 'treatment', 'period', '.', 'During', 'the', 'treatment', 'period', ',', 'the', 'patients', 'were', 'divided', 'into', 'two', 'groups', ':', 'oral', 'fecal', 'bacteria', 'capsules', '+', 'antipsychotics', 'group', ';', 'Oral', 'placebo', '+', 'antipsychotic', 'group', '.', 'During', 'the', 'follow', '-', 'up', 'period', ',', 'both', 'groups', 'were', 'treated', 'with', 'stable', 'dose', 'of', 'antipsychotic', 'drugs', 'during', 'the', 'treatment', 'period', '.', 'Before', 'and', 'after', 'the', 'intervention', ',', 'venous', 'blood', 'samples', 'of', 'patients', 'were', 'collected', 'for', 'routine', 'tests', 'such', 'as', 'liver', 'and', 'kidney', 'function', 'to', 'determine', 'the', 'safety', 'of', 'treatment', '.', 'The', 'scale', 'evaluated', 'the', 'improvement', 'of', 'patients', ""'"", 'psychotic', 'symptoms', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'FMT', 'combined', 'with', 'antipsychotics', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-DRUG', 'O']",NCT05850585,NCT05850585,"A Prospective, Double-blind, Randomized Controlled Trial of FMT Combined With Antipsychotic Drugs to Improve the Efficacy of Schizophrenia | The purpose of this study was to explore whether repeated oral fecal capsules could improve outcomes in patients with schizophrenia receiving conventional antipsychotic drugs. This study was divided into screening period (1 week) and treatment period (8 weeks). Subjects who met the inclusion criteria during the screening period entered the treatment period. During the treatment period, the patients were divided into two groups: oral fecal bacteria capsules + antipsychotics group; Oral placebo + antipsychotic group. During the follow-up period, both groups were treated with stable dose of antipsychotic drugs during the treatment period. Before and after the intervention, venous blood samples of patients were collected for routine tests such as liver and kidney function to determine the safety of treatment. The scale evaluated the improvement of patients' psychotic symptoms to determine the efficacy and safety of FMT combined with antipsychotics.","[(60, 63, 'OTHER', 'FMT'), (78, 91, 'DRUG', 'Antipsychotic'), (125, 138, 'CONDITION', 'Schizophrenia'), (199, 218, 'OTHER', 'oral fecal capsules'), (259, 272, 'CONDITION', 'schizophrenia'), (296, 309, 'DRUG', 'antipsychotic'), (573, 601, 'OTHER', 'oral fecal bacteria capsules'), (604, 618, 'DRUG', 'antipsychotics'), (631, 638, 'CONTROL', 'placebo'), (641, 654, 'DRUG', 'antipsychotic'), (736, 749, 'DRUG', 'antipsychotic'), (1007, 1016, 'CONDITION', 'psychotic'), (1066, 1069, 'OTHER', 'FMT'), (1084, 1098, 'DRUG', 'antipsychotics')]"
"['Cognitive', '-', 'Behavioral', 'Therapy', 'for', 'Disruptive', 'Behavior', 'in', 'Children', 'and', 'Adolescents', '(', 'An', 'Open', 'Pilot', 'Study', 'in', 'Autism', 'Spectrum', 'Disorder', ')', '|', 'In', 'addition', 'to', 'the', 'core', 'symptoms', ',', 'children', 'and', 'adolescents', 'with', 'Autism', 'Spectrum', 'Disorder', '(', 'ASD', ')', 'often', 'exhibit', 'disruptive', 'behavior', 'problems', 'including', 'irritability', ',', 'tantrums', ',', 'noncompliance', ',', 'and', 'aggression', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'cognitive', '-', 'behavioral', 'therapy', '(', 'CBT', ')', 'for', 'disruptive', 'behavior', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', 'and', 'intellectual', 'disability', '.', 'This', 'pilot', 'study', 'will', 'include', 'children', 'with', 'ASD', 'and', 'IQ', 'between', '55', 'and', '85', 'in', 'an', 'open', 'study', 'of', 'CBT', '.', 'CBT', 'is', 'modified', 'in', 'this', 'study', 'to', 'reduce', 'complexity', 'of', 'activities', 'during', 'therapy', 'sessions', 'but', 'retains', 'all', 'key', 'elements', 'and', 'principles', 'of', 'CBT', '.', 'Assessments', 'of', 'irritability', 'and', 'disruptive', 'behavior', 'will', 'include', 'clinical', 'interviews', ',', 'parent', 'ratings', 'and', 'child', 'self', '-', 'report', 'measures', '.', 'Study', 'participants', 'will', 'be', 'asked', 'to', 'complete', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'to', 'evaluate', 'biomarkers', 'of', 'social', 'perception', 'and', 'emotion', 'regulation', 'before', 'and', 'after', 'CBT', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O']",NCT02914951,NCT02914951,"Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents (An Open Pilot Study in Autism Spectrum Disorder) | In addition to the core symptoms, children and adolescents with Autism Spectrum Disorder (ASD) often exhibit disruptive behavior problems including irritability, tantrums, noncompliance, and aggression. The purpose of this study is to investigate cognitive-behavioral therapy (CBT) for disruptive behavior in children with autism spectrum disorders and intellectual disability. This pilot study will include children with ASD and IQ between 55 and 85 in an open study of CBT. CBT is modified in this study to reduce complexity of activities during therapy sessions but retains all key elements and principles of CBT. Assessments of irritability and disruptive behavior will include clinical interviews, parent ratings and child self-report measures. Study participants will be asked to complete functional magnetic resonance imaging (fMRI) to evaluate biomarkers of social perception and emotion regulation before and after CBT.","[(0, 28, 'BEHAVIOURAL', 'Cognitive-Behavioral Therapy'), (33, 52, 'CONDITION', 'Disruptive Behavior'), (105, 129, 'CONDITION', 'Autism Spectrum Disorder'), (197, 221, 'CONDITION', 'Autism Spectrum Disorder'), (223, 226, 'CONDITION', 'ASD'), (242, 261, 'CONDITION', 'disruptive behavior'), (380, 408, 'BEHAVIOURAL', 'cognitive-behavioral therapy'), (410, 413, 'BEHAVIOURAL', 'CBT'), (419, 438, 'CONDITION', 'disruptive behavior'), (456, 481, 'CONDITION', 'autism spectrum disorders'), (486, 509, 'CONDITION', 'intellectual disability'), (555, 558, 'CONDITION', 'ASD'), (604, 607, 'BEHAVIOURAL', 'CBT'), (609, 612, 'BEHAVIOURAL', 'CBT'), (745, 748, 'BEHAVIOURAL', 'CBT'), (782, 801, 'CONDITION', 'disruptive behavior'), (1057, 1060, 'BEHAVIOURAL', 'CBT')]"
"['Ketamine', ""'s"", 'Efficiency', 'in', 'the', 'Treatment', 'of', 'Chronic', 'Pain', 'With', 'an', 'Added', 'Inflammatory', 'Component', 'Exploring', 'the', 'Kynurenin', 'Pathway', '.', 'A', 'Randomized', ',', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'kynurenine', 'pathway', 'is', 'involved', 'in', 'hyperalgesia', '.', 'This', 'pathway', 'is', 'activated', 'by', 'inflammation', '.', 'Ketamine', 'would', 'interact', 'with', 'the', 'kynurenine', 'pathway', 'and', 'inflammation', '.', 'Our', 'working', 'hypotheses', 'are', ':', 'the', 'clinical', 'effects', 'of', 'ketamine', 'on', 'neuropathic', 'pain', 'are', 'greater', 'in', 'the', 'presence', 'of', 'systemic', 'inflammation', 'and', 'the', 'mechanism', 'of', 'action', 'involves', 'an', 'interaction', 'on', 'the', 'kynurenine', 'pathway', '.', '\n\n', 'Study', 'design', ':', 'Interventional', 'randomized', 'placebo', '-', 'controlled', 'clinical', 'trial', '.', '\n\n', '￼', 'Main', 'goals', ':', '\n\n', 'To', 'show', 'a', 'better', 'clinical', 'efficacy', 'of', 'ketamine', 'in', 'chronic', 'pain', 'in', 'patients', 'with', 'an', 'inflammatory', 'component', '.', '\n', 'Explore', 'the', 'anti', '-', 'inflammatory', 'activity', 'of', 'ketamine', 'through', 'the', 'Kynurenine', 'pathway', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",NCT03513822,NCT03513822,"Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial | The kynurenine pathway is involved in hyperalgesia. This pathway is activated by inflammation. Ketamine would interact with the kynurenine pathway and inflammation. Our working hypotheses are: the clinical effects of ketamine on neuropathic pain are greater in the presence of systemic inflammation and the mechanism of action involves an interaction on the kynurenine pathway.

Study design: Interventional randomized placebo-controlled clinical trial.

￼Main goals:

To show a better clinical efficacy of ketamine in chronic pain in patients with an inflammatory component.
Explore the anti-inflammatory activity of ketamine through the Kynurenine pathway.","[(0, 8, 'DRUG', 'Ketamine'), (42, 54, 'CONDITION', 'Chronic Pain'), (153, 160, 'CONTROL', 'Placebo'), (275, 283, 'DRUG', 'Ketamine'), (397, 405, 'DRUG', 'ketamine'), (409, 425, 'CONDITION', 'neuropathic pain'), (599, 606, 'CONTROL', 'placebo'), (687, 695, 'DRUG', 'ketamine'), (699, 711, 'CONDITION', 'chronic pain'), (798, 806, 'DRUG', 'ketamine')]"
"['L', '-', 'carnitine', 'for', 'Reducing', 'Cardio', '-', 'metabolic', 'Risk', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '-', 'Double', 'Blind', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'investigators', 'designed', 'this', 'intervention', 'to', 'investigate', 'the', 'potential', 'role', 'of', 'L', '-', 'C', 'in', 'lipid', 'and', 'carbohydrates', 'metabolism', '(', 'primary', 'outcome', ')', 'with', 'precision', 'noninvasively', 'measurement', 'of', ':', 'central', 'blood', 'pressure', ',', 'pulse', 'wave', 'velocity', 'and', 'peripheral', 'arterial', 'stiffness', '(', 'secondary', 'outcome', ')', 'in', 'OSA', 'patients', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT02645942,NCT02645942,"L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea - Double Blind Randomized Clinical Trial | The investigators designed this intervention to investigate the potential role of L-C in lipid and carbohydrates metabolism (primary outcome) with precision noninvasively measurement of: central blood pressure, pulse wave velocity and peripheral arterial stiffness (secondary outcome) in OSA patients.","[(0, 11, 'DRUG', 'L-carnitine'), (64, 87, 'CONDITION', 'Obstructive Sleep Apnea'), (213, 216, 'DRUG', 'L-C'), (419, 422, 'CONDITION', 'OSA')]"
"['""', 'Get', 'up', '""', '-', 'The', 'Sleep', 'Study', 'in', 'Oppegard', '(', 'Stå', 'Opp', '-', 'Søvnstudien', 'i', 'Oppegård', ')', '|', 'A', 'randomized', ',', 'controlled', 'study', 'to', 'examine', 'the', 'effect', 'of', 'group', 'treatment', 'for', 'insomnia', '(', 'CBT', '-', 'I', ')', 'in', 'an', 'outpatient', 'clinic', 'compared', 'with', 'waiting', 'list', 'and', 'treatment', '-', 'as', '-', 'usual', '(', 'sleep', '-', 'hygiene', 'based', 'educational', 'course', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT03177967,NCT03177967,"""Get up"" - The Sleep Study in Oppegard (Stå Opp - Søvnstudien i Oppegård) | A randomized, controlled study to examine the effect of group treatment for insomnia (CBT-I) in an outpatient clinic compared with waiting list and treatment-as-usual (sleep-hygiene based educational course)","[(132, 147, 'BEHAVIOURAL', 'group treatment'), (152, 160, 'CONDITION', 'insomnia'), (207, 219, 'CONTROL', 'waiting list'), (224, 242, 'CONTROL', 'treatment-as-usual'), (244, 282, 'CONTROL', 'sleep-hygiene based educational course')]"
"['Phase', 'I', '/', 'II', 'Interventional', 'Clinical', 'Trial', 'of', 'Balloon', 'Venoplasty', 'for', 'Chronic', 'Cerebrospinal', 'Venous', 'Insufficiency', 'in', 'Multiple', 'Sclerosis', 'Patients', '|', 'To', 'investigate', 'the', 'safety', 'and', 'tolerability', 'of', 'balloon', 'venoplasty', 'compared', 'to', 'sham', 'in', 'Multiple', 'Sclerosis', 'patients', 'with', 'Chronic', 'Cerebrospinal', 'Venous', 'Insufficiency', '(', 'CCSVI', ')', 'as', 'measured', 'by', 'adverse', 'events', 'occurring', 'within', '48', 'weeks', 'of', 'the', 'procedure', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'B-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01864941,NCT01864941,Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients | To investigate the safety and tolerability of balloon venoplasty compared to sham in Multiple Sclerosis patients with Chronic Cerebrospinal Venous Insufficiency (CCSVI) as measured by adverse events occurring within 48 weeks of the procedure.,"[(44, 62, 'SURGICAL', 'Balloon Venoplasty'), (67, 109, 'CONDITION', 'Chronic Cerebrospinal Venous Insufficiency'), (113, 131, 'CONDITION', 'Multiple Sclerosis'), (189, 207, 'SURGICAL', 'balloon venoplasty'), (220, 224, 'CONTROL', 'sham'), (228, 246, 'CONDITION', 'Multiple Sclerosis'), (261, 303, 'CONDITION', 'Chronic Cerebrospinal Venous Insufficiency'), (305, 310, 'CONDITION', 'CCSVI')]"
"['Pharmacist', 'Intervention', 'Programme', 'to', 'Improve', 'Medication', 'Adherence', 'in', 'Stroke', 'Patients', '|', 'Patient', 'suffering', 'a', 'Transient', 'Ischemic', 'Attack', '(', 'TIA', ')', 'or', 'stroke', 'are', 'subsequently', 'at', 'high', 'risk', 'of', 'a', 'new', 'stroke', ',', 'however', ',', 'poor', 'adherence', 'to', 'secondary', 'prevention', 'medications', 'occurs', 'frequently', 'within', 'this', 'patient', 'group', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'a', 'complex', 'tailored', 'pharmacist', 'intervention', 'will', 'lead', 'to', 'increased', 'adherence', 'to', 'secondary', 'stroke', 'prevention', 'medications', 'and', 'less', 'new', 'stroke', 'events', 'when', 'compared', 'to', 'a', 'usual', 'care', 'group', '.', 'Interventions', 'focus', 'on', 'motivational', 'interviewing', ',', 'medication', 'review', 'and', 'telephone', 'follow', 'up', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O']",NCT01684176,NCT01684176,"Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients | Patient suffering a Transient Ischemic Attack (TIA) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. The purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.","[(0, 33, 'BEHAVIOURAL', 'Pharmacist Intervention Programme'), (69, 75, 'CONDITION', 'Stroke'), (107, 132, 'CONDITION', 'Transient Ischemic Attack'), (134, 137, 'CONDITION', 'TIA'), (142, 148, 'CONDITION', 'stroke'), (188, 194, 'CONDITION', 'stroke'), (360, 392, 'BEHAVIOURAL', 'tailored pharmacist intervention'), (439, 445, 'CONDITION', 'stroke'), (482, 488, 'CONDITION', 'stroke'), (556, 581, 'BEHAVIOURAL', 'motivational interviewing'), (583, 600, 'BEHAVIOURAL', 'medication review'), (605, 624, 'BEHAVIOURAL', 'telephone follow up')]"
"['Development', 'of', 'New', 'Multi', '-', 'contrasts', 'Approaches', 'by', 'Magnetic', 'Resonance', 'Imaging', 'at', '3', 'Tesla', 'Dedicated', 'to', 'Targeting', 'Subthalamic', 'Nucleus', 'on', 'Parkinsonian', 'Patients', '.', '|', 'Deep', 'brain', 'stimulation', '(', 'DBS', ')', 'of', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', 'is', 'a', 'validated', 'procedure', ',', 'used', 'in', 'many', 'French', 'and', 'international', 'centers', 'for', 'the', 'treatment', 'of', 'severe', 'forms', 'of', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'improvement', 'of', 'parkinsonian', 'motor', 'symptoms', 'by', 'stimulation', 'of', 'the', 'STN', 'is', '50', 'to', '80', '%', 'on', 'average', '.', 'The', 'main', 'advantage', 'of', 'DBS', 'is', 'that', 'the', 'surgery', 'has', 'low', 'morbidity', 'and', 'mortality', ',', 'it', 'is', 'adaptable', 'to', 'the', 'patient', ""'s"", 'symptoms', 'and', 'its', 'effect', 'is', 'reversible', '.', 'This', 'treatment', 'is', 'now', 'a', 'routine', 'and', 'more', 'than', '85,000', 'patients', 'worldwide', 'have', 'benefited', 'from', 'the', 'installation', 'of', 'this', 'system', '.', 'Since', '1997', ',', 'this', 'treatment', 'is', 'available', 'to', 'patients', 'followed', 'in', 'the', 'Pitié', 'Salpêtrière', '(', 'GHPS', ')', '.', '\n\n', 'The', 'accuracy', 'of', 'preoperative', 'anatomic', 'targeting', 'in', 'stereotactic', 'neurosurgery', 'will', 'improve', 'with', 'the', 'use', 'of', 'high', '-', 'field', 'MRI', '.', 'However', ',', 'several', 'new', 'issues', 'and', 'inherent', 'in', 'that', 'high', '-', 'field', 'MRI', 'should', 'be', 'evaluated', 'before', 'the', 'images', 'can', 'be', 'used', 'directly', '.', '\n\n', 'The', 'chosen', 'sequences', 'must', 'be', 'short', 'to', 'be', 'feasible', ',', 'minimizing', 'patient', 'discomfort', ',', 'and', 'evaluated', 'on', 'several', 'patients', 'to', 'ensure', 'the', 'low', 'interindividual', 'variability', '.', 'In', 'addition', ',', 'the', 'quality', 'of', 'the', 'display', 'on', 'all', 'of', 'the', 'sections', 'should', 'provide', 'a', 'reliable', 'three', '-', 'dimensional', 'information', '.', 'Finally', ',', 'the', 'quality', 'of', 'targeting', 'and', 'its', 'possible', 'improvement', 'should', 'be', 'checked', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02800460,NCT02800460,"Development of New Multi-contrasts Approaches by Magnetic Resonance Imaging at 3 Tesla Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients. | Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a validated procedure, used in many French and international centers for the treatment of severe forms of Parkinson's disease (PD). The improvement of parkinsonian motor symptoms by stimulation of the STN is 50 to 80% on average. The main advantage of DBS is that the surgery has low morbidity and mortality, it is adaptable to the patient's symptoms and its effect is reversible. This treatment is now a routine and more than 85,000 patients worldwide have benefited from the installation of this system. Since 1997, this treatment is available to patients followed in the Pitié Salpêtrière (GHPS).

The accuracy of preoperative anatomic targeting in stereotactic neurosurgery will improve with the use of high-field MRI. However, several new issues and inherent in that high-field MRI should be evaluated before the images can be used directly.

The chosen sequences must be short to be feasible, minimizing patient discomfort, and evaluated on several patients to ensure the low interindividual variability. In addition, the quality of the display on all of the sections should provide a reliable three-dimensional information. Finally, the quality of targeting and its possible improvement should be checked.","[(133, 145, 'CONDITION', 'Parkinsonian'), (329, 348, 'CONDITION', ""Parkinson's disease""), (350, 352, 'CONDITION', 'PD'), (374, 386, 'CONDITION', 'parkinsonian')]"
"['Pilot', 'Study', 'on', 'the', 'Feasibility', 'of', 'Using', 'Smartphone', 'Data', 'as', 'a', 'Diagnostic', 'Marker', 'for', 'Alzheimer', ""'s"", 'Disease', '.', '|', 'This', 'study', 'will', 'compare', 'smartphone', 'usage', 'data', 'between', 'three', 'groups', 'of', 'patients', 'diagnosed', 'with', 'either', 'a', 'memory', 'complaint', ',', 'mild', 'cognitive', 'decline', ',', 'or', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05709210,NCT05709210,"Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease. | This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.","[(83, 102, 'CONDITION', ""Alzheimer's Disease""), (209, 225, 'CONDITION', 'memory complaint'), (227, 249, 'CONDITION', 'mild cognitive decline'), (254, 273, 'CONDITION', ""Alzheimer's disease"")]"
"['An', 'Open', '-', 'Label', 'Phase', '1b/2', 'Study', 'to', 'Assess', 'Safety', 'and', 'Target', 'Engagement', 'of', 'E2814', 'in', 'Subjects', 'With', 'Mild', 'to', 'Moderate', 'Cognitive', 'Impairment', 'Due', 'to', 'Dominantly', 'Inherited', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'intravenous', '(', 'IV', ')', 'infusions', 'of', 'E2814', 'in', 'participants', 'with', 'dominantly', 'inherited', 'Alzheimer', ""'s"", 'disease', '(', 'DIAD', ')', ',', 'and', 'to', 'evaluate', 'target', 'engagement', '(', 'TE', ')', 'of', 'E2814', 'on', 'microtubule', 'binding', 'region', '(', 'MTBR)-tau', 'species', 'in', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'in', 'participants', 'with', 'DIAD', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04971733,NCT04971733,"An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease | The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.","[(73, 78, 'DRUG', 'E2814'), (96, 133, 'CONDITION', 'Mild to Moderate Cognitive Impairment'), (141, 181, 'CONDITION', ""Dominantly Inherited Alzheimer's Disease""), (293, 298, 'DRUG', 'E2814'), (320, 360, 'CONDITION', ""dominantly inherited Alzheimer's disease""), (362, 366, 'CONDITION', 'DIAD'), (411, 416, 'DRUG', 'E2814'), (516, 520, 'CONDITION', 'DIAD')]"
"['Safety', 'and', 'Usability', 'of', 'the', 'STELO', 'Exoskeleton', 'in', 'People', 'With', 'Acquired', 'Brain', 'Injury', 'and', 'Spinal', 'Cord', 'Injury', '|', 'Gait', 'impairment', 'in', 'people', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'and', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'can', 'be', 'very', 'heterogeneous', '.', 'For', 'this', 'reason', ',', 'STELO', 'has', 'been', 'developed', ':', 'a', 'new', 'concept', 'of', 'exoskeleton', 'based', 'on', 'modular', 'technology', 'for', 'gait', 'assistance', '.', 'It', 'allows', 'a', 'personalised', 'configuration', 'according', 'to', 'the', 'functional', 'capacity', 'of', 'each', 'patient', ',', 'as', 'the', 'therapist', 'can', 'choose', 'which', 'robotic', 'joints', 'to', 'use', 'depending', 'on', 'the', 'therapeutic', 'goal', 'and', 'on', 'the', 'patient', 'recovery', 'phase', '.', 'The', 'objective', 'is', 'to', 'analyse', 'the', 'usability', 'of', 'the', 'STELO', 'modular', 'exoskeleton', 'in', 'people', 'with', 'ABI', 'and', 'SCI', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",NCT05265377,NCT05265377,"Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury | Gait impairment in people with acquired brain injury (ABI) and spinal cord injury (SCI) can be very heterogeneous. For this reason, STELO has been developed: a new concept of exoskeleton based on modular technology for gait assistance. It allows a personalised configuration according to the functional capacity of each patient, as the therapist can choose which robotic joints to use depending on the therapeutic goal and on the patient recovery phase. The objective is to analyse the usability of the STELO modular exoskeleton in people with ABI and SCI.","[(28, 45, 'OTHER', 'STELO Exoskeleton'), (61, 82, 'CONDITION', 'Acquired Brain Injury'), (87, 105, 'CONDITION', 'Spinal Cord Injury'), (108, 123, 'CONDITION', 'Gait impairment'), (139, 160, 'CONDITION', 'acquired brain injury'), (162, 165, 'CONDITION', 'ABI'), (171, 189, 'CONDITION', 'spinal cord injury'), (191, 194, 'CONDITION', 'SCI'), (240, 245, 'OTHER', 'STELO'), (283, 322, 'OTHER', 'exoskeleton based on modular technology'), (611, 636, 'OTHER', 'STELO modular exoskeleton'), (652, 655, 'CONDITION', 'ABI'), (660, 663, 'CONDITION', 'SCI')]"
"['An', 'Open', '-', 'Label', ',', 'Two', '-', 'Part', ',', 'Single', '-', 'Dose', 'Study', 'to', 'Investigate', 'the', 'Pharmacokinetics', 'of', 'MK-8931', 'in', 'Subjects', 'With', 'Renal', 'Insufficiency', '(', 'Protocol', 'No', '.', 'MK-8931', '-', '009', '[', 'P08535', ']', ')', '|', 'This', 'study', 'will', 'assess', 'the', 'pharmacokinetics', 'of', 'MK-8931', ',', 'a', 'ß', '-', 'secretase', 'inhibitor', ',', 'in', 'participants', 'with', 'renal', 'insufficiency', '.', 'In', 'Part', '1', 'of', 'the', 'study', ',', 'pharmacokinetics', 'of', 'MK-8931', 'in', 'participants', 'with', 'severe', 'renal', 'disease', 'and', 'in', 'healthy', 'matched', 'control', 'participants', 'will', 'be', 'studied', '.', 'If', 'data', 'from', 'Part', '1', 'confirms', 'that', 'severe', 'renal', 'impairment', 'does', 'not', 'alter', 'the', 'pharmacokinetics', 'of', 'MK-8931', 'to', 'the', 'extent', 'requiring', 'dosage', 'adjustment', ',', 'then', 'no', 'further', 'study', 'will', 'be', 'required', 'and', 'Part', '2', 'will', 'be', 'optional', '.', 'If', 'the', 'data', 'does', 'not', 'support', 'this', 'conclusion', ',', 'then', 'Part', '2', 'will', 'be', 'conducted', 'to', 'study', 'the', 'pharmacokinetics', 'of', 'MK-8931', 'in', 'participants', 'with', 'moderate', 'and', 'mild', 'renal', 'impairment', 'compared', 'to', 'healthy', 'matched', 'controls', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01537757,NCT01537757,"An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535]) | This study will assess the pharmacokinetics of MK-8931, a ß-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in healthy matched control participants will be studied. If data from Part 1 confirms that severe renal impairment does not alter the pharmacokinetics of MK-8931 to the extent requiring dosage adjustment, then no further study will be required and Part 2 will be optional. If the data does not support this conclusion, then Part 2 will be conducted to study the pharmacokinetics of MK-8931 in participants with moderate and mild renal impairment compared to healthy matched controls.","[(82, 89, 'DRUG', 'MK-8931'), (107, 126, 'CONDITION', 'Renal Insufficiency'), (212, 219, 'DRUG', 'MK-8931'), (223, 244, 'DRUG', 'ß-secretase inhibitor'), (267, 286, 'CONDITION', 'renal insufficiency'), (332, 339, 'DRUG', 'MK-8931'), (361, 381, 'CONDITION', 'severe renal disease'), (540, 547, 'DRUG', 'MK-8931'), (768, 775, 'DRUG', 'MK-8931'), (797, 831, 'CONDITION', 'moderate and mild renal impairment')]"
"['Mechanical', 'Ventilation', 'in', 'Severe', 'Brain', 'Injury', ':', 'The', 'Effect', 'of', 'Positive', 'End', 'Expiratory', 'Pressure', 'on', 'Intracranial', 'Pressure', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'collect', 'physiologic', 'data', 'from', 'patients', 'with', 'severe', 'brain', 'injury', 'who', 'require', 'mechanical', 'ventilation', 'in', 'order', 'to', 'describe', 'the', 'impact', 'of', 'ventilation', ',', 'specifically', 'positive', 'end', 'expiratory', 'pressure', '(', 'PEEP', ')', ',', 'on', 'intracranial', 'pressure', '(', 'ICP', ')', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02680704,NCT02680704,"Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure | The purpose of this study is to collect physiologic data from patients with severe brain injury who require mechanical ventilation in order to describe the impact of ventilation, specifically positive end expiratory pressure (PEEP), on intracranial pressure (ICP).","[(0, 22, 'OTHER', 'Mechanical Ventilation'), (26, 45, 'CONDITION', 'Severe Brain Injury'), (61, 93, 'OTHER', 'Positive End Expiratory Pressure'), (197, 216, 'CONDITION', 'severe brain injury'), (229, 251, 'OTHER', 'mechanical ventilation'), (313, 345, 'OTHER', 'positive end expiratory pressure'), (347, 351, 'OTHER', 'PEEP')]"
"['The', 'Effect', 'of', 'Niacin', 'Supplementation', 'on', 'Systemic', 'Nicotinamide', 'Adenine', 'Dinucleotide', '(', 'NAD+', ')', 'Metabolism', ',', 'Physiology', 'and', 'Muscle', 'Performance', 'in', 'Healthy', 'Controls', 'and', 'Mitochondrial', 'Myopathy', 'Patients', '|', 'The', 'most', 'frequent', 'form', 'of', 'adult', '-', 'onset', 'mitochondrial', 'disorders', 'is', 'mitochondrial', 'myopathy', ',', 'often', 'manifesting', 'with', 'progressive', 'external', 'ophthalmoplegia', '(', 'PEO', ')', ',', 'progressive', 'muscle', 'weakness', 'and', 'exercise', 'intolerance', '.', 'Mitochondrial', 'myopathy', 'is', 'often', 'caused', 'by', 'single', 'heteroplasmic', 'mitochondrial', 'DNA', '(', 'mtDNA', ')', 'deletions', 'or', 'multiple', 'mtDNA', 'deletions', ',', 'the', 'former', 'being', 'sporadic', 'and', 'latter', 'caused', 'by', 'mutations', 'in', 'nuclear', '-', 'encoded', 'proteins', 'of', 'mtDNA', 'maintenance', '.', 'Currently', ',', 'no', 'curative', 'treatment', 'exists', 'for', 'this', 'disease', '.', 'The', 'investigators', 'have', 'previously', 'observed', 'that', 'supplementation', 'with', 'an', 'NAD+', 'precursor', 'vitamin', 'B3', ',', 'nicotinamide', 'riboside', ',', 'prevented', 'and', 'delayed', 'disease', 'symptoms', 'by', 'increasing', 'mitochondrial', 'biogenesis', 'in', 'a', 'mouse', 'model', 'for', 'mitochondrial', 'myopathy', '.', 'Vitamin', 'B3', 'exists', 'in', 'several', 'forms', ':', 'nicotinic', 'acid', '(', 'niacin', ')', ',', 'nicotinamide', ',', 'and', 'nicotinamide', 'riboside', ',', 'and', 'it', 'has', 'been', 'demonstrated', 'to', 'give', 'power', 'to', 'diseased', 'mitochondria', 'in', 'animal', 'studies', 'by', 'increasing', 'intracellular', 'levels', 'of', 'NAD+', ',', 'the', 'important', 'cofactor', 'required', 'for', 'the', 'cellular', 'energy', 'metabolism', '.', '\n\n', 'In', 'this', 'study', ',', 'the', 'form', 'of', 'vitamin', 'B3', ',', 'niacin', ',', 'was', 'used', 'to', 'activate', 'dysfunctional', 'mitochondria', 'and', 'to', 'rescue', 'signs', 'of', 'mitochondrial', 'myopathy', '.', 'Of', 'the', 'vitamin', 'B3', 'forms', ',', 'niacin', ',', 'is', 'employed', ',', 'because', 'it', 'has', 'been', 'used', 'in', 'large', 'doses', 'to', 'treat', 'hypercholesterolemia', 'patients', ',', 'and', 'has', 'a', 'proven', 'safety', 'record', 'in', 'humans', '.', 'Phenotypically', 'similar', 'mitochondrial', 'myopathy', 'patients', 'are', 'studied', ',', 'as', 'the', 'investigator', ""'s"", 'previous', 'expertise', 'indicates', 'that', 'similar', 'presenting', 'phenotypes', 'predict', 'uniform', 'physiological', 'and', 'clinical', 'responses', 'to', 'interventions', ',', 'despite', 'varying', 'genetic', 'backgrounds', '.', 'Patients', 'either', 'with', 'sporadic', 'single', 'mtDNA', 'deletions', 'or', 'a', 'mutation', 'in', 'a', 'Twinkle', 'gene', 'causing', 'multiple', 'mtDNA', 'deletions', 'were', 'recruited', '.', 'In', 'addition', ',', 'for', 'every', 'patient', ',', 'two', 'gender-', 'and', 'age', '-', 'matched', 'healthy', 'controls', 'are', 'recruited', '.', 'Clinical', 'examinations', 'and', 'collection', 'of', 'muscle', 'biopsies', 'are', 'performed', 'at', 'the', 'time', 'points', '0', ',', '4', 'and', '10', 'months', '(', 'patients', ')', 'or', 'at', '0', 'and', '4', 'months', '(', 'controls', ')', '.', 'Fasting', 'blood', 'samples', 'are', 'collected', 'every', 'second', 'week', 'until', '4', 'months', 'and', 'thereafter', 'every', 'six', 'weeks', 'until', 'the', 'end', 'of', 'the', 'study', '.', 'The', 'effects', 'of', 'niacin', 'on', 'disease', 'markers', ',', 'muscle', 'mitochondrial', 'biogenesis', ',', 'muscle', 'strength', 'and', 'the', 'metabolism', 'of', 'the', 'whole', 'body', 'are', 'studied', 'in', 'patients', 'and', 'healthy', 'controls', '.', '\n\n', 'The', 'hypothesis', 'is', 'that', 'an', 'NAD+', 'precursor', ',', 'niacin', ',', 'will', 'increase', 'intracellular', 'NAD+', 'levels', ',', 'improve', 'mitochondrial', 'biogenesis', 'and', 'alleviate', 'the', 'symptoms', 'of', 'mitochondrial', 'myopathy', 'in', 'humans', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",NCT03973203,NCT03973203,"The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients | The most frequent form of adult-onset mitochondrial disorders is mitochondrial myopathy, often manifesting with progressive external ophthalmoplegia (PEO), progressive muscle weakness and exercise intolerance. Mitochondrial myopathy is often caused by single heteroplasmic mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions, the former being sporadic and latter caused by mutations in nuclear-encoded proteins of mtDNA maintenance. Currently, no curative treatment exists for this disease. The investigators have previously observed that supplementation with an NAD+ precursor vitamin B3, nicotinamide riboside, prevented and delayed disease symptoms by increasing mitochondrial biogenesis in a mouse model for mitochondrial myopathy. Vitamin B3 exists in several forms: nicotinic acid (niacin), nicotinamide, and nicotinamide riboside, and it has been demonstrated to give power to diseased mitochondria in animal studies by increasing intracellular levels of NAD+, the important cofactor required for the cellular energy metabolism.

In this study, the form of vitamin B3, niacin, was used to activate dysfunctional mitochondria and to rescue signs of mitochondrial myopathy. Of the vitamin B3 forms, niacin, is employed, because it has been used in large doses to treat hypercholesterolemia patients, and has a proven safety record in humans. Phenotypically similar mitochondrial myopathy patients are studied, as the investigator's previous expertise indicates that similar presenting phenotypes predict uniform physiological and clinical responses to interventions, despite varying genetic backgrounds. Patients either with sporadic single mtDNA deletions or a mutation in a Twinkle gene causing multiple mtDNA deletions were recruited. In addition, for every patient, two gender- and age-matched healthy controls are recruited. Clinical examinations and collection of muscle biopsies are performed at the time points 0, 4 and 10 months (patients) or at 0 and 4 months (controls). Fasting blood samples are collected every second week until 4 months and thereafter every six weeks until the end of the study. The effects of niacin on disease markers, muscle mitochondrial biogenesis, muscle strength and the metabolism of the whole body are studied in patients and healthy controls.

The hypothesis is that an NAD+ precursor, niacin, will increase intracellular NAD+ levels, improve mitochondrial biogenesis and alleviate the symptoms of mitochondrial myopathy in humans.","[(14, 20, 'DRUG', 'Niacin'), (160, 182, 'CONDITION', 'Mitochondrial Myopathy'), (259, 281, 'CONDITION', 'mitochondrial myopathy'), (404, 426, 'CONDITION', 'Mitochondrial myopathy'), (918, 940, 'CONDITION', 'mitochondrial myopathy'), (978, 992, 'DRUG', 'nicotinic acid'), (994, 1000, 'DRUG', 'niacin'), (1282, 1288, 'DRUG', 'niacin'), (1361, 1383, 'CONDITION', 'mitochondrial myopathy'), (1410, 1416, 'DRUG', 'niacin'), (1576, 1598, 'CONDITION', 'mitochondrial myopathy'), (2336, 2342, 'DRUG', 'niacin'), (2538, 2544, 'DRUG', 'niacin'), (2650, 2672, 'CONDITION', 'mitochondrial myopathy')]"
"['Is', 'a', 'Two', '-', 'Film', 'Skull', 'X', '-', 'ray', 'Series', 'as', 'Sensitive', 'as', 'a', 'Four', '-', 'Film', 'Series', 'in', 'the', 'Diagnosis', 'of', 'Skull', 'Fractures', 'in', 'Paediatric', 'Patients', 'With', 'Minor', 'Head', 'Trauma', '?', '|', 'Minor', 'head', 'injuries', 'are', 'a', 'common', 'presenting', 'complaint', 'in', 'the', 'pediatric', 'emergency', 'department', '.', 'Skull', 'x', '-', 'rays', 'are', 'a', 'useful', 'tool', 'in', 'the', 'evaluation', 'of', 'paediatric', 'patients', 'with', 'a', 'history', 'of', 'minor', 'head', 'trauma', '.', 'However', ',', 'there', 'exists', 'ongoing', 'controversy', 'regarding', 'the', 'ideal', 'number', 'of', 'views', 'that', 'should', 'be', 'obtained', 'in', 'a', 'skull', 'series', '.', 'This', 'study', 'aims', 'to', 'determine', 'if', 'there', 'is', 'a', 'significant', 'difference', 'in', 'the', 'diagnostic', 'accuracy', 'of', 'skull', 'x', '-', 'rays', 'in', 'the', 'diagnosis', 'of', 'fracture', 'in', 'paediatric', 'minor', 'head', 'trauma', 'patients', 'when', 'a', '2', '-', 'film', 'series', 'as', 'opposed', 'to', 'a', '4', '-', 'film', 'series', 'is', 'provided', 'to', 'participating', 'pediatric', 'emergency', 'physicians', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01448473,NCT01448473,"Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients With Minor Head Trauma? | Minor head injuries are a common presenting complaint in the pediatric emergency department. Skull x-rays are a useful tool in the evaluation of paediatric patients with a history of minor head trauma. However, there exists ongoing controversy regarding the ideal number of views that should be obtained in a skull series. This study aims to determine if there is a significant difference in the diagnostic accuracy of skull x-rays in the diagnosis of fracture in paediatric minor head trauma patients when a 2-film series as opposed to a 4-film series is provided to participating pediatric emergency physicians.","[(88, 103, 'CONDITION', 'Skull Fractures'), (132, 149, 'CONDITION', 'Minor Head Trauma'), (153, 172, 'CONDITION', 'Minor head injuries'), (336, 353, 'CONDITION', 'minor head trauma'), (605, 613, 'CONDITION', 'fracture'), (628, 645, 'CONDITION', 'minor head trauma')]"
"['Intraoperative', 'Molecular', 'Imaging', 'of', 'Central', 'Nervous', 'System', 'Tumors', 'Using', 'Same', 'Day', 'Second', 'Window', 'Imaging', 'With', 'Indocyanine', 'Green', '(', 'TumorGlow', '™', '-', 'CNS', ')', '|', 'The', 'study', 'is', 'being', 'conducted', 'to', 'determine', 'if', 'a', 'same', '-', 'day', ',', 'low', '-', 'dose', 'intravenous', '(', 'into', 'a', 'vein', ')', 'injection', 'of', 'indocyanine', 'green', '(', 'ICG', ')', '(', 'FDA', '-', 'approved', 'dye', ')', 'being', 'detected', 'by', 'using', 'an', 'imaging', 'system', 'can', 'be', 'a', 'useful', 'tool', 'in', 'identifying', 'and', 'differentiating', 'tumor', 'tissue', 'from', 'normal', 'tissues', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT05746104,NCT05746104,"Intraoperative Molecular Imaging of Central Nervous System Tumors Using Same Day Second Window Imaging With Indocyanine Green (TumorGlow™ - CNS) | The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.","[(36, 65, 'CONDITION', 'Central Nervous System Tumors'), (108, 125, 'OTHER', 'Indocyanine Green'), (127, 136, 'OTHER', 'TumorGlow'), (252, 269, 'OTHER', 'indocyanine green'), (271, 274, 'OTHER', 'ICG'), (393, 398, 'CONDITION', 'tumor')]"
"['Effect', 'of', 'Intravenous', 'Versus', 'Intrathecal', 'Dexamethazone', 'in', 'Bupivacaine', 'Spinal', 'Anesthesia', 'on', 'Postdural', 'Puncture', 'Headache', '|', 'This', 'study', 'will', 'be', 'conducted', 'at', 'Ain', 'Shams', 'University', 'Hospital', 'in', 'Operating', 'Theatre', 'after', 'ethical', 'committe', 'approval', 'number', '(', 'MS', '32/', '2020', ')', '.', 'It', 'is', 'a', 'prospective', 'randomized', 'controlled', 'study', 'will', 'be', 'done', 'on', 'patients', 'undergoing', 'lower', 'abdominal', 'and', 'lower', 'limb', 'surgeries', 'under', 'spinal', 'anethesia', ',', 'Eligible', 'patients', 'will', 'be', 'randomized', 'by', 'computer', 'system', 'to', 'one', 'of', 'two', 'groups', ',', 'either', 'intravenous', 'dexamethazzoe', '8', 'mg', 'with', 'intrathecal', 'heavy', 'bupivacaine', '0.5', '%', 'or', 'intrathecal', '4', 'mg', 'dexamethazone', 'with', 'intrathecal', 'heavy', 'bupivacaine', '0.5', '%', '.', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT04709029,NCT04709029,"Effect of Intravenous Versus Intrathecal Dexamethazone in Bupivacaine Spinal Anesthesia on Postdural Puncture Headache | This study will be conducted at Ain Shams University Hospital in Operating Theatre after ethical committe approval number (MS 32/ 2020). It is a prospective randomized controlled study will be done on patients undergoing lower abdominal and lower limb surgeries under spinal anethesia,Eligible patients will be randomized by computer system to one of two groups, either intravenous dexamethazzoe 8 mg with intrathecal heavy bupivacaine 0.5% or intrathecal 4mg dexamethazone with intrathecal heavy bupivacaine 0.5%. .","[(41, 54, 'DRUG', 'Dexamethazone'), (58, 69, 'DRUG', 'Bupivacaine'), (91, 118, 'CONDITION', 'Postdural Puncture Headache'), (342, 382, 'CONDITION', 'lower abdominal and lower limb surgeries'), (503, 516, 'DRUG', 'dexamethazzoe'), (545, 556, 'DRUG', 'bupivacaine'), (581, 594, 'DRUG', 'dexamethazone'), (618, 629, 'DRUG', 'bupivacaine')]"
"['Electro', 'Physiological', 'Responses', 'to', 'Kabat', 'Motor', 'Control', 'Re', '-', 'education', 'on', 'Bell', ""'s"", 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Study', '|', 'To', 'investigate', 'the', 'Effect', 'of', 'Kabat', 'motor', 'control', 're', '-', 'education', 'therapy', 'on', 'facial', 'nerve', 'Electro', 'physiological', 'responses', 'and', 'facial', 'muscles', 'function', 'in', 'bell', ""'s"", 'palsy', '.', '\n\n', 'BACKGROUND', ':', 'facial', 'nerve', 'recovery', 'in', 'children', 'could', 'be', 'improved', 'through', 'facilitation', 'of', 'nerve', 'regeneration', 'which', 'can', 'be', 'enhanced', 'through', 'Kabat', 'motor', 'control', 're', '-', 'education', 'therapy', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",NCT04894513,NCT04894513,"Electro Physiological Responses to Kabat Motor Control Re-education on Bell's Palsy: A Randomized Controlled Study | To investigate the Effect of Kabat motor control re-education therapy on facial nerve Electro physiological responses and facial muscles function in bell's palsy.

BACKGROUND: facial nerve recovery in children could be improved through facilitation of nerve regeneration which can be enhanced through Kabat motor control re-education therapy.","[(35, 67, 'PHYSICAL', 'Kabat Motor Control Re-education'), (71, 83, 'CONDITION', ""Bell's Palsy""), (146, 186, 'PHYSICAL', 'Kabat motor control re-education therapy'), (266, 278, 'CONDITION', ""bell's palsy""), (418, 458, 'PHYSICAL', 'Kabat motor control re-education therapy')]"
"['ENGAGE', '-', 'PD', ':', 'Enhancing', 'Gait', 'Using', 'Alternating', '-', 'Frequency', 'DBS', 'in', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'how', 'alternating', '-', 'frequency', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'works', 'to', 'improve', 'postural', 'instability', 'and', 'gait', ',', 'while', 'also', 'treating', 'other', 'motor', 'symptoms', 'of', 'Parkinson', 'Disease', '(', 'PD', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05022147,NCT05022147,"ENGAGE-PD: Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease | The purpose of this study is to assess how alternating-frequency Deep Brain Stimulation (DBS) works to improve postural instability and gait, while also treating other motor symptoms of Parkinson Disease (PD).","[(32, 57, 'OTHER', 'Alternating-Frequency DBS'), (61, 78, 'CONDITION', 'Parkinson Disease'), (124, 168, 'OTHER', 'alternating-frequency Deep Brain Stimulation'), (170, 173, 'OTHER', 'DBS'), (267, 284, 'CONDITION', 'Parkinson Disease'), (286, 288, 'CONDITION', 'PD')]"
"['Contributions', 'of', 'the', 'Reticulospinal', 'System', 'to', 'Movement', 'Control', 'and', 'Functional', 'Recovery', 'in', 'Patients', 'With', 'Spinal', 'Cord', 'Injury', '|', 'Accurate', 'movement', 'execution', 'is', 'a', 'result', 'of', 'a', 'complex', 'interplay', 'between', 'various', 'muscle', 'groups', 'whose', 'activity', 'is', 'controlled', 'by', 'different', 'areas', 'of', 'the', 'central', 'nervous', 'system', '.', 'Besides', 'the', 'corticospinal', 'system', ',', 'the', 'phylogenetically', 'old', 'reticulospinal', 'system', 'is', 'a', 'key', 'motor', 'system', 'controlling', 'different', 'elementary', 'movements', 'including', 'posture', ',', 'locomotion', 'and', 'reaching', 'across', 'all', 'mammals', '.', 'In', 'contrast', 'to', 'the', 'extensively', 'investigated', 'corticospinal', 'system', ',', 'there', 'is', 'only', 'sparse', 'knowledge', 'on', 'the', 'motor', 'physiology', 'of', 'the', 'functionally', 'important', 'reticulospinal', 'system', 'in', 'humans', '.', 'Reticulospinal', 'motor', 'control', 'can', 'be', 'assessed', 'with', 'the', 'StartReact', 'paradigm', 'which', 'is', 'based', 'on', 'the', 'activation', 'of', 'reticulospinal', 'motor', 'circuitries', 'by', 'startling', 'acoustic', 'stimuli', '.', 'The', 'StartReact', 'phenomenon', 'is', 'characterized', 'by', 'a', 'shortening', 'in', 'movement', 'reaction', 'time', 'which', 'is', 'mediated', 'by', 'a', 'startle', '-', 'triggered', ',', 'early', 'release', 'of', 'a', 'planned', 'motor', 'program', 'by', 'the', 'reticulospinal', 'system', '.', 'Thus', ',', 'StartReact', 'is', 'a', 'unique', 'tool', 'to', 'examine', 'reticulospinal', 'involvement', 'on', 'human', 'motor', 'control', 'under', 'physiological', 'and', 'pathological', 'conditions', '.', 'StartReact', 'assessments', 'will', 'be', 'supplemented', 'by', 'comprehensive', '3', '-', 'D', 'kinematic', 'analysis', 'and', 'muscle', 'activity', 'recordings', '(', 'i.e.', 'electromyography', ')', 'to', 'gain', 'quantitative', 'insights', 'into', 'reticulospinal', 'movement', 'control', '.', '\n\n', 'The', 'first', 'objective', 'of', 'this', 'clinical', 'study', 'is', 'to', 'gain', 'more', 'insights', 'into', 'the', 'mechanisms', 'underlying', 'StartReact', 'and', 'to', 'advance', 'the', 'knowledge', 'on', 'reticulo', '-', 'spinal', 'motor', 'physiology', 'regarding', 'different', 'movement', 'tasks', '(', 'i.e.', 'simple', 'single', '-', 'joint', 'movements', ',', 'complex', 'multi', '-', 'joint', 'movements', 'and', 'bilateral', 'hand', 'movements', ')', 'in', 'healthy', 'subjects', '.', 'The', 'findings', 'of', 'these', 'experiments', 'will', 'provide', 'new', 'insights', 'into', 'proximal', '-', 'distal', ',', 'flexor', '-', 'extensor', 'and', 'upper', '-', 'lower', 'extremity', 'gradients', 'in', 'reticulospinal', 'motor', 'control', 'of', 'healthy', 'subjects', '.', 'Moreover', ',', 'the', 'results', 'will', 'expand', 'the', 'StartReact', 'paradigm', 'to', 'complex', ',', 'functionally', 'more', 'relevant', 'movements', '(', 'i.e.', 'reaching', 'and', 'stepping', 'tasks', 'requiring', 'endpoint', 'accuracy', ';', 'co', '-', 'operative', ',', 'bilateral', 'hand', 'movements', ')', 'for', 'which', 'the', 'involvement', 'of', 'the', 'reticulo', '-', 'spinal', 'system', 'is', 'not', 'yet', 'understood', '.', '\n\n', 'The', 'second', 'goal', 'of', 'this', 'project', 'is', 'to', 'use', 'the', 'StartReact', 'paradigm', 'to', 'shed', 'more', 'light', 'onto', 'the', 'role', 'of', 'reticulospinal', 'plasticity', 'in', 'functional', 'recovery', 'of', 'patients', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'Whereas', 'preclinical', 'findings', 'emphasize', 'a', 'remarkable', 'potential', 'of', 'the', 'reticulospinal', 'system', 'for', 'neuroplastic', 'adaptations', 'underlying', 'functional', 'recovery', ',', 'there', 'is', 'only', 'little', 'evidence', 'from', 'clinical', 'trials', 'in', 'the', 'field', 'of', 'SCI', '.', 'First', ',', 'the', 'study', 'aims', 'at', 'monitoring', 'StartReact', 'effects', 'in', 'hand', 'and', 'leg', 'muscles', 'of', 'patients', 'with', 'acute', 'SCI', 'over', 'a', 'period', 'of', '6', 'months', '.', 'Simultaneous', 'tracking', 'of', 'StartReact', 'effects', 'and', 'motor', 'recovery', 'will', 'allow', 'to', 'closely', 'relate', 'processes', 'of', 'reticulospinal', 'plasticity', 'to', 'functional', 'recovery', 'in', 'patients', 'with', 'acute', 'SCI', '.', 'Second', ',', 'the', 'focus', 'will', 'be', 'on', 'the', 're', '-', 'weighting', 'of', 'descending', 'motor', 'control', '(', 'i.e.', 'cortico-', 'vs.', 'reticulospinal', 'system', ')', 'in', 'response', 'to', 'SCI', 'and', 'investigate', 'the', 'distinct', 'contributions', 'of', 'the', 'cortico-', 'and', 'reticulospinal', 'system', 'to', 'motor', 'recovery', 'in', 'patients', 'with', 'chronic', 'SCI', '.', '\n\n', 'The', 'findings', 'of', 'this', 'project', 'will', 'advance', 'the', 'mechanistic', 'understanding', 'on', 'the', 'motor', 'physiology', 'and', 'neurorestorative', 'capacity', 'of', 'the', 'reticulospinal', 'system', 'in', 'humans', '.', 'New', 'insights', 'from', 'these', 'projects', 'will', 'hopefully', 'translate', 'into', 'a', 'better', 'exploitation', 'of', 'this', 'important', 'motor', 'system', 'in', 'clinical', 'trials', 'that', 'aim', 'to', 'improve', 'motor', 'recovery', 'in', 'patients', 'with', 'SCI', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04967274,NCT04967274,"Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury | Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.

The first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.

The second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.

The findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.","[(104, 122, 'CONDITION', 'Spinal Cord Injury'), (2387, 2405, 'CONDITION', 'spinal cord injury'), (2407, 2410, 'CONDITION', 'SCI'), (2632, 2635, 'CONDITION', 'SCI'), (2733, 2742, 'CONDITION', 'acute SCI'), (2941, 2950, 'CONDITION', 'acute SCI'), (3083, 3086, 'CONDITION', 'SCI'), (3207, 3218, 'CONDITION', 'chronic SCI'), (3574, 3577, 'CONDITION', 'SCI')]"
"['The', 'Role', 'of', 'Exercise', 'in', 'Modifying', 'Outcomes', 'for', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'Despite', 'the', 'benefits', 'of', 'exercise', 'and', 'physical', 'activity', 'people', 'with', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'are', 'relatively', 'inactive', '.', 'Physical', 'activity', 'is', 'important', 'for', 'persons', 'with', 'disabilities', 'to', 'maintain', 'physical', 'function', '.', 'A', 'lack', 'of', 'physical', 'activity', 'can', 'contribute', 'to', 'heart', 'disease', ',', 'osteoporosis', ',', 'obesity', ',', 'and', 'diabetes', '.', 'At', 'the', 'moment', ',', 'the', 'best', 'way', 'for', 'people', 'with', 'MS', 'to', 'exercise', 'and', 'be', 'physical', 'activity', 'is', 'unknown', '.', 'People', 'with', 'MS', 'report', 'not', 'knowing', 'what', 'to', 'do', '.', 'This', 'is', 'a', 'barrier', 'to', 'exercise', '.', '\n\n', 'The', 'global', 'aim', 'of', 'this', 'study', 'is', 'to', 'contribute', 'evidence', 'for', 'the', 'role', 'of', 'targeted', 'exercise', 'in', 'altering', 'MS', 'outcomes', 'over', 'time', '.', 'The', 'design', 'is', 'a', 'randomized', 'controlled', 'trial', '(', 'RCT', ')', '.', 'The', 'primary', 'research', 'question', 'is', 'to', 'what', 'extent', 'does', 'an', 'MS', 'Tailored', 'Exercise', 'Program', '(', 'MSTEP', ')', 'result', 'in', 'greater', 'improvements', 'in', 'exercise', 'capacity', 'and', 'related', 'outcomes', 'in', 'comparison', 'to', 'a', 'program', 'based', 'on', 'general', 'guidelines', 'for', 'exercise', 'among', 'people', 'with', 'MS', 'who', 'are', 'sedentary', 'and', 'wish', 'to', 'engage', 'in', 'exercise', 'as', 'part', 'of', 'MS', 'self', '-', 'management', '.', 'The', 'primary', 'outcome', 'for', 'this', 'question', 'is', 'exercise', 'capacity', 'measured', 'using', 'cycle', 'ergometry', '.', 'However', 'exercise', 'efficiency', ',', 'functional', 'ambulation', ',', 'strength', ',', 'components', 'of', 'quality', 'of', 'life', 'including', 'frequency', 'and', 'intensity', 'of', 'fatigue', 'symptoms', ',', 'mood', ',', 'global', 'physical', 'function', ',', 'health', 'perception', ',', 'and', 'illness', 'intrusiveness', ',', 'will', 'also', 'be', 'measured', 'as', 'components', 'of', 'a', 'global', 'response', 'outcome', '.', 'The', 'first', 'confirmatory', 'hypothesis', 'is', 'that', 'MSTEP', 'will', 'result', 'in', 'a', 'greater', 'proportion', 'of', 'people', 'making', 'clinically', 'relevant', 'gains', '(', 'at', 'least', '10', '%', 'change', ')', 'in', 'exercise', 'capacity', 'than', 'with', 'general', 'guidelines', 'after', '12', 'months', 'of', 'intervention', ';', 'a', 'secondary', 'hypothesis', 'is', 'that', ',', 'while', 'there', 'may', 'be', 'some', 'decline', 'in', 'exercise', 'capacity', 'among', 'individuals', 'from', 'end', 'of', 'intervention', 'to', 'follow', '-', 'up', 'one', 'year', 'later', ',', 'the', 'decline', 'will', 'be', 'greater', 'in', 'the', 'general', 'guideline', 'group', 'augmenting', 'the', 'difference', 'between', 'groups', 'in', 'the', 'proportion', 'making', '10', '%', 'change', 'from', 'study', 'entry', 'to', '24', 'months', '.', 'In', 'other', 'words', ',', 'gains', 'will', 'be', 'maintained', 'more', 'for', 'the', 'MSTEP', 'group', 'over', 'the', 'general', 'guideline', 'group', '.', '\n\n', 'An', 'exploratory', 'hypothesis', 'is', 'that', 'more', 'of', 'the', 'targeted', 'outcomes', 'will', 'improve', 'with', 'the', 'MSTEP', 'program', 'than', 'the', 'general', 'guideline', 'approach', '.', 'An', 'explanatory', 'hypothesis', 'is', 'that', 'these', 'gains', 'will', 'be', 'accompanied', 'by', 'reports', 'of', 'greater', 'exercise', 'enjoyment', 'and', 'exercise', 'self', '-', 'efficacy', '(', 'confidence', ')', 'with', 'the', 'MSTEP', 'program', 'than', 'with', 'the', 'general', 'guideline', 'program', 'leading', 'to', 'more', 'consistent', 'exercise', 'engagement', 'and', 'improved', 'long', '-', 'term', 'adherence', '.']","['O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01611987,NCT01611987,"The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis | Despite the benefits of exercise and physical activity people with Multiple Sclerosis (MS) are relatively inactive. Physical activity is important for persons with disabilities to maintain physical function. A lack of physical activity can contribute to heart disease, osteoporosis, obesity, and diabetes. At the moment, the best way for people with MS to exercise and be physical activity is unknown. People with MS report not knowing what to do. This is a barrier to exercise.

The global aim of this study is to contribute evidence for the role of targeted exercise in altering MS outcomes over time. The design is a randomized controlled trial (RCT). The primary research question is to what extent does an MS Tailored Exercise Program (MSTEP) result in greater improvements in exercise capacity and related outcomes in comparison to a program based on general guidelines for exercise among people with MS who are sedentary and wish to engage in exercise as part of MS self-management. The primary outcome for this question is exercise capacity measured using cycle ergometry. However exercise efficiency, functional ambulation, strength, components of quality of life including frequency and intensity of fatigue symptoms, mood, global physical function, health perception, and illness intrusiveness, will also be measured as components of a global response outcome. The first confirmatory hypothesis is that MSTEP will result in a greater proportion of people making clinically relevant gains (at least 10% change) in exercise capacity than with general guidelines after 12 months of intervention; a secondary hypothesis is that, while there may be some decline in exercise capacity among individuals from end of intervention to follow-up one year later, the decline will be greater in the general guideline group augmenting the difference between groups in the proportion making 10% change from study entry to 24 months. In other words, gains will be maintained more for the MSTEP group over the general guideline group.

An exploratory hypothesis is that more of the targeted outcomes will improve with the MSTEP program than the general guideline approach. An explanatory hypothesis is that these gains will be accompanied by reports of greater exercise enjoyment and exercise self-efficacy (confidence) with the MSTEP program than with the general guideline program leading to more consistent exercise engagement and improved long-term adherence.","[(12, 20, 'PHYSICAL', 'Exercise'), (59, 77, 'CONDITION', 'Multiple Sclerosis'), (104, 112, 'PHYSICAL', 'exercise'), (117, 134, 'PHYSICAL', 'physical activity'), (147, 165, 'CONDITION', 'Multiple Sclerosis'), (167, 169, 'CONDITION', 'MS'), (196, 213, 'PHYSICAL', 'Physical activity'), (298, 315, 'PHYSICAL', 'physical activity'), (430, 432, 'CONDITION', 'MS'), (436, 444, 'PHYSICAL', 'exercise'), (452, 469, 'PHYSICAL', 'physical activity'), (494, 496, 'CONDITION', 'MS'), (549, 557, 'PHYSICAL', 'exercise'), (631, 648, 'PHYSICAL', 'targeted exercise'), (661, 663, 'CONDITION', 'MS'), (791, 819, 'PHYSICAL', 'MS Tailored Exercise Program'), (821, 826, 'PHYSICAL', 'MSTEP'), (920, 968, 'CONTROL', 'program based on general guidelines for exercise'), (987, 989, 'CONDITION', 'MS'), (1050, 1052, 'CONDITION', 'MS'), (1494, 1499, 'PHYSICAL', 'MSTEP'), (1632, 1650, 'CONTROL', 'general guidelines'), (1876, 1893, 'CONTROL', 'general guideline'), (2062, 2067, 'PHYSICAL', 'MSTEP'), (2083, 2100, 'CONTROL', 'general guideline'), (2195, 2200, 'PHYSICAL', 'MSTEP'), (2218, 2235, 'CONTROL', 'general guideline'), (2402, 2407, 'PHYSICAL', 'MSTEP'), (2430, 2447, 'CONTROL', 'general guideline'), (2483, 2491, 'PHYSICAL', 'exercise')]"
"['Effects', 'of', 'Improvisational', 'Dance', 'on', 'Cognition', 'and', 'Daily', 'Function', 'Among', 'People', 'With', 'Parkinson', 'Disease', '|', 'The', 'long', '-', 'term', 'goal', 'of', 'this', 'work', 'is', 'to', 'maintain', 'or', 'improve', 'daily', 'function', 'of', 'people', 'with', 'PD', 'by', 'addressing', 'cognition', '.', 'The', 'overall', 'objective', 'is', 'to', 'discover', 'interventions', 'that', 'aid', 'in', 'cognitive', 'functioning', '.', 'The', 'central', 'hypothesis', 'is', 'that', 'engagement', 'in', 'an', 'improvisational', 'dance', '(', 'ID', ')', 'class', 'will', 'benefit', 'cognition', 'among', 'people', 'with', 'PD', '.', 'Improvisational', 'dance', 'involves', 'spontaneously', 'generated', 'movement', ',', 'similar', 'to', 'how', 'one', 'moves', 'in', 'everyday', 'life', '.', 'The', 'literature', 'shows', 'that', 'ID', 'classes', 'positively', 'impact', 'motor', 'impairments', 'associated', 'with', 'PD', ',', 'such', 'as', 'balance', ',', 'gait', ',', 'and', 'functional', 'mobility', '.', 'Along', 'with', 'being', 'physically', 'demanding', ',', 'ID', 'requires', 'the', 'use', 'and', 'coordination', 'of', 'a', 'number', 'of', 'cognitive', 'capacities', 'to', 'properly', 'execute', 'movements', '.', 'This', 'type', 'of', 'activity', 'challenges', ',', 'and', 'thus', 'may', 'strengthen', ',', 'cognitive', 'processes', 'such', 'as', 'motor', 'planning', ',', 'decision', 'making', ',', 'flexible', 'thinking', ',', 'initiation', ',', 'and', 'execution', ',', 'which', 'may', 'give', 'people', 'cognitive', 'based', 'strategies', 'to', 'be', 'utilized', 'in', 'various', 'aspects', 'of', 'daily', 'life', '.', 'By', 'improving', 'motor', 'function', 'and/or', 'cognition', ',', 'ID', 'may', 'also', 'contribute', 'to', 'improved', 'daily', 'functioning', ',', 'or', 'the', 'ability', 'to', 'perform', 'and', 'participate', 'in', 'daily', 'activities', '.', 'Despite', 'these', 'theoretical', 'links', ',', 'evidence', 'for', 'the', 'effect', 'of', 'ID', 'on', 'cognition', 'and', 'overall', 'daily', 'function', 'is', 'limited', '.', 'The', 'current', 'project', 'objective', 'is', 'to', 'address', 'this', 'gap', 'and', 'better', 'understand', 'the', 'effects', 'of', 'ID', 'for', 'people', 'with', 'PD', '.', 'Specifically', ',', 'it', 'will', 'test', 'the', 'effect', 'of', 'IMPROVment', '®', ',', 'a', 'method', 'of', 'ID', 'designed', 'for', 'people', 'with', 'PD', ',', 'on', 'cognition', 'and', 'daily', 'function', '.', '\n\n', 'Participants', ""'"", 'cognition', 'will', 'be', 'assessed', 'at', 'baseline', '(', 'T1', ')', 'using', 'the', 'NIH', 'Toolbox', 'Cognitive', 'Battery', ',', 'the', 'Alternate', 'Uses', 'Task', ',', 'and', 'the', 'Weekly', 'Calendar', 'Planning', 'Activity', '.', 'Global', 'cognition', 'will', 'be', 'assessed', 'using', 'the', 'Montreal', 'Cognitive', 'Assessment', '.', 'They', 'then', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'the', 'immediate', 'intervention', '(', 'ID', ')', 'or', 'waitlist', '-', 'control', '(', 'WC', ')', 'group', '.', 'The', 'ID', 'group', 'will', 'start', 'the', '12', '-', 'week', 'IMPROVment', '®', 'intervention', ',', 'which', 'consists', 'of', 'weekly', 'ID', 'classes', 'that', 'progress', 'according', 'to', 'a', 'standardized', 'method', 'while', 'the', 'WC', 'group', 'will', 'receive', 'no', 'intervention', 'and', 'continue', 'with', 'their', 'regular', 'daily', 'routine', 'and', 'activity', 'level', '.', 'After', '12', 'weeks', ',', 'both', 'groups', 'will', 'complete', 'cognitive', 'testing', 'again', '(', 'T2', ')', '.', 'Cognitive', 'test', 'scores', 'will', 'be', 'compared', 'across', 'time', 'points', 'and', 'between', 'groups', 'using', 'a', 'mixed', 'model', 'repeated', 'measures', 'ANOVA', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '®', 'will', 'have', 'positive', 'effects', 'on', 'the', 'cognitive', 'abilities', 'of', 'people', 'with', 'PD', '.', 'Participants', 'will', 'also', 'complete', 'two', 'questionnaires', 'to', 'assess', 'daily', 'function', 'at', 'T1', 'and', 'T2', ':', 'Older', 'Americans', 'Resources', 'and', 'Services', 'Scale-', 'Extended', 'Version', 'and', 'PROMIS', 'Satisfaction', 'with', 'Participation', 'in', 'Discretionary', 'Social', 'Activities', '.', 'These', 'scores', 'will', 'be', 'compared', 'similar', 'to', 'the', 'above', 'aim', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '®', 'will', 'have', 'positive', 'effects', 'on', 'daily', 'function', 'in', 'people', 'with', 'PD', '.', '\n\n', 'Participant', 'mood', 'will', 'be', 'assessed', 'in', 'two', 'different', 'ways', '.', 'The', 'first', 'being', 'to', 'investigate', 'the', 'immediate', 'effect', 'of', 'participating', 'in', 'an', 'IMPROVment', '®', 'class', 'on', 'mood', ',', 'fatigue', ',', 'and', 'anxiety', '.', 'The', 'investigators', 'hypothesize', 'that', 'mood', 'will', 'positively', 'improve', 'from', 'pre', 'to', 'post', 'of', 'each', 'class', '.', 'To', 'assess', 'this', ',', 'participants', 'will', 'respond', 'to', 'a', 'scale', 'assessing', 'mood', ',', 'specifically', 'sadness', ',', 'nervousness', ',', 'energy', ',', 'and', 'overall', 'well', '-', 'being', 'before', 'and', 'after', 'each', 'class', 'every', 'week', '.', 'The', 'second', 'measurement', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'IMPROVment', '®', 'on', 'anxiety', ',', 'fatigue', ',', 'and', 'depression', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '®', 'class', 'will', 'decrease', 'feelings', 'of', 'depression', 'for', 'those', 'with', 'PD', '.', 'All', 'participants', 'will', 'fill', 'out', 'the', 'Parkinson', ""'s"", 'Anxiety', 'Scale', ',', 'the', 'Parkinson', ""'s"", 'Disease', 'Fatigue', 'Scale', ',', 'and', 'the', 'Geriatric', 'Depression', 'Scale', 'short', 'form', 'before', 'and', 'after', 'participating', 'in', 'the', '12', '-', 'week', 'IMPROVment', '®', 'program', '.', '\n\n', 'Achievement', 'of', 'these', 'aims', 'will', 'provide', 'further', 'support', 'for', 'the', 'IMPROVment', '®', 'method', 'for', 'people', 'with', 'PD', 'experiencing', 'cognitive', 'deficits', '.', 'The', 'long', '-', 'term', 'impact', 'will', 'better', 'cognition', 'and', 'daily', 'functioning', 'in', 'people', 'with', 'PD', ',', 'and', 'thus', 'enhanced', 'everyday', 'lives', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04354298,NCT04354298,"Effects of Improvisational Dance on Cognition and Daily Function Among People With Parkinson Disease | The long-term goal of this work is to maintain or improve daily function of people with PD by addressing cognition. The overall objective is to discover interventions that aid in cognitive functioning. The central hypothesis is that engagement in an improvisational dance (ID) class will benefit cognition among people with PD. Improvisational dance involves spontaneously generated movement, similar to how one moves in everyday life. The literature shows that ID classes positively impact motor impairments associated with PD, such as balance, gait, and functional mobility. Along with being physically demanding, ID requires the use and coordination of a number of cognitive capacities to properly execute movements. This type of activity challenges, and thus may strengthen, cognitive processes such as motor planning, decision making, flexible thinking, initiation, and execution, which may give people cognitive based strategies to be utilized in various aspects of daily life. By improving motor function and/or cognition, ID may also contribute to improved daily functioning, or the ability to perform and participate in daily activities. Despite these theoretical links, evidence for the effect of ID on cognition and overall daily function is limited. The current project objective is to address this gap and better understand the effects of ID for people with PD. Specifically, it will test the effect of IMPROVment®, a method of ID designed for people with PD, on cognition and daily function.

Participants' cognition will be assessed at baseline (T1) using the NIH Toolbox Cognitive Battery, the Alternate Uses Task, and the Weekly Calendar Planning Activity. Global cognition will be assessed using the Montreal Cognitive Assessment. They then will be randomly assigned to either the immediate intervention (ID) or waitlist-control (WC) group. The ID group will start the 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method while the WC group will receive no intervention and continue with their regular daily routine and activity level. After 12 weeks, both groups will complete cognitive testing again (T2). Cognitive test scores will be compared across time points and between groups using a mixed model repeated measures ANOVA. The investigators hypothesize that IMPROVment® will have positive effects on the cognitive abilities of people with PD. Participants will also complete two questionnaires to assess daily function at T1 and T2: Older Americans Resources and Services Scale- Extended Version and PROMIS Satisfaction with Participation in Discretionary Social Activities. These scores will be compared similar to the above aim. The investigators hypothesize that IMPROVment® will have positive effects on daily function in people with PD.

Participant mood will be assessed in two different ways. The first being to investigate the immediate effect of participating in an IMPROVment® class on mood, fatigue, and anxiety. The investigators hypothesize that mood will positively improve from pre to post of each class. To assess this, participants will respond to a scale assessing mood, specifically sadness, nervousness, energy, and overall well-being before and after each class every week. The second measurement is to investigate the effect of IMPROVment® on anxiety, fatigue, and depression. The investigators hypothesize that IMPROVment® class will decrease feelings of depression for those with PD. All participants will fill out the Parkinson's Anxiety Scale, the Parkinson's Disease Fatigue Scale, and the Geriatric Depression Scale short form before and after participating in the 12-week IMPROVment® program.

Achievement of these aims will provide further support for the IMPROVment® method for people with PD experiencing cognitive deficits. The long-term impact will better cognition and daily functioning in people with PD, and thus enhanced everyday lives.","[(11, 32, 'PHYSICAL', 'Improvisational Dance'), (83, 100, 'CONDITION', 'Parkinson Disease'), (191, 193, 'CONDITION', 'PD'), (353, 374, 'PHYSICAL', 'improvisational dance'), (376, 378, 'PHYSICAL', 'ID'), (427, 429, 'CONDITION', 'PD'), (431, 452, 'PHYSICAL', 'Improvisational dance'), (565, 567, 'PHYSICAL', 'ID'), (628, 630, 'CONDITION', 'PD'), (719, 721, 'PHYSICAL', 'ID'), (1133, 1135, 'PHYSICAL', 'ID'), (1310, 1312, 'PHYSICAL', 'ID'), (1455, 1457, 'PHYSICAL', 'ID'), (1474, 1476, 'CONDITION', 'PD'), (1519, 1529, 'PHYSICAL', 'IMPROVment'), (1544, 1546, 'PHYSICAL', 'ID'), (1572, 1574, 'CONDITION', 'PD'), (1926, 1928, 'PHYSICAL', 'ID'), (1933, 1949, 'CONTROL', 'waitlist-control'), (1951, 1953, 'CONTROL', 'WC'), (1966, 1968, 'PHYSICAL', 'ID'), (1998, 2008, 'PHYSICAL', 'IMPROVment'), (2049, 2051, 'PHYSICAL', 'ID'), (2119, 2121, 'CONTROL', 'WC'), (2452, 2462, 'PHYSICAL', 'IMPROVment'), (2533, 2535, 'CONDITION', 'PD'), (2860, 2870, 'PHYSICAL', 'IMPROVment'), (2932, 2934, 'CONDITION', 'PD'), (3069, 3079, 'PHYSICAL', 'IMPROVment'), (3096, 3103, 'CONDITION', 'fatigue'), (3109, 3116, 'CONDITION', 'anxiety'), (3444, 3454, 'PHYSICAL', 'IMPROVment'), (3459, 3466, 'CONDITION', 'anxiety'), (3468, 3475, 'CONDITION', 'fatigue'), (3481, 3491, 'CONDITION', 'depression'), (3528, 3538, 'PHYSICAL', 'IMPROVment'), (3572, 3582, 'CONDITION', 'depression'), (3598, 3600, 'CONDITION', 'PD'), (3795, 3805, 'PHYSICAL', 'IMPROVment'), (3880, 3890, 'PHYSICAL', 'IMPROVment'), (3915, 3917, 'CONDITION', 'PD'), (4031, 4033, 'CONDITION', 'PD')]"
"['Factors', 'Associated', 'With', 'Falling', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'a', 'Multidisciplinary', 'Prospective', 'Study', '|', 'The', 'objective', 'of', 'this', 'study', 'will', 'be', 'to', 'identify', 'multidisciplinary', 'fall', 'risk', 'factors', 'in', 'persons', 'with', 'stage', '3', 'idiopathic', 'Parkinson', ""'s"", 'Disease', 'compared', 'to', 'age', 'and', 'sex', '-', 'matched', 'healthy', 'adults', '.', 'Both', 'the', 'relative', 'contribution', 'of', 'each', 'independent', 'factor', ',', 'as', 'well', 'as', 'the', 'interaction', 'between', 'these', 'factors', ',', 'will', 'be', 'examined', '.', 'The', 'study', 'will', 'include', 'multidisciplinary', 'assessments', ',', 'including', 'locomotor', ',', 'speech', ',', 'auditory', ',', 'vestibular', 'and', 'opthalmologic', 'assessments', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04440033,NCT04440033,"Factors Associated With Falling in Parkinson's Disease: a Multidisciplinary Prospective Study | The objective of this study will be to identify multidisciplinary fall risk factors in persons with stage 3 idiopathic Parkinson's Disease compared to age and sex-matched healthy adults. Both the relative contribution of each independent factor, as well as the interaction between these factors, will be examined. The study will include multidisciplinary assessments, including locomotor, speech, auditory, vestibular and opthalmologic assessments.","[(35, 54, 'CONDITION', ""Parkinson's Disease""), (196, 234, 'CONDITION', ""stage 3 idiopathic Parkinson's Disease"")]"
"['Multicentre', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', 'Evaluating', 'the', 'Effect', 'of', 'a', '30', '-', 'week', 'Caffeine', 'Treatment', 'on', 'Cognition', 'in', 'Alzheimer', ""'s"", 'Disease', 'at', 'Beginning', 'to', 'Moderate', 'Stages', '|', 'Sporadic', 'Alzheimer', ""'s"", 'disease', 'is', 'a', 'multifactorial', 'illness', 'arising', 'a', 'major', 'medico', '-', 'economic', 'stakes', 'for', 'our', 'aging', 'societies', '.', 'There', 'is', 'currently', 'no', 'curative', 'treatment', 'available', '.', '\n\n', 'Coffee', 'is', 'a', 'complex', 'beverage', 'with', 'psychostimulant', 'properties', 'whose', 'main', 'effective', 'element', ',', 'caffeine', ',', 'has', 'a', 'pleiotropic', 'effect', 'on', 'the', 'central', 'nervous', 'system', '.', 'Caffeine', 'pharmacological', 'properties', 'enable', 'its', 'use', 'like', 'an', 'Alzheimer', ""'s"", 'disease', 'symptomatic', 'treatment', '.', 'Its', 'supposed', 'benefits', 'must', ""n't"", 'obscure', 'anxiety', 'and', 'insomnia', 'caffeine', 'effect', 'at', 'large', 'dose', ',', 'which', 'Alzheimer', ""'s"", 'patients', 'might', 'be', 'more', 'vulnerable', '.', '\n\n', 'The', 'main', 'study', 'objective', 'is', 'to', 'evaluate', 'placebo', '-', 'controlled', 'caffeine', 'efficacy', '(', '30', 'treatments', 'weeks', ')', 'on', 'cognitive', 'decline', 'in', 'Alzheimer', ""'s"", 'disease', 'dementia', 'at', 'beginning', 'to', 'moderate', 'stage', '(', 'MMSE', '16', '-', '24', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04570085,NCT04570085,"Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages | Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available.

Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable.

The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).","[(39, 46, 'CONTROL', 'Placebo'), (99, 107, 'DRUG', 'Caffeine'), (134, 185, 'CONDITION', ""Alzheimer's Disease at Beginning to Moderate Stages""), (188, 216, 'CONDITION', ""Sporadic Alzheimer's disease""), (453, 461, 'DRUG', 'caffeine'), (519, 527, 'DRUG', 'Caffeine'), (578, 597, 'CONDITION', ""Alzheimer's disease""), (680, 688, 'DRUG', 'caffeine'), (717, 728, 'CONDITION', ""Alzheimer's""), (805, 812, 'CONTROL', 'placebo'), (824, 832, 'DRUG', 'caffeine'), (888, 947, 'CONDITION', ""Alzheimer's disease dementia at beginning to moderate stage"")]"
"['Restore', 'Motor', 'Function', 'Through', 'Robotic', 'Arm', 'Exoskeleton', 'and', 'Brain', 'Computer', 'Interface', '|', 'The', 'current', 'project', 'will', 'aid', 'patients', 'with', 'motor', 'impairment', 'to', 'reduce', 'the', 'need', 'for', 'homecare', '.', 'Specifically', 'the', 'aim', 'is', 'to', 'develop', 'and', 'implement', 'a', 'robotic', 'exoskeleton', 'and', 'brain', 'computer', 'interface', 'to', 'assist', 'and', 'eventually', 'perform', 'arm', 'and', 'hand', 'movement', 'in', 'patients', 'with', 'the', 'progressive', 'neurodegenerative', 'disease', 'ALS', '.', 'This', 'proposal', 'brings', 'together', 'state', '-', 'of', '-', 'the', '-', 'art', 'robotic', 'technology', ',', 'EEG', '-', 'based', 'brain', 'computer', 'interface', '(', 'BCI', ')', 'know', '-', 'how', ',', 'clinical', 'expertise', ',', 'patient', 'perspective', 'and', 'industrial', 'partners', 'to', 'develop', 'and', 'implement', 'a', 'robotic', 'arm', '/', 'hand', 'device', 'that', 'will', 'adapt', ',', 'with', 'increasing', 'brain', '-', 'computer', 'control', ',', 'based', 'on', 'the', 'need', 'of', 'the', 'patient', '.', 'In', 'short', 'the', 'BCI', 'will', 'measure', 'electroencephalography', '(', 'EEG', ')', 'from', 'the', 'surface', 'of', 'the', 'scalp', 'and', 'recognize', 'signature', 'EEG', 'as', 'the', 'patient', 'intents', 'to', 'move', '.', 'As', 'the', 'patient', 'loses', 'muscle', 'power', 'the', 'BCI', 'robotic', '-', 'device', 'will', 'gradually', 'take', 'over', 'and', 'support', 'motor', 'activity', ',', 'even', 'when', 'the', 'patient', 'is', 'totally', 'paralyzed', '.', 'As', 'the', 'device', 'supports', 'hand', '/', 'arm', 'function', 'only', ',', 'the', 'investigators', 'aim', 'to', 'address', 'ADLs', 'associated', 'to', 'hand', 'function', ',', 'specifically', 'eating', 'activities', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03900247,NCT03900247,"Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface | The current project will aid patients with motor impairment to reduce the need for homecare. Specifically the aim is to develop and implement a robotic exoskeleton and brain computer interface to assist and eventually perform arm and hand movement in patients with the progressive neurodegenerative disease ALS. This proposal brings together state-of-the-art robotic technology, EEG-based brain computer interface (BCI) know-how, clinical expertise, patient perspective and industrial partners to develop and implement a robotic arm/hand device that will adapt, with increasing brain-computer control, based on the need of the patient. In short the BCI will measure electroencephalography (EEG) from the surface of the scalp and recognize signature EEG as the patient intents to move. As the patient loses muscle power the BCI robotic-device will gradually take over and support motor activity, even when the patient is totally paralyzed. As the device supports hand/arm function only, the investigators aim to address ADLs associated to hand function, specifically eating activities.","[(31, 54, 'OTHER', 'Robotic Arm Exoskeleton'), (59, 83, 'OTHER', 'Brain Computer Interface'), (129, 145, 'CONDITION', 'motor impairment'), (230, 249, 'OTHER', 'robotic exoskeleton'), (254, 278, 'OTHER', 'brain computer interface'), (393, 396, 'CONDITION', 'ALS'), (445, 463, 'OTHER', 'robotic technology'), (475, 499, 'OTHER', 'brain computer interface'), (501, 504, 'OTHER', 'BCI'), (607, 630, 'OTHER', 'robotic arm/hand device'), (735, 738, 'OTHER', 'BCI'), (909, 927, 'OTHER', 'BCI robotic-device'), (1014, 1023, 'CONDITION', 'paralyzed')]"
"['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Pilot', 'Study', 'in', 'Huntington', ""'s"", 'Disease', '(', 'CIT', '-', 'HD', ')', '|', 'This', 'research', 'plan', 'proposes', 'to', 'conduct', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'pilot', 'clinical', 'trial', 'in', '36', 'adults', 'with', 'mild', 'Huntington', ""'s"", 'disease', '(', 'HD', ')', 'to', 'address', 'the', 'following', 'research', 'aims', ':', '\n\n', 'To', 'determine', 'the', 'effect', 'of', 'citalopram', 'compared', 'to', 'placebo', 'in', 'patients', 'with', 'early', 'HD', 'on', 'executive', 'function', 'and', 'other', 'outcome', 'variables', 'including', 'functional', 'measures', '(', 'health', '-', 'related', 'quality', 'of', 'life', ',', 'work', 'productivity', ',', 'and', 'self', '-', 'reported', 'attention', ')', ',', 'motor', 'performance', ',', 'and', 'psychiatric', 'status', ',', '\n', 'To', 'study', 'the', 'relationship', 'between', 'executive', 'function', 'and', 'functional', 'status', 'in', 'patients', 'with', 'early', 'HD', 'after', 'selective', 'serotonin', 'reuptake', 'inhibitor', '(', 'SSRI', ')', 'treatment', ',', 'and', '\n', 'To', 'examine', 'the', 'effect', 'of', 'citalopram', 'treatment', 'on', 'volumetric', 'and', 'metabolic', '(', 'i.e', ',', 'N', '-', 'acetyl', '-', 'aspartate', 'concentration', ')', 'measures', 'in', 'the', 'neostriatum', 'among', 'patients', 'with', 'recently', 'diagnosed', 'Huntington', ""'s"", 'disease', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00271596,NCT00271596,"A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) | This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims:

To determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status,
To study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and
To examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.","[(14, 21, 'CONTROL', 'Placebo'), (48, 68, 'CONDITION', ""Huntington's Disease""), (135, 142, 'CONTROL', 'placebo'), (193, 218, 'CONDITION', ""mild Huntington's disease""), (220, 222, 'CONDITION', 'HD'), (292, 302, 'DRUG', 'citalopram'), (315, 322, 'CONTROL', 'placebo'), (340, 348, 'CONDITION', 'early HD'), (646, 654, 'CONDITION', 'early HD'), (671, 699, 'DRUG', 'serotonin reuptake inhibitor'), (701, 705, 'DRUG', 'SSRI'), (747, 757, 'DRUG', 'citalopram'), (903, 923, 'CONDITION', ""Huntington's disease"")]"
"['Longitudinal', 'Study', 'Examining', 'At', '-', 'Home', 'Transcranial', 'Direct', 'Current', 'Stimulation', '|', 'Participants', 'with', 'dementia', 'have', 'reported', 'improvements', 'after', 'receiving', 'tDCS', 'in', 'a', 'study', 'at', 'our', 'lab', '.', 'Although', 'we', 'make', 'an', 'effort', 'to', 'enroll', 'such', 'participants', 'in', 'further', 'tDCS', 'research', 'studies', ',', 'some', 'participants', 'are', 'ineligible', 'for', 'further', 'studies', 'or', 'simply', 'unwilling', 'to', 'continue', 'being', 'a', 'research', 'participant', '.', 'These', 'same', 'individuals', ',', 'however', ',', 'are', 'interested', 'in', 'purchasing', 'their', 'own', 'tDCS', 'machine', 'and', 'have', 'approached', 'us', 'for', 'advice', 'on', 'how', 'to', 'purchase', 'their', 'own', 'machine', '.', 'Because', 'these', 'devices', 'are', 'commercially', 'available', ',', 'there', 'is', 'nothing', 'theoretically', 'stopping', 'these', 'participants', 'from', 'purchasing', 'their', 'own', 'machine', '.', 'Therefore', ',', 'we', 'have', 'chosen', 'to', 'carry', 'out', 'a', 'longitudinal', 'study', 'that', 'will', 'allow', 'us', 'to', 'serve', 'as', 'an', 'advisory', 'role', 'for', 'participants', 'who', 'have', 'decided', 'to', 'continue', 'administering', 'tDCS', 'at', 'home', '.', 'We', 'will', 'recommend', 'the', 'tDCS', 'related', 'items', 'that', 'should', 'be', 'purchased', ',', 'and', 'train', 'participants', 'on', 'how', 'to', 'properly', 'administer', 'tDCS', '.', 'Monthly', 'reports', 'will', 'also', 'be', 'collected', ',', 'which', 'will', 'allow', 'us', 'to', 'monitor', 'the', 'person', ""'s"", 'condition', '.', 'We', 'plan', 'to', 'monitor', 'participants', 'for', 'at', 'least', 'two', 'years', '.', 'From', 'these', 'reports', ',', 'we', 'will', 'be', 'able', 'determine', 'to', 'what', 'extent', 'tDCS', 'is', 'beneficial', 'when', 'done', 'at', 'home', 'as', 'a', 'treatment', 'for', 'dementia', 'symptoms', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04524338,NCT04524338,"Longitudinal Study Examining At-Home Transcranial Direct Current Stimulation | Participants with dementia have reported improvements after receiving tDCS in a study at our lab. Although we make an effort to enroll such participants in further tDCS research studies, some participants are ineligible for further studies or simply unwilling to continue being a research participant. These same individuals, however, are interested in purchasing their own tDCS machine and have approached us for advice on how to purchase their own machine. Because these devices are commercially available, there is nothing theoretically stopping these participants from purchasing their own machine. Therefore, we have chosen to carry out a longitudinal study that will allow us to serve as an advisory role for participants who have decided to continue administering tDCS at home. We will recommend the tDCS related items that should be purchased, and train participants on how to properly administer tDCS. Monthly reports will also be collected, which will allow us to monitor the person's condition. We plan to monitor participants for at least two years. From these reports, we will be able determine to what extent tDCS is beneficial when done at home as a treatment for dementia symptoms.","[(29, 76, 'OTHER', 'At-Home Transcranial Direct Current Stimulation'), (97, 105, 'CONDITION', 'dementia'), (149, 153, 'OTHER', 'tDCS'), (243, 247, 'OTHER', 'tDCS'), (453, 457, 'OTHER', 'tDCS'), (850, 862, 'OTHER', 'tDCS at home'), (886, 890, 'OTHER', 'tDCS'), (984, 988, 'OTHER', 'tDCS'), (1202, 1206, 'OTHER', 'tDCS'), (1258, 1266, 'CONDITION', 'dementia')]"
"['Transcranial', 'Direct', 'Current', 'Stimulation', 'to', 'Lower', 'Neuropathic', 'Pain', 'in', 'People', 'With', 'Multiple', 'Sclerosis', ':', 'a', 'Mechanistic', 'FDG', '-', 'PET', 'Study', '|', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'is', 'a', 'noninvasive', 'brain', 'stimulation', 'technique', 'that', 'utilizes', 'low', 'amplitude', 'direct', 'currents', 'applied', 'via', 'scalp', 'electrodes', 'to', 'apply', 'currents', 'to', 'the', 'brain', 'and', 'modulate', 'the', 'level', 'of', 'cortical', 'excitability', '.', 'tDCS', 'applied', 'over', 'the', 'dorsolateral', 'prefrontal', 'and', 'motor', 'cortex', 'has', 'been', 'reported', 'to', 'be', 'able', 'to', 'decrease', 'pain', 'sensation', 'and', 'to', 'increase', 'pain', 'threshold', 'in', 'healthy', 'subjects', 'and', 'is', 'effective', 'in', 'reducing', 'central', 'chronic', 'pain', 'in', 'patients', 'with', 'multiple', 'sclerosis', '(', 'PwMS', '.', ')', 'In', 'spite', 'of', 'the', 'encouraging', 'results', 'of', 'tDCS', 'in', 'PwMS', ',', 'detailed', 'mechanisms', 'accounting', 'for', 'its', 'analgesic', 'effect', 'have', 'not', 'yet', 'been', 'elucidated', '.', '\n\n', 'This', 'will', 'be', 'the', 'first', 'study', 'to', 'determine', 'the', 'effects', 'of', 'tDCS', 'on', 'whole', 'and', 'regional', 'brain', 'activity', 'in', 'PwMS', 'with', 'neuropathic', 'pain', 'to', 'identify', 'potential', 'mechanisms', 'of', 'the', 'analgesic', 'effects', 'of', 'tDCS', '.', 'These', 'findings', 'will', 'provide', 'targets', 'for', 'future', 'studies', 'investigating', 'different', 'stimulation', 'areas', ',', 'possible', 'short-', 'and', 'long', '-', 'term', 'side', 'effects', ',', 'and', 'specific', 'target', 'areas', 'for', 'other', 'precise', 'stimulation', 'techniques', 'such', 'as', 'transcranial', 'magnetic', 'stimulation', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT03219073,NCT03219073,"Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis: a Mechanistic FDG-PET Study | Transcranial Direct Current Stimulation (tDCS) is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in patients with multiple sclerosis (PwMS.) In spite of the encouraging results of tDCS in PwMS, detailed mechanisms accounting for its analgesic effect have not yet been elucidated.

This will be the first study to determine the effects of tDCS on whole and regional brain activity in PwMS with neuropathic pain to identify potential mechanisms of the analgesic effects of tDCS. These findings will provide targets for future studies investigating different stimulation areas, possible short- and long-term side effects, and specific target areas for other precise stimulation techniques such as transcranial magnetic stimulation.","[(0, 39, 'OTHER', 'Transcranial Direct Current Stimulation'), (49, 65, 'CONDITION', 'Neuropathic Pain'), (81, 100, 'CONDITION', 'Multiple Sclerosis:'), (131, 170, 'OTHER', 'Transcranial Direct Current Stimulation'), (172, 176, 'OTHER', 'tDCS'), (376, 438, 'OTHER', 'tDCS applied over the dorsolateral prefrontal and motor cortex'), (480, 484, 'CONDITION', 'pain'), (511, 515, 'CONDITION', 'pain'), (583, 595, 'CONDITION', 'chronic pain'), (613, 631, 'CONDITION', 'multiple sclerosis'), (679, 683, 'OTHER', 'tDCS'), (837, 841, 'OTHER', 'tDCS'), (892, 908, 'CONDITION', 'neuropathic pain'), (970, 974, 'OTHER', 'tDCS'), (1193, 1226, 'OTHER', 'transcranial magnetic stimulation')]"
"['Physiologic', 'Effects', 'of', 'Sleep', 'Restriction', '|', 'Evidence', 'suggests', 'a', 'relationship', 'between', 'sleep', 'deprivation', 'and', 'cardiovascular', 'disease', '.', 'The', 'investigators', 'wish', 'to', 'determine', 'whether', '9', 'nights', 'of', 'modest', 'sleep', 'restriction', 'results', 'in', 'activation', 'of', 'cardiovascular', 'disease', 'mechanisms', ',', 'thus', 'potentially', 'increasing', 'the', 'risk', 'of', 'cardiovascular', 'disease', '.', 'The', 'investigators', 'hypothesize', 'that', 'sleep', 'restriction', 'will', 'result', 'in', 'elevated', 'blood', 'pressure', ',', 'inflammation', ',', 'and', 'neurocognitive', 'deficits', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01433315,NCT01433315,"Physiologic Effects of Sleep Restriction | Evidence suggests a relationship between sleep deprivation and cardiovascular disease. The investigators wish to determine whether 9 nights of modest sleep restriction results in activation of cardiovascular disease mechanisms, thus potentially increasing the risk of cardiovascular disease. The investigators hypothesize that sleep restriction will result in elevated blood pressure, inflammation, and neurocognitive deficits.","[(106, 128, 'CONDITION', 'cardiovascular disease'), (236, 258, 'CONDITION', 'cardiovascular disease'), (311, 333, 'CONDITION', 'cardiovascular disease')]"
"['Phase', '1', 'Safety', 'Study', 'of', 'RTL1000', '(', 'Recombinant', 'T', 'Cell', 'Receptor', 'Ligand', ')', 'in', 'Subjects', 'With', 'Multiple', 'Sclerosis', '|', 'RTL1000', 'is', 'a', 'new', 'agent', 'that', 'has', 'not', 'been', 'previously', 'tested', 'in', 'humans', '.', 'It', 'is', 'thought', 'that', 'RTL', 'may', 'specifically', 'control', 'the', 'abnormal', 'immune', 'response', 'or', 'attack', 'against', 'the', 'insulation', 'on', 'the', 'nerves', 'that', 'occurs', 'in', 'multiple', 'sclerosis', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'possible', 'side', 'effects', 'of', 'a', 'single', 'intravenous', 'dose', 'of', 'RTL1000', 'in', 'subjects', 'with', 'multiple', 'sclerosis', '.', 'Some', 'subjects', 'will', 'also', 'be', 'asked', 'to', 'participate', 'in', 'one', 'or', 'both', 'of', 'two', 'substudies', ',', 'one', 'to', 'test', 'blood', 'samples', 'to', 'see', 'how', 'the', 'body', ""'s"", 'immune', 'system', 'responds', 'after', 'administration', 'of', 'RTL1000', ',', 'and', 'the', 'other', 'to', 'test', 'blood', 'samples', 'to', 'see', 'how', 'the', 'body', 'absorbs', 'and', 'eliminates', 'the', 'RTL1000', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00411723,NCT00411723,"Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | RTL1000 is a new agent that has not been previously tested in humans. It is thought that RTL may specifically control the abnormal immune response or attack against the insulation on the nerves that occurs in multiple sclerosis.

The purpose of this study is to evaluate the possible side effects of a single intravenous dose of RTL1000 in subjects with multiple sclerosis. Some subjects will also be asked to participate in one or both of two substudies, one to test blood samples to see how the body's immune system responds after administration of RTL1000, and the other to test blood samples to see how the body absorbs and eliminates the RTL1000.","[(24, 31, 'DRUG', 'RTL1000'), (33, 67, 'DRUG', 'Recombinant T Cell Receptor Ligand'), (86, 104, 'CONDITION', 'Multiple Sclerosis'), (107, 114, 'DRUG', 'RTL1000'), (196, 199, 'DRUG', 'RTL'), (316, 334, 'CONDITION', 'multiple sclerosis'), (436, 443, 'DRUG', 'RTL1000'), (461, 479, 'CONDITION', 'multiple sclerosis'), (658, 665, 'DRUG', 'RTL1000'), (750, 757, 'DRUG', 'RTL1000')]"
"['This', 'is', 'a', 'safety', 'and', 'efficacy', 'trial', 'of', 'ranirestat(AS-3201', ')', 'which', 'is', 'an', 'aldose', 'reductase', 'inhibitor', 'in', 'patients', 'with', 'diabetic', 'sensorimotor', 'polyneuropathy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",NCT00101426,NCT00101426,This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.,"[(39, 57, 'DRUG', 'ranirestat(AS-3201'), (71, 97, 'DRUG', 'aldose reductase inhibitor'), (115, 123, 'CONDITION', 'diabetic'), (124, 151, 'CONDITION', 'sensorimotor polyneuropathy')]"
"['Deep', 'Brain', 'Stimulation', 'for', 'Parkinson', ""'s"", 'Disease', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'deep', 'brain', 'stimulation', 'in', 'the', 'the', 'globus', 'pallidus', '(', 'Gpi', ')', 'and', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', 'on', 'motor', ',', 'neuropsychological', 'and', 'psychiatric', 'function', ',', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00053625,NCT00053625,"Deep Brain Stimulation for Parkinson's Disease Trial | The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.","[(0, 22, 'OTHER', 'Deep Brain Stimulation'), (27, 46, 'CONDITION', ""Parkinson's Disease""), (110, 132, 'OTHER', 'deep brain stimulation'), (292, 311, 'CONDITION', ""Parkinson's disease"")]"
"['The', 'Ontario', 'Prehospital', 'Advanced', 'Life', 'Support', '(', 'OPALS', ')', 'Study', 'for', 'Critically', 'Ill', 'and', 'Injured', 'Pediatric', 'Patients', '|', 'The', 'OPALS', 'Pediatric', 'Study', 'will', 'examine', 'the', 'incremental', 'impact', 'of', 'introducing', 'a', 'prehospital', 'full', 'advanced', 'life', 'support', 'in', 'pediatric', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",NCT00298532,NCT00298532,The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients | The OPALS Pediatric Study will examine the incremental impact of introducing a prehospital full advanced life support in pediatric patients.,"[(64, 78, 'CONDITION', 'Critically Ill'), (191, 229, 'OTHER', 'prehospital full advanced life support')]"
"['Adaptative', 'Servoventilation', 'Compliance', 'in', 'Left', 'Ventricular', 'Dysfunction', 'Patients', 'With', 'Central', 'Sleep', 'Apnea', ':', 'Benefit', 'of', 'One', 'Month', 'Hypnotic', '(', 'Zopiclone', ')', 'Versus', 'Placebo', '|', 'The', 'study', 'evaluate', 'the', 'effect', 'of', 'adaptative', 'servoventilation', '(', 'ASV', ')', 'initiation', 'combined', 'with', '14', 'days', 'Zopiclone', 'vs', 'Placebo', 'treatment', 'in', 'patients', 'with', 'central', 'sleep', 'apnea', '(', 'CSA', ')', 'syndrome', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT02820441,NCT02820441,Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo | The study evaluate the effect of adaptative servoventilation (ASV) initiation combined with 14 days Zopiclone vs Placebo treatment in patients with central sleep apnea (CSA) syndrome.,"[(0, 27, 'OTHER', 'Adaptative Servoventilation'), (42, 70, 'CONDITION', 'Left Ventricular Dysfunction'), (85, 104, 'CONDITION', 'Central Sleep Apnea'), (137, 146, 'DRUG', 'Zopiclone'), (155, 162, 'CONTROL', 'Placebo'), (198, 225, 'OTHER', 'adaptative servoventilation'), (227, 230, 'OTHER', 'ASV'), (265, 274, 'DRUG', 'Zopiclone'), (278, 285, 'CONTROL', 'Placebo'), (313, 332, 'CONDITION', 'central sleep apnea'), (334, 337, 'CONDITION', 'CSA')]"
"['Effects', 'of', 'Remote', 'Ischemic', 'Preconditioning', 'on', 'Biochemical', 'Markers', 'and', 'Neurological', 'Outcomes', 'in', 'Patients', 'Undergoing', 'Elective', 'Cervical', 'Decompression', 'Surgery', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'whether', 'a', 'large', 'clinical', 'trial', 'testing', 'the', 'effect', 'of', 'RIPC', 'on', 'neurologic', 'outcome', 'in', 'patients', 'undergoing', 'elective', 'cervical', 'decompression', 'surge', 'is', 'warranted', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O']",NCT00778323,NCT00778323,Effects of Remote Ischemic Preconditioning on Biochemical Markers and Neurological Outcomes in Patients Undergoing Elective Cervical Decompression Surgery | The purpose of this study is to assess whether a large clinical trial testing the effect of RIPC on neurologic outcome in patients undergoing elective cervical decompression surge is warranted.,"[(11, 42, 'OTHER', 'Remote Ischemic Preconditioning'), (124, 154, 'CONDITION', 'Cervical Decompression Surgery'), (249, 253, 'OTHER', 'RIPC'), (308, 336, 'CONDITION', 'cervical decompression surge')]"
"['""', 'Evaluation', 'of', 'Usability', 'and', 'Safety', 'of', 'the', 'Self', '-', 'balancing', 'Walking', 'System', 'Atalante', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '""', '|', 'Multiple', 'sclerosis', '(', 'MS', ')', 'is', 'the', 'most', 'prevalent', 'chronic', 'inflammatory', 'disease', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', ',', 'affecting', 'more', 'than', '2', 'million', 'people', 'worldwide,1', 'it', 'is', 'a', 'degenerative', 'disease', 'that', 'selectively', 'affects', 'the', 'central', 'nervous', 'system', 'and', 'represents', 'the', 'main', 'cause', 'of', 'non', '-', 'traumatic', 'disability', 'in', 'young', 'adults', '.', '\n\n', 'Gait', 'and', 'balance', 'disturbances', 'in', 'MS', 'are', 'common', 'even', 'in', 'the', 'early', 'stages', 'of', 'the', 'disease', '.', 'Half', 'of', 'the', 'patients', 'report', 'some', 'alteration', 'in', 'the', 'quality', 'of', 'walking', 'within', 'the', 'first', 'month', 'after', 'diagnosis', ',', 'reaching', '90', '%', 'after', '10', 'years', 'of', 'evolution', '.', '4', '5', 'In', 'addition', ',', 'it', 'is', 'the', 'symptom', 'to', 'which', 'patients', 'give', 'the', 'most', 'importance', '6', 'and', 'the', 'one', 'that', 'most', 'conditions', 'their', 'activity', 'and', 'participation', '.', '7', 'The', 'causes', 'of', 'gait', 'disturbance', 'are', 'multifactorial', 'and', 'are', 'influenced', 'by', 'different', 'aspects', 'such', 'as', 'muscle', 'strength', ',', 'balance', ',', 'coordination', ',', 'proprioception', ',', 'vision', ',', 'spasticity', ',', 'fatigue', 'and', 'even', 'cognitive', 'aspects4', '.', '\n\n', 'There', 'are', 'multiple', 'interventions', ',', 'including', 'aerobic', ',', 'resistance', 'training', ',', 'yoga', ',', 'and', 'combined', 'exercise', ',', 'that', 'have', 'shown', 'significant', 'improvements', 'in', 'walking', 'endurance', ',', 'regardless', 'of', 'outcome', 'measures', '(', 'six', '-', 'minute', 'walking', 'test', '(', '6MWT', ')', ',', 'two', '-', 'minute', 'walking', 'test', '2MWT', ')', '.', '8', '\n\n', 'In', 'recent', 'years', ',', 'evidence', 'has', 'been', 'growing', 'around', 'rehabilitation', 'with', 'robotic', 'equipment', 'in', 'people', 'with', 'multiple', 'sclerosis', '(', 'PwMS', ')', ',', 'in', 'their', 'study', 'Ye', 'et', 'al', '.', 'concluded', 'that', 'robotic', 'locomotor', 'training', 'has', 'limited', 'impact', 'on', 'motor', 'functions', 'in', 'multiple', 'sclerosis', ',', 'but', 'improves', 'fatigue', 'and', 'spasticity', ',', 'is', 'safe', 'and', 'well', '-', 'tolerated', 'for', 'PwMS', ',', 'and', 'less', 'demanding', 'for', 'physical', 'therapists.10', 'Bowman', 'et', 'al', '.', 'concluded', 'that', 'robot', '-', 'assisted', 'gait', 'therapy', '(', 'RAGT', ')', 'improves', 'balance', 'and', 'gait', 'outcomes', 'in', 'a', 'clinically', 'significant', 'way', 'in', 'PwMS', ',', 'RAGT', 'appears', 'more', 'effective', 'compared', 'to', 'non', '-', 'specific', 'rehabilitation', ',', 'while', 'showing', 'similar', 'effects', 'compared', 'to', 'non', '-', 'specific', 'rehabilitation', '.', 'specific', 'balance', 'and', 'gait', 'training', 'in', 'studies', 'with', 'level', '2', 'evidence', '.', 'RAGT', 'has', 'several', 'advantages', 'in', 'terms', 'of', 'patient', 'motor', 'assistance', ',', 'training', 'intensity', ',', 'safety', 'and', 'the', 'possibility', 'of', 'combining', 'other', 'therapeutic', 'approaches', 'and', 'should', 'be', 'promoted', 'for', 'PwMS', 'with', 'disability', 'in', 'a', 'multimodal', 'rehabilitation', 'setting', 'as', 'an', 'opportunity', 'to', 'maximize', 'recovery.11', 'In', 'this', 'setting', ',', 'more', 'larger', '-', 'scale', 'and', 'better', '-', 'designed', 'studies', 'with', 'longer', 'training', 'duration', 'and', 'more', 'studies', 'evaluating', 'satisfaction', ',', 'usability', ',', 'and', 'effectiveness', 'are', 'needed', '.', 'of', 'RAGT', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O']",NCT05563402,NCT05563402,"""Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis"" | Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide,1 it is a degenerative disease that selectively affects the central nervous system and represents the main cause of non-traumatic disability in young adults.

Gait and balance disturbances in MS are common even in the early stages of the disease. Half of the patients report some alteration in the quality of walking within the first month after diagnosis, reaching 90% after 10 years of evolution. 4 5 In addition, it is the symptom to which patients give the most importance 6 and the one that most conditions their activity and participation. 7 The causes of gait disturbance are multifactorial and are influenced by different aspects such as muscle strength, balance, coordination, proprioception, vision, spasticity, fatigue and even cognitive aspects4.

There are multiple interventions, including aerobic, resistance training, yoga, and combined exercise, that have shown significant improvements in walking endurance, regardless of outcome measures (six-minute walking test (6MWT), two-minute walking test 2MWT). 8

In recent years, evidence has been growing around rehabilitation with robotic equipment in people with multiple sclerosis (PwMS), in their study Ye et al. concluded that robotic locomotor training has limited impact on motor functions in multiple sclerosis, but improves fatigue and spasticity, is safe and well-tolerated for PwMS, and less demanding for physical therapists.10 Bowman et al. concluded that robot-assisted gait therapy (RAGT) improves balance and gait outcomes in a clinically significant way in PwMS, RAGT appears more effective compared to non-specific rehabilitation, while showing similar effects compared to non-specific rehabilitation. specific balance and gait training in studies with level 2 evidence. RAGT has several advantages in terms of patient motor assistance, training intensity, safety and the possibility of combining other therapeutic approaches and should be promoted for PwMS with disability in a multimodal rehabilitation setting as an opportunity to maximize recovery.11 In this setting, more larger-scale and better-designed studies with longer training duration and more studies evaluating satisfaction, usability, and effectiveness are needed. of RAGT.","[(43, 81, 'PHYSICAL', 'Self-balancing Walking System Atalante'), (99, 117, 'CONDITION', 'Multiple Sclerosis'), (121, 139, 'CONDITION', 'Multiple sclerosis'), (141, 143, 'CONDITION', 'MS'), (472, 474, 'CONDITION', 'MS'), (1407, 1425, 'CONDITION', 'multiple sclerosis'), (1474, 1500, 'PHYSICAL', 'robotic locomotor training'), (1711, 1738, 'PHYSICAL', 'robot-assisted gait therapy'), (1740, 1744, 'PHYSICAL', 'RAGT'), (1822, 1826, 'PHYSICAL', 'RAGT'), (2031, 2035, 'PHYSICAL', 'RAGT'), (2494, 2498, 'PHYSICAL', 'RAGT')]"
"['The', 'Volume', 'Effect', 'of', 'Hydrodissection', 'for', 'Injection', 'Therapies', 'in', 'Patients', 'With', 'Carpal', 'Tunnel', 'Syndrome', '-', 'Evaluation', 'Model', 'by', 'Shear', 'Wave', 'Ultrasound', 'Elastography', 'and', 'Artificial', 'Intelligence', 'Imaging', 'Analysis', '|', 'The', 'investigators', 'investigated', 'the', 'volume', 'effect', 'of', 'hydrodissection', 'for', 'Injection', 'therapies', 'in', 'patients', 'with', 'Carpal', 'Tunnel', 'Syndrome', '.', 'The', 'investigators', 'evaluated', 'participants', 'by', 'Shear', 'Wave', 'Ultrasound', 'Elastography', 'and', 'Artificial', 'Intelligence', 'Imaging', 'Analysis']","['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03598322,NCT03598322,The Volume Effect of Hydrodissection for Injection Therapies in Patients With Carpal Tunnel Syndrome - Evaluation Model by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis | The investigators investigated the volume effect of hydrodissection for Injection therapies in patients with Carpal Tunnel Syndrome. The investigators evaluated participants by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis,"[(21, 36, 'OTHER', 'Hydrodissection'), (78, 100, 'CONDITION', 'Carpal Tunnel Syndrome'), (257, 272, 'OTHER', 'hydrodissection'), (314, 336, 'CONDITION', 'Carpal Tunnel Syndrome')]"
"['Recombinant', 'Human', 'Endostatin', 'Injection', 'Study', 'for', 'Patients', 'With', 'Neurofibromatosis', 'Type', '2', '(', 'NF2', ')', 'and', 'NF2', '-', 'Related', 'Tumors', 'by', 'Continuous', 'Intravenous', 'Pumping', '|', '1)Preliminarily', 'evaluate', 'the', 'treatment', 'effect', 'of', 'continuous', 'vein', 'injection', 'of', 'recombinant', 'human', 'endostatin', 'on', 'NF2', ';', '2)Preliminarily', 'evaluate', 'the', 'safety', 'and', 'the', 'patient', ""'s"", 'tolerance', 'of', 'the', 'treatment', 'of', 'endostatin', ';', '3)Provide', 'an', 'objective', 'basis', 'for', 'an', 'enlarged', 'randomized', 'double', '-', 'blind', 'trial', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02104323,NCT02104323,Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping | 1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.,"[(0, 28, 'DRUG', 'Recombinant Human Endostatin'), (63, 87, 'CONDITION', 'Neurofibromatosis Type 2'), (89, 92, 'CONDITION', 'NF2'), (98, 116, 'CONDITION', 'NF2-Related Tumors'), (231, 259, 'DRUG', 'recombinant human endostatin'), (263, 266, 'CONDITION', 'NF2'), (352, 362, 'DRUG', 'endostatin')]"
"['Pharmacokinetics', 'and', 'Nitrative', '-', 'Oxidative', 'Stress', 'Pharmacodynamics', 'in', 'Amyotrophic', 'Lateral', 'Sclerosis', 'Subjects', 'Taking', 'Daily', 'High', '-', 'Dose', 'R(+', ')', 'Pramipexole', 'Dihydrochloride', 'for', 'Six', 'Months', '|', 'R(+)pramipexole', 'is', 'administered', 'in', 'escalating', 'doses', 'to', 'patients', 'with', 'early', 'ALS', '.', 'Plasma', 'and', 'spinal', 'fluid', 'levels', 'of', 'R(+)PPX', 'are', 'monitored', ',', 'in', 'addition', 'to', 'biochemical', 'markers', 'of', 'oxidative', 'stress', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00600873,NCT00600873,"Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months | R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.","[(68, 97, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (130, 162, 'DRUG', 'R(+) Pramipexole Dihydrochloride'), (180, 195, 'DRUG', 'R(+)pramipexole'), (249, 258, 'CONDITION', 'early ALS'), (294, 301, 'DRUG', 'R(+)PPX')]"
"['Phase', 'II', 'Study', 'of', '18F', '-', 'DTBZ', ':', 'The', 'Differential', 'Diagnosis', 'of', 'Parkinson', ""'s"", 'Disease', 'and', 'Monitoring', 'the', 'Severity', 'of', 'Disease', 'by', 'VMAT2', 'PET', 'Imaging', '|', 'The', 'primary', 'objective', 'of', 'this', 'protocol', 'is', 'to', 'analyze', 'the', 'sensitivity', 'and', 'specificity', 'of', '18F', '-', 'DTBZ', 'PET', 'to', 'the', 'differential', 'diagnosis', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'and', 'normality', '.', 'Secondary', ',', 'the', 'investigators', 'will', 'analyze', 'the', 'correlation', 'between', 'the', '18F', '-', 'DTBZ', 'binding', 'and', 'the', 'severity', 'of', 'disease', 'of', 'PD', 'and', 'the', 'role', 'of', '18F', '-', 'DTBZ', 'PET', 'in', 'the', 'monitoring', 'disease', 'severity', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01283347,NCT01283347,"Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging | The primary objective of this protocol is to analyze the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of Parkinson's Disease (PD) and normality. Secondary, the investigators will analyze the correlation between the 18F-DTBZ binding and the severity of disease of PD and the role of 18F-DTBZ PET in the monitoring disease severity.","[(58, 77, 'CONDITION', ""Parkinson's Disease""), (274, 293, 'CONDITION', ""Parkinson's Disease""), (295, 297, 'CONDITION', 'PD'), (432, 434, 'CONDITION', 'PD')]"
"['Comparison', 'of', 'the', 'Effects', 'of', 'Ultrasound', '-', 'guided', 'Suprascapular', 'Nerve', 'Block', 'and', 'Subacromial', 'Injection', 'in', 'Hemiplegic', 'Shoulder', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Hemiplegic', 'shoulder', 'pain', 'is', 'the', 'most', 'common', 'poststroke', 'painful', 'condition', '.', 'Hemiplegic', 'shoulder', 'pain', 'reduces', 'range', 'of', 'motion', '(', 'ROM', ')', 'and', 'hand', 'function', ',', 'resulting', 'in', 'limited', 'daily', 'life', 'activity', 'and', 'decreased', 'quality', 'of', 'life', '.', '\n\n', 'In', 'the', 'literature', ',', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', 'has', 'been', 'previously', 'evaluated', ',', 'but', 'these', 'injection', 'treatments', 'have', 'not', 'been', 'compared', '.', '\n\n', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'on', 'pain', ',', 'shoulder', '(', 'ROM', ')', ',', 'function', 'and', 'quality', 'of', 'life', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04433377,NCT04433377,"Comparison of the Effects of Ultrasound-guided Suprascapular Nerve Block and Subacromial Injection in Hemiplegic Shoulder Pain: a Randomized Controlled Trial | Hemiplegic shoulder pain is the most common poststroke painful condition. Hemiplegic shoulder pain reduces range of motion (ROM) and hand function, resulting in limited daily life activity and decreased quality of life.

In the literature, the effectiveness of suprascapular nerve block and subacromial injection in hemiplegia patients with shoulder pain has been previously evaluated, but these injection treatments have not been compared.

Therefore, the aim of this study is to compare the effectiveness of suprascapular nerve block and subacromial injection on pain, shoulder (ROM), function and quality of life in hemiplegia patients with shoulder pain.","[(29, 72, 'OTHER', 'Ultrasound-guided Suprascapular Nerve Block'), (77, 98, 'OTHER', 'Subacromial Injection'), (102, 112, 'CONDITION', 'Hemiplegic'), (113, 126, 'CONDITION', 'Shoulder Pain'), (160, 170, 'CONDITION', 'Hemiplegic'), (171, 184, 'CONDITION', 'shoulder pain'), (204, 214, 'CONDITION', 'poststroke'), (234, 244, 'CONDITION', 'Hemiplegic'), (245, 258, 'CONDITION', 'shoulder pain'), (421, 446, 'OTHER', 'suprascapular nerve block'), (451, 472, 'OTHER', 'subacromial injection'), (476, 486, 'CONDITION', 'hemiplegia'), (501, 514, 'CONDITION', 'shoulder pain'), (670, 695, 'OTHER', 'suprascapular nerve block'), (700, 721, 'OTHER', 'subacromial injection'), (725, 729, 'CONDITION', 'pain'), (779, 789, 'CONDITION', 'hemiplegia'), (804, 817, 'CONDITION', 'shoulder pain')]"
"['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Pramipexole', 'With', 'the', 'Dose', 'Range', 'From', '0.125', 'mg', 'to', '0.75', 'mg', 'Orally', 'Once', 'Daily', 'for', '6', 'Weeks', 'in', 'Patients', 'With', 'Primary', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'objective', 'of', 'this', 'trial', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'pramipexole', '(', '0.125', '-', '0.75', 'mg', ')', 'orally', 'once', 'daily', 'as', 'compared', 'with', 'placebo', 'for', '6', 'weeks', 'in', 'patients', 'with', 'primary', 'restless', 'legs', 'syndrome', '(', 'RLS', ')', 'and', 'to', 'investigate', 'the', 'reliability', 'of', 'the', 'Japanese', 'version', 'of', 'the', 'RLS', 'rating', 'scale', 'by', 'the', 'International', 'Restless', 'Legs', 'Syndrome', 'Study', 'Group', '(', 'IRLSSG', ')', 'as', 'a', 'sub', '-', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00152997,NCT00152997,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome. | The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.","[(28, 35, 'CONTROL', 'Placebo'), (92, 103, 'DRUG', 'Pramipexole'), (196, 226, 'CONDITION', 'Primary Restless Legs Syndrome'), (303, 314, 'DRUG', 'pramipexole'), (366, 373, 'CONTROL', 'placebo'), (403, 433, 'CONDITION', 'primary restless legs syndrome'), (435, 438, 'CONDITION', 'RLS'), (506, 509, 'CONDITION', 'RLS')]"
"['Multi', '-', 'centre', 'Randomised', 'Trial', 'to', 'Evaluate', 'the', 'Effect', 'of', 'Early', 'Hypothermia', 'on', 'Neurological', 'Function', 'in', 'Patients', 'With', 'Severe', 'Traumatic', 'Brain', 'Injury', '.', 'Including', 'Renal', 'Sub', 'Study', '|', 'Traumatic', 'brain', 'injury', '(', 'TBI', ')', 'is', 'a', 'leading', 'cause', 'of', 'death', 'and', 'long', 'term', 'disability', ',', 'particularly', 'in', 'young', 'adults', '.', 'Studies', 'from', 'Australia', 'have', 'shown', 'that', 'approximately', 'half', 'of', 'those', 'with', 'severe', 'traumatic', 'brain', 'injury', 'will', 'be', 'severely', 'disabled', 'or', 'dead', '6', 'months', 'post', 'injury', '.', 'Given', 'the', 'young', 'age', 'of', 'many', 'patients', 'with', 'severe', 'TBI', 'and', 'the', 'long', 'term', 'prevalence', 'of', 'major', 'disability', ',', 'the', 'economic', 'and', 'more', 'importantly', 'the', 'social', 'cost', 'to', 'the', 'community', 'is', 'very', 'high', '.', '\n\n', 'Pre', '-', 'hospital', 'and', 'hospital', 'management', 'of', 'patients', 'with', 'severe', 'brain', 'injury', 'focuses', 'on', 'prevention', 'of', 'additional', 'injury', 'due', 'primarily', 'to', 'lack', 'of', 'oxygen', 'and', 'insufficient', 'blood', 'pressure', '.', 'This', 'includes', 'optimising', 'sedation', 'and', 'ventilation', ',', 'maintaining', 'the', 'fluid', 'balance', 'and', 'draining', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'and', 'performing', 'surgery', 'where', 'appropriate', '.', 'In', 'recent', 'years', 'there', 'has', 'been', 'a', 'research', 'focus', 'on', 'specific', 'pharmacologic', 'interventions', ',', 'however', ',', 'to', 'date', ',', 'there', 'has', 'been', 'no', 'treatment', 'that', 'has', 'been', 'associated', 'with', 'improvement', 'of', 'neurological', 'outcomes', '.', '\n\n', 'One', 'treatment', 'that', 'shows', 'promise', 'is', 'the', 'application', 'of', 'hypothermia', '(', 'cooling', ')', '.', 'This', 'treatment', 'is', 'commonly', 'used', 'in', 'Australia', 'to', 'decrease', 'brain', 'injury', 'in', 'patients', 'with', 'brain', 'injury', 'following', 'out', '-', 'of', '-', 'hospital', 'cardiac', 'arrest', '.', 'Cooling', 'is', 'thought', 'to', 'protect', 'the', 'brain', 'using', 'a', 'number', 'of', 'mechanisms', '.', 'There', 'have', 'been', 'a', 'number', 'of', 'animal', 'studies', 'that', 'have', 'looked', 'at', 'how', 'cooling', 'is', 'protective', 'and', 'also', 'some', 'clinical', 'research', 'that', 'suggests', 'some', 'benefit', '.', 'However', 'at', 'the', 'current', 'time', 'there', 'is', 'insufficient', 'evidence', 'to', 'provide', 'enough', 'proof', 'that', 'cooling', 'should', 'be', 'used', 'routinely', 'for', 'patients', 'with', 'brain', 'injury', 'and', 'like', 'all', 'treatments', 'there', 'can', 'be', 'some', 'risks', 'and', 'side', 'effects', '.', '\n\n', 'The', 'POLAR', 'trial', 'has', 'been', 'developed', 'to', 'investigate', 'whether', 'early', 'cooling', 'of', 'patients', 'with', 'severe', 'traumatic', 'brain', 'injury', 'is', 'associated', 'with', 'better', 'outcomes', '.', 'It', 'is', 'a', 'randomised', 'controlled', 'trial', ',', 'which', 'is', 'a', 'type', 'of', 'trial', 'that', 'provides', 'the', 'highest', 'quality', 'of', 'evidence', '.', '\n\n', 'The', 'null', 'hypothesis', 'is', 'that', 'there', 'is', 'no', 'difference', 'in', 'the', 'proportion', 'of', 'favourable', 'neurological', 'outcomes', 'six', 'months', 'after', 'severe', 'traumatic', 'brain', 'injury', 'in', 'patients', 'treated', 'with', 'early', 'and', 'sustained', 'hypothermia', ',', 'compared', 'to', 'standard', 'normothermic', 'management', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT00987688,NCT00987688,"Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study | Traumatic brain injury (TBI) is a leading cause of death and long term disability, particularly in young adults. Studies from Australia have shown that approximately half of those with severe traumatic brain injury will be severely disabled or dead 6 months post injury. Given the young age of many patients with severe TBI and the long term prevalence of major disability, the economic and more importantly the social cost to the community is very high.

Pre-hospital and hospital management of patients with severe brain injury focuses on prevention of additional injury due primarily to lack of oxygen and insufficient blood pressure. This includes optimising sedation and ventilation, maintaining the fluid balance and draining Cerebrospinal Fluid (CSF) and performing surgery where appropriate. In recent years there has been a research focus on specific pharmacologic interventions, however, to date, there has been no treatment that has been associated with improvement of neurological outcomes.

One treatment that shows promise is the application of hypothermia (cooling). This treatment is commonly used in Australia to decrease brain injury in patients with brain injury following out-of-hospital cardiac arrest. Cooling is thought to protect the brain using a number of mechanisms. There have been a number of animal studies that have looked at how cooling is protective and also some clinical research that suggests some benefit. However at the current time there is insufficient evidence to provide enough proof that cooling should be used routinely for patients with brain injury and like all treatments there can be some risks and side effects.

The POLAR trial has been developed to investigate whether early cooling of patients with severe traumatic brain injury is associated with better outcomes. It is a randomised controlled trial, which is a type of trial that provides the highest quality of evidence.

The null hypothesis is that there is no difference in the proportion of favourable neurological outcomes six months after severe traumatic brain injury in patients treated with early and sustained hypothermia, compared to standard normothermic management.","[(62, 73, 'OTHER', 'Hypothermia'), (116, 145, 'CONDITION', 'Severe Traumatic Brain Injury'), (175, 197, 'CONDITION', 'Traumatic brain injury'), (199, 202, 'CONDITION', 'TBI'), (360, 389, 'CONDITION', 'severe traumatic brain injury'), (488, 498, 'CONDITION', 'severe TBI'), (685, 704, 'CONDITION', 'severe brain injury'), (1234, 1245, 'OTHER', 'hypothermia'), (1247, 1254, 'OTHER', 'cooling'), (1344, 1356, 'CONDITION', 'brain injury'), (1399, 1406, 'OTHER', 'Cooling'), (1536, 1543, 'OTHER', 'cooling'), (1706, 1713, 'OTHER', 'cooling'), (1757, 1769, 'CONDITION', 'brain injury'), (1901, 1908, 'OTHER', 'cooling'), (1926, 1955, 'CONDITION', 'severe traumatic brain injury'), (2224, 2253, 'CONDITION', 'severe traumatic brain injury'), (2299, 2310, 'OTHER', 'hypothermia'), (2324, 2356, 'CONTROL', 'standard normothermic management')]"
"['Phase', 'IIa', ',', 'Open', 'Label', ',', 'Dose', 'Ascending', 'Study', 'to', 'Determine', 'the', 'Maximum', 'Tolerated', 'Dose', ',', 'Safety', 'and', 'Tolerability', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'a', 'Single', 'Dose', 'of', 'Lanreotide', 'PRF', 'in', 'Subjects', 'With', 'Acromegaly', 'Previously', 'Treated', 'and', 'Controlled', 'With', 'Either', 'Octreotide', 'LAR', 'or', 'Lanreotide', 'Autogel', '|', 'The', 'objectives', 'of', 'the', 'protocol', 'is', 'to', 'determine', 'the', 'maximum', 'tolerated', 'dose', 'and', 'to', 'investigate', 'the', 'pharmacokinetics', 'of', 'a', 'single', 'dose', 'of', 'lanreotide', 'PRF', 'in', 'subjects', 'with', 'acromegaly', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02396953,NCT02396953,"Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel | The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.","[(168, 178, 'DRUG', 'Lanreotide'), (200, 210, 'CONDITION', 'Acromegaly'), (257, 267, 'DRUG', 'Octreotide'), (275, 285, 'DRUG', 'Lanreotide'), (430, 440, 'DRUG', 'lanreotide'), (462, 472, 'CONDITION', 'acromegaly')]"
"['Quantitative', 'Requirements', 'of', 'Docosahexaenoic', 'Acid', 'for', 'Neural', 'Function', 'in', 'Children', 'With', 'Phenylketonuria', '|', 'Patients', 'with', 'phenylketonuria', '(', 'PKU', ')', 'have', 'an', 'inborn', 'error', 'in', 'the', 'metabolism', 'of', 'the', 'amino', 'acid', 'phenylalanine', '(', 'Phe', ')', 'and', 'thus', 'must', 'follow', 'a', 'strictly', 'controlled', 'protein', '-', 'restricted', 'diet', 'from', 'early', 'infancy', '.', 'This', 'protein', '-', 'restricted', 'diet', 'is', 'devoid', 'of', 'natural', 'dietary', 'sources', 'of', 'n-3', 'long', 'chain', 'polyunsaturated', 'fatty', 'acids', '(', 'LC', '-', 'PUFA', ')', ',', 'such', 'as', 'eggs', ',', 'meat', ',', 'milk', 'or', 'fish', '.', 'Therefore', ',', 'blood', 'concentrations', 'of', 'n-3', 'LC', '-', 'PUFA', ',', 'especially', 'of', 'docosahexaenoic', 'acid', '(', 'DHA', ')', 'are', 'reduced', 'in', 'PKU', 'children', 'compared', 'to', 'healthy', 'controls', '.', 'DHA', 'availability', 'is', 'considered', 'important', 'for', 'optimal', 'neurological', 'function', '.', 'Previous', 'studies', 'have', 'shown', 'that', 'neural', 'function', 'of', 'PKU', 'children', 'is', 'improved', 'by', 'high', 'dose', 'supplementation', 'of', 'fish', 'oil', 'providing', 'DHA', ',', 'as', 'shown', 'by', 'significant', 'improvements', 'of', 'both', 'visual', 'evoked', 'potential', 'latencies', 'and', 'of', 'fine', 'motor', 'skills', 'and', 'coordination', ',', 'but', 'no', 'dose', 'response', 'relationship', 'has', 'been', 'established', 'so', 'far', '.', '\n\n', 'This', 'multicentric', 'double', '-', 'blind', 'randomized', 'trial', 'aims', 'at', 'determining', 'quantitative', 'DHA', 'requirements', 'for', 'optimal', 'neural', 'function', 'in', 'PKU', 'children', '.', 'Patients', 'with', 'classical', 'PKU', 'from', 'several', 'major', 'treatment', 'centers', 'in', 'Europe', 'will', 'be', 'randomized', 'to', 'receive', 'between', '0', 'and', '8', 'mg', 'of', 'DHA', 'per', 'kg', 'body', 'weight', 'daily', 'for', 'a', 'duration', 'of', '6', 'months', '.', 'Biochemical', '(', 'fatty', 'acid', 'composition', 'of', 'plasma', 'phospholipids', ',', 'lipoprotein', 'metabolism', 'and', 'metabolic', 'profiles', ')', ',', 'and', 'functional', 'testing', '(', 'visual', 'evoked', 'potentials', ',', 'fine', 'motor', 'skills', ',', 'cognitive', 'function', 'and', 'markers', 'of', 'immune', 'function', ')', 'will', 'be', 'performed', 'at', 'baseline', 'and', 'after', '6', 'months', '.', 'Intake', 'per', 'kg', 'body', 'weight', 'will', 'be', 'related', 'to', 'outcome', 'parameters', 'and', 'thus', 'a', 'possible', 'dose', 'response', 'relationship', 'will', 'be', 'defined', '.', 'The', 'results', 'from', 'this', 'study', 'are', 'expected', 'to', 'contribute', 'to', 'the', 'improvement', 'of', 'the', 'diet', 'of', 'PKU', 'patients', ',', 'but', 'they', 'also', 'have', 'the', 'potential', 'to', 'help', 'defining', 'quantitative', 'DHA', 'needs', 'of', 'healthy', 'children', '.', '\n\n', 'The', 'primary', 'hypothesis', 'is', 'that', 'supplementation', 'with', 'DHA', 'improves', 'visual', 'function', 'in', 'children', 'with', 'PKU', '.']","['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00909012,NCT00909012,"Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria | Patients with phenylketonuria (PKU) have an inborn error in the metabolism of the amino acid phenylalanine (Phe) and thus must follow a strictly controlled protein-restricted diet from early infancy. This protein-restricted diet is devoid of natural dietary sources of n-3 long chain polyunsaturated fatty acids (LC-PUFA), such as eggs, meat, milk or fish. Therefore, blood concentrations of n-3 LC-PUFA, especially of docosahexaenoic acid (DHA) are reduced in PKU children compared to healthy controls. DHA availability is considered important for optimal neurological function. Previous studies have shown that neural function of PKU children is improved by high dose supplementation of fish oil providing DHA, as shown by significant improvements of both visual evoked potential latencies and of fine motor skills and coordination, but no dose response relationship has been established so far.

This multicentric double-blind randomized trial aims at determining quantitative DHA requirements for optimal neural function in PKU children. Patients with classical PKU from several major treatment centers in Europe will be randomized to receive between 0 and 8 mg of DHA per kg body weight daily for a duration of 6 months. Biochemical (fatty acid composition of plasma phospholipids, lipoprotein metabolism and metabolic profiles), and functional testing (visual evoked potentials, fine motor skills, cognitive function and markers of immune function) will be performed at baseline and after 6 months. Intake per kg body weight will be related to outcome parameters and thus a possible dose response relationship will be defined. The results from this study are expected to contribute to the improvement of the diet of PKU patients, but they also have the potential to help defining quantitative DHA needs of healthy children.

The primary hypothesis is that supplementation with DHA improves visual function in children with PKU.","[(29, 49, 'DRUG', 'Docosahexaenoic Acid'), (87, 102, 'CONDITION', 'Phenylketonuria'), (119, 134, 'CONDITION', 'phenylketonuria'), (136, 139, 'CONDITION', 'PKU'), (524, 544, 'DRUG', 'docosahexaenoic acid'), (546, 549, 'DRUG', 'DHA'), (566, 569, 'CONDITION', 'PKU'), (609, 612, 'DRUG', 'DHA'), (737, 740, 'CONDITION', 'PKU'), (813, 816, 'DRUG', 'DHA'), (1085, 1088, 'DRUG', 'DHA'), (1133, 1136, 'CONDITION', 'PKU'), (1171, 1174, 'CONDITION', 'PKU'), (1274, 1277, 'DRUG', 'DHA'), (1827, 1830, 'CONDITION', 'PKU'), (1904, 1907, 'DRUG', 'DHA'), (1988, 1991, 'DRUG', 'DHA'), (2034, 2037, 'CONDITION', 'PKU')]"
"['Comparison', 'of', 'Esmolol', 'and', 'Dexmedetomidine', 'on', 'Sympathetic', 'Control', 'During', 'Intracranial', 'Procedures', '|', 'Patients', 'undergoing', 'intracranial', 'procedures', 'may', 'experience', 'severe', 'hypertension', 'and', 'tachycardia', 'due', 'to', 'intracranial', 'hypertension', 'and', 'to', 'increased', 'release', 'of', 'adrenaline', '.', 'Preventing', 'perioperative', 'sympathetic', 'activity', 'is', 'of', 'great', 'importance', '.', 'A', 'common', 'technique', 'is', 'using', 'b', '-', 'blockers', 'like', 'esmolol', ',', 'which', 'effectively', 'block', 'perioperative', 'hemodynamic', 'changes', 'during', 'intracranial', 'surgery', '.', 'A2', 'agonists', ',', 'like', 'Dexmedetomidine', '-', 'Dex', 'are', 'now', 'being', 'used', 'as', 'a', 'component', 'of', 'a', 'balanced', 'anesthesia', 'during', 'neurosurgical', 'procedures', '.', 'This', 'study', 'aimed', 'to', 'evaluate', 'whether', 'esmolol', 'or', 'dex', 'attenuates', 'perioperative', 'changes', 'in', 'patients', 'undergoing', 'elective', 'craniotomy', 'with', 'fast', 'track', 'neuroanesthesia', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT02563288,NCT02563288,"Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures | Patients undergoing intracranial procedures may experience severe hypertension and tachycardia due to intracranial hypertension and to increased release of adrenaline. Preventing perioperative sympathetic activity is of great importance. A common technique is using b-blockers like esmolol, which effectively block perioperative hemodynamic changes during intracranial surgery. A2 agonists, like Dexmedetomidine-Dex are now being used as a component of a balanced anesthesia during neurosurgical procedures. This study aimed to evaluate whether esmolol or dex attenuates perioperative changes in patients undergoing elective craniotomy with fast track neuroanesthesia.","[(14, 21, 'DRUG', 'Esmolol'), (26, 41, 'DRUG', 'Dexmedetomidine'), (72, 95, 'CONDITION', 'Intracranial Procedures'), (118, 141, 'CONDITION', 'intracranial procedures'), (164, 176, 'CONDITION', 'hypertension'), (181, 192, 'CONDITION', 'tachycardia'), (200, 225, 'CONDITION', 'intracranial hypertension'), (364, 374, 'DRUG', 'b-blockers'), (380, 387, 'DRUG', 'esmolol'), (476, 487, 'DRUG', 'A2 agonists'), (494, 509, 'DRUG', 'Dexmedetomidine'), (510, 513, 'DRUG', 'Dex'), (643, 650, 'DRUG', 'esmolol'), (654, 657, 'DRUG', 'dex'), (714, 733, 'CONDITION', 'elective craniotomy')]"
"['A', 'Phase', 'IIa', ',', 'Randomized', ',', 'Open', '-', 'label', ',', 'Multi', '-', 'Center', ',', 'Multi', '-', 'Dose', 'Study', 'to', 'Evaluate', 'the', 'Effects', 'of', 'ALZT', '-', 'OP1a', 'in', 'Subjects', 'With', 'Mild', '-', 'Moderate', 'Stage', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'This', 'is', 'a', 'Phase', 'IIa', ',', 'randomized', ',', 'open', '-', 'label', ',', 'multi', '-', 'center', ',', 'multi', '-', 'dose', 'study', 'for', 'subjects', 'with', 'mild', 'to', 'moderate', 'ALS', '.', 'The', 'protocol', 'is', 'designed', 'to', 'determine', 'whether', 'ALZT', '-', 'OP1a', 'treatment', 'will', 'positively', 'impact', 'neuro', '-', 'inflammatory', 'biomarkers', 'and', 'slow', 'down', 'or', 'arrest', 'functional', 'decline', 'in', 'subjects', 'with', 'mild', 'to', 'moderate', 'ALS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04428775,NCT04428775,"A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS) | This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.","[(95, 104, 'DRUG', 'ALZT-OP1a'), (122, 171, 'CONDITION', 'Mild-Moderate Stage Amyotrophic Lateral Sclerosis'), (173, 176, 'CONDITION', 'ALS'), (274, 294, 'CONDITION', 'mild to moderate ALS'), (342, 351, 'DRUG', 'ALZT-OP1a'), (475, 495, 'CONDITION', 'mild to moderate ALS')]"
"['Cognitive', ',', 'Morphological', 'and', 'Neurobiological', 'Progressive', 'Aspects', 'in', 'Bipolar', 'Disorders', 'in', 'the', 'Elderly', ':', 'Toward', 'to', 'a', 'Neurodegenerescence', 'Detection', '?', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'identify', 'association', 'between', 'cerebrospinal', 'fluid', 'Alzheimer', ""'s"", 'Disease', ""'s"", 'neurodegenerescence', 'biomarkers', '(', 'tau', ',', 'ptau', ',', 'Aß40', 'and', 'Aß1', '-', '42', ')', 'and', 'occurrence', 'of', 'cognitive', 'deficits', 'in', 'older', 'patients', 'with', 'bipolar', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02843906,NCT02843906,"Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection? | The purpose of this study is to identify association between cerebrospinal fluid Alzheimer's Disease's neurodegenerescence biomarkers (tau, ptau, Aß40 and Aß1-42) and occurrence of cognitive deficits in older patients with bipolar disorders.","[(68, 85, 'CONDITION', 'Bipolar Disorders'), (228, 247, 'CONDITION', ""Alzheimer's Disease""), (328, 346, 'CONDITION', 'cognitive deficits'), (370, 387, 'CONDITION', 'bipolar disorders')]"
"['A', 'Randomised', ',', 'Cross', '-', 'over', ',', 'Open', '-', 'labelled', 'Study', 'Evaluating', 'the', 'Acceptance', 'of', 'Test', 'Catheters', 'Compared', 'to', 'SpeediCath', 'Catheters', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'that', 'the', 'test', 'catheter', 'is', 'no', 'less', 'accepted', 'than', 'the', 'SpeediCath', '(', 'SC', ')', 'catheter', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT00990093,NCT00990093,"A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters | The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.","[(75, 89, 'OTHER', 'Test Catheters'), (102, 122, 'OTHER', 'SpeediCath Catheters'), (175, 188, 'OTHER', 'test catheter'), (218, 242, 'OTHER', 'SpeediCath (SC) catheter')]"
"['CONFIDENCE', ':', 'A', 'Multinational', ',', 'Multicenter', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Open', '-', 'Label', 'Study', 'to', 'Assess', 'Medication', 'Satisfaction', 'in', 'Patients', 'With', 'Relapsing', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', 'Treated', 'With', 'Subcutaneous', 'Injections', 'of', 'Copaxone(R', ')', '(', 'Glatiramer', 'Acetate', ')', '40', 'mg', '/', 'mL', 'Three', 'Times', 'a', 'Week', 'Compared', 'to', '20', 'mg', '/', 'mL', 'Daily', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'patient', 'medication', 'satisfaction', 'as', 'measured', 'by', 'the', 'Medication', 'Satisfaction', 'Questionnaire', '(', 'MSQ', ')', 'scores', 'between', 'the', 'Copaxone', '40', 'mg', '/', 'mL', 'three', 'time', 'a', 'week', '(', 'TIW', ')', 'group', 'and', 'the', 'Copaxone', '20', 'mg', '/', 'mL', 'once', 'daily', '(', 'QD', ')', 'group', 'over', '6', 'months', 'of', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02499900,NCT02499900,"CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily | The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.","[(138, 176, 'CONDITION', 'Relapsing Remitting Multiple Sclerosis'), (178, 182, 'CONDITION', 'RRMS'), (224, 235, 'DRUG', 'Copaxone(R)'), (237, 255, 'DRUG', 'Glatiramer Acetate'), (478, 486, 'DRUG', 'Copaxone'), (534, 542, 'DRUG', 'Copaxone')]"
"['Effect', 'of', 'Psychoeducation', 'Upon', 'Exposure', 'to', 'Sounds', 'and', 'Hyperacusis', 'Severity', '|', 'This', 'study', 'focuses', 'on', 'patients', 'with', 'a', 'primary', 'complaint', 'of', 'hyperacusis', '.', 'Hyperacusis', 'has', 'been', 'defined', 'as', ""'"", 'abnormally', 'reduced', 'tolerance', 'to', 'sound', ""'"", '.', 'It', 'shows', 'a', 'high', 'comorbidity', 'with', 'tinnitus', ',', 'the', 'perception', 'of', 'sound', 'in', 'the', 'absence', 'of', 'a', 'sound', 'source', '.', 'For', 'the', 'period', 'of', 'one', 'month', ',', 'hyperacusis', 'and', 'tinnitus', 'severity', 'and', 'exposure', 'to', 'sounds', 'will', 'be', 'evaluated', 'by', 'use', 'of', 'Ecological', 'Momentary', 'Assessment', '(', 'EMA', ')', 'in', 'all', 'participants', '.', 'A', 'novel', 'approach', 'to', 'assessments', ',', 'EMA', 'prompts', 'participants', 'during', 'their', 'daily', 'life', 'to', 'answer', 'short', 'questionnaires', ',', 'increasing', 'ecological', 'validity', 'and', 'minimizing', 'the', 'risk', 'for', 'recall', 'and', 'memory', 'biases', '.', 'At', 'a', 'randomized', 'time', 'point', 'during', 'the', 'one', '-', 'month', 'period', ',', 'participants', 'will', 'individually', 'receive', 'a', 'single', 'psychoeducation', 'session', '(', '1h', ')', 'delivered', 'by', 'an', 'experienced', 'audiologist', '.', 'The', 'goal', 'of', 'the', 'study', 'is', 'to', 'investigate', 'if', 'the', 'psychoeducation', 'session', 'leads', 'to', 'an', 'increase', 'in', 'exposure', 'to', 'sound', 'and', 'a', 'decrease', 'in', 'hyperacusis', 'severity', '.']","['O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04705246,NCT04705246,"Effect of Psychoeducation Upon Exposure to Sounds and Hyperacusis Severity | This study focuses on patients with a primary complaint of hyperacusis. Hyperacusis has been defined as 'abnormally reduced tolerance to sound'. It shows a high comorbidity with tinnitus, the perception of sound in the absence of a sound source. For the period of one month, hyperacusis and tinnitus severity and exposure to sounds will be evaluated by use of Ecological Momentary Assessment (EMA) in all participants. A novel approach to assessments, EMA prompts participants during their daily life to answer short questionnaires, increasing ecological validity and minimizing the risk for recall and memory biases. At a randomized time point during the one-month period, participants will individually receive a single psychoeducation session (1h) delivered by an experienced audiologist. The goal of the study is to investigate if the psychoeducation session leads to an increase in exposure to sound and a decrease in hyperacusis severity.","[(10, 25, 'BEHAVIOURAL', 'Psychoeducation'), (54, 65, 'CONDITION', 'Hyperacusis'), (136, 147, 'CONDITION', 'hyperacusis'), (149, 160, 'CONDITION', 'Hyperacusis'), (255, 263, 'CONDITION', 'tinnitus'), (352, 363, 'CONDITION', 'hyperacusis'), (368, 376, 'CONDITION', 'tinnitus'), (799, 822, 'BEHAVIOURAL', 'psychoeducation session'), (916, 939, 'BEHAVIOURAL', 'psychoeducation session'), (1000, 1011, 'CONDITION', 'hyperacusis')]"
"['Chronic', 'Treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'With', 'Gamma', 'Frequency', 'Stimulation', '|', 'In', 'this', 'trial', ',', 'the', 'safety', 'and', 'effect', 'of', 'daily', 'exposure', 'to', 'light', 'and', 'sound', 'stimulation', 'on', 'people', 'with', 'mild', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'will', 'be', 'studied', '.', '\n\n', 'COVID-19', 'Amendment', ':', 'Due', 'to', 'the', 'ongoing', 'suspension', 'of', 'all', 'in', '-', 'person', 'humans', 'subject', 'research', 'across', 'MIT', 'in', 'response', 'to', 'the', 'COVID-19', 'pandemic', ',', 'all', 'enrolled', 'participants', 'who', 'have', 'not', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'have', 'their', 'visit', 'postponed', 'to', '9', 'months', 'with', 'a', 'follow', 'up', 'at', '18', 'months', '.', 'Subjects', 'who', 'have', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'still', 'be', 'instructed', 'to', 'continue', 'and', 'return', 'at', 'Month', '12', 'for', 'an', 'evaluation', '.', '\n\n', 'OPTIONAL', ':', 'If', 'the', 'subject', 'would', 'like', 'to', 'come', 'in', 'for', 'an', 'evaluation', 'between', 'Month', '9', 'and', '18', ',', 'we', 'will', 'invite', 'participants', 'to', 'come', 'on', 'Month', '12', 'to', 'complete', 'cognitive', 'testing', 'and', 'EEG', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04055376,NCT04055376,"Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation | In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied.

COVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation.

OPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.","[(21, 40, 'CONDITION', ""Alzheimer's Disease""), (46, 73, 'OTHER', 'Gamma Frequency Stimulation'), (116, 161, 'OTHER', 'daily exposure to light and sound stimulation'), (177, 201, 'CONDITION', ""mild Alzheimer's Disease""), (203, 205, 'CONDITION', 'AD')]"
"['Motor', 'Learning', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'Underlying', 'Effective', 'Connectivity', 'and', 'Influential', 'Factors', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'characterized', 'by', 'severe', 'motor', 'symptoms', 'that', 'can', 'only', 'be', 'partially', 'alleviated', 'by', 'medication', '.', 'It', 'was', 'shown', 'previously', 'that', 'rehabilitation', 'is', 'an', 'important', 'therapeutic', 'supplement', 'for', 'micrographia', 'in', 'early', 'disease', '.', 'However', ',', 'what', 'is', 'unknown', 'is', 'how', 'motor', 'learning', 'impacts', 'on', 'the', 'underlying', 'neural', 'networks', 'in', 'patients', 'with', 'different', 'disease', 'progression', 'and', 'how', 'this', 'interacts', 'with', 'dopaminergic', 'medication', '.', 'Furthermore', ',', 'difficulties', 'with', 'upper', 'limb', 'motor', 'control', 'has', 'a', 'severe', 'impact', 'on', 'the', 'daily', 'lives', 'of', 'PD', 'patients', 'since', 'fine', 'motor', 'skills', 'become', 'increasingly', 'important', 'for', 'the', 'use', 'of', 'smartphones', 'and', 'tablets', '.', 'Therefore', ',', 'the', 'current', 'project', 'will', 'include', 'a', 'newly', 'developed', 'Swipe', '-', 'Slide', 'Pattern', 'test', ',', 'resembling', 'the', 'pattern', 'codes', 'used', 'to', 'unlock', 'smartphones', 'and', 'tablets', '.', 'This', 'task', 'will', 'be', 'used', 'to', 'determine', 'learning', '-', 'induced', 'neuroplasticity', 'of', 'cortico', '-', 'striatal', 'effective', 'connectivity', 'across', 'disease', 'stages', 'in', 'PD', '.', 'Using', 'a', 'combination', 'of', 'behavioral', 'assessment', 'and', 'functional', 'magnetic', 'resonance', 'imaging', ',', 'the', 'investigators', 'aim', 'to', 'contribute', 'to', 'the', 'understanding', 'of', 'upper', 'limb', 'motor', 'learning', 'in', 'patients', 'with', 'PD', 'for', 'the', 'development', 'of', 'individualized', 'rehabilitation', 'programs', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04269577,NCT04269577,"Motor Learning in Parkinson's Disease: Underlying Effective Connectivity and Influential Factors | Parkinson's disease (PD) is characterized by severe motor symptoms that can only be partially alleviated by medication. It was shown previously that rehabilitation is an important therapeutic supplement for micrographia in early disease. However, what is unknown is how motor learning impacts on the underlying neural networks in patients with different disease progression and how this interacts with dopaminergic medication. Furthermore, difficulties with upper limb motor control has a severe impact on the daily lives of PD patients since fine motor skills become increasingly important for the use of smartphones and tablets. Therefore, the current project will include a newly developed Swipe-Slide Pattern test, resembling the pattern codes used to unlock smartphones and tablets. This task will be used to determine learning-induced neuroplasticity of cortico-striatal effective connectivity across disease stages in PD. Using a combination of behavioral assessment and functional magnetic resonance imaging, the investigators aim to contribute to the understanding of upper limb motor learning in patients with PD for the development of individualized rehabilitation programs.","[(18, 37, 'CONDITION', ""Parkinson's Disease""), (99, 118, 'CONDITION', ""Parkinson's disease""), (120, 122, 'CONDITION', 'PD'), (624, 626, 'CONDITION', 'PD'), (1024, 1026, 'CONDITION', 'PD'), (1219, 1221, 'CONDITION', 'PD')]"
"['Solian', 'Solution', 'to', 'Treat', 'Schizophrenic', 'Patients', 'During', 'an', 'Acute', 'Episode', '|', 'During', 'this', 'study', 'the', 'efficacy', 'and', 'safety', 'profile', 'will', 'be', 'evaluated', 'of', 'the', 'use', 'of', 'amisulpride', 'in', 'the', 'form', 'of', 'a', 'solution', 'in', 'schizophrenic', 'patients', 'with', 'an', 'acute', 'episode', '.', '\n\n', 'The', 'main', 'purpose', 'of', 'the', 'study', 'is', 'to', 'observe', 'the', 'anti', '-', 'psychotic', 'effect', 'of', 'amisulpride', 'as', 'a', 'solution', 'during', 'the', 'first', 'days', 'of', 'an', 'acute', 'episode', 'of', 'schizophrenia', '.']","['B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00245674,NCT00245674,"Solian Solution to Treat Schizophrenic Patients During an Acute Episode | During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.

The main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.","[(0, 15, 'DRUG', 'Solian Solution'), (25, 38, 'CONDITION', 'Schizophrenic'), (58, 71, 'CONDITION', 'Acute Episode'), (156, 167, 'DRUG', 'amisulpride'), (197, 210, 'CONDITION', 'schizophrenic'), (228, 241, 'CONDITION', 'acute episode'), (317, 328, 'DRUG', 'amisulpride'), (371, 384, 'CONDITION', 'acute episode'), (388, 401, 'CONDITION', 'schizophrenia')]"
"['Stereotactic', 'Operation', 'Integrating', 'With', 'Thrombolysis', 'in', 'Basal', 'Ganglion', 'Hemorrhage', 'Evacuation', 'II', '(', 'SOITBE', 'II', ')', '|', 'Spontaneous', 'cerebral', 'hemorrhage', 'is', 'one', 'of', 'the', 'main', 'causes', 'of', 'death', 'and', 'disability', 'all', 'over', 'the', 'world', ',', 'accounting', 'for', '20%-30', '%', 'of', 'all', 'cerebrovascular', 'diseases', '.', 'Minimally', 'invasive', 'surgery', 'of', 'cerebral', 'hemorrhage', ',', 'especially', 'puncture', 'aspiration', ',', 'can', 'improve', 'early', 'and', 'long', '-', 'term', 'neurological', 'recovery', 'in', 'patients', 'with', 'cerebral', 'hemorrhage', '.', 'Until', 'now', ',', 'no', 'standardized', 'practice', 'for', 'minimally', 'invasive', 'surgery', 'of', 'spontaneous', 'cerebral', 'hemorrhage', 'has', 'been', 'established', '.', 'Hematoma', 'puncture', 'and', 'drainage', 'based', 'on', 'CT', 'scans', 'without', 'precise', 'localization', 'and', 'personalized', 'approach', 'design', ',', 'which', 'may', 'lead', 'to', 'poor', 'efficacy', 'and', 'high', 'risk', 'of', 'complications', '.', 'The', 'investigators', ""'"", 'hospital', 'has', 'much', 'experience', 'in', 'treating', 'cerebral', 'hemorrhage', 'with', 'stereotactic', 'puncture', 'and', 'aspiration', '.', 'So', 'the', 'investigators', 'conduct', 'a', 'prospective', 'multicenter', 'randomized', 'controlled', 'clinical', 'trial', 'across', 'the', 'country', 'to', 'determine', 'the', 'therapeutic', 'effects', 'of', 'puncture', 'aspiration', 'plus', 'thrombolysis', 'treatment', 'for', 'the', 'perioperative', 'and', 'long', '-', 'term', 'recovery', 'of', 'patients', 'with', 'small', 'hematoma', 'in', 'deep', 'basal', 'ganglia', 'via', 'computerized', 'precision', 'coordinates', 'and', 'personalized', 'approach', 'design', '.']","['B-SURG', 'I-SURG', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04172376,NCT04172376,"Stereotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation II (SOITBE II) | Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. The investigators' hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So the investigators conduct a prospective multicenter randomized controlled clinical trial across the country to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.","[(0, 22, 'SURGICAL', 'Stereotactic Operation'), (40, 52, 'OTHER', 'Thrombolysis'), (56, 81, 'CONDITION', 'Basal Ganglion Hemorrhage'), (110, 141, 'CONDITION', 'Spontaneous cerebral hemorrhage'), (330, 349, 'SURGICAL', 'puncture aspiration'), (422, 441, 'CONDITION', 'cerebral hemorrhage'), (513, 544, 'CONDITION', 'spontaneous cerebral hemorrhage'), (803, 822, 'CONDITION', 'cerebral hemorrhage'), (828, 849, 'SURGICAL', 'stereotactic puncture'), (854, 864, 'SURGICAL', 'aspiration'), (1017, 1036, 'SURGICAL', 'puncture aspiration'), (1042, 1054, 'OTHER', 'thrombolysis'), (1127, 1163, 'CONDITION', 'small hematoma in deep basal ganglia')]"
"['Low', 'Level', 'Laser', 'Therapy', 'and', 'Neuromuscular', 'Electrical', 'Stimulation', 'on', 'Knee', 'Extension', 'Strength', 'and', 'Jump', 'in', 'Volleyball', 'Athletes', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Background', ':', 'Volleyball', 'players', 'constantly', 'perform', 'vertical', 'jumps', ',', 'the', 'higher', 'the', 'height', 'of', 'the', 'jump', 'is', 'better', 'sports', 'performance', 'of', 'these', 'players', '.', 'Several', 'methods', 'have', 'been', 'tested', 'to', 'improve', 'jumping', 'performance', 'in', 'these', 'players', '.', 'It', 'will', 'be', 'investigated', 'the', 'addition', 'of', 'electrical', 'stimulation', 'and', 'phototherapy', 'to', 'jump', 'training', 'in', 'volleyball', 'athletes', '.', 'DESIGN', ':', 'randomized', 'controlled', 'trial', '.', 'METHODS', ':', 'This', 'study', 'will', 'be', 'conducted', 'with', '36', 'male', 'athletes', 'volleyball', 'with', 'minimum', 'experience', 'of', '12', 'months', 'sport', '.', 'Will', 'be', 'randomized', 'and', 'assigned', 'to', '3', 'groups', '(', 'control', 'group', ',', 'NEMES', 'group', 'and', 'group', 'phototherapy', ')', '.', 'All', '36', 'healthy', 'volleyball', 'athletes', 'who', 'passed', 'the', 'initial', 'selection', 'and', 'agreed', 'to', 'participate', 'in', 'the', 'study', ',', 'conduct', 'a', 'muscle', 'strength', 'and', 'jump', 'training', 'program', ',', 'which', 'is', 'held', 'in', 'both', 'legs', 'simultaneously', '.', 'The', '12', 'healthy', 'athletes', 'electrical', 'stimulation', 'group', 'will', 'perform', 'the', 'same', 'training', 'program', 'described', 'above', ',', 'but', 'strength', 'training', 'is', 'associated', 'with', 'electrical', 'stimulation', '.', 'The', '12', 'healthy', 'athletes', 'participating', 'in', 'the', 'phototherapy', 'group', 'will', 'undergo', 'a', 'phototherapy', 'protocol', 'before', 'performing', 'the', 'strength', 'and', 'jump', 'training', '.', 'All', 'selected', 'participants', 'will', 'undergo', 'an', 'assessment', 'of', 'muscle', 'strength', 'of', 'knee', 'extensors', 'and', 'evaluate', 'the', 'jump', '.', 'These', 'evaluations', 'were', 'baseline', ',', '6', 'weeks', 'and', '8', 'weeks', 'after', 'baseline', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02443701,NCT02443701,"Low Level Laser Therapy and Neuromuscular Electrical Stimulation on Knee Extension Strength and Jump in Volleyball Athletes: a Randomized Controlled Trial | Background: Volleyball players constantly perform vertical jumps, the higher the height of the jump is better sports performance of these players. Several methods have been tested to improve jumping performance in these players. It will be investigated the addition of electrical stimulation and phototherapy to jump training in volleyball athletes. DESIGN: randomized controlled trial. METHODS: This study will be conducted with 36 male athletes volleyball with minimum experience of 12 months sport. Will be randomized and assigned to 3 groups (control group, NEMES group and group phototherapy). All 36 healthy volleyball athletes who passed the initial selection and agreed to participate in the study, conduct a muscle strength and jump training program, which is held in both legs simultaneously. The 12 healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation. The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. All selected participants will undergo an assessment of muscle strength of knee extensors and evaluate the jump. These evaluations were baseline, 6 weeks and 8 weeks after baseline.","[(0, 23, 'OTHER', 'Low Level Laser Therapy'), (28, 64, 'OTHER', 'Neuromuscular Electrical Stimulation'), (426, 448, 'OTHER', 'electrical stimulation'), (453, 465, 'OTHER', 'phototherapy'), (719, 724, 'OTHER', 'NEMES'), (741, 753, 'OTHER', 'phototherapy'), (874, 915, 'PHYSICAL', 'muscle strength and jump training program'), (984, 1006, 'OTHER', 'electrical stimulation'), (1035, 1043, 'PHYSICAL', 'training'), (1110, 1132, 'OTHER', 'electrical stimulation'), (1179, 1191, 'OTHER', 'phototherapy'), (1213, 1225, 'OTHER', 'phototherapy'), (1257, 1283, 'PHYSICAL', 'strength and jump training')]"
"['Effects', 'of', 'Rhythmic', 'Auditory', 'Cueing', 'on', 'Stepping', 'in', 'Place', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'Patients', 'with', 'Parkinson', ""'s"", 'disease', 'have', 'internal', 'rhythm', 'dysfunction', ',', 'which', 'may', 'affect', 'the', 'rhythmic', 'movements', 'such', 'as', 'walking', '.', 'Poor', 'regularity', 'of', 'the', 'rhythmic', 'movement', 'may', 'lead', 'to', 'freezing', 'of', 'gait', '.', 'This', 'study', 'will', 'apply', 'rhythmic', 'auditory', 'cues', 'on', 'the', 'stepping', '-', 'in', '-', 'place', 'training', 'and', 'the', 'investigators', 'will', 'examine', 'if', 'the', 'behavior', 'and', 'neuroelectrophysiology', 'would', 'change', 'after', 'auditory', 'cueing', 'training', '.', 'The', 'investigators', 'hypothesize', 'the', 'variation', 'of', 'rhythmic', 'movements', 'such', 'as', 'walking', 'and', 'stepping', '-', 'in', '-', 'place', 'will', 'be', 'reduced', ',', 'and', 'the', 'cortical', 'excitability', 'would', 'be', 'modulated', 'after', 'training', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03271736,NCT03271736,"Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease | Patients with Parkinson's disease have internal rhythm dysfunction, which may affect the rhythmic movements such as walking. Poor regularity of the rhythmic movement may lead to freezing of gait. This study will apply rhythmic auditory cues on the stepping-in-place training and the investigators will examine if the behavior and neuroelectrophysiology would change after auditory cueing training. The investigators hypothesize the variation of rhythmic movements such as walking and stepping-in-place will be reduced, and the cortical excitability would be modulated after training.","[(11, 35, 'OTHER', 'Rhythmic Auditory Cueing'), (74, 93, 'CONDITION', ""Parkinson's Disease""), (110, 129, 'CONDITION', ""Parkinson's disease""), (135, 162, 'CONDITION', 'internal rhythm dysfunction'), (274, 290, 'CONDITION', 'freezing of gait'), (314, 336, 'OTHER', 'rhythmic auditory cues'), (344, 370, 'PHYSICAL', 'stepping-in-place training'), (468, 492, 'OTHER', 'auditory cueing training'), (541, 559, 'PHYSICAL', 'rhythmic movements')]"
"['Effect', 'of', 'Vibration', 'Exercise', 'on', 'Upper', 'Limb', 'Strength', ',', 'Function', ',', 'and', 'Pain', '|', 'The', 'primary', 'purpose', 'of', 'this', 'study', 'is', 'to', 'explore', 'the', 'benefits', 'of', 'vibration', 'dumbbell', 'resistance', 'training', 'over', 'standard', 'dumbbell', 'resistance', 'training', 'for', 'improving', 'upper', 'limb', 'strength', ',', 'function', 'and', 'pain', 'among', 'manual', 'wheelchair', 'users', 'with', 'paraplegia', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02998021,NCT02998021,"Effect of Vibration Exercise on Upper Limb Strength, Function, and Pain | The primary purpose of this study is to explore the benefits of vibration dumbbell resistance training over standard dumbbell resistance training for improving upper limb strength, function and pain among manual wheelchair users with paraplegia.","[(10, 28, 'PHYSICAL', 'Vibration Exercise'), (67, 71, 'CONDITION', 'Pain'), (138, 176, 'PHYSICAL', 'vibration dumbbell resistance training'), (182, 219, 'CONTROL', 'standard dumbbell resistance training'), (268, 272, 'CONDITION', 'pain'), (308, 318, 'CONDITION', 'paraplegia')]"
"['Novel', 'Neuroimage', 'Study', 'in', 'Tauopathies', 'With', 'Parkinsonism', '|', 'The', 'aims', 'of', 'this', 'study', 'are', ':', '18F', '-', 'THK5351', 'PET(Positron', 'Emission', 'Tomography', ')', 'can', 'defect', 'the', 'tau', 'burden', 'in', 'PSP(Progressive', 'Supranuclear', 'Palsy', ')', 'and', 'CBS', '(', 'Corticobasal', 'syndrome)correlating', 'with', 'the', 'known', 'NFT(neurofibrillary', 'tangles', ')', 'topology', 'of', 'those', 'diseases', ',', '18F', '-', 'THK5351', 'PET', 'will', 'differentiate', 'subjects', 'with', 'suspected', 'tauopathy', 'due', 'to', 'PSP', 'and', 'CBS', 'from', 'subjects', 'with', 'suspected', 'synucleinopathy', 'due', 'to', 'idiopathic', 'PD(Parkinson', ""'s"", 'disease', ')', '.', 'The', 'distribution', 'of', 'PHF(paired', 'helical', 'filament', ')', 'tau', 'burden', 'will', 'correlate', 'with', 'specific', 'motor', 'and', 'cognitive', 'features', 'of', 'PSP', 'and', 'CBS', ';', 'and', 'regional', 'PHF', 'tau', 'burden', 'will', 'be', 'associated', 'with', 'cortical', 'thinning', '.', 'Together', ',', 'these', 'efforts', 'will', 'establish', 'the', 'potential', 'for', 'developing', '18F', '-', 'THK5351', 'PET', 'imaging', 'as', 'a', 'biomarker', 'and', 'diagnostic', 'tool', 'for', 'the', 'parkinsonian', 'tauopathies', '.']","['O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O']",NCT03386669,NCT03386669,"Novel Neuroimage Study in Tauopathies With Parkinsonism | The aims of this study are: 18F-THK5351 PET(Positron Emission Tomography) can defect the tau burden in PSP(Progressive Supranuclear Palsy) and CBS (Corticobasal syndrome)correlating with the known NFT(neurofibrillary tangles) topology of those diseases, 18F-THK5351 PET will differentiate subjects with suspected tauopathy due to PSP and CBS from subjects with suspected synucleinopathy due to idiopathic PD(Parkinson's disease). The distribution of PHF(paired helical filament) tau burden will correlate with specific motor and cognitive features of PSP and CBS; and regional PHF tau burden will be associated with cortical thinning. Together, these efforts will establish the potential for developing 18F-THK5351 PET imaging as a biomarker and diagnostic tool for the parkinsonian tauopathies.","[(26, 37, 'CONDITION', 'Tauopathies'), (43, 55, 'CONDITION', 'Parkinsonism'), (201, 204, 'CONDITION', 'CBS'), (371, 380, 'CONDITION', 'tauopathy'), (388, 391, 'CONDITION', 'PSP'), (396, 399, 'CONDITION', 'CBS'), (429, 444, 'CONDITION', 'synucleinopathy'), (609, 612, 'CONDITION', 'PSP'), (617, 620, 'CONDITION', 'CBS'), (828, 840, 'CONDITION', 'parkinsonian'), (841, 852, 'CONDITION', 'tauopathies')]"
"['Phase', 'I', 'Trial', 'Of', 'Pirfenidone', 'In', 'Children', 'With', 'Neurofibromatosis', 'Type', '1', 'And', 'Plexiform', 'Neurofibromas', '|', 'RATIONALE', ':', 'Chemoprevention', 'therapy', 'is', 'the', 'use', 'of', 'certain', 'drugs', 'to', 'try', 'to', 'prevent', 'the', 'development', 'or', 'recurrence', 'of', 'cancer', '.', 'Pirfenidone', 'may', 'slow', 'the', 'growth', 'or', 'prevent', 'further', 'development', 'of', 'plexiform', 'neurofibromas', '.', '\n\n', 'PURPOSE', ':', 'Phase', 'I', 'trial', 'to', 'study', 'the', 'effectiveness', 'of', 'pirfenidone', 'in', 'treating', 'young', 'patients', 'who', 'have', 'neurofibromatosis', 'type', '1', 'and', 'plexiform', 'neurofibroma', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT00053937,NCT00053937,"Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas.

PURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.","[(17, 28, 'DRUG', 'Pirfenidone'), (46, 70, 'CONDITION', 'Neurofibromatosis Type 1'), (75, 98, 'CONDITION', 'Plexiform Neurofibromas'), (223, 234, 'DRUG', 'Pirfenidone'), (289, 312, 'CONDITION', 'plexiform neurofibromas'), (368, 379, 'DRUG', 'pirfenidone'), (416, 440, 'CONDITION', 'neurofibromatosis type 1'), (445, 467, 'CONDITION', 'plexiform neurofibroma')]"
"['Pathogenesis', 'of', 'Rett', 'Syndrome', ':', 'Natural', 'History', 'and', 'Treatment', '|', 'Rett', 'syndrome', '(', 'RTT', ')', 'is', 'a', 'disorder', 'in', 'which', 'the', 'nervous', 'system', 'does', 'not', 'develop', 'properly', '.', 'RTT', 'generally', 'affects', 'girls', ',', 'but', 'there', 'are', 'some', 'boys', 'who', 'have', 'been', 'diagnosed', 'with', 'RTT', '.', 'Symptoms', 'of', 'RTT', 'include', 'small', 'brain', 'size', ',', 'poor', 'language', 'skills', ',', 'repetitive', 'hand', 'movements', ',', 'and', 'seizures', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effectiveness', 'of', 'two', 'drugs', 'in', 'treating', 'the', 'symptoms', 'of', 'RTT', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00069550,NCT00069550,"Pathogenesis of Rett Syndrome: Natural History and Treatment | Rett syndrome (RTT) is a disorder in which the nervous system does not develop properly. RTT generally affects girls, but there are some boys who have been diagnosed with RTT. Symptoms of RTT include small brain size, poor language skills, repetitive hand movements, and seizures. This study will evaluate the effectiveness of two drugs in treating the symptoms of RTT.","[(16, 29, 'CONDITION', 'Rett Syndrome'), (63, 76, 'CONDITION', 'Rett syndrome'), (78, 81, 'CONDITION', 'RTT'), (152, 155, 'CONDITION', 'RTT'), (234, 237, 'CONDITION', 'RTT'), (251, 254, 'CONDITION', 'RTT'), (428, 431, 'CONDITION', 'RTT')]"
"['This', 'study', 'mainly', 'evaluated', 'the', 'feasibility', 'and', 'safety', 'of', 'a', 'kind', 'of', 'Left', 'Atrial', 'Appendage', 'Occluders', 'which', 'is', 'to', 'prevent', 'ischemic', 'stroke', 'caused', 'by', 'nonvalvular', 'atrial', 'fibrillation', '(', 'AF', ')']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT02937025,NCT02937025,This study mainly evaluated the feasibility and safety of a kind of Left Atrial Appendage Occluders which is to prevent ischemic stroke caused by nonvalvular atrial fibrillation (AF),"[(68, 99, 'OTHER', 'Left Atrial Appendage Occluders'), (120, 135, 'CONDITION', 'ischemic stroke'), (146, 177, 'CONDITION', 'nonvalvular atrial fibrillation'), (179, 181, 'CONDITION', 'AF')]"
"['Study', 'on', 'the', 'Optimal', 'Scheme', 'of', 'Acupuncture', 'Treatment', 'for', 'Schizophrenia', '-', 'related', 'Central', 'Obesity', '|', 'This', 'clinical', 'trial', 'aims', 'to', 'test', 'the', 'effect', 'of', 'acupuncture', 'in', 'patients', 'with', 'schizophrenia', '-', 'related', 'central', 'obesity', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'is', ':', '\n\n', '•', 'The', 'effect', ',', 'safety', ',', 'and', 'maintenance', 'of', 'acupuncture', 'on', 'schizophrenia', '-', 'related', 'central', 'obesity', '.', '\n\n', 'Participants', 'will', 'receive', 'acupuncture', 'treatment', 'on', 'purpose', 'acupoints', ',', 'acupuncture', 'on', 'acupoint', 'peripheries', ',', 'or', 'fake', 'acupuncture', 'treatment', 'on', 'purpose', 'acupoints', 'for', '20', 'weeks', '.', 'And', 'they', 'need', 'three', 'follow', '-', 'up', 'visits', 'during', 'the', 'treatment', 'period', 'and', 'two', 'follow', '-', 'up', 'visits', 'after', 'treatment', '.', '\n\n', 'Researchers', 'will', 'compare', 'the', 'waist', 'circumstance', 'of', 'these', 'three', 'groups', 'to', 'see', 'if', 'the', 'purpose', 'acupoints', 'are', 'valid', 'for', 'schizophrenia', '-', 'related', 'central', 'obesity', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05833009,NCT05833009,"Study on the Optimal Scheme of Acupuncture Treatment for Schizophrenia-related Central Obesity | This clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. The main question it aims to answer is:

• The effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity.

Participants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. And they need three follow-up visits during the treatment period and two follow-up visits after treatment.

Researchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.","[(31, 52, 'PHYSICAL', 'Acupuncture Treatment'), (57, 70, 'CONDITION', 'Schizophrenia'), (79, 94, 'CONDITION', 'Central Obesity'), (144, 155, 'PHYSICAL', 'acupuncture'), (173, 186, 'CONDITION', 'schizophrenia'), (195, 210, 'CONDITION', 'central obesity'), (294, 305, 'PHYSICAL', 'acupuncture'), (309, 322, 'CONDITION', 'schizophrenia'), (331, 346, 'CONDITION', 'central obesity'), (375, 386, 'PHYSICAL', 'acupuncture'), (459, 475, 'CONTROL', 'fake acupuncture'), (745, 758, 'CONDITION', 'schizophrenia'), (767, 782, 'CONDITION', 'central obesity')]"
"['Study', 'of', 'the', 'Effectiveness', 'of', 'Functional', 'Electrical', 'Stimulation', 'Through', 'the', '""', 'Fesia', 'Grasp', '""', 'Device', 'in', 'the', 'Rehabilitative', 'Treatment', 'of', 'Patients', 'With', 'Affected', 'Upper', 'Limbs', 'After', 'a', 'Stroke', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'Fesia', 'Grasp', ',', 'a', 'Functional', 'Electrical', 'Stimulation', 'device', 'for', 'the', 'rehabilitation', 'of', 'upper', 'limb', 'in', 'post', '-', 'stroke', 'patients', '.', 'Fesia', 'Grasp', 'rehabilitation', 'will', 'be', 'compared', 'with', 'usual', 'care', 'rehabilitation', 'of', 'upper', 'limb', '.', '\n\n', 'Experimental', 'group', ':', 'patients', 'will', 'receive', 'Fesia', 'Grasp', 'therapy', '(', 'intensive', ',', 'repetitive', 'and', 'functional', 'exercises', 'assisted', 'by', 'functional', 'electrical', 'stimulation', ')', '\n', 'Control', 'group', '-', 'patients', 'will', 'receive', 'standard', 'care', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT04992910,NCT04992910,"Study of the Effectiveness of Functional Electrical Stimulation Through the ""Fesia Grasp"" Device in the Rehabilitative Treatment of Patients With Affected Upper Limbs After a Stroke. | The purpose of this study is to evaluate the effectiveness of Fesia Grasp, a Functional Electrical Stimulation device for the rehabilitation of upper limb in post-stroke patients. Fesia Grasp rehabilitation will be compared with usual care rehabilitation of upper limb.

Experimental group: patients will receive Fesia Grasp therapy (intensive, repetitive and functional exercises assisted by functional electrical stimulation)
Control group - patients will receive standard care.","[(30, 63, 'OTHER', 'Functional Electrical Stimulation'), (77, 88, 'OTHER', 'Fesia Grasp'), (104, 128, 'PHYSICAL', 'Rehabilitative Treatment'), (146, 166, 'CONDITION', 'Affected Upper Limbs'), (175, 181, 'CONDITION', 'Stroke'), (247, 258, 'OTHER', 'Fesia Grasp'), (262, 295, 'OTHER', 'Functional Electrical Stimulation'), (348, 354, 'CONDITION', 'stroke'), (414, 439, 'CONTROL', 'usual care rehabilitation'), (498, 509, 'OTHER', 'Fesia Grasp'), (519, 565, 'PHYSICAL', 'intensive, repetitive and functional exercises'), (578, 611, 'OTHER', 'functional electrical stimulation'), (651, 664, 'CONTROL', 'standard care')]"
"['Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'of', 'the', 'Nucleus', 'Basalis', 'of', 'Meynert', '(', 'nbM', ')', 'to', 'Treat', 'Parkinson', ""'s"", 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', ',', 'Amnestic', 'Subtype', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'effectiveness', 'of', 'deep', 'brain', 'stimulation', 'of', 'the', 'nucleus', 'basalis', 'of', 'Meynert', '(', 'also', 'called', 'the', '""', 'nbM', '""', ')', 'at', 'improving', 'memory', 'in', 'Parkinson', ""'s"", 'disease', 'patients', 'with', 'mild', 'cognitive', 'impairments', 'and', 'memory', 'difficulties', '.', 'Patients', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'that', 'are', 'eligible', 'for', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'therapy', 'for', 'improvement', 'of', 'their', 'motor', 'symptoms', 'and', 'with', 'evidence', 'of', 'mild', 'cognitive', 'impairments', 'and', 'memory', 'difficulties', 'will', 'be', 'enrolled', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT02924194,NCT02924194,"Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (nbM) to Treat Parkinson's Patients With Mild Cognitive Impairment, Amnestic Subtype | The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the ""nbM"") at improving memory in Parkinson's disease patients with mild cognitive impairments and memory difficulties. Patients with Parkinson's disease (PD) that are eligible for Deep Brain Stimulation (DBS) therapy for improvement of their motor symptoms and with evidence of mild cognitive impairments and memory difficulties will be enrolled.","[(0, 62, 'OTHER', 'Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert'), (78, 98, 'CONDITION', ""Parkinson's Patients""), (104, 147, 'CONDITION', 'Mild Cognitive Impairment, Amnestic Subtype'), (223, 279, 'OTHER', 'deep brain stimulation of the nucleus basalis of Meynert'), (327, 346, 'CONDITION', ""Parkinson's disease""), (361, 387, 'CONDITION', 'mild cognitive impairments'), (392, 411, 'CONDITION', 'memory difficulties'), (427, 446, 'CONDITION', ""Parkinson's disease""), (448, 450, 'CONDITION', 'PD'), (474, 496, 'OTHER', 'Deep Brain Stimulation'), (498, 501, 'OTHER', 'DBS'), (572, 598, 'CONDITION', 'mild cognitive impairments'), (603, 622, 'CONDITION', 'memory difficulties')]"
"['Cognitive', 'Remediation', 'in', 'Early', 'Phase', 'Psychosis', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'a', '30', 'hour', 'cognitive', 'remediation', 'program', 'for', 'young', 'patients', 'with', 'early', 'phase', 'schizophrenia', 'spectrum', 'disorders', 'on', 'cognitive', ',', 'clinical', 'and', 'functional', 'outcome', 'measures', '.', 'The', 'remediation', 'program', 'is', 'integrated', 'with', 'whatever', 'active', 'rehabilitation', 'the', 'participant', 'is', 'currently', 'attending', '(', 'school', ',', 'work', ',', 'day', 'program', 'etc', ')', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01546467,NCT01546467,"Cognitive Remediation in Early Phase Psychosis | The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures. The remediation program is integrated with whatever active rehabilitation the participant is currently attending (school, work, day program etc).","[(0, 21, 'BEHAVIOURAL', 'Cognitive Remediation'), (25, 46, 'CONDITION', 'Early Phase Psychosis'), (116, 145, 'BEHAVIOURAL', 'cognitive remediation program'), (170, 214, 'CONDITION', 'early phase schizophrenia spectrum disorders'), (275, 294, 'BEHAVIOURAL', 'remediation program')]"
"['Pediatric', 'Traumatic', 'Brain', 'Injury', 'Consortium', ':', 'Hypothermia', '|', 'The', 'primary', 'hypothesis', 'for', 'this', 'application', 'for', 'a', 'multicenter', 'phase', 'III', 'randomized', 'clinical', 'trial', '(', 'RCT', ')', 'is', 'that', 'induced', 'moderate', 'hypothermia', '(', 'HYPO', ')', '(', '32', '-', '33', '°', 'C', ')', 'after', 'severe', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', 'in', 'children', 'and', 'maintained', 'for', '48', 'hours', 'will', 'improve', 'mortality', 'at', '3', 'months', 'and', '12', 'month', 'functional', 'outcome', 'as', 'assessed', 'by', 'the', 'Glasgow', 'Outcome', 'Scale', '(', 'GOS', ')', '.']","['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00222742,NCT00222742,Pediatric Traumatic Brain Injury Consortium: Hypothermia | The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 °C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed by the Glasgow Outcome Scale (GOS).,"[(10, 32, 'CONDITION', 'Traumatic Brain Injury'), (45, 56, 'OTHER', 'Hypothermia'), (188, 199, 'OTHER', 'hypothermia'), (201, 205, 'OTHER', 'HYPO'), (224, 253, 'CONDITION', 'severe traumatic brain injury'), (255, 258, 'CONDITION', 'TBI')]"
"['An', 'Open', '-', 'label', 'Pharmacokinetic', 'and', 'Tolerability', 'Study', 'of', 'Eliglustat', 'Tartrate', 'Given', 'as', 'a', 'Single', 'Dose', 'in', 'Subjects', 'With', 'Mild', 'and', 'Moderate', 'Hepatic', 'Impairment', ',', 'and', 'in', 'Matched', 'Subjects', 'With', 'Normal', 'Hepatic', 'Function', '|', 'Primary', 'Objective', ':', '\n\n', 'To', 'study', 'the', 'effect', 'of', 'mild', 'and', 'moderate', 'hepatic', 'impairment', 'on', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'eliglustat', '.', '\n\n', 'Secondary', 'Objective', ':', '\n\n', 'To', 'assess', 'the', 'tolerability', 'of', 'eliglustat', 'tartrate', 'given', 'as', 'a', 'single', 'dose', 'in', 'subjects', 'with', 'mild', 'and', 'moderate', 'hepatic', 'impairment', 'in', 'comparison', 'with', 'matched', 'subjects', 'with', 'normal', 'hepatic', 'function', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02536911,NCT02536911,"An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function | Primary Objective:

To study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of eliglustat.

Secondary Objective:

To assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic function.","[(56, 75, 'DRUG', 'Eliglustat Tartrate'), (116, 152, 'CONDITION', 'Mild and Moderate Hepatic Impairment'), (252, 288, 'CONDITION', 'mild and moderate hepatic impairment'), (321, 331, 'DRUG', 'eliglustat'), (386, 405, 'DRUG', 'eliglustat tartrate'), (446, 482, 'CONDITION', 'mild and moderate hepatic impairment')]"
"['A', 'Phase', '3', ',', 'Open', '-', 'label', ',', 'Randomized', 'Trial', 'to', 'Evaluate', 'Humoral', 'Immunogenicity', 'of', 'Various', 'Schedules', 'of', 'Intramuscular', 'Full', 'Dose', 'and', 'Intradermal', 'Fractional', 'Dose', 'of', 'Inactivated', 'Polio', 'Vaccine', 'in', 'Infants', '|', 'The', 'study', 'will', 'evaluate', 'the', 'humoral', 'immunogenicity', 'in', 'various', 'schedule', 'combinations', 'of', 'full', 'dose', 'inactivated', 'polio', 'vaccines', '(', 'IPV', ')', 'via', 'intramuscular', 'administration', '(', 'IM', ')', 'and', 'of', 'the', 'fractional', 'dose', 'of', 'inactivated', 'poliovaccine', '(', 'f', '-', 'IPV', ')', 'via', 'intradermal', 'administration', '(', 'ID', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03016949,NCT03016949,"A Phase 3, Open-label, Randomized Trial to Evaluate Humoral Immunogenicity of Various Schedules of Intramuscular Full Dose and Intradermal Fractional Dose of Inactivated Polio Vaccine in Infants | The study will evaluate the humoral immunogenicity in various schedule combinations of full dose inactivated polio vaccines (IPV) via intramuscular administration (IM) and of the fractional dose of inactivated poliovaccine (f-IPV) via intradermal administration (ID).","[(158, 183, 'DRUG', 'Inactivated Polio Vaccine'), (294, 320, 'DRUG', 'inactivated polio vaccines'), (322, 325, 'DRUG', 'IPV'), (395, 419, 'DRUG', 'inactivated poliovaccine'), (421, 426, 'DRUG', 'f-IPV')]"
"['Effects', 'of', 'Aerobic', 'Training', 'on', 'Motor', 'and', 'Cognitive', 'Performances', 'in', 'Patients', 'With', 'MS', ':', 'an', 'Exploratory', 'Study', 'With', 'Structural', 'and', 'Functional', 'MRI', '|', 'Aerobic', 'training', '(', 'AT', ')', 'induces', 'cardiovascular', ',', 'metabolic', 'and', 'muscular', 'changes', 'and', 'has', 'been', 'proposed', 'as', 'a', 'promising', 'rehabilitative', 'approach', 'in', 'elderly', 'adults', 'and', 'in', 'neurological', 'patients', 'to', 'improve', 'both', 'motor', 'and', 'cognitive', 'performances', '.', 'The', 'Investigators', 'wish', 'to', 'explore', 'the', 'role', 'of', 'AT', 'in', 'multiple', 'sclerosis', '(', 'MS', ')', 'patients', 'on', 'physical', 'and', 'neuropsychological', 'functions', 'and', 'its', 'underlying', 'anatomical', 'and', 'functional', 'substrates', ',', 'using', 'advanced', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'methods', '.', '\n\n', 'In', 'this', 'project', ',', 'the', 'Investigators', 'wish', 'to', 'apply', 'aerobic', 'training', 'in', 'right', '-', 'handed', 'MS', 'patients', 'and', 'healthy', 'controls', 'to', 'assess', ':', '\n\n', 'the', 'effects', 'of', 'aerobic', 'training', 'compared', 'to', 'conventional', 'motor', 'training', 'on', 'motor', 'and', 'cardio', '-', 'vascular', 'parameters', ';', '\n', 'the', 'effect', 'of', 'aerobic', 'training', 'compared', 'to', 'conventional', 'motor', 'training', 'on', 'cognitive', 'performance', ',', 'depression', 'and', 'fatigue', ';', '\n', 'the', 'modifications', 'of', 'functional', 'activations', 'during', 'a', 'cognitive', 'task', 'and', 'of', 'functional', 'connectivity', 'in', 'motor', 'and', 'cognitive', 'networks', 'during', 'resting', 'state', 'following', 'aerobic', 'training', 'and', 'conventional', 'motor', 'training', '(', 'functional', 'plasticity', ')', ';', '\n', 'the', 'regional', 'variations', 'of', 'gray', 'matter', '(', 'GM', ')', 'volumes', 'and', 'white', 'matter', '(', 'WM', ')', 'architecture', 'after', 'aerobic', 'training', 'and', 'conventional', 'motor', 'training', '(', 'structural', 'plasticity', ')', ';', '\n', 'the', 'correlations', 'between', 'the', 'changes', 'detected', 'with', 'structural', 'and', 'functional', 'MRI', 'and', 'clinical', ',', 'motor', 'and', 'neuropsychological', 'scales', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04097418,NCT04097418,"Effects of Aerobic Training on Motor and Cognitive Performances in Patients With MS: an Exploratory Study With Structural and Functional MRI | Aerobic training (AT) induces cardiovascular, metabolic and muscular changes and has been proposed as a promising rehabilitative approach in elderly adults and in neurological patients to improve both motor and cognitive performances. The Investigators wish to explore the role of AT in multiple sclerosis (MS) patients on physical and neuropsychological functions and its underlying anatomical and functional substrates, using advanced magnetic resonance imaging (MRI) methods.

In this project, the Investigators wish to apply aerobic training in right-handed MS patients and healthy controls to assess:

the effects of aerobic training compared to conventional motor training on motor and cardio-vascular parameters;
the effect of aerobic training compared to conventional motor training on cognitive performance, depression and fatigue;
the modifications of functional activations during a cognitive task and of functional connectivity in motor and cognitive networks during resting state following aerobic training and conventional motor training (functional plasticity);
the regional variations of gray matter (GM) volumes and white matter (WM) architecture after aerobic training and conventional motor training (structural plasticity);
the correlations between the changes detected with structural and functional MRI and clinical, motor and neuropsychological scales.","[(11, 27, 'PHYSICAL', 'Aerobic Training'), (81, 83, 'CONDITION', 'MS'), (143, 159, 'PHYSICAL', 'Aerobic training'), (161, 163, 'PHYSICAL', 'AT'), (424, 426, 'PHYSICAL', 'AT'), (430, 448, 'CONDITION', 'multiple sclerosis'), (450, 452, 'CONDITION', 'MS'), (672, 688, 'PHYSICAL', 'aerobic training'), (705, 707, 'CONDITION', 'MS'), (765, 781, 'PHYSICAL', 'aerobic training'), (794, 821, 'CONTROL', 'conventional motor training'), (877, 893, 'PHYSICAL', 'aerobic training'), (906, 933, 'CONTROL', 'conventional motor training'), (960, 970, 'CONDITION', 'depression'), (975, 982, 'CONDITION', 'fatigue'), (1146, 1162, 'PHYSICAL', 'aerobic training'), (1167, 1194, 'CONTROL', 'conventional motor training'), (1313, 1329, 'PHYSICAL', 'aerobic training'), (1334, 1361, 'CONTROL', 'conventional motor training')]"
"['Effect', 'of', 'Intensive', 'Cognitive', 'Rehabilitation', 'on', 'Cognitive', ',', 'Motor', ',', 'and', 'Language', 'Functional', 'Networks', 'in', 'Subacute', 'Stroke', 'Patient', '|', 'Altered', 'brain', 'networks', ',', 'including', 'cognitive', ',', 'motor', ',', 'and', 'language', 'networks', ',', 'are', 'investigated', 'by', 'intensive', 'cognitive', 'rehabilitation', 'in', 'subacute', 'stroke', 'patients', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT05254964,NCT05254964,"Effect of Intensive Cognitive Rehabilitation on Cognitive, Motor, and Language Functional Networks in Subacute Stroke Patient | Altered brain networks, including cognitive, motor, and language networks, are investigated by intensive cognitive rehabilitation in subacute stroke patients.","[(10, 44, 'OTHER', 'Intensive Cognitive Rehabilitation'), (102, 117, 'CONDITION', 'Subacute Stroke'), (223, 257, 'OTHER', 'intensive cognitive rehabilitation'), (261, 276, 'CONDITION', 'subacute stroke')]"
"['The', 'Florida', 'REACH', 'Translation', 'Project', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'is', 'to', 'test', 'feasibility', 'of', 'a', 'modified', 'REACH', 'II', 'intervention', 'in', 'an', 'outpatient', 'clinic', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04956874,NCT04956874,The Florida REACH Translation Project | The primary aim of this study is to test feasibility of a modified REACH II intervention in an outpatient clinic.,[]
"['A', 'Randomized', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', 'Trial', 'to', 'Examine', 'the', 'Efficacy', 'of', 'Oral', 'Donepezil', '(', '5', 'mg', 'QD', 'for', '6', 'Weeks', ')', 'After', 'Single', 'Dose', 'and', 'Steady', 'State', 'Therapy', '(', '2', 'Weeks', 'and', '6', 'Weeks', ')', 'in', 'Subjects', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'To', 'purpose', 'of', 'this', 'study', 'is', 'to', 'estimate', 'the', 'effect', 'of', 'donepezil', 'on', 'Neuropsychological', 'Testing', '(', 'NPT', ')', 'and', 'brain', 'Proton', 'Magnetic', 'Resonance', 'Spectroscopy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00483028,NCT00483028,"A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment | To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.","[(37, 44, 'CONTROL', 'Placebo'), (94, 103, 'DRUG', 'Donepezil'), (208, 233, 'CONDITION', 'Mild Cognitive Impairment'), (290, 299, 'DRUG', 'donepezil')]"
"['Effects', 'of', 'Attention', 'Training', 'Interventions', 'on', 'Depression', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'the', 'effects', 'of', 'attention', 'training', 'interventions', 'on', 'symptoms', 'and', 'brain', 'function', 'in', 'major', 'depressive', 'disorder', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04184206,NCT04184206,Effects of Attention Training Interventions on Depression | The purpose of this study is to study the effects of attention training interventions on symptoms and brain function in major depressive disorder.,"[(11, 43, 'BEHAVIOURAL', 'Attention Training Interventions'), (47, 57, 'CONDITION', 'Depression'), (113, 145, 'BEHAVIOURAL', 'attention training interventions'), (180, 205, 'CONDITION', 'major depressive disorder')]"
"['Effects', 'of', 'Aerobic', 'Dance', 'Training', 'on', 'Cognitive', 'Functions', ',', 'Mood', 'and', 'Physical', 'Functions', 'in', 'Community', 'Elderly', 'Persons', 'With', 'Cerebral', 'Small', 'Vessel', 'Disease', '|', 'Introduction', ':', 'Cerebral', 'small', 'vessel', 'disease', '(', 'SVD', ')', 'is', 'associated', 'with', 'age', '-', 'related', 'disabilities', 'including', 'dementia', ',', 'depression', ',', 'physical', 'and', 'functional', 'impairment', '.', 'Chinese', 'are', 'more', 'prone', 'to', 'developing', 'SVD', 'than', 'Caucasians', '.', 'Physical', 'exercise', 'may', 'improve', 'multiple', 'negative', 'consequences', 'associated', 'with', 'SVD', '.', '\n\n', 'Objective', 'and', 'hypothesis', 'to', 'be', 'tested', ':', 'To', 'examine', 'the', 'effects', 'of', 'a', '24', '-', 'week', 'structured', 'aerobic', 'dance', 'training', 'on', 'cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'in', 'stroke', 'and', 'dementia', 'free', 'older', 'adults', 'with', 'SVD', ',', 'and', 'whether', 'such', 'effects', 'are', 'mediated', 'through', 'improved', 'cerebral', 'vasomotor', 'reactivity', '(', 'CVR', ')', ',', 'a', 'marker', 'of', 'cerebral', 'autoregulation', 'which', 'is', 'impaired', 'in', 'SVD', '.', '\n\n', 'Design', 'and', 'subjects', ':', 'Rater', '-', 'blind', 'RCT', 'comparing', 'the', 'effects', 'of', '24', '-', 'week', 'of', 'structured', 'aerobic', 'dance', 'training', 'upon', 'cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'on', '110', 'community', 'dwelling', ',', 'stroke-', 'and', 'dementia', '-', 'free', 'persons', 'aged', '≥65', 'with', 'MRI', 'evidence', 'of', 'significant', 'SVD', ',', 'defined', 'as', 'the', 'presence', 'of', 'multiple', '(', '≥2', ')', 'lacunes', 'and/or', 'early', 'confluent', 'or', 'confluent', 'WML', '.', '\n\n', 'Interventions', ':', 'Participants', 'are', 'randomized', 'in', 'a', '1:1', 'ratio', 'into', 'a', '24', '-', 'week', 'of', 'structured', 'therapist', '-', 'led', 'group', 'aerobic', 'dance', 'training', 'with', 'home', 'practice', 'or', 'simple', 'stretching', 'plus', 'health', 'education', 'control', 'group', '.', '\n\n', 'Main', 'outcome', 'measures', ':', 'Cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'and', 'CVR', 'measured', 'using', 'Transcranial', 'Doppler', 'at', 'baseline', ',', 'weeks', '12', ',', '24', 'and', '36', '.', '\n\n', 'Data', 'analysis', ':', 'Intent', '-', 'to', '-', 'treat', 'with', 'multiple', 'imputations', 'with', 'treatment', 'efficacy', 'analyzed', 'using', 'mixed', 'effects', 'models', '.', 'Mediation', 'effects', 'of', 'CVR', 'between', 'aerobic', 'dance', 'training', 'and', 'treatment', 'outcomes', 'tested', 'using', 'mediation', 'models', '.', '\n\n', 'Expected', 'results', ':', 'In', 'persons', 'with', 'significant', 'SVD', ',', 'aerobic', 'dance', 'training', 'improves', 'cognitive', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'and', 'such', 'effects', 'are', 'mediated', 'by', 'changes', 'in', 'CVR', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02730065,NCT02730065,"Effects of Aerobic Dance Training on Cognitive Functions, Mood and Physical Functions in Community Elderly Persons With Cerebral Small Vessel Disease | Introduction: Cerebral small vessel disease (SVD) is associated with age-related disabilities including dementia, depression, physical and functional impairment. Chinese are more prone to developing SVD than Caucasians. Physical exercise may improve multiple negative consequences associated with SVD.

Objective and hypothesis to be tested: To examine the effects of a 24-week structured aerobic dance training on cognition, mood, physical and daily functions in stroke and dementia free older adults with SVD, and whether such effects are mediated through improved cerebral vasomotor reactivity (CVR), a marker of cerebral autoregulation which is impaired in SVD.

Design and subjects: Rater-blind RCT comparing the effects of 24-week of structured aerobic dance training upon cognition, mood, physical and daily functions on 110 community dwelling, stroke- and dementia-free persons aged ≥65 with MRI evidence of significant SVD, defined as the presence of multiple (≥2) lacunes and/or early confluent or confluent WML.

Interventions: Participants are randomized in a 1:1 ratio into a 24-week of structured therapist-led group aerobic dance training with home practice or simple stretching plus health education control group.

Main outcome measures: Cognition, mood, physical and daily functions and CVR measured using Transcranial Doppler at baseline, weeks 12, 24 and 36.

Data analysis: Intent-to-treat with multiple imputations with treatment efficacy analyzed using mixed effects models. Mediation effects of CVR between aerobic dance training and treatment outcomes tested using mediation models.

Expected results: In persons with significant SVD, aerobic dance training improves cognitive, mood, physical and daily functions and such effects are mediated by changes in CVR.","[(11, 33, 'PHYSICAL', 'Aerobic Dance Training'), (120, 149, 'CONDITION', 'Cerebral Small Vessel Disease'), (166, 195, 'CONDITION', 'Cerebral small vessel disease'), (197, 200, 'CONDITION', 'SVD'), (351, 354, 'CONDITION', 'SVD'), (449, 452, 'CONDITION', 'SVD'), (541, 563, 'PHYSICAL', 'aerobic dance training'), (659, 662, 'CONDITION', 'SVD'), (813, 816, 'CONDITION', 'SVD'), (903, 925, 'PHYSICAL', 'aerobic dance training'), (1080, 1083, 'CONDITION', 'SVD'), (1283, 1324, 'PHYSICAL', 'aerobic dance training with home practice'), (1328, 1345, 'CONTROL', 'simple stretching'), (1351, 1367, 'CONTROL', 'health education'), (1683, 1705, 'PHYSICAL', 'aerobic dance training'), (1807, 1810, 'CONDITION', 'SVD'), (1812, 1834, 'PHYSICAL', 'aerobic dance training')]"
"['Phase', 'IB', 'Follow', '-', 'up', 'Study', 'to', 'Assess', 'a', 'Boost', 'Immunization', 'With', 'AFFITOPE', 'AD02', 'With', 'Regard', 'to', 'Safety', '/', 'Tolerability', ',', 'Immunological', 'and', 'Clinical', 'Activity', 'in', 'Alzheimer', 'Patients', 'Who', 'Have', 'Received', 'the', 'Vaccine', 'Within', 'the', 'Clinical', 'Study', 'AFF002', '|', 'This', 'is', 'a', 'phase', 'IB', 'follow', '-', 'up', 'study', 'to', 'assess', 'a', 'boost', 'immunization', 'with', 'AFFITOPE', 'AD02', 'with', 'regard', 'to', 'safety', '/', 'tolerability', ',', 'immunological', 'and', 'clinical', 'activity', 'in', 'Alzheimer', 'patients', 'who', 'have', 'received', 'the', 'vaccine', 'within', 'the', 'clinical', 'study', 'AFF002', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01093664,NCT01093664,"Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002 | This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.","[(61, 74, 'DRUG', 'AFFITOPE AD02'), (150, 159, 'CONDITION', 'Alzheimer'), (305, 318, 'DRUG', 'AFFITOPE AD02'), (394, 403, 'CONDITION', 'Alzheimer')]"
"['Phase', 'II', 'Double', '-', 'blind', 'Randomized', 'Placebo', '-', 'controlled', '1', '-', 'way', 'Crossover', 'Trial', 'to', 'Investigate', 'Safety', 'and', 'Efficacy', 'of', 'the', 'Ascorbic', 'Acid', 'and', 'Tocopherol', 'for', 'the', 'Treatment', 'of', 'the', 'Fragile', 'X', 'Syndrome', '|', 'The', 'Fragile', 'X', 'syndrome', '(', 'FXS', ')', 'was', 'first', 'described', 'by', 'Dr.', 'Martin', 'and', 'Dr.', 'Bell', 'in', '1943', ',', 'in', 'families', 'with', 'several', 'patients', 'affected', 'by', 'sex', '-', 'linked', 'mental', 'disability', '.', 'This', 'disorder', 'is', 'the', 'most', 'common', 'cause', 'of', 'inherited', 'mental', 'disability', '.', 'The', 'prevalence', 'of', 'the', 'Fragile', 'X', 'syndrome', 'has', 'been', 'established', 'at', '1', 'in', '2,500', 'males', 'and', '1', 'in', '4000', 'females', '.', '\n\n', 'Despite', 'moderate', 'to', 'severe', 'mental', 'retardation', ',', 'fragile', 'X', 'patients', 'exhibit', 'macroorchidism', ',', 'an', 'elongated', 'face', ',', 'long', 'ears', ',', 'connective', 'tissue', 'dysplasia', ',', 'hyperactivity', ',', 'autistic', '-', 'like', 'and', 'stereotypical', 'behaviours', ',', 'speech', 'delay', 'and', 'increased', 'sensory', 'sensitivity', '.', '\n\n', 'Objective', ':', 'To', 'evaluate', 'the', 'effect', 'of', 'the', 'combination', 'of', 'the', 'antioxidant', 'Ascorbic', 'acid', 'and', 'tocopherol', ',', 'as', 'therapy', 'of', 'the', 'Fragile', 'X', 'Syndrome', 'in', 'young', 'males', '.', '\n\n', 'Hypothesis', ':', 'It', 'is', 'proposed', 'that', 'part', 'of', 'the', 'pathophysiology', 'of', 'the', 'central', 'nervous', 'system', 'in', 'the', 'animal', 'model', 'of', 'the', 'fragile', 'X', 'syndrome', 'may', 'be', 'determined', 'by', 'oxidative', 'stress', '.', 'In', 'addition', ',', 'Fragile', 'X', 'patients', 'showed', 'a', 'significantly', 'low', 'level', 'of', 'ascorbic', 'acid', 'in', 'plasma', '.', 'The', 'biochemical', 'characteristics', 'of', 'oxidative', 'stress', 'may', 'be', 'reversed', 'in', 'the', 'FMR1', '-', 'KO', 'mice', ',', 'by', 'a', 'chronic', 'treatment', 'with', 'antioxidant', 'compounds', 'such', 'as', 'tocopherol', 'or', 'melatonin', ',', 'it', 'may', 'also', 'normalize', 'several', 'hallmarks', 'of', 'the', 'Syndrome', 'such', 'as', 'hyperactivity', ',', 'anxiety', 'and', 'cognitive', 'deficits', '.', 'The', 'normalization', 'of', 'the', 'oxidative', 'stress', 'is', 'proposed', 'as', 'a', 'new', 'therapeutic', 'pathway', 'to', 'alleviate', 'conditions', 'caused', 'by', 'an', 'excess', 'of', 'free', 'radicals', 'that', 'are', 'crucial', 'in', 'neurodevelopmental', 'diseases', 'such', 'as', 'autism', ',', 'down', 'syndrome', 'and', 'other', 'diseases', 'of', 'the', 'central', 'nervous', 'system', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01329770,NCT01329770,"Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome | The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.

Despite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.

Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.

Hypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.","[(33, 40, 'CONTROL', 'Placebo'), (116, 129, 'DRUG', 'Ascorbic Acid'), (134, 144, 'DRUG', 'Tocopherol'), (170, 188, 'CONDITION', 'Fragile X Syndrome'), (195, 213, 'CONDITION', 'Fragile X syndrome'), (215, 218, 'CONDITION', 'FXS'), (445, 463, 'CONDITION', 'Fragile X syndrome'), (576, 585, 'CONDITION', 'fragile X'), (846, 857, 'DRUG', 'antioxidant'), (858, 871, 'DRUG', 'Ascorbic acid'), (876, 886, 'DRUG', 'tocopherol'), (906, 924, 'CONDITION', 'Fragile X Syndrome'), (1059, 1068, 'CONDITION', 'fragile X'), (1099, 1115, 'CONDITION', 'oxidative stress'), (1130, 1139, 'CONDITION', 'Fragile X'), (1245, 1261, 'CONDITION', 'oxidative stress'), (1327, 1338, 'DRUG', 'antioxidant'), (1446, 1459, 'CONDITION', 'hyperactivity'), (1461, 1468, 'CONDITION', 'anxiety'), (1473, 1491, 'CONDITION', 'cognitive deficits'), (1518, 1534, 'CONDITION', 'oxidative stress')]"
"['Phase', '2', 'Double', '-', 'Blind', 'Study', 'of', 'PRX-03140', 'in', 'Subjects', 'With', 'Alzheimer', ""'s"", 'Disease', 'Receiving', 'a', 'Stable', 'Dose', 'of', 'Donepezil', '|', 'A', 'randomized', 'placebo', '-', 'controlled', 'study', 'to', 'evaluate', 'the', 'efficacy', 'of', 'PRX-03140', 'in', 'subjects', 'with', 'Alzheimer', ""'s"", 'Disease', 'receiving', 'a', 'stable', 'dose', 'of', 'donepezil', '.', 'The', 'study', 'consists', 'of', 'a', '26', '-', 'week', 'double', '-', 'blind', 'treatment', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00672945,NCT00672945,Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil | A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.,"[(30, 39, 'DRUG', 'PRX-03140'), (57, 76, 'CONDITION', ""Alzheimer's Disease""), (104, 113, 'DRUG', 'Donepezil'), (129, 136, 'CONTROL', 'placebo'), (182, 191, 'DRUG', 'PRX-03140'), (209, 228, 'CONDITION', ""Alzheimer's Disease""), (256, 265, 'DRUG', 'donepezil')]"
"['Seizure', 'Rescue', 'Medication', ':', 'Caregiver', 'Education', 'in', 'a', 'Simulation', 'Setting', '|', '1', '.', 'Design', 'an', 'educational', 'quality', 'improvement', 'program', 'to', 'assess', 'the', 'most', 'effective', 'educational', 'approach', 'on', 'caregiver', 'seizure', 'RM', 'application', '.', 'The', 'investigators', 'hypothesize', 'that', 'this', 'educational', 'program', 'will', 'improve', 'caregiver', 'comfort', ',', 'knowledge', 'of', 'emergent', 'seizure', 'care', ',', 'and', 'time', 'to', 'medication', 'application', '.', '\n\n', 'Specifically', ',', 'the', 'aims', 'include', ':', '\n\n', 'Create', 'an', 'educational', 'video', 'reviewing', 'RM', 'administration', '\n', 'Develop', 'and', 'validate', 'a', 'simulation', 'training', 'model', '/', 'mannequin', 'for', 'rectal', 'diazepam', 'administration', '\n', 'Expand', 'training', 'to', 'other', 'seizure', 'RMs', '(', 'e.g.', 'intranasal', 'midazolam', ',', 'buccal', 'lorazepam', ')', 'and', 'transition', 'the', 'most', 'effective', 'educational', 'model', 'back', 'to', 'the', 'clinics', '/', 'bedside', 'to', 'standardize', 'caregiver', 'teaching', 'throughout', 'the', 'department', '/', 'hospital']","['B-COND', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03562351,NCT03562351,"Seizure Rescue Medication: Caregiver Education in a Simulation Setting | 1. Design an educational quality improvement program to assess the most effective educational approach on caregiver seizure RM application. The investigators hypothesize that this educational program will improve caregiver comfort, knowledge of emergent seizure care, and time to medication application.

Specifically, the aims include:

Create an educational video reviewing RM administration
Develop and validate a simulation training model/mannequin for rectal diazepam administration
Expand training to other seizure RMs (e.g. intranasal midazolam, buccal lorazepam) and transition the most effective educational model back to the clinics/bedside to standardize caregiver teaching throughout the department/hospital","[(0, 7, 'CONDITION', 'Seizure'), (27, 70, 'BEHAVIOURAL', 'Caregiver Education in a Simulation Setting'), (86, 125, 'BEHAVIOURAL', 'educational quality improvement program'), (189, 196, 'CONDITION', 'seizure'), (253, 272, 'BEHAVIOURAL', 'educational program'), (318, 334, 'CONDITION', 'emergent seizure'), (421, 466, 'BEHAVIOURAL', 'educational video reviewing RM administration'), (490, 560, 'BEHAVIOURAL', 'simulation training model/mannequin for rectal diazepam administration'), (586, 593, 'CONDITION', 'seizure')]"
"['Evaluating', 'the', 'Effect', 'of', 'Acetazolamide', 'Administration', 'and', 'Prone', 'Positioning', 'Following', 'Lumbosacral', 'Spinal', 'Surgery', 'in', 'Preventing', 'Cerebro', 'Spinal', 'Fluid', 'Leakage', 'and', 'Collection', 'and', 'Wound', 'Dehiscence', 'in', 'Children', '.', '|', 'Purpose', 'of', 'study', ':', 'to', 'determine', 'the', 'preventive', 'effect', 'of', 'acetazolamide', 'administration', ',', 'prone', 'positioning', ',', 'and', 'the', 'combination', 'of', 'both', 'following', 'the', 'neurosurgical', 'interventions', 'in', 'lumbosacral', 'region', 'for', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'leak', ',', 'CSF', 'collection', 'and', 'wound', 'dehiscence', '.', '\n', 'Sample', 'size', ':', '144', '\n\n', 'intervention', 'groups', ':', '\n\n', 'Group', 'A', ':', 'Acetazolamide', 'administration', 'for', '10', 'days', '\n', 'Group', 'B', ':', 'prone', 'positioning', 'for', '10', 'days', '\n', 'Group', 'C', ':', 'Acetazolamide', 'administration', 'and', 'prone', 'positioning', 'for', '10', 'days', '\n', 'Group', 'D', ':', 'no', 'intervention', '\n', 'Period', 'of', 'study', ':', 'Autumn', '2012', 'to', 'the', 'end', 'of', 'winter', 'of', '2015']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01867268,NCT01867268,"Evaluating the Effect of Acetazolamide Administration and Prone Positioning Following Lumbosacral Spinal Surgery in Preventing Cerebro Spinal Fluid Leakage and Collection and Wound Dehiscence in Children. | Purpose of study : to determine the preventive effect of acetazolamide administration, prone positioning, and the combination of both following the neurosurgical interventions in lumbosacral region for cerebrospinal fluid (CSF) leak, CSF collection and wound dehiscence.
Sample size: 144

intervention groups:

Group A: Acetazolamide administration for 10 days
Group B: prone positioning for 10 days
Group C: Acetazolamide administration and prone positioning for 10 days
Group D: no intervention
Period of study: Autumn 2012 to the end of winter of 2015","[(25, 38, 'DRUG', 'Acetazolamide'), (58, 75, 'OTHER', 'Prone Positioning'), (127, 170, 'CONDITION', 'Cerebro Spinal Fluid Leakage and Collection'), (175, 191, 'CONDITION', 'Wound Dehiscence'), (264, 277, 'DRUG', 'acetazolamide'), (294, 311, 'OTHER', 'prone positioning'), (409, 439, 'CONDITION', 'cerebrospinal fluid (CSF) leak'), (441, 455, 'CONDITION', 'CSF collection'), (460, 476, 'CONDITION', 'wound dehiscence'), (527, 540, 'DRUG', 'Acetazolamide'), (577, 594, 'OTHER', 'prone positioning'), (616, 629, 'DRUG', 'Acetazolamide'), (649, 666, 'OTHER', 'prone positioning'), (688, 703, 'CONTROL', 'no intervention')]"
"['Intra', '-', 'Nasal', 'vs.', 'Intra', '-', 'Venous', 'Lorazepam', 'for', 'Control', 'of', 'Acute', 'Seizures', 'in', 'Children', ':', 'Prospective', 'Open', 'Labeled', 'Randomized', 'Equivalence', 'Trial', '|', 'Status', 'epilepticus', '(', 'SE', ')', 'is', 'a', 'common', 'pediatric', 'emergency', 'which', 'is', 'potentially', 'life', '-', 'threatening', 'and', 'requires', 'rapid', 'termination', '.', 'Early', 'and', 'effective', 'treatment', 'is', 'essential', 'to', 'prevent', 'the', 'morbidity', 'and', 'mortality', 'associated', 'with', 'prolonged', 'convulsive', 'SE', '.', 'Lorazepam', 'is', 'the', 'standard', 'of', 'care', 'for', 'control', 'of', 'SE', 'when', 'administered', 'by', 'intra', '-', 'venous', '(', 'IV', ')', 'route', '.', 'The', 'investigators', 'intend', 'to', 'compare', 'efficacy', 'and', 'adverse', 'effect', 'profile', 'of', 'intra', '-', 'nasal', 'vs.', 'intravenous', 'routes', 'of', 'administration', 'of', 'lorazepam', '.', 'In', 'resource', 'poor', 'settings', ',', 'sometimes', 'trained', 'personnel', 'or', 'appropriate', 'equipment', 'for', 'intra', '-', 'venous', 'cannulation', 'is', 'not', 'available', '.', 'Alternate', 'routes', 'of', 'administration', ',', 'if', 'shown', 'equivalent', 'to', 'conventional', 'IV', 'route', ',', 'will', 'be', 'very', 'useful', 'in', 'such', 'settings', 'or', 'for', 'out', 'of', 'hospital', 'management', 'of', 'seizures', 'in', 'children', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT00735527,NCT00735527,"Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial | Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening and requires rapid termination. Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of care for control of SE when administered by intra-venous (IV) route. The investigators intend to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of administration of lorazepam. In resource poor settings, sometimes trained personnel or appropriate equipment for intra-venous cannulation is not available. Alternate routes of administration, if shown equivalent to conventional IV route, will be very useful in such settings or for out of hospital management of seizures in children.","[(29, 38, 'DRUG', 'Lorazepam'), (54, 68, 'CONDITION', 'Acute Seizures'), (138, 156, 'CONDITION', 'Status epilepticus'), (158, 160, 'CONDITION', 'SE'), (362, 385, 'CONDITION', 'prolonged convulsive SE'), (387, 396, 'DRUG', 'Lorazepam'), (436, 438, 'CONDITION', 'SE'), (616, 625, 'DRUG', 'lorazepam'), (910, 918, 'CONDITION', 'seizures')]"
"['An', 'Internet', 'Intervention', 'for', 'Insomnia', ':', 'Efficacy', 'and', 'Dissemination', '|', 'This', 'study', 'will', 'compare', 'the', 'efficacy', 'of', 'an', 'interactive', 'Internet', 'intervention', 'for', 'adult', 'insomnia', '(', 'Sleep', 'Healthy', 'Using', 'the', 'Internet', ';', 'SHUTi', ')', 'to', 'that', 'of', 'a', 'static', 'educational', 'website', 'to', 'improve', 'sleep', ',', 'mood', 'related', 'symptoms', ',', 'perceived', 'health', 'status', ',', 'and', 'overall', 'quality', 'of', 'life', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01438697,NCT01438697,"An Internet Intervention for Insomnia: Efficacy and Dissemination | This study will compare the efficacy of an interactive Internet intervention for adult insomnia (Sleep Healthy Using the Internet; SHUTi) to that of a static educational website to improve sleep, mood related symptoms, perceived health status, and overall quality of life.","[(3, 24, 'OTHER', 'Internet Intervention'), (29, 37, 'CONDITION', 'Insomnia'), (111, 144, 'OTHER', 'interactive Internet intervention'), (155, 163, 'CONDITION', 'insomnia'), (219, 245, 'CONTROL', 'static educational website')]"
"['Supervisory', 'Neglect', ',', 'Non', '-', 'Accidental', 'Trauma', ',', 'Brief', 'Intervention', ',', 'and', 'Treatment', 'Referral', '(', 'SunBrite', ')', '|', 'The', 'Supervisory', 'Neglect', ',', 'Non', '-', 'Accidental', 'Trauma', ',', 'Brief', 'Intervention', ',', 'and', 'Treatment', 'Referral', '(', 'SunBrite', ')', 'protocol', 'is', 'a', 'family', '-', 'empowered', ',', 'risk', 'mitigation', 'strategy', 'that', 'targets', 'families', 'with', 'young', 'children', 'who', 'present', 'to', 'the', 'ED', 'with', 'intracranial', 'trauma', '.', 'Based', 'on', 'the', 'widely', 'utilized', 'screening', ',', 'brief', 'intervention', ',', 'and', 'referral', 'to', 'treatment', '(', 'SBIRT', ')', 'protocol', ',', 'SunBrite', 'has', '3', 'core', 'components', ':', 'screening', ',', 'brief', 'motivational', 'interview', ',', 'and', 'referral', 'for', 'treatment', '.', 'PCH', 'will', ':', '1', ')', 'engage', 'community', 'partnerships', 'to', 'support', 'SunBrite', 'development', ';', '2', ')', 'utilize', 'participatory', 'action', 'research', 'approach', 'for', 'design', ',', 'implementation', ',', 'process', 'evaluation', ',', 'and', 'dissemination', 'of', 'the', 'pilot', 'program', ';', 'and', '3', ')', 'evaluate', 'intervention', 'implementation', 'and', 'pilot', 'outcomes', '.', 'Over', 'a', '2', '-', 'year', 'period', ',', 'this', 'study', 'will', 'encompass', 'a', 'pilot', 'intervention', 'and', 'implementation', 'assessment', 'and', 'a', 'randomized', 'trial', 'to', 'evaluate', 'outcomes', '.', 'Implementation', 'of', 'SunBrite', 'will', 'yield', 'rigorous', 'scientific', 'evidence', 'for', 'a', 'sustainable', ',', 'evidenced', '-', 'based', ',', 'widely', '-', 'needed', 'non', '-', 'accidental', '(', 'NAT', ')', 'screening', 'and', 'intervention', 'for', 'families', 'with', 'young', 'children', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03704272,NCT03704272,"Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) | The Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) protocol is a family-empowered, risk mitigation strategy that targets families with young children who present to the ED with intracranial trauma. Based on the widely utilized screening, brief intervention, and referral to treatment (SBIRT) protocol, SunBrite has 3 core components: screening, brief motivational interview, and referral for treatment. PCH will: 1) engage community partnerships to support SunBrite development; 2) utilize participatory action research approach for design, implementation, process evaluation, and dissemination of the pilot program; and 3) evaluate intervention implementation and pilot outcomes. Over a 2-year period, this study will encompass a pilot intervention and implementation assessment and a randomized trial to evaluate outcomes. Implementation of SunBrite will yield rigorous scientific evidence for a sustainable, evidenced-based, widely-needed non-accidental (NAT) screening and intervention for families with young children.","[(0, 86, 'BEHAVIOURAL', 'Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral'), (88, 96, 'BEHAVIOURAL', 'SunBrite'), (104, 190, 'BEHAVIOURAL', 'Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral'), (192, 200, 'BEHAVIOURAL', 'SunBrite'), (328, 347, 'CONDITION', 'intracranial trauma'), (453, 461, 'BEHAVIOURAL', 'SunBrite'), (485, 494, 'BEHAVIOURAL', 'screening'), (496, 524, 'BEHAVIOURAL', 'brief motivational interview'), (530, 552, 'BEHAVIOURAL', 'referral for treatment'), (608, 616, 'BEHAVIOURAL', 'SunBrite'), (994, 1002, 'BEHAVIOURAL', 'SunBrite')]"
"['Magic', 'Camp', 'for', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'The', 'proposed', 'study', 'will', 'test', 'the', 'feasibility', 'and', 'effectiveness', 'of', 'a', '""', 'Magic', 'Camp', '""', 'in', 'children', 'with', 'spastic', 'hemiplegic', 'cerebral', 'palsy', '(', 'CP', ')', '.', 'A', 'single', 'group', 'pretest', '-', 'posttest', 'design', '(', 'n=10', ')', 'will', 'be', 'used', 'to', 'investigate', 'the', 'immediate', '(', '2', 'weeks', ')', 'and', 'longer', '-', 'term', 'effect', '(', '3', 'months', ')', 'of', 'a', '""', 'Magic', 'Camp', '""', 'on', 'improving', 'upper', 'limb', 'motor', 'function', 'and', 'health', '-', 'related', 'quality', 'of', 'life', '(', 'HRQoL', ')', 'in', 'children', 'with', 'hemiplegic', 'CP', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT03620279,NCT03620279,"Magic Camp for Children With Hemiplegic Cerebral Palsy | The proposed study will test the feasibility and effectiveness of a ""Magic Camp"" in children with spastic hemiplegic cerebral palsy (CP). A single group pretest-posttest design (n=10) will be used to investigate the immediate (2 weeks) and longer-term effect (3 months) of a ""Magic Camp"" on improving upper limb motor function and health-related quality of life (HRQoL) in children with hemiplegic CP.","[(0, 10, 'OTHER', 'Magic Camp'), (29, 54, 'CONDITION', 'Hemiplegic Cerebral Palsy'), (126, 136, 'OTHER', 'Magic Camp'), (155, 188, 'CONDITION', 'spastic hemiplegic cerebral palsy'), (190, 192, 'CONDITION', 'CP'), (333, 343, 'OTHER', 'Magic Camp'), (444, 457, 'CONDITION', 'hemiplegic CP')]"
"['Proactive', 'and', 'Reactive', 'Perturbation', 'Training', 'to', 'Reduce', 'Falls', 'and', 'Improve', 'Gait', 'Stability', 'in', 'People', 'With', 'Chronic', 'Stroke', '|', 'Following', 'a', 'stroke', ',', 'many', 'individuals', 'have', 'a', 'high', 'risk', 'of', 'falls', ',', 'which', 'can', 'negatively', 'influence', 'quality', 'of', 'life', '.', 'Unfortunately', ',', 'current', 'treatments', 'have', 'not', 'effectively', 'addressed', 'this', 'problem', '.', 'This', 'study', 'investigates', 'whether', 'two', 'methods', 'of', 'delivering', 'mechanical', 'perturbations', 'during', 'walking', 'have', 'the', 'potential', 'to', 'improve', 'post', '-', 'stroke', 'walking', 'balance', 'and', 'reduce', 'real', '-', 'world', 'fall', 'incidence', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04855032,NCT04855032,"Proactive and Reactive Perturbation Training to Reduce Falls and Improve Gait Stability in People With Chronic Stroke | Following a stroke, many individuals have a high risk of falls, which can negatively influence quality of life. Unfortunately, current treatments have not effectively addressed this problem. This study investigates whether two methods of delivering mechanical perturbations during walking have the potential to improve post-stroke walking balance and reduce real-world fall incidence.","[(0, 44, 'OTHER', 'Proactive and Reactive Perturbation Training'), (55, 60, 'CONDITION', 'Falls'), (103, 117, 'CONDITION', 'Chronic Stroke'), (132, 138, 'CONDITION', 'stroke'), (177, 182, 'CONDITION', 'falls'), (369, 408, 'OTHER', 'mechanical perturbations during walking'), (444, 450, 'CONDITION', 'stroke'), (489, 493, 'CONDITION', 'fall')]"
"['Self', '-', 'Supporting', 'Nasopharyngeal', 'Airway', '(', 'ssNPA', ')', 'Treating', 'Upper', 'Airway', 'Obstruction', 'in', 'Hypotonia', '|', 'The', 'researchers', 'are', 'investigating', 'if', 'the', 'Self', '-', 'Supporting', 'Nasopharyngeal', 'Airway', '(', 'ssNPA', ')', 'device', 'can', 'be', 'used', 'in', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', 'in', 'children', 'with', 'Hypotonic', 'Upper', 'Airway', 'Obstruction', '(', 'HUAO', ')', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05527652,NCT05527652,Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).,"[(0, 37, 'OTHER', 'Self-Supporting Nasopharyngeal Airway'), (39, 44, 'OTHER', 'ssNPA'), (55, 79, 'CONDITION', 'Upper Airway Obstruction'), (83, 92, 'CONDITION', 'Hypotonia'), (136, 173, 'OTHER', 'Self-Supporting Nasopharyngeal Airway'), (175, 180, 'OTHER', 'ssNPA'), (221, 244, 'CONDITION', 'obstructive sleep apnea'), (262, 296, 'CONDITION', 'Hypotonic Upper Airway Obstruction'), (298, 302, 'CONDITION', 'HUAO')]"
"['A', 'Randomized', ',', 'Blank', '-', 'controlled', ',', 'Open', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Propranolol', 'in', 'Reducing', 'Stroke', 'Associated', 'Pneumonia', 'and', 'Urinary', 'Tract', 'Infection', '|', 'Stroke', '-', 'associated', 'pneumonia', '(', 'SAP', ')', 'is', 'one', 'of', 'the', 'important', 'risk', 'factors', 'influencing', 'poor', 'outcomes', 'and', 'death', 'in', 'stroke', 'patients', '.', 'Over', 'the', 'past', 'two', 'decades', ',', 'accumulating', 'evidence', 'suggests', 'that', 'post', '-', 'stroke', 'brain', 'injury', 'mobilizes', 'the', 'adrenergic', 'system', ',', 'which', 'induces', 'post', '-', 'stroke', 'immunosuppression', 'and', 'SAP', '.', 'This', 'study', 'is', 'designed', 'to', 'test', 'the', 'safety', 'and', 'efficacy', 'of', 'an', 'adrenergic', 'β', '-', 'receptor', 'blocker', ',', 'propranolol', ',', 'with', 'or', 'without', 'combination', 'of', 'antibiotics', ',', 'in', 'reducing', 'SAP', 'in', 'stroke', 'patients', '.', 'The', 'underlying', 'immune', 'mechanisms', 'will', 'be', 'investigated', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05375240,NCT05375240,"A Randomized, Blank-controlled, Open Label Study of the Safety and Efficacy of Propranolol in Reducing Stroke Associated Pneumonia and Urinary Tract Infection | Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor outcomes and death in stroke patients. Over the past two decades, accumulating evidence suggests that post-stroke brain injury mobilizes the adrenergic system, which induces post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy of an adrenergic β-receptor blocker, propranolol, with or without combination of antibiotics, in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.","[(14, 19, 'CONTROL', 'Blank'), (79, 90, 'DRUG', 'Propranolol'), (103, 109, 'CONDITION', 'Stroke'), (121, 130, 'CONDITION', 'Pneumonia'), (135, 158, 'CONDITION', 'Urinary Tract Infection'), (161, 188, 'CONDITION', 'Stroke-associated pneumonia'), (190, 193, 'CONDITION', 'SAP'), (271, 277, 'CONDITION', 'stroke'), (351, 362, 'CONDITION', 'post-stroke'), (363, 375, 'CONDITION', 'brain injury'), (423, 434, 'CONDITION', 'post-stroke'), (435, 452, 'CONDITION', 'immunosuppression'), (457, 460, 'CONDITION', 'SAP'), (523, 552, 'DRUG', 'adrenergic β-receptor blocker'), (554, 565, 'DRUG', 'propranolol'), (598, 609, 'DRUG', 'antibiotics'), (623, 626, 'CONDITION', 'SAP'), (630, 636, 'CONDITION', 'stroke')]"
"['Evaluation', 'of', 'Post', 'Operative', 'Analgesia', 'of', 'the', 'Erector', 'Spinae', 'Plane', 'Block', 'in', 'Pediatric', 'Patients', 'Undergoing', 'Hip', 'Surgery', ':', 'a', 'Randomized', 'Control', 'Trial', '|', 'Hip', 'Surgery', 'in', 'pediatric', 'patients', 'is', 'considered', 'an', 'extremely', 'painful', 'procedure', '.', 'Managing', 'pain', 'in', 'this', 'surgery', 'is', 'challenging', 'even', 'with', 'several', 'available', 'options', ',', 'each', 'with', 'limitations', '.', 'Erector', 'spinae', 'plane', '(', 'ESP', ')', 'block', 'is', 'a', 'novel', 'technique', 'that', 'has', 'been', 'used', 'in', 'different', 'types', 'of', 'surgery', ',', 'with', 'promising', 'results', '.', 'Many', 'case', 'reports', 'for', 'use', 'of', 'ESPB', 'are', 'available', 'in', 'the', 'literature', 'but', 'to', 'our', 'knowledge', ',', 'no', 'cohort', 'studies', 'or', 'randomized', 'controlled', 'trials', 'have', 'been', 'performed', 'on', 'ESPB', 'for', 'hip', 'surgery', 'in', 'pediatrics', 'age', 'group', 'against', 'a', 'traditional', 'method', 'as', 'caudal', 'block.1,2', 'AIM', 'OF', 'WORK', '\n\n', '.', 'The', 'Primary', 'outcome', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'analgesia', 'resulting', 'from', 'the', 'Erector', 'spinae', 'plane', 'block', 'versus', 'the', 'caudal', 'block', 'in', 'pediatric', 'patients', 'undergoing', 'hip', 'surgery', 'using', 'the', 'FLACC', 'score', 'and', 'the', 'duration', 'of', 'the', 'analgesia', 'of', 'both', 'methods', 'till', 'the', 'first', 'rescue', 'analgesic', '.', '\n\n', 'The', 'Secondary', 'outcome', 'is', 'to', 'compare', 'the', 'analgesic', 'rescue', 'frequency', 'and', 'total', 'dose', 'given', 'in', 'both', 'groups', 'as', 'well', 'as', 'comparing', 'the', 'complications', 'that', 'might', 'occur', 'from', 'each', 'analgesic', 'technique', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04354571,NCT04354571,"Evaluation of Post Operative Analgesia of the Erector Spinae Plane Block in Pediatric Patients Undergoing Hip Surgery: a Randomized Control Trial | Hip Surgery in pediatric patients is considered an extremely painful procedure. Managing pain in this surgery is challenging even with several available options, each with limitations. Erector spinae plane (ESP) block is a novel technique that has been used in different types of surgery, with promising results. Many case reports for use of ESPB are available in the literature but to our knowledge, no cohort studies or randomized controlled trials have been performed on ESPB for hip surgery in pediatrics age group against a traditional method as caudal block.1,2 AIM OF WORK

. The Primary outcome of this study is to compare the efficacy of analgesia resulting from the Erector spinae plane block versus the caudal block in pediatric patients undergoing hip surgery using the FLACC score and the duration of the analgesia of both methods till the first rescue analgesic.

The Secondary outcome is to compare the analgesic rescue frequency and total dose given in both groups as well as comparing the complications that might occur from each analgesic technique.","[(46, 72, 'OTHER', 'Erector Spinae Plane Block'), (106, 117, 'CONDITION', 'Hip Surgery'), (148, 159, 'CONDITION', 'Hip Surgery'), (237, 241, 'CONDITION', 'pain'), (333, 365, 'OTHER', 'Erector spinae plane (ESP) block'), (490, 494, 'OTHER', 'ESPB'), (622, 626, 'OTHER', 'ESPB'), (824, 850, 'OTHER', 'Erector spinae plane block'), (862, 874, 'CONTROL', 'caudal block'), (908, 919, 'CONDITION', 'hip surgery')]"
"['A', 'Phase', 'IIa', 'Trial', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Biological', 'Activity', 'of', 'LAM-002A', '(', 'Apilimod', 'Dimesylate', 'Capsules', ')', 'in', 'C9ORF72', '-', 'Associated', 'Amyotrophic', 'Lateral', 'Sclerosis', '|', 'This', 'is', 'a', 'clinical', 'trial', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'and', 'biological', 'effect', 'of', 'LAM-002A', 'in', 'adults', 'with', 'C9ORF72', '-', 'associated', 'ALS', '(', 'C9ALS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05163886,NCT05163886,"A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis | This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).","[(83, 91, 'DRUG', 'LAM-002A'), (93, 112, 'DRUG', 'Apilimod Dimesylate'), (126, 174, 'CONDITION', 'C9ORF72-Associated Amyotrophic Lateral Sclerosis'), (265, 273, 'DRUG', 'LAM-002A'), (289, 311, 'CONDITION', 'C9ORF72-associated ALS'), (313, 318, 'CONDITION', 'C9ALS')]"
"['The', 'goal', 'of', 'this', 'project', 'is', 'the', 'development', 'of', 'an', 'EEG', '-', 'cap', '(', 'min', '.', '21', 'electrodes', ')', 'with', 'user', '-', 'friendly', 'active', 'dry', 'electrodes', 'that', 'meets', 'the', 'expectations', 'of', 'the', 'users', 'regarding', 'comfort', 'and', 'esthetics', ',', 'without', 'losing', 'sight', 'of', 'the', 'functional', 'and', 'technical', 'demands', 'for', 'recording', 'high', 'quality', 'EEG', 'signals', '.', 'The', 'purpose', 'is', 'to', 'use', 'the', 'EEG', '-', 'cap', 'to', 'investigate', 'clinical', 'neurological', 'disorders', '(', 'e.g.', 'epilepsy', ')', '.', 'The', 'EEG', '-', 'cap', 'could', 'also', 'be', 'used', 'at', 'home', 'so', 'that', 'hospital', 'admission', 'in', 'the', 'EMU', 'can', 'be', 'avoided', 'for', 'some', 'patients', 'and', 'an', 'increasing', 'number', 'of', 'patients', 'can', 'be', 'examined', '.', '\n\n', 'Phase', '3', 'of', 'the', 'Project', 'will', 'be', 'divided', 'into', 'a', 'Phase', '3a', 'and', 'Phase', '3b', '.', '\n\n', 'Phase', '3a', 'of', 'the', 'project', 'will', 'comprise', 'of', 'an', 'EEG', '-', 'registration', 'with', 'the', 'different', 'types', 'of', 'electrodes', 'in', 'epilepsy', 'patients', 'with', 'prominent', 'interictal', 'epileptiform', 'discharges', '(', 'IEDs', ')', 'on', 'EEG', '.', 'For', 'each', 'epilepsy', 'patient', 'the', 'EEG', '-', 'recording', 'with', 'dry', 'electrodes', 'will', 'be', 'compared', 'to', 'the', 'EEG', '-', 'recordings', 'with', 'conventionally', 'used', 'wet', 'electrodes', '(', 'bridge', 'and', 'cup', 'electrodes', ')', '.', 'Each', 'EEG', '-', 'recording', 'will', 'take', 'approximately', '10', 'minutes', '.', '\n\n', 'Minimum', '2', '-', 'maximum', '10', 'epilepsy', 'patients', 'will', 'be', 'included', '.', '\n\n', 'There', 'will', 'be', 'an', 'visual', 'and', 'clinical', 'evaluation', 'of', 'the', 'EEG', '-', 'signals', '(', 'blinded', ')', 'and', 'a', 'technical', 'evaluation', 'of', 'the', 'EEG', '-', 'signals', '.', 'User', 'experience', 'will', 'also', 'be', 'collected', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02408627,NCT02408627,"The goal of this project is the development of an EEG-cap (min. 21 electrodes) with user-friendly active dry electrodes that meets the expectations of the users regarding comfort and esthetics, without losing sight of the functional and technical demands for recording high quality EEG signals. The purpose is to use the EEG-cap to investigate clinical neurological disorders (e.g. epilepsy). The EEG-cap could also be used at home so that hospital admission in the EMU can be avoided for some patients and an increasing number of patients can be examined.

Phase 3 of the Project will be divided into a Phase 3a and Phase 3b.

Phase 3a of the project will comprise of an EEG-registration with the different types of electrodes in epilepsy patients with prominent interictal epileptiform discharges (IEDs) on EEG. For each epilepsy patient the EEG-recording with dry electrodes will be compared to the EEG-recordings with conventionally used wet electrodes (bridge and cup electrodes). Each EEG-recording will take approximately 10 minutes.

Minimum 2 - maximum 10 epilepsy patients will be included.

There will be an visual and clinical evaluation of the EEG-signals (blinded) and a technical evaluation of the EEG-signals. User experience will also be collected.","[(382, 390, 'CONDITION', 'epilepsy'), (731, 739, 'CONDITION', 'epilepsy'), (823, 831, 'CONDITION', 'epilepsy'), (1065, 1073, 'CONDITION', 'epilepsy')]"
"['PET', 'Imaging', 'of', 'Peripheral', 'Benzodiazepine', 'Receptors', 'in', 'Patients', 'With', 'Neurocysticercosis', 'Using', '[', 'F-18]FBR', '|', 'The', 'purpose', 'of', 'this', 'protocol', 'is', 'to', 'measure', 'peripheral', 'benzodiazepine', 'receptors', 'in', 'the', 'brain', 'using', 'positron', 'emission', 'tomography', '(', 'PET', ')', 'and', 'compare', 'the', 'imaging', 'results', 'between', 'patients', 'and', 'healthy', 'people', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00527579,NCT00527579,PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR | The purpose of this protocol is to measure peripheral benzodiazepine receptors in the brain using positron emission tomography (PET) and compare the imaging results between patients and healthy people.,"[(68, 86, 'CONDITION', 'Neurocysticercosis')]"
"['Memory', 'Consolidation', 'in', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'overarching', 'goal', 'of', 'the', 'research', 'proposed', 'here', 'is', 'to', 'test', 'the', 'hypothesis', '(', 'i', ')', 'that', 'the', 'pathophysiological', 'mechanisms', 'of', 'OSA', 'lead', 'to', 'deterioration', 'in', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'across', 'memory', 'systems', ',', 'with', 'the', 'genetic', 'marker', 'APOε4', 'as', 'a', 'modulator', ',', 'and', '(', 'ii', ')', 'that', 'CPAP', 'can', 'reverse', 'some', 'or', 'all', 'of', 'these', 'measured', 'memory', 'deficits', '.', '\n\n', 'In', 'addition', ',', 'we', 'are', 'exploring', 'which', 'aspects', 'of', 'OSA', '(', 'e.g.', ',', 'changes', 'in', 'sleep', 'architecture', ',', 'measures', 'of', 'hypoxemia', ',', 'or', 'the', 'EEG', 'power', 'spectrum', ')', 'most', 'likely', 'impact', 'sleep', '-', 'dependent', 'memory', 'processing', '.', 'To', 'this', 'end', ',', 'we', 'are', 'using', 'specific', 'cognitive', 'tasks', 'for', 'which', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'processes', 'have', 'previously', 'been', 'demonstrated', 'by', 'our', 'group', 'and', 'others', '.', 'In', 'addition', ',', 'we', 'are', 'carrying', 'out', 'quantitative', 'EEG', 'power', 'spectral', 'analyses', ',', 'to', 'delineate', 'abnormal', 'functioning', 'of', 'brain', 'regions', 'with', 'more', 'precision', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01800786,NCT01800786,"Memory Consolidation in Obstructive Sleep Apnea | The overarching goal of the research proposed here is to test the hypothesis (i) that the pathophysiological mechanisms of OSA lead to deterioration in sleep-dependent memory consolidation across memory systems, with the genetic marker APOε4 as a modulator, and (ii) that CPAP can reverse some or all of these measured memory deficits.

In addition, we are exploring which aspects of OSA (e.g., changes in sleep architecture, measures of hypoxemia, or the EEG power spectrum) most likely impact sleep-dependent memory processing.To this end, we are using specific cognitive tasks for which sleep-dependent memory consolidation processes have previously been demonstrated by our group and others. In addition, we are carrying out quantitative EEG power spectral analyses, to delineate abnormal functioning of brain regions with more precision.","[(24, 47, 'CONDITION', 'Obstructive Sleep Apnea'), (173, 176, 'CONDITION', 'OSA'), (322, 326, 'OTHER', 'CPAP'), (434, 437, 'CONDITION', 'OSA')]"
"['Evaluating', 'a', 'Caregiver', 'SMS', 'Reminder', 'Intervention', 'to', 'Reduce', 'Immunization', 'Drop', '-', 'out', 'in', 'Arua', ',', 'Uganda', '-', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Faced', 'with', 'high', 'rates', 'of', 'immunization', 'drop', '-', 'out', ',', 'Uganda', ""'s"", 'immunization', 'program', 'requires', 'innovative', 'approaches', 'to', 'address', 'this', 'weakness', '.', 'Building', 'upon', 'Uganda', ""'s"", 'growing', 'mHealth', 'infrastructure', 'to', 'pilot', 'a', 'scalable', 'short', 'message', 'service', '(', 'SMS', ')', 'system', 'to', 'remind', 'caregivers', 'of', 'their', 'children', ""'s"", 'upcoming', 'vaccination', 'visits', ',', 'it', 'was', 'hypothesized', 'that', 'the', 'SMS', 'intervention', 'will', 'increase', 'immunization', 'coverage', 'in', 'a', 'cost', '-', 'effective', 'and', 'affordable', 'manner', 'that', 'would', 'make', 'it', 'scalable', '.', 'The', 'study', 'design', 'was', 'an', 'investigator', '-', 'blinded', ',', 'multi', '-', 'center', ',', 'parallel', 'groups', 'randomized', 'controlled', 'trial', 'with', 'randomization', 'occurring', 'at', 'the', 'caregiver', 'level', 'in', 'select', 'health', 'facilities', 'of', 'Arua', 'District', 'in', 'Uganda', '.', 'Enrollment', 'took', 'place', 'at', 'the', 'time', 'of', 'Pentavalent', '1', 'vaccination', ',', 'and', 'both', 'arms', 'included', 'standard', 'of', 'care', 'provided', 'by', 'the', 'health', 'worker', '.', 'However', ',', 'in', 'the', 'intervention', 'arm', ',', 'caregivers', 'also', 'received', 'SMS', 'text', 'messages', 'reminding', 'them', 'to', 'return', 'for', 'their', 'children', ""'s"", 'second', 'and', 'third', 'doses', 'of', 'Pentavalent', 'vaccine', '(', 'four', 'and', 'eight', 'weeks', 'after', 'the', 'first', 'dose', 'of', 'Pentavalent', 'vaccine', ')', 'and', 'measles', '-', 'containing', 'vaccine', '(', '9', 'months', 'of', 'age', ')', '.', 'The', 'primary', 'outcome', 'of', 'interest', 'is', 'vaccination', 'coverage', 'at', '12', 'months', 'of', 'age', 'among', 'children', 'enrolled', 'in', 'the', 'study', 'and', 'will', 'be', 'measured', 'by', 'comparing', 'Penta3', 'and', 'MCV', 'coverage', 'between', 'arms', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'SMS', 'impact', 'on', 'timeliness', 'of', 'vaccine', 'receipt', ',', 'as', 'it', 'is', 'hypothesized', 'that', 'those', 'children', 'receiving', 'the', 'SMS', 'intervention', 'will', 'be', 'more', 'likely', 'to', 'have', 'timely', 'vaccination', 'than', 'those', 'in', 'the', 'control', 'group', '.', 'The', 'study', 'will', 'also', 'assess', 'caregiver', 'acceptability', 'and', 'cost', '-', 'effectiveness', 'of', 'the', 'SMS', 'intervention', '.', 'In', 'addition', 'to', 'assessing', 'its', 'impact', 'on', 'strengthening', 'the', 'immunization', 'program', ',', 'this', 'intervention', 'has', 'implications', 'for', 'strengthening', 'other', 'programs', 'of', 'the', 'health', 'system', 'through', 'similar', 'health', 'messaging', 'directed', 'toward', 'caregivers', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04177485,NCT04177485,"Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda-a Randomized Controlled Trial | Faced with high rates of immunization drop-out, Uganda's immunization program requires innovative approaches to address this weakness. Building upon Uganda's growing mHealth infrastructure to pilot a scalable short message service (SMS) system to remind caregivers of their children's upcoming vaccination visits, it was hypothesized that the SMS intervention will increase immunization coverage in a cost-effective and affordable manner that would make it scalable. The study design was an investigator-blinded, multi-center, parallel groups randomized controlled trial with randomization occurring at the caregiver level in select health facilities of Arua District in Uganda. Enrollment took place at the time of Pentavalent 1 vaccination, and both arms included standard of care provided by the health worker. However, in the intervention arm, caregivers also received SMS text messages reminding them to return for their children's second and third doses of Pentavalent vaccine (four and eight weeks after the first dose of Pentavalent vaccine) and measles-containing vaccine (9 months of age). The primary outcome of interest is vaccination coverage at 12 months of age among children enrolled in the study and will be measured by comparing Penta3 and MCV coverage between arms. The study will also examine the SMS impact on timeliness of vaccine receipt, as it is hypothesized that those children receiving the SMS intervention will be more likely to have timely vaccination than those in the control group. The study will also assess caregiver acceptability and cost-effectiveness of the SMS intervention. In addition to assessing its impact on strengthening the immunization program, this intervention has implications for strengthening other programs of the health system through similar health messaging directed toward caregivers.","[(13, 35, 'OTHER', 'Caregiver SMS Reminder'), (329, 372, 'OTHER', 'scalable short message service (SMS) system'), (472, 488, 'OTHER', 'SMS intervention'), (1002, 1019, 'OTHER', 'SMS text messages'), (1446, 1449, 'OTHER', 'SMS'), (1547, 1563, 'OTHER', 'SMS intervention'), (1725, 1741, 'OTHER', 'SMS intervention')]"
"['Combined', 'Botulinum', 'Toxin', 'Type', 'A', 'With', 'Modified', 'Constraint', '-', 'Induced', 'Movement', 'Therapy', 'for', 'Chronic', 'Stroke', 'Patients', 'With', 'Upper', 'Extremity', 'Spasticity', '|', 'Botulinum', 'toxin', 'type', 'A', '(', 'BtxA', ')', 'injection', 'and', 'modified', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'mCIMT', ')', 'are', 'both', 'promising', 'approaches', 'to', 'enhance', 'recovery', 'after', 'stroke', '.', 'However', ',', 'the', 'combined', 'application', 'of', 'the', 'two', 'modalities', 'has', 'rarely', 'been', 'studied', '.', 'The', 'aim', 'was', 'to', 'investigate', 'whether', 'combined', 'BtxA', 'and', 'mCIMT', 'would', 'produce', 'greater', 'improvements', 'in', 'spasticity', 'and', 'upper', 'extremity', 'function', 'than', 'BtxA', 'plus', 'conventional', 'rehabilitation', 'in', 'chronic', 'stroke', 'patients', 'with', 'upper', 'extremity', 'spasticity', '.']","['O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00723866,NCT00723866,"Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity | Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT) are both promising approaches to enhance recovery after stroke. However, the combined application of the two modalities has rarely been studied. The aim was to investigate whether combined BtxA and mCIMT would produce greater improvements in spasticity and upper extremity function than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity.","[(9, 31, 'DRUG', 'Botulinum Toxin Type A'), (37, 73, 'PHYSICAL', 'Modified Constraint-Induced Movement'), (86, 100, 'CONDITION', 'Chronic Stroke'), (131, 141, 'CONDITION', 'Spasticity'), (144, 166, 'DRUG', 'Botulinum toxin type A'), (168, 172, 'DRUG', 'BtxA'), (188, 232, 'PHYSICAL', 'modified constraint-induced movement therapy'), (234, 239, 'PHYSICAL', 'mCIMT'), (297, 303, 'CONDITION', 'stroke'), (430, 434, 'DRUG', 'BtxA'), (439, 444, 'PHYSICAL', 'mCIMT'), (483, 493, 'CONDITION', 'spasticity'), (528, 532, 'DRUG', 'BtxA'), (538, 565, 'CONTROL', 'conventional rehabilitation'), (569, 583, 'CONDITION', 'chronic stroke'), (614, 624, 'CONDITION', 'spasticity')]"
"['A', 'Phase', 'III', 'Randomized', 'Trial', 'for', 'the', 'Treatment', 'of', 'Pediatric', 'High', 'Grade', 'Gliomas', 'at', 'First', 'Recurrence', 'With', 'a', 'Single', 'High', 'Dose', 'Chemotherapy', 'and', 'Autologous', 'Stem', 'Cell', 'Transplant', 'Versus', 'Three', 'Courses', 'of', 'Intermediate', 'Dose', 'Chemotherapy', 'With', 'Peripheral', 'Blood', 'Stem', 'Cell', '(', 'PBSC', ')', 'Support', '|', 'RATIONALE', ':', 'Drugs', 'used', 'in', 'chemotherapy', ',', 'such', 'as', 'carboplatin', ',', 'thiotepa', ',', 'and', 'etoposide', ',', 'work', 'in', 'different', 'ways', 'to', 'stop', 'tumor', 'cells', 'from', 'dividing', 'so', 'they', 'stop', 'growing', 'or', 'die', '.', 'Combining', 'chemotherapy', 'with', 'autologous', 'stem', 'cell', 'transplantation', 'may', 'allow', 'the', 'doctor', 'to', 'give', 'higher', 'doses', 'of', 'chemotherapy', 'drugs', 'and', 'kill', 'more', 'tumor', 'cells', '.', 'Isotretinoin', 'may', 'be', 'effective', 'in', 'preventing', 'recurrence', 'of', 'glioma', '.', 'It', 'is', 'not', 'yet', 'known', 'which', 'regimen', 'of', 'chemotherapy', 'plus', 'autologous', 'stem', 'cell', 'transplantation', 'with', 'or', 'without', 'isotretinoin', 'is', 'more', 'effective', 'in', 'treating', 'recurrent', 'high', '-', 'grade', 'glioma', '.', '\n\n', 'PURPOSE', ':', 'This', 'randomized', 'phase', 'III', 'trial', 'is', 'studying', 'high', '-', 'dose', 'chemotherapy', 'or', 'intermediate', '-', 'dose', 'chemotherapy', 'followed', 'by', 'autologous', 'stem', 'cell', 'transplantation', 'to', 'see', 'how', 'well', 'it', 'works', 'compared', 'to', 'high', '-', 'dose', 'chemotherapy', 'or', 'intermediate', '-', 'dose', 'chemotherapy', 'followed', 'by', 'autologous', 'stem', 'cell', 'transplantation', 'and', 'isotretinoin', 'in', 'treating', 'young', 'patients', 'with', 'recurrent', 'high', '-', 'grade', 'glioma', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00078988,NCT00078988,"A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support | RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Isotretinoin may be effective in preventing recurrence of glioma. It is not yet known which regimen of chemotherapy plus autologous stem cell transplantation with or without isotretinoin is more effective in treating recurrent high-grade glioma.

PURPOSE: This randomized phase III trial is studying high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation to see how well it works compared to high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation and isotretinoin in treating young patients with recurrent high-grade glioma.","[(50, 98, 'CONDITION', 'Pediatric High Grade Gliomas at First Recurrence'), (123, 135, 'OTHER', 'Chemotherapy'), (140, 171, 'SURGICAL', 'Autologous Stem Cell Transplant'), (214, 226, 'OTHER', 'Chemotherapy'), (232, 258, 'SURGICAL', 'Peripheral Blood Stem Cell'), (260, 264, 'SURGICAL', 'PBSC'), (301, 313, 'OTHER', 'chemotherapy'), (323, 334, 'DRUG', 'carboplatin'), (336, 344, 'DRUG', 'thiotepa'), (350, 359, 'DRUG', 'etoposide'), (392, 397, 'CONDITION', 'tumor'), (457, 469, 'OTHER', 'chemotherapy'), (475, 511, 'SURGICAL', 'autologous stem cell transplantation'), (557, 569, 'OTHER', 'chemotherapy'), (590, 595, 'CONDITION', 'tumor'), (603, 615, 'DRUG', 'Isotretinoin'), (661, 667, 'CONDITION', 'glioma'), (706, 718, 'OTHER', 'chemotherapy'), (724, 760, 'SURGICAL', 'autologous stem cell transplantation'), (777, 789, 'DRUG', 'isotretinoin'), (820, 847, 'CONDITION', 'recurrent high-grade glioma'), (913, 925, 'OTHER', 'chemotherapy'), (947, 959, 'OTHER', 'chemotherapy'), (972, 1008, 'SURGICAL', 'autologous stem cell transplantation'), (1056, 1068, 'OTHER', 'chemotherapy'), (1090, 1102, 'OTHER', 'chemotherapy'), (1115, 1151, 'SURGICAL', 'autologous stem cell transplantation'), (1156, 1168, 'DRUG', 'isotretinoin'), (1201, 1228, 'CONDITION', 'recurrent high-grade glioma')]"
"['Follow', '-', 'up', 'Measurement', 'of', 'Brain', 'Phosphodiesterase', '10', 'A', '(', 'PDE10A', ')', 'Enzyme', 'Levels', 'in', 'Huntington´s', 'Disease', 'Gene', 'Expansion', 'Carriers', ',', '18', 'to', '28', 'Months', 'After', 'Initial', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'Measurement', 'in', 'CHDIKI1201', '/', 'PET', '-', 'HD', '-', 'PDE10A', '(', 'NCT02061722', ')', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'measure', 'longitudinally', 'the', 'availability', 'of', 'the', 'PDE10A', 'enzyme', 'in', 'HDGECs', 'using', 'the', 'radioligand', '[', '18F]MNI-659', '.', 'The', 'study', 'will', 'be', 'a', 'follow', '-', 'up', ',', 'examining', 'HDGECs', 'from', 'the', 'CHDIKI1201', '/', 'PET', '-', 'HD', '-', 'PDE10A', '(', 'NCT02061722', ')', 'study', 'from', '18', 'to', '28', 'months', 'after', 'the', 'initial', 'PET', 'measurement', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02956148,NCT02956148,"Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington´s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722) | The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.","[(80, 124, 'CONDITION', 'Huntington´s Disease Gene Expansion Carriers')]"
"['Randomized', ',', 'Triple', '-', 'blind', ',', 'Placebo', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Individualized', 'Homeopathic', 'Remedies', 'With', 'High', 'Grade', 'of', 'Pathological', 'Similarity', 'vs', 'Conventional', 'Standardized', 'Pharmacological', 'Treatment', 'in', 'Patients', 'With', 'Migraine', '.', '|', 'Migraine', ',', 'a', 'chronic', 'and', 'often', 'lifelong', 'neurological', 'disorder', ',', 'is', 'the', 'second', 'leading', 'cause', 'of', 'years', 'lived', 'with', 'disability', 'worldwide', '.', 'To', 'reduce', 'this', 'global', 'burden', ',', 'concerted', 'efforts', 'are', 'needed', 'to', 'implement', 'and', 'improve', 'migraine', 'health', '-', 'care', 'policies', '.', 'Several', 'observational', 'studies', 'showed', 'significant', 'improvement', 'of', 'different', 'headaches', 'types', 'with', 'homeopathy', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'the', 'assessment', 'of', 'the', 'efficacy', 'of', 'Individualized', 'Homeopathic', 'Remedies', '(', 'specific', 'remedies', 'for', 'each', 'patient', ')', 'versus', 'Conventional', 'pharmacological', 'treatment', 'in', 'patients', 'with', 'migraine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O']",NCT05468801,NCT05468801,"Randomized, Triple-blind, Placebo Controlled Study to Evaluate the Efficacy of Individualized Homeopathic Remedies With High Grade of Pathological Similarity vs Conventional Standardized Pharmacological Treatment in Patients With Migraine. | Migraine, a chronic and often lifelong neurological disorder, is the second leading cause of years lived with disability worldwide. To reduce this global burden, concerted efforts are needed to implement and improve migraine health-care policies. Several observational studies showed significant improvement of different headaches types with homeopathy. The purpose of this study is the assessment of the efficacy of Individualized Homeopathic Remedies (specific remedies for each patient) versus Conventional pharmacological treatment in patients with migraine.","[(26, 33, 'CONTROL', 'Placebo'), (79, 157, 'OTHER', 'Individualized Homeopathic Remedies With High Grade of Pathological Similarity'), (161, 212, 'CONTROL', 'Conventional Standardized Pharmacological Treatment'), (230, 238, 'CONDITION', 'Migraine'), (242, 250, 'CONDITION', 'Migraine'), (458, 466, 'CONDITION', 'migraine'), (563, 572, 'CONDITION', 'headaches'), (584, 594, 'OTHER', 'homeopathy'), (659, 694, 'OTHER', 'Individualized Homeopathic Remedies'), (739, 777, 'CONTROL', 'Conventional pharmacological treatment'), (795, 803, 'CONDITION', 'migraine')]"
"['A', 'Single', '-', 'Center', 'Pharmacoeconomic', 'Pilot', 'Study', 'of', 'BOTOX', '®', '(', 'Botulinum', 'Toxin', 'Type', 'A', ')', 'for', 'the', 'Prophylactic', 'Treatment', 'of', 'Migraine', 'Headaches', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'assess', 'whether', 'subjects', 'treated', 'with', 'BOTOX', 'will', ':', '\n\n', 'have', 'a', 'decrease', 'in', 'the', 'frequency', 'and', 'intensity', 'of', 'migraine', 'headaches', '\n', 'experience', 'improvements', 'in', 'quality', 'of', 'life', '\n', 'experience', 'a', 'reduction', 'in', 'the', 'frequency', 'of', 'health', 'care', 'services', 'obtained', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00850421,NCT00850421,"A Single-Center Pharmacoeconomic Pilot Study of BOTOX® (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches | The purposes of this study are to assess whether subjects treated with BOTOX will:

have a decrease in the frequency and intensity of migraine headaches
experience improvements in quality of life
experience a reduction in the frequency of health care services obtained.","[(48, 53, 'DRUG', 'BOTOX'), (56, 78, 'DRUG', 'Botulinum Toxin Type A'), (114, 132, 'CONDITION', 'Migraine Headaches'), (206, 211, 'DRUG', 'BOTOX'), (269, 287, 'CONDITION', 'migraine headaches')]"
"['Carbon', 'Monoxide', 'Headache', 'Triggering', 'Properties', 'as', 'Well', 'as', 'Effects', 'on', 'the', 'Brain', ""'s"", 'Vessels', 'and', 'Blood', 'Flow', '|', 'Studying', 'Carbon', 'monoxide', 'effects', 'on', 'brain', 'vessels', 'in', 'healthy', 'volunteers', 'with', 'magnetic', 'resonance', 'imaging', '.']","['O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03385174,NCT03385174,Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow | Studying Carbon monoxide effects on brain vessels in healthy volunteers with magnetic resonance imaging.,"[(16, 24, 'CONDITION', 'Headache')]"
"['Mobile', 'Phones', 'in', 'Cryptogenic', 'Stroke', 'Patients', 'Bringing', 'Single', 'Lead', 'ECGs', 'to', 'Detect', 'Atrial', 'Fibrillation', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'incidence', 'of', 'detected', 'atrial', 'fibrillation', '(', 'AF', ')', 'in', 'cryptogenic', 'stroke', 'patients', 'by', 'a', 'single', 'lead', 'ECG', 'device', 'with', 'the', 'incidence', 'of', 'detected', 'AF', 'by', 'a', '7', '-', 'Day', 'Holter', 'ECG', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02507986,NCT02507986,Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation | The main objective of this study is to compare the incidence of detected atrial fibrillation (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by a 7-Day Holter ECG.,"[(17, 35, 'CONDITION', 'Cryptogenic Stroke'), (81, 100, 'CONDITION', 'Atrial Fibrillation'), (176, 195, 'CONDITION', 'atrial fibrillation'), (197, 199, 'CONDITION', 'AF'), (204, 222, 'CONDITION', 'cryptogenic stroke'), (291, 293, 'CONDITION', 'AF')]"
"['The', 'Hearing', 'for', 'Learning', 'Initiative', '-', 'a', 'Service', '-', 'enhancement', 'Model', 'of', 'Ear', 'Health', 'Facilitators', 'to', 'Address', 'the', 'Crisis', 'in', 'Ear', 'and', 'Hearing', 'Health', 'of', 'Aboriginal', 'Children', 'in', 'the', 'Northern', 'Territory', ':', 'a', 'Stepped', '-', 'wedge', 'Cluster', 'Randomised', 'Trial', '|', 'The', 'Hearing', 'for', 'Learning', 'Initiative', 'is', 'a', 'stepped', '-', 'wedge', 'cluster', 'randomised', 'controlled', 'trial', '.', 'The', 'HfLI', 'will', 'implement', 'and', 'rigorously', 'evaluate', 'an', 'innovative', 'community', '-', 'based', 'service', '-', 'enhancement', 'model', 'of', 'ear', 'and', 'hearing', 'health', ',', 'in', 'partnership', 'with', 'participating', 'communities', 'and', 'health', 'and', 'education', 'services', '.', '\n\n', 'This', 'initiative', 'will', 'address', 'the', 'following', 'research', 'question', ':', 'In', 'urban', ',', 'rural', 'and', 'remote', 'Aboriginal', 'communities', 'in', 'the', 'Northern', 'Territory', ',', 'does', 'employment', ',', 'training', 'and', 'integration', 'of', 'local', 'Ear', 'and', 'Hearing', 'Clinical', 'and', 'Education', 'Support', 'Officers', 'into', 'health', 'and', 'education', 'services', '(', 'the', 'Hearing', 'for', 'Learning', 'initiative', ')', ',', 'compared', 'to', 'current', 'practice', ',', 'increase', 'the', 'proportion', 'of', 'children', 'who', 'receive', 'an', 'ear', 'assessment', ',', 'reduce', 'the', 'prevalence', 'of', 'ear', 'and', 'hearing', 'problems', 'and', 'improve', 'education', 'outcomes', 'of', 'Aboriginal', 'and', 'Torres', 'Strait', 'Islander', 'children', ',', 'during', 'a', 'four', 'year', 'trial', 'period', '?']","['O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03916029,NCT03916029,"The Hearing for Learning Initiative - a Service-enhancement Model of Ear Health Facilitators to Address the Crisis in Ear and Hearing Health of Aboriginal Children in the Northern Territory: a Stepped-wedge Cluster Randomised Trial | The Hearing for Learning Initiative is a stepped-wedge cluster randomised controlled trial. The HfLI will implement and rigorously evaluate an innovative community-based service-enhancement model of ear and hearing health, in partnership with participating communities and health and education services.

This initiative will address the following research question: In urban, rural and remote Aboriginal communities in the Northern Territory, does employment, training and integration of local Ear and Hearing Clinical and Education Support Officers into health and education services (the Hearing for Learning initiative), compared to current practice, increase the proportion of children who receive an ear assessment, reduce the prevalence of ear and hearing problems and improve education outcomes of Aboriginal and Torres Strait Islander children, during a four year trial period?","[(4, 35, 'BEHAVIOURAL', 'Hearing for Learning Initiative'), (40, 92, 'BEHAVIOURAL', 'Service-enhancement Model of Ear Health Facilitators'), (238, 269, 'BEHAVIOURAL', 'Hearing for Learning Initiative'), (330, 334, 'BEHAVIOURAL', 'HfLI'), (388, 455, 'BEHAVIOURAL', 'community-based service-enhancement model of ear and hearing health'), (729, 784, 'BEHAVIOURAL', 'Ear and Hearing Clinical and Education Support Officers'), (871, 887, 'CONTROL', 'current practice'), (981, 1005, 'CONDITION', 'ear and hearing problems')]"
"['A', 'Phase', '1', 'Randomized', ',', '2', '-', 'way', ',', 'Crossover', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacodynamics', 'and', 'Pharmacokinetics', 'of', 'ASP6981', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'primary', 'purpose', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', '.', '\n\n', 'Also', 'primary', 'purpose', 'is', 'to', 'evaluate', 'the', 'pharmacodynamics', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', 'as', 'measured', 'by', 'cognitive', 'function', 'and', 'neurophysiological', 'biomarkers', '.', '\n\n', 'The', 'secondary', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'pharmacokinetics', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",NCT03356639,NCT03356639,"A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Patients With Schizophrenia | The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia.

Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers.

The secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.","[(122, 129, 'DRUG', 'ASP6981'), (147, 160, 'CONDITION', 'Schizophrenia'), (229, 236, 'DRUG', 'ASP6981'), (258, 271, 'CONDITION', 'schizophrenia'), (334, 341, 'DRUG', 'ASP6981'), (363, 376, 'CONDITION', 'schizophrenia'), (522, 529, 'DRUG', 'ASP6981'), (551, 564, 'CONDITION', 'schizophrenia')]"
"['A', 'Multi', '-', 'center', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', 'Group', 'Study', 'to', 'Assess', 'Tolerability', ',', 'Safety', ',', 'Pharmacokinetics', 'and', 'Effect', 'of', 'AZP2006', 'on', 'Cerebrospinal', 'Fluid', 'Biomarkers', 'in', '36', 'Patients', 'With', 'Progressive', 'Supranuclear', 'Palsy', '|', 'A', 'phase', '2', 'study', 'to', 'assess', 'tolerability', ',', 'safety', ',', 'pharmacokinetics', 'and', 'effect', 'of', 'AZP2006', 'at', 'different', 'doses', 'versus', 'placebo', 'on', 'cerebrospinal', 'fluid', 'biomarkers', 'in', '36', 'patients', 'with', 'progressive', 'supranuclear', 'palsy', '.', 'The', 'patient', 'study', 'duration', 'is', '29', 'weeks', 'including', 'a', 'washout', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04008355,NCT04008355,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.","[(42, 49, 'CONTROL', 'Placebo'), (146, 153, 'DRUG', 'AZP2006'), (208, 238, 'CONDITION', 'Progressive Supranuclear Palsy'), (320, 327, 'DRUG', 'AZP2006'), (354, 361, 'CONTROL', 'placebo'), (416, 446, 'CONDITION', 'progressive supranuclear palsy')]"
"['The', 'Effect', 'of', 'Kinesiotaping', 'on', 'Glenohumeral', 'Shoulder', 'Subluxation', 'in', 'Post', '-', 'stroke', 'Patients', '|', 'To', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'kinesiotaping', 'on', 'pain', ',', 'recovery', 'of', 'movement', 'and', 'daily', 'life', 'activities', 'in', 'Turkish', 'hemiplegic', 'patients', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04468750,NCT04468750,"The Effect of Kinesiotaping on Glenohumeral Shoulder Subluxation in Post-stroke Patients | To evaluate the effectiveness of the kinesiotaping on pain, recovery of movement and daily life activities in Turkish hemiplegic patients.","[(14, 27, 'OTHER', 'Kinesiotaping'), (31, 64, 'CONDITION', 'Glenohumeral Shoulder Subluxation'), (73, 79, 'CONDITION', 'stroke'), (128, 141, 'OTHER', 'kinesiotaping'), (145, 149, 'CONDITION', 'pain'), (209, 219, 'CONDITION', 'hemiplegic')]"
"['Combination', 'of', 'NMDA', '-', 'enhancing', 'and', 'Anti', '-', 'inflammatory', 'Treatments', 'for', 'Ultra', '-', 'resistant', 'Schizophrenia', '|', 'Previous', 'study', 'found', 'that', 'some', 'NMDA', '-', 'enhancing', 'agent', 'was', 'able', 'to', 'augment', 'efficacy', 'of', 'clozapine', 'for', 'clinical', 'symptoms', 'but', 'not', 'cognitive', 'function', 'in', 'the', 'treatment', 'of', 'ultra', '-', 'resistant', 'schizophrenia', '.', 'In', 'addition', ',', 'several', 'drugs', 'with', 'anti', '-', 'inflammatory', 'properties', 'have', 'been', 'tested', 'in', 'clinical', 'trials', 'for', 'the', 'treatment', 'of', 'schizophrenia', '.', 'Whether', 'a', 'drug', 'with', 'anti', '-', 'inflammatory', 'property', 'can', 'strengthen', 'the', 'efficacy', 'of', 'an', 'NMDA', '-', 'enhancer', '(', 'NMDAE', ')', 'in', 'the', 'treatment', 'of', 'ultra', '-', 'resistant', 'schizophrenia', 'remains', 'unknown', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O']",NCT05240976,NCT05240976,"Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia | Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.","[(15, 62, 'OTHER', 'NMDA-enhancing and Anti-inflammatory Treatments'), (67, 96, 'CONDITION', 'Ultra-resistant Schizophrenia'), (130, 150, 'OTHER', 'NMDA-enhancing agent'), (183, 192, 'DRUG', 'clozapine'), (262, 291, 'CONDITION', 'ultra-resistant schizophrenia'), (314, 353, 'OTHER', 'drugs with anti-inflammatory properties'), (411, 424, 'CONDITION', 'schizophrenia'), (436, 472, 'OTHER', 'drug with anti-inflammatory property'), (507, 520, 'OTHER', 'NMDA-enhancer'), (522, 527, 'OTHER', 'NMDAE'), (549, 578, 'CONDITION', 'ultra-resistant schizophrenia')]"
"['Stereotactic', 'Body', 'Radiotherapy', '(', 'SBRT', ')', 'Boost', 'Following', 'Urgent', '3D', 'Conformal', 'Radiotherapy', 'in', 'the', 'Treatment', 'of', 'Metastatic', 'Epidural', 'Spinal', 'Cord', 'Compression', '(', 'SCC', '):', 'A', 'Phase', 'I', 'Feasibility', 'Trial', '|', 'Spinal', 'cord', 'compression', '(', 'SCC', ')', 'is', 'a', 'devastating', 'complication', 'of', 'advanced', 'malignancy', ',', 'and', 'can', 'cause', 'significant', 'deterioration', 'in', 'function', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', '.', 'The', 'goal', 'of', 'treatment', 'is', 'to', 'improve', 'functional', 'status', 'and', 'symptoms', ',', 'but', 'the', 'optimal', 'treatment', 'regimen', 'for', 'these', 'patients', 'has', 'not', 'been', 'thoroughly', 'established', '.', 'Many', 'patients', 'with', 'SCC', 'present', 'with', 'uncontrolled', 'systemic', 'disease', 'and', 'poor', 'performance', 'status', ',', 'and', 'are', 'not', 'eligible', 'for', 'standard', 'surgical', 'resection', '.', 'They', 'are', 'generally', 'treated', 'with', '3D', 'conformal', 'palliative', 'RT', '(', '3DCRT', ')', 'alone', ',', 'however', 'recent', 'trials', 'suggest', 'that', 'less', 'than', '70', '%', 'of', 'patients', 'are', 'ambulatory', ',', 'that', 'the', 're', '-', 'establishment', 'of', 'ambulation', 'in', 'non', '-', 'ambulatory', 'patients', 'is', 'poor', ',', 'and', 'the', 'duration', 'of', 'improvement', 'is', 'guarded', 'with', 'radiotherapy', 'alone', '.', '\n\n', 'Recently', ',', 'stereotactic', 'body', 'radiotherapy', '(', 'SBRT', ')', 'used', 'alone', 'or', 'after', 'previous', 'radiotherapy', 'to', 'treat', 'spinal', 'metastasis', 'has', 'demonstrated', 'superior', 'results', 'in', 'pain', 'control', ',', 'tumour', 'response', 'and', 'durability', '.', 'SBRT', 'requires', 'time', 'for', 'careful', 'planning', ',', 'and', 'many', 'patients', 'with', 'neurologic', 'symptoms', 'must', 'be', 'treated', 'immediately', 'to', 'prevent', 'progression', '.', 'Therefore', 'the', 'role', 'of', 'SBRT', 'is', 'still', 'unclear', 'in', 'this', 'patient', 'population', ',', 'although', 'it', 'seems', 'to', 'be', 'a', 'potential', 'alternative', 'to', 'surgical', 'decompression', 'in', 'patient', 'not', 'suitable', 'for', 'surgery', '.', 'The', 'investigators', 'propose', 'a', 'feasibility', 'study', 'to', 'investigate', 'the', 'potential', 'benefits', 'of', 'dose', 'escalation', 'with', 'a', 'sequential', 'SBRT', 'boost', 'to', 'urgent', '3D', 'CRT', 'in', 'the', 'setting', 'of', 'SCC', '.', 'This', 'regimen', 'will', 'allow', 'inoperable', 'patients', 'to', 'receive', 'urgent', '3DCRT', 'while', 'simultaneously', 'creating', 'the', 'opportunity', 'for', 'superior', 'outcomes', 'with', 'SBRT', '.', 'The', 'investigators', 'also', 'aim', 'to', 'characterize', 'the', 'effect', 'on', 'motor', 'function', 'and', 'ambulation', ',', 'pain', 'and', 'QoL.', 'This', 'study', 'could', 'stimulate', 'further', 'multi', '-', 'center', 'randomized', 'trials', 'in', 'this', 'area', ',', 'improve', 'motor', 'function', 'and', 'patient', '-', 'reported', 'QoL', ',', 'and', 'contribute', 'to', 'improving', 'oncology', 'care', 'in', 'Canada', 'in', 'a', 'meaningful', 'way', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03529708,NCT03529708,"Stereotactic Body Radiotherapy (SBRT) Boost Following Urgent 3D Conformal Radiotherapy in the Treatment of Metastatic Epidural Spinal Cord Compression (SCC): A Phase I Feasibility Trial | Spinal cord compression (SCC) is a devastating complication of advanced malignancy, and can cause significant deterioration in function and quality of life (QoL). The goal of treatment is to improve functional status and symptoms, but the optimal treatment regimen for these patients has not been thoroughly established. Many patients with SCC present with uncontrolled systemic disease and poor performance status, and are not eligible for standard surgical resection. They are generally treated with 3D conformal palliative RT (3DCRT) alone, however recent trials suggest that less than 70% of patients are ambulatory, that the re-establishment of ambulation in non-ambulatory patients is poor, and the duration of improvement is guarded with radiotherapy alone.

Recently, stereotactic body radiotherapy (SBRT) used alone or after previous radiotherapy to treat spinal metastasis has demonstrated superior results in pain control, tumour response and durability. SBRT requires time for careful planning, and many patients with neurologic symptoms must be treated immediately to prevent progression. Therefore the role of SBRT is still unclear in this patient population, although it seems to be a potential alternative to surgical decompression in patient not suitable for surgery. The investigators propose a feasibility study to investigate the potential benefits of dose escalation with a sequential SBRT boost to urgent 3D CRT in the setting of SCC. This regimen will allow inoperable patients to receive urgent 3DCRT while simultaneously creating the opportunity for superior outcomes with SBRT. The investigators also aim to characterize the effect on motor function and ambulation, pain and QoL. This study could stimulate further multi-center randomized trials in this area, improve motor function and patient-reported QoL, and contribute to improving oncology care in Canada in a meaningful way.","[(0, 30, 'RADIOTHERAPY', 'Stereotactic Body Radiotherapy'), (32, 36, 'RADIOTHERAPY', 'SBRT'), (61, 86, 'RADIOTHERAPY', '3D Conformal Radiotherapy'), (107, 150, 'CONDITION', 'Metastatic Epidural Spinal Cord Compression'), (152, 155, 'CONDITION', 'SCC'), (188, 211, 'CONDITION', 'Spinal cord compression'), (213, 216, 'CONDITION', 'SCC'), (528, 531, 'CONDITION', 'SCC'), (690, 716, 'RADIOTHERAPY', '3D conformal palliative RT'), (718, 723, 'RADIOTHERAPY', '3DCRT'), (933, 945, 'RADIOTHERAPY', 'radiotherapy'), (964, 994, 'RADIOTHERAPY', 'stereotactic body radiotherapy'), (996, 1000, 'RADIOTHERAPY', 'SBRT'), (1031, 1043, 'RADIOTHERAPY', 'radiotherapy'), (1053, 1070, 'CONDITION', 'spinal metastasis'), (1108, 1112, 'CONDITION', 'pain'), (1122, 1128, 'CONDITION', 'tumour'), (1154, 1158, 'RADIOTHERAPY', 'SBRT'), (1312, 1316, 'RADIOTHERAPY', 'SBRT'), (1594, 1598, 'RADIOTHERAPY', 'SBRT'), (1615, 1621, 'RADIOTHERAPY', '3D CRT'), (1640, 1643, 'CONDITION', 'SCC'), (1707, 1712, 'RADIOTHERAPY', '3DCRT'), (1786, 1790, 'RADIOTHERAPY', 'SBRT'), (1880, 1884, 'CONDITION', 'pain')]"
"['A', 'Blind', '-', 'adjudication', 'Multi', '-', 'center', 'Phase', 'II', 'Randomized', 'Clinical', 'Trial', 'of', 'Continuous', 'Low', '-', 'dose', 'Intravenous', 'Heparin', 'Therapy', 'in', 'Coiled', 'Low', '-', 'grade', 'Aneurysmal', 'Subarachnoid', 'Hemorrhage', 'Patients', 'With', 'Significant', 'Hemorrhage', 'Burden', '|', 'A', 'Blind', '-', 'adjudication', 'Multi', '-', 'center', 'Phase', 'II', 'Randomized', 'Clinical', 'Trial', 'of', 'Continuous', 'Low', '-', 'dose', 'Intravenous', 'Heparin', 'Therapy', 'in', 'Coiled', 'Low', '-', 'grade', 'Aneurysmal', 'Subarachnoid', 'Hemorrhage', 'Patients', 'with', 'Significant', 'Hemorrhage', 'Burden', '.', '-', 'STUDY', 'IS', 'TEMPORARILY', 'SUSPENDED', 'WITH', 'PLAN', 'TO', 'RESUME', 'SOON', '.', 'NO', 'SAFETY', 'CONCERNS']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02501434,NCT02501434,A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden | A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden. - STUDY IS TEMPORARILY SUSPENDED WITH PLAN TO RESUME SOON. NO SAFETY CONCERNS,"[(104, 111, 'DRUG', 'Heparin'), (123, 174, 'CONDITION', 'Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage'), (189, 218, 'CONDITION', 'Significant Hemorrhage Burden'), (325, 332, 'DRUG', 'Heparin'), (344, 395, 'CONDITION', 'Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage'), (410, 439, 'CONDITION', 'Significant Hemorrhage Burden')]"
"['Bioequivalence', 'Study', 'Between', 'Two', 'Medications', 'for', 'Administration', 'of', 'Oral', 'Gabapentin', 'in', '300', 'mg', 'Capsules', 'in', 'Healthy', 'Volunteers', '|', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'confirm', 'if', 'two', 'formulations', 'of', 'gabapentin', '(', 'capsules', ')', 'are', 'bioequivalent', '.', '\n\n', 'Test', 'product', 'was', 'Darbetin', '®', '300', 'mg', '(', 'Laboratorios', 'Dermatológicos', 'Darier', ')', 'and', 'reference', 'product', 'Nerotin', '®', '300', 'mg', '(', 'Pfizer', ')', '.', 'One', 'capsule', 'was', 'the', 'single', 'dosage', '.', '\n\n', 'The', 'study', 'was', 'prospective', ',', 'open', '-', 'label', ',', 'randomized', ',', 'crossover', ',', 'single', 'dose', ',', 'with', '02', 'treatments', ',', '02', 'sequences', 'and', '02', 'periods', ',', 'under', 'fasting', 'conditions', '.', '\n\n', 'The', 'population', 'was', 'composed', 'of', '26', 'healthy', 'volunteers', ',', 'both', 'genders', ',', 'adults', 'between', '18', '-', '55', 'years', '.', '\n\n', 'The', 'comparative', 'bioavailability', 'of', 'the', 'two', 'formulations', 'was', 'evaluated', 'based', 'in', 'statistical', 'comparisons', 'of', 'relevant', 'pharmacokinetic', 'parameters', ',', 'obtained', 'from', 'data', 'of', 'drug', 'concentrations', 'in', 'blood', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01738893,NCT01738893,"Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers | The objective of this study was to confirm if two formulations of gabapentin (capsules) are bioequivalent.

Test product was Darbetin® 300 mg (Laboratorios Dermatológicos Darier) and reference product Nerotin® 300 mg (Pfizer). One capsule was the single dosage.

The study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.

The population was composed of 26 healthy volunteers, both genders, adults between 18-55 years.

The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.","[(72, 82, 'DRUG', 'Gabapentin'), (192, 202, 'DRUG', 'gabapentin'), (251, 259, 'DRUG', 'Darbetin'), (327, 334, 'DRUG', 'Nerotin')]"
"['Physical', 'Exercise', 'in', 'Subjects', 'With', 'Juvenile', 'Myoclonic', 'Epilepsy', 'Aged', '15', '-', '50', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'Epilepsy', 'is', 'a', 'chronic', 'neurologic', 'disorder', 'characterized', 'by', 'seizures', '.', 'Beside', 'seizures', 'people', 'suffering', 'from', 'epilepsy', 'experience', 'several', 'challenges', 'related', 'to', 'education', ',', 'work', 'and', 'everyday', 'life', 'such', 'as', 'learning-', ',', 'problem', '-', 'solving-', ',', 'memory-', ',', 'concentration-', ',', 'attention', 'difficulties', 'and', 'fatigue', '.', '\n\n', 'It', 'is', 'generally', 'approved', 'that', 'physical', 'activity', '(', 'PA', ')', 'has', 'a', 'positive', 'effect', 'on', 'physical', 'as', 'well', 'as', 'mental', 'factors', '.', 'However', ',', 'people', 'with', 'epilepsy', 'are', 'found', 'to', 'be', 'less', 'active', 'and', 'PA', 'is', 'rarely', 'offered', 'or', 'recommended', 'as', 'supplement', 'to', 'anti', '-', 'epileptic', 'medical', 'treatment', '.', 'Few', 'studies', 'have', 'investigated', 'the', 'effect', 'of', 'PA', 'in', 'subjects', 'with', 'epilepsy', 'and', 'additional', 'studies', 'of', 'high', 'methodical', 'quality', 'are', 'needed', 'to', 'enable', 'evidence', '-', 'based', 'information', 'and', 'counselling', '.', '\n\n', 'This', 'study', 'is', 'carried', 'through', 'as', 'a', 'randomized', 'controlled', 'trial', 'which', 'investigates', 'the', 'effect', 'of', 'participation', 'in', 'a', '10', '-', 'week', 'cardio', 'exercise', 'program', 'in', 'people', 'with', 'Juvenile', 'Myoclonic', 'Epilepsy', 'aged', '15', '-', '50', '.', '\n\n', 'The', 'study', 'hypothesis', 'is', 'that', 'participation', 'in', 'a', '10', '-', 'week', 'cardio', 'exercise', 'program', 'will', 'induce', 'a', 'positive', 'change', 'in', 'cognitive', 'function', '(', 'concentration', 'and', 'attention', ')', 'and', 'possibly', 'in', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'BDNF', ')', '.', 'In', 'addition', 'it', 'is', 'expected', 'that', 'the', 'intensity', 'and', 'duration', 'of', 'the', '10', '-', 'week', 'cardio', 'exercise', 'program', 'is', 'sufficient', 'to', 'cause', 'changes', 'in', 'physiological', 'parameters', 'related', 'to', 'a', 'reduced', 'risk', 'of', 'lifestyle', 'diseases', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01450423,NCT01450423,"Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial | Epilepsy is a chronic neurologic disorder characterized by seizures. Beside seizures people suffering from epilepsy experience several challenges related to education, work and everyday life such as learning-, problem-solving-, memory-, concentration-, attention difficulties and fatigue.

It is generally approved that physical activity (PA) has a positive effect on physical as well as mental factors. However, people with epilepsy are found to be less active and PA is rarely offered or recommended as supplement to anti-epileptic medical treatment. Few studies have investigated the effect of PA in subjects with epilepsy and additional studies of high methodical quality are needed to enable evidence-based information and counselling.

This study is carried through as a randomized controlled trial which investigates the effect of participation in a 10-week cardio exercise program in people with Juvenile Myoclonic Epilepsy aged 15-50.

The study hypothesis is that participation in a 10-week cardio exercise program will induce a positive change in cognitive function (concentration and attention) and possibly in brain-derived neurotrophic factor (BDNF). In addition it is expected that the intensity and duration of the 10-week cardio exercise program is sufficient to cause changes in physiological parameters related to a reduced risk of lifestyle diseases.","[(0, 17, 'PHYSICAL', 'Physical Exercise'), (35, 62, 'CONDITION', 'Juvenile Myoclonic Epilepsy'), (107, 115, 'CONDITION', 'Epilepsy'), (166, 174, 'CONDITION', 'seizures'), (183, 191, 'CONDITION', 'seizures'), (214, 222, 'CONDITION', 'epilepsy'), (427, 444, 'PHYSICAL', 'physical activity'), (446, 448, 'PHYSICAL', 'PA'), (532, 540, 'CONDITION', 'epilepsy'), (573, 575, 'PHYSICAL', 'PA'), (704, 706, 'PHYSICAL', 'PA'), (724, 732, 'CONDITION', 'epilepsy'), (972, 995, 'PHYSICAL', 'cardio exercise program'), (1011, 1038, 'CONDITION', 'Juvenile Myoclonic Epilepsy'), (1108, 1131, 'PHYSICAL', 'cardio exercise program'), (1346, 1369, 'PHYSICAL', 'cardio exercise program')]"
"['Translating', 'a', 'Dementia', 'Caregiver', 'Intervention', 'Into', 'a', 'Mobile', 'Application', '|', 'The', 'overall', 'goal', 'of', 'this', 'development', 'project', 'is', 'to', 'combine', 'elements', 'of', 'two', 'efficacious', 'interventions', 'into', 'a', 'mobile', 'health', '(', 'mHealth', ')', 'App', 'for', 'informal', 'dementia', 'caregivers', '.', 'The', 'investigators', 'will', 'conduct', 'a', '3', '-', 'month', 'feasibility', 'trial', 'of', 'the', 'newly', '-', 'developed', 'CARE', '-', 'Well', 'App', 'in', '40', 'dementia', 'caregivers', 'to', 'establish', 'acceptability', 'and', 'feasibility', 'of', 'the', 'intervention', ',', 'study', 'procedures', ',', 'and', 'outcome', 'measures', '.']","['O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04330482,NCT04330482,"Translating a Dementia Caregiver Intervention Into a Mobile Application | The overall goal of this development project is to combine elements of two efficacious interventions into a mobile health (mHealth) App for informal dementia caregivers. The investigators will conduct a 3-month feasibility trial of the newly-developed CARE-Well App in 40 dementia caregivers to establish acceptability and feasibility of the intervention, study procedures, and outcome measures.","[(14, 22, 'CONDITION', 'Dementia'), (53, 71, 'OTHER', 'Mobile Application'), (182, 209, 'OTHER', 'mobile health (mHealth) App'), (223, 231, 'CONDITION', 'dementia'), (326, 339, 'OTHER', 'CARE-Well App'), (346, 354, 'CONDITION', 'dementia')]"
"['Evaluation', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'PRJ212', 'on', 'Improving', 'the', 'Memory', 'of', 'Patients', 'With', 'Mild', 'Severity', 'Alzheimer', ""'s"", 'Disease', ':', 'A', '6', '-', 'month', 'Randomized', ',', 'Double', '-', 'blind', 'and', 'Placebo', '-', 'controlled', ',', 'Followed', 'by', 'a', '6', '-', 'month', 'Open', 'Label', 'Extension', 'Study', '|', 'A', '6', '-', 'month', 'randomized', ',', 'double', '-', 'blind', 'and', 'placebo', '-', 'controlled', ',', 'followed', 'by', 'a', '6', '-', 'month', 'open', 'label', 'extension', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02991235,NCT02991235,"Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study | A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.","[(41, 47, 'DRUG', 'PRJ212'), (89, 122, 'CONDITION', ""Mild Severity Alzheimer's Disease""), (163, 170, 'CONTROL', 'Placebo'), (273, 280, 'CONTROL', 'placebo')]"
"['The', 'Effect', 'of', 'Oral', 'Vitamin', 'B12', 'Supplementation', 'on', 'Cognitive', 'Performance', 'in', 'Elderly', 'People', ':', 'the', 'Brain12', 'Study', '|', 'The', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'study', 'the', 'effects', 'of', 'oral', 'vitamin', 'B12', 'supplementation', 'and', 'vitamin', 'B12', 'combined', 'with', 'folic', 'acid', 'supplementation', 'on', 'cognitive', 'performance', 'for', '24', 'weeks', 'in', 'elderly', 'people', 'with', 'mild', 'vitamin', 'B12', 'deficiency', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00111267,NCT00111267,The Effect of Oral Vitamin B12 Supplementation on Cognitive Performance in Elderly People: the Brain12 Study | The purpose of this trial is to study the effects of oral vitamin B12 supplementation and vitamin B12 combined with folic acid supplementation on cognitive performance for 24 weeks in elderly people with mild vitamin B12 deficiency.,"[(19, 30, 'DRUG', 'Vitamin B12'), (169, 180, 'DRUG', 'vitamin B12'), (201, 212, 'DRUG', 'vitamin B12'), (227, 237, 'DRUG', 'folic acid'), (315, 342, 'CONDITION', 'mild vitamin B12 deficiency')]"
"['Effect', 'of', 'Increased', 'Body', 'Mass', 'Index', 'on', 'Auditory', 'Function', '|', 'Obesity', 'may', 'directly', 'or', 'indirectly', 'lead', 'to', 'hearing', 'loss']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT03172663,NCT03172663,Effect of Increased Body Mass Index on Auditory Function | Obesity may directly or indirectly lead to hearing loss,"[(10, 35, 'CONDITION', 'Increased Body Mass Index'), (59, 66, 'CONDITION', 'Obesity'), (102, 114, 'CONDITION', 'hearing loss')]"
"['The', 'Effect', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'on', 'Depression', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Depression', 'is', 'common', 'in', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', ',', 'but', 'the', 'effective', 'treatment', 'is', 'not', 'established', 'yet', '.', 'tDCS', 'is', 'a', 'non', '-', 'invasive', 'brain', 'stimulation', 'to', 'modulate', 'brain', 'function', '.', 'The', 'tDCS', 'on', 'the', 'depression', 'in', 'general', 'population', 'were', 'already', 'conducted', ',', 'but', 'not', 'in', 'PD', '.', 'This', 'study', 'is', 'to', 'know', 'whether', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'is', 'effective', 'for', 'the', 'treatment', 'of', 'depression', 'in', 'PD', '.', 'Participant', 'will', 'be', 'asked', 'to', 'visit', 'three', 'consecutive', 'days', 'for', 'the', 'non', '-', 'invasive', 'stimulation', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03227783,NCT03227783,"The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease | Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.","[(14, 53, 'OTHER', 'Transcranial Direct Current Stimulation'), (55, 59, 'OTHER', 'tDCS'), (64, 74, 'CONDITION', 'Depression'), (78, 97, 'CONDITION', ""Parkinson's Disease""), (100, 110, 'CONDITION', 'Depression'), (124, 143, 'CONDITION', ""Parkinson's disease""), (145, 147, 'CONDITION', 'PD'), (202, 206, 'OTHER', 'tDCS'), (275, 279, 'OTHER', 'tDCS'), (287, 297, 'CONDITION', 'depression'), (355, 357, 'CONDITION', 'PD'), (389, 428, 'OTHER', 'transcranial direct current stimulation'), (430, 434, 'OTHER', 'tDCS'), (470, 480, 'CONDITION', 'depression'), (484, 486, 'CONDITION', 'PD')]"
"['12', 'Month', 'Open', '-', 'Label', 'Extension', 'Study', 'of', 'the', 'Effect', 'of', 'Alendronate', 'on', 'Bone', 'in', 'People', 'With', 'Chronic', 'SCI', 'Previously', 'Treated', 'With', 'Teriparatide', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'a', 'year', 'of', 'alendronate', 'treatment', 'will', 'maintain', 'or', 'increase', 'bone', 'mass', 'density', '(', 'BMD', ')', 'compared', 'to', 'baseline', 'BMD', 'values', 'in', 'people', 'with', 'chronic', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', '\n\n', 'This', 'study', 'will', 'also', 'investigate', '1', ')', 'if', 'alendronate', 'therapy', 'will', 'increase', 'bone', 'strength', 'in', 'people', 'with', 'chronic', 'SCI', ',', '2', ')', 'the', 'number', 'of', 'participants', 'with', 'adverse', 'events', 'from', 'alendronate', ',', 'and', '3', ')', 'the', 'effects', 'of', 'alendronate', 'on', 'serum', 'markers', 'of', 'bone', 'metabolism', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02195895,NCT02195895,"12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide | The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).

This study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.","[(53, 64, 'DRUG', 'Alendronate'), (88, 99, 'CONDITION', 'Chronic SCI'), (124, 136, 'DRUG', 'Teriparatide'), (194, 205, 'DRUG', 'alendronate'), (313, 339, 'CONDITION', 'chronic spinal cord injury'), (341, 344, 'CONDITION', 'SCI'), (387, 398, 'DRUG', 'alendronate'), (450, 461, 'CONDITION', 'chronic SCI'), (518, 529, 'DRUG', 'alendronate'), (553, 564, 'DRUG', 'alendronate')]"
"['Patient', 'Reported', 'Outcomes', 'Following', 'Interventional', 'Procedures', 'in', 'Pelvic', 'Pain', '|', 'The', 'investigators', 'aim', 'from', 'this', 'study', ',', 'to', 'determine', 'the', 'safety', 'and', 'efficacy', 'of', 'pulsed', 'radiofrequency', 'in', 'the', 'management', 'of', 'pudendal', 'neuralgia', ',', 'compared', 'to', 'current', 'a', 'standard', 'intervention', ',', 'which', 'is', 'corticosteroid', 'injection', 'for', 'PN', ',', 'as', 'part', 'of', 'multidisciplinary', 'pain', 'management', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT05531500,NCT05531500,"Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain | The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.","[(65, 76, 'CONDITION', 'Pelvic Pain'), (158, 179, 'OTHER', 'pulsed radiofrequency'), (201, 219, 'CONDITION', 'pudendal neuralgia'), (275, 289, 'DRUG', 'corticosteroid'), (304, 306, 'CONDITION', 'PN'), (337, 341, 'CONDITION', 'pain')]"
"['Evolution', 'of', 'REM', 'Sleep', 'Behavior', 'Disorder', 'in', 'Parkinson', ""'s"", 'Disease', 'Patients', 'RBD', 'Diagnosed', 'Three', 'Years', 'Earlier', '|', 'About', '60', '%', 'of', 'Parkinson', ""'s"", 'Disease', '(', 'PD', ')', 'patients', 'have', 'REM', 'sleep', 'Behavior', 'Disorder', '(', 'RBD', ')', ',', 'a', 'parasomnia', 'characterized', 'by', 'partial', 'or', 'complete', 'loss', 'of', 'REM', 'sleep', 'muscle', 'atonia', 'and', 'dream', '-', 'enacting', 'behaviors', ',', 'usually', 'associated', 'to', 'vivid', 'dreams', '.', 'The', 'REM', 'Sleep', 'without', 'atonia', 'is', 'the', 'polysomnographic', 'hallmark', 'of', 'RBD', ',', 'and', 'its', 'quantification', 'is', 'necessary', 'for', 'the', 'diagnosis', '.', '\n\n', 'RBD', 'in', 'PD', 'is', 'believed', 'to', 'be', 'a', 'marker', 'of', 'a', 'more', 'widespread', 'degenerative', 'process', 'and', 'a', 'marker', 'of', 'malignant', 'phenotype', '.', 'Therefore', ',', 'PD', 'patients', 'with', 'RBD', '(', 'PD', '-', 'RBD', ')', 'are', 'more', 'severely', 'impaired', 'in', 'both', 'motor', 'and', 'non', '-', 'motor', 'domains', ',', 'compared', 'to', 'those', 'without', 'RBD', ',', 'with', 'an', 'increased', 'risk', 'of', 'dementia', '.', 'However', ',', 'little', 'is', 'know', 'about', 'the', 'relationship', 'between', 'the', 'evolution', 'of', 'RBD', ',', 'clinic', 'and', 'video', '-', 'polysomnographic', ',', 'and', 'the', 'progression', 'of', 'PD', '.', 'Besides', ',', 'an', 'improvement', 'of', 'RBD', 'symptoms', 'is', 'anecdotally', 'reported', 'in', 'PD', 'patients', 'over', 'time', '.', 'Longitudinal', 'evaluation', 'of', 'RBD', 'in', 'PD', ',', 'assessed', 'by', 'questionnaires', ',', 'led', 'to', 'controversial', 'results', ',', 'but', 'so', 'far', ',', 'no', 'longitudinal', 'vPSG', 'study', 'has', 'been', 'performed', 'in', 'PD', '-', 'RBD', 'population', '.', '\n\n', 'Thus', ',', 'the', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'longitudinally', 'evaluate', 'clinical', 'and', 'video', '-', 'polysomnographic', 'features', 'of', 'RBD', ',', 'including', 'measure', 'of', 'REM', 'Sleep', 'without', 'atonia', ',', 'in', 'patients', 'with', 'PD', '-', 'RBD', ',', 'after', 'three', 'years', 'from', 'the', 'diagnosis', 'of', 'RBD', ',', 'in', 'order', 'to', 'ascertain', 'whether', 'RBD', 'features', 'remain', 'stable', 'over', 'time', '.', 'The', 'possible', 'remission', 'of', 'RBD', 'with', 'the', 'progression', 'of', 'PD', 'would', 'question', 'indeed', 'its', 'reliability', 'as', 'prognostic', 'bio', '-', 'marker', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03047408,NCT03047408,"Evolution of REM Sleep Behavior Disorder in Parkinson's Disease Patients RBD Diagnosed Three Years Earlier | About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid dreams. The REM Sleep without atonia is the polysomnographic hallmark of RBD, and its quantification is necessary for the diagnosis.

RBD in PD is believed to be a marker of a more widespread degenerative process and a marker of malignant phenotype. Therefore, PD patients with RBD (PD-RBD) are more severely impaired in both motor and non-motor domains, compared to those without RBD, with an increased risk of dementia. However, little is know about the relationship between the evolution of RBD, clinic and video-polysomnographic, and the progression of PD. Besides, an improvement of RBD symptoms is anecdotally reported in PD patients over time. Longitudinal evaluation of RBD in PD, assessed by questionnaires, led to controversial results, but so far, no longitudinal vPSG study has been performed in PD-RBD population.

Thus, the main objective of this study is to longitudinally evaluate clinical and video-polysomnographic features of RBD, including measure of REM Sleep without atonia, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.","[(13, 40, 'CONDITION', 'REM Sleep Behavior Disorder'), (44, 63, 'CONDITION', ""Parkinson's Disease""), (73, 76, 'CONDITION', 'RBD'), (122, 141, 'CONDITION', ""Parkinson's Disease""), (143, 145, 'CONDITION', 'PD'), (161, 188, 'CONDITION', 'REM sleep Behavior Disorder'), (190, 193, 'CONDITION', 'RBD'), (409, 412, 'CONDITION', 'RBD'), (470, 473, 'CONDITION', 'RBD'), (477, 479, 'CONDITION', 'PD'), (597, 599, 'CONDITION', 'PD'), (614, 617, 'CONDITION', 'RBD'), (619, 625, 'CONDITION', 'PD-RBD'), (717, 720, 'CONDITION', 'RBD'), (830, 833, 'CONDITION', 'RBD'), (893, 895, 'CONDITION', 'PD'), (924, 927, 'CONDITION', 'RBD'), (964, 966, 'CONDITION', 'PD'), (1014, 1017, 'CONDITION', 'RBD'), (1021, 1023, 'CONDITION', 'PD'), (1144, 1146, 'CONDITION', 'PD'), (1147, 1150, 'CONDITION', 'RBD'), (1281, 1284, 'CONDITION', 'RBD'), (1350, 1352, 'CONDITION', 'PD'), (1353, 1356, 'CONDITION', 'RBD'), (1398, 1401, 'CONDITION', 'RBD'), (1433, 1436, 'CONDITION', 'RBD'), (1497, 1500, 'CONDITION', 'RBD'), (1525, 1527, 'CONDITION', 'PD')]"
"['Positive', 'Airway', 'Pressure', 'for', 'the', 'Treatment', 'of', 'the', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'in', 'Children', 'With', 'Down', 'Syndrome', '(', 'Stage', '1', ')', '|', 'To', 'identify', 'the', 'perceptions', ',', 'beliefs', ',', 'and', 'family', '-', 'relevant', 'outcomes', 'regarding', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', 'syndrome', '(', 'OSAS', ')', 'with', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'in', 'children', 'with', 'Down', ""'s"", 'Syndrome', '(', 'DS', ')', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04124471,NCT04124471,"Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children With Down Syndrome (Stage 1) | To identify the perceptions, beliefs, and family-relevant outcomes regarding the treatment of obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) in children with Down's Syndrome (DS).","[(0, 24, 'OTHER', 'Positive Airway Pressure'), (50, 82, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (100, 113, 'CONDITION', 'Down Syndrome'), (220, 252, 'CONDITION', 'obstructive sleep apnea syndrome'), (254, 258, 'CONDITION', 'OSAS'), (265, 289, 'OTHER', 'positive airway pressure'), (291, 294, 'OTHER', 'PAP'), (313, 328, 'CONDITION', ""Down's Syndrome""), (330, 332, 'CONDITION', 'DS')]"
"['Phase', 'I', '/', 'II', 'Study', 'of', 'Oral', 'Capecitabine', 'and', 'Temozolomide', '(', 'CAPTEM', ')', 'for', 'Newly', 'Diagnosed', 'Glioblastoma', '(', 'GBM', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'administering', 'the', 'medication', 'capecitabine', 'along', 'with', 'temozolomide', 'when', 'you', 'start', 'your', 'monthly', 'regimen', 'of', 'oral', 'temozolomide', 'for', 'the', 'treatment', 'of', 'your', 'newly', 'diagnosed', 'glioblastoma', 'multiforme', '(', 'GBM', ')', '.', '\n\n', 'Capecitabine', 'is', 'an', 'oral', 'chemotherapy', 'that', 'is', 'given', 'to', 'patients', 'with', 'other', 'types', 'of', 'cancer', '.', 'The', 'study', 'will', 'evaluate', 'whether', 'the', 'dosage', 'of', '1500', 'mg', '/', 'm2', 'of', 'capecitabine', 'is', 'tolerable', 'after', 'radiation', ',', 'when', 'taken', 'along', 'with', 'temozolomide', '.', 'It', 'will', 'also', 'try', 'to', 'determine', 'if', 'the', 'medication', 'capecitabine', 'helps', 'patients', 'respond', 'to', 'treatment', 'for', 'a', 'longer', 'period', 'of', 'time', 'compared', 'to', 'just', 'temozolomide', 'alone', ',', 'which', 'is', 'the', 'standard', 'of', 'care', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03213002,NCT03213002,"Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM) | The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM).

Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.","[(25, 37, 'DRUG', 'Capecitabine'), (42, 54, 'DRUG', 'Temozolomide'), (56, 62, 'DRUG', 'CAPTEM'), (84, 96, 'CONDITION', 'Glioblastoma'), (98, 101, 'CONDITION', 'GBM'), (202, 214, 'DRUG', 'capecitabine'), (226, 238, 'DRUG', 'temozolomide'), (283, 295, 'DRUG', 'temozolomide'), (338, 361, 'CONDITION', 'glioblastoma multiforme'), (363, 366, 'CONDITION', 'GBM'), (370, 382, 'DRUG', 'Capecitabine'), (521, 533, 'DRUG', 'capecitabine'), (553, 562, 'RADIOTHERAPY', 'radiation'), (586, 598, 'DRUG', 'temozolomide'), (648, 660, 'DRUG', 'capecitabine'), (742, 754, 'DRUG', 'temozolomide')]"
"['The', 'Effect', 'of', 'Spacing', 'of', 'Lidcombe', 'Program', 'Clinic', 'Visits', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficiency', 'of', 'the', 'Lidcombe', 'Program', 'for', 'early', 'stuttering', 'by', 'varying', 'the', 'time', 'between', 'clinic', 'visits', 'during', 'the', 'first', 'stage', 'of', 'the', 'program', '.']","['O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00680303,NCT00680303,The Effect of Spacing of Lidcombe Program Clinic Visits | The purpose of this study is to evaluate the efficiency of the Lidcombe Program for early stuttering by varying the time between clinic visits during the first stage of the program.,"[(25, 41, 'BEHAVIOURAL', 'Lidcombe Program'), (121, 137, 'BEHAVIOURAL', 'Lidcombe Program'), (142, 158, 'CONDITION', 'early stuttering')]"
"['Clinical', 'Efficacy', 'of', 'an', 'External', 'Shoe', 'Lift', 'in', 'the', 'Contralateral', 'Limb', 'to', 'Improve', 'Healing', 'and', 'Adherence', 'in', 'Patients', 'With', 'Diabetic', 'Foot', 'Ulcers', '|', 'Previous', 'researches', 'hipothesize', 'that', 'imposed', 'limb', '-', 'length', 'discrepancies', 'may', 'discourage', 'adherence', 'in', 'patients', 'with', 'active', 'diabetic', 'foot', 'ulcer', 'and', 'using', 'offloading', 'devices', '.', 'Our', 'hipothesis', 'is', 'that', 'the', 'use', 'of', 'an', 'external', 'shoe', 'lift', 'contralaterally', 'to', 'the', 'affected', 'foot', 'may', 'improve', 'adherence', 'to', 'offloading', 'devices', 'and', 'improve', 'healing', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04117269,NCT04117269,Clinical Efficacy of an External Shoe Lift in the Contralateral Limb to Improve Healing and Adherence in Patients With Diabetic Foot Ulcers | Previous researches hipothesize that imposed limb-length discrepancies may discourage adherence in patients with active diabetic foot ulcer and using offloading devices. Our hipothesis is that the use of an external shoe lift contralaterally to the affected foot may improve adherence to offloading devices and improve healing.,"[(24, 42, 'OTHER', 'External Shoe Lift'), (119, 139, 'CONDITION', 'Diabetic Foot Ulcers'), (255, 281, 'CONDITION', 'active diabetic foot ulcer'), (349, 367, 'OTHER', 'external shoe lift')]"
"['A', 'Phase', 'II', 'Study', 'of', 'Conformal', 'Radiotherapy', 'In', 'Patients', 'With', 'Low', '-', 'Grade', 'Gliomas', '|', 'RATIONALE', ':', 'Specialized', 'radiation', 'therapy', 'that', 'delivers', 'radiation', 'directly', 'to', 'the', 'tumor', 'may', 'kill', 'more', 'tumor', 'cells', 'and', 'cause', 'less', 'damage', 'to', 'normal', 'tissue', '.', '\n\n', 'PURPOSE', ':', 'This', 'phase', 'II', 'trial', 'is', 'studying', 'how', 'well', 'radiation', 'therapy', 'works', 'in', 'treating', 'young', 'patients', 'with', 'gliomas', '.']","['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00238264,NCT00238264,"A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas | RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.","[(20, 42, 'RADIOTHERAPY', 'Conformal Radiotherapy'), (60, 77, 'CONDITION', 'Low-Grade Gliomas'), (103, 120, 'RADIOTHERAPY', 'radiation therapy'), (161, 166, 'CONDITION', 'tumor'), (181, 186, 'CONDITION', 'tumor'), (284, 301, 'RADIOTHERAPY', 'radiation therapy'), (340, 347, 'CONDITION', 'gliomas')]"
"['Transmuscular', 'Quadratus', 'Lumborum', 'Block', 'Versus', 'Supra', '-', 'inguinal', 'Fascial', 'Iliac', 'Compartment', 'Block', 'for', 'Total', 'Hip', 'Arthroplasty', ':', 'a', 'Randomized', ',', 'Prospective', 'Study', '|', 'Iliac', 'fascia', 'block', 'has', 'a', 'long', 'history', 'of', 'analgesia', 'in', 'patients', 'with', 'hip', 'fractures', '.', 'A', 'large', 'number', 'of', 'clinical', 'studies', 'have', 'confirmed', 'its', 'efficacy', ',', 'and', 'there', 'are', 'also', 'randomized', 'controlled', 'studies', 'supporting', 'its', 'effectiveness', 'in', 'analgesia', 'after', 'total', 'hip', 'replacement', 'surgery', '.', 'Quadratus', 'lumborum', 'block', 'is', 'a', 'new', 'block', 'technique', 'developed', 'in', 'last', 'decade', ',', 'and', 'there', 'are', 'also', 'a', 'few', 'randomized', 'controlled', 'studies', 'supporting', 'its', 'effectiveness', 'in', 'postoperative', 'analgesia', 'for', 'total', 'hip', 'replacement', '.', 'The', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'find', 'out', 'whether', 'these', 'two', 'different', 'approaches', 'of', 'fascial', 'compartment', 'block', 'have', 'similar', 'effects', 'on', 'postoperative', 'analgesia', 'after', 'total', 'hip', 'replacement', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04827121,NCT04827121,"Transmuscular Quadratus Lumborum Block Versus Supra-inguinal Fascial Iliac Compartment Block for Total Hip Arthroplasty: a Randomized, Prospective Study | Iliac fascia block has a long history of analgesia in patients with hip fractures. A large number of clinical studies have confirmed its efficacy, and there are also randomized controlled studies supporting its effectiveness in analgesia after total hip replacement surgery.Quadratus lumborum block is a new block technique developed in last decade, and there are also a few randomized controlled studies supporting its effectiveness in postoperative analgesia for total hip replacement.The purpose of the present study was to find out whether these two different approaches of fascial compartment block have similar effects on postoperative analgesia after total hip replacement.","[(0, 38, 'OTHER', 'Transmuscular Quadratus Lumborum Block'), (46, 92, 'OTHER', 'Supra-inguinal Fascial Iliac Compartment Block'), (97, 119, 'CONDITION', 'Total Hip Arthroplasty'), (155, 173, 'OTHER', 'Iliac fascia block'), (223, 236, 'CONDITION', 'hip fractures'), (399, 428, 'CONDITION', 'total hip replacement surgery'), (429, 453, 'OTHER', 'Quadratus lumborum block'), (620, 641, 'CONDITION', 'total hip replacement'), (813, 834, 'CONDITION', 'total hip replacement')]"
"['Bright', 'Light', 'Treatment', 'at', 'Home', 'to', 'Improve', 'Symptom', 'Management', 'of', 'Fibromyalgia', 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'a', 'morning', 'light', 'treatment', 'has', 'on', 'improving', 'physical', 'function', ',', 'pain', 'intensity', ',', 'and', 'pain', 'sensitivity', 'in', 'people', 'with', 'fibromyalgia', 'syndrome', '(', 'FMS', ')', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT03794908,NCT03794908,"Bright Light Treatment at Home to Improve Symptom Management of Fibromyalgia Syndrome | The purpose of this study is to determine the effect a morning light treatment has on improving physical function, pain intensity, and pain sensitivity in people with fibromyalgia syndrome (FMS).","[(0, 22, 'OTHER', 'Bright Light Treatment'), (64, 85, 'CONDITION', 'Fibromyalgia Syndrome'), (143, 166, 'OTHER', 'morning light treatment'), (203, 207, 'CONDITION', 'pain'), (223, 227, 'CONDITION', 'pain'), (255, 276, 'CONDITION', 'fibromyalgia syndrome'), (278, 281, 'CONDITION', 'FMS')]"
"['Treatment', 'and', 'Mapping', 'of', 'Self', '-', 'compassion', ',', 'Perfectionism', ',', 'Stress', ',', 'Anxiety', 'and', 'Impostor', 'Phenomenon', 'in', 'Patients', 'With', 'Different', 'Dermatological', 'Diseases', 'and', 'Pain', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'persons', '/', 'patients', 'with', 'different', 'skin', 'diseases', 'or', 'pain', 'to', 'evaluate', 'whether', 'unhealthy', 'perfectionism', ',', 'stress', ',', 'anxiety', ',', 'impostor', 'phenomenon', '(', 'inability', 'to', 'realistically', 'assess', 'your', 'competence', 'and', 'skills', ')', 'and', 'lack', 'of', 'self', '-', 'compassion', '(', 'a', 'positive', 'attitude', 'towards', 'ourselves', ')', ',', 'have', 'impact', 'on', 'symptoms', ',', 'handling', ',', 'and', 'treatment', 'regarding', 'some', 'dermatological', 'diseases', '/', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05805696,NCT05805696,"Treatment and Mapping of Self-compassion, Perfectionism, Stress, Anxiety and Impostor Phenomenon in Patients With Different Dermatological Diseases and Pain | The aim of this study is to evaluate persons/patients with different skin diseases or pain to evaluate whether unhealthy perfectionism, stress, anxiety, impostor phenomenon (inability to realistically assess your competence and skills) and lack of self-compassion (a positive attitude towards ourselves), have impact on symptoms, handling, and treatment regarding some dermatological diseases/pain.","[(152, 156, 'CONDITION', 'Pain'), (245, 249, 'CONDITION', 'pain'), (552, 556, 'CONDITION', 'pain')]"
"['The', 'Effects', 'of', 'Kinesiotaping', 'on', 'Balance', 'in', 'Children', 'With', 'Down', 'Syndrome', '.', '|', 'This', 'study', 'aimed', 'to', 'explore', 'the', 'effects', 'of', 'Kinesio', 'tape', 'applied', 'to', 'plantar', 'soles', 'on', 'balance', 'in', 'children', 'with', 'Down', 'Syndrome', '(', 'DS', ')', '.', 'Two', 'groups', 'including', 'children', 'with', 'DS', 'and', 'a', 'group', 'with', 'their', 'typically', 'developing', 'peers', 'evaluated', '.', 'Half', 'of', 'the', 'children', 'with', 'DS', 'took', 'Kinesio', 'tape', 'application', 'to', 'the', 'plantar', 'soles', 'and', 'the', 'other', 'half', 'took', 'sham', 'taping', 'application', '.', 'All', 'children', 'evaluated', 'with', 'dynamic', 'and', 'static', 'balance', 'measurements', 'and', 'DS', 'children', 'evaluated', 'immediately', 'after', 'taping', 'and', '45', 'minutes', 'after', 'taping', 'again', 'with', 'the', 'same', 'measurements', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04156607,NCT04156607,The Effects of Kinesiotaping on Balance in Children With Down Syndrome. | This study aimed to explore the effects of Kinesio tape applied to plantar soles on balance in children with Down Syndrome (DS). Two groups including children with DS and a group with their typically developing peers evaluated. Half of the children with DS took Kinesio tape application to the plantar soles and the other half took sham taping application. All children evaluated with dynamic and static balance measurements and DS children evaluated immediately after taping and 45 minutes after taping again with the same measurements.,"[(15, 28, 'OTHER', 'Kinesiotaping'), (57, 70, 'CONDITION', 'Down Syndrome'), (117, 129, 'OTHER', 'Kinesio tape'), (183, 196, 'CONDITION', 'Down Syndrome'), (198, 200, 'CONDITION', 'DS'), (238, 240, 'CONDITION', 'DS'), (328, 330, 'CONDITION', 'DS'), (336, 348, 'OTHER', 'Kinesio tape'), (406, 417, 'CONTROL', 'sham taping'), (503, 505, 'CONDITION', 'DS'), (571, 577, 'OTHER', 'taping')]"
"['A', 'Phase', 'I', ',', 'Open', 'Label', ',', 'Single', '-', 'Dose', ',', 'Four', '-', 'Way', 'Crossover', 'Study', 'Comparing', 'the', 'Pharmacokinetics', 'of', 'NP101', '(', 'Sumatriptan', 'Iontophoretic', 'Transdermal', 'Patch', ')', 'With', 'an', 'Oral', 'Formulation', 'of', 'Imitrex', '®', '(', '50', 'mg', ')', 'in', 'Migraine', 'Subjects', 'During', 'an', 'Acute', 'Migraine', 'Attack', 'and', 'During', 'a', 'Non', '-', 'Migraine', 'Period', '|', 'To', 'compare', 'the', 'pharmacokinetics', 'of', 'NP101', 'with', 'a', 'currently', 'approved', 'oral', 'formulation', 'of', 'Imitrex', '®', '(', '50', 'mg', ')', 'in', 'migraine', 'subjects', 'both', 'during', 'an', 'acute', 'migraine', 'attack', 'and', 'during', 'a', 'non', '-', 'migraine', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00723983,NCT00723983,"A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period | To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.","[(95, 100, 'DRUG', 'NP101'), (102, 113, 'DRUG', 'Sumatriptan'), (175, 182, 'DRUG', 'Imitrex'), (194, 202, 'CONDITION', 'Migraine'), (222, 243, 'CONDITION', 'Acute Migraine Attack'), (314, 319, 'DRUG', 'NP101'), (366, 373, 'DRUG', 'Imitrex'), (386, 394, 'CONDITION', 'migraine'), (419, 440, 'CONDITION', 'acute migraine attack')]"
"['Intraosseous', 'Administration', 'of', 'Hypertonic', 'Saline', 'in', 'Acute', 'Brain', '-', 'injured', 'Patients', ':', 'A', 'Prospective', 'Case', 'Series', 'and', 'Literature', 'Review', '|', 'Hypertonic', 'saline', 'is', 'used', 'to', 'treat', 'elevated', 'intracranial', 'pressure', '.', 'Intraosseous', 'vascular', 'access', 'has', 'been', 'used', 'to', 'administer', 'fluids', 'and', 'medications', '.', 'This', 'study', 'combines', 'these', 'to', 'administer', '3', '%', 'hypertonic', 'saline', 'via', 'IO', '.']","['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O']",NCT03276494,NCT03276494,Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review | Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.,"[(31, 48, 'DRUG', 'Hypertonic Saline'), (52, 71, 'CONDITION', 'Acute Brain-injured'), (132, 149, 'DRUG', 'Hypertonic saline'), (167, 197, 'CONDITION', 'elevated intracranial pressure'), (323, 340, 'DRUG', 'hypertonic saline')]"
"['Effect', 'of', 'Inspiratory', 'Muscle', 'Training', '(', 'IMT', ')', 'on', 'Breathing', ',', 'Balance', ',', 'and', 'Blood', 'Pressure', 'Maintenance', 'in', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'help', 'understand', 'how', 'training', 'breathing', 'muscles', 'will', 'impact', 'balance', ',', 'blood', 'pressure', ',', 'and', 'quality', 'of', 'life', 'of', 'participants', 'with', 'spinal', 'cord', 'injury', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04210063,NCT04210063,"Effect of Inspiratory Muscle Training (IMT) on Breathing, Balance, and Blood Pressure Maintenance in Spinal Cord Injury (SCI) | The purpose of this study is to help understand how training breathing muscles will impact balance, blood pressure, and quality of life of participants with spinal cord injury.","[(10, 37, 'PHYSICAL', 'Inspiratory Muscle Training'), (39, 42, 'PHYSICAL', 'IMT'), (101, 119, 'CONDITION', 'Spinal Cord Injury'), (121, 124, 'CONDITION', 'SCI'), (180, 206, 'PHYSICAL', 'training breathing muscles'), (285, 303, 'CONDITION', 'spinal cord injury')]"
"['Dementia', 'Pain', 'Management', 'Knowledge', 'Scale', 'Development', 'and', 'Impact', 'of', 'an', 'Educational', 'Program', 'on', 'Hospital', 'Nurses', ""'"", 'Knowledge', 'Evaluation', '|', 'This', 'study', 'aims', 'to', 'develop', 'and', 'test', 'a', 'scale', 'for', 'exploring', 'hospital', 'nurses', ""'"", 'knowledge', 'about', 'dementia', 'pain', 'and', 'dementia', 'pain', 'management', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04256382,NCT04256382,Dementia Pain Management Knowledge Scale Development and Impact of an Educational Program on Hospital Nurses' Knowledge Evaluation | This study aims to develop and test a scale for exploring hospital nurses' knowledge about dementia pain and dementia pain management.,"[(70, 89, 'BEHAVIOURAL', 'Educational Program')]"
"['Randomised', 'controlled', 'trial', 'of', 'the', 'use', 'of', 'phenobarbitone', 'and', 'carbamazepine', 'in', 'childhood', 'epilepsy', 'in', 'Bangladesh', 'with', 'particular', 'reference', 'to', 'behavioural', 'side', 'effects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00381537,NCT00381537,Randomised controlled trial of the use of phenobarbitone and carbamazepine in childhood epilepsy in Bangladesh with particular reference to behavioural side effects.,"[(42, 56, 'DRUG', 'phenobarbitone'), (61, 74, 'DRUG', 'carbamazepine'), (88, 96, 'CONDITION', 'epilepsy')]"
"['Investigation', 'the', 'Effect', 'of', 'Cervical', 'Mobilization', 'on', 'Balance', 'and', 'Plantar', 'Pressure', 'Distribution', 'in', 'Multiple', 'Sclerosis', 'Patients', ':', 'A', 'Randomized', 'Crossover', 'Controlled', 'Study', '|', 'MS', 'patients', 'were', 'randomly', 'divided', 'into', 'traditional', 'therapy', 'and', 'traditional', 'therapy', '+', 'cervical', 'mobilization', 'groups', '.', 'While', 'muscle', 'strengthening', ',', 'stretching', ',', 'balance', 'and', 'coordination', 'exercises', 'were', 'given', 'to', 'the', 'traditional', 'group', ',', 'cervical', 'mobilization', 'was', 'applied', 'in', 'addition', 'to', 'these', 'in', 'cervical', 'group', '.', 'Patients', 'received', 'treatments', 'twice', 'a', 'week', 'for', '4', 'weeks', '.', 'The', 'effect', 'of', 'the', 'applied', 'treatment', 'on', 'the', 'tonus', 'and', 'plantar', 'pressure', 'distribution', 'was', 'analyzed', '.', 'Treatments', 'were', 'interrupted', 'for', '4', 'weeks', 'and', 'the', 'groups', 'continued', 'with', 'the', 'treatment', 'they', 'did', 'not', 'receive', '(', 'crossover', 'design', ')', '.', 'The', 'group', 'that', 'received', 'traditional', 'treatment', 'in', 'the', 'first', 'period', 'completed', 'traditional', '+', 'cervical', 'mobilization', ',', 'and', 'the', 'other', 'group', 'with', 'traditional', '+', 'cervical', 'mobilization', 'traditionally', 'completed', 'the', 'treatment', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O']",NCT04543448,NCT04543448,"Investigation the Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis Patients: A Randomized Crossover Controlled Study | MS patients were randomly divided into traditional therapy and traditional therapy + cervical mobilization groups. While muscle strengthening, stretching, balance and coordination exercises were given to the traditional group, cervical mobilization was applied in addition to these in cervical group. Patients received treatments twice a week for 4 weeks. The effect of the applied treatment on the tonus and plantar pressure distribution was analyzed. Treatments were interrupted for 4 weeks and the groups continued with the treatment they did not receive (crossover design). The group that received traditional treatment in the first period completed traditional + cervical mobilization, and the other group with traditional + cervical mobilization traditionally completed the treatment.","[(28, 49, 'PHYSICAL', 'Cervical Mobilization'), (98, 116, 'CONDITION', 'Multiple Sclerosis'), (169, 171, 'CONDITION', 'MS'), (208, 227, 'CONTROL', 'traditional therapy'), (232, 251, 'CONTROL', 'traditional therapy'), (254, 275, 'PHYSICAL', 'cervical mobilization'), (290, 310, 'CONTROL', 'muscle strengthening'), (312, 322, 'CONTROL', 'stretching'), (324, 358, 'CONTROL', 'balance and coordination exercises'), (396, 417, 'PHYSICAL', 'cervical mobilization'), (771, 792, 'CONTROL', 'traditional treatment'), (823, 858, 'PHYSICAL', 'traditional + cervical mobilization'), (885, 920, 'PHYSICAL', 'traditional + cervical mobilization')]"
"['Combined', 'Upper', '-', 'airway', 'and', 'Breathing', 'Control', 'Therapies', 'for', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'current', 'study', 'combines', 'two', 'treatments', 'for', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'oral', 'appliances', 'and', 'supplemental', 'inspired', 'oxygen', '.', 'The', 'following', 'aims', 'will', 'be', 'tested', ':', '\n\n', 'Aim', '1', '.', 'To', 'determine', 'whether', 'supplemental', 'inspired', 'oxygen', 'further', 'reduces', 'OSA', 'severity', '(', 'apnea', '-', 'hypopnea', 'index', ')', 'in', 'patients', 'using', 'an', 'oral', 'appliance', '.', '\n\n', 'Aim', '2', '.', 'To', 'determine', 'whether', 'baseline', 'OSA', 'phenotypes', 'can', 'predict', 'the', 'efficacy', 'of', 'oral', 'appliances', 'versus', 'supplemental', 'oxygen', 'versus', 'both', 'treatments', 'in', 'combination', '.', 'We', 'will', 'test', 'whether', 'responders', 'to', 'oral', 'appliances', 'have', 'distinct', 'pathophysiological', 'characteristics', 'compared', 'with', 'oxygen', 'responders', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O']",NCT03189173,NCT03189173,"Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea | The current study combines two treatments for obstructive sleep apnea (OSA), oral appliances and supplemental inspired oxygen. The following aims will be tested:

Aim 1. To determine whether supplemental inspired oxygen further reduces OSA severity (apnea-hypopnea index) in patients using an oral appliance.

Aim 2. To determine whether baseline OSA phenotypes can predict the efficacy of oral appliances versus supplemental oxygen versus both treatments in combination. We will test whether responders to oral appliances have distinct pathophysiological characteristics compared with oxygen responders.","[(9, 53, 'OTHER', 'Upper-airway and Breathing Control Therapies'), (58, 81, 'CONDITION', 'Obstructive Sleep Apnea'), (130, 153, 'CONDITION', 'obstructive sleep apnea'), (155, 158, 'CONDITION', 'OSA'), (161, 176, 'OTHER', 'oral appliances'), (181, 209, 'OTHER', 'supplemental inspired oxygen'), (275, 303, 'OTHER', 'supplemental inspired oxygen'), (320, 323, 'CONDITION', 'OSA'), (377, 391, 'OTHER', 'oral appliance'), (431, 434, 'CONDITION', 'OSA'), (474, 489, 'OTHER', 'oral appliances'), (497, 516, 'OTHER', 'supplemental oxygen'), (591, 606, 'OTHER', 'oral appliances'), (670, 676, 'OTHER', 'oxygen')]"
"['Impact', 'of', 'Dexmedetomidine', 'Supplemented', 'Analgesia', 'on', 'Delirium', 'and', 'Long', '-', 'term', 'Outcomes', 'in', 'Elderly', 'After', 'Hip', 'Fracture', 'Surgery', ':', 'A', 'Multicenter', ',', 'Double', '-', 'blinded', ',', 'Randomized', 'Controlled', 'Trial', '|', 'Delirium', 'is', 'common', 'in', 'the', 'elderly', 'after', 'hip', 'fracture', 'surgery', ',', 'and', 'is', 'associated', 'with', 'worse', 'outcomes', '.', 'The', 'investigators', 'hypothesize', 'that', ',', 'for', 'elderly', 'patients', 'after', 'hip', 'fracture', 'surgery', ',', 'dexmedetomidine', 'supplemented', 'analgesia', 'can', 'reduce', 'the', 'incidence', 'of', 'delirium', 'and', 'improve', 'the', 'long', '-', 'term', 'outcomes', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04955249,NCT04955249,"Impact of Dexmedetomidine Supplemented Analgesia on Delirium and Long-term Outcomes in Elderly After Hip Fracture Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial | Delirium is common in the elderly after hip fracture surgery, and is associated with worse outcomes. The investigators hypothesize that, for elderly patients after hip fracture surgery, dexmedetomidine supplemented analgesia can reduce the incidence of delirium and improve the long-term outcomes.","[(10, 25, 'DRUG', 'Dexmedetomidine'), (52, 60, 'CONDITION', 'Delirium'), (101, 121, 'CONDITION', 'Hip Fracture Surgery'), (184, 192, 'CONDITION', 'Delirium'), (224, 244, 'CONDITION', 'hip fracture surgery'), (348, 368, 'CONDITION', 'hip fracture surgery'), (370, 385, 'DRUG', 'dexmedetomidine'), (437, 445, 'CONDITION', 'delirium')]"
"['The', 'Changes', 'of', 'Patterns', 'of', 'Microarray', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'aim', 'of', 'this', 'study', 'are', '(', '1', ')', 'To', 'genome', '-', 'wide', 'profile', 'the', 'gene', 'expression', 'patterns', 'of', 'peripheral', 'blood', 'mononuclear', 'cell', '(', 'PBMC', ')', 'in', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '(', '2', ')', 'To', 'profile', 'the', 'gene', 'expression', 'patterns', 'change', 'before', 'and', 'after', 'treatment', 'with', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', '(', '3', ')', 'To', 'correlate', 'the', 'altered', 'gene', 'expression', 'with', 'the', 'severity', 'of', 'the', 'disease', 'and', 'outcome', 'of', 'OSA', 'patients']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00498849,NCT00498849,The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea | The aim of this study are (1) To genome-wide profile the gene expression patterns of peripheral blood mononuclear cell (PBMC) in patients with obstructive sleep apnea (OSA) (2) To profile the gene expression patterns change before and after treatment with continuous positive airway pressure (CPAP) (3) To correlate the altered gene expression with the severity of the disease and outcome of OSA patients,"[(55, 78, 'CONDITION', 'Obstructive Sleep Apnea'), (224, 247, 'CONDITION', 'obstructive sleep apnea'), (249, 252, 'CONDITION', 'OSA'), (337, 372, 'OTHER', 'continuous positive airway pressure'), (374, 378, 'OTHER', 'CPAP'), (473, 476, 'CONDITION', 'OSA')]"
"['Effects', 'of', 'Neurodevelopment', 'Therapy', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'was', 'conducted', 'to', 'find', 'out', 'the', 'Effects', 'of', 'Neurodevelopment', 'therapy', '(', 'a', 'rehabilitative', 'program', 'designed', 'by', 'Bobath', ')', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.', 'To', 'investigate', 'either', 'there', 'was', 'a', 'significant', 'difference', 'between', 'the', 'effects', 'of', 'neurodevelopment', 'therapy', 'and', 'routine', 'physical', 'therapy', 'on', 'gross', 'motor', 'function', 'and', 'postural', 'control', 'in', 'children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05231538,NCT05231538,Effects of Neurodevelopment Therapy on Gross Motor Function and Postural Control in Children With Spastic Cerebral Palsy: A Randomized Controlled Trial | This study was conducted to find out the Effects of Neurodevelopment therapy (a rehabilitative program designed by Bobath) on Gross Motor Function and Postural Control in Children with Spastic Cerebral Palsy. To investigate either there was a significant difference between the effects of neurodevelopment therapy and routine physical therapy on gross motor function and postural control in children with Spastic Cerebral Palsy.,"[(11, 35, 'OTHER', 'Neurodevelopment Therapy'), (98, 120, 'CONDITION', 'Spastic Cerebral Palsy'), (206, 230, 'OTHER', 'Neurodevelopment therapy'), (339, 361, 'CONDITION', 'Spastic Cerebral Palsy'), (443, 467, 'OTHER', 'neurodevelopment therapy'), (559, 581, 'CONDITION', 'Spastic Cerebral Palsy')]"
"['The', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'on', 'Spasticity', 'in', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Extended', 'periods', 'of', 'tilt', 'table', 'standing', 'have', 'been', 'observed', 'to', 'improve', 'spasticity', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'three', 'sessions', 'of', 'whole', 'body', 'vibration', 'while', 'tilt', 'table', 'standing', 'on', 'spasticity', 'in', 'individuals', 'with', 'a', 'complete', 'or', 'incomplete', 'SCI', 'above', 'the', 'neurological', 'level', 'of', 'T10', '.', 'Participants', 'in', 'this', 'study', 'will', 'undergo', 'whole', 'body', 'vibration', 'while', 'standing', 'on', 'a', 'tilt', 'table', 'for', 'a', 'total', 'of', 'approximately', '14', 'minutes', 'for', 'a', 'total', 'of', '3', 'sessions', 'on', '3', 'separate', 'days', '.', 'Spasticity', 'monitoring', 'will', 'be', 'evaluated', 'prior', 'to', 'and', 'after', 'the', 'intervention', 'with', 'the', 'Modified', 'Penn', 'Spasm', 'Frequency', 'Scale', ',', 'an', 'interview', 'to', 'obtain', 'the', 'individual', ""'s"", 'perception', 'and', 'impression', 'of', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'the', 'performance', 'of', 'activities', 'of', 'daily', 'living', ',', 'quality', 'of', 'life', ',', 'pain', 'scale', ',', 'and', 'global', 'impression', 'of', 'change', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02127606,NCT02127606,"The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients | Extended periods of tilt table standing have been observed to improve spasticity in individuals with spinal cord injury (SCI). The purpose of this study is to determine the effect of three sessions of whole body vibration while tilt table standing on spasticity in individuals with a complete or incomplete SCI above the neurological level of T10. Participants in this study will undergo whole body vibration while standing on a tilt table for a total of approximately 14 minutes for a total of 3 sessions on 3 separate days. Spasticity monitoring will be evaluated prior to and after the intervention with the Modified Penn Spasm Frequency Scale, an interview to obtain the individual's perception and impression of the effect of whole body vibration on the performance of activities of daily living, quality of life, pain scale, and global impression of change.","[(14, 34, 'OTHER', 'Whole Body Vibration'), (38, 48, 'CONDITION', 'Spasticity'), (52, 70, 'CONDITION', 'Spinal Cord Injury'), (183, 201, 'CONDITION', 'spinal cord injury'), (203, 206, 'CONDITION', 'SCI'), (283, 303, 'OTHER', 'whole body vibration'), (333, 343, 'CONDITION', 'spasticity'), (366, 392, 'CONDITION', 'complete or incomplete SCI'), (470, 490, 'OTHER', 'whole body vibration'), (608, 618, 'CONDITION', 'Spasticity'), (813, 833, 'OTHER', 'whole body vibration')]"
"['""', 'Cognitus', '&', 'Moi', '""', ':', 'a', 'New', 'Cognitive', 'Remediation', 'Tool', 'for', 'Children', 'With', 'Intellectual', 'Deficiency', 'With', 'Behavioral', 'Disorders', '|', 'Holders', 'children', 'with', 'intellectual', 'disabilities', 'have', 'great', 'difficulty', 'in', 'adapting', 'to', 'social', 'situations', 'and', 'relationships', '.', 'Cognitive', 'impairment', 'associated', 'with', 'intellectual', 'disability', 'are', 'important', 'factors', 'to', 'understand', 'their', 'difficulties', 'in', 'processing', 'social', 'information', '.', 'In', 'the', 'field', 'of', 'recognition', 'of', 'facial', 'emotions', 'in', 'particular', ',', 'basic', 'cognitive', 'processes', 'such', 'as', 'visuospatial', 'and', 'attentional', 'functions', ',', 'are', 'heavily', 'involved', '.', 'Cognitive', 'remediation', 'is', 'a', 'management', 'tool', 'widely', 'used', 'by', 'practitioners', 'to', 'help', 'patients', 'who', 'experience', 'cognitive', 'difficulties', '.', 'Currently', ',', 'no', 'program', 'can', 'meet', 'specific', 'and', 'validated', 'the', 'problems', 'are', 'children', 'with', 'intellectual', 'disabilities', 'manner', 'in', 'their', 'daily', 'functioning', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02797418,NCT02797418,"""Cognitus & Moi"": a New Cognitive Remediation Tool for Children With Intellectual Deficiency With Behavioral Disorders | Holders children with intellectual disabilities have great difficulty in adapting to social situations and relationships.Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved.Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are children with intellectual disabilities manner in their daily functioning.","[(1, 15, 'OTHER', 'Cognitus & Moi'), (24, 50, 'OTHER', 'Cognitive Remediation Tool'), (69, 92, 'CONDITION', 'Intellectual Deficiency'), (98, 118, 'CONDITION', 'Behavioral Disorders'), (143, 168, 'CONDITION', 'intellectual disabilities'), (242, 262, 'CONDITION', 'Cognitive impairment'), (279, 302, 'CONDITION', 'intellectual disability'), (549, 570, 'OTHER', 'Cognitive remediation'), (653, 675, 'CONDITION', 'cognitive difficulties'), (762, 787, 'CONDITION', 'intellectual disabilities')]"
"['Effects', 'of', 'Video', 'Game', '-', 'based', 'Physical', 'Activity', 'Training', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', 'With', 'Restless', 'Legs', 'Syndrome', '|', 'In', 'this', 'studly', ',', 'the', 'effects', 'of', 'an', '8', '-', 'week', 'videogame', '-', 'based', 'physical', 'activity', 'training', 'in', 'persons', 'with', 'multiple', 'sclerosis', 'will', 'be', 'investigated', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT03878810,NCT03878810,"Effects of Video Game-based Physical Activity Training in Persons With Multiple Sclerosis With Restless Legs Syndrome | In this studly, the effects of an 8-week videogame-based physical activity training in persons with multiple sclerosis will be investigated.","[(11, 54, 'PHYSICAL', 'Video Game-based Physical Activity Training'), (71, 89, 'CONDITION', 'Multiple Sclerosis'), (95, 117, 'CONDITION', 'Restless Legs Syndrome'), (161, 203, 'PHYSICAL', 'videogame-based physical activity training'), (220, 238, 'CONDITION', 'multiple sclerosis')]"
"['Restoration', 'of', 'Standing', 'and', 'Walking', 'With', 'ISMS', 'in', 'Humans', '|', 'Spinal', 'cord', 'neural', 'circuitry', 'exists', 'in', 'the', 'lumbar', 'enlargement', 'that', 'makes', 'it', 'possible', 'to', 'stand', 'and', 'create', 'synergistic', ',', 'rhythmic', 'stepping', 'activity', 'in', 'the', 'lower', 'limbs', '.', 'In', 'the', 'past', '20', 'years', ',', 'clinicians', 'have', 'tried', 'to', 'reengage', 'such', 'these', 'circuits', 'for', 'standing', 'and', 'walking', 'in', 'the', 'lower', 'spinal', 'cord', 'of', 'paralyzed', 'humans', 'through', 'novel', 'paradigms', 'of', 'physical', 'therapy', ',', 'pharmacological', 'stimulation', 'of', 'the', 'spinal', 'cord', ',', 'or', 'recently', '-', 'epidural', 'stimulation', 'of', 'the', 'spinal', 'cord', '.', 'Although', 'standing', 'and', 'stepping', 'with', 'these', 'maneuvers', 'are', 'rudimentary', 'at', 'best', ',', 'these', 'human', 'studies', 'offer', 'promise', 'to', 'restore', 'controlled', ',', 'lower', 'extremity', 'movement', 'to', 'the', 'spinal', 'cord', 'injured', '(', 'SCI', ')', 'individual', '.', 'Evidence', 'from', 'animal', 'data', 'suggests', 'that', 'more', 'focal', 'activation', 'of', 'intraspinal', 'circuitry', '(', 'IntraSpinal', 'Micro', '-', 'Stimulation', '-', 'ISMS', ')', 'would', 'produce', 'more', 'fatigue', 'resistant', ',', 'natural', 'standing', 'and', 'stepping', 'activity', 'in', 'humans', '.', 'To', 'date', ',', 'there', 'has', 'been', 'no', 'direct', 'confirmation', 'of', 'such', 'circuitry', 'in', 'the', 'spinal', 'cord', 'of', 'bipedal', 'humans', 'who', 'have', 'been', 'paralyzed', '.', 'Furthermore', ',', 'mapping', 'of', 'such', 'circuitry', 'would', 'provide', 'the', 'basis', 'of', 'a', 'novel', 'intraspinal', 'neuroprosthetic', 'that', 'should', 'be', 'able', 'to', 'restore', 'control', 'of', 'standing', 'or', 'walking', 'in', 'a', 'manner', 'that', 'is', 'much', 'more', 'physiologically', 'normal', 'and', 'tolerable', 'than', 'by', 'stimulating', 'each', 'individual', 'muscle', 'group', '.', 'Proof', 'of', 'the', 'existence', 'of', 'these', 'spinal', 'circuits', 'in', 'man', ',', 'and', 'the', 'ability', 'to', 'activate', 'and', 'control', 'these', 'circuits', 'by', 'first', 'mapping', 'the', 'spinal', 'cord', 'is', 'the', 'basis', 'of', 'this', 'proposal', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02899858,NCT02899858,"Restoration of Standing and Walking With ISMS in Humans | Spinal cord neural circuitry exists in the lumbar enlargement that makes it possible to stand and create synergistic, rhythmic stepping activity in the lower limbs. In the past 20 years, clinicians have tried to reengage such these circuits for standing and walking in the lower spinal cord of paralyzed humans through novel paradigms of physical therapy, pharmacological stimulation of the spinal cord, or recently - epidural stimulation of the spinal cord. Although standing and stepping with these maneuvers are rudimentary at best, these human studies offer promise to restore controlled, lower extremity movement to the spinal cord injured (SCI) individual. Evidence from animal data suggests that more focal activation of intraspinal circuitry (IntraSpinal Micro-Stimulation - ISMS) would produce more fatigue resistant, natural standing and stepping activity in humans. To date, there has been no direct confirmation of such circuitry in the spinal cord of bipedal humans who have been paralyzed. Furthermore, mapping of such circuitry would provide the basis of a novel intraspinal neuroprosthetic that should be able to restore control of standing or walking in a manner that is much more physiologically normal and tolerable than by stimulating each individual muscle group. Proof of the existence of these spinal circuits in man, and the ability to activate and control these circuits by first mapping the spinal cord is the basis of this proposal.","[(41, 45, 'OTHER', 'ISMS'), (352, 361, 'CONDITION', 'paralyzed'), (683, 702, 'CONDITION', 'spinal cord injured'), (704, 707, 'CONDITION', 'SCI'), (766, 807, 'OTHER', 'focal activation of intraspinal circuitry'), (809, 838, 'OTHER', 'IntraSpinal Micro-Stimulation'), (841, 845, 'OTHER', 'ISMS'), (1051, 1060, 'CONDITION', 'paralyzed')]"
"['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'whether', 'remote', 'ischemic', 'conditioning(RIC', ')', 'would', 'reduce', 'the', 'stroke', 'risk', 'of', 'patients', 'with', 'symptomatic', 'vertebrobasilar', 'lesion', 'of', 'atherosclerosis', ',', 'then', 'we', 'would', 'observe', 'the', 'haemodynamics', 'and', 'plasma', 'biomarkers', 'changes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02971462,NCT02971462,"The purpose of this study is to investigate whether remote ischemic conditioning(RIC) would reduce the stroke risk of patients with symptomatic vertebrobasilar lesion of atherosclerosis,then we would observe the haemodynamics and plasma biomarkers changes.","[(52, 84, 'OTHER', 'remote ischemic conditioning(RIC'), (103, 109, 'CONDITION', 'stroke'), (132, 185, 'CONDITION', 'symptomatic vertebrobasilar lesion of atherosclerosis')]"
"['Etude', 'de', 'la', 'Performance', 'Diagnostique', 'de', ""l'EEG"", '-', 'Haute', 'Résolution', 'Sur', 'la', 'Localisation', 'de', 'la', 'Zone', 'épileptogène', 'Pour', 'le', 'Traitement', 'Chirurgical', 'Des', 'épilepsies', 'Partielles', 'Pharmaco', '-', 'résistantes', '|', 'Multicenter', 'prospective', 'study', 'comparing', 'the', 'diagnosis', 'value', 'of', 'high', '-', 'resolution', 'EEG', 'and', 'depth', '-', 'EEG', 'to', 'localize', 'the', 'epileptogenic', 'zone', 'in', 'drug', 'resistant', 'partial', 'epilepsies', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01090934,NCT01090934,Etude de la Performance Diagnostique de l'EEG-Haute Résolution Sur la Localisation de la Zone épileptogène Pour le Traitement Chirurgical Des épilepsies Partielles Pharmaco-résistantes | Multicenter prospective study comparing the diagnosis value of high-resolution EEG and depth-EEG to localize the epileptogenic zone in drug resistant partial epilepsies.,"[(300, 313, 'CONDITION', 'epileptogenic'), (322, 355, 'CONDITION', 'drug resistant partial epilepsies')]"
"['Investigating', 'the', 'Effects', 'of', 'Wearable', 'Robotic', 'Exoskeleton', 'for', 'Improving', 'Mobility', 'and', 'Cognition', 'in', 'Persons', 'With', 'MS', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'usefulness', 'of', 'a', 'wearable', 'robotic', 'exoskeleton', 'device', '(', 'Ekso', '-', 'GT', ')', ',', 'to', 'improve', 'learning', 'and', 'memory', ',', 'and', 'gait', 'therapy', 'in', 'persons', 'with', 'walking', 'disability', 'due', 'to', 'Multiple', 'Sclerosis', '.', 'The', 'study', 'will', 'evaluate', 'the', 'mobility', ',', 'learning', 'and', 'memory', ',', 'and', 'walking', 'abilities', 'of', 'individuals', 'with', 'multiple', 'sclerosis', 'who', 'went', 'through', 'the', 'traditional', 'as', 'compared', 'to', 'others', 'who', 'used', 'the', 'robotic', 'exoskeleton', 'as', 'part', 'of', 'their', 'therapy', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04855825,NCT04855825,"Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS | The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.","[(29, 57, 'PHYSICAL', 'Wearable Robotic Exoskeleton'), (111, 113, 'CONDITION', 'MS'), (195, 221, 'PHYSICAL', 'robotic exoskeleton device'), (223, 230, 'PHYSICAL', 'Ekso-GT'), (298, 316, 'CONDITION', 'walking disability'), (324, 342, 'CONDITION', 'Multiple Sclerosis'), (445, 463, 'CONDITION', 'multiple sclerosis'), (485, 496, 'CONTROL', 'traditional'), (532, 551, 'PHYSICAL', 'robotic exoskeleton')]"
"['Venlafaxine', 'for', 'Depression', 'in', 'Alzheimer', ""'s"", 'Disease', '|', 'This', 'study', 'will', 'test', 'the', 'use', 'of', 'venlafaxine', 'to', 'treat', 'the', 'depression', 'in', 'Alzheimer', ""'s"", 'Disease', '.', 'Venlafaxine', 'works', 'by', 'increasing', 'natural', 'substances', 'in', 'the', 'brain', '(', 'serotonin', 'and', 'norepinephrine', ')', 'that', 'help', 'maintain', 'mental', 'balance', '.', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'is', 'the', 'commonest', 'neurodegenerative', 'disease', 'of', 'aging', 'and', 'the', 'cause', 'of', 'major', 'financial', 'and', 'emotional', 'burden', 'to', 'patients', ',', 'families', 'and', 'caregivers', ',', 'and', 'society', '.', 'Depression', 'is', 'a', 'very', 'common', 'symptom', 'of', 'AD', ',', 'affecting', 'as', 'many', 'as', '50', '%', 'of', 'patients', 'over', 'their', 'illness', '.', 'Depression', 'in', 'AD', '(', 'Alzheimer', ""'s"", 'disease', ')', 'contributes', 'greatly', 'to', 'patient', 'disability', 'and', 'caregiver', 'distress', '.', 'Neither', 'psychosocial', 'interventions', 'nor', 'psychotropic', 'medications', 'have', 'proven', 'effective', 'to', 'date', 'for', 'the', 'treatment', 'of', 'depression', 'in', 'AD.Venlafaxine', 'is', 'approved', 'by', 'the', 'U.S.', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'for', 'the', 'treatment', 'of', 'major', 'depression', 'but', 'it', 'is', 'not', 'known', 'whether', 'or', 'not', 'it', 'can', 'help', 'depression', 'in', 'Alzheimer', ""'s"", 'Disease', '.']","['B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01609348,NCT01609348,"Venlafaxine for Depression in Alzheimer's Disease | This study will test the use of venlafaxine to treat the depression in Alzheimer's Disease. Venlafaxine works by increasing natural substances in the brain (serotonin and norepinephrine) that help maintain mental balance. Alzheimer's disease (AD) is the commonest neurodegenerative disease of aging and the cause of major financial and emotional burden to patients, families and caregivers, and society. Depression is a very common symptom of AD, affecting as many as 50% of patients over their illness. Depression in AD (Alzheimer's disease) contributes greatly to patient disability and caregiver distress. Neither psychosocial interventions nor psychotropic medications have proven effective to date for the treatment of depression in AD.Venlafaxine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depression but it is not known whether or not it can help depression in Alzheimer's Disease.","[(0, 11, 'DRUG', 'Venlafaxine'), (16, 26, 'CONDITION', 'Depression'), (30, 49, 'CONDITION', ""Alzheimer's Disease""), (84, 95, 'DRUG', 'venlafaxine'), (109, 119, 'CONDITION', 'depression'), (123, 142, 'CONDITION', ""Alzheimer's Disease""), (144, 155, 'DRUG', 'Venlafaxine'), (274, 293, 'CONDITION', ""Alzheimer's disease""), (295, 297, 'CONDITION', 'AD'), (456, 466, 'CONDITION', 'Depression'), (495, 497, 'CONDITION', 'AD'), (556, 566, 'CONDITION', 'Depression'), (570, 572, 'CONDITION', 'AD'), (574, 593, 'CONDITION', ""Alzheimer's disease""), (776, 786, 'CONDITION', 'depression'), (885, 901, 'CONDITION', 'major depression'), (949, 959, 'CONDITION', 'depression'), (963, 982, 'CONDITION', ""Alzheimer's Disease"")]"
"['Validation', 'of', 'a', 'Shared', 'Decision', '-', 'Making', 'Tool', ',', 'MS', '-', 'SUPPORT', ',', 'to', 'Improve', 'Decisions', 'About', 'Disease', 'Modifying', 'Therapies', '(', 'DMT', ')', 'for', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'evaluates', 'a', 'novel', 'shared', 'decision', 'making', 'tool', 'for', 'multiple', 'sclerosis', '(', 'MS', ')', '.', 'Half', 'the', 'patients', 'will', 'be', 'given', 'access', 'to', 'MS', '-', 'SUPPORT', 'before', 'their', 'scheduled', 'appointment', 'with', 'their', 'healthcare', 'provider', ',', 'the', 'other', 'half', 'will', 'not', 'be', 'given', 'access', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04122989,NCT04122989,"Validation of a Shared Decision-Making Tool, MS-SUPPORT, to Improve Decisions About Disease Modifying Therapies (DMT) for Multiple Sclerosis | This study evaluates a novel shared decision making tool for multiple sclerosis (MS). Half the patients will be given access to MS-SUPPORT before their scheduled appointment with their healthcare provider, the other half will not be given access.","[(16, 43, 'OTHER', 'Shared Decision-Making Tool'), (45, 55, 'OTHER', 'MS-SUPPORT'), (122, 140, 'CONDITION', 'Multiple Sclerosis'), (172, 199, 'OTHER', 'shared decision making tool'), (204, 222, 'CONDITION', 'multiple sclerosis'), (224, 226, 'CONDITION', 'MS'), (271, 281, 'OTHER', 'MS-SUPPORT')]"
"['Effects', 'of', 'Rhythmic', 'Auditory', 'Cueing', 'With', 'Locomotion', 'Training', 'on', 'Cortical', 'Excitability', 'and', 'Behavior', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'In', 'this', 'study', ',', '51', 'subjects', 'include', '17', 'freezers,17', 'non', '-', 'freezers', 'and', '17', 'aged', '-', 'matched', 'healthy', 'subjects', 'will', 'be', 'recruited', '.', 'We', 'will', 'compare', 'the', 'cortical', 'excitability', ',', 'gait', 'performance', ',', 'and', 'stepping', '-', 'in', '-', 'place', 'performance', 'before', 'and', 'after', 'intervention', 'of', 'auditory', 'cues', 'combined', 'with', 'gait', 'training', '.', 'The', 'cortical', 'excitability', 'will', 'be', 'assessed', 'by', 'transcranial', 'magnetic', 'stimulation', '(', 'TMS', ')', '.', 'The', 'purpose', 'in', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'auditory', 'cues', 'with', 'gait', 'training', 'on', 'cortical', 'excitability', 'and', 'rhythmic', 'movements', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03656796,NCT03656796,"Effects of Rhythmic Auditory Cueing With Locomotion Training on Cortical Excitability and Behavior in Patients With Parkinson's Disease | In this study, 51 subjects include 17 freezers,17 non-freezers and 17 aged-matched healthy subjects will be recruited. We will compare the cortical excitability, gait performance, and stepping-in-place performance before and after intervention of auditory cues combined with gait training. The cortical excitability will be assessed by transcranial magnetic stimulation (TMS). The purpose in this study is to investigate the effects of auditory cues with gait training on cortical excitability and rhythmic movements in patients with Parkinson's disease.","[(11, 35, 'OTHER', 'Rhythmic Auditory Cueing'), (41, 60, 'PHYSICAL', 'Locomotion Training'), (116, 135, 'CONDITION', ""Parkinson's Disease""), (385, 398, 'OTHER', 'auditory cues'), (413, 426, 'PHYSICAL', 'gait training'), (574, 587, 'OTHER', 'auditory cues'), (593, 606, 'PHYSICAL', 'gait training'), (672, 691, 'CONDITION', ""Parkinson's disease"")]"
"['Effects', 'of', 'Air', 'Stacking', 'Versus', 'Glossopharyngeal', 'Breathing', 'on', 'Maximum', 'Insufflation', 'Capacity', 'in', 'Children', 'and', 'Adolescents', 'With', 'Neuromuscular', 'Disease', '|', 'Neuromuscular', 'diseases', '(', 'NMD', ')', 'are', 'characterized', 'by', 'a', 'reduced', 'maximum', 'insufflation', 'capacity', '(', 'MIC', ')', ',', 'which', 'contributes', 'to', 'increased', 'morbidity', 'and', 'mortality', 'from', 'respiratory', 'diseases', '.', 'Techniques', 'such', 'as', 'glossopharyngeal', 'breathing', '(', 'GPB', ')', 'and', 'insufflation', 'using', 'a', 'manual', 'resuscitation', 'bag', ',', 'or', '""', 'air', 'stacking', '(', 'AS', ')', '""', ',', 'can', 'be', 'used', 'to', 'increase', 'the', 'MIC', '.', 'These', 'techniques', 'employ', 'different', 'mechanisms', ',', 'and', 'the', 'ability', 'to', 'learn', 'the', 'technique', 'plays', 'a', 'key', 'role', 'in', 'its', 'proper', 'implementation', 'and', 'effectiveness', '.', 'The', 'objective', 'is', 'compare', 'the', 'effects', 'of', 'AS', 'and', 'GPB', 'on', 'the', 'MIC', 'in', 'patients', 'with', 'NMD', '.', '\n\n', 'Children', 'and', 'adolescents', 'with', 'NMD', 'who', 'were', 'users', 'of', 'non', '-', 'invasive', 'mechanical', 'ventilation', 'were', 'recruited', '.', 'Vital', 'capacity', '(', 'VC', ')', 'and', 'MIC', 'were', 'measured', 'prior', 'to', 'and', 'after', 'the', 'intervention', 'with', 'AS', 'and', 'GPB', '.', 'Values', 'were', 'compared', 'pre-', 'and', 'post', '-', 'intervention', 'and', 'were', 'considered', 'statistically', 'significant', 'if', 'p', '<', '0.05', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02500030,NCT02500030,"Effects of Air Stacking Versus Glossopharyngeal Breathing on Maximum Insufflation Capacity in Children and Adolescents With Neuromuscular Disease | Neuromuscular diseases (NMD) are characterized by a reduced maximum insufflation capacity (MIC), which contributes to increased morbidity and mortality from respiratory diseases. Techniques such as glossopharyngeal breathing (GPB) and insufflation using a manual resuscitation bag, or ""air stacking (AS)"", can be used to increase the MIC. These techniques employ different mechanisms, and the ability to learn the technique plays a key role in its proper implementation and effectiveness. The objective is compare the effects of AS and GPB on the MIC in patients with NMD.

Children and adolescents with NMD who were users of non-invasive mechanical ventilation were recruited. Vital capacity (VC) and MIC were measured prior to and after the intervention with AS and GPB. Values were compared pre- and post-intervention and were considered statistically significant if p <0.05.","[(11, 23, 'OTHER', 'Air Stacking'), (31, 57, 'OTHER', 'Glossopharyngeal Breathing'), (124, 145, 'CONDITION', 'Neuromuscular Disease'), (148, 170, 'CONDITION', 'Neuromuscular diseases'), (172, 175, 'CONDITION', 'NMD'), (346, 372, 'OTHER', 'glossopharyngeal breathing'), (374, 377, 'OTHER', 'GPB'), (434, 446, 'OTHER', 'air stacking'), (448, 450, 'OTHER', 'AS'), (677, 679, 'OTHER', 'AS'), (684, 687, 'OTHER', 'GPB'), (716, 719, 'CONDITION', 'NMD'), (752, 755, 'CONDITION', 'NMD'), (909, 911, 'OTHER', 'AS'), (916, 919, 'OTHER', 'GPB')]"
"['Phase', 'II', 'Study', 'of', 'Intrathecal', 'Ziconotide', 'for', 'the', 'Treatment', 'of', 'Neuropathic', 'Pain', 'in', 'Patients', 'With', 'Cancer', '|', 'Neuropathic', 'pain', 'is', 'difficult', 'to', 'control', 'because', 'it', 'is', 'only', 'partially', 'sensitive', 'to', 'opioid', 'analgesics', ',', 'and', 'requires', 'the', 'addition', 'of', 'other', 'therapies', 'such', 'as', 'antidepressants', 'and', 'epileptics', '.', 'Ziconotide', 'is', 'a', 'drug', 'that', 'is', 'used', 'to', 'treat', 'neuropathic', 'pain', 'in', 'patients', 'who', 'have', 'had', 'inadequate', 'pain', 'control', 'with', 'prior', 'combination', 'of', 'medicines', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00996983,NCT00996983,"Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer | Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.","[(30, 40, 'DRUG', 'Ziconotide'), (62, 78, 'CONDITION', 'Neuropathic Pain'), (96, 102, 'CONDITION', 'Cancer'), (105, 121, 'CONDITION', 'Neuropathic pain'), (292, 302, 'DRUG', 'Ziconotide'), (335, 351, 'CONDITION', 'neuropathic pain'), (388, 392, 'CONDITION', 'pain')]"
"['Ambroxol', 'as', 'a', 'Disease', '-', 'modifying', 'Treatment', 'to', 'Reduce', 'the', 'Risk', 'of', 'Cognitive', 'Impairment', 'in', 'GBA', '-', 'associated', 'Parkinson', ""'s"", 'Disease', '.', 'A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '2', 'Trial', '|', 'The', 'present', 'multicenter', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'clinical', 'trial', 'will', 'investigate', 'whether', 'the', 'prolonged', 'administration', 'of', 'high', '-', 'dose', 'oral', 'Ambroxol', 'over', '52', 'weeks', 'is', 'safe', ',', 'tolerable', ',', 'able', 'to', 'change', 'Glucocerebrosidase', 'enzyme', 'activity', 'and', 'alpha', '-', 'synuclein', 'levels', 'in', 'the', 'central', 'nervous', 'system', 'and', ',', 'ultimately', ',', 'to', 'reduce', 'the', 'progression', 'of', 'cognitive', 'decline', 'and', 'motor', 'disability', 'in', '60', 'individuals', 'with', 'Parkinson', ""'s"", 'disease', 'with', 'mutations', 'of', 'the', 'glucocerebrosidase', 'gene', '(', 'GBA1', ';', 'OMIM', '606463', ')', '.', '\n\n', 'Participants', 'will', 'undergo', 'clinical', ',', 'biomarker', 'blood', 'and', 'cerebrospinal', 'fluid', 'analysis', ',', 'neuropsychological', ',', 'neuroimaging', 'assessment', 'throughout', 'the', 'course', 'of', 'the', 'study', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05287503,NCT05287503,"Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial | The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463).

Participants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.","[(0, 8, 'DRUG', 'Ambroxol'), (88, 122, 'CONDITION', ""GBA-associated Parkinson's Disease""), (358, 366, 'DRUG', 'Ambroxol'), (616, 681, 'CONDITION', ""Parkinson's disease with mutations of the glucocerebrosidase gene"")]"
"['Efficacy', 'of', 'Lacosamide', 'in', 'Neonatal', 'Status', 'Epilepticus', ':', 'A', 'Randomized', 'Controlled', 'Study', '|', 'Lacosamide', 'in', 'neonatal', 'status', 'epilepticus']","['O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND']",NCT05291455,NCT05291455,Efficacy of Lacosamide in Neonatal Status Epilepticus: A Randomized Controlled Study | Lacosamide in neonatal status epilepticus,"[(12, 22, 'DRUG', 'Lacosamide'), (35, 53, 'CONDITION', 'Status Epilepticus'), (87, 97, 'DRUG', 'Lacosamide'), (110, 128, 'CONDITION', 'status epilepticus')]"
"['Follow', '-', 'up', 'Study', 'of', 'the', 'Effectiveness', 'of', 'Virtual', 'Reality', 'Therapy', 'in', 'MS', 'Patients', '|', 'Different', 'therapies', 'can', 'improve', 'clinical', 'and', 'motor', 'symptoms', 'of', 'multiple', 'sclerosis', '(', 'MS', ')', 'similarly', ',', 'but', 'studies', 'comparing', 'the', 'effects', 'of', 'different', 'exercise', 'therapies', 'on', 'clinical', 'and', 'motor', 'outcomes', 'are', 'scant', '.', 'We', 'compared', 'the', 'effects', 'of', 'exergaming', '(', 'EXE', ')', ',', 'balance', '(', 'BAL', ')', ',', 'cycling', '(', 'CYC', ')', ',', 'proprioceptive', 'neuromuscular', 'facilitation', '(', 'PNF', ')', ',', 'and', 'a', 'standard', 'care', 'wait', '-', 'listed', 'control', 'group', '(', 'CON', ')', 'on', 'clinical', 'and', 'motor', 'symptoms', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'people', 'with', 'MS', '(', 'PwMS', ')', '.', '\n\n', 'Methods', ':', 'PwMS', '(', 'n', '=', '68', ',', '90', '%', 'female', ';', 'age', ',', '47.0', 'yr', ';', 'Expanded', 'Disability', 'Status', 'Scale', 'score', '5', '-', '6', ')', 'were', 'randomized', 'into', 'five', 'groups', '.', 'Before', 'and', 'after', 'the', 'interventions', '(', 'five', 'times', 'a', 'week', 'for', '5', 'wk', ')', ',', 'PwMS', 'were', 'tested', 'for', 'MS', '-', 'related', 'clinical', 'and', 'motor', 'symptoms', '(', 'Multiple', 'Sclerosis', 'Impact', 'Scale-29', '(', 'MSIS-29', ')', ',', 'primary', 'outcome', ')', ',', 'QoL', '(', 'EuroQol', 'Five', 'Dimensions', 'Questionnaire', ')', ',', 'symptoms', 'of', 'depression', ',', 'gait', 'and', 'balance', 'ability', '(', 'Tinetti', 'Assessment', 'Tool', ')', ',', 'static', 'and', 'dynamic', 'balance', 'and', 'fall', 'risk', '(', 'Berg', 'Balance', 'Scale', ')', ',', 'walking', 'capacity', '(', '6', '-', 'min', 'walk', 'test', ')', ',', 'and', 'standing', 'posturography', 'on', 'a', 'force', 'platform', '.', '\n\n', 'Patients', 'were', 'followed', 'up', 'for', '2', 'years', 'after', '5', 'weeks', 'of', 'intensive', 'care', '.', 'Tests', 'are', 'performed', 'every', 'six', 'months', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04550650,NCT04550650,"Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients | Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant. We compared the effects of exergaming (EXE), balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group (CON) on clinical and motor symptoms and quality of life (QoL) in people with MS (PwMS).

Methods: PwMS (n = 68, 90% female; age, 47.0 yr; Expanded Disability Status Scale score 5-6) were randomized into five groups. Before and after the interventions (five times a week for 5 wk), PwMS were tested for MS-related clinical and motor symptoms (Multiple Sclerosis Impact Scale-29 (MSIS-29), primary outcome), QoL (EuroQol Five Dimensions Questionnaire), symptoms of depression, gait and balance ability (Tinetti Assessment Tool), static and dynamic balance and fall risk (Berg Balance Scale), walking capacity (6-min walk test), and standing posturography on a force platform.

Patients were followed up for 2 years after 5 weeks of intensive care. Tests are performed every six months.","[(40, 63, 'OTHER', 'Virtual Reality Therapy'), (67, 69, 'CONDITION', 'MS'), (144, 162, 'CONDITION', 'multiple sclerosis'), (164, 166, 'CONDITION', 'MS'), (314, 324, 'PHYSICAL', 'exergaming'), (326, 329, 'PHYSICAL', 'EXE'), (332, 339, 'PHYSICAL', 'balance'), (341, 344, 'PHYSICAL', 'BAL'), (347, 354, 'PHYSICAL', 'cycling'), (356, 359, 'PHYSICAL', 'CYC'), (362, 403, 'PHYSICAL', 'proprioceptive neuromuscular facilitation'), (405, 408, 'PHYSICAL', 'PNF'), (417, 442, 'CONTROL', 'standard care wait-listed'), (535, 537, 'CONDITION', 'MS'), (760, 762, 'CONDITION', 'MS'), (800, 818, 'CONDITION', 'Multiple Sclerosis'), (921, 931, 'CONDITION', 'depression')]"
"['Paired', 'Integrative', 'Exercise', 'Program', 'for', 'People', 'With', 'Dementia', 'and', 'Caregivers', '|', 'Preventing', 'Loss', 'of', 'Independence', 'through', 'Exercise', '(', 'PLIÉ', ')', 'is', 'a', 'unique', ',', 'multimodal', 'movement', 'program', 'for', 'people', 'with', 'dementia', '(', 'affected', 'individuals', ')', 'that', 'is', 'taught', 'by', 'trained', 'instructors', 'and', 'combines', 'physical', ',', 'mental', 'and', 'social', 'activities', '.', 'The', 'Paired', 'PLIÉ', 'Program', 'is', 'an', 'adapted', 'version', 'designed', 'for', 'pairs', 'of', 'affected', 'individuals', 'and', 'care', 'partners', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'perform', 'a', 'randomized', ',', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'a', 'delayed', 'start', 'design', 'to', 'examine', 'the', 'effects', 'of', 'the', 'Paired', 'PLIÉ', 'Program', 'on', 'function', 'and', 'quality', 'of', 'life', 'in', 'affected', 'individuals', 'and', 'care', 'partners', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02729311,NCT02729311,"Paired Integrative Exercise Program for People With Dementia and Caregivers | Preventing Loss of Independence through Exercise (PLIÉ) is a unique, multimodal movement program for people with dementia (affected individuals) that is taught by trained instructors and combines physical, mental and social activities. The Paired PLIÉ Program is an adapted version designed for pairs of affected individuals and care partners. The goal of this study is to perform a randomized, controlled trial (RCT) with a delayed start design to examine the effects of the Paired PLIÉ Program on function and quality of life in affected individuals and care partners.","[(0, 35, 'PHYSICAL', 'Paired Integrative Exercise Program'), (52, 60, 'CONDITION', 'Dementia'), (78, 126, 'PHYSICAL', 'Preventing Loss of Independence through Exercise'), (128, 132, 'PHYSICAL', 'PLIÉ'), (191, 199, 'CONDITION', 'dementia'), (318, 337, 'PHYSICAL', 'Paired PLIÉ Program'), (554, 573, 'PHYSICAL', 'Paired PLIÉ Program')]"
"['Study', 'Of', 'Reduced', 'Dose', 'Craniospinal', 'Radiotherapy', '(', '1800', 'cGy', ')', 'And', 'Chemotherapy', 'In', 'Children', 'With', 'Newly', '-', 'Diagnosed', 'Standard', '-', 'Risk', 'Posterior', 'Fossa', 'Primitive', 'Neuro', '-', 'ectodermal', 'Tumor', '(', 'PNET', '/', 'Medulloblastoma', ')', '|', 'RATIONALE', ':', 'Radiation', 'therapy', 'uses', 'high', '-', 'energy', 'x', '-', 'rays', 'to', 'damage', 'tumor', 'cells', ',', 'but', 'also', 'damages', 'normal', 'cells', 'in', 'the', 'developing', 'brains', 'of', 'children', '.', 'Combining', 'low', '-', 'dose', 'radiation', 'therapy', 'in', 'combination', 'with', 'chemotherapy', 'should', 'be', 'effective', 'in', 'treating', 'medulloblastoma', 'while', 'avoiding', 'the', 'long', '-', 'term', 'side', 'effects', 'of', 'giving', 'higher', 'dose', 'radiation', 'to', 'children', 'with', 'newly', 'diagnosed', 'average', 'risk', 'medulloblastoma', '.']","['O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00031590,NCT00031590,"Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma) | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher dose radiation to children with newly diagnosed average risk medulloblastoma.","[(9, 47, 'RADIOTHERAPY', 'Reduced Dose Craniospinal Radiotherapy'), (63, 75, 'DRUG', 'Chemotherapy'), (93, 171, 'CONDITION', 'Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor'), (173, 177, 'CONDITION', 'PNET'), (178, 193, 'CONDITION', 'Medulloblastoma'), (208, 225, 'RADIOTHERAPY', 'Radiation therapy'), (351, 377, 'RADIOTHERAPY', 'low-dose radiation therapy'), (398, 410, 'DRUG', 'chemotherapy'), (443, 458, 'CONDITION', 'medulloblastoma'), (523, 532, 'RADIOTHERAPY', 'radiation'), (550, 594, 'CONDITION', 'newly diagnosed average risk medulloblastoma')]"
"['Follow', '-', 'up', 'of', 'Patients', ""'"", 'Physical', 'Activity', 'in', 'Post', '-', 'hospitalization', 'by', 'Implementation', 'of', 'Systems', 'of', 'Active', 'Monitoring', '.', '|', 'Physical', 'exercise', 'has', 'been', 'identified', 'as', 'a', 'major', 'item', 'of', 'many', 'affecting', 'many', 'chronic', 'diseases', 'and', 'stroke', 'rehabilitation', '.', 'It', 'contributes', 'to', 'an', 'improvement', 'in', 'the', 'quality', 'of', 'life', 'and', 'to', 'a', 'decrease', 'in', 'the', 'current', 'treatment', 'side', '-', 'effects', 'and', 'mortality', '.', 'Stroke', 'in', 'association', 'with', 'an', 'inactive', 'lifestyle', 'lead', 'to', 'a', 'decrease', 'in', 'physical', 'capability', 'and', 'causes', 'problems', 'in', 'daily', 'activities', '.', 'The', 'physical', 'capacity', 'and', 'the', 'tolerance', 'for', 'exercise', 'fall', 'simultaneously', 'leading', 'to', 'vicious', 'circle', 'of', 'less', 'and', 'less', 'mobility', '.', 'Therefore', ',', 'physical', 'activity', 'for', 'the', 'health', 'is', 'a', 'valid', 'and', 'relevant', 'way', 'to', 'improve', 'the', 'quality', 'of', 'life', 'and', 'to', 'recover', 'functional', 'capacity', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'the', 'assessment', 'of', 'the', 'effects', 'of', 'a', 'incentive', 'program', 'for', 'physical', 'activity', 'on', 'people', 'following', '/', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01822938,NCT01822938,"Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring. | Physical exercise has been identified as a major item of many affecting many chronic diseases and stroke rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side-effects and mortality. Stroke in association with an inactive lifestyle lead to a decrease in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to vicious circle of less and less mobility. Therefore, physical activity for the health is a valid and relevant way to improve the quality of life and to recover functional capacity. The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke.","[(86, 114, 'OTHER', 'Systems of Active Monitoring'), (216, 222, 'CONDITION', 'stroke'), (366, 372, 'CONDITION', 'Stroke'), (822, 861, 'OTHER', 'incentive program for physical activity'), (887, 893, 'CONDITION', 'stroke')]"
"['Open', '-', 'label', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'Study', 'of', 'Central', 'D2', '-', 'receptor', 'Occupancy', 'in', 'Healthy', 'Subjects', 'Following', 'a', 'Single', 'Oral', 'Dose', 'of', 'OROS', 'Paliperidone', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'estimate', 'the', 'relationship', 'of', 'D2', '-', 'receptor', 'occupancy', 'to', 'plasma', 'concentration', 'and', 'to', 'assess', 'the', 'safety', 'of', 'OROS', 'paliperidone', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00796432,NCT00796432,Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone | The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.,"[(142, 154, 'DRUG', 'Paliperidone'), (299, 311, 'DRUG', 'paliperidone')]"
"['Cerebellar', 'rTMS', 'Theta', 'Burst', 'for', 'Dual', '-', 'task', 'Walking', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'a', 'Double', 'Blind', 'Cross', '-', 'over', 'Sham', '-', 'controlled', 'Study', 'Using', 'Wearing', 'Sensors', 'Technology', '|', 'Objective', 'of', 'the', 'study', ':', '\n\n', 'To', 'test', 'the', 'efficacy', 'of', 'theta', 'burst', 'cerebellar', 'stimulation', 'on', 'dual', 'task', 'walking', 'in', 'Parkinson', ""'s"", 'disease', 'using', 'a', 'cross', '-', 'over', 'design', 'and', 'wearing', 'sensors', 'technology', '\n\n', 'Design', ':', '\n\n', 'Twenty', 'Parkinson', ""'s"", 'disease', 'patients', 'with', 'no', 'dementia', 'will', 'be', 'recruited', 'for', 'a', 'cross', '-', 'over', 'sham', '-', 'controlled', 'study', '.', 'Each', 'patient', 'will', 'undergo', 'a', 'sham', 'stimulation', 'or', 'a', 'single', 'session', 'of', 'cerebellar', 'theta', 'burst', 'stimulation', 'with', 'a', 'wash', 'out', 'period', 'of', 'at', 'least', '14', 'days', '.', '\n\n', 'Each', 'patient', 'will', 'be', 'evaluated', 'before', 'and', 'after', 'stimulation', 'by', 'a', 'battery', 'of', 'gait', 'and', 'movement', 'tests', 'using', 'wearing', 'sensors', 'technology', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",NCT04238000,NCT04238000,"Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease:a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology | Objective of the study:

To test the efficacy of theta burst cerebellar stimulation on dual task walking in Parkinson's disease using a cross-over design and wearing sensors technology

Design:

Twenty Parkinson's disease patients with no dementia will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days.

Each patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology .","[(0, 27, 'OTHER', 'Cerebellar rTMS Theta Burst'), (53, 72, 'CONDITION', ""Parkinson's Disease""), (99, 103, 'CONTROL', 'Sham'), (135, 153, 'OTHER', 'Sensors Technology'), (205, 239, 'OTHER', 'theta burst cerebellar stimulation'), (264, 283, 'CONDITION', ""Parkinson's disease""), (322, 340, 'OTHER', 'sensors technology'), (358, 377, 'CONDITION', ""Parkinson's disease""), (439, 443, 'CONTROL', 'sham'), (490, 506, 'CONTROL', 'sham stimulation'), (530, 564, 'OTHER', 'cerebellar theta burst stimulation'), (724, 742, 'OTHER', 'sensors technology')]"
"['Phase', '2B', 'Study', 'of', 'Tenecteplase', '(', 'TNK', ')', 'in', 'Acute', 'Ischemic', 'Stroke', '(', 'TNK', '-', 'S2B', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'which', 'of', '3', 'different', 'doses', 'of', 'tenecteplase', '(', 'TNK', ')', 'is', 'better', 'for', 'treating', 'stroke', 'patients', 'and', 'if', 'TNK', 'offers', 'an', 'advantage', 'over', 'currently', 'available', 'treatment', 'with', 'tissue', 'plasminogen', 'activator', '(', 'tPA', ')', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O']",NCT00252239,NCT00252239,Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B) | The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).,"[(18, 30, 'DRUG', 'Tenecteplase'), (32, 35, 'DRUG', 'TNK'), (40, 61, 'CONDITION', 'Acute Ischemic Stroke'), (146, 158, 'DRUG', 'tenecteplase'), (160, 163, 'DRUG', 'TNK'), (188, 194, 'CONDITION', 'stroke'), (211, 214, 'DRUG', 'TNK'), (275, 303, 'CONTROL', 'tissue plasminogen activator'), (305, 308, 'CONTROL', 'tPA')]"
"['An', 'Integrated', 'Solution', 'for', 'Sustainable', 'Care', 'for', 'Multimorbid', 'Elderly', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'or', 'Mild', 'Dementia', '(', 'CAREPATH', ')', '|', 'The', 'CAREPATH', 'will', 'conduct', 'Technical', 'Validation', 'and', 'Usability', '(', 'TVU', ')', 'study', 'by', 'involving', '≥', '45', 'target', 'end', 'users', '(', '16', 'patients', 'with', 'MCI', 'or', 'mild', 'dementia', 'with', 'their', 'informal', 'caregivers', 'and', '16', 'healthcare', 'professionals', 'from', 'various', 'disciplines', ')', 'and', 'Clinical', 'Investigation', '(', 'CI', ')', 'study', 'involving', '≥', '200', 'patients', '(', '≥', '100', 'users', 'to', 'pilot', 'the', 'CAREPATH', 'platform', 'and', '≥', '100', 'patients', 'as', 'reference', 'cases', ')', '.', 'Both', 'of', 'these', 'pilot', 'studies', 'will', 'be', 'coordinated', 'in', 'four', 'European', 'countries', '(', 'Spain', ',', 'Romania', ',', 'Germany', 'and', 'UK', ')', 'with', 'diverse', 'health', 'and', 'social', 'care', 'systems', ',', 'ICT', 'landscape', '/', 'digital', 'maturity', 'of', 'healthcare', 'provision', 'and', 'dementia', 'national', 'programs', ',', 'which', 'will', 'allow', 'for', 'strengthening', 'the', 'evidence', 'base', 'on', 'health', 'outcomes', 'and', 'efficiency', 'gains', '.', '\n\n', 'The', 'CAREPATH', 'outcomes', 'can', 'be', 'summarized', 'as', ':', '\n\n', 'An', 'Integrated', 'Care', 'Platform', 'that', 'jointly', 'addresses', 'multimorbidity', ',', 'dementia', 'and', 'diminished', 'intrinsic', 'capacity', 'and', 'optimally', 'manages', 'healthcare', 'interventions', 'for', 'its', 'users', '(', 'patients', ',', 'informal', 'caregiver', ',', 'healthcare', 'providers', ',', 'etc', ')', '.', '\n', 'Technical', 'Validation', 'and', 'Usability', '(', 'TVU', ')', 'study', 'involving', 'over', '45', 'users', 'and', 'Clinical', 'Investigation', '(', 'CI', ')', 'involving', 'over', '200', 'patients', 'that', 'will', 'be', 'conducted', 'in', 'four', 'European', 'countries', '(', 'Spain', ',', 'Romania', ',', 'Germany', 'and', 'UK', ')', 'during', 'two', 'years', 'and', 'mobilizing', 'the', 'other', 'necessary', 'actors', ',', 'such', 'as', 'caregivers', 'and', 'healthcare', 'professionals', ',', 'for', 'the', 'validation', 'of', 'healthcare', 'interventions', '.', '\n', 'Dementia', '/', 'Multimorbidity', 'Guidelines', 'that', 'will', 'be', 'conceived', 'for', 'best', 'healthcare', 'delivery', '.', '\n', 'Health', 'Economics', 'Impact', 'Assessment', 'for', 'healthcare', 'cost', 'effectiveness', 'and', 'care', 'provision', 'equalities', '.', 'The', 'incremental', 'cost', '-', 'effectiveness', 'and', 'the', 'incremental', 'cost', '-', 'utility', 'ratio', 'would', 'allow', 'revealing', 'the', 'incremental', 'cost', '(', 'or', 'the', 'potential', 'savings', ')', 'per', 'unit', 'of', 'benefit', 'of', 'switching', 'from', 'usual', 'care', 'to', 'CAREPATH', '-', 'an', 'integrated', 'patient', '-', 'centred', 'approach-', 'in', 'multimorbid', 'elderly', 'patients', 'with', 'dementia', ',', 'and', 'therefore', ',', 'to', 'determinate', 'whether', 'the', 'CAREPATH', 'approach', 'would', 'be', 'considered', 'as', 'a', 'cost', '-', 'effective', 'alternative', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05104593,NCT05104593,"An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Mild Cognitive Impairment or Mild Dementia (CAREPATH) | The CAREPATH will conduct Technical Validation and Usability (TVU) study by involving ≥ 45 target end users (16 patients with MCI or mild dementia with their informal caregivers and 16 healthcare professionals from various disciplines) and Clinical Investigation (CI) study involving ≥ 200 patients (≥ 100 users to pilot the CAREPATH platform and ≥ 100 patients as reference cases). Both of these pilot studies will be coordinated in four European countries (Spain, Romania, Germany and UK) with diverse health and social care systems, ICT landscape/digital maturity of healthcare provision and dementia national programs, which will allow for strengthening the evidence base on health outcomes and efficiency gains.

The CAREPATH outcomes can be summarized as:

An Integrated Care Platform that jointly addresses multimorbidity, dementia and diminished intrinsic capacity and optimally manages healthcare interventions for its users (patients, informal caregiver, healthcare providers, etc).
Technical Validation and Usability (TVU) study involving over 45 users and Clinical Investigation (CI) involving over 200 patients that will be conducted in four European countries (Spain, Romania, Germany and UK) during two years and mobilizing the other necessary actors, such as caregivers and healthcare professionals, for the validation of healthcare interventions.
Dementia / Multimorbidity Guidelines that will be conceived for best healthcare delivery.
Health Economics Impact Assessment for healthcare cost effectiveness and care provision equalities. The incremental cost-effectiveness and the incremental cost-utility ratio would allow revealing the incremental cost (or the potential savings) per unit of benefit of switching from usual care to CAREPATH-an integrated patient-centred approach- in multimorbid elderly patients with dementia, and therefore, to determinate whether the CAREPATH approach would be considered as a cost-effective alternative.","[(3, 43, 'OTHER', 'Integrated Solution for Sustainable Care'), (48, 59, 'CONDITION', 'Multimorbid'), (82, 107, 'CONDITION', 'Mild Cognitive Impairment'), (111, 124, 'CONDITION', 'Mild Dementia'), (126, 134, 'OTHER', 'CAREPATH'), (142, 150, 'OTHER', 'CAREPATH'), (264, 267, 'CONDITION', 'MCI'), (271, 284, 'CONDITION', 'mild dementia'), (463, 471, 'OTHER', 'CAREPATH'), (860, 868, 'OTHER', 'CAREPATH'), (904, 928, 'OTHER', 'Integrated Care Platform'), (952, 966, 'CONDITION', 'multimorbidity'), (968, 976, 'CONDITION', 'dementia'), (981, 1010, 'CONDITION', 'diminished intrinsic capacity'), (1888, 1896, 'OTHER', 'CAREPATH'), (1900, 1936, 'OTHER', 'integrated patient-centred approach-'), (1940, 1951, 'CONDITION', 'multimorbid'), (1974, 1982, 'CONDITION', 'dementia'), (2026, 2034, 'OTHER', 'CAREPATH')]"
"['Physical', 'Therapy', 'Versus', 'Control', 'in', 'the', 'Treatment', 'of', 'Carpal', 'Tunnel', 'Syndrome', '|', 'In', 'the', 'present', 'investigation', 'the', 'pain', 'reduction', 'effects', 'of', 'a', 'physical', 'therapy', 'technique', 'will', 'be', 'compared', 'to', 'those', 'produced', 'by', 'the', 'absence', 'of', 'treatment', ',', 'in', 'subjects', 'who', 'suffer', 'the', 'signs', 'and', 'symptoms', 'of', 'carpal', 'tunnel', 'syndrome', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04329247,NCT04329247,"Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome | In the present investigation the pain reduction effects of a physical therapy technique will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.","[(0, 16, 'PHYSICAL', 'Physical Therapy'), (52, 74, 'CONDITION', 'Carpal Tunnel Syndrome'), (110, 114, 'CONDITION', 'pain'), (138, 154, 'PHYSICAL', 'physical therapy'), (207, 227, 'CONTROL', 'absence of treatment'), (278, 300, 'CONDITION', 'carpal tunnel syndrome')]"
"['The', 'Acute', 'Effect', 'of', 'Lumbo', '-', 'sacral', 'Mobilization', 'on', 'Functional', 'Activities', ',', 'Balance', 'and', 'Gait', 'in', 'Patients', 'With', 'Idiopathic', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', 'is', 'a', 'neurodegenerative', 'disease', 'including', 'resting', 'tremor', ',', 'bradykinesia', ',', 'rigidity', 'and', 'postural', 'instability', '.', 'In', 'addition', ',', 'postural', 'disorders', ',', 'motor', 'freezing', ',', 'gait', 'disturbances', ',', 'decreased', 'arm', 'swing', 'and', 'axial', 'rotation', 'loss', 'accompany', 'the', 'disease', '.', 'There', 'is', 'an', 'important', 'relationship', 'between', 'axial', 'rotation', 'and', 'turning', ',', 'which', 'is', 'one', 'of', 'many', 'activities', 'in', 'daily', 'life', '.', 'Parkinson', ""'s"", 'patients', 'with', 'loss', 'of', 'axial', 'rotation', 'have', 'a', 'difficulty', 'gait', ',', 'daily', 'living', 'activities', 'and', 'is', 'associated', 'with', 'falls', '.', '\n\n', 'Classical', 'physiotherapy', 'methods', 'for', 'Parkinson', ""'s"", 'patients', 'such', 'as', 'stretching', ',', 'strengthening', 'and', 'posture', 'exercises', ',', 'balance', ',', 'coordination', 'and', 'gait', 'training', ',', 'and', 'different', 'methods', 'such', 'as', 'motor', 'imagery', ',', 'sensory', 'stimuli', 'and', 'neurophysiological', 'approaches', 'can', 'be', 'used', 'in', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'patients', '.', 'Although', 'there', 'are', 'applications', 'that', 'can', 'increase', 'axial', 'rotation', 'in', 'physiotherapy', 'programs', ',', 'all', 'programs', 'may', 'be', 'able', 'to', 'focus', 'adequately', 'on', 'the', 'treatment', 'of', 'this', 'symptom', '.', 'In', 'addition', ',', 'according', 'to', 'the', 'literature', ',', 'the', 'effects', 'of', 'all', 'physiotherapy', 'approaches', 'emerge', 'as', 'a', 'result', 'of', 'long', '-', 'term', 'training', '.', '\n\n', 'Mobilization', 'techniques', 'are', 'applications', 'that', 'are', 'included', 'in', 'physiotherapy', 'programs', 'and', 'have', 'a', 'wide', 'area', 'of', 'use', '.', 'It', 'is', 'divided', 'into', 'three', 'subtitles', 'according', 'to', 'its', 'severity', 'and', 'degree', ':', 'Grade', 'A', '(', 'mobilization', ')', ',', 'grade', 'B', '(', 'mobilization', ')', 'and', 'grade', 'C', '(', 'manipulation', ')', '.', '\n\n', 'Considering', 'the', 'effects', 'of', 'mobilization', 'on', 'muscle', 'activation', 'and', 'balance', ',', 'grade', 'A', 'and', 'grade', 'B', 'mobilization', 'applications', 'are', 'likely', 'to', 'increase', 'the', 'mobility', 'of', 'this', 'area', 'when', 'applied', 'on', 'the', 'lumbosacral', 'region', '.', 'Therefore', ',', 'these', 'practices', 'can', 'affect', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'by', 'regulating', 'muscle', 'tone', '(', 'rigidity', ')', 'and', 'muscle', 'activation', 'and', 'reducing', 'axial', 'symptoms', 'in', 'Parkinson', ""'s"", 'patients', '.', 'Based', 'on', 'this', 'information', ',', 'the', 'aim', 'of', 'our', 'study', 'is', 'to', 'investigate', 'the', 'acute', 'effect', 'of', 'lumbosacral', 'mobilization', 'on', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04524182,NCT04524182,"The Acute Effect of Lumbo-sacral Mobilization on Functional Activities, Balance and Gait in Patients With Idiopathic Parkinson's Disease | Parkinson's disease is a neurodegenerative disease including resting tremor, bradykinesia, rigidity and postural instability. In addition, postural disorders, motor freezing, gait disturbances, decreased arm swing and axial rotation loss accompany the disease. There is an important relationship between axial rotation and turning, which is one of many activities in daily life. Parkinson's patients with loss of axial rotation have a difficulty gait, daily living activities and is associated with falls.

Classical physiotherapy methods for Parkinson's patients such as stretching, strengthening and posture exercises, balance, coordination and gait training, and different methods such as motor imagery, sensory stimuli and neurophysiological approaches can be used in the treatment of Parkinson's patients. Although there are applications that can increase axial rotation in physiotherapy programs, all programs may be able to focus adequately on the treatment of this symptom. In addition, according to the literature, the effects of all physiotherapy approaches emerge as a result of long-term training.

Mobilization techniques are applications that are included in physiotherapy programs and have a wide area of use. It is divided into three subtitles according to its severity and degree: Grade A (mobilization), grade B (mobilization) and grade C (manipulation).

Considering the effects of mobilization on muscle activation and balance, grade A and grade B mobilization applications are likely to increase the mobility of this area when applied on the lumbosacral region. Therefore, these practices can affect balance, gait and functional activities by regulating muscle tone (rigidity) and muscle activation and reducing axial symptoms in Parkinson's patients. Based on this information, the aim of our study is to investigate the acute effect of lumbosacral mobilization on balance, gait and functional activities in patients with Parkinson's disease.","[(20, 45, 'OTHER', 'Lumbo-sacral Mobilization'), (106, 136, 'CONDITION', ""Idiopathic Parkinson's Disease""), (139, 158, 'CONDITION', ""Parkinson's disease""), (518, 529, 'CONDITION', ""Parkinson's""), (544, 566, 'CONDITION', 'loss of axial rotation'), (682, 693, 'CONDITION', ""Parkinson's""), (928, 939, 'CONDITION', ""Parkinson's""), (1250, 1273, 'OTHER', 'Mobilization techniques'), (1446, 1458, 'OTHER', 'mobilization'), (1470, 1482, 'OTHER', 'mobilization'), (1497, 1509, 'OTHER', 'manipulation'), (1587, 1632, 'OTHER', 'grade A and grade B mobilization applications'), (1890, 1901, 'CONDITION', ""Parkinson's""), (1998, 2022, 'OTHER', 'lumbosacral mobilization'), (2083, 2102, 'CONDITION', ""Parkinson's disease"")]"
"['Facial', 'Expression', 'Perception', 'by', 'Intensity', 'in', 'Schizophrenia', 'and', '22q11.2', 'Deletion', 'Syndrome', ':', 'Neural', 'Electrophysiological', 'Evidence', 'by', 'Means', 'of', 'Fast', 'Periodic', 'Visual', 'Stimulation', '|', 'Background', ':', '\n\n', 'The', 'present', 'study', 'aims', 'to', 'identify', 'the', 'mechanisms', 'underlying', 'the', 'deficit', 'in', 'facial', 'emotion', 'recognition', 'reported', 'both', 'in', 'schizophrenia', 'and', 'the', '22q11.2', 'deletion', 'syndrome', ',', 'and', 'thus', ',', 'reveal', 'a', 'distinction', 'between', 'the', 'two', 'disorders', '.', 'Indeed', ',', 'despite', 'the', 'clinical', 'overlap', 'between', 'the', 'two', 'syndromes', ',', 'some', 'of', 'the', 'symptoms', 'appear', 'to', 'be', 'specific', 'to', 'only', 'one', 'of', 'them', '.', 'In', 'particular', ',', 'the', 'disturbance', 'of', 'visual', 'functions', 'is', 'specifically', 'observed', 'in', 'the', '22q11.2DS', '.', 'Hence', ',', 'the', 'difficulties', 'in', 'facial', 'emotion', 'recognition', 'in', 'schizophrenia', 'and', 'in', 'the', '22q11.DS', 'are', 'likely', 'accounted', 'by', 'different', 'cognitive', 'impairments', '.', 'Investigating', 'which', 'mechanisms', 'are', 'disturbed', 'would', 'allow', 'a', 'specialized', 'support', 'for', 'patients', '.', '\n\n', 'Our', 'main', 'hypothesis', 'is', 'that', 'the', 'deficit', 'in', 'facial', 'emotion', 'recognition', 'is', 'more', 'related', 'to', 'visual', 'impairments', 'in', 'the', '22q11.2DS', 'than', 'in', 'schizophrenia', '.', 'This', 'hypothesis', 'will', 'be', 'tested', 'in', 'two', 'groups', 'of', 'patients', '(', '22q11.2DS', 'and', 'schizophrenic', 'patients', ')', 'and', 'a', 'control', 'group', '(', 'healthy', 'subjects', ')', 'using', 'an', 'experimental', 'paradigm', 'based', 'on', 'electroencephalography', '(', 'EEG', ')', '.', '\n\n', 'A', 'second', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'the', 'severity', 'of', 'the', 'two', 'disorders', ""'"", 'symptoms', 'is', 'correlated', 'with', 'the', 'cerebral', 'response', 'to', 'facial', 'expressions', '.', 'To', 'answer', 'this', 'question', ',', 'a', 'set', 'of', 'clinical', 'and', 'neuropsychological', 'tests', 'will', 'be', 'conducted', 'for', 'each', 'patient', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02634671,NCT02634671,"Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation | Background:

The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients.

Our main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG).

A second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.","[(45, 58, 'CONDITION', 'Schizophrenia'), (63, 88, 'CONDITION', '22q11.2 Deletion Syndrome'), (307, 320, 'CONDITION', 'schizophrenia'), (329, 354, 'CONDITION', '22q11.2 deletion syndrome'), (625, 634, 'CONDITION', '22q11.2DS'), (693, 706, 'CONDITION', 'schizophrenia'), (718, 726, 'CONDITION', '22q11.DS'), (993, 1002, 'CONDITION', '22q11.2DS'), (1011, 1024, 'CONDITION', 'schizophrenia'), (1084, 1093, 'CONDITION', '22q11.2DS'), (1098, 1111, 'CONDITION', 'schizophrenic')]"
"['An', 'Open', '-', 'Label', 'Long', 'Term', 'Effectiveness', 'and', 'Safety', 'Study', 'of', 'Oxymorphone', 'Extended', 'Release', 'Tablets', 'in', 'Patients', 'With', 'Cancer', 'or', 'Neuropathic', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'Oxymorphone', 'Extended', 'Release', 'is', 'effective', 'and', 'safe', 'in', 'treating', 'chronic', 'pain', 'in', 'patients', 'with', 'cancer', 'or', 'neuropathic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT00911261,NCT00911261,An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain | The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.,"[(58, 69, 'DRUG', 'Oxymorphone'), (112, 118, 'CONDITION', 'Cancer'), (122, 138, 'CONDITION', 'Neuropathic Pain'), (186, 197, 'DRUG', 'Oxymorphone'), (249, 261, 'CONDITION', 'chronic pain'), (279, 285, 'CONDITION', 'cancer'), (289, 305, 'CONDITION', 'neuropathic pain')]"
"['The', 'Acute', 'Effects', 'of', 'Passive', 'Vibration', 'on', 'Cardiovascular', 'Function', 'in', 'Individuals', 'With', 'Stroke', '|', 'Stroke', 'is', 'the', 'third', 'leading', 'cause', 'of', 'death', 'in', 'the', 'United', 'States', '.', 'Of', 'those', 'who', 'are', 'affected', 'by', 'stroke', ',', 'a', 'third', 'becomes', 'permanently', 'disabled', '.', 'Risk', 'factors', 'for', 'stroke', 'include', ',', 'but', 'are', 'not', 'limited', 'to', ',', 'advancing', 'age', ',', 'physical', 'inactivity', ',', 'arterial', 'stiffness', ',', 'and', 'most', 'commonly', ',', 'high', 'blood', 'pressure', '.', 'Stroke', 'is', 'a', 'major', 'form', 'of', 'a', 'much', 'boarder', 'problem', ',', 'cardiovascular', 'disease', '(', 'CVD', ')', '.', 'CVD', 'is', 'considered', 'the', 'primary', 'cause', 'of', 'death', 'in', 'the', 'US', '.', 'Interestingly', ',', 'increased', 'arterial', 'stiffness', 'of', 'elastic', 'arteries', '(', 'carotid', 'and', 'aorta', ')', 'has', 'been', 'shown', 'to', 'be', 'strongly', 'correlated', 'to', 'CVD', 'and', 'stroke', '.', 'Increased', 'arterial', 'stiffness', 'is', 'considered', 'an', 'independent', 'risk', 'for', 'the', 'development', 'of', 'CVD', 'and', 'stroke', '.', 'Hence', ',', 'arterial', 'stiffness', 'has', 'been', 'suggested', 'as', 'a', 'potential', 'therapeutic', 'target', 'for', 'CVD', 'and', 'more', 'specifically', 'stroke', '.', '\n\n', 'Recently', ',', 'whole', '-', 'body', 'vibration', '(', 'WBV', ')', 'exercise', 'has', 'been', 'proposed', 'as', 'a', 'new', 'and', 'effective', 'method', 'to', 'improve', 'muscle', 'mass', 'and', 'muscle', 'strength', 'in', 'younger', 'and', 'older', 'individuals', '.', 'It', 'is', 'known', 'that', 'systemic', 'arterial', 'stiffness', 'decreased', '40', 'min', 'after', 'a', 'single', 'WBV', 'session', 'in', 'healthy', 'men', '.', 'In', 'our', 'laboratory', ',', 'we', 'have', 'shown', 'that', 'leg', 'arterial', 'stiffness', 'decreases', 'after', 'a', 'session', 'of', 'WBV', '.', 'Taken', 'together', ',', 'this', 'data', 'seems', 'to', 'suggest', 'WBV', 'may', 'be', 'used', 'as', 'a', 'viable', 'way', 'to', 'decrease', 'arterial', 'stiffness', '.', 'Special', 'populations', ',', 'such', 'as', 'post', '-', 'stroke', 'patients', ',', 'may', 'be', 'unwilling', 'or', 'unable', 'to', 'perform', 'WBV', 'exercise', 'so', 'an', 'inactive', 'form', 'of', 'exercise', '(', 'vibration', ')', 'therapy', 'is', 'needed', '.', '\n\n', 'Passive', 'vibration', '(', 'PV', ')', ',', 'allows', 'patients', 'to', 'lie', 'in', 'an', 'inactive', ',', 'supine', 'position', ',', 'with', 'their', 'legs', 'placed', 'onto', 'the', 'vibration', 'plate', '.', 'This', 'exposes', 'the', 'lower', 'limbs', 'to', 'continuous', 'vibration', 'without', 'performing', 'voluntary', 'muscle', 'contraction', '.', 'PV', 'has', 'been', 'shown', 'to', 'increase', 'skin', 'blood', 'flow', 'on', 'the', 'vibrated', 'extremity', 'through', 'vasodilation', 'in', 'healthy', 'individuals', 'and', 'type', '2', 'diabetics', '.', 'Previous', 'work', 'in', 'our', 'laboratory', 'has', 'demonstrated', 'that', 'a', '10', '-', 'min', 'session', 'of', 'PV', 'on', 'the', 'legs', 'decreases', 'augmentation', 'index', '(', 'AIx', ')', ',', 'a', 'marker', 'of', 'pressure', 'wave', 'reflection', ',', 'as', 'well', 'as', 'leg', 'and', 'systemic', 'PWV', 'through', 'decreases', 'in', 'local', 'peripheral', 'resistance', 'in', 'young', 'men', '.', 'However', ',', 'the', 'effects', 'of', 'PV', 'on', 'arterial', 'function', 'in', 'post', '-', 'stroke', 'patients', 'are', 'unknown', '.', '\n\n', 'It', 'is', 'hypothesized', 'that', 'post', '-', 'stroke', 'patients', 'will', 'demonstrate', 'a', 'decrease', 'in', 'leg', 'PWV', 'and', 'central', 'AIx', '.', 'However', ',', 'greater', 'responses', 'are', 'expected', 'with', 'the', 'lower', 'vibration', 'frequency', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01841840,NCT01841840,"The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke | Stroke is the third leading cause of death in the United States. Of those who are affected by stroke, a third becomes permanently disabled. Risk factors for stroke include, but are not limited to, advancing age, physical inactivity, arterial stiffness, and most commonly, high blood pressure. Stroke is a major form of a much boarder problem, cardiovascular disease (CVD). CVD is considered the primary cause of death in the US. Interestingly, increased arterial stiffness of elastic arteries (carotid and aorta) has been shown to be strongly correlated to CVD and stroke. Increased arterial stiffness is considered an independent risk for the development of CVD and stroke. Hence, arterial stiffness has been suggested as a potential therapeutic target for CVD and more specifically stroke.

Recently, whole-body vibration (WBV) exercise has been proposed as a new and effective method to improve muscle mass and muscle strength in younger and older individuals. It is known that systemic arterial stiffness decreased 40 min after a single WBV session in healthy men. In our laboratory, we have shown that leg arterial stiffness decreases after a session of WBV. Taken together, this data seems to suggest WBV may be used as a viable way to decrease arterial stiffness. Special populations, such as post-stroke patients, may be unwilling or unable to perform WBV exercise so an inactive form of exercise (vibration) therapy is needed.

Passive vibration (PV), allows patients to lie in an inactive, supine position, with their legs placed onto the vibration plate. This exposes the lower limbs to continuous vibration without performing voluntary muscle contraction. PV has been shown to increase skin blood flow on the vibrated extremity through vasodilation in healthy individuals and type 2 diabetics. Previous work in our laboratory has demonstrated that a 10-min session of PV on the legs decreases augmentation index (AIx) , a marker of pressure wave reflection, as well as leg and systemic PWV through decreases in local peripheral resistance in young men. However, the effects of PV on arterial function in post-stroke patients are unknown.

It is hypothesized that post-stroke patients will demonstrate a decrease in leg PWV and central AIx. However, greater responses are expected with the lower vibration frequency.","[(21, 38, 'OTHER', 'Passive Vibration'), (86, 92, 'CONDITION', 'Stroke'), (95, 101, 'CONDITION', 'Stroke'), (189, 195, 'CONDITION', 'stroke'), (252, 258, 'CONDITION', 'stroke'), (388, 394, 'CONDITION', 'Stroke'), (438, 460, 'CONDITION', 'cardiovascular disease'), (462, 465, 'CONDITION', 'CVD'), (468, 471, 'CONDITION', 'CVD'), (539, 587, 'CONDITION', 'increased arterial stiffness of elastic arteries'), (652, 655, 'CONDITION', 'CVD'), (660, 666, 'CONDITION', 'stroke'), (668, 696, 'CONDITION', 'Increased arterial stiffness'), (754, 757, 'CONDITION', 'CVD'), (762, 768, 'CONDITION', 'stroke'), (777, 795, 'CONDITION', 'arterial stiffness'), (853, 856, 'CONDITION', 'CVD'), (879, 885, 'CONDITION', 'stroke'), (1076, 1103, 'CONDITION', 'systemic arterial stiffness'), (1206, 1224, 'CONDITION', 'arterial stiffness'), (1346, 1364, 'CONDITION', 'arterial stiffness'), (1400, 1406, 'CONDITION', 'stroke'), (1532, 1549, 'PHYSICAL', 'Passive vibration'), (1551, 1553, 'PHYSICAL', 'PV'), (1693, 1713, 'PHYSICAL', 'continuous vibration'), (1763, 1765, 'PHYSICAL', 'PV'), (1975, 1977, 'PHYSICAL', 'PV'), (2076, 2096, 'PHYSICAL', 'leg and systemic PWV'), (2184, 2186, 'PHYSICAL', 'PV'), (2216, 2222, 'CONDITION', 'stroke'), (2275, 2281, 'CONDITION', 'stroke'), (2322, 2329, 'PHYSICAL', 'leg PWV')]"
"['Effects', 'of', 'Cerebellar', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'During', 'Balance', 'Training', 'on', 'Cerebellar', 'Ataxia', '|', 'Cerebellar', 'ataxia', 'is', 'a', 'neurologic', 'symptom', 'caused', 'by', 'damage', 'or', 'dysfunction', 'in', 'the', 'cerebellum', 'and', 'its', 'pathways', 'that', 'results', 'in', 'loss', 'of', 'coordination', ',', 'balance', 'and', 'postural', 'control', '.', 'There', 'is', 'a', 'high', 'rate', '(', '93', '%', ')', 'of', 'fallings', 'for', 'this', 'population', 'that', 'could', 'limit', 'daily', 'life', 'activities', '.', 'Pharmacological', 'interventions', 'are', 'not', 'able', 'to', 'modify', 'the', 'balance', ',', 'therefore', ',', 'new', 'approaches', 'to', 'rehabilitate', 'must', 'be', 'studied', '.', 'ctDCS', 'is', 'a', 'non', '-', 'invasive', 'brain', 'stimulation', 'that', 'seems', 'to', 'be', 'a', 'new', 'and', 'innovator', 'technique', 'to', 'restore', 'ataxia', 'symptoms', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'ctDCS', 'associated', 'with', 'balance', 'training', 'on', 'cerebellar', 'ataxia', 'patients', '.', 'A', 'counterbalanced', 'crossover', ',', 'sham', '-', 'controlled', ',', 'triple', 'blind', 'trial', 'will', 'be', 'performed', '.', 'All', 'subjects', 'will', 'receive', 'the', 'real', 'and', 'sham', 'ctDCS', 'associated', 'to', 'balance', 'training', '.', 'The', 'anodal', 'ctDCS', '(', '2', 'mA', ',', '20', 'minutes', ')', 'or', 'sham', '(', '2mA', ',', '30', 'seconds', ')', 'will', 'be', 'applied', 'during', 'balance', 'training', 'at', 'Biodex', 'Balance', 'System', '(', 'BBS', ')', '.', 'The', 'balance', 'will', 'be', 'the', 'primary', 'outcome', 'and', 'will', 'be', 'evaluated', 'through', 'Posture', 'Control', 'at', 'Biodex', 'Balance', 'System', '.', 'Ataxia', ""'"", 'severity', 'and', 'functional', 'mobility', 'will', 'be', 'the', 'secondary', 'outcomes', 'and', 'will', 'be', 'evaluated', 'by', 'the', 'scale', 'for', 'the', 'assessment', 'and', 'rating', 'of', 'ataxia', '(', 'SARA', ')', 'and', '10', 'meters', 'walking', 'test', ',', 'respectively', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04039048,NCT04039048,"Effects of Cerebellar Transcranial Direct Current Stimulation During Balance Training on Cerebellar Ataxia | Cerebellar ataxia is a neurologic symptom caused by damage or dysfunction in the cerebellum and its pathways that results in loss of coordination, balance and postural control. There is a high rate (93%) of fallings for this population that could limit daily life activities. Pharmacological interventions are not able to modify the balance, therefore, new approaches to rehabilitate must be studied. ctDCS is a non-invasive brain stimulation that seems to be a new and innovator technique to restore ataxia symptoms. The purpose of this study is to evaluate the effects of ctDCS associated with balance training on cerebellar ataxia patients. A counterbalanced crossover, sham-controlled, triple blind trial will be performed. All subjects will receive the real and sham ctDCS associated to balance training. The anodal ctDCS (2 mA, 20 minutes) or sham (2mA, 30 seconds) will be applied during balance training at Biodex Balance System (BBS). The balance will be the primary outcome and will be evaluated through Posture Control at Biodex Balance System. Ataxia' severity and functional mobility will be the secondary outcomes and will be evaluated by the scale for the assessment and rating of ataxia (SARA) and 10 meters walking test, respectively.","[(11, 61, 'OTHER', 'Cerebellar Transcranial Direct Current Stimulation'), (69, 85, 'PHYSICAL', 'Balance Training'), (89, 106, 'CONDITION', 'Cerebellar Ataxia'), (109, 126, 'CONDITION', 'Cerebellar ataxia'), (510, 515, 'OTHER', 'ctDCS'), (610, 616, 'CONDITION', 'ataxia'), (683, 688, 'OTHER', 'ctDCS'), (725, 742, 'CONDITION', 'cerebellar ataxia'), (782, 786, 'CONTROL', 'sham'), (876, 886, 'CONTROL', 'sham ctDCS'), (930, 935, 'OTHER', 'ctDCS'), (958, 962, 'CONTROL', 'sham'), (1004, 1020, 'PHYSICAL', 'balance training'), (1024, 1045, 'PHYSICAL', 'Biodex Balance System'), (1047, 1050, 'PHYSICAL', 'BBS'), (1142, 1163, 'PHYSICAL', 'Biodex Balance System'), (1165, 1171, 'CONDITION', 'Ataxia'), (1305, 1311, 'CONDITION', 'ataxia')]"
"['Pediatric', 'POTS', ':', 'Does', 'a', 'Periaqueductal', 'Gray', '-', 'vagus', 'Nerve', 'Interface', 'Malfunction', 'Explain', 'the', 'Natural', 'History', 'With', 'Its', 'Numerous', 'Co', '-', 'morbidities', '?', '|', 'This', 'study', 'is', 'being', 'conducted', 'to', 'see', 'how', 'people', 'with', 'Postural', 'tachycardia', 'syndrome', '(', 'POTS', ')', 'make', 'sense', 'of', 'the', 'things', 'they', 'see', '.', 'The', 'information', 'may', 'help', 'doctors', 'to', 'learn', 'more', 'about', 'how', 'the', 'different', 'parts', 'of', 'people', ""'s"", 'brains', 'communicate', '.']","['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05618054,NCT05618054,Pediatric POTS: Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? | This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.,"[(10, 14, 'CONDITION', 'POTS'), (194, 223, 'CONDITION', 'Postural tachycardia syndrome'), (225, 229, 'CONDITION', 'POTS')]"
"['Study', 'to', 'Assess', 'the', 'Immunogenicity', 'and', 'Reactogenicity', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', 'Vaccine', 'Mixed', 'With', 'Hib', 'Vaccine', 'to', 'Healthy', 'Infants', 'at', '3', ',', '5', 'and', '11', 'Months', 'of', 'Age', ',', 'Compared', 'to', 'Each', 'Vaccine', 'Administered', 'Separately', '|', 'This', 'study', 'will', 'assess', 'the', 'immunogenicity', 'and', 'safety', 'of', 'GlaxoSmithKline', '(', 'GSK', ')', 'Biologicals', ""'"", '(', 'formerly', 'SB', 'Biologicals', ""'"", ')', 'DTPa', '-', 'HBV', '-', 'IPV', '/', 'Hib', '(', 'Infanrix', 'hexa', '™', ')', 'vaccine', 'compared', 'with', 'separate', 'administration', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', '(', 'Infanrix', 'penta', '™', ')', 'and', 'Hib', '(', 'Hiberix', '™', ')', 'vaccine', 'administered', 'at', '3', ',', '5', 'and', '11', '(', 'or', '12', ')', 'months', 'of', 'age', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01457508,NCT01457508,"Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately | This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' (formerly SB Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix penta™) and Hib (Hiberix™) vaccine administered at 3, 5 and 11 (or 12) months of age.","[(57, 77, 'DRUG', 'DTPa-HBV-IPV Vaccine'), (89, 100, 'DRUG', 'Hib Vaccine'), (319, 331, 'DRUG', 'DTPa-HBV-IPV'), (332, 335, 'DRUG', 'Hib'), (337, 350, 'DRUG', 'Infanrix hexa'), (402, 414, 'DRUG', 'DTPa-HBV-IPV'), (416, 430, 'DRUG', 'Infanrix penta'), (437, 440, 'DRUG', 'Hib'), (442, 449, 'DRUG', 'Hiberix')]"
"['Effects', 'of', 'Task', '-', 'oriented', 'Training', 'on', 'Functional', 'Mobility', 'and', 'Fatigue', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'inflammatory', ',', 'demyelinating', 'and', 'autoimmune', 'disease', 'of', 'the', 'central', 'nervous', 'system', '.', 'It', 'is', 'usually', 'seen', 'with', 'relapses', 'and', 'genetic', 'and', 'environmental', 'factors', 'play', 'a', 'role', 'in', 'the', 'etiology', '.', 'Neurological', 'symptoms', 'seen', 'in', 'MS', 'restrict', 'the', 'patient', ""'s"", 'daily', 'activity', 'and', 'social', 'role', 'participation', '.', 'Mobility', 'problems', 'and', 'fatigue', 'are', 'the', 'most', 'important', 'reasons', 'of', 'role', 'limitations', 'and', 'decreased', 'quality', 'of', 'life', '.', 'The', 'importance', 'of', 'exercise', 'training', 'in', 'disease', 'management', 'has', 'been', 'emphasized', 'in', 'recent', 'years', '.', 'However', ',', 'few', 'studies', 'have', 'investigated', 'the', 'effects', 'of', 'task', '-', 'oriented', 'trainings', 'on', 'symptoms', 'of', 'the', 'disease', '.', 'The', 'aim', 'of', 'this', 'sudy', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'task', '-', 'oriented', 'training', 'additional', 'to', 'combined', 'exercise', 'training', 'on', 'functional', 'capacity', ',', 'mobility', ',', 'balance', ',', 'fatigue', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'MS', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03497468,NCT03497468,"Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis | Multiple Sclerosis (MS) is inflammatory, demyelinating and autoimmune disease of the central nervous system. It is usually seen with relapses and genetic and environmental factors play a role in the etiology. Neurological symptoms seen in MS restrict the patient's daily activity and social role participation. Mobility problems and fatigue are the most important reasons of role limitations and decreased quality of life. The importance of exercise training in disease management has been emphasized in recent years. However, few studies have investigated the effects of task-oriented trainings on symptoms of the disease. The aim of this sudy is to investigate the effects of task-oriented training additional to combined exercise training on functional capacity, mobility, balance, fatigue and quality of life in patients with MS.","[(11, 33, 'PHYSICAL', 'Task-oriented Training'), (61, 68, 'CONDITION', 'Fatigue'), (86, 104, 'CONDITION', 'Multiple Sclerosis'), (107, 125, 'CONDITION', 'Multiple Sclerosis'), (127, 129, 'CONDITION', 'MS'), (346, 348, 'CONDITION', 'MS'), (418, 435, 'CONDITION', 'Mobility problems'), (440, 447, 'CONDITION', 'fatigue'), (548, 565, 'PHYSICAL', 'exercise training'), (679, 702, 'PHYSICAL', 'task-oriented trainings'), (785, 807, 'PHYSICAL', 'task-oriented training'), (822, 848, 'PHYSICAL', 'combined exercise training'), (892, 899, 'CONDITION', 'fatigue'), (937, 939, 'CONDITION', 'MS')]"
"['Assessing', 'the', 'Effect', 'of', 'Shatavari', 'Supplementation', 'on', 'Bone', 'and', 'Skeletal', 'Muscle', 'Health', 'in', 'Healthy', 'Postmenopausal', 'Women', ':', 'A', 'Randomised', 'Double', 'Blind', 'Clinical', 'Trial', '|', 'Shatavari', 'is', 'a', 'plant', 'that', 'grows', 'in', 'Nepal', ',', 'Sri', 'Lanka', ',', 'India', 'and', 'the', 'Himalayas', 'and', 'its', 'root', 'has', 'long', 'been', 'used', 'in', 'Ayurvedic', 'medicine', '.', 'Its', 'traditional', 'uses', 'include', 'supporting', 'women', ""'s"", 'health', ',', 'particularly', 'during', 'breastfeeding', 'and', 'during', 'the', 'perimenopausal', 'period', '.', 'Shatavari', 'has', 'been', 'found', 'to', 'contain', 'substances', 'that', 'have', 'similar', 'chemical', 'properties', 'to', 'estrogen', '.', 'A', 'decrease', 'in', 'the', 'amount', 'of', 'ovarian', 'estrogen', 'production', 'causes', 'the', 'menopause', 'and', 'this', 'reduction', 'in', 'circulating', 'estrogen', 'has', 'widespread', 'effects', ',', 'including', 'promoting', 'a', 'decrease', 'in', 'bone', 'density', '.', 'This', 'increases', 'the', 'risk', 'of', 'bone', 'fractures', '.', 'Having', 'less', 'oestrogen', 'is', 'also', 'thought', 'to', 'contribute', 'to', 'a', 'loss', 'of', 'muscle', 'strength', 'in', 'postmenopausal', 'women', '.', '\n\n', 'As', 'shatavari', 'may', 'act', 'on', 'the', 'body', ""'s"", 'tissues', 'in', 'a', 'similar', 'way', 'to', 'estrogen', ',', 'shatavari', 'supplementation', 'may', 'represent', 'one', 'way', 'of', 'preventing', 'postmenopausal', 'bone', 'and', 'muscle', 'loss', '.', 'This', 'study', 'will', 'investigate', 'these', 'questions', '.', '24', 'healthy', 'postmenopausal', 'women', 'aged', '60', 'years', 'or', 'older', 'will', 'be', 'recruited', '.', 'The', 'participants', 'will', 'be', 'randomly', 'assigned', 'to', 'consume', 'shatavari', '(', '1000', 'mg', 'per', 'day', ',', 'equivalent', 'to', '26,500', 'mg', 'per', 'day', 'fresh', 'weight', 'shatavari', ')', 'or', 'placebo', '(', '1000', 'mg', 'per', 'day', 'magnesium', 'stearate', ')', 'for', '6', 'weeks', '.', 'Handgrip', 'and', 'knee', 'extensor', 'strength', 'will', 'be', 'measured', 'at', 'baseline', 'and', 'at', '6', 'weeks', '.', 'Vastus', 'lateralis', '(', 'VL', ')', 'muscle', 'biopsy', 'samples', 'will', 'be', 'obtained', 'at', 'baseline', 'and', 'at', '6', 'weeks', 'and', 'analysed', 'for', 'markers', 'of', 'muscle', 'function', 'and', 'protein', 'turnover', '.', 'Plasma', 'and', 'serum', 'samples', 'will', 'be', 'collected', 'via', 'venepuncture', 'and', 'markers', 'of', 'bone', 'turnover', '(', 'P1NP', ',', 'β', '-', 'CTX', ')', 'will', 'be', 'measured', 'at', 'baseline', 'and', 'at', '6', 'weeks', '.', 'Primary', 'human', 'osteoblasts', '(', 'not', 'obtained', 'from', 'these', 'participants', ')', 'will', 'be', 'stimulated', 'with', 'pooled', 'sera', 'from', 'the', 'placebo', 'and', 'shatavari', 'supplementation', 'conditions', 'to', 'assess', 'markers', 'of', 'osteoblast', '(', 'bone', '-', 'building', ')', 'activity', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05025917,NCT05025917,"Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women: A Randomised Double Blind Clinical Trial | Shatavari is a plant that grows in Nepal, Sri Lanka, India and the Himalayas and its root has long been used in Ayurvedic medicine. Its traditional uses include supporting women's health, particularly during breastfeeding and during the perimenopausal period. Shatavari has been found to contain substances that have similar chemical properties to estrogen. A decrease in the amount of ovarian estrogen production causes the menopause and this reduction in circulating estrogen has widespread effects, including promoting a decrease in bone density. This increases the risk of bone fractures. Having less oestrogen is also thought to contribute to a loss of muscle strength in postmenopausal women.

As shatavari may act on the body's tissues in a similar way to estrogen, shatavari supplementation may represent one way of preventing postmenopausal bone and muscle loss. This study will investigate these questions. 24 healthy postmenopausal women aged 60 years or older will be recruited. The participants will be randomly assigned to consume shatavari (1000 mg per day, equivalent to 26,500 mg per day fresh weight shatavari) or placebo (1000 mg per day magnesium stearate) for 6 weeks. Handgrip and knee extensor strength will be measured at baseline and at 6 weeks. Vastus lateralis (VL) muscle biopsy samples will be obtained at baseline and at 6 weeks and analysed for markers of muscle function and protein turnover. Plasma and serum samples will be collected via venepuncture and markers of bone turnover (P1NP, β-CTX) will be measured at baseline and at 6 weeks. Primary human osteoblasts (not obtained from these participants) will be stimulated with pooled sera from the placebo and shatavari supplementation conditions to assess markers of osteoblast (bone-building) activity.","[(24, 49, 'OTHER', 'Shatavari Supplementation'), (96, 110, 'CONDITION', 'Postmenopausal'), (161, 170, 'OTHER', 'Shatavari'), (421, 430, 'OTHER', 'Shatavari'), (838, 852, 'CONDITION', 'postmenopausal'), (864, 873, 'OTHER', 'shatavari'), (934, 959, 'OTHER', 'shatavari supplementation'), (1089, 1103, 'CONDITION', 'postmenopausal'), (1206, 1215, 'OTHER', 'shatavari'), (1279, 1288, 'OTHER', 'shatavari'), (1318, 1336, 'DRUG', 'magnesium stearate'), (1856, 1881, 'OTHER', 'shatavari supplementation')]"
"['Effects', 'of', 'Action', 'Observation', 'Therapy', 'on', 'Stair', 'Walking', ',', 'Balance', ',', 'and', 'Self', '-', 'efficacy', 'in', 'Chronic', 'Stroke', '|', 'This', 'study', 'focuses', 'on', 'the', 'effects', 'of', 'Action', 'Observation', 'therapy', 'on', 'stair', 'walking', ',', 'balance', 'and', 'self', '-', 'efficacy', 'in', 'chronic', 'stroke', 'patients', '.', 'This', 'study', 'will', 'be', 'conducted', 'in', 'Helping', 'Hands', 'Institute', 'of', 'Rehabilitation', 'Sciences', 'and', 'Shifa', 'Surgical', 'Hospital', 'Mansehra', '.', '\n\n', 'It', 'is', 'a', 'Randomized', 'Control', 'Trial', '.', 'Non', 'probability', 'convenient', 'sampling', 'technique', 'will', 'be', 'used', 'to', 'assess', 'a', 'total', 'number', 'of', '40', 'respondents', '.', 'Questionnaires', 'and', 'consent', 'forms', 'will', 'be', 'filled', 'by', 'the', 'respondents', '.', 'Each', 'patient', 'will', 'be', 'screened', 'by', 'using', 'a', 'simple', 'selection', 'Performa', 'relevant', 'to', 'inclusion', 'and', 'exclusion', 'criteria', '.', '\n\n', 'Total', '30', 'patients', 'will', 'be', 'included', 'in', 'the', 'study', 'and', 'then', 'divided', 'into', 'two', 'groups', 'i.e.', 'Action', 'observation', 'therapy', 'and', 'Convention', 'Therapy', 'group', 'with', '15', 'individuals', 'in', 'each', '.', 'Each', 'group', 'will', 'be', 'assessed', 'thrice', 'i.e.', 'pre', ',', 'post', 'and', 'follow', 'up', 'surveys', '.', 'Each', 'of', 'them', 'will', 'receive', 'the', 'convention', 'therapy', 'for', '30', 'mins', 'except', 'for', 'the', 'Action', 'Observation', 'therapy', '(', 'AOT', ')', 'group', ',', 'which', 'will', 'also', 'receive', 'the', 'additional', '30', 'minutes', 'session', 'of', 'action', 'observational', 'training', '.', 'Total', '18', 'sessions', ',', '3', 'days', 'a', 'week', 'for', 'a', 'total', 'of', 'six', 'weeks', 'will', 'be', 'performed', 'on', 'each', 'patient', '.', '\n\n', 'Fugel', 'Meyer', 'Assessment', 'Scale', 'for', 'lower', 'limb', ',', 'Timed', 'Up', 'and', 'Go', 'test', ',', 'Timed', 'Stair', 'Test', ',', 'Step', 'test', 'and', 'self', '-', 'efficacy', 'scale', 'will', 'be', 'used', 'for', 'the', 'assessment', '.', 'Baseline', 'assessments', 'of', 'both', 'group', 'will', 'be', 'done', 'on', '1st', 'week', 'before', 'the', 'application', 'of', 'protocol', ',', 'second', 'assessment', 'will', 'be', 'done', 'on', '4th', 'week', 'and', 'then', 'final', 'assessment', 'will', 'be', 'done', 'on', '6th', 'week', 'of', 'the', 'protocol', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05557968,NCT05557968,"Effects of Action Observation Therapy on Stair Walking, Balance, and Self-efficacy in Chronic Stroke | This study focuses on the effects of Action Observation therapy on stair walking, balance and self-efficacy in chronic stroke patients. This study will be conducted in Helping Hands Institute of Rehabilitation Sciences and Shifa Surgical Hospital Mansehra.

It is a Randomized Control Trial. Non probability convenient sampling technique will be used to assess a total number of 40 respondents. Questionnaires and consent forms will be filled by the respondents. Each patient will be screened by using a simple selection Performa relevant to inclusion and exclusion criteria.

Total 30 patients will be included in the study and then divided into two groups i.e. Action observation therapy and Convention Therapy group with 15 individuals in each. Each group will be assessed thrice i.e. pre, post and follow up surveys. Each of them will receive the convention therapy for 30 mins except for the Action Observation therapy (AOT) group, which will also receive the additional 30 minutes session of action observational training. Total 18 sessions, 3 days a week for a total of six weeks will be performed on each patient.

Fugel Meyer Assessment Scale for lower limb, Timed Up and Go test, Timed Stair Test, Step test and self-efficacy scale will be used for the assessment. Baseline assessments of both group will be done on 1st week before the application of protocol, second assessment will be done on 4th week and then final assessment will be done on 6th week of the protocol.","[(11, 37, 'BEHAVIOURAL', 'Action Observation Therapy'), (86, 100, 'CONDITION', 'Chronic Stroke'), (140, 166, 'OTHER', 'Action Observation therapy'), (214, 228, 'CONDITION', 'chronic stroke'), (766, 792, 'OTHER', 'Action observation therapy'), (797, 815, 'CONTROL', 'Convention Therapy'), (954, 972, 'CONTROL', 'convention therapy'), (1000, 1026, 'BEHAVIOURAL', 'Action Observation therapy'), (1028, 1031, 'BEHAVIOURAL', 'AOT'), (1101, 1130, 'BEHAVIOURAL', 'action observational training')]"
"['EFFECTS', 'OF', 'VAGUS', 'NERVE', 'STIMULATION', 'IN', 'POST', 'COVID-19', 'SYNDROME', ':', 'A', 'RANDOMIZED', 'CONTROLLED', 'TRIAL', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'increase', 'parasympathetic', 'activity', 'and', 'decrease', 'the', 'severity', 'of', 'symptoms', 'by', 'providing', 'vagal', 'stimulation', 'with', 'the', 't', '-', 'VNS', 'method', 'in', 'order', 'to', 'suppress', 'the', 'increased', 'sympathetic', 'activity', 'in', 'patients', 'with', 'prolonged', 'Covid', 'symptoms', '.', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'Question', '1', ':', 'Is', 'left', 'ear', 'transcutaneous', 'vagus', 'nerve', 'stimulation', 'effective', 'in', 'suppressing', 'the', 'symptoms', 'of', 'patients', 'in', 'Post', 'Covid', 'syndrome', '?', '\n\n', 'Question', '2', ':', 'Is', 'bilateral', 'auricular', 'transcutaneous', 'vagus', 'nerve', 'stimulation', 'effective', 'in', 'suppressing', 'the', 'symptoms', 'of', 'patients', 'in', 'Post', 'Covid', 'syndrome', '?', '\n\n', 'A', '5', '-', 'minute', 'heart', 'rate', 'variability', 'measurement', 'will', 'be', 'performed', 'to', 'measure', 'the', 'effectiveness', 'of', 'vagus', 'nerve', 'stimulation', 'in', 'participants', '.', 'HRV', 'is', 'a', 'non', '-', 'invasive', 'method', 'used', 'to', 'evaluate', 'ANS', 'activity', 'and', 'is', 'a', 'measure', 'of', 'heart', 'rate', 'change', 'over', 'a', 'period', 'of', 'time']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05679505,NCT05679505,"EFFECTS OF VAGUS NERVE STIMULATION IN POST COVID-19 SYNDROME: A RANDOMIZED CONTROLLED TRIAL | The aim of this study is to increase parasympathetic activity and decrease the severity of symptoms by providing vagal stimulation with the t-VNS method in order to suppress the increased sympathetic activity in patients with prolonged Covid symptoms.The main question[s] it aims to answer are:

Question 1:Is left ear transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?

Question 2:Is bilateral auricular transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?

A 5-minute heart rate variability measurement will be performed to measure the effectiveness of vagus nerve stimulation in participants.HRV is a non-invasive method used to evaluate ANS activity and is a measure of heart rate change over a period of time","[(11, 34, 'OTHER', 'VAGUS NERVE STIMULATION'), (38, 60, 'CONDITION', 'POST COVID-19 SYNDROME'), (207, 246, 'OTHER', 'vagal stimulation with the t-VNS method'), (320, 335, 'CONDITION', 'prolonged Covid'), (404, 451, 'OTHER', 'left ear transcutaneous vagus nerve stimulation'), (505, 524, 'CONDITION', 'Post Covid syndrome'), (541, 599, 'OTHER', 'bilateral auricular transcutaneous vagus nerve stimulation'), (653, 672, 'CONDITION', 'Post Covid syndrome'), (771, 794, 'OTHER', 'vagus nerve stimulation')]"
"['Influence', 'of', 'Catechol', '-', 'O', '-', 'methyltransferase', 'Polymorphism', 'on', 'Entacapone', 'Efficacy', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Entacapone', 'is', 'an', 'antiparkinsonian', 'drug', 'which', 'block', 'L', '-', 'dopa', 'metabolism', ',', 'inhibiting', 'the', 'C', '-', 'O', '-', 'methyltransferase', '(', 'COMT', ')', 'enzyme', '.', 'There', 'is', 'an', 'individual', 'variability', 'of', 'the', 'COMT', 'activity', 'determined', 'by', 'a', 'genetic', 'polymorphism', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'whether', 'the', 'genetic', 'variability', 'influences', 'entacapone', 'efficacy', 'in', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00373087,NCT00373087,"Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease | Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity determined by a genetic polymorphism. The aim of this study is to investigate whether the genetic variability influences entacapone efficacy in Parkinson's disease.","[(58, 68, 'DRUG', 'Entacapone'), (81, 100, 'CONDITION', ""Parkinson's Disease""), (103, 113, 'DRUG', 'Entacapone'), (402, 412, 'DRUG', 'entacapone'), (425, 444, 'CONDITION', ""Parkinson's disease"")]"
"['The', 'Effect', 'of', 'a', 'Telerehabilitation', 'Virtual', 'Reality', 'Intervention', 'on', 'Functional', 'Upper', 'Limb', 'Activities', 'in', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'aims', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'home', '-', 'based', 'telerehabilitation', 'program', 'specifically', 'designed', 'for', 'upper', 'limbs', ',', 'based', 'on', 'Virtual', 'Reality', '(', 'VR', ')', 'in', 'individuals', 'affected', 'by', 'Multiple', 'Sclerosis', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04032431,NCT04032431,"The Effect of a Telerehabilitation Virtual Reality Intervention on Functional Upper Limb Activities in People With Multiple Sclerosis | This study aims to investigate the effectiveness of a home-based telerehabilitation program specifically designed for upper limbs, based on Virtual Reality (VR) in individuals affected by Multiple Sclerosis.","[(16, 50, 'OTHER', 'Telerehabilitation Virtual Reality'), (115, 133, 'CONDITION', 'Multiple Sclerosis'), (201, 291, 'OTHER', 'telerehabilitation program specifically designed for upper limbs, based on Virtual Reality'), (293, 295, 'OTHER', 'VR'), (324, 342, 'CONDITION', 'Multiple Sclerosis')]"
"['Transformation', 'of', 'Dormant', 'Spinal', 'Networks', 'to', 'Mitigate', 'Symptoms', 'of', 'Neurogenic', 'Bladder', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'SCONE', 'neuromodulation', 'therapy', 'after', '12', 'weeks', 'of', 'therapy', 'in', 'comparison', 'to', 'inactive', 'sham', 'control', 'in', 'improving', 'symptoms', 'of', 'Neurogenic', 'Lower', 'Urinary', 'Tract', 'Dysfunction']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT05301335,NCT05301335,Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder | The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction,"[(0, 41, 'OTHER', 'Transformation of Dormant Spinal Networks'), (66, 84, 'CONDITION', 'Neurogenic Bladder'), (160, 189, 'OTHER', 'SCONE neuromodulation therapy'), (233, 246, 'CONTROL', 'inactive sham'), (280, 322, 'CONDITION', 'Neurogenic Lower Urinary Tract Dysfunction')]"
"['A', 'Phase', 'Ib', 'Study', 'of', 'Nivolumab', 'in', 'Patients', 'With', 'Autoimmune', 'Disorders', 'and', 'Advanced', 'Malignancies', '(', 'AIM', '-', 'NIVO', ')', '|', 'This', 'phase', 'Ib', 'trial', 'studies', 'the', 'side', 'effects', 'of', 'nivolumab', 'and', 'to', 'see', 'how', 'well', 'it', 'works', 'in', 'treating', 'patients', 'with', 'autoimmune', 'disorders', 'and', 'cancer', 'that', 'has', 'spread', 'to', 'other', 'places', 'in', 'the', 'body', 'or', 'can', 'not', 'removed', 'by', 'surgery', '.', 'Immunotherapy', 'with', 'monoclonal', 'antibodies', ',', 'such', 'as', 'nivolumab', ',', 'may', 'help', 'the', 'body', ""'s"", 'immune', 'system', 'attack', 'the', 'cancer', ',', 'and', 'may', 'interfere', 'with', 'the', 'ability', 'of', 'tumor', 'cells', 'to', 'grow', 'and', 'spread', '.']","['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03816345,NCT03816345,"A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.","[(20, 29, 'DRUG', 'Nivolumab'), (47, 67, 'CONDITION', 'Autoimmune Disorders'), (72, 93, 'CONDITION', 'Advanced Malignancies'), (155, 164, 'DRUG', 'nivolumab'), (220, 240, 'CONDITION', 'autoimmune disorders'), (245, 251, 'CONDITION', 'cancer'), (376, 385, 'DRUG', 'nivolumab'), (432, 438, 'CONDITION', 'cancer'), (478, 483, 'CONDITION', 'tumor')]"
"['Dopaminergic', 'Therapy', 'for', 'Frontotemporal', 'Dementia', 'Patients', ':', 'an', 'Interventional', ',', 'Multi', '-', 'site', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'on', 'the', 'Efficacy', 'and', 'Safety', 'of', 'RTG', 'Treatment', 'in', 'Patients', 'With', 'Behavioral', 'FTD', '|', 'This', 'is', 'a', 'phase', 'IIa', '24', '-', 'week', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', '.', 'The', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'Rotigotine', '(', 'RTG', ')', 'transdermal', 'administration', 'at', 'the', 'dosage', 'of', '4', 'mg', 'or', '6', 'mg', 'per', 'day', 'versus', 'Placebo', '(', 'PLC', ')', 'in', 'newly', 'diagnosed', 'behavioural', 'Frontotemporal', 'Dementia', '(', 'bvFTD', ')', 'patients', '.', '75', 'patients', 'with', 'a', 'diagnosis', 'of', 'probable', 'bvFTD', 'will', 'be', 'randomly', 'allocated', 'to', 'the', '3', 'treatment', 'arms', '(', 'RTG', '4mg', '/', 'day', ',', 'RTG', '6mg', '/', 'day', 'or', 'PLC', ')', ',', 'with', '25', 'patients', 'per', 'group', '.', 'Clinical', 'and', 'neurophysiological', 'measurements', 'and', 'brain', 'metabolism', 'via', 'FDG', '-', 'PET', 'will', 'be', 'collected', 'before', 'and', 'after', 'drug', 'administration', '.']","['B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04937452,NCT04937452,"Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients With Behavioral FTD | This is a phase IIa 24-week randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy and safety of Rotigotine (RTG) transdermal administration at the dosage of 4 mg or 6 mg per day versus Placebo (PLC) in newly diagnosed behavioural Frontotemporal Dementia (bvFTD) patients. 75 patients with a diagnosis of probable bvFTD will be randomly allocated to the 3 treatment arms (RTG 4mg/day, RTG 6mg/day or PLC), with 25 patients per group. Clinical and neurophysiological measurements and brain metabolism via FDG-PET will be collected before and after drug administration.","[(0, 20, 'DRUG', 'Dopaminergic Therapy'), (25, 48, 'CONDITION', 'Frontotemporal Dementia'), (116, 123, 'CONTROL', 'Placebo'), (171, 174, 'DRUG', 'RTG'), (202, 216, 'CONDITION', 'Behavioral FTD'), (273, 280, 'CONTROL', 'placebo'), (360, 370, 'DRUG', 'Rotigotine'), (372, 375, 'DRUG', 'RTG'), (449, 456, 'CONTROL', 'Placebo'), (458, 461, 'CONTROL', 'PLC'), (482, 517, 'CONDITION', 'behavioural Frontotemporal Dementia'), (519, 524, 'CONDITION', 'bvFTD'), (577, 582, 'CONDITION', 'bvFTD'), (635, 638, 'DRUG', 'RTG'), (648, 651, 'DRUG', 'RTG'), (663, 666, 'CONTROL', 'PLC')]"
"['Demonstration', 'of', 'mGluR5', 'Overexpression', 'in', 'Amish', 'and', 'Mennonite', 'CNTNAP2', 'Mutation', 'Carriers', '|', 'The', 'primary', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'evaluate', 'the', 'utility', 'of', 'mGluR5', 'binding', 'as', 'measured', 'by', 'PET', 'as', 'a', 'biomarker', 'of', 'the', 'CNTNAP2', 'mutation', 'and', 'related', '/mTOR', 'kinase', 'pathway', 'dysregulation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02572206,NCT02572206,Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers | The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.,"[(62, 87, 'CONDITION', 'CNTNAP2 Mutation Carriers')]"
"['A', 'Pilot', 'Study', 'of', 'Mitoxantrone', 'for', 'the', 'Treatment', 'of', 'Recurrent', 'Neuromyelitis', 'Optica', '(', 'Devic', ""'s"", 'Disease', ')', '|', 'Neuromyelitis', 'optica', '(', 'NMO', ')', 'is', 'a', 'severe', 'demyelinating', 'disease', 'that', 'selectively', 'involves', 'the', 'optic', 'nerves', 'and', 'the', 'spinal', 'cord', 'but', 'usually', 'spares', 'the', 'brain', '.', 'NMO', 'is', 'considered', 'to', 'have', 'a', 'B', 'cell', 'induced', 'pathogenesis', '.', 'Mitoxantrone', '(', 'MITO', ',', 'Novantrone', '®', ')', ',', 'a', 'synthetic', 'anthracenedione', 'approved', 'for', 'worsening', 'relapsing', '-', 'remitting', 'multiple', 'sclerosis', '(', 'MS', ')', 'and', 'secondary', 'progressive', 'MS', ',', 'has', 'been', 'shown', 'to', 'primarily', 'suppress', 'the', 'humoral', 'response', '.', 'We', 'conducted', 'a', 'prospective', '2', '-', 'year', 'study', 'to', 'evaluate', 'the', 'benefit', 'of', 'MITO', 'in', 'five', 'relapsing', 'NMO', 'patients', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",NCT00304291,NCT00304291,"A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to primarily suppress the humoral response. We conducted a prospective 2-year study to evaluate the benefit of MITO in five relapsing NMO patients.","[(17, 29, 'DRUG', 'Mitoxantrone'), (51, 81, 'CONDITION', 'Recurrent Neuromyelitis Optica'), (83, 98, 'CONDITION', ""Devic's Disease""), (102, 122, 'CONDITION', 'Neuromyelitis optica'), (124, 127, 'CONDITION', 'NMO'), (256, 259, 'CONDITION', 'NMO'), (313, 325, 'DRUG', 'Mitoxantrone'), (327, 331, 'DRUG', 'MITO'), (333, 343, 'DRUG', 'Novantrone'), (359, 374, 'DRUG', 'anthracenedione'), (398, 436, 'CONDITION', 'relapsing-remitting multiple sclerosis'), (438, 440, 'CONDITION', 'MS'), (446, 470, 'CONDITION', 'secondary progressive MS'), (598, 602, 'DRUG', 'MITO'), (611, 624, 'CONDITION', 'relapsing NMO')]"
"['Two', 'Interventions', 'for', 'Early', 'Stage', 'Dementia', ':', 'A', 'Comparative', 'Efficacy', 'Trial', '|', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'is', 'increasing', 'exponentially', ',', 'with', 'a', 'projected', 'quadrupling', 'of', 'cases', 'by', 'the', 'mid', '21st', 'century', '.', 'Individuals', 'with', 'AD', 'are', 'at', 'increased', 'risk', 'for', 'a', 'host', 'of', 'medical', 'and', 'psychiatric', 'conditions', ',', 'and', 'evidence', 'is', 'accumulating', 'supporting', 'the', 'efficacy', 'and', 'effectiveness', 'of', 'psychosocial', 'interventions', 'for', 'improving', 'their', 'mood', ',', 'function', ',', 'health', ',', 'and', 'quality', 'of', 'life', '.', 'Such', 'interventions', 'are', 'likely', 'to', 'be', 'most', 'effective', 'when', 'they', 'are', 'implemented', 'during', 'the', 'early', 'stages', 'of', 'dementia', ',', 'when', 'individuals', 'and', 'their', 'family', 'members', 'are', 'coping', 'with', 'the', 'initial', 'diagnosis', 'and', 'associated', 'changes', 'in', 'abilities', 'and', 'activities', '.', 'Recent', 'randomized', 'clinical', 'trials', 'by', 'the', 'Principal', 'Investigator', 'and', 'colleagues', 'have', 'developed', 'two', 'non', '-', 'pharmacologic', 'interventions', 'to', 'reduce', 'the', 'social', ',', 'psychological', ',', 'physical', ',', 'and', 'behavioral', 'impact', 'of', 'dementia', '.', 'This', 'investigation', 'is', 'focused', 'on', 'facilitating', 'their', 'translation', 'into', 'ongoing', 'community', '-', 'based', 'programs', ',', 'such', 'as', 'those', 'provided', 'by', 'Alzheimer', ""'s"", 'Association', 'chapters', ',', 'senior', 'centers', ',', 'retirement', 'homes', ',', 'and', 'other', 'health', 'care', 'providers', '.', 'The', 'core', 'content', 'of', 'each', 'intervention', 'has', 'been', 'retained', 'in', 'order', 'to', 'maintain', 'or', 'improve', 'their', 'efficacy', ',', 'and', 'each', 'has', 'been', 'modified', 'to', 'a', '4', '-', 'week', 'group', 'format', 'to', 'increase', 'efficiency', 'of', 'delivery', '.', 'These', 'modified', 'interventions', '(', 'ESML', '-', 'Social', 'and', 'ESML', '-', 'Ex', ')', 'will', 'be', 'compared', 'to', 'each', 'other', 'and', 'to', 'a', 'usual', 'care', '(', 'UC', ')', 'control', 'group', '.', 'Outcomes', 'will', 'be', 'assessed', 'at', 'baseline', ',', '1', '-', 'month', 'post', 'treatment', ',', 'and', '4', 'month', 'follow', '-', 'up', '.', 'Primary', 'outcomes', 'at', 'the', '1', '-', 'month', 'assessment', 'include', ':', 'social', 'activity', 'participation', ',', 'family', 'communication', ',', 'physical', 'activity', 'participation', ',', 'and', 'physical', 'function', '.', 'Primary', 'outcomes', 'at', '4', '-', 'month', 'follow', 'up', 'include', 'overall', 'quality', 'of', 'life', 'and', 'depression', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Ex', 'and', 'ESML', '-', 'Social', 'both', 'will', 'have', 'greater', 'improvements', 'than', 'UC', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Social', 'will', 'have', 'greater', 'improvements', 'in', 'social', 'participation', 'and', 'family', 'communication', 'than', 'ESML', '-', 'Ex', 'and', 'UC', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Ex', 'will', 'have', 'greater', 'improvements', 'in', 'physical', 'activity', 'participation', 'and', 'physical', 'functioning', 'than', 'ESML', '-', 'Social', 'and', 'UC', '.', 'If', 'successful', ',', 'these', '4', '-', 'week', 'programs', 'may', 'be', 'developed', 'into', '""', 'modules', '""', 'that', 'can', 'be', 'incorporated', 'into', 'programming', 'for', 'individuals', 'with', 'early', 'stage', 'dementia', 'in', 'a', 'variety', 'of', 'community', 'settings', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01550718,NCT01550718,"Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial | Alzheimer's disease (AD) is increasing exponentially, with a projected quadrupling of cases by the mid 21st century. Individuals with AD are at increased risk for a host of medical and psychiatric conditions, and evidence is accumulating supporting the efficacy and effectiveness of psychosocial interventions for improving their mood, function, health, and quality of life. Such interventions are likely to be most effective when they are implemented during the early stages of dementia, when individuals and their family members are coping with the initial diagnosis and associated changes in abilities and activities. Recent randomized clinical trials by the Principal Investigator and colleagues have developed two non-pharmacologic interventions to reduce the social, psychological, physical, and behavioral impact of dementia. This investigation is focused on facilitating their translation into ongoing community-based programs, such as those provided by Alzheimer's Association chapters, senior centers, retirement homes, and other health care providers. The core content of each intervention has been retained in order to maintain or improve their efficacy, and each has been modified to a 4-week group format to increase efficiency of delivery. These modified interventions (ESML-Social and ESML-Ex) will be compared to each other and to a usual care (UC) control group. Outcomes will be assessed at baseline, 1-month post treatment, and 4 month follow-up. Primary outcomes at the 1-month assessment include: social activity participation, family communication, physical activity participation, and physical function. Primary outcomes at 4-month follow up include overall quality of life and depression. It is hypothesized that ESML-Ex and ESML-Social both will have greater improvements than UC. It is hypothesized that ESML-Social will have greater improvements in social participation and family communication than ESML-Ex and UC. It is hypothesized that ESML-Ex will have greater improvements in physical activity participation and physical functioning than ESML-Social and UC. If successful, these 4-week programs may be developed into ""modules"" that can be incorporated into programming for individuals with early stage dementia in a variety of community settings.","[(22, 42, 'CONDITION', 'Early Stage Dementia'), (75, 94, 'CONDITION', ""Alzheimer's disease""), (96, 98, 'CONDITION', 'AD'), (209, 211, 'CONDITION', 'AD'), (554, 562, 'CONDITION', 'dementia'), (1360, 1371, 'OTHER', 'ESML-Social'), (1376, 1383, 'OTHER', 'ESML-Ex'), (1425, 1435, 'CONTROL', 'usual care'), (1437, 1439, 'CONTROL', 'UC'), (1813, 1820, 'OTHER', 'ESML-Ex'), (1825, 1836, 'OTHER', 'ESML-Social'), (1878, 1880, 'CONTROL', 'UC'), (1906, 1917, 'OTHER', 'ESML-Social'), (2003, 2010, 'OTHER', 'ESML-Ex'), (2015, 2017, 'CONTROL', 'UC'), (2043, 2050, 'OTHER', 'ESML-Ex'), (2147, 2158, 'OTHER', 'ESML-Social'), (2163, 2165, 'CONTROL', 'UC'), (2299, 2319, 'CONDITION', 'early stage dementia')]"
"['The', 'Role', 'of', 'Autologous', 'Bone', 'Marrow', 'Mononuclear', 'Cell', 'Therapy', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'study', 'the', 'effect', 'of', 'stem', 'cell', 'therapy', 'in', 'patients', 'with', 'Duchenne', 'Muscular', 'Dystrophy', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02241434,NCT02241434,The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy | The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.,"[(12, 59, 'SURGICAL', 'Autologous Bone Marrow Mononuclear Cell Therapy'), (63, 90, 'CONDITION', 'Duchenne Muscular Dystrophy'), (146, 163, 'SURGICAL', 'stem cell therapy'), (181, 208, 'CONDITION', 'Duchenne Muscular Dystrophy')]"
"['Effect', 'of', 'Fentanyl', 'Given', 'Approximately', 'Ten', 'Minutes', 'to', 'the', 'End', 'of', 'Surgery', 'on', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Adeno', '-', 'tonsilectomy', 'at', 'Kenyatta', 'National', 'Hospital', ':', 'A', 'Randomized', 'Placebo', 'Controlled', 'Clinical', 'Trial', '|', 'This', 'study', 'will', 'be', 'a', 'randomized', 'double', 'blind', 'placebo', 'controlled', 'clinical', 'trial', 'among', 'children', 'undergoing', 'adeno', '-', 'tonsillectomy', 'in', 'KNH', '.', 'The', 'intervention', 'arm', 'will', 'comprise', 'Fentanyl', 'given', 'at', 'a', 'dose', 'of', '1ug', '/', 'while', 'the', 'placebo', 'arm', 'will', 'be', 'given', 'normal', 'saline', 'at', 'a', 'volume', 'equivalent', 'to', 'Fentanyl', 'dose', ',', 'treatment', 'will', 'be', 'administered', 'approximately', 'ten', 'minutes', 'to', 'the', 'end', 'of', 'surgery', 'determined', 'by', 'the', 'time', 'when', 'the', 'mouth', 'gag', 'will', 'be', 'removed', '.', 'The', 'main', 'outcome', 'will', 'be', 'incidence', 'of', 'ED', 'at', 'the', 'recovery', 'room', 'using', 'Watcha', 'scale', 'and', 'secondary', 'outcomes', 'will', 'be', 'delay', 'in', 'emergence', 'time', 'from', 'anaesthesia', 'and', 'effectiveness', 'of', 'fentanyl', 'in', 'preventing', 'ED', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O']",NCT02753725,NCT02753725,"Effect of Fentanyl Given Approximately Ten Minutes to the End of Surgery on Emergence Delirium in Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital: A Randomized Placebo Controlled Clinical Trial | This study will be a randomized double blind placebo controlled clinical trial among children undergoing adeno-tonsillectomy in KNH. The intervention arm will comprise Fentanyl given at a dose of 1ug/while the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose, treatment will be administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed. The main outcome will be incidence of ED at the recovery room using Watcha scale and secondary outcomes will be delay in emergence time from anaesthesia and effectiveness of fentanyl in preventing ED.","[(10, 18, 'DRUG', 'Fentanyl'), (76, 94, 'CONDITION', 'Emergence Delirium'), (118, 136, 'CONDITION', 'Adeno-tonsilectomy'), (181, 188, 'CONTROL', 'Placebo'), (262, 269, 'CONTROL', 'placebo'), (322, 341, 'CONDITION', 'adeno-tonsillectomy'), (385, 393, 'DRUG', 'Fentanyl'), (427, 434, 'CONTROL', 'placebo'), (460, 466, 'CONTROL', 'saline'), (493, 501, 'DRUG', 'Fentanyl'), (684, 686, 'CONDITION', 'ED'), (820, 828, 'DRUG', 'fentanyl'), (843, 845, 'CONDITION', 'ED')]"
"['Effects', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', 'on', 'Ataxia', '-', 'Telangiectasia', '(', 'A', '-', 'T', '):', 'A', 'Multinational', ',', 'Multicenter', ',', 'Open', '-', 'label', ',', 'Rater', '-', 'blinded', 'Phase', 'II', 'Study', '|', 'This', 'is', 'a', 'multinational', ',', 'multicenter', ',', 'open', '-', 'label', ',', 'rater', '-', 'blinded', 'prospective', 'Phase', 'II', 'study', 'which', 'will', 'assess', 'the', 'safety', 'and', 'efficacy', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', '(', 'IB1001', ')', 'for', 'the', 'treatment', 'of', 'Ataxia', '-', 'Telangiectasia', '(', 'A', '-', 'T', ')', '.', '\n\n', 'There', 'are', 'two', 'phases', 'to', 'this', 'study', ':', 'the', 'Parent', 'Study', ',', 'and', 'the', 'Extension', 'Phase', '.', '\n\n', 'The', 'Parent', 'Study', 'evaluates', 'the', 'safety', 'and', 'efficacy', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', '(', 'IB1001', ')', 'for', 'the', 'symptomatic', 'treatment', 'of', 'A', '-', 'T.', '\n\n', 'The', 'Extension', 'Phase', 'evaluates', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'IB1001', 'for', 'the', 'neuroprotective', ',', 'disease', '-', 'modifying', 'treatment', 'of', 'A', '-', 'T.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT03759678,NCT03759678,"Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study | This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T).

There are two phases to this study: the Parent Study, and the Extension Phase.

The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of A-T.

The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of A-T.","[(11, 29, 'DRUG', 'N-Acetyl-L-Leucine'), (33, 54, 'CONDITION', 'Ataxia-Telangiectasia'), (56, 59, 'CONDITION', 'A-T'), (271, 289, 'DRUG', 'N-Acetyl-L-Leucine'), (291, 297, 'DRUG', 'IB1001'), (320, 341, 'CONDITION', 'Ataxia-Telangiectasia'), (343, 346, 'CONDITION', 'A-T'), (484, 502, 'DRUG', 'N-Acetyl-L-Leucine'), (504, 510, 'DRUG', 'IB1001'), (545, 549, 'CONDITION', 'A-T.'), (618, 624, 'DRUG', 'IB1001'), (681, 685, 'CONDITION', 'A-T.')]"
"['ChronOS', 'Stability', 'Study', ':', 'For', 'Metastatic', 'Cancer', '|', 'This', 'pilot', 'clinical', 'trial', 'studies', 'beta', '-', 'tricalcium', 'phosphate', 'bone', 'graft', 'in', 'treating', 'patients', 'undergoing', 'surgery', 'for', 'metastatic', 'spine', 'cancer', '.', 'A', 'bone', 'graft', 'may', 'help', 'healing', 'and', 'bone', 'growth', 'in', 'patients', 'undergoing', 'surgery', 'for', 'spine', 'cancer']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT01407341,NCT01407341,ChronOS Stability Study: For Metastatic Cancer | This pilot clinical trial studies beta-tricalcium phosphate bone graft in treating patients undergoing surgery for metastatic spine cancer. A bone graft may help healing and bone growth in patients undergoing surgery for spine cancer,"[(29, 46, 'CONDITION', 'Metastatic Cancer'), (83, 108, 'DRUG', 'beta-tricalcium phosphate'), (109, 119, 'SURGICAL', 'bone graft'), (164, 187, 'CONDITION', 'metastatic spine cancer'), (191, 201, 'SURGICAL', 'bone graft'), (270, 282, 'CONDITION', 'spine cancer')]"
"['Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '20', '-', 'Week', ',', 'Parallel', 'Group', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', 'and', 'Activity', 'of', 'Oral', 'Fampridine', '-', 'SR', 'in', 'Subjects', 'With', 'Multiple', 'Sclerosis', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'disorder', 'of', 'the', 'body', ""'s"", 'immune', 'system', 'that', 'affects', 'the', 'Central', 'Nervous', 'System', '(', 'CNS', ')', '.', 'Normally', ',', 'nerve', 'fibers', 'carry', 'electrical', 'impulses', 'through', 'the', 'spinal', 'cord', ',', 'providing', 'communication', 'between', 'the', 'brain', 'and', 'the', 'arms', 'and', 'legs', '.', 'In', 'people', 'with', 'MS', ',', 'the', 'fatty', 'sheath', 'that', 'surrounds', 'and', 'insulates', 'the', 'nerve', 'fibers', '(', 'called', '""', 'myelin', '""', ')', 'deteriorates', ',', 'causing', 'nerve', 'impulses', 'to', 'be', 'slowed', 'or', 'stopped', '.', 'As', 'a', 'result', 'patients', 'with', 'MS', 'may', 'experience', 'periods', 'of', 'muscle', 'weakness', 'and', 'other', 'symptoms', 'such', 'as', 'numbness', ',', 'loss', 'of', 'vision', ',', 'loss', 'of', 'coordination', ',', 'paralysis', ',', 'spasticity', ',', 'mental', 'and', 'physical', 'fatigue', 'and', 'a', 'decrease', 'in', 'the', 'ability', 'to', 'think', 'and/or', 'remember', '.', 'These', 'periods', 'of', 'illness', 'may', 'come', '(', 'exacerbations', ')', 'and', 'go', '(', 'remissions', ')', '.', 'Fampridine', '-', 'SR', '(', 'Sustained', 'Release', ',', 'SR', ')', 'is', 'an', 'experimental', 'drug', 'that', 'increases', 'the', 'ability', 'of', 'the', 'nerve', 'to', 'conduct', 'electrical', 'impulses', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effects', 'of', 'Fampridine', '-', 'SR', 'on', 'the', 'walking', 'ability', 'of', 'subjects', 'with', 'MS', ',', 'as', 'well', 'as', 'to', 'examine', 'the', 'effects', 'on', 'muscle', 'strength', 'and', 'spasticity', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'possible', 'risks', 'of', 'taking', 'Fampridine', '-', 'SR', '.']","['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",NCT00053417,NCT00053417,"Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis | Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called ""myelin"") deteriorates, causing nerve impulses to be slowed or stopped. As a result patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR (Sustained Release, SR) is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will evaluate the effects of Fampridine-SR on the walking ability of subjects with MS, as well as to examine the effects on muscle strength and spasticity. The study will also examine the possible risks of taking Fampridine-SR.","[(14, 21, 'CONTROL', 'Placebo'), (118, 128, 'DRUG', 'Fampridine'), (149, 167, 'CONDITION', 'Multiple Sclerosis'), (170, 188, 'CONDITION', 'Multiple Sclerosis'), (190, 192, 'CONDITION', 'MS'), (437, 439, 'CONDITION', 'MS'), (610, 612, 'CONDITION', 'MS'), (741, 751, 'CONDITION', 'spasticity'), (908, 918, 'DRUG', 'Fampridine'), (1082, 1092, 'DRUG', 'Fampridine'), (1136, 1138, 'CONDITION', 'MS'), (1197, 1207, 'CONDITION', 'spasticity'), (1266, 1276, 'DRUG', 'Fampridine')]"
"['Study', 'Proposal', '-', 'A', 'Randomized', 'Double', '-', 'blinded', 'Study', 'Comparing', 'Adding', 'Etoricoxib', 'Versus', 'Placebo', 'to', 'Female', 'Patients', 'With', 'Fibromyalgia', '-', 'analysis', 'of', 'Organic', 'and', 'Psychiatric', 'Measures', '|', 'The', 'main', 'of', 'the', 'proposed', 'study', 'is', 'to', 'assess', 'whether', 'the', 'use', 'of', 'the', 'Cox-2', 'inhibitor', 'Etoricoxib', 'is', 'beneficial', 'for', 'the', 'use', 'in', 'fibromyalgia', '.', 'We', 'intend', 'to', 'seek', 'whether', 'this', 'medication', 'may', 'improve', 'psychiatric', 'and', 'rheumatologic', 'parameters', 'of', 'the', 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00755521,NCT00755521,Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures | The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib is beneficial for the use in fibromyalgia. We intend to seek whether this medication may improve psychiatric and rheumatologic parameters of the disease.,"[(68, 78, 'DRUG', 'Etoricoxib'), (86, 93, 'CONTROL', 'Placebo'), (118, 130, 'CONDITION', 'Fibromyalgia'), (261, 271, 'DRUG', 'Etoricoxib'), (301, 313, 'CONDITION', 'fibromyalgia')]"
"['A', 'Placebo', 'Controlled', 'Double', 'Blind', 'Randomised', 'Controlled', 'Proof', 'of', 'Concept', 'Study', 'of', 'Zolpidem', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Cognitive', 'Deficits', 'in', 'Late', '-', 'stage', 'Parkinson', ""'s"", '|', 'This', 'study', 'will', 'evaluate', 'the', 'motor', 'and', 'cognitive', 'benefits', 'of', 'low', '-', 'dose', 'zolpidem', 'in', 'Parkinson', ""'s"", '.']","['O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O']",NCT03621046,NCT03621046,A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's | This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.,"[(2, 9, 'CONTROL', 'Placebo'), (82, 90, 'DRUG', 'Zolpidem'), (112, 140, 'CONDITION', 'Motor and Cognitive Deficits'), (144, 164, 'CONDITION', 'Late-stage Parkinson'), (239, 247, 'DRUG', 'zolpidem'), (251, 262, 'CONDITION', ""Parkinson's"")]"
"['Feasibility', 'of', 'Virtual', 'Reality', 'Games', 'Using', 'Head', '-', 'mounted', 'Display', 'on', 'Patients', 'With', 'Brain', 'Disorders', '|', 'Because', 'virtual', 'reality', 'can', 'provide', 'more', 'enriched', 'environment', ',', 'repetitive', 'goal', '-', 'oriented', 'tasks', ',', 'and', 'increased', 'patients', ""'"", 'interest', 'and', 'motivation', ',', 'it', 'is', 'expected', 'to', 'stimulate', 'neuroplasticity', 'of', 'injured', 'brain', 'and', 'promote', 'recovery', 'in', 'patients', 'with', 'brain', 'disorders', '.', 'On', 'the', 'other', 'hand', ',', 'immersive', 'virtual', 'reality', 'using', 'a', 'head', '-', 'mounted', 'display', 'has', 'not', 'yet', 'been', 'attempted', 'in', 'the', 'rehabilitation', 'of', 'patients', 'with', 'brain', 'disorders', '.', 'In', 'addition', 'to', 'the', 'benefits', 'of', 'existing', 'virtual', 'reality', 'or', 'game', 'rehabilitation', ',', 'immersive', 'virtual', 'reality', 'can', 'further', 'enhance', 'brain', 'plasticity', ',', 'such', 'as', 'the', 'effect', 'of', 'mirror', 'therapy', 'or', 'action', 'observation', ',', 'through', 'self', '-', 'awareness', 'of', 'the', 'body', 'in', 'the', 'virtual', 'space', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'feasibility', 'of', 'applying', 'the', 'immersive', 'virtual', 'reality', 'using', 'a', 'head', '-', 'mounted', 'display', 'in', 'patients', 'with', 'upper', 'extremity', 'dysfunction', 'due', 'to', 'brain', 'disorders', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT03196739,NCT03196739,"Feasibility of Virtual Reality Games Using Head-mounted Display on Patients With Brain Disorders | Because virtual reality can provide more enriched environment, repetitive goal-oriented tasks, and increased patients' interest and motivation, it is expected to stimulate neuroplasticity of injured brain and promote recovery in patients with brain disorders. On the other hand, immersive virtual reality using a head-mounted display has not yet been attempted in the rehabilitation of patients with brain disorders. In addition to the benefits of existing virtual reality or game rehabilitation, immersive virtual reality can further enhance brain plasticity, such as the effect of mirror therapy or action observation, through self-awareness of the body in the virtual space. The purpose of this study is to investigate the feasibility of applying the immersive virtual reality using a head-mounted display in patients with upper extremity dysfunction due to brain disorders.","[(15, 36, 'OTHER', 'Virtual Reality Games'), (43, 63, 'OTHER', 'Head-mounted Display'), (107, 122, 'OTHER', 'virtual reality'), (378, 403, 'OTHER', 'immersive virtual reality'), (412, 432, 'OTHER', 'head-mounted display'), (556, 571, 'OTHER', 'virtual reality'), (575, 594, 'OTHER', 'game rehabilitation'), (596, 621, 'OTHER', 'immersive virtual reality'), (853, 878, 'OTHER', 'immersive virtual reality'), (887, 907, 'OTHER', 'head-mounted display'), (925, 952, 'CONDITION', 'upper extremity dysfunction')]"
"['An', 'Open', '-', 'label', 'Safety', 'and', 'Efficacy', 'Study', 'of', 'VY', '-', 'AADC01', 'Administered', 'by', 'MRI', '-', 'Guided', 'Convective', 'Infusion', 'Using', 'a', 'Posterior', 'Trajectory', 'Into', 'the', 'Putamen', 'of', 'Participants', 'With', 'Parkinson', ""'s"", 'Disease', 'With', 'Fluctuating', 'Responses', 'to', 'Levodopa', '|', 'Safety', 'and', 'efficacy', 'of', 'AADC', 'gene', 'transfer', 'in', 'participants', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03065192,NCT03065192,An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa | Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.,"[(43, 52, 'OTHER', 'VY-AADC01'), (167, 186, 'CONDITION', ""Parkinson's Disease""), (192, 225, 'CONDITION', 'Fluctuating Responses to Levodopa'), (251, 269, 'OTHER', 'AADC gene transfer'), (291, 310, 'CONDITION', ""Parkinson's disease"")]"
"['Multimodal', 'Opiate', '-', 'sparing', 'Analgesia', 'Versus', 'Traditional', 'Opiate', 'Based', 'Analgesia', 'After', 'Cardiac', 'Surgery', ',', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'To', 'test', 'if', 'multimodal', 'analgesia', 'with', 'different', 'analgesic', 'medication', 'offer', 'better', 'pain', 'relief', ',', 'lesser', 'side', 'effects', 'and', 'is', 'safe', 'compared', 'to', 'conventionel', 'opiod', 'analgesia', 'after', 'cardiac', 'surgery', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O']",NCT01966172,NCT01966172,"Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial | To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.","[(0, 35, 'OTHER', 'Multimodal Opiate-sparing Analgesia'), (43, 77, 'OTHER', 'Traditional Opiate Based Analgesia'), (84, 99, 'CONDITION', 'Cardiac Surgery'), (144, 164, 'OTHER', 'multimodal analgesia'), (271, 299, 'OTHER', 'conventionel opiod analgesia'), (306, 321, 'CONDITION', 'cardiac surgery')]"
"['Randomized', 'Double', 'Blind', 'Placebo', 'Controlled', 'Cross', '-', 'Over', 'Study', 'of', 'Incobotulinum', 'Toxin', 'A', '(', 'Xeomin', '®', ')', 'for', 'Troublesome', 'Sialorrhea', 'in', 'Parkinson', ""'s"", 'Disease', '(', 'PD)/Parkinsonism', 'and', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'Incobotulinum', 'Toxin', 'A', '(', 'Xeomin', '®', ')', 'injections', 'into', 'the', 'parotid', 'and', 'submandibular', 'glands', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'Disease', '/', 'Parkinsonism', 'and', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', 'with', 'troublesome', 'sialorrhea', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT01565395,NCT01565395,Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.,"[(24, 31, 'CONTROL', 'Placebo'), (63, 84, 'DRUG', 'Incobotulinum Toxin A'), (86, 92, 'DRUG', 'Xeomin'), (111, 121, 'CONDITION', 'Sialorrhea'), (125, 144, 'CONDITION', ""Parkinson's Disease""), (167, 196, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (198, 201, 'CONDITION', 'ALS'), (273, 294, 'DRUG', 'Incobotulinum Toxin A'), (296, 302, 'DRUG', 'Xeomin'), (375, 394, 'CONDITION', ""Parkinson's Disease""), (395, 407, 'CONDITION', 'Parkinsonism'), (412, 441, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (443, 446, 'CONDITION', 'ALS'), (465, 475, 'CONDITION', 'sialorrhea')]"
"['An', 'Open', 'Label', 'Study', 'of', 'the', 'Effects', 'of', 'Eculizumab', 'in', 'Neuromyelitis', 'Optica', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'drug', 'eculizumab', 'reduces', 'the', 'attack', 'rate', 'and', 'improves', 'outcome', 'in', 'patients', 'with', 'neuromyelitis', 'optica', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00904826,NCT00904826,An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.,"[(38, 48, 'DRUG', 'Eculizumab'), (52, 72, 'CONDITION', 'Neuromyelitis Optica'), (129, 139, 'DRUG', 'eculizumab'), (202, 222, 'CONDITION', 'neuromyelitis optica')]"
"['Phase', '1', 'Study', 'to', 'Determine', 'the', 'Efficacy', 'of', 'Using', 'Far', 'Infrared', 'Radiation', 'for', 'Stroke', 'Rehabilitation', '|', 'A', 'stroke', 'is', 'a', 'sudden', 'loss', 'of', 'brain', 'function', '.', 'It', 'is', 'caused', 'by', 'the', 'interruption', 'of', 'flow', 'of', 'blood', 'to', 'the', 'brain', '(', 'ischemic', 'stroke', ')', 'or', 'the', 'rupture', 'of', 'blood', 'vessels', 'in', 'the', 'brain', '(', 'hemorrhagic', 'stroke', ')', '.', 'This', 'study', 'will', 'investigate', 'the', 'use', 'of', 'far', 'infrared', 'radiation', 'for', 'stroke', 'rehabilitation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'O', 'O']",NCT00675155,NCT00675155,Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation | A stroke is a sudden loss of brain function. It is caused by the interruption of flow of blood to the brain (ischemic stroke) or the rupture of blood vessels in the brain (hemorrhagic stroke). This study will investigate the use of far infrared radiation for stroke rehabilitation.,"[(49, 71, 'RADIOTHERAPY', 'Far Infrared Radiation'), (76, 82, 'CONDITION', 'Stroke'), (102, 108, 'CONDITION', 'stroke'), (209, 224, 'CONDITION', 'ischemic stroke'), (272, 290, 'CONDITION', 'hemorrhagic stroke'), (332, 354, 'RADIOTHERAPY', 'far infrared radiation'), (359, 365, 'CONDITION', 'stroke')]"
"['A', 'Phase', '2a', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo-', 'and', 'Active', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Multicenter', 'Study', 'to', 'Assess', 'the', 'Safety', 'and', 'Efficacy', 'of', 'ADL5859', '100', 'mg', 'BID', 'in', 'Subjects', 'With', 'Neuropathic', 'Pain', 'Associated', 'With', 'Diabetic', 'Peripheral', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'ADL5859', 'in', 'relieving', 'the', 'pain', 'associated', 'with', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', 'compared', 'with', 'placebo', 'and', 'duloxetine', '(', 'a', 'marketed', 'drug', 'approved', 'for', 'the', 'treatment', 'of', 'painful', 'DPN', ')', '.', 'The', 'pain', 'symptoms', 'of', 'DPN', 'are', 'thought', 'to', 'be', 'due', 'to', 'damage', 'to', 'nerves', 'caused', 'by', 'the', 'diabetes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00603265,NCT00603265,"A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes.","[(38, 46, 'CONTROL', 'Placebo-'), (141, 148, 'DRUG', 'ADL5859'), (177, 193, 'CONDITION', 'Neuropathic Pain'), (210, 240, 'CONDITION', 'Diabetic Peripheral Neuropathy'), (305, 312, 'DRUG', 'ADL5859'), (330, 334, 'CONDITION', 'pain'), (351, 381, 'CONDITION', 'diabetic peripheral neuropathy'), (383, 386, 'CONDITION', 'DPN'), (402, 409, 'CONTROL', 'placebo'), (414, 424, 'DRUG', 'duloxetine'), (480, 483, 'CONDITION', 'DPN'), (490, 494, 'CONDITION', 'pain'), (507, 510, 'CONDITION', 'DPN'), (567, 575, 'CONDITION', 'diabetes')]"
"['Study', 'by', 'Electroencephalography', 'of', 'the', 'Link', 'Between', 'the', 'Lack', 'of', 'Self', '-', 'compassion', 'and', 'the', 'Disorder', 'of', 'Empathy', 'in', 'Schizophrenia', '|', 'This', 'research', 'project', 'focuses', 'on', 'a', 'fundamental', 'element', 'of', 'the', 'psychopathology', 'of', 'schizophrenia', ',', 'that', 'is', 'to', 'say', ',', 'the', 'disorders', 'of', 'self', '-', 'awareness', 'and', 'on', 'the', 'functional', 'alterations', 'associated', 'with', 'it', ',', 'that', 'is', 'to', 'say', ',', 'self', '-', 'compassion', 'deficit', 'and', 'empathy', 'disorder', '.', '\n\n', 'It', 'will', 'be', 'a', 'question', 'of', 'better', 'understanding', 'the', 'neuro', '-', 'functional', 'mechanisms', 'which', 'underlie', 'the', 'lack', 'of', 'self', '-', 'compassion', 'and', 'the', 'disorder', 'of', 'empathy', 'in', 'schizophrenia', ',', 'the', 'relationship', 'that', 'these', 'disorders', 'maintain', 'between', 'them', 'but', 'also', 'the', 'relationship', 'that', 'they', 'maintain', 'with', 'the', 'general', 'psychopathology', 'of', 'schizophrenia', 'and', ',', 'in', 'particular', ',', 'with', 'the', 'abnormalities', 'of', 'the', 'self', '.', 'In', 'other', 'words', ',', 'the', 'overall', 'framework', 'of', 'this', 'project', 'is', 'that', 'of', 'the', 'link', 'between', 'the', 'psychopathology', 'of', 'schizophrenia', 'and', 'the', 'functional', 'impairment', 'associated', 'with', 'it', '.', 'Its', 'specific', 'field', 'of', 'application', 'is', 'that', 'of', 'the', 'link', 'between', 'self', '-', 'awareness', 'disorders', ',', 'self', '-', 'compassion', 'deficit', 'and', 'empathy', 'disorder', '.', 'For', 'this', ',', 'this', 'project', 'proposes', 'a', 'methodological', 'approach', 'combining', 'the', 'recording', 'of', 'intrinsic', 'and', 'extrinsic', 'brain', 'activity', 'using', 'high', '-', 'density', 'electroencephalography', '(', 'EEG', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05464563,NCT05464563,"Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia | This research project focuses on a fundamental element of the psychopathology of schizophrenia, that is to say, the disorders of self-awareness and on the functional alterations associated with it, that is to say, self-compassion deficit and empathy disorder.

It will be a question of better understanding the neuro-functional mechanisms which underlie the lack of self-compassion and the disorder of empathy in schizophrenia, the relationship that these disorders maintain between them but also the relationship that they maintain with the general psychopathology of schizophrenia and, in particular, with the abnormalities of the self. In other words, the overall framework of this project is that of the link between the psychopathology of schizophrenia and the functional impairment associated with it. Its specific field of application is that of the link between self-awareness disorders, self-compassion deficit and empathy disorder. For this, this project proposes a methodological approach combining the recording of intrinsic and extrinsic brain activity using high-density electroencephalography (EEG).","[(56, 79, 'CONDITION', 'Lack of Self-compassion'), (88, 107, 'CONDITION', 'Disorder of Empathy'), (111, 124, 'CONDITION', 'Schizophrenia'), (208, 221, 'CONDITION', 'schizophrenia'), (341, 364, 'CONDITION', 'self-compassion deficit'), (369, 385, 'CONDITION', 'empathy disorder'), (485, 508, 'CONDITION', 'lack of self-compassion'), (517, 536, 'CONDITION', 'disorder of empathy'), (540, 553, 'CONDITION', 'schizophrenia'), (696, 709, 'CONDITION', 'schizophrenia'), (871, 884, 'CONDITION', 'schizophrenia'), (997, 1021, 'CONDITION', 'self-awareness disorders'), (1023, 1046, 'CONDITION', 'self-compassion deficit'), (1051, 1067, 'CONDITION', 'empathy disorder')]"
"['Phase', '1', 'Evaluation', 'of', '[', '18F]MK-6240', 'PET', 'as', 'an', 'Imaging', 'Marker', 'for', 'Tau', 'Protein', 'in', 'the', 'Brain', 'of', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', 'Compared', 'to', 'Healthy', 'Volunteers', '|', 'The', 'overall', 'goal', 'of', 'this', 'protocol', 'is', 'to', 'evaluate', '[', '18F]MK-6240', '(', 'also', 'known', 'as', '[', '18F]MNI-946', ')', 'a', 'tau', 'targeted', 'radiopharmaceutical', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03071224,NCT03071224,Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers | The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.,"[(106, 125, 'CONDITION', ""Alzheimer's Disease"")]"
"['The', 'Impact', 'of', 'Three', 'Distinct', 'Exercise', 'Types', 'on', 'Fatigue', ',', 'Anxiety', ',', 'and', 'Depression', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'learn', 'about', 'the', 'impact', 'of', 'exercise', 'on', 'fatigue', ',', 'anxiety', ',', 'and', 'depression', 'in', 'Parkinson', ""'s"", 'disease', '.', 'It', 'is', 'well', 'established', 'that', 'exercise', 'improves', 'the', 'motor', 'symptoms', 'of', 'Parkinson', ""'s"", 'disease', '.', 'However', ',', 'it', 'is', 'not', 'clear', 'which', 'types', 'of', 'exercise', 'are', 'most', 'beneficial', 'for', 'specific', 'non', '-', 'motor', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02885285,NCT02885285,"The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease | The purpose of the study is to learn about the impact of exercise on fatigue, anxiety, and depression in Parkinson's disease. It is well established that exercise improves the motor symptoms of Parkinson's disease. However, it is not clear which types of exercise are most beneficial for specific non-motor symptoms.","[(29, 37, 'PHYSICAL', 'Exercise'), (47, 54, 'CONDITION', 'Fatigue'), (56, 63, 'CONDITION', 'Anxiety'), (69, 79, 'CONDITION', 'Depression'), (83, 102, 'CONDITION', ""Parkinson's Disease""), (162, 170, 'PHYSICAL', 'exercise'), (174, 181, 'CONDITION', 'fatigue'), (183, 190, 'CONDITION', 'anxiety'), (196, 206, 'CONDITION', 'depression'), (210, 229, 'CONDITION', ""Parkinson's disease""), (259, 267, 'PHYSICAL', 'exercise'), (299, 318, 'CONDITION', ""Parkinson's disease""), (360, 368, 'PHYSICAL', 'exercise')]"
"['A', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', ',', 'Parallel', 'Group', 'Study', 'of', 'Sativex', 'in', 'the', 'Treatment', 'of', 'Subjects', 'With', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'Sativex', '®', 'compared', 'with', 'placebo', 'in', 'relieving', 'pain', 'due', 'to', 'Diabetic', 'Neuropathy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00710424,NCT00710424,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy | The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving pain due to Diabetic Neuropathy.","[(28, 35, 'CONTROL', 'Placebo'), (72, 79, 'DRUG', 'Sativex'), (114, 118, 'CONDITION', 'Pain'), (126, 145, 'CONDITION', 'Diabetic Neuropathy'), (205, 212, 'DRUG', 'Sativex'), (228, 235, 'CONTROL', 'placebo'), (261, 280, 'CONDITION', 'Diabetic Neuropathy')]"
"['A', 'Single', '-', 'Arm', 'Study', 'to', 'Assess', 'the', 'Safety', 'of', 'Transplantation', 'With', 'Human', 'Placental', '-', 'Derived', 'Stem', '-', 'Cells', 'Combined', 'With', 'Unrelated', 'and', 'Related', 'Cord', 'Blood', 'in', 'Subjects', 'With', 'Certain', 'Malignant', 'Hematologic', 'Diseases', 'and', 'Non', '-', 'Malignant', 'Disorders', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'investigate', 'the', 'safety', 'of', 'human', 'placental', '-', 'derived', 'stem', 'cells', '(', 'HPDSC', ')', 'given', 'in', 'conjunction', 'with', 'umbilical', 'cord', 'blood', '(', 'UCB', ')', 'stem', 'cells', 'in', 'patients', 'with', 'various', 'malignant', 'or', 'nonmalignant', 'disorders', 'who', 'require', 'a', 'stem', 'cell', 'transplant', '.', 'Patients', 'will', 'get', 'either', 'full', 'dose', '(', 'high', '-', 'intensity', ')', 'or', 'lower', 'dose', '(', 'low', 'intensity', ')', 'chemo-', 'and', 'immunotherapy', 'followed', 'by', 'a', 'stem', 'cell', 'transplantation', 'with', 'UCB', 'and', 'HPDSC', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O']",NCT01586455,NCT01586455,A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders | The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.,"[(64, 98, 'SURGICAL', 'Human Placental-Derived Stem-Cells'), (113, 145, 'SURGICAL', 'Unrelated and Related Cord Blood'), (171, 201, 'CONDITION', 'Malignant Hematologic Diseases'), (206, 229, 'CONDITION', 'Non-Malignant Disorders'), (299, 333, 'SURGICAL', 'human placental-derived stem cells'), (335, 340, 'SURGICAL', 'HPDSC'), (368, 405, 'SURGICAL', 'umbilical cord blood (UCB) stem cells'), (444, 466, 'CONDITION', 'nonmalignant disorders'), (585, 609, 'DRUG', 'chemo- and immunotherapy'), (655, 658, 'SURGICAL', 'UCB'), (663, 668, 'SURGICAL', 'HPDSC')]"
"['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Trial', 'Evaluating', 'Rasagiline', 'Effects', 'on', 'Cognition', 'in', 'Parkinson', ""'s"", 'Disease', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'Receiving', 'Dopaminergic', 'Therapy', '|', 'The', 'present', 'pilot', 'study', 'is', 'designed', 'to', 'assess', 'the', 'extent', 'to', 'which', 'rasagiline', 'may', 'improve', 'cognition', 'in', 'Parkinson', ""'s"", 'disease', 'patients', 'requiring', 'dopaminergic', 'therapy', '.', 'The', 'primary', 'objective', 'is', 'to', 'assess', 'improvement', 'in', 'the', 'Montreal', 'Cognitive', 'Assessment', '(', 'MoCA', ')', 'in', 'patients', 'who', 'have', 'been', 'on', 'rasagiline', 'at', '1', 'mg', 'daily', 'for', 'twelve', 'weeks', '.', 'The', 'secondary', 'objective', 'is', 'to', 'assess', 'changes', 'in', 'the', 'SCOPA', '-', 'COG', ',', 'FAB', ',', 'and', 'UPDRS', 'II', '&', 'III', 'at', 'the', 'end', 'of', 'week', '14', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01497652,NCT01497652,"A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy | The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II & III at the end of week 14.","[(15, 22, 'CONTROL', 'Placebo'), (51, 61, 'DRUG', 'Rasagiline'), (86, 105, 'CONDITION', ""Parkinson's Disease""), (120, 145, 'CONDITION', 'Mild Cognitive Impairment'), (156, 176, 'CONDITION', 'Dopaminergic Therapy'), (245, 255, 'DRUG', 'rasagiline'), (281, 300, 'CONDITION', ""Parkinson's disease""), (320, 340, 'CONDITION', 'dopaminergic therapy'), (462, 472, 'DRUG', 'rasagiline')]"
"['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'analyze', 'the', 'benefit', 'of', 'autologous', 'mononuclear', 'cell', 'therapy', 'in', 'mental', 'retardation', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O']",NCT02245724,NCT02245724,The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.,"[(56, 91, 'SURGICAL', 'autologous mononuclear cell therapy'), (95, 113, 'CONDITION', 'mental retardation')]"
"['Open', 'Label', 'Extension', 'to', 'R076477', '-', 'SCH-305', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Paliperidone', 'ER', 'in', 'Subjects', 'With', 'Schizophrenia', '.', '|', 'Open', '-', 'Label', 'Extension', 'to', 'the', 'double', '-', 'blind', 'effectiveness', 'and', 'safety', 'study', 'R076477', '-', 'SCH-305', 'to', 'evaluate', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'in', 'patients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00668837,NCT00668837,Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. | Open-Label Extension to the double-blind effectiveness and safety study R076477-SCH-305 to evaluate long-term safety and tolerability in patients with schizophrenia.,"[(83, 95, 'DRUG', 'Paliperidone'), (116, 129, 'CONDITION', 'Schizophrenia'), (284, 297, 'CONDITION', 'schizophrenia')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', ',', 'Dose', '-', 'response', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', '3', 'Fixed', 'Doses', '(', '25', 'mg', 'eq', ',', '50', 'mg', 'eq', ',', 'and', '100', 'mg', 'eq', ')', 'of', 'Paliperidone', 'Palmitate', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'efficacy', '(', 'how', 'well', 'the', 'drug', 'works', ')', ',', 'safety', ',', 'and', 'side', 'effects', 'of', 'paliperidone', 'palmitate', 'compared', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'the', 'symptoms', 'of', 'schizophrenia', 'in', 'adults', '.', 'The', 'placebo', 'used', 'in', 'this', 'study', 'was', 'a', 'nutritional', 'substance', 'known', 'as', '20', '%', 'Intralipid', 'emulsion', 'given', 'to', 'patients', 'requiring', 'intravenous', 'feedings', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00101634,NCT00101634,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.","[(28, 35, 'CONTROL', 'Placebo'), (176, 198, 'DRUG', 'Paliperidone Palmitate'), (216, 229, 'CONDITION', 'Schizophrenia'), (342, 364, 'DRUG', 'paliperidone palmitate'), (377, 384, 'CONTROL', 'placebo'), (421, 434, 'CONDITION', 'schizophrenia'), (450, 457, 'CONTROL', 'placebo'), (518, 537, 'CONTROL', 'Intralipid emulsion')]"
"['Target', 'Controlled', 'Infusion', 'of', 'Etomidate', 'or', 'Propofol', 'for', 'Anesthesia', 'of', 'Thoracoscopic', 'Mitral', 'Valve', 'Replacement', 'Surgery', ',', 'A', 'Randomized', 'Controlled', 'Double', '-', 'Blinded', 'Study', '|', 'For', 'patients', 'requiring', 'the', 'heart', 'valve', 'replacement', 'surgery', ',', 'heart', 'function', 'is', 'injured', 'in', 'different', 'degree', '.', 'Thus', ',', 'minimizing', 'the', 'impact', 'of', 'the', 'anesthesia', 'drug', 'on', 'the', 'cardiovascular', 'system', 'has', 'important', 'clinical', 'meanings', '.', 'Etomidate', 'has', 'slight', 'effect', 'on', 'the', 'cardiovascular', 'system', ',', 'often', 'used', 'in', 'the', 'induction', 'of', 'anesthesia', ',', 'however', 'target', 'controlled', 'infusion', 'etomidate', 'in', 'maintenance', 'of', 'anesthesia', 'is', 'less', 'used', '.', 'So', ',', 'the', 'trial', 'is', 'designed', 'to', 'observe', 'the', 'application', 'value', 'of', 'TCI', 'etomidate', 'in', 'thoracoscopic', 'mitral', 'valve', 'replacement', 'surgery', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O']",NCT02644980,NCT02644980,"Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study | For patients requiring the heart valve replacement surgery, heart function is injured in different degree.Thus, minimizing the impact of the anesthesia drug on the cardiovascular system has important clinical meanings. Etomidate has slight effect on the cardiovascular system, often used in the induction of anesthesia, however target controlled infusion etomidate in maintenance of anesthesia is less used. So, the trial is designed to observe the application value of TCI etomidate in thoracoscopic mitral valve replacement surgery.","[(30, 39, 'DRUG', 'Etomidate'), (43, 51, 'DRUG', 'Propofol'), (70, 108, 'CONDITION', 'Thoracoscopic Mitral Valve Replacement'), (191, 214, 'CONDITION', 'heart valve replacement'), (383, 392, 'DRUG', 'Etomidate'), (519, 528, 'DRUG', 'etomidate'), (638, 647, 'DRUG', 'etomidate'), (651, 689, 'CONDITION', 'thoracoscopic mitral valve replacement')]"
"['Examining', 'Dose', '-', 'Related', 'Effects', 'of', 'Oxytocin', 'on', 'Social', 'Cognition', 'Across', 'Populations', '|', 'Social', 'cognition', 'impairment', 'is', 'critical', 'to', 'the', 'pathology', 'and', 'morbidity', 'of', 'a', 'number', 'of', 'psychiatric', 'disorders', ',', 'including', 'the', 'schizophrenia', 'spectrum', ',', 'the', 'autism', 'spectrum', 'and', 'the', 'personality', 'disorders', ',', 'thus', 'representing', 'a', 'dimension', 'consistent', 'with', 'RDoC.', 'As', 'such', ',', 'this', 'study', 'aims', 'to', 'a', ')', 'further', 'characterize', 'the', 'unique', 'deficits', 'in', 'social', 'cognition', '(', 'recognition', 'and', 'interpretation', 'of', 'social', 'cues', 'and', 'representation', 'of', 'thoughts', ',', 'intentions', ',', 'and', 'feelings', 'of', 'others', ')', 'across', 'disorders', ',', 'including', 'the', 'schizophrenia', 'spectrum', '(', 'which', 'includes', 'schizophrenia', ',', 'SCZ', ',', 'schizoaffective', 'disorder', ',', 'SAD', ',', 'bipolar', 'disorder', ',', 'BD', ',', 'and', 'schizotypal', 'personality', 'disorder', ',', 'SPD', ')', ',', 'the', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', ',', 'and', 'borderline', 'personality', 'disorder', '(', 'BPD', ')', 'compared', 'to', 'healthy', 'controls', '(', 'HC', ')', ';', 'b', ')', 'assess', 'the', 'effect', 'of', 'intranasal', 'oxytocin', '(', 'OXT', ')', 'as', 'a', 'regulator', 'and', 'novel', 'treatment', 'of', 'social', 'cognition', 'impairment', 'in', 'these', 'disorders', ';', 'and', 'c', ')', 'enhance', 'our', 'understanding', 'of', 'the', 'specificity', 'and', 'exact', 'mechanisms', 'of', 'impairment', 'to', 'inform', 'the', 'accurate', 'dosing', 'of', 'OXT', 'required', 'to', 'modulate', 'social', 'cognition', 'in', 'these', 'disorders', 'and', 'identify', 'a', 'model', 'of', 'optimum', 'social', 'cognitive', 'function', '.', 'Addressing', 'these', 'questions', 'will', 'further', 'catalyze', 'research', 'into', 'a', 'model', 'of', 'optimum', 'social', 'cognitive', 'activity', ',', 'and', 'accelerate', 'industry', 'development', 'of', 'agents', 'suited', 'to', 'routine', 'clinical', 'administration', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02149823,NCT02149823,"Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations | Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension consistent with RDoC. As such, this study aims to a) further characterize the unique deficits in social cognition (recognition and interpretation of social cues and representation of thoughts, intentions, and feelings of others) across disorders, including the schizophrenia spectrum (which includes schizophrenia, SCZ, schizoaffective disorder, SAD, bipolar disorder, BD, and schizotypal personality disorder, SPD), the autism spectrum disorders (ASD), and borderline personality disorder (BPD) compared to healthy controls (HC); b) assess the effect of intranasal oxytocin (OXT) as a regulator and novel treatment of social cognition impairment in these disorders; and c) enhance our understanding of the specificity and exact mechanisms of impairment to inform the accurate dosing of OXT required to modulate social cognition in these disorders and identify a model of optimum social cognitive function. Addressing these questions will further catalyze research into a model of optimum social cognitive activity, and accelerate industry development of agents suited to routine clinical administration.","[(34, 42, 'DRUG', 'Oxytocin'), (84, 111, 'CONDITION', 'Social cognition impairment'), (207, 229, 'CONDITION', 'schizophrenia spectrum'), (235, 250, 'CONDITION', 'autism spectrum'), (259, 280, 'CONDITION', 'personality disorders'), (612, 625, 'CONDITION', 'schizophrenia'), (627, 630, 'CONDITION', 'SCZ'), (632, 656, 'CONDITION', 'schizoaffective disorder'), (658, 661, 'CONDITION', 'SAD'), (663, 679, 'CONDITION', 'bipolar disorder'), (681, 683, 'CONDITION', 'BD'), (689, 721, 'CONDITION', 'schizotypal personality disorder'), (723, 726, 'CONDITION', 'SPD'), (733, 758, 'CONDITION', 'autism spectrum disorders'), (760, 763, 'CONDITION', 'ASD'), (770, 801, 'CONDITION', 'borderline personality disorder'), (803, 806, 'CONDITION', 'BPD'), (878, 886, 'DRUG', 'oxytocin'), (888, 891, 'DRUG', 'OXT'), (931, 958, 'CONDITION', 'social cognition impairment'), (1099, 1102, 'DRUG', 'OXT')]"
"['Carbon', '-', 'Dioxide', 'Flushing', 'Versus', 'Saline', 'Flushing', 'in', 'Thoracic', 'Endovascular', 'Aortic', 'Repair', 'to', 'Reduce', 'Neurological', 'Injury', ':', 'A', 'Pilot', 'Randomised', 'Controlled', 'Trial', '|', 'Vascular', 'brain', 'infarction', '(', 'VBI', ')', 'occurs', 'in', '67', '%', 'of', 'patients', 'undergoing', 'TEVAR', '.', 'Overt', 'stroke', 'occurs', 'in', '13', '%', 'of', 'these', 'patients', 'and', '88', '%', 'of', 'patients', 'suffer', 'from', 'neurocognitive', 'impairment', '.', '\n\n', 'Cerebral', 'air', 'embolisation', 'during', 'the', 'stent', '-', 'graft', 'deployment', 'phase', 'of', 'TEVAR', 'may', 'be', 'a', 'cause', 'of', 'VBI', '.', 'Standard', 'treatment', 'to', 'de', '-', 'air', 'stent', '-', 'grafts', 'is', 'through', 'the', 'use', 'of', 'a', 'saline', 'flush', '.', '\n\n', 'This', 'study', 'aims', 'to', 'investigate', 'whether', 'carbon', '-', 'dioxide', 'or', 'saline', 'is', 'the', 'better', 'fluid', 'to', 'de', '-', 'air', 'TEVAR', 'stent', '-', 'grafts', 'prior', 'to', 'insertion', 'in', 'to', 'the', 'patient', 'and', 'compare', 'VBI', 'rate', 'in', 'the', 'carbon', '-', 'dioxide', 'group', 'and', 'saline', 'group', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O']",NCT03886675,NCT03886675,"Carbon-Dioxide Flushing Versus Saline Flushing in Thoracic Endovascular Aortic Repair to Reduce Neurological Injury: A Pilot Randomised Controlled Trial | Vascular brain infarction (VBI) occurs in 67% of patients undergoing TEVAR. Overt stroke occurs in 13% of these patients and 88% of patients suffer from neurocognitive impairment.

Cerebral air embolisation during the stent-graft deployment phase of TEVAR may be a cause of VBI. Standard treatment to de-air stent-grafts is through the use of a saline flush.

This study aims to investigate whether carbon-dioxide or saline is the better fluid to de-air TEVAR stent-grafts prior to insertion in to the patient and compare VBI rate in the carbon-dioxide group and saline group.","[(0, 14, 'DRUG', 'Carbon-Dioxide'), (31, 37, 'CONTROL', 'Saline'), (50, 85, 'CONDITION', 'Thoracic Endovascular Aortic Repair'), (96, 115, 'CONDITION', 'Neurological Injury'), (155, 180, 'CONDITION', 'Vascular brain infarction'), (182, 185, 'CONDITION', 'VBI'), (224, 229, 'CONDITION', 'TEVAR'), (237, 243, 'CONDITION', 'stroke'), (308, 333, 'CONDITION', 'neurocognitive impairment'), (405, 410, 'CONDITION', 'TEVAR'), (429, 432, 'CONDITION', 'VBI'), (500, 506, 'CONTROL', 'saline'), (554, 568, 'DRUG', 'carbon-dioxide'), (572, 578, 'CONTROL', 'saline'), (609, 614, 'CONDITION', 'TEVAR'), (677, 680, 'CONDITION', 'VBI'), (693, 707, 'DRUG', 'carbon-dioxide'), (718, 724, 'CONTROL', 'saline')]"
"['PRET', ':', 'Patients', 'Prone', 'to', 'Recurrence', 'After', 'Endovascular', 'Treatment', '.', 'A', 'Randomized', 'Trial', 'Comparing', 'Platinum', 'and', 'Hydrogel', '-', 'coated', 'Coils', '|', 'The', 'PRET', 'study', 'aims', 'at', 'comparing', 'two', 'types', 'of', 'coils', 'used', 'in', 'the', 'endovascular', 'treatment', 'of', 'intracranial', 'aneurysms', '.', 'The', 'first', 'type', 'made', 'of', 'platinum', 'has', 'been', 'used', 'for', 'more', 'than', '15', 'years', '.', 'The', 'other', ',', 'referred', 'to', 'as', 'hydrocoil', ',', 'containing', 'in', 'addition', 'to', 'platinum', 'a', 'polymer', 'layer', 'that', 'expands', 'when', 'in', 'contact', 'with', 'blood', ',', 'has', 'been', 'in', 'use', 'since', '2002', '.', 'The', 'hypothesis', 'of', 'the', 'PRET', 'study', 'is', 'that', 'the', 'newer', 'hydrocoil', 'will', 'be', 'more', 'effective', 'and', 'yet', 'as', 'safe', 'as', 'the', 'older', 'platinum', 'coil', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT00626912,NCT00626912,"PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils | The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first type made of platinum has been used for more than 15 years. The other, referred to as hydrocoil, containing in addition to platinum a polymer layer that expands when in contact with blood, has been in use since 2002. The hypothesis of the PRET study is that the newer hydrocoil will be more effective and yet as safe as the older platinum coil.","[(41, 63, 'CONDITION', 'Endovascular Treatment'), (94, 128, 'OTHER', 'Platinum and Hydrogel-coated Coils'), (195, 217, 'CONDITION', 'endovascular treatment'), (221, 243, 'CONDITION', 'intracranial aneurysms'), (341, 350, 'OTHER', 'hydrocoil'), (523, 532, 'OTHER', 'hydrocoil'), (585, 598, 'CONTROL', 'platinum coil')]"
"['Neuromodulation', 'Technique', 'for', 'the', 'Rehabilitation', 'of', 'Social', 'Skills', 'in', 'Childhood', 'Ataxia', '|', 'The', 'present', 'study', 'aims', 'to', 'define', 'a', 'protocol', 'of', 'electrical', 'stimulation', 'of', 'the', 'cerebellum', 'via', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'combined', 'with', 'a', 'virtual', 'reality', 'protocol', 'to', 'assist', 'the', 'rehabilitation', 'of', 'social', 'skills', 'in', 'adolescents', 'and', 'young', 'adults', 'with', 'childhood', 'ataxia', '.', '\n\n', 'Taking', 'into', 'account', 'the', 'high', 'neuronal', 'density', 'of', 'the', 'cerebellum', ',', 'its', 'strong', 'connection', 'with', 'the', 'cerebral', 'cortex', ',', 'and', 'its', 'involvement', 'in', 'motor', ',', 'cognitive', 'and', 'affective', 'processes', ',', 'as', 'well', 'its', 'involvement', 'in', 'social', 'prediction', 'abilities', ',', 'the', 'investigators', 'hypothesized', 'that', 'excitatory', 'stimulation', 'of', 'the', 'cerebellum', 'might', 'improve', 'social', 'prediction', 'abilities', 'in', 'adolescents', 'and', 'young', 'adults', 'with', 'childhood', 'ataxia', '.', 'Moreover', ',', 'as', 'suggested', 'by', 'previous', 'studies', 'investigating', 'the', 'effect', 'of', 'tDCS', 'in', 'paediatric', 'population', ',', 'the', 'investigators', 'expected', 'that', 'tDCS', 'will', 'be', 'safe', 'and', 'well', 'tolerated', '.', 'Such', 'a', 'result', 'would', 'encourage', 'the', 'use', 'of', 'non', '-', 'invasive', 'brain', 'stimulation', 'in', 'the', 'rehabilitation', 'of', 'social', 'skills', 'in', 'childhood', 'ataxia', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04297540,NCT04297540,"Neuromodulation Technique for the Rehabilitation of Social Skills in Childhood Ataxia | The present study aims to define a protocol of electrical stimulation of the cerebellum via transcranial direct current stimulation (tDCS) combined with a virtual reality protocol to assist the rehabilitation of social skills in adolescents and young adults with childhood ataxia.

Taking into account the high neuronal density of the cerebellum, its strong connection with the cerebral cortex, and its involvement in motor, cognitive and affective processes, as well its involvement in social prediction abilities, the investigators hypothesized that excitatory stimulation of the cerebellum might improve social prediction abilities in adolescents and young adults with childhood ataxia. Moreover, as suggested by previous studies investigating the effect of tDCS in paediatric population, the investigators expected that tDCS will be safe and well tolerated. Such a result would encourage the use of non-invasive brain stimulation in the rehabilitation of social skills in childhood ataxia.","[(0, 25, 'OTHER', 'Neuromodulation Technique'), (79, 85, 'CONDITION', 'Ataxia'), (135, 175, 'OTHER', 'electrical stimulation of the cerebellum'), (180, 219, 'OTHER', 'transcranial direct current stimulation'), (221, 225, 'OTHER', 'tDCS'), (243, 267, 'OTHER', 'virtual reality protocol'), (361, 367, 'CONDITION', 'ataxia'), (640, 680, 'OTHER', 'excitatory stimulation of the cerebellum'), (770, 776, 'CONDITION', 'ataxia'), (849, 853, 'OTHER', 'tDCS'), (912, 916, 'OTHER', 'tDCS'), (991, 1021, 'OTHER', 'non-invasive brain stimulation'), (1074, 1080, 'CONDITION', 'ataxia')]"
"['Safety', 'and', 'Feasibility', 'of', 'a', 'Protocol', 'of', 'Targeted', 'Temperature', 'Management', 'After', 'Intracerebral', 'Hemorrhage', '|', 'Though', 'TTM', 'is', 'ubiquitously', 'used', 'in', 'the', 'neuro', '-', 'intensive', 'care', 'unit', ',', 'there', 'is', 'limited', 'experience', 'with', 'the', 'use', 'of', 'TTM', 'after', 'intracerebral', 'hemorrhage', '(', 'ICH', ')', ',', 'the', 'most', 'devastating', 'type', 'of', 'stroke', '.', 'TTM', 'may', 'be', 'a', 'an', 'intervention', 'to', 'improve', 'patient', 'outcomes', '.', 'This', 'trial', 'addresses', 'the', 'safety', 'and', 'tolerability', 'of', 'a', 'protocol', 'of', 'ultra', '-', 'early', 'TTM', 'after', 'ICH', '/', 'IPH', 'and', 'may', 'be', 'the', 'basis', 'for', 'future', 'larger', 'clinical', 'trials', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01607151,NCT01607151,"Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage | Though TTM is ubiquitously used in the neuro-intensive care unit, there is limited experience with the use of TTM after intracerebral hemorrhage (ICH), the most devastating type of stroke. TTM may be a an intervention to improve patient outcomes. This trial addresses the safety and tolerability of a protocol of ultra-early TTM after ICH/IPH and may be the basis for future larger clinical trials.","[(40, 71, 'OTHER', 'Targeted Temperature Management'), (78, 102, 'CONDITION', 'Intracerebral Hemorrhage'), (112, 115, 'OTHER', 'TTM'), (215, 218, 'OTHER', 'TTM'), (225, 249, 'CONDITION', 'intracerebral hemorrhage'), (251, 254, 'CONDITION', 'ICH'), (286, 292, 'CONDITION', 'stroke'), (294, 297, 'OTHER', 'TTM'), (418, 433, 'OTHER', 'ultra-early TTM'), (440, 443, 'CONDITION', 'ICH'), (444, 447, 'CONDITION', 'IPH')]"
"['""', 'Outwalk', 'MS', '""', '-', 'Benefits', 'of', 'Outdoor', 'Walking', 'Exercise', 'Therapy', 'on', 'Walking', 'Capacity', 'and', 'Well', '-', 'being', 'in', 'Multiple', 'Sclerosis', '|', 'Deterioration', 'of', 'walking', 'capacity', 'is', 'a', 'common', 'symptom', 'in', 'persons', 'with', 'multiple', 'sclerosis', '(', 'pwMS', ')', ',', 'furthermore', 'having', 'a', 'negative', 'influence', 'on', 'well', '-', 'being', '.', 'Studies', 'have', 'nevertheless', 'shown', 'that', 'walking', 'exercise', 'therapy', 'can', 'improve', 'walking', 'capacity', 'in', 'pwMS', '.', 'This', 'may', 'be', 'particularly', 'potent', 'if', 'occurring', 'outdoors', 'due', 'to', 'the', 'varying', 'stimuli', 'it', 'can', 'provide', '(', 'different', 'surfaces', 'and', 'terrain', 'etc', '.', ')', ',', 'and', 'if', 'the', 'intensity', 'and', 'duration', 'is', 'adequate', '.', 'Furthermore', ',', 'outdoor', 'walking', 'is', '(', '1', ')', 'suitable', 'as', 'a', 'group', 'intervention', 'facilitating', 'interaction', 'between', 'pwMS', 'and', '(', '2', ')', 'advantageous', 'due', 'to', 'the', 'health', 'benefits', 'offered', 'through', 'the', 'interaction', 'with', 'nature', 'itself', '.', 'Both', 'these', 'aspects', 'are', 'also', 'relevant', 'for', 'well', '-', 'being', '.', '\n\n', 'Few', 'studies', 'have', 'nevertheless', 'examined', 'the', 'effects', 'of', 'outdoor', 'walking', 'exercise', 'therapy', 'in', 'pwMS', '.', 'The', 'purpose', 'of', 'the', 'present', 'study', 'is', 'therefore', 'to', 'examine', 'the', 'effects', 'of', '7', 'weeks', 'of', 'moderate', '-', 'to', '-', 'high', 'intensity', 'outdoor', 'walking', 'exercise', 'therapy', 'on', 'walking', 'capacity', '(', 'primary', 'outcome', ':', '6', '-', 'minute', 'walk', 'test', ')', 'and', 'well', '-', 'being', 'in', 'pwMS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05415956,NCT05415956,"""Outwalk MS"" - Benefits of Outdoor Walking Exercise Therapy on Walking Capacity and Well-being in Multiple Sclerosis | Deterioration of walking capacity is a common symptom in persons with multiple sclerosis (pwMS), furthermore having a negative influence on well-being. Studies have nevertheless shown that walking exercise therapy can improve walking capacity in pwMS. This may be particularly potent if occurring outdoors due to the varying stimuli it can provide (different surfaces and terrain etc.), and if the intensity and duration is adequate. Furthermore, outdoor walking is (1) suitable as a group intervention facilitating interaction between pwMS and (2) advantageous due to the health benefits offered through the interaction with nature itself. Both these aspects are also relevant for well-being.

Few studies have nevertheless examined the effects of outdoor walking exercise therapy in pwMS. The purpose of the present study is therefore to examine the effects of 7 weeks of moderate-to-high intensity outdoor walking exercise therapy on walking capacity (primary outcome: 6-minute walk test) and well-being in pwMS.","[(27, 42, 'PHYSICAL', 'Outdoor Walking'), (98, 116, 'CONDITION', 'Multiple Sclerosis'), (189, 207, 'CONDITION', 'multiple sclerosis'), (308, 324, 'PHYSICAL', 'walking exercise'), (566, 581, 'PHYSICAL', 'outdoor walking'), (868, 883, 'PHYSICAL', 'outdoor walking'), (993, 1035, 'PHYSICAL', 'moderate-to-high intensity outdoor walking')]"
"['Electronic', 'Recording', 'of', 'Compliance', 'With', 'Occlusion', 'Therapy', 'for', 'Amblyopia', ':', '1', 'Effects', 'of', 'Patient', 'Education', 'on', 'Compliance', '2', 'Predictors', 'for', 'Non', '-', 'Compliance', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'whether', 'compliance', 'with', 'occlusion', 'therapy', 'for', 'amblyopia', 'could', 'be', 'improved', 'and', ',', 'secondly', ',', 'if', 'risk', 'factors', 'for', 'non', '-', 'compliance', 'could', 'be', 'identified', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00131729,NCT00131729,"Electronic Recording of Compliance With Occlusion Therapy for Amblyopia: 1 Effects of Patient Education on Compliance 2 Predictors for Non-Compliance | The purpose of this study was to determine whether compliance with occlusion therapy for amblyopia could be improved and, secondly, if risk factors for non-compliance could be identified.","[(62, 71, 'CONDITION', 'Amblyopia'), (86, 103, 'BEHAVIOURAL', 'Patient Education'), (241, 250, 'CONDITION', 'amblyopia')]"
"['Building', 'Online', 'Community', 'to', 'Improve', 'Patient', 'and', 'Caregiver', 'Outcomes', 'in', 'Parkinson', 'Disease', ',', 'Lewy', 'Body', 'Dementia', 'and', 'Related', 'Disorders', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'learn', 'more', 'about', 'the', 'effectiveness', 'of', 'palliative', 'care', 'training', 'for', 'community', 'physicians', 'and', 'telemedicine', 'support', 'services', 'for', 'patients', 'and', 'carepartners', 'with', 'Parkinson', ""'s"", 'disease', 'and', 'Lewy', 'Body', 'Dementia', '(', 'LBD', ')', 'or', 'related', 'conditions', 'and', 'their', 'care', 'partners', '.', 'Palliative', 'care', 'is', 'a', 'treatment', 'approach', 'focused', 'on', 'improving', 'quality', 'of', 'life', 'by', 'relieving', 'suffering', 'in', 'the', 'areas', 'of', 'physical', 'symptoms', 'such', 'as', 'pain', ',', 'psychiatric', 'symptoms', 'such', 'as', 'depression', ',', 'psychosocial', 'issues', 'and', 'spiritual', 'needs', '.', 'Telemedicine', 'is', 'the', 'use', 'of', 'technology', 'that', 'allows', 'participants', 'to', 'interact', 'with', 'a', 'health', 'care', 'provider', 'without', 'being', 'physically', 'near', 'the', 'provider', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05222386,NCT05222386,"Building Online Community to Improve Patient and Caregiver Outcomes in Parkinson Disease, Lewy Body Dementia and Related Disorders | The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.","[(71, 88, 'CONDITION', 'Parkinson Disease'), (90, 108, 'CONDITION', 'Lewy Body Dementia'), (203, 252, 'BEHAVIOURAL', 'palliative care training for community physicians'), (257, 286, 'OTHER', 'telemedicine support services'), (322, 341, 'CONDITION', ""Parkinson's disease""), (346, 364, 'CONDITION', 'Lewy Body Dementia'), (366, 369, 'CONDITION', 'LBD'), (418, 433, 'OTHER', 'Palliative care'), (648, 660, 'OTHER', 'Telemedicine')]"
"['Training', 'of', 'Persons', 'With', 'Complete', 'Spinal', 'Cord', 'Injury', 'for', 'Pedaling', 'on', 'a', 'Tricycle', ',', 'Induced', 'by', 'Electrical', 'Stimulation', 'of', 'the', 'Paralysed', 'Muscles', ':', 'a', 'Case', 'Series', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'validate', 'the', 'effectivity', 'of', 'a', 'simple', 'home', '-', 'based', 'training', 'for', 'cycling', 'with', 'functional', 'electrical', 'stimulation', '(', 'FES', ')', '.', 'The', 'training', 'is', 'designed', 'to', 'progressively', 'increase', 'strength', 'and', 'endurance', 'of', 'the', 'paralysed', 'muscles', 'of', 'a', 'person', 'with', 'complete', 'spinal', 'cord', 'injury', '.', 'After', 'a', 'limited', 'period', 'of', 'only', 'several', 'months', ',', 'performance', 'will', 'be', 'assessed', 'during', 'FES', '-', 'assisted', 'cycling', 'on', 'a', 'recumbent', 'tricycle', 'over', 'flat', 'ground', '.', 'The', 'outcomes', 'of', 'this', 'study', 'should', 'provide', 'evidence', 'for', 'the', 'effectivity', 'of', 'FES', '-', 'cycling', 'as', 'potential', 'rehabilitation', 'method', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O']",NCT04412447,NCT04412447,"Training of Persons With Complete Spinal Cord Injury for Pedaling on a Tricycle, Induced by Electrical Stimulation of the Paralysed Muscles: a Case Series | The main objective of this study is to validate the effectivity of a simple home-based training for cycling with functional electrical stimulation (FES). The training is designed to progressively increase strength and endurance of the paralysed muscles of a person with complete spinal cord injury. After a limited period of only several months, performance will be assessed during FES-assisted cycling on a recumbent tricycle over flat ground. The outcomes of this study should provide evidence for the effectivity of FES-cycling as potential rehabilitation method.","[(25, 52, 'CONDITION', 'Complete Spinal Cord Injury'), (57, 139, 'PHYSICAL', 'Pedaling on a Tricycle, Induced by Electrical Stimulation of the Paralysed Muscles'), (233, 303, 'PHYSICAL', 'home-based training for cycling with functional electrical stimulation'), (305, 308, 'PHYSICAL', 'FES'), (427, 454, 'CONDITION', 'complete spinal cord injury'), (539, 559, 'PHYSICAL', 'FES-assisted cycling'), (676, 687, 'PHYSICAL', 'FES-cycling')]"
"['Development', 'and', 'Evaluation', 'of', 'a', 'Self', '-', 'management', 'Guide', 'for', 'Community', '-', 'dwelling', 'People', 'With', 'Parkinson', ""'s"", 'Disease', 'Who', 'Fall', 'and', 'Their', 'Informal', 'Caregivers', '|', 'This', 'study', 'will', 'investigate', 'whether', 'it', 'is', 'possible', ',', 'through', 'the', 'development', 'and', 'evaluation', 'of', 'a', 'self', '-', 'management', 'guide', ',', 'to', 'improve', 'health', 'related', 'quality', 'of', 'life', 'and', 'concern', 'of', 'falling', 'in', 'people', 'with', 'Parkinson', ""'s"", 'disease', 'who', 'fall', ',', 'and', 'reduce', 'caregiver', 'burden', 'in', 'their', 'informal', 'caregivers', '.']","['O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03111472,NCT03111472,"Development and Evaluation of a Self-management Guide for Community-dwelling People With Parkinson's Disease Who Fall and Their Informal Caregivers | This study will investigate whether it is possible, through the development and evaluation of a self-management guide, to improve health related quality of life and concern of falling in people with Parkinson's disease who fall, and reduce caregiver burden in their informal caregivers.","[(32, 53, 'BEHAVIOURAL', 'Self-management Guide'), (89, 108, 'CONDITION', ""Parkinson's Disease""), (246, 267, 'BEHAVIOURAL', 'self-management guide'), (349, 368, 'CONDITION', ""Parkinson's disease"")]"
"['Elucidation', 'of', 'the', 'Influence', 'of', 'Sleep', 'Apnea', 'on', 'Risk', 'of', 'Atrial', 'Fibrillation', '|', 'The', 'Elucidation', 'of', 'the', 'Influence', 'of', 'Sleep', 'Apnea', 'on', 'Risk', 'of', 'Atrial', 'Fibrillation', 'study', '.', '\n\n', 'The', 'study', 'involves', 'a', 'case', 'control', 'design', 'to', 'investigate', 'the', 'extent', 'to', 'which', 'there', 'is', 'an', 'independent', 'relationship', 'of', 'sleep', 'disordered', 'breathing', '(', 'SDB', ')', 'and', 'paroxysmal', 'atrial', 'fibrillation', '(', 'PAF', ')', '.', 'Cases', 'will', 'be', 'defined', 'as', 'clinically', 'identified', 'patients', 'with', 'PAF', 'and', 'controls', 'as', 'those', 'without', 'AF', '.', 'In', 'order', 'to', 'rigorously', 'address', 'important', 'biologic', 'confounding', 'influences', ',', 'the', 'cases', 'and', 'controls', 'will', 'be', 'individually', 'matched', 'based', 'upon', 'age', ',', 'gender', ',', 'race', ',', 'and', 'body', 'mass', 'index', '.', 'Those', 'participants', 'with', 'both', 'PAF', 'and', 'SDB', '(', 'Apnea', 'Hypopnea', 'Index', ',', 'AHI>=15', ')', 'will', 'be', 'asked', 'to', 'return', 'for', 'a', 'follow', 'up', 'exam', 'after', '3', 'months', 'of', 'SDB', 'treatment', 'in', 'the', 'Clinical', 'Research', 'Unit', '(', 'CRU', ')', 'for', 'collection', 'of', 'the', 'same', 'measures', 'collected', 'at', 'the', 'baseline', 'exam', 'to', 'observe', 'for', 'any', 'significant', 'changes', 'with', 'the', 'purpose', 'of', 'collecting', 'effect', 'size', 'data', 'to', 'inform', 'future', 'clinical', 'trials', '.', '\n\n', 'The', 'total', 'duration', 'of', 'the', 'study', 'is', '4', 'years', '.', 'The', 'duration', 'for', 'any', 'individual', 'participant', 'is', 'up', 'to', 'from', 'one', 'to', '13', 'weeks', 'months', ',', 'including', 'a', '3', '-', 'month', 'treatment', 'period', 'for', 'those', 'with', 'moderate', 'to', 'severe', 'SDB', ',', 'i.e.', 'AHI>15', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT02576587,NCT02576587,"Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation | The Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation study.

The study involves a case control design to investigate the extent to which there is an independent relationship of sleep disordered breathing (SDB) and paroxysmal atrial fibrillation (PAF). Cases will be defined as clinically identified patients with PAF and controls as those without AF. In order to rigorously address important biologic confounding influences, the cases and controls will be individually matched based upon age, gender, race, and body mass index. Those participants with both PAF and SDB (Apnea Hypopnea Index, AHI>=15) will be asked to return for a follow up exam after 3 months of SDB treatment in the Clinical Research Unit (CRU) for collection of the same measures collected at the baseline exam to observe for any significant changes with the purpose of collecting effect size data to inform future clinical trials.

The total duration of the study is 4 years. The duration for any individual participant is up to from one to 13 weeks months, including a 3-month treatment period for those with moderate to severe SDB, i.e. AHI>15.","[(32, 43, 'CONDITION', 'Sleep Apnea'), (55, 74, 'CONDITION', 'Atrial Fibrillation'), (113, 124, 'CONDITION', 'Sleep Apnea'), (136, 155, 'CONDITION', 'Atrial Fibrillation'), (280, 306, 'CONDITION', 'sleep disordered breathing'), (308, 311, 'CONDITION', 'SDB'), (317, 347, 'CONDITION', 'paroxysmal atrial fibrillation'), (349, 352, 'CONDITION', 'PAF'), (416, 419, 'CONDITION', 'PAF'), (450, 452, 'CONDITION', 'AF'), (660, 663, 'CONDITION', 'PAF'), (668, 671, 'CONDITION', 'SDB'), (767, 770, 'CONDITION', 'SDB'), (1184, 1206, 'CONDITION', 'moderate to severe SDB')]"
"['A', 'Randomised', 'Placebo', 'Controlled', 'Trial', 'of', 'a', 'Cholinesterase', 'Inhibitor', 'in', 'the', 'Management', 'of', 'Agitation', 'in', 'Dementia', 'That', 'is', 'Unresponsive', 'to', 'a', 'Psychological', 'Intervention', '|', 'Primary', 'Aim', '\n\n', 'To', 'determine', 'whether', ';', '\n\n', 'Donepezil', 'is', 'significantly', 'better', 'than', 'placebo', 'in', 'the', 'management', 'of', 'agitation', 'in', 'Alzheimer', ""'s"", 'Disease', 'that', 'has', 'not', 'responded', 'to', ',', 'or', 'is', 'inappropriate', 'for', 'a', 'standardised', 'brief', 'psychosocial', 'treatment', '\n\n', 'Secondary', 'Aims', '\n\n', 'To', 'determine', 'whether', ';', '\n\n', 'Donepezil', 'has', 'a', 'significant', 'positive', 'or', 'negative', 'impact', 'upon', 'quality', 'of', 'life', 'compared', 'with', 'placebo', '\n', 'whether', 'there', 'is', 'a', 'significant', 'difference', 'between', 'Donepezil', 'and', 'placebo', 'with', 'respect', 'to', 'cognitive', 'performance', '\n', 'the', 'cost', 'effectiveness', 'of', 'the', 'pharmacological', 'treatment', 'for', 'agitation']","['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",NCT00142324,NCT00142324,"A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention | Primary Aim

To determine whether;

Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment

Secondary Aims

To determine whether;

Donepezil has a significant positive or negative impact upon quality of life compared with placebo
whether there is a significant difference between Donepezil and placebo with respect to cognitive performance
the cost effectiveness of the pharmacological treatment for agitation","[(13, 20, 'CONTROL', 'Placebo'), (43, 67, 'DRUG', 'Cholinesterase Inhibitor'), (89, 98, 'CONDITION', 'Agitation'), (102, 110, 'CONDITION', 'Dementia'), (202, 211, 'DRUG', 'Donepezil'), (241, 248, 'CONTROL', 'placebo'), (270, 279, 'CONDITION', 'agitation'), (283, 302, 'CONDITION', ""Alzheimer's Disease""), (438, 447, 'DRUG', 'Donepezil'), (529, 536, 'CONTROL', 'placebo'), (587, 596, 'DRUG', 'Donepezil'), (707, 716, 'CONDITION', 'agitation')]"
"['A', 'Pilot', 'Study', 'of', 'Amygdala', 'Retraining', 'Program', '(', 'ARP', ')', 'Versus', 'Control', '(', 'C', ')', 'in', 'Patients', 'With', 'Chronic', 'Fatigue', 'Syndrome', '(', 'CFS', ')', ',', 'Chronic', 'Fatigue', '(', 'CF', ')', 'and', 'Fibromyalgia', '(', 'FM', ')', '|', 'The', 'purpose', 'of', 'this', 'pilot', 'study', 'is', 'to', 'gather', 'preliminary', 'data', 'on', 'the', 'efficacy', 'and', 'feasibility', 'of', 'the', 'Amygdala', 'Retraining', 'Program', '(', 'ARP', ')', ',', 'a', 'mind', '-', 'body', 'practice', 'versus', 'a', 'control', '(', 'C', ')', 'on', 'fatigue', ',', 'quality', 'of', 'life', 'and', 'sleep', 'in', 'patients', 'with', 'Chronic', 'Fatigue', 'Syndrome', '(', 'CFS', ')', ',', 'Chronic', 'Fatigue', '(', 'CF', ')', 'and', 'Fibromyalgia', '(', 'FM', ')', '.', '\n\n', 'CFS', ',', 'CF', 'and', 'FM', 'are', 'incapacitating', 'disorders', 'characterized', 'by', 'profound', 'fatigue', ',', 'muscle', 'pain', ',', 'impaired', 'memory', ',', 'insomnia', ',', 'and', 'post', '-', 'exertional', 'malaise', '(', 'Fukuda', '1994', ')', '.', 'Current', 'literature', 'points', 'to', 'a', 'centrally', 'sensitized', 'state', 'in', 'CFS', ',', 'CF', 'and', 'FM', '(', 'Meeus', '2007', ')', '.', 'The', 'ARP', 'attempts', 'to', 'retrain', 'this', 'neuronal', 'network', 'through', 'mind', '-', 'body', 'practices', 'such', 'as', 'cognitive', 'restructuring', 'via', 'neurolinguistic', 'programming', ',', 'yoga', 'based', 'breathing', 'and', 'simple', 'mindfulness', 'based', 'meditation', '.', 'A', 'case', 'series', 'of', '33', 'patients', 'with', 'CFS', 'and', 'ARP', 'reported', 'improvement', 'in', '92', '%', 'of', 'patients', 'with', 'two', '-', 'thirds', 'of', 'patients', 'reaching', '80', '-', '100', '%', 'of', 'pre', '-', 'illness', 'levels', 'of', 'health', '(', 'Gupta', '2009', ')', '.', 'However', 'ARP', 'has', 'never', 'been', 'formally', 'studied', 'in', 'CFS', '.', '\n\n', 'We', 'propose', 'to', 'gather', 'preliminary', 'data', 'on', 'the', 'efficacy', 'and', 'feasibility', 'of', 'ARP', 'versus', 'C', 'on', 'fatigue', ',', 'quality', 'of', 'life', 'and', 'sleep', 'in', '30', 'patients', 'with', 'CFS', ',', 'CF', 'and', 'FM', '.', 'All', 'participants', 'will', 'undergo', 'standard', 'clinical', 'treatment', 'which', 'consist', 'of', 'a', '2', 'day', 'self', '-', 'management', 'program', 'in', 'the', 'Chronic', 'Fatigue', 'Clinic', '.', 'Following', 'this', ',', 'participants', 'will', 'be', 'randomized', 'into', 'the', 'ARP', 'or', 'C', 'group', '.', 'The', 'ARP', 'group', 'will', 'receive', 'an', 'additional', '2.5', 'hour', 'training', 'surrounding', 'core', 'concepts', 'of', 'the', 'ARP', 'program', '.', 'They', 'will', 'then', 'be', 'given', 'the', 'ARP', 'DVD', 'program', 'and', 'booklet', ',', 'to', 'reinforce', 'and', 'continue', 'the', 'practice', '.', 'They', 'will', 'then', 'receive', 'scheduled', 'bi', '-', 'monthly', 'phone', 'calls', 'for', '3', 'months', 'from', 'a', 'study', 'investigator', 'for', 'support', '.', 'The', 'C', 'group', 'will', 'receive', 'only', 'standard', 'care', '.', 'However', 'they', 'will', 'receive', 'a', 'complementary', 'copy', 'of', 'the', 'ARP', 'program', 'at', 'the', 'end', 'of', 'the', 'study', '(', '6', 'month', 'time', 'point', ')', 'as', 'a', 'gift', 'for', 'participation', 'in', 'the', 'study', '.', '\n\n', 'Preliminary', 'data', 'on', 'efficacy', 'will', 'be', 'assessed', 'at', 'baseline', ',', '1', ',', '3', 'and', '6', 'months', 'using', 'the', 'following', 'validated', 'questionnaires', ':', 'Multidimensional', 'Fatigue', 'Inventory', '(', 'MDFI', ')', ',', 'Short', 'form-36', '(', 'SF36', ')', 'Fibromyalgia', 'Impact', 'Questionnaire', '(', 'FIQ', ')', ',', 'Epworth', 'Sleep', 'Scale', '(', 'ESS', ')', 'and', 'Measure', 'Your', 'Medical', 'Outcome', 'Profile', '(', 'MYMOP-2', ')', '.', 'Feasibility', 'will', 'be', 'assessed', 'by', 'evaluation', 'of', 'a', 'daily', 'practice', 'log', 'where', 'patients', 'record', 'the', 'total', 'time', 'spent', 'daily', 'in', 'the', 'practice', 'of', 'ARP', 'and', 'any', 'specific', 'difficulties', 'they', 'encountered', 'in', 'the', 'practice', 'of', 'the', 'program', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01046370,NCT01046370,"A Pilot Study of Amygdala Retraining Program (ARP) Versus Control (C) in Patients With Chronic Fatigue Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia (FM) | The purpose of this pilot study is to gather preliminary data on the efficacy and feasibility of the Amygdala Retraining Program (ARP), a mind-body practice versus a control (C) on fatigue, quality of life and sleep in patients with Chronic Fatigue Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia (FM).

CFS, CF and FM are incapacitating disorders characterized by profound fatigue, muscle pain, impaired memory, insomnia, and post-exertional malaise (Fukuda 1994). Current literature points to a centrally sensitized state in CFS, CF and FM (Meeus 2007). The ARP attempts to retrain this neuronal network through mind-body practices such as cognitive restructuring via neurolinguistic programming, yoga based breathing and simple mindfulness based meditation. A case series of 33 patients with CFS and ARP reported improvement in 92% of patients with two-thirds of patients reaching 80-100% of pre-illness levels of health (Gupta 2009). However ARP has never been formally studied in CFS.

We propose to gather preliminary data on the efficacy and feasibility of ARP versus C on fatigue, quality of life and sleep in 30 patients with CFS, CF and FM. All participants will undergo standard clinical treatment which consist of a 2 day self-management program in the Chronic Fatigue Clinic. Following this, participants will be randomized into the ARP or C group. The ARP group will receive an additional 2.5 hour training surrounding core concepts of the ARP program. They will then be given the ARP DVD program and booklet, to reinforce and continue the practice. They will then receive scheduled bi-monthly phone calls for 3 months from a study investigator for support. The C group will receive only standard care. However they will receive a complementary copy of the ARP program at the end of the study (6 month time point) as a gift for participation in the study.

Preliminary data on efficacy will be assessed at baseline, 1, 3 and 6 months using the following validated questionnaires: Multidimensional Fatigue Inventory (MDFI), Short form-36 (SF36) Fibromyalgia Impact Questionnaire (FIQ), Epworth Sleep Scale (ESS) and Measure Your Medical Outcome Profile (MYMOP-2). Feasibility will be assessed by evaluation of a daily practice log where patients record the total time spent daily in the practice of ARP and any specific difficulties they encountered in the practice of the program.","[(17, 44, 'BEHAVIOURAL', 'Amygdala Retraining Program'), (46, 49, 'BEHAVIOURAL', 'ARP'), (58, 65, 'CONTROL', 'Control'), (87, 111, 'CONDITION', 'Chronic Fatigue Syndrome'), (113, 116, 'CONDITION', 'CFS'), (119, 134, 'CONDITION', 'Chronic Fatigue'), (136, 138, 'CONDITION', 'CF'), (144, 156, 'CONDITION', 'Fibromyalgia'), (158, 160, 'CONDITION', 'FM'), (265, 292, 'BEHAVIOURAL', 'Amygdala Retraining Program'), (294, 297, 'BEHAVIOURAL', 'ARP'), (330, 337, 'CONTROL', 'control'), (345, 352, 'CONDITION', 'fatigue'), (397, 421, 'CONDITION', 'Chronic Fatigue Syndrome'), (423, 426, 'CONDITION', 'CFS'), (429, 444, 'CONDITION', 'Chronic Fatigue'), (446, 448, 'CONDITION', 'CF'), (454, 466, 'CONDITION', 'Fibromyalgia'), (468, 470, 'CONDITION', 'FM'), (474, 477, 'CONDITION', 'CFS'), (479, 481, 'CONDITION', 'CF'), (486, 488, 'CONDITION', 'FM'), (544, 551, 'CONDITION', 'fatigue'), (553, 564, 'CONDITION', 'muscle pain'), (566, 581, 'CONDITION', 'impaired memory'), (583, 591, 'CONDITION', 'insomnia'), (697, 700, 'CONDITION', 'CFS'), (702, 704, 'CONDITION', 'CF'), (709, 711, 'CONDITION', 'FM'), (730, 733, 'BEHAVIOURAL', 'ARP'), (965, 968, 'CONDITION', 'CFS'), (973, 976, 'BEHAVIOURAL', 'ARP'), (1116, 1119, 'BEHAVIOURAL', 'ARP'), (1155, 1158, 'CONDITION', 'CFS'), (1234, 1237, 'BEHAVIOURAL', 'ARP'), (1250, 1257, 'CONDITION', 'fatigue'), (1305, 1308, 'CONDITION', 'CFS'), (1310, 1312, 'CONDITION', 'CF'), (1317, 1319, 'CONDITION', 'FM'), (1398, 1427, 'BEHAVIOURAL', '2 day self-management program'), (1435, 1450, 'CONDITION', 'Chronic Fatigue'), (1516, 1519, 'BEHAVIOURAL', 'ARP'), (1536, 1539, 'BEHAVIOURAL', 'ARP'), (1624, 1635, 'BEHAVIOURAL', 'ARP program'), (1665, 1680, 'BEHAVIOURAL', 'ARP DVD program'), (1872, 1885, 'CONTROL', 'standard care'), (1941, 1952, 'BEHAVIOURAL', 'ARP program'), (2482, 2485, 'BEHAVIOURAL', 'ARP')]"
"['The', 'Influence', 'of', 'Cardiovascular', 'Autonomic', 'Function', 'on', 'Endogenous', 'Pain', 'Modulation', 'Before', 'and', 'After', 'Exercise', 'and', 'Cognitive', 'Task', 'in', 'Fibromyalgia', '|', 'The', 'study', 'has', 'three', 'aims', ':', '\n\n', 'To', 'investigate', 'the', 'influence', 'of', 'cardiovascular', 'autonomic', 'function', 'on', 'pain', 'sensitivity', 'at', 'rest', 'in', 'patients', 'with', 'fibromyalgia', 'and', 'age-', 'and', 'sex', '-', 'matched', 'controls', '\n', 'To', 'investigate', 'the', 'influence', 'of', 'cardiovascular', 'autonomic', 'function', 'at', 'baseline', 'and', 'during', 'exercise', 'on', 'the', 'pain', 'response', 'following', 'submaximal', 'isometric', 'exercise', '\n', 'To', 'study', 'the', 'relation', 'between', 'the', 'pain', 'response', 'following', 'physical', 'and', 'cognitive', 'tasks', '(', 'exercise', 'and', 'mental', 'math', ',', 'respectively', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",NCT03911609,NCT03911609,"The Influence of Cardiovascular Autonomic Function on Endogenous Pain Modulation Before and After Exercise and Cognitive Task in Fibromyalgia | The study has three aims:

To investigate the influence of cardiovascular autonomic function on pain sensitivity at rest in patients with fibromyalgia and age- and sex-matched controls
To investigate the influence of cardiovascular autonomic function at baseline and during exercise on the pain response following submaximal isometric exercise
To study the relation between the pain response following physical and cognitive tasks (exercise and mental math, respectively).","[(65, 69, 'CONDITION', 'Pain'), (98, 106, 'PHYSICAL', 'Exercise'), (111, 125, 'OTHER', 'Cognitive Task'), (129, 141, 'CONDITION', 'Fibromyalgia'), (240, 244, 'CONDITION', 'pain'), (282, 294, 'CONDITION', 'fibromyalgia'), (418, 426, 'PHYSICAL', 'exercise'), (434, 438, 'CONDITION', 'pain'), (458, 487, 'PHYSICAL', 'submaximal isometric exercise'), (522, 526, 'CONDITION', 'pain'), (546, 574, 'OTHER', 'physical and cognitive tasks'), (576, 584, 'PHYSICAL', 'exercise'), (589, 600, 'OTHER', 'mental math')]"
"['Adapted', 'Cognitive', '/', 'Affective', 'Remediation', 'for', 'Cannabis', 'Misuse', 'in', 'Schizophrenia', '|', 'This', 'study', 'will', 'integrate', 'and', 'adapt', 'a', 'cognitive', 'remediation', '(', 'Cognitive', 'Enhancement', 'Therapy', '[', 'CET', ']', ')', 'and', 'an', 'affect', 'regulation', '(', 'Personal', 'Therapy', '[', 'PT', ']', ')', 'intervention', 'for', '50', 'individuals', 'with', 'schizophrenia', 'that', 'misuse', 'cannabis', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'CET', '/', 'PT', 'plus', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'or', 'TAU', 'alone', 'and', 'treated', 'for', '18', 'months', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01292577,NCT01292577,Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia | This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy [CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with schizophrenia that misuse cannabis. Participants will be randomized to CET/PT plus treatment as usual (TAU) or TAU alone and treated for 18 months.,"[(0, 39, 'BEHAVIOURAL', 'Adapted Cognitive/Affective Remediation'), (44, 59, 'CONDITION', 'Cannabis Misuse'), (63, 76, 'CONDITION', 'Schizophrenia'), (117, 138, 'BEHAVIOURAL', 'cognitive remediation'), (140, 169, 'BEHAVIOURAL', 'Cognitive Enhancement Therapy'), (171, 174, 'BEHAVIOURAL', 'CET'), (184, 201, 'BEHAVIOURAL', 'affect regulation'), (203, 219, 'BEHAVIOURAL', 'Personal Therapy'), (221, 223, 'BEHAVIOURAL', 'PT'), (263, 276, 'CONDITION', 'schizophrenia'), (282, 297, 'CONDITION', 'misuse cannabis'), (334, 337, 'BEHAVIOURAL', 'CET'), (338, 340, 'BEHAVIOURAL', 'PT'), (346, 364, 'CONTROL', 'treatment as usual'), (366, 369, 'CONTROL', 'TAU'), (374, 383, 'CONTROL', 'TAU alone')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', 'Multi', '-', 'center', 'Comparative', 'Flexible', '-', 'dose', 'Trial', 'Of', 'Pregabalin', 'Versus', 'Gabapentin', 'As', 'Adjunctive', 'Therapy', 'In', 'Subjects', 'With', 'Partial', 'Seizures', '.', '|', 'To', 'compare', 'the', 'efficacy', 'of', 'pregabalin', 'and', 'gabapentin', ',', 'as', 'adjunctive', 'therapy', 'in', 'subjects', 'with', 'partial', 'seizures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00537940,NCT00537940,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. | To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.","[(91, 101, 'DRUG', 'Pregabalin'), (109, 119, 'DRUG', 'Gabapentin'), (159, 175, 'CONDITION', 'Partial Seizures'), (206, 216, 'DRUG', 'pregabalin'), (221, 231, 'DRUG', 'gabapentin'), (272, 288, 'CONDITION', 'partial seizures')]"
"['Feasibility', 'and', 'Effectiveness', 'of', 'a', 'Specific', 'App', 'to', 'Delivery', 'Mindfulness', 'Sessions', 'to', 'Patients', 'With', 'Different', 'Kinds', 'of', 'Pain', 'Condition', ':', 'a', 'Pilot', 'Study', '|', 'A', 'standardized', 'behavioural', 'approach', 'based', 'on', 'mindfulness', 'delivered', 'mainly', 'by', 'a', 'specific', 'APP', 'on', 'android', 'will', 'be', 'developed', 'and', 'applied', 'for', 'patients', 'with', 'chronic', 'pain', 'conditions', ',', 'as', 'migraine', 'and', 'neuropathic', 'pain', '.', '\n\n', 'The', 'aim', 'of', 'this', 'pilot', 'study', ':', '\n\n', 'The', 'investigators', 'propose', 'a', 'pilot', 'study', 'to', 'enforce', 'the', 'application', 'of', 'a', 'Home', '-', 'program', 'for', 'patients', 'with', 'different', 'pain', 'conditions', ',', 'to', 'learn', 'mindfulness', 'practice', ',', 'added', 'to', 'a', 'regular', 'mindfulness', 'guided', 'face', '-', 'to', '-', 'face', 'program', ',', 'by', 'using', 'the', 'technology', 'with', 'android', 'to', 'receive', 'mindfulness', 'sessions', 'for', 'daily', 'practice', 'and', 'to', 'assess', 'the', 'feasibility', 'and', 'the', 'effectiveness', 'of', 'behavioural', 'approach', 'base', 'on', 'mindfulness', 'delivered', 'with', 'this', 'modality', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O']",NCT05101837,NCT05101837,"Feasibility and Effectiveness of a Specific App to Delivery Mindfulness Sessions to Patients With Different Kinds of Pain Condition: a Pilot Study | A standardized behavioural approach based on mindfulness delivered mainly by a specific APP on android will be developed and applied for patients with chronic pain conditions, as migraine and neuropathic pain.

The aim of this pilot study:

The investigators propose a pilot study to enforce the application of a Home-program for patients with different pain conditions, to learn mindfulness practice, added to a regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality.","[(35, 80, 'OTHER', 'Specific App to Delivery Mindfulness Sessions'), (117, 121, 'CONDITION', 'Pain'), (194, 240, 'OTHER', 'mindfulness delivered mainly by a specific APP'), (300, 312, 'CONDITION', 'chronic pain'), (328, 336, 'CONDITION', 'migraine'), (341, 357, 'CONDITION', 'neuropathic pain'), (462, 474, 'BEHAVIOURAL', 'Home-program'), (503, 507, 'CONDITION', 'pain'), (529, 540, 'BEHAVIOURAL', 'mindfulness'), (570, 609, 'BEHAVIOURAL', 'mindfulness guided face-to-face program'), (659, 670, 'BEHAVIOURAL', 'mindfulness'), (783, 794, 'BEHAVIOURAL', 'mindfulness')]"
"['Enhancing', 'Physical', 'Therapy', 'Best', 'Practice', 'for', 'Improving', 'Walking', 'After', 'Stroke', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'implementing', 'best', 'practices', 'into', 'current', 'stroke', 'rehabilitation', 'physical', 'therapy', 'on', 'walking', 'outcomes', '.', 'Participants', 'will', 'also', 'be', 'provided', 'an', 'activity', 'monitor', 'to', 'help', 'them', 'track', 'and', 'target', 'their', 'walking', 'practice', 'to', 'determine', 'if', 'this', 'can', 'improve', 'walking', 'ability', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04238260,NCT04238260,Enhancing Physical Therapy Best Practice for Improving Walking After Stroke | The aim of this study is to assess the effect of implementing best practices into current stroke rehabilitation physical therapy on walking outcomes. Participants will also be provided an activity monitor to help them track and target their walking practice to determine if this can improve walking ability.,"[(10, 40, 'OTHER', 'Physical Therapy Best Practice'), (69, 75, 'CONDITION', 'Stroke'), (140, 206, 'OTHER', 'best practices into current stroke rehabilitation physical therapy'), (266, 282, 'OTHER', 'activity monitor')]"
"['Combining', 'SSRIs', 'and', 'TDCS', 'to', 'Enhance', 'Motor', 'Recovery', 'After', 'Stroke', '|', 'Post', '-', 'stroke', 'motor', 'recovery', 'is', 'compelling', 'but', 'limited', '.', 'Current', 'rehabilitation', 'has', 'less', 'impacts', 'on', 'the', 'plateau', 'that', 'spontaneous', 'biological', 'recovery', 'could', 'be', 'expected', '.', 'The', 'advances', 'in', 'non', '-', 'invasive', 'neuromodulation', 'and', 'neurophysiological', 'characterization', 'of', 'critical', 'motor', 'recovery', 'period', 'enable', 'breaking', 'the', 'proportional', 'recovery', 'limitation', '.', 'Our', 'pilot', 'studies', 'demonstrated', 'the', 'safety', 'and', 'responsiveness', 'of', 'combing', 'dual', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'and', 'motor', 'training', 'in', 'subacute', 'stroke', 'patients', '.', 'There', 'is', 'also', 'strong', 'evidence', 'that', 'selective', 'serotonin', 'reuptake', 'inhibitors', '(', 'SSRIs', ')', 'can', 'substantially', 'increase', 'the', 'effects', 'of', 'tDCS', 'and', 'improve', 'motor', 'function', 'after', 'stroke', ',', 'even', 'in', 'the', 'absence', 'of', 'depression', '.', 'This', 'proposal', 'aims', 'to', 'prove', 'the', 'potential', 'of', 'combining', 'of', 'tDCS', 'and', 'the', 'commonly', 'used', 'SSRI', 'citalopram', 'to', 'improve', 'response', 'to', 'a', 'daily', 'motor', 'training', 'intervention', 'in', 'acute', 'stroke', 'patients', '(', 'Co', '-', 'STARS', 'trial', ')', '.']","['O', 'B-DRUG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05041582,NCT05041582,"Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke | Post-stroke motor recovery is compelling but limited. Current rehabilitation has less impacts on the plateau that spontaneous biological recovery could be expected. The advances in non-invasive neuromodulation and neurophysiological characterization of critical motor recovery period enable breaking the proportional recovery limitation. Our pilot studies demonstrated the safety and responsiveness of combing dual transcranial direct current stimulation (tDCS) and motor training in subacute stroke patients. There is also strong evidence that selective serotonin reuptake inhibitors (SSRIs) can substantially increase the effects of tDCS and improve motor function after stroke, even in the absence of depression. This proposal aims to prove the potential of combining of tDCS and the commonly used SSRI citalopram to improve response to a daily motor training intervention in acute stroke patients (Co-STARS trial).","[(10, 15, 'DRUG', 'SSRIs'), (20, 24, 'OTHER', 'TDCS'), (57, 63, 'CONDITION', 'Stroke'), (66, 77, 'CONDITION', 'Post-stroke'), (247, 275, 'OTHER', 'non-invasive neuromodulation'), (476, 520, 'OTHER', 'dual transcranial direct current stimulation'), (522, 526, 'OTHER', 'tDCS'), (532, 546, 'PHYSICAL', 'motor training'), (550, 565, 'CONDITION', 'subacute stroke'), (611, 650, 'DRUG', 'selective serotonin reuptake inhibitors'), (652, 657, 'DRUG', 'SSRIs'), (701, 705, 'OTHER', 'tDCS'), (739, 745, 'CONDITION', 'stroke'), (840, 844, 'OTHER', 'tDCS'), (867, 871, 'DRUG', 'SSRI'), (872, 882, 'DRUG', 'citalopram'), (914, 941, 'PHYSICAL', 'motor training intervention'), (945, 957, 'CONDITION', 'acute stroke')]"
"['Sleep', ',', 'Aging', 'and', 'Risk', 'for', 'Alzheimer', ""'s"", 'Disease', '(', 'SARA', ')', 'Study', '|', 'Our', 'preliminary', 'data', 'show', 'for', 'in', 'cognitively', '-', 'normal', 'elderly', ',', 'that', 'Sleep', 'Disordered', 'Breathing', '(', 'SDB', ')', 'is', 'associated', 'with', 'the', 'increase', 'of', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'phosphorylated', '-', 'Tau', '(', 'P', '-', 'Tau', ')', 'and', 'total', '-', 'Tau', '(', 'T', '-', 'Tau', ')', ',', 'decreases', 'in', 'medial', 'temporal', 'lobe', 'glucose', 'uptake', '(', 'FDG', '-', 'PET', ')', 'and', 'volume', '(', 'MRI', ')', 'and', 'progressive', 'memory', 'decline', ',', 'all', 'of', 'which', 'have', 'been', 'shown', 'to', 'be', 'useful', 'in', 'predicting', 'future', 'dementia', 'in', 'older', 'adults', '.', 'These', 'findings', 'raise', 'the', 'question', 'as', 'to', 'whether', 'Alzheimer', ""'s"", 'disease', '(', 'AD', ')', 'tissue', 'damage', 'causes', 'SDB', 'in', 'the', 'elderly', ',', 'or', 'alternatively', ',', 'if', 'SDB', 'acts', 'as', 'a', 'risk', 'factor', 'for', 'AD', 'neurodegeneration', '.', 'In', 'the', 'proposed', 'study', ',', 'we', 'will', 'investigate', 'these', 'mechanistic', 'hypotheses', 'in', 'cognitively', 'normal', 'elderly', 'by', 'examining', 'the', 'longitudinal', 'associations', 'between', 'SDB', 'and', 'cognitive', 'decline', ',', 'novel', 'MR', 'neuroimaging', 'and', 'CSF', 'biomarkers', 'for', 'neurodegeneration', ';', 'while', 'our', 'secondary', 'goal', 'is', 'to', 'launch', 'a', 'pilot', 'treatment', 'study', 'to', 'aid', 'in', 'interpreting', 'the', 'mechanistic', 'hypotheses', 'and', 'to', 'examine', 'the', 'effects', 'of', 'nasal', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'on', 'cognitive', 'decline', 'and', 'neurodegeneration', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",NCT01962779,NCT01962779,"Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study | Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial temporal lobe glucose uptake (FDG-PET) and volume (MRI) and progressive memory decline, all of which have been shown to be useful in predicting future dementia in older adults. These findings raise the question as to whether Alzheimer's disease (AD) tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for AD neurodegeneration. In the proposed study, we will investigate these mechanistic hypotheses in cognitively normal elderly by examining the longitudinal associations between SDB and cognitive decline, novel MR neuroimaging and CSF biomarkers for neurodegeneration; while our secondary goal is to launch a pilot treatment study to aid in interpreting the mechanistic hypotheses and to examine the effects of nasal continuous positive airway pressure (CPAP) on cognitive decline and neurodegeneration.","[(26, 45, 'CONDITION', ""Alzheimer's Disease""), (127, 153, 'CONDITION', 'Sleep Disordered Breathing'), (155, 158, 'CONDITION', 'SDB'), (363, 377, 'CONDITION', 'memory decline'), (442, 450, 'CONDITION', 'dementia'), (516, 535, 'CONDITION', ""Alzheimer's disease""), (537, 539, 'CONDITION', 'AD'), (562, 565, 'CONDITION', 'SDB'), (603, 606, 'CONDITION', 'SDB'), (633, 635, 'CONDITION', 'AD'), (808, 811, 'CONDITION', 'SDB'), (1047, 1082, 'OTHER', 'continuous positive airway pressure'), (1084, 1088, 'OTHER', 'CPAP'), (1093, 1110, 'CONDITION', 'cognitive decline')]"
"['Precision', 'Gait', 'Retraining', 'for', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'This', 'project', 'will', 'develop', 'the', 'first', 'sensor', '-', 'based', 'mobile', 'Pelvic', 'Assist', 'Device', '(', 'mPAD', ')', 'that', 'can', 'deliver', 'precise', ',', 'adaptable', ',', 'pelvic', 'control', 'to', 'restore', 'natural', 'coordination', 'of', 'upper-', 'and', 'lower', '-', 'limb', 'movements', 'during', 'gait', 'in', 'children', 'with', 'Cerebral', 'Palsy']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT04717323,NCT04717323,"Precision Gait Retraining for Children With Cerebral Palsy | This project will develop the first sensor-based mobile Pelvic Assist Device (mPAD) that can deliver precise, adaptable, pelvic control to restore natural coordination of upper- and lower-limb movements during gait in children with Cerebral Palsy","[(0, 25, 'PHYSICAL', 'Precision Gait Retraining'), (44, 58, 'CONDITION', 'Cerebral Palsy'), (97, 137, 'OTHER', 'sensor-based mobile Pelvic Assist Device'), (139, 143, 'OTHER', 'mPAD'), (293, 307, 'CONDITION', 'Cerebral Palsy')]"
"['Randomized', 'Controlled', 'Pilot', 'Trial', 'of', 'HIRREM', '-', 'SOP', 'for', 'Insomnia', '|', 'Prior', 'research', 'studies', 'have', 'shown', 'benefit', 'for', 'use', 'of', 'a', 'technique', 'called', 'High', '-', 'resolution', ',', 'relational', ',', 'resonance', '-', 'based', ',', 'electroencephalic', 'mirroring', '(', 'HIRREM', '®', ')', ',', 'to', 'reduce', 'symptoms', 'of', 'moderate', 'to', 'severe', 'insomnia', '.', 'HIRREM', 'uses', 'scalp', 'sensors', 'to', 'monitor', 'brain', 'electrical', 'activity', ',', 'and', 'software', 'algorithms', 'translate', 'selected', 'brain', 'frequencies', 'into', 'audible', 'tones', 'in', 'real', 'time', '.', 'Those', 'tones', '(', 'acoustic', 'stimulation', ')', 'are', 'reflected', 'back', 'to', 'participants', 'via', 'ear', 'buds', 'in', 'as', 'little', 'as', 'four', 'milliseconds', ',', 'providing', 'the', 'brain', 'an', 'opportunity', 'to', 'self', '-', 'adjust', 'and', 'balance', 'its', 'electrical', 'pattern', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'determine', 'the', 'effects', 'of', 'HIRREM', '-', 'SOP', ',', 'an', 'updated', 'version', 'of', 'this', 'technology', 'that', 'is', 'based', 'on', 'the', 'HIRREM', 'approach', ',', 'but', 'now', 'includes', 'new', 'hardware', 'and', 'software', ',', 'a', 'standardized', 'series', 'of', 'HIRREM', 'protocols', ',', 'and', 'a', 'fixed', 'number', 'of', 'sessions', '.', 'Adults', 'over', 'the', 'age', 'of', '18', 'who', 'have', 'documented', 'sleep', 'trouble', 'that', 'place', 'them', 'in', 'the', 'category', 'of', 'subthreshold', '(', 'mild', ')', ',', 'moderate', ',', 'or', 'severe', 'clinical', 'insomnia', 'as', 'defined', 'by', 'the', 'Insomnia', 'Severity', 'Index', ',', 'are', 'eligible', 'to', 'participate', 'in', 'the', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03607994,NCT03607994,"Randomized Controlled Pilot Trial of HIRREM-SOP for Insomnia | Prior research studies have shown benefit for use of a technique called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM®), to reduce symptoms of moderate to severe insomnia. HIRREM uses scalp sensors to monitor brain electrical activity, and software algorithms translate selected brain frequencies into audible tones in real time. Those tones (acoustic stimulation) are reflected back to participants via ear buds in as little as four milliseconds, providing the brain an opportunity to self-adjust and balance its electrical pattern.

The purpose of this research study is to determine the effects of HIRREM-SOP, an updated version of this technology that is based on the HIRREM approach, but now includes new hardware and software, a standardized series of HIRREM protocols, and a fixed number of sessions. Adults over the age of 18 who have documented sleep trouble that place them in the category of subthreshold (mild), moderate, or severe clinical insomnia as defined by the Insomnia Severity Index, are eligible to participate in the study.","[(37, 47, 'OTHER', 'HIRREM-SOP'), (52, 60, 'CONDITION', 'Insomnia'), (135, 208, 'OTHER', 'High-resolution, relational, resonance-based, electroencephalic mirroring'), (210, 216, 'OTHER', 'HIRREM'), (242, 269, 'CONDITION', 'moderate to severe insomnia'), (271, 277, 'OTHER', 'HIRREM'), (700, 710, 'OTHER', 'HIRREM-SOP'), (771, 777, 'OTHER', 'HIRREM'), (857, 863, 'OTHER', 'HIRREM'), (953, 966, 'CONDITION', 'sleep trouble'), (1002, 1060, 'CONDITION', 'subthreshold (mild), moderate, or severe clinical insomnia')]"
"['Rivastigmine', 'for', 'the', 'Prevention', 'of', 'Postoperative', 'Delirium', 'After', 'Cardiac', 'Surgery', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'Rivastigmine', 'is', 'effective', 'for', 'the', 'prevention', 'of', 'postoperative', 'delirium', 'in', 'patients', 'undergoing', 'cardiac', 'surgery', '.']","['B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00257868,NCT00257868,Rivastigmine for the Prevention of Postoperative Delirium After Cardiac Surgery | The purpose of this study is to determine whether Rivastigmine is effective for the prevention of postoperative delirium in patients undergoing cardiac surgery.,"[(0, 12, 'DRUG', 'Rivastigmine'), (35, 57, 'CONDITION', 'Postoperative Delirium'), (64, 79, 'CONDITION', 'Cardiac Surgery'), (132, 144, 'DRUG', 'Rivastigmine'), (180, 202, 'CONDITION', 'postoperative delirium'), (226, 241, 'CONDITION', 'cardiac surgery')]"
"['Clevidipine', 'for', 'Vasospasm', 'After', 'Subarachnoid', 'Hemorrhage', '|', 'Vasospasm', 'occurs', 'frequently', 'after', 'aneurysmal', 'subarachnoid', 'hemorrhage', 'and', 'can', 'lead', 'to', 'strokes', '.', 'The', 'investigators', 'will', 'investigate', 'if', 'infusion', 'of', 'a', 'novel', 'drug', ',', 'clevidipine', ',', 'will', 'decrease', 'vasospasm', 'during', 'the', 'infusion', 'and', 'post', 'infusion', 'period', 'using', 'transcranial', 'doppler', 'monitoring', 'of', 'patients', 'with', 'subarachnoid', 'hemorrhage', 'and', 'moderate', 'severity', 'vasospasm']","['B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT02011321,NCT02011321,"Clevidipine for Vasospasm After Subarachnoid Hemorrhage | Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm","[(0, 11, 'DRUG', 'Clevidipine'), (16, 25, 'CONDITION', 'Vasospasm'), (32, 55, 'CONDITION', 'Subarachnoid Hemorrhage'), (58, 67, 'CONDITION', 'Vasospasm'), (92, 126, 'CONDITION', 'aneurysmal subarachnoid hemorrhage'), (216, 227, 'DRUG', 'clevidipine'), (243, 252, 'CONDITION', 'vasospasm'), (353, 376, 'CONDITION', 'subarachnoid hemorrhage'), (381, 408, 'CONDITION', 'moderate severity vasospasm')]"
"['Migraine', 'Prevention', 'Using', 'Pulsed', 'Shortwave', 'Therapy', '|', 'Chronic', 'pain', 'is', 'now', 'widely', 'understood', 'to', 'be', 'due', 'to', 'central', 'sensitization', ',', 'which', 'leads', 'to', 'exaggerated', 'pain', 'perception', '.', 'Migraine', 'is', 'no', 'exception', ',', 'since', 'it', 'is', 'well', 'known', 'that', 'sensitization', 'of', 'the', 'trigeminovascular', 'pain', 'pathway', 'can', 'occur', 'during', 'a', 'migraine', 'attach', '.', 'There', 'is', 'early', 'evidence', 'that', 'ActiPatch', 'can', 'help', 'mitigate', 'this', 'sensitization', ',', 'so', 'this', 'study', 'is', 'being', 'conducted', 'to', 'determine', 'the', 'efficacy', 'of', 'ActiPatch', 'in', 'preventing', 'chronic', ',', 'episodic', 'migraines', '.']","['B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT03166046,NCT03166046,"Migraine Prevention Using Pulsed Shortwave Therapy | Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attach. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic, episodic migraines.","[(0, 8, 'CONDITION', 'Migraine'), (26, 50, 'OTHER', 'Pulsed Shortwave Therapy'), (53, 65, 'CONDITION', 'Chronic pain'), (154, 158, 'CONDITION', 'pain'), (171, 179, 'CONDITION', 'Migraine'), (296, 311, 'CONDITION', 'migraine attach'), (342, 351, 'OTHER', 'ActiPatch'), (452, 461, 'OTHER', 'ActiPatch'), (476, 503, 'CONDITION', 'chronic, episodic migraines')]"
"['MELAtonin', 'for', 'Prevention', 'of', 'Postoperative', 'Agitation', 'and', 'Emergence', 'Delirium', 'in', 'Children', '.', 'The', 'MELA', '-', 'PAED', 'Trial', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '.', '|', 'Postoperative', 'agitation', 'and', 'emergence', 'delirium', 'describe', 'a', 'spectrum', 'of', 'symptoms', 'of', 'early', 'postoperative', 'negative', 'behavior', ',', 'in', 'which', 'the', 'child', 'experiences', 'a', 'variety', 'of', 'behavioral', 'disturbances', 'including', 'crying', ',', 'thrashing', ',', 'and', 'disorientation', 'during', 'early', 'awakening', 'from', 'anaesthesia', '.', 'The', 'symptoms', 'are', 'common', 'with', 'a', 'reported', 'incidence', 'of', 'approximately', '25', '%', '.', 'Some', 'clinical', 'trials', 'have', 'studied', 'the', 'effect', 'of', 'prophylactic', 'oral', 'melatonin', 'for', 'reducing', 'the', 'risk', 'of', 'emergence', 'agitation', 'in', 'children', ',', 'some', 'finding', 'a', 'considerable', 'dose', '-', 'response', 'effect', '.', 'Melatonin', 'has', 'a', 'low', 'bio', '-', 'availability', 'of', 'approximately', '15', '%', '.', 'The', 'safety', 'of', 'exogenous', 'melatonin', 'for', 'pediatric', 'patients', 'has', 'been', 'studied', 'with', 'no', 'apparent', 'serious', 'adverse', 'effects', ',', 'even', 'at', 'repeated', 'short', '-', 'term', 'use', 'of', 'high', 'doses', 'of', 'intravenous', 'melatonin', '.', 'The', 'aim', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'investigate', 'the', 'prophylactic', 'effects', 'and', 'safety', 'of', 'intravenous', 'melatonin', 'administered', 'intraoperatively', 'for', 'prevention', 'of', 'postopreative', 'agitation', 'and', 'emergence', 'delirium', 'in', 'children', 'after', 'an', 'elective', 'surgical', 'procedure', '.', 'The', 'study', 'is', 'designed', 'as', 'a', 'randomised', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'clinical', 'trial', '.']","['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O']",NCT05541276,NCT05541276,"MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial. | Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.","[(0, 9, 'DRUG', 'MELAtonin'), (28, 51, 'CONDITION', 'Postoperative Agitation'), (56, 74, 'CONDITION', 'Emergence Delirium'), (137, 144, 'CONTROL', 'Placebo'), (165, 188, 'CONDITION', 'Postoperative agitation'), (193, 211, 'CONDITION', 'emergence delirium'), (581, 590, 'DRUG', 'melatonin'), (616, 635, 'CONDITION', 'emergence agitation'), (699, 708, 'DRUG', 'Melatonin'), (783, 792, 'DRUG', 'melatonin'), (936, 945, 'DRUG', 'melatonin'), (1047, 1056, 'DRUG', 'melatonin'), (1105, 1128, 'CONDITION', 'postopreative agitation'), (1133, 1151, 'CONDITION', 'emergence delirium'), (1255, 1262, 'CONTROL', 'placebo')]"
"['A', 'Phase', 'II', 'Study', 'of', 'Conformal', 'Radiotherapy', 'In', 'Patients', 'With', 'Low', '-', 'Grade', 'Gliomas', '|', 'RATIONALE', ':', 'Specialized', 'radiation', 'therapy', 'that', 'delivers', 'radiation', 'directly', 'to', 'the', 'tumor', 'may', 'kill', 'more', 'tumor', 'cells', 'and', 'cause', 'less', 'damage', 'to', 'normal', 'tissue', '.', '\n\n', 'PURPOSE', ':', 'This', 'phase', 'II', 'trial', 'is', 'studying', 'how', 'well', 'radiation', 'therapy', 'works', 'in', 'treating', 'young', 'patients', 'with', 'gliomas', '.']","['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00238264,NCT00238264,"A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas | RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.","[(20, 42, 'RADIOTHERAPY', 'Conformal Radiotherapy'), (60, 77, 'CONDITION', 'Low-Grade Gliomas'), (103, 120, 'RADIOTHERAPY', 'radiation therapy'), (181, 186, 'CONDITION', 'tumor'), (284, 301, 'RADIOTHERAPY', 'radiation therapy'), (340, 347, 'CONDITION', 'gliomas')]"
"['Comparison', 'of', 'the', 'Effectiveness', 'of', 'Craniosacral', 'Therapy', 'and', 'Myofacial', 'Relaxation', 'Techniques', 'in', 'People', 'Diagnosed', 'With', 'Migraine', '|', 'Headache', 'is', 'a', 'neurological', 'condition', 'that', 'is', 'very', 'common', 'all', 'over', 'the', 'world', 'and', 'is', 'observed', 'at', 'some', 'time', 'in', 'life', 'in', 'more', 'than', '90', '%', 'of', 'society', '.', 'Migraine', 'headache', ',', 'known', 'for', 'thousands', 'of', 'years', ',', 'is', 'one', 'of', 'the', 'oldest', 'diseases', 'of', 'humanity', '.', 'The', 'word', ""'"", 'hemicrania', ""'"", ',', 'meaning', ""'"", 'half', 'of', 'a', 'head', ""'"", ',', 'is', 'used', 'due', 'to', 'unilateral', 'pain', '.', 'Approaches', 'to', 'treating', 'migraine', 'include', 'medication', ',', 'relaxation', ',', 'biofeedback', ',', 'living', 'a', 'regular', 'life', ',', 'adequate', 'sleep', ',', 'exercise', ',', 'and', 'stress', 'management', '.', 'Neck', 'pain', 'is', 'especially', 'common', 'in', 'migraine', 'patients', '.', 'Exercise', ',', 'manual', 'practices', ',', 'electrop', 'novelties', 'are', 'used', 'to', 'reduce', 'musculoskeletal', 'problems', ',', 'thus', 'reducing', 'the', 'effects', 'of', 'migraine', '.', 'Myofascial', 'relaxation', 'techniques', ',', 'which', 'are', 'included', 'in', 'the', 'manipulative', 'techniques', 'in', 'the', 'literature', ',', 'are', 'relaxation', 'methods', 'performed', 'on', 'myofascial', 'trigger', 'points', '.', 'Osteopathic', 'manual', 'therapy', '(', 'OMT', ')', ',', 'which', 'has', 'recently', 'entered', 'the', 'literature', ',', '19', '.', 'osteopathy', ',', 'developed', 'by', 'Andrew', 'Taylor', 'STILL', 'at', 'the', 'end', 'of', 'the', 'century', ',', 'is', 'a', 'treatment', 'system', 'characterized', 'by', 'focusing', 'on', 'integrity', 'and', 'using', 'it', 'by', 'hand', 'to', 'heal', 'diseases', '.', 'The', 'study', 'of', 'cranial', 'OMM', 'kraniyum', 'first', 'anatomical', 'and', 'physiological', 'mechanisms', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'disease', 'as', 'a', 'whole', 'is', 'concerned', 'with', 'the', 'relationship', 'of', 'the', 'body', ',', 'including', 'diagnostic', 'and', 'therapeutic', 'methods', '.', 'It', 'is', 'used', 'in', 'the', 'treatment', 'of', 'somatic', 'dysfunction', 'of', 'the', 'head', 'and', 'other', 'body', 'parts', '.', 'An', 'important', 'component', 'of', 'cranial', 'Omm', 'is', 'the', 'primary', 'respiratory', 'mechanism', ',', 'which', 'occurs', 'as', 'movement', 'of', 'the', 'head', 'bones', ',', 'sacrum', ',', 'dural', 'membranes', ',', 'central', 'nervous', 'system', 'and', 'cerebrospinal', 'fluid', '.', 'The', 'primary', 'respiratory', 'mechanism', 'is', 'synchronous', 'with', 'the', 'cranial', 'rhythmic', 'impulse', ',', 'a', '2', '-', 'phase', 'rhythmic', 'cycle', 'that', 'represents', 'a', 'dynamic', 'metabolic', 'exchange', 'with', 'each', 'stage', 'of', 'the', 'body', '.', 'This', 'cycle', 'is', 'indicated', 'as', 'loops', 'between', '7', 'and', '14', 'per', 'minute', '.', 'Fascial', 'mobilization', 'therapy', 'increases', 'energy', 'use', 'in', 'segments', 'implemented', 'by', 'mechanical', 'changes', '.', 'Accordingly', ',', 'it', 'helps', 'to', 'reduce', 'the', 'spasm', 'of', 'these', 'layers', 'extending', 'fascially', ',', 'to', 'dissolve', 'adhesions', ',', 'and', 'to', 'increase', 'the', 'range', 'of', 'motion', 'of', 'the', 'joint', '.', '\n\n', 'H0', ':', 'Osteopathic', 'Manipulative', 'Therapy', 'has', 'no', 'effect', 'on', 'migraine', 'symptoms', '.', 'H1', ':', 'Osteopathic', 'Manipulative', 'Therapy', 'has', 'an', 'effect', 'on', 'migraine', 'symptoms', '.', 'H2', ':', 'myofascial', 'relaxation', 'techniques', 'have', 'no', 'effect', 'on', 'migraine', 'symptoms', '.', 'H3', ':', 'methods', 'of', 'Osteopathic', 'Manipulative', 'Therapy', 'have', 'an', 'effect', 'on', 'migraine', 'symptoms', '.', '\n\n', 'H4', ':', 'myofascial', 'relaxation', 'techniques', 'and', 'osteopathic', 'manipulative', 'treatment', 'methods', 'have', 'no', 'superiority', 'over', 'each', 'other', '.', '\n\n', 'H5', ':', 'myofascial', 'relaxation', 'techniques', 'and', 'osteopathic', 'manipulative', 'treatment', 'methods', 'have', 'superiority', 'over', 'each', 'other', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04976725,NCT04976725,"Comparison of the Effectiveness of Craniosacral Therapy and Myofacial Relaxation Techniques in People Diagnosed With Migraine | Headache is a neurological condition that is very common all over the world and is observed at some time in life in more than 90% of society. Migraine headache, known for thousands of years, is one of the oldest diseases of humanity. The word 'hemicrania', meaning 'half of a head', is used due to unilateral pain. Approaches to treating migraine include medication, relaxation, biofeedback, living a regular life, adequate sleep, exercise, and stress management. Neck pain is especially common in migraine patients. Exercise, manual practices, electrop novelties are used to reduce musculoskeletal problems, thus reducing the effects of migraine. Myofascial relaxation techniques, which are included in the manipulative techniques in the literature, are relaxation methods performed on myofascial trigger points.Osteopathic manual therapy (OMT) , which has recently entered the literature, 19. osteopathy, developed by Andrew Taylor STILL at the end of the century, is a treatment system characterized by focusing on integrity and using it by hand to heal diseases.The study of cranial OMM kraniyum first anatomical and physiological mechanisms for the prevention and treatment of disease as a whole is concerned with the relationship of the body, including diagnostic and therapeutic methods.It is used in the treatment of somatic dysfunction of the head and other body parts. An important component of cranial Omm is the primary respiratory mechanism, which occurs as movement of the head bones, sacrum, dural membranes, central nervous system and cerebrospinal fluid. The primary respiratory mechanism is synchronous with the cranial rhythmic impulse, a 2-phase rhythmic cycle that represents a dynamic metabolic exchange with each stage of the body. This cycle is indicated as loops between 7 and 14 per minute.Fascial mobilization therapy increases energy use in segments implemented by mechanical changes.Accordingly, it helps to reduce the spasm of these layers extending fascially, to dissolve adhesions, and to increase the range of motion of the joint.

H0: Osteopathic Manipulative Therapy has no effect on migraine symptoms. H1: Osteopathic Manipulative Therapy has an effect on migraine symptoms. H2: myofascial relaxation techniques have no effect on migraine symptoms. H3: methods of Osteopathic Manipulative Therapy have an effect on migraine symptoms.

H4: myofascial relaxation techniques and osteopathic manipulative treatment methods have no superiority over each other.

H5: myofascial relaxation techniques and osteopathic manipulative treatment methods have superiority over each other.","[(35, 55, 'OTHER', 'Craniosacral Therapy'), (60, 91, 'OTHER', 'Myofacial Relaxation Techniques'), (117, 125, 'CONDITION', 'Migraine'), (128, 136, 'CONDITION', 'Headache'), (270, 278, 'CONDITION', 'Migraine'), (372, 382, 'CONDITION', 'hemicrania'), (437, 441, 'CONDITION', 'pain'), (466, 474, 'CONDITION', 'migraine'), (592, 601, 'CONDITION', 'Neck pain'), (626, 634, 'CONDITION', 'migraine'), (766, 774, 'CONDITION', 'migraine'), (776, 808, 'OTHER', 'Myofascial relaxation techniques'), (941, 967, 'OTHER', 'Osteopathic manual therapy'), (969, 972, 'OTHER', 'OMT'), (1207, 1227, 'OTHER', 'cranial OMM kraniyum'), (1533, 1544, 'OTHER', 'cranial Omm'), (1944, 1972, 'OTHER', 'Fascial mobilization therapy'), (2197, 2229, 'OTHER', 'Osteopathic Manipulative Therapy'), (2247, 2255, 'CONDITION', 'migraine'), (2270, 2302, 'OTHER', 'Osteopathic Manipulative Therapy'), (2320, 2328, 'CONDITION', 'migraine'), (2343, 2375, 'OTHER', 'myofascial relaxation techniques'), (2394, 2402, 'CONDITION', 'migraine'), (2428, 2460, 'OTHER', 'Osteopathic Manipulative Therapy'), (2479, 2487, 'CONDITION', 'migraine'), (2503, 2535, 'OTHER', 'myofascial relaxation techniques'), (2540, 2574, 'OTHER', 'osteopathic manipulative treatment'), (2625, 2657, 'OTHER', 'myofascial relaxation techniques'), (2662, 2696, 'OTHER', 'osteopathic manipulative treatment')]"
"['A', 'Phase', 'II', 'Multicenter', ',', 'Randomized', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Autologous', 'Incubated', 'Macrophages', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Complete', 'Spinal', 'Cord', 'Injuries', '|', 'Autologous', 'Incubated', 'Macrophages', '(', 'ProCord', ')', 'is', 'being', 'developed', 'as', 'a', 'therapy', 'for', 'acute', ',', 'complete', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'therapy', 'is', 'intended', 'to', 'reverse', 'the', 'loss', 'of', 'motor', 'and', 'sensory', 'function', '.', '\n\n', 'Following', 'non', '-', 'CNS', 'tissue', 'injury', ',', 'macrophages', 'quickly', 'arrive', 'on', 'the', 'scene', ',', 'where', 'they', 'clean', 'up', 'cell', 'debris', ',', 'secrete', 'different', 'molecules', 'thus', 'promoting', 'a', 'controlled', 'inflammatory', 'reaction', 'that', 'forms', 'the', 'first', 'phase', 'of', 'the', 'wound', 'healing', 'process', '.', 'While', 'this', 'process', 'occurs', 'in', 'most', 'tissues', ',', 'including', 'peripheral', 'nerves', ',', 'it', 'does', 'not', 'occur', 'in', 'the', 'CNS', ',', 'where', 'macrophages', 'and', 'other', 'immune', 'cells', 'are', 'relatively', 'rare', ',', 'and', 'their', 'activities', 'curtailed', 'by', 'a', 'biochemical', 'mechanism', 'known', 'as', '""', 'immune', 'privilege', '.', '""', '\n\n', 'In', 'animal', 'studies', ',', 'it', 'appears', 'that', 'incubated', 'macrophages', 'circumvent', 'the', 'immune', 'privilege', ',', 'thus', 'supporting', 'the', 'regrowth', 'of', 'axons', 'through', 'the', 'injury', 'site', 'and', 'enabling', 'the', 'recovery', 'of', 'neurological', 'function', '.', 'The', 'concept', 'derives', 'from', 'the', 'pioneering', 'research', 'of', 'Prof.', 'Michal', 'Schwartz', 'at', 'the', 'Weizmann', 'Institute', 'of', 'Science', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00073853,NCT00073853,"A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries | Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function.

Following non-CNS tissue injury, macrophages quickly arrive on the scene, where they clean up cell debris, secrete different molecules thus promoting a controlled inflammatory reaction that forms the first phase of the wound healing process. While this process occurs in most tissues, including peripheral nerves, it does not occur in the CNS, where macrophages and other immune cells are relatively rare, and their activities curtailed by a biochemical mechanism known as ""immune privilege.""

In animal studies, it appears that incubated macrophages circumvent the immune privilege, thus supporting the regrowth of axons through the injury site and enabling the recovery of neurological function. The concept derives from the pioneering research of Prof. Michal Schwartz at the Weizmann Institute of Science.","[(91, 123, 'SURGICAL', 'Autologous Incubated Macrophages'), (159, 188, 'CONDITION', 'Complete Spinal Cord Injuries'), (191, 223, 'SURGICAL', 'Autologous Incubated Macrophages'), (225, 232, 'SURGICAL', 'ProCord'), (270, 304, 'CONDITION', 'acute, complete spinal cord injury'), (306, 309, 'CONDITION', 'SCI')]"
"['Improving', 'Gait', 'Adaptability', 'in', 'Hereditary', 'Spastic', 'Paraplegia', 'During', 'Task', '-', 'specific', 'Training', 'on', 'the', 'C', '-', 'Mill', ':', 'Towards', 'Evidence', '-', 'Based', 'and', 'Individually', 'Tailored', 'Rehabilitation', '|', 'This', 'study', 'evaluates', 'the', 'effects', 'of', 'ten', 'hours', 'C', '-', 'mill', 'training', 'on', 'gait', 'adaptability', 'in', 'participants', 'with', 'hereditary', 'spastic', 'paraplegia', '(', 'HSP', ')', '.', 'Half', 'of', 'the', 'participants', 'start', 'with', 'five', 'weeks', 'of', 'C', '-', 'mill', 'training', '(', 'ten', '1', '-', 'hour', 'sessions', ')', '.', 'The', 'other', 'participants', 'are', 'placed', 'on', 'a', 'waiting', 'list', ',', 'which', 'is', 'followed', 'by', 'the', 'same', 'five', 'weeks', 'of', 'C', '-', 'mill', 'training', '(', 'ten', '1', '-', 'hour', 'sessions', ')', '.', 'It', 'is', 'hypothesized', 'that', 'ten', 'hours', 'of', 'context', 'specific', 'C', '-', 'mill', 'training', 'is', 'effective', 'in', 'improving', 'gait', 'adaptability', 'in', 'participants', 'with', 'pure', 'HSP', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04180098,NCT04180098,"Improving Gait Adaptability in Hereditary Spastic Paraplegia During Task-specific Training on the C-Mill: Towards Evidence-Based and Individually Tailored Rehabilitation | This study evaluates the effects of ten hours C-mill training on gait adaptability in participants with hereditary spastic paraplegia (HSP). Half of the participants start with five weeks of C-mill training (ten 1-hour sessions). The other participants are placed on a waiting list, which is followed by the same five weeks of C-mill training (ten 1-hour sessions). It is hypothesized that ten hours of context specific C-mill training is effective in improving gait adaptability in participants with pure HSP.","[(31, 60, 'CONDITION', 'Hereditary Spastic Paraplegia'), (68, 104, 'PHYSICAL', 'Task-specific Training on the C-Mill'), (218, 233, 'PHYSICAL', 'C-mill training'), (276, 305, 'CONDITION', 'hereditary spastic paraplegia'), (307, 310, 'CONDITION', 'HSP'), (363, 378, 'PHYSICAL', 'C-mill training'), (441, 453, 'CONTROL', 'waiting list'), (499, 514, 'PHYSICAL', 'C-mill training'), (592, 607, 'PHYSICAL', 'C-mill training'), (678, 681, 'CONDITION', 'HSP')]"
"['A', 'Placebo', '-', 'Controlled', ',', 'Single', '-', 'Blind', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Nasal', 'Carbon', 'Dioxide', 'for', 'the', 'Symptomatic', 'Treatment', 'of', 'Classical', 'Trigeminal', 'Neuralgia', '|', 'A', 'placebo', '-', 'controlled', ',', 'single', '-', 'blind', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'preliminary', 'efficacy', 'of', 'nasal', 'carbon', 'dioxide', 'for', 'the', 'symptomatic', 'treatment', 'of', 'classical', 'trigeminal', 'neuralgia', '.']","['O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02473016,NCT02473016,"A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia | A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.","[(2, 9, 'CONTROL', 'Placebo'), (85, 99, 'DRUG', 'Carbon Dioxide'), (133, 163, 'CONDITION', 'Classical Trigeminal Neuralgia'), (168, 175, 'CONTROL', 'placebo'), (264, 278, 'DRUG', 'carbon dioxide'), (312, 342, 'CONDITION', 'classical trigeminal neuralgia')]"
"['Clinical', 'Study', 'of', 'Released', 'Unitron', 'RIC', '(', 'Receiver', 'in', 'Canal', ')', 'and', 'BTE', '(', 'Behind', 'the', 'Ear', ')', 'Hearing', 'Aid', 'Models', '|', 'Participants', 'will', 'wear', 'two', 'sets', 'of', 'Unitron', 'released', 'hearing', 'aids', '(', 'RIC', 'and', 'BTE', ')', 'programmed', 'based', 'on', 'a', 'prescriptive', 'approach', 'and', 'will', 'perform', 'a', 'standardized', 'speech', 'discrimination', 'test', 'in', 'noise', 'in', 'both', 'aided', 'conditions', 'as', 'well', 'as', 'in', 'unaided', 'condition', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05197803,NCT05197803,Clinical Study of Released Unitron RIC (Receiver in Canal) and BTE (Behind the Ear) Hearing Aid Models | Participants will wear two sets of Unitron released hearing aids (RIC and BTE) programmed based on a prescriptive approach and will perform a standardized speech discrimination test in noise in both aided conditions as well as in unaided condition.,"[(18, 102, 'OTHER', 'Released Unitron RIC (Receiver in Canal) and BTE (Behind the Ear) Hearing Aid Models'), (140, 169, 'OTHER', 'Unitron released hearing aids'), (171, 174, 'OTHER', 'RIC'), (179, 182, 'OTHER', 'BTE')]"
"['Validation', 'of', 'an', 'Algorithm', 'for', 'Identification', 'and', 'Notification', 'of', 'Generalized', 'Major', 'Motor', 'Seizures', '|', 'The', 'specificity', 'and', 'sensitivity', 'of', 'a', 'novel', 'seizure', '-', 'detection', 'mobile', 'software', 'application', 'with', 'a', 'generalized', 'tonic', '/', 'clonic', 'seizure', 'detection', 'algorithm', '(', 'Motor', 'Seizure', 'Detection', 'Algorithm', '[', 'mSDA', ']', ')', 'installed', 'on', 'a', 'wearable', 'device', 'to', 'be', 'worn', 'by', 'the', 'subject', '.', 'The', 'software', 'will', 'be', 'tested', 'using', 'subjects', 'from', 'a', 'patient', 'population', 'in', 'an', 'epilepsy', 'monitoring', 'unit', '(', 'EMU', ')', 'undergoing', 'video', 'and', 'electroencephalograph', '(', 'VEEG', ')', 'observation', '.', 'The', 'number', 'of', 'generalized', 'major', 'motor', 'seizures', 'detected', 'by', 'the', 'mSDA', 'will', 'be', 'compared', 'with', 'those', 'detected', 'by', 'VEEG', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04291716,NCT04291716,Validation of an Algorithm for Identification and Notification of Generalized Major Motor Seizures | The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm [mSDA]) installed on a wearable device to be worn by the subject. The software will be tested using subjects from a patient population in an epilepsy monitoring unit (EMU) undergoing video and electroencephalograph (VEEG) observation. The number of generalized major motor seizures detected by the mSDA will be compared with those detected by VEEG.,"[(66, 98, 'CONDITION', 'Generalized Major Motor Seizures'), (144, 151, 'CONDITION', 'seizure'), (197, 229, 'CONDITION', 'generalized tonic/clonic seizure'), (426, 434, 'CONDITION', 'epilepsy'), (534, 566, 'CONDITION', 'generalized major motor seizures')]"
"['The', 'Effects', 'of', 'a', 'Sub', '-', 'maximal', 'Exercise', 'Program', 'on', 'Adolescents', 'Who', 'Sustained', 'a', 'Concussion', '|', 'Patients', 'who', 'sustain', 'a', 'concussion', 'will', 'undergo', 'a', 'sub', '-', 'maximal', 'exercise', 'protocol', 'throughout', 'their', 'recovery', '.', 'Cerebrovascular', 'function', ',', 'heart', 'rate', ',', 'and', 'symptom', 'severity', ',', 'and', 'exercise', 'volume', 'will', 'be', 'monitored', 'throughout', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03170856,NCT03170856,"The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion | Patients who sustain a concussion will undergo a sub-maximal exercise protocol throughout their recovery. Cerebrovascular function, heart rate, and symptom severity, and exercise volume will be monitored throughout.","[(17, 45, 'PHYSICAL', 'Sub-maximal Exercise Program'), (77, 87, 'CONDITION', 'Concussion'), (113, 123, 'CONDITION', 'concussion'), (139, 168, 'PHYSICAL', 'sub-maximal exercise protocol')]"
"['An', 'Open', '-', 'label', ',', 'Un', '-', 'controlled', ',', 'Single', '-', 'centre', 'Trial', 'Investigating', 'the', 'Efficacy', 'and', 'Safety', 'of', 'CRD007', 'in', 'Children', 'With', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', 'or', 'Becker', 'Muscular', 'Dystrophy', '(', 'BMD', ')', 'or', 'Children', 'Being', 'Symptomatic', 'Carriers', 'for', 'DMD', 'or', 'BMD', '|', 'This', 'is', 'an', 'investigation', 'of', 'the', 'efficacy', 'and', 'safety', 'of', 'CRD007', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', ',', 'Becker', 'Muscular', 'Dystrophy', '(', 'BMD', ')', 'and', 'symptomatic', 'carriers', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT01540604,NCT01540604,"An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD | This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.","[(91, 97, 'DRUG', 'CRD007'), (115, 142, 'CONDITION', 'Duchenne Muscular Dystrophy'), (144, 147, 'CONDITION', 'DMD'), (152, 177, 'CONDITION', 'Becker Muscular Dystrophy'), (179, 182, 'CONDITION', 'BMD'), (202, 237, 'CONDITION', 'Symptomatic Carriers for DMD or BMD'), (295, 301, 'DRUG', 'CRD007'), (305, 332, 'CONDITION', 'Duchenne Muscular Dystrophy'), (334, 337, 'CONDITION', 'DMD'), (340, 365, 'CONDITION', 'Becker Muscular Dystrophy'), (367, 370, 'CONDITION', 'BMD'), (376, 396, 'CONDITION', 'symptomatic carriers')]"
"['Improving', 'Access', 'and', 'Affordability', 'of', 'Adult', 'Hearing', 'Healthcare', ':', 'Effectiveness', 'of', 'Community', '-', 'based', 'Interventions', 'in', 'West', 'Central', 'and', 'South', 'Alabama', '|', 'This', 'project', 'will', 'address', 'quality', 'of', 'care', 'issues', 'associated', 'with', 'hearing', 'loss', 'in', 'adults', 'who', 'have', 'mild', '-', 'to', '-', 'moderate', 'hearing', 'loss', 'and', 'who', 'have', 'no', 'access', 'to', 'hearing', 'healthcare', '.', 'Through', 'the', 'use', 'of', 'three', 'different', 'interventions', 'involving', 'personal', 'sound', 'amplification', 'products', '(', 'PSAPs', ')', ',', 'it', 'will', 'lead', 'to', 'options', 'that', 'will', 'increase', 'access', 'and', 'affordability', 'of', 'hearing', 'healthcare', 'for', 'adults', 'with', 'mild', '-', 'to', '-', 'moderate', 'hearing', 'loss', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04671381,NCT04671381,"Improving Access and Affordability of Adult Hearing Healthcare: Effectiveness of Community-based Interventions in West Central and South Alabama | This project will address quality of care issues associated with hearing loss in adults who have mild-to-moderate hearing loss and who have no access to hearing healthcare. Through the use of three different interventions involving personal sound amplification products (PSAPs), it will lead to options that will increase access and affordability of hearing healthcare for adults with mild-to-moderate hearing loss.","[(212, 224, 'CONDITION', 'hearing loss'), (244, 273, 'CONDITION', 'mild-to-moderate hearing loss'), (379, 416, 'OTHER', 'personal sound amplification products'), (418, 423, 'OTHER', 'PSAPs'), (532, 561, 'CONDITION', 'mild-to-moderate hearing loss')]"
"['Interventional', ',', 'Open', '-', 'label', ',', 'Multiple', '-', 'immunization', 'Extension', 'Study', 'on', 'the', 'Safety', ',', 'Tolerability', 'and', 'Immunogenicity', 'of', 'Lu', 'AF20513', '/', 'Adjuvant', 'in', 'Patients', 'With', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'multiple', 'immunizations', 'with', 'Lu', 'AF20513', 'is', 'tolerable', 'and', 'safe', 'in', 'patients', 'with', 'mild', 'Alzheimer', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT02388152,NCT02388152,"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease | The purpose of this study is to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease.","[(116, 126, 'DRUG', 'Lu AF20513'), (127, 135, 'CONTROL', 'Adjuvant'), (153, 172, 'CONDITION', ""Alzheimer's Disease""), (248, 258, 'DRUG', 'Lu AF20513'), (298, 322, 'CONDITION', ""mild Alzheimer's disease"")]"
"['The', 'primary', 'objective', 'was', 'to', 'assess', 'whether', 'long', '-', 'term', 'administration', 'of', 'antihypertensive', 'therapy', 'to', 'elderly', 'subjects', 'with', 'isolated', 'systolic', 'hypertension', 'reduced', 'the', 'combined', 'incidence', 'of', 'fatal', 'and', 'non', '-', 'fatal', 'stroke', '.', 'The', 'secondary', 'objectives', 'were', 'to', 'evaluate', ':', 'the', 'effect', 'of', 'long', '-', 'term', 'antihypertensive', 'therapy', 'on', 'mortality', 'from', 'any', 'cause', 'in', 'elderly', 'people', 'with', 'isolated', 'systolic', 'hypertension', ';', 'possible', 'adverse', 'effects', 'of', 'chronic', 'use', 'of', 'antihypertensive', 'drug', 'treatment', 'in', 'this', 'population', ';', 'the', 'effect', 'of', 'therapy', 'on', 'indices', 'of', 'quality', '-', 'of', '-', 'life', ';', 'the', 'natural', 'history', 'of', 'isolated', 'systolic', 'hypertension', 'in', 'the', 'placebo', 'population', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'O']",NCT00000514,NCT00000514,The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.,"[(72, 96, 'DRUG', 'antihypertensive therapy'), (122, 152, 'CONDITION', 'isolated systolic hypertension'), (207, 213, 'CONDITION', 'stroke'), (282, 306, 'DRUG', 'antihypertensive therapy'), (358, 388, 'CONDITION', 'isolated systolic hypertension'), (433, 464, 'DRUG', 'antihypertensive drug treatment'), (561, 591, 'CONDITION', 'isolated systolic hypertension'), (599, 606, 'CONTROL', 'placebo')]"
"['Using', 'the', 'Electronic', 'Health', 'Record', 'to', 'Identify', 'and', 'Promote', 'Goals', '-', 'of', '-', 'Care', 'Communication', '|', 'This', 'two', '-', 'year', 'pilot', 'study', 'will', 'test', 'whether', 'a', 'one', '-', 'page', '""', 'Jumpstart', 'Form', '""', 'will', 'affect', 'goals', '-', 'of', '-', 'care', 'discussions', 'in', 'the', 'hospital', '.', 'This', 'form', 'will', 'be', 'provided', 'to', 'clinicians', 'and', 'will', 'include', 'patient', '-', 'specific', 'information', 'about', 'preferences', 'for', 'goals', '-', 'of', '-', 'care', 'communication', 'and', 'for', 'care', ',', 'as', 'well', 'as', 'tips', 'to', 'improve', 'this', 'communication', '.', 'Jumpstart', 'forms', 'will', 'also', 'be', 'provided', 'to', 'patients', 'or', ',', 'if', 'they', 'are', 'unable', 'to', 'communicate', ',', 'their', 'surrogates', '/', 'family', 'members', '.', 'The', 'information', 'on', 'the', 'form', 'will', 'be', 'obtained', 'from', 'questionnaires', '.', 'The', 'form', 'is', 'tailored', 'to', 'help', 'patients', 'and', 'surrogates', 'talk', 'with', 'clinicians', 'about', 'goals', 'of', 'care', '.', 'This', 'study', 'is', 'based', 'on', 'a', 'successful', 'application', 'of', 'Jumpstart', 'Form', 'in', 'the', 'outpatient', 'clinic', 'setting', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03746392,NCT03746392,"Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication | This two-year pilot study will test whether a one-page ""Jumpstart Form"" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about preferences for goals-of-care communication and for care, as well as tips to improve this communication. Jumpstart forms will also be provided to patients or, if they are unable to communicate, their surrogates/family members. The information on the form will be obtained from questionnaires. The form is tailored to help patients and surrogates talk with clinicians about goals of care. This study is based on a successful application of Jumpstart Form in the outpatient clinic setting.","[(145, 159, 'BEHAVIOURAL', 'Jumpstart Form'), (414, 429, 'BEHAVIOURAL', 'Jumpstart forms'), (748, 762, 'BEHAVIOURAL', 'Jumpstart Form')]"
"['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Phase', '2', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'ABT-126', 'in', 'the', 'Treatment', 'of', 'Cognitive', 'Deficits', 'in', 'Schizophrenia', '(', 'CDS', ')', 'in', 'Smokers', '|', 'This', 'is', 'an', 'efficacy', 'study', 'evaluating', 'a', 'experimental', 'treatment', 'for', 'cognitive', 'deficits', 'in', 'adults', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT01678755,NCT01678755,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers | This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.","[(28, 35, 'CONTROL', 'Placebo'), (108, 115, 'DRUG', 'ABT-126'), (136, 154, 'CONDITION', 'Cognitive Deficits'), (158, 171, 'CONDITION', 'Schizophrenia'), (173, 176, 'CONDITION', 'CDS'), (181, 188, 'CONDITION', 'Smokers'), (257, 275, 'CONDITION', 'cognitive deficits'), (291, 304, 'CONDITION', 'schizophrenia')]"
"['A', 'Comparative', 'Single', 'Center', ',', 'Randomized', 'Neuropathic', 'Pain', 'Assessment', 'Study', 'Involving', 'Patients', 'With', 'Clinically', 'Definite', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'Receiving', 'Treatment', 'With', 'Either', 'Pregabalin', 'or', 'Paroxetine', '|', 'This', 'is', 'a', 'comparative', 'drug', 'trial', 'involving', 'patients', 'with', 'clinically', 'definite', 'Multiple', 'Sclerosis', 'and', 'documented', 'neuropathic', 'pain', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'receive', 'treatment', 'with', 'either', 'paroxetine', 'or', 'pregabalin', '.', 'After', 'dose', 'titration', ',', 'participants', 'will', 'complete', 'various', 'pain', 'scale', 'assessments', 'at', 'several', 'points', 'during', 'the', 'study', 'in', 'order', 'to', 'determine', 'the', 'effectiveness', 'of', 'their', 'assigned', 'pain', 'medication', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00291148,NCT00291148,"A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine | This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.","[(40, 56, 'CONDITION', 'Neuropathic Pain'), (98, 136, 'CONDITION', 'Clinically Definite Multiple Sclerosis'), (138, 140, 'CONDITION', 'MS'), (174, 184, 'DRUG', 'Pregabalin'), (188, 198, 'DRUG', 'Paroxetine'), (258, 296, 'CONDITION', 'clinically definite Multiple Sclerosis'), (312, 328, 'CONDITION', 'neuropathic pain'), (391, 401, 'DRUG', 'paroxetine'), (405, 415, 'DRUG', 'pregabalin'), (474, 478, 'CONDITION', 'pain'), (590, 594, 'CONDITION', 'pain')]"
"['The', 'Effects', 'Upon', 'the', 'Bladder', 'of', 'Transcutaneous', 'Tibial', 'Nerve', 'Stimulation', 'in', 'Acute', 'Traumatic', 'Spinal', 'Cord', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'upon', 'the', 'bladder', 'of', 'electric', 'stimulation', 'of', 'the', 'leg', ""'s"", 'tibial', 'nerve', 'in', 'people', 'with', 'acute', 'spinal', 'cord', 'injury', 'with', 'an', 'intervention', 'called', 'transcutaneous', 'tibial', 'nerve', 'stimulation', '(', 'TTNS', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O']",NCT02573402,NCT02573402,The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury | The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve stimulation (TTNS).,"[(32, 71, 'OTHER', 'Transcutaneous Tibial Nerve Stimulation'), (75, 109, 'CONDITION', 'Acute Traumatic Spinal Cord Injury'), (194, 240, 'OTHER', ""electric stimulation of the leg's tibial nerve""), (256, 280, 'CONDITION', 'acute spinal cord injury'), (309, 348, 'OTHER', 'transcutaneous tibial nerve stimulation'), (350, 354, 'OTHER', 'TTNS')]"
"['Randomised', 'Controlled', 'Trial', 'to', 'Compare', 'Two', 'Methods', 'of', 'Constraint', 'Induced', 'Movement', 'Therapy', 'to', 'Improve', 'Functional', 'Ability', 'in', 'the', 'Affected', 'Upper', 'Limb', 'in', 'Pre', '-', 'school', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'Cerebral', 'palsy', 'remains', 'a', 'major', 'cause', 'of', 'lifelong', 'disability', 'affecting', 'approximately', '2', 'per', '1,000', 'children', '.', 'Of', 'those', 'about', '30', '%', 'have', 'hemiplegic', 'cerebral', 'palsy', '(', 'HPC),a', 'unilateral', 'impairment', ',', 'which', 'can', 'often', 'lead', 'to', 'major', 'difficulties', 'with', 'manual', 'dexterity', 'and', 'upper', 'limb', ',', 'functional', 'ability', 'and', 'independence', '.', 'Therapists', 'employ', 'a', 'number', 'of', 'strategies', 'in', 'upper', 'limb', 'rehabilitation', 'however', 'they', 'are', 'poorly', 'understood', 'and', 'their', 'efficacy', 'has', 'been', 'questioned', '.', 'Constraint', 'induced', 'movement', 'therapy', '(', 'CIMT)has', 'been', 'found', 'to', 'be', 'an', 'effective', 'intervention', 'with', 'HCP', 'however', 'its', 'use', 'in', 'the', 'preschool', 'child', 'within', 'a', 'national', 'health', 'service', '(', 'NHS', ')', 'setting', 'has', 'not', 'been', 'evaluated', '.', 'The', 'investigators', 'aim', 'is', 'to', 'compare', 'CIMT', 'using', 'prolonged', 'restraint', 'with', 'CIMT', 'using', 'brief', 'manual', 'restraint', 'which', 'may', 'be', 'standard', 'practice', 'and', 'acts', 'as', 'the', 'control', '.', 'This', 'age', 'group', 'has', 'been', 'targeted', 'as', 'there', 'may', 'be', 'greatest', 'neural', 'plasticity', '(', 'change)and', 'minimal', 'disruption', 'to', 'compulsory', 'education', '.', 'The', 'investigators', 'intend', 'to', 'recruit', '60', 'patients', 'from', 'treatment', 'databases', 'of', 'participating', 'trusts', '.', 'Patients', 'will', 'be', 'randomised', 'following', 'baseline', 'assessments', 'which', 'will', 'include', '2', 'upper', 'limb', 'assessments(The', 'Assisting', 'Hand', 'Assessment', 'and', 'the', 'Quality', 'of', 'Upper', 'Extremity', 'Skills', 'Test', ')', 'and', 'a', 'quality', 'of', 'life', 'questionnaire', '(', 'PedsQL', 'Generic', 'Core', 'Scales', 'and', 'the', 'Cerebral', 'Palsy', 'Module', ')', 'for', 'parents', '.', 'The', 'intervention', 'period', 'will', 'be', 'for', '6', 'weeks', 'offered', 'intermittently', '(', '2week', 'blocks', ')', 'over', '10', 'weeks', '.', 'Parents', '/guardians', 'and', 'possibly', 'preschool', 'workers', 'will', 'be', 'expected', 'to', 'carry', 'out', 'a', 'therapy', 'guided', 'programme', '.', 'The', 'amount', 'of', 'intervention', 'and', 'compliance', 'will', 'be', 'recorded', 'by', 'parents', '/', 'guardians', 'and', 'therapists', '.', 'Assessments', 'will', 'be', 'repeated', 'at', '10', 'weeks', 'and', '24', 'weeks', 'from', 'the', 'beginning', 'of', 'the', 'trial', '.', 'The', 'results', 'of', 'the', 'trial', 'will', 'contribute', 'to', 'the', 'evidence', 'on', 'the', 'effectiveness', 'of', 'CIMT', 'in', 'the', 'preschool', 'child', 'with', 'HCP', ',', 'and', 'will', 'also', 'provide', 'evidence', 'on', 'the', 'implementation', 'of', 'CIMT', 'delivery', 'within', 'the', 'current', 'NHS', 'therapy', 'services', '.', '\n\n', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01770678,NCT01770678,"Randomised Controlled Trial to Compare Two Methods of Constraint Induced Movement Therapy to Improve Functional Ability in the Affected Upper Limb in Pre-school Children With Hemiplegic Cerebral Palsy | Cerebral palsy remains a major cause of lifelong disability affecting approximately 2 per 1,000 children. Of those about 30% have hemiplegic cerebral palsy (HPC),a unilateral impairment, which can often lead to major difficulties with manual dexterity and upper limb,functional ability and independence. Therapists employ a number of strategies in upper limb rehabilitation however they are poorly understood and their efficacy has been questioned. Constraint induced movement therapy (CIMT)has been found to be an effective intervention with HCP however its use in the preschool child within a national health service (NHS) setting has not been evaluated. The investigators aim is to compare CIMT using prolonged restraint with CIMT using brief manual restraint which may be standard practice and acts as the control. This age group has been targeted as there may be greatest neural plasticity (change)and minimal disruption to compulsory education. The investigators intend to recruit 60 patients from treatment databases of participating trusts. Patients will be randomised following baseline assessments which will include 2 upper limb assessments(The Assisting Hand Assessment and the Quality of Upper Extremity Skills Test) and a quality of life questionnaire (PedsQL Generic Core Scales and the Cerebral Palsy Module) for parents. The intervention period will be for 6 weeks offered intermittently (2week blocks) over 10 weeks. Parents /guardians and possibly preschool workers will be expected to carry out a therapy guided programme. The amount of intervention and compliance will be recorded by parents/guardians and therapists. Assessments will be repeated at 10 weeks and 24 weeks from the beginning of the trial. The results of the trial will contribute to the evidence on the effectiveness of CIMT in the preschool child with HCP, and will also provide evidence on the implementation of CIMT delivery within the current NHS therapy services.

.","[(54, 89, 'OTHER', 'Constraint Induced Movement Therapy'), (175, 200, 'CONDITION', 'Hemiplegic Cerebral Palsy'), (203, 217, 'CONDITION', 'Cerebral palsy'), (333, 358, 'CONDITION', 'hemiplegic cerebral palsy'), (652, 687, 'OTHER', 'Constraint induced movement therapy'), (746, 749, 'CONDITION', 'HCP'), (896, 926, 'OTHER', 'CIMT using prolonged restraint'), (932, 965, 'OTHER', 'CIMT using brief manual restraint'), (2010, 2014, 'OTHER', 'CIMT'), (2043, 2046, 'CONDITION', 'HCP'), (2104, 2108, 'OTHER', 'CIMT')]"
"['The', 'Neural', 'Coding', 'of', 'Speech', 'Across', 'Human', 'Languages', '|', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'reveal', 'the', 'fundamental', 'neural', 'mechanisms', 'that', 'underlie', 'comprehension', 'across', 'human', 'spoken', 'languages', '.', 'An', 'understanding', 'of', 'how', 'speech', 'is', 'coded', 'in', 'the', 'brain', 'has', 'significant', 'implications', 'for', 'the', 'development', 'of', 'new', 'diagnostic', 'and', 'rehabilitative', 'strategies', 'for', 'language', 'disorders', '(', 'e.g.', 'aphasia', ',', 'dyslexia', ',', 'autism', ',', 'et', 'alia', ')', '.', 'The', 'basic', 'mechanisms', 'underlying', 'comprehension', 'of', 'spoken', 'language', 'are', 'unknown', '.', 'Researchers', 'are', 'only', 'beginning', 'to', 'understand', 'how', 'the', 'human', 'brain', 'extracts', 'the', 'most', 'fundamental', 'linguistic', 'elements', '(', 'consonants', 'and', 'vowels', ')', 'from', 'a', 'complex', 'and', 'highly', 'variable', 'acoustic', 'signal', '.', 'Traditional', 'theories', 'have', 'posited', 'a', ""'"", 'universal', ""'"", 'phonetic', 'inventory', 'shared', 'by', 'all', 'humans', ',', 'but', 'this', 'has', 'been', 'challenged', 'by', 'other', 'newer', 'theories', 'that', 'each', 'language', 'has', 'its', 'own', 'unique', 'and', 'specialized', 'code', '.', 'An', 'investigation', 'of', 'the', 'cortical', 'representation', 'of', 'speech', 'sounds', 'across', 'languages', 'can', 'likely', 'shed', 'light', 'on', 'this', 'fundamental', 'question', '.', 'Previous', 'research', 'has', 'implicated', 'the', 'superior', 'temporal', 'cortex', 'in', 'the', 'processing', 'of', 'speech', 'sounds', '.', 'Most', 'of', 'this', 'work', 'has', 'been', 'entirely', 'carried', 'out', 'in', 'English', '.', 'The', 'recording', 'of', 'neural', 'activity', 'directly', 'from', 'the', 'cortical', 'surface', 'from', 'individuals', 'with', 'different', 'language', 'experience', 'is', 'a', 'promising', 'approach', 'since', 'it', 'can', 'provide', 'both', 'high', 'spatial', 'and', 'temporal', 'resolution', '.', 'This', 'study', 'will', 'examine', 'the', 'mechanisms', 'of', 'phonetic', 'encoding', ',', 'by', 'utilizing', 'neurophysiological', 'recordings', 'obtained', 'during', 'neurosurgical', 'procedures', '.', 'High', '-', 'density', 'electrode', 'arrays', ',', 'advanced', 'signal', 'processing', ',', 'and', 'direct', 'electrocortical', 'stimulation', 'will', 'be', 'utilized', 'to', 'unravel', 'both', 'local', 'and', 'population', 'encoding', 'of', 'speech', 'sounds', 'in', 'the', 'lateral', 'temporal', 'cortex', '.', 'This', 'study', 'will', 'also', 'examine', 'the', 'neural', 'encoding', 'of', 'speech', 'in', 'patients', 'who', 'are', 'monolingual', 'and', 'bilingual', 'in', 'Mandarin', ',', 'Spanish', ',', 'and', 'English', ',', 'the', 'most', 'common', 'spoken', 'languages', 'worldwide', ',', 'and', 'feature', 'important', 'contrastive', 'differences', 'of', 'pitch', ',', 'formant', ',', 'and', 'temporal', 'envelope', '.', 'A', 'cross', '-', 'linguistic', 'approach', 'is', 'critical', 'for', 'a', 'true', 'understanding', 'of', 'language', ',', 'while', 'also', 'striving', 'to', 'achieve', 'a', 'broader', 'approach', 'of', 'diversity', 'and', 'inclusion', 'in', 'neuroscience', 'of', 'language', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05014841,NCT05014841,"The Neural Coding of Speech Across Human Languages | The overall goal of this study is to reveal the fundamental neural mechanisms that underlie comprehension across human spoken languages. An understanding of how speech is coded in the brain has significant implications for the development of new diagnostic and rehabilitative strategies for language disorders (e.g. aphasia, dyslexia, autism, et alia). The basic mechanisms underlying comprehension of spoken language are unknown. Researchers are only beginning to understand how the human brain extracts the most fundamental linguistic elements (consonants and vowels) from a complex and highly variable acoustic signal. Traditional theories have posited a 'universal' phonetic inventory shared by all humans, but this has been challenged by other newer theories that each language has its own unique and specialized code. An investigation of the cortical representation of speech sounds across languages can likely shed light on this fundamental question. Previous research has implicated the superior temporal cortex in the processing of speech sounds. Most of this work has been entirely carried out in English. The recording of neural activity directly from the cortical surface from individuals with different language experience is a promising approach since it can provide both high spatial and temporal resolution. This study will examine the mechanisms of phonetic encoding, by utilizing neurophysiological recordings obtained during neurosurgical procedures. High-density electrode arrays, advanced signal processing, and direct electrocortical stimulation will be utilized to unravel both local and population encoding of speech sounds in the lateral temporal cortex. This study will also examine the neural encoding of speech in patients who are monolingual and bilingual in Mandarin, Spanish, and English, the most common spoken languages worldwide, and feature important contrastive differences of pitch, formant, and temporal envelope. A cross-linguistic approach is critical for a true understanding of language, while also striving to achieve a broader approach of diversity and inclusion in neuroscience of language.",[]
"['Effect', 'of', 'Individualized', 'rTMS', 'Based', 'on', 'fNIRS', 'on', 'the', 'Upper', 'Limb', 'Spasticity', 'After', 'Stroke', '|', 'Stroke', 'is', 'of', 'high', 'morbidity', 'and', 'mortality', ',', 'and', 'surviving', 'patients', 'are', 'often', 'unable', 'to', 'take', 'care', 'of', 'themselves', 'because', 'of', 'severe', 'motor', 'dysfunction', '.', 'The', 'brain', 'has', 'plasticity', ',', 'and', 'makes', 'adaptive', 'changes', 'after', 'stroke', ',', 'resulting', 'in', 'the', 'reorganization', 'and', 'compensation', 'of', 'neural', 'networks', '.', 'However', ',', 'the', 'muscle', 'tone', 'of', 'some', 'patients', 'will', 'significantly', 'increase', 'during', 'the', 'recovery', 'process', ',', 'which', 'affects', 'the', 'rehabilitation', 'effect', '.', 'Neuromodulation', 'techniques', 'such', 'as', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'have', 'been', 'widely', 'used', 'to', 'promote', 'brain', 'network', 'remodeling', 'after', 'stroke', '.', 'The', 'investigators', 'attempted', 'to', 'evaluate', 'the', 'motor', 'brain', 'network', 'characteristics', 'of', 'spastic', 'patients', 'by', 'fNIRS', ',', 'and', 'used', 'the', 'most', 'active', 'brain', 'regions', 'as', 'rTMS', 'stimulation', 'regions', 'to', 'evaluate', 'the', 'improvement', 'effect', 'of', 'this', 'individualized', 'treatment', 'on', 'post', '-', 'stroke', 'spasticity', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O']",NCT05318586,NCT05318586,"Effect of Individualized rTMS Based on fNIRS on the Upper Limb Spasticity After Stroke | Stroke is of high morbidity and mortality, and surviving patients are often unable to take care of themselves because of severe motor dysfunction. The brain has plasticity, and makes adaptive changes after stroke, resulting in the reorganization and compensation of neural networks. However, the muscle tone of some patients will significantly increase during the recovery process, which affects the rehabilitation effect. Neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS) have been widely used to promote brain network remodeling after stroke. The investigators attempted to evaluate the motor brain network characteristics of spastic patients by fNIRS, and used the most active brain regions as rTMS stimulation regions to evaluate the improvement effect of this individualized treatment on post-stroke spasticity.","[(10, 29, 'OTHER', 'Individualized rTMS'), (63, 73, 'CONDITION', 'Spasticity'), (80, 86, 'CONDITION', 'Stroke'), (89, 95, 'CONDITION', 'Stroke'), (547, 591, 'OTHER', 'repetitive transcranial magnetic stimulation'), (593, 597, 'OTHER', 'rTMS'), (663, 669, 'CONDITION', 'stroke'), (754, 761, 'CONDITION', 'spastic'), (823, 827, 'OTHER', 'rTMS'), (924, 930, 'CONDITION', 'stroke'), (931, 941, 'CONDITION', 'spasticity')]"
"['PeRiodontal', 'Treatment', 'to', 'Eliminate', 'Minority', 'InEquality', 'and', 'Rural', 'Disparities', 'in', 'Stroke', '|', 'The', 'PREMIERS', 'study', 'is', 'a', 'proposal', 'for', 'conducting', 'an', 'adequately', 'powered', 'two', 'center', 'phase', 'III', 'randomized', 'controlled', 'trial', 'to', 'test', 'whether', 'intensive', 'periodontal', 'treatment', 'reduces', 'the', 'risk', 'of', 'recurrent', 'vascular', 'events', 'among', 'ischemic', 'stroke', 'and', 'TIA', 'survivors', '.', 'The', 'study', 'uses', 'the', 'resources', 'in', 'both', 'states', 'including', 'established', 'dental', 'centers', ',', 'Joint', 'Commission', 'Certified', 'Stroke', 'Centers', ',', 'the', 'Schools', 'of', 'Public', 'Health', ',', 'and', 'the', 'Institute', 'for', 'Partnerships', 'to', 'Eliminate', 'Health', 'Disparities', '.', 'The', 'proposal', 'addresses', 'specific', 'issues', 'with', 'regards', 'to', 'recruitment', 'of', 'African', '-', 'American', 'and', 'rural', 'stroke', '/', 'TIA', 'patients', 'advocating', 'the', 'use', 'of', 'culturally', 'appropriate', 'strategies', 'to', 'educate', 'the', 'study', 'subjects', 'regarding', 'stroke', ',', 'periodontal', 'disease', 'and', 'the', 'periodontal', 'stroke', 'link', '.', '\n\n', 'The', 'study', 'proposes', 'to', 'utilize', 'economic', 'evaluation', 'of', 'the', 'periodontal', 'intervention', 'from', 'the', 'budgetary', 'perspective', '.', 'The', 'focus', 'will', 'be', 'on', 'the', 'financial', 'sustainability', 'of', 'providing', 'aggressive', 'periodontal', 'therapy', '(', 'with', 'certain', ',', 'although', 'relatively', 'low', 'expenditures', ')', 'in', 'exchange', 'for', 'a', 'reduction', 'of', 'uncertain', 'recurrent', 'vascular', 'events', 'that', 'may', 'require', 'high', 'cost', 'emergency', 'department', 'utilization', 'and/or', 'inpatient', 'care', '.', 'The', 'sustainability', 'of', 'the', 'proposed', 'intervention', 'after', 'the', 'completion', 'of', 'the', 'project', 'is', 'integrally', 'linked', 'to', 'the', 'health', 'economic', 'assessment', 'to', 'show', 'the', 'health', 'care', 'cost', 'savings', '.', 'By', 'integration', 'with', 'a', 'rural', 'primary', 'care', 'center', ',', 'with', 'an', 'African', 'American', 'majority', 'and', 'households', 'with', 'average', 'incomes', 'below', 'the', 'state', 'average', ',', 'the', 'study', 'ensures', 'that', 'the', 'proposed', 'intervention', 'to', 'reduce', 'stroke', 'disparity', 'is', 'applicable', 'to', 'this', 'target', 'population', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02541032,NCT02541032,"PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke | The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link.

The study proposes to utilize economic evaluation of the periodontal intervention from the budgetary perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events that may require high cost emergency department utilization and/or inpatient care. The sustainability of the proposed intervention after the completion of the project is integrally linked to the health economic assessment to show the health care cost savings. By integration with a rural primary care center, with an African American majority and households with average incomes below the state average, the study ensures that the proposed intervention to reduce stroke disparity is applicable to this target population.","[(0, 21, 'OTHER', 'PeRiodontal Treatment'), (80, 86, 'CONDITION', 'Stroke'), (224, 255, 'OTHER', 'intensive periodontal treatment'), (308, 323, 'CONDITION', 'ischemic stroke'), (328, 331, 'CONDITION', 'TIA'), (663, 669, 'CONDITION', 'stroke'), (670, 673, 'CONDITION', 'TIA'), (779, 785, 'CONDITION', 'stroke'), (787, 806, 'CONDITION', 'periodontal disease'), (815, 833, 'CONDITION', 'periodontal stroke'), (898, 922, 'OTHER', 'periodontal intervention'), (1018, 1048, 'OTHER', 'aggressive periodontal therapy'), (1632, 1638, 'CONDITION', 'stroke')]"
"['Evaluating', 'Tools', 'for', 'Health', 'Promotion', 'and', 'Disease', 'Prevention', '|', 'The', 'study', 'will', 'evaluate', 'the', 'effect', 'of', 'familial', 'risk', 'assessment', 'and', 'prevention', 'prompts', 'tailored', 'to', 'familial', 'risk', 'on', 'health', 'behaviors', 'and', 'use', 'of', 'preventive', 'services', 'among', 'adults', 'who', 'are', 'members', 'of', 'primary', 'care', 'practices', 'in', 'the', 'U.S.']","['O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00164658,NCT00164658,Evaluating Tools for Health Promotion and Disease Prevention | The study will evaluate the effect of familial risk assessment and prevention prompts tailored to familial risk on health behaviors and use of preventive services among adults who are members of primary care practices in the U.S.,"[(11, 60, 'BEHAVIOURAL', 'Tools for Health Promotion and Disease Prevention'), (101, 125, 'OTHER', 'familial risk assessment'), (130, 174, 'BEHAVIOURAL', 'prevention prompts tailored to familial risk')]"
"['Testing', 'the', 'Effectiveness', 'of', 'Telephone', 'Support', 'for', 'Dementia', 'Caregivers', '|', 'The', 'primary', 'goal', 'of', 'the', 'study', 'is', 'documentation', 'of', 'effectiveness', 'of', 'telephone', 'support', 'groups', 'to', 'reduce', 'caregiver', 'burden', 'and', 'stress', '.', 'Caregivers', 'who', 'participate', 'in', 'intervention', '(', 'Telephone', 'Support', ')', 'should', 'experience', 'lower', 'levels', 'of', 'stress', ',', 'burden', 'and', 'health', 'care', 'utilization', '(', 'lower', 'use', 'of', 'psychotropic', 'drugs', ',', 'fewer', 'scheduled', '/', 'unscheduled', 'medical', 'visits', ',', 'lower', 'rates', 'of', 'institutionalization', ',', 'more', 'efficient', 'use', 'of', 'time', 'in', 'managing', 'care', 'recipient', 'problems', ')', 'compared', 'to', 'those', 'caregivers', 'in', 'Usual', 'Care', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT00119561,NCT00119561,"Testing the Effectiveness of Telephone Support for Dementia Caregivers | The primary goal of the study is documentation of effectiveness of telephone support groups to reduce caregiver burden and stress. Caregivers who participate in intervention (Telephone Support) should experience lower levels of stress, burden and health care utilization (lower use of psychotropic drugs, fewer scheduled/unscheduled medical visits, lower rates of institutionalization, more efficient use of time in managing care recipient problems) compared to those caregivers in Usual Care.","[(29, 46, 'BEHAVIOURAL', 'Telephone Support'), (140, 157, 'BEHAVIOURAL', 'telephone support'), (196, 202, 'CONDITION', 'stress'), (248, 265, 'BEHAVIOURAL', 'Telephone Support'), (301, 307, 'CONDITION', 'stress'), (555, 565, 'CONTROL', 'Usual Care')]"
"['Phase', '1', '/', 'Phase', '2', ',', 'Open', 'Label', 'Study', 'Evaluating', 'the', 'Safety', ',', 'Dosing', 'and', 'Efficacy', 'of', 'Panitumumab', 'IRDye800', 'as', 'an', 'Optical', 'Imaging', 'Agent', 'to', 'Detect', 'Pediatric', 'Neoplasms', 'During', 'Neurosurgical', 'Procedures', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'safety', 'of', 'panitumumab', '-', 'IRDye800', 'in', 'pediatric', 'patients', 'undergoing', 'brain', 'surgery', 'to', 'remove', 'suspected', 'tumors', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT04085887,NCT04085887,"Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures | The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.","[(80, 100, 'DRUG', 'Panitumumab IRDye800'), (149, 158, 'CONDITION', 'Neoplasms'), (166, 190, 'CONDITION', 'Neurosurgical Procedures'), (243, 263, 'DRUG', 'panitumumab-IRDye800'), (297, 310, 'CONDITION', 'brain surgery'), (331, 337, 'CONDITION', 'tumors')]"
"['The', 'underlying', 'goal', 'of', 'this', 'study', 'is', 'to', 'assess', '[', '18F', ']', 'PBR06', 'PET', 'imaging', 'as', 'a', 'tool', 'to', 'detect', 'microglial', 'activation', 'in', 'the', 'brain', 'of', 'Alzheimer', 'Disease', '(', 'AD', ')', ',', 'Parkinson', 'Disease', '(', 'PD', ')', 'and', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'research', 'participants', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT01028209,NCT01028209,"The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.","[(129, 146, 'CONDITION', 'Alzheimer Disease'), (148, 150, 'CONDITION', 'AD'), (153, 170, 'CONDITION', 'Parkinson Disease'), (172, 174, 'CONDITION', 'PD'), (180, 198, 'CONDITION', 'Multiple Sclerosis'), (200, 202, 'CONDITION', 'MS')]"
"['A', 'Long', '-', 'Term', 'Safety', 'and', 'Maintenance', 'of', 'Efficacy', 'Study', 'ofJZP-110', '[', '(', 'R)-2', '-', 'amino-3', 'Phenylpropylcarbamate', 'Hydrochloride', ']', 'in', 'the', 'Treatment', 'of', 'Excessive', 'Sleepiness', 'in', 'Subjects', 'With', 'Narcolepsy', 'or', 'Obstructive', 'Sleep', 'Apnea', '|', 'This', 'is', 'a', 'Phase', '3', 'study', 'to', 'assess', 'the', 'long', '-', 'term', 'safety', 'and', 'maintenance', 'of', 'efficacy', 'of', 'JZP-110', 'in', 'subjects', 'who', 'have', 'completed', 'Study', '14', '-', '002', ',', '14', '-', '003', ',', '14', '-', '004', ',', '15', '-', '004', ',', '15', '-', '005', ',', 'ADX', '-', 'N05', '201', ',', 'or', 'ADX', '-', 'N05', '202', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02348632,NCT02348632,"A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea | This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.","[(64, 113, 'DRUG', '(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride'), (135, 155, 'CONDITION', 'Excessive Sleepiness'), (173, 183, 'CONDITION', 'Narcolepsy'), (187, 210, 'CONDITION', 'Obstructive Sleep Apnea'), (299, 306, 'DRUG', 'JZP-110')]"
